591 Records downloaded  - Fri Aug 12 15:19:15 UTC 2016


RECORD 1
TITLE
  Incidence of atrial fibrillation is associated with age and gender in 
subjects practicing physical exercise: A meta-analysis and meta-regression 
analysis
AUTHOR NAMES
  Brunetti N.D.
  Santoro F.
  Correale M.
  De Gennaro L.
  Conte G.
  Di Biase M.
AUTHOR ADDRESSES
  (Brunetti N.D., natale.brunetti@unifg.it; Santoro F.; Conte G.; Di Biase M.) 
Department of Medical and Surgical Sciences, University of Foggia, Italy.
(Santoro F.) Sankt Georg Asklepios Klinik, Hamburg, Germany.
(Correale M.) Cardiologia Universitaria, Ospedali Riuniti, Foggia, Italy.
(De Gennaro L.) U.O. Cardiologia, Ospedale San Paolo, Bari, Italy.
(Brunetti N.D., natale.brunetti@unifg.it; Santoro F.; Correale M.; De 
Gennaro L.; Conte G.; Di Biase M.) Cardiology Department, University of 
Foggia, Foggia, Italy.
CORRESPONDENCE ADDRESS
  N.D. Brunetti, Cardiology Department, University of Foggia, Viale Pinto n.1, 
Foggia, Italy. Email: natale.brunetti@unifg.it
SOURCE
  International Journal of Cardiology (2016) 221 (1056-1060). Date of 
Publication: 15 Oct 2016
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
ABSTRACT
  The link between physical activity and the risk of atrial fibrillation (AF) 
remains controversial. We therefore sought to further assess by a 
meta-analysis whether increased levels of physical activity may increase the 
risk of AF. In October 2015, a PubMed research was conducted for studies 
that investigated this topic. We identified 11 relevant studies with a total 
of 81,787 participants. The pooled analysis did not show an increased risk 
of AF in subjects practicing physical activity (odds ratio (OR) = 0.92, 95% 
C.I. = 0.84–1.01, p = 0.077, I(2) = 90%). However, given the observed large 
heterogeneity among studies, a subgroup analysis was performed in order to 
identify possible variables influencing the risk of AF. Significantly higher 
risk of AF in subjects with reported physical activity was found in studies 
enrolling exclusively male participants (OR = 7.49, 95% C.I. = 3.12–19.01, 
p < 0.001, I(2) = 0%) and subjects younger than 54 years (OR 5.30, 95% 
C.I. = 3.43–8.20, p < 0.001, I(2) = 1.7%), while results were opposite in 
studies enrolling male and/or female participants OR = 0.89 (95% 
C.I. = 0.81–0.97, p = 0.01) and subjects older than 54 years (OR = 0.84, 95% 
C.I. = 0.76–0.92, p < 0.001). A reverse correlation was also found at 
meta-regression analysis between age and OR of AF (p = 0.047). In 
conclusion, in our meta-analysis, there is a non-significant trend toward 
lower risk of AF in subjects practicing physical activity. The risk seems 
higher in male subjects. A reverse correlation between age and risk of AF 
seems to be evident.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  age distribution
  atrial fibrillation
  exercise
  incidence
  sex difference
EMTREE MEDICAL INDEX TERMS
  cardiovascular risk
  cohort analysis
  correlation analysis
  disease association
  high risk patient
  human
  physical activity
  priority journal
  regression analysis
  review
  systematic review
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160533305
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2016.07.133
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 2
TITLE
  Dabigatran in clinical practice: Contemporary overview of the evidence
AUTHOR NAMES
  Ageno W.
  Eikelboom J.
  Lip G.Y.H.
AUTHOR ADDRESSES
  (Ageno W.) Department of Clinical and Experimental Medicine, University of 
Insubria, Varese, Italy.
(Eikelboom J.) McMaster University, Hamilton, Canada.
(Lip G.Y.H., g.y.h.lip@bham.ac.uk) University of Birmingham Institute of 
Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom.
(Lip G.Y.H., g.y.h.lip@bham.ac.uk) Aalborg Thrombosis Research Unit, 
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
CORRESPONDENCE ADDRESS
  G.Y.H. Lip, University of Birmingham Institute of Cardiovascular Sciences, 
City Hospital, Birmingham, United Kingdom. Email: g.y.h.lip@bham.ac.uk
SOURCE
  International Journal of Cardiology (2016) 220 (417-428). Date of 
Publication: 1 Oct 2016
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
ABSTRACT
  Oral anticoagulation is the cornerstone of stroke prevention in non-valvular 
atrial fibrillation (AF) and management of venous thromboembolism (VTE), 
resulting in a reduction in thrombotic complications and mortality. Benefit 
of vitamin K antagonists (VKAs) in such patients has been unambiguously 
confirmed, but VKA use is complicated by need for regular monitoring of the 
international normalized ratio and multiple drug and food interactions. 
Dabigatran is an oral direct thrombin inhibitor that can be used with fixed 
doses, without the need for routine anticoagulation laboratory monitoring 
and the advantage of few drug or diet interactions. Dabigatran is effective 
for stroke and systemic thromboembolism in AF and for the prophylaxis and 
treatment of VTE. The drug has a good safety profile and consistently shows 
a reduction in intracranial hemorrhage risk compared to warfarin. A specific 
reversal agent for dabigatran has been approved by FDA and EU. This review 
provides a summary of publications assessing clinical utility of dabigatran 
for different indications.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dabigatran (adverse drug reaction, clinical trial, drug combination, drug 
comparison - placebo, drug comparison, drug dose, drug therapy, oral drug 
administration)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug combination, drug therapy)
  activated prothrombin complex (drug therapy)
  antivitamin K (drug therapy)
  apixaban (drug therapy)
  clopidogrel (drug combination, drug therapy)
  enoxaparin (adverse drug reaction, drug comparison, drug therapy)
  fondaparinux (drug therapy)
  heparin (drug therapy, intravenous drug administration)
  idarucizumab (drug therapy)
  low molecular weight heparin (drug therapy, subcutaneous drug 
administration)
  placebo
  rivaroxaban (drug therapy)
  ticagrelor (drug combination, drug therapy)
  warfarin (adverse drug reaction, drug combination, drug comparison, drug 
therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  cerebrovascular accident (drug therapy, drug therapy, prevention)
  venous thromboembolism (drug therapy, complication, drug therapy, 
prevention)
EMTREE MEDICAL INDEX TERMS
  aging
  bleeding (drug therapy, side effect)
  CHADS2 score
  dose response
  drug dose comparison
  drug efficacy
  drug response
  drug safety
  dyspepsia (side effect)
  embolism (drug therapy, prevention)
  evidence based practice
  hemostasis
  human
  joint surgery
  kidney function
  liver dysfunction (side effect)
  low drug dose
  mechanical heart valve
  multicenter study (topic)
  perioperative period
  phase 1 clinical trial (topic)
  phase 2 clinical trial (topic)
  phase 3 clinical trial (topic)
  priority journal
  pulmonary vein isolation
  randomized controlled trial (topic)
  review
  risk factor
  stent thrombosis (drug therapy)
DRUG TRADE NAMES
  FEIBA  , AustriaBaxter

DRUG MANUFACTURERS
   (Austria)Baxter
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  activated prothrombin complex (78690-13-8, 78690-39-8)
  apixaban (503612-47-3)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  enoxaparin (679809-58-6)
  fondaparinux (104993-28-4, 114870-03-0)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  idarucizumab (1362509-93-0)
  rivaroxaban (366789-02-8)
  ticagrelor (274693-27-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160507884
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2016.06.078
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 3
TITLE
  Accidental Bolus of Parenteral Nutrition
AUTHOR NAMES
  Lodeserto F.
  Al-Jaghbeer M.
  Huang D.
AUTHOR ADDRESSES
  (Lodeserto F., frank.lodeserto@upmc.edu; Al-Jaghbeer M.; Huang D.) 
Department of Critical Care Medicine, University of Pittsburgh, Childrens 
Hospital of Pittsburgh of UPMC, Faculty Pavilion, 4401 Penn Ave, Pittsburgh, 
United States.
(Huang D.) Clinical Research, Investigation, and Systems Modeling of Acute 
Illness (CRISMA) Center, University of Pittsburgh, Pittsburgh, United 
States.
CORRESPONDENCE ADDRESS
  F. Lodeserto, Department of Critical Care Medicine, University of 
Pittsburgh, Childrens Hospital of Pittsburgh of UPMC, Faculty Pavilion, 4401 
Penn Ave, Pittsburgh, United States. Email: frank.lodeserto@upmc.edu
SOURCE
  Journal of Parenteral and Enteral Nutrition (2016) 40:6 (883-885). Date of 
Publication: 1 Aug 2016
ISSN
  1941-2444 (electronic)
  0148-6071
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  There is a paucity of data that exists regarding acute toxicity and 
management in the setting of parental nutrition (PN) overdose. We describe a 
case of a patient who received an accidental rapid bolus of PN and fat 
emulsion. She developed a seizure, metabolic acidosis, arrhythmias, 
myocardial ischemia, altered mental status, hypotension, and hypoxemia 
likely caused by elevated triglycerides, leading to a hyperviscosity 
syndrome. After failing standard therapy, she was successfully treated with 
a single-volume plasma exchange with resolution of symptoms. Fat emulsion or 
intravenous lipid emulsion and much of its safety have been recently 
described in its use as a rescue therapy in resuscitation from drug-related 
toxicity. Elevated serum triglyceride levels can result in a picture similar 
to a hyperviscosity syndrome. Plasma exchange is a known therapeutic 
modality for the management of hyperviscosity syndrome and a novel therapy 
in the treatment of hyperviscosity syndrome due to fat emulsion therapy. In 
a patient receiving PN with development of rapid deterioration of clinical 
status, without an obvious etiology, there should be consideration of PN 
overdose. A rapid assessment and treatment of severe electrolyte 
abnormalities should be undertaken immediately to prevent life-threatening 
cardiovascular and central nervous system collapse. If fat emulsion was 
rapidly coadministered and there are signs and symptoms of hyperviscosity 
syndrome, then consideration should be given to plasma exchange as an 
effective therapeutic treatment option.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  lipid emulsion (drug toxicity)
  parenteral solution (drug toxicity)
EMTREE DRUG INDEX TERMS
  bicarbonate
  glucose (endogenous compound)
  hypertensive factor (drug therapy)
  infusion fluid
  insulin
  oxygen
  potassium (endogenous compound)
  triacylglycerol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  parenteral nutrition
  therapeutic error
EMTREE MEDICAL INDEX TERMS
  aged
  arterial gas
  article
  artificial ventilation
  atrial fibrillation (complication)
  case report
  electroencephalogram
  female
  glucose blood level
  heart infarction
  heart muscle ischemia (complication)
  human
  hyperglycemia (complication, diagnosis)
  hyperkalemia (complication, diagnosis)
  hypertriglyceridemia (complication, therapy)
  hyperviscosity syndrome (complication)
  hypotension (complication, drug therapy)
  hypoxemia (complication, therapy)
  insulin infusion
  intensive care unit
  intensivist
  intestine ischemia (complication, surgery)
  intestine resection
  lactic acidosis (diagnosis)
  length of stay
  mechanical ventilator
  medical history
  medical specialist
  mental health
  metabolic acidosis (complication, diagnosis)
  metabolic encephalopathy (complication)
  nursing staff
  plasmapheresis
  positive end expiratory pressure
  postoperative complication (complication, therapy)
  potassium blood level
  priority journal
  repeat procedure
  respiratory acidosis (complication, diagnosis)
  respiratory failure (complication, therapy)
  seizure (complication)
  short bowel syndrome (complication, therapy)
  ST segment depression
  treatment response
  triacylglycerol blood level
CAS REGISTRY NUMBERS
  bicarbonate (144-55-8, 71-52-3)
  glucose (50-99-7, 84778-64-3)
  insulin (9004-10-8)
  oxygen (7782-44-7)
  potassium (7440-09-7)
EMBASE CLASSIFICATIONS
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
  Toxicology (52)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160549211
FULL TEXT LINK
  http://dx.doi.org/10.1177/0148607115572194
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 4
TITLE
  Self-rating level of perceived exertion for guiding exercise intensity 
during a 12-week cardiac rehabilitation programme and the influence of heart 
rate reducing medication
AUTHOR NAMES
  Tang L.H.
  Zwisler A.-D.
  Taylor R.S.
  Doherty P.
  Zangger G.
  Berg S.K.
  Langberg H.
AUTHOR ADDRESSES
  (Tang L.H., Lars.hermann.tang@regionh.dk; Zwisler A.-D.; Zangger G.; Berg 
S.K.) Department of Cardiology, The Heart Centre, Rigshospitalet - 
Copenhagen University Hospital, Denmark.
(Tang L.H., Lars.hermann.tang@regionh.dk; Langberg H.) CopenRehab, Section 
of Social Medicine, Department of Public Health, University of Copenhagen, 
Denmark.
(Tang L.H., Lars.hermann.tang@regionh.dk) Department of Rehabilitation and 
Nutrition, Faculty of Health and Technology, Metropolitan University 
College, Denmark.
(Tang L.H., Lars.hermann.tang@regionh.dk) The Centre for Physical Activity 
Research, Rigshospitalet, University of Copenhagen, Denmark.
(Zwisler A.-D.) National Centre for Rehabilitation and Palliative Care, 
University of Southern Denmark, Odense University Hospital, Denmark.
(Taylor R.S.) Institute of Health Research, University of Exeter Medical 
School, United Kingdom.
(Taylor R.S.) National Institute of Public Health, University of Southern 
Denmark, Denmark.
(Doherty P.) Department of Health Sciences, University of York, United 
Kingdom.
CORRESPONDENCE ADDRESS
  L.H. Tang, Department of Cardiology, The Heart Centre, Rigshospitalet, 
Copenhagen University Hospital, Denmark. Email: Lars.hermann.tang@regionh.dk
SOURCE
  Journal of Science and Medicine in Sport (2016) 19:8 (611-615). Date of 
Publication: 1 Aug 2016
ISSN
  1878-1861 (electronic)
  1440-2440
BOOK PUBLISHER
  Elsevier Ltd
ABSTRACT
  Objectives: To investigate whether self-rating level of perceived exertion 
can adequately guide exercise intensity during a 12-week cardiac 
rehabilitation programme. Design: Linear regression analysis using 
rehabilitation data from two randomised controlled trials. Methods: Patients 
undergoing radiofrequency ablation for atrial fibrillation or following 
heart valve surgery and participating in exercise-based rehabilitation were 
included. The 12-week rehabilitation outpatient programme comprised three 
weekly training sessions, each consisting of 20 min aerobic exercise divided 
into three steps. Patients were asked to base their exercise intensity for 
each step on a predefined rating of perceived exertion specified in a 
training diary. Exercise intensity was objectively measured by heart rate 
during the last 2 min for each exercise step. Comparative analysis and 
linear regression of the rating of perceived exertion and heart rate were 
performed. Results: A total of 2622 ratings of perceived exertion were 
collected from 874 training sessions in 97 patients. Heart rate and rating 
of perceived exertion were associated both across all three exercise steps 
and individually for each step, with a mean of 6 to7 bpm per 1-point 
difference in the rating of perceived exertion (p < 0.001). Adjusting for 
rate-reducing medication slightly improved the strength of the association. 
Conclusions: The association between change in the rating of perceived 
exertion and change in heart rate indicates that a diary-led and 
self-regulated model using rating of perceived exertion can help guide 
exercise intensity in everyday clinical practice among patients with heart 
disease, irrespective if they are taking heart rate-reducing medication.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent
  calcium antagonist
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (rehabilitation, surgery)
  exercise intensity
  heart rate variability
  heart rehabilitation
  self concept
EMTREE MEDICAL INDEX TERMS
  adult
  aerobic exercise
  article
  controlled study
  female
  heart valve surgery
  human
  kinesiotherapy
  major clinical study
  male
  parallel design
  radiofrequency ablation
  randomized controlled trial
CAS REGISTRY NUMBERS
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015479544
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jsams.2015.08.004
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 5
TITLE
  Contact force monitoring during catheter ablation of intraatrial reentrant 
tachycardia in patients with congenital heart disease
AUTHOR NAMES
  Krause U.
  Backhoff D.
  Klehs S.
  Schneider H.E.
  Paul T.
AUTHOR ADDRESSES
  (Krause U., ukrause1@gwdg.de; Backhoff D.; Klehs S.; Schneider H.E.; Paul 
T.) Department of Pediatric Cardiology and Intensive Care Medicine, 
University Medical Center, Göttingen, Germany.
CORRESPONDENCE ADDRESS
  U. Krause, Department of Pediatric Cardiology and Intensive Care Medicine, 
University Medical Center, Göttingen, Germany. Email: ukrause1@gwdg.de
SOURCE
  Journal of Interventional Cardiac Electrophysiology (2016) 46:2 (191-198). 
Date of Publication: 1 Aug 2016
ISSN
  1572-8595 (electronic)
  1383-875X
BOOK PUBLISHER
  Springer New York LLC, barbara.b.bertram@gsk.com
ABSTRACT
  Background: Monitoring of catheter contact force during catheter ablation of 
atrial fibrillation has been shown to increase efficacy and safety. However, 
almost no data exists on the use of this technology in catheter ablation of 
intraatrial reentrant tachycardia in patients with congenital heart disease. 
The aim of the present study was to evaluate the impact of contact force 
monitoring during catheter ablation of intraatrial reentrant tachycardia in 
those patients. Methods: Catheter ablation of intraatrial reentrant 
tachycardia using monitoring of catheter contact force was performed in 28 
patients with congenital heart disease (CHD). Thirty-two patients matched 
according to gender, age, and body weight with congenital heart disease 
undergoing catheter ablation without contact force monitoring served as 
control group. Parameters reflecting acute procedural success, long-term 
efficacy, and safety were compared. Results: Acute procedural success was 
statistically not different in both groups (contact force 93 % vs. control 
84 %, p = 0.3). Likewise the recurrence rate 1 year after ablation as shown 
by Kaplan-Meier analysis did not differ (contact force 28 % vs. control 
37 %, p = 0.63). Major complications were restricted to groin vessel 
injuries and occurred in 3 out of 60 patients (contact force n = 1; control 
n = 2). Complications related to excessive catheter contact force were not 
observed. Conclusion: The present study did not show superiority of catheter 
contact force monitoring during ablation of intraatrial reentrant 
tachycardia in patients with CHD in terms of efficacy and safety. Higher 
contact force compared to pulmonary vein isolation might therefore be 
required to increase the efficacy of catheter ablation of intraatrial 
reentrant tachycardia in patients with congenital heart disease.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  catheter ablation
  congenital heart disease (congenital disorder)
  contact force monitoring
  intraatrial reentrant tachycardia (therapy)
  monitoring
  reentry tachycardia (therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  arteriovenous fistula (complication)
  article
  blood vessel injury (complication)
  clinical article
  controlled study
  false aneurysm (complication)
  female
  follow up
  human
  inguinal region
  male
  postoperative complication (complication)
  priority journal
  recurrence risk
  safety
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160026504
FULL TEXT LINK
  http://dx.doi.org/10.1007/s10840-015-0096-z
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 6
TITLE
  Ablation of Atrial Fibrillation: Patient Selection, Periprocedural 
Anticoagulation, Techniques, and Preventive Measures after Ablation
AUTHOR NAMES
  Link M.S.
  Haïssaguerre M.
  Natale A.
AUTHOR ADDRESSES
  (Link M.S., Mark.Link@UTSouthwestern.edu) Cardiac Arrhythmia Center, UT 
Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, United States.
(Haïssaguerre M.) Liryc Institute (Electrophysiology and Heart Modeling 
Institute), Hopital Cardiologique du Haut-Leveque, Universite de Bordeaux, 
France.
(Natale A.) Texas Cardiac Arrhythmia Institute, St. David's Medical Center, 
Austin, United States.
CORRESPONDENCE ADDRESS
  M.S. Link, Cardiac Arrhythmia Center, UT Southwestern Medical Center, 5323 
Harry Hines Blvd, Dallas, United States. Email: Mark.Link@UTSouthwestern.edu
SOURCE
  Circulation (2016) 134:4 (339-352). Date of Publication: 26 Jul 2016
ISSN
  1524-4539 (electronic)
  0009-7322
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Atrial fibrillation (AF) is the most common arrhythmia encountered by 
cardiologists and is a major cause of morbidity and mortality. Risk factors 
for AF include age, male sex, genetic predisposition, hypertension, diabetes 
mellitus, sleep apnea, obesity, excessive alcohol, smoking, hyperthyroidism, 
pulmonary disease, air pollution, heart failure, and possibly excessive 
exercise. The management of AF involves decisions about rate versus rhythm 
control. Asymptomatic patients are generally managed with rate control and 
anticoagulation. Symptomatic patients will desire rhythm control. Rhythm 
control options are either antiarrhythmic agents or ablation, with each 
having its own risks and benefits. Ablation of AF has evolved from a rare 
and complex procedure to a common electrophysiological technique. Selection 
of patients to undergo ablation is an important aspect of AF care. Patients 
with the highest success rates of ablation are those with normal structural 
hearts and paroxysmal AF, although those with congestive heart failure have 
the greatest potential benefit of the procedure. Although pulmonary vein 
isolation of any means/energy source is the approach generally agreed on for 
those with paroxysmal AF, optimal techniques for the ablation of 
nonparoxysmal AF are not yet clear. Anticoagulation reduces thromboembolic 
complications; the newer anticoagulants have eased management for both the 
patient and the cardiologist. Aggressive management of modifiable risk 
factors (hypertension, diabetes mellitus, sleep apnea, obesity, excessive 
alcohol, smoking, hyperthyroidism, pulmonary disease, air pollution, and 
possibly excessive exercise) after ablation reduces the odds of recurrent AF 
and is an important element of care.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  antiarrhythmic agent
  anticoagulant agent
EMTREE DRUG INDEX TERMS
  alcohol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  ablation therapy
  anticoagulation
  paroxysmal atrial fibrillation
  patient selection
  pulsed radiofrequency treatment
EMTREE MEDICAL INDEX TERMS
  air pollution
  cardiologist
  clinical study
  congestive heart failure
  controlled study
  diabetes mellitus
  electrophysiological procedures
  energy resource
  exercise
  genetic predisposition
  heart arrhythmia
  human
  hypertension
  hyperthyroidism
  lung disease
  male
  morbidity
  mortality
  obesity
  pulmonary vein isolation
  risk factor
  sleep disordered breathing
  smoking
  thromboembolism
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160571191
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021727
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 7
TITLE
  Cardiovascular benefits and risks across the physical activity continuum
AUTHOR NAMES
  Eijsvogels T.M.H.
  George K.P.
  Thompson P.D.
AUTHOR ADDRESSES
  (Eijsvogels T.M.H.) aResearch Institute for Sports and Exercise Sciences, 
Liverpool John Moores University, Liverpool, UK bDepartment of Physiology, 
Radboud University Medical Center, Nijmegen, The Netherlands cDivision of 
Cardiology, Hartford Hospital, Hartford, Connecticut, USA
(George K.P.; Thompson P.D.)
CORRESPONDENCE ADDRESS
  T.M.H. Eijsvogels, aResearch Institute for Sports and Exercise Sciences, 
Liverpool John Moores University, Liverpool, UK bDepartment of Physiology, 
Radboud University Medical Center, Nijmegen, The Netherlands cDivision of 
Cardiology, Hartford Hospital, Hartford, Connecticut, USA
SOURCE
  Current Opinion in Cardiology (2016). Date of Publication: 22 Jul 2016
ISSN
  1531-7080 (electronic)
  0268-4705
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  PURPOSE OF REVIEW: Habitual physical activity can reduce the risk of future 
cardiovascular morbidity and mortality. This review evaluates recent 
publications that have assessed the impact of the dose of physical 
(in)activity on cardiovascular outcomes. RECENT FINDINGS: Sedentary 
behavior, characterized by prolonged sitting, is increasingly prevalent 
across the globe and increases the risk for cardiovascular events in a 
dose-dependent fashion. Similarly, the number of individuals performing 
endurance exercise events has tripled over the last 2 decades, and some 
studies suggest that the high volumes of exercise training and competition 
may attenuate the health benefits of a physically active lifestyle. SUMMARY: 
Breaking up sitting time or replacing sitting by (light) physical activity 
are effective strategies to attenuate its detrimental health effects. Low 
doses of physical activity, preferably at a high intensity, significantly 
reduce the risk for cardiovascular and all-cause mortality. Larger doses of 
exercise yield larger health benefits. Extreme doses of exercise neither 
increase nor decrease the risk for adverse outcomes. Athletes demonstrate a 
transient cardiac dysfunction and biomarker release directly postexercise. 
Chronic exercise training may increase the risk for atrial fibrillation, but 
is also associated with a superior life expectancy compared with the general 
population.
EMTREE DRUG INDEX TERMS
  biological marker
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular system
  physical activity
EMTREE MEDICAL INDEX TERMS
  adverse outcome
  athlete
  atrial fibrillation
  behavior
  competition
  endurance training
  human
  human experiment
  life expectancy
  lifestyle
  morbidity
  mortality
  population
  publication
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160561094
FULL TEXT LINK
  http://dx.doi.org/10.1097/HCO.0000000000000321
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 8
TITLE
  Factors Affecting Patients’ Perception On, and Adherence To, Anticoagulant 
Therapy: Anticipating the Role of Direct Oral Anticoagulants
AUTHOR NAMES
  Pandya E.Y.
  Bajorek B.
AUTHOR ADDRESSES
  (Pandya E.Y., Ekta.Y.Pandya@student.uts.edu.au; Bajorek B., 
Beata.Bajorek@uts.edu.au) Graduate School of Health, University of 
Technology Sydney, Building 7, 67 Thomas Street, Ultimo, Australia.
(Bajorek B., Beata.Bajorek@uts.edu.au) Pharmacy Department, Royal North 
Shore Hospital, St Leonards, Australia.
CORRESPONDENCE ADDRESS
  E.Y. Pandya, Graduate School of Health, University of Technology Sydney, 
Building 7, 67 Thomas Street, Ultimo, Australia. Email: 
Ekta.Y.Pandya@student.uts.edu.au
SOURCE
  Patient (2016) (1-23). Date of Publication: 20 Jul 2016
ISSN
  1178-1661 (electronic)
  1178-1653
BOOK PUBLISHER
  Springer International Publishing
ABSTRACT
  The role of the direct oral anticoagulants (DOACs) in practice has been 
given extensive consideration recently, albeit largely from the clinician’s 
perspective. However, the effectiveness and safety of using anticoagulants 
is highly dependent on the patient’s ability to manage and take these 
complex, high-risk medicines. This structured narrative review explores the 
published literature to identify the factors underpinning patients’ 
non-adherence to anticoagulants in atrial fibrillation (AF), and 
subsequently contemplates to what extent the DOACs might overcome the known 
challenges with traditional warfarin therapy. This review comprised a 
two-tier search of various databases and search platforms (CINAHL, Cochrane, 
Current Contents Connect, EMBASE, MEDLINE Ovid, EBSCO, PubMed, Google, 
Google Scholar) to yield 47 articles reporting patients perspectives on, and 
patients adherence to, anticoagulant therapy. The findings from the 
literature were synthesised under five interacting dimensions of adherence: 
therapy-related factors, patient-related factors, condition-related factors, 
social–economic factors and health system factors. Factors negatively 
affecting patients’ day-to-day lives (especially regular therapeutic drug 
monitoring, dose adjustments, dietary considerations) predominantly underpin 
a patient’s reluctance to take warfarin therapy, leading to non-adherence. 
Other patient-related factors underpinning non-adherence include patients’ 
perceptions and knowledge about the purpose of anticoagulation; 
understanding of the risks and benefits of therapy; socioeconomic status; 
and expectations of care from health professionals. In considering these 
findings, it is apparent that the DOACs may overcome some of the barriers to 
traditional warfarin therapy at least to an extent, particularly the need 
for regular monitoring, frequent dose adjustment and dietary considerations. 
However, their high cost, twice-daily dosing and gastrointestinal adverse 
effects may present additional challenges for patients and health systems. 
The review highlights the need to explicitly incorporate patients’ 
perspectives in decision-making processes for anticoagulant selection, to 
obtain optimum adherence and treatment outcomes. Further studies should 
explore resources that can better engage patients in decision making around 
the selection of anticoagulant therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  perception
EMTREE MEDICAL INDEX TERMS
  adverse drug reaction
  Cinahl
  consensus development
  decision making
  diet
  doctor patient relation
  drug monitoring
  drug therapy
  Embase
  expectation
  gastrointestinal tract
  human
  Medline
  SciSearch
  social status
  systematic review
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160550822
FULL TEXT LINK
  http://dx.doi.org/10.1007/s40271-016-0180-1
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 9
TITLE
  Clinical neurocardiology defining the value of neuroscience-based 
cardiovascular therapeutics
AUTHOR NAMES
  Shivkumar K.
  Ajijola O.A.
  Anand I.
  Armour J.A.
  Chen P.-S.
  Esler M.
  De Ferrari G.M.
  Fishbein M.C.
  Goldberger J.J.
  Harper R.M.
  Joyner M.J.
  Khalsa S.S.
  Kumar R.
  Lane R.
  Mahajan A.
  Po S.
  Schwartz P.J.
  Somers V.K.
  Valderrabano M.
  Vaseghi M.
  Zipes D.P.
AUTHOR ADDRESSES
  (Shivkumar K., kshivkumar@mednet.ucla.edu; Ajijola O.A.; Armour J.A.; 
Vaseghi M.) UCLA Cardiac Arrhythmia Center and Neurocardiology Research 
Center of Excellence, Los Angeles, United States.
(Anand I.) Department of Cardiology, University of Minnesota Medical School, 
Minneapolis, United States.
(Chen P.-S.) Krannert Institute of Cardiology, Indiana University School of 
Medicine, Indianapolis, United States.
(Esler M.) Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
(De Ferrari G.M.) Department of Molecular Medicine, University of Pavia, 
Pavia, Italy.
(Fishbein M.C.) Department of Pathology and Laboratory Medicine, David 
Geffen School of Medicine at UCLA, Los Angeles, United States.
(Goldberger J.J.) Division of Cardiology, University of Miami Miller School 
of Medicine, Miami, United States.
(Harper R.M.) Department of Neurobiology and the Brain Research Institute, 
University of California, Los Angeles, United States.
(Joyner M.J.; Somers V.K.) Division of Cardiovascular Diseases, Mayo Clinic 
and Mayo Foundation, Rochester, United States.
(Khalsa S.S.) Laureate Institute for Brain Research, Tulsa, United States.
(Kumar R.) Departments of Anesthesiology and Radiological Sciences, David 
Geffen School of Medicine at UCLA, Los Angeles, United States.
(Lane R.) Department of Psychiatry, University of Arizona College of 
Medicine, Tucson, United States.
(Mahajan A.) Department of Anesthesia, UCLA, Los Angeles, United States.
(Po S.) Heart Rhythm Institute, University of Oklahoma Health Sciences 
Center, Oklahoma City, United States.
(Po S.) University of Tulsa Oxley College of Health Sciences, Tulsa, United 
States.
(Schwartz P.J.) Center for Cardiac Arrhythmias of Genetic Origin, IRCCS 
Instituto Auxologico Italiano, c/o Centro Diagnostico e di Ricerrca San 
Carlo, Milan, Italy.
(Valderrabano M.) Methodist DeBakey Heart and Vascular Center and Methodist 
Hospital Research Institute, Houston Methodist Hospital, Houston, United 
States.
(Zipes D.P.) Indiana University School of Medicine, Indianapolis, United 
States.
CORRESPONDENCE ADDRESS
  K. Shivkumar, UCLA Cardiac Arrhythmia Center and Neurocardiology Research 
Center of Excellence, Los Angeles, United States. Email: 
kshivkumar@mednet.ucla.edu
SOURCE
  Journal of Physiology (2016) 594:14 (3911-3954). Date of Publication: 15 Jul 
2016
ISSN
  1469-7793 (electronic)
  0022-3751
BOOK PUBLISHER
  Blackwell Publishing Ltd, customerservices@oxonblackwellpublishing.com
ABSTRACT
  Abstract: The autonomic nervous system regulates all aspects of normal 
cardiac function, and is recognized to play a critical role in the 
pathophysiology of many cardiovascular diseases. As such, the value of 
neuroscience-based cardiovascular therapeutics is increasingly evident. This 
White Paper reviews the current state of understanding of human cardiac 
neuroanatomy, neurophysiology, pathophysiology in specific disease 
conditions, autonomic testing, risk stratification, and neuromodulatory 
strategies to mitigate the progression of cardiovascular diseases.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart function
  neuroscience
EMTREE MEDICAL INDEX TERMS
  adrenergic transmission
  aerobic exercise
  article
  atrial fibrillation
  cardiac resynchronization therapy
  cardiopulmonary function
  cardiovascular risk
  cholinergic transmission
  functional anatomy
  heart conduction
  heart denervation
  heart failure
  holistic care
  human
  interoception
  ischemic heart disease
  kidney denervation
  meditation
  motoneuron
  nerve cell network
  nerve stimulation
  neuroanatomy
  neuromodulation
  pressoreceptor reflex
  priority journal
  risk assessment
  sinus rhythm
  sleep disordered breathing
  spinal cord stimulation
  stellate ganglion block
  thorax epidural anesthesia
  vagus nerve stimulation
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160528001
MEDLINE PMID
  27114333 (http://www.ncbi.nlm.nih.gov/pubmed/27114333)
FULL TEXT LINK
  http://dx.doi.org/10.1113/JP271870
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 10
TITLE
  Heart rate reduction in coronary artery disease and heart failure
AUTHOR NAMES
  Ferrari R.
  Fox K.
AUTHOR ADDRESSES
  (Ferrari R., fri@unife.it) Department of Cardiology, Ospedale di Cona, Via 
Aldo Moro 8, Cona Ferrara, Italy.
(Fox K.) National Heart and Lung Institute, Institute of Cardiovascular 
Medicine and Science, Royal Brompton Hospital, Sydney Street, London, United 
Kingdom.
CORRESPONDENCE ADDRESS
  R. Ferrari, Department of Cardiology, Ospedale di Cona, Via Aldo Moro 8, 
Cona Ferrara, Italy. Email: fri@unife.it
SOURCE
  Nature Reviews Cardiology (2016) 13:8 (493-501). Date of Publication: 14 Jul 
2016
ISSN
  1759-5010 (electronic)
  1759-5002
BOOK PUBLISHER
  Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
  Elevated heart rate is known to induce myocardial ischaemia in patients with 
coronary artery disease (CAD), and heart rate reduction is a recognized 
strategy to prevent ischaemic episodes. In addition, clinical evidence shows 
that slowing the heart rate reduces the symptoms of angina by improving 
microcirculation and coronary flow. Elevated heart rate is an established 
risk factor for cardiovascular events in patients with CAD and in those with 
chronic heart failure (HF). Accordingly, reducing heart rate improves 
prognosis in patients with HF, as demonstrated in SHIFT. By contrast, data 
from SIGNIFY indicate that heart rate is not a modifiable risk factor in 
patients with CAD who do not also have HF. Heart rate is also an important 
determinant of cardiac arrhythmias; low heart rate can be associated with 
atrial fibrillation, and high heart rate after exercise can be associated 
with sudden cardiac death. In this Review, we critically assess these 
clinical findings, and propose hypotheses for the variable effect of heart 
rate reduction in cardiovascular disease.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  ivabradine (pharmacology)
EMTREE DRUG INDEX TERMS
  angiotensin II
  beta adrenergic receptor blocking agent
  metoprolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  coronary artery disease
  heart failure
  heart rate
  heart rate reduction
EMTREE MEDICAL INDEX TERMS
  angina pectoris
  atrial fibrillation
  bradycardia
  cardiovascular risk
  coronary artery blood flow
  coronary flow reserve
  disease course
  drug effect
  exercise
  heart arrhythmia
  heart left ventricle function
  heart muscle ischemia
  human
  microcirculation
  nonhuman
  outcome assessment
  priority journal
  prognosis
  review
  sudden cardiac death
CAS REGISTRY NUMBERS
  angiotensin II (11128-99-7)
  ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
  metoprolol (37350-58-6)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160399497
FULL TEXT LINK
  http://dx.doi.org/10.1038/nrcardio.2016.84
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 11
TITLE
  Low preoperative selenium is associated with post-operative atrial 
fibrillation in patients having intermediate-risk coronary artery surgery
AUTHOR NAMES
  McDonald C.
  Fraser J.
  Shekar K.
  Clarke A.
  Coombes J.
  Barnett A.
  Pearse B.
  Fung L.
AUTHOR ADDRESSES
  (Clarke A.) Department of Cardiac Surgery, The Prince Charles Hospital, 
Chermside, Queensland, Australia
(McDonald C.; Fraser J.; Shekar K.; Coombes J.; Barnett A.; Pearse B.; Fung 
L.)
CORRESPONDENCE ADDRESS
  A. Clarke, Department of Cardiac Surgery, The Prince Charles Hospital, 
Chermside, Queensland, Australia
SOURCE
  European Journal of Clinical Nutrition (2016). Date of Publication: 13 Jul 
2016
ISSN
  1476-5640 (electronic)
  0954-3007
BOOK PUBLISHER
  Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
  Background/objectives:Post-operative atrial fibrillation (POAF) is a 
frequent complication of cardiac surgery. Oxidative stress and reduced 
antioxidant function have major roles in its development. Selenium is a key 
to normal antioxidant function, and levels are often low before cardiac 
surgery. This study investigated whether low preoperative selenium levels 
were associated with POAF in cardiac surgical 
patients.Subjects/methods:Using the Society of Thoracic Surgeons (STS) 
Mortality risk score, 50 patients having primary coronary artery bypass 
grafts (CABG) surgery were divided into two groups: (i) low-risk group (STS 
⩽0.5%; n=26) and (ii) intermediate-risk group (STS ⩾2.0%; n=24). Plasma 
levels of selenium, glutathione peroxidase (GPx) and malondialdehyde (MDA) 
were measured in all patients at anaesthetic induction, after aortic 
cross-clamp removal, 3 h post cardiopulmonary bypass and on post-operative 
days 1 and 5. Multiple logistic regression was used to assess whether 
selenium levels were associated with POAF development.Results:Seventeen 
patients developed POAF (14 patients in the intermediate-risk group and 3 
patients in the low-risk group). Preoperative selenium was lower in patients 
who developed POAF compared with those with normal sinus rhythm (0.73±0.16 
vs 0.89±0.13 μmol/l, P=0.005), and this was independently associated with 
POAF (PR 0.32; 95% confidence credible interval (95%cI) 0.06–0.85, P=0.016). 
Regardless of POAF, preoperative selenium was lower in the intermediate-risk 
patients than in the low-risk patients (0.77±0.15 vs 0.89±0.14 μmol/l; 
P=0.004).Conclusions:Intermediate-risk patients with low preoperative 
selenium levels may be at a greater risk of developing POAF following CABG. 
This raises the question of whether selenium supplementation in select 
cardiac surgical patients may reduce their POAF risk.European Journal of 
Clinical Nutrition advance online publication, 13 July 2016; 
doi:10.1038/ejcn.2016.125.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  selenium
EMTREE DRUG INDEX TERMS
  glutathione peroxidase
  malonaldehyde
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  coronary artery bypass graft
EMTREE MEDICAL INDEX TERMS
  anesthesia induction
  cardiopulmonary bypass
  clamp
  clinical article
  clinical trial
  controlled study
  gene expression
  human
  human tissue
  intermediate risk patient
  intermediate risk population
  low risk patient
  low risk population
  multivariate logistic regression analysis
  nutrition
  plasma
  publication
  sinus rhythm
  Society of Thoracic Surgeons score
  surgery
  surgical patient
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160523219
FULL TEXT LINK
  http://dx.doi.org/10.1038/ejcn.2016.125
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 12
TITLE
  Evaluation of the effects of olodaterol on exercise endurance in patients 
with chronic obstructive pulmonary disease: Results from two 6-week 
crossover studies
AUTHOR NAMES
  Maltais F.
  Kirsten A.-M.
  Hamilton A.
  De Sousa D.
  Voß F.
  Decramer M.
AUTHOR ADDRESSES
  (Maltais F., Francois.Maltais@fmed.ulaval.ca) Centre de Recherche, Institut 
Universitaire de Cardiologie et de Pneumologie de Québec, 2725 Chemin Sainte 
Foy, , Canada.
(Kirsten A.-M.) Member of the German Center for Lung Research, Pulmonary 
Research Institute at Lung Clinic Grosshansdorf, Airway Research Center 
North, Grosshansdorf, Germany.
(Hamilton A.; De Sousa D.) Boehringer Ingelheim, Burlington, Canada.
(Voß F.) Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany.
(Decramer M.) University Hospitals Leuven, Department of Pulmonology, 
Leuven, Belgium.
CORRESPONDENCE ADDRESS
  F. Maltais, Centre de Recherche, Institut Universitaire de Cardiologie et de 
Pneumologie de Québec, 2725 Chemin Sainte Foy, , Canada. Email: 
Francois.Maltais@fmed.ulaval.ca
SOURCE
  Respiratory Research (2016) 17:1 Article Number: 77. Date of Publication: 6 
Jul 2016
ISSN
  1465-993X (electronic)
  1465-9921
BOOK PUBLISHER
  BioMed Central Ltd., info@biomedcentral.com
ABSTRACT
  Background: Two replicate, double-blind, placebo-controlled, 6-week 
crossover studies assessed the effect of the once-daily long-acting 
β(2)-agonist olodaterol 5 μg and 10 μg on constant work-rate cycle endurance 
in patients with moderate to very severe chronic obstructive pulmonary 
disease. Methods: Patients received placebo, olodaterol 5 μg once daily (QD) 
and olodaterol 10 μg QD in a randomised order for 6 weeks each, with a 
2-week washout period in between. The primary end point was change in 
endurance time during constant work-rate cycle ergometry to symptom 
limitation at 75 % maximal work capacity after 6 weeks of treatment (2 h 
post-dose), based on log(10)-transformed data. Key secondary end points were 
inspiratory capacity at isotime and intensity of breathing discomfort at 
isotime. Results: 151 and 157 patients were randomised and treated in 
Studies 1222.37 and 1222.38, respectively, with 147 and 154 being included 
in the full analysis sets. Mean endurance time at week 6 was increased 
compared to placebo by 14.0 % (Study 1222.37; p < 0.001) and 11.8 % (Study 
1222.38; p < 0.01) with olodaterol 5 μg, and by 13.8 % (Study 1222.37; p < 
0.001) and 10.5 % (Study 1222.38; p < 0.01) with olodaterol 10 μg. 
Inspiratory capacity at isotime increased with olodaterol 5 μg (Study 
1222.37, 0.182 L, p < 0.0001; Study 1222.38, 0.084 L, p < 0.05) and 10 μg 
(Study 1222.37, 0.174 L; Study 1222.38, 0.166 L; both studies, p < 0.0001), 
and breathing discomfort was significantly reduced in Study 1222.37 
(olodaterol 5 μg, 0.77 Borg units, p < 0.001; olodaterol 10 μg, 0.63 Borg 
units, p < 0.01) but not Study 1222.38. Conclusions: These studies provide 
further characterisation of the efficacy of olodaterol, showing that 
improvements in airflow (forced expiratory volume in 1 s) are associated 
with increases in inspiratory capacity and improvements in exercise 
endurance time. Trial registrations:NCT01040130(1222.37) and 
NCT01040793(1222.38).
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  olodaterol (adverse drug reaction, clinical trial, drug comparison - 
placebo, drug therapy, inhalational drug administration)
EMTREE DRUG INDEX TERMS
  placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  chronic obstructive lung disease (drug therapy, drug therapy)
  endurance
  exercise
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation (side effect)
  bicycle ergometry
  coughing (side effect)
  disease exacerbation (side effect)
  drug dose comparison
  drug efficacy
  drug withdrawal
  dyspnea (side effect)
  female
  forced expiratory volume
  functional residual capacity
  headache (side effect)
  human
  hyperinflation
  insomnia (side effect)
  inspiratory capacity
  major clinical study
  male
  multicenter study (topic)
  oropharynx pain (side effect)
  randomized controlled trial (topic)
  rhinopharyngitis (side effect)
  soft mist inhaler
DEVICE TRADE NAMES
  Respimat
CAS REGISTRY NUMBERS
  olodaterol (868049-49-4, 869477-96-3)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT01040130, NCT01040793)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160508803
FULL TEXT LINK
  http://dx.doi.org/10.1186/s12931-016-0389-5
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 13
TITLE
  Phenotype-specific treatment of heart failure with preserved ejection 
fraction
AUTHOR NAMES
  Shah S.J.
  Kitzman D.W.
  Borlaug B.A.
  Van Heerebeek L.
  Zile M.R.
  Kass D.A.
  Paulus W.J.
AUTHOR ADDRESSES
  (Shah S.J.) Division of Cardiology, Feinberg Cardiovascular Research 
Institute, Northwestern University Feinberg School of Medicine, Chicago, 
United States.
(Kitzman D.W.) Sections on Cardiovascular Medicine and Geriatrics, Wake 
Forest School of Medicine, Winston-Salem, United States.
(Borlaug B.A.) Division of Cardiovascular Diseases, Department of Internal 
Medicine, Mayo Clinic, Rochester, United States.
(Van Heerebeek L.; Paulus W.J., wj.paulus@vumc.nl) Department of Physiology, 
Institute for Cardiovascular Research, VU University Medical Center, 
Amsterdam, Netherlands.
(Van Heerebeek L.) Department of Cardiology, Onze Lieve Vrouw Gasthuis, 
Amsterdam, Netherlands.
(Zile M.R.) Department of Medicine, Medical University of South Carolina 
(MUSC), RHJ Department of Veterans Affairs Medical Center, Charleston, 
United States.
(Kass D.A.) Division of Cardiology, Department of Medicine, Johns Hopkins 
Medical Institutions, Baltimore, United States.
CORRESPONDENCE ADDRESS
  W.J. Paulus, Department of Physiology, Institute for Cardiovascular 
Research, VU University Medical Center, Amsterdam, Netherlands. Email: 
wj.paulus@vumc.nl
SOURCE
  Circulation (2016) 134:1 (73-90). Date of Publication: 5 Jul 2016
ISSN
  1524-4539 (electronic)
  0009-7322
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 
50% of HF cases, and its prevalence relative to HF with reduced EF continues 
to rise. In contrast to HF with reduced EF, large trials testing 
neurohumoral inhibition in HFpEF failed to reach a positive outcome. This 
failure was recently attributed to distinct systemic and myocardial 
signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an 
HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling 
and phenotypic diversity. In HFpEF, extracardiac comorbidities such as 
metabolic risk, arterial hypertension, and renal insufficiency drive left 
ventricular remodeling and dysfunction through systemic inflammation and 
coronary microvascular endothelial dysfunction. The latter affects left 
ventricular diastolic dysfunction through macrophage infiltration, resulting 
in interstitial fibrosis, and through altered paracrine signaling to 
cardiomyocytes, which become hypertrophied and stiff because of low nitric 
oxide and cyclic guanosine monophosphate. Systemic inflammation also affects 
other organs such as lungs, skeletal muscle, and kidneys, leading, 
respectively, to pulmonary hypertension, muscle weakness, and sodium 
retention. Individual steps of these signaling cascades can be targeted by 
specific interventions: metabolic risk by caloric restriction, systemic 
inflammation by statins, pulmonary hypertension by phosphodiesterase 5 
inhibitors, muscle weakness by exercise training, sodium retention by 
diuretics and monitoring devices, myocardial nitric oxide bioavailability by 
inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content 
by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by 
spironolactone. Because of phenotypic diversity in HFpEF, personalized 
therapeutic strategies are proposed, which are configured in a matrix with 
HFpEF presentations in the abscissa and HFpEF predispositions in the 
ordinate.
EMTREE DRUG INDEX TERMS
  cyclic GMP (endogenous compound)
  diuretic agent (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  membrane metalloendopeptidase (endogenous compound)
  nitrate
  nitric oxide (endogenous compound)
  nitrite
  phosphodiesterase V inhibitor
  sacubitril (drug therapy)
  spironolactone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure with preserved ejection fraction (drug therapy, drug therapy)
  phenotype
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  caloric restriction
  chronotropism
  comorbidity
  coronary artery disease
  disease predisposition
  endothelial dysfunction
  exercise
  fibrosing alveolitis
  heart left ventricle function
  heart muscle fibrosis
  heart ventricle remodeling
  human
  hypertension
  kidney
  kidney failure
  left ventricular diastolic dysfunction
  lung
  lung congestion
  muscle weakness
  paracrine signaling
  priority journal
  pulmonary hypertension
  skeletal muscle
  sodium retention
CAS REGISTRY NUMBERS
  cyclic GMP (7665-99-8)
  membrane metalloendopeptidase (82707-54-8, 88201-55-2)
  nitrate (14797-55-8)
  nitric oxide (10102-43-9)
  nitrite (14797-65-0)
  sacubitril (149709-62-6)
  spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160502544
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021884
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 14
TITLE
  Evaluation of SAMe-TT(2)R(2) score and other clinical factors influencing 
the quality of anticoagulation therapy in non-valvular atrial fibrillation: 
A nationwide study in Spain
AUTHOR NAMES
  Lobos-Bejarano J.M.
  Barrios V.
  Polo-García J.
  Escobar C.
  Vargas-Ortega D.
  Marín-Montañés N.
  Prieto-Valiente L.
  Fuentes S.
  Prieto M.A.
  García-Ortiz L.
AUTHOR ADDRESSES
  (Lobos-Bejarano J.M., jmlobos@gmail.com) Jazmin Primary Care Health Center, 
East Area Primary Care, Madrid, Spain.
(Barrios V.) Cardiology Department, University Hospital Ramon y Cajal, 
Madrid, Spain.
(Polo-García J.) Primary Care Health Center Casar de Cáceres, Cáceres, 
Spain.
(Escobar C.) Cardiology Department, University Hospital La Paz, Madrid, 
Spain.
(Vargas-Ortega D.) High Resolution Hospitalization Unit, Hospital el Toyo, 
Hospital de Poniente El Ejido, Almeria, Spain.
(Marín-Montañés N.) Medical Department, Bayer Hispania, Barcelona, Spain.
(Prieto-Valiente L.) Medical Biostatistics, Universidad Católica San Antonio 
de Murcia, Murcia, Spain.
(Fuentes S.) Primary Care Health Center, Barcelona, Spain.
(Prieto M.A.) Vallobín-La Florida Primary Care Health Center, Oviedo, Spain.
(Prieto M.A.) Medicine Preventive Department, Oviedo University, Spain.
(García-Ortiz L.) Unit of Clinical Research La Alamedilla, Salamanca, Spain.
()
CORRESPONDENCE ADDRESS
  J.M. Lobos-Bejarano, Jazmin Primary Care Health Center, Calle del Jazmin 33, 
Madrid, Spain. Email: jmlobos@gmail.com
SOURCE
  Current Medical Research and Opinion (2016) 32:7 (1201-1207). Date of 
Publication: 2 Jul 2016
ISSN
  1473-4877 (electronic)
  0300-7995
BOOK PUBLISHER
  Taylor and Francis Ltd, healthcare.enquiries@informa.com
ABSTRACT
  Objective: To assess the major clinical factors affecting the quality of 
anticoagulation and evaluate the predictive value of the SAMe-TT(2)R(2) 
score to identify patients who will achieve a high average time in 
therapeutic range (T.T.R.) with vitamin K antagonist (V.K.A.) treatment. 
Research design and methods: This observational, cross-sectional, 
retrospective and nationwide multicenter study included 1524 patients from 
the primary care setting with non-valvular atrial fibrillation receiving 
V.K.A. (≥12 months). We performed a bivariate analysis to identify factors 
individually associated with the T.T.R. and a multiple regression analysis 
to identify the independent predictive factors. For the validation of the 
SAMe-TT(2)R(2) score, the receiver operating characteristic (R.O.C.) curve 
was calculated and the Hosmer–Lemeshow test was used to test calibration. 
Results: A total of 94.8% of patients received acenocumarol (4.8% warfarin). 
A progressive decrease in mean T.T.R. was found when the SAMe-TT(2)R(2) 
score increased from 0 points (72.1 ± 17.1%) to 4 points (64.1 ± 23.2%), p < 
0.001. Other risk scores (CHADS(2) and CHA(2)DS(2)-VASc, HAS-BLED) were also 
associated with the mean T.T.R. We found a significant association between 
low T.T.R. and the following clinical factors: female sex, three or more 
comorbidities, amiodarone treatment, dietary habits, bleeding history and 
the intake of ≥7 tablets per day besides V.K.A. (p < 0.01). Regarding 
SAMe-TT(2)R(2) score validation, the R.O.C. curve showed significant 
capability, although not high, of discriminating good anticoagulation 
control (T.T.R. ≥65%) with an area under the curve of 0.562 (95% C.I. 
0.533–0.592, p < 0.001) which increased, remaining modest, to 0.594 (95% 
C.I. 0.564–0.624, p < 0.001) when the factors not included in SAMe-TT(2)R(2) 
score were added. Conclusion: In this cohort, the SAMe-TT(2)R(2) score had a 
significant, although modest, ability to assess the likelihood of good 
international normalized ration (I.N.R.) control, and its predictive value 
might slightly improve by adding other simple clinical factors. Further 
research is needed to refine the predictive scales.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (drug therapy)
EMTREE DRUG INDEX TERMS
  acenocoumarol (drug therapy)
  amiodarone (drug therapy)
  antivitamin K (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  atrial fibrillation (drug therapy, drug therapy)
  cardiovascular disease assessment
  non valvular atrial fibrillation (drug therapy, drug therapy)
  SAMe TT2R2 score
EMTREE MEDICAL INDEX TERMS
  aged
  article
  bleeding
  CHA2DS2 VASc score
  CHADS2 score
  cohort analysis
  comorbidity assessment
  cross-sectional study
  dietary intake
  female
  HAS BLED score
  human
  major clinical study
  male
  medical history
  multicenter study
  observational study
  predictive value
  primary medical care
  retrospective study
  sex difference
  Spain
  time
CAS REGISTRY NUMBERS
  acenocoumarol (152-72-7)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160288799
FULL TEXT LINK
  http://dx.doi.org/10.1185/03007995.2016.1164676
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 15
TITLE
  The role of comprehensive geriatric assessment and functional status in 
evaluating the patterns of antithrombotic use among older people with atrial 
fibrillation
AUTHOR NAMES
  Mazzone A.
  Bo M.
  Lucenti A.
  Galimberti S.
  Bellelli G.
  Annoni G.
AUTHOR ADDRESSES
  (Mazzone A.; Lucenti A.; Galimberti S.; Bellelli G., 
giuseppe.bellelli@unimib.it; Annoni G.) School of Medicine and Surgery, 
University of Milano-Bicocca, Italy.
(Mazzone A.; Bellelli G., giuseppe.bellelli@unimib.it; Annoni G.) Geriatric 
Unit, S. Gerardo Hospital, Monza, Italy.
(Bellelli G., giuseppe.bellelli@unimib.it; Annoni G.) Milan Center for 
Neuroscience (Neuro-Mi), Milan, Italy.
(Bo M.) SCDU Geriatria e Malattie Metaboliche dell'Osso, Città della Salute 
e della Scienza-Molinette, Torino, Italy.
(Lucenti A.; Galimberti S.) Center of Biostatistics for Clinical 
Epidemiology, University of Milano-Bicocca, Milan, Italy.
(Mazzone A.) Redaelli Geriatric Institute, Milan, Italy.
CORRESPONDENCE ADDRESS
  G. Bellelli, School of Medicine and Surgery, University of Milano-Bicocca, 
Italy. Email: giuseppe.bellelli@unimib.it
SOURCE
  Archives of Gerontology and Geriatrics (2016) 65 (248-254). Date of 
Publication: 1 Jul 2016
ISSN
  1872-6976 (electronic)
  0167-4943
BOOK PUBLISHER
  Elsevier Ireland Ltd
ABSTRACT
  Aim of the study is to investigate the use of antithrombotic drugs in older 
patients with atrial fibrillation (AF) at the time of hospital discharge. We 
enrolled 399 ≥65 years old patients with AF consecutively admitted to our 
acute geriatric unit from September 2012 to February 2014. Utilization of 
antithrombotic drugs, comorbidities, functional, mental and nutritional 
status were evaluated through a comprehensive geriatric assessment (CGA). A 
Logistic regression model was used to assess variables associated with 
antithrombotic use. On admission, 198 patients (49.6%) used oral 
anticoagulants (OAC), 125 (21.3%) antiplatelets, 32 (8%) low weight 
molecular heparin (LMWH) and 44 (11%) none of them. At discharge the 
proportion of patients on OAC increased to 55.7%. Age > 90 years (OR = 2.57, 
CI = 1.28-5.16, p-value = 0.008), severe functional impairment (OR = 3.38, 
CI = 1.63-7.01, p-value = 0.001), polypharmacy (OR = 2.07, CI = 1.1-3.86, 
p-value = 0.023), HAS-BLED score (OR = 1.64, CI = 1.09-2.47, p-value = 
0.019) and ≥1 OAC contraindication (OR = 5.01, CI = 2.68-9.34, p-value < 
0.001) were all associated with OAC underuse.In conclusion, OAC is underused 
in geriatric patients with AF, while antiplatelet, LMWH and no 
antithrombotic therapy are relatively overused. Factors associated with the 
decision to not prescribe OAC lie on a mix of clinical and geriatric 
variables, among which functional status is particularly relevant.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (drug therapy, oral drug administration)
EMTREE DRUG INDEX TERMS
  acenocoumarol (drug therapy)
  acetylsalicylic acid (drug therapy)
  angiotensin receptor antagonist
  antithrombocytic agent (drug therapy)
  beta adrenergic receptor blocking agent
  calcium channel blocking agent
  clopidogrel (drug therapy)
  dipeptidyl carboxypeptidase inhibitor
  dipyridamole (drug therapy)
  diuretic agent
  enoxaparin (drug therapy)
  glyceryl trinitrate (transdermal drug administration)
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  nadroparin (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  drug use
  functional assessment
  functional status
  geriatric assessment
EMTREE MEDICAL INDEX TERMS
  aged
  article
  cohort analysis
  comorbidity
  controlled study
  disease severity
  drug contraindication
  drug utilization
  emergency ward
  female
  functional disease
  hospital admission
  hospital discharge
  human
  major clinical study
  male
  mental health
  nutritional status
  observational study
  polypharmacy
  priority journal
  retrospective study
  thromboembolism (drug therapy)
  very elderly
CAS REGISTRY NUMBERS
  acenocoumarol (152-72-7)
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  dipyridamole (58-32-2)
  enoxaparin (679809-58-6)
  glyceryl trinitrate (55-63-0, 80738-44-9)
  nadroparin (104521-37-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160330164
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.archger.2016.04.008
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 16
TITLE
  The effects of rikkunshito on body weight loss after esophagectomy
AUTHOR NAMES
  Nakamura M.
  Nakamori M.
  Ojima T.
  Katsuda M.
  Hayata K.
  Iwahashi M.
  Yamaue H.
AUTHOR ADDRESSES
  (Nakamura M.; Nakamori M.; Ojima T.; Katsuda M.; Hayata K.; Iwahashi M.; 
Yamaue H., yamaue-h@wakayama-med.ac.jp) Second Department of Surgery, 
Wakayama Medical University, School of Medicine, Wakayama, Japan.
CORRESPONDENCE ADDRESS
  H. Yamaue, Second Department of Surgery, Wakayama Medical University, School 
of Medicine, Wakayama, Japan. Email: yamaue-h@wakayama-med.ac.jp
SOURCE
  Journal of Surgical Research (2016) 204:1 (130-138). Date of Publication: 1 
Jul 2016
ISSN
  1095-8673 (electronic)
  0022-4804
BOOK PUBLISHER
  Academic Press Inc., apjcs@harcourt.com
ABSTRACT
  Background After esophagectomy, esophageal cancer patients suffer from 
malnutrition, anorexia, and dysfunction of digestion and absorption. 
Rikkunshito, a traditional Japanese herbal medicine, reportedly attenuates 
gastrointestinal symptoms and appetite loss after gastrointestinal surgery. 
We evaluated the clinical effect of rikkunshito and its relationship with 
ghrelin in esophageal cancer patients after esophagectomy. Methods This 
prospective nonrandomized study included 40 patients with esophageal cancer 
who underwent esophagectomy at Wakayama Medical University Hospital. They 
were assigned to either the control group (n = 20, April 2011-January 2012) 
or the rikkunshito group (n = 20, January 2012-August 2012). Patients in the 
rikkunshito group received 2.5 g of rikkunshito before every meal for 48 wk 
beginning 4 wk after surgery. During the 48-week treatment, we assessed body 
weight loss, nutritional parameters, and quality of life (Functional 
Assessment of Cancer Therapy-Esophageal scale). The primary end point was 
the rate of body weight loss in two groups after the 48-week treatments. 
Results The rate of body weight loss was significantly less in the 
rikkunshito group than in the control group (P = 0.016). The acyl ghrelin 
level after the 48-week treatments was significantly higher in the 
rikkunshito group (131.7% ± 74.5%) than in the control group (75.6% ± 47.5%, 
P = 0.039). For the Functional Assessment of Cancer Therapy-Esophageal 
symptom scale, satisfaction of food consumption in the rikkunshito group was 
significantly better than in the control group at 52 wk postoperatively (P = 
0.031). Conclusions For esophageal cancer patients after esophagectomy, 
rikkunshito is useful for improving body weight loss in connection with an 
increase in plasma acyl ghrelin levels.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  prokinetic agent (drug development, pharmacology)
  rikkunshito (drug development, pharmacology)
EMTREE DRUG INDEX TERMS
  unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  esophagus resection
  weight reduction
EMTREE MEDICAL INDEX TERMS
  adjuvant therapy
  adult
  aged
  angina pectoris (complication)
  anorexia
  article
  asthma (complication)
  Atractylodis lanceae rhizoma
  atrial fibrillation (complication)
  Aurantii nobilis pericarpium
  cancer adjuvant therapy
  cancer patient
  cancer surgery
  cholecystitis (complication)
  clinical article
  comparative study
  controlled study
  esophagus cancer (surgery)
  female
  follow up
  food intake
  functional assessment
  ginger
  ginseng
  Glycyrrhiza
  herbal medicine
  Hoelen
  human
  loss of appetite
  male
  malnutrition
  medicinal plant
  pericardial effusion (complication)
  Pinelliae tuber
  pneumonia (complication)
  postoperative complication (complication)
  priority journal
  prospective study
  quality of life
  recurrent laryngeal nerve palsy (complication)
  surgical patient
  treatment duration
  Zizyphi fructus
DRUG TRADE NAMES
  rikkunshito  , JapanTsumura

DRUG MANUFACTURERS
   (Japan)Tsumura
EMBASE CLASSIFICATIONS
  Otorhinolaryngology (11)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160384772
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jss.2016.04.004
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 17
TITLE
  A patient with parenteral nutrition-dependent short bowel syndrome and 
cardiovascular disease with 4-year exposure to teduglutide
AUTHOR NAMES
  Compher C.
  Levinson K.B.
  Cambor C.L.
  Stoner N.
  Boullata J.I.
  Piarulli A.
  Kinosian B.
AUTHOR ADDRESSES
  (Compher C., compherc@nursing.upenn.edu; Boullata J.I.; Piarulli A.) 
University of Pennsylvania, School of Nursing, Claire M. Fagin Hall, 331, 
418 Curie Blvd, Philadelphia, United States.
(Compher C., compherc@nursing.upenn.edu; Levinson K.B.; Cambor C.L.; 
Kinosian B.) University of Pennsylvania, Perelman School of Medicine, 
Philadelphia, United States.
(Compher C., compherc@nursing.upenn.edu; Stoner N.; Boullata J.I.; Kinosian 
B.) Hospital of the University of Pennsylvania, Clinical Nutrition Support 
Service, Philadelphia, United States.
(Levinson K.B.; Cambor C.L.) Hospital of the University of Pennsylvania, 
Department of Pathology and Laboratory Medicine, Philadelphia, United 
States.
(Kinosian B.) Department of Medicine, University of Pennsylvania, 
Philadelphia, United States.
CORRESPONDENCE ADDRESS
  C. Compher, University of Pennsylvania, School of Nursing, Claire M. Fagin 
Hall, 331, 418 Curie Blvd, Philadelphia, United States. Email: 
compherc@nursing.upenn.edu
SOURCE
  Journal of Parenteral and Enteral Nutrition (2016) 40:5 (725-729). Date of 
Publication: 1 Jul 2016
ISSN
  1941-2444 (electronic)
  0148-6071
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  Clinical trials of the glucagon-like peptide 2 analogue teduglutide resulted 
in approval of the drug by the Food and Drug Administration in 2012 as a 
treatment for parenteral nutrition-dependent short bowel syndrome in adults. 
This report presents the case study of a man with short bowel syndrome 
caused by portal vein thrombosis who had 4 years exposure to the drug at the 
time of his death due to cardiovascular disease.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  teduglutide (adverse drug reaction, clinical trial, drug therapy, 
subcutaneous drug administration)
EMTREE DRUG INDEX TERMS
  amino acid
  amiodarone (drug therapy)
  antibiotic agent (drug therapy, intravenous drug administration)
  brain natriuretic peptide (endogenous compound)
  C reactive protein (endogenous compound)
  cholesterol (endogenous compound)
  cimetidine
  creatinine (endogenous compound)
  electrolyte
  enoxaparin (drug therapy)
  glucose
  lipid
  loperamide
  sodium (endogenous compound)
  sodium chloride
  trace element
  triacylglycerol (endogenous compound)
  vancomycin (adverse drug reaction, drug therapy, intravenous drug 
administration)
  vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease
  drug exposure
  long term care
  long term exposure
  parenteral nutrition
  short bowel syndrome (drug therapy, complication, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal aorta
  abdominal aorta aneurysm
  abdominal radiography
  acute abdomen
  acute cholecystitis (surgery)
  adenomatous polyp
  adult
  antibiotic therapy
  aorta atherosclerosis
  aortography
  arm weakness
  arousal
  article
  atherosclerotic plaque
  atrial fibrillation (drug therapy)
  bacteremia (drug therapy)
  body mass
  cardioversion
  case report
  catheter infection (complication, drug therapy)
  catheter removal
  central venous catheter (adverse device effect)
  cholecystectomy
  cholelithiasis
  cholesterol blood level
  chronic cholecystitis (surgery)
  colon resection
  congestive heart failure
  coronary artery atherosclerosis
  creatinine blood level
  dehydration
  dizziness
  drug efficacy
  drug safety
  dry weight
  dyspnea (side effect)
  echocardiography
  electrocardiogram
  fatigue
  fluid intake
  food intake
  heart function
  heart left ventricle ejection fraction
  Hickman catheter
  home care
  hospital admission
  hospitalization
  human
  hypomania
  ileum resection
  increased appetite
  intestine necrosis (complication)
  jejunostomy
  length of stay
  liver nodule
  male
  medication compliance
  middle aged
  mitral valve regurgitation
  nuclear magnetic resonance imaging
  osteomyelitis
  pain severity
  patient compliance
  peripherally inserted central venous catheter
  phase 3 clinical trial (topic)
  portal vein thrombosis
  priority journal
  psoriasis
  randomized controlled trial (topic)
  rectum polyp
  side effect (side effect)
  sigmoidoscopy
  smoking
  sodium urine level
  sudden cardiac death
  suppuration (complication)
  tachycardia (therapy)
  tachycardia induced cardiomyopathy
  thorax pain
  triacylglycerol blood level
  ultrasound
  urea nitrogen blood level
  urine volume
  virus myocarditis
  weight gain
  weight reduction
DRUG TRADE NAMES
  gattex  , United StatesNPS

DRUG MANUFACTURERS
   (United States)NPS
CAS REGISTRY NUMBERS
  amino acid (65072-01-7)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  brain natriuretic peptide (114471-18-0)
  C reactive protein (9007-41-4)
  cholesterol (57-88-5)
  cimetidine (51481-61-9, 70059-30-2)
  creatinine (19230-81-0, 60-27-5)
  enoxaparin (679809-58-6)
  glucose (50-99-7, 84778-64-3)
  lipid (66455-18-3)
  loperamide (34552-83-5, 53179-11-6)
  sodium (7440-23-5)
  sodium chloride (7647-14-5)
  teduglutide (197922-42-2, 287714-30-1)
  vancomycin (1404-90-6, 1404-93-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160482001
FULL TEXT LINK
  http://dx.doi.org/10.1177/0148607114566466
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 18
TITLE
  NOAC monitoring, reversal agents, and post-approval safety and effectiveness 
evaluation: A cardiac safety research consortium think tank
AUTHOR NAMES
  Reiffel J.A.
  Weitz J.I.
  Reilly P.
  Kaminskas E.
  Sarich T.
  Sager P.
  Seltzer J.
AUTHOR ADDRESSES
  (Reiffel J.A., jar2@cumc.columbia.edu) Columbia University, New York, United 
States.
(Weitz J.I.) McMaster University, Thrombosis and Atherosclerosis Research 
Institute, Canada.
(Reilly P.) Employee of Boehringer Ingelheim Pharmaceuticals, Ridgefield, 
United States.
(Kaminskas E.) Division of Hematology Products, CDER, FDA, Silver Springs, 
United States.
(Sarich T.) Employee of Janssen Scientific Affairs, LLC, Titusville, United 
States.
(Sager P.) Stanford University, Sager Consulting Experts, San Francisco, 
United States.
(Seltzer J.) ACI Clinical and Lankenau Heart Institute, Wynnewood, United 
States.
CORRESPONDENCE ADDRESS
  J.A. Reiffel, Columbia University, c/o 202 Birkdale Lane, Jupiter, United 
States. Email: jar2@cumc.columbia.edu
SOURCE
  American Heart Journal (2016) 177 (74-86). Date of Publication: 1 Jul 2016
ISSN
  1097-6744 (electronic)
  0002-8703
BOOK PUBLISHER
  Mosby Inc., customerservice@mosby.com
ABSTRACT
  Four non-vitamin K antagonist oral anticoagulants (dabigatran, rivaroxaban, 
apixaban, and edoxaban) have been approved in the United States for 
treatment of atrial fibrillation (AF) and venous thromboembolic disease. 
They have been as or more effective than the prior standards of care, with 
less fatal or intracranial bleeding, fewer drug and dietary interactions, 
and greater patient convenience. Nonetheless, the absence of the ability for 
clinicians to assess compliance or washout with a simple laboratory test (or 
to adjust dosing with a similar assessment) and the absence of an antidote 
to rapidly stop major hemorrhage or to enhance safety in the setting of 
emergent or urgent surgery/procedures have been limitations to greater 
non-vitamin K antagonist oral anticoagulant usage and better thromboembolic 
prevention. Accordingly, a Cardiac Research Safety Consortium "think tank" 
meeting was held in February 2015 to address these concerns. This manuscript 
reports on the discussions held and the conclusions reached at that meeting.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (oral drug administration)
  non vitamin K antagonist oral anticoagulant (oral drug administration)
EMTREE DRUG INDEX TERMS
  antidote
  unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  drug monitoring
EMTREE MEDICAL INDEX TERMS
  anticoagulation
  drug antigenicity
  drug approval
  drug efficacy
  drug indication
  drug safety
  food and drug administration
  human
  nonhuman
  phase 1 clinical trial (topic)
  phase 2 clinical trial (topic)
  phase 3 clinical trial (topic)
  phase 4 clinical trial (topic)
  postmarketing surveillance
  priority journal
  randomized controlled trial (topic)
  review
  risk benefit analysis
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160433791
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ahj.2016.04.010
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 19
TITLE
  Temporary transvenous pacemaker implantation during carotid endarterectomy 
in patients with trifascicular block
AUTHOR NAMES
  Marrocco-Trischitta M.M.
  Mazzone P.
  Vitale R.
  Regazzoli D.
  Laricchia A.
  Chiesa R.
AUTHOR ADDRESSES
  (Marrocco-Trischitta M.M., max_marrocco@yahoo.com; Vitale R.; Chiesa R.) 
Cardiothoracic and Vascular Department, Vascular Surgery Unit, IRCCS 
Ospedale San Raffaele, Via Olgettina, 60, Milan, Italy.
(Mazzone P.; Regazzoli D.) Cardiothoracic and Vascular Department, 
Arrhythmology and Cardiac Pacing Unit, IRCCS Ospedale San Raffaele, Milano, 
Italy.
(Laricchia A.) Cardiothoracic and Vascular Department, Cardiology Unit, 
IRCCS Ospedale San Raffaele, Milano, Italy.
(Chiesa R.) Cardiothoracic and Vascular Department, IRCCS Ospedale San 
Raffaele, Università Vita-Salute San Raffaele, Milano, Italy.
CORRESPONDENCE ADDRESS
  M.M. Marrocco-Trischitta, Cardiothoracic and Vascular Department, Vascular 
Surgery Unit, IRCCS Ospedale San Raffaele, Via Olgettina, 60, Milan, Italy. 
Email: max_marrocco@yahoo.com
SOURCE
  Annals of Vascular Surgery (2016) 34 (206-211). Date of Publication: 1 Jul 
2016
ISSN
  1615-5947 (electronic)
  0890-5096
BOOK PUBLISHER
  Elsevier Inc., usjcs@elsevier.com
ABSTRACT
  Background The risk of severe perioperative bradyarrhythmias in patients 
with chronic left bundle branch, or bifascicular block, and an additional 
first-degree atrioventricular block undergoing carotid endarterectomy (CEA) 
has never been specifically addressed. In this study, we aimed to 
investigate whether these conduction abnormalities entail an increased risk 
of hemodynamic compromise during CEA and the role of temporary transvenous 
pacemaker (TTVPM) implantation as a prophylactic measure in this subgroup of 
patients. Methods Between June 2006 and June 2013, 37 CEAs were performed in 
31 patients (29 men, mean age 76 ± 6 years), in whom a TTVPM was implanted 
for a trifascicular block. Thirty-seven concurrent, consecutive patients 
operated for other vascular pathologies also with a prophylactic TTVPM for 
an asymptomatic trifascicular block served as controls. Adverse events were 
considered: pacemaker activation, block progression, bradycardia ≤40 
beats/min, and asystole. Results Study and control groups were overall 
comparable. No perioperative mortality was recorded. All patients undergoing 
CEA were asymptomatic for syncope preoperatively. Among them, in 34 cases, 
indication for TTVPM was based on preoperative EKG, and in 4, a pacemaker 
activation was recorded. Three additional patients were also included in the 
study group in whom TTVPM was implanted due to the occurrence of adverse 
advents, and not prophylactically. In 2 of these, severe bradycardia with 
eventual asystole occurred intraoperatively. In both cases, the procedure 
was discontinued and rescheduled for the following day after a TTVPM was 
implanted. In the last additional case, the patient had a block progression 
on day 1 after an uneventful CEA and was emergently treated with a TTVPM. 
Overall, 7 adverse events were recorded in the study group, and none in the 
control group (P < 0.011). Morbidity in the CEA group also included 1 
myocardial infarction, 1 minor stroke, 1 surgical revision for cervical 
hematoma, 1 new-onset atrial fibrillation, and 1 femoral artery 
pseudoaneurysm. Conclusions In our experience, TTVPM implantation was a 
clinically useful adjunct in patients with trifascicular block submitted to 
CEA, as compared with other vascular surgical procedures. However, the risks 
inherent to CEA in this subgroup of patients suggest that surgical treatment 
may not be warranted for those with asymptomatic carotid disease.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrioventricular block (surgery)
  carotid endarterectomy
  pacemaker implantation
  temporary transvenous pacemaker implantation
  trifascicular block (surgery)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  bradycardia (complication)
  cardiac patient
  cardiovascular mortality
  cerebrovascular accident
  clinical article
  comparative study
  controlled study
  faintness
  false aneurysm
  female
  glomerulus filtration rate
  heart arrest (complication)
  heart infarction
  hematoma
  human
  male
  morbidity
  New York Heart Association class
  new-onset atrial fibrillation
  peroperative complication (complication)
  priority journal
  retrospective study
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160421732
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.avsg.2015.12.025
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 20
TITLE
  Characterization of the Myocarditis during the worst outbreak of dengue 
infection in China
AUTHOR NAMES
  Li Y.
  Hu Z.
  Huang Y.
  Li J.
  Hong W.
  Qin Z.
  Tong Y.
  Li J.
  Lv M.
  Li M.
  Zheng X.
  Hu J.
  Hua J.
  Zhang F.
  Xu D.-L.
AUTHOR ADDRESSES
  (Li Y.; Huang Y.; Hua J.; Xu D.-L., dinglixu@fimmu.com) State Key Laboratory 
of Organ Failure Research, Department of Cardiology, Nanfang Hospital, 
Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, China.
(Li Y.; Hu Z.; Qin Z.; Tong Y.; Li J.; Lv M.; Li M.) Department of 
Cardiology, Guangzhou 8th People's Hospital, Guangzhou Medical University, 
China.
(Li J.; Hong W.; Zhang F.) Department of Infectious Disease, Guangzhou 8th 
People's Hospital, Guangzhou Medical University, China.
(Zheng X.) Department of Pathology, First Affiliated Hospital, China.
(Hu J.) Department of Microbiology, Zhongshan School of Medicine, Sun 
Yat-Sen University, Guangzhou, China.
CORRESPONDENCE ADDRESS
  D.-L. Xu, State Key Laboratory of Organ Failure Research, Department of 
Cardiology, Nanfang Hospital, Southern Medical University, 1838 North 
Guangzhou Avenue, Guangzhou, China. Email: dinglixu@fimmu.com
SOURCE
  Medicine (United States) (2016) 95:27 Article Number: e4051. Date of 
Publication: 1 Jul 2016
ISSN
  1536-5964 (electronic)
  0025-7974
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Myocarditis is a common complication of severe dengue infection. However, 
data about prevalence and characterization of myocarditis in dengue are 
still lacking. In 2014, the worst outbreak of dengue in the last two decades 
in China occurred. In this study, we described the clinical and laboratory 
diagnostic features of dengue with myocarditis. Totally, 1782 diagnosed 
dengue patients were admitted from August to October, 2014, all of whom were 
subjected to electrocardiogram, ultrasound cardiogram, and cardiac enzyme 
test. About 201 cases of dengue patients were diagnosed with myocarditis and 
the prevalence of myocarditis in hospitalized dengue was 11.28%. The 
prevalence of myocarditis in nonsevere dengue with warning signs and severe 
dengue [NSD(WS+)/SD] and nonsevere dengue without warning signs [NSD(WS-)] 
was 46.66% and 9.72%, respectively. The NSD(WS+)/SD patients with 
myocarditis presented with higher incidence of cardiac symptoms, 
supraventricular tachycardia (14.29% vs. 0%, P < 0.001), atrial fibrillation 
(25.71% vs. 10.24%, P = 0.019) and heart failure compared with NSD (WS-) 
patients with myocarditis. About 150 cases of dengue patients without 
myocarditis in the same period of time in department of Cardiology were 
recruited as control group. The proportion of NSD(WS+)/SD in dengue patients 
with and without myocarditis was 17.41% and 2.53%, respectively. Dengue 
patients with myocarditis experienced longer hospital stay than those 
without myocarditis (7.17 ± 4.64 vs. 5.98 ± 2.69, P = 0.008). There was no 
difference between patients with and without myocarditis in the proportion 
of symptoms, auxiliary methods abnormality, arrhythmia, and heart failure on 
the discharge day. Our study demonstrates the prevalence of myocarditis in 
worst outbreak of dengue in China was 11.28% and the incidence of 
myocarditis increased with the severity of dengue. The NSD(WS+)/SD patients 
with myocarditis presented with higher incidence of cardiac complication 
compared with NSD (WS-) patients with myocarditis. The prognosis of dengue 
patients with and without myocarditis had no significant difference even if 
myocarditis patients experienced longer hospital stay.
EMTREE DRUG INDEX TERMS
  alanine aminotransferase (endogenous compound)
  aspartate aminotransferase (endogenous compound)
  immunoglobulin G (endogenous compound)
  immunoglobulin M (endogenous compound)
  nonstructural protein 1 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  dengue (diagnosis)
  epidemic (diagnosis)
  myocarditis (diagnosis)
EMTREE MEDICAL INDEX TERMS
  abdominal pain
  adult
  alanine aminotransferase blood level
  aphasia
  arthralgia
  article
  aspartate aminotransferase blood level
  atrial fibrillation
  bleeding
  cardiogenic shock
  China
  clinical feature
  coma
  controlled study
  convulsion
  diarrhea
  disease severity
  dyspnea
  ECG abnormality
  electrocardiogram
  enzyme assay
  exercise
  faintness
  female
  headache
  heart arrhythmia
  heart failure
  heart palpitation
  hepatomegaly
  hospitalization
  human
  jaundice
  major clinical study
  male
  middle aged
  myalgia
  outcome assessment
  prevalence
  priority journal
  prognosis
  rapid test
  rash
  sudden cardiac death
  supraventricular tachycardia
  thorax pain
  vomiting
CAS REGISTRY NUMBERS
  alanine aminotransferase (9000-86-6, 9014-30-6)
  aspartate aminotransferase (9000-97-9)
  immunoglobulin G (97794-27-9)
  immunoglobulin M (9007-85-6)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Microbiology: Bacteriology, Mycology, Parasitology and Virology (4)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160540249
FULL TEXT LINK
  http://dx.doi.org/10.1097/MD.0000000000004051
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 21
TITLE
  Catheter ablation versus medical rate control for persistent atrial 
fibrillation in patients with heart failure: A PRISMA-compliant systematic 
review and meta-analysis of randomized controlled trials
AUTHOR NAMES
  Zhu M.
  Zhou X.
  Cai H.
  Wang Z.
  Xu H.
  Chen S.
  Chen J.
  Xu X.
  Xu H.
  Mao W.
AUTHOR ADDRESSES
  (Zhu M.; Zhou X.; Cai H.; Wang Z.; Chen S.; Chen J.; Xu X.; Xu H.; Mao W., 
maoweilw@163.com) Department of Cardiology, First Affiliated Hospital of 
Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
(Xu H.) Department of Pharmacy, Second Affiliated Hospital, Zhejiang 
University School of Medicine, Hangzhou, Zhejiang, China.
CORRESPONDENCE ADDRESS
  W. Mao, Department of Cardiology, First Affiliated Hospital of Zhejiang 
Chinese Medical University, Hangzhou, Zhejiang, China. Email: 
maoweilw@163.com
SOURCE
  Medicine (United States) (2016) 95:30 Article Number: 1857. Date of 
Publication: 1 Jul 2016
ISSN
  1536-5964 (electronic)
  0025-7974
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Background: The effectiveness of restoring the sinus rhythm by catheter 
ablation relative to that of medical rate control for persistent atrial 
fibrillation (AF) patients with heart failure (HF) remains to be defined. 
Methods: We systematically searched Embase, Pubmed, the Cochrane Library, 
and ClinicalTrials.gov for articles that compared the outcomes of interest 
between catheter ablation and medical rate control therapy in persistent AF 
patients with HF and left ventricular systolic dysfunction (LVSD). The 
primary endpoint was the change in the left ventricular ejection fraction 
(LVEF) following catheter ablation or medical rate control therapy relative 
to baseline. Other endpoints included changes in cardiac function and 
exercise capacity, including the New York Heart Association (NYHA) class, 
the brain natriuretic peptide (BNP) level, the peak oxygen consumption (peak 
VO 2), the 6-minute walk test (6MWT) results, and quality of life (QOL). 
Results: Three randomized controlled trials (RCTs) with 143 patients were 
included. At the overall term follow-up, catheter ablation significantly 
improved the LVEF (mean difference [MD]: 6.22%; 95% confidence interval 
[CI]: 0.7-11.74, P = 0.03) and peak VO 2 (MD: 2.81 mL/kg/min; 95% CI: 
0.78-4.85, P = 0.007) and reduced the NYHA class (MD: 0.9; 95% CI: 
0.59-1.21, P < 0.001) and the Minnesota Living with Heart Failure 
Questionnaires (MLHFQ) scores (MD: -11.05; 95% CI: -19.45 - 2.66, P = 0.01) 
compared with the medical rate control for persistent AF patients with HF. 
Alterations in parameters, such as the BNP level, 6MWT, and Short Form-36 
(SF-36) questionnaire scores also revealed trends that favored catheter 
ablation therapy, although these differences were not significant. 
Conclusion: Catheter ablation resulted in improved LVEF, cardiac function, 
exercise capacity, and QOL for persistent AF patients with HF compared with 
the medical rate control strategy.
EMTREE DRUG INDEX TERMS
  brain natriuretic peptide
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  catheter ablation
  left ventricular systolic dysfunction
  persistent atrial fibrillation
EMTREE MEDICAL INDEX TERMS
  aerobic capacity
  Cochrane Library
  confidence interval
  control strategy
  controlled study
  doctor patient relation
  Embase
  exercise
  follow up
  heart left ventricle ejection fraction
  human
  Medline
  meta analysis
  New York Heart Association class
  normal human
  questionnaire
  randomized controlled trial
  Short Form 36
  systematic review
  United States
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160579986
FULL TEXT LINK
  http://dx.doi.org/10.1097/MD.0000000000004377
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 22
TITLE
  Erratum: Deceptive meaning of oxygen uptake measured at the anaerobic 
threshold in patients with systolic heart failure and atrial fibrillation 
(European Journal of Preventive Cardiology (2015) 22 (1046-1055) DOI: 
10.1177/2047487314551546)
AUTHOR ADDRESSES
  SOURCE
  European Journal of Preventive Cardiology (2016) 23:11 (NP97). Date of 
Publication: 1 Jul 2016
ISSN
  2047-4881 (electronic)
  2047-4873
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  In the above paper Gianfranco Parati's affiliation was incorrect, the 
correct version is below: Department of Cardiovascular, Neural and Metabolic 
Sciences, San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy & 
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, 
Italy.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  error
EMTREE MEDICAL INDEX TERMS
  erratum
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160548710
FULL TEXT LINK
  http://dx.doi.org/10.1177/2047487316652336
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 23
TITLE
  Left atrial remodeling, early repolarization pattern, and inflammatory 
cytokines in professional soccer players
AUTHOR NAMES
  Stumpf C.
  Simon M.
  Wilhelm M.
  Zimmermann S.
  Rost C.
  Achenbach S.
  Brem M.H.
AUTHOR ADDRESSES
  (Stumpf C., ch.stumpf@web.de; Simon M.; Wilhelm M.; Zimmermann S.; Rost C.; 
Achenbach S.) Department of Cardiology, University of Erlangen-Nuremberg, 
Erlangen, Germany.
(Wilhelm M.) Division of Cardiovascular Prevention, Rehabilitation and 
Sports Medicine, Inselspital, University Hospital and University of Bern, 
Bern, Switzerland.
(Brem M.H.) Department of Traumatology and Orthopaedy, Nuremberg Hospital 
South, Nuremberg, Germany.
CORRESPONDENCE ADDRESS
  C. Stumpf, Medical Clinic 2, Dept. of Cardiology, University Clinic of 
Erlangen, Ulmenweg 18, Erlangen, Germany. Email: ch.stumpf@web.de
SOURCE
  Journal of Cardiology (2016) 68:1 (64-70). Date of Publication: 1 Jul 2016
ISSN
  1876-4738 (electronic)
  0914-5087
BOOK PUBLISHER
  Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
ABSTRACT
  Objectives: Although regular physical exercise clearly reduces 
cardiovascular morbidity risk, long-term endurance sports practice has been 
recognized as a risk factor for atrial fibrillation (AF). However, the 
mechanisms how endurance sports can lead to AF are not yet clear. The aim of 
our present study was to investigate the influence of long-term endurance 
training on vagal tone, atrial size, and inflammatory profile in 
professional elite soccer players. Methods: A total of 25 professional major 
league soccer players (mean age 24 ± 4 years) and 20 sedentary controls 
(mean age 26 ± 3 years) were included in the study and consecutively 
examined. All subjects underwent a sports cardiology check-up with physical 
examination, electrocardiography, echocardiography, exercise testing on a 
bicycle ergometer, and laboratory analysis [standard laboratory and cytokine 
profile: interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-8, IL-10]. 
Results: Athletes were divided into two groups according to presence or 
absence of an early repolarization (ER) pattern, defined as a ST-segment 
elevation at the J-point (STE) ≥0.1 mm in 2 leads.Athletes with an ER 
pattern showed significantly lower heart rate and an increased E/e' ratio 
compared to athletes without an ER pattern. STE significantly correlated 
with E/e' ratio as well as with left atrial (LA) volume. The 
pro-inflammatory cytokines IL-6, IL-8, TNF-α as well as the 
anti-inflammatory cytokine IL-10 were significantly elevated in all soccer 
players. However, athletes with an ER pattern had significantly higher IL-6 
plasma levels than athletes without ER pattern. Furthermore, athletes with 
"high" level IL-6 had significantly larger LA volumes than players with 
"low" level IL-6. Conclusions: Athletes with an ER pattern had significantly 
higher E/e' ratios, reflecting higher atrial filling pressures, higher LA 
volume, and higher IL-6 plasma levels. All these factors may contribute to 
atrial remodeling over time and thus increase the risk of AF in long-term 
endurance sports.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  cytokine (endogenous compound)
EMTREE DRUG INDEX TERMS
  interleukin 10 (endogenous compound)
  interleukin 6 (endogenous compound)
  interleukin 8 (endogenous compound)
  tumor necrosis factor alpha (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart atrium remodeling
  heart repolarization
  inflammation
EMTREE MEDICAL INDEX TERMS
  adult
  article
  athlete
  bicycle ergometer
  clinical article
  controlled study
  echocardiography
  electrocardiograph electrode
  electrocardiography
  endurance training
  exercise test
  heart left atrium
  heart rate
  human
  male
  physical examination
  real time ultrasound scanner
  ST segment elevation
  vagus tone
  young adult
DEVICE TRADE NAMES
  cardiosoft 5  , GermanyGE Healthcare

  Ergoline ERG 900  , GermanyErgoline

  Vivid 7 Dimension machine  , NorwayGE Vingmed

DEVICE MANUFACTURERS
   (Germany)Ergoline
   (Germany)GE Healthcare
   (Norway)GE Vingmed
CAS REGISTRY NUMBERS
  interleukin 8 (114308-91-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015527304
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jjcc.2015.08.013
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 24
TITLE
  Community Screening for Nonischemic Cardiomyopathy in Asymptomatic Subjects 
≥65 Years with Stage B Heart Failure
AUTHOR NAMES
  Yang H.
  Wang Y.
  Nolan M.
  Negishi K.
  Okin P.M.
  Marwick T.H.
AUTHOR ADDRESSES
  (Yang H.; Wang Y.; Nolan M.; Negishi K.; Marwick T.H., 
tom.marwick@bakeridi.edu.au) Menzies Institute for Medical Research, 
University of Tasmania, Hobart, Australia.
(Negishi K.; Marwick T.H., tom.marwick@bakeridi.edu.au) Baker-IDI Heart and 
Diabetes Institute, Melbourne, Australia.
(Okin P.M.) Division of Cardiology, Department of Medicine, Weill Medical 
College of Cornell University, New York, United States.
CORRESPONDENCE ADDRESS
  T.H. Marwick, Menzies Institute for Medical Research, University of 
Tasmania, Hobart, Australia. Email: tom.marwick@bakeridi.edu.au
SOURCE
  American Journal of Cardiology (2016) 117:12 (1959-1965). Date of 
Publication: 15 Jun 2016
ISSN
  1879-1913 (electronic)
  0002-9149
BOOK PUBLISHER
  Elsevier Inc., usjcs@elsevier.com
ABSTRACT
  A process to identify and target a selected population at risk of heart 
failure (HF) could facilitate screening and prevention. We sought to develop 
an effective screening process from clinical characteristics, functional 
capacity, and electrocardiogram (ECG). Asymptomatic subjects ≥65 years, with 
≥1 HF risks were recruited from the community. Subjects with valvular 
disease, ejection fraction <40%, and atrial fibrillation were excluded. All 
underwent clinical evaluation including assessment of HF risk using 
Framingham HF score and Atherosclerosis Risk in Communities (ARIC) score, 
ECG, echocardiography, and 6-minute walk (6 MW) test. After 14 ± 4 months, 
new HF was assessed using Framingham criteria. A randomly selected 
derivation cohort was used to integrate ARIC score and 6 MW in a 
classification and regression tree (CART) analysis, with the remaining 
population used for validation. Of the 419 subjects (age 70 ± 5; 48% men), 
52 developed HF. ARIC was more effective than the Framingham HF score (area 
under the curve 0.65 vs 0.53, p = 0.01). CART selected ARIC (>9.5%) and 6 MW 
(<501 m) as cutoffs to define low-, intermediate-, and high-risk groups. 
Abnormal ECG further divided the intermediate group into high and low risks. 
The 134 subjects identified as high risk by a combined clinical and 
electrocardiographic strategy showed more echocardiographic features of 
cardiac dysfunction including LV mass, mitral e′, mitral E/e′, and 
longitudinal strain (p <0.01). New HF was significantly more frequent than 
in the remaining patients (20% vs 10%, p = 0.003; hazard ratio 2.08, 95% 
confidence interval 1.21 to 3.57, p = 0.008). Thus, initial clinical risk 
and electrocardiographic assessment facilitate effective HF screening by 
identifying a high-risk group.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  community care
  heart failure
  mass screening
  nonischemic cardiomyopathy (diagnosis)
EMTREE MEDICAL INDEX TERMS
  6 minute walk test
  adult
  aged
  area under the curve
  article
  asymptomatic disease
  Atherosclerosis Risk in Communities score
  cardiovascular disease assessment
  cardiovascular risk
  clinical assessment
  clinical classification
  clinical effectiveness
  clinical evaluation
  clinical feature
  comparative study
  controlled study
  diabetes mellitus
  echocardiography
  electrocardiogram
  exercise
  female
  follow up
  Framingham risk score
  functional status
  heart disease
  heart left ventricle mass
  high risk population
  human
  hypertension
  low risk population
  major clinical study
  male
  mitral valve
  obesity
  patient risk
  physical activity
  population
  primary prevention
  priority journal
  prospective study
  risk assessment
  risk factor
  screening test
  validation study
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160338318
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.amjcard.2016.03.045
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 25
TITLE
  Correlation between impedance cardiography and 6 min walk distance in atrial 
fibrillation patients
AUTHOR NAMES
  Ding L.
  Quan X.-Q.
  Zhang S.
  Ruan L.
  Zhang L.
  Zheng K.
  Yu W.-W.
  Wu X.-F.
  Mi T.
  Zhang C.-T.
  Zhou H.-L.
AUTHOR ADDRESSES
  (Ding L.; Quan X.-Q.; Zhang S.; Yu W.-W.; Wu X.-F.; Mi T.; Zhang C.-T.; Zhou 
H.-L., zhouhonglian63@163.com) Huazhong University of Science and 
Technology, Department of Geriatrics, Tongji Hospital, Tongji Medical 
College, Wuhan, China.
(Ruan L.; Zhang L.; Zheng K.) Huazhong University of Science and Technology, 
Department of Cardiology, Tongji Hospital, Tongji Medical College, Wuhan, 
China.
CORRESPONDENCE ADDRESS
  H.-L. Zhou, Huazhong University of Science and Technology, Department of 
Geriatrics, Tongji Hospital, Tongji Medical College, Wuhan, China. Email: 
zhouhonglian63@163.com
SOURCE
  BMC Cardiovascular Disorders (2016) 16:1 Article Number: 133. Date of 
Publication: 10 Jun 2016
ISSN
  1471-2261 (electronic)
BOOK PUBLISHER
  BioMed Central Ltd., info@biomedcentral.com
ABSTRACT
  Background: The correlation between impedance cardiography (ICG) and 6 min 
walk distance (6MWD) in atrial fibrillation (AF) patients remains unknown. 
Methods: We recruited 49 subjects in the study (21 AF patients and 28 
patients without AF) and estimated hemodynamic parameters: cardiac output 
(CO), stroke volume (SV), stroke volume index (SVI), left stroke work (LSW), 
left stroke work index (LSWI), stroke systemic vascular resistance (SSVR), 
stroke systemic vascular resistance index (SSVRI); 6MWD, left ventricle 
ejection fraction (LVEF), NT-pro brain natriuretic peptide (NT-pro BNP) for 
the two groups. Results: The AF group have apparently lower CO (2.26 ± 0.14 
VS 4.11 ± 0.20 L/min, p = 0.039) and distinctly higher SVR (677.60 ± 69.10 
VS 344.41 ± 22.98 dynes/cm(5), p = 0.001), SSVRI (396.97 ± 36.80 VS 199.01 ± 
11.72 dynes/cm(5)/m(2), p < 0.001) than the control group. NT-pro BNP 
(1409.48 ± 239.90 VS 332.59 ± 68.85 pg/ml, p = 0.001) in the AF group was 
significantly higher than the control group and 6MWD (264.33 ± 14.55 VS 
428.79 ± 29.98 m, p < 0.001) in the AF group was lower than the control 
group. There was no significant difference in LVEF between the two groups 
(62.67 ± 7.62 % VS 63.93 ± 5.03 %, p = 0.470). Pearson correlation analysis 
revealed that CO (R = 0.494, p = 0.023), SV (R = 0.633, p = 0.002), LSW (R = 
0.615, p = 0.003) and LSWI (R = 0.491, p = 0.024) significantly correlated 
positively with 6MWD in AF patients. Conclusions: AF patients had lower 
cardiac output, shorter 6MWD and higher NT-pro BNP than patients with sinus 
rhythm. The cardiac output measured by impedance cardiography significantly 
correlated positively with 6MWD in AF patients.
EMTREE DRUG INDEX TERMS
  amino terminal pro brain natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  cardiography
  physical activity, capacity and performance
  walk distance
EMTREE MEDICAL INDEX TERMS
  aged
  article
  cardiovascular parameters
  clinical article
  controlled study
  disease association
  female
  heart hemodynamics
  heart left ventricle ejection fraction
  heart output
  heart stroke volume
  human
  left stroke work index
  male
  priority journal
  sinus rhythm
  stroke systemic vascular resistance
  stroke systemic vascular resistance index
  stroke volume index
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160439956
FULL TEXT LINK
  http://dx.doi.org/10.1186/s12872-016-0297-0
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 26
TITLE
  Mechanism of Action and Clinical Application of Tafamidis in Hereditary 
Transthyretin Amyloidosis
AUTHOR NAMES
  Coelho T.
  Merlini G.
  Bulawa C.E.
  Fleming J.A.
  Judge D.P.
  Kelly J.W.
  Maurer M.S.
  Planté-Bordeneuve V.
  Labaudinière R.
  Mundayat R.
  Riley S.
  Lombardo I.
  Huertas P.
AUTHOR ADDRESSES
  (Coelho T., tcoelho@netcabo.pt) Hospital de Santo António, Centro Hospitalar 
do Porto, Porto, Portugal.
(Merlini G.) Foundation IRCCS Policlinico San Matteo, University of Pavia, 
Pavia, Italy.
(Bulawa C.E.; Fleming J.A.) Pfizer Rare Disease Research Unit, Cambridge, 
United States.
(Judge D.P.) Johns Hopkins University School of Medicine, Baltimore, United 
States.
(Kelly J.W.) The Scripps Research Institute, La Jolla, United States.
(Maurer M.S.) Columbia University College of Physicians and Surgeons, New 
York, United States.
(Planté-Bordeneuve V.) CHU Henri Mondor, Créteil, France.
(Labaudinière R.) Labaudiniere Consulting LLC, Lewes, United States.
(Mundayat R.; Riley S.) Pfizer Inc., New York, United States.
(Huertas P.) Massachusetts General and McLean Hospitals, Harvard Medical 
School, Boston, United States.
(Lombardo I.) FORUM Pharmaceuticals, Watertown, United States.
CORRESPONDENCE ADDRESS
  T. Coelho, Hospital de Santo António, Centro Hospitalar do Porto, Porto, 
Portugal. Email: tcoelho@netcabo.pt
SOURCE
  Neurology and Therapy (2016) 5:1. Date of Publication: 1 Jun 2016
ISSN
  2193-6536 (electronic)
  2193-8253
BOOK PUBLISHER
  Springer Healthcare
ABSTRACT
  Transthyretin (TTR) transports the retinol-binding protein–vitamin A complex 
and is a minor transporter of thyroxine in blood. Its tetrameric structure 
undergoes rate-limiting dissociation and monomer misfolding, enabling TTR to 
aggregate or to become amyloidogenic. Mutations in the TTR gene generally 
destabilize the tetramer and/or accelerate tetramer dissociation, promoting 
amyloidogenesis. TTR-related amyloidoses are rare, fatal, protein-misfolding 
disorders, characterized by formation of soluble aggregates of variable 
structure and tissue deposition of amyloid. The TTR amyloidoses present with 
a spectrum of manifestations, encompassing progressive neuropathy and/or 
cardiomyopathy. Until recently, the only accepted treatment to halt 
progression of hereditary TTR amyloidosis was liver transplantation, which 
replaces the hepatic source of mutant TTR with the less amyloidogenic 
wild-type TTR. Tafamidis meglumine is a rationally designed, non-NSAID 
benzoxazole derivative that binds with high affinity and selectivity to TTR 
and kinetically stabilizes the tetramer, slowing monomer formation, 
misfolding, and amyloidogenesis. Tafamidis is the first pharmacotherapy 
approved to slow the progression of peripheral neurologic impairment in TTR 
familial amyloid polyneuropathy. Here we describe the mechanism of action of 
tafamidis and review the clinical data, demonstrating that tafamidis 
treatment slows neurologic deterioration and preserves nutritional status, 
as well as quality of life in patients with early-stage Val30Met 
amyloidosis.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  tafamidis (adverse drug reaction, clinical trial, drug therapy, oral drug 
administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  diflunisal (drug therapy)
  nonsteroid antiinflammatory agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  amyloidosis (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (side effect)
  brain hemorrhage (side effect)
  Child Pugh score
  creatinine clearance
  crystal structure
  diarrhea (side effect)
  drug bioavailability
  faintness (side effect)
  gene mutation
  gene sequence
  genotype phenotype correlation
  heart ejection fraction
  heart failure (side effect)
  human
  polyneuropathy
  priority journal
  quality of life
  randomized controlled trial (topic)
  review
  sequence analysis
  urinary tract infection (side effect)
CAS REGISTRY NUMBERS
  diflunisal (22494-42-4)
  tafamidis (594839-88-0)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Internal Medicine (6)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT01655511)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160488314
FULL TEXT LINK
  http://dx.doi.org/10.1007/s40120-016-0040-x
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 27
TITLE
  Alcoholic beverage consumption and chronic diseases
AUTHOR NAMES
  Zhou Y.
  Zheng J.
  Li S.
  Zhou T.
  Zhang P.
  Li H.-B.
AUTHOR ADDRESSES
  (Zhou Y., zhouyue3@mail2.sysu.edu.cn; Zheng J., zhengj37@mail2.sysu.edu.cn; 
Zhou T., zwky740359@163.com; Zhang P., daidaolangman@126.com; Li H.-B., 
lihuabin@mail.sysu.edu.cn) Guangdong Provincial Key Laboratory of Food, 
Nutrition and Health, School of Public Health, Sun Yat-Sen University, 
Guangzhou, China.
(Li S., lishasl0308@163.com) School of Chinese Medicine, The University of 
Hong Kong, Sassoon Road, , Hong Kong.
(Li H.-B., lihuabin@mail.sysu.edu.cn) South China Sea Bioresource 
Exploitation and Utilization Collaborative Innovation Center, Sun Yat-Sen 
University, Guangzhou, China.
CORRESPONDENCE ADDRESS
  H.-B. Li, Guangdong Provincial Key Laboratory of Food, Nutrition and Health, 
School of Public Health, Sun Yat-Sen University, Guangzhou, China. Email: 
lihuabin@mail.sysu.edu.cn
SOURCE
  International Journal of Environmental Research and Public Health (2016) 
13:6 Article Number: 522. Date of Publication: 1 Jun 2016
ISSN
  1660-4601 (electronic)
  1661-7827
BOOK PUBLISHER
  MDPI AG, Postfach, Basel, Switzerland.
ABSTRACT
  Epidemiological and experimental studies have consistently linked alcoholic 
beverage consumption with the development of several chronic disorders, such 
as cancer, cardiovascular diseases, diabetes mellitus and obesity. The 
impact of drinking is usually dose-dependent, and light to moderate drinking 
tends to lower risks of certain diseases, while heavy drinking tends to 
increase the risks. Besides, other factors such as drinking frequency, 
genetic susceptibility, smoking, diet, and hormone status can modify the 
association. The amount of ethanol in alcoholic beverages is the determining 
factor in most cases, and beverage types could also make an influence. This 
review summarizes recent studies on alcoholic beverage consumption and 
several chronic diseases, trying to assess the effects of different drinking 
patterns, beverage types, interaction with other risk factors, and provide 
mechanistic explanations.
EMTREE DRUG INDEX TERMS
  acetaldehyde (endogenous compound)
  androstenedione (endogenous compound)
  anthocyanidin
  anthocyanin
  apigenin
  catechin
  ellagic acid
  epicatechin gallate
  estradiol (endogenous compound)
  estrone (endogenous compound)
  isohumulone
  kaempferol
  myricetin
  naringenin
  nitric oxide (endogenous compound)
  phenolic acid
  polyphenol
  prasterone sulfate (endogenous compound)
  procyanidin
  quercetin
  resveratrol
  sex hormone (endogenous compound)
  sex hormone binding globulin (endogenous compound)
  testosterone (endogenous compound)
  unclassified drug
  xanthohumol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alcohol consumption
  alcoholic beverage
  chronic disease
EMTREE MEDICAL INDEX TERMS
  aging
  androgen blood level
  atrial fibrillation
  breast cancer
  cancer cell
  carcinogenesis
  carcinogenicity
  cell invasion
  cerebrovascular accident
  chemoprophylaxis
  colorectal cancer
  coronary artery disease
  diabetes mellitus
  disease association
  endometrium cancer
  esophageal squamous cell carcinoma
  esophagus cancer
  estradiol blood level
  estrone blood level
  folate metabolism
  heart failure
  heart protection
  hormone blood level
  human
  hypertension
  insulin resistance
  insulin sensitivity
  kidney carcinoma
  larynx cancer
  liver cancer
  melanoma
  metastasis
  mouth cancer
  nonhuman
  obesity
  pancreas cancer
  pharynx cancer
  prostate cancer
  review
  stomach cancer
  testosterone blood level
  uterine cervix carcinoma in situ
CAS REGISTRY NUMBERS
  acetaldehyde (75-07-0)
  androstenedione (26264-53-9, 63-05-8)
  apigenin (520-36-5)
  catechin (13392-26-2, 154-23-4)
  ellagic acid (476-66-4)
  epicatechin gallate (863-03-6)
  estradiol (50-28-2)
  estrone (53-16-7)
  kaempferol (520-18-3)
  myricetin (529-44-2)
  naringenin (480-41-1, 67604-48-2)
  nitric oxide (10102-43-9)
  polyphenol (37331-26-3)
  prasterone sulfate (651-48-9)
  procyanidin (4852-22-6)
  quercetin (117-39-5)
  resveratrol (501-36-0)
  testosterone (58-22-0)
  xanthohumol (6754-58-1)
EMBASE CLASSIFICATIONS
  Cancer (16)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Endocrinology (3)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160393157
FULL TEXT LINK
  http://dx.doi.org/10.3390/ijerph13060522
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 28
TITLE
  Dietary vitamin D and risk of heart failure in the Physicians' Health Study
AUTHOR NAMES
  Robbins J.
  Petrone A.B.
  Gaziano J.M.
  Djoussé L.
AUTHOR ADDRESSES
  (Robbins J.; Petrone A.B.; Gaziano J.M.; Djoussé L., 
ldjousse@rics.bwh.harvard.edu) Division of Aging, Department of Medicine, 
Brigham and Women's Hospital and Harvard Medical School, Boston, United 
States.
(Robbins J.; Gaziano J.M.; Djoussé L., ldjousse@rics.bwh.harvard.edu) 
Massachusetts Veterans Epidemiology and Research Information Center and 
Geriatric Research, Education, and Clinical Center, Boston Veterans Affairs 
Healthcare System, Boston, United States.
CORRESPONDENCE ADDRESS
  L. Djoussé, Division of Aging, Brigham and Women's Hospital, Harvard Medical 
School, 1620 Tremont Street, 3rd Floor, Boston, United States. Email: 
ldjousse@rics.bwh.harvard.edu
SOURCE
  Clinical Nutrition (2016) 35:3 (650-653). Date of Publication: 1 Jun 2016
ISSN
  1532-1983 (electronic)
  0261-5614
BOOK PUBLISHER
  Churchill Livingstone
ABSTRACT
  Background: Experimental studies have demonstrated the role of vitamin D in 
key pathways related to cardiovascular health. While several studies have 
investigated the impact of vitamin D therapy on outcomes in subjects with 
prevalent heart failure, limited research exists on the relationship of 
dietary vitamin D consumption with the risk of heart failure. Thus, we 
sought to investigate whether dietary vitamin D consumption was associated 
with a lower risk of incident heart failure in a large prospective cohort of 
male physicians. Methods and results: We prospectively studied 19,635 males 
from the Physicians' Health Study. Dietary vitamin D information was 
obtained from a baseline food frequency questionnaire, and heart failure 
information was obtained by questionnaire and validated in a subsample. Mean 
age was 66.4 years. Median dietary vitamin D consumption was 200.4 IU and 
only 2.3% of the subjects used vitamin D supplements. After an average 
follow-up of 9.3 years, there were 858 new cases of heart failure 
identified. Higher intake of dietary vitamin D was not associated with 
incident heart failure in a multivariable adjusted model: hazard ratios (95% 
CI) of incident heart failure were 1.0 (reference), 1.29 (1.04-1.60), 1.17 
(0.94-1.46), 1.22 (0.98-1.53), and 1.16 (0.92-1.46) from lowest to highest 
age- and energy-adjusted vitamin D quintile, respectively, after adjusting 
for age, BMI, race, exercise, alcohol use, smoking, calories, and prevalent 
atrial fibrillation (p for linear trend = 0.64). Conclusions: These data are 
consistent with a lack of an association between dietary vitamin D and 
incident heart failure in this population of professionally-employed 
middle-aged males.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  vitamin D
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (clinical trial, drug combination, drug comparison - 
placebo, drug therapy)
  alpha tocopherol (clinical trial, drug combination, drug comparison - 
placebo, drug therapy)
  ascorbic acid (clinical trial, drug combination, drug comparison - placebo, 
drug therapy)
  beta carotene (clinical trial, drug combination, drug comparison - placebo, 
drug therapy)
  multivitamin (clinical trial, drug combination, drug comparison - placebo, 
drug therapy)
  placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure
  vitamin intake
EMTREE MEDICAL INDEX TERMS
  adult
  age distribution
  aged
  alcohol consumption
  article
  atrial fibrillation
  body mass
  caloric intake
  cardiovascular disease (drug therapy, prevention)
  cardiovascular risk
  cohort analysis
  controlled study
  disease association
  exercise
  factorial design
  follow up
  food frequency questionnaire
  human
  major clinical study
  male
  malignant neoplastic disease (drug therapy, prevention)
  physician
  population research
  primary prevention
  prospective study
  race difference
  randomized controlled trial (topic)
  risk reduction
  smoking
  vitamin supplementation
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
  beta carotene (7235-40-7)
EMBASE CLASSIFICATIONS
  Cancer (16)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015119978
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.clnu.2015.04.011
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 29
TITLE
  Aggregation of Marginal Gains in Cardiac Surgery: Feasibility of a 
Perioperative Care Bundle for Enhanced Recovery in Cardiac Surgical Patients
AUTHOR NAMES
  Fleming I.O.
  Garratt C.
  Guha R.
  Desai J.
  Chaubey S.
  Wang Y.
  Leonard S.
  Kunst G.
AUTHOR ADDRESSES
  (Fleming I.O.; Garratt C.; Guha R.; Leonard S.; Kunst G., 
gudrun.kunst@kcl.ac.uk) Anaesthesia, Denmark Hill, London, United Kingdom.
(Desai J.; Chaubey S.) Department of Cardiac Surgery, King's College 
Hospital NHS Foundation Trust, London, United Kingdom.
(Wang Y.) Division of Health and Social Care Research, King's College 
London, London, United Kingdom.
(Leonard S.) Department of Critical Care, King's College Hospital NHS 
Foundation Trust, London, United Kingdom.
CORRESPONDENCE ADDRESS
  G. Kunst, Anaesthesia, Denmark Hill, London, United Kingdom. Email: 
gudrun.kunst@kcl.ac.uk
SOURCE
  Journal of Cardiothoracic and Vascular Anesthesia (2016) 30:3 (665-670). 
Date of Publication: 1 Jun 2016
ISSN
  1532-8422 (electronic)
  1053-0770
BOOK PUBLISHER
  W.B. Saunders
ABSTRACT
  Objectives The aim of this pilot study was to assess the feasibility of a 
perioperative care bundle for enhanced recovery after cardiac surgery 
(ERACS). Design A prospective, observational study. Setting A major urban 
teaching and university hospital and tertiary referral center. Participants 
The study included 53 patients undergoing cardiac surgery before 
implementation of an ERACS protocol (pre-ERACS group) and 52 patients 
undergoing cardiac surgery after implementation of an ERACS protocol (ERACS 
group). Interventions Based on recommendations from a consensus review in 
colorectal surgery, the following enhanced recovery perioperative care 
bundle was applied: detailed preoperative information, avoidance of 
prolonged fasting periods preoperatively, preoperative carbohydrate 
beverages, optimization of analgesia with avoidance of long-acting opioids, 
prevention of postoperative nausea and vomiting, early enteral nutrition 
postoperatively, and early mobilization. Measurements and Main Results The 
authors hypothesized that length of hospital stay would be reduced with 
ERACS. Secondary outcome variables included a composite of postoperative 
complications and pain scores. Whereas the length of stay in the group of 
patients receiving the bundle of enhanced recovery interventions remained 
unchanged compared with the non-ERACS group, there was a statistically 
significant reduction in the number of patients in the ERACS group 
presenting with one or more postoperative complications (including 
hospital-acquired infections, acute kidney injury, atrial fibrillation, 
respiratory failure, postoperative myocardial infarction, and death). In 
addition, postoperative pain scores were improved significantly in the ERACS 
group. Conclusions This pilot study demonstrated that ERACS is feasible and 
has the potential for improved postoperative morbidity after cardiac 
surgery. A larger multicenter quality improvement study implementing 
perioperative care bundles would be the next step to further assess outcomes 
in ERACS patients.
EMTREE DRUG INDEX TERMS
  carbohydrate
  opiate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  care bundle
  heart surgery
  perioperative care bundle
EMTREE MEDICAL INDEX TERMS
  acute kidney failure (complication)
  aged
  article
  atrial fibrillation (complication)
  cause of death
  clinical protocol
  colorectal surgery
  consensus
  controlled study
  enteric feeding
  feasibility study
  female
  heart death (complication)
  heart infarction (complication)
  heart tamponade (complication)
  hospital infection (complication)
  hospitalization
  human
  length of stay
  major clinical study
  male
  mobilization
  multiple organ failure
  observational study
  pilot study
  postoperative nausea and vomiting (complication, prevention)
  preoperative evaluation
  priority journal
  prospective study
  respiratory failure (complication)
  sepsis
  surgical patient
  teaching hospital
  tertiary care center
  university hospital
CAS REGISTRY NUMBERS
  opiate (53663-61-9, 8002-76-4, 8008-60-4)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160457248
FULL TEXT LINK
  http://dx.doi.org/10.1053/j.jvca.2016.01.017
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 30
TITLE
  Neurotrophic and neuroprotective effects of muscle contraction
AUTHOR NAMES
  Arnao V.
  Di Raimondo D.
  Tuttolomondo A.
  Pinto A.
AUTHOR ADDRESSES
  (Arnao V., arnao.valentina@gmail.com; Di Raimondo D.; Tuttolomondo A.; Pinto 
A.) U. O. C. Di Medicina Interna e Cardioangiologia Dipartimento Biomedico 
di Medicina Interna e Specialistica, Università degli Studi di Palermo 
Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (BioNeC), 
Università degli Studi di Palermo, Italy.
CORRESPONDENCE ADDRESS
  V. Arnao, U. O di Neurologia e Neurofisiopatologia, Università degli Studi 
di Palermo, Via G. La Loggia n 1, , Italy. Email: arnao.valentina@gmail.com
SOURCE
  Current Pharmaceutical Design (2016) 22:24 (3749-3763). Date of Publication: 
1 Jun 2016
ISSN
  1873-4286 (electronic)
  1381-6128
BOOK PUBLISHER
  Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
  Background: Physical activity has been shown to be associated with reduced 
risk of coronary heart disease but the same effect seems to be produced in 
neurological diseases. Objective: In this review, we focused on the 
interplay between physical activity and some neurological conditions 
(Stroke, dementia, epilepsy, headache, Parkinson’ s disease, amyotrophic 
lateral sclerosis, multiple sclerosis, insomnia, depression and anxiety) 
with the aim of describing the potential role of physical activity in the 
prevention of such diseases and the physiological mechanisms involved in 
these processes. Results: Despite a growing body of evidence which reveals 
that physical activity is able to reduce the frequency of neurological 
diseases, directly or indirectly by enhancing cardiovascular conditions, 
further studies are necessary to better characterize which type of exercise 
is useful for each condition. Conclusion: Physical activity could represent 
an additional approach to fight against such diseases.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  neuroprotective agent
  neurotrophic factor
EMTREE DRUG INDEX TERMS
  4 aminobutyric acid (endogenous compound)
  brain derived neurotrophic factor (endogenous compound)
  catecholamine (endogenous compound)
  dopamine (endogenous compound)
  dopamine transporter (endogenous compound)
  endocannabinoid
  endorphin (endogenous compound)
  glutamic acid (endogenous compound)
  neurotransmitter
  tumor necrosis factor alpha (endogenous compound)
  tumor necrosis factor alpha receptor (endogenous compound)
  vasculotropin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  muscle contraction
EMTREE MEDICAL INDEX TERMS
  aerobic exercise
  alcohol consumption
  Alzheimer disease
  amyotrophic lateral sclerosis (etiology)
  anxiety
  atrial fibrillation
  balance disorder
  blood brain barrier
  brain blood flow
  brain ischemia
  cerebrovascular accident (etiology)
  cognition
  cognitive defect
  cycling
  dementia (etiology)
  dentate gyrus
  depression (etiology)
  dopamine brain level
  dopamine release
  dyslipidemia
  epilepsy (etiology)
  exercise
  experimental autoimmune encephalomyelitis
  headache (etiology)
  heart infarction
  hormesis
  human
  hyperlipidemia
  hypertension
  insomnia (etiology)
  metabolic equivalent
  middle cerebral artery occlusion
  mood
  multiple sclerosis (etiology)
  neuroprotection
  nonhuman
  orthostatic hypotension
  oxidative stress
  Parkinson disease (etiology)
  physical activity
  physical inactivity
  practice guideline
  priority journal
  quality of life
  randomized controlled trial (topic)
  resistance training
  review
  running
  sedentary lifestyle
  sleep disorder
  smoking
  spasticity
  stretching
  treadmill exercise
CAS REGISTRY NUMBERS
  4 aminobutyric acid (28805-76-7, 56-12-2)
  brain derived neurotrophic factor (218441-99-7)
  dopamine (51-61-6, 62-31-7)
  endorphin (60118-07-2)
  glutamic acid (11070-68-1, 138-15-8, 56-86-0, 6899-05-4)
  vasculotropin (127464-60-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Psychiatry (32)
  Drug Literature Index (37)
  General Pathology and Pathological Anatomy (5)
  Epilepsy Abstracts (50)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160525532
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 31
TITLE
  Delayed anaerobic threshold in heart failure patients with atrial 
fibrillation
AUTHOR NAMES
  Palermo P.
  Magrì D.
  Sciomer S.
  Stefanini E.
  Agalbato C.
  Compagnino E.
  Chircu C.M.
  Maffessanti F.
  Teodoru M.
  Agostoni P.
AUTHOR ADDRESSES
  (Palermo P.; Stefanini E.; Agalbato C.; Compagnino E.; Maffessanti F.; 
Agostoni P., piergiuseppe.agostoni@unimi.it) Centro Cardiologico Monzino, 
IRCCS, Via Parea 4, Milan, Italy.
(Magrì D.) Dipartimento di Medicina Clinica e Molecolare, Università degli 
Studi di Roma la Sapienza, Rome, Italy.
(Sciomer S.) Dipartimento di Scienze Cardiovascolari, Respiratorie, 
Anestesiologiche, Nefrologiche e Geriatriche, La Sapienza, Rome, Italy.
(Chircu C.M.) Emergency Clinical Hospital Sibiu, Sibiu, Romania.
(Teodoru M.) Faculty of Medicine, Lucian Blaga University, Sibiu, Romania.
(Agostoni P., piergiuseppe.agostoni@unimi.it) Department of Clinical 
Sciences and Community Health, University of Milan, Milan, Italy.
CORRESPONDENCE ADDRESS
  P. Agostoni, Centro Cardiologico Monzino, IRCCS, Via Parea 4, Milan, Italy. 
Email: piergiuseppe.agostoni@unimi.it
SOURCE
  Journal of Cardiopulmonary Rehabilitation and Prevention (2016) 36:3 
(174-179). Date of Publication: 25 May 2016
ISSN
  1932-751X (electronic)
  1932-7501
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Purpose: To assess whether atrial fibrillation (AF) in heart failure (HF) 
affects oxygen uptake at anaerobic threshold (V E O 2 AT) and heart rate 
(HR) kinetics. METHODS: A total of 15 patients with HF and AF and 18 with HF 
and sinus rhythm (SR) performed a maximal incremental and 2 constant 
workload cycle ergometer cardiopulmonary exercise tests (below and above AT, 
at 25% and 75% of maximal workload, respectively). At constant workload 
tests, kinetics of VO(2) and HR were assessed by calculating time constant 
(τ).RESULTS: HF patients with AF showed a similar peak VO(2) to those with 
SR (16.7±4.5 mL/kg/min vs 16.6±3.9 mL/kg/min). However, VO(2) AT (11.3±2.9 
mL/kg/min vs 9.3±2.8 mL/kg/min; P <.05), peak HR (149±18.8 bpm vs 116.4±20.4 
bpm; P <.001), HR AT (125.3±19.1 bpm vs 90.3±15.5 bpm; P <.001), and HR 
increase during exercise were greater in HF patients with AF. Finally,τHR 
andτVO(2) below and above AT were not significantly different.CONCLUSIONS: 
In HF patients with AF, despite a similar peak VO(2) compared with patients 
with HF and SR, VO(2) AT is higher because of a higher HR and a greater HR 
increase during exercise. One postulated mechanism would be a greater 
cardiac output increase at the beginning of exercise in HF patients with AF. 
The delayed AT generates uncertainty about the meaning of a VO(2) value at 
AT in HF patients with AF, because a higher AT is usually associated with 
better performance and a better prognosis.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anaerobic threshold
  atrial fibrillation
  heart failure
EMTREE MEDICAL INDEX TERMS
  adult
  article
  bicycle ergometer
  cardiopulmonary exercise test
  clinical article
  female
  heart rate
  human
  male
  middle aged
  oxygen consumption
  priority journal
  sinus rhythm
  workload
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160386708
FULL TEXT LINK
  http://dx.doi.org/10.1097/HCR.0000000000000159
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 32
TITLE
  The impact of physical training on endothelial function in myocardial 
infarction survivors: Pilot study
AUTHOR NAMES
  Peller M.
  Balsam P.
  Główczynska R.
  Ossolinski K.
  Gilarowska A.
  Kołtowski Ł.
  Grabowski M.
  Filipiak K.J.
  Opolski G.
AUTHOR ADDRESSES
  (Peller M.; Balsam P., pawel@balsam.com.pl; Główczynska R.; Ossolinski K.; 
Gilarowska A.; Kołtowski Ł.; Grabowski M.; Filipiak K.J.; Opolski G.) 1st 
Department and Department of Cardiology, Medical University of Warsaw, ul. 
Banacha 1a, Warsaw, Poland.
CORRESPONDENCE ADDRESS
  P. Balsam, 1st Department and Department of Cardiology, Medical University 
of Warsaw, ul. Banacha 1a, Warsaw, Poland. Email: pawel@balsam.com.pl
SOURCE
  Kardiologia Polska (2016) 74:5 (439-446). Date of Publication: 17 May 2016
ISSN
  0022-9032
BOOK PUBLISHER
  Via Medica, Ul. Swietokrzyska 73, Gdansk, Poland.
ABSTRACT
  Background: Endothelial dysfunction (ED) may indirectly influence the 
outcome of patients with coronary artery disease. Aim: To assess the 
influence of cardiac rehabilitation (CR) on endothelial function in patients 
after ST-segment elevation myocardial infarction (STEMI). Methods: 
Twenty-nine patients scheduled for CR were included in the study. CR began 
at least four weeks after STEMI and consisted of 12 or 24 training sessions. 
Endothelial function assessment was performed before and after CR, using 
reactive hyperaemia peripheral arterial tonometry. Results: Before the CR, 
ED was diagnosed in 16 of 29 (55.2%) patients. A total of 25 patients had 
two assessments of endothelial function: before and after CR. In univariate 
analysis the factors of negative response of endothelial function to CR 
were: higher baseline hyperaemia index (lnRHI) (odds ratio [OR] for positive 
response to CR 0.01; 95% confidence interval [CI] 0.00-0.33; p = 0.01) and 
higher peak serum troponin I level during index hospitalisation (OR 0.97; 
95% CI 0.94-1.00; p = 0.04). The independent, negative predictor of response 
to CR was lnRHI (OR 0.01; 95% CI 0.01-0.16; p = 0.03). Patients training for 
24 sessions (n = 16) had similar lnRHI changes to those of patients training 
for 12 sessions (n = 9); [0.16 (-0.06)-0.30 vs. 0.10 (0.05-0.15); p = 0.44, 
respectively]. Conclusions: ED is a frequent abnormality in STEMI survivors. 
Despite the lack of statistically significant improvement of endothelial 
function after CR in the analysed group of patients, some factors can 
influence the efficacy of this type of physical activity. The best effect of 
CR on endothelial function was observed in patients with baseline ED.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  angiotensin 2 receptor antagonist (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
  creatine kinase MB (endogenous compound)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  diuretic agent (drug therapy)
  hemoglobin (endogenous compound)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  nitric acid derivative (drug therapy)
  purinergic P2Y12 receptor (endogenous compound)
  troponin I (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  endothelial dysfunction
  physical activity
  ST segment elevation myocardial infarction (diagnosis, rehabilitation, 
therapy)
  survivor
  training
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation (drug therapy)
  blood clot lysis
  body mass
  body weight
  clinical article
  clinical assessment
  controlled study
  coronary artery disease
  diagnostic test accuracy study
  diastolic blood pressure
  exercise
  female
  heart left ventricle ejection fraction
  heart rate
  heart rehabilitation
  hospitalization
  human
  hyperemia
  hypertension (drug therapy)
  jogging
  male
  myocarditis
  non insulin dependent diabetes mellitus
  percutaneous coronary intervention
  peripheral arterial tonometry
  pilot study
  prediction
  pregnancy
  prospective study
  sensitivity and specificity
  swimming
  systolic blood pressure
  walking
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  hemoglobin (9008-02-0)
  troponin I (77108-40-8)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, Polish
EMBASE ACCESSION NUMBER
  20160504702
FULL TEXT LINK
  http://dx.doi.org/10.5603/KP.a2015.0177
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 33
TITLE
  Troponin I levels in permanent atrial fibrillation-impact of rate control 
and exercise testing
AUTHOR NAMES
  Horjen A.W.
  Ulimoen S.R.
  Enger S.
  Norseth J.
  Seljeflot I.
  Arnesen H.
  Tveit A.
AUTHOR ADDRESSES
  (Horjen A.W., awhorjen@gmail.com; Ulimoen S.R.; Enger S.; Tveit A.) Vestre 
Viken Hospital Trust, Department of Medical Research, Baerum Hospital, 
Drammen, Norway.
(Horjen A.W., awhorjen@gmail.com; Seljeflot I.; Arnesen H.) University of 
Oslo, Faculty of Medicine, Oslo, Norway.
(Norseth J.) Clinic for Medical Diagnostics, Vestre Viken Hospital Trust, 
Drammen, Norway.
(Seljeflot I.; Arnesen H.) Oslo University Hospital Ullevål, Center for 
Clinical Heart Research, Department of Cardiology, Oslo, Norway.
CORRESPONDENCE ADDRESS
  A.W. Horjen, University of Oslo, Faculty of Medicine, Oslo, Norway. Email: 
awhorjen@gmail.com
SOURCE
  BMC Cardiovascular Disorders (2016) 16:1 Article Number: 79. Date of 
Publication: 4 May 2016
ISSN
  1471-2261 (electronic)
BOOK PUBLISHER
  BioMed Central Ltd., info@biomedcentral.com
ABSTRACT
  Background: High-sensitivity troponin I (hs-TnI) and troponin T (hs-TnT) are 
moderately correlated and independently related to outcome in atrial 
fibrillation (AF). Rate controlling therapy has been shown to reduce hs-TnT, 
however the potential impact on hs-TnI levels, and whether this differs from 
the effects on hs-TnT, has not been investigated previously. Methods: Sixty 
patients with stable, permanent AF without heart failure or known ischemic 
heart disease were included in a randomised crossover study (mean age 71 ± 9 
years, 18 women). Diltiazem 360 mg, verapamil 240 mg, metoprolol 100 mg, and 
carvedilol 25 mg were administered once daily for three weeks, in a 
randomised sequence. At baseline and on the last day of each treatment 
period, hs-TnI was measured at rest and after a maximal exercise test and 
compared to hs-TnT. Results: Hs-TnI and hs-TnT correlated moderately at 
baseline (r(s) = 0.582, p < 0.001). All drugs reduced both the resting and 
the peak exercise levels of hs-TnI compared with baseline (p < 0.001 for 
all). The decline in resting hs-TnI and hs-TnT values relative to baseline 
levels was similar for all drugs except for verapamil, which reduced hs-TnI 
more than hs-TnT (p = 0.017). Levels of hs-TnI increased significantly in 
response to exercise testing at baseline and at all treatment regimens (p < 
0.001 for all). The relative exercise-induced increase in hs-TnI was 
significantly larger compared to hs-TnT at baseline (p < 0.001), on 
diltiazem (p < 0.001) and on verapamil (p = 0.001). Conclusions: In our 
population of stable, permanent AF patients, all four rate control drug 
regimens reduced hs-TnI significantly, both at rest and during exercise. The 
decline in hs-TnI and hs-TnT levels associated with beta-blocker and calcium 
channel blocker treatment was similar, except for a larger relative decrease 
in hs-TnI levels following verapamil treatment. Trial 
registration:www.clinicaltrials.gov( NCT00313157 ).
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  troponin I (endogenous compound)
EMTREE DRUG INDEX TERMS
  amino terminal pro brain natriuretic peptide (endogenous compound)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
  carvedilol (clinical trial, drug therapy)
  diltiazem (clinical trial, drug therapy)
  metoprolol (clinical trial, drug therapy)
  troponin T (endogenous compound)
  verapamil (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  disease control
  exercise test
  heart rate control
  permanent atrial fibrillation (drug therapy, drug therapy)
  randomized controlled trial (topic)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  CHADS2 score
  comorbidity
  comparative study
  controlled study
  drug response
  female
  human
  major clinical study
  male
  outcome assessment
  priority journal
  protein analysis
  resting heart rate
  systolic blood pressure
  treatment duration
DRUG MANUFACTURERS
  Abbott
  Astra Zeneca
  Hexal
  Hoffmann La Roche
  Pfizer
CAS REGISTRY NUMBERS
  carvedilol (72956-09-3)
  diltiazem (33286-22-5, 42399-41-7)
  metoprolol (37350-58-6)
  troponin I (77108-40-8)
  troponin T (60304-72-5)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
  Internal Medicine (6)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00313157)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160509592
FULL TEXT LINK
  http://dx.doi.org/10.1186/s12872-016-0255-x
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 34
TITLE
  A MET a Day Keeps Arrhythmia at Bay: The Association between Exercise or 
Cardiorespiratory Fitness and Atrial Fibrillation
AUTHOR NAMES
  Kapa S.
  Asirvatham S.J.
AUTHOR ADDRESSES
  (Kapa S.; Asirvatham S.J., Asirvatham.samuel@mayo.edu) Department of 
Pediatric and Adolescent Medicine, Mayo Clinic, 200 First St SW, Rochester, 
United States.
CORRESPONDENCE ADDRESS
  S.J. Asirvatham, Department of Pediatric and Adolescent Medicine, Mayo 
Clinic, 200 First St SW, Rochester, United States. Email: 
Asirvatham.samuel@mayo.edu
SOURCE
  Mayo Clinic Proceedings (2016) 91:5 (545-550). Date of Publication: 1 May 
2016
ISSN
  1942-5546 (electronic)
  0025-6196
BOOK PUBLISHER
  Elsevier Ltd
EMTREE DRUG INDEX TERMS
  troponin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (etiology)
  cardiorespiratory fitness
  exercise
EMTREE MEDICAL INDEX TERMS
  atherosclerosis
  autonomic nervous system
  body mass
  cardiovascular risk
  cerebrovascular accident
  diabetes mellitus
  diastolic dysfunction
  diet
  endurance training
  health care system
  heart conduction
  heart function
  heart size
  human
  hypertension
  lifestyle
  medical practice
  obesity
  pathophysiology
  physical activity
  review
  risk factor
  vagus tone
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  20160369558
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.mayocp.2016.03.003
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 35
TITLE
  Newer oral anticoagulants: Stroke prevention and pitfalls
AUTHOR NAMES
  Patel A.
  Goddeau R.P.
  Henninger N.
AUTHOR ADDRESSES
  (Patel A., Anand.Patel@umassmemorial.org; Goddeau R.P.; Henninger N.) 
Department of Neurology, University of Massachusetts Medical School, 
Worcester, United States.
(Henninger N.) Department of Psychiatry, University of Massachusetts Medical 
School, Worcester, United States.
CORRESPONDENCE ADDRESS
  A. Patel, Department of Neurology, University of Massachusetts Medical 
School, 55 Lake Ave, North, Worcester, United States. Email: 
Anand.Patel@umassmemorial.org
SOURCE
  Open Cardiovascular Medicine Journal (2016) 10 Supplement-1, M4 (94-104). 
Date of Publication: 1 May 2016
ISSN
  1874-1924 (electronic)
BOOK PUBLISHER
  Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
  Warfarin is very effective in preventing stroke in patients with atrial 
fibrillation. However, its use is limited due to fear of hemorrhagic 
complications, unpredictable anticoagulant effects related to multiple drug 
interactions and dietary restrictions, a narrow therapeutic window, frequent 
difficulty maintaining the anticoagulant effect within a narrow therapeutic 
window, and the need for inconvenient monitoring. Several newer oral 
anticoagulants have been approved for primary and secondary prevention of 
stroke in patients with non-valvular atrial fibrillation. These agents have 
several advantages relative to warfarin therapy. As a group, these direct 
oral anticoagulants (DOAC), which include the direct thrombin inhibitor, 
dabigatran, and the factor Xa inhibitors (rivaroxaban, apixaban, and 
edoxaban), are more effective than dose adjusted warfarin for prevention of 
all-cause stroke (including both ischemic and hemorrhagic stroke), and have 
an overall more favorable safety profile. Nevertheless, an increased risk of 
gastrointestinal bleeding (with the exception of apixaban), increased risk 
for thrombotic complication with sudden discontinuation, and inability to 
accurately assess and reverse anticoagulant effect require consideration 
prior to therapy initiation, and pose a challenge for decision making in 
acute stroke therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  apixaban
EMTREE DRUG INDEX TERMS
  dabigatran
  edoxaban
  rivaroxaban
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulation
  atrial fibrillation
  blood clot lysis
  brain hemorrhage
  brain ischemia
  prevention
EMTREE MEDICAL INDEX TERMS
  clinical study
  complication
  consensus development
  decision making
  diet restriction
  drug combination
  drug therapy
  fear
  gastrointestinal hemorrhage
  human
  monitoring
  pharmacokinetics
  secondary prevention
  therapeutic index
  thrombosis
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160572545
FULL TEXT LINK
  http://dx.doi.org/10.2174/1874192401610010094
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 36
TITLE
  Influence of Transiently Increased Nutritional Risk on a Left Ventricle 
Myocardial Mass Assessed by Echocardiography
AUTHOR NAMES
  Boban M.
  Laviano A.
  Persic V.
  Biocina B.
  Petricevic M.
  Zekanovic D.
  Rotim C.
  Aleric I.
  Vcev A.
AUTHOR ADDRESSES
  (Boban M., marcoboban@yahoo.com; Persic V.) Department of Cardiology, 
University Hospital 'Thalassotherapia Opatija', Medical Faculty University 
of Rijeka, Rijeka, Croatia.
(Boban M., marcoboban@yahoo.com; Persic V.; Zekanovic D.; Aleric I.; Vcev 
A.) Department of Internal Medicine, Medical Faculty 'J.j. Strossmayer' 
University of Osijek, Osijek, Croatia.
(Biocina B.; Petricevic M.) Department of Cardiac Surgery, Medical Faculty 
University of Zagreb, University Hospital Centre, Zagreb, Croatia.
(Rotim C.) Department of Surgery, University Hospital Centre 'Sestre 
Milosrdnice', Zagreb, Croatia.
(Laviano A.) Department of Clinical Medicine, University 'La Sapienza', 
Roma, Italy.
SOURCE
  Annals of Nutrition and Metabolism (2016) 68:3 (197-202). Date of 
Publication: 1 May 2016
ISSN
  1421-9697 (electronic)
  0250-6807
BOOK PUBLISHER
  S. Karger AG
ABSTRACT
  Background/Aim: Metabolic derangements due to increased nutritional risk 
lead to catabolism and loss of proteins, muscle tissue and eventually mass 
of parenchymatous organs. The aim of our study was to assess whether 
transitory nutritional risk after heart surgery influences on the left 
ventricle myocardial mass (LVMM), assessed by echocardiography. Methods: 
Consecutive sample of patients scheduled for cardiovascular rehabilitation, 
in period 0-3 months after surgery. Nutritional risk screening (NRS) was 
analyzed using the NRS-2002 tool. Results: Study sample included 330 
patients after heart surgery for ischemic 186 (56.4%); valvular 91 (27.6%) 
and valvular plus ischemic 53 (16.1%) heart disease. Age was 65.5 ± 10.6 
(range 23-84) and there were more male patients than female - 240 (72.7%) 
and 90 (27.3%), respectively. The percentage of unintentional loss of weight 
was 10.8 ± 3.4%, in range 0-23.81%, whereas NRS-2002 was 4.4 ± 1.1. LVMM was 
218.7 ± 65.9 g vs. 252.3 ± 51.7 (p = 0.015); for patients with increased 
nutritional risk and controls, respectively. There was no significant 
correlation of LVMM with NRS-2002, while the percentage of unintentional 
loss of weight displayed only weakly inverse correlation (Rho CC = -0.197; p 
= 0.007). LVMM also correlated significantly with body mass index (Rho CC = 
0.247; p < 0.001) and waist-to-hip ratio (Rho CC = 0.291; p < 0.001). In 
conclusion, LVMM was found to decrease slightly in the period of increased 
nutritional risk, following heart surgery. Changes in LVMM are partially 
consequences of systemic catabolic response, as well as anthropometric 
changes due to unintentional loss of weight.
EMTREE DRUG INDEX TERMS
  cholesterol (endogenous compound)
  high density lipoprotein cholesterol (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  echocardiography
  left ventricle myocardial mass (diagnosis)
  myocardial disease (diagnosis)
  nutritional assessment
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  anthropometry
  article
  atrial fibrillation
  body height
  body mass
  body weight
  cardiovascular risk
  cholesterol blood level
  chronic kidney disease
  chronic obstructive lung disease
  cohort analysis
  controlled study
  coronary artery disease
  diabetes mellitus
  diagnostic test accuracy study
  disease severity
  electrocardiography
  female
  glucose intolerance
  heart infarction
  heart left ventricle ejection fraction
  heart surgery
  hip circumference
  human
  hypertension
  major clinical study
  male
  middle aged
  nutritional status
  obesity
  priority journal
  sensitivity and specificity
  smoking
  thromboembolism
  transthoracic echocardiography
  triacylglycerol blood level
  waist circumference
  waist hip ratio
  weight reduction
CAS REGISTRY NUMBERS
  cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160267631
FULL TEXT LINK
  http://dx.doi.org/10.1159/000445301
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 37
TITLE
  Exercise Capacity and Atrial Fibrillation Risk in Veterans A Cohort Study
AUTHOR NAMES
  Faselis C.
  Kokkinos P.
  Tsimploulis A.
  Pittaras A.
  Myers J.
  Lavie C.J.
  Kyritsi F.
  Lovic D.
  Karasik P.
  Moore H.
AUTHOR ADDRESSES
  (Faselis C.; Kokkinos P., peter.kokkinos@va.gov; Tsimploulis A.; Pittaras 
A.; Kyritsi F.; Lovic D.; Karasik P.; Moore H.) Cardiology Division, 
Veterans Affairs Medical Center, 50 Irving St NW, Washington, United States.
(Faselis C.; Karasik P.) George Washington University, School of Medicine, 
Washington, United States.
(Kokkinos P., peter.kokkinos@va.gov; Karasik P.; Moore H.) Georgetown 
University, School of Medicine, Washington, United States.
(Kokkinos P., peter.kokkinos@va.gov) Department of Exercise Science, Arnold 
School of Public Health, University of South Carolina, Columbia, United 
States.
(Myers J.) Veterans Affairs Palo Alto Health Care System, Cardiology 
Division, Palo Alto, United States.
(Myers J.) Stanford University, Stanford, United States.
(Lavie C.J.) Department of Cardiovascular Diseases, John Ochsner Heart and 
Vascular Institute, Ochsner Clinical School, University Queensland, School 
of Medicine, New Orleans, United States.
CORRESPONDENCE ADDRESS
  P. Kokkinos, Cardiology Division, Veterans Affairs Medical Center, 50 Irving 
St NW, Washington, United States. Email: peter.kokkinos@va.gov
SOURCE
  Mayo Clinic Proceedings (2016) 91:5 (558-566). Date of Publication: 1 May 
2016
ISSN
  1942-5546 (electronic)
  0025-6196
BOOK PUBLISHER
  Elsevier Ltd
ABSTRACT
  Objective To assess the association between exercise capacity and the risk 
of developing atrial fibrillation (AF). Patients and Methods A 
symptom-limited exercise tolerance test was conducted to assess exercise 
capacity in 5962 veterans (mean age, 56.8±11.0 years) from the Veterans 
Affairs Medical Center, Washington, DC. None had evidence of AF or ischemia 
at the time of or before undergoing their exercise tolerance test. We 
established 4 fitness categories based on age-stratified quartiles of peak 
metabolic equivalent task (MET) achieved: least fit (4.9±1.10 METs; n=1446); 
moderately fit (6.7±1.0 METs; n=1490); fit (7.9±1.0 METs; n=1585), and 
highly fit (9.3±1.2 METs; n=1441). Multivariable Cox proportional hazards 
regression models were used to compare the AF-exercise capacity association 
between fitness categories. Results During a median follow-up period of 8.3 
years, 722 (12.1%) individuals developed AF (14.5 per 1000 person-years; 95% 
CI, 13.9-15.9 per 1000 person-years). Exercise capacity was inversely 
related to AF incidence. The risk was 21% lower (hazard ratio, 0.79; 95% CI, 
0.76-0.82) for each 1-MET increase in exercise capacity. Compared with the 
least fit individuals, hazard ratios were 0.80 (95% CI, 0.67-0.97) for 
moderately fit individuals, 0.55 (95% CI, 0.45-0.68) for fit individuals, 
and 0.37 (95% CI, 0.29-0.47) for highly fit individuals. Similar trends were 
observed in those younger than 65 years and those 65 years or older. 
Conclusion Increased fitness is inversely and independently associated with 
the reduced risk of developing AF. The decrease in risk was graded and 
precipitous with only modest increases in exercise capacity. These findings 
counter previous suggestions that even moderate increases in physical 
activity, as recommended by national and international guidelines, increase 
the risk of AF, with marked protection against AF noted with increasing 
levels of fitness.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
  cholesterol (endogenous compound)
  glucose (endogenous compound)
  high density lipoprotein (endogenous compound)
  low density lipoprotein (endogenous compound)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy)
  cardiorespiratory fitness
  exercise
  veteran
EMTREE MEDICAL INDEX TERMS
  adult
  age
  aged
  article
  body mass
  cholesterol blood level
  cohort analysis
  controlled study
  diabetes mellitus
  diastolic blood pressure
  drug use
  dyslipidemia
  exercise test
  female
  follow up
  glucose blood level
  human
  hypertension
  incidence
  ischemia
  lipoprotein blood level
  male
  middle aged
  observational study
  prospective study
  resting heart rate
  smoking
  symptom limited exercise tolerance test
  systolic blood pressure
  triacylglycerol blood level
  United States
CAS REGISTRY NUMBERS
  cholesterol (57-88-5)
  glucose (50-99-7, 84778-64-3)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160369559
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.mayocp.2016.03.002
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 38
TITLE
  Pathological remodelling of the athlete's heart
AUTHOR NAMES
  Keteepe-Arachi T.
  Sharma S.
AUTHOR ADDRESSES
  (Keteepe-Arachi T.; Sharma S., sasharma@sgul.ac.uk) St George's University 
Hospital, University of London, United Kingdom.
CORRESPONDENCE ADDRESS
  S. Sharma, Cardiac Research Centre, Department of Cardiovascular Sciences, 
St George's University of London, Cranmer Terrace, UK-London, United 
Kingdom. Email: sasharma@sgul.ac.uk
SOURCE
  Kardiovaskulare Medizin (2016) 19:5 (147-151). Date of Publication: 1 May 
2016
ISSN
  1662-629X (electronic)
  1423-5528
BOOK PUBLISHER
  EMH Swiss Medical Publishers Ltd., verlag@emh.ch
ABSTRACT
  Engaging in regular physical activity affords significant health benefits, 
while a lack of exercise is associated with increased cardiovascular 
morbidity and mortality. The amount of physical activity required to achieve 
these benefits is relatively modest, equating to 20-30 minutes of moderate 
intensity exercise per day. Most athletes far exceed these recommendations 
and now perform athletic feats previously considered insurmountable. Studies 
in veteran athletes have demonstrated favourable outcomes such as reduced 
incidence of cardiac disease and a greater lifespan. However, in 
asymptomatic athletes concealing underlying cardiac disease, intense 
exercise may be associated with sudden cardiac death. Despite the 
devastating and highly visible effects of life-threatening arrhythmias, 
exercise has retained its reputation as a prolonger of life as it is not the 
primary cause of death but merely a trigger for such catastrophes. More 
recent studies, however, have suggested that the effects of regular intense 
exercise may result in adverse remodelling in otherwise healthy hearts. This 
article will explore this concept and whether chronic intensive exercise can 
adversely impact cardiovascular health.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  heart disease
  heart remodeling
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (epidemiology, prevention)
  cardiovascular mortality
  cardiovascular risk
  coronary artery atherosclerosis
  cycling
  endurance training
  epidemic
  exercise intensity
  heart arrhythmia
  heart failure (prevention)
  heart infarction (rehabilitation, therapy)
  heart muscle fibrosis
  heart rehabilitation
  heart ventricle arrhythmia
  heart ventricle tachycardia (epidemiology)
  human
  life extension
  marathon runner
  morbidity
  nonhuman
  physical activity
  physical inactivity
  prevalence
  review
  risk reduction
  sedentary lifestyle
  sudden cardiac death
  therapy effect
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160423428
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 39
TITLE
  Chronotropic Incompetence Does Not Limit Exercise Capacity in Chronic Heart 
Failure
AUTHOR NAMES
  Jamil H.A.
  Gierula J.
  Paton M.F.
  Byrom R.
  Lowry J.E.
  Cubbon R.M.
  Cairns D.A.
  Kearney M.T.
  Witte K.K.
AUTHOR ADDRESSES
  (Jamil H.A.; Paton M.F.; Byrom R.; Lowry J.E.; Cubbon R.M.; Kearney M.T.; 
Witte K.K., k.k.witte@leeds.ac.uk) Division of Cardiovascular and Diabetes 
Research, Multidisciplinary Cardiovascular Research Centre (MCRC), Leeds 
Institute of Cardiovascular and Metabolic Medicine, LIGHT Building, 
University of Leeds, Clarendon Way, Leeds, United Kingdom.
(Gierula J.; Cairns D.A.) Clinical Trials Research Unit, Leeds Institute of 
Clinical Trials Research, Leeds, United Kingdom.
CORRESPONDENCE ADDRESS
  K.K. Witte, Division of Cardiovascular and Diabetes Research, 
Multidisciplinary Cardiovascular Research Centre (MCRC), Leeds Institute of 
Cardiovascular and Metabolic Medicine, LIGHT Building, University of Leeds, 
Clarendon Way, Leeds, United Kingdom. Email: k.k.witte@leeds.ac.uk
SOURCE
  Journal of the American College of Cardiology (2016) 67:16 (1885-1896). Date 
of Publication: 26 Apr 2016
ISSN
  1558-3597 (electronic)
  0735-1097
BOOK PUBLISHER
  Elsevier USA
ABSTRACT
  Background Limited heart rate (HR) rise (HRR) during exercise, known as 
chronotropic incompetence (CI), is commonly observed in chronic heart 
failure (CHF). HRR is closely related to workload, the limitation of which 
is characteristic of CHF. Whether CI is a causal factor for exercise 
intolerance, or simply an associated feature remains unknown. Objectives 
This study sought to clarify the role of the HR on exercise capacity in CHF. 
Methods This series of investigations consisted of a retrospective cohort 
study and 2 interventional randomized crossover studies to assess: 1) the 
relationship between HRR and exercise capacity in CHF; and 2) the effect of 
increasing and lowering HR on exercise capacity in CHF as assessed by 
symptom-limited treadmill exercise testing and measurement of peak oxygen 
consumption in patients with CHF due to left ventricular systolic 
dysfunction. Results The 3 key findings were: 1) the association of exercise 
capacity and HRR is much weaker in severe CHF compared to normal left 
ventricular function; 2) increasing HRR using rate-adaptive pacing (versus 
fixed-rate pacing) in unselected patients with CHF does not improve peak 
exercise capacity; and 3) acutely lowering baseline and peak HR by adjusting 
pacemaker variables in conjunction with a single dose of ivabradine does not 
adversely affect exercise capacity in unselected CHF patients. Conclusions 
The data refute the contention that CI contributes to impaired exercise 
capacity in CHF. This finding has widespread implications for pacemaker 
programming and the use of heart-rate lowering agents. (The Influence of 
Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients [TREPPE]; 
NCT02247245)
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (drug therapy)
  angiotensin receptor antagonist (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
  carbon dioxide
  digoxin (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  furosemide (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  ivabradine (drug comparison - placebo, drug dose, drug therapy)
  oxygen
  placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise
  heart failure (drug therapy, diagnosis, drug therapy, therapy)
  heart rate
  left ventricular systolic dysfunction (drug therapy, diagnosis, drug 
therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation (diagnosis, drug therapy, therapy)
  cardiac resynchronization therapy
  cardiopulmonary exercise test
  chronotropic incompetence
  clinical article
  cohort analysis
  comorbidity
  controlled study
  drug contraindication
  dyspnea
  end tidal carbon dioxide tension
  female
  heart ejection fraction
  heart left ventricle function
  heart rate rise
  heart ventricle pacing
  human
  intervention study
  leg disease
  leg weakness
  lung gas exchange
  lung ventilation
  male
  observational study
  oxygen consumption
  pacemaker
  priority journal
  resting heart rate
  retrospective study
  single drug dose
  sinus rhythm
  symptomatology
  transthoracic echocardiography
  treadmill exercise
  very elderly
CAS REGISTRY NUMBERS
  carbon dioxide (124-38-9, 58561-67-4)
  digoxin (20830-75-5, 57285-89-9)
  furosemide (54-31-9)
  ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
  oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT02247245)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160311463
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jacc.2016.02.042
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 40
TITLE
  Effects of oral anticoagulant therapy in older medical in-patients with 
atrial fibrillation: a prospective cohort observational study
AUTHOR NAMES
  Bo M.
  Li Puma F.
  Badinella Martini M.
  Falcone Y.
  Iacovino M.
  Grisoglio E.
  Menditto E.
  Fonte G.
  Brunetti E.
  Isaia G.C.
  D’Ascenzo F.
  Gaita F.
AUTHOR ADDRESSES
  (Bo M.; Li Puma F.; Badinella Martini M.; Falcone Y., 
yolanda.falcone@yahoo.it; Iacovino M.; Grisoglio E.; Menditto E.; Fonte G.; 
Brunetti E.; Isaia G.C.) SCDU Geriatria e Malattie Metaboliche dell’Osso, 
Città della Salute e della Scienza-Molinette., Corso Bramante 88, Turin, 
Italy.
(D’Ascenzo F.; Gaita F.) SCDU Cardiologia; Città della Salute e della 
Scienza-Molinette., C.so Bramante 88, Turin, Italy.
CORRESPONDENCE ADDRESS
  Y. Falcone, SCDU Geriatria e Malattie Metaboliche dell’Osso, Città della 
Salute e della Scienza-Molinette., Corso Bramante 88, Turin, Italy. Email: 
yolanda.falcone@yahoo.it
SOURCE
  Aging Clinical and Experimental Research (2016) (1-7). Date of Publication: 
21 Apr 2016
ISSN
  1720-8319 (electronic)
  1594-0667
BOOK PUBLISHER
  Springer International Publishing
ABSTRACT
  Background: Uncertainties about efficacy and safety of oral anticoagulant 
therapy (OAT) among older and frail medical patients with atrial 
fibrillation (AF) largely contribute to under-prescription of these drugs. 
Aims: In this prospective observational cohort study, we investigated 
mortality, and ischemic and hemorrhagic events, in hospital-discharged older 
patients with AF. Methods: Stroke and bleeding risk were evaluated using 
CHA2DS2-VASC and HAS-BLED scores. Comorbidity, frailty, cognitive and 
nutritional status and functional autonomy were evaluated using standardized 
scales. Independent associations between clinical variables, including OAT 
use, and all-cause mortality, fatal and non-fatal ischemic and hemorrhagic 
events, were evaluated. Further clinical outcomes comparison between 
patients treated with OAT and those untreated was performed after adjustment 
for significant differences in patient baseline characteristics with 
propensity score matching. Results: Of 452 patients included (mean age 81.6 
years, 54.9 % women, roughly 30 % cognitively impaired and/or functionally 
dependent, mean CHA2DS2-VASC and HAS-BLED scores 4.6 and 2.8, respectively), 
151 (33.4 %) died during a mean follow-up period of 300.5 days; ischemic and 
hemorrhagic stroke occurred in 4.0 and 0.4 % of patients, respectively, and 
major bleedings in 6.2 %. Discussion: After multivariate analysis, OAT at 
discharge was associated with lower overall mortality and reduced occurrence 
of ischemic stroke, the first finding being confirmed in propensity score 
matched analysis. Conclusions: Among older vulnerable AF patients with high 
post discharge death rate, OAT was associated, among other multiple factors, 
with reduced mortality and lower occurrence of ischemic stroke.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  hospital patient
  observational study
EMTREE MEDICAL INDEX TERMS
  aged
  brain hemorrhage
  brain ischemia
  cohort analysis
  comorbidity
  controlled study
  follow up
  human
  major clinical study
  mortality rate
  multivariate analysis
  nutritional status
  propensity score
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160319769
FULL TEXT LINK
  http://dx.doi.org/10.1007/s40520-016-0569-7
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 41
TITLE
  Volume and morphology of left atrial appendage as determinants of stroke 
subtype in patients with atrial fibrillation
AUTHOR NAMES
  Jeong W.K.
  Choi J.-H.
  Son J.P.
  Lee S.
  Lee M.J.
  Choe Y.H.
  Bang O.Y.
AUTHOR ADDRESSES
  (Jeong W.K.; Lee M.J.; Bang O.Y., ohyoung.bang@samsung.com) Department of 
Neurology, Samsung Medical Center, Sungkyunkwan University, School of 
Medicine, 81, Irwon-Ro, Gangnam-gu, Seoul, South Korea.
(Choi J.-H.) Department Cardiology, Samsung Medical Center, Sungkyunkwan 
University School of Medicine, Seoul, South Korea.
(Son J.P.; Lee S.; Bang O.Y., ohyoung.bang@samsung.com) Department of Health 
Sciences and Technology, Samsung Advanced Institute for Health Sciences and 
Technology, Sungkyunkwan University, Seoul, South Korea.
(Choe Y.H.) Department of Radiology, Samsung Medical Center, Sungkyunkwan 
University School of Medicine, Seoul, South Korea.
CORRESPONDENCE ADDRESS
  O.Y. Bang, Department of Neurology, Samsung Medical Center, Sungkyunkwan 
University, School of Medicine, 81, Irwon-Ro, Gangnam-gu, Seoul, South 
Korea. Email: ohyoung.bang@samsung.com
SOURCE
  Heart Rhythm (2016) 13:4 (820-827). Date of Publication: 1 Apr 2016
ISSN
  1556-3871 (electronic)
  1547-5271
BOOK PUBLISHER
  Elsevier
ABSTRACT
  Background Atrial fibrillation (AF) is a leading cause of stroke, but not 
all cases of stroke in patients with AF are due to AF. Objective The purpose 
of this study was to determine whether morphometric or volumetric parameters 
of left atrial appendage (LAA) would be related to the development of 
cardioembolism in subjects with AF. Methods A total of 433 consecutive 
patients with acute ischemic stroke underwent multidetector cardiac computed 
tomography (MDCT). Of these patients, 88 with AF were divided into 
cardioembolic stroke (CES; n = 57) and non-CES (n = 31) groups, and 95 age- 
and sex-matched patients with non-CES without AF served as controls. 
Clinical factors, echocardiographic findings, and MDCT parameters were 
evaluated. Results Brain infarct volume, LAA orifice diameter, and LAA 
volume were larger in patients with CES with AF than in those with non-CES 
with AF (P<.05 in all cases), but no difference was observed between 
patients with non-CES with AF and those with non-CES without AF. MDCT and 
echocardiographic parameters of left atrial (LA) dysfunction were different 
depending on the presence of AF but not between patients with CES with AF vs 
non-CES with AF. After adjusting for covariates, LAA orifice diameter (odds 
ratio 1.19, 95% confidence interval 1.06-1.33, P =.004) and LAA volume (odds 
ratio 12.20, 95% confidence interval 2.58-57.79, P =.002) were independently 
associated with CES with AF, as was infarct volume. Conclusion In patients 
with AF, LAA orifice diameter and LAA volume, but not left atrial 
dysfunction, were determinants of CES and were useful for stratifying 
noncardioembolic risk in patients with AF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  cerebrovascular accident
  heart atrium appendage
  heart volume
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  brain infarction size
  cardioembolic stroke
  computer assisted tomography
  controlled study
  female
  human
  major clinical study
  male
  multidetector computed tomography
  priority journal
  prospective study
  receiver operating characteristic
  risk assessment
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160107817
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.hrthm.2015.12.026
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 42
TITLE
  Improvement of gastric emptying by enhanced recovery after 
pancreaticoduodenectomy
AUTHOR NAMES
  Zouros E.
  Liakakos T.
  MacHairas A.
  Patapis P.
  Agalianos C.
  Dervenis C.
AUTHOR ADDRESSES
  (Zouros E., stratiszouros@gmail.com; Agalianos C.; Dervenis C.) Department 
of Surgery, Konstantopouleio General Hospital, 3-5 Agias Olgas Str., Athens, 
Greece.
(Liakakos T.) First Department of Surgery, Laiko University Hospital, Ag. 
Thoma 17, Athens, Greece.
(MacHairas A.; Patapis P.) Third Department of Surgery, Attikon University 
Hospital, Rimini 1, Athens, Greece.
CORRESPONDENCE ADDRESS
  E. Zouros, Department of Surgery, Konstantopouleio General Hospital, 3-5 
Agias Olgas Str., Athens, Greece. Email: stratiszouros@gmail.com
SOURCE
  Hepatobiliary and Pancreatic Diseases International (2016) 15:2 (198-208). 
Date of Publication: 1 Apr 2016
ISSN
  1499-3872
BOOK PUBLISHER
  Elsevier (Singapore) Pte Ltd, 3 Killiney Road, 08-01, Winsland House I, 
Singapore, Singapore.
ABSTRACT
  Background Enhanced recovery after surgery (ERAS) has improved postoperative 
outcomes particularly in colorectal surgery. This study aimed to assess 
compliance with an ERAS protocol and evaluate its effect on postoperative 
outcomes in patients undergoing pancreaticoduodenectomy. Methods Fifty 
patients who had received conventional perioperative management from 2005 to 
2009 (conventional group) were compared with 75 patients who had received 
perioperative care with an ERAS protocol (fast-track group) from 2010 to 
2014. Mortality, complications, readmissions and length of hospital stay 
were evaluated and compared in the groups. Results Compliance with each 
element of the ERAS protocol ranged from 74.7% to 100%. Uneventful patients 
had a significant higher adherence to the ERAS protocol (87.5% vs 40.7%; 
P<0.001). There were no significant differences in demographics and 
perioperative characteristics between the two groups. Patients in the 
fast-track group had a shorter time to remove the nasogastric tube, start 
liquid diet and solid food, pass flatus and stools, and remove drains. No 
difference was found in mortality, relaparotomy, readmission rates and 
overall morbidity. However, delayed gastric emptying and length of hospital 
stay were significantly reduced in the fast-track group. The independent 
effect of the ERAS protocol in reducing delayed gastric emptying and length 
of hospital stay was confirmed by multivariate analysis. Conclusion ERAS 
pathway was feasible and safe in improving gastric emptying, yielding an 
earlier postoperative recovery, and reducing the length of hospital stay.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  pancreaticoduodenectomy
  stomach emptying
EMTREE MEDICAL INDEX TERMS
  abdominal abscess (complication)
  adult
  article
  atrial fibrillation (complication)
  bile leakage (complication)
  biliary tract drainage
  controlled study
  diet
  female
  flatulence
  follow up
  hospital readmission
  hospitalization
  human
  length of stay
  major clinical study
  male
  morbidity
  nasogastric tube
  pancreas disease
  pancreas fistula (complication)
  patient compliance
  perioperative period
  pneumonia (complication)
  postoperative hemorrhage (complication)
  protocol compliance
  reoperation
  safety
  surgical infection (complication)
  tertiary care center
  total parenteral nutrition
EMBASE CLASSIFICATIONS
  Gastroenterology (48)
  Surgery (9)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160286028
FULL TEXT LINK
  http://dx.doi.org/10.1016/S1499-3872(16)60061-9
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 43
TITLE
  Risk of Malnutrition Is an Independent Predictor of Mortality, Length of 
Hospital Stay, and Hospitalization Costs in Stroke Patients
AUTHOR NAMES
  Gomes F.
  Emery P.W.
  Weekes C.E.
AUTHOR ADDRESSES
  (Gomes F., filomena.gomes@kcl.ac.uk; Emery P.W.) Diabetes and Nutritional 
Sciences Division, King's College London, Franklin Wilkins Building, 150 
Stamford Street, London, United Kingdom.
(Weekes C.E.) Department of Nutrition and Dietetics, Guy's and St Thomas' 
NHS Foundation Trust, London, United Kingdom.
CORRESPONDENCE ADDRESS
  F. Gomes, Diabetes and Nutritional Sciences Division, King's College London, 
Franklin Wilkins Building, 150 Stamford Street, London, United Kingdom. 
Email: filomena.gomes@kcl.ac.uk
SOURCE
  Journal of Stroke and Cerebrovascular Diseases (2016) 25:4 (799-806). Date 
of Publication: 1 Apr 2016
ISSN
  1532-8511 (electronic)
  1052-3057
BOOK PUBLISHER
  W.B. Saunders
ABSTRACT
  Background Malnutrition is associated with poor outcomes after stroke. 
Nutrition screening tools (NSTs) are used to identify patients at risk of 
malnutrition, but so far no NST has been validated for use with patients who 
have had a stroke. This study aimed to determine the ability of the 
Malnutrition Universal Screening Tool (MUST) to predict poor outcomes in 
stroke patients, including mortality, cumulative length of hospital stay 
(LOS), and hospitalization costs. Methods Patients were recruited from 
consecutive admissions at 2 hyperacute stroke units in London and were 
screened for risk of malnutrition (low, medium, and high) according to MUST. 
Six-month outcomes were obtained for each patient through a national 
database. Results Of 543 recruited patients, 51% were males, the mean age 
was 75 years, and 87% had an ischemic stroke. Results showed a highly 
significant increase in mortality with increasing risk of malnutrition (P 
<.001). This association remained significant after adjusting for age, 
severity of stroke, and a range of stroke risk factors (P <.001). For those 
patients who survived, the LOS and hospitalization costs increased with 
increasing risk of malnutrition (P <.001 and P =.049, respectively). This 
association remained significant in the adjusted model (P <.001 and P =.001, 
respectively). Conclusions Risk of malnutrition is an independent predictor 
of mortality, LOS, and hospitalization costs at 6 months post stroke. 
Research is needed to determine if nutritional support for medium- or 
high-risk patients results in better outcomes. Routine screening of stroke 
patients for risk of malnutrition is recommended.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (disease management)
  hospitalization cost
  length of stay
  malnutrition
  Malnutrition Universal Screening Tool
  screening test
  stroke patient
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  brain hemorrhage
  brain ischemia (disease management)
  dysphagia
  female
  follow up
  gastrointestinal disease
  groups by age
  high risk patient
  hospital readmission
  human
  intermediate risk patient
  low risk patient
  major clinical study
  male
  mortality
  observational study
  predictive value
  priority journal
  prospective study
  risk
  risk assessment
  social support
  terminal care
EMBASE CLASSIFICATIONS
  Health Policy, Economics and Management (36)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160087191
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.12.017
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 44
TITLE
  The Potential Cardiotoxic Effects of Exercise
AUTHOR NAMES
  La Gerche A.
AUTHOR ADDRESSES
  (La Gerche A., Andre.LaGerche@bakeridi.edu.au) Baker IDI Heart and Diabetes 
Institute, And Department of Cardiology, Alfred Hospital, Melbourne, 
Australia.
(La Gerche A., Andre.LaGerche@bakeridi.edu.au) The Department of 
Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
CORRESPONDENCE ADDRESS
  A. La Gerche, Sports Cardiology, Baker IDI Heart and Diabetes Institute, 
Level 4 Alfred Centre, 99 Commercial Rd, Melbourne, Australia. Email: 
Andre.LaGerche@bakeridi.edu.au
SOURCE
  Canadian Journal of Cardiology (2016) 32:4 (421-428). Date of Publication: 1 
Apr 2016
ISSN
  0828-282X
BOOK PUBLISHER
  Pulsus Group Inc.
ABSTRACT
  The emerging controversy related to the potential cardiotoxic effects of 
high doses of intense exercise need to be considered among the much stronger 
evidence that supports the pleomorphic benefits of exercise as a whole. 
However, there is fairly compelling evidence to support the association 
between long-term sport practice and an increased prevalence of atrial 
fibrillation and the fact that this relates to a chronic altered atrial 
substrate. This article was designed to challenge the reader with 
speculative science that suggests that exercise might promote permanent 
structural changes in the myocardium which can, in some individuals, 
predispose to arrhythmias. In terms of long-term health outcomes, it would 
seem that these small risks are outweighed by the many other benefits of 
exercise, including a likely decrease in atherosclerotic vascular events, 
although some recent results have brought into question whether the 
protective benefits of exercise on vascular events also extends to 
high-intensity exercise training. Above all else, in this article we sought 
to highlight current controversies to stimulate research on the many 
unanswered questions. In particular, there is a lack of adequately powered 
prospective studies from which we can measure health outcomes and their 
relationship to exercise-induced cardiac remodelling.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiotoxicity
  exercise
EMTREE MEDICAL INDEX TERMS
  athlete
  endurance training
  heart arrhythmia
  heart muscle
  heart right ventricle dysplasia
  human
  ischemic heart disease
  morbidity
  mortality
  review
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, French
EMBASE ACCESSION NUMBER
  20160167001
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.cjca.2015.11.010
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 45
TITLE
  Atrioventricular Junction Ablation for Atrial Fibrillation
AUTHOR NAMES
  Patel D.
  Daoud E.G.
AUTHOR ADDRESSES
  (Patel D.; Daoud E.G., emile.daoud@osumc.edu) Electrophysiology Section, 
Division of Cardiology, Ross Heart Hospital, Wexner Medical Center at The 
Ohio State University, Columbus, United States.
(Daoud E.G., emile.daoud@osumc.edu) Internal Medicine, Wexner Medical Center 
at The Ohio State University, 473 West 12th Avenue, DHLRI, Suite 200, 
Columbus, United States.
CORRESPONDENCE ADDRESS
  E.G. Daoud, Internal Medicine, 473 West 12th Avenue, DHLRI, Suite 200, 
Columbus, United States. Email: emile.daoud@osumc.edu
SOURCE
  Heart Failure Clinics (2016) 12:2 (245-255). Date of Publication: 1 Apr 2016
ISSN
  1551-7136
BOOK PUBLISHER
  Elsevier Inc., usjcs@elsevier.com
ABSTRACT
  Atrioventricular junction (AVJ) ablation is an effective therapy in patients 
with symptomatic atrial fibrillation who are intolerant to or unsuccessfully 
managed with rhythm control or medical rate control strategies. A drawback 
is that the procedure mandates a pacing system. Overall, the safety and 
efficacy of AVJ ablation is high with a majority of the patients reporting 
significant improvement in symptoms and quality-of-life measures. Risk of 
sudden cardiac death after device implantation is low, especially with an 
appropriate postprocedure pacing rate. Mortality benefit with AVJ ablation 
has been shown in patients with heart failure and cardiac resynchronization 
therapy devices.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  ablation therapy
  atrial fibrillation (surgery, therapy)
  atrioventricular junction ablation
  heart atrioventricular node
EMTREE MEDICAL INDEX TERMS
  ablation catheter
  cardiac resynchronization therapy
  clinical effectiveness
  exercise
  heart atrium flutter
  heart atrium pacing
  heart ejection fraction
  heart failure
  heart rate
  heart ventricle tachycardia (complication)
  hemodynamics
  human
  long term survival
  microelectrode
  mortality
  pacemaker
  polymorphic ventricular tachycardia (complication)
  review
  safety
  sudden cardiac death (complication)
  tachycardia induced cardiomyopathy (complication)
  therapy effect
  treatment outcome
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160196848
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.hfc.2015.08.020
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 46
TITLE
  Almanac 2015: Atrial fibrillation research in Heart
AUTHOR NAMES
  Jawad-Ul-Qamar M.
  Kirchhof P.
AUTHOR ADDRESSES
  (Jawad-Ul-Qamar M.; Kirchhof P., p.kirchhof@bham.ac.uk) Institute of 
Cardiovascular Sciences, University of Birmingham, Institute for Biomedical 
Research, Vincent Drive, Birmingham, United Kingdom.
(Jawad-Ul-Qamar M.; Kirchhof P., p.kirchhof@bham.ac.uk) SWBH NHS Trust, 
Birmingham, United Kingdom.
(Kirchhof P., p.kirchhof@bham.ac.uk) UHB NHS Trust, Birmingham, United 
Kingdom.
(Kirchhof P., p.kirchhof@bham.ac.uk) Atrial Fibrillation NETwork (AFNET), 
Münster, Germany.
(Kirchhof P., p.kirchhof@bham.ac.uk) Department of Cardiovascular Medicine, 
Hospital of the University of Münster, Münster, Germany.
CORRESPONDENCE ADDRESS
  P. Kirchhof, Institute of Cardiovascular Sciences, University of Birmingham, 
Institute for Biomedical Research, Vincent Drive, Birmingham, United 
Kingdom. Email: p.kirchhof@bham.ac.uk
SOURCE
  Heart (2016) 102:8 (573-580). Date of Publication: 1 Apr 2016
ISSN
  1468-201X (electronic)
  1355-6037
BOOK PUBLISHER
  BMJ Publishing Group, subscriptions@bmjgroup.com
ABSTRACT
  Atrial fibrillation continues to attract interest in the cardiovascular 
community and in Heart. Over 60 original research and review papers 
published in Heart in 2014-2015 cover various aspects of atrial 
fibrillation, from associated conditions and precipitating factors to new 
approaches to management. Here, we provide an overview of articles on atrial 
fibrillation published in Heart in 2014-2015, highlighting new developments, 
emerging concepts and novel approaches to treatment.
EMTREE DRUG INDEX TERMS
  adiponectin (endogenous compound)
  alanine aminotransferase (endogenous compound)
  anticoagulant agent (drug therapy, oral drug administration)
  antivitamin K (drug therapy)
  aspartate aminotransferase (endogenous compound)
  biological marker (endogenous compound)
  gamma glutamyltransferase (endogenous compound)
  ivabradine (drug therapy)
  natriuretic factor (endogenous compound)
  noradrenalin (endogenous compound)
  troponin I (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, diagnosis, drug therapy, surgery, 
therapy)
  medical research
EMTREE MEDICAL INDEX TERMS
  ablation therapy
  anticoagulant therapy
  aorta stenosis
  cardiovascular disease assessment
  cardiovascular mortality
  cardiovascular risk
  catheter ablation
  cerebrovascular accident (drug therapy, prevention)
  CHA2DS2Vasc score
  CHADS2 score
  diagnostic imaging
  diastolic dysfunction
  differential diagnosis
  disease association
  electrocardiogram
  electrocardiography
  exercise
  heart arrhythmia
  heart atrium flutter (drug therapy)
  heart atrium septum defect
  heart failure
  heart rate
  heart surgery
  hemodialysis
  hospital patient
  human
  inappropriate shock
  incidence
  kidney function
  nuclear magnetic resonance imaging
  predictive value
  prevalence
  priority journal
  prognosis
  recurrent disease
  review
  risk assessment
  screening test
  shock
  silent atrial fibrillation
  United Kingdom
CAS REGISTRY NUMBERS
  adiponectin (283182-39-8)
  alanine aminotransferase (9000-86-6, 9014-30-6)
  aspartate aminotransferase (9000-97-9)
  gamma glutamyltransferase (85876-02-4)
  ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
  natriuretic factor (9088-07-7)
  noradrenalin (1407-84-7, 51-41-2)
  troponin I (77108-40-8)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160099385
FULL TEXT LINK
  http://dx.doi.org/10.1136/heartjnl-2015-307809
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 47
TITLE
  Asynchronous Bilateral Renal Infarction and Thrombophilia with Associated 
Gene Mutations in a 43-Year-Old Man
AUTHOR NAMES
  Zhou X.-J.
  Liu L.-J.
  Chen M.
  Zhou F.-D.
AUTHOR ADDRESSES
  (Zhou X.-J.; Liu L.-J.; Chen M.; Zhou F.-D., zhoufude1801@vip.sina.com) 
Renal Division, Peking University First Hospital, Peking University 
Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health 
of China, China.
(Zhou X.-J.; Liu L.-J.; Chen M.; Zhou F.-D., zhoufude1801@vip.sina.com) Key 
Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking 
University, Ministry of Education, Beijing, China.
(Zhou F.-D., zhoufude1801@vip.sina.com) Renal Division, Peking University 
First Hospital, Peking University Institute of Nephrology, Beijing, China.
CORRESPONDENCE ADDRESS
  F.-D. Zhou, Renal Division, Peking University First Hospital, Peking 
University Institute of Nephrology, Beijing, China. Email: 
zhoufude1801@vip.sina.com
SOURCE
  Medicine (United States) (2016) 95:14 Article Number: e3258. Date of 
Publication: 1 Apr 2016
ISSN
  1536-5964 (electronic)
  0025-7974
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Renal infarction (RI) is frequently misdiagnosed or diagnosed late because 
of its rarity and nonspecific clinical presentation, which may result in 
irreversible damage to the renal parenchyma or increase the risk of other 
embolic events affecting additional organs. Multiple causal mechanisms and 
cases of idiopathic RI have been reported, but the causal factors are not 
clear in most cases. Here, we report the case of a patient with 
heterochronic bilateral RI caused by thrombophilia. Although he had several 
risk factors for hypercoagulation disorders, two gene mutations-MTHFR 677 
C>T and PLG 1858G>A-were identified by genome sequencing of the entire 
exome. The findings suggest the possibility of a synergistic relationship 
between the two gene mutations. Thus, screening for gene mutations may 
provide additional clues for clarifying the cause of RI and thrombophilia.
EMTREE DRUG INDEX TERMS
  alanine aminotransferase (endogenous compound)
  albumin (endogenous compound)
  amlodipine besylate (oral drug administration)
  antacid agent (oral drug administration)
  aspartate aminotransferase (endogenous compound)
  C reactive protein (endogenous compound)
  cephalosporin derivative (oral drug administration)
  creatine kinase (endogenous compound)
  creatinine (endogenous compound)
  lactate dehydrogenase (endogenous compound)
  urea (endogenous compound)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  gene mutation
  kidney infarction (etiology)
  thrombophilia (drug therapy, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
  abdominal pain
  acupuncture
  acute appendicitis (diagnosis, surgery)
  adult
  appendectomy
  article
  atrial fibrillation
  blood cell count
  body temperature
  case report
  computer assisted tomography
  creatinine blood level
  diabetes mellitus
  dyslipidemia
  echography
  erythrocyte sedimentation rate
  follow up
  genetic association
  hematuria
  hemoglobin determination
  human
  international normalized ratio
  kidney function
  lactate dehydrogenase blood level
  leukocyte count
  leukocytosis
  male
  nausea and vomiting
  next generation sequencing
  nuclear magnetic resonance imaging
  pain
  physical examination
  priority journal
  protein urine level
  risk factor
  smoking
  systolic blood pressure
  thrombocyte count
  urea blood level
  urinalysis
CAS REGISTRY NUMBERS
  alanine aminotransferase (9000-86-6, 9014-30-6)
  amlodipine besylate (111470-99-6)
  aspartate aminotransferase (9000-97-9)
  C reactive protein (9007-41-4)
  creatine kinase (9001-15-4)
  creatinine (19230-81-0, 60-27-5)
  lactate dehydrogenase (9001-60-9)
  urea (57-13-6)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Urology and Nephrology (28)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160336311
FULL TEXT LINK
  http://dx.doi.org/10.1097/MD.0000000000003258
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 48
TITLE
  Propafenone shows class Ic and class II antiarrhythmic effects
AUTHOR NAMES
  Stoschitzky K.
  Stoschitzky G.
  Lercher P.
  Brussee H.
  Lamprecht G.
  Lindner W.
AUTHOR ADDRESSES
  (Stoschitzky K., kurt.stoschitzky@medunigraz.at; Stoschitzky G.; Lercher P.; 
Brussee H.) Division of Cardiology, Department of Internal Medicine, Medical 
University of Graz, Graz, Austria.
(Lamprecht G.; Lindner W.) Institute of Analytical Chemistry, University of 
Vienna, Vienna, Austria.
CORRESPONDENCE ADDRESS
  K. Stoschitzky, Division of Cardiology, Department of Internal Medicine, 
Medical University of Graz, Graz, Austria. Email: 
kurt.stoschitzky@medunigraz.at
SOURCE
  Europace (2016) 18:4 (568-571). Date of Publication: 1 Apr 2016
ISSN
  1532-2092 (electronic)
  1099-5129
BOOK PUBLISHER
  Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
  Aims Propafenone is a well-known Class Ic antiarrhythmic agent. It has the 
typical chemical structure of a beta-blocker, but human studies on its 
beta-blocking effects revealed conflicting results. Methods and results 
Twelve healthy males received single oral doses of 600 mg propafenone and 
placebo according to a randomized, double-blind, placebo-controlled, 
cross-over protocol. Four hours following drug intake, heart rate and blood 
pressure were measured, and plasma concentrations of propafenone were 
determined at rest, during exercise and after recovery. At exercise, 
propafenone significantly decreased heart rate (-6%, P < 0.05), systolic 
blood pressure (-6%, P < 0.05), and the rate-pressure product (-11%, P < 
0.05). Plasma concentrations of propafenone increased during exercise (+23%, 
P < 0.05) and decreased during recovery (-33%, P < 0.05). Conclusion Both 
effects on heart rate and blood pressure as well as the changes of plasma 
concentrations of propafenone during exercise represent two particular 
features of beta-blockers. Therefore, we conclude that propafenone is both a 
Class Ic and a Class II antiarrhythmic agent, and 600 mg propafenone, i.e. 
the dose recommended in current guidelines for cardioversion of paroxysmal 
atrial fibrillation, cause clinically significant beta-blockade. Thus, 
single oral doses of 600 mg propafenone appear also suitable for 
cardioversion of paroxysmal atrial fibrillation in patients with structural 
heart disease since beta-blockers are explicitly indicated in the treatment 
of both coronary artery disease and heart failure.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  propafenone (clinical trial, drug comparison - placebo, drug concentration, 
oral drug administration, pharmacology)
EMTREE DRUG INDEX TERMS
  placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  antiarrhythmic activity
  beta adrenergic receptor blocking
  drug mechanism
EMTREE MEDICAL INDEX TERMS
  adult
  article
  cardioversion
  controlled study
  crossover procedure
  diastolic blood pressure
  drug blood level
  electrocardiography monitoring
  exercise
  heart rate
  human
  human experiment
  male
  normal human
  priority journal
  randomized controlled trial
  rest
  single drug dose
  systolic blood pressure
CAS REGISTRY NUMBERS
  propafenone (34183-22-7, 54063-53-5)
EMBASE CLASSIFICATIONS
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
  EudraCT (EudraCT200500018311)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160474538
FULL TEXT LINK
  http://dx.doi.org/10.1093/europace/euv195
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 49
TITLE
  Reducing Heart Failure Risks in Obese Patients
AUTHOR NAMES
  Parto P.
  Lavie C.J.
  Ventura H.O.
AUTHOR ADDRESSES
  (Parto P., parto22@gmail.com; Lavie C.J., clavie@ochsner.org; Ventura H.O., 
hventura@ochsner.org) Department of Cardiovascular Diseases, John Ochsner 
Heart and Vascular Institute, Ochsner Clinical School, The University of 
Queensland School of Medicine, 1514 Jefferson Highway, New Orleans, United 
States.
CORRESPONDENCE ADDRESS
  C.J. Lavie, Department of Cardiovascular Diseases, John Ochsner Heart and 
Vascular Institute, Ochsner Clinical School, The University of Queensland 
School of Medicine, 1514 Jefferson Highway, New Orleans, United States. 
Email: clavie@ochsner.org
SOURCE
  Current Cardiovascular Risk Reports (2016) 10:4 (1-8) Article Number: 15. 
Date of Publication: 1 Apr 2016
ISSN
  1932-9563 (electronic)
  1932-9520
BOOK PUBLISHER
  Current Medicine Group LLC 1, info@phl.cursci.com
ABSTRACT
  Heart failure (HF) and obesity have both become major epidemics and 
recognized as public health problems. Obesity has known adverse effects on 
cardiac structure and function; therefore, it is not surprising that there 
is an increased prevalence and incidence of HF in obese patients. 
Additionally, numerous cardiovascular (CV) risk factors associated with 
obesity, such as hypertension, coronary heart disease, dyslipidemia, atrial 
fibrillation, and depression, are also known to play a role in the 
development of HF. Numerous studies have suggested the presence of an 
“obesity paradox,” where obese patients with HF have a better prognosis than 
do lean or normal-weight HF patients. This review discusses the role of 
these risk factors in obese HF patients and the utility of purposeful weight 
loss.
EMTREE DRUG INDEX TERMS
  cholesterol (endogenous compound)
  high density lipoprotein cholesterol (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular risk
  heart failure
  obesity
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  blood pressure monitoring
  coronary vascular resistance
  depression
  dyslipidemia
  echocardiography
  exercise
  heart function
  heart hemodynamics
  heart left ventricle hypertrophy
  heart output
  human
  hypertension
  ischemic heart disease
  left ventricular diastolic dysfunction
  left ventricular systolic dysfunction
  New York Heart Association class
  randomized controlled trial (topic)
  review
  risk assessment
  thromboembolism
  weight reduction
CAS REGISTRY NUMBERS
  cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160172240
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12170-016-0498-1
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 50
TITLE
  Medical acupuncture for intracerebral bleed: A case history
AUTHOR NAMES
  McDaniels A.
AUTHOR ADDRESSES
  (McDaniels A., qmcduck@pacbell.net) Helms Medical Institute, 732 West Ninth 
Street, San Pedro, United States.
CORRESPONDENCE ADDRESS
  A. McDaniels, Helms Medical Institute, 732 West Ninth Street, San Pedro, 
United States. Email: qmcduck@pacbell.net
SOURCE
  Medical Acupuncture (2016) 28:2 (96-99). Date of Publication: 1 Apr 2016
ISSN
  1933-6594 (electronic)
  1933-6586
BOOK PUBLISHER
  Mary Ann Liebert Inc., info@liebertpub.com
ABSTRACT
  Background: A 75-year-old woman with a history of atrial fibrillation, 
anticoagulant therapy, and grand mal seizures sustained a right lateral 
ventricular intracerebral bleed. After being unconscious for 1 week in the 
intensive care unit of a general hospital, she spent another 2 weeks in 
intensive care before being transferred to a long-term acute care hospital 
for a month and to a comprehensive rehabilitation hospital for 3 weeks. 
Objective: To describe an important role for medical acupuncture in treating 
stroke and complementing standard medical management. Methods: Medical 
acupuncture was used to reverse left hemiparesis, improve mental awareness 
and focus, and hasten the course of recovery. Conclusion: Medical 
acupuncture should have an important role in the acute and subacute phases 
of treatment of hemorrhagic stroke.
EMTREE DRUG INDEX TERMS
  atenolol (drug therapy)
  phenytoin (drug therapy)
  warfarin (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  brain hemorrhage (therapy)
EMTREE MEDICAL INDEX TERMS
  aged
  anticonvulsant therapy
  article
  atrial fibrillation (drug therapy)
  brain edema
  case report
  cerebrovascular accident
  Chinese medicine
  coma
  computer assisted tomography
  female
  Glasgow coma scale
  hemiparesis
  human
  international normalized ratio
  neuroimaging
  partial thromboplastin time
  patient compliance
  priority journal
  prothrombin time
  tonic clonic seizure (drug therapy)
DRUG TRADE NAMES
  coumadin  , United StatesBristol Myers Squibb

  dilantin  , United StatesPfizer

  tenormin  , United StatesAstra Zeneca

DRUG MANUFACTURERS
   (United States)Astra Zeneca
   (United States)Bristol Myers Squibb
   (United States)Pfizer
CAS REGISTRY NUMBERS
  atenolol (29122-68-7, 93379-54-5)
  phenytoin (57-41-0, 630-93-3)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160342028
FULL TEXT LINK
  http://dx.doi.org/10.1089/acu.2015.1160
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 51
TITLE
  Impaired right ventricular-pulmonary arterial coupling and effect of 
sildenafil in heart failure with preserved ejection fraction
AUTHOR NAMES
  Hussain I.
  Mohammed S.F.
  Forfia P.R.
  Lewis G.D.
  Borlaug B.A.
  Gallup D.S.
  Redfield M.M.
AUTHOR ADDRESSES
  (Hussain I.; Mohammed S.F.; Borlaug B.A.; Redfield M.M., 
redfield.margaret@mayo.edu) Division of Cardiovascular Diseases, Mayo 
Clinic, 200 First St SW, Rochester, United States.
(Forfia P.R.) Temple University, Philadelphia, United States.
(Lewis G.D.) Cardiology Division, Massachusetts General Hospital, Harvard 
Medical School, Boston, United States.
(Gallup D.S.) Duke Clinical Research Institute, Durham, United States.
CORRESPONDENCE ADDRESS
  M.M. Redfield, Division of Cardiovascular Diseases, Mayo Clinic, 200 First 
St SW, Rochester, United States. Email: redfield.margaret@mayo.edu
SOURCE
  Circulation: Heart Failure (2016) 9:4 Article Number: e002729. Date of 
Publication: 1 Apr 2016
ISSN
  1941-3297 (electronic)
  1941-3289
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Background - Right ventricular (RV) dysfunction (RVD) is a poor prognostic 
factor in heart failure with preserved ejection fraction (HFpEF). The 
physiological perturbations associated with RVD or RV function indexed to 
load (RV-pulmonary arterial [PA] coupling) in HFpEF have not been defined. 
HFpEF patients with marked impairment in RV-PA coupling may be uniquely 
sensitive to sildenafil. Methods and Results - In a subset of HFpEF patients 
enrolled in the Phosphodiesteas-5 Inhibition to Improve Clinical Status And 
Exercise Capacity in Diastolic Heart Failure (RELAX) trial, physiological 
variables and therapeutic effect of sildenafil were examined relative to the 
severity of RVD (tricuspid annular plane systolic excursion [TAPSE]) and 
according to impairment in RV-PA coupling (TAPSE/pulmonary artery systolic 
pressure) ratio. The prevalence of atrial fibrillation and diuretic use, 
n-terminal probrain natriuretic peptide levels, renal dysfunction, 
neurohumoral activation, myocardial necrosis and fibrosis biomarkers, and 
the severity of diastolic dysfunction all increased with severity of RVD. 
Peak oxygen consumption decreased and ventilatory inefficiency (VE/VCO 2 
slope) increased with increasing severity of RVD. Many but not all 
physiological derangements were more closely associated with the 
TAPSE/pulmonary artery systolic pressure ratio. Compared with placebo, at 24 
weeks, TAPSE decreased, and peak oxygen consumption and VE/CO 2 slope were 
unchanged with sildenafil. There was no interaction between RV-PA coupling 
and treatment effect, and sildenafil did not improve TAPSE, peak oxygen 
consumption, or VE/VCO 2 in patients with pulmonary hypertension and RVD. 
Conclusions - HFpEF patients with RVD and impaired RV-PA coupling have more 
advanced heart failure. In RELAX patients with RVD and impaired RV-PA 
coupling, sildenafil did not improve RV function, exercise capacity, or 
ventilatory efficiency.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  sildenafil (drug therapy)
EMTREE DRUG INDEX TERMS
  aldosterone (endogenous compound)
  amino terminal pro brain natriuretic peptide (endogenous compound)
  beta adrenergic receptor blocking agent
  biological marker (endogenous compound)
  C reactive protein (endogenous compound)
  c telopeptide for type I collagen (endogenous compound)
  cystatin C (endogenous compound)
  digoxin
  endothelin 1 (endogenous compound)
  galectin 3 (endogenous compound)
  loop diuretic agent
  phosphodiesterase V (endogenous compound)
  placebo
  procollagen iii n terminal peptide (endogenous compound)
  troponin I (endogenous compound)
  unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure with preserved ejection fraction (drug therapy, drug therapy)
  heart right ventricle failure
  heart right ventricle function
  right ventricular pulmonary arterial coupling
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation
  cardiovascular parameters
  controlled study
  diastolic dysfunction
  disease severity
  diuretic therapy
  drug effect
  enzyme inhibition
  exercise
  female
  heart left ventricle ejection fraction
  heart left ventricle function
  heart left ventricle mass
  heart muscle necrosis
  heart muscle oxygen consumption
  human
  kidney dysfunction
  major clinical study
  male
  priority journal
  pulmonary artery systolic pressure ratio
  pulmonary hypertension
  randomized controlled trial
  treatment duration
  tricuspid annular plane systolic excursion
  ventilatory inefficiency
CAS REGISTRY NUMBERS
  aldosterone (52-39-1, 6251-69-0)
  C reactive protein (9007-41-4)
  digoxin (20830-75-5, 57285-89-9)
  endothelin 1 (117399-94-7)
  galectin 3 (208128-56-7)
  sildenafil (139755-83-2)
  troponin I (77108-40-8)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
  Internal Medicine (6)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (00763867)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160332538
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002729
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 52
TITLE
  Exercise as an adjuvant therapy against chronic atrial fibrillation
AUTHOR NAMES
  Santos-Lozano A.
  Sanchis-Gomar F.
  Barrero-Santalla S.
  Pareja-Galeano H.
  Cristi-Montero C.
  Sanz-Ayan P.
  Garatachea N.
  Fiuza-Luces C.
  Lucia A.
AUTHOR ADDRESSES
  (Santos-Lozano A.; Sanchis-Gomar F., fabian.sanchis@uv.es; Pareja-Galeano 
H.; Sanz-Ayan P.; Garatachea N.; Fiuza-Luces C.; Lucia A.) Research 
Institute of Hospital, Edificio Actividades Ambulatorias, 12de Octubre 
(i+12) 6a planta Avda. de Córdoba s/n, Madrid, Spain.
(Santos-Lozano A.) GIDFYS, European University Miguel de Cervantes, 
Department of Health Sciences, Valladolid, Spain.
(Barrero-Santalla S.) School of Health Sciences, University of León, León, 
Spain.
(Pareja-Galeano H.; Lucia A.) European University of Madrid, Madrid, Spain.
(Cristi-Montero C.) IRyS Group, School of Physical Education, Pontificia 
Universidad Católica de Valparaíso, Valparaíso, Chile.
(Cristi-Montero C.) Universidad Autónoma de Chile, Temuco, Chile.
(Garatachea N.) Facultad de Ciencias de la Salud y Del Deporte, Universidad 
de Zaragoza, Huesca, Spain.
CORRESPONDENCE ADDRESS
  F. Sanchis-Gomar, Research Institute of Hospital, Edificio Actividades 
Ambulatorias, 12de Octubre (i+12) 6a planta Avda. de Córdoba s/n, Madrid, 
Spain. Email: fabian.sanchis@uv.es
SOURCE
  International Journal of Cardiology (2016) 207 (180-184). Date of 
Publication: 15 Mar 2016
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
EMTREE DRUG INDEX TERMS
  angiotensin receptor antagonist (drug therapy)
  anticoagulant agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium antagonist (drug therapy)
  digoxin (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  diuretic agent (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  adjuvant therapy
  chronic atrial fibrillation (drug therapy, drug therapy, therapy)
  exercise
EMTREE MEDICAL INDEX TERMS
  article
  cardiovascular parameters
  coronary artery disease (drug therapy)
  disease association
  disease classification
  disease duration
  heart disease (drug therapy)
  heart failure (drug therapy)
  human
  hypertension (drug therapy)
  ischemic heart disease
  outcome assessment
  oxygen consumption
  priority journal
  quality of life
  systematic review
  therapy effect
  treatment duration
  treatment response
CAS REGISTRY NUMBERS
  digoxin (20830-75-5, 57285-89-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  20160129604
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2016.01.140
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 53
TITLE
  Interaction between dietary Vitamin K intake and anticoagulation by Vitamin 
K antagonists: is it really true?: A systematic review
AUTHOR NAMES
  Violi F.
  Lip G.Y.H.
  Pignatelli P.
  Pastori D.
AUTHOR ADDRESSES
  (Violi F., francesco.violi@uniroma1.it; Pignatelli P.; Pastori D.) Center of 
Atherothrombosis, I Medical Clinic, Department of Internal Medicine and 
Medical Specialties, Sapienza University of Rome, Umberto i Policlinic of 
Rome, Viale del Policlinico 155, Rome, Italy.
(Lip G.Y.H.) Centre for Cardiovascular Sciences, City Hospital, University 
of Birmingham, Birmingham, United Kingdom.
CORRESPONDENCE ADDRESS
  F. Violi, Center of Atherothrombosis, I Medical Clinic, Department of 
Internal Medicine and Medical Specialties, Sapienza University of Rome, 
Umberto i Policlinic of Rome, Viale del Policlinico 155, Rome, Italy. Email: 
francesco.violi@uniroma1.it
SOURCE
  Medicine (United States) (2016) 95:10 Article Number: e2895. Date of 
Publication: 4 Mar 2016
ISSN
  1536-5964 (electronic)
  0025-7974
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Educational advice is often given to patients starting treatment with 
vitamin K Antagonists (VKAs). A great emphasis is made on nutritional 
information. Common belief is that dietary vitamin K intake could counteract 
the anticoagulant effect by VKAs and for many years, patients have been 
discouraged to consume vitamin-K-rich foods, such as green leafy vegetables. 
The objective of this study is to summarize the current evidence supporting 
the putative interaction between dietary vitamin K intake and changes in INR 
with the VKAs. Data sources are MEDLINE via PubMed and Cochrane database. 
All clinical studies investigating the relationship between dietary vitamin 
K and measures of anticoagulation were included. We excluded all studies of 
supplementation of vitamin K alone. We performed a systematic review of the 
literature up to October 2015, searching for a combination of "food," 
"diet," "vitamin K," "phylloquinone," "warfarin," "INR," "coagulation," and 
"anticoagulant." Two dietary interventional trials and 9 observational 
studies were included. We found conflicting evidence on the effect of 
dietary intake of vitamin K on coagulation response. Some studies found a 
negative correlation between vitamin K intake and INR changes, while others 
suggested that a minimum amount of vitamin K is required to maintain an 
adequate anticoagulation. Median dietary intake of vitamin K1 ranged from 76 
to 217mg/day among studies, and an effect on coagulation may be detected 
only for high amount of vitamin intake (>150mg/day). Most studies included 
patients with various indications for VKAs therapy, such as atrial 
fibrillation, prosthetic heart valves, and venous thromboembolism. Thus, INR 
target was dishomogeneous and no subanalyses for specific populations or 
different anticoagulants were conducted. Measures used to evaluate 
anticoagulation stability were variable. The available evidence does not 
support current advice to modify dietary habits when starting therapy with 
VKAs. Restriction of dietary vitamin K intake does not seem to be a valid 
strategy to improve anticoagulation quality with VKAs. It would be, perhaps, 
more relevant to maintain stable dietary habit, avoiding wide changes in the 
intake of vitamin K.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  antivitamin K (drug interaction, drug therapy)
  vitamin K group (drug interaction)
EMTREE DRUG INDEX TERMS
  phytomenadione
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulation
  dietary intake
  international normalized ratio
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation (drug therapy)
  clinical trial (topic)
  Cochrane Library
  diet restriction
  heart valve prosthesis
  human
  intervention study
  Medline
  meta analysis (topic)
  observational study
  practice guideline
  priority journal
  systematic review
  treatment indication
  venous thromboembolism (drug therapy)
  vitamin intake
CAS REGISTRY NUMBERS
  phytomenadione (11104-38-4, 84-80-0)
  vitamin K group (12001-79-5)
EMBASE CLASSIFICATIONS
  Hematology (25)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160236808
FULL TEXT LINK
  http://dx.doi.org/10.1097/MD.0000000000002895
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 54
TITLE
  Prevention, management, and rehabilitation of stroke in low- and 
middle-income countries
AUTHOR NAMES
  Yan L.L.
  Li C.
  Chen J.
  Miranda J.J.
  Luo R.
  Bettger J.
  Zhu Y.
  Feigin V.
  O'Donnell M.
  Zhao D.
  Wu Y.
AUTHOR ADDRESSES
  (Yan L.L., lijing.yan@duke.edu; Li C.) Global Health Research Center, Duke 
Kunshan University, Kunshan, China.
(Yan L.L., lijing.yan@duke.edu) Duke Global Health Institute, Duke 
University, Durham, United States.
(Yan L.L., lijing.yan@duke.edu; Luo R.; Zhu Y.; Wu Y., ywu@george.org.cn) 
George Institute for Global Health, Peking University, Health Science 
Center, Beijing, China.
(Chen J.) Institute for Medical Humanities, Peking University, Health 
Science Center, Beijing, China.
(Miranda J.J.) CRONICAS Center of Excellence for Chronic Diseases, 
Universidad Peruana Cayetano Heredia, Lima, Peru.
(Miranda J.J.) Department of Medicine, School of Medicine, Universidad 
Peruana Cayetano Heredia, Lima, Peru.
(Bettger J.) Duke School of Nursing, Duke University, Durham, United States.
(Bettger J.) Duke Clinical Research Institute, Duke University, Durham, 
United States.
(Feigin V.) National Institute for Stroke and Applied Neuroscience, Auckland 
University of Technology, Auckland, New Zealand.
(O'Donnell M.) National University of Ireland Galway, Galway, Ireland.
(Zhao D.) Department of Epidemiology, Beijing Anzhen Hospital, Capital 
Medical University, Beijing, China.
(Wu Y., ywu@george.org.cn) Department of Epidemiology and Biostatistics, 
Peking University, School of Public Health, Clinical Research Institute, 
Beijing, China.
CORRESPONDENCE ADDRESS
  L.L. Yan, Duke Global Health Institute, Global Health Research Center, Duke 
Kunshan University, No. 8 Duke Avenue, Kunshan, China. Email: 
lijing.yan@duke.edu
SOURCE
  eNeurologicalSci (2016) 2 (21-30). Date of Publication: 1 Mar 2016
ISSN
  2405-6502 (electronic)
BOOK PUBLISHER
  Elsevier
ABSTRACT
  Although stroke incidence in high-income countries (HICs) decreased over the 
past four decades, it increased dramatically in low- and middle-income 
countries (LMICs). In this review, we describe the current status of primary 
prevention, treatment, and management of acute stroke and secondary 
prevention of and rehabilitation after stroke in LMICs. Although 
surveillance, screening, and accurate diagnosis are important for stroke 
prevention, LMICs face challenges in these areas due to lack of resources, 
awareness, and technical capacity. Maintaining a healthy lifestyle, such as 
no tobacco use, healthful diet, and physical activity are important 
strategies for both primary and secondary prevention of stroke. Controlling 
high blood pressure is also critically important in the general population 
and in the acute stage of hemorrhagic stroke. Additional primary prevention 
strategies include community-based education programs, polypill, prevention 
and management of atrial fibrillation, and digital health technology. For 
treatment of stroke during the acute stage, specific surgical procedures and 
medications are recommended, and inpatient stroke care units have been 
proven to provide high quality care. Patients with a chronic condition like 
stroke may require lifelong pharmaceutical treatment, lifestyle maintenance 
and self-management skills, and caregiver and family support, in order to 
achieve optimal health outcomes. Rehabilitation improves physical, speech, 
and cognitive functioning of disabled stroke patients. It is expected that 
home- or community-based services and tele-rehabilitation may hold special 
promise for stroke patients in LMICs.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (diagnosis, disease management, etiology, 
prevention, rehabilitation, therapy)
  lowest income group
  middle income group
  rehabilitation care
  social status
EMTREE MEDICAL INDEX TERMS
  age
  atrial fibrillation
  blood pressure regulation
  brain hemorrhage
  brain ischemia
  caregiver
  carotid artery obstruction
  cognition
  cost effectiveness analysis
  diabetes mellitus
  diagnostic accuracy
  dietary intake
  disabled person
  disease control
  disease surveillance
  family
  gender
  health care quality
  health education
  hypertension
  lifestyle
  movement therapy
  obesity
  occupational therapy
  physical activity
  physical capacity
  physiotherapy
  primary prevention
  priority journal
  review
  risk factor
  screening
  secondary prevention
  self care
  smoking cessation program
  speech
  stroke patient
  stroke unit
  telerehabilitation
  tobacco use
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Rehabilitation and Physical Medicine (19)
  Health Policy, Economics and Management (36)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160249865
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ensci.2016.02.011
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 55
TITLE
  Thrombotic events in patients with antiphospholipid syndrome treated with 
rivaroxaban: a series of eight cases
AUTHOR NAMES
  Signorelli F.
  Nogueira F.
  Domingues V.
  Mariz H.A.
  Levy R.A.
AUTHOR ADDRESSES
  (Signorelli F., flasigno@hotmail.com) Hospital Universitário Clementino 
Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
(Signorelli F., flasigno@hotmail.com) Hospital Universitário Pedro Ernesto, 
Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
(Nogueira F.; Levy R.A.) Faculdade de Ciências Médicas, Universidade do 
Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
(Domingues V.) New York University Langone Medical Center, New York 
University School of Medicine, New York, United States.
(Mariz H.A.) Faculdade de Ciências Médicas, Universidade Federal de 
Pernambuco, Recife, Brazil.
(Levy R.A.) Centro de Imunoterapia de Ipanema - CITIPA, Rio de Janeiro, 
Brazil.
CORRESPONDENCE ADDRESS
  F. Signorelli, Hospital Universitário Clementino Fraga Filho, Universidade 
Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Email: 
flasigno@hotmail.com
SOURCE
  Clinical Rheumatology (2016) 35:3 (801-805). Date of Publication: 1 Mar 2016
ISSN
  1434-9949 (electronic)
  0770-3198
BOOK PUBLISHER
  Springer-Verlag London Ltd
ABSTRACT
  The current treatment for antiphospholipid syndrome (APS) with thrombotic 
manifestation is long-term anticoagulation. Vitamin K antagonists (VKA) are 
usually the agents of choice. However, VKA limitations, such as 
unpredictable anticoagulation effects due to interaction with diet and other 
drugs, require regular monitoring. This may impact on patients’ quality of 
life. Since the approval of new oral anticoagulants (NOAC) for non-valvular 
atrial fibrillation and deep vein thrombosis prevention, much has been 
speculated about its use in APS patients. We report here a series of eight 
APS patients with failure of thrombotic prevention during rivaroxaban use. 
All patients had venous thrombosis as the initial manifestation of APS, and 
two of them also had arterial manifestations. Three patients had triple 
antibody positivity. Five patients developed arterial events during the 
treatment with rivaroxaban. Until the results of ongoing trials of 
rivaroxaban for APS are presented, NOAC should not be recommended to APS 
patients. Our preliminary experience as well cases previously reported in 
the literature suggest that there is a high-risk group that is less 
protected with rivaroxaban, namely those with previous arterial thrombosis 
or triple positivity. VKA remains to be the mainstay treatment for 
thrombotic APS.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  rivaroxaban (drug therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  antivitamin K (drug therapy)
  beta2 glycoprotein 1 antibody (endogenous compound)
  cardiolipin antibody (endogenous compound)
  clopidogrel (drug therapy)
  enoxaparin (drug therapy, subcutaneous drug administration)
  phospholipid antibody (endogenous compound)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  antiphospholipid syndrome (drug therapy, drug therapy)
  thrombosis (prevention)
EMTREE MEDICAL INDEX TERMS
  adult
  anticoagulant therapy
  artery thrombosis (drug therapy, prevention)
  cerebral artery disease (diagnosis)
  clinical article
  computer assisted tomography
  coronary artery occlusion (drug therapy, therapy)
  deep vein thrombosis (drug therapy, prevention)
  drug eluting stent
  drug substitution
  drug treatment failure
  drug withdrawal
  female
  human
  international normalized ratio
  kidney infarction (diagnosis)
  lower extremity deep vein thrombosis (drug therapy, prevention)
  lung embolism (drug therapy, prevention)
  male
  middle aged
  priority journal
  review
  thrombosis prevention
  young adult
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  enoxaparin (679809-58-6)
  rivaroxaban (366789-02-8)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Immunology, Serology and Transplantation (26)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015232120
FULL TEXT LINK
  http://dx.doi.org/10.1007/s10067-015-3030-y
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 56
TITLE
  Heart Failure with Preserved Ejection Fraction: Do You Know Your Left Atrial 
Strain?
AUTHOR NAMES
  Jellis C.L.
  Klein A.L.
AUTHOR ADDRESSES
  (Jellis C.L.; Klein A.L., kleina@ccf.org) Department of Cardiovascular 
Medicine, Cleveland Clinic, United States.
CORRESPONDENCE ADDRESS
  A.L. Klein, Cardiovascular Imaging J1-5, Heart and Vascular Institute, 
Cleveland Clinic, 9500 Euclid Ave, Cleveland, United States. Email: 
kleina@ccf.org
SOURCE
  Circulation: Cardiovascular Imaging (2016) 9:3 Article Number: e004521. Date 
of Publication: 1 Mar 2016
ISSN
  1942-0080 (electronic)
  1941-9651
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure with preserved ejection fraction
  heart left atrium
EMTREE MEDICAL INDEX TERMS
  diastolic dysfunction
  echocardiography
  electrocardiogram
  exercise
  heart death
  human
  hypertension
  paroxysmal atrial fibrillation
  priority journal
  review
  systolic heart failure
  tissue Doppler imaging
  two dimensional echocardiography
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  20160236933
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCIMAGING.116.004521
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 57
TITLE
  Brugada syndrome: More than 20 years of scientific excitement
AUTHOR NAMES
  Brugada P.
AUTHOR ADDRESSES
  (Brugada P., pedro@brugada.org) Department of Cardiology, Heart Rhythm 
Management Center, UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels, 
Belgium.
CORRESPONDENCE ADDRESS
  P. Brugada, Department of Cardiology, Heart Rhythm Management Center, UZ 
Brussel, Vrije Universiteit Brussel (VUB), 101 Laarbeeklaan, Brussels, 
Belgium. Email: pedro@brugada.org
SOURCE
  Journal of Cardiology (2016) 67:3 (215-220). Date of Publication: 1 Mar 2016
ISSN
  1876-4738 (electronic)
  0914-5087
BOOK PUBLISHER
  Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
ABSTRACT
  In 1992 we reported on eight patients with a particular electrocardiograph 
(ECG) showing ST segment elevation in the right precordial leads. All 
patients had a structurally normal heart and had survived one or multiple 
episodes of near sudden death caused by ventricular fibrillation. We showed 
6 years later that this disease, known nowadays as Brugada syndrome, was 
caused by mutations in the SCN5A gene which encodes for the cardiac sodium 
channel. Other genes where mutations result in the same ECG have been also 
identified, with at present more than 17 different genes published. These 
data show that Brugada syndrome is a genetically heterogeneous disease as is 
also the case in the long QT syndrome. In Brugada syndrome, the clue to the 
initial clinical diagnosis remains the abnormal ECG. However, it was evident 
from the beginning that the ECG of Brugada syndrome is variable and 
sensitive to many autonomic, drug, exercise, emotions and other external 
influences such as a meal, fever, changes in heart rate from any cause, and 
even body position. When followed intensively, all patients with a Brugada 
ECG will show a completely normal ECG at one or another moment in their 
lives. The spontaneous normalization of the ECG represents a major 
diagnostic challenge, because a patient with Brugada syndrome seen during 
normalization of the ECG may fail to get the correct diagnosis.In these more 
than 20 years great challenges have been overcome but some remain, mainly 
the approach to the asymptomatic individual with a diagnosis of Brugada 
syndrome. In 30-50% of individuals who die suddenly because of documented or 
suspected Brugada syndrome, sudden death is the first manifestation of the 
disease. Thus, these individuals were fully asymptomatic until the first 
fatal event.
EMTREE DRUG INDEX TERMS
  sodium channel Nav1.5 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Brugada syndrome
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  autonomic nervous system
  body position
  ECG abnormality
  electrocardiogram
  embryonic stem cell
  emotion
  exercise
  faintness
  gene mutation
  genetics
  heart rate
  heart right bundle branch block
  heart right ventricle dysplasia
  heart right ventricle outflow tract
  human
  long QT syndrome
  pathophysiology
  pluripotent stem cell
  review
  ST segment elevation
  sudden cardiac death
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20151027516
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jjcc.2015.08.009
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 58
TITLE
  Efficacy and safety of ablation for patients with non-paroxysmal atrial 
fibrillation
AUTHOR NAMES
  Amit G.
  Adler A.J.
  Owolabi O.O.
  Nyong J.
  Casas J.P.
  Prieto-Merino D.
  Perel P.
  Lambiase P.
  Morillo C.A.
AUTHOR ADDRESSES
  (Amit G.) Hamilton General Hospital, Division of Cardiology, Department of 
Medicine, 237 Barton Street East, Hamilton, Canada.
(Adler A.J.; Prieto-Merino D.) London School of Hygiene and Tropical 
Medicine, Department of Non-communicable Disease Epidemiology, Keppel 
Street, London, United Kingdom.
(Owolabi O.O.) London School of Hygiene and Tropical Medicine, Department of 
Epidemiology and Population Health, Keppel Street, London, United Kingdom.
(Nyong J.) FARR Institute UCL, Clinical Epidemiology, 222 Euston Road, 
London, United Kingdom.
(Casas J.P.) University College London, Institute of Health Informatics, 
Faculty of Population Health Sciences, London, United Kingdom.
(Perel P.) London School of Hygiene and Tropical Medicine, Department of 
Population Health, Keppel Street, London, United Kingdom.
(Lambiase P.) The Heart Hospital, University College London Hospitals, 
Centre for Cardiology in the Young, 16-18 Westmoreland Street, London, 
United Kingdom.
(Morillo C.A., morillo@hhsc.ca) McMaster University HHSC, Department of 
Medicine, Cardiology Division, Population Health Research Institute, 237 
Barton Street East, David Braley CVRSI, Hamilton, Canada.
CORRESPONDENCE ADDRESS
  C.A. Morillo, McMaster University HHSC, Department of Medicine, Cardiology 
Division, Population Health Research Institute, 237 Barton Street East, 
David Braley CVRSI, Hamilton, Canada. Email: morillo@hhsc.ca
SOURCE
  Cochrane Database of Systematic Reviews (2016) 2016:2 Article Number: 
CD012088. Date of Publication: 24 Feb 2016
ISSN
  1361-6137 (electronic)
  1469-493X
BOOK PUBLISHER
  John Wiley and Sons Ltd, Southern Gate, Chichester, West Sussex, United 
Kingdom.
ABSTRACT
  This is the protocol for a review and there is no abstract. The objectives 
are as follows: To determine the effect of ablation to maintain sinus rhythm 
in patients with persistent or long-standing persistent atrial fibrillation 
compared to anti-arrhythmic drugs.
EMTREE DRUG INDEX TERMS
  amiodarone
  dofetilide
  dronedarone
  flecainide
  propafenone
  quinidine
  sotalol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (therapy)
  catheter ablation
  non paroxysmal atrial fibrillation (therapy)
EMTREE MEDICAL INDEX TERMS
  exercise
  human
  persistent atrial fibrillation
  pulmonary vein isolation
  radiofrequency ablation
  randomized controlled trial (topic)
  review
  sinus rhythm
  systematic review
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  dofetilide (115256-11-6)
  dronedarone (141626-36-0)
  flecainide (54143-55-4)
  propafenone (34183-22-7, 54063-53-5)
  quinidine (56-54-2)
  sotalol (3930-20-9, 80456-07-1, 959-24-0)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160262892
FULL TEXT LINK
  http://dx.doi.org/10.1002/14651858.CD012088
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 59
TITLE
  Safety of vasodilator stress myocardial perfusion imaging in patients with 
elevated cardiac biomarkers
AUTHOR NAMES
  Rai M.
  Ahlberg A.W.
  Marwell J.
  Chaudhary W.
  Savino J.A.
  Alter E.L.
  Henzlova M.J.
  Duvall W.L.
AUTHOR ADDRESSES
  (Rai M.; Ahlberg A.W.; Chaudhary W.; Duvall W.L., lane.duvall@hhchealth.org) 
Division of Cardiology (Henry Low Heart Center), Hartford Hospital, 80 
Seymour Street, Hartford, United States.
(Marwell J.) Department of Medicine, University of Connecticut, Farmington, 
United States.
(Savino J.A.; Henzlova M.J.) Division of Cardiology (Mount Sinai Heart), 
Mount Sinai Medical Center, New York, United States.
(Alter E.L.) Department of Medicine, Mount Sinai Medical Center, New York, 
United States.
CORRESPONDENCE ADDRESS
  W.L. Duvall, Division of Cardiology (Henry Low Heart Center), Hartford 
Hospital, 80 Seymour Street, Hartford, United States. Email: 
lane.duvall@hhchealth.org
SOURCE
  Journal of Nuclear Cardiology (2016) (1-11). Date of Publication: 22 Feb 
2016
ISSN
  1532-6551 (electronic)
  1071-3581
BOOK PUBLISHER
  Springer New York LLC, barbara.b.bertram@gsk.com
ABSTRACT
  Background: While adenosine and dipyridamole as myocardial perfusion imaging 
(MPI) stress agents have literature supporting their safety in the setting 
of myocardial infarction (MI), regadenoson does not. Studying a high risk 
cohort of patients with elevated cardiac biomarkers may shed light on 
potential safety issues of these agents which might also affect lower risk 
cohorts. Methods: All patients who had undergone a clinically indicated 
stress MPI study at two academic centers from 1/1/2010 through 12/31/2012 
with elevated troponin ≤7 days prior to testing were included. The primary 
endpoint was a composite of death, non-fatal MI, congestive heart failure 
(CHF), stroke, ventricular arrhythmias, atrial fibrillation/flutter, or 
atrioventricular block requiring intervention within 24 h of testing. 
Results: Of the 703 stress MPI studies that met inclusion criteria, 360 
(51.2%), 199 (28.3%), 74 (10.5%), 9 (1.3%), and 61 (8.7%) underwent 
regadenoson, dipyridamole, adenosine, dobutamine, and exercise stress, 
respectively. The primary endpoint occurred in 11 (1.6%) patients with an 
incidence of 1.4% (n = 5), 1.0% (n = 2), 1.4% (n = 1), 11.1% (n = 1), and 
3.3% (n = 2) following regadenoson, dipyridamole, adenosine, dobutamine, and 
exercise stress, respectively (P = 0.137). The adverse events included 
non-fatal MI in 7 (1.0%) patients, death in 1 (0.1%) patient, CHF in 1 
(0.1%) patient, ventricular arrhythmia in 1 (0.1%) patient, and atrial 
arrhythmia in 1 (0.1%) patient. Conclusion: In the setting of elevated 
troponin, serious complications associated with either exercise or 
vasodilator stress testing appear to be relatively rare with no increased 
risk attributable to a particular vasodilator agent.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  vasodilator agent
EMTREE DRUG INDEX TERMS
  adenosine
  dipyridamole
  dobutamine
  regadenoson
  troponin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart
  myocardial perfusion imaging
  safety
  stress
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  atrioventricular block
  cerebrovascular accident
  chemical stress
  clinical article
  clinical trial
  congestive heart failure
  controlled clinical trial
  death
  exercise
  heart infarction
  heart ventricle arrhythmia
  human
  multicenter study
  side effect
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160165049
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12350-016-0448-9
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 60
TITLE
  Acute heart failure admissions in New South Wales and the Australian Capital 
Territory: The NSW HF snapshot study
AUTHOR NAMES
  Newton P.J.
  Davidson P.M.
  Reid C.M.
  Krum H.
  Hayward C.
  Sibbritt D.W.
  Banks E.
  Macdonald P.S.
AUTHOR ADDRESSES
  (Newton P.J., phillip.newton@uts.edu.au; Davidson P.M.) Centre for 
Cardiovascular and Chronic Care, University of Technology Sydney, Sydney, 
Australia.
(Davidson P.M.) Johns Hopkins University, Baltimore, United States.
(Reid C.M.) Curtin University, Perth, Australia.
(Reid C.M.; Krum H.) Monash Centre of Cardiovascular Research and Education 
in Therapeutics, Monash University, Melbourne, Australia.
(Hayward C.; Macdonald P.S.) St Vincent’s Hospital, Sydney, Australia.
(Sibbritt D.W.) Australian Research Centre in Complementary and Integrative 
Medicine, University of Technology Sydney, Sydney, Australia.
(Banks E.) National Centre for Epidemiology and Population Health, 
Australian National University, Canberra, Australia.
SOURCE
  Medical Journal of Australia (2016) 204:3 (113.e1-113.e8). Date of 
Publication: 15 Feb 2016
ISSN
  1326-5377 (electronic)
  0025-729X
BOOK PUBLISHER
  Australasian Medical Publishing Co. Ltd, ampco@ampco.com.au
ABSTRACT
  The primary aim of the NSW Heart Failure (HF) Snapshot was to obtain a 
representative cross-sectional view of patients with acute HF and their 
management in New South Wales and Australian Capital Territory hospitals 
Design and setting: A prospective audit of consecutive patients admitted to 
24 participating hospitals in NSW and the ACT with a diagnosis of acute HF 
was conducted from 8 July 2013 to 8 August 2013. Results: A total of 811 
participants were recruited (mean age, 77 13 years; 58% were men; 42% had a 
left ventricular ejection fraction 50%). The median Charlson Comorbidity 
Index score was 3, with is chaemic heart disease (56%), renal disease (55%), 
diabetes (38%) and chronic lung disease (32%) the most frequent 
comorbidities; 71% of patients were assessed as frail. Inter-current 
infection (22%), non-adherence to prescribed medication (5%) or to dietary 
or fluid restrictions (16%), and atrial fibrillation/flutter (15%) were the 
most commonly identified precipitants of HF. Initial treatment included 
intravenous diuretics (81%), oxygen therapy (87%), and bimodal positive 
airways pressure or continuous positive airways pressure ventilation (17%). 
During the index admission, 6% of patients died. The median length of stay 
in hospital was 6 days, but ranged between 3 and 12 days at different 
hospitals. Just over half the patients (59%) were referred to a 
multidisciplinary HF service. Discharge medications included 
angiotensin-converting enzyme inhibitors/angiotensin receptor blockers 
(59%), ß-blockers (66%) and loop diuretics (88%). Conclusions: Patients 
admitted to hospital with acute HF in NSW and the ACT were generally elderly 
and frail, with multiple comorbidities. Evidence-based therapies were 
underused, and there was substantial inter-hospital variation in the length 
of stay. We anticipate that the results of the HF Snapshot will inform the 
development of strategies for improving the uptake of evidence-based 
therapies, and hence outcomes, for HF patients.
EMTREE DRUG INDEX TERMS
  angiotensin receptor antagonist
  beta adrenergic receptor blocking agent
  dipeptidyl carboxypeptidase inhibitor
  diuretic agent (intravenous drug administration)
  glyceryl trinitrate (intravenous drug administration)
  loop diuretic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acute heart failure
EMTREE MEDICAL INDEX TERMS
  adolescent
  adult
  aged
  article
  artificial ventilation
  Australia
  Charlson Comorbidity Index
  child
  chronic lung disease
  death
  diabetes mellitus
  dialysis
  diet restriction
  female
  heart atrium flutter
  heart muscle ischemia
  human
  infection
  kidney disease
  length of stay
  major clinical study
  male
  medical audit
  medication compliance
  oxygen therapy
  positive end expiratory pressure
  resuscitation
CAS REGISTRY NUMBERS
  glyceryl trinitrate (55-63-0, 80738-44-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160137355
FULL TEXT LINK
  http://dx.doi.org/10.5694/mja15.00801
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 61
TITLE
  Is it always Alzheimer’s? Let’s talk to our patients about 
“cardiocerebrovascular” prevention
AUTHOR NAMES
  Volpe R.
  Sotis G.
  Cianciabella M.
AUTHOR ADDRESSES
  (Volpe R., roberto.volpe@cnr.it; Sotis G.) EWHETA (Eat Well for an HEalthy 
Third Age) Project, Italian National Research Council, Rome, Italy.
(Cianciabella M.) EWHETA (Eat Well for an HEalthy Third Age) Project, 
Italian National Research Council, Bologna, Italy.
CORRESPONDENCE ADDRESS
  R. Volpe, EWHETA (Eat Well for an HEalthy Third Age) Project, Italian 
National Research Council, Rome, Italy. Email: roberto.volpe@cnr.it
SOURCE
  Aging Clinical and Experimental Research (2016) 28:1 (159-160). Date of 
Publication: 1 Feb 2016
ISSN
  1720-8319 (electronic)
  1594-0667
BOOK PUBLISHER
  Springer International Publishing
ABSTRACT
  Unlike Alzheimer’s, vascular dementia can, in part, be prevented. The 
preventive approach foresees treatment for high blood pressure, atrial 
fibrillation, diabetes, high cholesterol, low HDL cholesterol, sedentary 
lifestyle, smoking, alcohol abuse, obesity, and sleep apnea. Moreover, also 
a well-balanced diet and physical activity are cornerstones of prevention, 
with beneficial effects on the brain and cognition.
EMTREE DRUG INDEX TERMS
  cholesterol (endogenous compound)
  high density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Alzheimer disease
  cerebrovascular disease (prevention)
EMTREE MEDICAL INDEX TERMS
  alcohol abuse
  article
  atrial fibrillation
  cardiovascular risk
  cholesterol blood level
  diabetes mellitus
  genetic predisposition
  human
  hypertension
  Mediterranean diet
  obesity
  physical activity
  risk factor
  sedentary lifestyle
  sleep disordered breathing
  smoking
CAS REGISTRY NUMBERS
  cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
  Clinical and Experimental Biochemistry (29)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015507459
FULL TEXT LINK
  http://dx.doi.org/10.1007/s40520-015-0480-7
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 62
TITLE
  Weight loss to prevent atrial fibrillation: The role of epicardial adipose 
tissue
AUTHOR NAMES
  Liu F.
  Li Y.
  Xu Y.
AUTHOR ADDRESSES
  (Liu F.; Xu Y.) Medical College of Hebei University of Engineering, Handan, 
China.
(Li Y., heibeiliyan@sina.com) Affiliated Hospital of Hebei University of 
Engineering, Guangming South Street 199, Handan City, China.
CORRESPONDENCE ADDRESS
  Y. Li, Affiliated Hospital of Hebei University of Engineering, Guangming 
South Street 199, Handan City, China. Email: heibeiliyan@sina.com
SOURCE
  International Journal of Cardiology (2016) 204 (124-125). Date of 
Publication: 1 Feb 2016
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  adipose tissue
  atrial fibrillation
  epicardial adipose tissue
  weight reduction
EMTREE MEDICAL INDEX TERMS
  article
  autonomic nervous system
  body mass
  body weight management
  cardiovascular risk
  comorbidity
  cytokine release
  heart atrium remodeling
  heart protection
  human
  lipid diet
  obesity
  priority journal
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  20160069467
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2015.08.159
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 63
TITLE
  Physical activity, symptoms, medication and subjective health among veteran 
endurance athletes with atrial fibrillation
AUTHOR NAMES
  Myrstad M.
  Aarønæs M.
  Graff-Iversen S.
  Ariansen I.
  Nystad W.
  Ranhoff A.H.
AUTHOR ADDRESSES
  (Myrstad M., m-myrsta@online.no; Aarønæs M.; Ranhoff A.H.) Department of 
Internal Medicine, Diakonhjemmet Hospital, Medisinsk avdeling, Diakonhjemmet 
sykehus, Pb 23 Vindern, Oslo, Norway.
(Graff-Iversen S.; Ariansen I.; Nystad W.) Division of Epidemiology, 
Norwegian Institute of Public Health, Oslo, Norway.
(Ranhoff A.H.) Department of Clinical Science, Kavli Research Centre for 
Geriatrics and Dementia, University of Bergen, Bergen, Norway.
CORRESPONDENCE ADDRESS
  M. Myrstad, Department of Internal Medicine, Diakonhjemmet Hospital, 
Medisinsk avdeling, Diakonhjemmet sykehus, Pb 23 Vindern, Oslo, Norway. 
Email: m-myrsta@online.no
SOURCE
  Clinical Research in Cardiology (2016) 105:2 (154-161). Date of Publication: 
1 Feb 2016
ISSN
  1861-0692 (electronic)
  1861-0684
BOOK PUBLISHER
  Dr. Dietrich Steinkopff Verlag GmbH and Co. KG
ABSTRACT
  Background: Atrial fibrillation (AF) is highly prevalent, but has not 
previously been characterized in detail in veteran athletes. We aimed to 
describe physical activity (PA), symptoms, medication and subjective health 
in relation to AF subtype and co-morbidity among veteran cross-country 
skiers with AF. Methods: In total, 4952 Norwegian men and women aged 
53–85 years took part in this cohort study, 2626 veteran cross-country 
skiers and 2326 from the general population. PA, endurance exercise, 
functional capacity, co-morbidity, drug use and subjective health were 
self-reported by questionnaires. AF was self-reported and confirmed by 
electrocardiograms in a medical record review. Results: The prevalence of 
self-reported AF among veteran skiers was 12.3 %. AF was confirmed in 140 
skiers and 118 individuals from the general population. Among skiers with AF 
(mean age 69 years), 52 % had paroxysmal, 23 % persistent and 24 % permanent 
AF. AF was associated with poor subjective health, but 89 % of the veteran 
skiers were physically active and 64 % engaged in regular endurance exercise 
after the onset of AF. While 59 % had experienced palpitations during the 
past year, 32 % reported reduced functional capacity. Two out of three with 
AF and a CHA(2)DS(2)-VASc score ≥2 used oral anticoagulants (OACs). 
Conclusions: AF was associated with poor subjective health, but the vast 
majority of veteran athletes engaged in regular PA and endurance exercise 
also after the onset of AF. This is important, as PA and exercise might 
reduce AF symptoms, mortality and morbidity. Many veteran skiers with AF 
were not optimally treated with OACs.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  amiodarone (drug therapy)
  anticoagulant agent (drug therapy, oral drug administration)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
  dabigatran (drug therapy)
  digitoxin (drug therapy)
  digoxin (drug therapy)
  dronedarone (drug therapy)
  flecainide (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  atrial fibrillation (drug therapy, drug therapy)
  health status
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  comorbidity
  drug use
  electrocardiography
  endurance
  endurance training
  female
  functional status
  human
  major clinical study
  male
  medical record review
  middle aged
  New York Heart Association class
  physical activity
  questionnaire
  skiing
  very elderly
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digitoxin (71-63-6)
  digoxin (20830-75-5, 57285-89-9)
  dronedarone (141626-36-0)
  flecainide (54143-55-4)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015226083
FULL TEXT LINK
  http://dx.doi.org/10.1007/s00392-015-0898-0
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 64
TITLE
  Weight loss and coronary heart disease: Sensitivity analysis for unmeasured 
confounding by undiagnosed disease
AUTHOR NAMES
  Danaei G.
  Robins J.M.
  Young J.G.
  Hu F.B.
  Manson J.E.
  Hernán M.A.
AUTHOR ADDRESSES
  (Danaei G., gdanaei@hsph.harvard.edu) Department of Global Health and 
Population, Harvard T.H. Chan School of Public Health, 665 Huntington 
Avenue, Boston, United States.
(Danaei G., gdanaei@hsph.harvard.edu; Robins J.M.; Young J.G.; Hu F.B.; 
Manson J.E.; Hernán M.A.) Department of Epidemiology, Harvard T.H. Chan 
School of Public Health, Boston, United States.
(Robins J.M.; Hernán M.A.) Department of Biostatistics, Harvard T.H. Chan 
School of Public Health, Boston, United States.
(Hu F.B.) Department of Nutrition, Harvard T.H. Chan School of Public 
Health, Boston, United States.
(Hu F.B.) Channing Laboratory, Harvard Medical School, Brigham and Women's 
Hospital, Boston, United States.
(Manson J.E.) Division of Preventive Medicine, Brigham and Women's Hospital, 
Harvard Medical School, Boston, United States.
(Hernán M.A.) Harvard-MIT Division of Health Sciences and Technology, 
Cambridge, United States.
CORRESPONDENCE ADDRESS
  G. Danaei, Department of Global Health and Population, Harvard T.H. Chan 
School of Public Health, 665 Huntington Avenue, Boston, United States. 
Email: gdanaei@hsph.harvard.edu
SOURCE
  Epidemiology (2016) 27:2 (302-310). Date of Publication: 28 Jan 2016
ISSN
  1531-5487 (electronic)
  1044-3983
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Background: Evidence for the effect of weight loss on coronary heart disease 
(CHD) or mortality has been mixed. The effect estimates can be confounded 
due to undiagnosed diseases that may affect weight loss. Methods: We used 
data from the Nurses' Health Study to estimate the 26-year risk of CHD under 
several hypothetical weight loss strategies. We applied the parametric 
g-formula and implemented a novel sensitivity analysis for unmeasured 
confounding due to undiagnosed disease by imposing a lag time for the effect 
of weight loss on chronic disease. Several sensitivity analyses were 
conducted. Results: The estimated 26-year risk of CHD did not change under 
weight loss strategies using lag times from 0 to 18 years. For a 6-year lag 
time, the risk ratios of CHD for weight loss compared with no weight loss 
ranged from 1.00 (0.99, 1.02) to 1.02 (0.99, 1.05) for different degrees of 
weight loss with and without restricting the weight loss strategy to 
participants with no major chronic disease. Similarly, no protective effect 
of weight loss was estimated for mortality risk. In contrast, we estimated a 
protective effect of weight loss on risk of type 2 diabetes. Conclusion: We 
estimated that maintaining or losing weight after becoming overweight or 
obese does not reduce the risk of CHD or death in this cohort of middle-age 
US women. Unmeasured confounding, measurement error, and model 
misspecification are possible explanations but these did not prevent us from 
estimating a beneficial effect of weight loss on diabetes.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  multivitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  ischemic heart disease
  weight reduction
EMTREE MEDICAL INDEX TERMS
  adult
  alcohol consumption
  Alzheimer disease
  amyotrophic lateral sclerosis
  angina pectoris
  article
  atrial fibrillation
  cardiovascular risk
  cerebrovascular accident
  chronic disease
  chronic kidney disease
  depression
  diabetes mellitus
  emphysema
  exercise
  female
  follow up
  gout
  heart failure
  heart infarction
  human
  lung embolism
  major clinical study
  male
  multiple sclerosis
  neoplasm
  non insulin dependent diabetes mellitus
  Parkinson disease
  peripheral vascular disease
  priority journal
  rheumatoid arthritis
  smoking
  systemic lupus erythematosus
  ulcerative colitis
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20151003346
FULL TEXT LINK
  http://dx.doi.org/10.1097/EDE.0000000000000428
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 65
TITLE
  Executive summary: Heart disease and stroke statistics-2016 update: A Report 
from the American Heart Association
AUTHOR NAMES
  Mozaffarian D.
  Benjamin E.J.
  Go A.S.
  Arnett D.K.
  Blaha M.J.
  Cushman M.
  Das S.R.
  De Ferranti S.
  Després J.-P.
  Fullerton H.J.
  Howard V.J.
  Huffman M.D.
  Isasi C.R.
  Jiménez M.C.
  Judd S.E.
  Kissela B.M.
  Lichtman J.H.
  Lisabeth L.D.
  Liu S.
  MacKey R.H.
  Magid D.J.
  McGuire D.K.
  Mohler E.R.
  Moy C.S.
  Muntner P.
  Mussolino M.E.
  Nasir K.
  Neumar R.W.
  Nichol G.
  Palaniappan L.
  Pandey D.K.
  Reeves M.J.
  Rodriguez C.J.
  Rosamond W.
  Sorlie P.D.
  Stein J.
  Towfighi A.
  Turan T.N.
  Virani S.S.
  Woo D.
  Yeh R.W.
  Turner M.B.
AUTHOR ADDRESSES
  (Mozaffarian D.; Benjamin E.J.; Go A.S.; Arnett D.K.; Blaha M.J.; Cushman 
M.; Das S.R.; De Ferranti S.; Després J.-P.; Fullerton H.J.; Howard V.J.; 
Huffman M.D.; Isasi C.R.; Jiménez M.C.; Judd S.E.; Kissela B.M.; Lichtman 
J.H.; Lisabeth L.D.; Liu S.; MacKey R.H.; Magid D.J.; McGuire D.K.; Mohler 
E.R.; Moy C.S.; Muntner P.; Mussolino M.E.; Nasir K.; Neumar R.W.; Nichol 
G.; Palaniappan L.; Pandey D.K.; Reeves M.J.; Rodriguez C.J.; Rosamond W.; 
Sorlie P.D.; Stein J.; Towfighi A.; Turan T.N.; Virani S.S.; Woo D.; Yeh 
R.W.; Turner M.B.)
SOURCE
  Circulation (2016) 133:4 (447-454). Date of Publication: 26 Jan 2016
ISSN
  1524-4539 (electronic)
  0009-7322
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Each year, the American Heart Association (AHA), in conjunction with the 
Centers for Disease Control and Prevention, the National Institutes of 
Health, and other government agencies, brings together the most up-to-date 
statistics related to heart disease, stroke, and other cardiovascular and 
metabolic diseases and presents them in its Heart Disease and Stroke 
Statistical Update. The Statistical Update represents a critical resource 
for the lay public, policy makers, media professionals, clinicians, 
healthcare administrators, researchers, and others seeking the best 
available data on these conditions. Together, cardiovascular disease (CVD) 
and stroke produce immense health and economic burdens in the United States 
and globally. The Statistical Update brings together in a single document 
up-to-date information on the core health behaviors (including diet, 
physical activity [PA], smoking, and energy balance) and health factors 
(including blood pressure, cholesterol, and glucose) that define 
cardiovascular health; a range of major clinical disease conditions 
(including stroke, congenital heart disease, rhythm disorders, subclinical 
atherosclerosis, coronary heart disease, heart failure, valvular disease, 
and peripheral arterial disease); and the associated outcomes (including 
quality of care, procedures, and economic costs). Since 2006, the annual 
versions of the Statistical Update have been cited >28 000 times in the 
literature. In 2014 alone, the various Statistical Updates were cited >5000 
times. Each annual version of the Statistical Update undergoes major 
revisions to include the newest nationally representative data, add 
additional relevant published scientific findings, remove older information, 
add new sections or chapters, and increase the number of ways to access and 
use the assembled information. This year-long process, which begins as soon 
as the previous Statistical Update is published, is performed by the AHA 
Statistics Committee faculty volunteers and staff. For example, this year's 
edition includes new data on the monitoring and benefits of cardiovascular 
health in the population, new metrics to assess and monitor healthy diets, 
additional information in many chapters on the global CVD and stroke burden, 
new information on stroke in young adults, a new focus on underserved and 
minority populations, and further evidencebased approaches to changing 
behaviors, implementation strategies, and implications of the AHA's 2020 
Impact Goals. Below are a few highlights from this year's Update.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident
  health statistics
  heart disease
EMTREE MEDICAL INDEX TERMS
  aorta disease
  atherosclerosis
  atrial fibrillation
  cardiovascular disease
  cholesterol blood level
  diabetes mellitus
  energy balance
  family history
  health behavior
  health promotion
  heart failure
  human
  hypertension
  ischemic heart disease
  medical society
  metabolic syndrome X
  national health organization
  nutrition
  obesity
  peripheral occlusive artery disease
  physical inactivity
  priority journal
  review
  risk assessment
  sudden cardiac death
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160100755
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIR.0000000000000366
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 66
TITLE
  Heart disease and stroke statistics-2016 update a report from the American 
Heart Association
AUTHOR NAMES
  Mozaffarian D.
  Benjamin E.J.
  Go A.S.
  Arnett D.K.
  Blaha M.J.
  Cushman M.
  Das S.R.
  Ferranti S.D.
  Després J.-P.
  Fullerton H.J.
  Howard V.J.
  Huffman M.D.
  Isasi C.R.
  Jiménez M.C.
  Judd S.E.
  Kissela B.M.
  Lichtman J.H.
  Lisabeth L.D.
  Liu S.
  MacKey R.H.
  Magid D.J.
  McGuire D.K.
  Mohler Iii E.R.
  Moy C.S.
  Muntner P.
  Mussolino M.E.
  Nasir K.
  Neumar R.W.
  Nichol G.
  Palaniappan L.
  Pandey D.K.
  Reeves M.J.
  Rodriguez C.J.
  Rosamond W.
  Sorlie P.D.
  Stein J.
  Towfighi A.
  Turan T.N.
  Virani S.S.
  Woo D.
  Yeh R.W.
  Turner M.B.
AUTHOR ADDRESSES
  (Mozaffarian D.; Benjamin E.J.; Go A.S.; Arnett D.K.; Blaha M.J.; Cushman 
M.; Das S.R.; Ferranti S.D.; Després J.-P.; Fullerton H.J.; Howard V.J.; 
Huffman M.D.; Isasi C.R.; Jiménez M.C.; Judd S.E.; Kissela B.M.; Lichtman 
J.H.; Lisabeth L.D.; Liu S.; MacKey R.H.; Magid D.J.; McGuire D.K.; Mohler 
Iii E.R.; Moy C.S.; Muntner P.; Mussolino M.E.; Nasir K.; Neumar R.W.; 
Nichol G.; Palaniappan L.; Pandey D.K.; Reeves M.J.; Rodriguez C.J.; 
Rosamond W.; Sorlie P.D.; Stein J.; Towfighi A.; Turan T.N.; Virani S.S.; 
Woo D.; Yeh R.W.; Turner M.B.)
SOURCE
  Circulation (2016) 133:4 (e38-e48). Date of Publication: 26 Jan 2016
ISSN
  1524-4539 (electronic)
  0009-7322
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Each year, the American Heart Association (AHA), in conjunction with the 
Centers for Disease Control and Prevention, the National Institutes of 
Health, and other government agencies, brings together the most up-to-date 
statistics related to heart disease, stroke, and other cardiovascular and 
metabolic diseases and presents them in its Heart Disease and Stroke 
Statistical Update. The Statistical Update represents a critical resource 
for the lay public, policy makers, media professionals, clinicians, 
healthcare administrators, researchers, and others seeking the best 
available data on these conditions. Together, cardiovascular disease (CVD) 
and stroke produce immense health and economic burdens in the United States 
and globally. The Statistical Update brings together in a single document 
up-to-date information on the core health behaviors (including diet, 
physical activity [PA], smoking, and energy balance) and health factors 
(including blood pressure, cholesterol, and glucose) that define 
cardiovascular health; a range of major clinical disease conditions 
(including stroke, congenital heart disease, rhythm disorders, subclinical 
atherosclerosis, coronary heart disease, heart failure, valvular disease, 
and peripheral arterial disease); and the associated outcomes (including 
quality of care, procedures, and economic costs). Since 2006, the annual 
versions of the Statistical Update have been cited >28 000 times in the 
literature. In 2014 alone, the various Statistical Updates were cited >5000 
times. Each annual version of the Statistical Update undergoes major 
revisions to include the newest nationally representative data, add 
additional relevant published scientific findings, remove older information, 
add new sections or chapters, and increase the number of ways to access and 
use the assembled information. This year-long process, which begins as soon 
as the previous Statistical Update is published, is performed by the AHA 
Statistics Committee faculty volunteers and staff. For example, this year's 
edition includes new data on the monitoring and benefits of cardiovascular 
health in the population, new metrics to assess and monitor healthy diets, 
additional information in many chapters on the global CVD and stroke burden, 
new information on stroke in young adults, a new focus on underserved and 
minority populations, and further evidence-based approaches to changing 
behaviors, implementation strategies, and implications of the AHA's 2020 
Impact Goals. Below are a few highlights from this year's Update.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident
  heart disease
EMTREE MEDICAL INDEX TERMS
  acute coronary syndrome
  angina pectoris
  aorta disease
  atherosclerosis
  atrial fibrillation
  cardiomyopathy
  cardiovascular disease
  cardiovascular procedure
  cholesterol blood level
  chronic kidney disease
  diabetes mellitus
  family history
  genetics
  health behavior
  health care cost
  health care delivery
  health care quality
  health care utilization
  heart arrhythmia
  heart failure
  human
  hypertension
  ischemic heart disease
  medical society
  metabolic syndrome X
  mucocutaneous lymph node syndrome
  nutrition
  obesity
  peripheral occlusive artery disease
  physical activity
  physical inactivity
  priority journal
  review
  smoking
  sudden cardiac death
  tobacco use
  valvular heart disease
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20151042454
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIR.0000000000000350
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 67
TITLE
  The metabolic exercise test data combined with Cardiac and Kidney Indexes 
(MECKI) score and prognosis in heart failure. A validation study
AUTHOR NAMES
  Corrà U.
  Agostoni P.
  Giordano A.
  Cattadori G.
  Battaia E.
  La Gioia R.
  Scardovi A.B.
  Emdin M.
  Metra M.
  Sinagra G.
  Limongelli G.
  Raimondo R.
  Re F.
  Guazzi M.
  Belardinelli R.
  Parati G.
  Magrì D.
  Fiorentini C.
  Cicoira M.
  Salvioni E.
  Giovannardi M.
  Veglia F.
  Mezzani A.
  Scrutinio D.
  Di Lenarda A.
  Ricci R.
  Apostolo A.
  Iorio A.M.
  Paolillo S.
  Palermo P.
  Contini M.
  Vassanelli C.
  Passino C.
  Giannuzzi P.
  Piepoli M.F.
AUTHOR ADDRESSES
  (Corrà U., ucorra@fsm.it; Mezzani A.; Giannuzzi P.) Divisione di Cardiologia 
Riabilitativa, Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di 
Veruno, Veruno, Italy.
(Agostoni P.; Cattadori G.; Battaia E.; Fiorentini C.; Salvioni E.; 
Giovannardi M.; Veglia F.; Apostolo A.; Palermo P.; Contini M.) Centro 
Cardiologico Monzino, IRCCS, Milano, Italy.
(Agostoni P.; Fiorentini C.) Department of Clinical Sciences and Community 
Health, Cardiovascular Section, Università di Milano, Milano, Italy.
(Giordano A.) Bioengineering Department, Salvatore Maugeri Foundation, 
IRCCS, Veruno, Italy.
(Battaia E.; Cicoira M.; Vassanelli C.) Section of Cardiology, Department of 
Medicine, University of Verona, Italy.
(La Gioia R.; Scrutinio D.) Division of Cardiology, S. Maugeri Foundation, 
IRCCS, Institute of Cassano Murge, Bari, Italy.
(Scardovi A.B.; Ricci R.) UOC Cardiologia Ospedale S. Spirito, Roma 
Lungotevere in Sassia 3, Roma, Italy.
(Emdin M.; Passino C.) Fondazione Gabriele Monasterio, CNR-Regione Toscana, 
Pisa, Italy.
(Metra M.) Cardiology, Department of Medical and Surgical Specialties, 
Radiological Sciences, and Public Health, University of Brescia, Italy.
(Sinagra G.) Cardiovascular Department, Ospedali Riuniti, University of 
Trieste, Trieste, Italy.
(Limongelli G.; Iorio A.M.) Cardiologia SUN, Ospedale Monaldi (Azienda Dei 
Colli), Seconda Università di Napoli, Napoli, Italy.
(Raimondo R.) Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di 
Tradate, Dipartimento di Medicina e Riabilitazione Cardiorespiratoria, Unità 
Operativa di Cardiologia Riabilitativa, Tradate, Italy.
(Re F.) Cardiology Division, Cardiac Arrhythmia Center, Cardiomyopathies 
Unit, St.Camillo-Forlanini Hospital, Roma, Italy.
(Guazzi M.) Department of Medical Sciences, Cardiology, I.R.C.C.S. San 
Donato Hospital, University of Milan, San Donato Milanese, Milano, Italy.
(Belardinelli R.) Cardiologia Riabilitativa, Azienda Ospedali Riuniti, 
Ancona, Italy.
(Parati G.) Dept of Health Science, University of Milano Bicocca, Dept of 
Cardiology, S.Luca Hospital, Istituto Auxologico Italiano, Milano, Italy.
(Magrì D.) Dipartimento di Medicina Clinica e Molecolare, Sapienza 
Università Degli Studi di Roma, Roma, Italy.
(Di Lenarda A.) Centro Cardiovascolare, Azienda per i Servizi Sanitari no1, 
Trieste, Italy.
(Paolillo S.) Department of Advanced Biomedical Sciences, Federico II 
University, Italy.
(Passino C.) Scuola Superiore S. Anna, Pisa, Italy.
(Piepoli M.F.) UOC Cardiologia, G da Saliceto Hospital, Piacenza, Italy.
()
CORRESPONDENCE ADDRESS
  U. Corrà, Laboratory for the Analysis of Cardio-respiratory Signals, 
Divisione di Cardiologia Riabilitativa, Fondazione Salvatore Maugeri, IRCCS, 
Istituto Scientifico di Veruno, Via per Revislate, 13, Veruno, Italy. Email: 
ucorra@fsm.it
SOURCE
  International Journal of Cardiology (2016) 203 (1067-1072). Date of 
Publication: 15 Jan 2016
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
ABSTRACT
  Background The Metabolic Exercise test data combined with Cardiac and Kidney 
Indexes (MECKI) score is a prognostic model to identify heart failure (HF) 
patients at risk for cardiovascular mortality (CVM) and urgent heart 
transplantation (uHT) based on 6 routine clinical parameters: hemoglobin, 
sodium, kidney function by the Modification of Diet in Renal Disease (MDRD) 
equation, left ventricle ejection fraction (LVEF), percentage of predicted 
peak oxygen consumption (VO2) and VE/VCO2 slope. Objectives MECKI score must 
be generalizable to be considered useful: therefore, its performance was 
validated in a new sequence of HF patients. Methods Both the development 
(MECKI-D) and the validation (MECKI-V) cohorts were composed of consecutive 
HF patients with LVEF < 40% able to perform a symptom-limited 
cardiopulmonary exercise testing. The CVM or uHT rates were analyzed at one, 
two and three years in both cohorts: all patients with a censoring time 
shorter than the scheduled follow-up were excluded, while those with events 
occurring after 1, 2 and 3 years were considered as censored. Results 
MECKI-D and MECKI-V consisted of 2009 and 992 patients, respectively. 
MECKI-V patients had a higher LVEF, higher peak VO2 and lower VE/VCO2 slope, 
higher prescription of beta-blockers and device therapy: after the 3-year 
follow-up, CVM or uHT occurred in 206 (18%) MECKI-D and 44 (13%) MECKI-V 
patients (p < 0.000), respectively. MECKI-V AUC values at one, two and three 
years were 0.81 ± 0.04, 0.76 ± 0.04, and 0.80 ± 0.03, respectively, not 
significantly different from MECKI-D. Conclusions MECKI score preserves its 
predictive ability in a HF population at a lower risk.
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (drug therapy)
  amiodarone (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  digitalis (drug therapy)
  hemoglobin (endogenous compound)
  loop diuretic agent (drug therapy)
  sodium (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular mortality
  heart failure (drug therapy, diagnosis, drug therapy)
  metabolic exercise test data combined with Cardiac And Kidney Indexes score
  prognosis
  risk assessment
  scoring system
EMTREE MEDICAL INDEX TERMS
  adult
  anaerobic threshold
  article
  atrial fibrillation (drug therapy)
  cardiopulmonary exercise test
  cohort analysis
  controlled study
  criterion variable
  defibrillator
  female
  follow up
  heart left ventricle ejection fraction
  heart transplantation
  hemoglobin blood level
  human
  kidney function by the Modification of Diet in Renal Disease equation
  lung gas exchange
  major clinical study
  male
  New York Heart Association class
  oxygen consumption
  predictive value
  priority journal
  receiver operating characteristic
  sodium blood level
  validation study
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digitalis (8031-42-3, 8053-83-6)
  hemoglobin (9008-02-0)
  sodium (7440-23-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160013673
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2015.11.075
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 68
TITLE
  Prognostic significance of exercise capacity and resting heart rate: 
Comparison between atrial fibrillation and sinus rhythm
AUTHOR NAMES
  Kato Y.
  Suzuki S.
  Kano H.
  Semba H.
  Matsuno S.
  Takai H.
  Otsuka T.
  Uejima T.
  Oikawa Y.
  Nagashima K.
  Kirigaya H.
  Sagara K.
  Kunihara T.
  Yajima J.
  Sawada H.
  Aizawa T.
  Yamashita T.
AUTHOR ADDRESSES
  (Kato Y., kimuchi@nms.ac.jp; Suzuki S.; Kano H.; Semba H.; Matsuno S.; Takai 
H.; Otsuka T.; Uejima T.; Oikawa Y.; Nagashima K.; Kirigaya H.; Sagara K.; 
Kunihara T.; Yajima J.; Sawada H.; Aizawa T.; Yamashita T.) Department of 
Cardiovascular Medicine, Cardiovascular Institute, Nishiazabu 3-2-19, 
Minato-ku, Japan.
CORRESPONDENCE ADDRESS
  Y. Kato, Department of Cardiovascular Medicine, Cardiovascular Institute, 
Nishiazabu 3-2-19, Minato-ku, Japan. Email: kimuchi@nms.ac.jp
SOURCE
  International Journal of Cardiology (2016) 203 (561-563). Date of 
Publication: 15 Jan 2016
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  oxygen consumption
  peak oxygen consumption
  resting heart rate
  sinus rhythm
EMTREE MEDICAL INDEX TERMS
  adult
  article
  cardiopulmonary exercise test
  cohort analysis
  controlled study
  disease association
  exercise
  female
  health impact assessment
  heart failure
  hospitalization
  human
  major clinical study
  male
  middle aged
  outcome assessment
  prediction
  priority journal
  prognosis
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  20160016972
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2015.10.227
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 69
TITLE
  Combined impact of healthy lifestyle factors on risk of atrial fibrillation: 
Prospective study in men and women
AUTHOR NAMES
  Larsson S.C.
  Drca N.
  Jensen-Urstad M.
  Wolk A.
AUTHOR ADDRESSES
  (Larsson S.C., susanna.larsson@ki.se; Wolk A.) Unit of Nutritional 
Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 
Box 210, Stockholm, Sweden.
(Drca N.; Jensen-Urstad M.) Department of Cardiology, Karolinska University 
Hospital, Karolinska Institutet, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
  S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental 
Medicine, Karolinska Institutet, Box 210, Stockholm, Sweden. Email: 
susanna.larsson@ki.se
SOURCE
  International Journal of Cardiology (2016) 203 (46-49). Date of Publication: 
15 Jan 2016
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
ABSTRACT
  Background The combined impact of multiple lifestyle factors on risk of 
atrial fibrillation (AF) remains unclear. We investigated the joint 
association of four modifiable lifestyle factors on incidence of AF in a 
prospective study of men and women. Methods The study cohort comprised 39 
300 men in the Cohort of Swedish Men and 33 090 women in the Swedish 
Mammography Cohort who were 45-83 years of age and free from atrial 
fibrillation at baseline. Healthy lifestyle was defined as body mass index < 
25 kg/m(2), regular exercise for ≥ 20 min/day, no or light-to-moderate 
alcohol consumption (≤ 2 drinks/day for men and ≤ 1 drink/day for women), 
and not smoking. Incident AF cases were identified through linkage with the 
Swedish National Inpatient Register. Results During a mean follow-up of 10.9 
years, AF occurred in 4028 men and 2539 women. Compared with men and women 
with no healthy lifestyle factors, the multivariable relative risks (95% 
confidence interval) of AF were 0.83 (0.65-1.07) for one, 0.74 (0.58-0.94) 
for two, 0.62 (0.49-0.79) for three, and 0.50 (0.39-0.64) for four healthy 
lifestyle factors (P for trend < 0.0001). The inverse association was 
similar in men and women. Conclusions Four healthy lifestyle factors 
combined were associated with a halving of the risk of AF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  cardiovascular risk
  lifestyle
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  alcohol consumption
  article
  body mass
  cohort analysis
  cycling
  disease association
  exercise
  female
  follow up
  human
  incidence
  male
  priority journal
  prospective study
  risk factor
  sensitivity analysis
  smoking
  walking
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160016974
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2015.10.106
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 70
TITLE
  Behavioral influences on cardiac arrhythmias
AUTHOR NAMES
  Lampert R.
AUTHOR ADDRESSES
  (Lampert R., rachel.lampert@yale.edu) Section of Cardiovascular Medicine, 
Yale University School of Medicine, New Haven, United States.
CORRESPONDENCE ADDRESS
  R. Lampert, Section of Cardiovascular Medicine, Yale University School of 
Medicine, 789 Howard Avenue, Dana 319, New Haven, United States. Email: 
rachel.lampert@yale.edu
SOURCE
  Trends in Cardiovascular Medicine (2016) 26:1 (68-77). Date of Publication: 
1 Jan 2016
ISSN
  1873-2615 (electronic)
  1050-1738
BOOK PUBLISHER
  Elsevier Inc., usjcs@elsevier.com
ABSTRACT
  Stress can trigger both ventricular and atrial arrhythmias, as evidenced by 
epidemiological, clinical, and laboratory studies, through its impact on 
autonomic activity. Chronic stress also increases vulnerability to 
arrhythmias. Novel therapies aimed at decreasing the psychological and 
physiological response to stress may decrease arrhythmia frequency and 
improve quality of life.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart arrhythmia (therapy)
EMTREE MEDICAL INDEX TERMS
  acute stress
  alternative medicine
  atrial fibrillation (therapy)
  chronic stress
  cognitive therapy
  disease predisposition
  emotion
  genetic disorder
  heart electrophysiology
  heart ventricle arrhythmia
  human
  priority journal
  quality of life
  review
  sudden death
  yoga
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015039575
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.tcm.2015.04.008
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 71
TITLE
  The predictive role of renal function and systemic inflammation on the onset 
of de novo atrial fibrillation after cardiac surgery
AUTHOR NAMES
  Limite L.R.
  Magnoni M.
  Berteotti M.
  Peretto G.
  Durante A.
  Cristell N.
  Laricchia A.
  Camici P.G.
  Alfieri O.
  Cianflone D.
AUTHOR ADDRESSES
  (Limite L.R.; Magnoni M.; Berteotti M.; Peretto G.; Durante A.; Cristell N.; 
Laricchia A.; Camici P.G.; Alfieri O.; Cianflone D., 
cianflone.domenico@hsr.it) Cardiovascular Department, San Raffaele 
Scientific Institute, Italy.
CORRESPONDENCE ADDRESS
  D. Cianflone, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, Italy. 
Email: cianflone.domenico@hsr.it
SOURCE
  European Journal of Preventive Cardiology (2016) 23:2 (206-213). Date of 
Publication: 1 Jan 2016
ISSN
  2047-4881 (electronic)
  2047-4873
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  Background The association between postoperative atrial fibrillation (POAF) 
and renal function was previously grounded in patients undergoing coronary 
artery bypass grafting through unknown mechanisms. We aim to investigate the 
association between renal function and POAF in a cohort composed mostly of 
patients undergoing valve surgery and to explore the role of inflammation as 
a pathogenic mechanism linking renal dysfunction and arrhythmogenesis. 
Methods Altogether 444 patients who underwent cardiac surgery without 
previous history of atrial fibrillation were analysed. Serum creatinine and 
high sensitivity C-reactive protein (hs-CRP) concentrations were obtained at 
baseline and on the 3rd, 8th and 15th postoperative day; estimated 
glomerular filtration rate (EGFR) was calculated by the Modified Diet Renal 
Disease (MDRD) formula. Patients were divided into three groups on the basis 
of baseline EGFR. Results Overall, 173 (39%) patients developed POAF, 29.5% 
in the group with normal EGFR (≥90 ml/min/1.73 m(2)), 43.3% among patients 
with EGFR 60-90 ml/min/1.73 m(2) and 55.6% in the group with EGFR ‰60 
ml/min/1.73 m. Patients developing POAF had lower EGFR on all the samples. 
At baseline preoperatively hs-CRP levels did not differ in the two groups. 
On multivariate analysis, age and EGFR were identified as independent 
predictors of POAF. The risk of POAF progressively increased from mild 
impairment (odds ratio (OR) 1.59, 95% confidence interval (CI) 1.01-2.50) to 
severe reduction of renal function (OR 2.35, 95% CI 1.25-4.48). Conclusions 
Age and EGFR were identified as the strongest predictors of POAF in a 
population largely composed of valve surgery patients. Renal function, even 
from early stage, is independently associated with the increasing risk of 
developing POAF.
EMTREE DRUG INDEX TERMS
  C reactive protein (endogenous compound)
  creatinine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (epidemiology)
  heart surgery
  inflammation
  kidney dysfunction
  postoperative atrial fibrillation (epidemiology)
  predictive value
EMTREE MEDICAL INDEX TERMS
  adult
  arrhythmogenesis
  article
  creatinine blood level
  disease association
  glomerulus filtration rate
  human
  major clinical study
  prevalence
  priority journal
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  creatinine (19230-81-0, 60-27-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Urology and Nephrology (28)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160018345
FULL TEXT LINK
  http://dx.doi.org/10.1177/2047487314564896
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 72
TITLE
  Adult height, nutrition, and population health
AUTHOR NAMES
  Perkins J.M.
  Subramanian S.V.
  Smith G.D.
  Özaltin E.
AUTHOR ADDRESSES
  (Perkins J.M.; Subramanian S.V.) Harvard Center for Population and 
Development Studies, Cambridge, United States.
(Perkins J.M.; Subramanian S.V.) Harvard T.H. Chan School of Public Health, 
Boston, United States.
(Perkins J.M.; Subramanian S.V.) Massachusetts General Hospital Center for 
Global Health, Boston, United States.
(Subramanian S.V.) Department of Social and Behavioral Sciences, Harvard 
T.H. Chan School of Public Health, Boston, United States.
(Smith G.D.) MRC Integrative Epidemiology Unit, University of Bristol, 
Bristol, United Kingdom.
(Özaltin E., eozaltin@worldbank.org) Health, Nutrition and Population Global 
Practice, The World Bank, Washington, DC, United States.
CORRESPONDENCE ADDRESS
  E. Özaltin, Health, Nutrition and Population Global Practice, World Bank, 
1818 H St NW, MSN J-600, Washington, DC, United States. Email: 
eozaltin@worldbank.org
SOURCE
  Nutrition Reviews (2016) 74:3 (149-165). Date of Publication: 2016
ISSN
  1753-4887 (electronic)
  0029-6643
BOOK PUBLISHER
  Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
  In this review, the potential causes and consequences of adult height, a 
measure of cumulative net nutrition, in modern populations are summarized. 
The mechanisms linking adult height and health are examined, with a focus on 
the role of potential confounders. Evidence across studies indicates that 
short adult height (reflecting growth retardation) in low- and middle-income 
countries is driven by environmental conditions, especially net nutrition 
during early years. Some of the associations of height with health and 
social outcomes potentially reflect the association between these 
environmental factors and such outcomes. These conditions are manifested in 
the substantial differences in adult height that exist between and within 
countries and over time. This review suggests that adult height is a useful 
marker of variation in cumulative net nutrition, biological deprivation, and 
standard of living between and within populations and should be routinely 
measured. Linkages between adult height and health, within and across 
generations, suggest that adult height may be a potential tool for 
monitoring health conditions and that programs focused on offspring outcomes 
may consider maternal height as a potentially important influence.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  body height
  health status
  nutrition
EMTREE MEDICAL INDEX TERMS
  adolescence
  adult
  aorta aneurysm
  article
  atrial fibrillation
  body growth
  body mass
  cardiovascular disease
  catch up growth
  economic development
  educational status
  environmental factor
  growth disorder
  growth retardation
  growth, development and aging
  heritability
  human
  income
  infant mortality
  infection
  inflammatory disease
  ischemic heart disease
  malnutrition
  morbidity
  mortality
  occupation
  pregnancy
  progeny
  protein intake
  puberty
  respiratory tract infection
  sex difference
  social status
  venous thromboembolism
  vitamin intake
  wellbeing
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Developmental Biology and Teratology (21)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160329979
FULL TEXT LINK
  http://dx.doi.org/10.1093/nutrit/nuv105
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 73
TITLE
  Measuring appetite with the simplified nutritional appetite questionnaire 
identifies hospitalised older people at risk of worse health outcomes
AUTHOR NAMES
  Pilgrim A.L.
  Baylis D.
  Jameson K.A.
  Cooper C.
  Sayer A.A.
  Robinson S.M.
  Roberts H.C.
AUTHOR ADDRESSES
  (Pilgrim A.L., alp@mrc.soton.ac.uk; Baylis D.; Sayer A.A.; Robinson S.M.; 
Roberts H.C.) National Institute for Health Research Southampton Biomedical 
Research Centre, University of Southampton and University Hospital 
Southampton NHS Foundation Trust, Southampton, United Kingdom.
(Pilgrim A.L., alp@mrc.soton.ac.uk; Jameson K.A.; Cooper C.; Sayer A.A.; 
Robinson S.M.; Roberts H.C.) MRC Lifecourse Epidemiology Unit, Southampton, 
United Kingdom.
(Sayer A.A.; Roberts H.C.) Academic Geriatric Medicine, University of 
Southampton, Southampton, United Kingdom.
(Sayer A.A.; Roberts H.C.) National Institute for Health Research 
Collaboration for Leadership in Applied Health Research and Care: Wessex, 
Southampton, United Kingdom.
CORRESPONDENCE ADDRESS
  A.L. Pilgrim, National Institute for Health Research Southampton Biomedical 
Research Centre, University of Southampton and University Hospital 
Southampton NHS Foundation Trust, Southampton, United Kingdom. Email: 
alp@mrc.soton.ac.uk
SOURCE
  Journal of Nutrition, Health and Aging (2016) 20:1 (3-7). Date of 
Publication: 1 Jan 2016
ISSN
  1760-4788 (electronic)
  1279-7707
BOOK PUBLISHER
  Springer-Verlag France, 22, Rue de Palestro, Paris, France. 
york@springer-paris.fr
ABSTRACT
  Objectives: Poor appetite is commonly reported by older people but is rarely 
measured. The Simplified Nutritional Appetite Questionnaire (SNAQ) was 
validated to predict weight loss in community dwelling older adults but has 
been little used in hospitals. We evaluated it in older women on admission 
to hospital and examined associations with healthcare outcomes. Design: 
Longitudinal observational with followup at six months. Setting: Female 
acute Medicine for Older People wards at a University hospital in England. 
Participants: 179 female inpatients. Measurements: Age, weight, Body Mass 
Index (BMI), grip strength, SNAQ, Barthel Index Score, Mini Mental State 
Examination (MMSE), Geriatric Depression Scale: Short Form (GDSSF), 
Malnutrition Universal Screening Tool (MUST), category of domicile and 
receipt of care were measured soon after admission and repeated at six month 
follow-up. The length of hospital stay (LOS), hospital acquired infection, 
readmissions and deaths by follow-up were recorded. Results: 179 female 
participants mean age 87 (SD 4.7) years were recruited. 42% of participants 
had a low SNAQ score (<14, indicating poor appetite). A low SNAQ score was 
associated with an increased risk of hospital acquired infection (OR 3.53; 
95% CI: 1.48, 8.41; p=0.004) and with risk of death (HR 2.29; 95% CI: 1.12, 
4.68; p = 0.023) by follow-up. Conclusion: Poor appetite was common among 
the older hospitalised women studied, and was associated with higher risk of 
poor healthcare outcomes.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  appetite disorder
  clinical assessment tool
  geriatric nutrition
  geriatric patient
  hospital patient
  nutritional assessment
  poor appetite
  Simplified Nutritional Appetite Questionnaire
EMTREE MEDICAL INDEX TERMS
  aged
  anemia
  article
  atrial fibrillation
  Barthel index
  body mass
  body weight
  collapse
  comorbidity
  daily life activity
  disease association
  dyspnea
  falling
  female
  follow up
  Geriatric Depression Scale
  grip strength
  heart failure
  home care
  hospital admission
  hospital infection
  hospital readmission
  human
  infection risk
  kidney failure
  length of stay
  longitudinal study
  major clinical study
  Malnutrition Universal Screening Tool
  mortality
  observational study
  outcome assessment
  priority journal
  questionnaire
  thorax pain
  urinary tract infection
  very elderly
  walking difficulty
  weight reduction
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160028171
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12603-016-0668-3
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 74
TITLE
  Burden of stroke in women
AUTHOR NAMES
  Lundberg G.P.
  Volgman A.S.
AUTHOR ADDRESSES
  (Lundberg G.P., Gina.Lundberg@Emory.edu) Emory Women's Heart Center, 
Atlanta, United States.
(Lundberg G.P., Gina.Lundberg@Emory.edu) Emory University School of 
Medicine, Atlanta, United States.
(Lundberg G.P., Gina.Lundberg@Emory.edu) Emory Heart and Vascular Center 
East Cobb, Marietta, United States.
(Volgman A.S.) Rush College of Medicine, Rush University Medical Center, 
Chicago, United States.
(Volgman A.S.) Rush Heart Center for Women, Rush University Medical Center, 
Chicago, United States.
CORRESPONDENCE ADDRESS
  G.P. Lundberg, Emory Heart and Vascular East Cobb, 137 Johnson Ferry Road, 
Suite 1200, Marietta, United States. Email: Gina.Lundberg@Emory.edu
SOURCE
  Trends in Cardiovascular Medicine (2016) 26:1 (81-88). Date of Publication: 
1 Jan 2016
ISSN
  1873-2615 (electronic)
  1050-1738
BOOK PUBLISHER
  Elsevier Inc., usjcs@elsevier.com
ABSTRACT
  Stroke is the fifth cause of death in the United States and the first cause 
of disability. While reductions in stroke mortality have occurred, stroke 
remains a significant burden in women. In addition to traditional 
cardiovascular risk factors, there are specific risk factors in women that 
need to be addressed to further reduce deaths in women from stroke. Atrial 
fibrillation is common in women and needs proper evaluation for 
anticoagulation for risk reduction. Stroke in women remains a serious cause 
of preventable deaths, disability, and cost. Implementation of the new 
guidelines for stroke prevention in women is critical for reducing the 
burden of stroke in women.
EMTREE DRUG INDEX TERMS
  apixaban
  dabigatran
  high density lipoprotein cholesterol (endogenous compound)
  rivaroxaban
  tissue plasminogen activator (drug therapy)
  triacylglycerol (endogenous compound)
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (drug therapy, disease management, drug therapy, 
epidemiology, prevention)
EMTREE MEDICAL INDEX TERMS
  abdominal obesity
  age
  alcohol consumption
  anticoagulation
  aphasia
  arm weakness
  atrial fibrillation
  awareness
  Black person
  body mass
  brain hemorrhage
  brain ischemia
  cardiovascular mortality
  cardiovascular risk
  central venous thrombosis
  CHADS2 score
  cognitive defect
  diabetes mellitus
  diet
  disability
  dysarthria
  dyslipidemia
  educational status
  face disorder
  face drooping
  female
  fibrinolytic therapy
  geographic distribution
  health care cost
  human
  hypertension
  insulin resistance
  lifestyle modification
  maternal hypertension
  metabolic syndrome X
  migraine with aura
  oral contraceptive use
  physical activity
  physical inactivity
  postmenopause
  practice guideline
  preeclampsia
  pregnancy
  pregnancy diabetes mellitus
  priority journal
  race difference
  randomized controlled trial (topic)
  review
  risk reduction
  sex difference
  smoking
  smoking cessation
  speech disorder
  subarachnoid hemorrhage
  vein thrombosis
  waist circumference
  weight control
  word recognition
CAS REGISTRY NUMBERS
  apixaban (503612-47-3)
  rivaroxaban (366789-02-8)
  tissue plasminogen activator (105913-11-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015091967
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.tcm.2015.04.010
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 75
TITLE
  Soluble urokinase plasminogen activator receptor and incidence of venous 
thromboembolism
AUTHOR NAMES
  Engström G.
  Zöller B.
  Svensson P.J.
  Melander O.
  Persson M.
AUTHOR ADDRESSES
  (Engström G., Gunnar.Engstrom@med.lu.se; Svensson P.J.; Melander O.; Persson 
M.) Department of Clinical Sciences, Lund University, Malmö, Sweden.
(Zöller B.) Center for Primary Health Care Research, Lund University/Region 
Skåne, Sweden.
CORRESPONDENCE ADDRESS
  G. Engström, Lund University, Department of Clinical Science, CRC 60:13, Jan 
Waldenströms Gata 35, Malmö, Sweden. Email: Gunnar.Engstrom@med.lu.se
SOURCE
  Thrombosis and Haemostasis (2016) 115:3 (657-662). Date of Publication: 2016
ISSN
  0340-6245
BOOK PUBLISHER
  Schattauer GmbH, info@schattauer.de
ABSTRACT
  Raised plasma levels of the soluble urokinase plasminogen activator receptor 
(suPAR) have been associated with increased incidence of cardiovascular 
diseases. Whether suPAR is associated with venous thromboembolism (VTE) is 
largely unknown. The purpose of the present study was to investigate the 
relationship between suPAR and incidence of VTE in a cohort study. suPAR was 
measured in 5,203 subjects (aged 46–68 years, 58 % women) from the general 
population, who participated in the Malmö Diet and Cancer (MDC) study 
between 1991 and 1994. Incident cases of VTE were identified from the 
Swedish patient register during a mean follow-up of 15.7 years. Of 5,203 
subjects with measurements of suPAR, 239 had VTE during follow-up (127 
venous thrombosis, 86 lung embolism, 26 both). Incidence of VTE was 
significantly higher in subjects with suPAR levels in the top quartile. 
Adjusted for age and sex, the HR (4(th) vs 1(st) quartile) was 1.74 (95 %CI: 
1.2–2.6, p for trend=0.003). After adjustments for risk factors, the HR was 
1.66 (95 %CI: 1.1–2.5, p for trend=0.016). High level of suPAR was a risk 
indicator for incidence of VTE in this populationbased cohort study. The 
causal relationships between suPAR and VTE remain to be explored.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  urokinase receptor (endogenous compound)
EMTREE DRUG INDEX TERMS
  C reactive protein (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  venous thromboembolism
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation
  blood pressure
  body height
  body mass
  body weight
  controlled study
  enzyme linked immunosorbent assay
  female
  gene mutation
  glucose blood level
  human
  incidence
  major clinical study
  male
  middle aged
  priority journal
  questionnaire
  risk factor
  smoking
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
EMBASE CLASSIFICATIONS
  Hematology (25)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160342756
FULL TEXT LINK
  http://dx.doi.org/10.1160/TH15-06-0511
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 76
TITLE
  NOAC or warfarin for atrial fibrillation: Does time in therapeutic range 
matter?
AUTHOR NAMES
  Merinopoulos I.
  Venables P.
  Chalmers I.
  Vassiliou V.
AUTHOR ADDRESSES
  (Merinopoulos I., i_merinopoulos@hotmail.com; Venables P.) Department of 
Cardiology, Ipswich Hospital NHS Trust, United Kingdom.
(Chalmers I.) Department of Haematology, Ipswich Hospital NHS Trust, United 
Kingdom.
(Vassiliou V.) National Heart and Lung Institute, Imperial College, Royal 
Brompton Campus, London, United Kingdom.
CORRESPONDENCE ADDRESS
  I. Merinopoulos, The Department of Cardiology, Ipswich Hospital, Ipswich, 
United Kingdom. Email: i_merinopoulos@hotmail.com
SOURCE
  Recent Advances in Cardiovascular Drug Discovery (2015) 10:1 (60-64). Date 
of Publication: 1 Jan 2015
ISSN
  2212-3962 (electronic)
  1574-8901
BOOK PUBLISHER
  Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
  Atrial fibrillation (AF) is the commonest cardiac arrhythmia currently 
affecting 1-2% of the general population, with stroke being one of its most 
fearsome complications. Dose-adjusted warfarin is an established treatment 
for reduction of thromboembolic risk but mandates dietary restrictions and 
need for routine blood monitoring. Novel oral anticoagulants (Dabigatran - 
patent: US20110082299A1, manufactured by Boehringer Ingelheim; Rivaroxaban - 
patent: US20150175590A1, manufactured by Bayer; Apixaban - patent: 
US20140335178A1, manufactured jointly by Pfizer and Bristol-Myers Squibb; 
Edoxaban - patent: WO2013026553A1, manufactured by Daiichi Sankyo) have 
recently been introduced that might provide at least equal reduction in 
thromboembolic risk to patients; negating the need for dietary restrictions 
and routine blood tests. The most recent National Institute of Health and 
Care Excellence, UK guidelines from August 2014 suggest consideration of one 
of the novel oral anticoagulants if the time in therapeutic range is less 
than 65%. In this study, the evidence for four novel oral anticoagulants is 
reviewed and the anticoagulation success with warfarin with atrial 
fibrillation and mechanical heart valves assessed in a large UK District 
General Hospital. Fifty-eight patients were identified with mechanical heart 
valve and 2737 patients with atrial fibrillation. Patients with atrial 
fibrillation had a significantly better TTR when compared with the patients 
included in the NOAC trials. Our results were similar with the Auricula 
registry. However, 25% of patients had TTR<65% and they would need to be 
considered for NOACs. Our data suggest that the degree of benefit seen in 
the NOAC trials might not be expected in our cohort of patients with atrial 
fibrillation. Interestingly, our patients with atrial fibrillation had a 
much better mean TTR of 76.4% and required less INR tests (12/year) compared 
to patients with mechanical heart valve who had a mean TTR of 61.4% and 
required more INR tests (26/year).
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  apixaban (clinical trial, drug therapy, oral drug administration)
  dabigatran etexilate (clinical trial, drug therapy, oral drug 
administration)
  edoxaban (clinical trial, drug therapy, oral drug administration)
  rivaroxaban (clinical trial, drug therapy, oral drug administration)
  warfarin (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  atrial fibrillation (drug therapy, drug therapy, therapy)
  pharmacological parameters
  therapeutic range
  time
EMTREE MEDICAL INDEX TERMS
  article
  cardiac patient
  diet restriction
  general hospital
  human
  international normalized ratio
  mechanical heart valve
  patent
  phase 3 clinical trial (topic)
  practice guideline
  priority journal
  randomized controlled trial (topic)
  register
  risk reduction
  thromboembolism (drug therapy, prevention)
DRUG MANUFACTURERS
  Bayer
  Boehringer Ingelheim
  Bristol Myers Squibb
  Daiichi Sankyo
  Pfizer
CAS REGISTRY NUMBERS
  apixaban (503612-47-3)
  edoxaban (480449-70-5, 480449-71-6, 912273-65-5)
  rivaroxaban (366789-02-8)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160384262
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 77
TITLE
  Dietary approaches to stop hypertension diet and incidence of stroke: 
Results from 2 prospective cohorts
AUTHOR NAMES
  Larsson S.C.
  Wallin A.
  Wolk A.
AUTHOR ADDRESSES
  (Larsson S.C., susanna.larsson@ki.se; Wallin A.; Wolk A.) Unit of 
Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska 
Institutet, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
  S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental 
Medicine, Karolinska Institutet, Stockholm, Sweden. Email: 
susanna.larsson@ki.se
SOURCE
  Stroke (2016) 47:4 (986-990). Date of Publication: 2016
ISSN
  1524-4628 (electronic)
  0039-2499
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Background and Purpose-High adherence to the Dietary Approaches to Stop 
Hypertension (DASH) diet is associated with lower risk of hypertension, the 
major risk factor for stroke. We examined whether adherence to the DASH diet 
is inversely associated with the incidence of stroke. Methods-The study 
population comprised 74 404 men and women (45-83 years of age), without 
stroke at baseline, from the Cohort of Swedish Men and the Swedish 
Mammography Cohort. Diet was assessed with a food-frequency questionnaire. A 
modified DASH diet score was created based on consumption of vegetables, 
fruits, legumes and nuts, whole grains, low-fat dairy, red meat and 
processed meat, and sweetened beverages. Stroke cases were identified 
through linkage to the Swedish National Patient and Cause of Death 
Registers. Relative risks and 95% confidence intervals were estimated using 
Cox proportional hazards regression model. Results-During 882 727 
person-years (mean, 11.9 years) of follow-up, 3896 ischemic strokes, 560 
intracerebral hemorrhages, and 176 subarachnoid hemorrhages were 
ascertained. The modified DASH diet score was statistically significantly 
inversely associated with the risk of ischemic stroke (P for trend=0.002), 
with a multivariable relative risk of 0.86 (95% confidence interval, 
0.78-0.94) for the highest versus the lowest quartile of the score. The 
modified DASH diet score was nonsignificantly inversely associated with 
intracerebral hemorrhage (corresponding relative risk=0.81; 95% confidence 
interval, 0.63-1.05) but was not associated with subarachnoid hemorrhage. 
Conclusions-These findings indicate that high adherence to the DASH diet is 
associated with a reduced risk of ischemic stroke. Clinical Trial 
Registration-URL: http://www.clinicaltrials.gov. Unique identifiers: 
NCT01127698 and NCT01127711 for the Swedish Mammography Cohort and the 
Cohort of Swedish Men, respectively.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident
  diet therapy
  dietary approaches to stop hypertension diet
  hypertension
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation
  brain hemorrhage
  brain ischemia
  cohort analysis
  diabetes mellitus
  female
  follow up
  food intake
  human
  hypercholesterolemia
  major clinical study
  male
  patient compliance
  population research
  priority journal
  prospective study
  risk assessment
  risk factor
  risk reduction
  smoking
  subarachnoid hemorrhage
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Clinical and Experimental Biochemistry (29)
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT01127698)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160126582
FULL TEXT LINK
  http://dx.doi.org/10.1161/STROKEAHA.116.012675
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 78
TITLE
  Physician and Patient Preferences for Nonvalvular Atrial Fibrillation 
Therapies
AUTHOR NAMES
  Shafrin J.
  Bruno A.
  MacEwan J.P.
  Campinha-Bacote A.
  Trocio J.
  Shah M.
  Tan W.
  Romley J.A.
AUTHOR ADDRESSES
  (Shafrin J., Jason.shafrin@precisionhealtheconomics.com; MacEwan J.P.; 
Campinha-Bacote A.) Precision Health Economics, Los Angeles, CA, USA
(Bruno A.; Shah M.) Bristol-Myers Squibb, Plainsboro, NJ, USA
(Trocio J.; Tan W.) Pfizer, Inc., New York, NY, USA
(Romley J.A.) University of Southern California, Los Angeles, CA, USA
CORRESPONDENCE ADDRESS
  J. Shafrin, 11100 Santa Monica Boulevard, Suite 500, Los Angeles, CA 90025 
Email: Jason.shafrin@precisionhealtheconomics.com
SOURCE
  Value in Health (2016). Date of Publication: 2016
ISSN
  1524-4733 (electronic)
  1098-3015
BOOK PUBLISHER
  Elsevier Ltd
ABSTRACT
  Objectives: The objective of this study was to compare patient and physician 
preferences for different antithrombotic therapies used to treat nonvalvular 
atrial fibrillation (NVAF). Methods: Patients diagnosed with NVAF and 
physicians treating such patients completed 12 discrete choice questions 
comparing NVAF therapies that varied across five attributes: stroke risk, 
major bleeding risk, convenience (no regular blood testing/dietary 
restrictions), dosing frequency, and patients' out-of-pocket cost. We used a 
logistic regression to estimate the willingness-to-pay (WTP) value for each 
attribute. Results: The 200 physicians surveyed were willing to trade off 
$38 (95% confidence interval [CI] $22 to $54] in monthly out-of-pocket cost 
for a 1% (absolute) decrease in stroke risk, $14 (95% CI $8 to $21) for a 1% 
decrease in major bleeding risk, and $34 (95% CI $9 to $60) for more 
convenience. The WTP value among 201 patients surveyed was $30 (95% CI $18 
to $42) for reduced stroke risk, $16 (95% CI $9 to $24) for reduced bleeding 
risk, and -$52 (95% CI -$96 to -6) for convenience. The WTP value for 
convenience among patients using warfarin was $9 (95% CI $1 to $18) for more 
convenience, whereas patients not currently on warfarin had a WTP value of 
-$90 (95% CI -$290 to -$79). Both physicians' and patients' WTP value for 
once-daily dosing was not significantly different from zero. On the basis of 
survey results, 85.0% of the physicians preferred novel oral anticoagulants 
(NOACs) to warfarin. NOACs (73.0%) were preferred among patients using 
warfarin, but warfarin (78.2%) was preferred among patients not currently 
using warfarin. Among NOACs, both patients and physicians preferred 
apixaban. Conclusions: Both physicians and patients currently using warfarin 
preferred NOACs to warfarin. Patients not currently using warfarin preferred 
warfarin over NOACs because of an apparent preference for regular blood 
testing/dietary restrictions.
EMTREE DRUG INDEX TERMS
  apixaban
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  patient preference
  physician
EMTREE MEDICAL INDEX TERMS
  bleeding
  cerebrovascular accident
  clinical trial
  confidence interval
  controlled study
  diagnosis
  diet restriction
  doctor patient relation
  drug dosage form
  human
  logistic regression analysis
  major clinical study
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160227631
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jval.2016.01.001
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 79
TITLE
  Stroke of undetermined cause: Workup and secondary prevention
AUTHOR NAMES
  Weimar C.
AUTHOR ADDRESSES
  (Weimar C., christian.weimar@uk-essen.de) Department of Neurology and Stroke 
Center, University Duisburg-Essen, Hufelandstr. 55, Essen, Germany.
CORRESPONDENCE ADDRESS
  C. Weimar, Department of Neurology and Stroke Center, University 
Duisburg-Essen, Hufelandstr. 55, Essen, Germany. Email: 
christian.weimar@uk-essen.de
SOURCE
  Current Opinion in Neurology (2016) 29:1 (4-8). Date of Publication: 2016
ISSN
  1473-6551 (electronic)
  1350-7540
BOOK PUBLISHER
  Lippincott Williams and Wilkins, agents@lww.com
ABSTRACT
  Purpose of review The purpose of this review is to update the reader on 
current concepts of workup and secondary prevention in patients with stroke 
of undetermined cause. Recent findings Clinical research in patients with 
cryptogenic stroke has been hampered by the lack of standardized, widely 
accepted diagnostic criteria. The new definition of Embolic stroke of 
undetermined etiology postulates an embolic mechanism of ischemic stroke. It 
is based on the exclusion of lacunar infarction by brain imaging, arterial 
stenosis more than 50% or dissection of the respective brain-supplying 
artery by computed tomography/magnetic resonance-angiography or ultrasound, 
atrial fibrillation by at least 24 h EKG monitoring, as well as some rare 
etiologies such as vasculitis, drug abuse, or coagulopathies. However, it 
still comprises many patients with atherosclerotic etiologies (but <50% 
stenosis) as well as covert paroxysmal atrial fibrillation which can be 
detected by repeated Holter EKG or an implantable device. A patent foramen 
ovale can be found in up to 58% of cryptogenic stroke patients, but 
causality in an individual patient remains uncertain and can only be 
statistically inferred. Summary The new concept of embolic stroke of 
undetermined etiology enabled three ongoing randomized controlled trials 
which investigate oral anticoagulation versus aspirin for secondary stroke 
prevention.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident
  diagnostic procedure
  secondary prevention
EMTREE MEDICAL INDEX TERMS
  anticoagulant therapy
  atrial fibrillation
  blood pressure regulation
  brain ischemia
  computed tomographic angiography
  computer assisted tomography
  Doppler echography
  echocardiography
  exercise
  human
  Mediterranean diet
  nuclear magnetic resonance imaging
  paradoxical embolism
  prognosis
  review
  smoking cessation
  transesophageal echocardiography
  transient ischemic attack
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20151016713
FULL TEXT LINK
  http://dx.doi.org/10.1097/WCO.0000000000000280
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 80
TITLE
  Is dabigatran as effective as warfarin on cardiac thrombus in a patient with 
atrial fibrillation? A challenging question
AUTHOR NAMES
  Sunbul M.
  Cincin A.
  Mammadov C.
  Mutlu B.
AUTHOR ADDRESSES
  (Sunbul M., drsunbul@yahoo.com.tr; Cincin A.; Mammadov C.; Mutlu B.) 
Department of Cardiology, Faculty of Medicine, Marmara University, Fevzi 
CakmakM., Mimar Sinan C., No: 41, Pendik, Istanbul, Turkey.
CORRESPONDENCE ADDRESS
  M. Sunbul, Department of Cardiology, Faculty of Medicine, Marmara 
University, Fevzi CakmakM., Mimar Sinan C., No: 41, Pendik, Istanbul, 
Turkey. Email: drsunbul@yahoo.com.tr
SOURCE
  American Journal of Therapeutics (2016) 23:3 (e974-e976). Date of 
Publication: 2016
ISSN
  1536-3686 (electronic)
  1075-2765
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Atrial fibrillation (AF) is an important risk factor for cardioembolic 
stroke. Warfarin is an effective treatment in reducing the risk of 
cardioembolic stroke in patients with AF. New anticoagulants have been 
widely using for stroke prophylaxis in patients with nonvalvular AF. 
Previous studies have suggested that thrombolytic therapy is effective 
treatment choice in patients with pulmonary embolisms. Warfarin therapy is 
also effective on prevention or treatment of cardiac thrombus in patients 
with AF. However, there are no evidence-based data on treatment of cardiac 
thrombus with new oral anticoagulants in patients with AF. In our case 
report, we reported an AF patient with cardiac thrombus and pulmonary 
embolism under dabigatran therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dabigatran (drug comparison, drug therapy)
  warfarin (drug comparison, drug therapy)
EMTREE DRUG INDEX TERMS
  alanine aminotransferase (endogenous compound)
  aspartate aminotransferase (endogenous compound)
  carvedilol
  creatinine (endogenous compound)
  D dimer (endogenous compound)
  digoxin
  furosemide
  hemoglobin (endogenous compound)
  heparin (drug therapy)
  ramipril
  tissue plasminogen activator (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (diagnosis)
  heart atrium thrombosis (drug therapy, diagnosis, drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  article
  case report
  computed tomographic angiography
  coronary artery bypass graft
  Doppler ultrasonography
  drug efficacy
  dyspnea
  echocardiography
  exercise
  fatigue
  fibrinolytic therapy
  heart rate
  heart right atrium
  heart surgery
  human
  international normalized ratio
  leukocyte count
  low drug dose
  lung angiography
  lung embolism (diagnosis, drug therapy)
  male
  middle aged
  mitral valve disease (diagnosis)
  mitral valve regurgitation (diagnosis)
  priority journal
  surgical risk
  tachycardia
  three dimensional imaging
  transesophageal echocardiography
  transthoracic echocardiography
CAS REGISTRY NUMBERS
  alanine aminotransferase (9000-86-6, 9014-30-6)
  aspartate aminotransferase (9000-97-9)
  carvedilol (72956-09-3)
  creatinine (19230-81-0, 60-27-5)
  digoxin (20830-75-5, 57285-89-9)
  furosemide (54-31-9)
  hemoglobin (9008-02-0)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  ramipril (87333-19-5)
  tissue plasminogen activator (105913-11-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014933224
FULL TEXT LINK
  http://dx.doi.org/10.1097/MJT.0000000000000129
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 81
TITLE
  Exercise and Arrhythmias: A Double-Edged Sword
AUTHOR NAMES
  Manolis A.S.
  Manolis A.A.
AUTHOR ADDRESSES
  (Manolis A.S., asm@otenet.gr; Manolis A.A.) Third Department of Cardiology 
Athens University School of Medicine Athens Greece
CORRESPONDENCE ADDRESS
  A.S. Manolis, Third Department of Cardiology, Athens University School of 
Medicine, Vas.So?as 114, Athens 115 27, Greece Email: asm@otenet.gr
SOURCE
  PACE - Pacing and Clinical Electrophysiology (2016). Date of Publication: 
2016
ISSN
  1540-8159 (electronic)
  0147-8389
BOOK PUBLISHER
  Blackwell Publishing Inc., subscrip@blackwellpub.com
ABSTRACT
  Ample evidence indicates that moderate regular exercise is beneficial for 
both normal individuals and patients with cardiovascular (CV) disease. 
However, intense and strenuous exercise in individuals with evident or 
occult underlying CV abnormalities may have adverse effects with provocation 
and exacerbation of arrhythmias that may lead to life-threatening 
situations. Both of these aspects of exercise-induced effects are herein 
reviewed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  atrial fibrillation
  cardiomyopathy
  exercise
  heart ventricle extrasystole
  heart ventricle tachycardia
  screening
  sudden cardiac death
EMTREE MEDICAL INDEX TERMS
  adverse drug reaction
  cardiovascular malformation
  clinical study
  disease exacerbation
  human
  normal human
  provocation
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160411121
FULL TEXT LINK
  http://dx.doi.org/10.1111/pace.12879
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 82
TITLE
  Safety of symptom-limited exercise testing in a big cohort of a modern ICD 
population
AUTHOR NAMES
  Voss F.
  Schueler M.
  Lauterbach M.
  Bauer A.
  Katus H.A.
  Becker R.
AUTHOR ADDRESSES
  (Voss F., f.voss@bk-trier.de; Lauterbach M.) Department of Cardiology, 
Krankenhaus der Barmherzigen Brueder Trier, Nordallee 1, Trier, Germany.
(Bauer A.) Department of Cardiology, Diakonie-Klinikum Schwaebisch Hall, 
Diakoniestr. 10, Schwaebisch Hall, Germany.
(Schueler M.; Katus H.A.; Becker R.) Department of Cardiology, University of 
Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany.
CORRESPONDENCE ADDRESS
  F. Voss, Department of Cardiology, Krankenhaus der Barmherzigen Brueder 
Trier, Nordallee 1, Trier, Germany. Email: f.voss@bk-trier.de
SOURCE
  Clinical Research in Cardiology (2016) 105:1 (53-58). Date of Publication: 1 
Jan 2016
ISSN
  1861-0692 (electronic)
  1861-0684
BOOK PUBLISHER
  Dr. Dietrich Steinkopff Verlag GmbH and Co. KG
ABSTRACT
  Background: Exercise may predispose to ventricular arrhythmias especially in 
patients with congestive heart failure. As therapy with implanted 
cardioverter-defibrillators (ICDs) has become standard medical care, there 
is an emerging number of exercise tests that need to be performed in 
patients with ICDs. In contrast, little is known about the safety of 
symptom-limited exercise testing in these patients. Methods and results: 400 
ICD patients performed symptom-limited exercise treadmill testing. 200 
patients performed a ramp protocol with an initial workload of 0 W increased 
by 15 W every minute. Another 200 ICD patients did a slightly modified ramp 
protocol with again an initial workload of 0 W but with an increased 
capacity of 15 W every 2 min. The study population consists mainly of 
patients with ischemic (63 %) and non-ischemic (34 %) heart disease. Atrial 
fibrillation was present in 16 % of the subjects. The mean ejection fraction 
was 28 ± 8, and 78 % of the patients had an ejection fraction below 30 %. In 
this cohort of patients, no sustained ventricular arrhythmias and no deaths 
occurred during or after exercise testing. No inappropriate shock delivery 
was observed. The modified ramp protocol resulted in a prolonged exercise 
time with equal exercise capacity but does not result in an enhanced 
susceptibility for ventricular arrhythmias. Conclusions: Symptom-limited 
exercise treadmill testing in heart failure patients with ICDs is a safe 
procedure. The use of a ramp protocol is sufficient in terms of safety and 
is easy to perform in general practice. The exercise duration in heart 
failure patients with ICDs does not predict serious adverse events.
EMTREE DRUG INDEX TERMS
  angiotensin receptor antagonist
  antiarrhythmic agent
  beta adrenergic receptor blocking agent
  brain natriuretic peptide (endogenous compound)
  dipeptidyl carboxypeptidase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiac patient
  exercise test
  implantable cardioverter defibrillator
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation
  cardiac resynchronization therapy
  congestive cardiomyopathy
  coronary artery disease
  dyspnea (complication)
  electrocardiography
  electrophysiology
  female
  heart ejection fraction
  heart failure
  heart rate
  heart ventricle arrhythmia
  heart ventricle extrasystole (complication)
  human
  ischemic heart disease
  major clinical study
  male
  middle aged
  New York Heart Association class
  QRS interval
  treadmill exercise
  workload
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015168349
FULL TEXT LINK
  http://dx.doi.org/10.1007/s00392-015-0885-5
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 83
TITLE
  Exercise in patients with chronic atrial fibrillation
ORIGINAL (NON-ENGLISH) TITLE
  Inspanning bij chronisch atriumfibrilleren
AUTHOR NAMES
  Zutt J.
  Smelt A.
AUTHOR ADDRESSES
  (Zutt J.; Smelt A., a.f.h.smelt@lumc.nl) afdeling Public Health en 
Eerstelijnsgeneeskunde, LUMC, 9600, Leiden, Netherlands.
CORRESPONDENCE ADDRESS
  A. Smelt, afdeling Public Health en Eerstelijnsgeneeskunde, LUMC, 
Netherlands.
SOURCE
  Huisarts en Wetenschap (2016) 59:1 (38). Date of Publication: 2016
ISSN
  1876-5912 (electronic)
  0018-7070
BOOK PUBLISHER
  Bohn Stafleu van Loghum, e.smid@ntvg.nl
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  chronic atrial fibrillation
  exercise
EMTREE MEDICAL INDEX TERMS
  article
  human
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English, Dutch
EMBASE ACCESSION NUMBER
  20160046240
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12445-016-0026-z
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 84
TITLE
  Differential Association of Exercise Intensity With Risk of Atrial 
Fibrillation in Men and Women: Evidence from a Meta-Analysis
AUTHOR NAMES
  Mohanty S.
  Mohanty P.
  Tamaki M.
  Natale V.
  Gianni C.
  Trivedi C.
  Gokoglan Y.
  Di Biase L.
  Natale A.
AUTHOR ADDRESSES
  (Mohanty S.; Mohanty P.; Gianni C.; Trivedi C.; Gokoglan Y.; Di Biase L.; 
Natale A., dr.natale@gmail.com) Texas Cardiac Arrhythmia Institute St. 
David's Medical Center Austin, Texas
(Tamaki M.) Texas Cardiac Arrhythmia Research Foundation Austin, Texas
(Natale V.) Department of Natural Science University of Texas Austin, Texas
(Gianni C.) University of Milan Milan Italy
(Gokoglan Y.) Department of Cardiology Gülhane Military Academy of Medicine 
Ankara Turkey
(Di Biase L.) Albert Einstein College of Medicine Montefiore Hospital Bronx, 
New York
(Natale A., dr.natale@gmail.com) California Pacific Medical Center San 
Francisco, California USA
(Natale A., dr.natale@gmail.com) Interventional Electrophysiology Scripps 
Clinic San Diego, California USA
(Natale A., dr.natale@gmail.com) Department of Internal Medicine Dell 
Medical School Austin, Texas USA
(Natale A., dr.natale@gmail.com) Division of Cardiology Stanford University 
Palo Alto, California USA
CORRESPONDENCE ADDRESS
  A. Natale, Texas Cardiac Arrhythmia Institute, St David's Medical Center, 
3000 N. I-35, Suite 720; Austin, TX 78705, USA Email: dr.natale@gmail.com
SOURCE
  Journal of Cardiovascular Electrophysiology (2016). Date of Publication: 
2016
ISSN
  1540-8167 (electronic)
  1045-3873
BOOK PUBLISHER
  Blackwell Publishing Inc., subscrip@blackwellpub.com
ABSTRACT
  Gender-Specific Link of Exercise Intensity With AF: Background: Despite 
widespread interest and extensive research, the association between 
different levels of physical activity (PA) and risk of atrial fibrillation 
(AF) is still not clearly defined. Therefore, we systematically evaluated 
and summarized the evidences regarding association of different intensity of 
PA with the risk of AF in this meta-analysis. Methods and Results: An 
extensive literature search was performed on databases for studies showing 
association of exercise with AF risk. Twenty-two studies were identified 
that included 656,750 subjects. Meta-analytic estimates were derived using 
random-effects models and pooled odds ratio estimates were obtained. 
Potential sources of heterogeneity were examined in sensitivity analyses, 
and publication biases were estimated. Pooled analysis of 7 studies with 
93,995 participants reported high risk of incident AF with sedentary 
lifestyle (pooled OR 2.47 [95% CI 1.25-3.7], P = 0.005). In 3 trials, 
149,048 women involved in moderate PA were 8.6% less likely to develop AF 
compared to women with sedentary life (OR 0.91 [95% CI 0.78-0.97], P = 
0.002). Women performing intense exercise were found to have 28% lower risk 
of AF (OR 0.72 [95% CI 0.57-0.88], P < 0.001). The overall pooled estimate 
indicated a protective impact of moderate PA in men (pooled OR 0.8133 [95% 
CI 0.26-1.004], P = 0.06) whereas vigorous PA was associated with a 
significantly increased AF risk (pooled OR 3.30 [1.97-4.63], P = 0.0002). 
Conclusion: Sedentary lifestyle significantly increases and moderate amount 
of physical activity reduces the risk of AF in both men and women. However, 
intense exercise has a gender-specific association with AF risk.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  exercise intensity
  gender
  physical activity
EMTREE MEDICAL INDEX TERMS
  controlled study
  data base
  female
  human
  male
  meta analysis
  model
  odds ratio
  publication
  sitting
  systematic review
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160523749
FULL TEXT LINK
  http://dx.doi.org/10.1111/jce.13023
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 85
TITLE
  Are there deleterious cardiac effects of acute and chronic endurance 
exercise?
AUTHOR NAMES
  Eijsvogels T.M.H.
  Fernandez A.B.
  Thompson P.D.
AUTHOR ADDRESSES
  (Eijsvogels T.M.H.; Fernandez A.B.; Thompson P.D.) Department of Cardiology, 
Hartford Hospital, Hartford, United States.
(Eijsvogels T.M.H.; Fernandez A.B.; Thompson P.D., 
Paul.Thompson@hhchealth.org) Department of Physiology, Radboud University 
Medical Center, Nijmegen, Netherlands.
CORRESPONDENCE ADDRESS
  P.D. Thompson, Hartford Hospital, 80 Seymour St., Hartford, United States. 
Email: Paul.Thompson@hhchealth.org
SOURCE
  Physiological Reviews (2016) 96:1 (1-2) Article Number: A04. Date of 
Publication: 2016
ISSN
  1522-1210 (electronic)
  0031-9333
BOOK PUBLISHER
  American Physiological Society, subscrip@the-aps.org
ABSTRACT
  Multiple epidemiological studies document that habitual physical activity 
reduces the risk of atherosclerotic cardiovascular disease (ASCVD), and most 
demonstrate progressively lower rates of ASCVD with progressively more 
physical activity. Few studies have included individuals performing 
high-intensity, lifelong endurance exercise, however, and recent reports 
suggest that prodigious amounts of exercise may increase markers for, and 
even the incidence of, cardiovascular disease. This review examines the 
evidence that extremes of endurance exercise may increase cardiovascular 
disease risk by reviewing the causes and incidence of exercise-related 
cardiac events, and the acute effects of exercise on cardiovascular 
function, the effect of exercise on cardiac biomarkers, including 
“myocardial” creatine kinase, cardiac troponins, and cardiac natriuretic 
peptides. This review also examines the effect of exercise on coronary 
atherosclerosis and calcification, the frequency of atrial fibrillation in 
aging athletes, and the possibility that exercise may be deleterious in 
individuals genetically predisposed to such cardiac abnormalities as long QT 
syndrome, right ventricular cardiomyopathy, and hypertrophic cardiomyopathy. 
This review is to our knowledge unique because it addresses all known 
potentially adverse cardiovascular effects of endurance exercise. The best 
evidence remains that physical activity and exercise training benefit the 
population, but it is possible that prolonged exercise and exercise training 
can adversely affect cardiac function in some individuals. This hypothesis 
warrants further examination.
EMTREE DRUG INDEX TERMS
  amino terminal pro brain natriuretic peptide
  catecholamine (endogenous compound)
  creatine kinase MB (endogenous compound)
  creatine kinase MM (endogenous compound)
  natriuretic factor (endogenous compound)
  tropomyosin (endogenous compound)
  troponin C (endogenous compound)
  troponin I (endogenous compound)
  troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  endurance training
  heart function
EMTREE MEDICAL INDEX TERMS
  adaptation
  aging
  aorta
  aorta root
  aorta rupture
  aorta valve stenosis
  article
  athlete
  atrial fibrillation
  blood volume
  bradycardia
  cardiomyopathy
  cardiovascular disease
  cardiovascular mortality
  cardiovascular risk
  channelopathy
  complete heart block
  coronary artery anomaly
  coronary artery atherosclerosis
  coronary artery calcification
  coronary artery disease
  dynamic exercise
  emotion
  exercise intensity
  fatigue
  gene mutation
  heart atrium arrhythmia
  heart atrium flutter
  heart disease
  heart failure
  heart left ventricle contractility
  heart left ventricle hypertrophy
  heart muscle cell
  heart muscle fibrosis
  heart muscle injury
  heart muscle ischemia
  heart muscle necrosis
  heart performance
  heart rate
  heart right ventricle dysplasia
  heart size
  heart ventricle extrasystole
  heart ventricle fibrillation
  heart ventricle tachycardia
  human
  hypertrophic cardiomyopathy
  inflammatory infiltrate
  long QT syndrome
  longevity
  lung congestion
  mechanical stress
  membrane damage
  membrane permeability
  mitral valve prolapse
  muscle training
  nonhuman
  oxidative stress
  pathophysiology
  physical activity
  priority journal
  sarcoidosis
  sleep
  sport
  sudden cardiac death
  sweating
  thermogenesis
  venous return
CAS REGISTRY NUMBERS
  natriuretic factor (9088-07-7)
  tropomyosin (72067-79-9)
  troponin C (56094-11-2)
  troponin I (77108-40-8)
  troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Physiology (2)
  Clinical and Experimental Biochemistry (29)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20151002286
FULL TEXT LINK
  http://dx.doi.org/10.1152/physrev.00029.2014
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 86
TITLE
  Management of Cognitive Impairment in Heart Failure
AUTHOR NAMES
  Yzeiraj E.
  Tam D.M.
  Gorodeski E.Z.
AUTHOR ADDRESSES
  (Yzeiraj E.) Department of Internal Medicine, Medicine Institute, Cleveland 
Clinic, Cleveland, United States.
(Tam D.M.) NYU Comprehensive Epilepsy Center, New York, United States.
(Gorodeski E.Z., gorodee@ccf.org) Section of Heart Failure and Cardiac 
Transplantation, Tomsich Family Department of Cardiovascular Medicine, Heart 
and Vascular Institute, Cleveland Clinic, Cleveland, United States.
(Gorodeski E.Z., gorodee@ccf.org) Center for Connected Care, Cleveland 
Clinic, Desk J3-4, 9500 Euclid Avenue, Cleveland, United States.
CORRESPONDENCE ADDRESS
  E.Z. Gorodeski, Center for Connected Care, Cleveland Clinic, Desk J3-4, 9500 
Euclid Avenue, Cleveland, United States. Email: gorodee@ccf.org
SOURCE
  Current Treatment Options in Cardiovascular Medicine (2016) 18:1 (1-11) 
Article Number: 4. Date of Publication: 1 Jan 2016
ISSN
  1534-3189 (electronic)
  1092-8464
BOOK PUBLISHER
  Springer Healthcare
ABSTRACT
  Cognitive impairment (CI) is an inclusive term to describe trouble with 
memory, learning, concentration, or decision-making. CI is highly prevalent 
in patients with heart failure (HF) and is known to be associated with a 
variety of poor outcomes. While published HF guidelines recommend screening 
for CI, they do not indicate how, due to a lack of consensus in the 
literature about which instrument to use. Our recommendation is to use the 
Mini-Cog for this purpose because of its brevity and utility in identifying 
patients with HF at high risk for hospitalization or mortality. At this 
time, there is minimal published clinical trial evidence about how to manage 
CI in patients with HF. Reasonable approaches to management may include 
following guideline-directed medical therapy for HF, treatment of 
hypertension and atrial fibrillation, management of depression, proactive 
diagnosis and treatment of sleep apnea, and encouragement of aerobic 
exercise and weight loss. Left ventricular assist device (LVAD) therapy in 
patients with Stage D HF may improve CI in the short term after 
implantation, though there is a risk of worsening CI in the intermediate and 
long term. Clinicians who care for patients with HF should routinely screen 
for CI and when identified should encourage interventions to support 
self-care, increase family involvement, and arrange for more frequent 
follow-up.
EMTREE DRUG INDEX TERMS
  cholinesterase inhibitor (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cognitive defect (drug therapy, complication, drug therapy, therapy)
  heart failure (therapy)
EMTREE MEDICAL INDEX TERMS
  aerobic exercise
  assisted circulation
  atrial fibrillation
  depression
  diet therapy
  disease exacerbation
  external counterpulsation device
  family therapy
  high risk patient
  hospitalization
  human
  hypertension
  left ventricular assist device
  Mini Mental State Examination
  Montreal cognitive assessment
  mortality
  outcome assessment
  practice guideline
  prevalence
  review
  self care
  sleep disordered breathing
  weight reduction
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160031648
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11936-015-0425-7
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 87
TITLE
  Safety, feasibility, and efficacy of vagus nerve stimulation paired with 
upper-limb rehabilitation after ischemic stroke
AUTHOR NAMES
  Dawson J.
  Pierce D.
  Dixit A.
  Kimberley T.J.
  Robertson M.
  Tarver B.
  Hilmi O.
  Mclean J.
  Forbes K.
  Kilgard M.P.
  Rennaker R.L.
  Cramer S.C.
  Walters M.
  Engineer N.
AUTHOR ADDRESSES
  (Dawson J., jesse.dawson@glasgow.ac.uk; Walters M.) Institute of 
Cardiovascular and Medical Sciences, College of Medical,Veterinary and Life 
Sciences, University of Glasgow, Glasgow, United Kingdom.
(Robertson M.) Robertson Centre for Biostatistics, University of Glasgow, 
Western Infirmary, Glasgow, United Kingdom.
(Pierce D.) MicroTransponder Inc., Austin, United States.
(Pierce D.; Tarver B.; Engineer N.) University of Texas at Dallas, 
Richardson, United States.
(Dixit A.) Royal Victoria Infirmary, Newcastle upon Tyne Hospitals, NHS 
Foundation Trust, Newcastle upon Tyne, United Kingdom.
(Kimberley T.J.) Programs in Physical Therapy and Rehabilitation Science, 
Department of Physical Medicine and Rehabilitation, University of Minnesota, 
Minneapolis, United States.
(Hilmi O.) Department of Otolaryngology, Glasgow Royal Infirmary, Greater 
Glasgow and Clyde, Glasgow, United Kingdom.
(Mclean J.; Forbes K.) Department of Neuroradiology, Institute of 
Neurological Sciences, Greater Glasgow and Clyde, Glasgow, United Kingdom.
(Kilgard M.P.; Rennaker R.L.) School of Behavioral and Brain Sciences, 
University of Texas at Dallas, Richardson, United States.
(Kilgard M.P.) Department of Bioengineering, Erik Jonsson School of 
Engineering and Computer Science, University of Texas at Dallas, Richardson, 
United States.
(Cramer S.C.) Sue and Bill Gross Stem Cell Research Center, Departments of 
Neurology, Anatomy and Neurobiology, and Physical Medicine and 
Rehabilitation, University of California, Irvine, United Kingdom.
CORRESPONDENCE ADDRESS
  J. Dawson, Institute of Cardiovascular and Medical Sciences, College of 
Medical,Veterinary and Life Sciences, University of Glasgow, Glasgow, United 
Kingdom. Email: jesse.dawson@glasgow.ac.uk
SOURCE
  Stroke (2016) 47:1 (143-150). Date of Publication: 1 Jan 2016
ISSN
  1524-4628 (electronic)
  0039-2499
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Background and Purpose - Recent animal studies demonstrate that vagus nerve 
stimulation (VNS) paired with movement induces movement-specific plasticity 
in motor cortex and improves forelimb function after stroke. We conducted a 
randomized controlled clinical pilot study of VNS paired with rehabilitation 
on upper-limb function after ischemic stroke. Methods - Twenty-one 
participants with ischemic stroke >6 months before and moderate to severe 
upper-limb impairment were randomized to VNS plus rehabilitation or 
rehabilitation alone. Rehabilitation consisted of three 2-hour sessions per 
week for 6 weeks, each involving >400 movement trials. In the VNS group, 
movements were paired with 0.5-second VNS. The primary objective was to 
assess safety and feasibility. Secondary end points included change in 
upper-limb measures (including the Fugl-Meyer Assessment-Upper Extremity). 
Results - Nine participants were randomized to VNS plus rehabilitation and 
11 to rehabilitation alone. There were no serious adverse device effects. 
One patient had transient vocal cord palsy and dysphagia after implantation. 
Five had minor adverse device effects including nausea and taste disturbance 
on the evening of therapy. In the intention-to-treat analysis, the change in 
Fugl-Meyer Assessment-Upper Extremity scores was not significantly different 
(between-group difference, 5.7 points; 95% confidence interval, -0.4 to 
11.8). In the per-protocol analysis, there was a significant difference in 
change in Fugl-Meyer Assessment-Upper Extremity score (between-group 
difference, 6.5 points; 95% confidence interval, 0.4 to 12.6). Conclusions - 
This study suggests that VNS paired with rehabilitation is feasible and has 
not raised safety concerns. Additional studies of VNS in adults with chronic 
stroke will now be performed. Clinical Trial Registration - URL: 
https://www.clinicaltrials.gov. Unique identifier: NCT01669161.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  arm movement
  brain ischemia (rehabilitation, therapy)
  patient safety
  upper limb rehabilitation
  vagus nerve stimulation
EMTREE MEDICAL INDEX TERMS
  adult
  article
  assessment of humans
  clinical article
  colon cancer (complication)
  controlled study
  dysphagia (complication)
  dyspnea (complication)
  feasibility study
  female
  Fugl Meyer Assessment Upper Extremity score
  grip strength
  head and neck disease (complication)
  hoarseness (complication)
  human
  implanted vagus nerve stimulator (adverse device effect)
  intention to treat analysis
  male
  middle aged
  nausea (complication)
  neck tingling (complication)
  nephrolithiasis (complication, therapy)
  nuclear magnetic resonance imaging
  oxygen saturation
  paroxysmal atrial fibrillation (complication)
  phrenic nerve paralysis (complication)
  pilot study
  priority journal
  randomized controlled trial
  rectum hemorrhage (complication)
  stretching exercise
  taste disorder (complication)
  thorax pain (complication)
  treatment duration
  vocal cord paralysis (complication)
DEVICE MANUFACTURERS
   (United States)Cyberonics
EMBASE CLASSIFICATIONS
  Rehabilitation and Physical Medicine (19)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Neurology and Neurosurgery (8)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT01669161)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20151016667
FULL TEXT LINK
  http://dx.doi.org/10.1161/STROKEAHA.115.010477
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 88
TITLE
  Metronome cueing of walking reduces gait variability after a cerebellar 
stroke
AUTHOR NAMES
  Wright R.L.
  Bevins J.W.
  Pratt D.
  Sackley C.M.
  Wing A.M.
AUTHOR ADDRESSES
  (Wright R.L., r.wright.1@bham.ac.uk) School of Sport, Exercise and 
Rehabilitation Sciences, University of Birmingham, Birmingham, United 
Kingdom.
(Wright R.L., r.wright.1@bham.ac.uk; Wing A.M.) School of Psychology, 
University of Birmingham, Birmingham, United Kingdom.
(Bevins J.W.) Institute of Sport and Exercise Science, University of 
Worcester, Worcester, United Kingdom.
(Pratt D.) West Midlands Rehabilitation Centre, Birmingham Community 
Healthcare Trust, Birmingham, United Kingdom.
(Sackley C.M.) Faculty of Life Sciences and Medicine, King's College London, 
London, United Kingdom.
CORRESPONDENCE ADDRESS
  R.L. Wright, School of Sport, Exercise and Rehabilitation Sciences, 
University of Birmingham, Birmingham, United Kingdom. Email: 
r.wright.1@bham.ac.uk
SOURCE
  Frontiers in Neurology (2016) 7:JUN Article Number: 84. Date of Publication: 
2016
ISSN
  1664-2295 (electronic)
BOOK PUBLISHER
  Frontiers Research Foundation, info@frontiersin.org
ABSTRACT
  Cerebellar stroke typically results in increased variability during walking. 
Previous research has suggested that auditory cueing reduces excessive 
variability in conditions such as Parkinson's disease and post-stroke 
hemiparesis. The aim of this case report was to investigate whether the use 
of a metronome cue during walking could reduce excessive variability in gait 
parameters after a cerebellar stroke. An elderly female with a history of 
cerebellar stroke and recurrent falling undertook three standard gait trials 
and three gait trials with an auditory metronome. A Vicon system was used to 
collect 3-D marker trajectory data. The coefficient of variation was 
calculated for temporal and spatial gait parameters. SDs of the joint angles 
were calculated and used to give a measure of joint kinematic variability. 
Step time, stance time, and double support time variability were reduced 
with metronome cueing. Variability in the sagittal hip, knee, and ankle 
angles were reduced to normal values when walking to the metronome. In 
summary, metronome cueing resulted in a decrease in variability for step, 
stance, and double support times and joint kinematics. Further research is 
needed to establish whether a metronome may be useful in gait rehabilitation 
after cerebellar stroke and whether this leads to a decreased risk of 
falling.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  auditory system function
  cerebrovascular accident
  gait
  metronome cueing
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  auditory stimulation
  brain infarction
  case report
  clinical protocol
  computer assisted tomography
  fall risk
  falling
  female
  human
  medical history
  neuroimaging
  very elderly
  walking speed
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160508908
FULL TEXT LINK
  http://dx.doi.org/10.3389/fneur.2016.00084
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 89
TITLE
  MicroRNAs as biomarkers for acute atrial remodeling in marathon runners (The 
miRathon study - A sub-study of the Munich marathon study)
AUTHOR NAMES
  Clauss S.
  Wakili R.
  Hildebrand B.
  Kääb S.
  Hoster E.
  Klier I.
  Martens E.
  Hanley A.
  Hanssen H.
  Halle M.
  Nickel T.
AUTHOR ADDRESSES
  (Clauss S., sebastian.clauss@med.uni-muenchen.de; Wakili R.; Hildebrand B.; 
Kääb S.; Klier I.; Martens E.; Nickel T.) Medizinische Klinik und Poliklinik 
1, Campus Grosshadern, Ludwig-Maximilians-Universität München (LMU), Munich, 
Germany.
(Clauss S., sebastian.clauss@med.uni-muenchen.de; Wakili R.; Kääb S.; Halle 
M.) DZHK (German Centre for Cardiovascular Research), Partner Site Munich, 
Munich Heart Alliance, Munich, Germany.
(Clauss S., sebastian.clauss@med.uni-muenchen.de; Hanley A.) Cardiovascular 
Research Center, Massachusetts General Hospital, Charlestown, United States.
(Hoster E.) Institute for Medical Informatics Biometry and Epidemiology, 
Ludwig-Maximilians-UniversitätMünchen, Munich, Germany.
(Hanssen H.; Halle M.) Department of Prevention and Sports Medicine, 
Technische Universität München, Klinikumrechts der Isar (MRI), Munich, 
Germany.
(Hanssen H.) Sports Medicine, Institute of Exercise and Health Sciences, 
University Basel, Basel, Switzerland.
SOURCE
  PLoS ONE (2016) 11:2 Article Number: e0148599. Date of Publication: 2016
ISSN
  1932-6203 (electronic)
BOOK PUBLISHER
  Public Library of Science, plos@plos.org
ABSTRACT
  Introduction: Physical activity is beneficial for individual health, but 
endurance sport is associated with the development of arrhythmias like 
atrial fibrillation. The underlying mechanisms leading to this increased 
risk are still not fully understood. MicroRNAs are importantmediators of 
proarrhythmogenic remodeling and have potential value as biomarkers in 
cardiovascular diseases. Therefore, the objective of our study was to 
determine the value of circulating microRNAs as potential biomarkers for 
atrial remodeling in marathon runners (miRathon study). Methods: 30 marathon 
runners were recruited into our study and were divided into two age-matched 
groups depending on the training status: elite (ER, ≥55 km/week, n = 15) and 
non-elite runners (NER, ≤40 km/week, n = 15). All runners participated in a 
10 week training program before the marathon. MiRNA plasma levels were 
measured at 4 time points: at baseline (V1), after a 10 week training period 
(V2), immediately after the marathon (V3) and 24h later (V4). Additionally, 
we obtained clinical data including serum chemistry and echocardiography at 
each time point. Results: MiRNA plasma levels were similar in both groups 
over time with more pronounced changes in ER. After the marathon miR-30a 
plasma levels increased significantly in both groups. MiR-1 and miR-133a 
plasma levels also increased but showed significant changes in ER only. 24h 
after the marathon plasma levels returned to baseline. MiR-26a decreased 
significantly after the marathon in elite runners only and miR-29b showed a 
non-significant decrease over time in both groups. In ER miRNA plasma levels 
showed a significant correlation with LA diameter, in NER miRNA plasma 
levels did not correlate with echocardiographic parameters. Conclusion: 
MiRNAs were differentially expressed in the plasma of marathon runners with 
more pronounced changes in ER. Plasma levels in ER correlate with left 
atrial diameter suggesting that circulating miRNAs could potentially serve 
as biomarkers of atrial remodeling in athletes.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  microRNA (endogenous compound)
EMTREE DRUG INDEX TERMS
  creatine kinase (endogenous compound)
  creatine kinase MB (endogenous compound)
  troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart atrium remodeling (diagnosis)
  marathon runner
EMTREE MEDICAL INDEX TERMS
  adult
  anaerobic threshold
  article
  chemiluminescence immunoassay
  controlled study
  diagnostic value
  diastolic blood pressure
  disease marker
  echocardiography
  endurance training
  ergometry
  hemolysis
  human
  human experiment
  male
  normal human
  protein blood level
  pulse wave
  RNA analysis
  systolic blood pressure
  treadmill
CAS REGISTRY NUMBERS
  creatine kinase (9001-15-4)
  troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160175609
FULL TEXT LINK
  http://dx.doi.org/10.1371/journal.pone.0148599
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 90
TITLE
  Good at heart: Preserving cardiac metabolism during aging
AUTHOR NAMES
  Sorriento D.
  Franco A.
  Rusciano M.R.
  Maione A.S.
  Soprano M.
  Illario M.
  Iaccarino G.
  Ciccarelli M.
AUTHOR ADDRESSES
  (Sorriento D.) Institute of Biostructure and Bioimaging (IBB), Naples, 
Italy.
(Franco A.) Department of Advanced Biomedical Sciences, Federico II” 
University, Naples, Italy.
(Rusciano M.R.; Maione A.S.; Soprano M.; Illario M.) Department of 
Translational Medicine, Federico II” University, Naples, Italy.
(Iaccarino G.; Ciccarelli M., mciccarelli@unisa.it) Department of Medicine 
and Surgery, University of Salerno, Italy.
CORRESPONDENCE ADDRESS
  M. Ciccarelli, Department of Medicine and Surgery, University of Salerno, 
Italy. Email: mciccarelli@unisa.it
SOURCE
  Current Diabetes Reviews (2016) 12:2 (90-99). Date of Publication: 1 Jan 
2016
ISSN
  1875-6417 (electronic)
  1573-3998
BOOK PUBLISHER
  Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
  The natural process of aging determinates several cardiac modifications with 
increased susceptibility to heart diseases and ultimately converging on 
development of chronic heart failure as final stage. These changes mainly 
include left ventricular hypertrophy, diastolic dysfunction, valvular 
degeneration, increased cardiac fibrosis, increased prevalence of atrial 
fibrillation, and decreased maximal exercise capacity, as demonstrated in 
several humans and animal models of aging. While different theories have 
been proposed to explain the natural process of aging, it is clear that most 
of the alterations affect mechanisms involved in cell homeostasis and 
maintenance. Latest research studies have in particular focused on role of 
mitochondrial oxidative stress, energy production and mitochondria quality 
control. This article reviews the central role played by this organelle in 
aging and the role of new molecular players involved into the progression 
toward heart failure and potentially susceptible of new “anti-aging” 
strategies.
EMTREE DRUG INDEX TERMS
  adenylate kinase (endogenous compound)
  insulin (endogenous compound)
  mammalian target of rapamycin (endogenous compound)
  neurohormone (endogenous compound)
  sirtuin (endogenous compound)
  transcription factor FOXO (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aging
  heart muscle metabolism
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  autophagy
  diastolic dysfunction
  disorders of mitochondrial functions
  energy yield
  exercise
  heart left ventricle hypertrophy
  heart muscle fibrosis
  homeostasis
  human
  insulin resistance
  mitochondrion
  mitophagy
  nonhuman
  oxidative stress
  priority journal
  valvular heart disease
CAS REGISTRY NUMBERS
  adenylate kinase (9013-02-9)
  insulin (9004-10-8)
EMBASE CLASSIFICATIONS
  Gerontology and Geriatrics (20)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160188002
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 91
TITLE
  Atrial and Ventricular Arrhythmia-Associated Factors in Stable Patients with 
Chronic Obstructive Pulmonary Disease
AUTHOR NAMES
  Kusunoki Y.
  Nakamura T.
  Hattori K.
  Motegi T.
  Ishii T.
  Gemma A.
  Kida K.
AUTHOR ADDRESSES
  (Kusunoki Y.; Hattori K.; Motegi T.; Ishii T.; Gemma A.; Kida K., 
kkida@nms.ac.jp) Respiratory Care Clinic, Nippon Medical School, 4-7-15-8F, 
Kudan-minami, Chiyoda-ku Tokyo, Japan.
(Kusunoki Y.; Nakamura T.; Hattori K.; Motegi T.; Ishii T.; Kida K., 
kkida@nms.ac.jp) Department of Pulmonary Medicine, Infection, and Oncology, 
Nippon Medical School, Tokyo, Japan.
SOURCE
  Respiration (2016) 91:1 (34-42). Date of Publication: 1 Jan 2016
ISSN
  1423-0356 (electronic)
  0025-7931
BOOK PUBLISHER
  S. Karger AG
ABSTRACT
  Background: Supraventricular and ventricular premature complexes (SVPC and 
VPC, respectively) are associated with chronic obstructive pulmonary disease 
(COPD) and with increased mortality in COPD patients. However, there are few 
reports on the causes of arrhythmia in COPD patients. Objectives: This study 
explores the associations between cardiopulmonary dysfunction and COPD by 
comparing patients with defined arrhythmias (>100 beats per 24 h) and those 
without, based on 24-hour electrocardiogram (ECG) recordings. Methods: 
Patients with arrhythmia underwent a 24-hour ECG and subsequent pulmonary 
function tests, computed tomography, ECG, 6-min walk test (6MWT), and BODE 
(body mass index, airflow obstruction, modified Medical Research Council 
Dyspnoea Scale, exercise capacity) index calculation. Results: Of 103 study 
patients (71 COPD patients and 32 at-risk patients), 36 had VPC, 45 had 
SVPC, 20 had both, and 42 had neither. The predicted post-bronchodilator 
forced expiratory volume in 1 s, the proportion of low-attenuation area on 
computed tomography, and BODE index values were significantly worse in the 
SVPC and VPC groups compared with the corresponding reference groups. 
Patients in the VPC group showed significantly increased right ventricular 
pressure and increased desaturation in the 6MWT compared with the reference 
group. In the multivariate analyses, bronchodilator use was a significant 
risk factor in the SVPC group, whereas in the VPC group, all parameters of 
the BODE index except for the dyspnoea score were identified as risk 
factors. Conclusions: Increased SVPC might be caused by bronchodilator use, 
whereas increased VPC is likely related to the peculiar pathophysiology of 
COPD.
EMTREE DRUG INDEX TERMS
  beta 2 adrenergic receptor stimulating agent (drug therapy)
  bronchodilating agent (drug therapy)
  long acting beta 2 agonist (drug therapy)
  long acting muscarinic antagonist (drug therapy)
  muscarinic receptor blocking agent (drug therapy)
  theophylline (drug therapy)
  unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  chronic obstructive lung disease (drug therapy, drug therapy, epidemiology)
  heart atrium arrhythmia
  heart ventricle arrhythmia
EMTREE MEDICAL INDEX TERMS
  6 min walk test
  adult
  aged
  article
  assessment of humans
  blood chemistry
  BODE index
  body mass
  cardiopulmonary insufficiency
  cohort analysis
  computer assisted tomography
  controlled study
  correlation coefficient
  diagnostic test accuracy study
  disease association
  disease severity
  dyspnea
  electrocardiography
  exercise
  experimental locomotor activity test
  female
  forced expiratory volume
  heart right ventricle pressure
  heart ventricle extrasystole
  heart ventricle tachycardia
  human
  lung function test
  major clinical study
  male
  middle aged
  multivariate analysis
  oxygen desaturation
  pathophysiology
  predictive value
  prevalence
  priority journal
  prospective study
  risk factor
  supraventricular premature beat
  very elderly
CAS REGISTRY NUMBERS
  theophylline (58-55-9, 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  General Pathology and Pathological Anatomy (5)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160029934
FULL TEXT LINK
  http://dx.doi.org/10.1159/000442447
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 92
TITLE
  Surgical treatment of bronchiectasis: A review of 20 years of experience
AUTHOR NAMES
  Coutinho D.
  Fernandes P.
  Guerra M.
  Miranda J.
  Vouga L.
AUTHOR ADDRESSES
  (Coutinho D., dpcoutinho@gmail.com) Pulmonology Department, Centro 
Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de Gaia, Portugal.
(Fernandes P.; Guerra M.; Miranda J.; Vouga L.) Cardiothoracic Surgery 
Department, Centro Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de 
Gaia, Portugal.
CORRESPONDENCE ADDRESS
  D. Coutinho, Pulmonology Department, Centro Hospitalar de Vila Nova de Gaia 
e Espinho, Vila Nova de Gaia, Portugal. Email: dpcoutinho@gmail.com
SOURCE
  Revista Portuguesa de Pneumologia (2016) 22:2 (82-85). Date of Publication: 
2016
ISSN
  0873-2159
BOOK PUBLISHER
  Elsevier Doyma, editorial@elsevier.com
ABSTRACT
  Background: Bronchiectasis is defined as an abnormal and irreversible 
dilation and distortion of the bronchi, which has numerous causes. Surgical 
treatment of this disease is usually reserved for focal disease and when the 
medical treatment is no longer effective. We report our center experience 
and outcomes in bronchiectasis surgery during the last 20 years. Methods: 
Between 1994 and 2014, sixty-nine patients underwent surgical resection for 
bronchiectasis. Patient demographics, presenting symptoms, indications for 
surgical treatment, type of lung resection, morbidity and mortality, as well 
as clinical follow-up and outcomes were analyzed. Results: From the 69 
patients included, 31 (44.9%) were male and 38 (55.1%) were female. Surgery 
was indicated because of unsuccessful medical therapy in 33 patients 
(47.8%), haemoptysis in 22 patients (31.9%), nondiagnostic lung mass in 9 
patients (13.0%) and lung abscess in 5 patients (7.3%). The surgical 
procedures were lobectomy in 45 (65.2%) patients, pneumonectomy in 10 
(14.5%) patients, bilobectomy in 8 (11.6%) patients, lobectomy plus 
segmentectomy in 3 (4.3%) patients and only segmentectomy in 3 (4.3%) 
patients. Morbidity rate was 14.5% and there was no perioperative mortality. 
The follow-up was possible in 60 patients, with an outcome reported as 
excellent in 44 (73.3%) patients, as improved in 11 (18.3%) and as unchanged 
in 5 (8.3%). Conclusion: Although the number of patients with bronchiectasis 
referred for surgical treatment has decreased, pulmonary resection still 
plays a significant role. Surgical resection of localized bronchiectasis is 
a safe procedure with proven improvement of quality of life for the majority 
of patients.
EMTREE DRUG INDEX TERMS
  antibiotic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  bronchiectasis (disease management, surgery, therapy)
  lung resection
EMTREE MEDICAL INDEX TERMS
  adolescent
  adult
  age distribution
  aged
  antibiotic therapy
  article
  atrial fibrillation (complication)
  bleeding (complication)
  breathing exercise
  bronchopleural fistula (complication)
  child
  drug treatment failure
  female
  follow up
  hemoptysis
  hospital infection (complication)
  human
  human tissue
  lung abscess (surgery)
  lung bilobectomy
  lung lobectomy
  lung segmentectomy
  lung tumor (surgery)
  major clinical study
  male
  middle aged
  morbidity
  outcome assessment
  pneumonia (complication)
  pneumothorax (complication)
  postoperative care
  quality of life
  retrospective study
  surgical mortality
  surgical technique
  symptom
  thoracotomy
  treatment indication
  wound dehiscence (complication)
  young adult
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160495648
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.rppnen.2015.09.007
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 93
TITLE
  Eosinophilic Myocarditis due to Toxocariasis: Not a Rare Cause
AUTHOR NAMES
  Shibazaki S.
  Eguchi S.
  Endo T.
  Wakabayashi T.
  Araki M.
  Gu Y.
  Imai T.
  Asano K.
  Taniuchi N.
AUTHOR ADDRESSES
  (Shibazaki S., sn1.shibazaki@gmail.com; Araki M., makoto.araki@gmail.com; 
Taniuchi N., ntaniuchi@suwachuo.jp) Department of Internal Medicine, Suwa 
Central Hospital, 4300 Tamagawa, Chino, Nagano, Japan.
(Eguchi S., shunsuke219ncu@yahoo.co.jp) Department of Cardiology, Nagoya 
University Hospital, 65 Tsurumai, Showa, Nagoya, Aichi, Japan.
(Endo T., mamemametakashi@gmail.com) Department of Internal Medicine, 
Ishinomaki City Hospital, 25-1 Minamisakai-Shinkozutsumi, Ishinomaki, 
Miyagi, Japan.
(Wakabayashi T., tada_wakabayashi@yahoo.co.jp; Imai T., titi7110@aol.com) 
Department of Cardiology, Suwa Central Hospital, 4300 Tamagawa, Chino, 
Nagano, Japan.
(Gu Y., ygu@med.tohoku.ac.jp) Department of Infectious Disease, Tohoku 
University Hospital, 1-1 Seiryou, Aoba, Sendai, Miyagi, Japan.
(Asano K., kasano@suwachuo.jp) Department of Pathology, Suwa Central 
Hospital, 4300 Tamagawa, Chino, Nagano, Japan.
CORRESPONDENCE ADDRESS
  S. Shibazaki, Department of Internal Medicine, Suwa Central Hospital, 4300 
Tamagawa, Chino, Nagano, Japan. Email: sn1.shibazaki@gmail.com
SOURCE
  Case Reports in Cardiology (2016) 2016 Article Number: 2586292. Date of 
Publication: 2016
ISSN
  2090-6412 (electronic)
  2090-6404
BOOK PUBLISHER
  Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New 
York, United States.
ABSTRACT
  Myocarditis is a clinically important disease because of the high mortality. 
From the perspective of treatment strategy, eosinophilic myocarditis should 
be distinguished from other types of myocarditis. Toxocariasis, caused by 
Toxocara canis or Toxocara cati, is known as a cause of eosinophilic 
myocarditis but is considered rare. As it is an unpopular disease, 
eosinophilic myocarditis due to toxocariasis may be underdiagnosed. We 
experienced two cases of eosinophilic myocarditis due to toxocariasis from 
different geographical areas in quick succession between 2013 and 2014. Case 
1 is 32-year-old man. Case 2 is 66-year-old woman. In both cases, diagnosis 
was done by endomyocardial biopsy and IgG-ELISA against Toxocara 
excretory-secretory antigen. Only a corticosteroid was used in Case 1, 
whereas a corticosteroid and albendazole were used in Case 2 as induction 
therapy. Both patients recovered. Albendazole was also used in Case 1 to 
prevent recurrence after induction therapy. Eosinophilic myocarditis by 
toxocariasis may in actuality not be a rare disease, and corticosteroid is 
an effective drug as induction therapy even before use of albendazole.
EMTREE DRUG INDEX TERMS
  albendazole (drug therapy, oral drug administration)
  creatine kinase (endogenous compound)
  immunoglobulin G (endogenous compound)
  parasite antigen
  prednisolone (drug therapy, oral drug administration)
  troponin I (endogenous compound)
  troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  eosinophilia (drug therapy, drug therapy)
  eosinophilic myocarditis (drug therapy, complication, drug therapy)
  myocarditis (drug therapy, complication, drug therapy)
  toxocariasis (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  angiocardiography
  article
  case report
  chronic diarrhea
  chronic kidney disease
  computer assisted tomography
  contrast enhancement
  dyspnea
  electrocardiogram
  ELISA kit
  enzyme linked immunosorbent assay
  eosinophil count
  exercise
  female
  heart failure
  heart left ventricle ejection fraction
  heart muscle biopsy
  heart right bundle branch block
  human
  Japanese (people)
  laboratory test
  leukocyte count
  male
  persistent atrial fibrillation
  pyrexia idiopathica
  Q wave
  T wave
  thorax pain
  thorax radiography
  Toxocara canis
  transthoracic echocardiography
  visceral larva migrans syndrome
  Western blotting
CAS REGISTRY NUMBERS
  albendazole (54965-21-8)
  creatine kinase (9001-15-4)
  immunoglobulin G (97794-27-9)
  prednisolone (50-24-8)
  troponin I (77108-40-8)
  troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160411364
FULL TEXT LINK
  http://dx.doi.org/10.1155/2016/2586292
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 94
TITLE
  Emerging risk factors and the dose-response relationship between physical 
activity and lone atrial fibrillation: A prospective case-control study
AUTHOR NAMES
  Calvo N.
  Ramos P.
  Montserrat S.
  Guasch E.
  Coll-Vinent B.
  Domenech M.
  Bisbal F.
  Hevia S.
  Vidorreta S.
  Borras R.
  Falces C.
  Embid C.
  Montserrat J.M.
  Berruezo A.
  Coca A.
  Sitges M.
  Brugada J.
  Mont L.
AUTHOR ADDRESSES
  (Calvo N.; Ramos P.; Montserrat S.; Guasch E.; Coll-Vinent B.; Bisbal F.; 
Falces C.; Embid C.; Montserrat J.M.; Berruezo A.; Coca A.; Sitges M.; 
Brugada J.; Mont L., lmont@clinic.ub.es) Unitat de Fibril.lació Auricular, 
Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
(Calvo N.; Ramos P.; Montserrat S.; Guasch E.; Coll-Vinent B.; Domenech M.; 
Bisbal F.; Hevia S.; Vidorreta S.; Borras R.; Falces C.; Embid C.; 
Montserrat J.M.; Berruezo A.; Coca A.; Sitges M.; Brugada J.; Mont L., 
lmont@clinic.ub.es) Institut d'Investigacions Biomédiques August Pi i Sunyer 
(IDIBAPS), Catalonia, Spain.
(Domenech M.; Coca A.) Unitat d'Hipertensió i Risc Vascular, Hospital 
Clínic, Catalonia, Spain.
(Embid C.; Montserrat J.M.) Unitat del Son. Servei Pneumologia, Hospital 
Clínic, CIBERES Barcelona, Catalonia, Spain.
CORRESPONDENCE ADDRESS
  L. Mont, Unitat de Fibril.lació Auricular, Hospital Clínic, Universitat de 
Barcelona, Barcelona, Catalonia, Spain. Email: lmont@clinic.ub.es
SOURCE
  Europace (2015) 18:1 (57-63). Date of Publication: 28 Dec 2015
ISSN
  1532-2092 (electronic)
  1099-5129
BOOK PUBLISHER
  Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
  Aims The role of high-intensity exercise and other emerging risk factors in 
lone atrial fibrillation (Ln-AF) epidemiology is still under debate. The aim 
of this study was to analyse the contribution of each of the emerging risk 
factors and the impact of physical activity dose in patients with Ln-AF. 
Methods and results Patients with Ln-AF and age- and sex-matched healthy 
controls were included in a 2:1 prospective case-control study. We obtained 
clinical and anthropometric data transthoracic echocardiography, lifetime 
physical activity questionnaire, 24-h ambulatory blood pressure monitoring, 
Berlin questionnaire score, and, in patients at high risk for obstructive 
sleep apnoea (OSA) syndrome, a polysomnography. A total of 115 cases and 57 
controls were enrolled. Conditional logistic regression analysis associated 
height [odds ratio (OR) 1.06 [1.01-1.11]], waist circumference (OR 1.06 
[1.02-1.11]), OSA (OR 5.04 [1.44-17.45]), and 2000 or more hours of 
cumulative high-intensity endurance training to a higher AF risk. Our data 
indicated a U-shaped association between the extent of high-intensity 
training and AF risk. The risk of AF increased with an accumulated lifetime 
endurance sport activity ≥2000 h compared with sedentary individuals (OR 
3.88 [1.55-9.73]). Nevertheless, a history of <2000 h of high-intensity 
training protected against AF when compared with sedentary individuals (OR 
0.38 [0.12-0.98]). Conclusion A history of ≥2000 h of vigorous endurance 
training, tall stature, abdominal obesity, and OSA are frequently 
encountered as risk factors in patients with Ln-AF. Fewer than 2000 total 
hours of high-intensity endurance training associates with reduced Ln-AF 
risk.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent (drug therapy)
  brain natriuretic peptide (endogenous compound)
  C reactive protein (endogenous compound)
  calcium antagonist (drug therapy)
  interleukin 1 (endogenous compound)
  isoatrial natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  abdominal obesity
  atrial fibrillation (drug therapy, drug therapy)
  endurance training
  sleep disordered breathing
  tall stature
EMTREE MEDICAL INDEX TERMS
  adult
  article
  cardiovascular risk
  case control study
  controlled study
  cross-sectional study
  cycling
  echocardiography
  endurance sport
  female
  heart left ventricle ejection fraction
  human
  inflammation
  major clinical study
  male
  marathon runner
  masked hypertension
  observational study
  physical activity
  prevalence
  priority journal
  prospective study
  risk assessment
  risk reduction
  sedentary lifestyle
  team sport
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
  C reactive protein (9007-41-4)
  isoatrial natriuretic peptide (124147-23-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Physiology (2)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160266623
FULL TEXT LINK
  http://dx.doi.org/10.1093/europace/euv216
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 95
TITLE
  Risk stratification for large artery or chronic coronary artery 
disease-related ischemic stroke in octogenarians undergoing exercise stress 
myocardial perfusion imaging: A cohort study
AUTHOR NAMES
  Katsikis A.
  Theodorakos A.
  Drosatos A.
  Konstantinou K.
  Papaioannou S.
  Koutelou M.
AUTHOR ADDRESSES
  (Katsikis A., tkatsikis@gmail.com; Theodorakos A.; Papaioannou S.; Koutelou 
M.) Nuclear Medicine Department, Onassis Cardiac Surgery Center, Kallithea, 
Greece.
(Drosatos A.) Cardiology Department, Attikon University Hospital, Athens, 
Greece.
(Katsikis A., tkatsikis@gmail.com; Drosatos A.; Konstantinou K.) Cardiology 
Department, 401 General Military Hospital of Athens, Athens, Greece.
(Papaioannou S.) Cardiology Department, Athens Naval Hospital, Athens, 
Greece.
CORRESPONDENCE ADDRESS
  A. Katsikis, Cardiology Department, 401 General Military Hospital of Athens, 
Athens, Greece. Email: tkatsikis@gmail.com
SOURCE
  Journal of Nuclear Cardiology (2015) (1-5). Date of Publication: 16 Dec 2015
ISSN
  1532-6551 (electronic)
  1071-3581
BOOK PUBLISHER
  Springer New York LLC, barbara.b.bertram@gsk.com
ABSTRACT
  Objectives: To test, if in octogenarians, treadmill exercise with myocardial 
perfusion imaging (exercise-MPI) can risk stratify for large artery or 
chronic CAD-related ischemic stroke (LACCIS). Methods: Exercise-MPI-related 
data of 237 octogenarians (55% prior MI or revascularization) without 
previous stroke were registered and prospective follow-up was performed to 
document LACCIS. LACCIS was defined as acute onset of neurological symptoms 
with CT/MRI findings of non-lacunar-type infarcts in the absence of atrial 
fibrillation or intracardiac embolic sources. Results: After 7.3 years, 10 
LACCIS were documented. SSS [HR 1.08 (1.02-1.13 95% CIs), SDS [HR 1.1 
(1.04-1.16 95% CIs)], and non-sustained VT or transient AV block during 
exercise [HR 3.9 (1.7-9.0 95% CIs)] were predictors of LACCIS (P < .01 for 
all). A SSS threshold of 16 had 81% specificity for identification of future 
LACCIS and risk groups formed according to this cut-off had significantly 
different LACCIS-free survival (P = .015). Conclusion: Exercise-MPI in 
octogenarians can provide risk stratification markers for LACCIS.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  artery
  brain ischemia
  cohort analysis
  coronary artery disease
  exercise
  myocardial perfusion imaging
  stratification
  stress
  very elderly
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  atrioventricular block
  controlled study
  follow up
  high risk population
  human
  infarction
  nuclear magnetic resonance imaging
  revascularization
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20151038951
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12350-015-0361-7
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 96
TITLE
  Thyroidectomy in a patient with thyroid storm: report of a case
AUTHOR NAMES
  Uchida N.
  Suda T.
  Ishiguro K.
AUTHOR ADDRESSES
  (Uchida N., uchidana@pref.tottori.jp) Department of Surgery, Tottori 
Prefectural Kousei Hospital, 150 Higashisyouwa-machi, Kurayoshi, Japan.
(Uchida N., uchidana@pref.tottori.jp; Suda T.; Ishiguro K.) Department of 
Breast and Endocrine Surgery, Tottori University Hospital, 36-1 Nishi-cho, 
Yonago, Japan.
CORRESPONDENCE ADDRESS
  N. Uchida, Department of Surgery, Tottori Prefectural Kousei Hospital, 150 
Higashisyouwa-machi, Kurayoshi, Japan.
SOURCE
  Surgery Today (2015) 45:1 (110-114). Date of Publication: 13 Dec 2015
ISSN
  1436-2813 (electronic)
  0941-1291
BOOK PUBLISHER
  Springer-Verlag Tokyo, orders@springer.jp
ABSTRACT
  Thyroid storm is a life-threatening condition that is generally considered 
to be a contradiction to surgical intervention. We herein describe the case 
of a 37-year-old patient with a history of Graves’ disease who was 
transferred to Tottori University Hospital with thyroid storm. She had been 
followed by her family doctor since 2006, but she had stopped taking her 
medication of her own volition in 2010. About ten days prior to her 
admission at our hospital, she consulted her family doctor with complaints 
of dyspnea, palpitations and general fatigue. Subsequent thyroid function 
tests showed TSH < 0.01 μU/ml, FT3 25.0 pg/ml and FT4 8.0 ng/dl. She also 
had acute heart failure, atrial fibrillation and hepatic failure. A 
diagnosis of thyroid storm was made and she was transferred to our hospital. 
She received steroids, beta blockade, potassium iodide, and plasma exchange, 
but her hepatic failure did not resolve and her clinical condition 
deteriorated. The decision was made to proceed with thyroidectomy. 
Postoperatively, her hepatic function normalized. Thus, thyroidectomy is a 
potential therapeutic choice for cases of thyroid storm refractory to 
medical management.
EMTREE DRUG INDEX TERMS
  alanine aminotransferase (endogenous compound)
  aspartate aminotransferase (endogenous compound)
  atrial natriuretic factor alpha (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  betamethasone sodium phosphate (drug therapy)
  bilirubin (endogenous compound)
  digoxin (drug therapy)
  diuretic agent (drug therapy)
  heparin (drug therapy)
  hydrocortisone sodium succinate (drug therapy)
  levothyroxine sodium (drug therapy)
  potassium iodide (drug therapy)
  prednisolone (drug therapy)
  thiamazole (drug therapy)
  thyrotropin (endogenous compound)
  thyroxine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  thyroid crisis (drug therapy, diagnosis, drug therapy, surgery)
  thyroidectomy
EMTREE MEDICAL INDEX TERMS
  acute heart failure
  adult
  alanine aminotransferase blood level
  article
  aspartate aminotransferase blood level
  atrial fibrillation
  bilirubin blood level
  case report
  consultation
  dyspnea
  emergency surgery
  fatigue
  female
  follow up
  general practitioner
  Graves disease
  heart palpitation
  hepatitis
  hospital admission
  human
  liver failure
  liver function
  medical history
  patient transport
  plasmapheresis
  postoperative period
  prothrombin time
  severe hepatic impairment
  steroid therapy
  thyroid function test
  thyrotropin blood level
  thyroxine blood level
  university hospital
CAS REGISTRY NUMBERS
  alanine aminotransferase (9000-86-6, 9014-30-6)
  aspartate aminotransferase (9000-97-9)
  atrial natriuretic factor alpha (89213-87-6)
  betamethasone sodium phosphate (151-73-5, 360-63-4)
  bilirubin (18422-02-1, 635-65-4)
  digoxin (20830-75-5, 57285-89-9)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  hydrocortisone sodium succinate (125-04-2, 2203-97-6)
  levothyroxine sodium (55-03-8)
  potassium iodide (7681-11-0)
  prednisolone (50-24-8)
  thiamazole (60-56-0)
  thyrotropin (9002-71-5)
  thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015651971
MEDLINE PMID
  24132684 (http://www.ncbi.nlm.nih.gov/pubmed/24132684)
FULL TEXT LINK
  http://dx.doi.org/10.1007/s00595-013-0754-7
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 97
TITLE
  Ischemic stroke: the impact of renal dysfunction on 1-year mortality
AUTHOR NAMES
  Fabjan T.H.
  Hojs R.
AUTHOR ADDRESSES
  (Fabjan T.H., tanja.hojs@ukc-mb.si) Department of Neurology, University 
Clinical Centre Maribor, Ljubljanska 5, Maribor, Slovenia.
(Hojs R.) Clinic for Internal Medicine, Department of Nephrology, University 
Clinical Centre Maribor, Maribor, Slovenia.
(Fabjan T.H., tanja.hojs@ukc-mb.si; Hojs R.) University of Maribor, Maribor, 
Slovenia.
CORRESPONDENCE ADDRESS
  T.H. Fabjan, Department of Neurology, University Clinical Centre Maribor, 
Ljubljanska 5, Maribor, Slovenia. Email: tanja.hojs@ukc-mb.si
SOURCE
  Wiener Klinische Wochenschrift (2015) 127 Supplement 5 (175-180). Date of 
Publication: 1 Dec 2015
ISSN
  1613-7671 (electronic)
  0043-5325
BOOK PUBLISHER
  Springer-Verlag Wien, michaela.bolli@springer.at
ABSTRACT
  Background: Atherosclerosis is accelerated in patients with different stages 
of chronic renal failure. Renal dysfunction predicts mortality in patients 
with myocardial infarction and congestive heart failure. Less is known about 
the impact of renal dysfunction on mortality after ischemic stroke. The aim 
of the study was to investigate the impact of renal dysfunction on 1-year 
mortality. Patients and methods: All 390 patients (207 men and 183 women) 
suffered from ischemic stroke in 1-year period were included in our study. 
Telephonic follow-up after 1 year was performed. The mean age of our 
patients was 71.0 ± 11.6 years, ranged from 36 to 96 years. Glomerular 
filtration rate (GFR) was calculated according to abbreviated Modification 
of Diet in Renal Disease formula. At admission and at discharge National 
Institutes of Health Stroke Scale (NIHSS) were performed. Results: The mean 
GFR in our patients was 66.0 ± 20.68 ml/min/1.73 m(2). There were 123 (31.5 
%) deaths in 1-year period. Patients who died were older (P < 0.001), had 
higher NIHSS at admission and at discharge (both P < 0.001), higher 
high-sensitive C-reactive protein (P = 0.002), lower albumin (P < 0.001), 
lower GFR (P = 0.044), had more frequent atrial fibrillation (P < 0.001), 
and were less frequent actual smokers (P = 0.003). No differences in 
presence of diabetes and hypertension, high-density lipoprotein cholesterol, 
low-density lipoprotein cholesterol and triglycerides between patients who 
died or survived were found. With Cox multivariable regression analysis age 
(P = 0.037), gender (P = 0.005), NIHSS at admission (P = 0.005) and 
discharge (P < 0.001), albumin (P = 0.005) and also GFR (P = 0.025) were 
predictors of 1-year mortality. Conclusions: In patients with ischemic 
stroke, renal dysfunction (decreased GFR) was associated with 1-year 
mortality. GFR was independent predictor of mortality.
EMTREE DRUG INDEX TERMS
  albumin (endogenous compound)
  C reactive protein (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia
  kidney disease
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation
  controlled study
  female
  follow up
  glomerulus filtration rate
  human
  major clinical study
  male
  mortality
  National Institutes of Health Stroke Scale
  very elderly
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
EMBASE CLASSIFICATIONS
  Urology and Nephrology (28)
  Clinical and Experimental Biochemistry (29)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015846366
FULL TEXT LINK
  http://dx.doi.org/10.1007/s00508-015-0705-y
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 98
TITLE
  Cardiac resynchronization in patients with atrial fibrillation
AUTHOR NAMES
  Barold S.S.
  Herweg B.
AUTHOR ADDRESSES
  (Barold S.S.) Department of Medicine, University of Rochester, School of 
Medicine and Dentistry, Rochester, United States.
(Herweg B.) Arrhythmia Service, University of South Florida, College of 
Medicine, Tampa General Hospital, Tampa, United States.
CORRESPONDENCE ADDRESS
  S.S. Barold, Department of Medicine, University of Rochester, School of 
Medicine and Dentistry, Rochester, United States.
SOURCE
  Journal of Atrial Fibrillation (2015/2016) 8:4. Date of Publication: 1 Dec 
2015
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, editors.office@jafib.com
ABSTRACT
  Atrial fibrillation (AF) occurs in one of four patients undergoing cardiac 
resynchronization therapy (CRT).-Without special therapy, the prognosis of 
AF patients with CRT has been generally worse than those in sinus rhythm. 
The importance of a high percentage of biventricular pacing (BIV%) was 
confirmed in a large study where the mortality was inversely associated with 
BIV% both in the presence of normal sinus and atrial paced rhythm and with 
AF. The greatest reduction in mortality was observed with BIV% >98%. 
Patients with BIV% >99.6% experienced a 24% reduction in mortality (p < 
0.001) while those with BIV% <94.8% had a 19% increase in mortality. The 
optimal BIV% cut-point was 98.7%. This cutoff would appear mandatory but it 
would be best to approach 100%. Careful evaluation of device interrogation 
data upon which the BiV% is based is essential because the memorized data 
can vastly overestimate the percentage of truly resynchronized beats since 
it does not account for fusion and pseudofusion between intrinsic (not 
paced) and paced beats. The recently published randomized CERTIFY trial 
provides unequivocal proof of the value of AV junctional (AVJ) ablation in 
CRT patients with AF. This trial confirmed the favorable results of AVJ 
ablation by many other studies and two important meta-analyses and therefore 
established the firm recommendation that the procedure should be performed 
in most, if not all, patients with permanent AF as well as those with 
frequent and prolonged episodes of paroxysmal AF. Patients after AVJ have 
improved mortality with a mortality similar to those in sinus rhythm. The 
AVJ ablation procedure carries the theoretical risk of device failure and 
death in pacemaker dependent patients. An inappropriate first ICD shock for 
AF seems to increase mortality. Increased long-term mortality after an 
inappropriate shock may be due to the underlying atrial arrhythmia substrate 
as opposed to the effect of the shock itself.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (therapy)
  cardiac resynchronization therapy
EMTREE MEDICAL INDEX TERMS
  ablation therapy
  AV junctional ablation
  cardiovascular mortality
  clinical effectiveness
  death
  device failure
  disease control
  exercise
  follow up
  heart atrium arrhythmia
  heart atrium pacing
  heart beat
  heart failure
  heart left ventricle ejection fraction
  heart left ventricle endsystolic volume
  heart ventricle arrhythmia
  Holter monitoring
  hospitalization
  human
  implantable cardioverter defibrillator
  incidence
  meta analysis (topic)
  pacemaker
  paroxysmal atrial fibrillation
  practice guideline
  prognosis
  randomized controlled trial (topic)
  resting heart rate
  review
  sinus rhythm
  treatment outcome
  treatment response
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160185165
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 99
TITLE
  Atrial fibrillation and physical activity Should we exercise caution?
ORIGINAL (NON-ENGLISH) TITLE
  Fibrillation auriculaire et activité physique: Faut-il être prudent?
AUTHOR NAMES
  John Bosomworth N.
AUTHOR ADDRESSES
  (John Bosomworth N., jbosomworth@gmail.com) Department of Family Practice, 
University of British Columbia, Vancouver, Canada.
CORRESPONDENCE ADDRESS
  N. John Bosomworth, Department of Family Practice, University of British 
Columbia, Vancouver, Canada. Email: jbosomworth@gmail.com
SOURCE
  Canadian Family Physician (2015) 61:12 (1061-1070 and e542-e552). Date of 
Publication: 1 Dec 2015
ISSN
  0008-350X
BOOK PUBLISHER
  College of Family Physicians of Canada
ABSTRACT
  Objective To review the evidence on the effects of various levels of 
physical activity (PA) on the incidence of atrial fibrillation (AF) in both 
the general population and in endurance athletes. Data sources A PubMed 
search was done initially using the MeSH headings or text words (with the 
search-field descriptor TIAB [title and abstract]) atrial fibrillation and 
exercise or physical activity or athlet∗or sport∗, without additional 
filters. Conclusions regarding quality and strength of evidence were based 
on the GRADE (grading of recommendations, assessment, development, and 
evaluation) system. Study selection No interventional studies were 
available. Observational studies were therefore considered acceptable, and, 
although larger long-term prospective cohort studies were preferred, 
case-control or cross-sectional trials were also included in this review. 
Synthesis Available evidence suggests a dose-response association linking 
increased exercise levels with reduced incident AF in women. The same is 
true in men at low and moderate levels of exertional activity. In men only, 
high levels of PA are associated with increased risk of AF in most, but not 
all, studies. This risk is moderate, with a hazard ratio of 1.29 in one of 
the better studies. The risk of AF for most people who exercise regularly is 
lower than that of a matched sedentary population. Conclusion Atrial 
fibrillation is probably less common as PA increases, with a demonstrable 
dose-response relationship. Exercise at any level should be promoted for its 
effect on physical well-being and mortality reduction. In men exercising at 
high levels, beneficial effects on AF might be lost and risk might exceed 
that of the sedentary population; however, the evidence is neither robust 
nor consistent. These men should be made aware of this modest increase in 
risk should they choose to continue to engage in high levels of PA.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  atrial fibrillation
  endurance training
  physical activity
EMTREE MEDICAL INDEX TERMS
  athletic performance
  borderline hypertension
  bradycardia
  cardiovascular mortality
  cardiovascular risk
  endurance
  exercise intensity
  follow up
  heart atrium flutter
  heart function
  human
  pathophysiology
  prognosis
  review
  risk reduction
  running
  sedentary lifestyle
  vagus tone
  walking
  wellbeing
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Physiology (2)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English, French
LANGUAGE OF SUMMARY
  English, French
EMBASE ACCESSION NUMBER
  20151052505
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 100
TITLE
  Atrial fibrillation in athletes: Pathophysiology, clinical presentation, 
evaluation and management
AUTHOR NAMES
  Turagam M.K.
  Flaker G.C.
  Velagapudi P.
  Vadali S.
  Alpert M.A.
AUTHOR ADDRESSES
  (Turagam M.K.; Flaker G.C.; Velagapudi P.; Vadali S.; Alpert M.A.) Division 
of Cardiovascular, Medicine University of Missouri, School of Medicine, 
Health Sciences Center, 5 Hospital Drive, Columbia, United States.
CORRESPONDENCE ADDRESS
  M.A. Alpert, Division of Cardiovascular, Medicine University of Missouri, 
School of Medicine, Health Sciences Center, 5 Hospital Drive, Columbia, 
United States.
SOURCE
  Journal of Atrial Fibrillation (2015/2016) 8:4. Date of Publication: 1 Dec 
2015
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, editors.office@jafib.com
ABSTRACT
  Atrial fibrillation (AF) is the most common cardiac arrhythmia in athletes, 
especially in middle-aged athletes. Studies have demonstrated that athletes 
who engage in endurance sports such as runners, cyclists and skiers are more 
prone to AF than other athletes. The effects of exercise on the onset and 
progression of AF is complex. Triggers of AF in athletes may include atrial 
ectopy and sports supplements. Substrates for AF in athletes include atrial 
remodeling, fibrosis, and inflammation. Modulators of AF in athletes include 
autonomic activation, electrolyte abnormalities, and possibly, 
gastroesophageal reflux. Management of AF in athletes with rate-controlling 
agents and antiarrhythmic drugs remains a challenge and can be associated 
with impaired athletic performance. The value of catheter ablation is 
emerging and should be considered in suitable athletes with AF.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
  anabolic agent
  disopyramide (drug therapy)
  electrolyte
  flecainide (drug therapy)
  performance enhancing substance
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  atrial fibrillation (drug therapy, drug therapy, etiology, therapy)
EMTREE MEDICAL INDEX TERMS
  autonomic innervation
  cardioversion
  carditis
  catheter ablation
  clinical evaluation
  clinical feature
  direct current
  dyspnea
  electrolyte disturbance
  energy drink
  exercise
  faintness
  gastroesophageal reflux
  heart muscle fibrosis
  heart palpitation
  Holter monitoring
  human
  pathogenesis
  physical examination
  pulmonary vein isolation
  review
  sport
  supraventricular premature beat
  transthoracic echocardiography
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  disopyramide (3737-09-5)
  flecainide (54143-55-4)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160185170
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 101
TITLE
  Giant Caseous Calcification on Tricuspid Annulus Mimicking Cardiac 
Metastasis in a Patient with Colon Cancer
AUTHOR NAMES
  Yesin M.
  Toprak C.
  Kalçik M.
  Bayam E.
  ̄nanir M.
  Özkan M.
AUTHOR ADDRESSES
  (Yesin M., mahmutyesin@yahoo.com; Toprak C.; Bayam E.; ̄nanir M.; Özkan M.) 
Department of Cardiology, Kosuyolu Kartal Heart Training and Research 
Hospital, Istanbul, Turkey.
(Kalçik M.) Department of Cardiology, Iskilip Atif Hoca State Hospital, 
Çorum, Turkey.
(Özkan M.) Division of Health Sciences, Ardahan University, Ardahan, Turkey.
CORRESPONDENCE ADDRESS
  M. Yesin, Denizer Cad. Cevizli Kvs. No:2 Cevizli, Kartal/Istanbul, Turkey. 
Email: mahmutyesin@yahoo.com
SOURCE
  Echocardiography (2015) 32:12 (1885-1886). Date of Publication: 1 Dec 2015
ISSN
  1540-8175 (electronic)
  0742-2822
BOOK PUBLISHER
  Blackwell Publishing Inc., subscrip@blackwellpub.com
ABSTRACT
  Mini-Abstract Caseous calcification is usually an incidental finding on the 
atrioventricular valvular annulus. The exact mechanism of pathogenicity for 
the caseous calcifications has not been defined yet. Differential diagnosis 
includes vegetation, thrombus, or metastatic tumors. We presented a case of 
a large tricuspid mass as an incidental finding by transthoracic 
echocardiography in a patient with metastatic colon cancer. The distinction 
between caseous calcification and metastatic tumor was made based on the 
typical location of calcification, possible extension to the whole mitral 
annulus, well-defined borders, and the internal echolucent area.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  colon cancer
  heart metastasis (diagnosis)
  tricuspid valve annulus caseous calcification (diagnosis)
  tricuspid valve disease (diagnosis)
EMTREE MEDICAL INDEX TERMS
  aged
  atrial fibrillation
  case report
  computer assisted tomography
  differential diagnosis
  dyspnea
  electrocardiography
  exercise
  female
  human
  image analysis
  mitral valve regurgitation
  physical examination
  pleura effusion
  pneumonia
  positron emission tomography
  priority journal
  short survey
  systolic heart murmur
  thorax radiography
  transthoracic echocardiography
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cancer (16)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015213337
FULL TEXT LINK
  http://dx.doi.org/10.1111/echo.13018
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 102
TITLE
  New insights into the pros and cons of the clinical use of vitamin K 
antagonists (VKAs) versus direct oral anticoagulants (DOACs)
AUTHOR NAMES
  van Gorp R.H.
  Schurgers L.J.
AUTHOR ADDRESSES
  (van Gorp R.H., rick.vangorp@maastrichtuniversity; Schurgers L.J., 
l.schurgers@maastrichtuniversity.nl) Department of Biochemistry, 
Cardiovascular Research Institute Maastricht, Maastricht University, PO Box 
616, Maastricht, Netherlands.
(van Gorp R.H., rick.vangorp@maastrichtuniversity) Nattopharma ASA, Høvik, 
Norway.
CORRESPONDENCE ADDRESS
  L.J. Schurgers, Department of Biochemistry, Cardiovascular Research 
Institute Maastricht, Maastricht University, PO Box 616, Maastricht, 
Netherlands. Email: l.schurgers@maastrichtuniversity.nl
SOURCE
  Nutrients (2015) 7:11 (9538-9557). Date of Publication: 17 Nov 2015
ISSN
  2072-6643 (electronic)
BOOK PUBLISHER
  MDPI AG, Postfach, Basel, Switzerland.
ABSTRACT
  Vitamin K-antagonists (VKA) are the most widely used anticoagulant drugs to 
treat patients at risk of arterial and venous thrombosis for the past 50 
years. Due to unfavorable pharmacokinetics VKA have a small therapeutic 
window, require frequent monitoring, and are susceptible to drug and 
nutritional interactions. Additionally, the effect of VKA is not limited to 
coagulation, but affects all vitamin K-dependent proteins. As a consequence, 
VKA have detrimental side effects by enhancing medial and intimal 
calcification. These limitations stimulated the development of alternative 
anticoagulant drugs, resulting in direct oral anticoagulant (DOAC) drugs, 
which specifically target coagulation factor Xa and thrombin. DOACs also 
display non-hemostatic vascular effects via protease-activated receptors 
(PARs). As atherosclerosis is characterized by a hypercoagulable state 
indicating the involvement of activated coagulation factors in the genesis 
of atherosclerosis, anticoagulation could have beneficial effects on 
atherosclerosis. Additionally, accumulating evidence demonstrates vascular 
benefit from high vitamin K intake. This review gives an update on oral 
anticoagulant treatment on the vasculature with a special focus on 
calcification and vitamin K interaction.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (clinical trial, drug comparison, drug therapy)
  antivitamin K (adverse drug reaction, clinical trial, drug comparison, drug 
therapy)
  direct oral anticoagulant agent (clinical trial, drug comparison, drug 
therapy)
EMTREE DRUG INDEX TERMS
  acenocoumarol (drug therapy)
  antistasin (drug therapy)
  apixaban (clinical trial, drug comparison, drug therapy)
  blood clotting factor 10a (endogenous compound)
  dabigatran (clinical trial, drug comparison, drug therapy)
  dabigatran etexilate (clinical trial, drug comparison, drug therapy)
  dicoumarol (clinical trial, drug comparison, drug therapy)
  enoxaparin (clinical trial, drug comparison, drug therapy)
  fibrin (endogenous compound)
  heparin (drug comparison, drug therapy)
  hirudin (drug therapy)
  menadione
  menaquinone
  osteocalcin (endogenous compound)
  phenprocoumon (drug therapy)
  phytomenadione
  proteinase activated receptor (endogenous compound)
  rivaroxaban (clinical trial, drug comparison, drug therapy)
  thrombin (endogenous compound)
  tick anticoagulant peptide (drug therapy)
  unclassified drug
  warfarin (adverse drug reaction, clinical trial, drug comparison, drug 
therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  blood vessel calcification (side effect, side effect)
EMTREE MEDICAL INDEX TERMS
  artery thrombosis (drug therapy)
  atherosclerosis
  atrial fibrillation (drug therapy)
  bleeding (side effect)
  comparative effectiveness
  drug bioavailability
  drug efficacy
  drug half life
  drug monitoring
  drug safety
  human
  meta analysis (topic)
  nonhuman
  nutrition
  protein expression
  prothrombin time
  randomized controlled trial (topic)
  review
  vascularization
  vein thrombosis (drug therapy)
  venous thromboembolism (drug therapy)
CAS REGISTRY NUMBERS
  acenocoumarol (152-72-7)
  antistasin (110119-38-5)
  apixaban (503612-47-3)
  blood clotting factor 10a (72162-96-0, 9002-05-5)
  dicoumarol (66-76-2)
  enoxaparin (679809-58-6)
  fibrin (9001-31-4)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  hirudin (8001-27-2)
  menadione (58-27-5)
  osteocalcin (136461-80-8)
  phenprocoumon (435-97-2)
  phytomenadione (11104-38-4, 84-80-0)
  rivaroxaban (366789-02-8)
  thrombin (9002-04-4, 869858-13-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015525662
FULL TEXT LINK
  http://dx.doi.org/10.3390/nu7115479
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 103
TITLE
  Atrial fibrillation cardioversion following acupuncture
AUTHOR NAMES
  Dilber D.
  Čerkez-Habek J.
  Barić H.
  Gradišer M.
AUTHOR ADDRESSES
  (Dilber D.) Departments of Cardiology, County Hospital Čakovec, Čakovec, 
Croatia.
(Čerkez-Habek J.) Departments of Endocrinology and Diabetes, County Hospital 
Čakovec, Čakovec, Croatia.
(Barić H., hrvojebaric00@gmail.com) Međimurje County Institute for Emergency 
Medicine, Čakovec, Croatia.
(Gradišer M.) Department of Internal Medicine, University Hospital Sveti 
Duh, Zagreb, Croatia.
CORRESPONDENCE ADDRESS
  H. Barić, Međimurje County Institute for Emergency Medicine, Čakovec, 
Croatia. Email: hrvojebaric00@gmail.com
SOURCE
  Saudi Medical Journal (2015) 36:11 (1351-1353). Date of Publication: 1 Nov 
2015
ISSN
  1658-3175 (electronic)
  0379-5284
BOOK PUBLISHER
  Saudi Arabian Armed Forces Hospital, smjns.ksa@zajil.net
ABSTRACT
  Atrial fibrillation (AF) is the most common arrhythmia and it is an 
independent risk for serious events. Acupuncture has been growing in 
popularity in the West, and there are reports of its benefits in treating 
AF. We report a 57-year-old man who was admitted after having an allergic 
reaction to amiodarone administered to treat paroxysmal AF with fast 
ventricular response. Cardioversion with intravenous propafenone was 
uneventful. Before an attempt of electric cardioversion, he was treated with 
acupuncture as additional therapy to peroral propafenone. After acupuncture 
treatment consisting of 10 treatments during 30 days period, both immediate 
cardioversion to sinus rhythm and no paroxysmal AF during 30 days period 
were recorded.
EMTREE DRUG INDEX TERMS
  amiodarone (adverse drug reaction, drug therapy, intravenous drug 
administration)
  amlodipine (drug therapy)
  bisoprolol (drug therapy)
  nadroparin (drug therapy, subcutaneous drug administration)
  propafenone (drug therapy, oral drug administration)
  ramipril (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  atrial fibrillation (drug therapy, diagnosis, drug therapy, therapy)
  cardioversion
EMTREE MEDICAL INDEX TERMS
  acupuncture needle
  adult
  allergic reaction (side effect)
  article
  case report
  drug substitution
  drug withdrawal
  echocardiography
  echography
  electrocardiography
  heart palpitation
  human
  hypertension (drug therapy)
  male
  middle aged
  nervousness
  telemetry
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  amlodipine (88150-42-9, 103129-82-4, 736178-83-9)
  bisoprolol (66722-44-9)
  nadroparin (104521-37-1)
  propafenone (34183-22-7, 54063-53-5)
  ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, Arabic
EMBASE ACCESSION NUMBER
  20151036402
FULL TEXT LINK
  http://dx.doi.org/10.15537/smj.2015.11.12891
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 104
TITLE
  Dilated left ventricular cardiomyopathy secondary to noncompaction in a 
patient with paroxysmal atrial fibrillation
AUTHOR NAMES
  Chin J.
  Seidensticker D.
  Lin A.
AUTHOR ADDRESSES
  (Chin J.; Seidensticker D.; Lin A.)
SOURCE
  Consultant (2015) 55:11 (949-950). Date of Publication: 1 Nov 2015
ISSN
  0010-7069
BOOK PUBLISHER
  Cliggott Publishing Co.
EMTREE DRUG INDEX TERMS
  carvedilol
  dofetilide
  furosemide
  losartan
  spironolactone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  congestive cardiomyopathy
  dilated left ventricular cardiomyopathy
  paroxysmal atrial fibrillation
  ventricular noncompaction
EMTREE MEDICAL INDEX TERMS
  adult
  anticoagulant therapy
  article
  cardiologist
  cardiovascular magnetic resonance
  case report
  CHADS2 score
  computed tomographic angiography
  exercise
  heart catheterization
  heart failure
  heart left ventricle ejection fraction
  heart muscle ischemia
  hospital admission
  human
  male
  medical history
  monomorphic ventricular tachycardia
  New York Heart Association class
  priority journal
  QTc interval
  transthoracic echocardiography
CAS REGISTRY NUMBERS
  carvedilol (72956-09-3)
  dofetilide (115256-11-6)
  furosemide (54-31-9)
  losartan (114798-26-4)
  spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  20160148284
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 105
TITLE
  Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and 
prognosis of cardiac amyloidosis
AUTHOR NAMES
  Galat A.
  Rosso J.
  Guellich A.
  Van Der Gucht A.
  Rappeneau S.
  Bodez D.
  Guendouz S.
  Tissot C.-M.
  Hittinger L.
  Dubois-Randé J.-L.
  Plante-Bordeneuve V.
  Itti E.
  Meignan M.
  Damy T.
AUTHOR ADDRESSES
  (Galat A.; Rosso J.; Guellich A.; Van Der Gucht A.; Rappeneau S.; Bodez D.; 
Guendouz S.; Tissot C.-M.; Hittinger L.; Dubois-Randé J.-L.; 
Plante-Bordeneuve V.; Itti E.; Meignan M.; Damy T., 
thibaud.damy@hmn.aphp.fr) UPEC, Créteil, France.
(Galat A.; Rosso J.; Guellich A.; Van Der Gucht A.; Rappeneau S.; Bodez D.; 
Guendouz S.; Tissot C.-M.; Hittinger L.; Dubois-Randé J.-L.; 
Plante-Bordeneuve V.; Itti E.; Meignan M.; Damy T., 
thibaud.damy@hmn.aphp.fr) Mondor Amyloidosis Network, Créteil, France.
(Galat A.; Guellich A.; Rappeneau S.; Bodez D.; Guendouz S.; Tissot C.-M.; 
Hittinger L.; Dubois-Randé J.-L.; Damy T., thibaud.damy@hmn.aphp.fr) 
Department of Cardiology, AP-HP, Henri-Mondor Teaching Hospital, 51 Av de 
Lattre de Tassigny, Créteil, France.
(Galat A.; Guellich A.; Damy T., thibaud.damy@hmn.aphp.fr) INSERM U955, GRC 
Réseau Amylose Mondor, Créteil, France.
(Galat A.; Rosso J.; Guellich A.; Van Der Gucht A.; Rappeneau S.; Bodez D.; 
Guendouz S.; Tissot C.-M.; Hittinger L.; Dubois-Randé J.-L.; 
Plante-Bordeneuve V.; Itti E.; Meignan M.; Damy T., 
thibaud.damy@hmn.aphp.fr) DHU ATVB, Créteil, France.
(Rosso J.; Van Der Gucht A.; Itti E.; Meignan M.) Department of Nuclear 
Medicine, AP-HP, Henri-Mondor Teaching Hospital, Créteil, France.
(Guellich A.; Rappeneau S.; Damy T., thibaud.damy@hmn.aphp.fr) INSERM 
Clinical Investigation Centre 006, Créteil, France.
(Plante-Bordeneuve V.) Department of Neurology, AP-HP, Henri-Mondor Teaching 
Hospital, Créteil, France.
CORRESPONDENCE ADDRESS
  T. Damy, Department of Cardiology, AP-HP, Henri-Mondor Teaching Hospital, 51 
Av de Lattre de Tassigny, Créteil, France. Email: thibaud.damy@hmn.aphp.fr
SOURCE
  Amyloid (2015) 22:4 (210-220). Date of Publication: 2 Oct 2015
ISSN
  1744-2818 (electronic)
  1350-6129
BOOK PUBLISHER
  Taylor and Francis Ltd, healthcare.enquiries@informa.com
ABSTRACT
  Background: Amyloidosis is characterized by extracellular deposits of 
insoluble proteins that cause tissue damage. The three main types are 
monoclonal light chain (AL), wild-type transthyretin (wt-TTR) and mutated 
transthyretin (m-TTR) amyloidosis. Cardiac amyloidosis (CA) raises 
diagnostic challenges.Objective: To assess the diagnostic accuracy of 
(99m)Tc-HMDP-scintigraphy for typing CA, differentiating CA from non-amyloid 
left ventricle hypertrophy (LVH), and predicting outcomes.Methods: 121 
patients with suspected CA underwent (99m)Tc-HMDP-scintigraphy in addition 
to standard investigations.Results: CA was diagnosed in all AL (n = 14) and 
wt-TTR (n = 21). Among m-TTR (n = 34), 26 had CA, 4 neuropathy without CA 
and 4 were asymptomatic carriers. Of the 52 patients with non-amyloid heart 
disease, 37 had LVH and served as controls. (99m)Tc-HMDP cardiac uptake 
occurred in all wt-TTR, in m-TTR with CA except two and in one AL. A visual 
score ≥ 2 was 100% specific for diagnosing TTR-CA. Among TTR-CA, 
heart-to-skull retention (HR/SR) correlated with CA severity (LVEF and 
NT-proBNP). Median follow-up was 111 days (50;343). In a multivariate Cox 
model including clinical, echocardiographic and scintigraphic variables, 
NYHA III-IV and HR/SR > 1.94 predicted acute heart failure and/or 
death.Conclusions: This preliminary study suggests that 
(99m)Tc-HMDP-scintigraphy may aid differentiation between transthyretin and 
AL-CA as well as CA from other LVHs. (99m)Tc-HMDP-scintigraphy appears to 
provide prognostic information in CA.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  oxidronate technetium tc 99m (intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart amyloidosis (diagnosis)
  heart scintiscanning
EMTREE MEDICAL INDEX TERMS
  acute heart failure
  adult
  aged
  article
  atrial fibrillation
  cardiovascular magnetic resonance
  carpal tunnel syndrome
  computed tomography scanner
  controlled study
  diagnostic accuracy
  diagnostic test accuracy study
  diastolic dysfunction
  disease severity
  echocardiography
  female
  follow up
  heart disease
  heart left ventricle ejection fraction
  heart left ventricle hypertrophy
  heart muscle biopsy
  human
  human tissue
  hypertension
  major clinical study
  male
  neurologic disease
  neuropathy
  outcome assessment
  pacemaker implantation
  prediction
  priority journal
DRUG MANUFACTURERS
   (France)CIS
DEVICE TRADE NAMES
  Philips Precedence SPECT/CT  , NetherlandsPhilips Healthcare

  Vivid 7 system  , NorwayGE Vingmed

DEVICE MANUFACTURERS
   (Netherlands)Philips Healthcare
   (Norway)GE Vingmed
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Nuclear Medicine (23)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015457531
FULL TEXT LINK
  http://dx.doi.org/10.3109/13506129.2015.1072089
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 106
TITLE
  Incidence and Predictors of Hemorrhagic Stroke in Users of Low-Dose 
Acetylsalicylic Acid
AUTHOR NAMES
  González-Pérez A.
  Sáez M.E.
  Johansson S.
  Himmelmann A.
  García Rodríguez L.A.
AUTHOR ADDRESSES
  (González-Pérez A.; Sáez M.E.; García Rodríguez L.A., lagarcia@ceife.es) 
Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Almirante 28-2, 
Madrid, Spain.
(González-Pérez A.; Sáez M.E.) Andalusian Bioinformatics Research Center 
(CAEBi), Seville, Spain.
(Johansson S.; Himmelmann A.) Global Medicines Development, Medical Affairs, 
Observational Research Center, AstraZeneca R and D, Mölndal, Sweden.
CORRESPONDENCE ADDRESS
  L.A. García Rodríguez, Spanish Centre for Pharmacoepidemiologic Research 
(CEIFE), Almirante 28-2, Madrid, Spain. Email: lagarcia@ceife.es
SOURCE
  Journal of Stroke and Cerebrovascular Diseases (2015) 24:10 (2321-2328). 
Date of Publication: 1 Oct 2015
ISSN
  1532-8511 (electronic)
  1052-3057
BOOK PUBLISHER
  W.B. Saunders
ABSTRACT
  Background The use of antithrombotic drugs (anticoagulants and antiplatelet 
drugs) has been reported to increase the risk of hemorrhagic stroke (HS) 
relative to no treatment. This study was performed to characterize the 
incidence and predictors of HS in users of acetylsalicylic acid (ASA) for 
the secondary prevention of cardiovascular events. Methods A cohort of 
36,775 ASA users aged 50-84 years in 2000-2007 was identified from The 
Health Improvement Network database. The incidence of HS was calculated, and 
a nested case-control analysis, adjusted for potential confounding factors, 
was performed to calculate the odds ratios (ORs) and 95% confidence 
intervals (CIs) for the association of potential risk factors with HS in 
current users of ASA. Results The overall incidence of HS was 5.70 cases per 
10,000 person-years and increased with age. In current ASA users, the 
incidence of HS was 4.91 cases per 10,000 person-years. Predictors of HS in 
patients taking ASA for secondary prevention included a history of HS (OR, 
4.84; 95% CI, 1.48-15.88), a history of atrial fibrillation (OR, 4.03; 95% 
CI, 1.53-10.62), and hypnotic/anxiolytic drug use (OR, 2.67; 95% CI, 
1.17-6.05). The small number of patients using warfarin also had an 
increased risk of HS (OR, 23.42; 95% CI, 4.89-112.10). Conclusions 
Physicians should consider additional risk factors for HS, such as a history 
of HS or atrial fibrillation, and the use of warfarin, before prescribing 
ASA for the secondary prevention of cardiovascular events.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  acetylsalicylic acid (adverse drug reaction, drug dose, drug therapy)
EMTREE DRUG INDEX TERMS
  anxiolytic agent
  hypnotic agent
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain hemorrhage (side effect, side effect)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation
  cardiovascular disease (prevention)
  case control study
  cerebrovascular disease (drug therapy)
  cohort analysis
  controlled study
  female
  heart infarction (drug therapy)
  human
  ischemic heart disease (drug therapy)
  low drug dose
  major clinical study
  male
  medical history
  middle aged
  priority journal
  retrospective study
  risk factor
  secondary prevention
  unstable angina pectoris (drug therapy)
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015418297
MEDLINE PMID
  26189158 (http://www.ncbi.nlm.nih.gov/pubmed/26189158)
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.06.016
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 107
TITLE
  Right ventricular changes in highly trained athletes: Between physiology and 
pathophysiology
AUTHOR NAMES
  D'andrea A.
  Morello A.
  Iacono A.M.
  Scarafile R.
  Cocchia R.
  Riegler L.
  Pezzullo E.
  Golia E.
  Bossone E.
  Calabro R.
  Russo M.G.
AUTHOR ADDRESSES
  (D'andrea A., antonellodandrea@libero.it; Morello A.; Iacono A.M.; Scarafile 
R.; Cocchia R.; Riegler L.; Pezzullo E.; Golia E.; Calabro R.; Russo M.G.) 
Department of Cardiology, Integrated Diagnostic Cardiology, AORN Dei Colli, 
Second University of Naples, Via M. Schipa, 44, Naples, Italy.
(Bossone E.) Department of Heart, Cardiology Division, Cava De' Tirreni and 
Amalfi Coast Hospital, University of Salerno, Salerno, Italy.
CORRESPONDENCE ADDRESS
  A. D'andrea, Department of Cardiology, Integrated Diagnostic Cardiology, 
AORN Dei Colli, Second University of Naples, Via M. Schipa, 44, Naples, 
Italy. Email: antonellodandrea@libero.it
SOURCE
  Journal of Cardiovascular Echography (2015) 25:4 (97-102). Date of 
Publication: 1 Oct 2015
ISSN
  2347-193X (electronic)
  2211-4122
BOOK PUBLISHER
  Medknow Publications, B9, Kanara Business Centre, off Link Road, Ghatkopar 
(E), Mumbai, India.
ABSTRACT
  Several studies have described the adaptive remodeling of the heart during 
exercise. In some more practiced endurance athletes, there is a 
disproportionate load on the right ventricle (RV), at least during exercise, 
and this might be the basis for a chronic pro-arrhythmic RV remodeling. 
Especially, in these kinds of athletes the recovery after detraining might 
be incomplete, in particular for RV changes. The observation of acute 
myocardial injury based on transient elevation of biomarkers and chronic 
myocardial scar, not completely reversible changes of the RV and an 
increased prevalence of some arrhythmias support the existence of an 
"exercise-induced cardiomyopathy." The aim of this paper is to review 
current knowledge about changes in the right heart in highly trained 
athletes and how these change influence cardiac function.
EMTREE DRUG INDEX TERMS
  biological marker
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  heart function
  heart right ventricle
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  cardiomyopathy
  cardiovascular magnetic resonance
  color ultrasound flowmetry
  disease predisposition
  echocardiography
  electrocardiography
  endurance training
  exercise intensity
  exercise-induced cardiomyopathy
  heart hemodynamics
  heart injury
  heart muscle conduction disturbance
  heart muscle contractility
  heart muscle fibrosis
  heart muscle injury
  heart right atrium
  heart right bundle branch block
  heart right ventricle dysplasia
  heart stroke volume
  heart ventricle extrasystole
  heart ventricle performance
  heart ventricle remodeling
  human
  lung artery pressure
  lung circulation
  marathon runner
  meta analysis (topic)
  muscle hypertrophy
  normal human
  prevalence
  pulmonary artery
  pulmonary valve
  review
  sports medicine
  systole
  systolic blood pressure
  tricuspid valve
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Physiology (2)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160039850
FULL TEXT LINK
  http://dx.doi.org/10.4103/2211-4122.172486
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 108
TITLE
  Optimising the management of heart failure
AUTHOR NAMES
  Bakhai A.
  Backman W.
  Krishnamurthy V.
AUTHOR ADDRESSES
  (Bakhai A.; Krishnamurthy V.) Royal Free London NHS Foundation Trust, United 
Kingdom.
(Backman W.) Boston Medical Center, Massachusetts, United States.
SOURCE
  Primary Care Cardiovascular Journal (2015) 12 Supplement 1 (S12-S17). Date 
of Publication: 1 Oct 2015
ISSN
  1756-5146 (electronic)
  1756-5138
BOOK PUBLISHER
  Sherborne Gibbs Limited, agreathead@sherbornegibbs.co.uk
ABSTRACT
  Heart failure (HF) is an important cause of morbidity, mortality and misery 
for patients. However, there are many ways to improve and extend the lives 
of people with HF, if clinicians are familiar with and apply the numerous 
traditional, less mainstream and more innovative evidence-based treatment 
options. This article reviews current best practice in the management of 
chronic HF and of acute decompensated HF, and considers recent insights, 
controversies and innovations in this important, fast moving field.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
  angiotensin receptor antagonist (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  digoxin (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  diuretic agent (drug therapy)
  dronedarone (drug therapy)
  eplerenone (drug therapy)
  hydralazine (drug therapy)
  inotropic agent (drug therapy)
  iron (drug therapy, intravenous drug administration)
  isosorbide mononitrate (drug therapy)
  ivabradine (drug therapy)
  loop diuretic agent (drug therapy)
  nitric acid derivative (drug therapy)
  spironolactone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (drug therapy, disease management, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  acute heart failure
  article
  atrial fibrillation
  body weight
  cardiac resynchronization therapy
  cardiovascular mortality
  clinical trial (topic)
  diuretic therapy
  dyspnea
  exercise
  fluid retention
  hospital discharge
  human
  implantable cardioverter defibrillator
  integrated health care system
  meta analysis (topic)
  noninvasive ventilation
  palliative therapy
  patient education
  positive end expiratory pressure
  prognosis
  pulse rate
  randomized controlled trial (topic)
  risk reduction
  self care
  sodium restriction
  ultrafiltration
  ventricular assist device
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digoxin (20830-75-5, 57285-89-9)
  dronedarone (141626-36-0)
  eplerenone (107724-20-9)
  hydralazine (304-20-1, 86-54-4)
  iron (14093-02-8, 53858-86-9, 7439-89-6)
  isosorbide mononitrate (1320-91-8)
  ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
  spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20151051918
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 109
TITLE
  The current role of Omega-3 fatty acids in the management of atrial 
fibrillation
AUTHOR NAMES
  Christou G.A.
  Christou K.A.
  Korantzopoulos P.
  Rizos E.C.
  Nikas D.N.
  Goudevenos J.A.
AUTHOR ADDRESSES
  (Christou G.A.) Laboratory of Physiology, Medical School, University of 
Ioannina, Ioannina, Greece.
(Christou K.A.) First Department of Internal Medicine, University Hospital 
of Ioannina, Ioannina, Greece.
(Korantzopoulos P.; Nikas D.N.; Goudevenos J.A.) First Department of 
Cardiology, University Hospital of Ioannina, Ioannina, Greece.
(Rizos E.C.) Second Medical Department and Outpatient Lipid Clinic, 
University Hospital of Ioannina, Ioannina, Greece.
CORRESPONDENCE ADDRESS
  G.A. Christou, Laboratory of Physiology, Medical School, University of 
Ioannina, Ioannina, Greece.
SOURCE
  International Journal of Molecular Sciences (2015) 16:9 (22870-22887). Date 
of Publication: 22 Sep 2015
ISSN
  1422-0067 (electronic)
  1661-6596
BOOK PUBLISHER
  MDPI AG, Postfach, Basel, Switzerland. membranes@mdpi.com
ABSTRACT
  Background: The main dietary source of omega-3 polyunsaturated fatty acids 
(n-3 PUFA) is fish, which contains eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). In the present manuscript, we aimed to review 
the current evidence regarding the clinical role of n-3 PUFA in the 
prevention of atrial fibrillation (AF) and the possible underlying 
mechanisms. Methods: A literature search based on PubMed listings was 
performed using “Omega-3 fatty acids” and “atrial fibrilation” as key search 
terms. Results: n-3 PUFA have been shown to attenuate structural atrial 
remodeling, prolong atrial effective refractory period through the 
prevention of reentry and suppress ectopic firing from pulmonary veins. 
Dietary fish intake has been found to have no effect on the incidence of AF 
in the majority of studies. Circulating DHA has been consistently reported 
to be inversely associated with AF risk, whereas EPA has no such effect. The 
majority of studies investigating the impact of n-3 PUFA supplementation on 
the incidence of AF following cardiac surgery reported no benefit, though 
most of them did not use n-3 PUFA pretreatment for adequate duration. 
Studies using adequate four-week pretreatment withn-3 PUFA before 
cardioversion of AF showed a reduction of the AF incidence. Conclusions: 
Although n-3 PUFA have antiarrhythmogenic properties, their clinical 
efficacy on the prevention of AF is not consistently supported. Further 
well-designed studies are needed to overcome the limitations of the existing 
studies and provide robust conclusions.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  omega 3 fatty acid
EMTREE DRUG INDEX TERMS
  docosahexaenoic acid
  farnesoid X receptor (endogenous compound)
  icosapentaenoic acid
  retinoid X receptor (endogenous compound)
  voltage gated sodium channel (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (disease management, etiology)
EMTREE MEDICAL INDEX TERMS
  cardioversion
  clinical effectiveness
  congestive heart failure
  diet supplementation
  dietary intake
  food frequency questionnaire
  genetic transcription
  heart infarction
  heart muscle refractory period
  heart surgery
  human
  hypertension
  review
  upregulation
CAS REGISTRY NUMBERS
  docosahexaenoic acid (25167-62-8, 32839-18-2)
  icosapentaenoic acid (25378-27-2, 32839-30-8)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT01841944)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015399616
FULL TEXT LINK
  http://dx.doi.org/10.3390/ijms160922870
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 110
TITLE
  Fish, long-chain omega-3 polyunsaturated fatty acid intake and incidence of 
atrial fibrillation: A pooled analysis of two prospective studies
AUTHOR NAMES
  Larsson S.C.
  Wolk A.
AUTHOR ADDRESSES
  (Larsson S.C., susanna.larsson@ki.se; Wolk A.) Unit of Nutritional 
Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 
Stockholm, Sweden
CORRESPONDENCE ADDRESS
  S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental 
Medicine, Karolinska Institutet, SE-17177 Stockholm, Sweden Email: 
susanna.larsson@ki.se
SOURCE
  Clinical Nutrition (2016). Date of Publication: 17 Aug 2015
ISSN
  1532-1983 (electronic)
  0261-5614
BOOK PUBLISHER
  Churchill Livingstone
ABSTRACT
  Background & aims: Whether high intakes of fish and long-chain omega-3 
polyunsaturated fatty acids (PUFAs) reduce the risk of atrial fibrillation 
(AF) remains uncertain. Thus, we aimed to evaluate the associations of total 
fish, types of fish, and omega-3 PUFA intake with AF incidence in a large 
prospective study. Methods: We used data from the Cohort of Swedish Men and 
the Swedish Mammography Cohort to examine the associations of fish 
consumption and long-chain omega-3 PUFA intake with AF incidence. At 
baseline, information on fish and omega-3 PUFA intakes was available from 
72,984 men and women, aged 45-83 years, without cardiac disease. Cases of AF 
were identified through linkage with the Swedish National Patient Register. 
Multivariable-adjusted relative risks were estimated with the use of Cox 
proportional hazards models. Results: Over a follow-up period of 12 years, 
6095 participants (3595 men and 2500 women) developed AF. Intakes of total 
fish, fatty fish (herring/mackerel and salmon/whitefish/char), and 
long-chain omega-3 PUFAs were not associated with AF incidence after 
adjustment for other risk factors. However, high consumption of lean fish 
(cod/saithe/fish fingers) was associated with a lower risk; multivariable 
relative risk of AF for ≥3 servings/week compared with never consumption was 
0.79 (95% confidence interval, 0.65-0.95). Conclusions: These findings do 
not support a beneficial association of fatty fish or omega-3 PUFA intake 
with incident AF. The association between lean fish consumption and AF risk 
warrants further investigation.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  omega 3 fatty acid
  polyunsaturated fatty acid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  diet
  prospective study
EMTREE MEDICAL INDEX TERMS
  adult
  confidence interval
  coregonine
  female
  finger
  follow up
  herring
  human
  male
  mammography
  meta analysis
  proportional hazards model
  risk factor
  Swedish citizen
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160409248
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.clnu.2016.01.019
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 111
TITLE
  Secondary stroke prevention: Challenges and solutions
AUTHOR NAMES
  Esenwa C.
  Gutierrez J.
AUTHOR ADDRESSES
  (Esenwa C.; Gutierrez J., jg3233@cumc.columbia.edu) Department of Neurology, 
College of Physicians and Surgeons, Columbia University Medical Center, New 
York, United States.
CORRESPONDENCE ADDRESS
  J. Gutierrez, Department of Neurology, College of Physicians and Surgeons, 
Columbia University Medical Center, 710 W 168th Street, 6th floor, Suite 
639, New York, United States.
SOURCE
  Vascular Health and Risk Management (2015) 11 (437-450). Date of 
Publication: 7 Aug 2015
ISSN
  1178-2048 (electronic)
  1176-6344
BOOK PUBLISHER
  Dove Medical Press Ltd., PO Box 300-008, Albany, Auckland, New Zealand.
ABSTRACT
  Stroke is the leading cause of disability in the USA and a major cause of 
mortality worldwide. One out of four strokes is recurrent. Secondary stroke 
prevention starts with deci­phering the most likely stroke mechanism. In 
general, one of the main goals in stroke reduction is to control vascular 
risk factors such as hypertension, diabetes, dyslipidemia, and smoking 
cessation. Changes in lifestyle like a healthy diet and aerobic exercise are 
also recommended strategies. In the case of cardioembolism due to atrial 
fibrillation, mechanical valves, or cardiac thrombus, anticoagulation is the 
mainstay of therapy. The role of anticoagulation is less evident in the case 
of bioprosthetic valves, patent foramen ovale, and dilated cardiomyopathy 
with low ejection fraction. Strokes due to larger artery atherosclerosis 
account for approximately a third of all strokes. In the case of symptomatic 
extracranial carotid stenosis, surgical intervention as close as possible in 
time to the index event seems highly beneficial. In the case of intracranial 
large artery atherosclerosis, the best medical therapy consists of 
antiplatelets, high-dose statins, aggressive controls of vascular risk 
factors, and lifestyle modifications, with no role for intracra­nial 
arterial stenting or angioplasty. For patients with small artery occlusion 
(ie, lacunar stroke), the therapy is similar to that used in patients with 
intracranial large artery atherosclerosis. Despite the constant new evidence 
on how to best treat patients who have suffered a stroke, the risk of stroke 
recurrence remains unacceptably high, thus evidencing the need for novel 
therapies.
EMTREE DRUG INDEX TERMS
  hydroxymethylglutaryl coenzyme A reductase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident
  diabetes mellitus
  dyslipidemia
  hypertension
  prevention
  risk
EMTREE MEDICAL INDEX TERMS
  aerobic exercise
  angioplasty
  anticoagulation
  artery
  artery occlusion
  atherosclerosis
  atrial fibrillation
  carotid artery obstruction
  congestive cardiomyopathy
  diet
  disability
  drug megadose
  heart ejection fraction
  human
  lacunar stroke
  lifestyle
  lifestyle modification
  mortality
  patent foramen ovale
  patient
  risk factor
  smoking cessation
  stent
  surgery
  therapy
  thrombus
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015323172
FULL TEXT LINK
  http://dx.doi.org/10.2147/VHRM.S63791
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 112
TITLE
  ESC Congress 2015
AUTHOR ADDRESSES
  SOURCE
  European Heart Journal (2015) 36 SUPPL. 1. Date of Publication: 1 Aug 2015
CONFERENCE NAME
  European Society of Cardiology, ESC Congress 2015
CONFERENCE LOCATION
  London, United Kingdom
CONFERENCE DATE
  2015-08-29 to 2015-09-02
ISSN
  0195-668X
BOOK PUBLISHER
  Oxford University Press
ABSTRACT
  The proceedings contain 4481 papers. The topics discussed include: 
successful approaches in reduction of fluoroscopy time and radiation dose 
during catheter ablation for atrial fibrillation; atrial high rate episodes 
and silent ischemic brain lesions in patients with cardiac implantable 
electronic devices: unmasking silent atrial fibrillation embolic risk; 
mechanisms of improvement in claudication after exercise training in 
peripheral arterial disease; clinical impact of complete revascularization 
in elderly patients with multivessel coronary artery disease underwent 
percutaneous coronary intervention; clinical and economic outcome of 
telemonitoring versus usual care among patients with severe chronic heart 
failure; direct comparison of the safety and efficacy of two rule-out 
strategies for acute myocardial infarction; and direct comparison of the 
safety and efficacy of two rule-out strategies for acute myocardial 
infarction: 2h-algorithm versus undetectable levels at presentation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiology
  European
  society
EMTREE MEDICAL INDEX TERMS
  acute heart infarction
  aged
  algorithm
  atrial fibrillation
  brain damage
  catheter ablation
  claudication
  coronary artery disease
  devices
  exercise
  fluoroscopy
  heart failure
  human
  patient
  percutaneous coronary intervention
  peripheral occlusive artery disease
  radiation dose
  revascularization
  risk
  safety
  telemonitoring
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 113
TITLE
  Leriche-syndrome despite regular sport and non-compaction suggest 
neuromuscular disease
AUTHOR NAMES
  Finsterer J.
  Stöllberger C.
AUTHOR ADDRESSES
  (Finsterer J., fifigs1@yahoo.de) Krankenanstalt Rudolfstiftung, Postfach 20, 
Vienna, Austria.
(Stöllberger C.) 2nd Medical Department with Cardiology and Intensive Care 
Medicine, Krankenanstalt Rudolfstiftung, Vienna, Austria.
CORRESPONDENCE ADDRESS
  J. Finsterer, Krankenanstalt Rudolfstiftung, Postfach 20, Vienna, Austria. 
Email: fifigs1@yahoo.de
SOURCE
  International Journal of Cardiology (2015) 191 (15-17). Date of Publication: 
15 Jul 2015
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Leriche syndrome (diagnosis)
  neuromuscular disease
  ventricular noncompaction
EMTREE MEDICAL INDEX TERMS
  aged
  angiocardiography
  article
  ataxia
  atrial fibrillation
  case report
  Caucasian
  cerebrovascular accident
  congestive cardiomyopathy
  coronary artery atherosclerosis
  coronary artery obstruction
  exercise
  hearing impairment
  human
  hypertension
  left anterior descending coronary artery
  male
  mild cognitive impairment
  muscle atrophy
  myalgia
  myoclonus seizure
  nuclear magnetic resonance imaging
  nystagmus
  peripheral occlusive artery disease
  priority journal
  ptosis
  smoking
  sport
  superficial femoral artery
  tibial artery
  transthoracic echocardiography
  traumatic brain injury
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  20151060243
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2015.04.279
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 114
TITLE
  Association between renal dysfunction and 3-year mortality in patients with 
acute first-ever ischemic stroke
AUTHOR NAMES
  Lin S.-W.
  Weng W.-C.
  Huang Y.-H.
  Su F.-C.
  Peng T.-I.
  Chien Y.-Y.
  Wu C.-L.
  Lee K.-Y.
  Yu Y.-J.
  Zhu J.-X.
  Huang W.-Y.
AUTHOR ADDRESSES
  (Lin S.-W.; Weng W.-C.; Huang Y.-H.; Su F.-C.; Peng T.-I.; Chien Y.-Y.; Wu 
C.-L.; Lee K.-Y.; Yu Y.-J.; Zhu J.-X.; Huang W.-Y., 
wenyihuang2003@yahoo.com.tw) Department of Neurology, Chang-Gung Memorial 
Hospital, Keelung Branch, No. 222, Mai-Jin Road, Keelung, Taiwan.
(Lin S.-W.; Weng W.-C.; Huang Y.-H.; Su F.-C.; Peng T.-I.; Chien Y.-Y.; Wu 
C.-L.; Lee K.-Y.; Yu Y.-J.; Zhu J.-X.; Huang W.-Y., 
wenyihuang2003@yahoo.com.tw) Department of Medicine, College of Medicine, 
Chang Gung University, 259 Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan, Taiwan.
CORRESPONDENCE ADDRESS
  W.-Y. Huang, Department of Neurology, Chang-Gung Memorial Hospital, Keelung 
Branch, No. 222, Mai-Jin Road, Keelung, Taiwan.
SOURCE
  Clinical Neurology and Neurosurgery (2015) 137 (15-21). Date of Publication: 
10 Jul 2015
ISSN
  1872-6968 (electronic)
  0303-8467
BOOK PUBLISHER
  Elsevier
ABSTRACT
  Objective The influence of renal dysfunction on the clinical presentation 
and outcomes of patients with acute ischemic stroke is still controversial. 
We investigate the influence of renal dysfunction on the outcomes of 
patients with acute first-ever ischemic stroke. Methods Nine-hundred 
thirty-four patients with acute first-ever ischemic stroke were enrolled and 
followed for 3 years. Renal function was assessed using the equation of the 
Modification Diet for Renal Disease for estimated glomerular filtration rate 
(eGFR). Serum creatinine levels were obtained within 3 days of acute stroke 
onset. Reduced eGFR was defined as eGFR < 60 ml/min/1.73 m<sup>2</sup>. 
Clinical presentation, risk factors for stroke, laboratory data, 
co-morbidities, and outcomes were recorded. Results Total 264 patients 
(28.3%) had a reduced eGFR. The prevalence of older age, hypertension, and 
atrial fibrillation was significantly higher in patients with a reduced 
eGFR. Total anterior circulation syndrome occurred more frequently among 
patients with a reduced eGFR (P = 0.010). Multivariate Cox regression 
revealed that a reduced eGFR is a significant predictor of 3-year mortality 
(HR = 1.67, 95% CI = 1.06-2.62, P = 0.026). Conclusion Reduced eGFR during 
the acute stroke stage is associated with increased risk of 3-year 
mortality. Furthermore, risk of acute complications and poor functional 
outcomes following discharge was significantly higher in patients with a 
reduced eGFR.
EMTREE DRUG INDEX TERMS
  anticoagulant agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia (drug therapy, drug therapy)
  kidney dysfunction
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  cerebrovascular accident
  circulation
  controlled study
  creatinine blood level
  disease course
  female
  follow up
  glomerulus filtration rate
  hospital patient
  human
  hypertension
  kidney disease
  kidney function
  major clinical study
  male
  morbidity
  mortality
  prevalence
  recurrent disease
  secondary prevention
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Urology and Nephrology (28)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015188877
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.clineuro.2015.06.008
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 115
TITLE
  Current trends in tai chi for stroke rehabilitation
AUTHOR NAMES
  Zhang Y.
  Ning Y.
  Liu H.
  Zhou L.
  Zou Y.
  Li Z.
AUTHOR ADDRESSES
  (Zhang Y.; Zhou L.; Li Z., lee_zongheng@163.com) Department of 
Rehabilitation, Dongzhimen Hospital, Beijing University of Chinese Medicine, 
Beijing, China.
(Ning Y.; Liu H.; Zou Y.) Department of Neurology and Stroke Center, 
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
CORRESPONDENCE ADDRESS
  Z. Li, Department of Rehabilitation, Dongzhimen Hospital, Beijing University 
of Chinese Medicine, Beijing, China. Email: lee_zongheng@163.com
SOURCE
  Journal of Traditional Chinese Medical Sciences (2015) 2:3 (135-139). Date 
of Publication: 1 Jul 2015
ISSN
  2095-7548 (electronic)
BOOK PUBLISHER
  Beijing University of Chinese Medicine
ABSTRACT
  Background: There are an increasing number of studies focusing on the effect 
of tai chi for different diseases. As a special form of physical activity, 
tai chi may be beneficial for the rehabilitation of stroke, a leading cause 
of disability worldwide. Objective: This review summarizes the existing 
literature on the potential benefits of tai chi for stroke rehabilitation 
and offers recommendations for future research. Methods: Studies on the 
biomechanics and physiology of tai chi for stroke rehabilitation are 
reviewed. Research on tai chi for stroke rehabilitation and related diseases 
are summarized. Finally, the shortcomings of existing studies and 
recommendations for future studies are discussed. Conclusions: Tai chi 
appears to be beneficial for stroke rehabilitation. But reporting quality of 
existing studies are sub-optimal. Future trials should define tai chi style, 
apply rigorous methodology to sample size calculation, randomization, 
recruiting criteria, and outcome measures. To avoid inadequacies during the 
research and reporting processes, investigators may wish to follow CONSORT 
guidelines and refer to well-conducted clinical studies on tai chi.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (radiotherapy)
  Tai Chi
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  Barthel index
  biomechanics
  human
  hypertension
  National Institutes of Health Stroke Scale
  physiology
  physiotherapy
  Rankin scale
EMBASE CLASSIFICATIONS
  Rehabilitation and Physical Medicine (19)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20151065728
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jtcms.2014.12.001
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 116
TITLE
  Quality of anticoagulation control among patients with atrial fibrillation: 
An experience of a tertiary care center in Saudi Arabia
AUTHOR NAMES
  Alyousif S.M.
  Alsaileek A.A.
AUTHOR ADDRESSES
  (Alyousif S.M., alyousifsm@gmail.com; Alsaileek A.A.) King Abdullah 
Intentional Research Centre, Riyadh, Saudi Arabia
(Alyousif S.M., alyousifsm@gmail.com; Alsaileek A.A.) King Saud bin 
Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
(Alyousif S.M., alyousifsm@gmail.com) Pharmaceutical Care Department, King 
Abdulaziz Medical City, Riyadh, Saudi Arabia
(Alyousif S.M., alyousifsm@gmail.com; Alsaileek A.A.) Ministry of National 
Guard-Health Affair, Saudi Arabia
CORRESPONDENCE ADDRESS
  S.M. Alyousif, PO Box 22490, Riyadh 11426, Saudi Arabia Email: 
alyousifsm@gmail.com
SOURCE
  Journal of the Saudi Heart Association (2016). Date of Publication: 9 Jun 
2015
ISSN
  2212-5043 (electronic)
  1016-7315
BOOK PUBLISHER
  Elsevier
ABSTRACT
  Background: Atrial fibrillation (AF) is the most common chronic rhythm 
disorder. Patients with AF are at an increased risk of ischemic stroke. 
Therefore, optimal anticoagulation is essential to reduce the risk of 
stroke. The aim of this study was to assess the level of anticoagulation 
control achieved in patients with nonvalvular AF receiving medical care in a 
tertiary care hospital. Methods: This was a retrospective cohort study in 
ambulatory care clinics at tertiary care hospital in Saudi Arabia. We 
included 110 nonvalvular AF patients treated with warfarin for at least 3. 
months at King Abdulaziz Medical City, Riyadh, Saudi Arabia, between May 1, 
2012, and July 31, 2012. Thereafter, international normalized ratio results 
were collected for 1. year. Anticoagulation control was assessed by 
calculating time within therapeutic range (TTR) as per the Rosendaal method. 
Results: The mean age was 64.9. ±. 16.5. years; 60.9% were female. The mean 
TTR was 59%. Almost one third of the patients (32.7%) had poor 
anticoagulation control; TTR of <50%. Poor anticoagulation control was 
significantly associated with higher CHADS2 (congestive heart failure, 
hypertension, age, diabetes, stroke) score (p = 0.043). TTR was not 
significantly different between men and women. Similarly, TTR was not 
associated with age or duration of anticoagulation. There was no adequate 
information to assess the effect of other factors such as diet, compliance, 
and level of education on anticoagulation. Thirty-one patients (28.2%) had a 
history of prior stroke. The overall quality of anticoagulation was not 
significantly different between patients with and without stroke, (TTR was 
56.3% and 60.1%, respectively; p = 0.46). Conclusion: Quality of 
anticoagulation in patients with AF receiving medical care in a tertiary 
care hospital was suboptimal, with nearly 40% of the time spent outside the 
therapeutic range. Methods to improve anticoagulation control among patients 
with AF should be implemented.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulation
  atrial fibrillation
  Saudi Arabia
  tertiary care center
EMTREE MEDICAL INDEX TERMS
  adult
  ambulatory care
  cerebrovascular accident
  CHADS2 score
  clinical trial
  cohort analysis
  congestive heart failure
  controlled study
  diabetes mellitus
  dietary compliance
  drug therapy
  education
  female
  human
  hypertension
  international normalized ratio
  major clinical study
  male
  medical care
  normal human
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160356055
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jsha.2016.02.001
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 117
TITLE
  Impact of clinical and sociodemographic patient characteristics on the 
outcome of cardiac rehabilitation in older patients
AUTHOR NAMES
  Salzwedel A.
  Wegscheider K.
  Herich L.
  Rieck A.
  Strandt G.
  Völler H.
AUTHOR ADDRESSES
  (Salzwedel A., annett.salzwedel@uni-potsdam.de; Völler H.) Department of 
Clinical Pharmacology and Toxicology, Charité (CBF), Berlin, Germany.
(Salzwedel A., annett.salzwedel@uni-potsdam.de; Völler H.) Rehabilitation 
Centre for Internal Medicine, Klinik am See, Rüdersdorf, Germany.
(Salzwedel A., annett.salzwedel@uni-potsdam.de; Rieck A.; Völler H.) Centre 
of Rehabilitation Research, University of Potsdam, Am-Neuen-Palais 10, 
Potsdam, Germany.
(Wegscheider K.; Herich L.) Department of Medical Biometry and Epidemiology, 
University Medical Centre, Hamburg-Eppendorf, Germany.
(Herich L.) Institute of Medical Statistics, Informatics and Epidemiology, 
University of Cologne, Cologne, Germany.
(Strandt G.) Techniker Krankenkasse Hamburg, Hamburg, Germany.
CORRESPONDENCE ADDRESS
  A. Salzwedel, Centre of Rehabilitation Research, University of Potsdam, 
Am-Neuen-Palais 10, Potsdam, Germany.
SOURCE
  Aging Clinical and Experimental Research (2015) 27:3 (315-321). Date of 
Publication: 1 Jun 2015
ISSN
  1720-8319 (electronic)
  1594-0667
BOOK PUBLISHER
  Springer International Publishing
ABSTRACT
  Methods: The impact of baseline characteristics on the success of CR, 
measured by MOC, was analysed using a mixed model for 1,220 older patients 
(70.9 ± 7.0 years, 78.3 % men) who enrolled in 12 CR clinics. A multitude of 
potentially influential baseline patient characteristics was considered 
including sociodemographic variables, comorbidity, duration of hospital 
stay, exercise capacity, cardiovascular risk factors, emotional status, and 
laboratory and echocardiographic data.Background: Cardiac rehabilitation 
(CR) seeks to simultaneously improve several outcome parameters related to 
patient risk factors, exercise capacity and subjective health. A single 
score, the multiple outcome criterion (MOC), comprised of alterations in 13 
outcome variables was used to measure the overall success of CR in an older 
population. As this success depends on the older patient’s characteristics 
at the time of admission to CR, we attempted to determine the most important 
influences.Results: Overall, CR was successful, as indicated by the mean 
value of the MOC (0.6 ± 0.45; min −1.0, max 2.0; positive values denoting 
improvement, negative ones deterioration). Examples of association with 
negative MOC values included smoking (MOC −0.15, p < 0.001), female gender 
(MOC −0.07, p = 0.049), and a longer hospital stay (MOC −0.03, p = 0.03). An 
example of association with positive MOC value was depression score (MOC 
0.06, p = 0.003). Further associations included maximal exercise capacity, 
blood pressure, heart rate and the rehabilitation centre 
attended.Conclusion: Our results emphasize the necessity to take into 
consideration baseline characteristics when evaluating the success of CR and 
setting treatment targets for older patients.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  demography
  geriatric patient
  heart rehabilitation
  social aspect
  treatment outcome
EMTREE MEDICAL INDEX TERMS
  age
  aged
  article
  atrial fibrillation (complication)
  blood pressure
  comorbidity
  depression
  exercise
  exercise electrocardiography
  exercise test
  female
  heart arrhythmia (complication)
  heart rate
  Hospital Anxiety and Depression Scale
  human
  infection (complication)
  length of stay
  major clinical study
  male
  outcome assessment
  rehabilitation center
  sex difference
  smoking
  wound healing impairment (complication)
EMBASE CLASSIFICATIONS
  Rehabilitation and Physical Medicine (19)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015040745
FULL TEXT LINK
  http://dx.doi.org/10.1007/s40520-014-0283-2
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 118
TITLE
  Acute STEMI in the setting of a single coronary artery anomaly
AUTHOR NAMES
  McCarthy C.
  Khider W.
  Caplice N.
AUTHOR ADDRESSES
  (McCarthy C.; Khider W., wkhider@ucc.ie; Caplice N.) CRVB, University 
College Cork, Cork, Ireland.
CORRESPONDENCE ADDRESS
  W. Khider, CRVB, University College Cork, Cork, Ireland.
SOURCE
  BMJ Case Reports (2015) 2015 Article Number: 210002. Date of Publication: 13 
May 2015
ISSN
  1757-790X (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, subscriptions@bmjgroup.com
ABSTRACT
  We report a case of a patient admitted with an acute ST elevation myocardial 
infarction following occlusion of his right coronary artery, successfully 
treated with thrombectomy and percutaneous coronary intervention (PCI). 
Coronary angiography and multislice CT revealed a single right coronary 
artery with two anomalous branches (constituting the left coronary system); 
one branch passed between the pulmonary trunk and the aorta before dividing 
into three separate branches, while the other anomalous branch passed 
anterior to the pulmonary trunk, consistent with a Yamanaka R-IIIC 
classification. The course of this Yamanaka R-IIIC subtype is unusual as 
both anomalous branches combine to form a dual origin left anterior 
descending artery. The course of these anomalous branches places the patient 
at an increased risk of future myocardial ischaemia, infarction and sudden 
cardiac death. As symptoms typically develop on exertion, this cohort may 
benefit from exercise myocardial perfusion imaging to identify high-risk 
patients.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  apixaban (oral drug administration)
  bisoprolol (drug therapy)
  clopidogrel (oral drug administration)
  diuretic agent (drug therapy)
  dobutamine (drug therapy)
  eplerenone (drug therapy)
  ramipril (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acute disease (diagnosis, surgery, therapy)
  coronary artery occlusion (diagnosis, surgery, therapy)
  ST segment elevation myocardial infarction (diagnosis, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  akinesia
  angiocardiography
  angioplasty
  article
  atrial fibrillation
  blood vessel
  body mass
  case report
  differential diagnosis
  disease classification
  drug eluting stent
  electrocardiography
  exercise
  follow up
  heart ejection fraction
  heart failure (drug therapy)
  heart infarction
  heart left ventricle failure (drug therapy)
  heart left ventricle hypertrophy
  heart muscle contractility
  heart muscle ischemia
  high risk patient
  hospitalization
  human
  hyperkalemia
  hypotension (drug therapy)
  left anterior descending coronary artery
  left coronary artery
  lung edema (drug therapy)
  male
  multidetector computed tomography
  percutaneous coronary intervention
  pericarditis
  priority journal
  pulmonary trunk
  repolarization
  ST segment elevation
  sudden cardiac death
  thorax pain
  thrombectomy
  thrombus aspiration
  treatment outcome
  ventriculography
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  apixaban (503612-47-3)
  bisoprolol (66722-44-9)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  dobutamine (34368-04-2, 52663-81-7, 49745-95-1, 61661-06-1)
  eplerenone (107724-20-9)
  ramipril (87333-19-5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015058318
FULL TEXT LINK
  http://dx.doi.org/10.1136/bcr-2015-210002
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 119
TITLE
  Red cell distribution width in relation to incidence of stroke and carotid 
atherosclerosis: A population-based cohort study
AUTHOR NAMES
  Söderholm M.
  Borné Y.
  Hedblad B.
  Persson M.
  Engström G.
AUTHOR ADDRESSES
  (Söderholm M., martin.soderholm@med.lu.se; Borné Y.; Hedblad B.; Persson M.; 
Engström G.) Cardiovascular Epidemiology Research Group, Department of 
Clinical Sciences, Lund University, Malmö, Sweden.
SOURCE
  PLoS ONE (2015) 10:5 Article Number: e0124957. Date of Publication: 7 May 
2015
ISSN
  1932-6203 (electronic)
BOOK PUBLISHER
  Public Library of Science, plos@plos.org
ABSTRACT
  Background: Increased red cell distribution width (RDW) has been related to 
poor prognosis in patients with cardiovascular disease, and is a predictor 
of cardiovascular mortality in the general population. The purpose of the 
present study was to investigate if RDW is associated with increased 
incidence of stroke and its subtypes in individuals from the general 
population. Methods: Red cell distribution width was measured in 26,879 
participants (16,561 women and 10,318 men aged 45-73 years) without history 
of coronary events or stroke, from the population-based Malmö Diet and 
Cancer Study. Incidences of total stroke and stroke subtypes over a mean 
follow-up of 15.2 years were calculated in relation to sex-specific 
quartiles of RDW. The presence of carotid plaque and intima-media thickness, 
as assessed by ultrasound, was studied in relation to RDW in a randomly 
selected subcohort (n = 5,309). Results: Incidences of total stroke (n = 
1,869) and cerebral infarction (n = 1,544) were both increased in 
individuals with high RDW. Hazard ratios (HRs) in the highest compared to 
the lowest quartile were 1.31 for total stroke (95% confidence interval 
[CI]: 1.11-1.54, p for trend = 0.004) and 1.32 for cerebral infarction (95% 
CI: 1.10-1.58, p for trend = 0.004) after adjustment for stroke risk factors 
and hematological parameters. The adjusted HR for intracerebral hemorrhage 
(n = 230) was 1.44 (95% CI: 0.90-2.30) and the HR for subarachnoid 
hemorrhage (n = 75) was 0.94 (95% CI: 0.43-2.07), in the highest compared to 
the lowest quartile of RDW. Red cell distribution width was positively 
associated with intima-media thickness of the common carotid artery (p for 
trend = 0.011). Conclusions: Red cell distribution width in the highest 
quartile was associated with increased incidence of total stroke and 
cerebral infarction. There was no significant association between RDW and 
incidence of intracerebral or subarachnoid hemorrhage.
EMTREE DRUG INDEX TERMS
  high density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  carotid atherosclerosis (epidemiology)
  cerebrovascular accident (epidemiology)
  erythrocyte parameters
  incidence
  red cell distribution width
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  arterial wall thickness
  article
  atrial fibrillation
  blood sampling
  brain infarction
  brain ischemia
  cholesterol blood level
  cohort analysis
  controlled study
  disease association
  erythrocyte volume
  female
  follow up
  hemoglobin determination
  human
  leukocyte
  male
  nutritional assessment
  population research
  risk factor
  subarachnoid hemorrhage
  triacylglycerol blood level
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Hematology (25)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015038573
FULL TEXT LINK
  http://dx.doi.org/10.1371/journal.pone.0124957
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 120
TITLE
  Atrial fibrillation ablation using remote magnetic navigation and the risk 
of atrial-esophageal fistula: international multicenter experience
AUTHOR NAMES
  Danon A.
  Shurrab M.
  Nair K.M.
  Latcu D.G.
  Arruda M.S.
  Chen X.
  Szili-Torok T.
  Rossvol O.
  Wissner E.E.
  Lashevsky I.
  Crystal E.
AUTHOR ADDRESSES
  (Danon A., asdanon@gmail.com; Shurrab M.; Nair K.M.; Lashevsky I.; Crystal 
E.) Arrhythmia service, Schulich Heart Centre, Department of Cardiology, 
Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, Canada.
(Danon A., asdanon@gmail.com) Arrhythmia service, department of Cardiology, 
Carmel Medical Center, 7 Michal st., Haifa, Israel.
(Latcu D.G.) Service de Cardiologie, Centre Hospitalier Princesse Grace, 
Monaco (Principauté), Monaco.
(Arruda M.S.) Harrington-McLaughlin Heart and Vascular Institute, University 
Hospitals, Case Western Reserve University School of Medicine, Cleveland, 
United States.
(Chen X.) Department of Cardiology, The Heart Centre, Rigshospitalet, 
Copenhagen University Hospital, Copenhagen, Denmark.
(Szili-Torok T.) Clinical Electrophysiology, Department of Cardiology, 
Erasmus MC, Rotterdam, Netherlands.
(Rossvol O.) Section of Cardiology, Department of Medicine, University of 
Trondheim, Trondheim, Norway.
(Wissner E.E.) Department of Cardiology, Asklepios Klinik St. Georg, 
Lohmühlenstr. 5, Hamburg, Germany.
CORRESPONDENCE ADDRESS
  A. Danon, Arrhythmia service, Schulich Heart Centre, Department of 
Cardiology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, 
Canada.
SOURCE
  Journal of Interventional Cardiac Electrophysiology (2015) 43:2 (169-174). 
Date of Publication: 3 May 2015
ISSN
  1572-8595 (electronic)
  1383-875X
BOOK PUBLISHER
  Kluwer Academic Publishers
ABSTRACT
  Purpose: Remote magnetic navigation (RMN) has been used in various 
electrophysiological procedures, including atrial fibrillation (AF) 
ablation. Atrial-esophageal fistula (AEF) is one of most disastrous 
complications of AF ablation. We aimed to evaluate the incidence of AEF 
during AF ablation using RMN in comparison to manual ablation. Methods: We 
conducted the first international survey among RMN operators for assessment 
of the prevalence of AEF and procedural parameters affecting the risk. Data 
from parallel survey of AEF among Canadian interventional 
electrophysiologists (CIE) using only manual catheters served as control. 
Results: Fifteen RMN operators (who performed 3637 procedures) and 25 manual 
CIE operators (7016 procedures) responded to the survey. RMN operators were 
more experienced than CIE operators (16.3 ± 8.3 vs. 9.2 ± 5.4 practice years 
in electrophysiology, p = 0.007). The maximal energy output in the posterior 
wall was higher in the operator using RMN (33 ± 5 vs. 28.6 ± 4.9 W; p = 
0.02). Other parameters including use of preprocedural images, irrigated 
catheter, pump flow rate, esophageal temperature monitoring, intracardiac 
echocardiography (ICE), and general anesthesia were similar. CIE operators 
administered proton-pump inhibitors postoperatively significantly more than 
RMN operators (76 vs. 35 %, p = 0.01). AEF was reported in 5 of the 7016 
patients in the control group (0.07 %) but in none of the RMN group (p = 
0.11). Conclusions: AEF is a rare complication and its evaluation 
necessitates large-scale studies. Although no AEF case with RMN was reported 
in this large study or previously on the literature, the rarity of this 
complication prevents firm conclusion about the risk.
EMTREE DRUG INDEX TERMS
  anesthetic agent
  proton pump inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  ablation therapy
  atrial esophageal fistula
  atrial fibrillation (therapy)
  esophagus fistula (complication)
  medical procedures
  remote magnetic navigation
  risk factor
EMTREE MEDICAL INDEX TERMS
  article
  controlled study
  disease association
  flow rate
  follow up
  general anesthesia
  heart electrophysiology
  human
  intermethod comparison
  intracardiac echocardiography
  outcome assessment
  postoperative period
  priority journal
  risk assessment
  temperature measurement
  treatment response
DEVICE TRADE NAMES
  Niobe  , United StatesStereotaxis

DEVICE MANUFACTURERS
   (United States)Stereotaxis
EMBASE CLASSIFICATIONS
  Otorhinolaryngology (11)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015032185
FULL TEXT LINK
  http://dx.doi.org/10.1007/s10840-015-0003-7
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 121
TITLE
  Physiologic and pathophysiologic changes in the right heart in highly 
trained athletes
ORIGINAL (NON-ENGLISH) TITLE
  Physiologische und pathophysiologische Auswirkungen auf das rechte Herz bei 
Leistungssportlern
AUTHOR NAMES
  D’Andrea A.
  la Gerche A.
  Golia E.
  Padalino R.
  Calabrò R.
  Russo M.G.
  Bossone E.
AUTHOR ADDRESSES
  (D’Andrea A., antonellodandrea@libero.it) Second University of Naples, 
Monaldi Hospital, Via M. Schipa 44, Naples, Italy.
(la Gerche A.) Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
(Golia E.; Padalino R.; Calabrò R.; Russo M.G.; Bossone E.) Heart 
Department, Cava de’ Tirreni and Amalfi Coast Hospital, University of 
Salerno, Salerno, Italy.
CORRESPONDENCE ADDRESS
  A. D’Andrea, Second University of Naples, Monaldi Hospital, Via M. Schipa 
44, Naples, Italy.
SOURCE
  Herz (2015) . Date of Publication: 1 Apr 2015
ISSN
  1615-6692 (electronic)
  0340-9937
BOOK PUBLISHER
  Urban und Vogel GmbH, verlag@urban-vogel.de
ABSTRACT
  Exercise causes changes in the heart in response to the hemodynamic demands 
of increased systemic and pulmonary requirements during exercise. 
Understanding these adaptations is of great importance, since they may 
overlap with those caused by pathological conditions. Initial descriptions 
of athlete’s heart focused mainly on chronic adaptation of the left heart to 
training. In recent years, the substantial structural and functional 
adaptations of the right heart have been documented, highlighting the 
complex interplay with left heart. Moreover, there is evolving evidence of 
acute and chronic cardiac damage, mainly involving the right heart, which 
may predispose subjects to atrial and ventricular arrhythmias, configuring 
an exercise-induced cardiomyopathy. The aim of this article is to review the 
current knowledge on the physiologic and pathophysiologic changes in the 
right heart in highly trained athletes.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  cardiomyopathy
  endurance training
  exercise
  heart
  human
EMTREE MEDICAL INDEX TERMS
  adaptation
  heart injury
  heart ventricle arrhythmia
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, German
EMBASE ACCESSION NUMBER
  2015883230
FULL TEXT LINK
  http://dx.doi.org/10.1007/s00059-015-4220-8
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 122
TITLE
  Adding fentanyl to etomidate fails to reduce painful recall of external 
direct current cardioversion in adults: A randomised trial
AUTHOR NAMES
  Souvatzis X.
  Kalogridaki M.
  Mavrakis H.E.
  Kanoupakis E.M.
  Marouli D.
  Vardas P.
  Askitopoulou H.
AUTHOR ADDRESSES
  (Souvatzis X., x.souvatzis@gmx.de; Kalogridaki M.) Department of 
Anaesthesiology, University Hospital of Heraklion, Crete, Greece.
(Mavrakis H.E.; Kanoupakis E.M.; Vardas P.) Department of Cardiology, 
University Hospital of Heraklion, Crete, Greece.
(Marouli D.) Department of Intensive Care Medicine, University Hospital of 
Heraklion, Crete, Greece.
(Askitopoulou H.) Anaesthesiology, University of Crete, Heraklion, Crete, 
Greece.
CORRESPONDENCE ADDRESS
  X. Souvatzis, Dept. of Anaesthesiology, University Hospital of Heraklion, PO 
Box 1352, Heraklion, Greece.
SOURCE
  Hellenic Journal of Cardiology (2015) 56:2 (142-148). Date of Publication: 1 
Mar 2015
ISSN
  1109-9666
BOOK PUBLISHER
  Hellenic Cardiological Society
ABSTRACT
  Introduction: External electrical cardioversion under hypnotics, even when 
combined with opioids, has been consistently described as distressing or 
painful. The main objective of the present study was to determine if adding 
an opioid to a hypnotic, in comparison to the same hypnotic alone, would 
decrease the incidence of unpleasant or painful recall during anaesthesia 
for external electrical cardioversion. Methods: This was a single-centre, 
prospective, randomised, double-blinded clinical trial that took place from 
September 2011 to March 2012. Fifty-two adult patients with persistent 
atrial fibrillation, scheduled for external direct current cardioversion, 
were enrolled. Exclusion criteria were age >80 years, previous cardiac 
surgery, implanted pacemaker or defibrillator, and haemodynamic instability. 
Patients received intravenously either (group EF) fentanyl 50 μg and after 
60 s etomidate 0.1 mg/kg, or (group E) only etomidate 0.1 mg/kg. If the 
patients did not lose their eyelid reflex, repeated doses of etomidate 4 mg 
were given. Cardioversion was attempted with an extracardiac biphasic 
electrical shock from 200 to 300 J, at most three times. The primary 
endpoint was recall of something unpleasant or painful. Secondary outcome 
measures were predictors of the requirement for repeat doses of etomidate, 
and the number of shocks needed. Results: Fifty-one patients (35 male, 16 
female), aged 62.1 ± 10.2 years, completed the study. There were no 
differences between group EF and group E regarding recall (unpleasant recall 
0 vs. 2 patients, p=0.235; painful recall 1 vs. 0 patients, p=0.510). The 
administration of etomidate alone was a significant predictor for subsequent 
repeated doses of etomidate (p=0.049, odds ratio 4.312, 95% confidence 
interval 1.007-18.460). The number of shocks needed to restore sinus rhythm 
did not differ between the groups (p=0.846). Conclusions: In the present 
study, the addition of fentanyl to etomidate did not diminish distressing or 
painful experience during anaesthesia for external cardioversion.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  etomidate (drug combination, drug comparison, drug therapy, intravenous drug 
administration)
  fentanyl (drug combination, drug comparison, drug therapy, intravenous drug 
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardioversion
  pain (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  apnea
  article
  atrial fibrillation (therapy)
  consciousness level
  controlled study
  double blind procedure
  electrocardiogram
  eyelid reflex
  female
  heart left ventricle ejection fraction
  human
  major clinical study
  male
  manual ventilation
  middle aged
  myoclonus
  prospective study
  randomized controlled trial
  repeated drug dose
  sinus rhythm
  treatment outcome
CAS REGISTRY NUMBERS
  etomidate (15301-65-2, 33125-97-2, 51919-80-3)
  fentanyl (437-38-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Anesthesiology (24)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015943442
MEDLINE PMID
  25854443 (http://www.ncbi.nlm.nih.gov/pubmed/25854443)
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 123
TITLE
  Adherence to a Mediterranean diet and prediction of incident stroke
AUTHOR NAMES
  Tsivgoulis G.
  Psaltopoulou T.
  Wadley V.G.
  Alexandrov A.V.
  Howard G.
  Unverzagt F.W.
  Moy C.
  Howard V.J.
  Kissela B.
  Judd S.E.
AUTHOR ADDRESSES
  (Tsivgoulis G., tsivgoulisgiorg@yahoo.gr) Second Department of Neurology, 
Attikon Hospital, University of Athens, School of Medicine, Iras 39, Gerakas 
Attikis, Athens, Greece.
(Psaltopoulou T.) Department of Hygiene, Epidemiology and Medical 
Statistics, University of Athens, School of Medicine, Athens, Greece.
(Tsivgoulis G., tsivgoulisgiorg@yahoo.gr; Alexandrov A.V.) Department of 
Neurology, University of Tennessee, Health Science Center, Memphis, United 
States.
(Tsivgoulis G., tsivgoulisgiorg@yahoo.gr) International Clinical Research 
Center, St. Anne's University Hospital, Brno, Czech Republic.
(Wadley V.G.) Department of Medicine, University of Alabama, Birmingham, 
United States.
(Howard G.; Judd S.E.) Department of Biostatistics, School of Public Health, 
University of Alabama, Birmingham, United States.
(Howard V.J.) Department of Epidemiology, School of Public Health, 
University of Alabama, Birmingham, United States.
(Unverzagt F.W.) Department of Psychiatry, Indiana University, School of 
Medicine, Indianapolis, United States.
(Moy C.) National Institute of Neurological Disorders and Stroke, National 
Institutes of Health, Bethesda, United States.
(Kissela B.) Department of Neurology, University of Cincinnati, United 
States.
CORRESPONDENCE ADDRESS
  G. Tsivgoulis, Second Department of Neurology, Attikon Hospital, University 
of Athens, School of Medicine, Iras 39, Gerakas Attikis, Athens, Greece.
SOURCE
  Stroke (2015) 46:3 (780-785). Date of Publication: 1 Mar 2015
ISSN
  1524-4628 (electronic)
  0039-2499
BOOK PUBLISHER
  Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
  Background and Purpose: There are limited data on the potential association 
of adherence to Mediterranean diet (MeD) with incident stroke. We sought to 
assess the longitudinal association between greater adherence to MeD and 
risk of incident stroke. Methods: We prospectively evaluated a 
population-based cohort of 30 239 individuals enrolled in REasons for 
Geographic and Racial Differences in Stroke (REGARDS) study, after excluding 
participants with stroke history, missing demographic data or food frequency 
questionnaires, and unavailable follow-up information. Adherence to MeD was 
categorized using MeD score. Incident stroke was adjudicated by expert panel 
review of medical records during a mean follow-up period of 6.5 years. 
Results: Incident stroke was identified in 565 participants (2.8%; 497 and 
68 cases of ischemic stroke [IS] and hemorrhagic stroke, respectively) of 20 
197 individuals fulfilling the inclusion criteria. High adherence to MeD 
(MeD score, 5-9) was associated with lower risk of incident IS in unadjusted 
analyses (hazard ratio, 0.83; 95% confidence interval, 0.70-1.00; P=0.046). 
The former association retained its significance (hazard ratio, 0.79; 95% 
confidence interval, 0.65-0.96; P=0.016) after adjustment for demographics, 
vascular risk factors, blood pressure levels, and antihypertensive 
medications. When MeD was evaluated as a continuous variable, a 1-point 
increase in MeD score was independently associated with a 5% reduction in 
the risk of incident IS (95% confidence interval, 0-11%). We documented no 
association of adherence to MeD with incident hemorrhagic stroke. There was 
no interaction of race (P=0.37) on the association of adherence to MeD with 
incident IS. Conclusions: High adherence to MeD seems to be associated with 
a lower risk of incident IS independent of potential confounders. Adherence 
to MeD is not related to the risk of incident hemorrhagic stroke.
EMTREE DRUG INDEX TERMS
  antihypertensive agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident
  Mediterranean diet
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  antihypertensive therapy
  article
  atrial fibrillation
  Black person
  blood pressure
  brain hemorrhage
  brain ischemia
  demography
  diabetes mellitus
  female
  follow up
  food frequency questionnaire
  food intake
  human
  hypertension (drug therapy)
  major clinical study
  male
  medical record review
  nutritional assessment
  obesity
  patient compliance
  prediction
  priority journal
  race difference
  risk reduction
  sedentary lifestyle
  systolic blood pressure
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015424748
FULL TEXT LINK
  http://dx.doi.org/10.1161/STROKEAHA.114.007894
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 124
TITLE
  Clinical utility of exercise training in heart failure with reduced and 
preserved ejection fraction
AUTHOR NAMES
  Ul Haq M.A.
  Goh C.Y.
  Levinger I.
  Wong C.
  Hare D.L.
AUTHOR ADDRESSES
  (Ul Haq M.A., muhammad.asrar@unimelb.edu.au; Goh C.Y.; Wong C.) Northern 
Heart, The Northern Hospital, Melbourne, Australia.
(Ul Haq M.A.; Hare D.L.) Austin Health, Melbourne, Australia.
(Ul Haq M.A.; Wong C.; Hare D.L.) University of Melbourne, Melbourne, 
Australia.
(Levinger I.) Institute of Sport, Exercise and Active Living (ISEAL), 
College of Sport and Exercise Science, Victoria University, Melbourne, 
Australia.
CORRESPONDENCE ADDRESS
  M.A. Ul Haq, Northern Heart, The Northern Hospital, Melbourne, Australia.
SOURCE
  Clinical Medicine Insights: Cardiology (2015) 9 (1-9). Date of Publication: 
9 Feb 2015
ISSN
  1179-5468 (electronic)
  1179-5468
BOOK PUBLISHER
  Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay, 
Auckland, New Zealand.
ABSTRACT
  Reduced exercise tolerance is an independent predictor of hospital 
readmission and mortality in patients with heart failure (HF). Exercise 
training for HF patients is well established as an adjunct therapy, and 
there is sufficient evidence to support the favorable role of exercise 
training programs for HF patients over and above the optimal medical 
therapy. Some of the documented benefits include improved functional 
capacity, quality of life (QoL), fatigue, and dyspnea. Major trials to 
assess exercise training in HF have, however, focused on heart failure with 
reduced ejection fraction (HFREF). At least half of the patients presenting 
with HF have heart failure with preserved ejection fraction (HFPEF) and 
experience similar symptoms of exercise intolerance, dyspnea, and early 
fatigue, and similar mortality risk and rehospitalization rates. The role of 
exercise training in the management of HFPEF remains less clear. This 
article provides a brief overview of pathophysiology of reduced exercise 
tolerance in HFREF and heart failure with preserved ejection fraction 
(HFPEF), and summarizes the evidence and mechanisms by which exercise 
training can improve symptoms and HF. Clinical and practical aspects of 
exercise training prescription are also discussed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aerobic exercise
  heart failure (etiology)
  heart failure with preserved ejection fraction (etiology)
  heart failure with reduced ejection fraction (etiology)
  resistance training
EMTREE MEDICAL INDEX TERMS
  arterial stiffness
  article
  atrial fibrillation
  cardiovascular parameters
  disease association
  dyspnea
  endothelial dysfunction
  exercise intolerance
  fatigue
  heart left ventricle failure
  hospital readmission
  human
  left ventricular enddiastolic diameter
  lung congestion
  mitral valve regurgitation
  mortality
  non insulin dependent diabetes mellitus
  pathophysiology
  physical activity
  practice guideline
  pulmonary hypertension
  quality of life
  randomized controlled trial (topic)
  risk factor
  sudden cardiac death
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015735964
FULL TEXT LINK
  http://dx.doi.org/10.4137/CMC.S21372
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 125
TITLE
  Abstracts of the 18th Annual SCMR Scientific Sessions
AUTHOR ADDRESSES
  SOURCE
  Journal of Cardiovascular Magnetic Resonance (2015) 17 SUPPL. 1. Date of 
Publication: 3 Feb 2015
CONFERENCE NAME
  18th Annual SCMR Scientific Sessions
CONFERENCE LOCATION
  Nice, France
CONFERENCE DATE
  2015-02-04 to 2015-02-07
ISSN
  1097-6647
BOOK PUBLISHER
  BioMed Central Ltd.
ABSTRACT
  The proceedings contain 707 papers. The topics discussed include: inter 
breathhold reproducibility of temporal patterns of coronary artery blood 
flow; MRI assessment of aortic flow and pulse wave velocity in response to 
exercise; assessment of left atrial and left atrial appendage flow and 
stasis in atrial fibrillation; regional assessment of myocardial 
regeneration therapies in rats using magnetic resonance tagging; ischemic 
post-conditioning diminishes intramyocardial hemorrhage in acute reperfused 
myocardial infarction in rats, evaluated by CMR at 7T; cardiovascular 
magnetic resonance feature tracking in patients with acute myocarditis and 
normal ejection fraction: potential for improved diagnosis and prognosis; 
and myocardial fibrosis is associated with subsequent death and 
hospitalization for heart failure in obese adults.
EMTREE MEDICAL INDEX TERMS
  adult
  aorta flow
  atrial fibrillation
  bleeding
  cardiovascular magnetic resonance
  conditioning
  coronary artery blood flow
  death
  diagnosis
  exercise
  heart atrium appendage
  heart ejection fraction
  heart failure
  heart infarction
  heart muscle fibrosis
  hospitalization
  human
  myocarditis
  nuclear magnetic resonance
  nuclear magnetic resonance imaging
  patient
  prognosis
  pulse wave
  rat
  regeneration
  reproducibility
  therapy
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 126
TITLE
  Mucosal healing and the risk of ischemic heart disease or atrial 
fibrillation in patients with celiac disease; a population-based study
AUTHOR NAMES
  Lebwohl B.
  Emilsson L.
  Fröbert O.
  Einstein A.J.
  Green P.H.R.
  Ludvigsson J.F.
AUTHOR ADDRESSES
  (Lebwohl B.; Green P.H.R.) Celiac Disease Center, Department of Medicine, 
Columbia University College of Physicians and Surgeons, New York, United 
States.
(Lebwohl B.; Ludvigsson J.F., jonasludvigsson@yahoo.com) Department of 
Medical Epidemiology and Biostatistics, Karolinska University Hospital and 
Karolinska Institute, Stockholm, Sweden.
(Emilsson L.) Primary Care Research Unit, Department of Medicine, Örebro 
University, Örebro, Sweden.
(Fröbert O.) Department of Cardiology, Örebro University Hospital, Örebro, 
Sweden.
(Einstein A.J.) Department of Medicine, Columbia University College of 
Physicians and Surgeons, New York-Presbyterian Hospital, New York, United 
States.
(Ludvigsson J.F., jonasludvigsson@yahoo.com) Department of Pediatrics, 
Örebro University Hospital, Örebro, Sweden.
SOURCE
  PLoS ONE (2015) 10:1 Article Number: e0117529. Date of Publication: 30 Jan 
2015
ISSN
  1932-6203 (electronic)
BOOK PUBLISHER
  Public Library of Science, plos@plos.org
ABSTRACT
  Background: Patients with celiac disease (CD), characterized histologically 
by villous atrophy (VA) of the small intestine, have an increased risk of 
ischemic heart disease (IHD) and atrial fibrillation (AF), risks that 
persist for years after commencing the gluten-free diet. It is unknown 
whether persistent VA on follow-up biopsy, rather than mucosal healing, 
affects the risk of IHD or AF. Methods: We identified patients with 
histologic evidence of CD diagnosed at all 28 pathology departments in 
Sweden. Among patients who underwent a follow-up small intestinal biopsy, we 
compared patients with persistent VA to those who showed histologic 
improvement, with regard to the development of IHD (angina pectoris or 
myocardial infarction) or AF. Results: Among patients with CD and a 
follow-up biopsy (n = 7,440), the median age at follow-up biopsy was 25 
years, with 1,063 (14%) patients who were ≥60 years at the time of follow-up 
biopsy. Some 196 patients developed IHD and 205 patients developed AF. After 
adjusting for age, gender, duration of CD, calendar period, and educational 
attainment, there was no significant effect of persistent VA on IHD 
(adjusted HR 0.97; 95%CI 0.73-1.30). Adjusting for diabetes had a negligible 
effect (adjusted HR 0.98; 95%CI 0.73-1.31). There was no significant 
association between persistent VA and the risk of AF (adjusted HR 0.98; 
95%CI0.74-1.30). Conclusions: In this population-based study of patients 
with CD, persistent VA on follow-up biopsy was not associated with an 
increased risk of IHD or AF. Failed mucosal healing does not influence the 
risk of these cardiac events.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  angina pectoris
  atrial fibrillation
  celiac disease
  fatal myocardial infarction
  healing
  heart infarction
  ischemic heart disease
  mucosal healing
  unstable angina pectoris
EMTREE MEDICAL INDEX TERMS
  adolescent
  adult
  age distribution
  article
  child
  controlled study
  diabetes mellitus
  disease association
  disease duration
  duodenum biopsy
  educational status
  female
  follow up
  gender
  histology
  human
  human cell
  human tissue
  incidence
  intestine villus atrophy
  major clinical study
  male
  population research
  Sweden
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015716769
FULL TEXT LINK
  http://dx.doi.org/10.1371/journal.pone.0117529
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 127
TITLE
  Increased left atrial size is associated with reduced atrial stiffness and 
preserved reservoir function in athlete’s heart
AUTHOR NAMES
  D’Ascenzi F.
  Pelliccia A.
  Natali B.M.
  Cameli M.
  Andrei V.
  Incampo E.
  Alvino F.
  Lisi M.
  Padeletti M.
  Focardi M.
  Bonifazi M.
  Mondillo S.
AUTHOR ADDRESSES
  (D’Ascenzi F., flavio.dascenzi@libero.it; Natali B.M.; Cameli M.; Andrei V.; 
Incampo E.; Alvino F.; Lisi M.; Padeletti M.; Focardi M.; Mondillo S.) 
Department of Cardiovascular Diseases, University of Siena, Viale M. Bracci, 
Siena, Italy.
(Pelliccia A.) Institute of Sports Medicine and Science, Rome, Italy.
(Bonifazi M.) Department of Medicine, Surgery, and NeuroScience, University 
of Siena, Siena, Italy.
CORRESPONDENCE ADDRESS
  F. D’Ascenzi, Department of Cardiovascular Diseases, University of Siena, 
Viale M. Bracci, Siena, Italy.
SOURCE
  International Journal of Cardiovascular Imaging (2015) . Date of 
Publication: 28 Jan 2015
ISSN
  1573-0743 (electronic)
  1569-5794
BOOK PUBLISHER
  Kluwer Academic Publishers
ABSTRACT
  Left atrial (LA) fibrosis with increased stiffness has been assumed to be 
the substrates for occurrence of atrial arrhythmias in athletes. However, 
this hypothesis has not yet been confirmed in humans. Aim of this study was, 
therefore, to assess LA remodeling and stiffness in competitive athletes. 
150 competitive athletes and 90 age and sex-matched sedentary subjects were 
analyzed by speckle-tracking echocardiography to measure peak atrial 
longitudinal strain (PALS) and peak atrial contraction strain (PACS). LA 
stiffness was determined using E/e’ ratio in conjunction with PALS. Left 
ventricular (LV) stiffness was also calculated. LA volume index was greater 
in athletes as compared with controls (24.6 ± 7.3 vs. 18.4 ± 7.8 mL/m(2), p 
< .0001). LA PALS, LA PACS, and E/e’ ratio were lower in athletes in 
comparison with controls (p < .05, p ≤ .001, and p < .0001, respectively). 
Despite greater LA size, competitive athletes had lower LA stiffness as 
compared with controls (0.13 ± 0.04 vs. 0.16 ± 0.06, p ≤ .001). In addition, 
LV stiffness was lower in athletes (0.84 ± 0.27 vs. 1.07 ± 0.46, p ≤ .001). 
The only independent predictor of LA stiffness was LV stiffness (β = 0.46, p 
< .0001), while the only independent predictor of LA volume index was LV 
end-systolic volume index (β = 0.25, p = .002). Competitive athletes showed 
greater LA size associated with lower stiffness as compared with controls. 
Thus, LA remodeling in the context of the athlete’s heart is not associated 
with increased LA stiffness. These findings support the benign nature of LA 
remodeling in athletes, occurring as a physiological adaptation to exercise 
conditioning.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  echocardiography
  exercise
  heart
  heart atrium function
  human
  rigidity
EMTREE MEDICAL INDEX TERMS
  adaptation
  conditioning
  fibrosis
  heart atrium arrhythmia
  heart atrium contraction
  heart left ventricle endsystolic volume
  hypothesis
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015703725
FULL TEXT LINK
  http://dx.doi.org/10.1007/s10554-015-0600-7
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 128
TITLE
  Alternative medicine in atrial fibrillation treatment-Yoga, acupuncture, 
biofeedback and more
AUTHOR NAMES
  Kanmanthareddy A.
  Reddy M.
  Ponnaganti G.
  Sanjani H.P.
  Koripalli S.
  Adabala N.
  Buddam A.
  Janga P.
  Lakkireddy T.
  Bommana S.
  Vallakati A.
  Atkins D.
  Lakkireddy D.
AUTHOR ADDRESSES
  (Kanmanthareddy A.) School of Medicine, Creighton University, Omaha, United 
States.
(Kanmanthareddy A.) VA Nebraska-Western Iowa Health Care System, Omaha, 
United States.
(Reddy M.; Ponnaganti G.; Sanjani H.P.; Koripalli S.; Adabala N.; Buddam A.; 
Janga P.; Lakkireddy T.; Bommana S.; Atkins D.; Lakkireddy D., 
dlakkireddy@kumc.edu) The University of Kansas Medical Center and Hospital, 
Kansas City, United States.
(Vallakati A.) Case Western Reserve University, MetroHealth Medical Center, 
Cleveland, United States.
CORRESPONDENCE ADDRESS
  D. Lakkireddy, Center for Excellence in Atrial Fibrillation and oEP 
Research, Bloch Heart Rhythm Center, Mid America Cardiology, University of 
Kansas Hospital, 3901 Rainbow Blvd, Kansas City, United States.
SOURCE
  Journal of Thoracic Disease (2015) 7:2 (185-192). Date of Publication: 2015
ISSN
  2077-6624 (electronic)
  2072-1439
BOOK PUBLISHER
  Pioneer Bioscience Publishing, jtd@thepbpc.org
ABSTRACT
  The last decade has seen a significant improvement in the management of 
atrial fibrillation (AF) with the development of newer medications and 
improvement in catheter ablation techniques. Recurrence of AF remains a 
significant problem in these patients and medications offer limited 
supportive role. Complementary and alternative treatment strategies 
therefore remain a viable option for these AF patients. Several studies have 
shown improvement in AF symptoms with yoga therapy, acupuncture and 
biofeedback. There are also several herbal medicine and supplements such as 
omega-3 fatty acids, antioxidant vitamins, barberry, motherwort, cinchona, 
Shensongyangxin, hawthorn, Kella and Wenxin Keli that have been evaluated as 
potential therapeutic options in AF. These studies are however limited by 
small sample sizes with mixed results. Besides the pharmacological action, 
metabolism, interactions with other medications and the adverse effects of 
the herbal medications and supplements remain poorly understood. In spite of 
the above limitations, complementary therapies remain a promising option in 
the management of AF and further studies are necessary to validate their 
safety and efficacy.
EMTREE DRUG INDEX TERMS
  antiarrhythmic agent (drug therapy)
  antioxidant (drug therapy)
  Chinese drug (drug therapy)
  Crataegus extract (drug therapy)
  herbaceous agent (drug therapy)
  Motherwort extract (drug therapy)
  omega 3 fatty acid (drug therapy)
  plant extract (drug therapy)
  shensongyangxin (drug therapy)
  unclassified drug
  vitamin (drug therapy)
  Wenxin Keli extract (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  alternative medicine
  atrial fibrillation (drug therapy, drug therapy, therapy)
  feedback system
  yoga
EMTREE MEDICAL INDEX TERMS
  Apiaceae
  Berberidaceae
  catheter ablation
  Cinchona
  clinical effectiveness
  Crataegus
  diet supplementation
  herbal medicine
  human
  Khella
  Lamiaceae
  medicinal plant
  Motherwort
  nonhuman
  patient safety
  recurrent disease (therapy)
  review
  symptom
  Wenxin Keli
CAS REGISTRY NUMBERS
  Crataegus extract (82374-45-6)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015723843
FULL TEXT LINK
  http://dx.doi.org/10.3978/j.issn.2072-1439.2015.01.13
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 129
TITLE
  Mediterranean Dietary Patterns and Cardiovascular Health
AUTHOR NAMES
  Shen J.
  Wilmot K.A.
  Ghasemzadeh N.
  Molloy D.L.
  Burkman G.
  Mekonnen G.
  Gongora M.C.
  Quyyumi A.A.
  Sperling L.S.
AUTHOR ADDRESSES
  (Shen J., lsperli@emory.edu; Wilmot K.A.; Ghasemzadeh N.; Mekonnen G.; 
Gongora M.C.; Quyyumi A.A.; Sperling L.S.) Emory Clinical Cardiovascular 
Research Institute, United States.
(Shen J., lsperli@emory.edu; Wilmot K.A.; Ghasemzadeh N.; Molloy D.L.; 
Burkman G.; Mekonnen G.; Gongora M.C.; Quyyumi A.A.; Sperling L.S.) 
Department of Medicine, Division of Cardiology, Emory University, Atlanta, 
United States.
SOURCE
  Annual Review of Nutrition (2015) 35:1 (425-449). Date of Publication: 17 
Jul 2015
ISSN
  1545-4312 (electronic)
  0199-9885
BOOK PUBLISHER
  Annual Reviews Inc., 4139 El Camino Way, P.O. Box 10139, Palo Alto, United 
States.
ABSTRACT
  The Mediterranean dietary pattern has been linked with reduced 
cardiovascular disease incidence and mortality. Components of the 
Mediterranean diet associated with better cardiovascular health include low 
consumption of meat and meat products, moderate consumption of ethanol 
(mostly from wine), and high consumption of vegetables, fruits, nuts, 
legumes, fish, and olive oil. Increasing evidence indicates that the synergy 
among these components results in beneficial changes in intermediate 
pathways of cardiometabolic risk, such as lipids, insulin sensitivity, 
oxidative stress, inflammation, and vasoreactivity. As a result, consumption 
of a Mediterranean dietary pattern favorably affects numerous cardiovascular 
disease risk factors, such as dyslipidemia, hypertension, metabolic 
syndrome, and diabetes. Moreover, strong evidence links this dietary pattern 
with reduced cardiovascular disease incidence, reoccurrence, and mortality. 
This review evaluates the current evidence behind the cardioprotective 
effects of a Mediterranean dietary pattern.
EMTREE DRUG INDEX TERMS
  apolipoprotein B
  cholesterol
  lipoprotein
  olive oil
  protein
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (prevention)
  Mediterranean diet
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  arterial stiffness
  atrial fibrillation
  cardiovascular mortality
  cardiovascular risk
  cerebrovascular accident
  cerebrovascular disease
  dairy product
  diabetes mellitus
  food crop
  herb
  human
  hypertension
  insulin resistance
  lifestyle
  meta analysis (topic)
  metabolic syndrome X
  microangiopathy
  morbidity
  multicenter study (topic)
  nonhuman
  nut
  oxidative stress
  physical activity
  primary prevention
  priority journal
  randomized controlled trial (topic)
  review
  secondary prevention
  spice
  wine
CAS REGISTRY NUMBERS
  cholesterol (57-88-5)
  olive oil (8001-25-0)
  protein (67254-75-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015208873
FULL TEXT LINK
  http://dx.doi.org/10.1146/annurev-nutr-011215-025104
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 130
TITLE
  Dietary fat intake is differentially associated with risk of paroxysmal 
compared with sustained atrial fibrillation in women
AUTHOR NAMES
  Chiuve S.E.
  Sandhu R.K.
  Moorthy M.V.
  Glynn R.J.
  Albert C.M.
AUTHOR ADDRESSES
  (Chiuve S.E., schiuve@hsph.harvard.edu; Albert C.M.) Center for Arrhythmia 
Prevention, Brigham and Women's Hospital and Harvard Medical School, Boston, 
United States.
(Chiuve S.E., schiuve@hsph.harvard.edu; Sandhu R.K.; Moorthy M.V.; Glynn 
R.J.; Albert C.M.) Division of Preventive Medicine, Brigham and Women's 
Hospital and Harvard Medical School, Boston, United States.
(Albert C.M.) Cardiovascular Division, Department of Medicine, Brigham and 
Women's Hospital and Harvard Medical School, Boston, United States.
(Chiuve S.E., schiuve@hsph.harvard.edu) Department of Nutrition, Harvard 
T.H. Chan School of Public Health, Boston, United States.
(Sandhu R.K.) Division of Cardiology, University of Alberta, Edmonton, 
Canada.
CORRESPONDENCE ADDRESS
  S.E. Chiuve, Center for Arrhythmia Prevention, Brigham and Women's Hospital 
and Harvard Medical School, Boston, United States.
SOURCE
  Journal of Nutrition (2015) 145:9 (2092-2101). Date of Publication: 2015
ISSN
  1541-6100 (electronic)
  0022-3166
BOOK PUBLISHER
  American Society for Nutrition, staff@dues.faseb.org
ABSTRACT
  Background: Dietary fats have effects on biological pathways that may 
influence the development and maintenance of atrial fibrillation (AF). 
However, associations between n-3 (ω-3) polyunsaturated fatty acids and AF 
are inconsistent, and data on other dietary fats and AF risk are sparse. 
Objectives: We examined the association between dietary fatty acid (FA) 
subclasses and risk of incident AF and explored whether these associations 
differed for sustained and paroxysmal AF. Methods: We conducted a 
prospective cohort study in 33,665 women ≥45 y old without cardiovascular 
disease (CVD) and AF at baseline in 1993. Fat intake was estimated from food 
frequency questionnaires at baseline and in 2004. Incident AF was confirmed 
by medical records through October 2013. AF patterns were classified 
according to the most sustained form of AF within 2 y of diagnosis. Cox 
proportional hazards models with the use of a competing risk model approach 
estimated the RR. Results: Over 19.2 y, 1441 cases of incident AF (929 
paroxysmal and 467 persistent/chronic) were confirmed. Intakes of total fat 
and FA subclasses were not associated with risk of AF. Saturated fatty acids 
(SFAs) and monounsaturated fatty acids (MUFAs) were differentially 
associated with AF patterns. The RR for a 5% increment of energy from SFAs 
was 1.47 (95% CI: 1.04, 2.09) for persistent/chronic and 0.85 (95% CI: 0.66, 
1.08) for paroxysmal AF (P-difference = 0.01). For MUFAs, the RR for a 5% 
increment was 0.67 (95% CI: 0.46, 0.98) for persistent/chronic and 1.03 (95% 
CI: 0.78, 1.34) for paroxysmal AF, although the difference between patterns 
was not significant (P-difference = 0.07). Conclusions: Dietary fat was not 
associated with risk of incident AF in women without established CVD or AF. 
High SFA and low MUFA intakes were associated with greater risk of 
persistent or chronic, but not paroxysmal, AF. Improving dietary fat quality 
may play a role in the prevention of sustained forms of AF.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  fatty acid (drug therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  alpha tocopherol (drug therapy)
  beta carotene (drug therapy)
  docosahexaenoic acid (drug therapy)
  icosapentaenoic acid (drug therapy)
  linolenic acid (drug therapy)
  monounsaturated fatty acid (drug therapy)
  omega 3 fatty acid (drug therapy)
  omega 6 fatty acid (drug therapy)
  saturated fatty acid (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (diagnosis, epidemiology, therapy)
  fat intake
  paroxysmal atrial fibrillation (diagnosis, epidemiology, therapy)
  sustained atrial fibrillation (diagnosis, epidemiology, therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  article
  cardiovascular disease (drug therapy, prevention, therapy)
  chronic atrial fibrillation (epidemiology, therapy)
  cohort analysis
  controlled study
  disease association
  drug efficacy
  energy
  female
  food frequency questionnaire
  human
  incidence
  low drug dose
  major clinical study
  medical record
  middle aged
  persistent atrial fibrillation (epidemiology, therapy)
  proportional hazards model
  prospective study
  randomized controlled trial
  risk factor
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  beta carotene (7235-40-7)
  docosahexaenoic acid (25167-62-8, 32839-18-2)
  icosapentaenoic acid (25378-27-2, 32839-30-8)
  linolenic acid (1955-33-5, 463-40-1)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00000479)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015364105
FULL TEXT LINK
  http://dx.doi.org/10.3945/jn.115.212860
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 131
TITLE
  Renal function assessment in atrial fibrillation: Usefulness of chronic 
kidney disease epidemiology collaboration vs reexpressed 4 variable 
modification of diet in renal disease
AUTHOR NAMES
  Abumuaileq R.R.-Y.
  Abu-Assi E.
  López-López A.
  Raposeiras-Roubin S.
  Rodríguez-Mañero M.
  Martínez-Sande L.
  García-Seara F.J.
  Fernandez-López X.A.
  González-Juanatey J.R.
AUTHOR ADDRESSES
  (Abumuaileq R.R.-Y., drrami2012@hotmail.com; Abu-Assi E.; López-López A.; 
Raposeiras-Roubin S.; Rodríguez-Mañero M.; Martínez-Sande L.; García-Seara 
F.J.; Fernandez-López X.A.; González-Juanatey J.R.) Cardiology Department, 
University Clinical Hospital of Santiago de Compostela, A choupana s/n, 
Santiago de Compostela, Spain.
CORRESPONDENCE ADDRESS
  R.R.-Y. Abumuaileq, Cardiology Department, University Clinical Hospital of 
Santiago de Compostela, A choupana s/n, Santiago de Compostela, Spain. 
Email: drrami2012@hotmail.com
SOURCE
  World Journal of Cardiology (2015) 7:10 (685-694). Date of Publication: 2015
ISSN
  1949-8462 (electronic)
BOOK PUBLISHER
  Baishideng Publishing Group Co, bpg@baishideng.com
ABSTRACT
  AIM: To compare the performance of the re-expressed Modification of Diet in 
Renal Disease equation vs the new Chronic Kidney Disease Epidemiology 
Collaboration equation in patients with non-valvular atrial fibrillation. 
METHODS: We studied 911 consecutive patients with non-valvular atrial 
fibrillation on vitamin-K antagonist. The performance of the re-expressed 
Modification of Diet in Renal Disease equation vs the new Chronic Kidney 
Disease Epidemiology Collaboration equation in patients with non-valvular 
atrial fibrillation with respect to either a composite endpoint of major 
bleeding, thromboembolic events and all-cause mortality or each individual 
component of the composite endpoint was assessed using continuous and 
categorical = 60, 59-30, and < 30 mL/min per 1.73 m2 estimated glomerular 
filtration rate. RESULTS: During 10 ± 3 mo, the composite endpoint occurred 
in 98 (10.8%) patients: 30 patients developed major bleeding, 18 had 
thromboembolic events, and 60 died. The new equation provided lower 
prevalence of renal dysfunction < 60 mL/min per 1.73 m2 (32.9%), compared 
with the re-expressed equation (34.1%). Estimated glomerular filtration rate 
from both equations was independent predictor of composite endpoint (HR = 
0.98 and 0.97 for the re-expressed and the new equation, respectively; P < 
0.0001) and all-cause mortality (HR = 0.98 for both equations, P < 0.01). 
Strong association with thromboembolic events was observed only when 
estimated glomerular filtration rate was < 30 mL/min per 1.73 m2: HR is 5.1 
for the re-expressed equation, and HR = 5.0 for the new equation. No 
significant association with major bleeding was observed for both 
equations.CONCLUSION: The new equation reduced the prevalence of renal 
dysfunction. Both equations performed similarly in predicting major adverse 
outcomes.
EMTREE DRUG INDEX TERMS
  acenocoumarol (drug therapy)
  antivitamin K (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy)
  chronic kidney disease (epidemiology)
  Chronic Kidney Disease Epidemiology Collaboration
  clinical assessment tool
  diet supplementation
  kidney disease (therapy)
  kidney function
  Modification of Diet in Renal Disease
EMTREE MEDICAL INDEX TERMS
  adult
  adverse outcome
  aged
  article
  bleeding
  clinical article
  clinical assessment
  female
  glomerulus filtration rate
  human
  male
  mortality
  performance
  prevalence
  thromboembolism
CAS REGISTRY NUMBERS
  acenocoumarol (152-72-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Urology and Nephrology (28)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015526663
FULL TEXT LINK
  http://dx.doi.org/10.4330/wjc.v7.i10.685
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 132
TITLE
  Optimizing pain management to facilitate Enhanced Recovery After Surgery 
pathways
ORIGINAL (NON-ENGLISH) TITLE
  Optimiser le contrôle de la douleur pour faciliter la Récupération rapide 
après la chirurgie
AUTHOR NAMES
  Tan M.
  Law L.S.-C.
  Gan T.J.
AUTHOR ADDRESSES
  (Tan M.; Law L.S.-C.) Duke-NUS Graduate Medical School, Singapore, 
Singapore.
(Gan T.J., tong.gan@stonybrookmedicine.edu) Department of Anesthesiology, 
Stony Brook Medicine, Stony Brook, United States.
CORRESPONDENCE ADDRESS
  T.J. Gan, Department of Anesthesiology, Stony Brook Medicine, Stony Brook, 
United States.
SOURCE
  Canadian Journal of Anesthesia (2015) 62:2 (203-218). Date of Publication: 
2015
ISSN
  1496-8975 (electronic)
  0832-610X
BOOK PUBLISHER
  Springer New York LLC, journals@springer-sbm.com
ABSTRACT
  Purpose: The optimal management of postoperative pain using multimodal 
analgesia is a key component of Enhanced Recovery After Surgery (ERAS). Pain 
has adverse clinical implications on postoperative recovery, including 
prolonging the time to recovery milestones and length of hospital stay. 
Moreover, the ubiquity of opioids in postoperative analgesic regimens 
results in adverse effects, such as sedation, postoperative nausea and 
vomiting, urinary retention, ileus, and respiratory depression, which can 
delay discharge. Thus, multimodal analgesia, i.e., the use of more than one 
analgesic modality to achieve effective pain control while reducing 
opioid-related side effects, has become the cornerstone of enhanced 
recovery. The purpose of this review is to address the analgesic techniques 
used as part of multimodal analgesic regimens to optimize postoperative pain 
control and to summarize the evidence for their use in reducing opioid 
requirements and side effects.Principal findings: There is a wide variety of 
analgesic techniques available for multimodal postoperative analgesia. These 
modalities are divided into pharmacological and non-pharmacological 
techniques. Systemic pharmacological modalities involve opioids and 
non-opioids such as acetaminophen, non-steroidal anti-inflammatory drugs, 
N-methyl-D-aspartate receptor antagonists, anticonvulsants (e.g., 
gamma-aminobutyric acid analogues), beta-blockers, alpha-2 agonists, 
transient receptor potential vanilloid receptor agonists (capsaicin), and 
glucocorticoids. Other pharmacological modalities include central neuraxial 
techniques, surgical-site infiltration, and regional anesthesia. Evidence 
supports the use of these pharmacological techniques as part of multimodal 
analgesia, but each has its own advantages and specific safety profile, 
which highlights the importance of selecting the appropriate analgesics for 
each patient. Adjunctive non-pharmacological techniques include acupuncture, 
music therapy, transcutaneous electrical nerve stimulation, and hypnosis. 
There is mixed evidence regarding such techniques, although a lack of harm 
is associated with their use.Conclusion: There are continuing advancements 
in multimodal analgesic techniques; however, postoperative pain in general 
continues to be undermanaged. Furthermore, a continuing challenge in 
multimodal pain research related to ERAS is the difficulty in carrying out 
randomized trials to determine the relative importance of any one component, 
including analgesia.
EMTREE DRUG INDEX TERMS
  4 aminobutyric acid
  alpha 2 adrenergic receptor stimulating agent (adverse drug reaction, drug 
therapy, pharmacology)
  beta adrenergic receptor blocking agent (pharmacology)
  bupivacaine
  capsaicin (drug therapy, pharmacology)
  celecoxib (oral drug administration)
  clonidine (clinical trial, epidural drug administration, pharmacology)
  dexamethasone (adverse drug reaction, drug therapy)
  diamorphine
  fentanyl
  gabapentin (drug therapy, oral drug administration)
  glucocorticoid (pharmacology)
  ibuprofen (oral drug administration)
  infusion fluid
  ketamine (drug therapy, intravenous drug administration, pharmacology)
  ketorolac (intravenous drug administration)
  lidocaine (transdermal drug administration)
  midazolam
  morphine (intravenous drug administration)
  n methyl dextro aspartic acid receptor blocking agent (drug therapy, 
pharmacology)
  nonsteroid antiinflammatory agent (adverse drug reaction, drug therapy, 
pharmacology)
  opiate (adverse drug reaction, drug therapy, intravenous drug 
administration, parenteral drug administration, pharmacology)
  oxycodone (oral drug administration)
  paracetamol (drug therapy, intravenous drug administration, oral drug 
administration, pharmacology)
  propofol
  remifentanil
  ropivacaine
  transient receptor potential channel (endogenous compound)
  unindexed drug
  vanilloid receptor agonist (pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  analgesia
  Enhanced Recovery After Surgery Program
  health program
  postoperative pain (drug therapy, complication, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  agranulocytosis (side effect)
  analgesic activity
  article
  atrial fibrillation
  clinical practice
  continuous infusion
  controlled study
  dermatitis (side effect)
  drug mechanism
  drug safety
  epidural anesthesia
  erythema (side effect)
  hepatomegaly (side effect)
  hospitalization
  human
  hyperglycemia (side effect)
  hypnosis
  ileus (side effect)
  length of stay
  leukocytosis (side effect)
  music therapy
  nausea (side effect)
  postoperative analgesia
  postoperative nausea and vomiting (drug therapy, side effect)
  postoperative period
  priority journal
  regional anesthesia
  respiration depression (side effect)
  sedation
  skin irritation (side effect)
  spinal anesthesia
  supraventricular tachycardia
  thrombocytopenia (side effect)
  transcutaneous nerve stimulation
  urine retention (side effect)
  urticaria (side effect)
  vomiting (side effect)
CAS REGISTRY NUMBERS
  4 aminobutyric acid (28805-76-7, 56-12-2)
  bupivacaine (18010-40-7, 2180-92-9, 55750-21-5, 38396-39-3)
  capsaicin (404-86-4)
  celecoxib (169590-42-5)
  clonidine (4205-90-7, 4205-91-8, 57066-25-8)
  dexamethasone (50-02-2)
  diamorphine (1502-95-0, 561-27-3)
  fentanyl (437-38-7)
  gabapentin (60142-96-3)
  ibuprofen (15687-27-1, 79261-49-7, 31121-93-4, 527688-20-6)
  ketamine (1867-66-9, 6740-88-1, 81771-21-3)
  ketorolac (74103-06-3)
  lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
  midazolam (59467-70-8)
  morphine (52-26-6, 57-27-2)
  opiate (53663-61-9, 8002-76-4, 8008-60-4)
  oxycodone (124-90-3, 76-42-6)
  paracetamol (103-90-2)
  propofol (2078-54-8)
  remifentanil (132539-07-2)
  ropivacaine (84057-95-4)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Anesthesiology (24)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, French
EMBASE ACCESSION NUMBER
  2014973583
MEDLINE PMID
  25501696 (http://www.ncbi.nlm.nih.gov/pubmed/25501696)
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12630-014-0275-x
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 133
TITLE
  Unexplained acute chest pain in young adults: Disease patterns and 
medication use 25 years later
AUTHOR NAMES
  Roll M.
  Rosenqvist M.
  Sjöborg B.
  Wettermark B.
AUTHOR ADDRESSES
  (Roll M., martin.roll@ds.se; Rosenqvist M.) Departments of Clinical 
Sciences, Danderyd Hospital, Stockholm, Sweden.
(Roll M., martin.roll@ds.se; Rosenqvist M.) Departments of Cardiology, 
Sweden.
(Sjöborg B.; Wettermark B.) Division of Cardiovascular Medicine, Danderyd 
University, Karolinska Institutet, Stockholm, Sweden.
(Sjöborg B.; Wettermark B.) Public Healthcare Services Committee, Sweden.
(Wettermark B.) Stockholm County Council, Stockholm, Sweden.
(Wettermark B.) Centre for Pharmacoepidemiology and Clinical Pharmacology, 
Karolinska Institutet, Karolinska University, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
  M. Roll, Departments of Clinical Sciences, Danderyd Hospital, Stockholm, 
Sweden.
SOURCE
  Psychosomatic Medicine (2015) 77:5 (567-574). Date of Publication: 13 Jun 
2015
ISSN
  1534-7796 (electronic)
  0033-3174
BOOK PUBLISHER
  Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
  Patients with unexplained chest pain are commonly revisiting an emergency 
department with various symptoms, but comprehensive long-term studies are 
lacking. Methods A total of 150 young adults (aged 18-40 years) with 
unexplained chest pain who presented at an emergency unit for 16 weeks in 
mid-1980s were included in a prospective cohort study. An age-And 
sex-matched control group was randomly selected from the same area. Data 
were retrieved from registers that recorded death, income, education, 
country of birth, diagnoses, hospitalizations, outpatient visits, and 
medications dispensed. Results Patients with unexplained acute chest pain 
had lower levels of education and income and were more often immigrants. 
Long-term mortality rates did not differ between cases (4%) and controls 
(5%) during 25 years of follow-up, nor were there differences in diagnosis 
of ischemic heart disease. Patients with unexplained acute chest pain had 
more outpatient visits (median, 5 versus 2; p <.0001) and had more often 
been hospitalized (61.6% ever versus 41.8%; p <.001) during the follow-up 
period. Several disorders were more common among patients 20 to 25 years 
later, including atrial fibrillation, esophageal/gastric disorders, chest 
pain, palpitations, abdominal discomfort, musculoskeletal symptoms, sleeping 
disturbance, and stress reactions (p values <.05). More patients had been 
given antihypertensives, anticoagulants, antidepressants, analgesics, and 
hypnotics/tranquilizers (p values <.05). Conclusions Young patients admitted 
to the emergency department with unexplainedacute chest pain showed no 
increased risk of mortality or ischemic heart disease during 25 years of 
follow-up, but they had higher incidence of a wide range of disorders and 
used more medications. Early identification and preventive interventions may 
improve health outcomes in these patients.
EMTREE DRUG INDEX TERMS
  analgesic agent
  angiotensin receptor antagonist
  anticoagulant agent
  antidepressant agent
  antihypertensive agent (drug therapy)
  antithrombocytic agent
  calcium channel blocking agent
  dipeptidyl carboxypeptidase inhibitor
  diuretic agent
  hypnotic agent
  tranquilizer
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  drug use
  idiopathic disease
  thorax pain
EMTREE MEDICAL INDEX TERMS
  abdominal discomfort (diagnosis)
  adult
  alcoholism (diagnosis)
  angina pectoris (diagnosis)
  anxiety disorder (diagnosis)
  article
  atrial fibrillation (diagnosis)
  backache (diagnosis)
  cohort analysis
  controlled study
  diagnosis related group
  differential diagnosis
  dizziness (diagnosis)
  educational status
  emergency ward
  esophagus disease (diagnosis)
  fatigue (diagnosis)
  female
  follow up
  gastroesophageal reflux (diagnosis)
  headache (diagnosis)
  health care utilization
  heart infarction (diagnosis)
  heart palpitation (diagnosis)
  human
  hypertension (diagnosis, drug therapy)
  irritable colon (diagnosis)
  ischemic heart disease
  major clinical study
  male
  migraine (diagnosis)
  mood disorder (diagnosis)
  mortality
  musculoskeletal disease (diagnosis)
  myalgia (diagnosis)
  osteoarthritis (diagnosis)
  outpatient care
  panic (diagnosis)
  paroxysmal tachycardia (diagnosis)
  patient
  priority journal
  prospective study
  respiratory tract disease (diagnosis)
  sleep disorder (diagnosis)
  social status
  stomach disease (diagnosis)
  tendinitis (diagnosis)
  tension headache (diagnosis)
  unstable angina pectoris (diagnosis)
  upper respiratory tract infection (diagnosis)
  young adult
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015127751
FULL TEXT LINK
  http://dx.doi.org/10.1097/PSY.0000000000000188
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 134
TITLE
  Acupuncture antiarrhythmic effects on drug refractory persistent atrial 
fibrillation: Study protocol for a randomized, controlled trial
AUTHOR NAMES
  Park J.
  Kim H.S.
  Lee S.M.
  Yoon K.
  Kim W.-S.
  Woo J.S.
  Lee S.
  Kim J.-B.
  Kim W.
AUTHOR ADDRESSES
  (Park J., swarmy77@hanmail.net; Lee S.M., lollymin@nate.com; Yoon K., 
kkyoe@hanmail.net; Lee S., shlee777@gmail.com) Department of Acupuncture and 
Moxibustion, College of Korean Medicine, Kyung Hee University, Seoul, South 
Korea.
(Kim H.S., matheer2@gmail.com; Kim W.-S., kkabee@dreamwiz.com; Woo J.S., 
snowball77@hanmail.net; Kim J.-B., jinbbai@khu.ac.kr; Kim W., 
mylovekw@hanmail.net) Division of Cardiology, Department of Internal 
Medicine, Kyung Hee University, Seoul, South Korea.
CORRESPONDENCE ADDRESS
  S. Lee, Department of Acupuncture and Moxibustion, College of Korean 
Medicine, Kyung Hee University, Seoul, South Korea.
SOURCE
  Evidence-based Complementary and Alternative Medicine (2015) 2015 Article 
Number: 613970. Date of Publication: 2015
ISSN
  1741-4288 (electronic)
  1741-427X
BOOK PUBLISHER
  Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New 
York, United States.
ABSTRACT
  Background. Atrial fibrillation (AF) is the most common form of arrhythmia. 
Several trials have suggested that acupuncture may prevent AF. However, the 
efficacy of acupuncture for AF prevention has not been well investigated. 
Therefore, we designed a prospective, two-parallel-armed, participant and 
assessor blinded, randomized, sham-controlled clinical trial to investigate 
acupuncture in persistent AF (ACU-AF). Methods. A total of 80 participants 
will be randomly assigned to active acupuncture or sham acupuncture groups 
in a 1: 1 ratio. Both groups will take the same antiarrhythmic medication 
during the study period. Patients will receive 10 sessions of acupuncture 
treatment once a week for 10 weeks. The primary endpoint is AF recurrence 
rate. Secondary endpoints are left atrium (LA) and left atrial appendage 
(LAA) changes in function and volume, and inflammatory biomarker changes. 
Ethics. This study protocol was approved by the institutional review boards 
(IRBs) of Kyung Hee University Hospital (number 1335-04). This trial is 
registered with clinicaltrials.gov NCT02110537.
EMTREE DRUG INDEX TERMS
  flecainide (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  antiarrhythmic activity
  atrial fibrillation (drug therapy, drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  bleeding (complication)
  controlled study
  dizziness (complication)
  electroacupuncture
  heart atrium appendage
  heart left atrium
  hematoma (complication)
  human
  infection (complication)
  major clinical study
  outcome assessment
  pain (complication)
  priority journal
  prospective study
  randomized controlled trial
  recurrent disease (prevention)
  sinus rhythm
  therapy effect
  transesophageal echocardiography
CAS REGISTRY NUMBERS
  flecainide (54143-55-4)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT02110537)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015811345
FULL TEXT LINK
  http://dx.doi.org/10.1155/2015/613970
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 135
TITLE
  Symptom burden, Metabolic profile, Ultrasound findings, Rhythm, 
neurohormonal activation, haemodynamics and health-related quality of life 
in patients with atrial Fibrillation (SMURF): A protocol for an 
observational study with a randomised interventional component
AUTHOR NAMES
  Charitakis E.
  Walfridsson U.
  Nyström F.
  Nylander E.
  Strömberg A.
  Alehagen U.
  Walfridsson H.
AUTHOR ADDRESSES
  (Charitakis E.; Walfridsson U.; Strömberg A.; Alehagen U.; Walfridsson H., 
hakan.walfridsson@regionostergotland.se) Department of Cardiology, Linköping 
University, Linköping, Sweden.
(Nyström F.) Department of Medical and Health Sciences, Faculty of Health 
Sciences, Linköping University, Linköping, Sweden.
(Nylander E.) Department of Clinical Physiology, Linköping University, 
Linköping, Sweden.
CORRESPONDENCE ADDRESS
  H. Walfridsson, Department of Cardiology, Linköping University, Linköping, 
Sweden. Email: hakan.walfridsson@regionostergotland.se
SOURCE
  BMJ Open (2015) 5:12 Article Number: e008723. Date of Publication: 2015
ISSN
  2044-6055 (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, subscriptions@bmjgroup.com
ABSTRACT
  Introduction: Atrial fibrillation (AF) is the most common cardiac 
arrhythmia, with an estimated prevalence of 1.5-2%. It is an independent 
risk factor for ischaemic stroke and is estimated to cause about 20-25% of 
all stroke cases. AF has a great impact on health-related quality of life 
(HRQoL); however, one unresolved issue related to AF is the wide variation 
in its symptoms. Methods and analysis: The symptom burden, metabolic 
profile, ultrasound findings, rhythm, neurohormonal activation, 
haemodynamics and HRQoL in patients with AF (Symptom burden, Metabolic 
profile, Ultrasound findings, Rhythm, neurohormonal activation, 
haemodynamics and health-related quality of life in patients with atrial 
Fibrillation, SMURF) study is a prospective observational, cohort study, 
with a randomised interventional part. The aim of the study is to 
investigate, in patients with AF, the relationship between symptom burden 
and metabolic aspects, atrial function and different neurohormones, and the 
effect of radiofrequency ablation (RFA). The interventional part of the 
study will give an insight into the neurohormonal and intracardiac pressure 
changes directly after initiation of AF. Consecutive patients with 
symptomatic AF accepted for treatment with RFA for the first time at 
Linköping University Hospital are eligible for participation. The enrolment 
started in January 2012, and a total of 200 patients are to be included into 
the study, with 45 of them being enrolled into the interventional study with 
initiation of AF. The sample size of the interventional study is based on a 
small pilot study with 5 patients induced to AF while 2 served as controls. 
The results indicated that, in order to find a statistically significant 
difference, there was a need to include 28 patients; for safety reasons, 45 
patients will be included. Ethics and dissemination: The SMURF study is 
approved by the Regional Ethical Review Board at the Faculty of Health 
Sciences, Linköping, Sweden. The results will be presented through 
peer-review journals and conference presentation.
EMTREE DRUG INDEX TERMS
  amino terminal pro brain natriuretic peptide (endogenous compound)
  copeptin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (disease management)
EMTREE MEDICAL INDEX TERMS
  article
  controlled study
  heart atrium function
  human
  major clinical study
  metabolic syndrome X
  observational study
  prospective study
  quality of life
  radiofrequency ablation
  randomized controlled trial
  speckle tracking echocardiography
  transesophageal echocardiography
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (nct01553045)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160201648
FULL TEXT LINK
  http://dx.doi.org/10.1136/bmjopen-2015-008723
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 136
TITLE
  Incidence of atrial fibrillation in relation to birth weight and preterm 
birth
AUTHOR NAMES
  Larsson S.C.
  Drca N.
  Jensen-Urstad M.
  Wolk A.
AUTHOR ADDRESSES
  (Larsson S.C., susanna.larsson@ki.se; Wolk A.) Unit of Nutritional 
Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 
Box 210, Stockholm, Sweden.
(Drca N.; Jensen-Urstad M.) Department of Cardiology, Karolinska University 
Hospital, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
  S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental 
Medicine, Karolinska Institutet, Box 210, Stockholm, Sweden.
SOURCE
  International Journal of Cardiology (2015) 178 (149-152). Date of 
Publication: 15 Jan 2015
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
ABSTRACT
  Background Hypertension, type 2 diabetes and other cardiovascular diseases, 
all risk factors for atrial fibrillation, are associated with birth weight. 
It remains unclear, however, whether risk of atrial fibrillation is also 
associated with birth weight. We investigated the associations of birth 
weight and preterm birth (i.e., born more than one month before term) with 
risk of atrial fibrillation (AF).Methods The study population comprised 29 
551 men and 23 454 women who were free from AF at baseline. Information on 
birth weight, preterm birth, and risk factors for AF was obtained from a 
questionnaire. Incident AF cases were ascertained by linkage to the Swedish 
Inpatient Register.Results During 12 years of follow-up, AF developed in 
2711 men and 1491 women. High birth weight (≥ 5000 g) was associated with an 
increased risk of AF after adjustment for age and other risk factors for AF, 
but the association did not persist after further adjustment for adult 
height. In men but not in women, low birth weight was associated with an 
increased risk of AF. Compared with men weighing 2500-3999 g at birth, the 
multivariable RR was 1.86 (95% CI, 1.15 to 3.00) for those weighing < 1500 
g. This association was stronger in men who were born full-term (RR 2.53; 
95% CI, 1.35 to 4.73).Conclusions Both high birth weight and low birth 
weight (in men), in particular in men born full-term, were associated with 
an increased risk of AF. The association with high birth weight appeared to 
be mediated through adult height.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (epidemiology)
  birth weight
  premature labor
EMTREE MEDICAL INDEX TERMS
  adult
  alcohol consumption
  article
  body height
  body mass
  cohort analysis
  diet
  disease association
  family history
  female
  follow up
  human
  incidence
  low birth weight
  male
  physical activity
  population research
  prospective study
  questionnaire
  risk assessment
  risk factor
  sex difference
  smoking
  Swedish citizen
  waist circumference
EMBASE CLASSIFICATIONS
  Obstetrics and Gynecology (10)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014962385
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2014.10.138
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 137
TITLE
  Midterm renal functions following acute renal infarction
AUTHOR NAMES
  Ongun S.
  Bozkurt O.
  Demir O.
  Cimen S.
  Aslan G.
AUTHOR ADDRESSES
  (Ongun S., sakirongun@hotmail.com) Department of Urology, SB Siverek State 
Hospital, Siverek-Sanliurfa Highway Thirteenth Kilometer, Sanliurfa, Turkey.
(Bozkurt O.; Demir O.) Department of Urology, Dokuz Eylul University, School 
of Medicine, Izmir, Turkey.
(Cimen S.; Aslan G.) Department of Urology, SB Ankara Dişkapi Training 
Hospital, Ankara, Turkey.
CORRESPONDENCE ADDRESS
  S. Ongun, Department of Urology, SB Siverek State Hospital, 
Siverek-Sanliurfa Highway Thirteenth Kilometer, Sanliurfa, Turkey. Email: 
sakirongun@hotmail.com
SOURCE
  Kaohsiung Journal of Medical Sciences (2015) 31:10 (529-533). Date of 
Publication: 2015
ISSN
  1607-551X
BOOK PUBLISHER
  Elsevier (Singapore) Pte Ltd, 3 Killiney Road, 08-01, Winsland House I, 
Singapore, Singapore.
ABSTRACT
  The aim of this study was to explore clinical features of renal infarction 
(RI) that may have a role in diagnosis and treatment in our patient cohort 
and provide data on midterm renal functions. Medical records of patients 
with diagnosis of acute RI, established by contrast enhanced computed 
tomography (CT) and at least 1 year follow-up data, who were hospitalized in 
our clinic between 1998 and 2012 were retrospectively reviewed; including 
descriptive data, clinical signs and symptoms, etiologic factors, laboratory 
findings, and prescribed treatments. Patients with solitary infarct were 
treated with acetylsalicylic acid (ASA) only, whereas patients with atrial 
fibrillation (AF) or multiple or global infarct were treated with 
anticoagulants. Estimated Glomerular Filtration Rate (EGFR) referring to 
renal functions was determined by the Modification of Diet in Renal Disease 
(MDRD) formula. Twenty-seven renal units of 23 patients with acute RI were 
identified. The mean age was 59.7 ± 15.7 years. Fourteen patients (60.8%) 
with RI had atrial fibrillation (AF) as an etiologic factor of which four 
had concomitant mesenteric ischemia at diagnosis. At presentation, 20 
patients (86.9%) had elevated serum lactate dehydrogenase (LDH), 18 patients 
(78.2%) had leukocytosis, and 16 patients (69.5%) had microscopic hematuria. 
Two patients with concomitant mesenteric ischemia and AF passed away during 
follow up. Mean EGFR was 70.8 ± 23.2 mL/min/1.73 m(2) at admission and 
increased to 82.3 ± 23.4 mL/min/1.73 m(2) at 1 year follow up. RI should be 
considered in patients with persistent flank or abdominal pain, particularly 
if they are at high risk of thromboembolism. Antiplatelet and/or 
anticoagulant drugs are both effective treatment options according to the 
amplitude of the infarct for preserving kidney functions.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  alanine aminotransferase (endogenous compound)
  alkaline phosphatase (endogenous compound)
  anticoagulant agent
  aspartate aminotransferase (endogenous compound)
  creatine kinase (endogenous compound)
  lactate dehydrogenase (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  kidney function
  kidney infarction
EMTREE MEDICAL INDEX TERMS
  abdominal pain
  abdominal tenderness
  adult
  alanine aminotransferase blood level
  alkaline phosphatase blood level
  article
  aspartate aminotransferase blood level
  atrial fibrillation
  body mass
  cardiovascular risk
  clinical article
  clinical feature
  computer assisted tomography
  creatine kinase blood level
  female
  flank pain
  glomerulus filtration rate
  human
  lactate dehydrogenase blood level
  leukocyte count
  leukocytosis
  male
  mesenteric ischemia
  middle aged
  thromboembolism
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alanine aminotransferase (9000-86-6, 9014-30-6)
  alkaline phosphatase (9001-78-9)
  aspartate aminotransferase (9000-97-9)
  creatine kinase (9001-15-4)
  lactate dehydrogenase (9001-60-9)
EMBASE CLASSIFICATIONS
  Urology and Nephrology (28)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015324602
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.kjms.2015.07.005
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 138
TITLE
  Risk of atrial fibrillation associated with coffee intake: Findings from the 
Danish Diet, Cancer, and Health study
AUTHOR NAMES
  Mostofsky E.
  Johansen M.B.
  Lundbye-Christensen Sø.
  Tjønneland A.
  Mittleman M.A.
  Overvad K.
AUTHOR ADDRESSES
  (Mostofsky E.; Mittleman M.A.) Cardiovascular Epidemiology Research Unit, 
Beth Israel Deaconess Medical Center, Boston, United States.
(Mostofsky E.; Mittleman M.A.) Department of Epidemiology, Harvard T.H. Chan 
School of Public Health, Boston, United States.
(Johansen M.B.; Overvad K., ko@ph.au.dk) Department of Cardiology, Aalborg 
University Hospital, Denmark.
(Johansen M.B.; Lundbye-Christensen Sø.) Unit of Clinical Biostatistics, 
Aalborg University Hospital, Denmark.
(Lundbye-Christensen Sø.) Aalborg Atrial Fibrillation Study Group, 
Department of Cardiology, Aalborg University Hospital, Denmark.
(Tjønneland A.) Danish Cancer Society Research Center, Copenhagen, Denmark.
(Overvad K., ko@ph.au.dk) Section for Epidemiology, Department of Public 
Health, Aarhus University, Bartholins Alle 2, , Denmark.
CORRESPONDENCE ADDRESS
  K. Overvad, Section for Epidemiology, Department of Public Health, Aarhus 
University, Bartholins Alle 2, , Denmark. Email: ko@ph.au.dk
SOURCE
  European Journal of Preventive Cardiology (2015) 23:9 (922-930). Date of 
Publication: 2015
ISSN
  2047-4881 (electronic)
  2047-4873
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  Background There have been discrepant findings on whether coffee consumption 
is associated with the rate of developing atrial fibrillation (AF). Methods 
and results We used data on 57,053 participants (27,178 men and 29,875 
women) aged 50-64 years in the Danish Diet, Cancer and Health study. All 
participants provided information on coffee intake via food-frequency 
questionnaires at baseline. Incident AF was identified using nationwide 
registries. During a median follow-up of 13.5 years, 3415 AF events 
occurred. Compared with no intake, coffee consumption was inversely 
associated with AF incidence, with multivariable-adjusted hazard ratios of 
0.93 (95% confidence interval [CI] 0.74-1.15) for more than none to <1 
cup/day, 0.88 (95% CI 0.71-1.10) for 1 cup/day, 0.86 (95% CI 0.71-1.04) for 
2-3 cups/day, 0.84 (95% CI 0.69-1.02) for 4-5 cups/day, 0.79 (95% CI 
0.64-0.98) for 6-7 cups/day and 0.79 (95% CI 0.63-1.00) for >7 cups/day 
(p-linear trend = 0.02). Conclusions In this large population-based cohort 
study, higher levels of coffee consumption were associated with a lower rate 
of incident AF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  coffee
EMTREE MEDICAL INDEX TERMS
  adult
  article
  Denmark
  dietary intake
  female
  food frequency questionnaire
  human
  incidence
  major clinical study
  male
  middle aged
  priority journal
  risk assessment
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160372477
FULL TEXT LINK
  http://dx.doi.org/10.1177/2047487315624524
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 139
TITLE
  Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging 
epidemic
AUTHOR NAMES
  Hajhosseiny R.
  Matthews G.K.
  Lip G.Y.H.
AUTHOR ADDRESSES
  (Hajhosseiny R., reza.hajhosseiny@kcl.ac.uk) British Heart Foundation, 
Centre of Cardiovascular Excellence, St. Thomas' Hospital, Westminster 
Bridge Rd, , United Kingdom.
(Matthews G.K.) Department of Physiology, Development and Neuroscience, 
University of Cambridge, Cambridge, United Kingdom.
(Lip G.Y.H.) University of Birmingham, Centre for Cardiovascular Sciences, 
City Hospital, Birmingham, United Kingdom.
(Lip G.Y.H.) Aalborg Thrombosis Research Unit, Department of Clinical 
Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.
CORRESPONDENCE ADDRESS
  R. Hajhosseiny, British Heart Foundation, Centre of Cardiovascular 
Excellence, St. Thomas' Hospital, Westminster Bridge Rd, , United Kingdom.
SOURCE
  Heart Rhythm (2015) 12:11 (2332-2343). Date of Publication: 1 Nov 2015
ISSN
  1556-3871 (electronic)
  1547-5271
BOOK PUBLISHER
  Elsevier
ABSTRACT
  The prevalence of atrial fibrillation (AF) and AF-related stroke is set to 
increase dramatically in coming decades, with developing regions such as 
Latin America experiencing the greatest impact. These trends are primarily 
driven by aging populations and by the increasing prevalence of the 
metabolic syndrome. The metabolic syndrome describes an association between 
diabetes, hypertension, obesity, and dyslipidemia and an increased risk of 
cardiovascular disease. It is in large part the result of unbalanced diet 
and sedentary lifestyle. These essentially modifiable risk factors are 
becoming more prevalent with the widespread adoption of so-called Western 
lifestyles. This review examines the physiology underlying the link between 
the metabolic syndrome and AF. Next, it highlights the importance of 
addressing lifestyle-related risk factors to mitigate the trend toward 
increasing AF prevalence. It then goes on to discuss the importance of 
stroke prevention therapy in patients with established AF, focusing on the 
relative merits of various available options for anticoagulation. Given the 
recent availability of comprehensive data on the 4 currently available 
non-vitamin K antagonist oral anticoagulant drugs, this review concludes by 
discussing the relative merits of specific agents in individual patient 
groups.
EMTREE DRUG INDEX TERMS
  anticoagulant agent (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy, epidemiology)
  cerebrovascular accident (drug therapy, drug therapy, epidemiology)
  metabolic syndrome X (epidemiology)
EMTREE MEDICAL INDEX TERMS
  aging
  anticoagulation
  article
  cardiovascular risk
  Central America
  diabetes mellitus
  dietary intake
  drug efficacy
  drug safety
  dyslipidemia
  epidemic
  evidence based medicine
  human
  hypertension
  obesity
  prevalence
  priority journal
  risk factor
  risk reduction
  sedentary lifestyle
  South America
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Endocrinology (3)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015346269
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.hrthm.2015.06.038
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 140
TITLE
  Intravenous administration of EGB 761 and 90-day functional outcome in 
patients with acute ischemic stroke
AUTHOR NAMES
  Shin D.-I.
  Lee H.-S.
  Baek S.-H.
  Han H.-S.
  Lee H.-L.
  Kim Y.-D.
AUTHOR ADDRESSES
  (Shin D.-I., sdi007@hanmail.net; Baek S.-H.; Lee H.-L.) Department of 
Neurology, Chungbuk National University College of Medicine, Chungbuk 
National University Hospital, Cheongju, South Korea.
(Lee H.-S.; Han H.-S.) Department of Neurology, Yuseong Sun General 
Hospital, DaeJeon, South Korea.
(Kim Y.-D.) Department of Preventive Medicine, Chungbuk National University 
College of Medicine, Cheongju, South Korea.
CORRESPONDENCE ADDRESS
  D.-I. Shin, Department of Neurology, Chungbuk National University College of 
Medicine, Chungbuk National University Hospital, Chungdae-ro 1, Seowon-ku, 
Cheongju, South Korea.
SOURCE
  Neurology Asia (2015) 20:3 (215-219). Date of Publication: 1 Sep 2015
ISSN
  1823-6138
BOOK PUBLISHER
  ASEAN Neurological Association
ABSTRACT
  Background & Objective: EGB 761 is a standardized natural extract used to 
treat impaired cerebral perfusion and nutrition (cerebrovascular 
insufficiency) in Korea. Although several animal studies have been 
conducted, few studies have investigated the clinical effects of EGB 761 in 
acute stroke. This study assessed the clinical benefit of intravenous EGB 
761 in patients with acute ischemic stroke. Methods: This retrospective 
study examined a prospectively collected stroke database. We evaluated 232 
patients with acute ischemic stroke within 48 hours of symptom onset. All 
patients were treated with antiplatelet or anticoagulation agents. We 
compared baseline characteristics between the EGB 761-treated and 
non-treated groups. The functional outcome measure was the modified Rankin 
Scale (mRS) score 90 days after stroke onset. Results: Of the 232 patients, 
170 received EGB 761 during the first 3 days after arrival in the emergency 
department. We found no significant differences in baseline characteristics 
between the groups, with the exception of atrial fibrillation (p=0.032). 
After adjusting for baseline factors, intravenous administration of EGB 761 
was associated with an improved 90-day functional outcome (mRS ≤2) compared 
with the control group (odds ratio, 2.56; p<0.05). Conclusions: Our results 
showed a clinical benefit of intravenous EGB 761 in patients with acute 
ischemic stroke.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  Ginkgo biloba extract (adverse drug reaction, drug therapy, intravenous drug 
administration, pharmacology)
EMTREE DRUG INDEX TERMS
  anticoagulant agent (drug therapy)
  antithrombocytic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation
  bleeding (diagnosis)
  computer assisted tomography
  controlled study
  emergency ward
  female
  functional assessment
  human
  major clinical study
  male
  National Institutes of Health Stroke Scale
  neuroprotection
  nuclear magnetic resonance imaging
  onset age
  Rankin scale
  retrospective study
  treatment duration
  unspecified side effect (side effect)
DRUG TRADE NAMES
  tanamin  , South KoreaYuyu

DRUG MANUFACTURERS
   (South Korea)Yuyu
EMBASE CLASSIFICATIONS
  Hematology (25)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015431065
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 141
TITLE
  Cadmium exposure and incidence of heart failure and atrial fibrillation: A 
population-based prospective cohort study
AUTHOR NAMES
  Borné Y.
  Barregard L.
  Persson M.
  Hedblad B.
  Fagerberg B.
  Engström G.
AUTHOR ADDRESSES
  (Borné Y., yan.borne@med.lu.se; Persson M.; Hedblad B.; Engström G.) 
Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden.
(Barregard L.) Department of Occupational and Environmental Medicine, 
Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, 
Sweden.
(Persson M.) Clinical Research Unit, Emergency Department, Skåne University 
Hospital, Malmö, Sweden.
(Fagerberg B.) Department of Molecular and Clinical Medicine, University of 
Gothenburg, Gothenburg, Sweden.
CORRESPONDENCE ADDRESS
  Y. Borné, Department of Clinical Sciences in Malmö, Lund University, Malmö, 
Sweden.
SOURCE
  BMJ Open (2015) 5:6 Article Number: e007366. Date of Publication: 2015
ISSN
  2044-6055 (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, subscriptions@bmjgroup.com
ABSTRACT
  Objectives: Cadmium is a non-essential toxic metal with multiple adverse 
health effects. Cadmium has been shown to be associated with cardiovascular 
diseases, but few studies have investigated heart failure (HF) and none of 
them reported atrial fibrillation (AF). We examined whether cadmium exposure 
is associated with incidence of HF or AF. Design: A prospective, 
observational cohort study with a 17-year follow-up. Setting: The city of 
Malmö, Sweden. Participants: Blood cadmium levels were measured in 4378 
participants without a history of HF or AF (aged 46-67 years, 60% women), 
who participated in the Malmö Diet and Cancer (MDC) study during 1992-1994. 
Primary and secondary outcome measures: Incidence of HF and AF were 
identified from the Swedish hospital discharge register. Results: 143 
participants (53% men) were diagnosed with new-onset HF and 385 individuals 
(52% men) were diagnosed with new-onset AF during follow-up for 17 years. 
Blood cadmium in the sex-specific 4th quartile of the distribution was 
significantly associated with incidence of HF. The (HR, 4th vs 1st quartile) 
was 2.64 (95% CI 1.60 to 4.36), adjusted for age, and 1.95 (1.02 to 3.71) 
after adjustment also for conventional risk factors and biomarkers. The 
blood cadmium level was not significantly associated with risk of incident 
AF. Conclusions: Blood cadmium levels in the 4th quartile were associated 
with increased incidence of HF in this cohort with comparatively low 
exposure to cadmium. Incidence of AF was not associated with cadmium.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  cadmium (drug toxicity)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  heart failure
EMTREE MEDICAL INDEX TERMS
  adult
  age
  aged
  article
  female
  follow up
  gender
  human
  incidence
  major clinical study
  male
  population based case control study
  prospective study
  register
CAS REGISTRY NUMBERS
  cadmium (22537-48-0, 7440-43-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Toxicology (52)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015203554
FULL TEXT LINK
  http://dx.doi.org/10.1136/bmjopen-2014-007366
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 142
TITLE
  Left atrial function following surgical ablation of atrial fibrillation: 
Prospective evaluation using dual-source cardiac computed tomography
AUTHOR NAMES
  Kim J.B.
  Yang D.H.
  Kang J.-W.
  Jung S.-H.
  Choo S.J.
  Chung C.H.
  Song J.-K.
  Lee J.W.
AUTHOR ADDRESSES
  (Kim J.B.; Jung S.-H.; Choo S.J.; Chung C.H.; Lee J.W., jwlee@amc.seoul.kr) 
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, 
University of Ulsan College of Medicine, Seoul, South Korea.
(Yang D.H.; Kang J.-W.) Department of Radiology, Asan Medical Center, 
University of Ulsan College of Medicine, Seoul, South Korea.
(Song J.-K.) Department of Cardiology, Asan Medical Center, University of 
Ulsan College of Medicine, Seoul, South Korea.
CORRESPONDENCE ADDRESS
  J.W. Lee, Department of Thoracic and Cardiovascular Surgery, Asan Medical 
Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, 
Songpa-gu Seoul, South Korea.
SOURCE
  Yonsei Medical Journal (2015) 56:3 (608-616). Date of Publication: 2015
ISSN
  0513-5796
BOOK PUBLISHER
  Yonsei University College of Medicine
ABSTRACT
  Purpose: The Maze procedure has shown excellent efficacy in the elimination 
of atrial fibrillation (AF); however, little is known about the quality of 
functional recovery in the left atrium (LA) following successful sinus 
rhythm conversion by the Maze procedure. Materials and Methods: We 
prospectively enrolled 12 patients (aged 52.5±10.1 years, 1 female) with 
valvular AF undergoing mitral valve surgery combined with the Maze 
procedure. Parameters of LA function in three anatomic compartments 
[anterior, posterior, and LA appendage (LAA)] were evaluated using 
electrocardiography-gated dual-source cardiac CT at one month and at six 
months after surgery. Twelve subjects matched by age, gender, and body 
surface area served as controls. Results: At one month after surgery, 
ejection fraction (EF) and emptying volume (EV) of the LA were 14.9±7.4% and 
21.3±9.7 mL, respectively, and they were significantly lower than those of 
the control group (EF, 47.9±11.2%; EV, 46.0±10.7%; p<0001). These values did 
not significantly change throughout late periods (p=0.22 and 0.21, 
respectively). Functional contributions of the anterior, posterior, and 
appendage compartments (EV of each compartment/overall EV) were 80.4%, 
-0.9%, and 20.5%, respectively, for those with LAA preservation (n=6); 
100.1%, -0.1%, and 0% for those with LAA resection (n=6; p<0.05); and 62.2%, 
28.2%, and 9.7% in the control subjects (p<0.001). Conclusion: Contractile 
functions of the LA significantly decreased after the Maze procedure. 
Functional contributions of three compartments of the LA were also altered. 
The influence of LAA preservation on postoperative LA functions needs to be 
evaluated through studies of larger populations.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (surgery, disease management)
  computer assisted tomography
  heart atrium function
  heart surgery
  maze procedure
EMTREE MEDICAL INDEX TERMS
  adult
  article
  cardiovascular parameters
  clinical article
  controlled study
  electrocardiography
  female
  heart atrium contractility
  heart atrium contraction
  heart atrium emptying volume
  heart ejection fraction
  heart rhythm
  human
  left atrial volume
  male
  mitral valve
  observational study
  prospective study
  randomized controlled trial
  surgical technique
  treatment outcome
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015895663
FULL TEXT LINK
  http://dx.doi.org/10.3349/ymj.2015.56.3.608
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 143
TITLE
  Performance of the CHARGE-AF risk model for incident atrial fibrillation in 
the EPIC Norfolk cohort
AUTHOR NAMES
  Pfister R.
  Brägelmann J.
  Michels G.
  Wareham N.J.
  Luben R.
  Khaw K.-T.
AUTHOR ADDRESSES
  (Pfister R., roman.pfister@uk-koeln.de; Brägelmann J.; Michels G.) 
Department III of Internal Medicine, University of Cologne, Kerpenerstr. 62, 
Cologne, Germany.
(Wareham N.J.) Medical Research Council Epidemiology Unit, Institute of 
Metabolic Science, University of Cambridge, United Kingdom.
(Luben R.; Khaw K.-T.) Department of Public Health and Primary Care, 
Institute of Public Health, University of Cambridge, United Kingdom.
CORRESPONDENCE ADDRESS
  R. Pfister, Department III of Internal Medicine, University of Cologne, 
Kerpenerstr. 62, Cologne, Germany.
SOURCE
  European Journal of Preventive Cardiology (2015) 22:7 (932-939). Date of 
Publication: 9 Jul 2015
ISSN
  2047-4881 (electronic)
  2047-4873
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  Background: Identification of individuals at risk for developing atrial 
fibrillation (AF) will help to target screening and preventive 
interventions. We aimed to validate the CHARGE-AF model (including variables 
age, race, height, weight, blood pressure, smoking, antihypertensive 
medication, diabetes, myocardial infarction and heart failure) for 
prediction of five-year incident AF in a representative European population 
with a wide age range. Methods and results: The CHARGE-AF model was 
calculated in 24,020 participants of the population-based EPIC Norfolk study 
with 236 cases of hospitalization with diagnosis of AF within five years. 
The model showed good discrimination (c-statistic 0.81, 95% confidence 
interval (CI) 0.75-0.85), but weak calibration (Chi -statistic 142) with an 
almost two-fold overestimation of AF incidence. A recalibration to 
characteristics of the European Prospective Investigation into Cancer and 
Nutrition (EPIC) Norfolk cohort improved calibration considerably 
(Chi2-statistic 13.3), with acceptable discrimination in participants both 
≥65 and <65 years of age (c-statistics 0.70, 95% CI 0.61-0.77 and 0.83, 95% 
CI 0.74-0.88). The recalibrated model also showed good discrimination in 
participants free of cardiovascular disease (c-statistics 0.80, 95% CI 
0.75-0.84). Categories of predicted risk (<2.5%, 2.5-5% or >5%) showed good 
concordance with observed five-year AF incidence of 0.62%, 3.49% and 8.74% 
(log rank test p < 0.001), respectively. Conclusion: A recalibration of the 
CHARGE-AF model is necessary for accurate predictions of five-year risk of 
AF in the EPIC Norfolk population. The recalibrated model showed good 
discrimination across a wide age range and in individuals free of 
cardiovascular disease, and hence is broadly applicable in primary care to 
identify people at risk for development of AF.
EMTREE DRUG INDEX TERMS
  antihypertensive agent (drug therapy)
  antivitamin K (drug therapy)
  digitalis (drug therapy)
  high density lipoprotein cholesterol (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, diagnosis, drug therapy)
  cardiovascular risk
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  antihypertensive therapy
  article
  blood pressure measurement
  controlled study
  demography
  diabetes mellitus
  diastolic blood pressure
  female
  follow up
  heart failure
  heart infarction
  hospital admission
  hospitalization
  human
  hypertension (drug therapy)
  incidence
  lifestyle
  low risk population
  major clinical study
  male
  primary medical care
  priority journal
  prospective study
  questionnaire
  self report
  task performance
CAS REGISTRY NUMBERS
  digitalis (8031-42-3, 8053-83-6)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015109713
FULL TEXT LINK
  http://dx.doi.org/10.1177/2047487314544045
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 144
TITLE
  Coronary Heart Disease Risk Factors and Outcomes in the Twenty-First 
Century: Findings from the REasons for Geographic and Racial Differences in 
Stroke (REGARDS) Study
AUTHOR NAMES
  Bhatt H.
  Safford M.
  Glasser S.
AUTHOR ADDRESSES
  (Bhatt H.) Division of Cardiovascular Medicine, University of Alabama at 
Birmingham, 1720 2nd Avenue South, Birmingham, United States.
(Safford M.; Glasser S., sglasser@uabmc.edu) Division of Preventive 
Medicine, University of Alabama at Birmingham, 1720 2nd Avenue South, 
Birmingham, United States.
(Glasser S., sglasser@uabmc.edu) 1717 11th Avenue South, MT 634, Birmingham, 
United States.
CORRESPONDENCE ADDRESS
  S. Glasser, 1717 11th Avenue South, MT 634, Birmingham, United States.
SOURCE
  Current Hypertension Reports (2015) 17:4. Date of Publication: 2015
ISSN
  1534-3111 (electronic)
  1522-6417
BOOK PUBLISHER
  Current Medicine Group LLC 1, info@phl.cursci.com
ABSTRACT
  REasons for Geographic and Racial Differences in Stroke (REGARDS) is a 
longitudinal study supported by the National Institutes of Health to 
determine the disparities in stroke-related mortality across USA. REGARDS 
has published a body of work designed to understand the disparities in 
prevalence, awareness, treatment, and control of coronary heart disease 
(CHD) and its risk factors in a biracial national cohort. REGARDS has 
focused on racial and geographical disparities in the quality and access to 
health care, the influence of lack of medical insurance, and has attempted 
to contrast current guidelines in lipid lowering for secondary prevention in 
a nationwide cohort. It has described CHD risk from nontraditional risk 
factors such as chronic kidney disease, atrial fibrillation, and 
inflammation (i.e., high-sensitivity C-reactive protein) and has also 
assessed the role of depression, psychosocial, environmental, and lifestyle 
factors in CHD risk with emphasis on risk factor modification and ideal 
lifestyle factors. REGARDS has examined the utility of various 
methodologies, e.g., the process of medical record adjudication, proxy-based 
cause of death, and use of claim-based algorithms to determine CHD risk. 
Some valuable insight into less well-studied concepts such as the 
reliability of current troponin assays to identify “microsize infarcts,” 
caregiving stress, and CHD, heart failure, and cognitive decline have also 
emerged. In this review, we discuss some of the most important findings from 
REGARDS in the context of the existing literature in an effort to identify 
gaps and directions for further research.
EMTREE DRUG INDEX TERMS
  C reactive protein (endogenous compound)
  troponin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular risk
  cerebrovascular accident
  ischemic heart disease (epidemiology)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  cardiovascular mortality
  cause of death
  chronic kidney disease
  depression
  diabetes mellitus
  diet
  dyslipidemia
  electrocardiography
  environmental factor
  geography
  health behavior
  health care quality
  heart failure
  heart infarction
  human
  impaired glucose tolerance
  incidence
  inflammation
  lifestyle
  lifestyle modification
  longitudinal study
  medical record
  mental deterioration
  obesity
  outcome assessment
  prehypertension
  pulse pressure
  race difference
  resistant hypertension
  review
  sex difference
  smoking
  social psychology
  systolic blood pressure
  treatment refusal
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015854834
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11906-015-0541-5
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 145
TITLE
  Respiratory sleep disorders in patients with congestive heart failure
AUTHOR NAMES
  Naughton M.T.
AUTHOR ADDRESSES
  (Naughton M.T., m.naughton@alfred.org.au) Department of Allergy, Immunology 
and Respiratory Medicine, General Respiratory and Sleep Medicine, Melbourne, 
Australia.
(Naughton M.T., m.naughton@alfred.org.au) Department of Medicine, Monash 
University, The Alfred Hospital, Melbourne, Australia.
CORRESPONDENCE ADDRESS
  M.T. Naughton, General Respiratory and Sleep Medicine, Department of 
Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, 
Melbourne, Australia.
SOURCE
  Journal of Thoracic Disease (2015) 7:8 (1298-1310). Date of Publication: 
2015
ISSN
  2077-6624 (electronic)
  2072-1439
BOOK PUBLISHER
  Pioneer Bioscience Publishing, jtd@thepbpc.org
ABSTRACT
  Respiratory sleep disorders (RSD) occur in about 40-50% of patients with 
symptomatic congestive heart failure (CHF). Obstructive sleep apnea (OSA) is 
considered a cause of CHF, whereas central sleep apnea (CSA) is considered a 
response to heart failure, perhaps even compensatory. In the setting of 
heart failure, continuous positive airway pressure (CPAP) has a definite 
role in treating OSA with improvements in cardiac parameters expected. 
However in CSA, CPAP is an adjunctive therapy to other standard therapies 
directed towards the heart failure (pharmacological, device and surgical 
options). Whether adaptive servo controlled ventilatory support, a variant 
of CPAP, is beneficial is yet to be proven. Supplemental oxygen therapy 
should be used with caution in heart failure, in particular, by avoiding 
hyperoxia as indicated by SpO<inf>2</inf> values > 95%.
EMTREE DRUG INDEX TERMS
  oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  central sleep apnea syndrome (etiology, therapy)
  congestive heart failure (etiology)
  sleep disordered breathing (etiology, therapy)
EMTREE MEDICAL INDEX TERMS
  apnea
  atrial fibrillation
  carbon dioxide tension
  cardiovascular response
  causal attribution
  clinical effectiveness
  disease severity
  fluid retention
  gas exchange
  heart output
  heart rate
  human
  hypertension
  hyperventilation
  nonREM sleep
  oxygen consumption
  oxygen therapy
  pathogenesis
  positive end expiratory pressure
  pulmonary artery occlusion pressure
  quality of life
  REM sleep
  review
  risk factor
  treatment duration
  treatment response
CAS REGISTRY NUMBERS
  oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  General Pathology and Pathological Anatomy (5)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00733343, NCT00738179, NCT01128816)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015343039
FULL TEXT LINK
  http://dx.doi.org/10.3978/j.issn.2072-1439.2015.07.02
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 146
TITLE
  Is there a difference in mad honey poisoning between geriatric and 
non-geriatric patient groups?
AUTHOR NAMES
  Yaylaci S.
  Ayyildiz O.
  Aydin E.
  Osken A.
  Karahalil F.
  Varim C.
  Demir M.V.
  Genç A.B.
  Sahinkus S.
  Can Y.
  Kocayigit I.
  Bilir C.
AUTHOR ADDRESSES
  (Yaylaci S., yaylacis@hotmail.com) Department of Internal Medicine, Findikli 
State Hospital, Rize, Turkey.
(Ayyildiz O.) Department of Emergency Medicine, Findikli State Hospital, 
Rize, Turkey.
(Aydin E.) Department of Cardiology, Vakfikebir State Hospital, Trabzon, 
Turkey.
(Osken A.) Department of Cardiology, Siyami Ersek Thoracic and 
Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.
(Karahalil F.) Department of Chemistry, Faculty of Arts and Sciences, 
Karadeniz Technical University, Trabzon, Turkey.
(Varim C.) Department of Internal Medicine, Faculty of Medicine, Sakarya 
University, Sakarya, Turkey.
(Demir M.V.) Department of Internal Medicine, Malatya State Hospital, 
Malatya, Turkey.
(Genç A.B.) Department of Internal Medicine, Kandira State Hospital, 
Kocaeli, Turkey.
(Sahinkus S.; Can Y.) Department of Cardiology, Faculty of Medicine, Sakarya 
University, Sakarya, Turkey.
(Kocayigit I.) Department of Cardiology, Sakarya Yenikent State Hospital, 
Sakarya, Turkey.
(Bilir C.) Department of Internal Medicine, Faculty of Medicine, Rize 
University, Rize, Turkey.
CORRESPONDENCE ADDRESS
  S. Yaylaci, Department of Internal Medicine, Findikli State Hospital, Rize, 
Turkey. Email: yaylacis@hotmail.com
SOURCE
  European Review for Medical and Pharmacological Sciences (2015) 19:23 
(4647-4653). Date of Publication: 2015
ISSN
  1128-3602
BOOK PUBLISHER
  Verduci Editore, g.lombardi@verduci.it
ABSTRACT
  OBJECTIVE: This study aims to investigate the demographic, toxicological 
characteristics of the mad honey intoxication at ages 65 and above, to 
analyze the electrocardiographic parameters, and to compare with the mad 
honey intoxication at ages below 65 years. PATIENTS AND METHODS: Eighty-two 
patients, who had been treated and followed-up between June 2013 and 
November 2014 in the Emergency Service of the Findikli State Hospital, 
Turkey, due to diagnosis of mad honey intoxication, were included in our 
observational study. Age, gender, toxicological characteristics, laboratory 
parameters, heart rates, systolic and diastolic blood pressures, laboratory 
analyses and electrocardiographic data of the patients were recorded and 
analyzed. Patients with known coronary artery disease, chronic renal 
failure, arrhythmias, valvular heart disease, history of thyroid disease and 
electrolyte imbalance were not included in the study. RESULTS: Eighty-two 
(80.5% was male and the mean age was 53 ± 15 years) patients followed- up 
due to mad honey intoxication were included in our study. There were 64 
(78%) patients aged below 65 years, and 18 (22%) patients aged 65 and above. 
The mean heart rate was 45 ± 7 beats/min, systolic blood pressure was 83 ± 
12 mmHg and diastolic blood pressure was 52 ± 9 mmHg on admission. The onset 
of symptoms of the patients was found as 0.84 hours on average after mad 
honey consumption, the average amount of honey consumed was 3.7 ± 1.1 
tablespoons, and the mean recovery time of the symptoms was found to be 1.04 
hours. The most common presenting symptoms were nausea-vomiting in 82 (100%) 
patients and dizziness in 73 (89%) patients. Patients were found to consume 
mad honey most ly for achieving a remission in gastrointestinal complaints 
(n=18, 22%), and for utilizing its blood pressure lowering properties (n=11, 
13.4%), in addition to the dietary consumption. Looking at the heart rates 
of the patients on admission to the emergency service, 65 (79.3%) patients 
had normal sinus rhythm/sinus bradycardia, 12 (14.6%) patients had a 1st 
degree atrioventricular block, 3 (3.7%) patients had nodal rhythm, 1 (1.2%) 
patient had atrial fibrillation and 1 (1.2%) patient had preexcitation. 
There were no significant pathological findings in the routine laboratory 
examinations of patients. It was found that all patients achieved normal 
sinus rhythm and normal blood pressure values after medical treatment, and 
were discharged approximately 5.65 hours after observation and follow-up. In 
our study, prolonged intensive-care need, pacemaker need and mortality 
caused by mad honey intoxication were not found. In the comparison of data 
of all patients above and below 65 years of age, there was a statistically 
significant finding that the geriatric patients consume mad honey mostly for 
hypotensive purposes and gastrointestinal complaints; in addition, the 
symptoms were starting early and the recovery period was longer in geriatric 
patients. CONCLUSIONS: The mad honey poisoning should be considered in 
previously healthy patients with unexplained symptoms of bradycardia, 
hypotension, and atrioventricular block. Therefore, diet history should 
carefully be obtained from the patients admitted with bradycardia and 
hypotension. And, in addition to the primary cardiac, neurological and 
metabolic disorders, mad honey intoxication should also be considered in the 
differential diagnosis. In geriatric patients admitted due to mad honey 
intoxication, the mad honey is usually consumed to reduce blood pressure and 
resolve gastrointestinal problems; and, their symptoms begin early, and last 
longer after mad honey consumption. In terms of other parameters, the 
geriatric age group has similar characteristics to non-geriatric age group.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  geriatric patient
  honey poisoning
  intoxication
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation
  atrioventricular block
  atrioventricular junction arrhythmia
  bradycardia
  chronic kidney failure
  coronary artery disease
  dietary intake
  dizziness
  electrocardiography
  electrolyte disturbance
  emergency care
  female
  follow up
  gastrointestinal symptom
  gender
  groups by age
  heart arrhythmia
  heart preexcitation
  heart rate
  hospital admission
  human
  hypotension
  ingestion
  intensive care
  laboratory test
  major clinical study
  male
  medical history
  mortality
  nausea
  observational study
  pacemaker
  sinus bradycardia
  sinus rhythm
  systolic blood pressure
  thyroid disease
  toxicological parameters
  valvular heart disease
  vomiting
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Toxicology (52)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160366916
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 147
TITLE
  Clinical predictors of fever in stroke patients: Relevance of nasogastric 
tube
AUTHOR NAMES
  Muscari A.
  Puddu G.M.
  Conte C.
  Falcone R.
  Kolce B.
  Lega M.V.
  Zoli M.
AUTHOR ADDRESSES
  (Muscari A., antonio.muscari@unibo.it; Puddu G.M.; Zoli M.) Stroke 
Unit-Medical Department of Continuity of Care and Disability 
S.Orsola-Malpighi Hospital Bologna Italy
(Muscari A., antonio.muscari@unibo.it; Conte C.; Falcone R.; Kolce B.; Lega 
M.V.; Zoli M.) Department of Medical and Surgical Sciences University of 
Bologna Bologna Italy
CORRESPONDENCE ADDRESS
  A. Muscari, Department of Medical and Surgical Sciences University of 
Bologna Bologna Italy
SOURCE
  Acta Neurologica Scandinavica (2015). Date of Publication: 2015
ISSN
  1600-0404 (electronic)
  0001-6314
BOOK PUBLISHER
  Blackwell Publishing Ltd, customerservices@oxonblackwellpublishing.com
ABSTRACT
  Objectives: Fever frequently occurs in stroke patients and worsens their 
prognosis. However, only few studies have assessed the determinants of fever 
in acute stroke, and no study has specifically addressed the possible 
prediction of the development of fever. Materials and methods: This 
investigation included 536 patients with acute stroke and a body temperature 
<=37°C during the first 24 h of stay. Ninety-two of them (17.2%) 
subsequently developed fever (defined as a temperature >=37.5°C starting 
after 24 h). Among the clinical variables available during the first 24 h 
from admission, those predictive of the subsequent appearance of fever were 
searched for. One hundred further patients had a temperature >37°C during 
the first 24 h. Results: In univariate analysis, many variables were 
predictive of the subsequent development of fever, but in multivariate 
analysis, only the following four predictors remained significant (odds 
ratio [95% confidence interval], P value): nasogastric tube (4.0 [2.2-7.4], 
<0.0001), atrial fibrillation (2.3 [1.4-3.8], 0.001), total anterior 
circulation syndrome (2.0 [1.2-3.5], 0.01), and urinary catheter (1.9 
[1.1-3.3], 0.01). Among the 52 (9.7%) patients with three or four 
predictors, 31 (59.6%) subsequently developed fever. In addition, the 
factors independently associated with a temperature >37°C during the first 
24 h were as follows: National Institutes of Health Stroke Scale (P < 
0.0001), hemorrhagic stroke (P = 0.0008), atrial fibrillation (P = 0.002), 
and total parenteral nutrition (P = 0.03). Conclusions: In patients with 
acute stroke, four clinical variables were found to be independently 
associated with the risk of developing fever and, of them, nasogastric tube 
was the strongest and most significant one.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident
  fever
  human
  nasogastric tube
  risk factor
  stroke patient
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  body temperature
  brain hemorrhage
  confidence interval
  multivariate analysis
  National Institutes of Health Stroke Scale
  patient
  prediction
  prognosis
  risk
  statistical significance
  temperature
  total parenteral nutrition
  univariate analysis
  urinary catheter
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015772565
FULL TEXT LINK
  http://dx.doi.org/10.1111/ane.12383
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 148
TITLE
  Knowledge regarding oral anticoagulation therapy among patients with stroke 
and those at high risk of thromboembolic events
AUTHOR NAMES
  Alphonsa A.
  Sharma K.K.
  Sharma G.
  Bhatia R.
AUTHOR ADDRESSES
  (Alphonsa A.; Sharma K.K.) College of Nursing, All India Institute of 
Medical Sciences, New Delhi, India.
(Sharma G.) Department of Cardiology, All India Institute of Medical 
Sciences, New Delhi, India.
(Bhatia R., rohitbhatia71@yahoo.com) Department of Neurology, All India 
Institute of Medical Sciences, New Delhi, India.
CORRESPONDENCE ADDRESS
  R. Bhatia, Department of Neurology, All India Institute of Medical Sciences, 
New Delhi, India.
SOURCE
  Journal of Stroke and Cerebrovascular Diseases (2015) 24:3 (668-672). Date 
of Publication: 1 Mar 2015
ISSN
  1532-8511 (electronic)
  1052-3057
BOOK PUBLISHER
  W.B. Saunders
ABSTRACT
  Background Apart from atrial fibrillation, indications for oral 
anticoagulation common in our clinical practice include rheumatic heart 
disease and mechanical heart valve replacement. Evaluation of current 
patient knowledge regarding oral anticoagulation therapy (OAT) is the first 
step in improving the quality of anticoagulation therapy and patient care. 
The aim of the present study was to assess the knowledge regarding OAT among 
patients with stroke and those at high risk of thromboembolic events in a 
tertiary care hospital in India. Methods A descriptive cross-sectional 
design was used; 240 patients on OAT because of various indications 
(mechanical heart valve replacement, rheumatic heart disease, atrial 
fibrillation, and stroke) attending the neurology and cardiology outpatient 
clinics and inpatient services were recruited. A structured self-developed 
questionnaire was used to assess the knowledge in these patients. Results 
Most patients (62.9%) were ignorant about the target prothrombin 
time/international normalized ratio (PT/INR) levels with only 30% having 
their recent INR within the target range; 50% of the patients had a poor 
knowledge score, and the knowledge gap was most prominent in the domains of 
dietary interactions followed by drug interactions, adverse effects, and 
PT/INR monitoring. Knowledge score also had a significant association with 
gender, education, monthly income, and place of residence (P <.05). 
Conclusion Patient's knowledge about OAT was suboptimal. The findings 
support the need for educational interventions to improve the knowledge 
regarding OAT and, thereby, achieve an appropriate and safe secondary 
prevention of stroke.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (adverse drug reaction, drug combination, drug 
interaction, drug therapy, oral drug administration)
EMTREE DRUG INDEX TERMS
  acenocoumarol (oral drug administration)
  acetylsalicylic acid (drug combination, drug interaction)
  dabigatran (oral drug administration)
  prothrombin (endogenous compound)
  warfarin (oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  cerebrovascular accident (drug therapy, complication, drug therapy, 
prevention)
  health literacy
  high risk patient
  knowledge
  patient attitude
  stroke patient
  thromboembolism (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  academic achievement
  adult
  aged
  article
  bleeding (side effect)
  cross-sectional study
  descriptive research
  drug drug interaction
  drug induced disease
  drug information
  drug interaction
  female
  food drug interaction
  graduate
  high school
  human
  income
  India
  international normalized ratio
  leafy vegetable
  major clinical study
  male
  married person
  patient monitoring
  primary school
  priority journal
  prothrombin time
  sex difference
  single (marital status)
  structured questionnaire
  urban rural difference
  widow
  widower
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acenocoumarol (152-72-7)
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  prothrombin (9001-26-7)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015659160
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.11.007
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 149
TITLE
  Copper and Zinc Deficiency in a Patient Receiving Long-Term Parenteral 
Nutrition during a Shortage of Parenteral Trace Element Products
AUTHOR NAMES
  Palm E.
  Dotson B.
AUTHOR ADDRESSES
  (Palm E.) Detroit Medical Center, Sinai-Grace Hospital, Detroit, United 
States.
(Dotson B., bdotson@dmc.org) Department of Pharmacy, Harper University 
Hospital, Detroit, United States.
(Dotson B., bdotson@dmc.org) Wayne State University, Detroit, United States.
CORRESPONDENCE ADDRESS
  B. Dotson, Harper University Hospital, 3990 John R., Detroit, United States.
SOURCE
  Journal of Parenteral and Enteral Nutrition (2015) 39:8 (986-989). Date of 
Publication: 1 Nov 2015
ISSN
  1941-2444 (electronic)
  0148-6071
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  Drug shortages in the United States, including parenteral nutrition (PN) 
components, have been common in recent years and can adversely affect 
patient care. Here we report a case of copper and zinc deficiency in a 
patient receiving PN during a shortage of parenteral trace element products. 
The management of the patient's deficiencies, including the use of an 
imported parenteral multi-trace element product, is described.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  copper (endogenous compound)
  trace element (endogenous compound)
  zinc (endogenous compound)
EMTREE DRUG INDEX TERMS
  antibiotic agent (drug therapy, intravenous drug administration)
  chromium (endogenous compound)
  cyanocobalamin (endogenous compound)
  diatrizoate
  ferritin (endogenous compound)
  folic acid (endogenous compound)
  hemoglobin (endogenous compound)
  heparin (drug therapy, subcutaneous drug administration)
  hydromorphone
  insulin lispro
  iron (endogenous compound)
  manganese (endogenous compound)
  multivitamin (oral drug administration)
  pantoprazole
  selenium
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  copper deficiency
  long term care
  parenteral nutrition
  zinc deficiency
EMTREE MEDICAL INDEX TERMS
  abdominal abscess (complication)
  abdominal infection (drug therapy)
  abdominal wall hernia (surgery)
  abnormal laboratory result
  absorption
  adult
  anemia
  article
  atrial fibrillation (complication)
  case report
  copper blood level
  day hospital
  enteric feeding
  enterocutaneous fistula (complication, surgery)
  excision
  female
  ferritin blood level
  folic acid blood level
  hematocrit
  hernioplasty
  hospital admission
  hospitalization
  human
  hypertension
  iron binding capacity
  iron blood level
  macronutrient
  mean corpuscular volume
  medical history
  middle aged
  neurologic examination
  obesity
  peritoneal cavity
  prescription
  priority journal
  stomach bypass
  vacuum assisted closure
  venous thromboembolism (drug therapy, prevention)
  vitamin blood level
  wound healing impairment
  zinc blood level
CAS REGISTRY NUMBERS
  chromium (16065-83-1, 7440-47-3, 14092-98-9)
  copper (15158-11-9, 7440-50-8)
  cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
  diatrizoate (117-96-4, 737-31-5)
  ferritin (9007-73-2)
  folic acid (59-30-3, 6484-89-5)
  hemoglobin (9008-02-0)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  hydromorphone (466-99-9, 71-68-1)
  insulin lispro (133107-64-9)
  iron (14093-02-8, 53858-86-9, 7439-89-6)
  manganese (16397-91-4, 7439-96-5)
  pantoprazole (102625-70-7)
  selenium (7782-49-2)
  zinc (7440-66-6, 14378-32-6)
EMBASE CLASSIFICATIONS
  Hematology (25)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015466573
FULL TEXT LINK
  http://dx.doi.org/10.1177/0148607114549255
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 150
TITLE
  The safety and efficacy of osteoporosis therapy
AUTHOR NAMES
  Mkele G.
AUTHOR ADDRESSES
  (Mkele G., gailmkele@hotmail.com)
CORRESPONDENCE ADDRESS
  G. Mkele, Email: gailmkele@hotmail.com
SOURCE
  SA Pharmaceutical Journal (2015) 82:9 (29-32). Date of Publication: 2015
ISSN
  1015-1362
BOOK PUBLISHER
  Medpharm Publications, PO Box 14804, Lyttelton, Gauteng, South Africa.
ABSTRACT
  Pharmacological agents used to manage osteoporosis act by decreasing the 
rate of bone resorption thus slowing down the rate of bone loss, by 
promoting bone formation, and with the newer generation of medicines, by 
combining both mechanisms. The aim of treating osteoporosis is to preserve 
bone mass, restore bone strength and prevent fractures. Although the 
treatment of osteoporosis is important, its detection and prevention are 
just as important.. Prevention involves maximising peak adult bone mass and 
reducing the rate of bone loss. This may be achieved by regular exercise, 
adequate dietary calcium and vitamin D intake, and the identification and 
management of risk factors.
EMTREE DRUG INDEX TERMS
  alendronic acid (drug therapy)
  bisphosphonic acid derivative (adverse drug reaction, drug therapy)
  calcitonin (adverse drug reaction, drug therapy)
  calcium (adverse drug reaction, drug therapy)
  calcium carbonate (drug therapy)
  calcium chloride (drug therapy)
  calcium lactate (drug therapy)
  calcium phosphate (drug therapy)
  citrate calcium (drug therapy)
  denosumab (adverse drug reaction, drug therapy)
  dolomite (drug therapy)
  gluconate calcium (drug therapy)
  ibandronic acid (drug therapy)
  parathyroid hormone[1-34] (adverse drug reaction, drug therapy)
  raloxifene (adverse drug reaction, drug therapy)
  risedronic acid (drug therapy)
  strontium ranelate (adverse drug reaction, drug therapy)
  unclassified drug
  vitamin D (adverse drug reaction, drug therapy)
  zoledronic acid (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  osteoporosis (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  allergic reaction (side effect)
  atrial fibrillation (side effect)
  backache (side effect)
  bone density
  bone mass
  bone strength
  calcium absorption
  calcium intake
  cystitis (side effect)
  diarrhea (side effect)
  dietary intake
  dizziness (side effect)
  eosinophilia (side effect)
  esophagitis (side effect)
  exercise
  flu like syndrome (side effect)
  fracture (prevention)
  fragility fracture (side effect)
  gastrointestinal irritation (side effect)
  gastrointestinal symptom (side effect)
  headache (side effect)
  hormonal therapy
  hot flush (side effect)
  human
  hypercalcemia (side effect)
  hypercholesterolemia (side effect)
  injection site pain (side effect)
  jaw osteonecrosis (side effect)
  leg cramp (side effect)
  limb pain (side effect)
  menopause
  monotherapy
  musculoskeletal pain (side effect)
  nausea (side effect)
  nose obstruction (side effect)
  osteolysis
  postmenopause
  review
  rhinitis (side effect)
  risk factor
  risk reduction
  skin disease (side effect)
  smoking cessation
  sun exposure
  systemic disease (side effect)
  vegetable
  venous thromboembolism (side effect)
  vitamin intake
  vitamin supplementation
  weight bearing
CAS REGISTRY NUMBERS
  alendronic acid (66376-36-1)
  calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
  calcium (7440-70-2, 14092-94-5)
  calcium carbonate (13397-26-7, 13701-58-1, 14791-73-2, 471-34-1)
  calcium chloride (10043-52-4)
  calcium lactate (814-80-2)
  calcium phosphate (10103-46-5, 13767-12-9, 14358-97-5, 7758-87-4)
  citrate calcium (7693-13-2)
  denosumab (615258-40-7)
  gluconate calcium (299-28-5)
  ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
  parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
  raloxifene (82640-04-8, 84449-90-1)
  risedronic acid (105462-24-6, 122458-82-6)
  strontium ranelate (135459-87-9)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Orthopedic Surgery (33)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015521490
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 151
TITLE
  Thromboembolic prevention in frail elderly patients with atrial 
fibrillation: A practical algorithm
AUTHOR NAMES
  Granziera S.
  Cohen A.T.
  Nante G.
  Manzato E.
  Sergi G.
AUTHOR ADDRESSES
  (Granziera S., serena.granziera@gmail.com; Nante G.; Manzato E.; Sergi G., 
giuseppe.sergi@unipd.it) University of Padova, Department of Medicine- 
DIMED, Padova, Italy.
(Granziera S., serena.granziera@gmail.com) King's College Hospital, London, 
United Kingdom.
(Cohen A.T.) Department of Thrombosis and Hemostasis, Guy's and St Thomas' 
Hospitals, London, United Kingdom.
CORRESPONDENCE ADDRESS
  S. Granziera, Clinica Geriatrica - Ospedale Giustinianeo (2o piano), Via 
Giustiniani 2, Padua, Italy.
SOURCE
  Journal of the American Medical Directors Association (2015) 16:5 (358-364). 
Date of Publication: 1 May 2015
ISSN
  1538-9375 (electronic)
  1525-8610
BOOK PUBLISHER
  Elsevier Inc., usjcs@elsevier.com
ABSTRACT
  Atrial fibrillation is a common condition in the elderly, and the incidence 
of thromboembolic events secondary to atrial fibrillation increases with 
age. Antithrombotic therapy effectively prevents stroke and systemic 
embolism but also exposes patients to the risk of bleeding. Because the risk 
of bleeding also increases with age, clinicians tend to withhold 
anticoagulation in the elderly. Anticoagulation is particularly complex in 
the frail elderly patient, who presents additional risk factors affecting 
both efficacy and safety of thromboembolic prevention. The main clinical 
trials rarely include frail elderly patients and, consequently, the 
guidelines do not provide guidance for their management. In the absence of 
clear indications for this class of patients, we identified some areas that 
should be taken into account both before starting and when discontinuing 
anticoagulation: comorbidities, polypharmacotherapy, adherence, cognitive 
impairment, mobility and monitoring barriers, nutritional status and 
swallowing disorders, risk of falls, and reduced life expectancy. We also 
suggest a multidimensional algorithm covering both a standard ischemic and 
bleeding risk assessment and an additional anticoagulation-focused frailty 
assessment. This is of particular relevance given the recent introduction of 
the oral direct inhibitors, as they are likely to widen the treatment 
options for the frail elderly. Depending on which aspect of frailty is 
present, anticoagulation can now be tailored accordingly.
EMTREE DRUG INDEX TERMS
  anticoagulant agent (adverse drug reaction, drug therapy, oral drug 
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  frail elderly
  thromboembolism (drug therapy, complication, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
  algorithm
  anticoagulation
  bleeding (side effect)
  cerebrovascular accident (complication, drug therapy)
  clinical trial (topic)
  cognitive defect
  comorbidity
  dysphagia
  fall risk assessment
  geriatric assessment
  human
  incidence
  life expectancy
  medication compliance
  mobilization
  nutritional status
  patient monitoring
  patient safety
  review
  risk assessment
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015783816
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jamda.2014.12.008
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 152
TITLE
  AHA and ASA release guideline for prevention of future stroke in patients 
with stroke or TIA
AUTHOR NAMES
  Randel A.
AUTHOR ADDRESSES
  (Randel A.)
SOURCE
  American Family Physician (2015) 91:2 (136-137). Date of Publication: 2015
ISSN
  1532-0650 (electronic)
  0002-838X
BOOK PUBLISHER
  American Academy of Family Physicians, foundation@aafp.org
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  antivitamin K
  clopidogrel (drug therapy)
  glucose (endogenous compound)
  hemoglobin A1c (endogenous compound)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (prevention)
  practice guideline
  transient ischemic attack (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  cardiovascular risk
  coronary artery disease (drug therapy)
  diastolic blood pressure
  dyslipidemia
  high sodium intake
  human
  hypertension
  medical society
  Mediterranean diet
  nutritional assessment
  obesity
  oral glucose tolerance test
  patient counseling
  physical activity
  positive end expiratory pressure
  sleep disordered breathing
  systolic blood pressure
  thrombocyte aggregation inhibition
DRUG TRADE NAMES
  plavix
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  glucose (50-99-7, 84778-64-3)
  hemoglobin A1c (62572-11-6)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2015698084
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 153
TITLE
  Red blood cell distribution width: A simple parameter with multiple clinical 
applications
AUTHOR NAMES
  Salvagno G.L.
  Sanchis-Gomar F.
  Picanza A.
  Lippi G.
AUTHOR ADDRESSES
  (Salvagno G.L.) Clinical Chemistry Section, Department of Life and 
Reproductive Sciences, Academic Hospital of Verona, Verona, Italy.
(Sanchis-Gomar F.) Department of Physiology, Faculty of Medicine, University 
of Valencia, Valencia, Spain.
(Picanza A.; Lippi G., glippi@ao.pr.it) Laboratory of Clinical Chemistry and 
Hematology, Academic Hospital of Parma, Parma, Italy.
CORRESPONDENCE ADDRESS
  G. Lippi, U.O. Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria 
di Parma, Via Gramsci, 14, Parma, Italy.
SOURCE
  Critical Reviews in Clinical Laboratory Sciences (2015) 52:2 (86-105). Date 
of Publication: 1 Apr 2015
ISSN
  1549-781X (electronic)
  1040-8363
BOOK PUBLISHER
  Informa Healthcare, healthcare.enquiries@informa.com
ABSTRACT
  The red blood cell distribution width (RDW) is a simple and inexpensive 
parameter, which reflects the degree of heterogeneity of erythrocyte volume 
(conventionally known as anisocytosis), and is traditionally used in 
laboratory hematology for differential diagnosis of anemias. Nonetheless, 
recent evidence attests that anisocytosis is commonplace in human disorders 
such as cardiovascular disease, venous thromboembolism, cancer, diabetes, 
community-acquired pneumonia, chronic obstructive pulmonary disease, liver 
and kidney failure, as well as in other acute or chronic conditions. Despite 
some demographic and analytical issues related to the routine assessment 
that may impair its clinical usefulness, an increased RDW has a high 
negative predictive value for diagnosing a variety of disorders, but also 
conveys important information for short- and long-term prognosis. Even more 
importantly, the value of RDW is now being regarded as a strong and 
independent risk factor for death in the general population. Although it has 
not been definitely established whether an increased value of RDW is a risk 
factor or should only be considered an epiphenomenon of an underlying 
biological and metabolic imbalance, it seems reasonable to suggest that the 
assessment of this parameter should be broadened far beyond the differential 
diagnosis of anemias. An increased RDW mirrors a profound deregulation of 
erythrocyte homeostasis involving both impaired erythropoiesis and abnormal 
red blood cell survival, which may be attributed to a variety of underlying 
metabolic abnormalities such as shortening of telomere length, oxidative 
stress, inflammation, poor nutritional status, dyslipidemia, hypertension, 
erythrocyte fragmentation and alteration of erythropoietin function. As 
such, the aim of this article is to provide general information about RDW 
and its routine assessment, to review the most relevant implications in 
health and disease and give some insights about its potential clinical 
applications.
EMTREE DRUG INDEX TERMS
  tobacco smoke
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  erythrocyte
  erythrocyte distribution width
EMTREE MEDICAL INDEX TERMS
  acute hepatitis B
  acute kidney failure
  air pollution
  alcohol consumption
  anemia
  anisocytosis
  antiviral therapy
  aplastic anemia
  atrial fibrillation
  autoimmune hemolytic anemia
  beta thalassemia
  blood transfusion
  cardiovascular disease
  cardiovascular risk
  cerebrovascular accident
  chemotherapy
  chronic hepatitis B
  chronic kidney disease
  chronic liver disease
  chronic obstructive lung disease
  community acquired pneumonia
  coronary artery disease
  coronary artery ectasia
  critically ill patient
  cyanocobalamin deficiency
  diabetes mellitus
  diabetic ketoacidosis
  diabetic nephropathy
  diabetic neuropathy
  differential diagnosis
  disease classification
  dust exposure
  dyslipidemia
  erythrocyte disorder
  erythrocyte function and characteristics
  erythrocyte lifespan
  erythrocyte volume
  erythropoiesis
  folic acid deficiency
  heart failure
  heart infarction
  heart ventricle function
  hematological parameters
  hematology analyzer
  hemolytic anemia
  hepatobiliary disease
  hereditary spherocytosis
  homeostasis
  human
  hypertension
  inflammation
  iron deficiency
  kidney disease
  kidney failure
  laboratory test
  liver cell carcinoma
  liver cirrhosis
  liver disease
  liver failure
  mean corpuscular volume
  metabolic syndrome X
  mortality
  neoplasm
  non ST segment elevation myocardial infarction
  nonalcoholic fatty liver
  nutritional status
  occupational exposure
  out of hospital cardiac arrest
  oxidative stress
  pathogenesis
  peripheral occlusive artery disease
  population
  predictive value
  primary biliary cirrhosis
  priority journal
  pulmonary hypertension
  review
  risk factor
  sickle cell anemia
  ST segment elevation myocardial infarction
  telomere
  thalassemia
  thrombotic thrombocytopenic purpura
  venous thromboembolism
DEVICE MANUFACTURERS
   (China)Mindray
   (Japan)Sysmex
   (United States)Abbott Diagnostics
   (United States)Beckman Coulter
   (United States)Siemens Healthcare Diagnostics
EMBASE CLASSIFICATIONS
  Hematology (25)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015121498
FULL TEXT LINK
  http://dx.doi.org/10.3109/10408363.2014.992064
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 154
TITLE
  Utility of a Dedicated Pediatric Cardiac Anticoagulation Program: The Boston 
Children’s Hospital Experience
AUTHOR NAMES
  Murray J.M.
  Hellinger A.
  Dionne R.
  Brown L.
  Galvin R.
  Griggs S.
  Mittler K.
  Harney K.
  Manzi S.
  VanderPluym C.
  Baker A.
  O’Brien P.
  O’Connell C.
  Almond C.S.
AUTHOR ADDRESSES
  (Murray J.M.; Brown L.; Galvin R.; Mittler K.; VanderPluym C.; Baker A.; 
O’Brien P.; O’Connell C.; Almond C.S., calmond@stanford.edu) Department of 
Cardiology, Boston Children’s Hospital, Boston, United States.
(Hellinger A.; Dionne R.; Manzi S.) Departments of Pharmacy and Medicine, 
Boston Children’s Hospital, Boston, United States.
(Griggs S.) Divisions of Gastroenterology and Nutrition, Boston Children’s 
Hospital, Boston, United States.
(Harney K.) Division of Hematology, Boston Children’s Hospital, Boston, 
United States.
(Murray J.M.; Hellinger A.; Dionne R.; Brown L.; Galvin R.; Griggs S.; 
Mittler K.; Harney K.; Manzi S.; VanderPluym C.; Baker A.; O’Brien P.; 
O’Connell C.; Almond C.S., calmond@stanford.edu) Department of Pediatrics, 
Harvard Medical School, 300 Longwood Avenue, Boston, United States.
(Murray J.M.; Almond C.S., calmond@stanford.edu) Division of Pediatric 
Cardiology, Stanford University, The Lucile Packard Children’s Hospital, 750 
Welch Road Suite 325, Palo Alto, United States.
CORRESPONDENCE ADDRESS
  C.S. Almond, Division of Pediatric Cardiology, Stanford University, The 
Lucile Packard Children’s Hospital, 750 Welch Road Suite 325, Palo Alto, 
United States.
SOURCE
  Pediatric Cardiology (2015) 36:4 (842-850). Date of Publication: 2015
ISSN
  1432-1971 (electronic)
  0172-0643
BOOK PUBLISHER
  Springer New York LLC, journals@springer-sbm.com
ABSTRACT
  Congenital heart disease is the leading cause of stroke in children. 
Warfarin therapy can be difficult to manage safely in this population 
because of its narrow therapeutic index, multiple drug and dietary 
interactions, small patient size, high-risk cardiac indications, and lack of 
data to support anticoagulation recommendations. We sought to describe our 
institution’s effort to develop a dedicated cardiac anticoagulation service 
to address the special needs of this population and to review the 
literature. In 2009, in response to Joint Commission National Patient Safety 
Goals for Anticoagulation, Boston Children’s Hospital created a dedicated 
pediatric Cardiac Anticoagulation Monitoring Program (CAMP). The primary 
purpose was to provide centralized management of outpatient anticoagulation 
to cardiac patients, to serve as a disease-specific resource to families and 
providers, and to devise strategies to evolve clinical care with rapidly 
emerging trends in anticoagulation care. Over 5 years the CAMP Service, 
staffed by a primary pediatric cardiology attending, a full-time nurse 
practitioner, and administrative assistant with dedicated support from 
pharmacy and nutrition, has enrolled over 240 patients ranging in age from 
5 months to 55 years. The most common indications include a prosthetic valve 
(34 %), Fontan prophylaxis (20 %), atrial arrhythmias (11 %), cardiomyopathy 
(10 %), Kawasaki disease (7 %), and a ventricular assist device (2 %). A 
patient-centered multi-disciplinary cardiac anticoagulation clinic was 
created in 2012. Overall program international normalized ratio (INR) time 
in therapeutic range (TTR) is favorable at 67 % (81 % with a 0.2 margin) and 
has improved steadily over 5 years. Pediatric-specific guidelines for VKOR1 
and CYP2C9 pharmacogenomics testing, procedural bridging with enoxaparin, 
novel anticoagulant use, and quality metrics have been developed. Program 
satisfaction is rated highly among families and providers. A dedicated 
pediatric cardiac anticoagulation program offers a safe and effective 
strategy to standardize anticoagulation care for pediatric cardiology 
patients, is associated with high patient and provider satisfaction, and is 
capable of evolving care strategies with emerging trends in anticoagulation.
EMTREE DRUG INDEX TERMS
  cytochrome P450 2C9 (endogenous compound)
  enoxaparin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulation
  child health care
  dedicated pediatric vardiac anticoagulation program
  health care utilization
  health program
  pediatric cardiology
EMTREE MEDICAL INDEX TERMS
  article
  cardiac patient
  cardiomyopathy
  child
  clinical medicine
  heart atrium arrhythmia
  heart valve prosthesis
  human
  international normalized ratio
  mucocutaneous lymph node syndrome
  nurse practitioner
  nutrition
  outpatient care
  patient satisfaction
  pediatric hospital
  pharmacogenomics
  practice guideline
  program development
  standardization
  United States
  ventricular assist device
CAS REGISTRY NUMBERS
  enoxaparin (679809-58-6)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Pediatrics and Pediatric Surgery (7)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015664991
FULL TEXT LINK
  http://dx.doi.org/10.1007/s00246-014-1089-x
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 155
TITLE
  Primary prevention of stroke by a healthy lifestyle in a high-risk group
AUTHOR NAMES
  Larsson S.C.
  Akesson A.
  Wolk A.
AUTHOR ADDRESSES
  (Larsson S.C., susanna.larsson@ki.se; Akesson A.; Wolk A.) Unit of 
Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska 
Institutet, Stockholm, Sweden.
CORRESPONDENCE ADDRESS
  S.C. Larsson, Unit of Nutritional Epidemiology, Institute of Environmental 
Medicine, Karolinska Institutet, Stockholm, Sweden.
SOURCE
  Neurology (2015) 84:22 (2224-2228). Date of Publication: 2 Jun 2015
ISSN
  1526-632X (electronic)
  0028-3878
BOOK PUBLISHER
  Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
  Objective: To examine the impact of a healthy lifestyle on stroke risk in 
men at higher risk of stroke because of other cardiovascular diseases or 
conditions. Methods: Our study population comprised 11,450 men in the Cohort 
of Swedish Men who had a history of hypertension, high cholesterol levels, 
diabetes, heart failure, or atrial fibrillation. Participants had completed 
a questionnaire about diet and lifestyle and were free from stroke and 
ischemic heart disease at baseline (January 1, 1998). We defined a healthy 
lifestyle as a lowrisk diet (≥5 servings/d of fruits and vegetables and <30 
g/d of processed meat), not smoking, ≥150 min/wk of physical activity, body 
mass index of 18.5 to 25 kg/m<sup>2</sup>, and low to moderate alcohol 
consumption (>0 to ≤30 g/d). Ascertainment of stroke cases was accomplished 
through linkage with the National Inpatient Register and the Swedish Cause 
of Death Register. Results: During a mean follow-up of 9.8 years, we 
ascertained 1,062 incident stroke cases. The risk of total stroke and stroke 
types decreased with increasing number of healthy lifestyle factors. The 
multivariable relative risk of total stroke for men who achieved all 5 
healthy lifestyle factors compared with men who achieved 0 or 1 factor was 
0.28 (95% confidence interval 0.14-0.55). The corresponding relative risks 
(95% confidence interval) were 0.31 (0.15-0.66) for ischemic stroke and 0.32 
(0.04-2.51) for hemorrhagic stroke. Conclusions: A healthy lifestyle is 
associated with a substantially reduced risk of stroke in men at higher risk 
of stroke.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (prevention, therapy)
  lifestyle modification
EMTREE MEDICAL INDEX TERMS
  adult
  alcohol consumption
  article
  body mass
  brain hemorrhage (prevention, therapy)
  brain ischemia (prevention, therapy)
  dietary intake
  fruit
  high risk population
  human
  major clinical study
  male
  middle aged
  physical activity
  priority journal
  processed meat
  risk assessment
  risk reduction
  smoking
  Sweden
  vegetable
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015089840
FULL TEXT LINK
  http://dx.doi.org/10.1212/WNL.0000000000001637
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 156
TITLE
  How to manage warfarin therapy
AUTHOR NAMES
  Tideman P.A.
  Tirimacco R.
  St. John A.
  Roberts G.W.
AUTHOR ADDRESSES
  (Tideman P.A.; Tirimacco R.; St. John A.) Australian Point of Care 
Practitioners Network, Adelaide, Australia.
(Tideman P.A.; Tirimacco R.) Integrated Cardiovascular Clinical Network 
Country Health South Australia, Adelaide, Australia.
(Roberts G.W.) Pharmacy Department Flinders Medical Centre, Adelaide, 
Australia.
SOURCE
  Australian Prescriber (2015) 38:2 (44-48). Date of Publication: 2015
ISSN
  0312-8008
BOOK PUBLISHER
  Australian Government Publishing Service, info@australianprescriber.com
ABSTRACT
  Long-term treatment with warfarin is recommended for patients with atrial 
fibrillation at risk of stroke and those with recurrent venous thrombosis or 
prosthetic heart valves. Patient education before commencing warfarin - 
regarding signs and symptoms of bleeding, the impact of diet, potential drug 
interactions and the actions to take if a dose is missed - is pivotal to 
successful use. Scoring systems such as the CHADS<inf>2</inf> score are used 
to determine if patients with atrial fibrillation are suitable for warfarin 
treatment. To rapidly achieve stable anticoagulation, use an age-adjusted 
protocol for starting warfarin. Regular monitoring of the anticoagulant 
effect is required. Evidence suggests that patients who self-monitor using 
point-of-care testing have better outcomes than other patients.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
  phytomenadione
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  medication therapy management
EMTREE MEDICAL INDEX TERMS
  age
  article
  atrial fibrillation (drug therapy)
  bleeding (side effect)
  cerebrovascular accident (drug therapy)
  CHADS2 score
  clinical protocol
  deep vein thrombosis (drug therapy)
  diet
  drug efficacy
  drug monitoring
  drug safety
  HAS BLED score
  human
  international normalized ratio
  laboratory diagnosis
  maintenance therapy
  meta analysis (topic)
  patient education
  pharmacodynamics
  point of care testing
  prophylaxis
  randomized controlled trial (topic)
  risk factor
  scoring system
  self monitoring
  systematic review (topic)
  treatment duration
  treatment indication
  treatment outcome
  treatment response
  valvular heart disease (drug therapy)
CAS REGISTRY NUMBERS
  phytomenadione (11104-38-4, 84-80-0)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015893317
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 157
TITLE
  Phytochemical Compounds and Protection from Cardiovascular Diseases: A State 
of the Art
AUTHOR NAMES
  Pagliaro B.
  Santolamazza C.
  Simonelli F.
  Rubattu S.
AUTHOR ADDRESSES
  (Pagliaro B., beniamino.pagliaro@libero.it; Santolamazza C., 
caterina.santolamazza@gmail.com; Simonelli F., 
francescasimonelli@hotmail.it; Rubattu S., rubattu.speranza@neuromed.it) 
Department of Clinical and Molecular Medicine, School of Medicine and 
Psychology, Saint Andrea Hospital, Sapienza University of Rome, Rome, Italy.
(Rubattu S., rubattu.speranza@neuromed.it) IRCCS Neuromed, Pozzilli, Italy.
CORRESPONDENCE ADDRESS
  S. Rubattu, Department of Clinical and Molecular Medicine, School of 
Medicine and Psychology, Saint Andrea Hospital, Sapienza University of Rome, 
Rome, Italy.
SOURCE
  BioMed Research International (2015) 2015 Article Number: 918069. Date of 
Publication: 2015
ISSN
  2314-6141 (electronic)
  2314-6133
BOOK PUBLISHER
  Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New 
York, United States.
ABSTRACT
  Cardiovascular diseases represent a worldwide relevant socioeconomical 
problem. Cardiovascular disease prevention relies also on lifestyle changes, 
including dietary habits. The cardioprotective effects of several foods and 
dietary supplements in both animal models and in humans have been explored. 
It was found that beneficial effects are mainly dependent on antioxidant and 
anti-inflammatory properties, also involving modulation of mitochondrial 
function. Resveratrol is one of the most studied phytochemical compounds and 
it is provided with several benefits in cardiovascular diseases as well as 
in other pathological conditions (such as cancer). Other relevant compounds 
are Brassica oleracea, curcumin, and berberine, and they all exert 
beneficial effects in several diseases. In the attempt to provide a 
comprehensive reference tool for both researchers and clinicians, we 
summarized in the present paper the existing literature on both preclinical 
and clinical cardioprotective effects of each mentioned phytochemical. We 
structured the discussion of each compound by analyzing, first, its cellular 
molecular targets of action, subsequently focusing on results from 
applications in both ex vivo and in vivo models, finally discussing the 
relevance of the compound in the context of human diseases.
EMTREE DRUG INDEX TERMS
  berberine (drug therapy, pharmacology)
  curcumin (drug therapy, pharmacology)
  hydroxymethylglutaryl coenzyme A reductase kinase (endogenous compound)
  immunoglobulin enhancer binding protein (endogenous compound)
  mitogen activated protein kinase (endogenous compound)
  peroxisome proliferator activated receptor alpha (endogenous compound)
  protein kinase B (endogenous compound)
  resveratrol (drug analysis, drug therapy, pharmacology)
  sirtuin 1 (endogenous compound)
  stress activated protein kinase (endogenous compound)
  transcription factor Nrf2 (endogenous compound)
  uncoupling protein 2 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (drug therapy, drug therapy, prevention)
  heart protection
  phytochemistry
EMTREE MEDICAL INDEX TERMS
  antiapoptotic activity
  antiarrhythmic activity
  antihypertensive activity
  antiinflammatory activity
  antioxidant activity
  atherosclerosis (drug therapy, prevention)
  atrial fibrillation (drug therapy, prevention)
  berry
  brain ischemia (drug therapy, prevention)
  Brassica oleracea
  cardiotoxicity (drug therapy, prevention)
  drug activity
  drug structure
  dyslipidemia (drug therapy, prevention)
  grape
  heart failure (drug therapy, prevention)
  heart ventricle fibrillation (drug therapy, prevention)
  heart ventricle hypertrophy (drug therapy, prevention)
  heart ventricle tachycardia (drug therapy, prevention)
  human
  hypertension (drug therapy, prevention)
  ischemic heart disease (drug therapy, prevention)
  lipogenesis
  non insulin dependent diabetes mellitus (drug therapy, prevention)
  nonhuman
  obesity (drug therapy, prevention)
  peanut
  Polygonum cuspidatum
  red wine
  review
CAS REGISTRY NUMBERS
  berberine (2086-83-1, 633-65-8)
  curcumin (458-37-7)
  hydroxymethylglutaryl coenzyme A reductase kinase (172522-01-9, 72060-32-3)
  mitogen activated protein kinase (142243-02-5)
  peroxisome proliferator activated receptor alpha (147258-70-6)
  protein kinase B (148640-14-6)
  resveratrol (501-36-0)
  stress activated protein kinase (155215-87-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015478488
FULL TEXT LINK
  http://dx.doi.org/10.1155/2015/918069
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 158
TITLE
  Hepatobiliary and Pancreatic: Pseudoachalasia from pancreatic cancer
AUTHOR NAMES
  García-Alonso F.
  Hernández Tejero M.
  Castanon-Deprit A.
AUTHOR ADDRESSES
  (García-Alonso F.; Hernández Tejero M.) Department of Gastroenterology, 
Fuenlabrada University Hospital, Fuenlabrada, Spain.
(Castanon-Deprit A.) Department of Pathology, Fuenlabrada University 
Hospital, Fuenlabrada, Spain.
SOURCE
  Journal of Gastroenterology and Hepatology (Australia) (2015) 30:9 (1336). 
Date of Publication: 1 Sep 2015
ISSN
  1440-1746 (electronic)
  0815-9319
BOOK PUBLISHER
  Blackwell Publishing, info@asia.blackpublishing.com.au
EMTREE DRUG INDEX TERMS
  acenocoumarol
  bisoprolol (drug therapy)
  fluticasone propionate plus salmeterol (drug therapy)
  insulin (drug therapy)
  tiotropium bromide (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  esophagus achalasia
  pancreas adenocarcinoma (diagnosis)
  pseudoachalasia
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation (drug therapy)
  cancer diagnosis
  case report
  chronic obstructive lung disease (drug therapy)
  computer assisted tomography
  diabetes mellitus (drug therapy)
  diet
  disease duration
  dysphagia
  esophagus biopsy
  esophagus dilatation
  follow up
  gastroesophageal reflux
  gastrointestinal endoscopy
  human
  human tissue
  hypertension
  liquid
  male
  medical history
  priority journal
  rare disease
  stomach biopsy
  thorax pain
  very elderly
  weight reduction
CAS REGISTRY NUMBERS
  acenocoumarol (152-72-7)
  bisoprolol (66722-44-9)
  insulin (9004-10-8)
  tiotropium bromide (136310-93-5)
EMBASE CLASSIFICATIONS
  Otorhinolaryngology (11)
  Radiology (14)
  Cancer (16)
  Drug Literature Index (37)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2015228930
FULL TEXT LINK
  http://dx.doi.org/10.1111/jgh.12961
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 159
TITLE
  Cardiorespiratory fitness and risk of incident atrial fibrillation: Results 
from the Henry Ford exercise testing (FIT) project
AUTHOR NAMES
  Qureshi W.T.
  Alirhayim Z.
  Blaha M.J.
  Juraschek S.P.
  Keteyian S.J.
  Brawner C.A.
  Al-Mallah M.H.
AUTHOR ADDRESSES
  (Qureshi W.T.; Alirhayim Z.; Keteyian S.J.; Brawner C.A.; Al-Mallah M.H., 
mouaz74@gmail.com) Henry Ford Hospital/Wayne State University, Detroit, 
United States.
(Qureshi W.T.) Wake Forest University School of Medicine, Winston Salem, 
United States.
(Alirhayim Z.) University of Kansas Medical Center, Kansas City, United 
States.
(Blaha M.J.; Juraschek S.P.) Johns Hopkins Ciccarone Center for the 
Prevention of Heart Disease, Baltimore, United States.
(Al-Mallah M.H., mouaz74@gmail.com) Wayne State University, Detroit, United 
States.
(Al-Mallah M.H., mouaz74@gmail.com) King Abdul-Aziz Cardiac Center, National 
Guard Health Affairs, Riyadh, Saudi Arabia.
CORRESPONDENCE ADDRESS
  M.H. Al-Mallah, Consultant Cardiologist and Division Head, King Abdul-Aziz 
Cardiac Center, Department Mail Code, 1413, PO Box 22490, Riyadh, Saudi 
Arabia.
SOURCE
  Circulation (2015) 131:21 (1827-1834). Date of Publication: 26 May 2015
ISSN
  1524-4539 (electronic)
  0009-7322
BOOK PUBLISHER
  Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
  Background: Poor cardiorespiratory fitness (CRF) is an independent risk 
factor for cardiovascular morbidity and mortality. However, the relationship 
between CRF and atrial fibrillation (AF) is less clear. The aim of this 
analysis was to investigate the association between CRF and incident AF in a 
large, multiracial cohort that underwent graded exercise treadmill testing. 
Methods and Results: From 1991 to 2009, a total of 64 561 adults (mean age, 
54.5±12.7 years; 46% female; 64% white) without AF underwent exercise 
treadmill testing at a tertiary care center. Baseline demographic and 
clinical variables were collected. Incident AF was ascertained by use of 
International Classification of Diseases, Ninth Revision code 427.31 and 
confirmed by linkage to medical claim files. Nested, multivariable Cox 
proportional hazards models were used to estimate the independent 
association of CRF with incident AF. During a median follow-up of 5.4 years 
(interquartile range, 3-9 years), 4616 new cases of AF were diagnosed. After 
adjustment for potential confounders, 1 higher metabolic equivalent achieved 
during treadmill testing was associated with a 7% lower risk of incident AF 
(hazard ratio, 0.93; 95% confidence interval, 0.92-0.94; P<0.001). This 
relationship remained significant after adjustment for incident coronary 
artery disease (hazard ratio, 0.92; 95% confidence interval, 0.91-0.93; 
P<0.001). The magnitude of the inverse association between CRF and incident 
AF was greater among obese compared with nonobese individuals (P for 
interaction=0.02). Conclusions: There is a graded, inverse relationship 
between cardiorespiratory fitness and incident AF, especially among obese 
patients. Future studies should examine whether changes in fitness increase 
or decrease risk of atrial fibrillation. This association was stronger for 
obese compared with nonobese, especially among obese patients.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  cardiorespiratory fitness
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  cardiovascular risk
  cohort analysis
  coronary artery disease
  demography
  disease association
  female
  follow up
  human
  ICD-9
  major clinical study
  male
  metabolic equivalent
  obesity
  priority journal
  tertiary care center
  treadmill test
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015414889
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014833
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 160
TITLE
  The Prevalence of Arrhythmias, Predictors for Arrhythmias, and Safety of 
Exercise Stress Testing in Children
AUTHOR NAMES
  Ghosh R.M.
  Gates G.J.
  Walsh C.A.
  Schiller M.S.
  Pass R.H.
  Ceresnak S.R.
AUTHOR ADDRESSES
  (Ghosh R.M.; Gates G.J.; Walsh C.A.; Schiller M.S.; Pass R.H.) Division of 
Pediatric Cardiology, Department of Pediatrics, The Children’s Hospital at 
Montefiore – Albert Einstein College of Medicine, 3415 Bainbridge Ave, 
Bronx, United States.
(Ceresnak S.R., ceresnak@yahoo.com) Division of Pediatric Cardiology, 
Department of Pediatrics, Stanford University – Lucille Packard Children’s 
Hospital, 750 Welch Road, Suite 305, Palo Alto, United States.
CORRESPONDENCE ADDRESS
  S.R. Ceresnak, Division of Pediatric Cardiology, Department of Pediatrics, 
Stanford University – Lucille Packard Children’s Hospital, 750 Welch Road, 
Suite 305, Palo Alto, United States.
SOURCE
  Pediatric Cardiology (2015) 36:3 (584-590). Date of Publication: 2015
ISSN
  1432-1971 (electronic)
  0172-0643
BOOK PUBLISHER
  Springer New York LLC, journals@springer-sbm.com
ABSTRACT
  Exercise testing is commonly performed in children for evaluation of cardiac 
disease. Few data exist, however, on the prevalence, types of arrhythmias, 
predictors for arrhythmias, and safety of exercise testing in children. A 
retrospective review of all patients ≤21 years undergoing exercise testing 
at our center from 2008 to 2012 was performed. Patients with clinically 
relevant arrhythmias were compared to those not experiencing a significant 
arrhythmia. 1,037 tests were performed in 916 patients. The mean age was 
14 ± 4 years, 537 (55 %) were male, 281 (27 %) had congenital heart disease, 
178 (17 %) had a history of a prior arrhythmia, and 17 (2 %) had a pacemaker 
or ICD. 291 (28 %) patients had a rhythm disturbance during the procedure. 
Clinically important arrhythmias were noted in 34 (3 %) patients and 
included: 19 (1.8 %) increasing ectopy with exercise, 5 (0.5 %) VT, 5 
(0.5 %) second degree AV block, 3 (0.3 %) SVT, and 2 (0.2 %) AFIB. On 
multivariate logistic regression, variables associated with the development 
of clinically relevant arrhythmias included severe left ventricular (LV) 
dysfunction on echo (OR 1.99, CI 1.20–3.30) and prior history of a 
documented arrhythmia (OR 2.94, CI 1.25–6.88). There were no adverse events 
related to testing with no patient requiring cardioversion, defibrillation, 
or acute anti-arrhythmic therapy. A total of 28 % of children developed a 
rhythm disturbance during exercise testing and 3 % were clinically 
important. Severe LV dysfunction and a history of documented arrhythmia were 
associated with the development of a clinically important arrhythmia.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise test
  heart arrhythmia
EMTREE MEDICAL INDEX TERMS
  adolescent
  article
  bicycle ergometer
  child
  congestive cardiomyopathy
  controlled study
  echocardiography
  exercise tolerance
  female
  heart palpitation
  human
  implantable cardioverter defibrillator
  major clinical study
  male
  non invasive procedure
  pacemaker
  prevalence
  retrospective study
  safety
  second degree atrioventricular block
  thorax pain
  treadmill exercise
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Pediatrics and Pediatric Surgery (7)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014892675
FULL TEXT LINK
  http://dx.doi.org/10.1007/s00246-014-1053-9
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 161
TITLE
  The relation of respiratory muscle strength to disease severity and abnormal 
ventilation during exercise in chronic heart failure patients
AUTHOR NAMES
  Kasahara Y.
  Izawa K.P.
  Watanabe S.
  Osada N.
  Omiya K.
AUTHOR ADDRESSES
  (Kasahara Y., kasahara.y@marianna-u.ac.jp) Department of Rehabilitation 
Medicine, St. Marianna University School of Medicine, Yokohama City Seibu 
Hospital, Yokohama, Japan.
(Izawa K.P.) Graduate School of Health Sciences, Kobe University, Kobe, 
Japan.
(Watanabe S.) Department of Rehabilitation Medicine, St. Marianna University 
School of Medicine Hospital, Kawasaki, Japan.
(Osada N.) Division of Cardiology, St. Marianna University School of 
Medicine Toyoko Hospital, Kawasaki, Japan.
(Omiya K.) Division of Cardiology, Department of Internal Medicine (NO, KO), 
St. Marianna University School of Medicine, Yokohama City Seibu Hospital, 
Yokohama, Japan.
CORRESPONDENCE ADDRESS
  Y. Kasahara, Department of Rehabilitation Medicine, St. Marianna University 
School of Medicine, Yokohama City Seibu Hospital, Yokohama, Japan.
SOURCE
  Research in Cardiovascular Medicine (2015) 4:4 (1-8) Article Number: e28944. 
Date of Publication: 1 Nov 2015
ISSN
  2251-9580 (electronic)
  2251-9572
BOOK PUBLISHER
  KOWSAR Medical Publishing Company, info@kowsarmed.com
ABSTRACT
  Background: Breathlessness is a common problem in chronic heart failure 
(CHF) patients, and respiratory muscle strength has been proposed to play an 
important role in causing breathlessness in these patients. Objectives: The 
aim of this study was to investigate the relation between respiratory muscle 
strength and the severity of CHF, and the influence of respiratory muscle 
strength on abnormal ventilation during exercise in CHF patients. Patients 
and Methods: In this case series study, we assessed clinically stable CHF 
outpatients (N = 66, age: 57.7 ± 14.6 years). The peak oxygen consumption 
(peak VO2), the slope relating minute ventilation to carbon dioxide 
production (VE/VCO2 slope), and the slope relating tidal volume to 
respiratory rate (TV/RR slope) were measured during cardiopulmonary exercise 
testing. Respiratory muscle strength was assessed by measuring the maximal 
inspiratory pressure (MIP) and maximal expiratory pressure (MEP). Results: 
The MIP and MEP decreased significantly as the New York Heart Association 
functional class increased (MIP, P = 0.021; MEP, P < 0.01). The MIP 
correlated with the TV/RR slope (r = 0.57, P < 0.001) and the VE/VCO2 slope 
(r = -0.44, P < 0.001), and the MEP also correlated with the TV/RR slope (r 
= 0.53, P < 0.001) and the VE/VCO2 slope (r = -0.25, P < 0.040). Stepwise 
multiple regression analysis revealed that age and MIP were statistically 
significant predictors of the TV/RR and VE/VCO2 slopes (both P < 0.05). 
Conclusions: Respiratory muscle strength is related to the severity of CHF, 
and associated with rapid and shallow ventilation or excessive ventilation 
during exercise.
EMTREE DRUG INDEX TERMS
  angiotensin receptor antagonist
  brain natriuretic peptide (endogenous compound)
  carbon dioxide
  dipeptidyl carboxypeptidase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aerobic exercise
  breathing disorder
  breathing muscle
  disease severity
  heart failure
  muscle strength
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation
  body mass
  breathing rate
  cardiopulmonary exercise test
  echocardiography
  female
  heart left ventricle ejection fraction
  heart muscle oxygen consumption
  human
  major clinical study
  male
  maximal expiratory pressure
  maximal inspiratory pressure
  respiratory tract parameters
  tidal volume
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
  carbon dioxide (124-38-9, 58561-67-4)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015354305
FULL TEXT LINK
  http://dx.doi.org/10.5812/cardiovascmed.28944
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 162
TITLE
  The controversial relationship between exercise and atrial fibrillation: 
Clinical studies and pathophysiological mechanisms
AUTHOR NAMES
  D'Ascenzi F.
  Cameli M.
  Ciccone M.M.
  Maiello M.
  Modesti P.A.
  Mondillo S.
  Muiesan M.L.
  Scicchitano P.
  Novo S.
  Palmiero P.
  Saba P.S.
  Pedrinelli R.
AUTHOR ADDRESSES
  (D'Ascenzi F., flavio.dascenzi@libero.it; Cameli M.; Mondillo S.) 
Cardiologia Universitaria, Università degli Studi di Siena, Viale M. Bracci, 
16, Siena, Italy.
(Ciccone M.M.; Scicchitano P.) Dipartimento di Emergenza e Trapianto Organi, 
Università degli Studi di Bari, Bari, Italy.
(Maiello M.; Palmiero P.) Azienda Sanitaria Locale di Brindisi, Brindisi, 
Italy.
(Modesti P.A.) Dipartimento di Medicina Clinica e Sperimentale, Università 
degli Studi di Firenze, Firenze, Italy.
(Muiesan M.L.) Dipartimento di Scienze Cliniche e Sperimentali, Università 
degli Studi di Brescia, Brescia, Italy.
(Novo S.) Dipartimentodi Medicina Interna e Malattie Cardiovascolari, 
Università degli Studi di Palermo, Palermo, Italy.
(Saba P.S.) Dipartimento di Medicina Clinica e Sperimentale, Università 
degli Studidi Sassari, Sassari, Italy.
(Pedrinelli R.) Dipartimento di Patologia Chirurgica, Medica, Molecolare e 
dell'Area Critica, Università di Pisa, Pisa, Italy.
CORRESPONDENCE ADDRESS
  F. D'Ascenzi, Cardiologia Universitaria, Università degli Studi di Siena, 
Viale M. Bracci, 16, Siena, Italy.
SOURCE
  Journal of Cardiovascular Medicine (2015) 16:12 (802-810). Date of 
Publication: 2015
ISSN
  1558-2035 (electronic)
  1558-2027
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Atrial fibrillation is the most common clinically significant arrhythmia 
observed both in the general population and in competitive athletes. The 
most important risk factors are all preventable by regular physical 
activity. However, although the benefits of moderate physical activity in 
controlling cardiovascular risk factors and decreasing the risk of atrial 
fibrillation have been extensively proved, concerns have arisen about the 
potential negative effects of vigorous exercise, particularly in endurance 
athletes. Furthermore, in a subset of patients with atrial fibrillation 
younger than 60 years, routine evaluation does not reveal any cardiovascular 
disease or any other known causal factor. This condition is called 'lone 
atrial fibrillation', and the potential mechanisms underlying this condition 
are speculative and remain to be clarified. Atrial ectopy, increased vagal 
tone, changes in electrolytes, left atrial dilatation, and fibrosis have 
been proposed among others as potential mechanisms. However, no convincing 
data still exist. Particularly, the increase in left atrial size represents 
in athletes a physiological adaptation to exercise conditioning and the 
presence of biatrial fibrosis has not been demonstrated in humans. Thus, 
contrary to patients with cardiovascular disorders, the atrial substrate 
seems to play a secondary role in healthy athletes. This review article 
analyzes the controversial relationship between atrial fibrillation and 
physical activity, with a particular attention on the pathophysiological 
mechanisms that could be responsible for atrial fibrillation in the athletic 
population.
EMTREE DRUG INDEX TERMS
  illicit drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  exercise
  physical activity
EMTREE MEDICAL INDEX TERMS
  athlete
  atrial ectopy
  autonomic nervous system
  cardiovascular risk
  disease association
  electrolyte disturbance
  exercise intensity
  genetics
  heart atrium flutter
  heart atrium function
  heart atrium remodeling
  heart disease
  heart left atrium
  heart left atrium fibrosis
  human
  jogging
  multifactorial inheritance
  physical performance
  review
  sport
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Physiology (2)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014952923
FULL TEXT LINK
  http://dx.doi.org/10.2459/JCM.0000000000000211
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 163
TITLE
  Exercise and the heart: The good, the bad, and the ugly
AUTHOR NAMES
  Sharma S.
  Merghani A.
  Mont L.
AUTHOR ADDRESSES
  (Sharma S., sasharma@sgul.ac.uk; Merghani A.) Department of Cardiovascular 
Sciences, St Georges University of London, Cranmer Terrace, London, United 
Kingdom.
(Mont L.) Hospital Clinic, Institut del Torax, Universitat de Barcelona, 
Barcelona, Spain.
CORRESPONDENCE ADDRESS
  S. Sharma, Department of Cardiovascular Sciences, St Georges University of 
London, Cranmer Terrace, London, United Kingdom.
SOURCE
  European Heart Journal (2015) 36:23 (1445-1453). Date of Publication: 2015
ISSN
  1522-9645 (electronic)
  0195-668X
BOOK PUBLISHER
  Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
  The benefits of exercise are irrefutable. Individuals engaging in regular 
exercise have a favourable cardiovascular risk profile for coronary artery 
disease and reduce their risk of myocardial infarction by 50%. Exercise 
promotes longevity of life, reduces the risk of some malignancies, retards 
the onset of dementia, and is as considered an antidepressant. Most of these 
benefits are attributable to moderate exercise, whereas athletes perform way 
beyond the recommended levels of physical activity and constantly push back 
the frontiers of human endurance. The cardiovascular adaptation for 
generating a large and sustained increase in cardiac output during prolonged 
exercise includes a 10-20% increase in cardiac dimensions. In rare 
instances, these physiological increases in cardiac size overlap with 
morphologically mild expressions of the primary cardiomyopathies and 
resolving the diagnostic dilemma can be challenging. Intense exercise may 
infrequently trigger arrhythmogenic sudden cardiac death in an athlete 
harbouring asymptomatic cardiac disease. In parallel with the extraordinary 
athletic milieu of physical performances previously considered unachievable, 
there is emerging data indicating that long-standing vigorous exercise may 
be associated with adverse electrical and structural remodelling in 
otherwise normal hearts. Finally, in the current era of celebrity athletes 
and lucrative sport contracts, several athletes have succumbed to using 
performance enhancing agents for success which are detrimental to cardiac 
health. This article discusses the issues abovementioned, which can be 
broadly classified as the good, bad, and ugly aspects of sports cardiology.
EMTREE DRUG INDEX TERMS
  performance enhancing substance
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular function
  exercise
EMTREE MEDICAL INDEX TERMS
  athlete
  atrial fibrillation
  cardiomyopathy
  cardiovascular magnetic resonance
  cardiovascular mortality
  cardiovascular risk
  electrocardiogram
  follow up
  heart output
  heart rehabilitation
  heart size
  heart ventricle arrhythmia
  human
  metabolic equivalent
  physical activity
  physical performance
  priority journal
  review
  sedentary lifestyle
  sinus node disease
  sport
  ST segment elevation
  sudden cardiac death
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015407364
FULL TEXT LINK
  http://dx.doi.org/10.1093/eurheartj/ehv090
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 164
TITLE
  Exercise-induced vasodilation in healthy males: A marker of reduced 
endothelial function
AUTHOR NAMES
  Wethal T.
  Roysland R.
  Torbjorn O.
  Kjekshus J.
AUTHOR ADDRESSES
  (Wethal T., torgeir.wethal@medisin.uio.no; Roysland R.; Torbjorn O.; 
Kjekshus J.) Institute of Clinical Medicine, University of Oslo, Norway.
(Wethal T., torgeir.wethal@medisin.uio.no) Department of Medicine, St. Olavs 
Hospital, Pb. 3250 Sluppen, Trondheim, Norway.
(Torbjorn O.) Division of Medicine, Akershus University Hospital, Lorenskog, 
Norway.
CORRESPONDENCE ADDRESS
  T. Wethal, Department of Medicine, St. Olavs Hospital, Pb. 3250 Sluppen, 
Trondheim, Norway.
SOURCE
  Scandinavian Cardiovascular Journal (2015) 49:3 (123-129). Date of 
Publication: 1 Jun 2015
ISSN
  1651-2006 (electronic)
  1401-7431
BOOK PUBLISHER
  Informa Healthcare, healthcare.enquiries@informa.com
ABSTRACT
  Objectives. Reduced arterial vasodilatatory capacity is a marker of coronary 
heart disease. The aim was to investigate if the difference between the 
vasodilatory response before and after exercise, as assessed by non-invasive 
methodology, is related to endothelial and inflammatory biomarkers. Design. 
Post-ischemic hyperemia after 5 min of arterial occlusion was examined 
before and after a bicycle test with strain-gauge plethysmography (measuring 
peak reactive hyperemia in the forearm) and peripheral arterial tonometry 
(PAT hyperemia ratio: measuring pulse waves in the index finger relative to 
the contra-lateral index finger) in 30 healthy males. A low PAT hyperemia 
ratio or a low peak reactive hyperemia reflects endothelial dysfunction. 
Inflammatory and endothelial biomarkers were assessed. Results. A low peak 
reactive hyperemia and a low PAT hyperemia ratio before the bicycle test was 
associated with a high percentage increase in peak reactive hyperemia after 
exercise (r = - 0.68, p < 0.001; r = - 0.35, p = 0.06, respectively). 
Asymmetric dimethylarginine and interleukin-10 were associated with the 
percentage increase in peak reactive hyperemia in multiple linear regression 
analyses (β: 165 (confidence interval [CI], 34-296), p = 0.02; β: 19 (CI, - 
0.5-39), p = 0.06, respectively). Conclusions. The difference in the 
vasodilatory response before and after exercise, as assessed by non-invasive 
methodology, is related to endothelial and inflammatory biomarkers in 
healthy males.
EMTREE DRUG INDEX TERMS
  beta 2 adrenergic receptor stimulating agent (drug therapy)
  biological marker (endogenous compound)
  C reactive protein (endogenous compound)
  glucose (endogenous compound)
  hemoglobin A1c (endogenous compound)
  high density lipoprotein cholesterol (endogenous compound)
  interleukin 10 (endogenous compound)
  interleukin 8 (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
  n(g),n(g) dimethylarginine (endogenous compound)
  osteoprotegerin (endogenous compound)
  PADGEM protein (endogenous compound)
  triacylglycerol (endogenous compound)
  tumor necrosis factor receptor (endogenous compound)
  von Willebrand factor (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular function
  endothelial function
  exercise
  vasodilatation
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  arterial stiffness
  article
  asthma (drug therapy)
  atrial fibrillation
  bicycle ergometry
  biochemical analysis
  blood pressure measurement
  borderline hypertension
  cholesterol blood level
  clinical article
  diastolic blood pressure
  endothelial dysfunction
  experimental hyperemia
  forearm blood flow
  human
  index finger
  male
  non insulin dependent diabetes mellitus
  non invasive procedure
  peripheral arterial tonometry
  plethysmography
  priority journal
  pulse wave
  strain gauge transducer
  systolic blood pressure
  vein occlusion
  venous stasis
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  glucose (50-99-7, 84778-64-3)
  hemoglobin A1c (62572-11-6)
  interleukin 8 (114308-91-7)
  n(g),n(g) dimethylarginine (30315-93-6)
  osteoprotegerin (205944-50-9)
  tumor necrosis factor receptor (129203-93-6, 184595-01-5)
  von Willebrand factor (109319-16-6)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Physiology (2)
  Immunology, Serology and Transplantation (26)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015051650
FULL TEXT LINK
  http://dx.doi.org/10.3109/14017431.2015.1021708
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 165
TITLE
  Delays in Referral and Enrolment Are Associated with Mitigated Benefits of 
Cardiac Rehabilitation after Coronary Artery Bypass Surgery
AUTHOR NAMES
  Marzolini S.
  Blanchard C.
  Alter D.A.
  Grace S.L.
  Oh P.I.
AUTHOR ADDRESSES
  (Marzolini S., Susan.marzolini@uhn.ca; Alter D.A.; Oh P.I.) Toronto 
Rehabilitation Institute, University Health Network, 347 Rumsey Rd, Toronto, 
Canada.
(Blanchard C.) Department of Medicine, Dalhousie University, Halifax, 
Canada.
(Grace S.L.) Faculty of Health, York University, Toronto, Canada.
CORRESPONDENCE ADDRESS
  S. Marzolini, Toronto Rehabilitation Institute, University Health Network, 
347 Rumsey Rd, Toronto, Canada. Email: Susan.marzolini@uhn.ca
SOURCE
  Circulation: Cardiovascular Quality and Outcomes (2015) 8:6 (608-620). Date 
of Publication: 1 Dec 2015
ISSN
  1941-7705 (electronic)
  1941-7713
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Background-Cardiac rehabilitation (CR) is recommended after coronary artery 
bypass graft surgery; however, the consequences of longer wait times to 
start CR have not been elucidated. Method and Results-Cardiopulmonary, 
demographic, and anthropometric assessments were conducted before and after 
6 months of CR in consecutively enrolled patients from January 1995 to 
October 2012. Wait times were ascertained from referral forms and charts. 
Neighborhood characteristics were ascertained using census data and 
cross-referencing with patients' home geographic location. Among 6497 
post-coronary artery bypass graft participants, mean and median total wait 
time (time from surgery to first exercise session) was 101.1±47.9 and 80 
days, respectively. In multiple linear regression, correlates of longer 
total wait time and the 2 wait-Time phases, time from surgery to CR referral 
and time from CR referral to first exercise session, were determined. 
Factors influencing longer wait times included female sex, greater age, 
being employed, less social support, longer drive time to CR, lower 
neighborhood socioeconomic status, higher systolic blood pressure, abdominal 
obesity, and a complex medical history. After adjusting for correlates of 
delayed entry, longer wait time for each of the total and 2 wait-Time phases 
was significantly associated with less improvement in cardiopulmonary 
fitness (VO2peak; β=-0.165, P<0.001), body fat percentage (β=0.032, P<0.02), 
resting heart rate (β=0.066, P<0.001), and poorer attendance to CR classes 
(β=-0.081, P<0.001) and completion rate (β=2.741, P<0.001). 
Conclusions-Strategies for timely access to CR at each phase of the process 
are important given the negative impact that wait time has on key clinical 
outcomes. This is relevant because optimizing VO2peak and attendance to CR 
has been shown to confer a mortality advantage.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  coronary artery bypass surgery
  heart rehabilitation
  patient referral
  postoperative care
EMTREE MEDICAL INDEX TERMS
  abdominal obesity
  adult
  anthropometry
  article
  atrial fibrillation
  body fat
  cardiomyopathy
  cardiopulmonary function
  cerebrovascular accident
  coronary artery bypass graft
  demography
  diabetes mellitus
  diastolic blood pressure
  exercise
  female
  functional status
  heart arrest
  heart failure
  heart infarction
  human
  major clinical study
  male
  medical history
  neighborhood
  outcome assessment
  peripheral vascular disease
  priority journal
  resting heart rate
  retrospective study
  sex difference
  skinfold thickness
  smoking
  social status
  social support
  systolic blood pressure
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015531807
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCOUTCOMES.115.001751
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 166
TITLE
  Heart failure and cognitive dysfunction
AUTHOR NAMES
  Ampadu J.
  Morley J.E.
AUTHOR ADDRESSES
  (Ampadu J.) PGY-2, Department of Internal Medicine, Saint Louis University 
Hospital, St. Louis, United States.
(Morley J.E., morley@slu.edu) Division of Geriatric Medicine, Department of 
Internal Medicine, Saint Louis University School of Medicine, 1402 S. Grand 
Blvd.,M238, St. Louis, United States.
(Morley J.E., morley@slu.edu) Division of Endocrinology, Department of 
Internal Medicine, Saint Louis University School of Medicine, St. Louis, 
United States.
CORRESPONDENCE ADDRESS
  J.E. Morley, Division of Geriatric Medicine, Department of Internal 
Medicine, Saint Louis University School of Medicine, 1402 S. Grand 
Blvd.,M238, St. Louis, United States.
SOURCE
  International Journal of Cardiology (2015) 178 (12-23). Date of Publication: 
15 Jan 2015
ISSN
  1874-1754 (electronic)
  0167-5273
BOOK PUBLISHER
  Elsevier Ireland Ltd
ABSTRACT
  It has been estimated that 5.1 million Americans suffer from heart failure. 
Cognitive impairment has been described as a consequence of heart failure in 
numerous studies spanning the last three decades. This systematic review 
helps differentiate "cognitive impairment" into mild cognitive impairment, 
dementia, and delirium. We evaluate the prevalence, pathophysiology, 
treatment modalities, and possible outcomes previously described with these 
associations in heart failure. This review also assesses the utility of the 
different screening modalities and their efficacy as they pertain to 
recognizing cognitive impairment.
EMTREE DRUG INDEX TERMS
  brain natriuretic peptide (endogenous compound)
  C reactive protein (endogenous compound)
  cardiovascular agent (adverse drug reaction)
  cholinergic receptor blocking agent (adverse drug reaction)
  cyclooxygenase 2 (endogenous compound)
  digoxin
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  folic acid
  homocysteine (endogenous compound)
  interleukin 1 (endogenous compound)
  interleukin 6 (endogenous compound)
  triacylglycerol (endogenous compound)
  tumor necrosis factor alpha (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cognitive defect (side effect, etiology, side effect)
  heart failure (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  ADL disability
  Alzheimer disease
  atrial fibrillation
  blood brain barrier
  brain blood flow
  brain hypoxia
  brain perfusion
  cachexia
  cardiac resynchronization therapy
  congestive heart failure
  counterpulsation
  cytokine production
  delirium (side effect)
  dementia
  depression
  exercise
  heart left ventricle failure
  hospital readmission
  human
  hyperglycemia
  hyperhomocysteinemia
  hypoglycemia
  hyponatremia
  lacunar stroke
  microembolism
  mild cognitive impairment
  Mini Mental State Examination
  Montreal cognitive assessment
  mortality
  neuroimaging
  New York Heart Association class
  nonhuman
  orthostatic hypotension (side effect)
  pathophysiology
  prevalence
  protein calorie malnutrition
  review
  screening test
  systematic review
  white matter
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
  C reactive protein (9007-41-4)
  digoxin (20830-75-5, 57285-89-9)
  folic acid (59-30-3, 6484-89-5)
  homocysteine (454-28-4, 6027-13-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014962361
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijcard.2014.10.087
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 167
TITLE
  Practical approaches for the treatment of chronic heart failure: Frequently 
asked questions, overlooked points and controversial issues in current 
clinical practice
AUTHOR NAMES
  Çavuşoğlu Y.
  Altay H.
  Ekmekçi A.
  Eren M.
  Küçükoğlu M.S.
  Nalbantgil S.
  Sarı İ.
  Selçuk T.
  Temizhan A.
  Ural D.
  Weinstein J.M.
  Yeşilbursa D.
  Yılmaz M.B.
  Zoghi M.
  Aydoğdu S.
  Kutlu M.
  Özer N.
  Şahin M.
  Tokgözoğlu L.
AUTHOR ADDRESSES
  (Çavuşoğlu Y., yukselc@ogu.edu.tr) Department of Cardiology, Eskişehir 
Osmangazi University, Eskişehir, Turkey.
(Altay H.) Department of Cardiology, Başkent University, İstanbul, Turkey.
(Ekmekçi A.; Eren M.) Department of Cardiology, Siyami Ersek Hospital, 
İstanbul, Turkey.
(Küçükoğlu M.S.) Department of Cardiology, İstanbul University, Cardiology 
Institute, İstanbul, Turkey.
(Nalbantgil S.; Zoghi M.) Department of Cardiology, Ege University, İzmir, 
Turkey.
(Sarı İ.) Department of Cardiology, Marmara University, İstanbul, Turkey.
(Selçuk T.; Temizhan A.; Aydoğdu S.) Department of Cardiology, Ankara 
Türkiye Yüksek İhtisas Hospital, Ankara, Turkey.
(Ural D.) Department of Cardiology, Kocaeli University, Turkey.
(Weinstein J.M.) Department of Cardiology, Ben Gurion University, Bersheva, 
Israel.
(Yeşilbursa D.) Department of Cardiology, Uludağ University, Bursa, Turkey.
(Yılmaz M.B.) Department of Cardiology, Cumhuriyet University, Sivas, 
Turkey.
(Kutlu M.) Department of Cardiology, Karadeniz Teknik University, Trabzon, 
Turkey.
(Özer N.; Tokgözoğlu L.) Department of Cardiology, Hacettepe University, 
Ankara, Turkey.
(Şahin M.) Department of Cardiology, 19 Mayıs University, Samsun, Turkey.
CORRESPONDENCE ADDRESS
  Y. Çavuşoğlu, Eskişehir Osmangazi Üniversitesi, Kardiyoloji Anabilim Dalı, 
Eskişehir, Turkey.
SOURCE
  Anadolu Kardiyoloji Dergisi (2015) 15 Supplement 2 (1-60). Date of 
Publication: 1 Oct 2015
ISSN
  1308-0032 (electronic)
  1302-8723
BOOK PUBLISHER
  AVES Ibrahim Kara, 105/9 Buyukdere Cad, Mecidiyekoy,Sisli, Istanbul, Turkey.
ABSTRACT
  Heart failure (HF) is a progressive disorder associated with impaired 
quality of life, high morbidity, mortality and frequent hospitalization and 
affects millions of people from all around the world. Despite further 
improvements in HF therapy, mortality and morbidity remains to be very high. 
The life-long treatment, frequent hospitalization, and sophisticated and 
very expensive device therapies for HF also leads a substantial economic 
burden on the health care system. Therefore, implementation of 
evidence-based guideline-recommended therapy is very important to overcome 
its worse clinical outcomes. However, HF therapy is a long process that has 
many drawbacks and sometimes HF guidelines cannot answers to every question 
which rises in everyday clinical practice. In this paper, commonly 
encountered questions, overlooked points, controversial issues, management 
strategies in grey zone and problems arising during follow up of a HF 
patient in real life clinical practice have been addressed in the form of 
expert opinions based on the available data in the literature.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  aliskiren
  amiloride
  bumetanide
  candesartan
  captopril
  carvedilol
  clopidogrel
  digoxin
  enalapril
  eplerenone
  furosemide
  hydralazine
  hydrochlorothiazide
  indapamide
  ivabradine
  lisinopril
  metolazone
  nebivolol
  nifedipine
  perindopril
  phenprocoumon
  ramipril
  spironolactone
  tolvaptan
  torasemide
  trandolapril
  triamterene
  unindexed drug
  valsartan
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  clinical practice
  heart failure
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  cardioselectivity
  cardiovascular mortality
  diet restriction
  exercise
  fatigue
  headache
  heart ejection fraction
  heart infarction
  heart rate
  hospital readmission
  human
  left ventricular diastolic dysfunction
  liver microsome metabolism
  oxidative stress
  oxygen consumption
  quality of life
  sodium restriction
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  aliskiren (173334-57-1, 173334-58-2, 173399-03-6)
  amiloride (2016-88-8, 2609-46-3)
  bumetanide (28395-03-1)
  candesartan (139481-59-7)
  captopril (62571-86-2)
  carvedilol (72956-09-3)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  digoxin (20830-75-5, 57285-89-9)
  enalapril (75847-73-3)
  eplerenone (107724-20-9)
  furosemide (54-31-9)
  hydralazine (304-20-1, 86-54-4)
  hydrochlorothiazide (58-93-5)
  indapamide (26807-65-8)
  ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
  lisinopril (76547-98-3, 83915-83-7)
  metolazone (17560-51-9)
  nebivolol (99200-09-6, 118457-15-1, 118457-16-2)
  nifedipine (21829-25-4)
  perindopril (82834-16-0, 99149-83-4)
  phenprocoumon (435-97-2)
  ramipril (87333-19-5)
  spironolactone (52-01-7)
  tolvaptan (150683-30-0)
  torasemide (56211-40-6)
  trandolapril (87679-37-6)
  triamterene (396-01-0)
  valsartan (137862-53-4)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015516339
FULL TEXT LINK
  http://dx.doi.org/10.5152/AnatolJCardiol.2015.6767
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 168
TITLE
  Propionibacterium acnes: A Treatable Cause of Constrictive Pericarditis
AUTHOR NAMES
  Cruz D.
  Ahmed H.
  Gandapur Y.
  Abraham M.R.
AUTHOR ADDRESSES
  (Cruz D., dcruz3@jhmi.edu) Osler Medical Service, Johns Hopkins School of 
Medicine, Baltimore, United States.
(Ahmed H., hahmed2@jhmi.edu; Abraham M.R., mabraha3@jhmi.edu) Division of 
Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, 
United States.
(Gandapur Y., gandapuryousuf@gmail.com) Department of Medicine, Good 
Samaritan Hospital, Baltimore, United States.
CORRESPONDENCE ADDRESS
  D. Cruz, Osler Medical Service, Johns Hopkins School of Medicine, Baltimore, 
United States.
SOURCE
  Case Reports in Medicine (2015) 2015 Article Number: 193272. Date of 
Publication: 2015
ISSN
  1687-9635 (electronic)
  1687-9627
BOOK PUBLISHER
  Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New 
York, United States.
ABSTRACT
  In this case report we share a case of infective Pericarditis caused by 
Propionibacterium acnes (P. acnes) in an immune-competent, nonsurgical 
patient. This case and review will illustrate the importance of considering 
P. acnes as a cause of idiopathic pericardial effusion and effusive 
constrictive disease. The patient was a 61-year-old male with history of 
osteoarthritis of the knee. He received an intra-articular steroid injection 
in July 2013. Two months later, he presented with atrial fibrillation and 
heart failure. He was found to have pericardial and bilateral pleural 
effusions which grew P. acnes. This organism was initially considered to be 
contaminant; however, as P. acnes was isolated from both pleural and 
pericardial fluids, he was started on oral amoxicillin. He was noted to have 
recurrence of effusions within 2 weeks with evidence of constrictive 
physiology by echocardiography. Treatment was subsequently changed to 
intravenous Penicillin G with marked symptomatic improvement, resolution of 
pericardial/pleural effusions, and no echocardiographic evidence of 
constrictive pericarditis at 10 weeks follow-up. Pursuit and treatment of P. 
acnes could lead to prevention of constrictive pericarditis. We believe that 
further studies are needed to assess prevalence of P. acnes and response to 
intravenous Penicillin G in patients presenting with effusive constrictive 
disease.
EMTREE DRUG INDEX TERMS
  amoxicillin (drug therapy, oral drug administration)
  colchicine (drug therapy)
  doxycycline (drug therapy, oral drug administration)
  gadolinium
  penicillin G (drug therapy, intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  constrictive pericarditis (drug therapy, drug therapy, etiology, surgery)
  Propionibacterium acnes
EMTREE MEDICAL INDEX TERMS
  Actinomycetales infection (drug therapy)
  adult
  article
  blood cell count
  blood culture
  case report
  echocardiography
  effusion
  exercise
  follow up
  human
  human cell
  lymphocyte
  male
  middle aged
  nuclear magnetic resonance imaging
  pericardial effusion (drug therapy)
  pericardiocentesis
  pleura effusion (drug therapy)
  pleura fluid
  priority journal
  Propionibacterium acnes infection
  Propionibacterium acnes infection (drug therapy)
  recurrent disease
  thoracocentesis
CAS REGISTRY NUMBERS
  amoxicillin (26787-78-0, 34642-77-8, 61336-70-7)
  colchicine (64-86-8)
  doxycycline (10592-13-9, 17086-28-1, 564-25-0, 94088-85-4)
  gadolinium (7440-54-2)
  penicillin G (1406-05-9, 61-33-6)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Microbiology: Bacteriology, Mycology, Parasitology and Virology (4)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015172393
FULL TEXT LINK
  http://dx.doi.org/10.1155/2015/193272
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 169
TITLE
  Electrocardiogram and arrhythmias
AUTHOR NAMES
  Singh R.
  Murphy J.J.
AUTHOR ADDRESSES
  (Singh R.; Murphy J.J.) County Durham and Darlington Foundation Trust, 
United Kingdom.
(Singh R.) Centre of Integrated Health Care Research, Durham Univrsty., 
United Kingdom.
(Murphy J.J.) Durham University, United Kingdom.
SOURCE
  Anaesthesia and Intensive Care Medicine (2015) 16:5 (220-223). Date of 
Publication: 1 May 2015
ISSN
  1878-7584 (electronic)
  1472-0299
BOOK PUBLISHER
  Elsevier Ltd
ABSTRACT
  Introduced by Einthoven, electrocardiography remains the most common 
diagnostic procedure readily available to the physician in primary and 
secondary care. It is a graphical display of the electrical potential 
difference as it spreads through the heart and is recorded at the body 
surface. The electrocardiogram (ECG) is an indispensable tool to screen and 
monitor cardiac patients. Exercise ECG is used to diagnose coronary artery 
disease and ambulatory ECG to assess arrhythmias.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  electrocardiogram
  heart arrhythmia
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  atrioventricular block
  bradycardia
  complete heart block
  coronary artery disease
  electric potential
  exercise
  first degree atrioventricular block
  heart left bundle branch block
  heart right bundle branch block
  heart ventricle tachycardia
  human
  P wave
  priority journal
  QRS complex
  second degree atrioventricular block
  T wave
  tachycardia
  U wave
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015894020
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.mpaic.2015.02.006
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 170
TITLE
  Infrapopliteal Bifurcated Dual Run-off Bypass in Critical Limb Ischemia: A 
Report of 2 Cases
AUTHOR NAMES
  Okazaki J.
  Ishida M.
  Kuma S.
  Morisaki K.
AUTHOR ADDRESSES
  (Okazaki J., okadoc2001@yahoo.co.jp; Ishida M.; Kuma S.; Morisaki K.) 
Department of Vascular Surgery, Kokura Memorial Hospital, 3-2-1, Asano, 
Kokurakita-ku, Kitakyushu-shi, Japan.
CORRESPONDENCE ADDRESS
  J. Okazaki, Department of Vascular Surgery, Kokura Memorial Hospital, 3-2-1, 
Asano, Kokurakita-ku, Kitakyushu-shi, Japan.
SOURCE
  Annals of Vascular Surgery (2015) 29:5 (1020.e17-1020.e21). Date of 
Publication: 1 Jul 2015
ISSN
  1615-5947 (electronic)
  0890-5096
BOOK PUBLISHER
  Elsevier Inc., usjcs@elsevier.com
ABSTRACT
  Recently, angiosome-oriented direct revascularization was advocated for 
infrapopliteal bypass in patients with critical limb ischemia. However, 
angiosome-matched target vessels, which supply direct blood flow into the 
ischemic tissue, are frequently small in diameter, severely calcified, have 
a very poor vascular bed, and might not be suitable technically for distal 
anastomosis. In such cases, creating a bifurcation in the graft could enable 
perfusion of a "direct" target vessel with poor quality and an "indirect" 
run-off vessel with better features. In this report, we present 2 cases of 
bifurcated dual run-off bypass (BDRB) in which we added a secondary outflow 
to the original single tibial bypass. Careful investigation and evaluation 
of the status of the collateral vessels and additional information regarding 
successful and unsuccessful cases are required to further understand the 
advantages and disadvantages of BDRB.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  bifurcated dual run off bypass
  critical limb ischemia (surgery)
  femoropopliteal bypass
EMTREE MEDICAL INDEX TERMS
  adult
  aorta valve replacement
  arteriography
  article
  atrial fibrillation
  bypass surgery
  case report
  coronary artery bypass graft
  debridement
  diabetes mellitus
  disease duration
  follow up
  foot ulcer (therapy)
  heel ulcer (therapy)
  human
  intraoperative period
  male
  medical history
  middle aged
  mitral valve replacement
  pain
  postoperative period
  priority journal
  renal replacement therapy
  saphenous vein graft
  toe gangrene
  ulcer healing
  vacuum assisted closure
  valvular heart disease
  wound care
EMBASE CLASSIFICATIONS
  Orthopedic Surgery (33)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015941282
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.avsg.2015.01.024
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 171
TITLE
  Organising pneumonia due to dronedarone
AUTHOR NAMES
  Thornton D.
  Avery S.
  Edey A.J.
  Medford A.R.L.
AUTHOR ADDRESSES
  (Thornton D.; Avery S.; Medford A.R.L., andrew.medford@nbt.nhs.uk) North 
Bristol Lung Centre, Southmead Hospital, Bristol, United Kingdom.
(Edey A.J.) Department of Radiology, Southmead Hospital, Bristol, United 
Kingdom.
CORRESPONDENCE ADDRESS
  A.R.L. Medford, North Bristol Lung Centre & University of Bristol, Southmead 
Hospital, Westbury-on-Trym, Bristol, United Kingdom.
SOURCE
  Journal of the Royal College of Physicians of Edinburgh (2015) 45:3 
(213-214). Date of Publication: 2015
ISSN
  1478-2715
BOOK PUBLISHER
  Royal College of Physicians of Edinburgh, k.oneill@rcpe.ac.uk
ABSTRACT
  Organising pneumonia is one of the responses of the lung to injury and can 
mimic bacterial pneumonia but importantly it does not respond to antibiotic 
therapy. We present the case of a 67-year-old male who was diagnosed with 
organising pneumonia secondary to dronedarone. Drug reactions are a common 
cause and early identification of the culprit is mandatory to prevent 
further morbidity and ensure a favourable outcome. On chest radiography 
there may be fleeting peripheral consolidation, while computed tomography 
can show a range of stereotyped patterns including perilobular 
consolidation. Bronchoscopic biopsy may not always be possible but response 
to steroids is often rapid following removal of the culprit drug. 
Dronedarone should be included in the list of possible drugs and the 
Pneumotox database remains a useful resource for the clinician when acute 
drug-related pneumotoxicity is suspected.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dronedarone (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
  C reactive protein (endogenous compound)
  methylprednisolone (drug therapy)
  prednisolone (oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  organizing pneumonia (drug therapy, side effect, diagnosis, drug therapy, 
side effect)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation (drug therapy)
  case report
  community acquired pneumonia
  computer assisted tomography
  coughing
  crackle (diagnosis)
  disease course
  dyspnea
  exercise
  fever
  hospital discharge
  human
  human tissue
  hypoxemia (diagnosis)
  leukocyte count
  lung lavage
  male
  oxygen tension
  physical examination
  respiratory failure
  thorax radiography
  transbronchial biopsy
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  dronedarone (141626-36-0)
  methylprednisolone (6923-42-8, 83-43-2)
  prednisolone (50-24-8)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015442235
FULL TEXT LINK
  http://dx.doi.org/10.4997/JRCPE.2015.308
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 172
TITLE
  Sexual counseling and cardiovascular disease: Practical approaches
AUTHOR NAMES
  Steinke E.E.
  Jaarsma T.
AUTHOR ADDRESSES
  (Steinke E.E., elaine.steinke@wichita.edu) School of Nursing, Wichita State 
University, 1845 Fairmount, Wichita, United States.
(Jaarsma T.) University of Linköping, Social and Welfare Studies, 
Norrköping, Sweden.
CORRESPONDENCE ADDRESS
  E.E. Steinke, School of Nursing, Wichita State University, 1845 Fairmount, 
Wichita, United States.
SOURCE
  Asian Journal of Andrology (2015) 17:1 (32-39). Date of Publication: 1 Jan 
2015
ISSN
  1745-7262 (electronic)
  1008-682X
BOOK PUBLISHER
  Medknow Publications, B9, Kanara Business Centre, off Link Road, Ghatkopar 
(E), Mumbai, India.
ABSTRACT
  Patients with cardiovascular disease and their partners expect health care 
providers to provide sexual counseling to assist them in maintaining sexual 
quality of life. Evidence suggests however, that there is a gap in 
integrating evidence into practice and that relatively few cardiac patients 
receive sexual counseling. This can result in negative psychological, 
physical, and quality of life outcomes for couples who may needlessly decide 
sexual activity is too risky and cease all sexual activity. Two scientific 
statements now exist that provide ample guidance to health care providers in 
discussing this important topic. Using a team approach that includes 
physicians, nurses, physical therapists, rehabilitation staff, and others is 
important to ensure that sexual counseling occurs throughout recovery. In 
addition, several trials using interventional approaches for sexual 
counseling provide insight into successful approaches for sexual counseling 
in practice. This article provides practical strategies and evidence-based 
approaches for assessment and sexual counseling for all cardiac patients and 
their partners, and specific counseling for those with ischemic conditions, 
heart failure, and implanted devices.
EMTREE DRUG INDEX TERMS
  nitric acid derivative
  phosphodiesterase V inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease
  sexual counseling
EMTREE MEDICAL INDEX TERMS
  angina pectoris
  anxiety
  atrial fibrillation
  cardiac patient
  depression
  energy expenditure
  erectile dysfunction
  exercise
  health care personnel
  health care policy
  heart failure
  heart infarction
  heart muscle revascularization
  heart ventricle tachycardia
  human
  hypertrophic cardiomyopathy
  male sexual dysfunction
  nurse
  patient education
  physical activity
  physician
  physiotherapist
  psychoeducation
  quality of life
  rehabilitation care
  review
  sexual behavior
  sexual intercourse
  sexual satisfaction
  sexuality
  stress management
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Urology and Nephrology (28)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015650567
FULL TEXT LINK
  http://dx.doi.org/10.4103/1008-682X.135982
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 173
TITLE
  Arrhytmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) and heart 
transplantation: Case series
AUTHOR NAMES
  Demirozu Z.T.
  Kucukaksu D.S.
AUTHOR ADDRESSES
  (Demirozu Z.T., tdemirozu@yahoo.com; Kucukaksu D.S.) Koç University Faculty 
of Medicine, Clinic of Cardiovascular Surgery, Istanbul, Turkey.
CORRESPONDENCE ADDRESS
  Z.T. Demirozu, Koç University Faculty of Medicine, Clinic of Cardiovascular 
Surgery, Istanbul, Turkey.
SOURCE
  Turkiye Klinikleri Cardiovascular Sciences (2015) 27:1 (36-42). Date of 
Publication: 30 Mar 2015
ISSN
  1306-7656
BOOK PUBLISHER
  Turkiye Klinikleri, Turkocagi Caddesi No. 30, Balgat, Turkey.
ABSTRACT
  Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) usually 
originates from right ventricle, has a prevalence 1 in 1000 and leading 
cause of death in people aged less than 35 years of age, also desmosome 
mutations and family history can be seen in this disease. We reviewed the 
literature and described three patients with arrhythmogenic right 
ventricular dysplasia/cardiomyopathy (ARVD/C). They had T wave inversion in 
chest leads V1 to V4 and had premature ventricular complexes of left bundle 
branch block and left axis deviation, or right bundle branch block (RBB) had 
implantable cardioverter defibrillator (ICD) implantation and fulfilled the 
task force criteria for diagnosis of ARVD/C. One patient had familial 
erythrocytosis and thrombus formation in the right atrium and the right 
ventricle. He was listed as status 1A and had 2 times phlebotomy during the 
hospitalization. The other patient had warfarin intoxication, and had 
hepatic congestion due to end-stage right heart failure. The third patient 
had a history of cerebrovascular event and had a family history of ARVD/C. 
All of our patients had the medical regimen for the management of ARVD/C. 
All of the patients were in NYHA Class III-IV while they admitted to our 
clinic and they had their final therapeutic option as an orthotopic heart 
transplantation and have a good quality of life.
EMTREE DRUG INDEX TERMS
  antibiotic agent (drug therapy)
  anticoagulant agent (drug therapy)
  anticonvulsive agent (drug therapy)
  diuretic agent (drug therapy)
  heparin (drug therapy)
  warfarin (drug therapy, drug toxicity)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart right ventricle dysplasia (drug therapy, diagnosis, drug therapy, 
surgery)
  heart transplantation
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation
  breathing exercise
  cardiovascular magnetic resonance
  case report
  cell degeneration
  coughing
  cyanosis
  disease classification
  diuretic therapy
  drug intoxication
  drug substitution
  drug withdrawal
  dyspnea
  emotional disorder (rehabilitation, therapy)
  erythrocytosis
  extubation
  faintness
  familial disease
  female
  fibrosing alveolitis
  focal epilepsy (drug therapy)
  follow up
  grief
  heart atrium enlargement
  heart atrium thrombosis (drug therapy)
  heart catheterization
  heart left bundle branch block
  heart left ventricle ejection fraction
  heart muscle biopsy
  heart palpitation
  heart right bundle branch block
  heart right ventricle failure
  heart ventricle extrasystole
  heart ventricle tachycardia
  heart ventricle thrombosis
  hematocrit
  hemiparesis
  hepatomegaly
  Holter monitoring
  hospital discharge
  human
  human tissue
  implantable cardioverter defibrillator
  international normalized ratio
  liver congestion (drug therapy)
  liver failure
  lung aspiration
  lung lavage
  male
  mental disease (rehabilitation, therapy)
  mental disease assessment
  methicillin-resistant Staphylococcus epidermidis
  muscle atrophy
  peripheral edema
  phlebotomy
  pneumocystosis (drug therapy)
  postoperative period
  psychosocial rehabilitation
  psychotherapy
  quality of life
  recurrent disease
  respiratory acidosis (therapy)
  suicide attempt
  systolic heart murmur
  T wave inversion
  tonic clonic seizure (drug therapy)
  tracheostomy
  transthoracic echocardiography
  treatment outcome
  treatment response
  tricuspid valve regurgitation
  young adult
CAS REGISTRY NUMBERS
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, Turkish
EMBASE ACCESSION NUMBER
  2015927433
FULL TEXT LINK
  http://dx.doi.org/10.5336/cardiosci.2014-42264
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 174
TITLE
  A novel human R25C-phospholamban mutation is associated with 
super-inhibition of calcium cycling and ventricular arrhythmia
AUTHOR NAMES
  Liu G.-S.
  Morales A.
  Vafiadaki E.
  Lam C.K.
  Cai W.-F.
  Haghighi K.
  Adly G.
  Hershberger R.E.
  Kranias E.G.
AUTHOR ADDRESSES
  (Liu G.-S.; Lam C.K.; Haghighi K.; Adly G.; Kranias E.G., 
litsa.kranias@uc.edu) Department of Pharmacology and Cell Biophysics, 
University of Cincinnati College of Medicine, 231 Albert Sabin Way, 
Cincinnati, United States.
(Morales A.; Hershberger R.E.) Division of Human Genetics, Ohio State 
University College of Medicine, Columbus, United States.
(Morales A.; Hershberger R.E.) Dorothy M. Davis Heart and Lung Research 
Institute, Ohio State University College of Medicine, Columbus, United 
States.
(Vafiadaki E.; Kranias E.G., litsa.kranias@uc.edu) Molecular Biology 
Division, Biomedical Research Foundation, Academy of Athens, Greece.
(Cai W.-F.) Department of Pathology and Laboratory Medicine, University of 
Cincinnati College of Medicine, Cincinnati, United States.
(Hershberger R.E.) Division of Cardiovascular Medicine, Department of 
Internal Medicine, Ohio State University College of Medicine, Columbus, 
United States.
CORRESPONDENCE ADDRESS
  E.G. Kranias, Department of Pharmacology and Cell Biophysics, University of 
Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, United 
States.
SOURCE
  Cardiovascular Research (2015) 107:1 (164-174). Date of Publication: 1 Jul 
2015
ISSN
  1755-3245 (electronic)
  0008-6363
BOOK PUBLISHER
  Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
  Aims Depressed sarcoplasmic reticulum (SR) Ca<sup>2+</sup> cycling, a 
universal characteristic of human and experimental heart failure, may be 
associated with genetic alterations in key Ca<sup>2+</sup>-handling 
proteins. In this study, we identified a novel PLN mutation (R25C) in 
dilated cardiomyopathy (DCM) and investigated its functional significance in 
cardiomyocyte Ca<sup>2+</sup>-handling and contractility. Methods and 
results Exome sequencing identified a C73T substitution in the coding region 
of PLN in a family with DCM. The four heterozygous family members had 
implantable cardiac defibrillators, and three developed prominent 
ventricular arrhythmias. Overexpression of R25C-PLN in adult rat 
cardiomyocytes significantly suppressed the Ca<sup>2+</sup> affinity of SR 
Ca<sup>2+</sup>-ATPase (SERCA2a), resulting in decreased SR Ca<sup>2+</sup> 
content, Ca<sup>2+</sup> transients, and impaired contractile function, 
compared with WT-PLN. These inhibitory effects were associated with enhanced 
interaction of R25C-PLN with SERCA2, which was prevented by PKA 
phosphorylation. Accordingly, isoproterenol stimulation relieved the 
depressive effects of R25C-PLN in cardiomyocytes. However, R25C-PLN also 
elicited increases in the frequency of Ca<sup>2+</sup> sparks and waves as 
well as stress-induced aftercontractions. This was accompanied by increased 
Ca<sup>2+</sup>/calmodulin-dependent protein kinase II activity and 
hyper-phosphorylation of RyR2 at serine 2814. Conclusion The findings 
demonstrate that human R25C-PLN is associated with super-inhibition of 
SERCA2a and Ca<sup>2+</sup> transport as well as increased SR 
Ca<sup>2+</sup> leak, promoting arrhythmogenesis under stress conditions. 
This is the first mechanistic evidence that increased PLN inhibition may 
impact both SR Ca<sup>2+</sup> uptake and Ca<sup>2+</sup> release activities 
and suggests that the human R25C-PLN may be a prognostic factor for 
increased ventricular arrhythmia risk in DCM carriers.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  arginine (endogenous compound)
  calcium ion (endogenous compound)
  cysteine (endogenous compound)
  phospholamban (endogenous compound)
EMTREE DRUG INDEX TERMS
  angiotensin receptor antagonist (drug therapy)
  calcium calmodulin dependent protein kinase II (endogenous compound)
  cyclic AMP dependent protein kinase (endogenous compound)
  isoprenaline (pharmacology)
  ryanodine receptor 2 (endogenous compound)
  sarcoplasmic reticulum calcium transporting adenosine triphosphatase 
(endogenous compound)
  serine (endogenous compound)
  threonine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  congestive cardiomyopathy
  heart ventricle arrhythmia
  missense mutation
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  amino acid substitution
  animal cell
  animal experiment
  animal model
  arrhythmogenesis
  article
  binding affinity
  cardioversion
  case report
  chronic atrial fibrillation (therapy)
  controlled study
  drug effect
  enzyme activity
  exome
  exome sequencing
  female
  gene overexpression
  heart failure (drug therapy, surgery, therapy)
  heart muscle cell
  heart muscle contractility
  heart transplantation
  human
  human cell
  in vitro study
  in vivo study
  male
  middle aged
  nonhuman
  priority journal
  protein phosphorylation
  protein protein interaction
  rat
  sarcoplasmic reticulum
  sequence analysis
  stress
  sudden cardiac death
  very elderly
CAS REGISTRY NUMBERS
  arginine (1119-34-2, 15595-35-4, 7004-12-8, 74-79-3)
  calcium calmodulin dependent protein kinase II (141467-21-2)
  calcium ion (14127-61-8)
  cyclic AMP dependent protein kinase ()
  cysteine (4371-52-2, 52-89-1, 52-90-4)
  isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
  phospholamban (113610-15-4)
  serine (56-45-1, 6898-95-9)
  threonine (36676-50-3, 72-19-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Human Genetics (22)
  Drug Literature Index (37)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015185608
FULL TEXT LINK
  http://dx.doi.org/10.1093/cvr/cvv127
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 175
TITLE
  Invasive electrophysiological evaluation and ablation in patients with 
asymptomatic ventricular pre-excitation persistent at exercise stress test
AUTHOR NAMES
  De Ponti R.
  Marazzi R.
  Doni L.A.
  Cremona V.
  Marazzato J.
  Salerno-Uriarte J.A.
AUTHOR ADDRESSES
  (De Ponti R., rdeponti@alice.it; Marazzi R.; Doni L.A.; Cremona V.; 
Marazzato J.; Salerno-Uriarte J.A.) Department of Heart and Vessels, 
Ospedale di Circolo e Fondazione Macchi, University of Insubria, Viale 
Borri, 57, Varese, Italy.
CORRESPONDENCE ADDRESS
  R. De Ponti, Department of Heart and Vessels, Ospedale di Circolo e 
Fondazione Macchi, University of Insubria, Viale Borri, 57, Varese, Italy.
SOURCE
  Europace (2015) 17:6 (946-952). Date of Publication: 2015
ISSN
  1532-2092 (electronic)
  1099-5129
BOOK PUBLISHER
  Oxford University Press, jnl.info@oup.co.uk
ABSTRACT
  Aims In patients with asymptomatic ventricular pre-excitation (VPE) 
persistent at exercise stress test, this study evaluates the proportion of 
cases with adverse conduction properties of the atrioventricular accessory 
pathway (AP) at invasive electrophysiological study and the long-term 
follow-up after they received treatment according to pre-determined 
criteria. Methods and results Over 10 years, asymptomatic patients with VPE 
persistent at exercise stress test referred for invasive 
electrophysiological evaluation including isoproterenol (IPN) infusion were 
included. Ablation was planned if they had at least one of the following 
criteria: (i) shortest pre-excited R-R interval (SPERRI) ≤250 ms and/or (ii) 
inducible atrioventricular re-entrant tachycardia (AVRT). Cryoablation was 
electively used in para-hisian and mid-septal APs. Patients non-eligible for 
ablation received no therapy. Sixty-three patients (45 males; mean age 26±14 
years) underwent electrophysiological evaluation: 7 had 
fasciculo-ventricular fibres and were excluded, whereas 56 had 58 APs. 
Thirty-one patients (55%)were eligible and underwent successful ablation: 
87% had at least the SPERRI ≤ 250 ms and 61% had at least inducible AVRT. In 
15 cases (48%) the ablation criteria were met only during IPN infusion. 
During follow-up (73±33 months), one patient was successfully retreated for 
resumption of VPE in the ablation group, whereas no event was observed in 
the group of patients who received no treatment. Conclusion In this subset 
of patients with asymptomatic VPE, invasive electrophysiological evaluation 
shows fast antegrade conduction over the AP and/or inducible AVRT in about 
half of the cases. Patients who received no therapy because of a benign 
electrophysiological profile had an event-free follow-up.
EMTREE DRUG INDEX TERMS
  isoprenaline
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cryoablation
  electrophysiology
  heart preexcitation
  ventricular preexcitation
EMTREE MEDICAL INDEX TERMS
  adolescent
  adult
  article
  atrial fibrillation
  atrioventricular reentrant tachycardia
  cardiopulmonary exercise test
  catheter ablation
  child
  cohort analysis
  female
  follow up
  heart atrium pacing
  human
  major clinical study
  male
  priority journal
  retrospective study
  tachycardia
CAS REGISTRY NUMBERS
  isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015397867
FULL TEXT LINK
  http://dx.doi.org/10.1093/europace/euu324
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 176
TITLE
  Challenging aspects of treatment strategies in heart failure with preserved 
ejection fraction: "Why did recent clinical trials fail?"
AUTHOR NAMES
  Becher P.M.
  Fluschnik N.
  Blankenberg S.
  Westermann D.
AUTHOR ADDRESSES
  (Becher P.M., m.becher@uke.de; Fluschnik N.; Blankenberg S.; Westermann D.) 
Department of General and Interventional Cardiology, University Heart Center 
Hamburg Eppendorf, Martinistraße 52, Hamburg, Germany.
CORRESPONDENCE ADDRESS
  P.M. Becher, Department of General and Interventional Cardiology, University 
Heart Center Hamburg Eppendorf, Martinistraße 52, Hamburg, Germany.
SOURCE
  World Journal of Cardiology (2015) 7:9 (544-554). Date of Publication: 2015
ISSN
  1949-8462 (electronic)
BOOK PUBLISHER
  Baishideng Publishing Group Co, bpg@baishideng.com
ABSTRACT
  Heart failure (HF) is the leading cause of hospitalization among older 
adults and the prevalence is growing with the aging populations in the 
Western countries. Epidemiologic reports suggest that approximately 50% of 
patients who have signs or symptoms of HF have preserved left ventricular 
ejection fraction. This HF type predominantly affects women and the elderly 
with other co-morbidities, such as diabetes, hypertension, and overt volume 
status. Most of the current treatment strategies are based on morbidity 
benefits such as quality of life and reduction of clinical HF symptoms. 
Treatment of patients with HF with preserved ejection fraction displayed 
disappointing results from several large randomized controlled trials. The 
heterogeneity of HF with preserved ejection fraction, understood as complex 
syndrome, seems to be one of the primary reasons. Here, we present an 
overview of the current management strategies with available evidence and 
new therapeutic approach from drugs currently in clinical trials, which 
target diastolic dysfunction, chronotropic incompetence, and risk factor 
management. We provide an outline and interpretation of recent clinical 
trials that failed to improve outcome and survival in patients with HF with 
preserved ejection fraction.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  cardiovascular agent (drug therapy)
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (clinical trial)
  angiotensin receptor antagonist
  candesartan
  digitalis
  digoxin
  diuretic agent
  endothelin 1 (endogenous compound)
  enkephalinase inhibitor
  guanylate cyclase inhibitor
  irbesartan
  ivabradine
  nebivolol
  perindopril
  phosphodiesterase V (endogenous compound)
  phosphodiesterase V inhibitor
  ranolazine (drug therapy)
  sacubitril plus valsartan
  sildenafil
  spironolactone
  valsartan
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart ejection fraction
  heart failure (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  action potential
  atrial fibrillation
  cardiac resynchronization therapy
  cardiovascular effect
  cardiovascular mortality
  cardiovascular risk
  chronotropism
  clinical trial (topic)
  coronary artery blood flow
  coronary artery bypass surgery
  device therapy
  diastolic dysfunction
  diastolic heart failure (drug therapy)
  drug effect
  echocardiography
  evidence based practice
  exercise
  functional status
  genetic heterogeneity
  heart function
  heart left ventricle ejection fraction
  heart muscle ischemia
  heart output
  heart performance
  heart ventricle performance
  high risk patient
  hospitalization
  human
  managed care
  multicenter study (topic)
  outcome assessment
  percutaneous coronary intervention
  phase 2 clinical trial (topic)
  phase 3 clinical trial (topic)
  practice guideline
  primary medical care
  quality of life
  randomized controlled trial (topic)
  risk assessment
  risk factor
  short survey
  survival rate
DRUG TRADE NAMES
  lcz 696
  nebivolol
CAS REGISTRY NUMBERS
  candesartan (139481-59-7)
  digitalis (8031-42-3, 8053-83-6)
  digoxin (20830-75-5, 57285-89-9)
  irbesartan (138402-11-6)
  ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
  nebivolol (99200-09-6, 118457-15-1, 118457-16-2)
  perindopril (82834-16-0, 99149-83-4)
  ranolazine (95635-55-5)
  sacubitril plus valsartan (936623-90-4)
  sildenafil (139755-83-2)
  spironolactone (52-01-7)
  valsartan (137862-53-4)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015490048
FULL TEXT LINK
  http://dx.doi.org/10.4330/wjc.v7.i9.544
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 177
TITLE
  Health information technologies in cardiology: Mobile devices, home 
monitoring, and E-prescribing
AUTHOR NAMES
  Figge H.L.
AUTHOR ADDRESSES
  (Figge H.L.) Lumira (USA), Inc. Senior Vice President Global Strategic 
Development, Waltham, United States.
CORRESPONDENCE ADDRESS
  H.L. Figge, Lumira (USA), Inc. Senior Vice President Global Strategic 
Development, Waltham, United States.
SOURCE
  U.S. Pharmacist (2015) 40:2 (58-60). Date of Publication: 2015
ISSN
  0148-4818
BOOK PUBLISHER
  Jobson Publishing Corporation
ABSTRACT
  Health information technology (HIT) is opening many new frontiers and 
possibilities in cardiology and pharmacy. Revolutionary advances have been 
fueled by the widespread adoption of mobile technology, the availability of 
home diagnostic devices, and the widespread use of electronic prescribing. 
This article presents an overview of each of these major developments.
EMTREE DRUG INDEX TERMS
  anticoagulant agent
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiology
  electronic prescribing
  home monitoring
  medical informatics
  mobile phone
EMTREE MEDICAL INDEX TERMS
  adoption
  anticoagulant therapy
  article
  atrial fibrillation
  blood pressure monitor
  cardiac patient
  decision support system
  emotional stability
  exercise
  human
  nutrition
  pharmacist
  prothrombin time
  smoking cessation
CAS REGISTRY NUMBERS
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015768640
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 178
TITLE
  The role of multimodality cardiac imaging for the assessment of sports 
eligibility in patients with bicuspid aortic valve
AUTHOR NAMES
  D'Andrea A.
  Corte A.D.
  Padalino R.
  Limongelli G.
  Scarafile R.
  Fratta F.
  Pezzullo E.
  Fusco A.
  Pisacane F.
  Coppola G.
  Caso P.
  Calabrò R.
  Russo M.G.
AUTHOR ADDRESSES
  (D'Andrea A., antonellodandrea@libero.it; Padalino R.; Limongelli G.; 
Scarafile R.; Fratta F.; Pezzullo E.; Fusco A.; Pisacane F.; Coppola G.; 
Caso P.; Calabrò R.; Russo M.G.) Chair of Cardiology, Second University of 
Naples, Monaldi Hospital, Naples, Italy.
(Corte A.D.) Department of Cardiothoracic Sciences, Second University of 
Naples, Monaldi Hospital, Naples, Italy.
CORRESPONDENCE ADDRESS
  A. D'Andrea, Via M. Schipa 44, Naples, Italy.
SOURCE
  Journal of Cardiovascular Echography (2015) 25:1 (9-18). Date of 
Publication: 1 Jan 2015
ISSN
  2347-193X (electronic)
  2211-4122
BOOK PUBLISHER
  Medknow Publications, B9, Kanara Business Centre, off Link Road, Ghatkopar 
(E), Mumbai, India.
ABSTRACT
  Bicuspid aortic valve (BAV) cannot be considered an innocent finding, but it 
is not necessarily a life-threatening condition. Athletes with BAV should 
undergo a thorough staging of the valve anatomy, taking into consideration 
hemodynamic factors, as well as aortic diameters and looking for other 
associated significant cardiovascular anomalies by use of a multimodality 
cardiac imaging approach. Furthermore an accurate follow-up is mandatory 
with serial cardiological controls in those allowed to continue sports.
EMTREE DRUG INDEX TERMS
  anabolic agent
  biological marker
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  bicuspid aortic valve
  cardiac imaging
  sport
EMTREE MEDICAL INDEX TERMS
  anatomy
  aorta aneurysm
  aorta coarctation
  aorta dissection
  aorta stenosis
  aorta valve regurgitation
  aorta valve replacement
  athlete
  atrial fibrillation
  cardiovascular disease
  cardiovascular magnetic resonance
  cardiovascular malformation
  color ultrasound flowmetry
  congestive cardiomyopathy
  diastolic dysfunction
  differential diagnosis
  disease association
  disease course
  dynamic exercise
  ECG abnormality
  endurance training
  faintness
  follow up
  health care system
  heart atrium enlargement
  heart function
  heart left ventricle enddiastolic volume
  heart left ventricle hypertrophy
  heart muscle ischemia
  heart stroke volume
  heredity
  Holter monitoring
  human
  hypoplastic left heart syndrome
  isometric exercise
  isotonic exercise
  life expectancy
  Marfan syndrome
  morphogenesis
  nuclear magnetic resonance imaging
  pathogenesis
  prognosis
  review
  Ross procedure
  shear stress
  systole
  systolic dysfunction
  three dimensional echocardiography
  transluminal valvuloplasty
  Turner syndrome
EMBASE CLASSIFICATIONS
  Radiology (14)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015149434
FULL TEXT LINK
  http://dx.doi.org/10.4103/2211-4122.158418
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 179
TITLE
  Postlobectomy Early Complications
AUTHOR NAMES
  Ziarnik E.
  Grogan E.L.
AUTHOR ADDRESSES
  (Ziarnik E.) Department of Thoracic Surgery, Vanderbilt University Medical 
Center, 1313 21st Avenue South, Nashville, United States.
(Grogan E.L., eric.grogan@vanderbilt.edu) Department of Thoracic Surgery, 
Tennessee Valley Healthcare System, Vanderbilt University Medical Center, 
Nashville Campus, 609 Oxford House, 1313 21st Avenue South, Nashville, 
United States.
CORRESPONDENCE ADDRESS
  E.L. Grogan, Department of Thoracic Surgery, Tennessee Valley Healthcare 
System, Vanderbilt University Medical Center, Nashville Campus, 609 Oxford 
House, 1313 21st Avenue South, Nashville, United States.
SOURCE
  Thoracic Surgery Clinics (2015) 25:3 (355-364). Date of Publication: 1 Aug 
2015
ISSN
  1558-5069 (electronic)
BOOK PUBLISHER
  W.B. Saunders
ABSTRACT
  Immediate postoperative complications are common after lobectomy. The most 
effective management of postoperative crises is prevention, which starts 
with preoperative preparation and patient screening. There are many factors 
that can be controlled and improved by the patient. Equally important is 
patient selection, which is influenced by pulmonary function tests, 
cardiopulmonary reserve, and preexisting comorbidities. After the operation, 
the care team can also greatly improve outcomes with aggressive 
cardiopulmonary therapies, ambulation, vigilant monitoring, and frequent 
assessments of the patient. Prevention strategies can minimize risks; 
however, when they occur, a proactive approach may minimize the long-term 
sequelae.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
  antibiotic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
  collagen (drug therapy)
  cyanoacrylate
  digoxin (drug therapy)
  diltiazem (drug therapy)
  fibrin glue
  magnesium sulfate (drug therapy)
  politef
  resorcinol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  lung lobectomy
  postoperative complication (complication, disease management, epidemiology, 
prevention)
EMTREE MEDICAL INDEX TERMS
  adult respiratory distress syndrome (complication, epidemiology)
  air leakage (complication, epidemiology, prevention, surgery, therapy)
  antibiotic therapy
  atelectasis (complication, diagnosis, epidemiology, prevention, therapy)
  atrial fibrillation (complication, drug therapy, epidemiology, etiology, 
prevention)
  autotransplantation
  azygous vein
  breathing exercise
  bronchopleural fistula (complication, epidemiology, prevention, surgery)
  bronchoscopy
  cauterization
  chest tube
  chylothorax (complication, epidemiology, surgery, therapy)
  computed tomographic angiography
  diaphragmatic plication
  disease severity
  empyema (complication, epidemiology)
  erythrocyte transfusion
  fluoroscopy
  hospital infection (complication, drug therapy, epidemiology, prevention)
  human
  implant
  incidence
  intermittent positive pressure ventilation
  laryngoscopy
  lung resection
  mediastinal fat pad
  mobilization
  mucolysis
  mucus plugging (complication, epidemiology, prevention, therapy)
  muscle flap
  nerve injury (complication, diagnosis, epidemiology, surgery)
  nonsurgical invasive therapy
  pericardial patch
  pleura
  pleural tent
  pneumonia (complication, epidemiology)
  postoperative analgesia
  postoperative hemorrhage (complication, epidemiology, prevention, surgery, 
therapy)
  postoperative lobar torsion (complication, diagnosis, epidemiology, 
prevention, surgery)
  practice guideline
  preoperative care
  pressure support ventilation
  priority journal
  prophylaxis
  quality of life
  recurrent laryngeal nerve injury (complication, diagnosis, drug therapy, 
epidemiology, surgery)
  reoperation
  respiratory therapeutic device
  respiratory tract disease (complication, epidemiology, prevention, therapy)
  respirometry
  review
  risk factor
  risk reduction
  sealant
  smoking cessation
  strategic planning
  surgical approach
  surgical drainage
  surgical mortality
  surgical stapling
  surgical technique
  suturing method
  thoracotomy
  thorax surgery
  tracheobronchial toilet
  transesophageal echocardiography
  treatment indication
  vein
  video assisted thoracoscopic surgery
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  collagen (9007-34-5)
  cyanoacrylate (15802-18-3)
  digoxin (20830-75-5, 57285-89-9)
  diltiazem (33286-22-5, 42399-41-7)
  magnesium sulfate (7487-88-9)
  politef (9002-84-0, 9039-02-5)
  resorcinol (108-46-3)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015220150
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.thorsurg.2015.04.003
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 180
TITLE
  A systematic review of the effects of telerehabilitation in patients with 
cardiopulmonary diseases
AUTHOR NAMES
  Hwang R.
  Bruning J.
  Morris N.
  Mandrusiak A.
  Russell T.
AUTHOR ADDRESSES
  (Hwang R., r.hwang@uq.net.au) Department of Physiotherapy, Princess 
Alexandra Hospital, Metro South Health, Brisbane, Australia.
(Bruning J.) Department of Physiotherapy, Heart Failure Support Service, 
Prince Charles Hospital, Brisbane, Australia.
(Morris N.) Menzies Health Institute Queensland, School of Allied Health 
Sciences, Griffith University, Gold Coast, Australia.
(Mandrusiak A.; Russell T.) Physiotherapy, School of Health and 
Rehabilitation Sciences, University of Queensland, Brisbane, Australia.
CORRESPONDENCE ADDRESS
  R. Hwang, Department of Physiotherapy, Princess Alexandra Hospital, Metro 
South Health, Brisbane, Australia.
SOURCE
  Journal of Cardiopulmonary Rehabilitation and Prevention (2015) 35:6 
(380-389). Date of Publication: 2015
ISSN
  1932-751X (electronic)
  1932-7501
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  PURPOSE: To examine the effects of telerehabilitation compared with other 
delivery models for improving physical or functional outcomes in patients 
with cardiopulmonary diseases. METHODS: A search was completed for English 
language publications from 1990 to August 2013 across 4 electronic databases 
and gray literature. Inclusion criteria were: (1) home-based 
telerehabilitation as a core component; (2) at least 2 exercise sessions; 
(3) randomized controlled trials; and (4) reporting of physical or 
functional outcome measures in adult patients with coronary heart disease, 
chronic heart failure, and chronic respiratory disease. Studies were 
independently screened by 2 reviewers and graded by a reviewer according to 
the Downs and Black checklist. A narrative synthesis of the included studies 
was undertaken. RESULTS: Eleven studies were analyzed. It appears that 
telerehabilitation is no different to other delivery models for patients 
with cardiopulmonary diseases, in terms of exercise capacity expressed as 
distance on the 6-minute walk test and peak oxygen consumption and quality 
of life. Telerehabilitation appears to have higher adherence rates compared 
with center-based exercise. There has been similar or no adverse events 
reported in telerehabilitation compared with center-based exercise. 
CONCLUSIONS: Although telerehabilitation shows promise in patients with 
cardiopulmonary diseases, compelling evidence is still limited. There is a 
need for more detailed, high-quality studies and for studies on the use of 
video-based telerehabilitation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiopulmonary disease (rehabilitation)
  cardiovascular disease (rehabilitation)
  heart rehabilitation
  pulmonary rehabilitation
  respiratory tract disease (rehabilitation)
  telehealth
  telerehabilitation
EMTREE MEDICAL INDEX TERMS
  6 minute walk test
  angina pectoris (complication)
  atrial fibrillation (complication)
  chronic obstructive lung disease (complication)
  chronic respiratory tract disease
  disease severity
  exercise
  function test
  health care utilization
  heart arrhythmia (complication)
  heart failure
  heart ventricle extrasystole (complication)
  human
  hypertension (complication)
  ischemic heart disease
  meta analysis
  muscle strength
  outcome assessment
  oxygen consumption
  patient compliance
  priority journal
  quality of life
  review
  supraventricular contraction (complication)
  systematic review
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015497950
FULL TEXT LINK
  http://dx.doi.org/10.1097/HCR.0000000000000121
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 181
TITLE
  How to walk the tightrope between harm and protection in selecting the 
optimal antiplatelet treatment strategy after transcatheter left atrial 
appendage occlusion
AUTHOR NAMES
  Pracoñ R.
  Demkow M.
AUTHOR ADDRESSES
  (Pracoñ R., radekpracon@yahoo.pl; Demkow M.) Coronary and Structural Heart 
Diseases Department, Institute of Cardiology, 42 Alpejska St, Warsaw, 
Poland.
CORRESPONDENCE ADDRESS
  R. Pracoñ, Coronary and Structural Heart Diseases Department, Institute of 
Cardiology, 42 Alpejska St, Warsaw, Poland.
SOURCE
  Postepy w Kardiologii Interwencyjnej (2015) 11:1 (5-8). Date of Publication: 
2015
ISSN
  1897-4295 (electronic)
  1734-9338
BOOK PUBLISHER
  Termedia Publishing House Ltd., Kleeberqa St.2, Poznan, Poland.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  antithrombocytic agent (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  anticoagulant agent
  antivitamin K
  apixaban
  clopidogrel
  fibrin
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  atrial fibrillation
  left atrial appendage closure device
  thromboembolism (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  bleeding (side effect)
  blood clotting
  cardiovascular risk
  cerebrovascular accident
  clinical practice
  drug efficacy
  drug safety
  embolism prevention
  fibrin formation
  follow up
  health care quality
  heart atrium appendage
  high risk patient
  human
  meta analysis (topic)
  practice guideline
  primary prevention
  randomized controlled trial (topic)
  review
  risk benefit analysis
DEVICE TRADE NAMES
  Amplatzer Cardiac Plug
  WATCHMAN
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  apixaban (503612-47-3)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  fibrin (9001-31-4)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2015812248
FULL TEXT LINK
  http://dx.doi.org/10.5114/pwki.2015.49177
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 182
TITLE
  Heart failure: Key points and recent developments in management
AUTHOR NAMES
  Davis R.
AUTHOR ADDRESSES
  (Davis R.) Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich, 
United Kingdom.
CORRESPONDENCE ADDRESS
  R. Davis, Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich, 
United Kingdom.
SOURCE
  Prescriber (2015) 26:6 (25-31). Date of Publication: 19 Mar 2015
ISSN
  1931-2253 (electronic)
  0959-6682
BOOK PUBLISHER
  Blackwell Publishing Ltd, customerservices@oxonblackwellpublishing.com
ABSTRACT
  Treatment of heart failure is evolving rapidly. Our drug review highlights 
recent developments in diagnosis and management and emerging new therapies.
EMTREE DRUG INDEX TERMS
  amino terminal pro brain natriuretic peptide (endogenous compound)
  beta adrenergic receptor blocking agent (clinical trial, drug comparison - 
placebo, drug therapy)
  brain natriuretic peptide (endogenous compound)
  diuretic agent (drug therapy, intravenous drug administration)
  electrolyte (endogenous compound)
  eplerenone (drug therapy)
  ivabradine (drug therapy)
  metformin (drug therapy)
  placebo
  sacubitril plus valsartan (drug therapy)
  spironolactone (drug therapy)
  ubidecarenone (clinical trial, drug comparison - placebo, drug therapy)
  urea (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (drug therapy, diagnosis, drug therapy, rehabilitation)
EMTREE MEDICAL INDEX TERMS
  adjuvant therapy
  anemia
  angiocardiography
  article
  atrial fibrillation
  cardiovascular magnetic resonance
  chronic obstructive lung disease
  computer assisted tomography
  contrast enhancement
  diabetes mellitus (drug therapy)
  echocardiography
  electrolyte blood level
  exercise
  heart failure with preserved ejection fraction
  heart infarction
  heart rehabilitation
  human
  nuclear magnetic resonance imaging
  protein blood level
  sinus rhythm
  terminal care
  thyroid function test
  urea blood level
DRUG TRADE NAMES
  inspra
  lcz 696
  procoralan
CAS REGISTRY NUMBERS
  3 (1 biphenyl 4 ylmethyl 3 ethoxycarbonyl 1 butylcarbamoyl)propionic acid 
plus valsartan (936623-90-4)
  brain natriuretic peptide (114471-18-0)
  eplerenone (107724-20-9)
  ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
  metformin (1115-70-4, 657-24-9)
  spironolactone (52-01-7)
  ubidecarenone (303-98-0)
  urea (57-13-6)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Endocrinology (3)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015841469
FULL TEXT LINK
  http://dx.doi.org/10.1002/psb.1325
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 183
TITLE
  Masked hypertension and cardiac remodeling in middle-aged endurance athletes
AUTHOR NAMES
  Trachsel L.D.
  Carlen F.
  Brugger N.
  Seiler C.
  Wilhelm M.
AUTHOR ADDRESSES
  (Trachsel L.D.; Carlen F.; Brugger N.; Seiler C.; Wilhelm M., 
matthias.wilhelm@insel.ch) University Clinic for Cardiology, Inselspital, 
University Hospital and University of Bern, Bern, Switzerland.
CORRESPONDENCE ADDRESS
  M. Wilhelm, University Clinic for Cardiology, Inselspital, University 
Hospital and University of Bern, Bern, Switzerland.
SOURCE
  Journal of Hypertension (2015) 33:6 (1276-1283). Date of Publication: 6 Jun 
2015
ISSN
  1473-5598 (electronic)
  0263-6352
BOOK PUBLISHER
  Lippincott Williams and Wilkins, agents@lww.com
ABSTRACT
  Objectives: Extensive endurance training and arterial hypertension are 
established risk factors for atrial fibrillation. We aimed to assess the 
proportion of masked hypertension in endurance athletes and the impact on 
cardiac remodeling, mechanics, and supraventricular tachycardias (SVT). 
Methods: Male participants of a 10-mile race were recruited and included if 
office blood pressure was normal (<140/90 mmHg). Athletes were stratified 
into a masked hypertension and normotension group by ambulatory blood 
pressure. Primary endpoint was diastolic function, expressed as peak early 
diastolic mitral annulus velocity (E'). Left ventricular global strain, left 
ventricular mass/volume ratio, left atrial volume index, signal-averaged 
P-wave duration (SAPWD), and SVT during 24-h Holter monitoring were 
recorded. Results: From 108 runners recruited, 87 were included in the final 
analysis. Thirty-three (38%) had masked hypertension. The mean age was 42 ± 
8 years. Groups did not differ with respect to age, body composition, 
cumulative training hours, and 10-mile race time. Athletes with masked 
hypertension had a lower E' and a higher left ventricular mass/volume ratio. 
Left ventricular global strain, left atrial volume index, SAPWD, and SVT 
showed no significant differences between the groups. In multiple linear 
regression analysis, masked hypertension was independently associated with 
E' (beta = - 0.270, P = 0.004) and left ventricular mass/volume ratio (beta 
= 0.206, P = 0.049). Cumulative training hours was the only independent 
predictor for left atrial volume index (beta = 0.474, P < 0.001) and SAPWD 
(beta = 0.481, P < 0.001). Conclusion: In our study, a relevant proportion 
of middle-aged athletes had masked hypertension, associated with a lower 
diastolic function and a higher left ventricular mass/volume ratio, but 
unrelated to left ventricular systolic function, atrial remodeling, or SVT.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  endurance sport
  heart atrium remodeling
  masked hypertension
  supraventricular tachycardia
EMTREE MEDICAL INDEX TERMS
  adult
  article
  athlete
  atrial fibrillation
  biomechanics
  blood pressure
  blood pressure monitoring
  body composition
  cardiovascular parameters
  clinical article
  clinical assessment
  diastolic blood pressure
  disease association
  endurance training
  heart left ventricle mass
  heart left ventricle volume
  Holter monitoring
  human
  left atrial volume index
  left ventricular global strain
  male
  middle aged
  P wave
  priority journal
  race
  risk factor
  signal averaged p wave duration
  systolic blood pressure
  transthoracic echocardiography
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015010514
FULL TEXT LINK
  http://dx.doi.org/10.1097/HJH.0000000000000558
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 184
TITLE
  Analysis and Thoughts about the Negative Results of International Clinical 
Trials on Acupuncture
AUTHOR NAMES
  Liu W.-H.
  Hao Y.
  Han Y.-J.
  Wang X.-H.
  Li C.
  Liu W.-N.
AUTHOR ADDRESSES
  (Liu W.-H., weihongliu010@sina.com; Hao Y., sjzj2468@sina.com; Han Y.-J., 
han19920714@sina.com; Wang X.-H., laomimami@hotmail.com; Li C., 
41446417@qq.com; Liu W.-N., lwn8864@163.com) Institute of Acupuncture and 
Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
CORRESPONDENCE ADDRESS
  W.-N. Liu, Institute of Acupuncture and Moxibustion, China Academy of 
Chinese Medical Sciences, Beijing, China.
SOURCE
  Evidence-based Complementary and Alternative Medicine (2015) 2015 Article 
Number: 671242. Date of Publication: 2015
ISSN
  1741-4288 (electronic)
  1741-427X
BOOK PUBLISHER
  Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New 
York, United States.
ABSTRACT
  An increasing number of randomized controlled trials (RCTs) of acupuncture 
have proved the clinical benefits of acupuncture; however, there are some 
results that have shown negative results or placebo effects. The paper 
carried out an in-depth analysis on 33 RCTs in the 2011 SCI database, the 
quality of the reports was judged according to Jadad scores, and the 
"Necessary Information Included in Reporting Interventions in Clinical 
Trials of Acupuncture (STRICTA 2010)" was taken as the standard to analyze 
the rationality of the therapeutic principle. The difference between the 
methodology (Jadad) scores of the two types of research reports did not 
constitute statistical significance (P>0.05). The studies with negative 
results or placebo effects showed the following deficiencies with respect to 
intervention details: (1) incompletely rational acupoint selection; (2) 
inconsistent ability of acupuncturists; (3) negligible needling response to 
needling; (4) acupuncture treatment frequency too low in most studies; and 
(5) irrational setting of placebo control. Thus, the primary basis for the 
negative results or placebo effects of international clinical trials on 
acupuncture is not in the quality of the methodology, but in noncompliance 
with the essential requirements proposed by acupuncture theory in terms of 
clinical manipulation details.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  placebo effect
  randomized controlled trial (topic)
EMTREE MEDICAL INDEX TERMS
  acupressure
  acupuncture analgesia
  article
  asthma (therapy)
  atrial fibrillation (therapy)
  cancer fatigue (therapy)
  cesarean section
  dysmenorrhea (therapy)
  eczema (therapy)
  electroacupuncture
  human
  infertility (therapy)
  knee osteoarthritis (therapy)
  low back pain (therapy)
  medical research
  menopausal syndrome (therapy)
  methodology
  migraine (therapy)
  motion sickness (therapy)
  moxibustion
  nausea and vomiting (therapy)
  neck pain (therapy)
  neurosis (therapy)
  obesity (therapy)
  peripheral neuropathy (therapy)
  physiotherapy
  postoperative nausea (therapy)
  premature ejaculation (therapy)
  priority journal
  statistical significance
  tinnitus (therapy)
  uterine cervix dilatation
EMBASE CLASSIFICATIONS
  Rehabilitation and Physical Medicine (19)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015172614
FULL TEXT LINK
  http://dx.doi.org/10.1155/2015/671242
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 185
TITLE
  Safety and efficacy of cardiac rehabilitation for patients with continuous 
flow left ventricular assist devices
AUTHOR NAMES
  Marko C.
  Danzinger G.
  Käferbäck M.
  Lackner T.
  Müller R.
  Zimpfer D.
  Schima H.
  Moscato F.
AUTHOR ADDRESSES
  (Marko C., christiane.marko@pensionsversicherung.at; Lackner T.) 
Rehabilitation Center Felbring, Austria.
(Danzinger G.; Käferbäck M.; Schima H.; Moscato F.) Center for Medical 
Physics and Biomedical Engineering, Medical University of Vienna, Austria.
(Danzinger G.; Käferbäck M.; Zimpfer D.; Schima H.; Moscato F.) Ludwig 
Boltzmann Cluster for Cardiovascular Research, Austria.
(Müller R.) Pensionsversicherungsanstalt, Austria.
(Schima H.) Department of Cardiac Surgery, Medical University of Vienna, 
Austria.
CORRESPONDENCE ADDRESS
  C. Marko, Rehabilitationszentrum Felbring der Pensionsversicherungsanstalt, 
Felbring 71, Muthmannsdorf, Austria.
SOURCE
  European Journal of Preventive Cardiology (2015) 22:11 (1378-1384). Date of 
Publication: 1 Nov 2015
ISSN
  2047-4881 (electronic)
  2047-4873
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  Background Despite the increasing use of left ventricular assist devices 
(LVADs) in terminal heart failure, cardiac rehabilitation protocols have not 
yet been documented in larger LVAD patient cohorts. The aim of this study 
was to investigate safety and efficacy of exercise training during a 
rehabilitation programme after post-operative discharge of LVAD patients. 
Methods Rehabilitation data obtained between 2010-2012 from 41 LVAD patients 
(mean age 54.8 ± 11.6 years; 20% female) were retrospectively analysed. The 
exercise protocol consisted of strength exercises for lower limbs, bicycle 
ergometry, walking and gymnastics. The numbers of training sessions, their 
duration and intensity as well as adverse events were documented. 
Spiroergometry was performed at least once and twice in a subgroup of 15 
patients (at the beginning and end of rehabilitation). Results 
Rehabilitation started 48 ± 38 days post LVAD implantation with an average 
duration of 32 ± 6 days. An increase in exercise capacity was observed. 
Duration (19 ± 4 vs 14 ± 2 min, p < 0.001) and intensity of bicycle 
ergometry increased (module number 6.2 ± 2.8 vs 2.0 ± 1.9, p < 0.001) as 
well as muscular strength all muscle groups trained (e.g. 33.6 ± 15.2 vs 
26.6 ± 11.9 kg at the leg press, p = 0.002). Spiroergometry revealed an 
increase of maximal oxygen consumption (14.5 ± 5.2 vs 11.3 ± 4.1 ml/min/kg, 
p = 0.007) in the subgroup that underwent two examinations. In the whole 
population the average increase was lower (12.81 ± 4.35 ml/min/kg). One 
training-related adverse event (non-sustained ventricular tachycardia) was 
observed. Conclusion Exercise training for LVAD patient as part of a 
multidisciplinary rehabilitation programme is effective and safe. This 
warrants the broad application of exercise training after LVAD implantation.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent
  dipeptidyl carboxypeptidase inhibitor
  furosemide
  ramipril
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  continuous flow left ventricular assist device
  device safety
  heart rehabilitation
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation
  bicycle ergometry
  cardiac resynchronization therapy
  clinical article
  exercise
  female
  human
  implantable cardioverter defibrillator
  male
  muscle strength
  oxygen consumption
  physical performance
  priority journal
  resistance training
  retrospective study
DEVICE TRADE NAMES
  heart mate ii  , United StatesThoratec

DEVICE MANUFACTURERS
   (United States)HeartWare
   (United States)Thoratec
CAS REGISTRY NUMBERS
  furosemide (54-31-9)
  ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015446178
FULL TEXT LINK
  http://dx.doi.org/10.1177/2047487314558772
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 186
TITLE
  Cross-country skiing injuries and training methods
AUTHOR NAMES
  Nagle K.B.
AUTHOR ADDRESSES
  (Nagle K.B., kyle.nagle@childrenscolorado.org) University of Colorado, 
Department of Orthopedics, Children's Hospital Colorado Orthopedics 
Institute, 13123 East 16th Avenue, Aurora, United States.
CORRESPONDENCE ADDRESS
  K.B. Nagle, University of Colorado, Department of Orthopedics, Children's 
Hospital Colorado Orthopedics Institute, 13123 East 16th Avenue, Aurora, 
United States. Email: kyle.nagle@childrenscolorado.org
SOURCE
  Current Sports Medicine Reports (2015) 14:6 (442-447). Date of Publication: 
1 Nov 2015
ISSN
  1537-8918 (electronic)
  1537-890X
BOOK PUBLISHER
  Lippincott Williams and Wilkins, kathiest.clai@apta.org
ABSTRACT
  Cross-country skiing is a low injury-risk sport that has many health 
benefits and few long-term health risks. Some concern exists that 
cross-country skiing may be associated with a higher incidence of atrial 
fibrillation; however, mortality rates among skiers are lower than those 
among the general population. While continuing to emphasize aerobic and 
anaerobic training, training methods also should promote ski-specific 
strength training to increase maximum force and its rate of delivery and to 
build muscular endurance to maintain that power through a race. Multiple 
tests are available to monitor training progress. Which tests are most 
appropriate depends on the specific events targeted. In addition to 
laboratory-based tests, there also are many simpler, more cost-effective 
tests, such as short time trials, that can be used to monitor training 
progress and predict performance particularly at the junior skier level 
where access and cost may be more prohibitive.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cross country skiing injury (epidemiology)
  skiing
  sport injury (epidemiology)
EMTREE MEDICAL INDEX TERMS
  aerobic capacity
  aerobic exercise
  anaerobic exercise
  article
  cost effectiveness analysis
  heart
  human
  low back pain
  lung gas exchange
  oxygen consumption
  resistance training
EMBASE CLASSIFICATIONS
  Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015517464
FULL TEXT LINK
  http://dx.doi.org/10.1249/JSR.0000000000000205
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 187
TITLE
  Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study 
of Serelaxin in Japanese Patients with Acute Heart Failure
AUTHOR NAMES
  Sato N.
  Takahashi W.
  Hirayama A.
  Ajioka M.
  Takahashi N.
  Okishige K.
  Wang X.
  Maki A.
  Maruyama H.
  Ebinger U.
  Yamaguchi M.
  Pang Y.
  Matsumoto H.
  Kawana M.
AUTHOR ADDRESSES
  (Sato N., nms-ns@nms.ac.jp; Takahashi N.) Cardiology and Intensive Care 
Unit, Nippon Medical School Musashi-Kosugi Hospital, Kanagawa, Japan.
(Takahashi W.) Department of Cardiology, National Hospital Organization 
Shinshu Ueda Medical Center, Nagano, Japan.
(Hirayama A.) Division of Cardiology, Nihon University School of Medicine, 
Tokyo, Japan.
(Ajioka M.) Department of Cardiology, Tosei General Hospital, Aichi, Japan.
(Okishige K.) Division of Cardiology, Yokohama City Minato Red Cross 
Hospital, Kanagawa, Japan.
(Wang X.; Ebinger U.) Novartis Pharmaceuticals Corporation, East Hanover, 
Japan.
(Pang Y.) Novartis Institute for BioMedical Research, Inc, Cambridge, United 
States.
(Maki A.; Maruyama H.; Yamaguchi M.; Matsumoto H.) Novartis Pharma K.K., 
Tokyo, Japan.
(Kawana M.) Department of General Medicine, Tokyo Women’s Medical University 
Hospital, Tokyo, Japan.
CORRESPONDENCE ADDRESS
  N. Sato, Cardiology and Intensive Care Unit, Nippon Medical School 
Musashi-Kosugi Hospital, 1-396 Kosugi-cho, Nakahra-ku, Kawasaki, Japan.
SOURCE
  Circulation Journal (2015) 79:6 (1237-1247). Date of Publication: 11 May 
2015
ISSN
  1347-4820 (electronic)
  1346-9843
BOOK PUBLISHER
  Japanese Circulation Society
ABSTRACT
  Background: Serelaxin, a recombinant form of human relaxin-2, is in 
development for treating acute heart failure (AHF) and a Phase II study in 
Japanese AHF patients was conducted. Methods and Results: A randomized, 
double-blind, placebo-controlled study of serelaxin at 10 and 30 µg · 
kg<sup>–1</sup> · day<sup>–1</sup> continuous intravenous infusion for up to 
48 h, added to standard care for Japanese AHF patients. Primary endpoints 
were adverse events (AEs) through Day 5, serious AEs (SAEs) through Day 14, 
and serelaxin pharmacokinetics. Secondary endpoints included changes in 
systolic blood pressure (SBP) and cardiorenal biomarkers. A total of 46 
patients received the study drug and were followed for 60 days. The observed 
AE profile was comparable between the groups, with no AEs of concern. 
Dose-dependent increase in the serum concentration of serelaxin was observed 
across the 2 dose rates of serelaxin. A greater reduction in SBP was 
observed with serelaxin 30 µg · kg<sup>–1</sup> · day<sup>–1</sup> vs. 
placebo (–7.7 [–16.4, 1.0] mmHg). A greater reduction in NT-proBNP was noted 
with serelaxin (–50.8% and –54.9% for 10 and 30 µg · kg<sup>–1</sup> · 
day<sup>–1</sup>, respectively at Day 2). Conclusions: Serelaxin was well 
tolerated in this study with Japanese AHF patients, with no AEs of concern 
and favorable beneficial trends on efficacy. These findings support further 
evaluation of serelaxin 30 µg · kg<sup>–1</sup> · day<sup>–1</sup> in this 
patient population.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  serelaxin (adverse drug reaction, clinical trial, drug comparison - placebo, 
drug therapy, intravenous drug administration, pharmacokinetics)
EMTREE DRUG INDEX TERMS
  aldosterone (endogenous compound)
  amino terminal pro brain natriuretic peptide (endogenous compound)
  biological marker (endogenous compound)
  cystatin C (endogenous compound)
  dobutamine (drug therapy, intravenous drug administration)
  neutrophil gelatinase associated lipocalin (endogenous compound)
  placebo
  troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acute heart failure (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  area under the curve
  article
  atrial fibrillation (side effect)
  clinical article
  comorbidity
  congestive heart failure (side effect)
  constipation (side effect)
  continuous infusion
  controlled study
  coronary artery obstruction (side effect)
  dehydration (side effect)
  dose response
  double blind procedure
  drug safety
  drug tolerability
  drug treatment failure
  drug withdrawal
  dyspnea
  edema
  esophagus carcinoma (side effect)
  exercise
  female
  heart ventricle tachycardia (side effect)
  human
  hypokalemia (side effect)
  hypotension (drug therapy)
  immunogenicity
  intestine ischemia (side effect)
  Japanese (people)
  Likert scale
  liver metastasis (side effect)
  lymph node metastasis (side effect)
  male
  maximum plasma concentration
  multicenter study
  multiple organ failure (side effect)
  peritoneum metastasis (side effect)
  pharmacodynamics
  phase 2 clinical trial
  pulse rate
  randomized controlled trial
  stomach cancer (side effect)
  systolic blood pressure
  visual analog scale
CAS REGISTRY NUMBERS
  aldosterone (52-39-1, 6251-69-0)
  dobutamine (34368-04-2, 52663-81-7, 49745-95-1, 61661-06-1)
  serelaxin (99489-94-8)
  troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT02002702)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015083288
FULL TEXT LINK
  http://dx.doi.org/10.1253/circj.CJ-15-0227
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 188
TITLE
  Efficacy of cardiopulmonary rehabilitation with adaptive servo-ventilation 
in patients undergoing off-pump coronary artery bypass grafting
AUTHOR NAMES
  Tashiro N.
  Takahashi S.
  Takasaki T.
  Katayama K.
  Taguchi T.
  Watanabe M.
  Kurosaki T.
  Imai K.
  Kimura H.
  Sueda T.
AUTHOR ADDRESSES
  (Tashiro N., tashiro@hiroshima-u.ac.jp; Kimura H.) Department of 
Rehabilitation, Hiroshima University Hospital, Hiroshima, Japan.
(Takahashi S.; Takasaki T.; Katayama K.; Taguchi T.; Watanabe M.; Kurosaki 
T.; Imai K.; Sueda T.) Department of Cardiovascular Surgery, Hiroshima 
University Hospital, Hiroshima, Japan.
CORRESPONDENCE ADDRESS
  N. Tashiro, Department of Rehabilitation, Hiroshima University Hospital, 
1-2-3 Kasumi, Minami-ku, Hiroshima, Japan.
SOURCE
  Circulation Journal (2015) 79:6 (1290-1298). Date of Publication: 11 May 
2015
ISSN
  1347-4820 (electronic)
  1346-9843
BOOK PUBLISHER
  Japanese Circulation Society
ABSTRACT
  Background: Postoperative complications after cardiac surgery increase 
mortality. This study aimed to evaluate the efficacy of cardiopulmonary 
rehabilitation with adaptive servo-ventilation (ASV) in patients undergoing 
off-pump coronary artery bypass grafting (OPCAB). Methods and Results: A 
total of 66 patients undergoing OPCAB were enrolled and divided into 2 
groups according to the use of ASV (ASV group, 30 patients; non-ASV group, 
36 patients). During the perioperative period, all patients undertook 
cardiopulmonary rehabilitation. ASV was used from postoperative day (POD) 1 
to POD5. Hemodynamics showed a different pattern in the 2 groups. Blood 
pressure (BP) on POD6 in the ASV group was significantly lower than that in 
the non-ASV group (systolic BP, 112.9±12.6 vs. 126.2±15.8 mmHg, P=0.0006; 
diastolic BP, 62.3±9.1 vs. 67.6±9.3 mmHg, P=0.0277). The incidence of 
postoperative atrial fibrillation (POAF) was lower in the ASV group than in 
the non-ASV group (10% vs. 33%, P=0.0377). The duration of oxygen inhalation 
in the ASV group was significantly shorter than that in the non-ASV group 
(5.1±2.2 vs. 7.6±6.0 days, P=0.0238). The duration of postoperative 
hospitalization was significantly shorter in the ASV group than in the 
non-ASV group (23.5±6.6 vs. 29.0±13.1 days, P=0.0392). Conclusions: 
Cardiopulmonary rehabilitation with ASV after OPCAB reduces both POAF 
occurrence and the duration of hospitalization.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  atrial natriuretic factor alpha
  C reactive protein (endogenous compound)
  diltiazem
  dobutamine
  dopamine
  glyceryl trinitrate
  landiolol
  nicardipine
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  adaptive servo ventilation
  cardiovascular procedure
  heart rehabilitation
  off pump coronary surgery
EMTREE MEDICAL INDEX TERMS
  aged
  artery spasm
  article
  atrial fibrillation (complication)
  blood pressure
  comparative study
  CPAP device
  echocardiography
  exercise
  female
  heart hemodynamics
  heart index
  heart rate
  hospitalization
  human
  major clinical study
  male
  oxygen breathing
  perioperative period
  peroperative care
  postoperative care
  preoperative evaluation
  sternotomy
  therapy effect
  weight gain
DEVICE TRADE NAMES
  AutoSet CS  , JapanResMed

DEVICE MANUFACTURERS
   (Japan)ResMed
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  atrial natriuretic factor alpha (89213-87-6)
  C reactive protein (9007-41-4)
  diltiazem (33286-22-5, 42399-41-7)
  dobutamine (34368-04-2, 52663-81-7, 49745-95-1, 61661-06-1)
  dopamine (51-61-6, 62-31-7)
  glyceryl trinitrate (55-63-0)
  landiolol (133242-30-5)
  nicardipine (54527-84-3, 55985-32-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015083295
FULL TEXT LINK
  http://dx.doi.org/10.1253/circj.CJ-14-1078
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 189
TITLE
  Effect of comprehensive cardiac telerehabilitation on one-year 
cardiovascular rehospitalization rate, medical costs and quality of life: A 
cost-effectiveness analysis
AUTHOR NAMES
  Frederix I.
  Hansen D.
  Coninx K.
  Vandervoort P.
  Vandijck D.
  Hens N.
  Van Craenenbroeck E.
  Van Driessche N.
  Dendale P.
AUTHOR ADDRESSES
  (Frederix I., ines.frederix@gmail.com; Dendale P.) Department of Cardiology, 
Jessa Hospital, Hasselt, Belgium.
(Frederix I., ines.frederix@gmail.com; Hansen D.; Vandervoort P.; Vandijck 
D.; Van Driessche N.; Dendale P.) Faculty of Medicine and Life Sciences, 
Hasselt University, Belgium.
(Coninx K.) Faculty of Sciences, Expertise Centre for Digital Media, Hasselt 
University, Belgium.
(Vandervoort P.) Department of Cardiology, Hospital East-Limburg, Genk, 
Belgium.
(Hens N.) Interuniversity Institute of Biostatistics and Statistical 
Bioinformatics, Hasselt University, Belgium.
(Hens N.) Centre for Health Economic Research and Modelling Infectious 
Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, 
Belgium.
(Van Craenenbroeck E.) Department of Cardiology, Antwerp University 
Hospital, Belgium.
CORRESPONDENCE ADDRESS
  I. Frederix, Beatrijslaan 105, Rotselaar, Belgium. Email: 
ines.frederix@gmail.com
SOURCE
  European Journal of Preventive Cardiology (2015) 23:7 (674-682). Date of 
Publication: 2015
ISSN
  2047-4881 (electronic)
  2047-4873
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  Background Notwithstanding the cardiovascular disease epidemic, current 
budgetary constraints do not allow for budget expansion of conventional 
cardiac rehabilitation programmes. Consequently, there is an increasing need 
for cost-effectiveness studies of alternative strategies such as 
telerehabilitation. The present study evaluated the cost-effectiveness of a 
comprehensive cardiac telerehabilitation programme. Design and methods This 
multi-centre randomized controlled trial comprised 140 cardiac 
rehabilitation patients, randomized (1:1) to a 24-week telerehabilitation 
programme in addition to conventional cardiac rehabilitation (intervention 
group) or to conventional cardiac rehabilitation alone (control group). The 
incremental cost-effectiveness ratio was calculated based on intervention 
and health care costs (incremental cost), and the differential incremental 
quality adjusted life years (QALYs) gained. Results The total average cost 
per patient was significantly lower in the intervention group (€2156 ± €126) 
than in the control group (€2720 ± €276) (p = 0.01) with an overall 
incremental cost of €-564.40. Dividing this incremental cost by the baseline 
adjusted differential incremental QALYs (0.026 QALYs) yielded an incremental 
cost-effectiveness ratio of €-21,707/QALY. The number of days lost due to 
cardiovascular rehospitalizations in the intervention group (0.33 ± 0.15) 
was significantly lower than in the control group (0.79 ± 0.20) (p = 0.037). 
Conclusions This paper shows the addition of cardiac telerehabilitation to 
conventional centre-based cardiac rehabilitation to be more effective and 
efficient than centre-based cardiac rehabilitation alone. These results are 
useful for policy makers charged with deciding how limited health care 
resources should best be allocated in the era of exploding need.
EMTREE DRUG INDEX TERMS
  antiarrhythmic agent (drug therapy)
  antithrombocytic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  insulin (drug therapy)
  oral antidiabetic agent (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cost effectiveness analysis
  health care cost
  heart rehabilitation
  hospital readmission
  quality of life
  telerehabilitation
EMTREE MEDICAL INDEX TERMS
  acute coronary syndrome
  adult
  anticoagulant therapy
  article
  atrial fibrillation (drug therapy)
  cardiac resynchronization therapy
  controlled study
  coronary artery disease (disease management, rehabilitation, therapy)
  cost utility analysis
  defibrillator
  diabetes mellitus (drug therapy)
  endurance training
  female
  heart failure (disease management, rehabilitation, therapy)
  heart supraventricular arrhythmia (drug therapy)
  heart ventricle arrhythmia (drug therapy)
  human
  in-stent restenosis
  length of stay
  major clinical study
  male
  middle aged
  multicenter study
  pericarditis
  peripheral occlusive artery disease (drug therapy)
  priority journal
  prospective study
  quality adjusted life year
  randomized controlled trial
  stable angina pectoris
  thorax pain
  treatment duration
CAS REGISTRY NUMBERS
  insulin (9004-10-8)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160276501
FULL TEXT LINK
  http://dx.doi.org/10.1177/2047487315602257
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 190
TITLE
  Impact of duration of mitral regurgitation on outcomes in asymptomatic 
patients with myxomatous mitral valve undergoing exercise stress 
echocardiography
AUTHOR NAMES
  Naji P.
  Asfahan F.
  Barr T.
  Rodriguez L.L.
  Grimm R.A.
  Agarwal S.
  Thomas J.D.
  Marc Gillinov A.
  Mihaljevic T.
  Griffin B.P.
  Desai M.Y.
AUTHOR ADDRESSES
  (Naji P.; Asfahan F.; Barr T.; Rodriguez L.L.; Grimm R.A.; Agarwal S.; 
Thomas J.D.; Marc Gillinov A.; Mihaljevic T.; Griffin B.P.; Desai M.Y., 
desaim2@ccf.org) Heart and Vascular Institute, Cleveland Clinic, Cleveland, 
United States.
CORRESPONDENCE ADDRESS
  M.Y. Desai, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, 
Desk J1-5, Cleveland, United States.
SOURCE
  Journal of the American Heart Association (2015) 4:2 Article Number: 
e001348. Date of Publication: 2015
ISSN
  2047-9980 (electronic)
BOOK PUBLISHER
  John Wiley and Sons Inc., P.O.Box 18667, Newark, United States.
ABSTRACT
  Background-Significant mitral regurgitation (MR) typically occurs as 
holosystolic (HS) or mid-late systolic (MLS), with differences in volumetric 
impact on the left ventricle (LV). We sought to assess outcomes of 
degenerative MR patients undergoing exercise echocardiography, separated 
based on MR duration (MLS versus HS). Methods and Results-We included 609 
consecutive patients with ≥III+myxomatous MR undergoing exercise 
echocardiography: HS (n=487) and MLS (n=122). MLS MR was defined as delayed 
appearance of MR signal during mid-late systole on continuouswave Doppler 
while HS MR occurred throughout systole. Composite events of death and 
congestive heart failure were recorded. Compared to MLS MR, HS MR patients 
were older (60±14 versus 53±14 years), more were males (72% versus 53%), and 
had greater prevalence of atrial fibrillation (16% versus 7%; all P<0.01). 
HS MR patients had higher right ventricular systolic pressure (RVSP) at rest 
(33±11 versus 27±9 mm Hg), more flail leaflets (36% versus 6%), and a lower 
number of metabolic equivalents (METs) achieved (9.5±3 versus 10.5±3), 
compared to the MLS MR group (all P<0.05). There were 54 events during 7.1±3 
years of follow-up. On step-wise multivariable analysis, HS versus MLS MR 
(HR 4.99 [1.21 to 20.14]), higher LV ejection fraction (hazard ratio [HR], 
0.94 [0.89 to 0.98]), atrial fibrillation (HR, 2.59 [1.33 to 5.11]), higher 
RVSP (HR, 1.05 [1.03 to 1.09]), and higher percentage of age- and 
gender-predicted METs (HR, 0.98 [0.97 to 0.99]) were independently 
associated with adverse outcomes (all P<0.05). Conclusion-In patients with 
≥III+myxomatous MR undergoing exercise echocardiography, holosystolic MR is 
associated with adverse outcomes, independent of other predictors.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  adverse outcome
  heart myxoma
  mitral valve regurgitation (surgery)
  stress echocardiography
EMTREE MEDICAL INDEX TERMS
  adult
  age
  article
  asymptomatic disease
  atrial fibrillation
  congestive heart failure
  controlled study
  death
  disease duration
  female
  gender
  heart left ventricle ejection fraction
  heart right ventricle pressure
  human
  major clinical study
  male
  metabolic equivalent
  middle aged
  mitral valve repair
  mitral valve replacement
  observational study
  priority journal
  retrospective study
  survival rate
  systole
  transthoracic echocardiography
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015883989
FULL TEXT LINK
  http://dx.doi.org/10.1161/JAHA.114.001348
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 191
TITLE
  Atrial fibrillation and long-term sports practice: epidemiology and 
mechanisms
AUTHOR NAMES
  Wernhart S.
  Halle M.
AUTHOR ADDRESSES
  (Wernhart S., simon.wernhart@hotmail.com; Halle M.) Klinikum Rechts der 
Isar, Centre for Prevention and Sports Medicine, Technische Universität 
München, Georg-Brauchle-Ring 56 (Campus C), Munich, Germany.
(Halle M.) German Centre for Cardiovascular Research, Partner Site Munich 
Heart Alliance, Munich, Germany.
(Halle M.) Klinikum Rechts der Isar, Else-Kröner-Fresenius-Zentrum, Munich, 
Germany.
CORRESPONDENCE ADDRESS
  S. Wernhart, Klinikum Rechts der Isar, Centre for Prevention and Sports 
Medicine, Technische Universität München, Georg-Brauchle-Ring 56 (Campus C), 
Munich, Germany.
SOURCE
  Clinical Research in Cardiology (2014) . Date of Publication: 25 Dec 2014
ISSN
  1861-0692 (electronic)
  1861-0684
BOOK PUBLISHER
  Dr. Dietrich Steinkopff Verlag GmbH and Co. KG
ABSTRACT
  Results: The majority of studies have methodological limitations due to 
different inclusion criteria, such as age, type of sport, training level as 
well as statistical bias. The inconsistency of data is reflected by the 
considerable range of AF occurrence, spanning from 0.3 to 12.8 
%.Conclusions: We consider it reasonable to separate a study population into 
sedentary individuals, leisure time sportsmen/women and elite athletes. A 
distinction between the categories may be achieved through a combination of 
exercise history, capacity (e.g. MET hours/week, e.g. VO2max) and 
competitive results. Since there is a large span in the analyzed age groups 
(24–84 years), we claim that the focus should be laid upon the 45- to 
65-year-olds due to a sound detection rate of true positives. Finally, we 
discuss ways to increase the detection rate of paroxysmal AF and comment on 
new therapeutic options.Background: Lone atrial fibrillation (AF) is the 
most common arrhythmia of the heart and is considered to have a higher 
prevalence in athletes, especially in endurance sports.Methods: We conducted 
an extensive literature research in pubmed using the key words sports and 
atrial fibrillation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  atrial fibrillation
  endurance sport
  epidemiology
  human
  sport
EMTREE MEDICAL INDEX TERMS
  exercise
  groups by age
  heart
  heart arrhythmia
  leisure
  Medline
  population
  prevalence
  sound detection
  statistical bias
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015635170
FULL TEXT LINK
  http://dx.doi.org/10.1007/s00392-014-0805-0
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 192
TITLE
  Critical Care Congress 2015
AUTHOR ADDRESSES
  SOURCE
  Critical Care Medicine (2014) 42:12 SUPPL. 1. Date of Publication: December 
2014
CONFERENCE NAME
  Critical Care Congress 2015
CONFERENCE LOCATION
  Phoenix, AZ, United States
CONFERENCE DATE
  2015-01-17 to 2015-01-21
ISSN
  0090-3493
BOOK PUBLISHER
  Lippincott Williams and Wilkins
ABSTRACT
  The proceedings contain 1238 papers. The topics discussed include: 
correlation of CHADS2 with new onset atrial fibrillation in thoracic and 
vascular surgical patients; mortality risk factors with carbapenem-resistant 
bacteremia: impact of combination therapy; immuno-modulating diet containing 
whey protein and EPA suppressed reactive oxygen species production; simple, 
reliable sepsis screening tool improves mortality in trauma patients; lower 
oxygen concentration reduced systemic inflammatory response and improved the 
outcome of CPR; teaching situation awareness during cardiac arrests and 
rapid responses - a simulation study; epidemiology and outcomes of 
in-hospital cardiac arrest across hospitals of varied center volume; ADR 
surveillance using a multicenter clinical database: propofol related 
infusion syndrome incidence; the obesity paradox is not observed in 
critically ill patients on early internal nutrition; and epidemiologic 
features and outcome of sepsis in neurologic intensive care unit patients.
EMTREE DRUG INDEX TERMS
  carbapenem
  protein
  reactive oxygen metabolite
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  intensive care
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  bacteremia
  critically ill patient
  data base
  diet
  epidemiology
  heart arrest
  hospital
  human
  inflammation
  injury
  intensive care unit
  mortality
  nutrition
  obesity
  oxygen concentration
  patient
  propofol infusion syndrome
  risk factor
  screening
  sepsis
  simulation
  surgical patient
  teaching
  therapy
  whey
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 193
TITLE
  Cardiovascular risk factors and future risk of Alzheimer's disease
AUTHOR NAMES
  de Bruijn R.F.A.G.
  Ikram M.A.
AUTHOR ADDRESSES
  (de Bruijn R.F.A.G., r.f.a.g.debruijn@erasmusmc.nl; Ikram M.A., 
m.a.ikram@erasmusmc.nl) Department of Epidemiology, Erasmus MC University 
Medical Center, Wytemaweg 80, Rotterdam, Netherlands.
(de Bruijn R.F.A.G., r.f.a.g.debruijn@erasmusmc.nl; Ikram M.A., 
m.a.ikram@erasmusmc.nl) Department of Neurology, Erasmus MC University 
Medical Center, 's-Gravendijkwal 230, Rotterdam, Netherlands.
(Ikram M.A., m.a.ikram@erasmusmc.nl) Department of Radiology, Erasmus MC 
University Medical Center, 's-Gravendijkwal 230, Rotterdam, Netherlands.
CORRESPONDENCE ADDRESS
  M.A. Ikram, Department of Epidemiology, Erasmus MC University Medical 
Center, Wytemaweg 80, Rotterdam, Netherlands.
SOURCE
  BMC Medicine (2014) 12:1 Article Number: 130. Date of Publication: 11 Nov 
2014
ISSN
  1741-7015 (electronic)
BOOK PUBLISHER
  BioMed Central Ltd., info@biomedcentral.com
ABSTRACT
  Alzheimer's disease (AD) is the most common neurodegenerative disorder in 
elderly people, but there are still no curative options. Senile plaques and 
neurofibrillary tangles are considered hallmarks of AD, but cerebrovascular 
pathology is also common. In this review, we summarize findings on 
cardiovascular disease (CVD) and risk factors in the etiology of AD. 
Firstly, we discuss the association of clinical CVD (such as stroke and 
heart disease) and AD. Secondly, we summarize the relation between imaging 
makers of pre-clinical vascular disease and AD. Lastly, we discuss the 
association of cardiovascular risk factors and AD. We discuss both 
established cardiovascular risk factors and emerging putative risk factors, 
which exert their effect partly via CVD.
EMTREE DRUG INDEX TERMS
  homocysteine (endogenous compound)
  thyroid hormone (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Alzheimer disease (etiology)
  cardiovascular disease
  cardiovascular risk
EMTREE MEDICAL INDEX TERMS
  arterial stiffness
  article
  atrial fibrillation
  blood pressure
  brain atrophy
  brain hemorrhage
  cerebrovascular accident
  cerebrovascular disease
  chronic kidney disease
  cognitive defect
  dementia
  diffusion tensor imaging
  disease association
  disease marker
  functional magnetic resonance imaging
  glucose metabolism
  heart disease
  heart failure
  human
  hypercholesterolemia
  hypertension
  inflammation
  ischemic heart disease
  Mediterranean diet
  non insulin dependent diabetes mellitus
  obesity
  physical activity
  pulse wave
  risk assessment
  smoking
  thyroid function
  white matter lesion
CAS REGISTRY NUMBERS
  homocysteine (454-28-4, 6027-13-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015812984
FULL TEXT LINK
  http://dx.doi.org/10.1186/s12916-014-0130-5
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 194
TITLE
  European Congress on e-Cardiology and e-Health 2014
AUTHOR ADDRESSES
  SOURCE
  European Journal of Preventive Cardiology (2014) 21:2 SUPPL. 1. Date of 
Publication: November 2014
CONFERENCE NAME
  European Congress on e-Cardiology and e-Health 2014
CONFERENCE LOCATION
  Bern, Switzerland
CONFERENCE DATE
  2014-10-29 to 2014-10-31
ISSN
  2047-4873
BOOK PUBLISHER
  SAGE Publications Inc.
ABSTRACT
  The proceedings contain 16 papers. The topics discussed include: MART Munich 
arterial hypertension register telemedicine; the revealing timely ECG 
changes decreases the likelihood of undesirable cardiac events-trial 
(REDUCE-Trial); telemedicine network for collaborative diagnosis and care of 
heart malformations; telerehabilitation in coronary artery disease 
(TRIC-study), 3 months data; smartphones, computer vision, artificial 
intelligence, and their application to carbohydrate counting; predictors of 
coronary heart disease patients' usage of a web-based intervention aimed at 
lifestyle change. results from lebensstil-aendern.de; clinical experiences 
with a mobile diet logging application; a miniature MEMS only based method 
of detecting atrial fibrillation; big data: time to remodel diagnostic 
paths; Skype and tele-ECG in control of home-based exercise training after 
planned PCI - a useful tool?; and integrating telemedicine systems with 
active learning solutions.
EMTREE DRUG INDEX TERMS
  carbohydrate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiology
  telehealth
EMTREE MEDICAL INDEX TERMS
  artificial intelligence
  atrial fibrillation
  computer
  congenital heart malformation
  coronary artery disease
  diagnosis
  diet
  electrocardiogram
  exercise
  human
  hypertension
  ischemic heart disease
  learning
  lifestyle modification
  logging
  microelectromechanical system
  patient
  register
  telemedicine
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 195
TITLE
  Impact of intensive physiotherapy on cognitive function after coronary 
artery bypass graft surgery
AUTHOR NAMES
  Cavalcante E.S.
  Magario R.
  Conforti C.A.
  Júnior G.C.
  Arena R.
  Carvalho A.C.C.
  Buffolo E.
  Filho B.L.
AUTHOR ADDRESSES
  (Cavalcante E.S., drelder@hotmail.com; Carvalho A.C.C.; Buffolo E.; Filho 
B.L.) UNIFESP-Universidade Federal de São Paulo, Brazil.
(Magario R.) USP-Universidade de São Paulo, Brazil.
(Conforti C.A.) Santa Casa de Misericórdia de Santos, Santos, Brazil.
(Júnior G.C.) UNB-Universidade de Brasília, Brazil.
(Arena R.) Virginia Commonwealth University, Richmond, United States.
CORRESPONDENCE ADDRESS
  E.S. Cavalcante, Av. Francisco Glicério 121, 63, Gonzaga, Santos, Brazil.
SOURCE
  Arquivos Brasileiros de Cardiologia (2014) 103:5 (391-397). Date of 
Publication: 1 Nov 2014
ISSN
  1678-4170 (electronic)
  0066-782X
BOOK PUBLISHER
  Arquivos Brasileiros de Cardiologia, arquivos@cardiol.br
ABSTRACT
  Background: Coronary artery bypass graft (CABG) is a standard surgical 
option for patients with diffuse and significant arterial plaque. This 
procedure, however, is not free of postoperative complications, especially 
pulmonary and cognitive disorders.Objective: This study aimed at comparing 
the impact of two different physiotherapy treatment approaches on pulmonary 
and cognitive function of patients undergoing CABG.Methods: 
Neuropsychological and pulmonary function tests were applied, prior to and 
following CABG, to 39 patients randomized into two groups as follows: Group 
1 (control)-20 patients underwent one physiotherapy session daily; and Group 
2 (intensive physiotherapy)-19 patients underwent three physiotherapy 
sessions daily during the recovery phase at the hospital. Non-paired and 
paired Student t tests were used to compare continuous variables. Variables 
without normal distribution were compared between groups by using 
Mann-Whitney test, and, within the same group at different times, by using 
Wilcoxon test. The chi-square test assessed differences of categorical 
variables. Statistical tests with a p value ≤ 0.05 were considered 
significant.Results: Changes in pulmonary function were not significantly 
different between the groups. However, while Group 2 patients showed no 
decline in their neurocognitive function, Group 1 patients showed a decline 
in their cognitive functions (P ≤ 0.01).Conclusion: Those results highlight 
the importance of physiotherapy after CABG and support the implementation of 
multiple sessions per day, providing patients with better psychosocial 
conditions and less morbidity.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cognition
  coronary artery bypass graft
  physiotherapy
EMTREE MEDICAL INDEX TERMS
  adult
  airway pressure
  article
  atelectasis (complication)
  atrial fibrillation (complication)
  breathing exercise
  breathing muscle
  breathing rate
  clinical article
  comparative study
  controlled study
  digit symbol substitution test
  expiratory reserve volume
  female
  forced expiratory volume
  forced vital capacity
  human
  intensive care
  lung function
  lung function test
  male
  medical record
  middle aged
  pericardial effusion (complication)
  pleura effusion (complication)
  pneumonia (complication)
  postoperative care
  prospective study
  randomized controlled trial
  scoring system
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Psychiatry (32)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014881436
FULL TEXT LINK
  http://dx.doi.org/10.5935/abc.20140161
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 196
TITLE
  Effect of Years of Endurance Exercise on Risk of Atrial Fibrillation and 
Atrial Flutter
AUTHOR NAMES
  Myrstad M.
  Nystad W.
  Graff-Iversen S.
  Thelle D.S.
  Stigum H.
  Aarønæs M.
  Ranhoff A.H.
AUTHOR ADDRESSES
  (Myrstad M., marius.myrstad@fhi.no; Aarønæs M.; Ranhoff A.H.) Department of 
Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway
(Myrstad M., marius.myrstad@fhi.no; Nystad W.; Graff-Iversen S.; Stigum H.) 
Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway
(Thelle D.S.) Department of Biostatistics, Institute of Basal Medical 
Sciences, University of Oslo, Oslo, Norway
(Stigum H.) Department of Preventive Medicine and Epidemiology, Institute of 
Health and Society, University of Oslo, Oslo, Norway
(Thelle D.S.) Department of Public Health and Community Medicine, Gothenburg 
University, Gothenburg, Sweden
(Ranhoff A.H.) Department of Clinical Science, Kavli Research Centre for 
Geriatrics and Dementia, University of Bergen, Bergen, Norway
CORRESPONDENCE ADDRESS
  M. Myrstad, Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, 
Norway, . Email: marius.myrstad@fhi.no
SOURCE
  American Journal of Cardiology (2014)
ISSN
  0002-9149
  1879-1913 (electronic)
ABSTRACT
  Emerging evidence suggests that endurance exercise increases the risk for 
atrial fibrillation (AF) in men, but few studies have investigated the 
dose-response relation between exercise and risk for atrial arrhythmias. 
Both exposure to exercise and reference points vary among studies, and 
previous studies have not differentiated between AF and atrial flutter. The 
aim of this study was to assess the risk for atrial arrhythmias by 
cumulative years of regular endurance exercise in men. To cover the range 
from physical inactivity to long-term endurance exercise, the study sample 
in this retrospective cohort study was based on 2 distinct cohorts: male 
participants in a long-distance cross-country ski race and men from the 
general population, in total 3,545 men aged ≥53 years. Arrhythmia diagnoses 
were validated by electrocardiograms during review of medical records. 
Regular endurance exercise was self-reported by questionnaire. A broad range 
of confounding factors was available for adjustment. The adjusted odds 
ratios per 10 years of regular endurance exercise were 1.16 (95% confidence 
interval 1.06 to 1.29) for AF and 1.42 (95% confidence interval 1.20 to 
1.69) for atrial flutter. In stratified analyses, the associations were 
significant in cross-country skiers and in men from the general population. 
In conclusion, cumulative years of regular endurance exercise were 
associated with a gradually increased risk for AF and atrial flutter. © 2014 
Elsevier Inc. All rights reserved.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  endurance training
  heart atrium flutter
  risk
EMTREE MEDICAL INDEX TERMS
  cohort analysis
  confidence interval
  diagnosis
  dose response
  electrocardiogram
  exercise
  exposure
  heart arrhythmia
  heart atrium arrhythmia
  human
  male
  medical record
  physical inactivity
  population
  questionnaire
  skiing
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.amjcard.2014.07.047
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 197
TITLE
  Demographic and clinical characteristics of patients with atrial 
fibrillation and cardioversion as planned therapeutic options in the 
International Registry on Cardioversion of Atrial Fibrillation RHYTHM-AF 
Polish substudy
AUTHOR NAMES
  Da̧browski R.
  Opolski G.
  Włodarczyk P.
  Kiliszek M.
  Ponikowski P.
AUTHOR ADDRESSES
  (Da̧browski R., rdabrowski45@gmail.com) Institute of Cardiology, ul. 
Spartańska 1, 02-637 Warszawa, Poland.
(Opolski G.; Kiliszek M.) 1St Department of Cardiology, Medical University 
of Warsaw, Warsaw, Poland.
(Włodarczyk P.) MSD, Poland.
(Ponikowski P.) Military Hospital, Wroclaw, Poland.
CORRESPONDENCE ADDRESS
  R. Da̧browski, Institute of Cardiology, ul. Spartańska 1, 02-637 Warszawa, 
Poland. Email: rdabrowski45@gmail.com
SOURCE
  Kardiologia Polska (2014) 72:8 (700-706). Date of Publication: 18 Aug 2014
ISSN
  0022-9032
ABSTRACT
  Background: Cardioversion of atrial fibrillation (AF) and maintenance of 
sinus rhythm are the basic strategies of treating AF patients. Precise data 
regarding the current practice of AF cardioversion in Europe in clinical 
practice is lacking. Aim: The primary objective of this prospective 
observational study was to characterise patients and treatment patterns in 
whom cardioversion was the planned therapeutic option. Methods: Patients 
with recent onset of AF were included, regardless of when the timing of the 
cardioversion was planned. Ten countries participated in the study, with 
Poland contributing 501 patients. The global enrollment period lasted from 
May 2010 to June 2011. Follow-up data was collected 60 days after enrollment 
via a medical chart abstraction or a telephone interview. Results: The 
average age of the Polish patient population was 64.2 years, and 38.5% of 
patients were female. Mean duration of arrhythmia was 3.3 years. Paroxysmal 
AF was diagnosed in 38.3% and persistent AF in 43.6% of patients. The most 
prevalent AF risk factors were hypertension (75.0%), diabetes mellitus 
(20.5%), and family history of AF (12.1%). Mean body mass index of study 
patients was 29.5 kg/m2. The most pertinent factors triggering AF were 
emotion (12.4%), exercise (6.5%), electrolyte disturbances (5.5%), and acute 
myocardial infarction (3.7%). Only 14.2% of patients were asymptomatic. 
Previous episodes of AF were present in 83.1% of patients and 58.5% of them 
had previous cardioversion: 49.8% pharmacological and 50.2% electrical. The 
most often used anti-arrhythmic drugs were amiodarone (53.4%) and 
propafenone (32.2%). The rate of antithrombotic treatment was low: 59.6%. 
Finally electrical cardioversion had been undergone by 165 (53%) patients 
and pharmacological by 146 (47%) patients. Conclusions: The population of 
patients with AF and planned cardioversion represented typical patients with 
non-valvular AF and standard symptoms, the vast majority of whom were 
symptomatic. The study group in terms of comprehensive characteristics is 
representative of the general population of AF patients. Copyright © Polskie 
Towarzystwo Kardiologiczne.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  amiodarone (drug therapy)
  antivitamin K
  beta adrenergic receptor blocking agent (drug therapy)
  digoxin (drug therapy)
  diltiazem (drug therapy)
  flecainide (drug therapy)
  propafenone (drug therapy)
  verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy, therapy)
  cardioversion
  demography
EMTREE MEDICAL INDEX TERMS
  acute coronary syndrome
  acute heart infarction
  adult
  article
  asymptomatic disease
  Austria
  body mass
  Brazil
  cardiovascular risk
  clinical feature
  comorbidity
  coronary artery disease
  diabetes mellitus
  disease duration
  dizziness
  electrolyte disturbance
  emotion
  exercise
  family history
  fatigue
  female
  follow up
  France
  Germany
  health care planning
  heart failure
  heart left ventricle ejection fraction
  heart palpitation
  human
  hypertension
  major clinical study
  male
  medical record review
  mitral valve regurgitation
  Netherlands
  observational study
  paroxysmal atrial fibrillation (drug therapy, therapy)
  persistent atrial fibrillation (drug therapy, therapy)
  persistent atrial fibrillation (drug therapy)
  Poland
  prospective study
  Spain
  Sweden
  telephone interview
  thorax pain
  United Kingdom
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digoxin (20830-75-5, 57285-89-9)
  diltiazem (33286-22-5, 42399-41-7)
  flecainide (54143-55-4)
  propafenone (34183-22-7, 54063-53-5)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, Polish
EMBASE ACCESSION NUMBER
  2014582661
FULL TEXT LINK
  http://dx.doi.org/10.5603/KP.a2014.0067
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 198
TITLE
  Traumatic oesophageal perforation due to haematoma
AUTHOR NAMES
  Larsen C.G.
  Brandt B.
AUTHOR ADDRESSES
  (Larsen C.G., c.gronhoj@gmail.com) Department of Oto-Rhinolaryngology, Head 
and Neck Surgery and Audiology, University Hospital Rigshospitalet, 
Blegdamsvej 9, Copenhagen, Denmark.
(Brandt B.) Department of Cardiothoracic Surgery, University Hospital 
Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark.
CORRESPONDENCE ADDRESS
  C.G. Larsen, Department of Oto-Rhinolaryngology, Head and Neck Surgery and 
Audiology, University Hospital Rigshospitalet, Blegdamsvej 9, Copenhagen, 
Denmark.
SOURCE
  International Journal of Surgery Case Reports (2014) 5:10 (659-661). Date of 
Publication: 11 Aug 2014
ISSN
  2210-2612
BOOK PUBLISHER
  Elsevier Ltd
ABSTRACT
  INTRODUCTION: Traumatic oesophageal perforation is a rare, life-threatening 
emergency that requires early recognition and prompt surgical 
management.PRESENTATION OF CASE: We present an unusual case of a patient on 
warfarin treatment developed an intramural oesophageal haematoma following 
blunt thoracic trauma leading to perforation on the 18th day.DISCUSSION: In 
treatment of oesophageal haematoma in patients on vitamin-K antagonists, 
strict control of the International Normalized Ratio (INR) is essential 
along with total parenteral nutrition therapy and refrainment through 
nasogastric tubes. Three explanations postulated to be the cause for late 
perforation which might be due to esophageal wall ischemia from pressure 
built up between the hematoma, azygos vein and the lower part of thoracic 
trachea; or could be an immediate rupture walled-off until the patient 
became symptomatic; or the intramural hematoma gradually lysed and causing 
late perforation.CONCLUSION: Although extremely rare, an oesophageal 
haematoma and late complications must be considered in patients on 
anti-coagulant therapy following blunt thoracic trauma and complaining only 
of chest pain.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
  albumin (endogenous compound)
  antibiotic agent
  proton pump inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  esophageal hematoma (side effect, side effect, therapy)
  esophagus perforation
  hematoma (side effect, side effect, therapy)
  thorax blunt trauma
EMTREE MEDICAL INDEX TERMS
  acidosis
  aged
  anticoagulant therapy
  article
  atrial fibrillation (drug therapy)
  azygos vein
  bacterial infection (complication)
  case report
  computer assisted tomography
  conservative treatment
  drug withdrawal
  dysphagia
  esophageal wall ischemia
  esophagus disease
  esophagus pressure
  face injury
  female
  fever
  human
  international normalized ratio
  leukocytosis
  lung embolism
  lung fibrosis
  mycosis (complication)
  nasogastric tube
  parenteral nutrition
  stent
  tachycardia
  thoracotomy
  thorax pain
  total parenteral nutrition
  urinary tract infection
  very elderly
CAS REGISTRY NUMBERS
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014840184
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ijscr.2014.04.008
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 199
TITLE
  Making use of equity sensitive QALYs: A case study on identifying the worse 
off across diseases
AUTHOR NAMES
  Lindemark F.
  Norheim O.F.
  Johansson K.A.
AUTHOR ADDRESSES
  (Lindemark F., frode.lindemark@igs.uib.no; Norheim O.F., 
ole.norheim@igs.uib.no; Johansson K.A., kjell.johansson@igs.uib.no) 
Department of Research and Development, Haukeland University Hospital, Jonas 
Liesvei 65, 5021 Bergen, Norway.
CORRESPONDENCE ADDRESS
  F. Lindemark, Department of Research and Development, Haukeland University 
Hospital, Jonas Liesvei 65, 5021 Bergen, Norway. Email: 
frode.lindemark@igs.uib.no
SOURCE
  Cost Effectiveness and Resource Allocation (2014) 12:1 Article Number: 16. 
Date of Publication: 23 Jul 2014
ISSN
  1478-7547 (electronic)
ABSTRACT
  Background: Resource allocation decisions currently lack standard 
quantitative methods for incorporating concerns about the worse off when 
analysing the cost-effectiveness of medical interventions.Objective: To 
explore and demonstrate how to identify who are the worse off without a new 
intervention by measuring lifetime Quality-Adjusted Life Years (QALYs) for 
patients across different conditions, and compare the results to using 
proportional shortfall of QALYs.Methods: Case study of eight 
condition-intervention pairs that are relevant to priority setting in 
Norway; childhood deafness (unilateral cochlear implant), unruptured 
cerebral aneurysm (coiling), morbid obesity (RY gastric bypass), adult 
deafness (unilateral cochlear implant), atrial fibrillation (catheter 
ablation), hip osteoarthritis (hip replacement), rheumatoid arthritis (TNF 
inhibitor) and acute stroke (stroke unit). We extracted prospective QALYs 
without and with new interventions from published health technology 
assessments and economic evaluations.Results: Among the eight cases, the 
lifetime QALY method and the proportional shortfall method yielded 
conflicting worse-off rank orders. Particularly two conditions had a 
substantial shift in ranking across the applications of the two methods: 
childhood deafness and acute stroke. Deaf children had the lowest expected 
lifetime QALYs (38.5 without a cochlear implant) and were worst off 
according to the lifetime approach, while patients with acute stroke had the 
second-highest lifetime QALYs (76.4 without stroke units). According to 
proportional shortfall of QALYs, patients with acute stroke were ranked as 
worse off than deaf children, which seems counterintuitive.Conclusion: This 
study shows that it is feasible to identify who are the worse off 
empirically by the application of lifetime QALYs and proportional 
shortfalls. These methods ease further examination of whether there is a 
true conflict between maximization and equity or whether these two concerns 
actually coincide in real world cases. It is yet to be solved whether 
proportional prospective health losses are more important than absolute 
shortfalls in expected lifetime health in judgements about who are worse 
off. © 2014 Lindemark et al.; licensee BioMed Central Ltd.
EMTREE DRUG INDEX TERMS
  antiarrhythmic agent (drug therapy, pharmacoeconomics)
  methotrexate (drug therapy, pharmacoeconomics)
  tumor necrosis factor inhibitor (drug therapy, pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  quality adjusted life year
EMTREE MEDICAL INDEX TERMS
  adult
  adult deafness (disease management, therapy)
  aged
  article
  atrial fibrillation (disease management, drug therapy, therapy)
  brain artery aneurysm (disease management, therapy)
  case study
  catheter ablation
  cerebrovascular accident (disease management)
  child
  childhood deafness (disease management, therapy)
  childhood disease (disease management, therapy)
  clinical article
  cochlea prosthesis
  coil embolization
  cost effectiveness analysis
  diet therapy
  disability
  disability severity
  economic evaluation
  exercise
  hearing impairment (disease management, therapy)
  hip arthroplasty
  hip osteoarthritis (disease management, surgery)
  human
  morbid obesity (disease management, surgery)
  Norway
  patient counseling
  rheumatoid arthritis (disease management, drug therapy)
  Roux Y anastomosis
  school child
  stomach bypass
  stroke unit
  unruptured cerebral aneurysm (disease management, therapy)
CAS REGISTRY NUMBERS
  methotrexate (15475-56-6, 59-05-2, 7413-34-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014521202
FULL TEXT LINK
  http://dx.doi.org/10.1186/1478-7547-12-16
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 200
TITLE
  The management of atrial fibrillation: Summary of updated NICE guidance
AUTHOR NAMES
  Jones C.
  Pollit V.
  Fitzmaurice D.
  Cowan C.
AUTHOR ADDRESSES
  (Jones C., clare.jones@rcplondon.ac.uk; Pollit V.) Royal College of 
Physicians, National Clinical Guideline Centre, London NW1 4LE, United 
Kingdom.
(Fitzmaurice D.) Primary Care Clinical Sciences, University of Birmingham, 
United Kingdom.
(Cowan C.) Department of Cardiology, Leeds General Infirmary, Leeds, United 
Kingdom.
CORRESPONDENCE ADDRESS
  C. Jones, Royal College of Physicians, National Clinical Guideline Centre, 
London NW1 4LE, United Kingdom. Email: clare.jones@rcplondon.ac.uk
SOURCE
  BMJ (Online) (2014) 348 Article Number: g3655. Date of Publication: 19 Jun 
2014
ISSN
  1756-1833 (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, subscriptions@bmjgroup.com
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  anticoagulant agent (drug therapy)
  apixaban (drug therapy)
  beta adrenergic receptor blocking agent (drug combination, drug therapy)
  calcium channel blocking agent (drug therapy)
  dabigatran etexilate (drug therapy)
  digoxin (drug combination, drug therapy)
  diltiazem (drug combination, drug therapy)
  nonsteroid antiinflammatory agent (drug therapy)
  rivaroxaban (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, diagnosis, disease management, drug 
therapy, surgery, therapy)
  health care organization
  National Institute for Health and Care Excellence
  practice guideline
EMTREE MEDICAL INDEX TERMS
  ablation therapy
  age
  alcohol consumption
  asthma
  bleeding (drug therapy)
  bradycardia
  cardiovascular mortality
  cardiovascular risk
  cardioversion
  catheter ablation
  cerebrovascular accident (drug therapy, prevention)
  CHA2DS2 VASc score
  cognition
  cost effectiveness analysis
  diabetes mellitus
  diet
  electrocardiography
  has bled score
  heart arrhythmia
  heart atrium appendage
  heart atrium flutter
  heart atrium pacing
  heart failure
  heart left ventricle failure
  heart rate
  heart rhythm
  human
  hypertension
  international normalized ratio
  ischemic heart disease
  palpation
  patient compliance
  patient referral
  peripheral occlusive artery disease
  peripheral vascular disease
  pharmacological parameters
  priority journal
  recurrence risk
  review
  risk assessment
  scoring system
  sex difference
  sinus rhythm
  systematic review (topic)
  thorax surgery
  thromboembolism
  time in therapeutic range
  transient ischemic attack
  treatment contraindication
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  apixaban (503612-47-3)
  digoxin (20830-75-5, 57285-89-9)
  diltiazem (33286-22-5, 42399-41-7)
  rivaroxaban (366789-02-8)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2014416285
FULL TEXT LINK
  http://dx.doi.org/10.1136/bmj.g3655
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 201
TITLE
  11th Annual Natural Supplements Research Competition
AUTHOR ADDRESSES
  SOURCE
  Journal of Alternative and Complementary Medicine (2014) 20:6. Date of 
Publication: June 2014
CONFERENCE NAME
  11th Annual Natural Supplements Research Competition
CONFERENCE LOCATION
  San Francisco, CA, United States
CONFERENCE DATE
  2014-01-29 to 2014-02-01
ISSN
  1075-5535
BOOK PUBLISHER
  Mary Ann Liebert Inc.
ABSTRACT
  The proceedings contain 9 papers. The topics discussed include: effect of 
chromium dinicocysteinate supplementation on insulin resistance, 
inflammation and oxidative stress in type 2 diabetic subjects: a post hoc 
analysis of a double-blind, randomized, placebo-controlled trial; the 
effects of homeopathic topical snake venom preparation in alleviating 
muscular discomfort: a randomized, double-blind, placebo-controlled clinical 
trial; an evaluation of cost versus quality in green tea dietary 
supplements; too much-too fast: new onset atrial fibrillation in 
bioidentical thyroid hormone supplementation; crowdsourced evidence vs. 
clinical research-based evidence for rating the effectiveness of commonly 
used dietary supplements; and national estimates for adult and children's 
multivitamins as reported in release 2 of the dietary supplement ingredient 
database (DSID).
EMTREE DRUG INDEX TERMS
  chromium
  multivitamin
  placebo
  snake venom
  thyroid hormone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  competition
EMTREE MEDICAL INDEX TERMS
  adult
  atrial fibrillation
  child
  clinical research
  controlled clinical trial
  controlled clinical trial (topic)
  controlled study
  data base
  diabetic patient
  diet supplementation
  human
  inflammation
  insulin resistance
  oxidative stress
  post hoc analysis
  supplementation
  tea
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 202
TITLE
  3rd World Congress on Vascular Access, WoCoVA 2014
AUTHOR ADDRESSES
  SOURCE
  Journal of Vascular Access (2014) 15:3 (193). Date of Publication: 2014
CONFERENCE NAME
  3rd World Congress on Vascular Access, WoCoVA 2014
CONFERENCE LOCATION
  Berlin, Germany
CONFERENCE DATE
  2014-06-18 to 2014-06-20
ISSN
  1129-7298
BOOK PUBLISHER
  Wichtig Publishing
ABSTRACT
  The proceedings contain 155 papers. The special focus in this conference is 
on Vascular Access. The topics include: A Bundle of interventions for the 
safe insertion of central venous catheters in adult patients; improvement of 
patient safety access for CVC – aggregation of CVC insertion and license 
system at central venous catheterization (CVC) center; a descriptive study 
of nerve injury related to upper arm PICC line placement; a global 
prevalence study on peripheral catheters (the OMG-PIVC study); the emergency 
department and peripheral cannulation; effectiveness interventions to reduce 
bloodstream infection and vascular access infection in a hemodialysis unit 
in Brazil; effect of a vascular access team on central-line associated 
bloodstream infections in infants admitted to a neonatal intensive care 
unit; a systematic review; central venous catheter placement by advanced 
practice nurses demonstrates low procedural complication and infection rates 
- a report from 13 years of service; beyond the bundle – health care 
associated (HCA) peripheral intravenous device (PIVD) related bloodstream 
infection (BSI), royal adelaide hospital (RAH) infection prevention and 
control unit (IPCU) improvement intervention; descriptive study in the use 
of lockings in hemodialysis catheters; benefits of ultrasound-guided early 
cannulation of AV fistulas and grafts; effectiveness & acceptability of a 
novel securement device in adult & teenage cancer patients with PICCs; 
securing arterial lines effectively in the operating theatre and the ICU; 
the accuracy of an all-in-one navigation and tip locating device based on a 
real time analysis of the patients’ physiological data – ECG guidance for 
CVC placement. CLB’s IV team expertise and decreasing of radiation exposure; 
proposal of an algorithm for verification of tip location of central venous 
access in patients with atrial fibrillation and pace-makers minimizing the 
use of X-ray exposure; a new wireless device for tip location using the 
intracavitary ECG technique; electrocardiographic (ECG) guidance during 
implantation of femoral ports; prospective randomized trial comparing distal 
(Arm Port) to central (Chest Port) technique in ambulatory cancer patients; 
long-term tunneled catheter removal by nurse specialists; determining 
evidence-based practice for site care; beyond the dressing for PICCs - 
strategy for cost-savings and work efficiency; a multicomponent bundle to 
minimize catheter-related bloodstream infection in a pediatric intensive 
care unit; the quality of published central venous catheter clinical 
practice guidelines; INCATIV (intravenous therapy quality indicators); the 
effectiveness of a nurse-led intravenous therapy team in terms of length of 
stay, venous access complications and satisfaction of patients requiring 
long-term intravenous therapy; building a model central vascular access 
program one change at a time; views on the value of vascular access teams – 
a survey of U.S. hospital nurse leaders; a new wireless ultrasound probe for 
ultrasound guided central venous access; translating vascular access 
research for clinicians; the use of PICC in the peripheral blood stem cell 
collection; the impact of 70% isopropyl alcohol port protection caps on 
catheter related bloodstream infection in patients on home parenteral 
nutrition; central vascular access for acute hemodialysis; PICCs handling in 
homecare; prevalence of venous access depletion and associated risk factors 
in high complexity hospitalised patients; indications and alternative for 
double lumen venous ports in Europe; the economic impact of device and site 
selection for peripheral artery catheterization; peripherally inserted 
central catheters in children; use of peripherally inserted central 
catheters in children with cancer; a new securing device to prevent 
accidental dislocation of central venous access devices in non-collaborating 
infants and children; assessment of guide-wire positioning in children 
during insertion of the short-term central venous catheter; vascular access 
training, exploitation and taking care of catheters in a new hematological 
hospital; patients empowerment; Porth-A-Cath versus peripherally inserted 
central catheter; a checklist for the PICC lines insertion; infections 
related to central venous catheters in cancer patients; application of 
association of perioperative registered nurses’ standards for bedside PICC 
and CVC insertions; thromboembolic events (TE) in men treated with BEP 
(Bleomycine-Etoposide-Cisplatine); the benefits of guided puncture ultrasson 
and modified seldinger technique PICC in the intensive care unit; a 
randomized controlled trial in the home care setting; efficiency of a CVC 
insertion bundle on hospital wide Crbsi Rate - a single center report; the 
role of the practice educator in facilitating expert PICC care; the use of 
power PICC in the intensive care unit and its main indications in a cancer 
center; a randomised experimental comparison of two safety Huber needles 
(HN) allowing manual or automatic positive pressure during needle removal; a 
practical pocket guide now downloadable; the formation process and 
implementation of a PICC team; BED-side versus fluoroscopically guided 
insertion of PICCS; the utilization of peripherally inserted central 
catheter in adults and a nurse’s core formation to venous access; are 
antibiotic resistant “super bugs” evaluation of a peripheral vein catheter 
with blood septum; use of intravascular device assessment records for 
patients admitted to sligo regional hospital – comparing risk assessments of 
central line bundles used in US hospitals by applying bowtie methodology; 10 
years of needless connector use – data enhanced by experience and function; 
trapezius totally implantable port and skin tunnelled CVC insertion; results 
of management for the 593 upper arm PICC -20,731 catheter days in single 
hospital; audit process in procedures of PICC catheters passages; 
complications experienced by patients that the passage of PICC catheter 
underwent; arterial lines need to be part of the vascular access bundle; 
starting up a midline catheter program; evaluation of peripherally inserted 
central catheter (PICC) malposition rates and the impact of the Sherlock 3CG 
tip confirmation system; comparison of novel TIP positioning technology 
(using ECG and Doppler) and 2-D echocardiography for the placement of 
central catheters; a time and motion study of peripheral venous catheter 
flushing practice using manually prepared and pre-filled syringes; an 
alternative procedure to improve acceptable placement of central venous 
catheter tip in adults; taurolidine-citrate line locks prevent recurrent 
catheter related bacteraemia - evaluation of this novel therapy in a 
paediatric population; an intervention to reduce catheter related blood 
stream infections in paediatric patients - a bundle of care; improving the 
“global use” of ultrasound for central venous access; using smartphone 
technology to calculate and monitor gravity infusions; an audit of IV 
devices, practice and consumables after an organisational merger; the 1st 
PICC team in Czech republic – experience of implementation of autologous 
marrow transplantation by PICC line; impact of the use of micro introduction 
technology in pediatric patients and newborns; the impact of the use of new 
X-ray technology to ensure the best placement of catheters; SVC catheter 
behavior in short trimmed catheter; evaluation of new materials “closed 
system” in intravenous therapy; randomised trial comparing Hickman lines 
with ports for chemotherapy; cost-effectiveness analysis of a new 
CHG-dressing for preventing catheter-related bloodstream infections; 
retrieval of a fractured long-term venous access device using a modified 
percutaneous capturing technique; central vascular access by Tesio catheters 
for chronic hemodialysis in neonates and infants; the intracavitary ECG 
method for positioning the tip of central venous access devices in pediatric 
patients; evaluation of the use of PICC in orthopedic patients at the day 
hospital; comparison of the insertion of peripherally inserted central 
catheters with ultrasound guidance and conventional methods in orthopedic 
patients; evaluation of the flushing efficiency of needleless connectors 
using a radioactive solution; community IV therapy – comparison of bacterial 
transfer and biofilm formation on intraluminal connector-catheter systems 
among eight needleless connectors in a clinically simulated in vitro model; 
peripheral IV blood control catheter design and biofilm formation; on the 
matter of selection of venous access systems and professionals involved in 
their installation; system of medical staff preparation in Russia as a cause 
of majority of complications in the treatment; the evolution of humanity and 
venous access; on the selection of venous access systems and professionals 
involved in their installation; experience of venous ports implantation in 
patients with hunter syndrome (Mucopolysaccharidosis II Type); the mid 
sternal length a practical anatomical landmark for optimal positioning of 
long term central venous catheters; impact of the delay time from the use of 
the ultrasonic in the insertions of central venous catheters of the 
peripheral insertions; complications of peripherally inserted central 
catheter in the intensive care unit; use of peripherally inserted central 
catheter (PICC) in intensive care unit - epidemiological profile; a 
single-incision technique for placement of implantable venous-access ports 
in medial pocket via the axillary vein; ultrasonographic predictors for 
feasibility of cephalic vein cut-down during totally implantable venous 
access device placement; bacterial colonization of two different 
antiseptic-impregnated central venous catheters in a rabbit model; the 
analysis on the implementation and effect of the PICC grading management 
mode; upper limb arterial tortuosity following arteriovenous fistula 
formation for haemodialysis access; study outcomes of a novel sutureless 
securement system; routine chest x-ray is not mandatory after 
fluoroscopy-guided totally implantable venous access device insertion; 
integrating performance-based needleless connector technology into clinical 
practice; dressings and securement devices for central venous catheters 
(CVC) and collaborative approach through simulated clinical use testing for 
the development of a new safety Huber needle (SHN)
EMTREE DRUG INDEX TERMS
  2 propanol
  antibiotic agent
  antiinfective agent
  bleomycin
  cisplatin
  citric acid
  etoposide
  taurolidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  vascular access
EMTREE MEDICAL INDEX TERMS
  adolescence
  adult
  advanced practice nurse
  algorithm
  arm
  arterial line
  arteriovenous fistula
  artery
  artery catheterization
  atrial fibrillation
  axillary vein
  bacteremia
  bacterial colonization
  biofilm
  blood
  bloodstream infection
  bone marrow
  book
  Brazil
  cancer center
  cancer patient
  cannulation
  catheter
  catheter infection
  catheter removal
  central venous catheter
  central venous catheterization
  cephalic vein
  checklist
  chemotherapy
  child
  clinical practice
  community
  cost control
  cost effectiveness analysis
  Czech Republic
  day hospital
  devices
  echocardiography
  electrocardiogram
  emergency ward
  empowerment
  Europe
  evidence based practice
  exposure
  fluoroscopy
  gravity
  guide wire
  health care
  hemodialysis
  home care
  hospital
  hospital infection
  hospital patient
  human
  humanities
  Hunter syndrome
  implantation
  in vitro study
  incision
  infant
  infection
  infection prevention
  infection rate
  infusion
  intensive care unit
  intravenous catheter
  intravenous drug administration
  length of stay
  licence
  male
  medical audit
  medical specialist
  medical staff
  methodology
  model
  needle
  neoplasm
  nerve injury
  newborn
  newborn intensive care
  nurse
  operating room
  parenteral nutrition
  patient
  patient safety
  peripheral blood stem cell
  peripheral vein
  peripheral venous catheter
  peripherally inserted central venous catheter
  population
  practice guideline
  prevalence
  prevention and control
  procedures
  protection
  puncture
  rabbit model
  radiation exposure
  radioactivity
  randomized controlled trial
  randomized controlled trial (topic)
  registered nurse
  risk assessment
  risk factor
  Russian Federation
  safety
  satisfaction
  skin
  syringe
  systematic review
  systematic review (topic)
  task performance
  technology
  therapy
  thorax
  thorax radiography
  thromboembolism
  transplantation
  trapezius muscle
  ultrasound
  United States
  X ray
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
FULL TEXT LINK
  http://dx.doi.org/10.5301/jva.5000275
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 203
TITLE
  Exercise-induced arterial hypertension - an independent factor for 
hypertrophy and a ticking clock for cardiac fatigue or atrial fibrillation 
in athletes?
AUTHOR NAMES
  Leischik R.
  Spelsberg N.
  Niggemann H.
  Dworrak B.
  Tiroch K.
AUTHOR ADDRESSES
  (Leischik R., info@dr-leischik.de; Spelsberg N.; Niggemann H.; Dworrak B.) 
Department of Cardiology, Section of Prevention, Health Promotion and Sports 
Medicine, Faculty of Health, School of Medicine, Witten/Herdecke University, 
Hagen, Germany.
(Tiroch K.) Department of Cardiology, Faculty of Health, School of Medicine, 
Helios Hospital, Witten/Herdecke University, Wuppertal, Germany.
CORRESPONDENCE ADDRESS
  R. Leischik, Department of Cardiology, Section of Prevention, Health 
Promotion and Sports Medicine, Faculty of Health, School of Medicine, 
Witten/Herdecke University, Hagen, Germany.
SOURCE
  F1000Research (2014) 3 Article Number: 4001.1. Date of Publication: 12 May 
2014
ISSN
  1759-796X (electronic)
  2046-1402
BOOK PUBLISHER
  Faculty of 1000 Ltd, info@f1000.com
ABSTRACT
  Background: Exercise-induced arterial hypertension (EIAH) leads to 
myocardial hypertrophy and is associated with a poor prognosis. EIAH might 
be related to the "cardiac fatigue"? caused by endurance training. The goal 
of this study was to examine whether there is any relationship between EIAH 
and left ventricular hypertrophy in Ironman-triathletes. Methods: We used 
echocardiography and spiroergometry to determine the left ventricular mass 
(LVM), the aerobic/anaerobic thresholds and the steady-state blood pressure 
of 51 healthy male triathletes. The main inclusion criterion was the 
participation in at least one middle or long distance triathlon. Results: 
When comparing triathletes with LVM &<220g and athletes with LVM >220g there 
was a significant difference between blood pressure values (BP) at the 
anaerobic threshold (185.2± 21.5 mmHg vs. 198.8 ±22.3 mmHg, p=0.037). The 
spiroergometric results were: maximum oxygen uptake (relative VO 2max) 57.3 
±7.5ml/min/kg vs. 59.8±9.5ml/min/kg (p=ns). Cut-point analysis for the 
relationship of BP >170 mmHg at the aerobic threshold and the probability of 
LVM >220g showed a sensitivity of 95.8%, a specificity of 33.3%, with a 
positive predictive value of 56.8 %, a good negative predictive value of 
90%. The probability of LVM >220g increased with higher BP during exercise 
(OR: 1.027, 95% CI 1.002-1.052, p= 0.034) or with higher training volume 
(OR: 1.23, 95% CI 1.04 -1.47, p = 0.019). Echocardiography showed 
predominantly concentric remodelling, followed by concentric hypertrophy. 
Conclusion: Significant left ventricular hypertrophy with LVM >220g is 
associated with higher arterial blood pressure at the aerobic or anaerobic 
threshold. The endurance athletes with EIAH may require a therapeutic 
intervention to at least prevent extensive stiffening of the heart muscle 
and exercise-induced cardiac fatigue.
EMTREE DRUG INDEX TERMS
  oxygen (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  atrial fibrillation
  cardiac fatigue
  exercise induced arterial hypertension
  fatigue
  heart hypertrophy
  hypertension
EMTREE MEDICAL INDEX TERMS
  adult
  aerobic exercise
  anaerobic exercise
  article
  blood pressure
  controlled study
  disease association
  echocardiography
  endurance training
  ergometry
  heart left ventricle hypertrophy
  heart left ventricle mass
  heart muscle
  heart ventricle remodeling
  human
  major clinical study
  male
  muscle rigidity
  oxygen consumption
  physical activity
  predictive value
  probability
  prognosis
  sensitivity and specificity
  steady state
CAS REGISTRY NUMBERS
  oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014955152
FULL TEXT LINK
  http://dx.doi.org/10.12688/f1000research.4001.1
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 204
TITLE
  Heart Rhythm 2014 - 35th Annual Scientific Sessions
AUTHOR ADDRESSES
  SOURCE
  Heart Rhythm (2014) 11:5 SUPPL. 1. Date of Publication: May 2014
CONFERENCE NAME
  35th Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm 
2014
CONFERENCE LOCATION
  San Francisco, CA, United States
CONFERENCE DATE
  2014-05-07 to 2014-05-10
ISSN
  1547-5271
BOOK PUBLISHER
  Elsevier
ABSTRACT
  The proceedings contain 1374 papers. The topics discussed include: 
implantable defibrillator early after primary percutaneous intervention for 
ST-elevation myocardial infarction: the defibrillator after primary 
angioplasty (DAPA) trial; device longevity in cardiac resynchronization 
therapy implantable cardioverter defibrillators differs between 
manufacturers; adverse outcomes associated with lead extractions; premature 
ventricular contraction-induced cardiomyopathy in children; predictors of 
myocardial recovery in pediatric tachycardia-induced cardiomyopathy; 
pediatric catecholaminergic polymorphic ventricular tachycardia (CPVT): a 
multicenterregistry; are there any region specific differences in the 
correlation between contact force and impedance fall during catheter 
ablation of atrial fibrillation in humans?; and a gain-of-function mutation 
of the SCN5A gene causes exercise-induced polymorphic ventricular 
arrhythmias resembling CPVT.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart rhythm
  society
EMTREE MEDICAL INDEX TERMS
  adverse outcome
  angioplasty
  atrial fibrillation
  cardiac resynchronization therapy
  cardiomyopathy
  catecholaminergic polymorphic ventricular tachycardia
  catheter ablation
  child
  defibrillator
  devices
  exercise
  extraction
  gain of function mutation
  gene
  heart ventricle arrhythmia
  heart ventricle extrasystole
  human
  impedance
  implantable cardioverter defibrillator
  longevity
  ST segment elevation myocardial infarction
  tachycardia induced cardiomyopathy
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 205
TITLE
  Belgian Society of Cardiology 33rd Annual Scientific Meeting
AUTHOR ADDRESSES
  SOURCE
  Acta Cardiologica (2014) 69:1. Date of Publication: 2014
CONFERENCE NAME
  33rd Annual Scientific Meeting of the Belgian Society of Cardiology
CONFERENCE LOCATION
  Brussels, Belgium
CONFERENCE DATE
  2014-01-30 to 2014-01-31
ISSN
  0001-5385
BOOK PUBLISHER
  Acta Cardiologica
ABSTRACT
  The proceedings contain 51 papers. The topics discussed include: the 
management of newly diagnosed atrial fibrillation in Belgium: data from the 
international prospective GARFIELD registry; pulmonary vein isolation using 
a novel multi-electrode circular catheter: first clinical experience; 
episodes of subclinical atrial tachyarrhythmia are not associated with worse 
outcome in cardiac resynchronization therapy patients; contact force sensing 
open irrigated catheter reduces by half the early recurrence of atrial 
fibrillation after pulmonary veins isolation for paroxysmal atrial 
fibrillation; partial or complete isolation of the left atrial posterior 
wall increase drastically the absence of AF recurrence after an index 
ablation for persistent atrial fibrillation; and right ventricular fatigue 
developing during endurance exercise: a real-time exercise cardiac magnetic 
resonance imaging study.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiology
  society
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  Belgium
  cardiac resynchronization therapy
  cardiovascular magnetic resonance
  catheter
  electrode
  endurance training
  exercise
  fatigue
  human
  patient
  pulmonary vein
  pulmonary vein isolation
  register
  tachycardia
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 206
TITLE
  Survey of the use of warfarin and the newer anticoagulant dabigatran in 
patients with atrial fibrillation
AUTHOR NAMES
  Choi J.C.
  DiBonaventura M.D.
  Kopenhafer L.
  Nelson W.W.
AUTHOR ADDRESSES
  (Choi J.C.) LifeScan, Inc., West Chester, PA, United States.
(DiBonaventura M.D.; Kopenhafer L.) Health Sciences Practice, Kantar Health, 
New York, NY, United States.
(Nelson W.W., wnelson@its.jnj.com) Janssen Scientific Affairs LLC, Raritan, 
NJ, United States.
CORRESPONDENCE ADDRESS
  W. W. Nelson, Janssen Scientific Affairs, LLC, 1000 US Highway 202 South, 
Raritan, NJ 08869, United States. Email: wnelson@its.jnj.com
SOURCE
  Patient Preference and Adherence (2014) 8 (167-177). Date of Publication: 7 
Feb 2014
ISSN
  1177-889X (electronic)
BOOK PUBLISHER
  Dove Medical Press Ltd, PO Box 300-008, Albany, 44 Corinthian Drive, 
Albany,Auckland, New Zealand.
ABSTRACT
  Background: Oral dabigatran was recently approved as an alternative to 
warfarin for prevention of stroke and systemic embolism in patients with 
nonvalvular atrial fibrillation. Unlike warfarin, dabigatran has a fixed 
dosage and few drug interactions, and does not require anticoagulation 
monitoring or dietary restrictions. Methods: This study aimed to describe 
and compare characteristics of patients with atrial fibrillation who used 
dabigatran or only warfarin. Patients with a self-reported diagnosis of 
atrial fibrillation aged ≥18 years who were receiving (or had received) 
warfarin or dabigatran completed an online survey. Differences in 
characteristics of dabigatran and warfarin users were tested using 
chi-squared tests and analysis of variance for categorical and continuous 
variables, respectively. Results: Overall, 364 patients were surveyed (204 
warfarin users, 160 dabigatran users). The mean age was 65.1 years, and 
68.7% were male. Dabigatran users were more likely than warfarin users to be 
female (36.9% versus 27.0%) and to have experienced adverse events, 
including gastrointestinal bleeding, in the 3 months before the survey 
(21.9% versus 6.9%; P<0.05). Both groups reported high medication adherence 
(dabigatran users 0.65 versus warfarin users 0.63 missed doses/month). 
Dabigatran users were more likely than warfarin users to discuss treatment 
options with their physician before beginning therapy (36.9% versus 24.5%; 
P<0.05) and less likely to switch anticoagulant medication (10.7% versus 
31.9%; P<0.05). Although dabigatran users were more likely to experience 
adverse events, they reported greater satisfaction with anticoagulation 
treatment than warfarin users. Conclusion: The efficacy and convenience 
reported by dabigatran users resulted in greater treatment satisfaction 
among dabigatran users, even though adverse events decreased it. Treatment 
strategies that minimize adverse events may improve treatment satisfaction 
and adherence among patients with atrial fibrillation. © 2014 Choi et al.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dabigatran (adverse drug reaction, drug therapy, pharmacoeconomics)
  warfarin (adverse drug reaction, drug comparison, drug therapy, 
pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, disease management, drug therapy)
EMTREE MEDICAL INDEX TERMS
  age distribution
  aged
  anticoagulant therapy
  article
  cerebrovascular accident (drug therapy, prevention)
  Charlson Comorbidity Index
  chemoprophylaxis
  controlled study
  cross-sectional study
  disease duration
  dizziness (side effect)
  drug cost
  drug efficacy
  drug use
  drug withdrawal
  dyspnea (side effect)
  female
  gastroesophageal reflux (side effect)
  gastrointestinal hemorrhage (side effect)
  health insurance
  health survey
  heart palpitation (side effect)
  heartburn (side effect)
  human
  indigestion (side effect)
  major clinical study
  male
  medication compliance
  nausea (side effect)
  obesity
  outcome assessment
  patient compliance
  patient decision making
  patient satisfaction
  sex ratio
  stomach pain (side effect)
  thorax pain (side effect)
CAS REGISTRY NUMBERS
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014130957
FULL TEXT LINK
  http://dx.doi.org/10.2147/PPA.S56187
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 207
TITLE
  Life-threatening hyperkalemia in a patient with normal renal function
AUTHOR NAMES
  Ayach T.
  Nappo R.W.
  Paugh-Miller J.L.
  Ross E.A.
AUTHOR ADDRESSES
  (Ayach T.; Paugh-Miller J.L.; Ross E.A., rossea@medicine.ufl.edu) Division 
of Nephrology, Hypertension and Renal Transplantation, University of 
Florida, Gainesville, FL, United States.
(Nappo R.W.) Shands Hospital, University of Florida, Gainesville, FL, United 
States.
CORRESPONDENCE ADDRESS
  E.A. Ross, Division of Nephrology, Hypertension and Renal Transplantation, 
University of Florida, Gainesville, FL, United States. Email: 
rossea@medicine.ufl.edu
SOURCE
  Clinical Kidney Journal (2014) 7:1 (49-52). Date of Publication: February 
2014
ISSN
  2048-8505
  2048-8513 (electronic)
BOOK PUBLISHER
  Oxford University Press, Great Clarendon Street, Oxford, United Kingdom.
ABSTRACT
  With media focus on benefits from reducing sodium intake, there is increased 
popularity of salt substitutes, typically potassium chloride. While viewed 
by the public as a healthy alternative to standard table salt, less 
appreciated is the severe risk with certain comorbidities and medications. 
We report the case of an elderly female with chronically high salt 
substitute intake, normal renal function, diabetes, hypertension treated 
with angiotensin-converting enzyme inhibitor and beta blockade, who 
developed life-threatening hyperkalemia after a minimally invasive 
outpatient procedure. We describe the pathophysiology of the disruption in 
potassium homeostasis and emphasize the importance of dietary history and 
educating high-risk patients to avoid salt substitutes. © The Author 2013. 
Published by Oxford University Press on behalf of ERA-EDTA. All rights 
reserved. For permissions, please email: journals.permissions@oup.com.
EMTREE DRUG INDEX TERMS
  amiodarone
  atropine (intravenous drug administration)
  bicarbonate (drug therapy)
  chloride (endogenous compound)
  furosemide (drug therapy)
  gluconate calcium (drug therapy)
  insulin (intravenous drug administration)
  metoprolol
  oral antidiabetic agent
  potassium (endogenous compound)
  quinapril
  sodium (endogenous compound)
  sodium chloride (intravenous drug administration)
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  hyperkalemia (drug therapy, drug therapy)
  kidney function
  life threat
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  atrioventricular junction arrhythmia
  bradycardia
  case report
  chloride blood level
  fatigue
  female
  follow up
  heart right bundle branch block
  hemodialysis
  human
  hypertension
  kyphoplasty
  lethargy
  limb weakness
  non insulin dependent diabetes mellitus
  P wave
  potassium blood level
  priority journal
  QRS complex
  respiratory tract intubation
  salt intake
  sodium blood level
  spine fracture
  vomiting
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  atropine (51-55-8, 55-48-1)
  bicarbonate (144-55-8, 71-52-3)
  chloride (16887-00-6)
  furosemide (54-31-9)
  gluconate calcium (299-28-5)
  insulin (9004-10-8)
  metoprolol (37350-58-6)
  potassium (7440-09-7)
  quinapril (82586-55-8, 85441-61-8)
  sodium (7440-23-5)
  sodium chloride (7647-14-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Urology and Nephrology (28)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014077071
FULL TEXT LINK
  http://dx.doi.org/10.1093/ckj/sft151
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 208
TITLE
  Yoga and meditation in cardiovascular disease
AUTHOR NAMES
  Manchanda S.C.
  Madan K.
AUTHOR ADDRESSES
  (Manchanda S.C., doctormanchanda@yahoo.com; Madan K.) Dharma Vira Heart 
Center, Sir Ganga Ram Hospital, New Delhi 110060, India.
CORRESPONDENCE ADDRESS
  S.C. Manchanda, Dharma Vira Heart Center, Sir Ganga Ram Hospital, New Delhi 
110060, India. Email: doctormanchanda@yahoo.com
SOURCE
  Clinical Research in Cardiology (2014) 103:9 (675-680). Date of Publication: 
September 2014
ISSN
  1861-0692 (electronic)
  1861-0684
BOOK PUBLISHER
  Dr. Dietrich Steinkopff Verlag GmbH and Co. KG
ABSTRACT
  Yoga is a holistic mind-body intervention aimed at physical, mental, 
emotional and spiritual well being. Several studies have shown that yoga 
and/or meditation can control risk factors for cardiovascular disease like 
hypertension, type II diabetes and insulin resistance, obesity, lipid 
profile, psychosocial stress and smoking. Some randomized studies suggest 
that yoga/meditation could retard or even regress early and advanced 
coronary atherosclerosis. A recent study suggests that transcendental 
meditation may be extremely useful in secondary prevention of coronary heart 
disease and may reduce cardiovascular events by 48 % over a 5-year period. 
Another small study suggests that yoga may be helpful in prevention of 
atrial fibrillation. However, most studies have several limitations like 
lack of adequate controls, small sample size, inconsistencies in baseline 
and different methodologies, etc. and therefore large trials with improved 
methodologies are required to confirm these findings. However, in view of 
the existing knowledge and yoga being a cost-effective technique without 
side effects, it appears appropriate to incorporate yoga/meditation for 
primary and secondary prevention of cardiovascular disease. © 2014 
Springer-Verlag.
EMTREE DRUG INDEX TERMS
  procoagulant
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (prevention)
  meditation
  yoga
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (prevention)
  body weight
  cardiovascular risk
  coronary artery atherosclerosis
  cost effectiveness analysis
  disease control
  heart arrhythmia
  heart rehabilitation
  human
  hypertension
  insulin resistance
  ischemic heart disease (prevention)
  lipid analysis
  mental stress
  non insulin dependent diabetes mellitus
  obesity
  oxidative stress
  prophylaxis
  review
  secondary prevention
  smoking
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014541175
MEDLINE PMID
  24464106 (http://www.ncbi.nlm.nih.gov/pubmed/24464106)
FULL TEXT LINK
  http://dx.doi.org/10.1007/s00392-014-0663-9
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 209
TITLE
  High level of education, healthy diet and moderate consumption of alcohol 
are associated with lower odds for first-ever ischemic stroke in hospital 
based case-control study in Varaždin County, Croatia
AUTHOR NAMES
  Pikija S.
  Lukić A.
  Vrček E.
  Malojčić B.
  Juvan L.
  Kudelić N.
  Štefinšćak M.
  Kujundžić S.
  Trkulja V.
AUTHOR ADDRESSES
  (Pikija S., spikija@gmail.com) Department of Neurology, Bezirkkrankenhaus 
Lienz, von Hibler-Strasse 5, Lienz, Austria.
(Lukić A.; Juvan L.) Department of Anesthesiology, Resuscitation and 
Intensive Care, Varaždin General Hospital, Varaždin, Croatia.
(Vrček E.) Department of Neurology, Varaždin General Hospital, Varaždin, 
Croatia.
(Malojčić B.) Clinical Department of Neurology, Zagreb University Hospital 
Center, Zagreb, Croatia.
(Kudelić N.; Štefinšćak M.) Department of Internal Medicine, General 
Hospital Varaždin, Varaždin, Croatia.
(Kujundžić S.) General Practitioner Office Novi Marof, Croatia.
(Trkulja V.) Department of Pharmacology, School of Medicine, University of 
Zagreb, Zagreb, Croatia.
CORRESPONDENCE ADDRESS
  S. Pikija, Department of Neurology, Bezirkkrankenhaus Lienz, von 
Hibler-Strasse 5, Lienz, Austria.
SOURCE
  Neurologia Croatica (2014) 63:3-4 (73-80). Date of Publication: 2014
ISSN
  0353-8842
BOOK PUBLISHER
  University Hospital School of Medicine Zagreb
ABSTRACT
  Croatia, a Central European middle-income country, has the highest incidence 
of first-ever stroke in Europe. Th is prompted us to search for preventable 
and/or treatable risk factors for ischemic stroke. We performed a 
case-control study of first-ever ischemic stroke. Cases were patients with 
first-ever ischemic stroke. Controls were free from stroke and were matched 
to patients. All participants or their proxies were asked to fill in a 
questionnaire. Biometrics and laboratory values were collected. Odds ratios 
(ORs) were calculated for the association of stroke with selected risk 
factors. We enrolled 219 stroke cases from Varaždin General Hospital and 144 
hospital and community controls. Th e risk factors significantly associated 
with higher odds for stroke were atrial fibrillation (OR 10.35, 95% CI 
3.96-27.06) and current smoking (OR 4.53, 95% CI 1.45-14.17). Arterial 
hypertension was not associated with higher odds for stroke. Protective 
factors were education higher than high school (OR 0.36, 95% CI 0.15-0.89), 
healthy diet (OR 0.40, 95% CI 0.18-0.89), high HDL cholesterol (OR 0.14, 95% 
CI 0.06-0.33) and in the second model without adjustment for laboratory 
values alcohol intake of 1-30 drinks per month (OR 0.51, 95% CI 0.29-0.89). 
Anticoagulant therapy for atrial fibrillation, promotion of more healthy 
diet patterns and smoking cessation seem to be the targets for prevention of 
ischemic stroke in the population of Varaždin County, Croatia.
EMTREE DRUG INDEX TERMS
  high density lipoprotein cholesterol (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
  triacylglycerol (endogenous compound)
  uric acid (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alcohol consumption
  brain ischemia (prevention)
  diet
  educational status
  first ever ischemic stroke (prevention)
EMTREE MEDICAL INDEX TERMS
  aged
  anticoagulant therapy
  article
  atrial fibrillation
  biometry
  cholesterol blood level
  controlled study
  Croatia
  high school
  hospital based case control study
  human
  hypertension
  major clinical study
  multicenter study
  prospective study
  risk factor
  smoking
  smoking cessation
  triacylglycerol blood level
  uric acid blood level
  waist circumference
CAS REGISTRY NUMBERS
  uric acid (69-93-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015292704
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 210
TITLE
  Critical conversations after coronary artery bypass grafting: Balancing the 
evidence and dealing with uncertainty
AUTHOR ADDRESSES
  SOURCE
  Circulation: Cardiovascular Quality and Outcomes (2014) 7:5 (783-784). Date 
of Publication: 1 Sep 2014
ISSN
  1941-7705 (electronic)
  1941-7713
BOOK PUBLISHER
  Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  coronary artery bypass graft
EMTREE MEDICAL INDEX TERMS
  anxiety
  arm pain
  atrial fibrillation (complication)
  blood pressure monitoring
  cardiologist
  doctor patient relation
  electrocardiogram
  exercise
  home monitoring
  human
  jaw pain
  meditation
  postoperative period
  practice guideline
  priority journal
  short survey
  spiritual care
  systolic blood pressure
  Taoism
  thorax pain
  white coat hypertension
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2015863785
MEDLINE PMID
  25097212 (http://www.ncbi.nlm.nih.gov/pubmed/25097212)
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCOUTCOMES.114.000951
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 211
TITLE
  Plasma natriuretic peptides and incidence of subtypes of ischemic stroke
AUTHOR NAMES
  Berntsson J.
  Zia E.
  Borné Y.
  Melander O.
  Hedblad B.
  Engström G.
AUTHOR ADDRESSES
  (Berntsson J., john.berntsson@med.lu.se; Zia E.; Borné Y.; Melander O.; 
Hedblad B.; Engström G.) Department of Clinical Sciences in Malmö, Lund 
University, House 60, Level 13, SE-20502 Malmo, Sweden.
SOURCE
  Cerebrovascular Diseases (2014) 37:6 (444-450). Date of Publication: 2014
ISSN
  1421-9786 (electronic)
  1015-9770
BOOK PUBLISHER
  S. Karger AG
ABSTRACT
  Background and Purpose: Natriuretic peptides predict poor outcomes in 
cardiovascular disease. However, the knowledge of their relationship to 
stroke is limited and prospective studies from the general population are 
few. The purpose of this study was to explore the relationship between 
N-terminal pro-brain natriuretic peptide (NT-proBNP) and midregional 
pro-atrial natriuretic peptide (MR-proANP) plasma levels and the risk for 
ischemic stroke and its subtypes. Methods: NT-proBNP and MR-proANP were 
measured in fasting blood samples from 4,862 subjects (40.2% men, mean age 
57.5 ± 6.0 years) without cardiovascular disease from the Malmö Diet and 
Cancer Study, a prospective, population-based study in Sweden. Incidence of 
ischemic stroke was monitored over a mean follow-up of 14.9 ± 3.0 years. 
Stroke cases were etiologically classified according to the TOAST 
classification. Cox proportional-hazards regression was used to study the 
incidence of stroke in relationship to NT-proBNP and MR-proANP. Results: 
During follow-up, 227 had a first-ever ischemic stroke (large-artery 
atherosclerosis, n = 35; cardioembolic stroke, n = 44; small-artery 
occlusion, n = 80; undetermined cause, n = 68). In the age-and sex-adjusted 
model, only NT-proBNP was associated with total ischemic stroke. This 
association was completely explained by an increased incidence of 
cardioembolic stroke. Adjusted for cardiovascular risk factors (age, sex, 
hypertension, diabetes, smoking, body mass index and low-density lipoprotein 
cholesterol), the hazard ratios (HRs, 95% confidence interval, 95% CI) for 
cardioembolic stroke were 1.00 (reference), 1.42 (0.34-6.00), 2.79 
(0.77-10.12) and 5.64 (1.66-19.20), respectively, for the 1st, 2nd, 3rd and 
4th quartiles of NT-proBNP. The corresponding HRs (95% CIs) for quartiles of 
MR-proANP were 1.00 (reference), 1.83 (0.55-6.14), 1.20 (0.33-4.34) and 3.96 
(1.31-11.99), respectively. In total, 335 (6.9%) subjects were diagnosed 
with atrial fibrillation during follow-up. Among the cardioembolic stroke 
cases, 30% were diagnosed with atrial fibrillation before the stroke event 
and another 36% within 6 months after the stroke. Of the cardioembolic 
stroke cases with atrial fibrillation, 59% were in the top quartile of 
NT-proBNP, 69% in the top quartile of MR-proANP and 79% were either in the 
top quartile of NT-proBNP or in the top quartile of MR-proANP. Conclusion: 
High plasma levels of NT-proBNP and MR-proANP are associated with a 
substantially increased risk of cardioembolic stroke, but not with other 
subtypes of ischemic stroke. The results suggest that assessment of stroke 
risk, including electrocardiography, is warranted in subjects with high 
NT-proBNP or MR-proANP.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  natriuretic factor (endogenous compound)
EMTREE DRUG INDEX TERMS
  amino terminal pro brain natriuretic peptide (endogenous compound)
  atrial natriuretic factor (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
  midregional pro atrial natriuretic peptide (endogenous compound)
  unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  artery occlusion
  article
  atrial fibrillation
  blood level
  blood sampling
  body mass
  brain atherosclerosis
  cardioembolic stroke
  cardiovascular risk
  diabetes mellitus
  female
  follow up
  human
  hypertension
  incidence
  major clinical study
  male
  priority journal
  proportional hazards model
  smoking
  treatment duration
CAS REGISTRY NUMBERS
  atrial natriuretic factor (85637-73-6)
  natriuretic factor (9088-07-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015968074
FULL TEXT LINK
  http://dx.doi.org/10.1159/000363279
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 212
TITLE
  A comparative study of outcomes for endoscopic diverticulotomy versus 
external diverticulectomy
AUTHOR NAMES
  Shahawy S.
  Janisiewicz A.M.
  Annino D.
  Shapiro J.
AUTHOR ADDRESSES
  (Shahawy S.) Harvard Medical School, Boston, United States.
(Janisiewicz A.M.) Rhinology, Otolaryngology Head and Neck Surgery, Kaiser 
Permanente, Irvine, United States.
(Annino D.; Shapiro J., Jshapiro@partners.org) Department of Otology and 
Laryngology, Harvard Medical School and Department of Surgery, Brigham and 
Women's Hospital, Boston, United States.
CORRESPONDENCE ADDRESS
  J. Shapiro, Brigham and Womens Hospital, Division of Otolaryngology, 45 
Francis St., Boston, United States.
SOURCE
  Otolaryngology - Head and Neck Surgery (United States) (2014) 151:4 
(646-651). Date of Publication: 12 Oct 2014
ISSN
  1097-6817 (electronic)
  0194-5998
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  Objectives. Current literature on the treatment of Zenkers diverticulum (ZD) 
favors the use of various endoscopic procedures over external surgical 
techniques for patients, arguing that endoscopic approaches reduce 
intraoperative time and anesthesia, length of hospital stay, and days until 
oral diet is restarted. However, such techniques often have higher 
symptomatic recurrence rates and require further interventions. Because of 
our experience with both endoscopic diverticulotomy (ENDO) and external 
diverticulectomy (EXT) using the GIA-stapler, we sought to compare these 2 
procedures in terms of in-hospital parameters, complications, return to 
normal diet, and rates of symptom recurrence.Study Design. Case series with 
chart review.Setting. Academic tertiary care hospital.Subjects. Patients 
with Zenkers diverticulum who underwent surgical repair.Methods. 
Retrospective analysis of 67 patients seen at Brigham and Womens Hospital 
between 1990 and 2012 with Zenkers diverticulum who underwent either an 
endoscopic Zenkers procedure (36) or an external staplerassisted 
diverticulectomy with cricopharyngeal myotomy (31).Results. Although the 
external stapler-assisted procedure for ZD does carry a longer 
intraoperative time and a slightly longer hospital stay than the endoscopic 
approach, it provides similar days until initiation of an oral diet and a 
similar incidence of postoperative complications. Further, it is superior to 
the endoscopic approach when one considers its much lower rate of 
symptomatic recurrence and need for revision procedures.Conclusion. We argue 
that the external stapler-assisted diverticulectomy with cricopharyngeal 
myotomy should be considered as a viable treatment in patients who need 
definitive, single-session treatment for ZD, especially to prevent 
lifethreatening aspiration pneumonia.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  endoscopic diverticulotomy
  endoscopic surgery
  esophagus surgery
  external diverticulectomy
  outcome assessment
EMTREE MEDICAL INDEX TERMS
  abdominal pain (complication)
  adult
  aged
  article
  atrial fibrillation (complication)
  bradycardia (complication)
  bronchospasm (complication)
  carbon dioxide laser
  case study
  diarrhea (complication)
  diet
  esophagus myotomy
  esophagus perforation (complication)
  esophagus stenosis (complication)
  female
  fever (complication)
  follow up
  gastrointestinal stapler
  hospitalization
  human
  intermethod comparison
  length of stay
  major clinical study
  male
  medical record review
  operation duration
  pneumonia (complication)
  postoperative pain (complication)
  recurrent disease
  retrospective study
  tertiary care center
  thorax pain (complication)
  urine retention (complication)
  vocal cord paralysis (complication)
  Zenker diverticulum (surgery)
EMBASE CLASSIFICATIONS
  Otorhinolaryngology (11)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014895631
FULL TEXT LINK
  http://dx.doi.org/10.1177/0194599814541920
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 213
TITLE
  Could some geriatric characteristics hinder the prescription of 
anticoagulants in atrial fibrillation in the elderly?
AUTHOR NAMES
  Denoël P.
  Vanderstraeten J.
  Mols P.
  Pepersack T.
AUTHOR ADDRESSES
  (Denoël P., doc.vds@gmail.com) Emergency Service, Europe Hospital, Brussels, 
Belgium.
(Vanderstraeten J., jacques.vanderstraeten@ulb.ac.be) Centre de Recherche en 
Santé Environnementale et en Santé du Travail, Ecole de Santé Publique, 
Université Libre de Bruxelles, Brussels, Belgium.
(Mols P., pierre.mols@gmail.com) Emergency Service, Saint-Pierre University 
Hospital, Université Libre de Bruxelles, Brussels, Belgium.
(Pepersack T., thierry.pepersack@erasme.ulb.ac.be) Department of Geriatrics, 
Erasme Hospital, Université Libre de Bruxelles, Lennik Street 808, Brussels, 
Belgium.
CORRESPONDENCE ADDRESS
  T. Pepersack, Department of Geriatrics, Erasme Hospital, Université Libre de 
Bruxelles, Lennik Street 808, Brussels, Belgium.
SOURCE
  Journal of Aging Research (2014) 2014 Article Number: 693740. Date of 
Publication: 2014
ISSN
  2090-2212 (electronic)
  2090-2204
BOOK PUBLISHER
  Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New 
York, United States.
ABSTRACT
  Several studies have reported underprescription of anticoagulants in atrial 
fibrillation (AF). We conducted an observational study on 142 out of a total 
of 995 consecutive ≥75 years old patients presenting AF (14%) when admitted 
in an emergency unit of a general hospital, in search of geriatric 
characteristics that might be associated with the underprescription of 
anticoagulation therapy (mostly antivitamin K at the time of the study). The 
following data was collected from patients presenting AF: medical history 
including treatment and comorbidities, CHADS2 score, ISAR scale (frailty), 
Lawton's scale (ADL), GDS scale (mood status), MUST (nutrition), and blood 
analysis (INR, kidney function, and albumin). Among those patients for who 
anticoagulation treatment was recommended (73%), only 61% were treated with 
it. In the group with anticoagulation therapy, the following characteristics 
were observed more often than in the group without such therapy: a recent 
(≤6 months) hospitalization and medical treatment including digoxin or based 
on >3 different drugs. Neither the value of the CHADS2 score, nor the 
geriatric characteristics could be correlated with the presence or the 
absence of an anticoagulation therapy. More research is thus required to 
identify and clarify the relative importance of patient-, physician-, and 
health care system-related hurdles for the prescription of oral 
anticoagulation therapy in older patients with AF.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (drug therapy)
EMTREE DRUG INDEX TERMS
  acenocoumarol (drug combination, drug therapy)
  acetylsalicylic acid (drug combination, drug therapy)
  albumin (endogenous compound)
  antivitamin K (drug therapy)
  digoxin
  low molecular weight heparin (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  atrial fibrillation (epidemiology)
  elderly care
  prescription
EMTREE MEDICAL INDEX TERMS
  aged
  albumin blood level
  article
  CHADS2 score
  comorbidity
  controlled study
  daily life activity
  frail elderly
  hospitalization
  human
  international normalized ratio
  kidney function
  major clinical study
  mood
  nutrition
  observational study
  prevalence
  priority journal
  thromboembolism (complication, drug therapy, prevention)
CAS REGISTRY NUMBERS
  acenocoumarol (152-72-7)
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Hematology (25)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015136289
FULL TEXT LINK
  http://dx.doi.org/10.1155/2014/693740
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 214
TITLE
  Correlation of atrial fibrillation with SCN5A and KCNE1 gene polymorphism in 
chongming adults of Shanghai
AUTHOR NAMES
  Lu Y.
  Huang C.
  Huang D.
  Luo X.
  Hou S.
AUTHOR ADDRESSES
  (Lu Y.; Huang C.) Department of Cardiology, Renmin Hospital, Institute of 
Cardiology, Wuhan University, Wuhan, Hubei, China.
(Huang D.; Luo X.; Hou S.) Department of Cardiology, Affiliated Xinhua 
Hospital of Shanghai Jiaotong University in Chongming, Shanghai, China.
CORRESPONDENCE ADDRESS
  C. Huang, Department of Cardiology, Renmin Hospital, Institute of 
Cardiology, Wuhan University, No. 238 Jiefang Road, Wuhan, Hubei, China.
SOURCE
  (2014) 30:6 (1311-1316). Date of Publication: 2014
ISSN
  0393-6384
BOOK PUBLISHER
  Acta Medica Mediterranea
ABSTRACT
  Aims: To investigate the correlation of atrial fibrillation (AF) with 
SCN5A-A1673G and KCNE1-A112G gene polymorphism in Chongming adults of 
Shanghai. Materials and methods: Cluster random sampling was performed in 18 
communities of 18 villages, and inhabitants aged >20 years were screened. A 
total of 122 patients with AF who were recruited from this epidemiological 
study served as case group, and 122 subjects without AF from the same study 
served as controls. These subjects were recruited for case-control study at 
a ratio of 1:1. Polymerase chain reaction - restriction endonuclease 
fragment length polymorphism (PCR-RFLP) was performed to detect the SCN5A 
-A1673G and KCNEl-A112G (S38G) gene polymorphism for genotyping. Samples 
were randomly selected for sequencing to evaluate the reliability. SPSS 
version 17.0 was used for statistical analysis. The genotype frequency and 
Hardy-Weinberg equilibrium were evaluated. Chi square test was performed to 
compare the genotypes and allele frequency. A value of P < 0.05 was 
considered statistically significant. Multivariate logistic regression 
analysis was employed to assess the correlation of AF and gene polymorphism. 
Results: There were 3 genotypes of SCN5A-A1673G in the subjects 
investigated: AA genotype (38.33% vs. 58.33%), AG (45% vs. 30.83%) and GG 
(16.67% vs. 10.83%). In case group, G allele frequency was significantly 
higher than that in control group (39.17% vs. 26.25%), and GG genotype 
significantly influenced the AF (P < 0.05). Logistic regression analysis 
showed G allele was associated with AF (R=1.46, 95%CI: 1.38-1.54). There 
were 3 genotypes of KCNEl-A112G in the subjects investigated: AA genotype 
(13.33% vs. 11.67%), AG genotype (25% vs. 38.33%) and GG genotype (61.67% 
vs. 50%). The frequency of GG genotype in case group was markedly higher 
than that in control group. The distribution of genotypes was different 
between 2 groups without statistical significance (P > 0.05). Conclusion: In 
Han Chinese of Chongming in Shanghai, AF is associated with SCN5A-A1673G 
gene polymorphism, but not with KCNE1-A112G (S38G) gene polymorphism.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  potassium channel KCNE1 (endogenous compound)
  sodium channel Nav1.5 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (diagnosis)
  DNA polymorphism
EMTREE MEDICAL INDEX TERMS
  adult
  agar gel electrophoresis
  article
  case control study
  chi square test
  controlled study
  correlation analysis
  female
  gene frequency
  gene sequence
  genotype
  Han Chinese
  human
  major clinical study
  male
  multivariate logistic regression analysis
  polymerase chain reaction
  restriction fragment length polymorphism
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Human Genetics (22)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014901049
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 215
TITLE
  Approach to the new oral anticoagulants in family practice: Part 2: 
Addressing frequently asked questions
ORIGINAL (NON-ENGLISH) TITLE
  Approche à l'égard des nouveaux anticoagulants oraux en pratique familiale: 
2e partie : Répondre aux questions souvent posées
AUTHOR NAMES
  Douketis J.
  Bell A.D.
  Eikelboom J.
  Liew A.
AUTHOR ADDRESSES
  (Douketis J., jdouket@mcmaster.ca; Eikelboom J.; Liew A.) Department of 
Medicine, McMaster University, 50 Charlton Ave E, Hamilton, Canada.
(Bell A.D.) Department of Family and Community Medicine, University of 
Toronto, Canada.
CORRESPONDENCE ADDRESS
  J. Douketis, Department of Medicine, McMaster University, 50 Charlton Ave E, 
Hamilton, Canada.
SOURCE
  Canadian Family Physician (2014) 60:11 (997-1001 and e512-e517). Date of 
Publication: 1 Nov 2014
ISSN
  0008-350X
BOOK PUBLISHER
  College of Family Physicians of Canada
ABSTRACT
  Objective To address common "what if" questions that arise relating to the 
long-term clinical follow-up and management of patients receiving the new 
oral anticoagulants (NOACs).Sources of information For this narrative 
review, we searched the PubMed database for recent (January 2008 to week 32 
of 2013) clinical studies relating to NOAC use for stroke prevention in 
atrial fibrillation and for the treatment of acute venous thromboembolism. 
We used this evidence base to address prespecified questions relating to 
NOAC use in primary care settings.Main message Dabigatran and rivaroxaban 
should be taken with meals to decrease dyspepsia and increase absorption, 
respectively. There are no dietary restrictions with any of the NOACs, 
beyond moderating alcohol intake, and rivaroxaban and apixaban can be 
crushed if required. The use of acid suppressive therapies does not appear 
to affect the efficacy of the NOACs. As with warfarin, patients taking NOACs 
should avoid long-term use of nonsteroidal anti-i flammatory and 
antiplatelet drugs. For patients requiring surgery, generally NOACs should 
be stopped 2 to 5 days before the procedure, depending on bleeding risk, and 
the NOAC should usually be resumed at least 24 hours after surgery. 
Preoperative coagulation testing is generally unnecessary. In patients who 
develop bleeding, minor bleeding typically does not require laboratory 
testing or discontinuation of NOACs; with major bleeding, the focus should 
be on local measures to control the bleeding and supportive care, and 
coagulation testing should be performed. There are currently no antidotes to 
reverse NOACs. The NOACs should not be used in patients with valvular heart 
disease, prosthetic heart valves, cancer-associated deep vein thrombosis, or 
superficial thrombophlebitis.Conclusion Management of "what if" scenarios 
for patients taking NOACs have been proposed, but additional study is needed 
to address these issues, especially periprocedural management and bleeding.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (adverse drug reaction, drug combination, drug 
interaction, drug therapy, oral drug administration)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug combination, drug interaction)
  alcohol
  antithrombocytic agent (drug combination, drug interaction)
  dabigatran (drug therapy, oral drug administration)
  heparin
  metformin (drug therapy)
  nonsteroid antiinflammatory agent (drug combination, drug interaction)
  paracetamol (drug combination, drug interaction)
  ramipril (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  general practice
EMTREE MEDICAL INDEX TERMS
  acute coronary syndrome (complication)
  acute disease (drug therapy)
  aged
  alcohol consumption
  atrial fibrillation
  bleeding (complication, side effect, therapy)
  blood clotting test
  case report
  cerebrovascular accident (complication, drug therapy, prevention)
  chronic disease
  colon polyp (surgery)
  colonoscopy
  deep vein thrombosis (complication)
  dental procedure
  drug contraindication
  drug efficacy
  drug use
  drug withdrawal
  dyspepsia (side effect)
  erythrocyte transfusion
  fluid therapy
  follow up
  gastrointestinal clip
  heart valve prosthesis
  human
  hypertension (drug therapy)
  kidney function
  long term care
  male
  malignant neoplastic disease
  meal
  non insulin dependent diabetes mellitus
  obesity
  polypectomy
  preoperative evaluation
  primary medical care
  review
  superficial thrombophlebitis
  surgical risk
  valvular heart disease
  venous thromboembolism (drug therapy)
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alcohol (64-17-5)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  metformin (1115-70-4, 657-24-9)
  paracetamol (103-90-2)
  ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English, French
LANGUAGE OF SUMMARY
  English, French
EMBASE ACCESSION NUMBER
  2014918895
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 216
TITLE
  Thrombocytopenia induced by a taurine-containing energy drink: An adverse 
reaction to herbal medicine
AUTHOR NAMES
  Pasin F.
  Porro E.
  Frattini F.
  Vescovi P.
  Franchini M.
  Sansoni P.
AUTHOR ADDRESSES
  (Pasin F., f.pasin@ospedale.cremona.it) Department of General Medicine, 
Hospital Institutes of Cremona, viale Concordia 1, Cremona, Italy.
(Porro E.; Sansoni P.) Department of Clinical and Experimental Medicine, 
University of Parma, Parma, Italy.
(Frattini F.; Vescovi P.) Medical Department, AO Carlo Poma, Mantova, Italy.
(Franchini M.) Department of Laboratory Medicine, AO Carlo Poma, Mantova, 
Italy.
CORRESPONDENCE ADDRESS
  F. Pasin, Department of General Medicine, Hospital Institutes of Cremona, 
viale Concordia 1, Cremona, Italy.
SOURCE
  Italian Journal of Medicine (2014) 8:4 (259-261). Date of Publication: 2014
ISSN
  1877-9352 (electronic)
  1877-9344
BOOK PUBLISHER
  Page Press Publications, via Giuseppe Belli, Pavia, Italy.
ABSTRACT
  Thrombocytopenia is a well-recognized adverse effect of many drugs. The 
association of thrombocytopenia with herbal remedies, nutritional 
supplements, foods and beverages, complementary or alternative medicines, 
has been rarely described. There are reports of thrombocytopenia caused by 
quinine-containing beverages, cow's milk, cranberry juice, Jui, a Chinese 
herbal tea, Lupinus termis bean and tahini. A definite evidence of a causal 
association with thrombocytopenia is warranted; nevertheless not always 
there is provided probable or possible evidence in the association with 
thrombocytopenia. We report the first case, to our knowledge, of 
thrombocytopenia induced by taurine, present in an energy drink prescribed 
to our patient as tonic treatment.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  herbaceous agent (drug toxicity)
  taurine (drug toxicity)
EMTREE DRUG INDEX TERMS
  anticoagulant agent (drug therapy)
  complement component C3 (endogenous compound)
  complement component C4 (endogenous compound)
  guarana extract
  methylprednisolone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  energy drink
  herbal medicine
  thrombocytopenia (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  aged
  anticoagulant therapy
  atrial fibrillation (drug therapy)
  case report
  ecchymosis
  echocardiography
  Eleutherococcus
  erythrocyte count
  female
  follow up
  heart hypertrophy
  human
  international normalized ratio
  laboratory test
  mitral valve prosthesis
  petechia
  prothrombin time
  review
  thrombocyte count
  very elderly
CAS REGISTRY NUMBERS
  complement component C3 (80295-41-6)
  complement component C4 (80295-48-3, 80295-71-2)
  methylprednisolone (6923-42-8, 83-43-2)
  taurine (107-35-7)
EMBASE CLASSIFICATIONS
  Hematology (25)
  Drug Literature Index (37)
  Toxicology (52)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014615786
FULL TEXT LINK
  http://dx.doi.org/10.4081/itjm.2014.466
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 217
TITLE
  New once-weekly treatment for type 2 DM
AUTHOR NAMES
  Wheeler K.
AUTHOR ADDRESSES
  (Wheeler K.)
CORRESPONDENCE ADDRESS
  K. Wheeler,
SOURCE
  Drug Topics (2014) :SEP 2014. Date of Publication: 15 Sep 2014
ISSN
  1937-8157 (electronic)
  0012-6616
BOOK PUBLISHER
  Advanstar Communications Inc., info@advanstar.com
EMTREE DRUG INDEX TERMS
  2,4 thiazolidinedione derivative (drug therapy)
  albiglutide (adverse drug reaction, clinical trial, drug therapy, 
subcutaneous drug administration)
  hemoglobin A1c (endogenous compound)
  insulin glargine (drug therapy)
  insulin lispro (drug therapy)
  liraglutide (drug therapy)
  metformin (drug therapy)
  sulfonylurea (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  non insulin dependent diabetes mellitus (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation (side effect)
  backache (side effect)
  coughing (side effect)
  diet
  drug efficacy
  drug safety
  exercise
  gastrointestinal symptom (side effect)
  glycemic control
  hoarseness (side effect)
  human
  hypoglycemia (side effect)
  influenza (side effect)
  injection site reaction (side effect)
  pancreatitis (side effect)
  sinusitis (side effect)
  stomach emptying
  thyroid medullary carcinoma (side effect)
  thyroid tumor (side effect)
  upper respiratory tract infection (side effect)
DRUG TRADE NAMES
  tanzeum  Glaxo SmithKline

CAS REGISTRY NUMBERS
  albiglutide (782500-75-8)
  hemoglobin A1c (62572-11-6)
  insulin glargine (160337-95-1)
  insulin lispro (133107-64-9)
  liraglutide (204656-20-2)
  metformin (1115-70-4, 657-24-9)
EMBASE CLASSIFICATIONS
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2014807235
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 218
TITLE
  Cognitive impairment and dementia in Type 2 diabetes
AUTHOR NAMES
  Bruce D.G.
AUTHOR ADDRESSES
  (Bruce D.G., David.Bruce@uwa.edu.au) School of Medicine and Pharmacology, 
Fremantle Hospital, PO Box 480, Fremantle, Australia.
CORRESPONDENCE ADDRESS
  D.G. Bruce, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 
480, Fremantle, Australia.
SOURCE
  Diabetes Management (2014) 4:6 (467-469). Date of Publication: 1 Oct 2014
ISSN
  1758-1915 (electronic)
  1758-1907
BOOK PUBLISHER
  Future Medicine Ltd., info@futuremedicine.com
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cognitive defect
  dementia
  non insulin dependent diabetes mellitus
EMTREE MEDICAL INDEX TERMS
  adverse outcome
  Alzheimer disease
  atrial fibrillation
  Australia
  brain infarction
  cerebrovascular disease
  chronic lung disease
  cognition
  diabetic patient
  diseases
  glycemic control
  hospital admission
  human
  hyperglycemia
  hypertension
  hypoglycemia
  lifestyle modification
  Mediterranean diet
  multiinfarct dementia
  neuropathology
  patient compliance
  physical activity
  review
  risk factor
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2014954519
FULL TEXT LINK
  http://dx.doi.org/10.2217/dmt.14.37
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 219
TITLE
  Prevention of ischemic stroke in clinical practice: A role of internists and 
general practitioners
AUTHOR NAMES
  Niewada M.
  Członkowska A.
AUTHOR ADDRESSES
  (Niewada M., maciej.niewada@wum.edu.pl; Członkowska A.) Department of 
Experimental and Clinical Pharmacology, Medical University of Warsaw, ul. 
Banacha 1b, Warszawa, Poland.
(Niewada M., maciej.niewada@wum.edu.pl; Członkowska A.) 2nd Neurological 
Department, Institute of Psychiatry and Neurology, Warsaw, Poland.
CORRESPONDENCE ADDRESS
  M. Niewada, Department of Experimental and Clinical Pharmacology, Medical 
University of Warsaw, ul. Banacha 1b, Warszawa, Poland.
SOURCE
  Polskie Archiwum Medycyny Wewnetrznej (2014) 124:10 (540-548). Date of 
Publication: 2014
ISSN
  1897-9483 (electronic)
  0032-3772
BOOK PUBLISHER
  Medycyna Praktyczna, listy@mp.pl
ABSTRACT
  Stroke constitutes a substantial clinical and socio-economic burden. It is 
currently the third cause of death worldwide and results in mortality or 
disability in every third patient at the end of the first year following an 
acute cerebrovascular event. Although in-hospital mortality rates in stroke 
patients have decreased, prevention and cardiovascular risk control remain 
critical for improving the prognosis and reducing stroke burden worldwide. 
The definitions of stroke and transient ischemic attack (TIA) have been 
recently modified following the findings from neuroimaging and thrombolysis 
research. Both stroke and TIA are recurrent and preventable disorders. Both 
patients with stroke and those with TIA require prompt clinical workup, risk 
assessment, and appropriate management because the risk of recurrence, 
stroke, and coronary events is significant. The 5 most common cardiovascular 
risk factors (high blood pressure, smoking, abdominal obesity, diet, and 
lack of physical activity) are responsible for 80% of the cases. Stroke 
prevention involves lifestyle modification and specific treatment. Secondary 
prevention of ischemic stroke involves early treatment (antiplatelets and 
carotid interventions) and long-term management including lifestyle changes, 
antihypertensive therapy, antiplatelets, antithrombotic drugs in patients 
with atrial fibrillation, and the use of statins and other lipid-lowering 
drugs. Stroke patients are at risk of depression, dementia, epilepsy, and 
other complications that also require targeted treatment.
EMTREE DRUG INDEX TERMS
  anticoagulant agent (drug therapy)
  antihypertensive agent (drug therapy)
  antilipemic agent (drug therapy)
  antithrombocytic agent (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia (drug therapy, drug therapy, epidemiology, prevention, 
therapy)
  general practitioner
  internist
EMTREE MEDICAL INDEX TERMS
  antihypertensive therapy
  atrial fibrillation (drug therapy)
  blood clot lysis
  cardiovascular risk
  clinical practice
  high risk patient
  human
  hypertension (drug therapy)
  lifestyle modification
  mortality
  neuroimaging
  prognosis
  review
  risk assessment
  stroke patient
  transient ischemic attack (prevention)
  treatment planning
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, Polish
EMBASE ACCESSION NUMBER
  2014875019
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 220
TITLE
  Safety of herbal medicine in treatment of weight loss
AUTHOR NAMES
  Najafian J.
  Abdar-Esfahani M.
  Arab-Momeni M.
  Akhavan-Tabib A.
AUTHOR ADDRESSES
  (Najafian J.; Abdar-Esfahani M.) Isfahan Cardiovascular Research Center, 
Isfahan Cardiovascular Research Institute, Isfahan University of Medical 
Sciences, Isfahan, Iran.
(Arab-Momeni M.) Hypertension Research Center, Isfahan Cardiovascular 
Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
(Akhavan-Tabib A., afshan.akhavantabib@gmail.com) Cardiac Rehabilitation 
Research Center, Isfahan Cardiovascular Research Institute, Isfahan 
University of Medical Sciences, Isfahan, Iran.
CORRESPONDENCE ADDRESS
  A. Akhavan-Tabib, Cardiac Rehabilitation Research Center, Isfahan 
Cardiovascular Research Institute, Isfahan University of Medical Sciences, 
Isfahan, Iran. Email: afshan.akhavantabib@gmail.com
SOURCE
  ARYA Atherosclerosis (2014) 10:1 (55-58). Date of Publication: 2014
ISSN
  2251-6638 (electronic)
  1735-3955
BOOK PUBLISHER
  Isfahan University of Medical Sciences, rmsj@mui.ac.iv
ABSTRACT
  BACKGROUND: Obesity is a common health problem in both developed and 
developing countries. There are many unconventional therapies, including 
herbal medicine, to treat this condition. Some people believe that herbal 
medicines are safe. This case and review is about adverse complication of 
treating obesity with some herbal medicine. CASE REPORT: A 19 year old male 
with sever obesity (120 KG) used green tea (15 cups of green tea per day) 
and an intensive dietary regimen to lose weight. He lost 30 kg after 2 
months. At that time, one day after usual exercise he suddenly lost 
consciousness due to left ventricular fibrillation. CONCLUSION: Use of 
herbal medicine for weight reduction is not always safe. Moreover, for some 
herbal medicine the risk is sufficient to shift the risk-benefit balance 
against the use that medicine.
EMTREE DRUG INDEX TERMS
  caffeine
  diazepam (drug therapy)
  epigallocatechin
  etiracetam (drug therapy)
  levodopa (drug therapy)
  magnesium (oral drug administration)
  magnesium sulfate
  midazolam (drug therapy)
  oxedrine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  drug safety
  herbal medicine
  obesity
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation
  Camellia sinensis
  case report
  diet
  Ephedra
  female
  guarana
  heart arrest
  heart ejection fraction
  heart ventricle fibrillation
  human
  hypokinesia
  magnesium blood level
  male
  middle aged
  Pausinystalia
  QT prolongation
  resuscitation
  seizure (drug therapy)
  tea
  weight reduction
  young adult
CAS REGISTRY NUMBERS
  caffeine (58-08-2)
  diazepam (439-14-5)
  epigallocatechin (970-74-1)
  etiracetam (102767-28-2, 33996-58-6)
  levodopa (59-92-7)
  magnesium (7439-95-4)
  magnesium sulfate (7487-88-9)
  midazolam (59467-70-8)
  oxedrine (94-07-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014212430
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 221
TITLE
  Relationship Between Obesity and Driving
AUTHOR NAMES
  Kay G.G.
  McLaughlin D.
AUTHOR ADDRESSES
  (Kay G.G., gkay@cogres.com; McLaughlin D.) Cognitive Research Corporation, 
200 Central Avenue, Suite 1230, St. Petersburg, FL, 33701, United States.
CORRESPONDENCE ADDRESS
  G. G. Kay, Cognitive Research Corporation, 200 Central Avenue, Suite 1230, 
St. Petersburg, FL, 33701, United States. Email: gkay@cogres.com
SOURCE
  Current Obesity Reports (2014) 3:3 (336-340). Date of Publication: September 
2014
ISSN
  2162-4968 (electronic)
BOOK PUBLISHER
  Current Medicine Group LLC 1, info@phl.cursci.com
ABSTRACT
  Obesity, which has become epidemic throughout many parts of the world, is 
known to be a risk factor for a range of diseases including hypertension, 
diabetes, and vascular disease. Based on this review, it also appears that 
obesity is associated with increased crash risk and increased risk of 
serious or fatal injury in a crash. The problem is particularly an issue for 
commercial truck drivers. Data are presented showing the high prevalence of 
obesity in truck drivers. Inadequate sleep, poor nutrition, lack of 
exercise, and the sedentary nature of driving all contribute to the risk of 
obesity. The obesity related condition of obstructive sleep apnea (OSA) is 
known to increase crash risk. Treatment of this condition has been 
demonstrated to improve driving performance and to reduce crash risk. 
Screening truck drivers for obesity related health conditions, such as OSA, 
would be expected to result in public safety benefits. © 2014 Springer 
Science+Business Media New York.
EMTREE DRUG INDEX TERMS
  ghrelin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  driver
  obesity
EMTREE MEDICAL INDEX TERMS
  apnea
  arthritis
  asthma
  atrial fibrillation
  daytime somnolence
  disease association
  gallbladder disease
  human
  hypercholesterolemia
  hypertension
  increased appetite
  injury scale
  injury severity
  insulin resistance
  leptin deficiency
  non insulin dependent diabetes mellitus
  osteoarthritis
  oxygen desaturation
  physical activity
  positive end expiratory pressure
  priority journal
  review
  sleep disordered breathing
  sleep quality
  traffic accident
CAS REGISTRY NUMBERS
  ghrelin (304853-26-7)
EMBASE CLASSIFICATIONS
  Occupational Health and Industrial Medicine (35)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014511386
FULL TEXT LINK
  http://dx.doi.org/10.1007/s13679-014-0109-8
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 222
TITLE
  Robotic ablation of atrial fibrillation with a new remote catheter system
AUTHOR NAMES
  Wutzler A.
  Wolber T.
  Parwani A.S.
  Huemer M.
  Attanasio P.
  Blaschke F.
  Haegeli L.
  Haverkamp W.
  Duru F.
  Boldt L.-H.
AUTHOR ADDRESSES
  (Wutzler A., alexander.wutzler@charite.de; Parwani A.S.; Huemer M.; 
Attanasio P.; Blaschke F.; Haverkamp W.; Boldt L.-H.) Department of 
Cardiology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, 
Augustenburger Platz 1, Berlin, Germany.
(Wolber T.; Haegeli L.; Duru F.) Cardiovascular Center, Cardiology, 
University Hospital, Zurich, Switzerland.
CORRESPONDENCE ADDRESS
  A. Wutzler, Department of Cardiology, Charité-Universitätsmedizin Berlin, 
Campus Virchow-Klinikum, Augustenburger Platz 1, Berlin, Germany.
SOURCE
  Journal of Interventional Cardiac Electrophysiology (2014) 40:3 (215-219). 
Date of Publication: 2014
ISSN
  1572-8595 (electronic)
  1383-875X
BOOK PUBLISHER
  Kluwer Academic Publishers
ABSTRACT
  Purpose: Pulmonary vein isolation (PVI) is widely established as a curative 
treatment option for atrial fibrillation (AF). A wide range of techniques to 
improve catheter manipulation and steerability has been developed over the 
past years. A new remote catheter system (RCS) has recently become available 
(Amigo Remote Catheter System, Catheter Robotics, Budd Lake, NJ, USA). Here, 
we present a dual-center study on the RCS for left atrial mapping and PVI in 
patients with paroxysmal AF compared to a control group undergoing 
conventional PVI.Methods: One hundred nineteen patients who underwent PVI 
for paroxysmal AF were studied. Forty patients underwent PVI with the use of 
the RCS. Seventy-nine patients, who underwent conventional PVI, served as 
control group. Procedural data were compared between the two groups.Results: 
PVI was achieved in all patients. In the RCS group compared to standard 
ablation group, there were no significant differences in procedure duration 
(159.1 ± 45.4 vs. 146 ± 30.1 min, p = 0.19), total energy delivery (78,146.3 
± 26,992.4 vs. 87,963.9 ± 79,202.1 Ws, p = 0.57), and total fluoroscopy time 
(21.2 ± 8.6 vs. 23.9 ± 5.4 min, p = 0.15). Operator fluoroscopy exposure was 
significantly reduced in the RCS group (13.4 ± 6.1 vs. 23.9 ± 5.4 min, p < 
0.001).Conclusions: These initial results suggest that left atrial mapping 
and PVI are feasible with the use of the Amigo RCS. Acute procedural 
efficacy is comparable to the standard approach. The use of the Amigo RCS 
leads to a significant reduction of operator fluoroscopy exposure.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  catheter
  pulmonary vein isolation
  radiation exposure
EMTREE MEDICAL INDEX TERMS
  control group
  exposure
  fluoroscopy
  human
  lake
  patient
  procedures
  robotics
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014724681
FULL TEXT LINK
  http://dx.doi.org/10.1007/s10840-014-9895-x
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 223
TITLE
  A case of thyroid storm induced by iodine-containing dietary supplements and 
homeopathic remedies
AUTHOR NAMES
  Karkowski K.
  Carroll J.L.
AUTHOR ADDRESSES
  (Karkowski K.) University of Rhode Island, Kingston, RI, United States.
(Carroll J.L., James.L.Carroll@Dartmouth.edu) Geisel School of Medicine at 
Dartmouth, Lebanon, NH, United States.
CORRESPONDENCE ADDRESS
  J.L. Carroll, Geisel School of Medicine at Dartmouth, Lebanon, NH, United 
States. Email: James.L.Carroll@Dartmouth.edu
SOURCE
  Journal of Pharmacy Technology (2014) 30:3 (102-105). Date of Publication: 
June 2014
ISSN
  1549-4810 (electronic)
  8755-1225
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  Objective: We report the case of a patient who presented to the hospital in 
thyroid storm following the use of several iodine-containing dietary 
supplements (DS) and homeopathic remedies (HR). Case Summary: The patient 
was a 76-yearold woman with no personal or family history of thyroid or 
autoimmune disease. On laboratory assessment, a thyroid panel showed that 
her total T3 and T4 were elevated at 334 ng/dL and 14.6 μg/dL, respectively; 
thyroid stimulating hormone was undetectable; and thyroid stimulating 
immunoglobulin was positive at 7.4. The patient had been consuming 170 μg of 
iodine daily for the past 2 months via her DS and HR. An objective causality 
assessment using the Naranjo adverse drug reaction probability scale 
revealed that an adverse effect was probable. The patient likely suffered 
from iodine-induced thyrotoxicosis secondary to the consumption of numerous 
DS and HR. Discussion: Dietary supplements and homeopathic remedies can pose 
significant health risks. The safety of these products is not assured as 
they are incompletely monitored by the Food and Drug Administration. 
Individuals who take these compounds do so at their own risk and should pay 
close attention to product contents. Conclusions: The labeling of DS and HR 
products may be misleading. Pharmacists and clinicians are advised to 
inquire about the use of DS and HR products. When use is identified, the 
products should be subject to a thorough review. © The Author(s) 2014.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  homeopathic agent (adverse drug reaction)
  iodine (adverse drug reaction)
EMTREE DRUG INDEX TERMS
  liothyronine (endogenous compound)
  thyroid stimulating immunoglobulin (endogenous compound)
  thyrotropin (endogenous compound)
  thyroxine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diet supplementation
  thyroid crisis (diagnosis)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  case report
  congestive heart failure
  dyspnea
  echocardiography
  fatigue
  female
  follow up
  heart left ventricle ejection fraction
  human
  length of stay
  liothyronine blood level
  peripheral edema
  thyrotoxicosis (side effect)
  thyrotropin blood level
  thyroxine blood level
  weight reduction
CAS REGISTRY NUMBERS
  iodine (7553-56-2)
  liothyronine (6138-47-2, 6893-02-3)
  thyrotropin (9002-71-5)
  thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
  Clinical and Experimental Biochemistry (29)
  Endocrinology (3)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014394681
FULL TEXT LINK
  http://dx.doi.org/10.1177/8755122514529414
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 224
TITLE
  N-3 Fatty Acids for Prevention of Cardiovascular Disease
AUTHOR NAMES
  Khawaja O.A.
  Gaziano J.M.
  Djoussé L.
AUTHOR ADDRESSES
  (Khawaja O.A., oajaz@yahoo.com) Department of Cardiology, Mercy St. Vincent 
Medical Center, 2213 Cherry Street, Toledo, United States.
(Gaziano J.M., JMGAZIANO@PARTNERS.ORG; Djoussé L., 
ldjousse@rics.bwh.harvard.edu) Massachusetts Veterans Epidemiology and 
Research Information Center (MAVERIC), Boston Veterans Affairs Healthcare 
System, Boston, United States.
(Gaziano J.M., JMGAZIANO@PARTNERS.ORG; Djoussé L., 
ldjousse@rics.bwh.harvard.edu) Geriatric Research, Education, and Clinical 
Center (GRECC), Boston Veterans Affairs Healthcare System, Boston, United 
States.
(Gaziano J.M., JMGAZIANO@PARTNERS.ORG; Djoussé L., 
ldjousse@rics.bwh.harvard.edu) Division of Aging, Brigham and Women’s 
Hospital and Harvard Medical School, 1620 Tremont St, OBC, 3rd floor, 
Boston, United States.
(Gaziano J.M., JMGAZIANO@PARTNERS.ORG) Division of Preventive Medicine, 
Brigham and Women’s Hospital and Harvard Medical School, Boston, United 
States.
CORRESPONDENCE ADDRESS
  L. Djoussé, Division of Aging, Brigham and Women’s Hospital and Harvard 
Medical School, 1620 Tremont St, OBC, 3rd floor, Boston, United States.
SOURCE
  Current Atherosclerosis Reports (2014) 16:11. Date of Publication: 2014
ISSN
  1534-6242 (electronic)
  1523-3804
BOOK PUBLISHER
  Current Medicine Group LLC 1, info@phl.cursci.com
ABSTRACT
  Cardiovascular disease (CVD) is the leading cause of death in the USA. A 
diet enriched with n-3 fatty acids (FA) has been reported to play an 
important role in preventing the development of CVD. Prior studies have 
demonstrated beneficial effects of n-3 FA on hypertriglyceridemia, blood 
pressure, inflammation, endothelial function, and platelet function. 
However, data on the relation of n-3 FA consumption with CVD risk remain 
inconsistent. This paper reviews current evidence on the effects of n-3 FA 
on CVD, CVD risk factors, and potential biologic mechanisms. Last, we 
discuss major limitations of currently available data and future directions 
in the field.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  omega 3 fatty acid (clinical trial, drug combination, drug comparison - 
placebo, drug comparison, drug dose, drug therapy, endogenous compound, 
pharmacology)
EMTREE DRUG INDEX TERMS
  colecalciferol (clinical trial, drug comparison, drug therapy)
  docosahexaenoic acid (clinical trial, drug comparison, drug therapy)
  fish oil (clinical trial, drug comparison - placebo, drug therapy)
  margarine
  olive oil (clinical trial, drug combination, drug comparison, drug therapy)
  omega 3 acid ethyl ester (clinical trial, drug comparison, drug therapy)
  placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (drug therapy, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
  antiinflammatory activity
  atrial fibrillation (drug therapy)
  blood pressure regulation
  cardiovascular risk
  computed tomographic angiography
  coronary artery atherosclerosis (drug therapy)
  defibrillation
  diabetes mellitus (drug therapy, prevention)
  diet supplementation
  diet therapy
  drug dose comparison
  drug megadose
  endothelial dysfunction (drug therapy)
  evidence based medicine
  fatty acid blood level
  heart arrhythmia (drug therapy, therapy)
  heart failure (drug therapy, therapy)
  high risk population
  human
  hyperlipidemia (drug therapy)
  hypertension (drug therapy)
  impaired glucose tolerance (drug therapy, prevention)
  inflammation (drug therapy)
  low drug dose
  malignant neoplastic disease (drug therapy)
  outcome assessment
  primary prevention
  randomized controlled trial (topic)
  restenosis (complication, drug therapy)
  review
  risk benefit analysis
  risk reduction
  thrombocyte function
  treatment duration
DRUG TRADE NAMES
  omacor
CAS REGISTRY NUMBERS
  colecalciferol (1406-16-2, 67-97-0)
  docosahexaenoic acid (25167-62-8, 32839-18-2)
  fish oil (8016-13-5)
  margarine (8029-82-1)
  olive oil (8001-25-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Endocrinology (3)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015641666
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11883-014-0450-0
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 225
TITLE
  Omega-3 supplements and cardiovascular diseases
AUTHOR NAMES
  Mohebi-Nejad A.
  Bikdeli B.
AUTHOR ADDRESSES
  (Mohebi-Nejad A.) Cardiovascular Department, National Research Institute of 
Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical 
Sciences, Tehran, Iran.
(Bikdeli B., Behnood.bikdeli@yale.edu) Section of Cardiovascular Medicine, 
Center for Outcomes Research and Evaluation (CORE), and Department of 
Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, 
United States.
CORRESPONDENCE ADDRESS
  B. Bikdeli, One Church Street, Suite #200, New Haven, CT 06510, United 
States. Email: Behnood.bikdeli@yale.edu
SOURCE
  Tanaffos (2014) 13:1 (6-14). Date of Publication: 2014
ISSN
  1735-0344
BOOK PUBLISHER
  Shaheed Beheshti University of Medical Sciences and Health Services, 
info@tanaffosjournal.ir
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  omega 3 fatty acid (adverse drug reaction, drug therapy, pharmacoeconomics, 
pharmacology)
EMTREE DRUG INDEX TERMS
  docosahexaenoic acid (drug therapy, pharmacology)
  high density lipoprotein (endogenous compound)
  icosapentaenoic acid (drug therapy, pharmacology)
  icosapentaenoic acid ethyl ester (drug therapy)
  low density lipoprotein (endogenous compound)
  omega 3 acid ethyl ester (drug therapy)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (drug therapy, disease management, drug therapy, 
prevention, therapy)
  diet supplementation
EMTREE MEDICAL INDEX TERMS
  antiarrhythmic activity
  antiinflammatory activity
  antithrombotic activity
  atrial fibrillation (drug therapy)
  blood pressure regulation
  brain hemorrhage (side effect)
  cardiovascular mortality
  cardiovascular risk
  cell function
  cerebrovascular accident (side effect)
  drug activity
  drug cost
  drug effect
  drug mechanism
  drug safety
  drug structure
  epistaxis (side effect)
  fatty acid synthesis
  fatty fish
  fish
  food intake
  gastrointestinal hemorrhage (side effect)
  heart infarction (drug therapy)
  human
  Mediterranean diet
  molecular dynamics
  molecular interaction
  nonhuman
  postoperative atrial fibrillation (drug therapy)
  postoperative atrial fibrillation (drug therapy)
  postoperative complication (drug therapy)
  primary prevention
  review
  risk benefit analysis
  risk reduction
  secondary prevention
  subcutaneous hemorrhage (side effect)
  tachycardia (drug therapy)
DRUG TRADE NAMES
  lovaza
  vascepa
CAS REGISTRY NUMBERS
  docosahexaenoic acid (25167-62-8, 32839-18-2)
  icosapentaenoic acid (25378-27-2, 32839-30-8)
  icosapentaenoic acid ethyl ester (73310-10-8, 86227-47-6)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2014554566
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 226
TITLE
  Electrocardiographic deep terminal negativity of the P wave in V1 and risk 
of mortality: The national health and nutrition examination survey III
AUTHOR NAMES
  Tereshchenko L.G.
  Shah A.J.
  Li Y.
  Soliman E.Z.
AUTHOR ADDRESSES
  (Tereshchenko L.G., tereshch@ohsu.edu) Knight Cardiovascular Institute, 
Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, UHN62, 
Portland, United States.
(Shah A.J.) Department of Epidemiology, Emory University, Atlanta, United 
States.
(Shah A.J.) Atlanta VA Medical Center, Decatur, United States.
(Li Y.; Soliman E.Z.) Epidemiological Cardiology Research Center (EPICARE), 
Division of Public Health Sciences, United States.
(Soliman E.Z.) Department of Medicine, Cardiology Section, Wake Forest 
School of Medicine, Winston Salem, United States.
CORRESPONDENCE ADDRESS
  L.G. Tereshchenko, Knight Cardiovascular Institute, Oregon Health and 
Science University, 3181 SW Sam Jackson Park Rd, UHN62, Portland, United 
States.
SOURCE
  Journal of Cardiovascular Electrophysiology (2014) 25:11 (1242-1248). Date 
of Publication: 1 Nov 2014
ISSN
  1540-8167 (electronic)
  1045-3873
BOOK PUBLISHER
  Blackwell Publishing Inc., subscrip@blackwellpub.com
ABSTRACT
  Terminal P(V1) Negativity in NHANES III Introduction Deep terminal 
negativity of P wave in V1 (DTNPV1), defined as negative P prime larger than 
one small box (1 mm, or 0.1 mV), could be easily detected by simple visual 
inspection of the resting 12-lead ECG. The objective of this study was to 
determine the relationship between DTNPV1 and all-cause-, cardiovascular 
disease (CVD), and ischemic heart disease (IHD) mortality in the National 
Health and Nutrition Examination Survey III (NHANES III).Methods and Results 
After exclusion of participants with atrial fibrillation and missing data, 
DTNPV1 was automatically measured from standard 12-lead ECG in 8,146 
participants. Minnesota and Novacode algorithms were used for the 
determination of major and minor ECG abnormalities. National Death Index was 
used to identify the date and cause of death. During a median follow-up of 
13.8 years, a total of 2,975 deaths (1,303 CVD and 742 IHD deaths) occurred. 
After adjustment for age, gender, race/ethnicity, IHD, heart failure, 
chronic obstructive pulmonary disease, cancer, diabetes, body mass index, 
smoking, dyslipidemia, hypertension, use of antihypertensive and 
lipid-lowering medications, and ECG abnormalities, DTNPV1 was associated 
with significantly increased risk of all-cause death (HR [95% CI]: 1.30 
[1.10, 1.53]; P = 0.002), CVD death (HR [95% CI]: 1.36 [1.08, 1.72]; P = 
0.010), and IHD death (HR [95% CI]: 1.36 [1.00, 1.85]; P = 0.047).Conclusion 
In a large sample of the adult United States population, DTNPV1 is 
independently associated with increased risk of death due to all-cause, CVD, 
and IHD, findings suggesting its potential usefulness as a simple marker to 
identify individuals at risk of poor outcomes.
EMTREE DRUG INDEX TERMS
  antihypertensive agent (drug therapy)
  antilipemic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular mortality
  cardiovascular risk
  deep terminal negativity of P wave
  electrocardiography
  P wave
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  antihypertensive therapy
  article
  body mass
  cause of death
  chronic obstructive lung disease
  controlled study
  diabetes mellitus
  disease association
  dyslipidemia
  ECG abnormality
  female
  follow up
  heart failure
  human
  hypercholesterolemia (drug therapy)
  hypertension (drug therapy)
  major clinical study
  male
  neoplasm
  smoking
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014729041
FULL TEXT LINK
  http://dx.doi.org/10.1111/jce.12453
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 227
TITLE
  Cardioprotective effects of moderate red wine consumption: Polyphenols vs. 
ethanol
AUTHOR NAMES
  Iriti M.
  Varoni E.M.
AUTHOR ADDRESSES
  (Iriti M., marcello.iriti@unimi.it) Department of Agricultural and 
Environmental Sciences, Milan State University, Milan, Italy.
(Varoni E.M.) Department of Biomedical, Surgical and Dental Sciences, Milan 
State University, Milan, Italy.
CORRESPONDENCE ADDRESS
  M. Iriti, via G. Celoria 2, Milan, Italy.
SOURCE
  Journal of Applied Biomedicine (2014) 12:4 (193-202). Date of Publication: 1 
Nov 2014
ISSN
  1214-0287 (electronic)
  1214-021X
BOOK PUBLISHER
  University of South Bohemia, Ema Destinn Street, Jirovcova 24, Ceske 
Budejovic, Czech Republic. berger@jcu.cz
ABSTRACT
  Since decades, it has been suggested that regular, moderate consumption of 
red wine, a major component of Mediterranean diet, at main meals, may 
contribute to explain the healthy properties attributed to this traditional 
dietary style. Despite preclinical in vitro/ in vivo data have shown a 
significant cardioprotective activity of grape phytochemicals, mostly 
polyphenols, evidence in humans is still debated. This lack of consensus may 
be due to the equilibrium between the two main components of wine relevant 
for health: ethanol and bioactive compounds or phytochemicals, which include 
not only polyphenols, but also newly detected molecules, such as melatonin 
and phytosterols. The state of art related to this delicate equilibrium 
represents the starting point for designing future clinical trials, in 
perspective of clinical recommendations. A better comprehension of the wine 
chemistry complexity with its major components embodies a pivotal issue in 
biomedicine, involving the fields of diet-related environmental medicine as 
well as chronomedicine. In this paper, we briefly reviewed putative 
beneficial effects of moderate red wine intake in humans, focusing on the 
reduction of cardiovascular risk.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  alcohol
  polyphenol
EMTREE DRUG INDEX TERMS
  biological marker (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (prevention)
  food intake
  heart protection
  red wine
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  antiinflammatory activity
  atherosclerosis
  atrial fibrillation
  blood pressure regulation
  body mass
  cardiovascular mortality
  cardiovascular risk
  cell activation
  chronobiology
  diastolic blood pressure
  drug structure
  endothelium cell
  environmental health
  genetic variability
  health promotion
  human
  hypertension
  randomized controlled trial (topic)
  review
  risk reduction
  thrombocyte volume
  white wine
CAS REGISTRY NUMBERS
  alcohol (64-17-5)
  polyphenol (37331-26-3)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015878947
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jab.2014.09.003
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 228
TITLE
  Atrial fibrillation and stroke
ORIGINAL (NON-ENGLISH) TITLE
  Fibrilação atrial e acidente vascular cerebral
AUTHOR NAMES
  Gagliardi R.J.
  Gagliardi V.D.B.
AUTHOR ADDRESSES
  (Gagliardi R.J., rubensjg@apm.org.br) Disciplina de Neurologia da Santa Casa 
de São Paulo, São Paulo-SP, Brazil.
(Gagliardi V.D.B.) Clínica Neurológica da Santa Casa de São Paulo, São 
Paulo-SP, Brazil.
CORRESPONDENCE ADDRESS
  R. J. Gagliardi, Disciplina de Neurologia da Santa Casa de São Paulo, Rua 
Dr. Cesário Motta Jr., 112, CEP 01221-020, São Paulo-SP, Brazil. Email: 
rubensjg@apm.org.br
SOURCE
  Revista Neurociencias (2014) 22:1 (144-148). Date of Publication: 2014
ISSN
  1984-4905 (electronic)
  0104-3579
BOOK PUBLISHER
  Universidade Federal de Sao Paulo, revistaneurociencias@yahoo.com
ABSTRACT
  Approximately 20-30 % of strokes are cardioembolic, and atrial fibrillation 
(AF) is the main cardiogenic cause. AF is not an uncommon issue in the 
population, and its prevalence increases with age and is related to a more 
severe stroke. The prevention of stroke in patients with AF should be 
performed with oral anticoagulation, and warfarin is the most frequently 
used medication; however, this medication is difficult to be managed due to 
multiple drug interactions and dietary interactions, which demands a 
periodical laboratory monitoring. Half of the patients who started on this 
treatment interrupt it in months, and half of the treated patients do not 
reach the therapeutic target. In addition, there is a risk of bleeding, 
including cerebral hemorrhage, and the benefit of the medication should be 
individualized to each patient. In this scenario the new oral anticoagulants 
(such as dabigatran, rivaroxaban, apixaban, edoxaban) have emerged as an 
option to warfarin, which present with similar or slightly better efficacy 
than warfarin and risk of hemorrhage slightly lower.
EMTREE DRUG INDEX TERMS
  apixaban
  dabigatran
  edoxaban
  rivaroxaban
  warfarin (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  cerebrovascular accident (drug therapy, complication, drug therapy)
EMTREE MEDICAL INDEX TERMS
  article
  bleeding
  brain hemorrhage
  cardioembolic stroke
  drug efficacy
  human
  prevalence
CAS REGISTRY NUMBERS
  apixaban (503612-47-3)
  edoxaban (480449-70-5, 480449-71-6, 912273-65-5)
  rivaroxaban (366789-02-8)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English, Portuguese
LANGUAGE OF SUMMARY
  English, Portuguese
EMBASE ACCESSION NUMBER
  2014317401
FULL TEXT LINK
  http://dx.doi.org/10.4181/RNC.2014.22.929.5p
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 229
TITLE
  Plasma natriuretic peptides and incidence of subtypes of ischemic stroke
AUTHOR NAMES
  Berntsson J.
  Zia E.
  Borné Y.
  Melander O.
  Hedblad B.
  Engström G.
AUTHOR ADDRESSES
  (Berntsson J., john.berntsson@med.lu.se; Zia E.; Borné Y.; Melander O.; 
Hedblad B.; Engström G.) Department of Clinical Sciences in Malmö, 
Cardiovascular Epidemiology Skåne University, Lund University, House 60, 
Level 13, SE-20502 Malmö, Lund, Sweden.
SOURCE
  Cerebrovascular Diseases (2014) 37:6 (444-450). Date of Publication: August 
2014
ISSN
  1421-9786 (electronic)
  1015-9770
BOOK PUBLISHER
  S. Karger AG
ABSTRACT
  Background and Purpose: Natriuretic peptides predict poor outcomes in 
cardiovascular disease. However, the knowledge of their relationship to 
stroke is limited and prospective studies from the general population are 
few. The purpose of this study was to explore the relationship between 
N-terminal pro-brain natriuretic peptide (NT-proBNP) and midregional 
pro-atrial natriuretic peptide (MR-proANP) plasma levels and the risk for 
ischemic stroke and its subtypes. Methods: NT-proBNP and MR-proANP were 
measured in fasting blood samples from 4,862 subjects (40.2% men, mean age 
57.5 ± 6.0 years) without cardiovascular disease from the Malmö Diet and 
Cancer Study, a prospective, population-based study in Sweden. Incidence of 
ischemic stroke was monitored over a mean follow-up of 14.9 ± 3.0 years. 
Stroke cases were etiologically classified according to the TOAST 
classification. Cox proportional-hazards regression was used to study the 
incidence of stroke in relationship to NT-proBNP and MR-proANP. Results: 
During follow-up, 227 had a first-ever ischemic stroke (large-artery 
atherosclerosis, n = 35; cardioembolic stroke, n = 44; small-artery 
occlusion, n = 80; undetermined cause, n = 68). In the age- and sex-adjusted 
model, only NT-proBNP was associated with total ischemic stroke. This 
association was completely explained by an increased incidence of 
cardioembolic stroke. Adjusted for cardiovascular risk factors (age, sex, 
hypertension, diabetes, smoking, body mass index and low-density lipoprotein 
cholesterol), the hazard ratios (HRs, 95% confidence interval, 95% CI) for 
cardioembolic stroke were 1.00 (reference), 1.42 (0.34-6.00), 2.79 
(0.77-10.12) and 5.64 (1.66-19.20), respectively, for the 1st, 2nd, 3rd and 
4th quartiles of NT-proBNP. The corresponding HRs (95% CIs) for quartiles of 
MR-proANP were 1.00 (reference), 1.83 (0.55-6.14), 1.20 (0.33-4.34) and 3.96 
(1.31-11.99), respectively. In total, 335 (6.9%) subjects were diagnosed 
with atrial fibrillation during follow-up. Among the cardioembolic stroke 
cases, 30% were diagnosed with atrial fibrillation before the stroke event 
and another 36% within 6 months after the stroke. Of the cardioembolic 
stroke cases with atrial fibrillation, 59% were in the top quartile of 
NT-proBNP, 69% in the top quartile of MR-proANP and 79% were either in the 
top quartile of NT-proBNP or in the top quartile of MR-proANP. Conclusion: 
High plasma levels of NT-proBNP and MR-proANP are associated with a 
substantially increased risk of cardioembolic stroke, but not with other 
subtypes of ischemic stroke. The results suggest that assessment of stroke 
risk, including electrocardiography, is warranted in subjects with high 
NT-proBNP or MR-proANP. © 2014 S. Karger AG, Basel.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  amino terminal pro brain natriuretic peptide (endogenous compound)
  brain natriuretic peptide (endogenous compound)
  midregional pro atrial natriuretic peptide (endogenous compound)
EMTREE DRUG INDEX TERMS
  unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia (diagnosis, epidemiology)
EMTREE MEDICAL INDEX TERMS
  adult
  age
  aged
  article
  atrial fibrillation (diagnosis)
  blood sampling
  cardioembolic stroke (diagnosis, epidemiology)
  cardiovascular risk
  diet restriction
  disease association
  disease classification
  female
  follow up
  human
  incidence
  large artery atherosclerosis (diagnosis, epidemiology)
  major clinical study
  male
  priority journal
  protein blood level
  reference value
  risk assessment
  sex ratio
  small artery occlusion (diagnosis, epidemiology)
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  General Pathology and Pathological Anatomy (5)
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014563094
FULL TEXT LINK
  http://dx.doi.org/10.1159/000363279
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 230
TITLE
  The effect of strict rate control on B-type natriuretic peptide values and 
echocardiographic parameters in chronic atrial fibrillation
AUTHOR NAMES
  Ozkurt Y.
  Özpelit E.
  Aslan Ö.
  Goldeli O.
AUTHOR ADDRESSES
  (Ozkurt Y.; Özpelit E., ebru.ozpelit@gmail.com; Aslan Ö.; Goldeli O.) 
Department of Cardiology, Dokuz Eylül University, Inciralti/Izmir, Turkey.
CORRESPONDENCE ADDRESS
  E. Özpelit, Department of Cardiology, Dokuz Eylül University, 
Inciralti/Izmir, Turkey.
SOURCE
  Kardiologia Polska (2014) 72:10 (934-940). Date of Publication: 2014
ISSN
  0022-9032 (electronic)
  0022-9032
BOOK PUBLISHER
  Via Medica, Ul. Swietokrzyska 73, Gdansk, Poland. viamedica@viamedica.com.pl
ABSTRACT
  Background: There have been conflicting results about the role of strict 
rate control on cardiovascular outcomes in patients with chronic atrial 
fibrillation (AF). To date, large clinical studies have not shown a net 
clinical benefit derived from the current trend to specify the target 
ventricular rate according to the patient's own clinical and laboratory 
characteristics. Although the existing literature shows no superiority of 
strict rate control in clinical end points, it is difficult to assess the 
pure rate effect without commonly coexisting medication side effects which 
can also influence clinical end points.Aim: To determine the effects of 
strict rate control in patients with chronic AF, regarding objective 
parameters such as echocardiographic data and B-type natriuretic peptide 
(BNP) values.Methods: 38 patients with chronic AF for whom strict rate 
control had been planned were enrolled in the study. Patients' 
echocardiographic parameters, BNP values and 24 h Holter electrocardiography 
findings showing the average heart rate (HR), were studied at baseline and 
then monthly, until the end of the 3rd month. Patients' negative dromotropic 
therapy was adjusted to achieve a target resting HR of below 80 bpm. 
Laboratory and echocardiographic parameters at baseline and at the end of 
the study were compared in the whole study group. The whole study group was 
subclassified according to the average resting HRs achieved, (group 1 with 
strict rate control < 80 bpm; n = 25, and group 2 without strict rate 
control; n = 13).Results: In group 1, the average HR declined from 101 ± 
16.3 bpm to 77 ± 5.2 bpm. In group 2, the average HR was 96.6 ± 6.8 bpm at 
baseline and there was no significant change at the end of the study (94.2 ± 
5.9 bpm). In group 1, there were significant decreases in BNP, left 
ventricular volumes, left atrial and right atrial areas at the end of the 
study. In group 2, BNP values were significantly higher at the end of the 
study despite similar ventricular and atrial dimensions according to the 
baseline. Diastolic functions were assessed roughly by septal E/e', but no 
significant change was observed in either group.Conclusions: Strict rate 
control in patients with chronic AF yielded a significant decrease in BNP 
values as well as a reduction in volumes of cardiac chambers.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  brain natriuretic peptide (endogenous compound)
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent (adverse drug reaction, drug 
therapy)
  calcium channel blocking agent (adverse drug reaction, drug therapy)
  digoxin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy)
  chronic atrial fibrillation (drug therapy, drug therapy)
  chronic disease (drug therapy, drug therapy)
  disease control
  echocardiography
  radiological parameters
EMTREE MEDICAL INDEX TERMS
  aged
  article
  clinical article
  constipation (side effect)
  controlled study
  drug dose titration
  exercise
  female
  follow up
  heart left ventricle enddiastolic volume
  heart left ventricle volume
  heart rate
  Holter monitoring
  human
  hypotension (side effect)
  male
  physical disease (side effect)
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
  digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, Polish
EMBASE ACCESSION NUMBER
  2014914182
FULL TEXT LINK
  http://dx.doi.org/10.5603/KP.a2014.0092
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 231
TITLE
  Self-measure of heart rate variability (HRV) and arrhythmia to monitor and 
to manage atrial arrhythmias: Personal experience with high intensity 
interval exercise (HIIE) for the conversion to sinus rhythm
AUTHOR NAMES
  Young D.W.
AUTHOR ADDRESSES
  (Young D.W., dwyoung@ieee.org) HEAL Research, Chehalis, WA, United States.
CORRESPONDENCE ADDRESS
  D.W. Young, HEAL Research, Chehalis, WA, United States. Email: 
dwyoung@ieee.org
SOURCE
  Frontiers in Physiology (2014) 5 JUL Article Number: 00251. Date of 
Publication: 2014
ISSN
  1664-042X (electronic)
BOOK PUBLISHER
  Frontiers Research Foundation, info@frontiersin.org
EMTREE DRUG INDEX TERMS
  sotalol (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise
  heart atrium arrhythmia (drug therapy, drug therapy, therapy)
  heart rate variability
  high intensity interval exercise
  personal experience
  self examination
  sinus rhythm
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation (drug therapy, therapy)
  cardiotachometer
  cerebrovascular accident
  cryoablation
  disease association
  disease course
  ECG abnormality
  electrocardiography monitoring
  human
  medical decision making
  risk assessment
  risk reduction
  supraventricular premature beat (drug therapy, therapy)
  survival rate
  treatment outcome
CAS REGISTRY NUMBERS
  sotalol (3930-20-9, 80456-07-1, 959-24-0)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2014477704
FULL TEXT LINK
  http://dx.doi.org/10.3389/fphys.2014.00251
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 232
TITLE
  Atrial fibrillation in endurance athletes
AUTHOR NAMES
  Wilhelm M.
AUTHOR ADDRESSES
  (Wilhelm M., matthias.wilhelm@insel.ch) University Clinic of Cardiology, 
Division of Cardiovascular Prevention, Rehabilitation and Sports Cardiology, 
University Hospital, CH-3010 Bern, Switzerland.
CORRESPONDENCE ADDRESS
  M. Wilhelm, University Clinic of Cardiology, Division of Cardiovascular 
Prevention, Rehabilitation and Sports Cardiology, University Hospital, 
CH-3010 Bern, Switzerland. Email: matthias.wilhelm@insel.ch
SOURCE
  European Journal of Preventive Cardiology (2014) 21:8 (1040-1048). Date of 
Publication: August 2014
ISSN
  2047-4881 (electronic)
  2047-4873
BOOK PUBLISHER
  SAGE Publications Inc., claims@sagepub.com
ABSTRACT
  There is a growing population of veteran endurance athletes, regularly 
participating in training and competition. Although the graded benefit of 
exercise on cardiovascular health and mortality is well established, recent 
studies have raised concern that prolonged and strenuous endurance exercise 
may predispose to atrial and ventricular arrhythmias. Atrial fibrillation 
(AF) and atrial flutter are facilitated by atrial remodelling, atrial 
ectopy, and an imbalance of the autonomic nervous system. Endurance sports 
practice has an impact on all of these factors and may therefore act as a 
promoter of these arrhythmias. In an animal model, long-term intensive 
exercise training induced fibrosis in both atria and increased 
susceptibility to AF. While the prevalence of AF is low in young competitive 
athletes, it increases substantially in the aging athlete, which is possibly 
associated with an accumulation of lifetime training hours and participation 
in competitions. A recent meta-analysis revealed a 5-fold increased risk of 
AF in middle-aged endurance athletes with a striking male predominance. 
Beside physical activity, height and absolute left atrial size are 
independent risk factors for lone AF and the stature of men per se may 
explain part of their higher risk of AF. Furthermore, for a comparable 
amount of training volume and performance, male non-elite athletes exhibit a 
higher blood pressure at rest and peak exercise, a more concentric type of 
left ventricular remodelling, and an altered diastolic function, possibly 
contributing to a more pronounced atrial remodelling. The sports 
cardiologist should be aware of the distinctive features of AF in athletes. 
Therapeutic recommendations should be given in close cooperation with an 
electrophysiologist. Reduction of training volume is often not desired and 
drug therapy not well tolerated. An early ablation strategy may be 
appropriate for some athletes with an impaired physical performance, 
especially when continuation of competitive activity is intended. This 
review focuses on the prevalence, risk factors, and mechanisms of AF in 
endurance athletes, and possible therapeutic options. © The European Society 
of Cardiology 2013 Reprints and permissions: 
sagepub.co.uk/journalsPermissions.nav. © The European Society of Cardiology 
2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.
EMTREE DRUG INDEX TERMS
  amiodarone (adverse drug reaction)
  angiotensin receptor antagonist (drug therapy)
  diltiazem (drug therapy)
  flecainide (drug therapy)
  verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy)
  endurance sport
  heart atrium flutter (drug therapy, drug therapy)
  heart supraventricular arrhythmia
  heart ventricle arrhythmia
  supraventricular premature beat
EMTREE MEDICAL INDEX TERMS
  autonomic nervous system
  body height
  cardiologist
  disease predisposition
  elevated blood pressure (drug therapy)
  endurance training
  exercise
  heart electrophysiology
  human
  hypertension (drug therapy)
  marathon runner
  nonhuman
  physical activity
  physical performance
  prevalence
  priority journal
  rest
  review
  sex difference
  unspecified side effect (side effect)
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  diltiazem (33286-22-5, 42399-41-7)
  flecainide (54143-55-4)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Occupational Health and Industrial Medicine (35)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014502945
FULL TEXT LINK
  http://dx.doi.org/10.1177/2047487313476414
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 233
TITLE
  Low diastolic wall strain is associated with raised post-exercise E/E′ ratio 
in elderly patients without obvious myocardial ischemia
AUTHOR NAMES
  Takagi T.
  Takagi A.
  Yoshikawa J.
AUTHOR ADDRESSES
  (Takagi T., tcardiol@qb4.so-net.ne.jp) Takagi Cardiology Clinic, Mibu 
Kayogosho-cho 3-3, Nakagyo-ku, Kyoto, Japan.
(Takagi A.) Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan.
(Yoshikawa J.) Nishinomiya Watanabe Cardiovascular Center, Nishinomiya, 
Japan.
CORRESPONDENCE ADDRESS
  T. Takagi, Takagi Cardiology Clinic, Mibu Kayogosho-cho 3-3, Nakagyo-ku, 
Kyoto, Japan.
SOURCE
  Journal of Echocardiography (2014) 12:3 (106-111). Date of Publication: 1 
Sep 2014
ISSN
  1880-344X (electronic)
  1349-0222
BOOK PUBLISHER
  Springer-Verlag Tokyo, orders@springer.jp
ABSTRACT
  Background: It has been reported that the diastolic wall strain (DWS) 
inversely correlates with the myocardial stiffness constant. The ratio of 
early diastolic transmitral flow velocity to annulus velocity (E/E′) 
correlates with the left ventricular (LV) filling pressure. Increased LV 
wall stiffness is thought be associated with increased LV filling pressure 
after exercise. The purpose of this study was to evaluate the correlation 
between the DWS and post-exercise E/E′ in elderly patients without obvious 
myocardial ischemia.Methods: Fifty-eight elderly patients 
(age = 74 ± 6 years) who underwent treadmill stress echocardiography were 
studied. All patients had normal LV wall motion at rest, and patients with 
exercise-induced wall motion abnormality were excluded. The DWS was 
calculated as follows: DWS = (PWTs − PWTd)/PWTs, where PWTs is the LV 
posterior wall thickness at end-systole and PWTd is that at end-diastole. As 
previously reported, DWS ≤ 0.33 was defined as low DWS and E/E′ ≥15.0 was 
defined as a marker of increased LV filling pressure.Results: Eighteen 
patients had low DWS. Patients with low DWS had greater post-exercise E/E′ 
(17.9 ± 3.2 vs. 12.8 ± 3.3, p < 0.0001). The DWS was inversely and strongly 
correlated with post-exercise E/E′ (r<sup>2</sup> = 0.534, p < 0.0001). Low 
DWS predicted the development of raised post-exercise E/E′ ≥15.0 with a 
positive predictive value of 94 % and a negative predictive value of 
85 %.Conclusion: In elderly patients without obvious myocardial ischemia, 
the DWS correlates strongly and inversely with post-exercise E/E′. Patients 
with low DWS were likely to develop raised E/E′ after exercise.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent
  dipeptidyl carboxypeptidase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular parameters
  diastolic wall strain
  heart muscle ischemia
  postexercise annulus velocity
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  blood pressure monitoring
  clinical assessment
  coronary artery disease
  diagnostic accuracy
  Doppler echocardiography
  echocardiography
  end systolic left atrial volume
  female
  heart left ventricle ejection fraction
  heart left ventricle filling pressure
  heart ventricle hypertrophy
  hemodynamics
  human
  major clinical study
  male
  metabolic equivalent
  predictive value
  sensitivity and specificity
  treadmill exercise
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014789228
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12574-014-0225-1
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 234
TITLE
  Relationship between exercise-induced heart rate increase and the formation 
of microbubbles and high-intensity transient signals in mechanical heart 
valve implanted patients
AUTHOR NAMES
  Sünbül A.
  Kirba�� A.
  Tanrikulu N.
  ��engül C.
  Da��deviren B.
  I��ik Ö.
AUTHOR ADDRESSES
  (Sünbül A.) Department of Cardiology, Medicana Camlica Hospitals, Istanbul, 
Turkey.
(Kirba�� A., ahmetkirbas@gmail.com; I��ik Ö.) Department of Cardiovascular 
Surgery, Medicana Camlica Hospitals, Istanbul, Turkey.
(Tanrikulu N.) Department of Anesthesiology and Reanimation, Medicana 
Camlica Hospital, Istanbul, Turkey.
(��engül C.) Department of Cardiology, Gaziosmanpa a Hospital, Istanbul, 
Turkey.
(Da��deviren B.) Department of Cardiology, Medical Park Hospital, Istanbul, 
Turkey.
CORRESPONDENCE ADDRESS
  A. Kirba��, Department of Cardiovascular Surgery, Medicana Camlica 
Hospitals, Istanbul, Turkey. Email: ahmetkirbas@gmail.com
SOURCE
  Archives of Medical Science (2014) 10:4 (701-705). Date of Publication: 
August 2014
ISSN
  1896-9151 (electronic)
  1734-1922
BOOK PUBLISHER
  Termedia Publishing House Ltd., Kleeberqa St.2, Poznan, Poland.
ABSTRACT
  Introduction: The formation and collapse of vapor-filled bubbles near a 
mechanical heart valve is called cavitation. Microbubbles can be detected in 
vivo by doppler ultrasonography (USG) as HITS (high intensity transient 
signals) in cranial circulation. We investigated the relationship between 
exercise induced heart rate increase and HITS formation in cranial 
circulation. Material and methods: Thirty-nine mechanical heart valve 
implanted (8 aortic valve replacement (AVR) + mitral valve replacement 
(MVR), 9 AVR, 22 MVR) patients aged 18-80 years old were included in our 
study. Microbubbles were counted in the left ventricular cavity via 
transthoracic echocardiography at rest per cardiac cycle. Afterwards 
transcranial Doppler USG was performed and HITS were counted in each 
patient's middle cerebral artery at 5 min duration. Subsequently an exercise 
test according to the Bruce protocol was performed. After achieving maximal 
heart rate, microbubbles in the left ventricle and HITS were counted again. 
Results: Microbubbles in the left ventricle and transcranial HITS increased 
after exercise significantly compared to resting values (15.79 ±10.91 
microbubbles/beat vs. 26.51 ±18.00 microbubbles/beat, p < 0.001; 6.13 ±8.07 
HITS/5 min vs. 13.15 ±15.87 HITS/5 min, p = 0.001). There was a significant 
correlation between microbubbles and HITS counts after peak exercise (r = 
0.55, p < 0.001). Conclusions: In our study, we found that the microbubbles 
were increasing as the heart rate increased and more HITS were propelled to 
the cerebral circulation. As previously shown, HITS can alter cognitive 
functions. Therefore heart rate control is essential in mechanical heart 
valve patients to protect neurocognitive functions. Copyright © 2014 
Termedia & Banach.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aorta valve replacement
  exercise
  exercise induced heart rate increase
  heart rate
  high intensity transient signal
  image display
  mechanical heart valve
  microbubble
  mitral valve replacement
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation
  brain circulation
  clinical article
  cognition
  Doppler echography
  exercise test
  female
  heart cycle
  heart left ventricle ejection fraction
  human
  male
  real time ultrasound scanner
  resting heart rate
  sinus rhythm
  transcranial doppler
  transthoracic echocardiography
  ultrasound transducer
DEVICE TRADE NAMES
  vivid 7 dimension  General Electric

DEVICE MANUFACTURERS
  General Electric
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014596453
FULL TEXT LINK
  http://dx.doi.org/10.5114/aoms.2013.34990
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 235
TITLE
  Kinetics of left ventricular rotation during exercise and its relation to 
exercise tolerance in atrial fibrillation: assessment by two-dimensional 
speckle tracking echocardiography
AUTHOR NAMES
  Uchida K.
  Wada Y.
  Ariyoshi T.
  Okuda S.
  Murakami W.
  Myoren T.
  Harada N.
  Yamamoto T.
  Ueyama T.
  Tanaka N.
  Yano M.
AUTHOR ADDRESSES
  (Uchida K.; Okuda S.; Murakami W.; Myoren T.; Harada N.; Yamamoto T.; Ueyama 
T.; Yano M.) Department of Medicine and Clinical Science, Yamaguchi 
University Graduate School of Medicine, Ube, Japan.
(Wada Y., wadayasu@yamaguchi-u.ac.jp; Ariyoshi T.) Division of Laboratory, 
Yamaguchi University Hospital, Minami-Kogushi 1-1-1, Ube, Japan.
(Tanaka N.) Department of Laboratory Science, Yamaguchi University Graduate 
School of Medicine, Ube, Japan.
CORRESPONDENCE ADDRESS
  Y. Wada, Division of Laboratory, Yamaguchi University Hospital, 
Minami-Kogushi 1-1-1, Ube, Japan.
SOURCE
  Journal of Echocardiography (2014) 12:3 (89-97). Date of Publication: 1 Sep 
2014
ISSN
  1880-344X (electronic)
  1349-0222
BOOK PUBLISHER
  Springer-Verlag Tokyo, orders@springer.jp
ABSTRACT
  Conclusions: The augmentation of apical rotation in response to exercise may 
coincide with an increase of the apical derotation rate, and apical rotation 
reserve may reflect exercise tolerance in patients with AF and preserved 
LVEF.Methods: Twenty-nine patients (age 62 ± 13 years, 6 females) with AF 
and preserved LV ejection fraction (LVEF) were studied using two-dimensional 
speckle tracking echocardiography at rest and during exercise with a supine 
bicycle ergometer (20 W, 10 min). We measured the systolic rotation (Rot) 
and the peak rotation rate in systole and early diastole (eRotR) at the 
apical and basal levels of the LV. All patients underwent cardiopulmonary 
exercise testing to obtain their percent achieved of the predicted peak 
oxygen consumption (% peak VO<inf>2</inf>) value.Results: During exercise, 
apical Rot-related indices were significantly increased only in the 
preserved % peak VO<inf>2</inf> group. In contrast, E/e′ was significantly 
elevated only in the reduced % peak VO<inf>2</inf> group. Multivariable 
stepwise regression analysis showed that apical ΔRot was independently 
associated with % peak VO<inf>2</inf> (β = 0.72; p < 0.01). Apical ΔeRotR, 
which could not be selected as an independent predictor of % peak 
VO<inf>2</inf>, had a good linear correlation with apical ΔRot (r = 0.81, 
p < 0.01).Background: Left ventricular (LV) rotation plays an important role 
in cardiac function both at rest and during exercise in sinus rhythm. The 
kinetics of rotation during exercise and the relation between exercise 
tolerance and rotation-related parameters in patients with atrial 
fibrillation (AF) are unknown.
EMTREE DRUG INDEX TERMS
  brain natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  echocardiography
  exercise tolerance
  heart left ventricle relaxation
  heart ventricle contraction
  two dimensional speckle tracking echocardiography
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  bicycle ergometer
  cardiopulmonary exercise test
  clinical article
  computer program
  diastole
  Doppler echocardiography
  echocardiograph
  female
  heart function
  heart left ventricle ejection fraction
  heart ventricle hypertrophy
  human
  male
  oxygen consumption
  reproducibility
  sinus rhythm
  ultrasound scanner
DEVICE TRADE NAMES
  Echo Stress Table 750EC
  EchoPAC  , United StatesGE Healthcare

  Vivid E9  , United StatesGE Healthcare

DEVICE MANUFACTURERS
   (United States)GE Healthcare
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014761334
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12574-014-0205-5
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 236
TITLE
  Exercise echocardiography in asymptomatic HCM: Exercise capacity, and not LV 
outflow tract gradient predicts long-term outcomes
AUTHOR NAMES
  Desai M.Y.
  Bhonsale A.
  Patel P.
  Naji P.
  Smedira N.G.
  Thamilarasan M.
  Lytle B.W.
  Lever H.M.
AUTHOR ADDRESSES
  (Desai M.Y., desaim2@ccf.org; Bhonsale A.; Patel P.; Naji P.; Smedira N.G.; 
Thamilarasan M.; Lytle B.W.; Lever H.M.) Heart and Vascular Institute, 
Cleveland Clinic, 9500 Euclid Avenue, Desk J1-5, Cleveland, OH 44195, United 
States.
CORRESPONDENCE ADDRESS
  M.Y. Desai, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid 
Avenue, Desk J1-5, Cleveland, OH 44195, United States. Email: 
desaim2@ccf.org
SOURCE
  JACC: Cardiovascular Imaging (2014) 7:1 (26-36). Date of Publication: 
January 2014
ISSN
  1936-878X
  1876-7591 (electronic)
BOOK PUBLISHER
  Elsevier Inc., 360 Park Avenue South, New York, United States.
ABSTRACT
  Objectives This study sought to assess long-term outcomes in asymptomatic or 
minimally symptomatic patients with hypertrophic cardiomyopathy (HCM) who 
underwent exercise echocardiography, without invasive therapies for relief 
of left ventricular outflow tract (LVOT) obstruction. Background Many HCM 
patients present with LVOT obstruction, mitral regurgitation (MR), and 
diastolic dysfunction, often requiring invasive therapies for symptomatic 
relief. However, a significant proportion of truly asymptomatic patients can 
be closely monitored. In HCM patients, exercise echocardiography has been 
shown to be a useful assessment of functional capacity and risk 
stratification. Methods We included 426 HCM patients (44 ± 14 years; 78% 
men) undergoing exercise echocardiography, excluding hypertensive heart 
disease of elderly, ejection fraction <50% and invasive therapy (myectomy or 
alcohol ablation) during follow-up. Clinical, echocardiographic (LV 
thickness, LVOT gradient, and MR) and exercise variables (percent of age-sex 
predicted metabolic equivalents [METs] and heart rate recovery [HRR] at 1 
min post-exercise) were recorded. A composite endpoint of death, appropriate 
internal defibrillator discharge, and admission for congestive heart failure 
was recorded. Results Patients were asymptomatic or minimally symptomatic on 
history, but 82% of patients achieved <100% of age-sex predicted METs, and 
43% had ≥II+ post-stress MR. The mean LV septal thickness, post-exercise 
LVOT gradient, and HRR were 2.0 ± 0.5 cm, 62 ± 47 mm Hg, and 31 ± 14 
beats/min, respectively. During a mean follow-up of 8.7 ± 3 years, there 
were 52 events (12%). Patients achieving >100% of age-sex predicted METs had 
1% event rate versus 12% in those achieving <85%. On stepwise multivariate 
survival analysis, percent of age-sex predicted METs (hazard ratio [HR]: 
0.76; 95% confidence interval [CI]: 0.64 to 0.90), abnormal HRR (HR: 0.89; 
95% CI: 0.82 to 0.97), and atrial fibrillation (HR: 2.73; 95% CI: 1.30 to 
5.74) (overall, p < 0.001) independently predicted outcomes. Conclusions In 
asymptomatic or minimally symptomatic HCM patients, exercise stress testing 
provides excellent risk stratification, with a low event rate in patients 
achieving >100% of predicted METs. © 2014 BY THE AMERICAN COLLEGE OF 
CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER INC.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  echocardiography
  exercise echocardiography
  hypertrophic cardiomyopathy
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation
  congestive heart failure
  defibrillator
  Doppler echocardiography
  echocardiograph
  female
  follow up
  heart left ventricle outflow tract obstruction
  heart left ventricle wall
  heart rate
  heart rate recovery
  human
  major clinical study
  male
  metabolic equivalent
  priority journal
  stress echocardiography
  survival
  treadmill exercise
DEVICE TRADE NAMES
  Acuson Sequoia  , United StatesSiemens Medical Solutions

  HDI 5000  , United StatesPhilips Medical Systems

DEVICE MANUFACTURERS
   (United States)Philips Medical Systems
   (United States)Siemens Medical Solutions
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014046095
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jcmg.2013.08.010
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 237
TITLE
  Acupuncture Needling Styles and Reports of Associated Adverse Reactions to 
Acupuncture
AUTHOR NAMES
  McDowell J.M.
  Johnson G.M.
AUTHOR ADDRESSES
  (McDowell J.M., jillianmmcdowell@gmail.com) Prohealth Physiotherapy, 124 
Kelvin Street, Invercargill, New Zealand.
(Johnson G.M.) Centre for Health, School of Physiotherapy, University of 
Otago, Dunedin, New Zealand.
CORRESPONDENCE ADDRESS
  J.M. McDowell, Prohealth Physiotherapy, 124 Kelvin Street, Invercargill, New 
Zealand.
SOURCE
  Medical Acupuncture (2014) 26:5 (271-278). Date of Publication: 1 Oct 2014
ISSN
  1933-6594 (electronic)
  1933-6586
BOOK PUBLISHER
  Mary Ann Liebert Inc., info@liebertpub.com
ABSTRACT
  Introduction: Physiotherapy acupuncturists in New Zealand are encouraged to 
voluntarily report adverse reactions to acupuncture (ARA) in a scheme 
administered by their professional organization and provide information 
regarding the style of acupuncture used in these events.Methods: This was a 
cross-sectional descriptive study.Results: An analysis of 176 reports 
submitted from 1998 to 2013 showed that 81% of signs and symptoms reported 
as an ARA were minor in nature. Of these reports, sustained needling and dry 
needling styles were associated with 76% and 18% of major ARA, respectively. 
Proportionately, dry needling, however, had a 3% more major-to-minor 
reactions, compared to sustained needling. Conclusions: On the basis of 
these findings, recommendations are made for future ARA reporting to include 
dry needling practitioners into ARA reporting systems. It is also 
recommended to incorporate details of acupuncture needling style into future 
reporting templates so as to understand harm associated with these different 
approaches better. © Copyright 2014, Mary Ann Liebert, Inc. 2014.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  acupuncture adverse reaction (complication)
  iatrogenic disease (complication)
EMTREE MEDICAL INDEX TERMS
  acupressure
  adolescent
  adult
  adverse outcome
  angina pectoris (complication)
  article
  atrial fibrillation (complication)
  child
  Chinese medicine
  cross-sectional study
  descriptive research
  faintness (complication)
  female
  headache (complication)
  heart palpitation (complication)
  hematoma (complication)
  human
  hyperhidrosis (complication)
  infection (complication)
  injection site pain (complication)
  major clinical study
  male
  medical society
  needlestick injury (complication)
  New Zealand
  periosteum
  physiotherapist
  pneumothorax (complication)
  skin manifestation (complication)
  swelling (complication)
  trigger point
  ulcerogenesis (complication)
  voluntary reporting
  vomiting (complication)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014934448
FULL TEXT LINK
  http://dx.doi.org/10.1089/acu.2014.1060
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 238
TITLE
  Three questions to the human brain
AUTHOR NAMES
  Secher N.H.
AUTHOR ADDRESSES
  (Secher N.H., niels.secher@regionh.dk) Department of Anesthesia, 
Rigshospitalet 2041, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark.
CORRESPONDENCE ADDRESS
  N. H. Secher, Department of Anesthesia, Rigshospitalet 2041, Blegdamsvej 9, 
DK-2100 Copenhagen Ø, Denmark. Email: niels.secher@regionh.dk
SOURCE
  Periodicum Biologorum (2014) 116:1 (9-14). Date of Publication: March 2014
ISSN
  0031-5362
BOOK PUBLISHER
  Croatian Society of Natural Sciences
ABSTRACT
  An approximately 20% increase in cerebral blood flow (CBF) and the cerebral 
metabolic rate for oxygen manifest during whole body exercise with 
determination of brain tissue flow and arterial inflow to the brain. Yet, 
during intense exercise CBF approaches the resting level in response to the 
decrease in arterial carbon dioxide tension with the exponential increase in 
ventilation. Here it is illustrated that the increase in CBF during exercise 
appears to depend to the ability to raise cardiac output and it is 
speculated whether there is a sympathetic restrain on CBF when the increase 
in cardiac output is small. Furthermore, it is considered whether the 
restrain in CBF during intense exercise affects cerebral oxygenation to an 
extent that it provokes so-called central fatigue. Finally it is highlighted 
that the cerebral activation associated with exercise provokes uptake of 
carbohydrate, notably of lactate, that cannot be accounted for by the 
concomitant increase in the cerebral metabolic rate for oxygen and it is 
pointed out that it remains unknown why that apparently surplus carbohydrate 
uptake by the brain is in need.
EMTREE DRUG INDEX TERMS
  noradrenalin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain
EMTREE MEDICAL INDEX TERMS
  arterial carbon dioxide tension
  article
  atrial fibrillation
  brain blood flow
  carotid artery
  cerebral metabolic rate of oxygen
  exercise
  heart output
  human
  near infrared spectroscopy
CAS REGISTRY NUMBERS
  noradrenalin (1407-84-7, 51-41-2)
EMBASE CLASSIFICATIONS
  Physiology (2)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014510848
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 239
TITLE
  A cohort study examination of established and emerging risk factors for 
atrial fibrillation: The Busselton Health Study
AUTHOR NAMES
  Knuiman M.
  Briffa T.
  Divitini M.
  Chew D.
  Eikelboom J.
  McQuillan B.
  Hung J.
AUTHOR ADDRESSES
  (Knuiman M., Matthew.knuiman@uwa.edu.au; Briffa T.; Divitini M.) School of 
Population Health (M431), University of Western Australia, Crawley, WA 6009, 
Australia.
(Chew D.) Department of Cardiovascular Medicine, Flinders University, 
Southern Adelaide Local Health Network, Flinders Drive, Bedford Park, SA 
5042, Australia.
(Eikelboom J.) Department of Medicine, McMaster Clinic, McMaster University, 
237 Barton St. E., Hamilton, ON L8L, Canada.
(McQuillan B.; Hung J.) School of Medicine and Pharmacology (M503), Sir 
Charles Gairdner Hospital, University of Western Australia, G Block Hospital 
Avenue, Nedlands, WA 6009, Australia.
CORRESPONDENCE ADDRESS
  M. Knuiman, School of Population Health (M431), University of Western 
Australia, Crawley, WA 6009, Australia. Email: Matthew.knuiman@uwa.edu.au
SOURCE
  European Journal of Epidemiology (2014) 29:3 (181-190). Date of Publication: 
March 2014
ISSN
  1573-7284 (electronic)
  0393-2990
BOOK PUBLISHER
  Kluwer Academic Publishers
ABSTRACT
  Atrial fibrillation (AF) is the most common chronic arrhythmia in adults and 
its prevalence is increasing. Due to its serious cardiovascular 
complications there is a strong need to understand predisposing risk factors 
to develop effective prevention strategies. There are a few established risk 
factors but a number of further risk factors have been suggested including 
obesity, metabolic syndrome, sleep-disordered breathing, and inflammation. 
The aim of this study was to investigate established and emerging risk 
factors for AF in a cohort study of 4,267 adults in Busselton, Western 
Australia, without a history of AF at baseline in 1994/95 who were followed 
for 15 years for incident AF events. Baseline measurement included 
questionnaire, clinical assessment and blood sample. A total of 343 (8 %) 
experienced AF during follow-up. Cox regression analysis confirmed advancing 
age, male sex, taller height, being on hypertension treatment and higher 
body mass index (BMI) as the major common risk factors (all p < 0.001). 
However, further modelling showed the effect of being on hypertension 
treatment may be stronger in women (p = 0.001) and the effect of BMI 
stronger in men (p = 0.004). After adjustment for these factors, no other 
factors were strongly related (p < 0.001) although short PR interval, 
history of valvular heart disease, stroke, chronic obstructive pulmonary 
disease, lung function and adiponectin level were marginally related (p < 
0.05). This cohort study of predictors for incident AF has confirmed the 
major established risk factors. However, recently suggested potential novel 
risk factors for AF (inflammation, sleep-disordered breathing, 
glucose/metabolic disorders) were not confirmed in this study. © 2014 
Springer Science+Business Media.
EMTREE DRUG INDEX TERMS
  adiponectin (endogenous compound)
  antilipemic agent
  cholesterol (endogenous compound)
  glucose (endogenous compound)
  high density lipoprotein cholesterol (endogenous compound)
  insulin (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (epidemiology)
  cardiovascular risk
EMTREE MEDICAL INDEX TERMS
  adult
  age distribution
  aged
  alcohol consumption
  antihypertensive therapy
  article
  Australia
  blood sampling
  body height
  body mass
  cerebrovascular accident
  chronic kidney disease
  chronic obstructive lung disease
  clinical assessment
  cohort analysis
  diabetes mellitus
  exercise
  female
  follow up
  heart failure
  heart infarction
  heart left bundle branch block
  heart left ventricle hypertrophy
  heart muscle revascularization
  human
  hypertension
  lung function
  major clinical study
  male
  medical history
  metabolic syndrome X
  middle aged
  peripheral occlusive artery disease
  PR interval
  predictor variable
  questionnaire
  risk assessment
  sex difference
  sleep disordered breathing
  smoking
  transient ischemic attack
  valvular heart disease
  waist circumference
  waist hip ratio
CAS REGISTRY NUMBERS
  adiponectin (283182-39-8)
  cholesterol (57-88-5)
  glucose (50-99-7, 84778-64-3)
  insulin (9004-10-8)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014320054
FULL TEXT LINK
  http://dx.doi.org/10.1007/s10654-013-9875-y
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 240
TITLE
  Familial arrhythmogenic right ventricular dysplasia in afrocaribbeans: 
Treadmill stress test the key to early diagnosis
AUTHOR NAMES
  Williams-Phillips S.
AUTHOR ADDRESSES
  (Williams-Phillips S., sandrap@cwjamaica.com) Andrews Memorial Hospital, TAI 
Wing, 27 Hope Road, Kingston 10, Jamaica.
CORRESPONDENCE ADDRESS
  S. Williams-Phillips, Andrews Memorial Hospital, TAI Wing, 27 Hope Road, 
Kingston 10, Jamaica. Email: sandrap@cwjamaica.com
SOURCE
  Cardiometry (2014) :4 (86-93). Date of Publication: 2014
ISSN
  2304-7232 (electronic)
BOOK PUBLISHER
  Novyi Russkii Universitet, info@rosnou.ru
ABSTRACT
  Arrhythmogenic right ventricular dysplasia is a rare entity and a 
significant cause of sudden death especially in the Italian population and 
athletes. The familial form is uncommon especially in the Afro-Caribbean 
population. This Index family represents an Autosomal Dominant form in a 
maternal parent who had sudden death at 39 years of age. The Index case was 
diagnosed at 18 years with increasing palpitations since 8 years of age, 
becoming symptomatic two decades younger than her mother. This was confirmed 
using the Treadmill Stress test. This is the 1st Case of Familial 
Arrhythmogenic right ventricular dysplasia documented in an Afro-Caribbean 
family. Learning objective Familial Arrhythmogenic right ventricular 
dysplasia is a rare entity and a significant cause of sudden death 
especially in the Italian population and athletes. This the first case of 
Autosomal Dominant type of ARVD with variable penetrance, documented in an 
Afro-Caribbean family where diagnosis was aided by Ventricular Tachycardia 
occurring during a Treadmill Stress Test.
EMTREE DRUG INDEX TERMS
  atenolol (drug therapy)
  digoxin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  early diagnosis
  exercise test
  familial arrhythmogenic right ventricular dysplasia (drug therapy, 
diagnosis, drug therapy)
  heart right ventricle dysplasia (drug therapy, diagnosis, drug therapy)
  treadmill
  treadmill stress test
EMTREE MEDICAL INDEX TERMS
  adult
  African Caribbean
  article
  athlete
  atrial fibrillation
  cardiovascular magnetic resonance
  case report
  computer assisted tomography
  defibrillator
  dizziness
  ECG abnormality
  exercise
  fatigue
  female
  heart atrium flutter
  heart palpitation
  heart rate
  heart ventricle contraction
  heart ventricle tachycardia
  human
  New York Heart Association class
  QRS complex
  repolarization
  sinus arrhythmia
  sudden death
  systolic heart murmur
  T wave
  thorax pain
  transthoracic echocardiography
  tricuspid valve regurgitation
  young adult
CAS REGISTRY NUMBERS
  atenolol (29122-68-7, 93379-54-5)
  digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014396646
FULL TEXT LINK
  http://dx.doi.org/10.12710/cardiometry.2014.4.8693
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 241
TITLE
  Regulatory and occupational considerations in cardiology
AUTHOR NAMES
  Nunain S.O.
  Jagathesan T.
AUTHOR ADDRESSES
  (Nunain S.O.) Royal Sussex County Hospital, Brighton, United Kingdom.
(Nunain S.O.) Civil Aviation Authority, United Kingdom.
(Jagathesan T.) Department in Occupational and Aviation Medicine, Civil 
Aviation Authority, United Kingdom.
SOURCE
  Medicine (United Kingdom) (2014) 42:11 (670-675). Date of Publication: 2014
ISSN
  1365-4357 (electronic)
  1357-3039
BOOK PUBLISHER
  Elsevier Ltd
ABSTRACT
  For any occupation, the level of acceptable medical incapacitation risk 
needs to be defined (e.g airline pilots ≤1% per annum, HGV drivers <2% per 
annum). Guidelines from Civil Aviation Authority (CAA), Driver Vehicle 
Licensing Agency (DVLA) and consensus statements for athletes are the most 
useful reference points when making occupational decisions in patients with 
cardiological disease particularly those in higher-risk occupations. Common 
findings on screening ECGs and regulatory decisions in arrhythmias, coronary 
artery and structural heart disease are discussed.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  ajmaline
  dipeptidyl carboxypeptidase inhibitor
  flecainide
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  isoprenaline
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiology
  heart disease
  occupational health
EMTREE MEDICAL INDEX TERMS
  anticoagulant therapy
  aorta valve disease
  aorta valve replacement
  article
  atrial fibrillation
  atrioventricular block
  Brugada syndrome
  cardiac resynchronization therapy
  cardiomyopathy
  catheter ablation
  clinical decision making
  congenital heart disease
  congestive cardiomyopathy
  consensus
  coronary artery bypass surgery
  coronary artery disease
  drug eluting stent
  electrocardiogram
  electrocardiography
  exercise
  family history
  first degree atrioventricular block
  heart arrhythmia
  heart atrium flutter
  heart bundle branch block
  heart infarction
  heart left bundle branch block
  heart pacing
  heart septum defect
  heart ventricle arrhythmia
  high risk patient
  human
  hypertrophic cardiomyopathy
  implantable cardioverter defibrillator
  long QT syndrome
  mitral valve disease
  mitral valve stenosis
  occupation
  occupational hazard
  physical examination
  PR interval
  priority journal
  provocation test
  risk factor
  second degree atrioventricular block
  supraventricular tachycardia
  transcatheter aortic valve implantation
  transluminal coronary angioplasty
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  ajmaline (4360-12-7, 73089-81-3)
  flecainide (54143-55-4)
  isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Occupational Health and Industrial Medicine (35)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015931099
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 242
TITLE
  Predictive factors for postoperative complications in radical nephrectomy 
for renal cell carcinoma
AUTHOR NAMES
  Wongvittavas N.
  Panumatrassamee K.
  Opanuraks J.
  Usawachintachit M.
  Ratchanon S.
  Tantiwongse K.
  Bunyaratavej C.
  Santi-ngamkun A.
  Prasopsanti K.
AUTHOR ADDRESSES
  (Wongvittavas N.; Panumatrassamee K., kamol_uro@hotmail.com; Opanuraks J.; 
Usawachintachit M.; Ratchanon S.; Tantiwongse K.; Bunyaratavej C.; 
Santi-ngamkun A.; Prasopsanti K.) Division of Urology, Department of 
Surgery, Chulalongkorn University, Bangkok, Thailand.
CORRESPONDENCE ADDRESS
  K. Panumatrassamee, Division of Urology, Department of Surgery, 
Chulalongkorn University, Bangkok, Thailand.
SOURCE
  Asian Biomedicine (2014) 8:6 (763-769). Date of Publication: 1 Dec 2014
ISSN
  1875-855X (electronic)
  1905-7415
BOOK PUBLISHER
  Asian Biomedicine, chulamed@md.chula.ac.th
ABSTRACT
  Background: Radical nephrectomy is the treatment of choice for large renal 
cell carcinoma (RCC). Objectives: To describe the complications after 
radical nephrectomy for suspected or proven RCC and analyze the risk 
factors. Materials and methods: We retrospectively reviewed medical records 
from 110 patients who underwent radical nephrectomy for RCC in our 
institution between January 2007 and December 2013. The clinicopathological 
data of all patients were recorded and complications were graded using 
modified Clavien classification. Univariate and multivariate analysis was 
made of the predictive factors for complications. Results: Fifty 
postoperative complications occurred in 34 patients (31%) within 30 days, 
including 11% transfusion related complications. There were 22% minor 
complications (6% grade 1, 16% grade 2) and 9% major complication (5% grade 
3, 2% grade 4, and 2% grade 5). The most common complications were 
transfusion-related, re-laparotomy because of bleeding, and prolong ileus. 
In univariate analysis, pathological T-stage (P = 0.001), American Society 
of Anesthesiologists (ASA) score (P = 0.007), tumor size (P = 0.01), and 
tumor diameter >4 cm (P = 0.03) were significant predicting factors. Major 
Charlson comorbidity index (CCI >2) was the only significant factor for 
major complications (P = 0.04). In multivariate analysis, ASA score was a 
significant independent predictor for overall complications (odds ratio 
4.83, P = 0.01). Conclusions: ASA score was a significant predictive factor 
for overall postoperative complications. Comorbidities was also a predictor 
for major complications in radical nephrectomy. Preoperative risk 
stratification for complications should be considered during decision-making 
and for proper counseling of patients.
EMTREE DRUG INDEX TERMS
  antibiotic agent (drug therapy)
  anticoagulant agent (drug therapy)
  antihypertensive agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  kidney carcinoma (surgery)
  nephrectomy
  postoperative complication (drug therapy, complication, drug therapy, 
therapy)
  radical nephrectomy
EMTREE MEDICAL INDEX TERMS
  abdominal surgery
  acute kidney failure (complication, therapy)
  acute kidney tubule necrosis (complication)
  adult
  American Society of Anesthesiologists score
  anemia (complication, therapy)
  aorta rupture (complication)
  article
  assessment of humans
  atelectasis (complication, therapy)
  atrial fibrillation (complication, drug therapy)
  body mass
  brain ischemia (complication)
  breathing exercise
  cancer staging
  cancer surgery
  Charlson Comorbidity Index
  comorbidity
  congestive heart failure (complication)
  conservative treatment
  controlled study
  epilepsy (complication)
  female
  fever (complication)
  hemodialysis
  human
  hypertension (complication, drug therapy)
  lung embolism (complication, drug therapy)
  major clinical study
  male
  metastasis
  multiple organ failure (complication)
  operation duration
  patient history of surgery
  percutaneous drainage
  pleura effusion (complication)
  pneumonia (complication, drug therapy)
  postoperative hemorrhage (complication)
  postoperative ileus (complication)
  prolonged drain leakage (complication)
  retrospective study
  risk factor
  septic shock (complication)
  small intestine obstruction (complication, therapy)
  surgical approach
  surgical infection (complication)
  total parenteral nutrition
  transfusion
  transient ischemic attack (complication, drug therapy)
  tumor volume
  urinary tract infection (complication, drug therapy)
  vertigo (complication)
  wound closure
  wound dehiscence (complication)
  wound dressing
EMBASE CLASSIFICATIONS
  Cancer (16)
  Urology and Nephrology (28)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015758100
FULL TEXT LINK
  http://dx.doi.org/10.5372/1905-7415.0806.355
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 243
TITLE
  Postoperative delirium: Risk factors, prevention, and treatment
AUTHOR NAMES
  Trabold B.
  Metterlein T.
AUTHOR ADDRESSES
  (Trabold B., benedikt.trabold@klinik.uni-regensburg.de; Metterlein T.) 
Department of Anesthesiology, University Hospital Regensburg, Franz-Jo- 
sef-Strauss-Allee 11, Regensburg, Germany.
CORRESPONDENCE ADDRESS
  B. Trabold, Department of Anesthesiology, University Hospital Regensburg, 
Franz-Jo- sef-Strauss-Allee 11, Regensburg, Germany.
SOURCE
  Journal of Cardiothoracic and Vascular Anesthesia (2014) 28:5 (1352-1360). 
Date of Publication: 1 Oct 2014
ISSN
  1532-8422 (electronic)
  1053-0770
BOOK PUBLISHER
  W.B. Saunders
EMTREE DRUG INDEX TERMS
  albumin (endogenous compound)
  antidepressant agent
  antihistaminic agent
  benzodiazepine derivative
  cholinergic receptor blocking agent
  clonidine
  dexmedetomidine
  fentanyl
  gabapentin
  haloperidol
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  inotropic agent
  olanzapine
  risperidone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  postoperative delirium
EMTREE MEDICAL INDEX TERMS
  anemia
  atrial fibrillation
  blood transfusion
  cerebrovascular accident
  cognitive defect
  dehydration
  dementia
  depression
  diabetes mellitus
  disease predisposition
  early diagnosis
  electrolyte disturbance
  epidemiology
  EuroSCORE
  exercise
  functional disease
  hearing aid
  heart infarction
  heart output
  human
  hyperthyroidism
  hypothyroidism
  hypoxia
  kidney failure
  malnutrition
  mobilization
  nutritional status
  operation duration
  pain
  patient education
  perfusion pressure
  pharmaceutical care
  review
  risk factor
  shock
  sleep
  sunlight
  systemic inflammatory response syndrome
  visual aid
CAS REGISTRY NUMBERS
  clonidine (4205-90-7, 4205-91-8, 57066-25-8)
  dexmedetomidine (113775-47-6)
  fentanyl (437-38-7)
  gabapentin (60142-96-3)
  haloperidol (52-86-8)
  olanzapine (132539-06-1)
  risperidone (106266-06-2)
EMBASE CLASSIFICATIONS
  Anesthesiology (24)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2014853089
FULL TEXT LINK
  http://dx.doi.org/10.1053/j.jvca.2014.03.017
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 244
TITLE
  The ESH/ESC guidelines for the management of arterial hypertension
AUTHOR NAMES
  Arden C.
AUTHOR ADDRESSES
  (Arden C.)
(Arden C.) GPSI Cardiology, Southampton, United Kingdom.
CORRESPONDENCE ADDRESS
  C. Arden, Chandlers Ford, United Kingdom.
SOURCE
  Primary Care Cardiovascular Journal (2014) 7:2 (85-88). Date of Publication: 
April-June 2014
ISSN
  1756-5146 (electronic)
  1756-5138
BOOK PUBLISHER
  Sherborne Gibbs Limited, agreathead@sherbornegibbs.co.uk
ABSTRACT
  There still remains a significant gap between the goal of optimal treatment 
of hypertension and 'real life' practice. As a consequence, hypertension 
remains a leading cause of cardiovascular-related morbidity and mortality. 
There is a continuing need to improve both the detection and management of 
hypertension, with a view to improving the efficacy of treatment including 
lifestyle interventions and outcomes. In order to address these issues, the 
European Society of Hypertension (ESH) and the European Society of 
Cardiology (ESC) have recently published guidance on the management of 
arterial hypertension.(1).
EMTREE DRUG INDEX TERMS
  alcohol
  alpha adrenergic receptor blocking agent
  angiotensin receptor antagonist (drug combination, drug therapy)
  beta adrenergic receptor blocking agent
  calcium antagonist (drug combination, drug therapy)
  creatinine (endogenous compound)
  dipeptidyl carboxypeptidase inhibitor (drug combination, drug therapy)
  mineralocorticoid antagonist
  thiazide diuretic agent (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  hypertension (drug therapy, drug therapy)
  practice guideline
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  antihypertensive therapy
  asymptomatic disease
  atrial fibrillation
  bleeding
  blood pressure monitoring
  blood pressure regulation
  cardiovascular mortality
  cardiovascular risk
  cerebrovascular accident
  chronic kidney disease
  comorbidity
  creatinine blood level
  diastolic blood pressure
  dynamic exercise
  geriatric patient
  glomerulus filtration rate
  human
  ischemic heart disease
  lifestyle modification
  long term care
  medical history
  medical society
  microalbuminuria
  papilledema
  physical examination
  physician
  prognosis
  renin angiotensin aldosterone system
  resistant hypertension
  review
  smoking cessation
  target organ
  transient ischemic attack
  treatment indication
CAS REGISTRY NUMBERS
  alcohol (64-17-5)
  creatinine (19230-81-0, 60-27-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014433725
FULL TEXT LINK
  http://dx.doi.org/10.3132/pccj.2014.011
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 245
TITLE
  33(rd) Annual Scientific Meeting of Belgian Society of Cardiology
AUTHOR ADDRESSES
  SOURCE
  Acta Cardiologica (2014) 68:1 (68). Date of Publication: 2014
CONFERENCE NAME
  33(rd) Annual Scientific Meeting of Belgian Society of Cardiology
CONFERENCE LOCATION
  Bruxelles, Belgium
CONFERENCE DATE
  2014-01-30 to 2014-01-31
ISSN
  0001-5385
  0373-7934 (electronic)
ABSTRACT
  The proceedings contain 51 papers. The special focus in this conference is 
on Cardiology. The topics include: The management of newly diagnosed atrial 
fibrillation in Belgium; duty-cycled multi-electrode RF versus irrigated 
point-by-point RF for ablation of recurrent atrial fibrillation; a family 
with recurrent sudden death; pulmonary vein isolation using a novel 
multi-electrode circular catheter; episodes of subclinical atrial 
tachyarrhythmia are not associated with worse outcome in cardiac 
resynchronization therapy patients; contact force sensing open irrigated 
catheter reduces by half the early recurrence of atrial fibrillation after 
pulmonary veins isolation for paroxysmal atrial fibrillation; partial or 
complete isolation of the left atrial posterior wall increase drastically 
the absence of AF recurrence after an index ablation for persistent atrial 
fibrillation; right ventricular fatigue developing during endurance 
exercise; myocardial inflammation in experimental acute right ventricular 
failure. effects of epoprostenol infusion; endothelin-1 contributes to the 
down regulation of the BMPR2 signalling observed in patients with pulmonary 
arterial hypertension; pulmonary vasoreactivity in spontaneously 
hypertensive rats; high fidelity simulation is useful to improve 
resuscitation skills in paediatric cardiology; myocardial expression of 
cytokines influence post-operative outcome after cardiac surgery for 
congenital cardiac defects; 20-year single centre experience of heart 
transplantation in children and adolescents; introduction of a heart failure 
nurse for the support of in-hospital management of mainly elderly patients 
with acute HF results in a shorter hospitalisation duration, a higher 
prescription of evidence based medication and a better outcome after 1 year 
follow-up; the impact of left ventricle assist device on microvascular 
function; galectin-3 testing with the Vidas® assay in patients with heart 
failure; novel urinary biomarkers in detecting acute kidney injury, 
persistent renal impairment and all-cause mortality following decongestive 
therapy in acute decompensated heart failure; implementation of transmural 
disease management in patients admitted with advanced heart failure; 
uptitration of neurohumoral blockers in hospitalized heart failure patients 
with reduced versus preserved ejection fraction; 3-year clinical follow-up 
of the PYTON (Prospective Evaluation of the TRYTON Side-Branch Stent TMwith 
an additional XIENCE-VTM Everolimus-Eluting Stent in Coronary Bifurcation 
Lesions) study; drug-eluting versus bare-metal stents after rotational 
atherectomy; multidimensional geriatric assessment in patients (> 75 years) 
suffering from severe, symptomatic aortic valve stenosis; interstrut 
cavities are associated with delayed vessel wall healing in biolimus- and 
everolimus-eluting stents; evaluation of peri-strut low intensity areas 
after biolimus--and everolimus-eluting stent implantation; adiponectin and 
ischemia-reperfusion injury in ST elevation myocardial infarction; a useful 
tool for discriminating between anterior infarction and transient left 
ventricular ballooning syndrome; improvement prehospital and inhospital 
delays before PCI for STEMI in a rural area over a 15-year period; 
functional performance and quality of life in highrisk comorbid patients 
undergoing transcatheter aortic valve implantation for symptomatic aortic 
valve stenosis; a simple clinical test to predict clopidogrel resistance; 
features of myocardial infarction in young patients; primary percutaneous 
coronary intervention in coronary artery bypass graft patients; comparison 
of temporal trends in mortality rates of cardiovascular origin in Belgium 
and in the ICAPROS area; drug-eluting stents for the treatment of pulmonary 
vein stenosis after atrial fibrillation ablation; cardiac malformations in 
neonates born from mothers with gestational diabetes; percutaneous left 
atrial appendage closure with the AmplatzerTM cardiac plug; functional 
impact of transmitral gradients at rest and during exercise after 
restrictive annuloplasty for ischemic mitral regurgitation; tricuspid 
annuloplasty concomitant with mitral valve surgery; reference values for the 
oxygen uptake efficiency slope in healthy men and women aged 20-60 years; 
huge multiple myxoma of the right ventricle revealed by right heart failure 
(about a case); ewing sarcoma invading the right atrium (about a single 
case); low gradient severe aortic stenosis in octogenarian patients with 
preserved ejection fraction; left atrium function in normal subjects, 
assessed by mitral annulus speckle tracking; acute exposure to diesel 
exhaust increases pulmonary arterial resistance but does not enhance 
pulmonary hypoxic vasoconstriction; retrospective analysis of treatment of 
hyperkalemia and prospective evaluation of the impact of remote monitoring 
to follow patient with implantable device in the routine practice of an 
electrophysiological centre.
EMTREE DRUG INDEX TERMS
  adiponectin
  biological marker
  clopidogrel
  cytokine
  endothelin 1
  everolimus
  galectin 3
  prostacyclin
  umirolimus
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiology
  society
EMTREE MEDICAL INDEX TERMS
  acute heart failure
  acute kidney failure
  adolescent
  aged
  annuloplasty
  aorta stenosis
  aorta valve stenosis
  artery resistance
  assay
  atrial fibrillation
  bare metal stent
  Belgium
  blood vessel wall
  cardiac resynchronization therapy
  catheter
  child
  congenital malformation
  coronary artery bypass graft
  coronary bifurcation lesion
  devices
  disease management
  down regulation
  drug eluting stent
  drug therapy
  electrode
  endurance training
  evidence based practice
  Ewing sarcoma
  exercise
  exhaust gas
  exposure
  fatigue
  female
  follow up
  geriatric assessment
  healing
  heart atrium appendage
  heart atrium function
  heart ejection fraction
  heart failure
  heart infarction
  heart left atrium
  heart left ventricle
  heart right atrium
  heart right ventricle
  heart right ventricle failure
  heart surgery
  heart transplantation
  hospital management
  human
  hyperkalemia
  implantation
  infarction
  infusion
  male
  mitral valve
  mitral valve regurgitation
  mortality
  mother
  myocarditis
  myxoma
  newborn
  normal human
  nurse
  oxygen consumption
  patient
  percutaneous coronary intervention
  pregnancy diabetes mellitus
  prescription
  pulmonary hypertension
  pulmonary vein
  pulmonary vein isolation
  pulmonary vein obstruction
  quality of life
  reference value
  remote sensing
  reperfusion injury
  resuscitation
  rotational atherectomy
  rural area
  simulation
  skill
  spontaneously hypertensive rat
  ST segment elevation myocardial infarction
  stent
  sudden death
  tachycardia
  takotsubo cardiomyopathy
  therapy
  transcatheter aortic valve implantation
  tricuspid annuloplasty
  vasoconstriction
  ventricular assist device
  very elderly
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
FULL TEXT LINK
  http://dx.doi.org/10.2143/AC.69.1.3011350
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 246
TITLE
  Safety of acupuncture treatments for patients taking warfarin or 
antiplatelet medications: Retrospective chart review study
AUTHOR NAMES
  Kim Y.-J.
  Kim S.-K.
  Cho S.-Y.
  Park S.-U.
  Jung W.-S.
  Moon S.-K.
  Ko C.-N.
  Cho K.-H.
  Kim S.-B.
  Shin W.-C.
  Park J.-M.
AUTHOR ADDRESSES
  (Kim Y.-J.; Kim S.-K.) Department of Korean Medicine Graduate School, Kyung 
Hee University, Seoul, South Korea.
(Cho S.-Y.; Park S.-U.; Ko C.-N.; Park J.-M., pajama@khu.ac.kr) Department 
of Korean Internal Medicine, Stroke and Neurological Disorders Center, Kyung 
Hee University Hospital at Gangdong Kyung Hee University, Seoul, South 
Korea.
(Jung W.-S.; Moon S.-K.; Cho K.-H.) Department of Cardiology and Neurology, 
College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
(Kim S.-B.; Shin W.-C.) Department of Neurology, Stroke and Neurological 
Disorders Center, Kyung Hee University Hospital at Gangdong Kyung Hee 
University, Seoul, South Korea.
CORRESPONDENCE ADDRESS
  J.-M. Park, Department of Korean Internal Medicine, Stroke and Neurological 
Disorders Center, Kyung Hee University Hospital at Gangdong, #892 Dongnam-ro 
Gangdong-gu, Seoul, South Korea.
SOURCE
  European Journal of Integrative Medicine (2014) 6:4 (492-496). Date of 
Publication: 2014
ISSN
  1876-3839 (electronic)
  1876-3820
BOOK PUBLISHER
  Elsevier GmbH, info@elsevier-deutschland.de
ABSTRACT
  Introduction: Anticoagulant and antiplatelet therapy are widely used as 
preventive measures and treatment for cardiovascular and cerebrovascular 
diseases. Bleeding is a significant complication of anticoagulant and 
antiplatelet medications. With the growing use of acupuncture and the 
potential concomitant use of such medications, studies on the safety of 
acupuncture are necessary. The objective of this study was to evaluate the 
safety of acupuncture for patients taking warfarin or antiplatelet 
medications by comparing the rate of side effects for patients who did not 
take either of these medications. Methodology: The medical records were 
searched to identify patients who had received acupuncture treatments at the 
Department of Korean Internal Medicine of Stroke and Neurological Disorders 
Center, Kyung Hee University Hospital at Gangdong between November 2010 and 
April 2012. Prescribed medications were identified from medical records and 
each patient was allocated to one of three groups based on the medication 
they were taking. Group A were taking warfarin, group B were taking 
antiplatelet medications but not warfarin, group C took neither warfarin nor 
antiplatelet medications and acted as a control group. Potential side 
effects that could be attributed to of acupuncture were identified. Results: 
A total of 242 patients and 4891 acupuncture treatments were identified. No 
patients experienced serious adverse events such as extensive bleeding. The 
occurrence rate of microbleeding (bleeding which stopped within 30. s) was 
4.8% for group A, 0.9% for group B and 3.0% for group C. Conclusion: 
Acupuncture treatment appears safe even for patients taking warfarin or 
antiplatelet medications. Large-scale, well-designed studies are needed to 
confirm these results. This article belongs to the Special Issue: 
'IG000019'.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  antithrombocytic agent
  warfarin
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  cilostazol
  clopidogrel
  indobufen
  triflusal
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  anticoagulant therapy
  patient safety
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation
  bleeding (complication)
  diabetes mellitus
  dizziness (complication)
  edema (complication)
  exhaustion (complication)
  faintness (complication)
  fatigue (complication)
  female
  human
  hypertension
  international normalized ratio
  major clinical study
  male
  nausea (complication)
  pain (complication)
  pneumothorax (complication)
  priority journal
  pruritus (complication)
  rash (complication)
  retrospective study
  skin bruising (complication)
  vomiting (complication)
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  cilostazol (73963-72-1)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  indobufen (36690-96-7, 63610-08-2)
  triflusal (322-79-2)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Hematology (25)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014711094
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.eujim.2014.04.004
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 247
TITLE
  Atrial Fibrillation and Heart Failure: Cause or Effect?
AUTHOR NAMES
  Luong C.
  Barnes M.E.
  Tsang T.S.M.
AUTHOR ADDRESSES
  (Luong C.; Barnes M.E.; Tsang T.S.M., t.tsang@ubc.ca) Division of 
Cardiology, University of British Columbia, 2775 Laurel Street, Vancouver, 
Canada.
CORRESPONDENCE ADDRESS
  T.S.M. Tsang, Division of Cardiology, University of British Columbia, 2775 
Laurel Street, Vancouver, Canada.
SOURCE
  Current Heart Failure Reports (2014) 11:4 (463-470). Date of Publication: 
2014
ISSN
  1546-9549 (electronic)
  1546-9530
BOOK PUBLISHER
  Current Science Inc., info@current-reports.com
ABSTRACT
  Atrial fibrillation (AF) and heart failure (HF) are two epidemics of the 
century that have a close and complex relationship. The mechanisms 
underlying this association remain an area of ongoing intense research. In 
this review, we will describe the relationship between these two public 
health concerns, the mechanisms that fuel the development and perpetuation 
of both, and the evolving concepts that may revolutionize our approach to 
this dual epidemic.
EMTREE DRUG INDEX TERMS
  antiarrhythmic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  heart failure
EMTREE MEDICAL INDEX TERMS
  age
  alcohol consumption
  cardiovascular mortality
  cardiovascular risk
  comorbidity
  coronary artery disease
  diabetes mellitus
  disease course
  disease free survival
  exercise
  genetic predisposition
  heart atrium contraction
  heart ejection fraction
  human
  hypertension
  incidence
  inflammation
  ischemic cardiomyopathy
  lifestyle modification
  lung disease
  metabolic syndrome X
  nonhuman
  nonischemic cardiomyopathy
  obesity
  prevalence
  primary prevention
  quality of life
  review
  sleep disordered breathing
  smoking
  tachycardia induced cardiomyopathy
  thyroid disease
  valvular heart disease
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014813374
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11897-014-0229-1
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 248
TITLE
  Dual atrioventricular nodal pathways physiology: A review of relevant 
anatomy, electrophysiology, and electrocardiographic manifestations
AUTHOR NAMES
  Mani B.C.
  Pavri B.B.
AUTHOR ADDRESSES
  (Mani B.C., bhalaghuru.cm@gmail.com; Pavri B.B.) Jefferson Medical College 
of Thomas Jefferson University, 925 Chestnut Street, Mezzanine, 
Philadelphia, PA19107, United States.
CORRESPONDENCE ADDRESS
  B. C. Mani, Department of Medicine, Thomas Jefferson University Hospital, 
803 College Building, 1025 Walnut Street, Philadelphia, PA19107, United 
States. Email: bhalaghuru.cm@gmail.com
SOURCE
  Indian Pacing and Electrophysiology Journal (2014) 14:1 (12-25). Date of 
Publication: January/February 2014
ISSN
  0972-6292 (electronic)
BOOK PUBLISHER
  Indian Pacing and Electrophysiology Group, Pulikkottil Thondayad, Calicut 
Kerala, India.
ABSTRACT
  More than half a century has passed since the concept of dual 
atrioventricular (AV) nodal pathways physiology was conceived. Dual AV nodal 
pathways have been shown to be responsible for many clinical arrhythmia 
syndromes, most notably AV nodal reentrant tachycardia. Although there has 
been a considerable amount of research on this topic, the subject of dual AV 
nodal pathways physiology remains heavily debated and discussed. Despite 
advances in understanding arrhythmia mechanisms and the widespread use of 
invasive electro physiologic studies, there is still disagreement on the 
anatomy and physiology of the AV node that is the basis of discontinuous 
antegrade AV conduction. The purpose of this paper is to review the concept 
of dual AV nodal pathways physiology and its varied electro cardiographic 
manifestations.
EMTREE DRUG INDEX TERMS
  adenosine (drug dose, drug therapy, pharmacology)
  antiarrhythmic agent (pharmacology)
  atropine (drug comparison, drug therapy, pharmacology)
  beta adrenergic receptor (endogenous compound)
  connexin 43 (endogenous compound)
  esmolol (pharmacology)
  isoprenaline (drug comparison, drug therapy, pharmacology)
  propranolol (pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  dual atrioventricular nodal pathway physiology
  ECG abnormality (diagnosis)
  heart electrophysiology
EMTREE MEDICAL INDEX TERMS
  adrenergic stimulation
  antiarrhythmic activity
  atrial fibrillation (diagnosis, etiology)
  atrioventricular conduction
  atrioventricular nodal reentry tachycardia (diagnosis, drug therapy, 
etiology)
  beta adrenergic receptor blocking
  complete heart block (diagnosis, etiology)
  double fire tachycardia (diagnosis, etiology)
  double ventricular response (diagnosis, etiology)
  drug activity
  drug efficacy
  drug megadose
  electrocardiography
  exercise
  heart arrhythmia (diagnosis, etiology)
  heart atrioventricular node
  heart depolarization
  heart excitation
  heart left ventricle filling
  heart muscle refractory period
  heart rate
  heart ventricle extrasystole (diagnosis, etiology)
  human
  long RP interval (diagnosis)
  low drug dose
  nonhuman
  parasympathetic block
  pathophysiology
  PR interval
  prolonged PR interval (diagnosis)
  protein expression
  pseudointerpolation (diagnosis)
  QRS complex
  retrograde P wave (diagnosis)
  review
  RR interval
  short PR interval (diagnosis)
  short RP interval (diagnosis)
  sinus rhythm
  supraventricular premature beat (diagnosis, etiology)
  sympathetic blocking
  tachycardia related cardiomyopathy (diagnosis, etiology)
  vagus nerve stimulation
  vagus tone
  Wenckebach period
CAS REGISTRY NUMBERS
  adenosine (58-61-7)
  atropine (51-55-8, 55-48-1)
  esmolol (81147-92-4, 81161-17-3)
  isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014007631
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 249
TITLE
  The left atrium: From the research laboratory to the clinic
AUTHOR NAMES
  Dean Boudoulas K.
  Paraskevaidis I.A.
  Boudoulas H.
  Triposkiadis F.K.
AUTHOR ADDRESSES
  (Dean Boudoulas K.; Boudoulas H.) Division of Cardiovascular Medicine, Ohio 
State University, Columbus, OH, United States.
(Paraskevaidis I.A.) Medical School, University of Athens, Greece.
(Boudoulas H.) Biomedical Research Foundation, Academy of Athens, Athens, 
Greece.
(Boudoulas H.) Aristotelian University of Thessaloniki, Thessaloniki, 
Greece.
(Triposkiadis F.K., filtrip@yahoo.com) Medical School, University of 
Thessaly, Larissa, Greece.
(Triposkiadis F.K., filtrip@yahoo.com) Department of Cardiology, Larissa 
University Hospital, PO Box 1425, GR-411 10 Larissa, Greece.
SOURCE
  Cardiology (Switzerland) (2014) 129:1 (1-17). Date of Publication: August 
2014
ISSN
  1421-9751 (electronic)
  0008-6312
BOOK PUBLISHER
  S. Karger AG
ABSTRACT
  Studies of left atrial (LA) function, until the latter part of the 20th 
century, were mostly limited to experimental animal models and to studies 
related to clinical research in the cardiac catheterization laboratory. For 
this reason, LA function has received considerably less attention than left 
ventricular (LV) functions, even though evidence suggests that LA myopathy 
and failure may exist as an isolated entity, precede and/or coexist with LV 
myopathy. The introduction of echocardiography and Doppler echocardiography 
in clinical practice has contributed significantly to our understanding of 
LA function and its interrelationships with the LV, aorta, pulmonary artery 
and other parts of the cardiovascular system. In addition, LA with the 
secretion of atrial natriuretic peptides is playing an important role in 
cardiovascular and neurohumoral homeostasis. Today, it is well known that LA 
structural and functional abnormalities that are present in many diseases 
and disorders constitute a powerful prognostic indicator. As technology 
(echocardiography, magnetic resonance imaging, computed tomography and 
others) continues to evolve, it is expected that, in the near future, LA 
structure and function will be routinely used as LV function is used today. 
© 2014 S. Karger AG, Basel.
EMTREE DRUG INDEX TERMS
  atrial natriuretic factor (endogenous compound)
  neurohormone (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart atrium function
  heart left atrium
EMTREE MEDICAL INDEX TERMS
  aging
  aorta
  article
  atrial fibrillation
  cardiomyopathy
  cardiopulmonary function
  cardiovascular function
  cardiovascular homeostasis
  cardiovascular system
  clinical practice
  clinical research
  computer assisted tomography
  Doppler echocardiography
  echocardiography
  electrocardiogram
  endocrine function
  exercise
  fluoroscopy
  heart atrium remodeling
  heart catheterization
  heart failure
  heart left ventricle function
  homeostasis
  human
  left atrium myopathy
  meta analysis (topic)
  myopathy
  neurohumoral homeostasis
  nonhuman
  nuclear magnetic resonance imaging
  physical examination
  priority journal
  prognosis
  protein secretion
  pulmonary artery
  thorax radiography
  three dimensional echocardiography
CAS REGISTRY NUMBERS
  atrial natriuretic factor (85637-73-6)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Physiology (2)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014578254
FULL TEXT LINK
  http://dx.doi.org/10.1159/000360935
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 250
TITLE
  Clinical characteristics and circumstances of death in the sudden arrhythmic 
death syndrome
AUTHOR NAMES
  Mellor G.
  Raju H.
  De Noronha S.V.
  Papadakis M.
  Sharma S.
  Behr E.R.
  Sheppard M.N.
AUTHOR ADDRESSES
  (Mellor G.; Raju H.; De Noronha S.V.; Papadakis M.; Sharma S.; Behr E.R.; 
Sheppard M.N., msheppar@sgul.ac.uk) Cardiovascular Sciences Research Centre, 
St george'S, University of London, London, United Kingdom.
(De Noronha S.V.; Sheppard M.N., msheppar@sgul.ac.uk) Cardiovascular 
Pathology Department, St george'S, University of London, Cranmer Terr, 
London, United Kingdom.
CORRESPONDENCE ADDRESS
  M.N. Sheppard, Cardiovascular Pathology Department, St george'S, University 
of London, Cranmer Terr, London, United Kingdom.
SOURCE
  Circulation: Arrhythmia and Electrophysiology (2014) 7:6 (1078-1083). Date 
of Publication: 1 Dec 2014
ISSN
  1941-3084 (electronic)
  1941-3149
BOOK PUBLISHER
  Lippincott Williams and Wilkins, LRorders@phl.lrpub.com
ABSTRACT
  Background: Sudden cardiac death (SCD) is a devastating event in the young. 
Referral to a specialist cardiac pathologist is recommended. Age, sex, and 
circumstances of death may reflect underlying diagnoses. We aim to describe 
the demographics of victims and circumstances surrounding sudden cardiac 
death with a normal heart (ie, sudden arrhythmic death syndrome). Methods 
and Results: There were 2156 cases of sudden cardiac death from across the 
United Kingdom referred to a tertiary cardiac pathology service from 1994 to 
2010. We analyzed 967 consecutive cases (61% male; median age 29 years) with 
a normal heart at postmortem. Information from referring coroners' reports 
was used to ascertain clinical information. Familial evaluation was 
performed in 5% of cases. Information from these cases was used to determine 
the likely accuracy of coronial reports. Deaths during sleep or at rest were 
more common than deaths during exercise or with emotional stress: 82% versus 
16%. Death with exercise/stress was more common in males (relative risk, 
2.33; 95% confidence interval, 1.56-3.47; P<0.001) and those under 18 years 
of age: males, relative risk, 2.41 (95% confidence interval, 1.69-3.13; 
P<0.001) and females, relative risk, 2.91 (95% confidence interval, 
1.80-4.01; P<0.001)). Prior syncope (4.1%), documented arrhythmia (3.4%), 
and family history of sudden death (4.2%) were uncommon. Epilepsy had been 
diagnosed in 6.6%. Conclusions: Death caused by sudden arrhythmic death 
syndrome is more common at rest or during sleep. Death with exercise/stress 
is more common in males and those aged below 18 years. Up to 90% of SADS 
victims have no preceding symptoms or recognized risk factors for sudden 
death. Epilepsy may be considered a risk factor for SADS.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  sudden cardiac death (etiology)
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation
  autopsy
  cause of death
  clinical evaluation
  clinical feature
  emotional stress
  epilepsy
  exercise
  faintness
  family history
  female
  heart arrhythmia
  heart atrioventricular node
  heart left bundle branch block
  heart muscle conduction disturbance
  heart ventricle tachycardia
  histopathology
  human
  long QT syndrome
  major clinical study
  male
  priority journal
  rest
  risk assessment
  sleep
  supraventricular tachycardia
  United Kingdom
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015868465
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCEP.114.001854
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 251
TITLE
  P-wave dispersion and its relationship to aortic stiffness in patients with 
acute myocardial infarction after cardiac rehabilitation
AUTHOR NAMES
  Acar R.D.
  Bulut M.
  Ergün S.
  Yesin M.
  Boztosun B.
  Akçakoyun M.
AUTHOR ADDRESSES
  (Acar R.D., denizacar_1999@yahoo.com; Bulut M.; Yesin M.; Boztosun B.; 
Akçakoyun M.) Department of Cardiology, Kartal Kosuyolu Education and 
Research Hospital, Istanbul, Turkey.
(Ergün S.) Department of Physical Therapy and Rehabilitation, Kartal 
Kosuyolu Education and Research Hospital, Istanbul, Turkey.
CORRESPONDENCE ADDRESS
  R. D. Acar, Department of Cardiology, Kartal Kosuyolu Education and Research 
Hospital, Istanbul, Turkey. Email: denizacar_1999@yahoo.com
SOURCE
  ARYA Atherosclerosis (2014) 10:4 (185-191). Date of Publication: 2014
ISSN
  2251-6638 (electronic)
  1735-3955
BOOK PUBLISHER
  Isfahan University of Medical Sciences(IUMS), Hezar Jerib Avenue, P.O. Box 
81745-319, Isfahan, Iran.
ABSTRACT
  BACKGROUND: The aim of our study was to investigate the P-wave dispersion 
from standard electrocardiograms (ECGs) in patients with acute myocardial 
infarction (AMI) after cardiac rehabilitation (CR) and determine its 
relation to arterial stiffness. METHODS: This is a prospective study 
included 33 patients with AMI and successfully re-vascularized by 
percutaneous coronary intervention (PCI) underwent CR. Left ventricular 
ejection fraction (LVEF) was measured by biplane Simpson's method. Left 
atrium (LA) volume was calculated. The maximum and minimum durations of 
P-waves (Pmax and Pmin, respectively) were detected, and the difference 
between Pmax and Pmin was defined as P-wave dispersion (Pd = Pmax-Pmin). 
Aortic elasticity parameters were measured. RESULTS: LVEF was better after 
CR. The systolic and diastolic blood pressures decreased after CR, these 
differences were statistically significant. With exercise training, LA 
volume decreased significantly. Pmax and Pd values were significantly 
shorter after the CR program. The maximum and minimum P-waves and P-wave 
dispersion after CR were 97 ± 6 ms, 53 ± 5 ms, and 44 ± 5 ms, respectively. 
Aortic strain and distensibility increased and aortic stiffness index was 
decreased significantly. Aortic stiffness index was 0.4 ± 0.2 versus 0.3 ± 
0.2, P = 0.001. Aortic stiffness and left atrial volume showed a moderate 
positive correlation with P-wave dispersion (r = 0.52, P = 0.005; r = 0.64, 
P = 0.000, respectively). CONCLUSION: This study showed decreased arterial 
stiffness indexes in AMI patient's participated CR, with a significant 
relationship between the electromechanical properties of the LA that may 
raise a question of the preventive effect of CR from atrial fibrillation and 
stroke in patients with acute myocardial infarction.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acute heart infarction (rehabilitation)
  arterial stiffness
  heart rehabilitation
  P wave
  p wave dispersion
EMTREE MEDICAL INDEX TERMS
  adult
  annulus fibrosus
  article
  blood pressure
  clinical article
  Doppler echocardiography
  exercise
  female
  heart atrium conduction
  heart left ventricle ejection fraction
  heart muscle revascularization
  human
  male
  percutaneous coronary intervention
  prospective study
  tissue Doppler imaging
DEVICE TRADE NAMES
  Vivid 7  , NorwayVingmed

DEVICE MANUFACTURERS
   (Norway)Vingmed
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014493629
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 252
TITLE
  Consumption of Nuts in the Prevention of Cardiovascular Disease
AUTHOR NAMES
  Sabaté J.
  Wien M.
AUTHOR ADDRESSES
  (Sabaté J., jsabate@llu.edu; Wien M., mwien@llu.edu) Department of 
Nutrition, School of Public Health, Loma Linda University, 24951 N. Circle 
Drive, Nichol Hall 1102, Loma Linda, CA, 92350, United States.
(Sabaté J., jsabate@llu.edu) Department of Epidemiology and Biostatistics, 
Loma Linda University, Loma Linda, CA, United States.
CORRESPONDENCE ADDRESS
  J. Sabaté, Department of Nutrition, School of Public Health, Loma Linda 
University, 24951 N. Circle Drive, Nichol Hall 1102, Loma Linda, CA, 92350, 
United States. Email: jsabate@llu.edu
SOURCE
  Current Nutrition Reports (2013) 2:4 (258-266). Date of Publication: 
December 2013
ISSN
  2161-3311 (electronic)
BOOK PUBLISHER
  Current Science Inc., 400 Market Street, Suite 700, Philadelphia, United 
States.
ABSTRACT
  The leading cause of morbidity and mortality in highly developed and low- 
and middle-income nations is cardiovascular disease (CVD). The establishment 
of healthy dietary patterns is one of the cornerstones of CVD prevention, 
and nuts have emerged as favorable components of dietary patterns associated 
with reducing the CVD epidemic. The etiological connection between nuts for 
the prevention of CVD is based upon several lines of evidence. First, nuts 
are nutrient-dense whole foods that contain a distinctive mix of 
macronutrients, specific micronutrients and non-nutrients that have been 
associated with cardioprotection. Second, numerous human feeding trials have 
demonstrated that nut intake improves the serum lipid profile, reduces 
oxidation and inflammation, and improves vascular reactivity. Third, nut 
consumption is consistently associated with a reduced risk of CVD in many 
epidemiological studies. Lastly, a recent large randomized clinical trial 
conducted in Spain demonstrated that consuming mixed nuts daily lowers CVD 
risk by 30 %. © 2013 Springer Science+Business Media New York.
EMTREE DRUG INDEX TERMS
  C reactive protein (endogenous compound)
  endothelial leukocyte adhesion molecule 1 (endogenous compound)
  high density lipoprotein (endogenous compound)
  intercellular adhesion molecule 1 (endogenous compound)
  interleukin 6 (endogenous compound)
  low density lipoprotein (endogenous compound)
  monounsaturated fatty acid (endogenous compound)
  polyunsaturated fatty acid (endogenous compound)
  saturated fatty acid (endogenous compound)
  trace element
  triacylglycerol (endogenous compound)
  unsaturated fatty acid (endogenous compound)
  vascular cell adhesion molecule 1 (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease
  nut
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  cardiovascular mortality
  cardiovascular risk
  dietary fiber
  disease association
  DNA damage
  food intake
  glycemic index
  human
  hypercholesterolemia
  hypertension
  incidence
  inflammation
  lipid analysis
  lipid oxidation
  macronutrient
  Mediterranean diet
  meta analysis (topic)
  outcome assessment
  oxidative stress
  prevalence
  priority journal
  randomized controlled trial (topic)
  review
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  endothelial leukocyte adhesion molecule 1 (128875-25-2)
  intercellular adhesion molecule 1 (126547-89-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013687472
FULL TEXT LINK
  http://dx.doi.org/10.1007/s13668-013-0059-x
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 253
TITLE
  Role of Echocardiography in the Assessment of Right Heart Disease: Update 
2013
AUTHOR NAMES
  Tan T.C.
  Hung J.
AUTHOR ADDRESSES
  (Tan T.C.; Hung J., jhung@partners.org) Cardiac Ultrasound Laboratory, Blake 
256 Division of Cardiology, Massachusetts General Hospital and Harvard 
Medical School, 55 Fruit Street, Boston, MA, 02114-2696, United States.
CORRESPONDENCE ADDRESS
  J. Hung, Cardiac Ultrasound Laboratory, Blake 256 Division of Cardiology, 
Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, 
Boston, MA, 02114-2696, United States. Email: jhung@partners.org
SOURCE
  Current Cardiovascular Imaging Reports (2013) 6:6 (486-497). Date of 
Publication: December 2013
ISSN
  1941-9066
  1941-9074 (electronic)
BOOK PUBLISHER
  Current Medicine Group LLC, 400 Market St,, Ste 700 Philadelphia, United 
States.
ABSTRACT
  The right heart plays a significant role in overall cardiac function, with 
right heart diseases shown to have similar clinical impact as left heart 
diseases. Despite the availability of a number of imaging modalities for the 
assessment of the right heart, echocardiography remains the first line 
imaging modality of choice based on its advantages of being safe, readily 
accessible and cost effective. Currently, echocardiography whether by the 
transthoracic or transesophageal approach, plays an important role in the 
diagnosis and ongoing management of patients with right heart disease. While 
two dimensional imaging is the mainstay of echocardiographic assessment of 
the right heart, the availability of more advanced echocardiographic 
techniques has improved our ability to assess right heart function and a 
range of right heart pathologies. These techniques apart from overcoming 
some of the inherent challenges associated with two dimensional imaging of 
the right heart, have also provided invaluable insights into the physiology 
of the right heart and pathophysiology of a range of right heart related 
diseases. © 2013 Springer Science+Business Media New York.
EMTREE DRUG INDEX TERMS
  phosphodiesterase inhibitor (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  echocardiography
  heart failure (drug therapy, diagnosis, drug therapy, therapy)
  heart left ventricle function
EMTREE MEDICAL INDEX TERMS
  algorithm
  atrial fibrillation
  diabetes mellitus
  Doppler echocardiography
  exercise
  heart atrium function
  heart failure with preserved ejection fraction
  heart infarction
  heart left ventricle filling pressure
  human
  hypertension
  left ventricular diastolic dysfunction
  mortality
  pathophysiology
  pulmonary hypertension
  quality of life
  randomized controlled trial (topic)
  review
  tricuspid valve regurgitation
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013714852
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12410-013-9235-z
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 254
TITLE
  Dramatic loss of weight in an obese patient with heart failure: A mighty 
heart in a big man
AUTHOR NAMES
  Di Bello V.
  Conte L.
  Fabiani I.
  Barletta V.
  Pieruzzi L.
  Scartabelli G.
  Santini F.
AUTHOR ADDRESSES
  (Di Bello V., vitantonio.dibello@med.unipi.it; Conte L.; Fabiani I.; 
Barletta V.) Department of Surgery, Medical, Molecular and Critical Area 
Pathology, University of Pisa, Via Paradisa 2, Cisanello, 56100 Pisa, Italy.
(Pieruzzi L.; Scartabelli G.; Santini F.) Department of Clinical and 
Experimental Medicine, University of Pisa, Pisa, Italy.
CORRESPONDENCE ADDRESS
  V. Di Bello, Department of Surgery, Medical, Molecular and Critical Area 
Pathology, University of Pisa, Via Paradisa 2, Cisanello, 56100 Pisa, Italy. 
Email: vitantonio.dibello@med.unipi.it
SOURCE
  Heart and Metabolism (2013) :61 (29-31). Date of Publication: November 2013
  Heart failure and metabolic disease, Book Series Title:
ISSN
  1566-0338
BOOK PUBLISHER
  Les Laboratoires Seriver, 50 Rue Carnot, F-92284, Suresnes Cedex, France.
ABSTRACT
  Obesity has reached global epidemic proportions and has been associated with 
numerous comorbidities, including major cardiovascular diseases and heart 
failure. It has many adverse effects on hemodynamics and cardiovascular 
structure and function; it increases total blood volume and cardiac output, 
and also activates several neurohumoral systems that play an important role 
in causing cardiac dysfunction. Typically, obese patients have a higher 
cardiac output but a lower level of total peripheral resistance at any given 
level of arterial pressure. Over the past few years, experimental evidence 
has unraveled some important pathogenetic mechanisms that may underlie a 
specific form of "obesity cardiomyopathy". However, many unanswered 
questions remain regarding the pathophysiological interactions between 
obesity and the heart. © 2013 by ISSN.
EMTREE DRUG INDEX TERMS
  albumin (intravenous drug administration)
  aldosterone antagonist
  brain natriuretic peptide (endogenous compound)
  canrenoate potassium
  carvedilol
  cholinesterase (endogenous compound)
  creatinine (endogenous compound)
  digitalis
  diuretic agent
  furosemide (intravenous drug administration, oral drug administration)
  hemoglobin (endogenous compound)
  ramipril
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  congestive heart failure (diagnosis)
  obesity
  weight reduction
EMTREE MEDICAL INDEX TERMS
  adult
  anasarca
  anemia
  angiocardiography
  article
  atrial fibrillation
  blood gas analysis
  blood sampling
  body mass
  body weight
  cardiomegaly
  case report
  cholinesterase blood level
  creatinine blood level
  dyspnea
  echocardiography
  electrocardiogram
  elephantiasis
  emergency ward
  gas exchange
  glomerulus filtration rate
  heart amyloidosis
  heart ejection fraction
  heart left ventricle enddiastolic volume
  heart left ventricle function
  heart left ventricle volume
  heart muscle perfusion
  heart right bundle branch block
  hemoglobin blood level
  hospital discharge
  hospitalization
  human
  human tissue
  hypergammaglobulinemia
  hypokinesia
  kidney failure (complication)
  kidney function
  light chain
  limb injury
  liver dysfunction
  liver failure (complication)
  liver function
  low calory diet
  lung congestion
  male
  middle aged
  myocardial perfusion imaging
  nuclear magnetic resonance imaging
  priority journal
  quality of life
  respiratory failure (complication)
  tachycardia
  tachypnea
  thorax radiography
  water deprivation
  weight gain
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
  canrenoate potassium (2181-04-6)
  carvedilol (72956-09-3)
  cholinesterase (9001-08-5)
  creatinine (19230-81-0, 60-27-5)
  digitalis (8031-42-3, 8053-83-6)
  furosemide (54-31-9)
  hemoglobin (9008-02-0)
  ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014027114
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 255
TITLE
  Ankle-brachial index long-term outcome after first-ever ischaemic stroke
AUTHOR NAMES
  Milionis H.
  Vemmou A.
  Ntaios G.
  Makaritsis K.
  Koroboki E.
  Papavasileiou V.
  Savvari P.
  Spengos K.
  Elisaf M.
  Vemmos K.
AUTHOR ADDRESSES
  (Milionis H., hmilioni@uoi.gr; Elisaf M.) Department of Internal Medicine, 
School of Medicine, University of Ioannina, Ioannina, Greece.
(Vemmou A.; Koroboki E.; Savvari P.; Spengos K.; Vemmos K.) Acute Stroke 
Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens, 
Greece.
(Ntaios G.; Makaritsis K.; Papavasileiou V.) Department of Medicine and 
Research lab, University of Thessaly, Larissa, Greece.
CORRESPONDENCE ADDRESS
  H. Milionis, Department of Internal Medicine, School of Medicine, University 
of Ioannina, Ioannina, Greece. Email: hmilioni@uoi.gr
SOURCE
  European Journal of Neurology (2013) 20:11 (1471-1478). Date of Publication: 
November 2013
ISSN
  1351-5101
  1468-1331 (electronic)
BOOK PUBLISHER
  Blackwell Publishing Ltd, 9600 Garsington Road, Oxford, United Kingdom.
ABSTRACT
  Background and purpose: Ankle-brachial blood pressure index (ABI) is a 
clinical tool to identify the presence of peripheral artery disease. There 
is a scarcity of data associating ABI with long-term outcome in patients 
with IS. The association between ABI and long-term outcome in patients with 
first-ever acute IS was assessed. Methods: Ankle-brachial blood pressure 
index was assessed in all consecutive patients with a first-ever acute IS 
admitted at Alexandra University hospital (Athens, Greece) between January 
2005 and December 2010. ABI was considered normal when > 0.90 and ≤ 1.30. 
The Kaplan-Meier product limit method was used to estimate the probability 
of 5-year composite cardiovascular event-free (defined as recurrent stroke, 
myocardial infarction or cardiovascular death) and overall survival. A 
multivariate analysis was performed to assess whether ABI is an independent 
predictor of 5-year mortality and dependence. Results: Amongst 653 patients, 
129 (19.8%) with ABI ≤ 0.9 were identified. Five-year cumulative composite 
cardiovascular event-free and overall survival rates were better in normal 
ABI stroke patients (log-rank test: 7.22, P = 0.007 and 23.40, P < 0.001, 
respectively). There was no difference in 5-year risk of stroke recurrence 
between low and normal ABI groups (hazard ratio, HR = 1.23, 95%CI 
0.68-2.23). In multivariate Cox regression analysis, independent predictors 
of 5-year mortality included age (HR = 2.55 per 10 years, 95%CI 1.86-3.48, P 
< 0.001), the National Institutes of Health Stroke Scale (per point increase 
HR = 1.12, 95%CI 1.08-1.16, P < 0.001), and low ABI (HR = 2.22, 95%CI 
1.22-4.03, P = 0.009). Age (HR = 1.21 per 10 years, 95%CI 1.01-1.45, P = 
0.04) and low ABI (HR = 1.72, 95%CI 1.11-2.67, P = 0.01) were independent 
predictors of the composite cardiovascular end-point. Conclusions: Low ABI 
in patients with acute IS is associated with increased 5-year cardiovascular 
event risk and mortality. However, ABI does not appear to predict long-term 
stroke recurrence. © 2013 EFNS.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  anticoagulant agent (drug therapy, oral drug administration)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium antagonist (drug therapy)
  diuretic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  ankle brachial index
  brain ischemia (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  anticoagulation
  article
  atrial fibrillation
  cardiovascular mortality
  cardiovascular risk
  carotid endarterectomy
  computer assisted tomography
  diabetes mellitus
  disease severity
  event free survival
  exercise
  female
  follow up
  heart failure
  heart infarction
  human
  hypertension (drug therapy)
  intermittent claudication
  major clinical study
  male
  mortality
  National Institutes of Health Stroke Scale
  outcome assessment
  priority journal
  Rankin scale
  recurrent disease
  sex ratio
  smoking cessation
  smoking habit
  stroke patient
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013657511
FULL TEXT LINK
  http://dx.doi.org/10.1111/ene.12208
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 256
TITLE
  Patient safety and estimation of renal function in patients prescribed new 
oral anticoagulants for stroke prevention in atrial fibrillation: A 
cross-sectional study
AUTHOR NAMES
  MacCallum P.K.
  Mathur R.
  Hull S.A.
  Saja K.
  Green L.
  Morris J.K.
  Ashman N.
AUTHOR ADDRESSES
  (MacCallum P.K., p.k.maccallum@qmul.ac.uk; Morris J.K.) Wolfson Institute of 
Preventive Medicine, Barts and The London School of Medicine and Dentistry, 
Queen Mary University of London, London, United Kingdom.
(MacCallum P.K., p.k.maccallum@qmul.ac.uk; Green L.) Department of 
Haematology, Barts Health NHS Trust, London, United Kingdom.
(Mathur R.; Hull S.A.) Blizard Institute, Barts and The London School of 
Medicine and Dentistry, Queen Mary University of London, London, United 
Kingdom.
(Saja K.) Department of Haematology, Barking, Havering and Redbridge 
University Hospitals NHS Trust, London, United Kingdom.
(Green L.) NHS Blood and Transplant, London, United Kingdom.
(Ashman N.) Department of Nephrology, Barts Health NHS Trust, London, United 
Kingdom.
CORRESPONDENCE ADDRESS
  P.K. MacCallum, Wolfson Institute of Preventive Medicine, Barts and The 
London School of Medicine and Dentistry, Queen Mary University of London, 
London, United Kingdom. Email: p.k.maccallum@qmul.ac.uk
SOURCE
  BMJ Open (2013) 3:9 Article Number: e003343. Date of Publication: 2013
ISSN
  2044-6055 (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
  Objective: In clinical trials of dabigatran and rivaroxaban for stroke 
prevention in atrial fibrillation (AF), drug eligibility and dosing were 
determined using the Cockcroft-Gault equation to estimate creatine clearance 
as a measure of renal function. This cross-sectional study aimed to compare 
whether using estimated glomerular filtration rate (eGFR) by the widely 
available and widely used Modified Diet in Renal Disease (MDRD) equation 
would alter prescribing or dosing of the renally excreted new oral 
anticoagulants. Participants: Of 4712 patients with known AF within a 
general practitioner-registered population of 930 079 in east London, data 
were available enabling renal function to be calculated by both 
Cockcroft-Gault and MDRD methods in 4120 (87.4%). Results: Of 4120 patients, 
2706 were <80 years and 1414 were ≥80 years of age. Among those ≥80 years, 
14.9% were ineligible for dabigatran according to Cockcroft-Gault equation 
but would have been judged eligible applying MDRD method. For those <80 
years, 0.8% would have been incorrectly judged eligible for dabigatran and 
5.3% would have received too high a dose. For rivaroxaban, 0.3% would have 
been incorrectly judged eligible for treatment and 13.5% would have received 
too high a dose. Conclusions: Were the MDRD-derived eGFR to be used instead 
of Cockcroft-Gault in prescribing these new agents, many elderly patients 
with AF would either incorrectly become eligible for them or would receive 
too high a dose. Safety has not been established using the MDRD equation, a 
concern since the risk of major bleeding would be increased in patients with 
unsuspected renal impairment. Given the potentially widespread use of these 
agents, particularly in primary care, regulatory authorities and drug 
companies should alert UK doctors of the need to use the Cockcroft-Gault 
formula to calculate eligibility for and dosing of the new oral 
anticoagulants in elderly patients with AF and not rely on the MDRD-derived 
eGFR.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (oral drug administration)
  dabigatran (drug dose, drug therapy)
  rivaroxaban (drug therapy)
EMTREE DRUG INDEX TERMS
  warfarin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  cerebrovascular accident (drug therapy, drug therapy, prevention)
  kidney function
  patient safety
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  bleeding (side effect)
  controlled study
  creatinine clearance
  cross-sectional study
  dose response
  drug dose reduction
  female
  general practitioner
  glomerulus filtration rate
  human
  major clinical study
  male
  modified diet in renal disease equation
  prescription
  primary medical care
  renal clearance
  scoring system
  United Kingdom
CAS REGISTRY NUMBERS
  rivaroxaban (366789-02-8)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013640634
FULL TEXT LINK
  http://dx.doi.org/10.1136/bmjopen-2013-003343
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 257
TITLE
  Physical activity ameliorates cardiovascular health in elderly subjects: The 
functional role of the β adrenergic system
AUTHOR NAMES
  Santulli G.
  Ciccarelli M.
  Trimarco B.
  Iaccarino G.
AUTHOR ADDRESSES
  (Santulli G., gaetano.santulli@unina.it) Department of Translational Medical 
Sciences, Federico II University, Naples, Italy.
(Santulli G., gaetano.santulli@unina.it; Trimarco B.) Department of Advanced 
Biomedical Sciences, Federico II University, Naples, Italy.
(Santulli G., gaetano.santulli@unina.it) College of Physicians and Surgeons, 
New York Presbyterian Hospital, Columbia University in the City of New York, 
Manhattan, NY, United States.
(Ciccarelli M.; Iaccarino G.) Department of Medicine and Surgery, University 
of Salerno, Salerno, Italy.
(Iaccarino G.) Multimedica Research Hospital, Milan, Italy.
CORRESPONDENCE ADDRESS
  G. Santulli, Department of Translational Medical Sciences, Department of 
Advanced Biomedical Sciences, Federico II University, Via Sergio Pansini, 5, 
n. 2, 80131 Naples, Italy. Email: gaetano.santulli@unina.it
SOURCE
  Frontiers in Physiology (2013) 4 AUG Article Number: Article 209. Date of 
Publication: 2013
ISSN
  1664-042X (electronic)
BOOK PUBLISHER
  Frontiers Media SA, EPFL Innovation Square, Building I, Lausanne, 
Switzerland.
ABSTRACT
  Aging is a complex process characterized by a gradual decline in organ 
functional reserves, which eventually reduces the ability to maintain 
homeostasis. An exquisite feature of elderly subjects, which constitute a 
growing proportion of the world population, is the high prevalence of 
cardiovascular disorders, which negatively affect both the quality of life 
and the life expectancy. It is widely acknowledged that physical activity 
represents one of the foremost interventions capable in reducing the health 
burden of cardiovascular disease. Interestingly, the benefits of 
moderate-intensity physical activity have been established both in young and 
elderly subjects. Herein we provide a systematic and updated appraisal of 
the literature exploring the pathophysiological mechanisms evoked by 
physical activity in the elderly, focusing on the functional role of the ß 
adrenergic system. © 2013 Santulli, Ciccarelli, Trimarco and Iaccarino.
EMTREE DRUG INDEX TERMS
  beta 2 adrenergic receptor (endogenous compound)
  catecholamine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  adrenergic system
  aging
  cardiovascular disease (etiology)
  physical activity
EMTREE MEDICAL INDEX TERMS
  aerobic exercise
  atherosclerosis (etiology)
  atrial fibrillation
  disease course
  functional disease
  functional status
  health status
  heart failure
  heart left ventricle hypertrophy
  heart muscle oxygen consumption
  heart performance
  heart ventricle hypertrophy
  heart work
  homeostasis
  human
  hypertension
  life expectancy
  molecular biology
  muscle exercise
  nonhuman
  pathophysiology
  physical capacity
  prevalence
  quality of life
  running
  short survey
  skeletal muscle
  treadmill exercise
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013604533
FULL TEXT LINK
  http://dx.doi.org/10.3389/fphys.2013.00209
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 258
TITLE
  Lymphangiopathy in neurofibromatosis 1 manifesting with chylothorax, 
pericardial effusion, and leg edema
AUTHOR NAMES
  Finsterer J.
  Stollberger C.
  Stubenberger E.
  Tschakoschian S.
AUTHOR ADDRESSES
  (Finsterer J., fifigs1@yahoo.de) Krankenanstalt Rudolfstiftung, Vienna, 
Austria.
(Stollberger C.) Medical Department, Krankenanstalt Rudolfstiftung, Vienna, 
Austria.
(Stubenberger E.) Thoracic Surgery Department, Vienna, Austria.
(Tschakoschian S.) Interne Lungenabt, Vienna, Austria.
CORRESPONDENCE ADDRESS
  J. Finsterer, Krankenanstalt Rudolfstiftung, Postfach 20, 1180 Vienna, 
Austria. Email: fifigs1@yahoo.de
SOURCE
  International Journal of General Medicine (2013) 6 (743-746). Date of 
Publication: 2013
ISSN
  1178-7074 (electronic)
BOOK PUBLISHER
  Dove Medical Press Ltd., PO Box 300-008, Albany, Auckland, New Zealand.
ABSTRACT
  Background: This case report documents the affliction of the lymph vessels 
as a phenotypic feature of neurofibromatosis-1 (NF-1). Methodology: Routine 
transthoracic echocardiography, computed tomography scan of the thorax, 
magnetic resonance angiography of the renal arteries, and conventional 
digital subtraction angiography were applied. Comprehensive NF-1 mutation 
analysis was carried out by fluorescence in situ hybridization analysis, 
long-range reverse transcriptase polymerase chain reaction, and 
multiple-ligation probe assay. All other investigations were performed using 
routine, well-established techniques. Results: The subject is a 34-year-old, 
half-Chinese male; NF-1 was suspected at age 15 years for the first time. 
His medical history included preterm birth, mild facial dysmorphism, "café 
au lait" spots, subcutaneous and paravertebral fibromas, multifocal 
tachycardia, atrial fibrillation, and heart failure in early infancy. 
Noncalcified bone fibromas in the femur and tibia were detected at age 8 
years. Surgical right leg lengthening was carried out at age 11 years. 
Bilateral renal artery stenosis, stenosis and aneurysm of the superior 
mesenteric artery, and an infrarenal aortic stenosis were detected at age 15 
years. Leg edema and ectasia of the basilar artery were diagnosed at age 18 
years. After an episode with an erysipela at age 34 years, he developed 
pericardial and pleural effusion during a 4-month period. Stenosis of the 
left subclavian vein at the level of thoracic duct insertion was detected. 
After repeated pleural punctures, pleural effusion was interpreted as 
chylothorax. Reduction of lymph fluid production by diet and injection of 
talcum into the pleural cavity had a long-term beneficial effect on the 
chylothorax. Leg edema and chylothorax were attributed to affliction of the 
lymph vessels by the NF-1. Discussion: Lymphangiopathy resulting in impaired 
lymph fluid flow and sequestration of lymph fluid into the pleural sinus and 
the legs may be a rare phenotypic feature of NF-1.
EMTREE DRUG INDEX TERMS
  neurofibromin (endogenous compound)
  talc (drug dose, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  chylothorax (drug therapy, diagnosis, drug therapy, surgery)
  lymphangiopathy
  lymphatic system disease
  neurofibromatosis (diagnosis)
  pericardial effusion
EMTREE MEDICAL INDEX TERMS
  adult
  artery occlusion (diagnosis)
  article
  cafe au lait spot
  case report
  clinical feature
  compression garment
  coronary artery ectasia (diagnosis)
  DNA determination
  gene
  gene mutation
  human
  leg edema (prevention)
  lung sequestration
  lymph flow
  lymph vessel
  magnetic resonance angiography
  male
  medical history
  neurofibroma (diagnosis)
  NF1 gene
  pleura effusion
  repeat procedure
  repeated drug dose
  reverse transcription polymerase chain reaction
  thorax drainage
  thorax radiography
CAS REGISTRY NUMBERS
  talc (14807-96-6)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Radiology (14)
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Human Genetics (22)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013597807
FULL TEXT LINK
  http://dx.doi.org/10.2147/IJGM.S45825
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 259
TITLE
  Performance of the cockcroft-GAULT, MDRD and CKD-EPI formulae in 
non-valvular atrial fibrillation: Which one should be used for risk 
stratification?
AUTHOR NAMES
  Barra S.
  Providência R.
  Faustino C.
  Paiva L.
  Fernandes A.
  Marques A.L.
AUTHOR ADDRESSES
  (Barra S.) Cardiology Department, Papworth Hospital NHS Foundation Trust, 
Papworth Everard ,Cambridge CB23 3RE, United Kingdom.
(Providência R.) Cardiology Department, Clinique Pasteur, Toulouse, France.
(Providência R.; Faustino C.; Paiva L.; Fernandes A.; Marques A.L.) 
Cardiology Department, Coimbra's Hospital, University Centre, Coimbra, 
Portugal.
(Providência R.) Cardiology Department, Faculty of Medicine, University of 
Coimbra, Coimbra, Portugal.
CORRESPONDENCE ADDRESS
  S. Barra, Cardiology Department, Papworth Hospital NHS Foundation Trust, 
Papworth Everard ,Cambridge CB23 3RE, United Kingdom.
SOURCE
  Journal of Atrial Fibrillation (2013) 6:3 (35-44). Date of Publication: 
October-November 2013
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
  Background: Renal dysfunction is a strong predictor of adverse events in 
patients with atrial fibrillation (AF). The Cokcroft-Gault, Modification of 
Diet in Renal Disease (MDRD) and Chronic Kidney Disease-Epidemiology 
Collaboration (CKD-EPI) equations are available for estimating the 
glomerular filtration rate (GFR). No comparisons between these equations 
have yet been performed in patients with non-valvular AF concerning their 
mid-term prognostic performance. Methods: Cross-sectional study of 555 
consecutive patients with non-valvular AF undergoing transesophageal 
echocardiogram. We tested the prognostic performance of the aforementioned 
GFR estimation formulae, namely their ability to predict all-cause mortality 
(primary endpoint) and major cardiac adverse or ischemic cerebrovascular 
events (secondary endpoints) during an average follow-up of 24 months. 
Results: Regarding the primary endpoint, Cockcroft-Gault (AUC=0.749±0.028) 
was superior to both MDRD (AUC=0.624±0.039) and CKD-EPI (AUC=0.641±0.034) 
[p<0.001 both comparisons] while CKD-EPI was superior to MDRD (p=0.011). 
Cockcroft-Gault was marginally superior to both MDRD (AUC=0.673±0.049 vs. 
AUC=0.586±0.054, p=0.041) and CKD-EPI (AUC=0.673±0.049 vs. AUC=0.604±0.054, 
p=0.063) in the prediction of ischemic cerebrovascular events, while no 
difference was found between CKD-EPI and MDRD. Concerning AUC for prediction 
of MACE, Cockcroft-Gault was superior to MDRD (p=0.009) and CKD-EPI 
(p=0.012), while CKD-EPI was similar to MDRD (p=0.215). Multivariate 
predictive models consistently included Cockcroft-Gault formula along with 
CHADS2, excluding the other two equations. Measures of reclassification 
revealed a significant improvement in risk stratification for all studied 
endpoints with Cockcroft-Gault instead of CKD-EPI.No adverse events were 
reported. Conclusions: In patients with non-valvular AF, the Cockcroft-Gault 
more appropriately classified individuals with respect to risk of all-cause 
mortality, ischaemic cerebrovascular event and major adverse cardiac event.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  chronic kidney disease epidemiology collaboration formula
  Cockcroft Gault formula
  kidney disease
  mathematical parameters
  modification of diet in renal disease formula
  nonvalvular atrial fibrillation
EMTREE MEDICAL INDEX TERMS
  aged
  area under the curve
  article
  CHADS2 score
  cross-sectional study
  female
  follow up
  heart disease
  human
  major clinical study
  male
  mortality
  performance
  prediction
  prognosis
  risk
  transesophageal echocardiography
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Urology and Nephrology (28)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014060520
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 260
TITLE
  Integrated approach to treatment-resistant atrial fibrillation: additional 
value of acupuncture
AUTHOR NAMES
  Jonkman F.A.
  Jonkman-Buidin M.L.
AUTHOR ADDRESSES
  (Jonkman F.A.; Jonkman-Buidin M.L.) Department of Acupuncture, Acupuncture 
Outpatient Clinic Heel de Mens, Heelsum, The Netherlands. 
info@humanbalance.nl
SOURCE
  Acupuncture in medicine : journal of the British Medical Acupuncture Society 
(2013) 31:3 (327-330). Date of Publication: 1 Sep 2013
ISSN
  1759-9873 (electronic)
ABSTRACT
  A 62-year-old patient with chronic bronchitis had treatment-resistant atrial 
fibrillation. Electrical cardioversion was performed, but sinus rhythm (SR) 
lasted only for some minutes. Administration of amiodarone was withheld in 
favour of a course of acupuncture treatment in order to increase the success 
rate of a second attempt of electrical cardioversion. After two acupuncture 
treatments, spontaneous conversion to SR occurred. Relapses into atrial 
fibrillation in the following five winters, associated with attacks of 
bronchitis, also responded to acupuncture. The mechanisms of action of the 
acupuncture treatment and the value of this integrated approach to treatment 
are discussed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  cardioversion
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (therapy)
  case report
  human
  male
  middle aged
  pathophysiology
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
MEDLINE PMID
  23884291 (http://www.ncbi.nlm.nih.gov/pubmed/23884291)
FULL TEXT LINK
  http://dx.doi.org/10.1136/acupmed-2013-010380
COPYRIGHT
  Copyright 2015 Medline is the source for the citation and abstract of this 
record.

RECORD 261
TITLE
  Precipitant profile of acute heart failure: Experience of a tertiary level 
cardiac centre in Sri Lanka
AUTHOR NAMES
  Matthias A.T.
  Ekanayaka R.
AUTHOR ADDRESSES
  (Matthias A.T., thushara.matthias@gmail.com; Ekanayaka R.) Cardiology Unit, 
National Hospital of Sri Lanka, Colombo, Sri Lanka.
CORRESPONDENCE ADDRESS
  A.T. Matthias, Dr C V S Corea Mawatha, Hokandara Road, Thalawathugoda, Sri 
Lanka. Email: thushara.matthias@gmail.com
SOURCE
  Heart Asia (2013) 5:1 (86-91). Date of Publication: 2013
ISSN
  1759-1104 (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
  Introduction and objectives: Heart failure (HF) is a common cause of 
hospitalisation in most countries. Data on acute precipitants of HF and 
hospitalisation is not available in Sri Lanka. Background and methods: A 
prospective study of 100 sequential admissions with HF to the cardiology 
unit (National Hospital of Sri Lanka) to describe the precipitants and 
clinical outcome of HF. Results: Fifty-eight male and 42 female admissions 
were studied. Mean age was 60.66 years. Mean hospital stay was 5.5(SD 4.6) 
days. Sixty had de novo HF and 40 had pre-existing HF. The most common 
identifiable precipitants were acute ischaemia 37 (37%), anaemia 41 (41%), 
respiratory tract infection 10 (10%), arrhythmia 11 (11%), worsening renal 
function 11 (11%) and alcohol 5 (5.7%). Non-adherence to medication 4 
(4.6%), smoking 3 (3.9%), exposure to environmental stress 3 (3.4%) and 
uncontrolled hypertension 1 (1%) were also observed as precipitants. The 
most common arrhythmia was atrial fibrillation. Out of 34 patients in whom 
angiotensin-converting enzyme inhibitors or angiotensin-converting enzyme 
receptor blockers were indicated, 11% were not on the drug. Among 29 
patients in whom spironolactone was indicated, seven patients were not on 
the drug. Conclusions: Most precipitating factors of HF are preventable. 
Early identification and prevention of anaemia, preventing respiratory tract 
infection by vaccination, aggressive revascularisation for patients with 
ischaemia, monitoring of renal functions, and patient education regarding 
drug and diet compliance, would reduce the number of admissions.
EMTREE DRUG INDEX TERMS
  dipeptidyl carboxypeptidase inhibitor
  spironolactone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acute heart failure
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  anemia
  article
  atrial fibrillation
  cross-sectional study
  disease severity
  environmental stress
  female
  heart arrhythmia
  hospital admission
  human
  hypertension
  ischemia
  kidney disease
  major clinical study
  male
  outcome assessment
  priority journal
  prospective study
  respiratory tract infection
  Sri Lanka
CAS REGISTRY NUMBERS
  spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013423940
FULL TEXT LINK
  http://dx.doi.org/10.1136/heartasia-2013-010250
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 262
TITLE
  The rates of effective INR levels and the relationship with etiology in 
patients with warfarin treatment
ORIGINAL (NON-ENGLISH) TITLE
  Varfarin kullanan hastalarda etkin INR düzeyi oranlari{dotless} ve etiyoloji 
ile olan İlişkisi
AUTHOR NAMES
  Alişir M.F.
  Keçebaş M.
  Beşli F.
  Çalişkan S.
  Güngören F.
  Yildirim A.
  Baran I.
  Aydinlar A.
AUTHOR ADDRESSES
  (Alişir M.F.) Kardiyoloji Kliniǧi, Bingöl Devlet Hastanesi, Bingöl, Turkey.
(Keçebaş M.; Beşli F., feyzullahbesli@hotmail.com; Çalişkan S.; Güngören F.; 
Yildirim A.; Baran I.; Aydinlar A.) Kardiyoloji AD, Uludaǧ Üniversitesi, 
Bursa, Turkey.
CORRESPONDENCE ADDRESS
  F. Beşli, Uludaǧ Üniversitesi, Kardiyoloji AD, Bursa, Turkey. Email: 
feyzullahbesli@hotmail.com
SOURCE
  Turkiye Klinikleri Journal of Medical Sciences (2013) 33:3 (868-873). Date 
of Publication: 2013
ISSN
  1300-0292
BOOK PUBLISHER
  Turkiye Klinikleri Journal of Medical Sciences, Talapapa Bulvary no. 102, 
Hamammonu, Turkey.
ABSTRACT
  Objective: Warfarin with a narrow therapeutic window has a wide range of 
use. Food and drug interactions of warfarin and the individual differences 
may affect the success of the warfarin treatment. The aim of this study was 
to investigate the rate of effective INR levels in patients receiving 
warfarin therapy due to the mechanical prosthetic valve, atrial fibrillation 
(AF), intracardiac thrombus or pulmonary embolism and the relationship 
between the etiology and the efficacy of warfarin. Material and Methods: 
Archive records of 6450 patients presenting to the outpatient clinic of the 
Department of Cardiology, Uludaǧ University, Faculty of Medicine between 
January 2012-June 2012 were reviewed retrospectively. Nine hundred and 
seventy-one patients receiving warfarin treatment due to mechanical 
prosthetic valve, atrial fibrillation (AF), intracardiac thrombus or 
pulmonary embolism were included in the study. Medical records were reviewed 
for age, gender, international normalized ratio (INR) levels and indications 
for the warfarin treatment given. Results: The study revealed that 47.6% of 
the patients had an effective level of INR. The lowest rate of effecitve INR 
levels was in groups with pulmonary embolism with 33.3% and in patients with 
mitral valve replacement (MVR) with 39.6%. The highest rate was in patients 
with aortic valve replacement (AVR) with 61.9%. Conclusion: The rate of 
effective INR levels was relatively low. Especially, the effective INR level 
of the MVR patients was significantly lower than the rate in other groups. 
For patients treated with warfarin and especially patients with mechanical 
prosthetic valves targeting higher INR levels, the compliance of the 
patients should be questioned. In addition, considering the use of other 
concomitant medications and the nutritional habits, more frequent monitoring 
of INR levels is required. © 2013 by Türkiye Klinikleri.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  international normalized ratio
EMTREE MEDICAL INDEX TERMS
  aorta valve replacement
  article
  atrial fibrillation
  drug efficacy
  female
  human
  intracardiac thrombosis (drug therapy)
  lung embolism (drug therapy)
  major clinical study
  male
  mitral valve replacement
CAS REGISTRY NUMBERS
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English, Turkish
LANGUAGE OF SUMMARY
  English, Turkish
EMBASE ACCESSION NUMBER
  2013387154
FULL TEXT LINK
  http://dx.doi.org/10.5336/medsci.2012-32101
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 263
TITLE
  Flavonoids in atherosclerosis: An overview of their mechanisms of action
AUTHOR NAMES
  Siasos G.
  Tousoulis D.
  Tsigkou V.
  Kokkou E.
  Oikonomou E.
  Vavuranakis M.
  Basdra E.K.
  Papavassiliou A.G.
  Stefanadis C.
AUTHOR ADDRESSES
  (Siasos G., ger_sias@hotmail.com; Tousoulis D.; Kokkou E.; Oikonomou E.; 
Vavuranakis M.; Stefanadis C.) 1st Cardiology Department, University of 
Athens, Medical School, Athens, Greece.
(Siasos G., ger_sias@hotmail.com; Tsigkou V.; Basdra E.K.; Papavassiliou 
A.G.) Department of Biological Chemistry, University of Athens, Medical 
School, Athens, Greece.
CORRESPONDENCE ADDRESS
  G. Siasos, 1st Cardiology Department, University of Athens, Medical School, 
Athens, Greece. Email: ger_sias@hotmail.com
SOURCE
  Current Medicinal Chemistry (2013) 20:21 (2641-2660). Date of Publication: 
July 2013
ISSN
  0929-8673
  1875-533X (electronic)
BOOK PUBLISHER
  Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
  Polyphenols are composed of a wide variety of molecules that are classified 
into several categories, according to their chemical type such as phenolic 
acids, flavonoids, stilbenes, and lignans. Many studies have proven the 
beneficial effects of flavonoids in atherosclerosis progression and 
cardiovascular disease. Dietary flavonoids reduce oxidative stress and exert 
anti-inflammatory actions. Moreover, flavonoids have the ability to avoid 
the thrombus formation, improve endothelial function, modify lipid levels 
and regulate glucose metabolism. In the context of this evidence in this 
review article we summarize the so far acquired knowledge of the most 
important mechanisms of action of flavonoids in atherosclerosis progression. 
© 2013 Bentham Science Publishers.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  flavonoid (drug combination, drug therapy, pharmacology)
EMTREE DRUG INDEX TERMS
  anthocyanin
  atorvastatin (drug combination)
  biological marker (endogenous compound)
  catechin (drug combination)
  flavanol derivative
  flavanone derivative
  isoflavone derivative
  lipid (endogenous compound)
  polyphenol derivative
  quercetin
  resveratrol (drug combination)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atherosclerosis (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  antihypertensive activity
  antiinflammatory activity
  antioxidant activity
  atrial fibrillation (drug therapy)
  colon flora
  conjugation
  coronary artery disease (drug therapy)
  diet supplementation
  disease course
  drug absorption
  drug bioavailability
  drug blood level
  drug effect
  drug elimination
  drug metabolism
  drug safety
  drug transport
  drug uptake
  environmental factor
  glycosylation
  heart failure (drug therapy)
  human
  non insulin dependent diabetes mellitus (drug therapy)
  nonhuman
  oxidative stress
  red wine
  regulatory mechanism
  review
  vasodilatation
CAS REGISTRY NUMBERS
  atorvastatin (134523-00-5, 134523-03-8)
  catechin (13392-26-2, 154-23-4)
  lipid (66455-18-3)
  quercetin (117-39-5)
  resveratrol (501-36-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013445544
FULL TEXT LINK
  http://dx.doi.org/10.2174/0929867311320210003
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 264
TITLE
  Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric 
bypass surgery
AUTHOR NAMES
  Lee D.
  DeFilipp Z.
  Judson K.
  Kennedy M.
AUTHOR ADDRESSES
  (Lee D., dlee@wpahs.org; DeFilipp Z.) Department of Internal Medicine, West 
Penn Allegheny Health System, 320 East North Avenue, Pittsburgh, PA 15212, 
United States.
(Judson K.) Division of Clinical Cardiac Electrophysiology, West Penn 
Allegheny Health System, Pittsburgh, PA, United States.
(Kennedy M.) Division of Hematology and Cellular Therapy, West Penn 
Allegheny Health System, Pittsburgh, PA, United States.
CORRESPONDENCE ADDRESS
  D. Lee, Department of Internal Medicine, West Penn Allegheny Health System, 
320 East North Avenue, Pittsburgh, PA 15212, United States. Email: 
dlee@wpahs.org
SOURCE
  Journal of Cardiology Cases (2013) 8:1 (e49-e50). Date of Publication: July 
2013
ISSN
  1878-5409 (electronic)
BOOK PUBLISHER
  Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
  We report a 66-year-old male with a history of Roux-en-Y gastric bypass 
surgery who began dabigatran for new onset atrial fibrillation. After 5 
weeks of therapy, his transesophageal echocardiogram prior to 
electrocardioversion showed severe spontaneous echo contrast. Cardioversion 
was postponed and anticoagulant therapy was continued. The following day, he 
suffered a thromboembolic stroke. Concern arose that postoperative 
malabsorption could have resulted in subtherapeutic anticoagulation. This 
notion was strengthened by a second patient who had subtherapeutic serum 
levels despite maximal dosing. To the best of our knowledge, we are the 
first to report impaired absorption of dabigatran following Roux-en-Y 
gastric bypass surgery. Learning objective: Dabigatran has a predictable 
pharmacokinetic profile, allowing for a fixed-dose regimen that does not 
require frequent monitoring or dietary modifications. However, its 
absorption in patients who have undergone Roux-en-Y gastric bypass surgery 
has not been studied. Postoperative malabsoprtion, a major complication 
following Roux-en-Y gastric bypass surgery, can result in inadequate 
anticoagulation. As a result of unpredictable absorption, strategies 
allowing for routine monitoring may be best in this population. © 2013 
Japanese College of Cardiology.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dabigatran (drug therapy, pharmacokinetics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, complication, drug therapy)
EMTREE MEDICAL INDEX TERMS
  aged
  anticoagulation
  article
  cardioversion
  case report
  cerebrovascular accident
  human
  malabsorption (complication)
  male
  morbid obesity (surgery)
  priority journal
  stomach bypass
  transesophageal echocardiography
  treatment duration
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013345612
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jccase.2013.03.013
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 265
TITLE
  Routine versus aggressive upstream rhythm control for prevention of early 
atrial fibrillation in heart failure: Background, aims and design of the 
RACE 3 study
AUTHOR NAMES
  Alings M.
  Smit M.D.
  Moes M.L.
  Crijns H.J.G.M.
  Tijssen J.G.P.
  Brügemann J.
  Hillege H.L.
  Lane D.A.
  Lip G.Y.H.
  Smeets J.R.L.M.
  Tieleman R.G.
  Tukkie R.
  Willems F.F.
  Vermond R.A.
  Van Veldhuisen D.J.
  Van Gelder I.C.
AUTHOR ADDRESSES
  (Alings M.) Department of Cardiology, Amphia Hospital, Breda, Netherlands.
(Smit M.D.; Moes M.L.; Brügemann J.; Hillege H.L.; Vermond R.A.; Van 
Veldhuisen D.J.; Van Gelder I.C., i.c.van.gelder@umcg.nl) Department of 
Cardiology, Thoraxcenter, University of Groningen, University Medical Center 
Groningen, P.O. Box 30.001, 9700 RB Groningen, Netherlands.
(Crijns H.J.G.M.) Department of Cardiology, Maastricht University Medical 
Center, Maastricht, Netherlands.
(Tijssen J.G.P.) Department of Cardiology, Academic Medical Center 
Amsterdam, Amsterdam, Netherlands.
(Brügemann J.) Cardiac Rehabilitation Center, University Medical Center 
Groningen, Groningen, Netherlands.
(Hillege H.L.) Trial Coordination Center, Department of Epidemiology, 
University of Groningen, University Medical Center Groningen, Groningen, 
Netherlands.
(Lane D.A.; Lip G.Y.H.) University of Birmingham Center for Cardiovascular 
Sciences, City Hospital, Birmingham, United Kingdom.
(Smeets J.R.L.M.) Department of Cardiology, University Medical Center 
Nijmegen, Nijmegen, Netherlands.
(Tieleman R.G.) Department of Cardiology, Martini Hospital Groningen, 
Groningen, Netherlands.
(Tukkie R.) Department of Cardiology, Kennemer Gasthuis, Haarlem, 
Netherlands.
(Willems F.F.) Department of Cardiology, Rijnstate Hospital, Arnhem/Velp, 
Netherlands.
CORRESPONDENCE ADDRESS
  Department of Cardiology, Amphia Hospital, Breda, Netherlands.
SOURCE
  Netherlands Heart Journal (2013) 21:7-8 (354-363). Date of Publication: July 
2013
ISSN
  1568-5888
  1876-6250 (electronic)
BOOK PUBLISHER
  Bohn Stafleu van Loghum, P.O. Box 75971, Amsterdam, Netherlands.
ABSTRACT
  Background Rhythm control for atrial fibrillation (AF) is cumbersome because 
of its progressive nature caused by structural remodelling. Upstream therapy 
refers to therapeutic interventions aiming to modify the atrial substrate, 
leading to prevention of AF. Objective The Routine versus Aggressive 
upstream rhythm Control for prevention of Early AF in heart failure (RACE 3) 
study hypothesises that aggressive upstream rhythm control increases 
persistence of sinus rhythm compared with conventional rhythm control in 
patients with early AF and mild-to-moderate early systolic or diastolic 
heart failure undergoing electrical cardioversion. Design RACE 3 is a 
prospective, randomised, open, multinational, multicenter trial. Upstream 
rhythm control consists of angiotensin converting enzyme inhibitors and/or 
angiotensin receptor blockers, mineralocorticoid receptor antagonists, 
statins, cardiac rehabilitation therapy, and intensive counselling on 
dietary restrictions, exercise maintenance, and drug adherence. Conventional 
rhythm control consists of routine rhythm control therapy without cardiac 
rehabilitation therapy and intensive counselling. In both arms, every effort 
is made to keep patients in the rhythm control strategy, and ion channel 
antiarrhythmic drugs or pulmonary vein ablation may be instituted if AF 
relapses. Total inclusion will be 250 patients. If upstream therapy proves 
to be effective in improving maintenance of sinus rhythm, it could become a 
new approach to rhythm control supporting conventional pharmacological and 
non-pharmacological rhythm control. © The Author(s) 2013.
EMTREE DRUG INDEX TERMS
  adrenergic receptor blocking agent (clinical trial, drug therapy)
  angiotensin receptor antagonist (clinical trial, drug therapy)
  antiarrhythmic agent (clinical trial, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (clinical trial, drug 
therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy, prevention)
  heart failure
  heart rhythm
EMTREE MEDICAL INDEX TERMS
  adult
  article
  computer assisted tomography
  controlled study
  follow up
  heart rehabilitation
  human
  major clinical study
  multicenter study
  nuclear magnetic resonance imaging
  open study
  patient counseling
  prospective study
  randomized controlled trial
EMBASE CLASSIFICATIONS
  Rehabilitation and Physical Medicine (19)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00877643)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013488239
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12471-013-0428-5
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 266
TITLE
  Cardiovascular toxicity of molecular targeted therapy in cancer patients: A 
double-edged sword
AUTHOR NAMES
  Liu K.-L.
  Chen J.-S.
  Chen S.-C.
  Chu P.-H.
AUTHOR ADDRESSES
  (Liu K.-L.; Chu P.-H., pchu@adm.cgmh.org.tw) Cardiovascular Division, 
Department of Internal Medicine, Chang Gung University, Tun-Hwa North Road, 
Taipei 105, Taiwan.
(Chen J.-S.) Department of Oncology, Chang GungMemorial Hospital, Taiwan.
(Chen S.-C.) Department of Surgery, Chang Gung University, College of 
Medicine, Taipei, Taiwan.
CORRESPONDENCE ADDRESS
  P.-H. Chu, Cardiovascular Division, Department of Internal Medicine, Chang 
Gung University, Tun-Hwa North Road, Taipei 105, Taiwan. Email: 
pchu@adm.cgmh.org.tw
SOURCE
  Acta Cardiologica Sinica (2013) 29:4 (295-303). Date of Publication: July 
2013
ISSN
  1011-6842
BOOK PUBLISHER
  Republic of China Society of Cardiology, 7F, No.27, Min-Chuan W.Road, 
Taipei, Taiwan.
ABSTRACT
  The annual incidence of cancer has increased over the past 20 years, yet the 
5-year relative survival rate for cancer has improved with the increasing 
availability of advanced therapies, including molecular targeted therapy. 
Cardiovascular toxicity can develop with this type of targeted therapy, 
which can cause serious side effects including left ventricular dysfunction, 
hypertension, hypotension, QT prolongation, thromboembolism, and myocardial 
ischemia. In many ways, the quality of life primarily depends on the health 
status of patient cardiopulmonary function. However, risk factor assessment, 
routine monitoring, and prompt intervention remain the best strategy to deal 
with these patients with malignancies, to ensure that their cardiopulmonary 
function is maintained at the highest possible level. Most previous studies 
on cardiovascular toxicity have focused on conventional chemotherapy. 
Molecular targeted therapy is a novel anticancer treatment; however, due to 
potentially adverse cardiovascular events from this therapy, oncologists and 
cardiologists need to work together to maximize the benefits. In this 
review, we focused on target therapy-induced cardiovascular toxicities, in 
particular cardiac structural, electrophysiological, and vascular effects.
EMTREE DRUG INDEX TERMS
  alemtuzumab (adverse drug reaction)
  anthracycline (pharmacology)
  bevacizumab (pharmacology)
  carvedilol
  cetuximab (adverse drug reaction)
  cisplatin (pharmacology)
  cyclophosphamide (pharmacology)
  dasatinib (adverse drug reaction, drug therapy, pharmacology)
  daunorubicin
  docetaxel
  doxorubicin
  enalapril
  epirubicin
  etoposide
  fluorouracil
  gemcitabine
  ifosfamide
  imatinib (drug therapy, pharmacology)
  interleukin 2 (adverse drug reaction)
  lapatinib
  melphalan
  mitomycin (pharmacology)
  mitoxantrone (pharmacology)
  paclitaxel
  retinoic acid (adverse drug reaction, pharmacology)
  rituximab (adverse drug reaction)
  sorafenib (pharmacology)
  sunitinib (pharmacology)
  trastuzumab (pharmacology)
  unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cancer patient
  cardiotoxicity
  heart left ventricle failure
  heart muscle ischemia (complication)
  hypertension
  hypotension (side effect, etiology, side effect)
  molecularly targeted therapy
  QT prolongation
  venous thromboembolism
EMTREE MEDICAL INDEX TERMS
  adjuvant therapy
  allergic reaction (etiology, side effect)
  anaphylaxis (etiology, side effect)
  atrial fibrillation
  blood pressure
  blood pressure monitoring
  blood vessel permeability
  cancer registry
  cancer research
  cancer therapy
  cardiomyopathy (prevention)
  cardiopulmonary function
  cardiovascular magnetic resonance
  cardiovascular mortality
  cell death
  cell growth
  cell junction
  cell proliferation
  chemotherapy induced cardiomyopathy (prevention)
  clinical practice
  concentration (parameters)
  congestive heart failure
  diabetes mellitus
  drug exposure
  drug withdrawal
  edema (drug therapy)
  electrophysiology
  endoplasmic reticulum stress
  endothelium cell
  exercise
  faintness
  fibrinolytic therapy
  fluid retention
  follow up
  gold standard
  heart arrhythmia
  heart catheterization
  heart failure
  heart injury
  heart left ventricle ejection fraction
  heart muscle biopsy
  heart rhythm
  heart right ventricle failure (side effect)
  heart ventricle arrhythmia
  hemodynamics
  high risk patient
  human
  hyperlipidemia
  immobilization
  implanted heart pacemaker
  kidney carcinoma
  lifestyle modification
  lung artery pressure
  lung capillary
  medical society
  membrane potential
  nephrotoxicity
  obesity
  pericardial effusion (drug therapy)
  physical examination
  pleura effusion (drug therapy)
  potassium current
  practice guideline
  predictive value
  premedication
  prospective study
  pulmonary hypertension (complication, drug therapy)
  QT interval
  review
  risk factor
  sinus bradycardia
  smoking
  smooth muscle fiber
  sudden death
  Taiwan
  thorax pain
  tissue Doppler imaging
  tissue pressure
  treatment duration
  United Kingdom
  vascular resistance
  vascular stent
  vasoconstriction
  weight reduction
CAS REGISTRY NUMBERS
  alemtuzumab (216503-57-0)
  bevacizumab (216974-75-3)
  carvedilol (72956-09-3)
  cetuximab (205923-56-4)
  cisplatin (15663-27-1, 26035-31-4, 96081-74-2)
  cyclophosphamide (50-18-0)
  dasatinib (302962-49-8, 863127-77-9)
  daunorubicin (12707-28-7, 20830-81-3, 23541-50-6)
  docetaxel (114977-28-5)
  doxorubicin (23214-92-8, 25316-40-9)
  enalapril (75847-73-3)
  epirubicin (56390-09-1, 56420-45-2)
  etoposide (33419-42-0)
  fluorouracil (51-21-8)
  gemcitabine (103882-84-4)
  ifosfamide (3778-73-2)
  imatinib (152459-95-5, 220127-57-1)
  interleukin 2 (85898-30-2)
  lapatinib (231277-92-2, 388082-78-8, 437755-78-7)
  melphalan (148-82-3)
  mitomycin (1404-00-8, 50-07-7, 74349-48-7)
  mitoxantrone (65271-80-9, 70476-82-3)
  paclitaxel (33069-62-4)
  retinoic acid (302-79-4)
  rituximab (174722-31-7)
  sorafenib (284461-73-0)
  sunitinib (341031-54-7, 557795-19-4)
  trastuzumab (180288-69-1)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013464594
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 267
TITLE
  Successful management of gastric perforation in stage IV diffuse large 
B-cell lymphoma with chemoradiation therapy, percutaneous endoscopy 
gastrostomy for gastric drainage, and percutaneous endoscopy jejunostomy for 
Nutrition
AUTHOR NAMES
  Khadraoui H.
  Feigin K.N.
  Fox J.J.
  Ong L.
  Shike M.
  Yahalom J.
  Noy A.
AUTHOR ADDRESSES
  (Khadraoui H.) Memorial Sloan-Kettering Cancer Center, New York, NY, United 
States.
(Feigin K.N.; Fox J.J.) Department of Radiology, Memorial Sloan-Kettering 
Cancer Center, New York, NY, United States.
(Ong L.) Graduate Medical Education, Memorial Sloan-Kettering Cancer Center, 
New York, NY, United States.
(Shike M.; Noy A., noya@mskcc.org) Department of Medicine, Memorial 
Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United 
States.
(Yahalom J.) Department of Radiation Oncology, Memorial Sloan-Kettering 
Cancer Center, New York, NY, United States.
CORRESPONDENCE ADDRESS
  A. Noy, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 
York Avenue, New York, NY 10065, United States. Email: noya@mskcc.org
SOURCE
  Clinical Lymphoma, Myeloma and Leukemia (2013) 13:3 (327-330). Date of 
Publication: June 2013
ISSN
  2152-2650
  2152-2669 (electronic)
BOOK PUBLISHER
  Elsevier Inc., 360 Park Avenue South, New York, United States.
EMTREE DRUG INDEX TERMS
  cisplatin (drug combination, drug therapy)
  cyclophosphamide (drug combination, drug therapy)
  doxorubicin (drug combination, drug therapy)
  etoposide (drug combination, drug therapy)
  fluorodeoxyglucose f 18
  prednisolone (drug combination, drug therapy)
  rituximab (drug combination, drug therapy)
  vincristine (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  chemoradiotherapy
  gastrojejunostomy
  large cell lymphoma (drug therapy, drug therapy, radiotherapy, surgery)
  nutrition
  percutaneous drainage
  percutaneous endoscopic gastrostomy
  stomach perforation (radiotherapy, surgery)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  cancer chemotherapy
  cancer patient
  cancer radiotherapy
  cancer regression
  cancer staging
  cancer surgery
  case report
  computer assisted tomography
  contrast medium extravasation
  febrile neutropenia
  hospital admission
  human
  hyperlipidemia
  hypermetabolism
  hypertension
  hypotension
  hypothyroidism
  immunohistochemistry
  insulin dependent diabetes mellitus
  intensity modulated radiation therapy
  kidney biopsy
  kidney carcinoma (radiotherapy)
  kidney failure
  lymphadenopathy
  male
  minimal residual disease (radiotherapy)
  multimodality cancer therapy
  multiple cycle treatment
  pancreas tumor (drug therapy)
  papillary carcinoma (radiotherapy)
  physical examination
  pleura effusion
  systemic therapy
  thorax radiography
  thyroid nodule
  treatment duration
  tumor volume
  weakness
  weight reduction
CAS REGISTRY NUMBERS
  cisplatin (15663-27-1, 26035-31-4, 96081-74-2)
  cyclophosphamide (50-18-0)
  doxorubicin (23214-92-8, 25316-40-9)
  etoposide (33419-42-0)
  fluorodeoxyglucose f 18 (63503-12-8)
  prednisolone (50-24-8)
  rituximab (174722-31-7)
  vincristine (57-22-7)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cancer (16)
  Hematology (25)
  Drug Literature Index (37)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2013308345
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.clml.2012.11.005
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 268
TITLE
  Post-exercise diastolic stunning detected by velocity vector imaging is a 
useful marker for induced ischemia in ischemic heart disease
AUTHOR NAMES
  Kurosawa K.
  Watanabe H.
  Aikawa M.
  Mihara H.
  Iguchi N.
  Asano R.
  Umemura J.
  Kurabayashi M.
  Sumiyoshi T.
AUTHOR ADDRESSES
  (Kurosawa K., k-kuro@kss.biglobe.ne.jp; Watanabe H.; Aikawa M.; Mihara H.; 
Iguchi N.; Asano R.; Umemura J.; Sumiyoshi T.) Department of Cardiology, 
Sakakibara Heart Institute, Tokyo, Japan.
(Kurosawa K., k-kuro@kss.biglobe.ne.jp; Kurabayashi M.) Department of 
Medicine and Biological Science, Graduate School of Medicine, Gunma 
University, 3-39-15 Showamachi, Maebashi, Gunma, 371-8511, Japan.
CORRESPONDENCE ADDRESS
  K. Kurosawa, Department of Medicine and Biological Science, Graduate School 
of Medicine, Gunma University, 3-39-15 Showamachi, Maebashi, Gunma, 
371-8511, Japan. Email: k-kuro@kss.biglobe.ne.jp
SOURCE
  Journal of Echocardiography (2013) 11:2 (50-58). Date of Publication: June 
2013
ISSN
  1349-0222
  1880-344X (electronic)
BOOK PUBLISHER
  Springer Japan, 1-11-11 Kudan-kita, Chiyoda-ku, No. 2 Funato Bldg., Tokyo, 
Japan.
ABSTRACT
  Background: Recently, post-exercise diastolic stunning (PES) has been 
reported as a new clinical marker of induced ischemia. Velocity vector 
imaging (VVI) has been developed to visualize regional wall motion 
abnormalities based on vectors detected by the tissue tracking technique, 
which has the potential to visualize PES. Thus, the aim of this study was to 
evaluate the usefulness of PES detection by VVI as an objective marker of 
ischemia compared to stress thallium-201 (Tl-201) single photon emission 
computed tomography (SPECT). Methods: We studied consecutive patients who 
were scheduled to undergo exercise stress Tl-201 SPECT for the diagnosis of 
ischemic heart disease. Transthoracic echocardiography was recorded 
digitally before and 20 min after exercise for Tl-201 SPECT, and the data 
were used subsequently for VVI analysis. We defined PES regions as those 
with new abnormal vectors observed during isovolumic relaxation. Results: 
After excluding 14 patients with old myocardial infarction and/or atrial 
fibrillation, echocardiograms suitable for VVI analysis were obtained from 
62 of 65 patients (feasibility, 95 %; 44 men; mean age, 64 ± 11 years). 
SPECT revealed induced ischemia in 20 patients, whereas VVI identified PES 
in 18 patients. VVI detected inducible ischemia with 85 % sensitivity and 98 
% specificity compared to SPECT. Conclusions: VVI detection of PES is a new 
clinical tool for induced ischemia. Regional diastolic wall motion 
abnormalities following induced ischemia can be noninvasively detected by 
VVI. © 2013 Japanese Society of Echocardiography.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  thallium 201
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
  nitric acid derivative (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diagnostic value
  disease marker
  exercise test
  ischemic heart disease (drug therapy, diagnosis, drug therapy)
  post exercise diastolic stunning
  single photon emission computer tomography
  velocity vector imaging
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation (diagnosis)
  blood pressure
  computer assisted diagnosis
  controlled study
  diagnostic test accuracy study
  feasibility study
  female
  heart left ventricle ejection fraction
  heart left ventricle enddiastolic volume
  heart muscle relaxation
  heart rate
  hemodynamics
  human
  image analysis
  intermethod comparison
  major clinical study
  male
  sensitivity and specificity
  SPECT scanner
  transthoracic echocardiography
DEVICE TRADE NAMES
  ACUSON Sequoia 512  , United StatesSiemens

  Millennium VG  , United StatesGeneral Electric

DEVICE MANUFACTURERS
   (United States)General Electric
   (United States)Siemens
CAS REGISTRY NUMBERS
  thallium 201 (15064-65-0)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Nuclear Medicine (23)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013359228
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12574-012-0163-8
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 269
TITLE
  What's in the literature?
AUTHOR NAMES
  Lacomis D.
  El-Dokla A.
AUTHOR ADDRESSES
  (Lacomis D.; El-Dokla A.) Department of Neurology, University of Pittsburgh 
School of Medicine, UPMC-Presbyterian, Pittsburgh, PA, United States.
CORRESPONDENCE ADDRESS
  Department of Neurology, University of Pittsburgh School of Medicine, 
UPMC-Presbyterian, Pittsburgh, PA, United States.
SOURCE
  Journal of Clinical Neuromuscular Disease (2013) 14:4 (218-223). Date of 
Publication: June 2013
ISSN
  1522-0443
  1537-1611 (electronic)
BOOK PUBLISHER
  Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327, 
Philadelphia, United States.
ABSTRACT
  We review new evidence that there is a difference in the electrophysiologic 
features of fasciculation potentials from patients with amyotrophic lateral 
sclerosis (ALS) versus those with benign fasciculations. A report on the 
entity of fasciculation anxiety syndrome in clinicians is also covered. An 
interesting association between ALS with the C9ORF72 mutation and multiple 
sclerosis has been reported; ALS is more severe in this setting. The genetic 
etiology of Welander distal myopathy is now known, and genetic 
predispositions for ambulatory loss in Duchenne muscular dystrophy and 
epilepsy were recently reported. Several recent articles on myasthenia 
gravis (MG) provide updates on the incidence of late-onset MG, genetic risk 
factors for MG development, and the complications of central versus 
peripheral access for plasma exchange. Last, several relatively recent 
articles address prevention and risk of developing paclitaxel-induced 
neuropathy. Copyright © 2013 by Lippincott Williams & Wilkins.
EMTREE DRUG INDEX TERMS
  caffeine
  calpain
  corticosteroid
  cytokine
  dystrophin (endogenous compound)
  glucocorticoid
  I kappa B kinase gamma
  ibudilast
  inositol 1,4,5 trisphosphate receptor
  interleukin 1
  leukotriene receptor blocking agent
  lithium
  messenger RNA
  omega 3 fatty acid (drug therapy)
  paclitaxel
  placebo
  protective agent
  protein tyrosine phosphatase
  pyridostigmine (drug therapy)
  RNA binding protein
  synapsin I
  transforming growth factor beta
  tumor necrosis factor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  amyotrophic lateral sclerosis
  fasciculation
  medical literature
EMTREE MEDICAL INDEX TERMS
  acute kidney failure (complication)
  allele
  anxiety
  atrial fibrillation (complication)
  autoimmune disease
  autosomal dominant inheritance
  blood clotting disorder (complication)
  cancer chemotherapy
  cell stress
  central venous catheter
  clinical feature
  cognitive defect
  cytotoxicity
  disease course
  distal myopathy
  double blind procedure
  Duchenne muscular dystrophy
  epilepsy
  exercise
  gene expression
  gene mutation
  genetic association
  genetic predisposition
  genetic risk
  genotype
  haplotype
  human
  hyperactivity
  immunosuppressive treatment
  incidence
  intelligence quotient
  Kugelberg Welander disease
  lung embolism (complication)
  lymphoblastoid cell line
  medical device complication
  mental deficiency
  motor nerve conduction
  motor unit potential
  multiple sclerosis
  muscular dystrophy
  myasthenia gravis (drug therapy)
  nervous system inflammation
  neuroblastoma cell
  neuropathy
  pathogenesis
  peripheral neuropathy (drug therapy, prevention)
  peripheral vein
  plasmapheresis
  pneumothorax (complication)
  priority journal
  protein aggregation
  randomized controlled trial (topic)
  receptor down regulation
  review
  seizure
  single nucleotide polymorphism
  stress
  upregulation
  weakness
CAS REGISTRY NUMBERS
  caffeine (58-08-2)
  calpain (78990-62-2)
  dystrophin (116978-02-0)
  ibudilast (50847-11-5)
  lithium (7439-93-2)
  paclitaxel (33069-62-4)
  protein tyrosine phosphatase (79747-53-8, 97162-86-2)
  pyridostigmine (101-26-8, 155-97-5)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Neurology and Neurosurgery (8)
  Human Genetics (22)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013515626
FULL TEXT LINK
  http://dx.doi.org/10.1097/CND.0b013e3182997b12
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 270
TITLE
  Pharmacological profile of antithrombotic, fibrinolytic and anticoagulant 
drugs
AUTHOR NAMES
  Kishore K.
AUTHOR ADDRESSES
  (Kishore K., kamalbareilly@yahoo.co.in) Department of Pharmacy, M.J.P. 
Rohilkhand University, Bareilly-243006 Uttar Pradesh, India.
CORRESPONDENCE ADDRESS
  K. Kishore, Department of Pharmacy, M.J.P. Rohilkhand University, 
Bareilly-243006 Uttar Pradesh, India. Email: kamalbareilly@yahoo.co.in
SOURCE
  Current Trends in Biotechnology and Pharmacy (2013) 7:2 (696-707). Date of 
Publication: 2013
ISSN
  0973-8916
  2230-7303 (electronic)
BOOK PUBLISHER
  Association of Biotechnology and Pharmacy, Acharya Nagarjuna University; 
Nagarjunanagar, Guntur, Andhra Pradesh, India.
ABSTRACT
  The blood is a specialized fluid connective tissue or transport system which 
plays an important part in the maintenance of life. the transport of gases, 
nutrition, excretion, acid-base equity, body defence, water balance, 
clotting, regulation of body temperature, blood pressure, ionic balance and 
as a vehicle are the main functions of the blood. The anaemia, purpura, 
haemophilia, thrombosis, and clotting related disorders are the major 
complications of the hemopoietic system. Thrombosis is one of the leading 
cause of thromboembolic disorders affecting million peoples worldwide. 
Thromboembolic disorders such as pulmonary emboli, deep vein thrombosis, 
strokes and heart attacks are the main causes of morbidity and mortality in 
developed countries. Hence, antithrombotics play a pivotal role as agents 
for the prevention and treatment of thromboembolic disorders. A current list 
of various products having antithrombotic activity incorporated and 
prototype agents discussed. The antithrombotic includes specific 
antithrombotics agents like aspirin, cilostazol, clopidogrel, prasugrel, 
epoprostenol, dipyridamole, indomethacin, sulfinpyrazone, thromboxane 
receptor antagonists, thromboxane synthesis inhibitors, ticlopidine, 
terutroban, abciximab, eptifibatide, tirofiban, and non-specific 
antithrombotics agents like Ca(2+) antagonists, ketanserin, nafazatron, 
α-receptor antagonists, β-blockers. The fibrinolytics like tissue 
plasminogen activators-streptokinase; urokinase, alteplase, duteplase, 
anistreplase, reteplase, saruplase, tenecteplase, snake venom, and 
anticoagulants also equally effective in the treatment of thrombotic 
disorders are discussed. This article includes general as well as recent 
pharmacological information on different aspects of antithrombotic, 
fibrinolytic and anticoagulant drugs that may be useful for their better 
understanding by users and health care professionals.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (drug therapy, pharmacology)
  fibrinolytic agent (drug therapy, pharmacology)
EMTREE DRUG INDEX TERMS
  abciximab (adverse drug reaction, drug therapy, intravenous drug 
administration, pharmacokinetics, pharmacology)
  acetylsalicylic acid (adverse drug reaction, drug interaction, drug therapy, 
pharmacology)
  alteplase (adverse drug reaction, drug therapy, intravenous drug 
administration, pharmacology)
  amiodarone (drug interaction)
  anistreplase (adverse drug reaction, intravenous drug administration)
  antithrombocytic agent (drug interaction, drug therapy, pharmacology)
  apixaban (adverse drug reaction, drug therapy, oral drug administration, 
pharmacokinetics, pharmacology)
  beraprost (adverse drug reaction, drug therapy, oral drug administration, 
pharmacokinetics, pharmacology)
  cephalosporin (drug interaction)
  clopidogrel (adverse drug reaction, drug interaction, drug therapy, oral 
drug administration, pharmacokinetics, pharmacology)
  dabigatran etexilate (adverse drug reaction, drug interaction, drug therapy, 
oral drug administration, pharmacology)
  dalteparin (adverse drug reaction, drug therapy, pharmacokinetics, 
pharmacology, subcutaneous drug administration)
  danaparoid (drug therapy, intravenous drug administration, pharmacokinetics, 
pharmacology, subcutaneous drug administration)
  dipyridamole (adverse drug reaction, drug interaction, drug therapy, oral 
drug administration, pharmacokinetics, pharmacology)
  eptifibatide (adverse drug reaction, drug therapy, intravenous drug 
administration, pharmacokinetics)
  heparin (adverse drug reaction, drug therapy, intravenous drug 
administration, pharmacokinetics, pharmacology, subcutaneous drug 
administration)
  ketanserin (adverse drug reaction, drug therapy, oral drug administration, 
pharmacokinetics, pharmacology)
  prostacyclin (adverse drug reaction, drug therapy, intravenous drug 
administration, pharmacokinetics, pharmacology)
  quinidine (drug interaction)
  saruplase (drug therapy, intravenous drug administration)
  streptokinase (adverse drug reaction, drug therapy, intravenous drug 
administration, pharmacology)
  tenecteplase (pharmacokinetics)
  terutroban (drug therapy, oral drug administration, pharmacokinetics, 
pharmacology)
  ticlopidine (adverse drug reaction, drug therapy, oral drug administration, 
pharmacokinetics, pharmacology)
  tissue plasminogen activator (drug therapy, pharmacology)
  unindexed drug
  urokinase (adverse drug reaction, drug therapy, intravenous drug 
administration, pharmacology)
  warfarin (adverse drug reaction, drug interaction, drug therapy, drug 
toxicity, oral drug administration, pharmacokinetics, pharmacology)
EMTREE MEDICAL INDEX TERMS
  abdominal pain (side effect)
  acute heart infarction (drug therapy)
  allergy (side effect)
  alopecia (side effect)
  anaphylaxis (side effect)
  angina pectoris (drug therapy)
  angioneurotic edema (side effect)
  anorexia (side effect)
  aplastic anemia (side effect)
  arterial thromboembolism (drug therapy)
  article
  asthma (side effect)
  atherosclerosis (drug therapy)
  atrial fibrillation (drug therapy)
  behavior disorder (drug therapy)
  biliary tract disease (side effect)
  bleeding (side effect)
  blood clotting
  blurred vision (side effect)
  brain hemorrhage (side effect)
  bronchospasm (side effect)
  carcinoid syndrome (drug therapy)
  central nervous system disease (side effect)
  cerebrovascular accident (drug therapy, prevention, side effect)
  cerebrovascular disease (drug therapy)
  chill (side effect)
  claudication (drug therapy)
  constipation (side effect)
  continuous infusion
  coronary artery aneurysm (drug therapy)
  coronary artery disease (drug therapy)
  coronary artery thrombosis (drug therapy)
  deep vein thrombosis (drug therapy, prevention)
  depression (drug therapy)
  dermatitis (side effect)
  diabetic neuropathy (drug therapy)
  diabetic retinopathy (drug therapy)
  diarrhea (side effect)
  dizziness (side effect)
  drowsiness (side effect)
  drug absorption
  drug antagonism
  drug classification
  drug contraindication
  drug distribution
  drug eruption (side effect)
  drug excretion
  drug fever (side effect)
  drug half life
  drug hypersensitivity (side effect)
  drug indication
  drug induced headache (side effect)
  drug mechanism
  drug metabolism
  drug potentiation
  drug use
  dyspepsia (drug therapy)
  eclampsia (drug therapy)
  fatigue (side effect)
  gangrene (side effect)
  gastroesophageal reflux (drug therapy)
  gastrointestinal hemorrhage (side effect)
  gastrointestinal symptom (side effect)
  glaucoma (side effect)
  heart arrhythmia (side effect)
  heart failure (side effect)
  heart infarction (drug therapy, prevention)
  heart palpitation (side effect)
  heart ventricle tachycardia (drug therapy)
  hematoma (side effect)
  hematuria (side effect)
  hemolysis (side effect)
  hot flush (side effect)
  human
  hypercholesterolemia (side effect)
  hyperglycemia (side effect)
  hyperkalemia (side effect)
  hypertension (drug therapy)
  hypotension (side effect)
  ileus (side effect)
  immune deficiency (side effect)
  inflammation (drug therapy)
  injection site erythema (side effect)
  injection site irritation (side effect)
  irritable colon (drug therapy)
  ischemia (drug therapy)
  jaundice (side effect)
  kidney dysfunction (side effect)
  leukopenia (side effect)
  liver disease (side effect)
  liver dysfunction (side effect)
  lung embolism (drug therapy, prevention)
  migraine (drug therapy)
  myalgia (side effect)
  nausea (side effect)
  necrosis (side effect)
  neutropenia (side effect)
  nonhuman
  orthostatic hypotension (side effect)
  osteoporosis (side effect)
  pain (side effect)
  pancreatitis (side effect)
  parkinsonism (drug therapy)
  pathologic fracture (side effect)
  peripheral occlusive artery disease (drug therapy)
  peripheral vascular disease (drug therapy)
  pulmonary hypertension (drug therapy)
  restenosis (drug therapy, prevention)
  rheumatic heart disease (drug therapy)
  schizophrenia (drug therapy)
  sedation
  side effect (side effect)
  skin necrosis (side effect)
  stable angina pectoris (drug therapy)
  stomach paresis (drug therapy)
  supraventricular tachycardia (drug therapy)
  tachycardia (side effect)
  thorax pain (side effect)
  thrombocytopenia (drug therapy, side effect)
  thromboembolism (drug therapy)
  thrombophlebitis (drug therapy)
  thrombosis (drug therapy, prevention)
  tinnitus (side effect)
  transient ischemic attack (drug therapy)
  unstable angina pectoris (drug therapy)
  urine retention (side effect)
  urticaria (drug therapy, side effect)
  vein thrombosis (drug therapy)
  venous thromboembolism (drug therapy)
  vertigo (side effect)
  vomiting (drug therapy, side effect)
  Wolff Parkinson White syndrome (drug therapy)
  wound healing impairment (side effect)
  xerostomia (side effect)
CAS REGISTRY NUMBERS
  abciximab (143653-53-6)
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alteplase (105857-23-6)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  anistreplase (81669-57-0)
  apixaban (503612-47-3)
  beraprost (88430-50-6, 88475-69-8)
  cephalosporin (11111-12-9)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  danaparoid (83513-48-8)
  dipyridamole (58-32-2)
  eptifibatide (148031-34-9)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  ketanserin (74050-98-9)
  prostacyclin (35121-78-9, 61849-14-7)
  quinidine (56-54-2)
  saruplase (99149-95-8)
  streptokinase (9002-01-1)
  tenecteplase (191588-94-0)
  terutroban (165537-73-5, 165538-40-9, 609340-89-8)
  ticlopidine (53885-35-1, 55142-85-3)
  tissue plasminogen activator (105913-11-9)
  urokinase (139639-24-0)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Hematology (25)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013301737
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 271
TITLE
  Alternative therapies in the treatment of atrial fibrillation
AUTHOR NAMES
  Lombardi F.
  Belletti S.
  Lomuscio A.
AUTHOR ADDRESSES
  (Lombardi F.; Belletti S.; Lomuscio A.) Cardiologia Osp. San Paolo, Dep. of 
Health Sciences, University of Milan, Via A. di Rudinì 8, 20142 Milan, 
Italy.
CORRESPONDENCE ADDRESS
  F. Lombardi, Cardiologia Osp. San Paolo, Dep. of Health Sciences, University 
of Milan, Via A. di Rudinì 8, 20142 Milan, Italy.
SOURCE
  Journal of Atrial Fibrillation (2013) 5:6 (175-181). Date of Publication: 
2013
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
  Atrial fibrillation (AF) is the most common clinical arrhythmia and 
represents a major social and economic problem. The number of subjects with 
AF is constantly increasing as a result of aging and improved survival in 
several cardiac and non-cardiac diseases. Patients with AF are often 
symptomatic, have a reduced physical capacity and are at high risk for 
thromboembolic events. Moreover, AF is associated with increased mortality 
and independent of the management, based either on rhythm or rate control 
strategy, The safety and efficacy of most anti-arrhythmic drugs are 
questionable. Increasing attention has therefore been addressed to evaluate 
the possible therapeutic and/or preventive effects of forms of treatment 
coming from ancient medical traditions of Far East, like acupuncture and 
yoga. In traditional Chinese medicine, acupuncture has been found effective 
in managing patients with paroxysmal supraventricular tachycardia. Recently, 
also in the Western literature, reports have been published supporting the 
clinical efficacy of acupuncture to treat arterial hypertension and to 
reduce chest pain. Other studies have evaluated the effects of acupuncture 
and other methods of Eastern Medicine, i.e., Qigong, Tai Chi Chuan and Yoga, 
in the treatment of cardiac illnesses associated with supraventricular 
arrhythmias. Two reports on the effects of acupuncture in preventing or 
reducing the rate of AF recurrences in patients with persistent or 
paroxysmal AF have been recently reported . Another ancient traditional 
eastern form of therapy and prevention, i.e., yoga, has been recently shown 
to reduce episodes of atrial fibrillation and improve the symptoms of 
anxiety and depression often associated with this arrhythmia. Growing 
evidence indicates that acupuncture and yoga are safe, without any 
pro-arrhythmic effect and with limited cost. All these factors should be 
considered when evaluating the efficacy of therapeutic intervention for an 
epidemic disease such as AF.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
  flecainide (drug therapy)
  propafenone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alternative medicine
  atrial fibrillation (drug therapy, drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  anxiety
  Chinese medicine
  depression
  electroacupuncture
  heart beat
  heart disease (therapy)
  heart supraventricular arrhythmia (therapy)
  human
  hypertension (therapy)
  mortality
  paroxysmal supraventricular tachycardia (therapy)
  physical capacity
  qigong
  recurrent disease
  review
  risk
  risk factor
  survival
  Tai Chi
  thorax pain (therapy)
  thromboembolism
  traditional medicine
  yoga
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  flecainide (54143-55-4)
  propafenone (34183-22-7, 54063-53-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013283320
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 272
TITLE
  Myocardial ischemia as a genuine cause responsible for the organization and 
"fertilization" of conflictogenic atrial fibrillation: New conceptual 
insights into arrhythmogenicity
AUTHOR NAMES
  Stirbys P.
AUTHOR ADDRESSES
  (Stirbys P.) Department of Cardiology, Hospital of Lithuanian University of 
Health Sciences, Kaunas Clinic, Kaunas, Lithuania.
CORRESPONDENCE ADDRESS
  P. Stirbys, A. Ramanausko-Vanago str. 4-7, 49306 Kaunas, Lithuania.
SOURCE
  Journal of Atrial Fibrillation (2013) 5:6 (101-109). Date of Publication: 
2013
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
  Atrial fibrillation continues to be a challenging arrhythmia. There are some 
conventional, time-tested explanations of atrial fibrillation genesis, 
however some uncertainty of its complete understanding still exists. We 
focused on atrial ischemia which, hypothetically, could be responsible for 
manifestation of the arrhythmia, irrespective of the underlying heart 
disease. Evidences abounds that atrial fibrillation has an extremely strong 
association with nutritional/oxidative status of myocardium. This arrhythmia 
seemingly may stem from the electrophysiological differences taking place in 
the boundary areas. To validate such assumptions we have surveyed widely 
accepted theories based on clinical and experimental evidence. There was an 
attempt to integrate some well-known theoretical explanations (focal, 
multifocal, ectopic, reentrant activity, atrial remodeling, etc.) into a new 
conceptually systematized arrhythmogenesis. Confronting ischemic and 
non-ischemic atrial zones electrophysiologically on their borderlines 
presumably creates a substrate vulnerable to the development of atrial 
fibrillation. The behavior of these interrelated areas is likely 
ischemia-dependent; the separating borderline(s) may be treated as 
conflictogenic, releasing triggers/drivers to commence and to perpetuate the 
arrhythmia. Ischemically damaged and non-damaged myocardial areas likely 
participate in the relay-race carousel of arrhythmogenicity due to their 
mutual interactions, accompanied by the "fireworks" at the separating 
borderlines. It could be concluded that myocardial ischemia as a nonspecific 
proarrhythmic factor presumably plays a key role in the genesis and 
sustenance of atrial fibrillation. Theoretically the most important step in 
eradication of arrhythmogenic substrate might be an overall abolition of 
ischemia regardless of the characteristics of underlying heart disease. 
Innovative intellectual and explorative research is needed to render 
innocuous the ischemia that might help us win the century's 
cardioarrhythmological battle.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (etiology)
  heart muscle ischemia
EMTREE MEDICAL INDEX TERMS
  arrhythmogenesis
  artery blood flow
  calcium current
  defibrillation
  heart atrium enlargement
  heart conduction
  heart electrophysiology
  heart muscle fibrosis
  heart muscle injury
  human
  inflammation
  potassium current
  review
  vascularization
  vasospasm
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013283313
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 273
TITLE
  Heart failure: Best options when ejection fraction is preserved
AUTHOR NAMES
  Mills G.D.
  Scott K.C.
AUTHOR ADDRESSES
  (Mills G.D., Geoffrey.Mills@jefferson.edu; Scott K.C.) Department of Family 
and Community Medicine, Jefferson Medical College, 833 Chestnut Street, 
Philadelphia, PA 19107, United States.
(Mills G.D., Geoffrey.Mills@jefferson.edu) Department of Physiology, 
Jefferson Medical College, Philadelphia, PA, United States.
CORRESPONDENCE ADDRESS
  G.D. Mills, Department of Family and Community Medicine, Jefferson Medical 
College, 833 Chestnut Street, Philadelphia, PA 19107, United States. Email: 
Geoffrey.Mills@jefferson.edu
SOURCE
  Journal of Family Practice (2013) 62:5 (236-243). Date of Publication: May 
2013
ISSN
  0094-3509
  1533-7294 (electronic)
BOOK PUBLISHER
  Dowden Health Media,Inc, 110 Summit Avenue, Montvale, United States.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  aldosterone antagonist (drug therapy)
  angiotensin receptor antagonist (adverse drug reaction, drug combination, 
drug therapy)
  antithrombocytic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  bisoprolol (drug therapy)
  brain natriuretic peptide (endogenous compound)
  calcium channel blocking agent (adverse drug reaction, drug therapy)
  candesartan (adverse drug reaction, clinical trial, drug therapy)
  carvedilol (drug therapy)
  digoxin
  diltiazem (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, drug 
combination, drug therapy)
  diuretic agent (adverse drug reaction, clinical trial, drug therapy)
  dobutamine
  eplerenone (drug therapy)
  hydrochlorothiazide (drug comparison, drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  irbesartan (clinical trial, drug therapy)
  lisinopril
  losartan (drug comparison, drug therapy)
  low density lipoprotein cholesterol (endogenous compound)
  metoprolol (drug therapy)
  mevinolin
  nebivolol (clinical trial, drug therapy)
  nitrate (adverse drug reaction, drug therapy)
  perindopril (clinical trial, drug therapy)
  spironolactone (drug therapy)
  verapamil (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure with preserved ejection fraction (drug therapy, diagnosis, 
disease management, drug therapy, etiology, therapy)
EMTREE MEDICAL INDEX TERMS
  acute kidney failure (side effect)
  anamnesis
  article
  atrial fibrillation (therapy)
  cardiopulmonary exercise test
  cardiovascular mortality
  cardioversion
  clinical trial (topic)
  consensus development
  coronary artery disease
  diet therapy
  disease course
  disease exacerbation
  Doppler echocardiography
  drug dose increase
  drug withdrawal
  echocardiography
  electrocardiogram
  evidence based medicine
  exercise
  fluid balance
  fluid retention
  heart atrium contraction
  heart atrium pressure
  heart catheterization
  heart left ventricle contraction
  heart left ventricle filling
  heart left ventricle hypertrophy
  heart muscle ischemia (prevention)
  heart rate
  human
  hypertension
  hypertrophic cardiomyopathy
  hypotension (side effect)
  lifestyle modification
  quality of life
  renin angiotensin aldosterone system
  screening
  sinus tachycardia
  sodium restriction
  tachycardia (prevention)
  thorax radiography
  unspecified side effect (side effect)
  vasoconstriction
  weight reduction
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  bisoprolol (66722-44-9)
  brain natriuretic peptide (114471-18-0)
  candesartan (139481-59-7)
  carvedilol (72956-09-3)
  digoxin (20830-75-5, 57285-89-9)
  diltiazem (33286-22-5, 42399-41-7)
  dobutamine (34368-04-2, 49745-95-1, 52663-81-7, 61661-06-1)
  eplerenone (107724-20-9)
  hydrochlorothiazide (58-93-5)
  irbesartan (138402-11-6)
  lisinopril (76547-98-3, 83915-83-7)
  losartan (114798-26-4)
  metoprolol (37350-58-6)
  mevinolin (75330-75-5)
  nebivolol (118457-15-1, 118457-16-2, 99200-09-6)
  nitrate (14797-55-8)
  perindopril (82834-16-0, 99149-83-4)
  spironolactone (52-01-7)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2013534555
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 274
TITLE
  Einthoven dissertation prizes 2012
AUTHOR NAMES
  Van der Wall E.E.
  Van Gilst W.H.
  Schalij M.J.
  Umans V.
AUTHOR ADDRESSES
  (Van der Wall E.E., e.e.van_der_wall@lumc.nl; Van Gilst W.H.) 
Interuniversity Cardiology Institute of the Netherlands (ICIN), Netherlands 
Heart Institute (NHI), Utrecht, Netherlands.
(Schalij M.J.) Department of Cardiology, Leiden University Medical Center, 
Leiden, Netherlands.
(Umans V.) Department of Cardiology, Medical Center Alkmaar, Alkmaar, 
Netherlands.
CORRESPONDENCE ADDRESS
  E. E. Van der wall, Interuniversity Cardiology Institute of the Netherlands 
(ICIN), Netherlands Heart Institute (NHI), Utrecht, Netherlands. Email: 
e.e.van_der_wall@lumc.nl
SOURCE
  Netherlands Heart Journal (2013) 21:5 (256-261). Date of Publication: May 
2013
ISSN
  1568-5888
  1876-6250 (electronic)
BOOK PUBLISHER
  Bohn Stafleu van Loghum, P.O. Box 75971, Amsterdam, Netherlands.
EMTREE DRUG INDEX TERMS
  anticoagulant agent
  apixaban (adverse drug reaction, drug therapy, oral drug administration)
  dabigatran (adverse drug reaction, drug therapy, oral drug administration)
  potassium channel KCNQ1 (endogenous compound)
  sodium channel Nav1.5 (endogenous compound)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  awards and prizes
  scientific literature
EMTREE MEDICAL INDEX TERMS
  3' untranslated region
  article
  atrial fibrillation
  bleeding (side effect)
  Brugada syndrome
  cardiac resynchronization therapy
  cardiovascular disease (drug therapy)
  exercise
  fever
  follow up
  health survey
  heart arrhythmia
  heart failure
  human
  long QT syndrome
  phenotype
  risk factor
  scoring system
  single nucleotide polymorphism
  treatment outcome
CAS REGISTRY NUMBERS
  apixaban (503612-47-3)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2013288943
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12471-013-0404-0
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 275
TITLE
  Heart disease as a risk factor for dementia
AUTHOR NAMES
  Ng J.B.
  Turek M.
  Hakim A.M.
AUTHOR ADDRESSES
  (Ng J.B.) Departments of Neuroscience and Psychology, McGill University, 
Montreal, QC, Canada.
(Turek M.) Division of Cardiology, The Ottawa Hospital, Ottawa, Canada.
(Turek M.) Department of Medicine, University of Ottawa, Ottawa, Canada.
(Hakim A.M., ahakim@ohri.ca) Division of Neurology, The Ottawa Hospital, 
Ottawa, Canada.
(Hakim A.M., ahakim@ohri.ca) Brain and Mind Research Institute, University 
of Ottawa, Ottawa, Canada.
(Hakim A.M., ahakim@ohri.ca) Ottawa Hospital Research Institute, The Ottawa 
Hospital, Ottawa, Canada.
(Hakim A.M., ahakim@ohri.ca) Canadian Stroke Network, Ottawa, ON, Canada.
CORRESPONDENCE ADDRESS
  A. M. Hakim, University of Ottawa, 2413-451 Smyth Road, Ottawa, ON K1H 8M5, 
Canada. Email: ahakim@ohri.ca
SOURCE
  Clinical Epidemiology (2013) 5:1 (135-145). Date of Publication: 25 Apr 2013
ISSN
  1179-1349 (electronic)
BOOK PUBLISHER
  Dove Medical Press Ltd, Beechfield House, Winterton Way, Macclesfield, 
United Kingdom.
ABSTRACT
  As life expectancy lengthens, dementia is becoming a significant human 
condition in terms of its prevalence and cost to society worldwide. It is 
important in that context to understand the preventable and treatable causes 
of dementia. This article exposes the link between dementia and heart 
disease in all its forms, including coronary artery disease, myocardial 
infarction, atrial fibrillation, valvular disease, and heart failure. This 
article also explores the cardiovascular risk factors and emphasizes that 
several of them are preventable and treatable. In addition to medical 
therapies, the lifestyle changes that may be useful in retarding the onset 
of dementia are also summarized. © 2013 Ng et al, publisher and licensee 
Dove Medical Press Ltd.
EMTREE DRUG INDEX TERMS
  advanced glycation end product (endogenous compound)
  amyloid beta protein (endogenous compound)
  antihypertensive agent (clinical trial, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  donepezil (drug therapy, pharmacology)
  gelatinase B (endogenous compound)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  nitrendipine (clinical trial, drug therapy)
  omega 3 fatty acid
  placebo
  tau protein (endogenous compound)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  dementia (complication, etiology, prevention)
  heart disease (prevention)
EMTREE MEDICAL INDEX TERMS
  Alzheimer disease (drug therapy, etiology, therapy)
  atherosclerosis
  atrial fibrillation (drug therapy)
  blood brain barrier
  brain blood flow
  brain embolism
  brain hemorrhage
  brain perfusion
  brain size
  cardiovascular risk
  cerebrovascular accident (drug therapy)
  cognitive defect (prevention)
  coronary artery disease
  disease association
  drug efficacy
  drug mechanism
  enzyme inhibition
  exercise
  food intake
  heart failure (drug therapy)
  heart infarction
  human
  hypercholesterolemia (drug therapy)
  hypertension (drug therapy)
  hypotension
  lifestyle modification
  Mediterranean diet
  multiinfarct dementia (etiology, prevention)
  obesity
  pathogenesis
  review
  risk assessment
  risk factor
  risk reduction
  smoking
  valvular heart disease
CAS REGISTRY NUMBERS
  amyloid beta protein (109770-29-8)
  donepezil (120011-70-3, 120014-06-4, 142057-77-0)
  gelatinase B (146480-36-6)
  nitrendipine (39562-70-4)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013280054
FULL TEXT LINK
  http://dx.doi.org/10.2147/CLEP.S30621
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 276
TITLE
  The YOGA my heart study
AUTHOR NAMES
  Baliga R.
AUTHOR ADDRESSES
  (Baliga R.) Division of Cardiovascular Medicine, Wexner Medical Center, 
United States.
(Baliga R.) The Ohio State University, Columbus, United States.
CORRESPONDENCE ADDRESS
  R. Baliga, Division of Cardiovascular Medicine, Wexner Medical Center, 
United States.
SOURCE
  Cardiology Review (2013) 29:2. Date of Publication: April 2013
ISSN
  1092-6607
BOOK PUBLISHER
  Ascend Media, 103 College Road East, Princeton, United States.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (therapy)
  yoga
EMTREE MEDICAL INDEX TERMS
  anxiety
  clinical effectiveness
  depression
  diastolic blood pressure
  functional status
  heart rate
  human
  mental health
  outcome assessment
  patient safety
  physical performance
  quality of life
  review
  Short Form 36
  social interaction
  systolic blood pressure
  therapy effect
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2013336286
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 277
TITLE
  EuroHeartCare 2013
AUTHOR ADDRESSES
  SOURCE
  European Journal of Cardiovascular Nursing (2013) 12 SUPPL. 1. Date of 
Publication: April 2013
CONFERENCE NAME
  EuroHeartCare 2013
CONFERENCE LOCATION
  Glasgow, United Kingdom
CONFERENCE DATE
  2013-03-22 to 2013-03-23
ISSN
  1474-5151
BOOK PUBLISHER
  SAGE Publications Inc.
ABSTRACT
  The proceedings contain 156 papers. The topics discussed include: 
deactivation of the implantable cardioverter defibrillator: the patient 
perspective; cost-effectiveness of a nurse-led integrated chronic care 
program for patients with atiral fibrillation; psychometric testing of the 
self-care of chronic angina Index (SCCAI); a nurse led pre admission 
education program for elective adult cardiac surgical patients- a pilot 
study using an interdiscplinary approach; the natural history of coronary 
calcification: a meta-analysis from St Francis and EBEAT trials; the burden 
of caregiving in chronic heart failure: a qualitative study; impact of acute 
hyperglycemia after angioplasty for acute myocardial infarction; effects of 
medical yoga in quality of life, blood pressure and heart rate in patients 
with paroxysmal atrial fibrillation; region-wide automatic referral to 
cardiac rehabilitation is associated with improved referral rates; and 
evidence of persisting Yentl syndrome in Romania.
EMTREE MEDICAL INDEX TERMS
  acute heart infarction
  adult
  angina pectoris
  angioplasty
  atrial fibrillation
  blood pressure
  calcification
  cost effectiveness analysis
  education program
  heart failure
  heart rate
  heart rehabilitation
  history
  human
  hyperglycemia
  implantable cardioverter defibrillator
  meta analysis
  meta analysis (topic)
  nurse
  patient
  pilot study
  qualitative research
  quality of life
  Romania
  self care
  surgical patient
  yoga
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 278
TITLE
  Winter cardiovascular diseases phenomenon
AUTHOR NAMES
  Fares A.
AUTHOR ADDRESSES
  (Fares A., audafares@yahoo.com) Department of Internal Medicine, Uinversity 
Hospital Bochum, Bedburg, Germany.
CORRESPONDENCE ADDRESS
  A. Fares, Albert-Schlangen Str. 36, 50181 Bedburg, Germany. Email: 
audafares@yahoo.com
SOURCE
  North American Journal of Medical Sciences (2013) 5:4 (266-279). Date of 
Publication: April 2013
ISSN
  2250-1541
  1947-2714 (electronic)
BOOK PUBLISHER
  North American Journal of Medical Sciences, T3330-50-B Charlton Ave, 
Hamilton, Canada.
ABSTRACT
  This paper review seasonal patterns across twelve cardiovascular diseases: 
Deep venous thrombosis, pulmonary embolism, aortic dissection and rupture, 
stroke, intracerebral hemorrhage, hypertension, heart failure, angina 
pectoris, myocardial infarction, sudden cardiac death, venricular arrythmia 
and atrial fibrillation, and discuss a possible cause of the occurrence of 
these diseases. There is a clear seasonal trend of cardiovascular diseases, 
with the highest incidence occurring during the colder winter months, which 
have been described in many countries. This phenomenon likely contributes to 
the numbers of deaths occurring in winter. The implications of this finding 
are important for testing the relative importance of the proposed 
mechanisms. Understanding the influence of season and other factors is 
essential when seeking to implement effective public health measures.
EMTREE DRUG INDEX TERMS
  aldosterone (endogenous compound)
  blood clotting factor 7 (endogenous compound)
  catecholamine (endogenous compound)
  cholesterol (endogenous compound)
  noradrenalin (endogenous compound)
  renin (endogenous compound)
  vitamin D (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease
  seasonal affective disorder
EMTREE MEDICAL INDEX TERMS
  acute heart infarction
  age
  air pollution
  angina pectoris
  aorta aneurysm
  aorta dissection
  aorta rupture
  atrial fibrillation
  blood pressure
  brain hemorrhage
  cardiovascular risk
  cerebrovascular accident
  death
  deep vein thrombosis
  diet
  disease association
  heart failure
  heart ventricle arrhythmia
  human
  hypertension
  incidence
  infection
  lung embolism
  meta analysis (topic)
  nonhuman
  obesity
  oxidative stress
  physical activity
  public health
  review
  seasonal variation
  sex
  sudden death
  systematic review (topic)
  temperature
  transient ischemic attack
  venous thromboembolism
  winter
CAS REGISTRY NUMBERS
  aldosterone (52-39-1, 6251-69-0)
  blood clotting factor 7 (9001-25-6)
  cholesterol (57-88-5)
  noradrenalin (1407-84-7, 51-41-2)
  renin (61506-93-2, 9015-94-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Public Health, Social Medicine and Epidemiology (17)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013236266
FULL TEXT LINK
  http://dx.doi.org/10.4103/1947-2714.110430
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 279
TITLE
  The influence of systematic pulse-limited physical exercise on the 
parameters of the cardiovascular system in patients over 65 years of age
AUTHOR NAMES
  Chomiuk T.
  Folga A.
  Mamcarz A.
AUTHOR ADDRESSES
  (Chomiuk T.; Folga A., and.folga@gmail.com; Mamcarz A.) 3rd Department of 
Internal Medicine and Cardiology, Medical University of Warsaw, 93 Solec St, 
00-382 Warsaw, Poland.
CORRESPONDENCE ADDRESS
  A. Folga, 3rd Department of Internal Medicine and Cardiology, Medical 
University of Warsaw, 93 Solec St, 00-382 Warsaw, Poland. Email: 
and.folga@gmail.com
SOURCE
  Archives of Medical Science (2013) 9:2 (201-209). Date of Publication: April 
2013
ISSN
  1734-1922
BOOK PUBLISHER
  Termedia Publishing House Ltd., Kleeberqa St.2, Poznan, Poland.
ABSTRACT
  Introduction: The influence of physical exercise on the parameters of the 
cardiovascular system of elderly persons has not been sufficiently 
investigated yet. The aim of the study was to assess the influence of 
regular 6-week physical exercise using the Nordic walking (NW) method in a 
group of elderly persons on their physical performance and regulation of 
selected parameters assessing the cardiovascular system. Material and 
methods: Fifty patients over 65 years of age participated in the study. The 
study encompassed: medical interview, physical examination, resting ECG, 
spiroergometry examination, 6MWT (6-minute walk test) and 24-hour ambulatory 
blood pressure monitoring (ABPM). During the exercise programme, the pulse 
was monitored using pulsometers. After the completion of the training, 
check-up tests assessing the same parameters were performed. The control 
group consisted of 18 persons over 65 years of age with similar 
cardiovascular problems. Results: In the test group, duration of the 
physical effort increased by 1.02 min (p = 0.0001), the maximum load 
increased by 10.68 W (p = 0.0001), values of VO(2max) by 2.10 (p = 0.0218), 
distance improved in 6MWT by 75.04 m (p = 0.00001), systolic blood pressure 
decreased by 5.50 mm Hg (p = 0.035) and diastolic blood pressure by 3.50 mm 
Hg (p = 0.054) as compared to the control group. Conclusions: Systematic NW 
physical exercise limited by the pulse had a beneficial effect on the 
physical performance of elderly persons as assessed with main parameters. A 
short 6-week programme of endurance exercises had a hypotensive effect in 
elderly persons over 65 years of age. Copyright © 2013 Termedia & Banach.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular system
  exercise
  pulse rate
EMTREE MEDICAL INDEX TERMS
  6 minute walk test
  aged
  anaerobic exercise
  article
  asthma
  atrial fibrillation
  blood pressure monitoring
  body surface
  cerebrovascular accident
  chronic obstructive lung disease
  clinical assessment
  clinical assessment tool
  controlled study
  diabetes mellitus
  diastolic blood pressure
  dyslipidemia
  echocardiography
  endurance training
  ergometry
  female
  heart failure
  heart infarction
  human
  hypertension
  hypothyroidism
  interview
  ischemic heart disease
  major clinical study
  male
  maximum allowable concentration
  medical history
  Nordic walking method
  osteoporosis
  physical examination
  physical performance
  smoking
  systolic blood pressure
  walking
EMBASE CLASSIFICATIONS
  Physiology (2)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013277981
FULL TEXT LINK
  http://dx.doi.org/10.5114/aoms.2013.34559
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 280
TITLE
  The effect of integrated cardiac rehabilitation versus treatment as usual 
for atrial fibrillation patients treated with ablation: The randomised 
CopenHeart(RFA) trial protocol
AUTHOR NAMES
  Risom S.S.
  Zwisler A.-D.O.
  Rasmussen T.B.
  Sibilitz K.L.
  Svendsen J.H.
  Gluud C.
  Hansen J.L.
  Winkel P.
  Thygesen L.C.
  Perhonen M.
  Hansen J.
  Dunbar S.B.
  Berg S.K.
AUTHOR ADDRESSES
  (Risom S.S., signe.stelling.risom@rh.regionh.dk; Zwisler A.-D.O.; Rasmussen 
T.B.; Sibilitz K.L.; Svendsen J.H.; Berg S.K.) Heart Centre, Copenhagen 
University Hospital, Rigshospitalet, Copenhagen, Denmark.
(Zwisler A.-D.O.; Thygesen L.C.) National Institute of Public Health, 
University of Southern Denmark, Copenhagen, Denmark.
(Rasmussen T.B.; Hansen J.; Berg S.K.) Danish National Research Foundation 
Centre for Cardiac Arrhythmia (DARC), Copenhagen, Denmark.
(Svendsen J.H.) Department of Cardiology, Gentofte Hospital, Gentofte, 
Denmark.
(Gluud C.; Hansen J.L.; Winkel P.) Copenhagen Trial Unit, Centre for 
Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, 
Denmark.
(Perhonen M.) CorusFit, Jyväskylä, Finland.
(Dunbar S.B.) Nell Hodgson Woodruff School of Nursing, Emory University 
Atlanta, Druid Hills, GA, United States.
CORRESPONDENCE ADDRESS
  S.S. Risom, Heart Centre, Copenhagen University Hospital, Rigshospitalet, 
Copenhagen, Denmark. Email: signe.stelling.risom@rh.regionh.dk
SOURCE
  BMJ Open (2013) 3:2 Article Number: e002377. Date of Publication: 2013
ISSN
  2044-6055 (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
  Introduction: Atrial fibrillation affects almost 2% of the population in the 
Western world. To preserve sinus rhythm, ablation is undertaken in 
symptomatic patients. Observational studies show that patients with atrial 
fibrillation often report a low quality of life and are less prone to be 
physically active due to fear of triggering fibrillation. Small trials 
indicate that exercise training has a positive effect on exercise capacity 
and mental health, and both patients with recurrent atrial fibrillation and 
in sinus rhythm may benefit from rehabilitation in managing life after 
ablation. No randomised trials have been published on cardiac rehabilitation 
for atrial fibrillation patients treated with ablation that includes 
exercise and psychoeducational components. Aim: To test the effects of an 
integrated cardiac rehabilitation programme versus treatment as usual for 
patients with atrial fibrillation treated with ablation. Methods and 
analysis design: The trial is a multicentre parallel arm design with 1:1 
randomisation to the intervention and control group with blinded outcome 
assessment. 210 patients treated for atrial fibrillation with radiofrequency 
ablation will be included. The intervention consists of a rehabilitation 
programme including four psychoeducative consultations with a specially 
trained nurse and 12 weeks of individualised exercise training, plus the 
standard medical follow-up. Patients in the control group will receive the 
standard medical follow-up. The primary outcome measure is exercise capacity 
measured by the VO(2) peak. The secondary outcome measure is self-rated 
mental health measured by the Short Form 36 questionnaire. Postintervention, 
qualitative interviews will be conducted in 10% of the intervention group. 
Ethics and dissemination: The protocol is approved by the regional research 
ethics committee (number H-1-2011-135), the Danish Data Protection Agency 
(reg. nr. 2007-58-0015) and follows the latest version of the Declaration of 
Helsinki. The results will be published in peer-reviewed journals and may 
possibly impact on rehabilitation guidelines.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (rehabilitation, surgery, therapy)
  heart rehabilitation
  radiofrequency ablation
EMTREE MEDICAL INDEX TERMS
  article
  consultation
  controlled study
  exercise
  female
  follow up
  human
  intermethod comparison
  interview
  major clinical study
  male
  multicenter study
  randomized controlled trial
  Short Form 36
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT01523145)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013164643
FULL TEXT LINK
  http://dx.doi.org/10.1136/bmjopen-2012-002377
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 281
TITLE
  Effect of yoga on arrhythmia burden, anxiety, depression, and quality of 
life in paroxysmal atrial fibrillation: The YOGA my heart study
AUTHOR NAMES
  Lakkireddy D.
  Atkins D.
  Pillarisetti J.
  Ryschon K.
  Bommana S.
  Drisko J.
  Vanga S.
  Dawn B.
AUTHOR ADDRESSES
  (Lakkireddy D., dlakkireddy@mac.md; Atkins D.; Pillarisetti J.; Bommana S.; 
Dawn B.) EP Research-KU Cardiovascular Research Institute, Bloch Heart 
Rhythm Center, University of Kansas Hospital, 3901 Rainbow Boulevard, Kansas 
City, KS 66160, United States.
(Ryschon K.) Ryschon Consulting Services LLC, Omaha, NB, United States.
(Drisko J.) Program in Integrative Medicine, University of Kansas, Medical 
Center, Kansas City, KS, United States.
(Vanga S.) Christiana Hospital, Newark, DE, United States.
CORRESPONDENCE ADDRESS
  D. Lakkireddy, EP Research-KU Cardiovascular Research Institute, Bloch Heart 
Rhythm Center, University of Kansas Hospital, 3901 Rainbow Boulevard, Kansas 
City, KS 66160, United States. Email: dlakkireddy@mac.md
SOURCE
  Journal of the American College of Cardiology (2013) 61:11 (1177-1182). Date 
of Publication: 19 Mar 2013
ISSN
  0735-1097
  1558-3597 (electronic)
BOOK PUBLISHER
  Elsevier USA, 6277 Sea Harbor Drive, Orlando, United States.
ABSTRACT
  Objectives: The purpose of this study was to examine the impact of yoga on 
atrial fibrillation (AF) burden, quality of life (QoL), depression, and 
anxiety scores. Background: Yoga is known to have significant benefit on 
cardiovascular health. The effect of yoga in reducing AF burden is unknown. 
Methods: This single-center, pre-post study enrolled patients with 
symptomatic paroxysmal AF with an initial 3-month noninterventional 
observation period followed by twice-weekly 60-min yoga training for next 3 
months. AF episodes during the control and study periods as well as SF-36, 
Zung self-rated anxiety, and Zung self-rated depression scores at baseline, 
before, and after the study phase were assessed. Results: Yoga training 
reduced symptomatic AF episodes (3.8 ± 3 vs. 2.1 ± 2.6, p < 0.001), 
symptomatic non-AF episodes (2.9 ± 3.4 vs. 1.4 ± 2.0; p < 0.001), 
asymptomatic AF episodes (0.12 ± 0.44 vs. 0.04 ± 0.20; p < 0.001), and 
depression and anxiety (p < 0.001), and improved the QoL parameters of 
physical functioning, general health, vitality, social functioning, and 
mental health domains on SF-36 (p = 0.017, p < 0.001, p < 0.001, p = 0.019, 
and p < 0.001, respectively). There was significant decrease in heart rate, 
and systolic and diastolic blood pressure before and after yoga (p < 0.001). 
Conclusions: In patients with paroxysmal AF, yoga improves symptoms, 
arrhythmia burden, heart rate, blood pressure, anxiety and depression 
scores, and several domains of QoL. © 2013 by the American College of 
Cardiology Foundation.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  angiotensin receptor antagonist (drug therapy)
  antiarrhythmic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anxiety disorder (therapy)
  atrial fibrillation (drug therapy, drug therapy, therapy)
  depression (therapy)
  heart arrhythmia (therapy)
  quality of life
  yoga
EMTREE MEDICAL INDEX TERMS
  adult
  article
  cardiovascular function
  clinical article
  clinical effectiveness
  controlled clinical trial
  controlled study
  correlation analysis
  diastolic blood pressure
  female
  health status
  heart rate
  hemodynamics
  human
  male
  mental health
  percutaneous coronary intervention
  priority journal
  prospective study
  social interaction
  systolic blood pressure
  therapy effect
  treatment duration
  treatment response
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Psychiatry (32)
  Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00798356)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014076347
MEDLINE PMID
  23375926 (http://www.ncbi.nlm.nih.gov/pubmed/23375926)
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.jacc.2012.11.060
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 282
TITLE
  Exercise testing for risk stratification of ventricular arrhythmias in the 
athlete
AUTHOR NAMES
  Schmied C.
  Brunckhorst C.
  Duru F.
  Haegeli L.
AUTHOR ADDRESSES
  (Schmied C., christian.schmied@usz.ch; Brunckhorst C.; Duru F.; Haegeli L.) 
Cardiovascular Centre, Division of Cardiology, University Hospital Zürich, 
Raemistrasse 100, Zürich 8091, Switzerland.
CORRESPONDENCE ADDRESS
  C. Schmied, Clinic for Cardiology, Cardiovascular Center, Division of 
Cardiology, University Hospital Zürich, Raemistrasse 100, Zürich 8091, 
Switzerland. Email: christian.schmied@usz.ch
SOURCE
  Cardiac Electrophysiology Clinics (2013) 5:1 (53-64). Date of Publication: 
2013
ISSN
  1877-9182
  1877-9190 (electronic)
BOOK PUBLISHER
  W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
  Exercise testing is an important diagnostic tool that creates an environment 
of automaticity at the electrical membrane, which tolerates premature beats 
and re-entrant arrhythmogenic circuits. Exercise testing mimics the 
authentic situation of physical activity and stress, recognized as a fatal 
trigger of critical arrhythmias in cases of underlying cardiac risk 
constellation. Although it is established as a second-line diagnostic tool, 
exercise testing can provide crucial information in an earlier setting, if 
there are exercise-dependent symptoms in an athlete's history, clinical 
suspicion of an underlying structural or primarily electrical heart disease, 
or known structural or electrical disease. © 2013 Elsevier Inc.
EMTREE DRUG INDEX TERMS
  adrenergic receptor stimulating agent (drug therapy)
  antiarrhythmic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium ion (endogenous compound)
  potassium (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, diagnosis, drug therapy, epidemiology, 
therapy)
  cardiovascular disease (diagnosis, epidemiology, therapy)
  catecholaminergic polymorphic ventricular tachycardia (drug therapy, 
diagnosis, drug therapy, epidemiology, therapy)
  exercise test
  heart ventricle arrhythmia (drug therapy, diagnosis, drug therapy, 
epidemiology, therapy)
  ischemic heart disease (drug therapy, diagnosis, drug therapy, epidemiology, 
therapy)
EMTREE MEDICAL INDEX TERMS
  athlete
  Chagas disease
  clinical protocol
  congenital heart disease (congenital disorder)
  cytosol
  defibrillation
  exercise
  heart right ventricle dysplasia
  heart ventricle tachycardia (drug therapy, therapy)
  Holter monitor
  Holter monitoring
  human
  hypertrophic cardiomyopathy
  implantable cardioverter defibrillator
  long QT syndrome
  mortality
  nonsustained ventricular tachycardia (therapy)
  pathophysiology
  potassium blood level
  priority journal
  prognosis
  QRS complex
  review
  risk assessment
  risk factor
  sports medicine
  sudden death
  Wolff Parkinson White syndrome
CAS REGISTRY NUMBERS
  calcium ion (14127-61-8)
  potassium (7440-09-7)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Occupational Health and Industrial Medicine (35)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013138838
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ccep.2012.11.003
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 283
TITLE
  Safety and tolerability of inhalational anticholinergics in COPD
AUTHOR NAMES
  Sharafkhaneh A.
  Majid H.
  Gross N.J.
AUTHOR ADDRESSES
  (Sharafkhaneh A., amirs@bcm.edu) Baylor College of Medicine, Department of 
Medicine, Houston, United States.
(Sharafkhaneh A., amirs@bcm.edu) Sleep Disorders Center, Michael E DeBakey 
VA Medical Center, Houston, United States.
(Majid H.) Aga Khan University, Karachi, Pakistan.
(Gross N.J.) Stritch School of Medicine Illinois, St Francis Hospital, 
Hartford, United States.
CORRESPONDENCE ADDRESS
  A. Sharafkhaneh, Baylor College of Medicine, Department of Medicine, MEDVA 
Medical Center Bldg. 100 (111i), Houston, TX 77030, United States. Email: 
amirs@bcm.edu
SOURCE
  Drug, Healthcare and Patient Safety (2013) 5:1 (49-55). Date of Publication: 
7 Mar 2013
ISSN
  1179-1365 (electronic)
BOOK PUBLISHER
  Dove Medical Press Ltd, Beechfield House, Winterton Way, Macclesfield, 
United Kingdom.
ABSTRACT
  Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity 
and mortality. With the significant toll of the disease, more resources have 
been invested in developing new treatment modalities. Among these 
medications, inhalational anticholinergics are widely used for the 
management of stable COPD. The newer agents, with longer half-lives and 
better safety profiles, have emerged and helped to improve management of 
COPD patients. The available data from randomized clinical trials support 
use of these agents. Multiple randomized clinical trials show safety and 
efficacy of the newer long-acting inhaled anticholinergics, including 
tiotropium and aclidinium. A recent meta-analysis of tiotropium delivered 
with Respimat® raised some safety concerns. A large trial, comparing 
different doses and delivery methods of inhaled tiotropium, is ongoing to 
determine the effect on mortality. As clinical trials may not 
comprehensively represent the entire COPD population, caution should be 
exercised when these agents are used in higher-risk populations, like 
individuals with cardiac arrhythmias or urinary obstruction. In this 
publication, we review the safety of inhalational anticholinergics. © 2013 
Sharafkhaneh et al, publisher and licensee Dove Medical Press Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  cholinergic receptor blocking agent (adverse drug reaction, drug therapy, 
inhalational drug administration)
EMTREE DRUG INDEX TERMS
  aclidinium bromide (adverse drug reaction, drug concentration, drug therapy, 
inhalational drug administration, pharmacokinetics)
  beta adrenergic receptor stimulating agent (drug combination, drug therapy, 
inhalational drug administration)
  ipratropium bromide (adverse drug reaction, drug combination, drug therapy, 
inhalational drug administration, pharmacokinetics)
  oxitropium bromide (drug combination, drug therapy, inhalational drug 
administration)
  placebo
  salbutamol (drug combination, drug therapy)
  tiotropium bromide (adverse drug reaction, clinical trial, drug therapy, 
inhalational drug administration, pharmacokinetics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  chronic obstructive lung disease (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal pain (side effect)
  angina pectoris (side effect)
  atrial fibrillation (side effect)
  blurred vision (side effect)
  bronchospasm (side effect)
  cardiovascular disease (side effect)
  cardiovascular risk
  cataract (side effect)
  cerebrovascular accident (side effect)
  closed angle glaucoma (side effect)
  combination chemotherapy
  congestive heart failure (side effect)
  constipation (side effect)
  coughing (side effect)
  disease exacerbation
  drug absorption
  drug blood level
  drug clearance
  drug efficacy
  drug elimination
  drug excretion
  drug half life
  drug metabolism
  drug safety
  drug tolerability
  dysgeusia (side effect)
  dyspepsia (side effect)
  dysphagia (side effect)
  edema (side effect)
  epistaxis (side effect)
  exercise
  heart arrhythmia (side effect)
  heart infarction (side effect)
  high risk population
  human
  intraocular pressure abnormality (side effect)
  laryngitis (side effect)
  mean residence time
  monotherapy
  mortality
  nausea (side effect)
  pain (side effect)
  paralytic ileus (side effect)
  pharyngitis (side effect)
  quality of life
  recommended drug dose
  review
  rhinitis (side effect)
  rhinorrhea (side effect)
  sinusitis (side effect)
  sore throat (side effect)
  stomatitis (side effect)
  supraventricular tachycardia (side effect)
  throat irritation (side effect)
  upper respiratory tract infection (side effect)
  urinary tract infection (side effect)
  urinary tract obstruction
  urine retention (side effect)
  urogenital tract disease (side effect)
  vomiting (side effect)
  xerostomia (side effect)
DRUG TRADE NAMES
  atrovent  Boehringer Ingelheim

DRUG MANUFACTURERS
  Boehringer Ingelheim
CAS REGISTRY NUMBERS
  aclidinium bromide (320345-99-1)
  ipratropium bromide (22254-24-6)
  oxitropium bromide (30286-75-0)
  salbutamol (18559-94-9, 35763-26-9)
  tiotropium bromide (136310-93-5)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013168937
FULL TEXT LINK
  http://dx.doi.org/10.2147/DHPS.S7771
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 284
TITLE
  Communications to the British Geriatrics Society Autumn Meeting 2012
AUTHOR ADDRESSES
  SOURCE
  Age and Ageing (2013) 42 SUPPL. 2. Date of Publication: March 2013
CONFERENCE NAME
  British Geriatrics Society Autumn Meeting 2012
CONFERENCE LOCATION
  Harrogate, United Kingdom
CONFERENCE DATE
  2012-11-28 to 2012-11-30
ISSN
  0002-0729
BOOK PUBLISHER
  Oxford University Press
ABSTRACT
  The proceedings contain 104 papers. The topics discussed include: 
deprivation in cold weather increases the risk of hospital admission with 
hypothermia in older people; depression associates with mini nutritional 
assessment (MNA), vitamin B12 and folate status; findings in the BELFAST 
elderly longitudinal free-living ageing study (BELFAST); outcomes of trauma 
admissions in the centenarian population; inflammaging: powering the 
biological clock of telomere length?; comparison of three fracture 
prediction tools in an osteoporosis clinic population; use of ace 
inhibitors, statins or thiazides is not associated with slower decline in 
grip strength in older people - results from the hertfordshire cohort study; 
relationship of orthostatic hypotension and bone mineral density; and atrial 
fibrillation is under recognised and inappropriately treated in older 
adults: cross-sectional findings from the Irish longitudinal study on ageing 
(TILDA).
EMTREE DRUG INDEX TERMS
  cyanocobalamin
  dipeptidyl carboxypeptidase inhibitor
  folic acid
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  thiazide diuretic agent
  vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  autumn
  geriatrics
  interpersonal communication
  society
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  aging
  atrial fibrillation
  biological rhythm
  bone density
  cohort analysis
  cold exposure
  fracture
  grip strength
  hospital
  hospital admission
  human
  hypothermia
  injury
  longitudinal study
  nutritional assessment
  orthostatic hypotension
  osteoporosis
  population
  prediction
  risk
  telomere
  very elderly
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 285
TITLE
  Effects of pharmacologic therapy on health-related quality of life in 
elderly patients with atrial fibrillation: A systematic review of randomized 
and nonrandomized trials
AUTHOR NAMES
  Pepine C.J.
AUTHOR ADDRESSES
  (Pepine C.J., carl.pepine@medicine.ufl.edu) Division of Cardiovascular 
Medicine, University of Florida College of Medicine, Gainesville, FL, United 
States.
CORRESPONDENCE ADDRESS
  C. J. Pepine, Division of Cardiovascular Medicine, University of Florida 
College of Medicine, Gainesville, FL, United States. Email: 
carl.pepine@medicine.ufl.edu
SOURCE
  Clinical Medicine Insights: Cardiology (2013) 7 (1-20). Date of Publication: 
2013
ISSN
  1179-5468
BOOK PUBLISHER
  Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay, 
Auckland, New Zealand.
ABSTRACT
  This systematic review assessed the impact of atrial fibrillation (AF) and 
pharmacotherapy on health-related quality of life (HRQOL) in elderly 
patients. Highly prevalent in the elderly, AF is associated with morbidity 
and symptoms affecting HRQOL. A PubMed and EMBASE search (1999-2010) was 
conducted using the terms atrial fibrillation, elderly, quality of life, 
Medicare, and Medicaid. In all, 504 articles were identified and 15 were 
selected (studies examining pharmacotherapy [rate or rhythm control] and 
HRQOL in AF patients with a mean age ≥ 65 years). Information, including 
study design, cohort size, and HRQOL instruments utilized, was extracted. 
Five observational studies, 5 randomized trials comparing rate and rhythm 
control, 3 randomized trials investigating pharmacologic agents, and 2 
trials examining HRQOL, depression, and anxiety were identified. Elderly AF 
patients had reduced HRQOL versus patients in normal sinus rhythm, 
particularly in domains related to physical functioning. HRQOL may be 
particularly affected in older AF patients. Although data do not indicate 
whether a pharmacologic intervention or single treatment strategy-namely 
rate versus rhythm control-is better at improving HRQOL, either of these 
strategies and many pharmacologic interventions may improve HRQOL in elderly 
AF patients. Based on reviewed data, an algorithm is suggested to optimize 
HRQOL among elderly patients. © the author(s), publisher and licensee 
Libertas Academica Ltd.
EMTREE DRUG INDEX TERMS
  amiodarone (clinical trial, drug comparison, drug therapy)
  beta adrenergic receptor blocking agent (clinical trial, drug comparison, 
drug therapy)
  calcium antagonist (clinical trial, drug comparison, drug therapy)
  digitalis (clinical trial, drug therapy)
  placebo
  propafenone (clinical trial, drug comparison, drug therapy)
  sotalol (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy, therapy)
  pharmaceutical care
  quality of life
EMTREE MEDICAL INDEX TERMS
  anxiety
  cardioversion
  depression
  disease severity
  drug effect
  drug efficacy
  exercise
  heart rate
  heart rhythm
  human
  paroxysmal atrial fibrillation
  questionnaire
  randomized controlled trial (topic)
  review
  Short Form 36
  sinus rhythm
  symptom
  systematic review
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digitalis (8031-42-3, 8053-83-6)
  propafenone (34183-22-7, 54063-53-5)
  sotalol (3930-20-9, 80456-07-1, 959-24-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013078519
FULL TEXT LINK
  http://dx.doi.org/10.4137/CMC.S10628
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 286
TITLE
  Paget's disease of bone
AUTHOR NAMES
  Ralston S.H.
AUTHOR ADDRESSES
  (Ralston S.H., stuart.ralston@ed.ac.uk) University of Edinburgh, Institute 
of Genetics and Molecular Medicine, Western General Hospital, Edinburgh EH4 
2XU, United Kingdom.
CORRESPONDENCE ADDRESS
  S.H. Ralston, University of Edinburgh, Institute of Genetics and Molecular 
Medicine, Western General Hospital, Edinburgh EH4 2XU, United Kingdom. 
Email: stuart.ralston@ed.ac.uk
SOURCE
  New England Journal of Medicine (2013) 368:7 (644-650). Date of Publication: 
14 Feb 2013
ISSN
  0028-4793
  1533-4406 (electronic)
BOOK PUBLISHER
  Massachussetts Medical Society, 860 Winter Street, Waltham, United States.
ABSTRACT
  A 73-year-old man presents with a 5-year history of low back pain that is 
exacerbated by standing. During the past year, pain has developed in his 
buttocks and legs when he walks, and it is not relieved by acetaminophen. 
The neurologic examination is unremarkable. Radiographs of the spine show 
coarsening of the trabecular pattern in several lumbar and lower thoracic 
vertebrae and expansion of several lumbar vertebral bodies. The total serum 
alkaline phosphatase level is 350 U per liter (reference range, 40 to 125); 
the results of liver-function tests and other routine laboratory tests are 
normal. How should he be further evaluated and treated? Copyright © 2013 
Massachusetts Medical Society.
EMTREE DRUG INDEX TERMS
  alendronic acid (adverse drug reaction, drug therapy)
  alkaline phosphatase (endogenous compound)
  bisphosphonic acid derivative (adverse drug reaction, clinical trial, drug 
therapy, intravenous drug administration)
  calcitonin (drug therapy)
  etidronic acid (adverse drug reaction, clinical trial, drug therapy, oral 
drug administration)
  pamidronic acid (adverse drug reaction, drug therapy, oral drug 
administration)
  risedronic acid (adverse drug reaction, clinical trial, drug combination)
  tiludronic acid (adverse drug reaction, clinical trial, drug therapy, oral 
drug administration)
  zoledronic acid (adverse drug reaction, clinical trial, drug combination, 
drug dose, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Paget bone disease (drug therapy, diagnosis, drug therapy, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal pain (side effect)
  acupuncture
  alkaline phosphatase blood level
  article
  atrial fibrillation (side effect)
  bone necrosis (side effect)
  bone pain (drug therapy, side effect)
  clinical feature
  diagnostic test
  diarrhea (side effect)
  differential diagnosis
  disease association
  disease exacerbation
  disease severity
  dose response
  drug efficacy
  drug eruption (side effect)
  drug fever (side effect)
  drug induced headache (side effect)
  drug safety
  dyspepsia (side effect)
  esophagitis (side effect)
  fatigue (side effect)
  femur subtrochanteric fracture (side effect)
  human
  hydrotherapy
  hypocalcemia (side effect)
  myalgia (side effect)
  nausea (side effect)
  osteotomy
  physiotherapy
  practice guideline
  priority journal
  single drug dose
  transcutaneous nerve stimulation
  treatment indication
  uveitis (side effect)
  vomiting (side effect)
CAS REGISTRY NUMBERS
  alendronic acid (66376-36-1)
  alkaline phosphatase (9001-78-9)
  calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
  etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
  pamidronic acid (40391-99-9, 57248-88-1)
  risedronic acid (105462-24-6, 122458-82-6)
  tiludronic acid (96538-83-9)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Orthopedic Surgery (33)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013101059
MEDLINE PMID
  23406029 (http://www.ncbi.nlm.nih.gov/pubmed/23406029)
FULL TEXT LINK
  http://dx.doi.org/10.1056/NEJMcp1204713
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 287
TITLE
  Walking unsteadily: A case of acute cerebellar ataxia
AUTHOR NAMES
  Simonetta F.
  Christou F.
  Vandoni R.E.
  Nierle T.
AUTHOR ADDRESSES
  (Simonetta F.; Christou F.; Nierle T., tomnierle@hotmail.com) Department of 
Internal Medicine, Hôpital du Jura Bernois SA, Moutier, Switzerland.
(Vandoni R.E.) Department of Surgery, Hôpital du Jura Bernois SA, Moutier, 
Switzerland.
CORRESPONDENCE ADDRESS
  T. Nierle, Department of Internal Medicine, Hôpital du Jura Bernois SA, 
Moutier, Switzerland. Email: tomnierle@hotmail.com
SOURCE
  BMJ Case Reports (2013) Article Number: 007688. Date of Publication: 2013
ISSN
  1757-790X (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
  Acute cerebellar ataxia is an infrequent neurological syndrome in adults 
especially if complicated by additional neurological deficits. We report the 
case of a 69-year-old woman who presented with sudden onset of left facial 
droop, dizziness, slurred speech and impaired balance. Her medical history 
included paroxysmal atrial fibrillation and a sigmoid diverticular abscess 
treated with ciprofloxacin and metronidazole. Cranial computed tomographic 
angiography and MRI showed no signs of acute ischaemia or haemorrhage but 
demonstrated symmetrically distributed lesions in the cerebellar dentate 
nuclei. A diagnosis of metronidazole-induced encephalopathy was suspected. 
Metronidazole was stopped and the patient completely recovered. 
Metronidazole is a commonly prescribed medication. Clinicians should be 
aware of the clinical and radiological presentation of metronidazole-induced 
encephalopathy so that this serious but completely reversible condition can 
be promptly diagnosed. Copyright © 2013 BMJ Publishing Group.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  metronidazole (adverse drug reaction, drug combination, drug therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  alprazolam (drug therapy)
  ciprofloxacin (drug combination, drug therapy, oral drug administration)
  flupentixol (drug therapy)
  melitracen (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebellar ataxia (side effect, diagnosis, side effect)
  walking difficulty
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation (diagnosis, drug therapy)
  balance impairment
  brain disease (side effect)
  brain hemorrhage (diagnosis)
  brain infection (diagnosis)
  brain ischemia (diagnosis)
  brain tumor (diagnosis)
  case report
  cerebellum injury
  colon diverticulosis (diagnosis, drug therapy)
  computed tomographic angiography
  dentate nucleus
  differential diagnosis
  dizziness
  drug withdrawal
  dysarthria
  face asymmetry
  facial nerve paralysis
  female
  human
  immunopathology (diagnosis)
  leukocyte count
  leukocytosis
  metabolic disorder (diagnosis)
  mixed anxiety and depression (drug therapy)
  nuclear magnetic resonance imaging
  nystagmus
  priority journal
  sigmoid diverticular abscess (diagnosis, drug therapy)
  sigmoid diverticular abscess (drug therapy)
  slurred speech
  traumatic brain injury (diagnosis)
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alprazolam (28981-97-7)
  ciprofloxacin (85721-33-1)
  flupentixol (2413-38-9, 2709-56-0)
  melitracen (5118-29-6)
  metronidazole (39322-38-8, 443-48-1)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013054356
FULL TEXT LINK
  http://dx.doi.org/10.1136/bcr-2012-007688
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 288
TITLE
  Obesity and cardiovascular disease: Steps to reduce the risk
AUTHOR NAMES
  Hodara R.
  Kacharava A.
AUTHOR ADDRESSES
  (Hodara R.; Kacharava A.) Department of medicine, Emory University, School 
of Medicine, Atlanta, GA, United States.
CORRESPONDENCE ADDRESS
  R. Hodara, Department of medicine, Emory University, School of Medicine, 
Atlanta, GA, United States.
SOURCE
  Consultant (2013) 53:2 (67-72). Date of Publication: February 2013
ISSN
  0010-7069
BOOK PUBLISHER
  Cliggott Publishing Co., 330 Boston Post Road, Box 4027, Darien, United 
States.
ABSTRACT
  Obesity is associated with conditions such as hypertension, insulin 
resistance, dyslipidemia, and thrombosis that markedly increase the risk of 
cardiovascular disease and overall mortality. In addition, the 
pro-inflammatory and pro-thrombotic cascades triggered by the extra adipose 
tissue appear to increase cardiovascular risk independently. For primary and 
secondary prevention of cardiovascular disease, expert panels recommend that 
obese patients, as well as those who are overweight with comorbid 
conditions, lose 10% of their initial body weight. A first approach should 
include a program of lifestyle modification, composed of diet, exercise, and 
behavioral changes. Given the limited long-term efficacy of pharmacological 
and behavioral interventions, bariatric surgery has emerged as a prominent 
and durable alterative to combating obesity and its related conditions.
EMTREE DRUG INDEX TERMS
  amfepramone (drug therapy)
  fatty acid (endogenous compound)
  fenfluramine (drug therapy)
  lorcaserin (drug therapy)
  phentermine (drug combination, drug therapy)
  sibutramine (drug therapy)
  tetrahydrolipstatin (adverse drug reaction, drug therapy)
  topiramate (drug combination, drug therapy)
  triacylglycerol (endogenous compound)
  very low density lipoprotein (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease
  obesity (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  atherosclerosis
  atrial fibrillation
  bariatric surgery
  body mass
  cardiovascular risk
  cerebrovascular accident
  childhood obesity
  diet therapy
  dyslipidemia
  gastrointestinal symptom (side effect)
  heart failure
  heart infarction
  human
  hypertension
  insulin resistance
  ischemic heart disease
  metabolic syndrome X
  non insulin dependent diabetes mellitus
  priority journal
  review
  waist circumference
  waist hip ratio
  weight reduction
CAS REGISTRY NUMBERS
  amfepramone (134-80-5, 90-84-6)
  fenfluramine (404-82-0, 458-24-2)
  lorcaserin (616202-92-7)
  phentermine (1197-21-3, 122-09-8)
  sibutramine (106650-56-0)
  tetrahydrolipstatin (96829-58-2)
  topiramate (97240-79-4)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013129846
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 289
TITLE
  The Relationship between physical activity and risk of atrial fibrillation-A 
systematic review and meta-Analysis
AUTHOR NAMES
  Nielsen J.R.
  Wachtell K.
  Abdulla J.
AUTHOR ADDRESSES
  (Nielsen J.R.; Wachtell K.) Division of Cardiology, Department of Medicine, 
Glostrup University Hospital, Copenhagen, Denmark.
(Abdulla J.) Glostrup Hospital, Ndr. Ringvej 57, DK-2600 Glostrup, Denmark.
CORRESPONDENCE ADDRESS
  J. Abdulla, Glostrup Hospital, Ndr. Ringvej 57, DK-2600 Glostrup, Denmark.
SOURCE
  Journal of Atrial Fibrillation (2013) 5:5 (20-27). Date of Publication: 
February-March 2013
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
  The aim of this systematic literature review and meta-Analyses was to 
explore the relationship between physical activity and risk of new-onset 
atrial fibrillation (AF) or flutter (AFlu).Results: The search revealed 10 
published studies that were eligible for three different meta-Analyses. A 
meta-Analysis of six case-control studies showed that risk of AF increased 
more than 5-fold in athletes compared to non-Athletic controls, OR=5.3 
[(3.6, 7.9; 95% confidence interval (CI)], p<0.0001. A second meta-Analysis 
of three case-control studies showed a significantly higher prevalence of 
athletes among AF populations compared to their healthy controls, OR=4.7 
(3.1-6.9; 95% CI), p<0.0001. A third meta-Analysis of three prospective 
large-scale long-Term studies showed that moderate/high habitual physical 
activity was associated with significantly reduced risk of AF compared with 
none or very low intensity physical activity OR=0.89(0.83, 0.96; 95% CI), 
p=002.Conclusions: Long-Term vigorous physical training or lack of physical 
activity both are associated with increased risk of AF, while habitual 
moderate physical activity may be associated with reduced risk. Further 
large-scale prospective randomized controlled studies particularly in 
athletes are needed to further confirm these findings.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (epidemiology)
  cardiovascular risk
  heart atrium flutter
  physical activity
EMTREE MEDICAL INDEX TERMS
  athlete
  case control study
  exercise intensity
  high risk population
  human
  meta analysis
  prevalence
  prospective study
  review
  risk reduction
  systematic review
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013200941
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 290
TITLE
  Electroacupuncture reduces duration of postoperative ileus after 
laparoscopic surgery for colorectal cancer
AUTHOR NAMES
  Ng S.S.M.
  Leung W.W.
  Mak T.W.C.
  Hon S.S.F.
  Li J.C.M.
  Wong C.Y.N.
  Tsoi K.K.F.
  Lee J.F.Y.
AUTHOR ADDRESSES
  (Ng S.S.M., simonng@surgery.cuhk.edu.hk; Leung W.W.; Mak T.W.C.; Hon S.S.F.; 
Li J.C.M.; Wong C.Y.N.; Tsoi K.K.F.; Lee J.F.Y.) Department of Surgery, 
Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong 
Kong.
CORRESPONDENCE ADDRESS
  S.S.M. Ng, Department of Surgery, Chinese University of Hong Kong, Prince of 
Wales Hospital, Shatin, Hong Kong. Email: simonng@surgery.cuhk.edu.hk
SOURCE
  Gastroenterology (2013) 144:2 (307-313.e1). Date of Publication: Feb 2013
ISSN
  0016-5085
  1528-0012 (electronic)
BOOK PUBLISHER
  W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
  BACKGROUND & AIMS: We investigated the efficacy of electroacupuncture in 
reducing the duration of postoperative ileus and hospital stay after 
laparoscopic surgery for colorectal cancer. METHODS: We performed a 
prospective study of 165 patients undergoing elective laparoscopic surgery 
for colonic and upper rectal cancer, enrolled from October 2008 to October 
2010. Patients were assigned randomly to groups that received 
electroacupuncture (n = 55) or sham acupuncture (n = 55), once daily from 
postoperative days 1-4, or no acupuncture (n = 55). The acupoints Zusanli, 
Sanyinjiao, Hegu, and Zhigou were used. The primary outcome was time to 
defecation. Secondary outcomes included postoperative analgesic requirement, 
time to ambulation, and length of hospital stay. RESULTS: Patients who 
received electroacupuncture had a shorter time to defecation than patients 
who received no acupuncture (85.9 ± 36.1 vs 122.1 ± 53.5 h; P<.001) and 
length of hospital stay (6.5±2.2 vs 8.5±4.8 days; P = .007). Patients who 
received electroacupuncture also had a shorter time to defecation than 
patients who received sham acupuncture (85.9 ± 36.1 vs 107.5 ± 46.2 h; P = 
.007). Electroacupuncture was more effective than no or sham acupuncture in 
reducing postoperative analgesic requirement and time to ambulation. In 
multiple linear regression analysis, an absence of complications and 
electroacupuncture were associated with a shorter duration of postoperative 
ileus and hospital stay after the surgery. CONCLUSIONS: In a clinical trial, 
electroacupuncture reduced the duration of postoperative ileus, time to 
ambulation, and postoperative analgesic requirement, compared with no or 
sham acupuncture, after laparoscopic surgery for colorectal cancer. © 2013 
by the AGA Institute.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  colorectal cancer (surgery)
  electroacupuncture
  hospitalization
  laparoscopic surgery
  postoperative ileus (complication, surgery)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  acute coronary syndrome (complication)
  adult
  aged
  article
  atrial fibrillation (complication)
  cancer surgery
  chest infection (complication)
  cholangitis (complication)
  comparative effectiveness
  confusion (complication)
  controlled study
  defecation
  disease duration
  female
  human
  intestine function
  major clinical study
  male
  mobilization
  postoperative complication (complication)
  priority journal
  prospective study
  randomized controlled trial
  single blind procedure
  surgical infection (complication)
  treatment duration
  treatment outcome
  urinary tract infection (complication)
  urine retention (complication)
EMBASE CLASSIFICATIONS
  Surgery (9)
  Internal Medicine (6)
  Cancer (16)
  Gastroenterology (48)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00464425)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014112624
MEDLINE PMID
  23142625 (http://www.ncbi.nlm.nih.gov/pubmed/23142625)
FULL TEXT LINK
  http://dx.doi.org/10.1053/j.gastro.2012.10.050
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 291
TITLE
  2013 SYR Accepted Poster Abstracts
AUTHOR ADDRESSES
  SOURCE
  International journal of yoga therapy (2013) 23 Supplement (32-53). Date of 
Publication: 2013
ISSN
  1531-2054
ABSTRACT
  SYR 2013 Accepted Poster abstracts: 1. Benefits of Yoga as a Wellness 
Practice in a Veterans Affairs (VA) Health Care Setting: If You Build It, 
Will They Come? 2. Yoga-based Psychotherapy Group With Urban Youth Exposed 
to Trauma. 3. Embodied Health: The Effects of a Mind�Body Course for Medical 
Students. 4. Interoceptive Awareness and Vegetable Intake After a Yoga and 
Stress Management Intervention. 5. Yoga Reduces Performance Anxiety in 
Adolescent Musicians. 6. Designing and Implementing a Therapeutic Yoga 
Program for Older Women With Knee Osteoarthritis. 7. Yoga and Life Skills 
Eating Disorder Prevention Among 5th Grade Females: A Controlled Trial. 8. A 
Randomized, Controlled Trial Comparing the Impact of Yoga and Physical 
Education on the Emotional and Behavioral Functioning of Middle School 
Children. 9. Feasibility of a Multisite, Community based Randomized Study of 
Yoga and Wellness Education for Women With Breast Cancer Undergoing 
Chemotherapy. 10. A Delphi Study for the Development of Protocol Guidelines 
for Yoga Interventions in Mental Health. 11. Impact Investigation of 
Breathwalk Daily Practice: Canada�India Collaborative Study. 12. Yoga 
Improves Distress, Fatigue, and Insomnia in Older Veteran Cancer Survivors: 
Results of a Pilot Study. 13. Assessment of Kundalini Mantra and Meditation 
as an Adjunctive Treatment With Mental Health Consumers. 14. Kundalini Yoga 
Therapy Versus Cognitive Behavior Therapy for Generalized Anxiety Disorder 
and Co-Occurring Mood Disorder. 15. Baseline Differences in Women Versus Men 
Initiating Yoga Programs to Aid Smoking Cessation: Quitting in Balance 
Versus QuitStrong. 16. Pranayam Practice: Impact on Focus and Everyday Life 
of Work and Relationships. 17. Participation in a Tailored Yoga Program is 
Associated With Improved Physical Health in Persons With Arthritis. 18. 
Effects of Yoga on Blood Pressure: Systematic Review and Meta-analysis. 19. 
A Quasi-experimental Trial of a Yoga based Intervention to Reduce Stress and 
Promote Health and Well-being Among Middle School Educators. 20. A 
Systematic Review of Yoga-based Interventions for Objective and Subjective 
Balance Measures. 21. Disparities in Yoga Use: A Multivariate Analysis of 
2007 National Health Interview Survey Data. 22. Implementing Yoga Therapy 
Adapted for Older Veterans Who Are Cancer Survivors. 23. Randomized, 
Controlled Trial of Yoga for Women With Major Depressive Disorder: Decreased 
Ruminations as Potential Mechanism for Effects on Depression? 24. Yoga 
Beyond the Metropolis: A Yoga Telehealth Program for Veterans. 25. Yoga 
Practice Frequency, Relationship Maintenance Behaviors, and the Potential 
Mediating Role of Relationally Interdependent Cognition. 26. Effects of 
Medical Yoga in Quality of Life, Blood Pressure, and Heart Rate in Patients 
With Paroxysmal Atrial Fibrillation. 27. Yoga During School May Promote 
Emotion Regulation Capacity in Adolescents: A Group Randomized, Controlled 
Study. 28. Integrated Yoga Therapy in a Single Session as a Stress 
Management Technique in Comparison With Other Techniques. 29. Effects of a 
Classroom-based Yoga Intervention on Stress and Attention in Second and 
Third Grade Students. 30. Improving Memory, Attention, and Executive 
Function in Older Adults with Yoga Therapy. 31. Reasons for Starting and 
Continuing Yoga. 32. Yoga and Stress Management May Buffer Against Sexual 
Risk-Taking Behavior Increases in College Freshmen. 33. Whole-systems 
Ayurveda and Yoga Therapy for Obesity: Outcomes of a Pilot Study. 34. 
Women�s Phenomenological Experiences of Exercise, Breathing, and the Body 
During Yoga for Smoking Cessation Treatment. 35. Mindfulness as a Tool for 
Trauma Recovery: Examination of a Gender-responsive Trauma-informed 
Integrative Mindfulness Program for Female Inmates. 36. Yoga After Stroke 
Leads to Multiple Physical Improvements. 37. Tele-Yoga in Patients With 
Chronic Obstructive Pulmonary Disease and Heart Failure: A Mixed-methods 
Study of Feasibility, Acceptability, and Safety. 38. Effects of an Ashtanga 
Yoga-based Health and Wellness Curriculum on Physical and Emotional 
Well-being, Engagement Toward School, and Academic Performance of K-6 
Students. 39. Yoga as a Facilitator for Participation Following an 8-week 
Yoga for Individuals With Chronic Stroke. 40. Standardization of Design and 
Reporting of Yoga Interventions for Musculoskeletal Conditions: A Delphi 
Approach. 41. Creating S.P.A.C.E. Through Yoga: Africa Yoga Project Teachers 
Promote Personal Transformation, Peaceful Communities, and Purpose-filled 
Service.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anxiety
  quality of life
EMTREE MEDICAL INDEX TERMS
  controlled study
  human
  major depression
  meta analysis
  national health organization
  pilot study
  psychology
  randomized controlled trial
  therapy
  yoga
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
MEDLINE PMID
  24176784 (http://www.ncbi.nlm.nih.gov/pubmed/24176784)
COPYRIGHT
  Copyright 2016 Medline is the source for the citation and abstract of this 
record.

RECORD 292
TITLE
  Non-communicable disease epidemic: epidemiology in action (EuroEpi 2013 and 
NordicEpi 2013): Aarhus, Denmark from 11 August to 14 August 2013
AUTHOR NAMES
  Tsukinoki R.
  Murakami Y.
AUTHOR ADDRESSES
  (Tsukinoki R., tukinoki@envi.med.osaka-u.ac.jp) Department of Public Health 
Nursing, Osaka Medical College, Takatsuki, Japan.
(Murakami Y.) Department of Medical Statistics, Shiga University of Medical 
Science, Otsu, Japan.
CORRESPONDENCE ADDRESS
  R. Tsukinoki, Department of Public Health Nursing, Osaka Medical College, 
Takatsuki, Japan.
SOURCE
  European Journal of Epidemiology (2013) 28:1 (1-270). Date of Publication: 
2013
ISSN
  1573-7284 (electronic)
  0393-2990
BOOK PUBLISHER
  Kluwer Academic Publishers
EMTREE DRUG INDEX TERMS
  11beta hydroxysteroid dehydrogenase 2 (endogenous compound)
  anti human immunodeficiency virus agent (drug therapy)
  BCG vaccine (drug therapy)
  C reactive protein (endogenous compound)
  caffeine
  clozapine (drug therapy)
  corticosteroid (adverse drug reaction, drug therapy, topical drug 
administration)
  diazepam (adverse drug reaction)
  diphtheria pertussis tetanus vaccine
  endothelial nitric oxide synthase (endogenous compound)
  enterolactone (endogenous compound)
  fibrinogen (endogenous compound)
  hemoglobin A1c (endogenous compound)
  hydrocortisone (endogenous compound)
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  immunoglobulin G antibody (endogenous compound)
  maternal antibody (endogenous compound)
  neuronal nitric oxide synthase (endogenous compound)
  nonsteroid antiinflammatory agent (drug combination)
  paracetamol (adverse drug reaction, drug combination)
  prostaglandin synthase inhibitor (drug combination)
  serotonin uptake inhibitor (drug combination)
  tamoxifen
  temazepam (adverse drug reaction)
  tissue antigen (endogenous compound)
  tricyclic antidepressant agent
  unindexed drug
  virus antibody (endogenous compound)
  vitamin D (endogenous compound)
  zopiclone (adverse drug reaction)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  epidemic (epidemiology)
  non communicable disease (epidemiology)
EMTREE MEDICAL INDEX TERMS
  2009 H1N1 influenza
  abortion
  absence
  absenteeism
  academic achievement
  accidental death
  acquired immune deficiency syndrome
  acute heart failure
  acute heart infarction
  acute kidney failure
  acute liver failure
  acute lymphoblastic leukemia
  adipose tissue
  adolescence
  adolescent behavior
  adolescent disease
  adolescent health
  adolescent pregnancy
  adulthood
  adverse outcome
  African
  air pollution
  air quality
  air temperature
  Albanian (people)
  alcohol consumption
  alcohol intoxication
  allele
  allergy
  allostatic load
  alternative medicine
  Alzheimer disease
  ambient air
  ambulance transportation
  anorectal malformation
  anorexia
  antibiotic therapy
  antibody blood level
  anticoagulant therapy
  antihypertensive therapy
  anxiety disorder
  arterial stiffness
  artery thrombosis
  article
  assessment of humans
  asthma
  atherosclerosis
  atopic dermatitis
  atrial fibrillation
  attributable risk
  Australian Aborigine
  autism
  automutilation
  awareness
  axillary lymph node
  bacterial load
  Bangladeshi
  bariatric surgery
  Barrett esophagus
  BCG vaccination
  behavior disorder (side effect)
  benign childhood epilepsy
  bereavement
  billing and claims
  binge drinking
  biomechanics
  bipolar disorder
  birth rate
  birth weight
  blood pressure
  body composition
  body fat
  body fat distribution
  body height
  body mass
  body size
  body weight
  Bosnia and Herzegovina
  Braden Scale
  brain hemorrhage
  brain ischemia
  Brazil
  Brazilian
  breast cancer (diagnosis)
  breast feeding
  bronchitis
  burn
  caloric intake
  cancer chemotherapy
  cancer diagnosis
  cancer epidemiology
  cancer incidence
  cancer localization
  cancer mortality
  cancer patient
  cancer prevention
  cancer prognosis
  cancer radiotherapy
  cancer recurrence
  cancer risk
  cancer screening
  cancer staging
  cancer surgery
  cancer survival
  cancer survivor
  cancer susceptibility
  cancer therapy
  carbohydrate intake
  cardiac patient
  cardiometabolic risk
  cardiovascular disease
  cardiovascular mortality
  cardiovascular risk
  cardiovascular system
  caregiver
  carpal tunnel syndrome
  Caucasian
  cause of death
  celiac disease
  cellular immunity
  central nervous system tumor
  cerebral palsy
  cerebrovascular accident (prevention)
  cesarean section
  child death
  child health
  child parent relation
  child welfare
  childbirth
  childhood
  childhood cancer
  childhood disease
  childhood injury
  childhood leukemia
  childhood obesity
  cholestatic hepatitis
  cholesterol blood level
  chronic disease
  chronic fatigue syndrome
  chronic inflammation
  chronic kidney disease
  chronic liver disease
  chronic obstructive lung disease
  chronic stress
  chronology
  clinical assessment tool
  clinical decision making
  clinical effectiveness
  clinical examination
  clinical protocol
  clinical research
  cognition
  cohabitation
  cold
  colic
  colon cancer
  colorectal cancer
  comorbidity
  computer assisted tomography
  conduct disorder
  congenital diaphragm hernia
  congenital heart disease
  congenital heart malformation
  congenital malformation (side effect)
  consumer
  coping behavior
  cost effectiveness analysis
  Crimean Congo hemorrhagic fever
  cubital tunnel syndrome
  cutaneous melanoma
  cytokine release
  cytopathology
  daily life activity
  daughter
  death certificate
  decubitus (prevention)
  delivery
  dementia
  demography
  dengue
  Denmark
  dental caries
  dental fluorosis
  dental health
  depression (diagnosis)
  developmental disorder
  diabetes mellitus
  diarrhea
  diet supplementation
  diet therapy
  dietary fiber
  dietary intake
  dietary recall assessment tool
  diphtheria
  disability
  disease association
  disease course
  disease exacerbation
  disease marker
  disease severity
  disease surveillance
  distress syndrome
  diverticulosis
  drinking behavior
  drug classification
  drug efficacy
  drug metabolism
  drug safety
  drug surveillance program
  drug transport
  drug use
  drug utilization
  eating disorder
  economic aspect
  ectopic pregnancy
  education
  educational status
  Egypt
  electronic medical record
  embryo disposition
  emergency ward
  emphysema
  encephalomyelitis
  endocrine tumor
  endometrium carcinoma
  enteric virus
  environmental exposure
  environmental factor
  environmental temperature
  epidemiology
  ethnicity
  evaluation study
  exhaust gas
  extrapulmonary tuberculosis
  family
  family history
  family planning
  family violence
  fast food
  fat free mass
  fat intake
  fat mass
  fatality
  feedback system
  feeding behavior
  female fertility
  female genital mutilation
  fertilization in vitro
  fetus death
  fetus growth
  fetus mortality
  fetus wastage
  fever
  fibrinogen blood level
  Finland
  first degree relative
  first trimester pregnancy
  fish meat
  follow up
  food
  food intake
  food poisoning
  food preference
  food security
  food selectivity
  forced expiratory volume
  France
  fruit
  fruit juice
  gender
  gene interaction
  gene locus
  General Health Questionnaire
  general practice
  genetic association
  genetic epidemiology
  genetic polymorphism
  genetic predisposition
  genetic variability
  genotype
  genotype environment interaction
  geographic distribution
  geriatric patient
  germ cell tumor
  Germany
  gestational age
  Giardia intestinalis
  giardiasis
  Gilles de la Tourette syndrome
  glucose blood level
  glucose tolerance
  groups by age
  Guinea-Bissau
  head circumference
  health behavior
  health care access
  health care management
  health care planning
  health care policy
  health care quality
  health care system
  health care utilization
  health disparity
  health program
  health status
  health survey
  hearing
  hearing impairment
  heart contraction
  heart failure
  heart infarction
  heart rate variability
  heart rehabilitation
  heart transplantation
  heatwave
  Helicobacter infection
  hematologic malignancy
  hemoglobin blood level
  hemorrhoid (drug therapy)
  hepatitis A
  hepatitis B
  hepatitis C
  Hepatitis C virus
  Hepatitis E virus
  hereditary nonpolyposis colorectal cancer
  heredity
  Herpes simplex virus 1
  herpes zoster
  high risk population
  highly active antiretroviral therapy
  hip fracture
  HIV test
  Hodgkin disease
  home accident
  honey
  hormone blood level
  hospital admission
  hospital care
  hospitalization
  household
  human
  Human immunodeficiency virus infected patient
  Human immunodeficiency virus infection (drug therapy)
  hyperactivity (side effect)
  hyperkinetic disorder
  hypertension
  hypospadias
  Iceland
  immigrant
  immune response
  income
  industrial noise
  industrial worker
  infertility
  infertility therapy
  inflammatory bowel disease
  injury
  insomnia
  insulin blood level
  insulin resistance
  intelligence quotient
  intensive care unit
  Internet
  interpregancy interval
  intestine flora
  intestine parasite
  intoxication
  intracytoplasmic sperm injection
  intravenous drug abuse
  ischemia
  ischemic heart disease
  Italy
  Japanese (people)
  job stress
  Kazakhstan
  kidney function
  kinesiotherapy
  larynx cancer
  latitude
  lean body weight
  leisure
  Lennox Gastaut syndrome
  leukemia
  life
  lifestyle
  lipoprotein blood level
  liver cell carcinoma
  liver cirrhosis
  liver fibrosis
  liver transplantation
  long term care
  long term survival
  low back pain
  low birth weight
  low risk population
  lung cancer (surgery)
  lung development
  lung function
  lymphoma
  Madagascar
  malignant neoplastic disease
  Malmo diet
  market
  marketing
  marriage
  maternal age
  maternal diabetes mellitus
  maternal disease
  maternal hypertension
  maternal mortality
  maternal obesity
  maternal serum
  maternal smoking
  measles
  measles vaccination
  medical care
  medical history
  medical information
  medical leave
  medical school
  medical specialist
  medical student
  medication compliance
  melanoma
  melanoma skin cancer
  menarche
  menstrual cycle
  mental deterioration
  mental disease
  mental health
  mental patient
  mesothelioma
  metabolic syndrome X
  microcephaly
  midwife
  migrant
  mobilization
  modifiable risk factor
  mother
  motor development
  multiple sclerosis
  mumps
  musculoskeletal disease
  musculoskeletal pain
  Muslim
  myeloid leukemia
  myeloma
  Namibia
  needlestick injury
  neighborhood
  neonatal hyperbilirubinemia
  nerve conduction
  neural tube defect
  newborn mortality
  nicotine replacement therapy
  noise
  non insulin dependent diabetes mellitus (etiology)
  nonalcoholic fatty liver
  nonhodgkin lymphoma
  North African
  Norwegian (people)
  nursery
  nutrition
  nutritional assessment
  nutritional status
  obesity
  obsessive compulsive disorder
  obstetrician
  occupation and occupation related phenomena
  occupational accident
  occupational exposure
  occupational hazard
  occupational prestige
  offender
  onset age
  organ donor
  ovary cancer
  overeducation
  Pakistani
  Papanicolaou test
  parent
  parental age
  parental attitude
  parental deprivation
  Parkinson disease
  patient care
  patient compliance
  patient counseling
  patient information
  patient participation
  patient satisfaction
  pedigree
  pedometer
  peer group
  pension
  percutaneous coronary intervention
  perinatal care
  peritoneal dialysis
  personality
  pertussis
  pet animal
  pharmacoepidemiology
  physical activity
  physical inactivity
  physician
  physiological process
  placenta weight
  pneumonia
  policy
  poliomyelitis
  pollen allergy
  polypharmacy
  Portugal
  postmenopause
  postnatal stress
  prediction
  predictive value
  preeclampsia
  pregnancy
  pregnancy outcome
  premature labor
  premature mortality
  premenopause
  prenatal care
  prenatal drug exposure
  prenatal exposure
  prenatal period
  prenatal stress
  prescription
  primary health care
  primary medical care
  primary prevention
  primary tumor
  productivity
  progeny
  prostate cancer
  protection
  protein blood level
  protein intake
  protein polymorphism
  psoriasis
  psychiatric department
  psychodynamics
  psychological aspect
  psychological well being
  psychophysiology
  psychosomatic disorder
  puberty
  public health problem
  publication
  puerperal depression
  puerperium
  quality of life
  radiation exposure
  rapid response team
  reading
  recreation
  recurrence risk
  recurrent disease
  religion
  reproduction
  reproductive health
  respiratory tract disease
  retirement
  return to work
  reward
  rheumatoid arthritis
  risk assessment
  risk factor
  rubella
  rural area
  rural population
  Russian Federation
  saliva level
  salt intake
  sandstorm
  sanitation
  sarcoidosis
  schizophrenia (drug therapy)
  school
  scientist
  screening test
  season
  second trimester pregnancy
  Serbia
  seroprevalence
  sex difference
  sexual behavior
  sexual intercourse
  shoulder impingement syndrome (etiology)
  sibling
  single nucleotide polymorphism
  skin disease
  sleep disordered breathing
  sleep pattern
  small for date infant
  smoking
  smoking cessation
  social class
  social interaction
  social norm
  social status
  social support
  socioeconomic inequality
  socioeconomics
  sodium excretion
  soft drink
  soft tissue sarcoma
  solutio placentae
  South Africa
  South American
  Spain
  speech
  sperm
  spontaneous abortion
  sport
  spouse
  standardization
  standing
  stillbirth
  stomach cancer
  Strengths and Difficulties Questionnaire
  stress
  student
  substance abuse
  suicidal ideation
  suicide (epidemiology)
  suicide attempt
  summer
  surgical patient
  Sweden
  systemic lupus erythematosus
  Tanzania
  telephone interview
  television viewing
  temperature related phenomena
  testis cancer
  tetanus
  thalassemia
  thorax pain
  thorax surgery
  thyroid cancer
  thyroid disease
  time series analysis
  time to pregnancy
  tobacco
  tonsil cancer
  topical treatment
  total knee replacement
  toxoplasmosis
  traffic and transport
  triacylglycerol blood level
  tuberculosis (drug therapy)
  tumor associated leukocyte
  Turk (people)
  twins
  undergraduate student
  underweight
  United Kingdom
  urban area
  uric acid blood level
  urinalysis
  urine incontinence
  uterine cervix cancer
  uterine cervix carcinoma
  uterine cervix small cell neuroendocrine carcinoma
  uterus cancer
  vaccination
  vacuum extraction
  vaginitis
  vagus reflex
  varicosis
  vegetable
  vegetarian diet
  vein thrombosis
  venous thromboembolism
  veterinary clinic
  viral clearance
  vitamin blood level
  volcano
  waist circumference
  weather
  Wegener granulomatosis
  weight change
  weight gain
  weight reduction
  welfare
  wild boar
  work capacity
  work disability
  work environment
  zoonosis
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  caffeine (58-08-2)
  clozapine (5786-21-0)
  diazepam (439-14-5)
  endothelial nitric oxide synthase (503473-02-7)
  enterolactone (78473-71-9)
  fibrinogen (9001-32-5)
  hemoglobin A1c (62572-11-6)
  hydrocortisone (50-23-7)
  neuronal nitric oxide synthase (506430-87-1)
  paracetamol (103-90-2)
  tamoxifen (10540-29-1)
  temazepam (846-50-4)
  zopiclone (43200-80-2)
EMBASE CLASSIFICATIONS
  Obstetrics and Gynecology (10)
  Cancer (16)
  Public Health, Social Medicine and Epidemiology (17)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Pediatrics and Pediatric Surgery (7)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2015648089
FULL TEXT LINK
  http://dx.doi.org/10.1007/s10654-013-9820-0
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 293
TITLE
  Abstracts for the Cardiac Society of Australia and New Zealand Annual 
Scientific Meeting and the International Society for Heart Research 
Australasian Section Annual Scientific Meeting 2013
AUTHOR ADDRESSES
  SOURCE
  Heart Lung and Circulation (2013) 22 SUPPL. 1. Date of Publication: 2013
CONFERENCE NAME
  Cardiac Society of Australia and New Zealand Annual Scientific Meeting and 
the International Society for Heart Research Australasian Section Annual 
Scientific Meeting 2013
CONFERENCE LOCATION
  Gold Coast, QLD, Australia
CONFERENCE DATE
  2013-08-08 to 2013-08-11
ISSN
  1443-9506
BOOK PUBLISHER
  Elsevier Ltd
ABSTRACT
  The proceedings contain 613 papers. The topics discussed include: atrial 
fibrillation and obesity: impact of weight reduction on the atrial 
substrate; intramyocardial adiposity of left ventricular (LV) scar borders 
postinfarction contributes to greater ventricular tachycardia susceptibility 
than collagen; abnormal left ventricular contractile response to exercise 
without obstructive coronary disease: a newly described phenomenon 
associated with subclinical myocardial dysfunction; impact of multivessel 
coronary artery disease on serum biochemical markers and clinical outcomes 
following acute myocardial infarction treated with percutaneous coronary 
intervention; poor health status and depression are associated with 
excessive daytime sleepiness in stable heart failure patients; an evaluation 
of peripheral vascular access site complications following cardiac 
angiography and percutaneous coronary intervention (PCI); and clinical 
utility of visual left ventricular ejection fraction assessment by 
echocardiography: comparison with three-dimensional echocardiography.
EMTREE DRUG INDEX TERMS
  biochemical marker
  collagen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Australia and New Zealand
  heart
  society
EMTREE MEDICAL INDEX TERMS
  acute heart infarction
  angiography
  atrial fibrillation
  coronary artery disease
  daytime somnolence
  echocardiography
  exercise
  health status
  heart failure
  heart left ventricle ejection fraction
  heart ventricle tachycardia
  human
  obesity
  patient
  percutaneous coronary intervention
  scar
  serum
  three dimensional echocardiography
  vascular access
  weight reduction
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 294
TITLE
  Competitive sports and the heart: Benefit or risk?
ORIGINAL (NON-ENGLISH) TITLE
  Herz und Leistungssport: Nutzen oder Schaden?
AUTHOR NAMES
  Scharhag J.
  Löllgen H.
  Kindermann W.
AUTHOR ADDRESSES
  (Scharhag J., juergen.scharhag@med.uni-heidelberg.de) Department of Internal 
Medicine III: Cardiology, Angiology and Pneumology, Heidelberg University 
Hospital, Im Neuenheimer Feld 410, Heidelberg, Germany.
(Löllgen H.) Internal Medicine, Cardiology and Sports Medicine Office, 
Remscheid, Germany.
(Kindermann W.) Institute of Sports and Preventive Medicine, Saarland 
University, Germany.
CORRESPONDENCE ADDRESS
  J. Scharhag, Department of Internal Medicine III: Cardiology, Angiology and 
Pneumology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 
Heidelberg, Germany.
SOURCE
  Deutsches Arzteblatt International (2013) 110:1-2 (14-24). Date of 
Publication: 7 Jan 2013
ISSN
  1866-0452
BOOK PUBLISHER
  Deutscher Arzte-Verlag GmbH, Dieselstrasse 2 (Postfach 0254), Cologne, 
Germany. verlag@aerzteblatt.de
ABSTRACT
  Background: Controversy surrounds the cardiac effects of competitive sports 
and the athlete's heart. In this review, we present and discuss the main 
cardiological findings in competitive athletes.Method: Selective review of 
pertinent literature retrieved by a search with the keywords "athlete's 
heart," "ECG," "echocardiography," "endurance exercise," "longevity," and 
others.Results: Regular exercise leads to functional and structural 
adaptations that improve cardiac function. Athlete's heart, which develops 
rarely, is a typical finding in endurance athletes. This condition is 
characterized by physiological, harmonically eccentric hypertrophy of all 
cardiac chambers. The athlete's ECG can be used to distinguish 
physiological, training-related changes from pathological training-unrelated 
changes. The athlete's heart function is normal at rest and increases 
appropriately during exercise. The cardiac markers troponin and B-type 
natriuretic peptide are within the normal range in healthy athletes at rest, 
but can temporarily be mildly elevated after exhausting endurance-exercise, 
without evidence of myocardial damage. The epidemiological data suggest that 
participation in competitive sports increases life expectancy.Conclusion: 
Competitive exercise does not induce cardiac damage in individuals with 
healthy hearts, but does induce physiological functional and structural 
cardiac adaptations which have positive effects on life expectancy.
EMTREE DRUG INDEX TERMS
  biological marker (endogenous compound)
  brain natriuretic peptide (endogenous compound)
  troponin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart
  risk benefit analysis
  sport
EMTREE MEDICAL INDEX TERMS
  arterial wall thickness
  article
  athlete
  atrial fibrillation
  cardiovascular magnetic resonance
  diastolic blood pressure
  dynamic exercise
  dynamic stress
  echocardiography
  electrocardiography
  endurance
  endurance sport
  endurance training
  exercise intensity
  first degree atrioventricular block
  heart function
  heart left bundle branch block
  heart left ventricle ejection fraction
  heart left ventricle hypertrophy
  heart output
  heart rate
  heart repolarization
  heart right bundle branch block
  heart right ventricle ejection fraction
  heart stroke volume
  heart ventricle extrasystole
  heart volume
  Holter monitoring
  human
  life expectancy
  oxygen consumption
  paroxysmal supraventricular tachycardia
  QT interval
  second degree atrioventricular block
  ST segment depression
  ST segment elevation
  static exercise
  stress
  supraventricular premature beat
  systolic blood pressure
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English, German
LANGUAGE OF SUMMARY
  English, German
EMBASE ACCESSION NUMBER
  2015113872
FULL TEXT LINK
  http://dx.doi.org/10.3238/arztebl.2013.0014
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 295
TITLE
  Chronotropic incompetence: Causes, implications, and management
AUTHOR NAMES
  Kitzman D.W.
AUTHOR ADDRESSES
  (Kitzman D.W., dkitzman@wfubmc.edu) Department of Internal Medicine 
(Cardiology), Wake Forest School of Medicine, Winston-Salem, United States.
CORRESPONDENCE ADDRESS
  D.W. Kitzman, Cardiology Section, Wake Forest University School of Medicine, 
Medical Center Boulevard, Winston-Salem, United States.
SOURCE
  Dialogues in Cardiovascular Medicine (2013) 18:3 (139-153). Date of 
Publication: 2013
ISSN
  1272-9949
BOOK PUBLISHER
  Les Laboratoires Seriver, 50 Rue Carnot, F-92284, Suresnes Cedex, France. 
sarah.novack@fr.netgrs.com
ABSTRACT
  The important role of heart rate (HR) in cardiovascular disease is well 
established, but attention to HR is usually limited to discussion of resting 
HR or HR at peak exercise. This article discusses the importance of 
evaluating HR profiles during and after exercise. Increasing HR to tightly 
match cardiac output with metabolic demand during exercise is critical to 
physical performance. The increase in HR during exercise is the greatest 
contributor to the ability to perform physical work, an important 
determinant of quality of life, and a strong predictor of prognosis. The 
high prevalence of impaired exercise HR response and its easy assessment in 
clinical practice provides the rationale for routine screening for 
inadequate HR response, particularly because this condition is potentially 
treatable and its management can lead to significant improvements in 
exercise tolerance and quality of life.
EMTREE DRUG INDEX TERMS
  adenylate cyclase
  adrenalin
  amiodarone
  beta adrenergic receptor blocking agent
  catecholamine
  digitalis
  isoprenaline
  noradrenalin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  chronotropism
  exercise tolerance
  heart rate
EMTREE MEDICAL INDEX TERMS
  aerobic exercise
  age distribution
  anaerobic threshold
  article
  atrial fibrillation
  cardiac resynchronization therapy
  cardiovascular disease
  cause of death
  cholinergic system
  clinical practice
  convalescence
  coronary artery disease
  endurance training
  exercise test
  functional status
  heart failure
  heart muscle perfusion
  heart output
  heart stroke volume
  human
  implanted heart pacemaker
  ischemic heart disease
  lung gas exchange
  manual labor
  muscle contraction
  oxygen consumption
  parasympathetic tone
  physical performance
  prevalence
  prognosis
  quality of life
  rest
  sinoatrial conduction
  stress
  sympathetic tone
CAS REGISTRY NUMBERS
  adenylate cyclase (9012-42-4)
  adrenalin (51-43-4, 55-31-2, 6912-68-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digitalis (8031-42-3, 8053-83-6)
  isoprenaline (299-95-6, 51-30-9, 6700-39-6, 7683-59-2)
  noradrenalin (1407-84-7, 51-41-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2015666585
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 296
TITLE
  Late-Breaking Clinical Trial and Clinical Science: Special Reports Abstracts 
from the American Heart Association's Scientific Sessions 2012
AUTHOR ADDRESSES
  SOURCE
  Circulation (2012) 126:23. Date of Publication: 4 Dec 2012
CONFERENCE NAME
  American Heart Association 2012 Scientific Sessions and Resuscitation 
Science Symposium
CONFERENCE LOCATION
  Los Angeles, CA, United States
CONFERENCE DATE
  2012-11-03 to 2012-11-06
ISSN
  0009-7322
BOOK PUBLISHER
  Lippincott Williams and Wilkins
ABSTRACT
  The proceedings contain 62 papers. The topics discussed include: Aspirin for 
the prevention of recurrent venous thromboembolism after a first unprovoked 
event: results of the aspire randomized controlled trial; a randomized trial 
of bedside platelet function monitoring to adjust antiplatelet therapy 
versus standard of care in patients undergoing drug eluting stent 
implantation: the ARCTIC study; main results of the future revascularization 
evaluation in patients with diabetes mellitus: optimal management of 
multivessel disease (FREEDOM) trial; economic outcomes of percutaneous 
coronary intervention performed at sites with and without on-site cardiac 
surgery; prospective evaluation of outcomes with stress perfusion imaging 
versus stress wall motion imaging during dobutamine or exercise 
echocardiography; and fish oil for the prevention of post-operative atrial 
fibrillation - the omega-3 fatty acids for prevention of post-operative 
atrial fibrillation (OPERA) trial.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid
  dobutamine
  fish oil
  omega 3 fatty acid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  clinical trial
  human
  medical society
  resuscitation
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  clinical trial (topic)
  diabetes mellitus
  drug eluting stent
  echocardiography
  exercise
  health care quality
  heart surgery
  imaging
  implantation
  monitoring
  patient
  percutaneous coronary intervention
  prevention
  randomized controlled trial
  randomized controlled trial (topic)
  revascularization
  scintigraphy
  therapy
  thrombocyte function
  venous thromboembolism
  wall stress
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 297
TITLE
  Omega-3 fatty acids and vitamin D in cardiology
AUTHOR NAMES
  Güttler N.
  Zheleva K.
  Parahuleva M.
  Chasan R.
  Bilgin M.
  Neuhof C.
  Burgazli M.
  Niemann B.
  Erdogan A.
  Böning A.
AUTHOR ADDRESSES
  (Güttler N., norbertguettler@bundeswehr.org; Zheleva K., 
kirillas2002@hotmail.com; Parahuleva M., 
mariana.parahuleva@innere.med.uni-giessen.de; Chasan R., 
ridvan.chasan@hotmail.de; Erdogan A., a.erdogan@web.de) Department of 
Cardiology and Angiology, University Hospital Giessen, 35390 Giessen, 
Germany.
(Bilgin M., mehmetbilgin62@yahoo.de) Department of Radiology, Bezmialem 
University of Istanbul, Istanbul, Turkey.
(Neuhof C., christiane.neuhof@innere.med.uni-giessen.de) Department of 
Cardiology, University of Giessen, 35390 Giessen, Germany.
(Burgazli M., mehmetburgazli@hotmail.de) Department of Internal Medicine, 
University of Giessen, 35390 Giessen, Germany.
(Niemann B., bernd.niemann@chiru.med.uni-giessen.de) Department of Cardiac 
Surgery, University of Giessen, 35390 Giessen, Germany.
(Böning A., andreas.boening@chiru.med.uni-giessen.de) Department of 
Cardiovascular Surgery, University Hospital Giessen, 35390 Giessen, Germany.
CORRESPONDENCE ADDRESS
  M. Bilgin, Department of Radiology, Bezmialem University of Istanbul, 
Istanbul, Turkey. Email: mehmetbilgin62@yahoo.de
SOURCE
  Cardiology Research and Practice (2012) 1:1 Article Number: 729670. Date of 
Publication: 2012
ISSN
  2090-0597 (electronic)
BOOK PUBLISHER
  Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New 
York, United States.
ABSTRACT
  Dietary modification and supplementation play an increasingly important role 
in the conservative treatment of cardiovascular disease. Current interest 
has focused on n-3 polyunsaturated fatty acids (PUFA) and vitamin D. 
Clinical trial results on this subject are contradictory in many aspects. 
Several studies indicate that n-3 PUFA consumption improves vascular and 
cardiac hemodynamics, triglycerides, and possibly endothelial function, 
autonomic control, inflammation, thrombosis, and arrhythmia. Experimental 
studies show effects on membrane structure and associated functions, ion 
channel properties, genetic regulation, and production of anti-inflammatory 
mediators. Clinical trials evaluating a possible reduction in cardiovascular 
disease by n-3 PUFA have shown different results. Supplementation of vitamin 
D is common regarding prevention and treatment of osteoporosis. But vitamin 
D also seems to have several effects on the cardiovascular system. Vitamin D 
deficiency appears to be related to an increase in parathyroid hormone 
levels and can predispose to essential hypertension and left ventricular 
hypertrophy, increased insulin resistance, and eventually to atherosclerosis 
and adverse cardiovascular events. Randomized prospective clinical trials 
are needed to determine whether vitamin D and omega-3 FA supplementation 
therapy should be recommended as a routine therapy for primary or secondary 
prevention of cardiovascular disease. © 2012 Norbert Güttler et al.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  omega 3 fatty acid (adverse drug reaction, clinical trial, drug combination, 
drug interaction, drug therapy, intravenous drug administration, 
pharmacology)
  vitamin D (drug therapy, endogenous compound)
EMTREE DRUG INDEX TERMS
  25 hydroxyvitamin D (endogenous compound)
  angiotensin (endogenous compound)
  anticoagulant agent (drug combination, drug interaction)
  antithrombocytic agent (drug combination, drug interaction)
  calcium
  docosahexaenoic acid
  docosapentaenoic acid
  fish oil
  icosapentaenoic acid
  insulin (endogenous compound)
  mercury
  omega 3 acid ethyl ester
  parathyroid hormone (endogenous compound)
  paricalcitol (drug therapy)
  placebo
  polychlorinated biphenyl
  renin (endogenous compound)
  sodium channel (endogenous compound)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (drug therapy, drug therapy, etiology, prevention, 
therapy)
  diet supplementation
EMTREE MEDICAL INDEX TERMS
  acute heart infarction (drug therapy, etiology, prevention, therapy)
  angiotensin blood level
  antiarrhythmic activity
  antiinflammatory activity
  atherogenesis
  atherosclerosis (etiology, prevention, therapy)
  atrial fibrillation (complication, prevention, therapy)
  biological activity
  bleeding (side effect)
  bleeding time
  blood pressure regulation
  cardiovascular risk
  cerebrovascular accident (drug therapy)
  chronic kidney disease (drug therapy)
  congestive heart failure (etiology, prevention, therapy)
  coronary artery bypass graft
  diastolic blood pressure
  disease association
  disease predisposition
  essential hypertension (etiology, prevention, therapy)
  genetic regulation
  heart arrhythmia (drug therapy, etiology, prevention, therapy)
  heart left ventricle hypertrophy (etiology, prevention, therapy)
  heart muscle cell
  heart protection
  heart rate
  human
  hypercalcemia
  inflammation
  insulin resistance
  kidney injury
  membrane structure
  non insulin dependent diabetes mellitus (side effect)
  nonhuman
  osteoporosis (drug therapy, prevention)
  parathyroid hormone blood level
  pathophysiology
  patient compliance
  peripheral vascular disease (etiology, prevention, therapy)
  plasma renin activity
  postoperative complication (complication, prevention, therapy)
  priority journal
  proteinuria (drug therapy)
  review
  risk factor
  risk reduction
  side effect (side effect)
  sudden death
  systolic blood pressure
  thrombocyte aggregation
  thrombosis (drug therapy, etiology, prevention, therapy)
  triacylglycerol blood level
  unspecified side effect (side effect)
  vascular endothelium
  vasodilatation
  vitamin blood level
  vitamin D deficiency (etiology)
DRUG TRADE NAMES
  lovaza
  omacor
CAS REGISTRY NUMBERS
  25 hydroxyvitamin D (64719-49-9)
  angiotensin (1407-47-2)
  calcium (14092-94-5, 7440-70-2)
  docosahexaenoic acid (25167-62-8, 32839-18-2)
  docosapentaenoic acid (25448-00-4, 32839-34-2)
  fish oil (8016-13-5)
  icosapentaenoic acid (25378-27-2, 32839-30-8)
  insulin (9004-10-8)
  mercury (14302-87-5, 7439-97-6)
  parathyroid hormone (12584-96-2, 68893-82-3, 9002-64-6)
  paricalcitol (131918-61-1)
  renin (61506-93-2, 9015-94-5)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013059377
FULL TEXT LINK
  http://dx.doi.org/10.1155/2012/729670
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 298
TITLE
  Hypertension in the elderly
AUTHOR NAMES
  Pinna G.
  Pascale C.
  La Regina M.
  Orlandini F.
AUTHOR ADDRESSES
  (Pinna G., giuliano.pinna@gmail.com; Pascale C.) Ospedale Cottolengo, 
Torino, Italy.
(La Regina M.; Orlandini F.) Ospedale S. Andrea, Presidio Unico Del Levante 
Ligure, La Spezia, Italy.
CORRESPONDENCE ADDRESS
  G. Pinna, Via Bertola 86, 10122 Torino, Italy. Email: 
giuliano.pinna@gmail.com
SOURCE
  Italian Journal of Medicine (2012) 6:4 (285-294). Date of Publication: 
December 2012
ISSN
  1877-9344
  1877-9352 (electronic)
BOOK PUBLISHER
  Elsevier Masson s.r.l., Via P. Paleocapa 7, Milan, Italy.
ABSTRACT
  Introduction: There is a high prevalence of hypertension in the elderly, as 
evidenced by clinical and health behavioral policies. Still, there are 
uncertainties on the treatment of hypertension, especially treatment of the 
very elderly. These considerations have largely been ignored in clinical 
trials due to concern regarding contamination by other pathologies that are 
difficult to frame and manage. Methods: We performed an effective and ample 
literature review and provided reflections on the Consensus Conference 
ACCF/AHA 2011 on the principle types of hypertension found in the elderly. 
We also considered the associated principle pathologies for various 
treatments and related organs. Discussion: Even if the goal of treatment of 
elevated blood pressure in the elderly is same as in younger population, it 
is no longer certain that a target systolic blood pressure (SBP) <140 mmHg 
should be persistently reached in the very elderly. It is important to note 
that for all studies these values have never been reached. In the treatment 
of isolated systolic hypertension (ISH) the preferred target is a SBP >160 
mmHg. Treating hypertension in the elderly and very elderly reduces the risk 
of stroke and heart failure, though the evidence is inconclusive for 
all-cause mortality. Conclusion: Hypertension in the elderly is very common 
and needs to be treated with criteria that consider the patient's age, 
comorbidities, lifestyle and adherence. Above all, in the very elderly, 
therapeutic treatment should be personalized according to the above 
criteria. Where possible pharmaceutical therapy should be limited at the 
preference of healthy lifestyle changes (physical activity, diet, etc.). © 
2012 Elsevier Srl. All rights reserved.
EMTREE DRUG INDEX TERMS
  alpha adrenergic receptor blocking agent (drug therapy)
  angiotensin receptor antagonist (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  blocking agent (drug therapy)
  calcium channel blocking agent (adverse drug reaction, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  diuretic agent (adverse drug reaction, drug therapy)
  renin inhibitor (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  geriatric patient
  hypertension (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  blood pressure regulation
  cardiovascular risk
  cerebrovascular accident
  cerebrovascular disease
  coronary artery disease
  dementia
  edema (side effect)
  glucose metabolism
  gout
  health care policy
  heart failure
  high risk patient
  human
  hyperglycemia (side effect)
  hyponatremia (side effect)
  obesity
  osteoarthritis
  quality of life
  risk
  risk reduction
  social status
  systolic blood pressure
  systolic hypertension
  vascular resistance
  very elderly
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012709750
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.itjm.2012.02.003
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 299
TITLE
  Stroke prevention: Recent achievements and new challenges
AUTHOR NAMES
  Katsnelson M.J.
  Della-Morte D.
  Sacco R.L.
  Rundek T.
AUTHOR ADDRESSES
  (Katsnelson M.J., trundek@med.miami.edu; Della-Morte D.; Sacco R.L.; Rundek 
T.) Department of Neurology, Miller School of Medicine, University of Miami, 
Miami, FL 33136, United States.
(Della-Morte D.) Department of Advanced Biotechnologies and Bioimaging, 
IRCCS San Raffaele Pisana, 00163 Rome, Italy.
CORRESPONDENCE ADDRESS
  M. J. Katsnelson, Department of Neurology, Miller School of Medicine, 
University of Miami, CRB13, 1120 NW 14th Street, Miami, FL 33136, United 
States. Email: trundek@med.miami.edu
SOURCE
  Periodicum Biologorum (2012) 114:3 (409-419). Date of Publication: 2012
ISSN
  0031-5362
BOOK PUBLISHER
  Croatian Society of Natural Sciences, Ilica 16/III, Zagreb, Croatia.
ABSTRACT
  Stroke remains a major health problem despite the great efforts made 
worldwide to fight against it. Despite therapeutic achievements to treat 
ischemic stroke patients in stroke units with tissue plasminogen activator 
(tPA), prevention remains the most powerful strategy to cure this complex 
disease. Stroke is a heterogeneous and multi-factorial disease caused by the 
combination of vascular risk factors, environment, and genetic factors. 
These risk factors can be subdivided into non-modifiable (age, sex, 
race-ethnicity, genetic variations and predispositions) and modifiable 
(hypertension, diabetes, dyslipidemia, atrial fibrillation, carotid artery 
stenosis, smoking, poor diet, physical inactivity and obesity). The 
metabolic syndrome, a cluster of metabolic risk factors within an 
individual, has been recognized as and important factor associated with an 
increased risk of stroke. Recently, a great emphasis has been given to the 
investigations of genetic factors and stroke risk, which may lead to the 
discovery of new biomarkers for prevention, diagnosis and to the alternative 
strategies for stroke treatment. In this review we sought to discuss the 
main risk factors for stroke and the current strategies of stroke 
prevention.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  angiotensin receptor antagonist (drug therapy)
  antidiabetic agent (drug therapy, oral drug administration)
  apixaban (adverse drug reaction, drug therapy)
  beta adrenergic receptor blocking agent (drug combination, drug therapy)
  C reactive protein (endogenous compound)
  calcium channel blocking agent (drug therapy)
  cholesterol (endogenous compound)
  cobalamin (drug combination, drug therapy)
  dabigatran (adverse drug reaction, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  ezetimibe (drug combination, drug therapy)
  fibric acid derivative (drug combination, drug therapy)
  folic acid (drug combination, drug therapy)
  high density lipoprotein (endogenous compound)
  homocysteine (endogenous compound)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  insulin (drug therapy)
  low density lipoprotein (endogenous compound)
  nicotinic acid (drug combination, drug therapy)
  omega 3 fatty acid (drug combination, drug therapy)
  rivaroxaban (adverse drug reaction, drug therapy)
  rosuvastatin (drug therapy)
  selectin (endogenous compound)
  thiazide diuretic agent (drug combination, drug therapy)
  tissue plasminogen activator (drug therapy, endogenous compound)
  varenicline
  warfarin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (drug therapy, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
  abdominal obesity
  alcohol consumption
  anticoagulant therapy
  atherosclerosis
  atrial fibrillation (drug therapy)
  brain hemorrhage (side effect)
  brain ischemia
  cardiomyopathy
  cardiovascular disease
  carotid artery stenting
  congestive heart failure
  diabetes mellitus (drug therapy)
  dyslipidemia (drug therapy)
  endarterectomy
  glycemic control
  heart infarction (drug therapy)
  heredity
  human
  hyperhomocysteinemia (drug therapy)
  hyperlipidemia
  hypertension (drug therapy)
  immobilization
  incidence
  lifestyle modification
  meta analysis (topic)
  metabolic syndrome X
  morbidity
  mortality
  prevalence
  public health problem
  randomized controlled trial (topic)
  retinopathy
  review
  risk factor
  risk reduction
  single nucleotide polymorphism
  sleep disordered breathing
  smoking
  substance abuse
  transient ischemic attack
  valvular heart disease
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  apixaban (503612-47-3)
  cholesterol (57-88-5)
  cobalamin (13408-78-1)
  ezetimibe (163222-33-1)
  folic acid (59-30-3, 6484-89-5)
  homocysteine (454-28-4, 6027-13-0)
  insulin (9004-10-8)
  nicotinic acid (54-86-4, 59-67-6)
  rivaroxaban (366789-02-8)
  rosuvastatin (147098-18-8, 147098-20-2)
  tissue plasminogen activator (105913-11-9)
  varenicline (249296-44-4, 375815-87-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013107164
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 300
TITLE
  Omega-3 polyunsaturated fatty acid supplementation: Mechanism and current 
evidence in atrial fibrillation
AUTHOR NAMES
  Nodari S.
  Triggiani M.
  Campia U.
  Cas L.D.
AUTHOR ADDRESSES
  (Nodari S., savinanodari@gmail.com; Triggiani M.; Cas L.D.) Department of 
Experimental and Applied Medicine, Section of Cardiovascular Diseases, 
University of Brescia, Brescia, Italy.
(Campia U.) Northwestern University Feinberg School of Medicine, Chicago 
(IL), United States.
CORRESPONDENCE ADDRESS
  S. Nodari, Department of Experimental and Applied Medicine, Section of 
Cardiovascular Diseases, University of Brescia, Brescia, Italy. Email: 
savinanodari@gmail.com
SOURCE
  Journal of Atrial Fibrillation (2012/2013) 5:4 (49-63). Date of Publication: 
December 2012-January 2013
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
  Atrial fibrillation (AF) is the most prevalent arrhythmia and is associated 
with considerable morbidity and mortality. Available pharmacologic 
antiarrhythmic therapies are often ineffective in preventing the recurrence 
of AF, possibly because these drugs target a single pathophysiological 
mechanism. Given their beneficial effects on ventricular arrhythmias, 
omega-3 polyunsaturated fatty acids (n-3 PUFAs) have recently been 
investigated as possible candidates in the treatment of supraventricular 
arrhythmias. In this review, we explore the current understanding of the 
antiarrhythmic effects attributed to n-3 PUFAs including direct modulation 
of ionic channels, improvement of membrane fluidity, anti-inflammatory and 
antifibrotic effects, and modulation of sympatho-vagal balance. We will then 
focus on the results of epidemiologic studies exploring the associations 
between nutritional intake of n3 PUFAs and the incidence of AF, and will 
review the findings of the clinical trials investigating the effects of n-3 
PUFAs supplementation in the prophylaxis of AF and in the prevention of its 
recurrences.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  omega 3 fatty acid (clinical trial, drug combination, drug therapy, 
intravenous drug administration, oral drug administration)
EMTREE DRUG INDEX TERMS
  alpha tocopherol (drug combination, drug therapy)
  amiodarone (clinical trial, drug therapy)
  ascorbic acid (drug combination, drug therapy)
  fish oil (clinical trial, drug therapy)
  flecainide (clinical trial, drug therapy)
  placebo
  propafenone (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy, surgery)
EMTREE MEDICAL INDEX TERMS
  antiinflammatory activity
  clinical trial
  dietary intake
  drug effect
  heart electrophysiology
  human
  nonhuman
  nutritional parameters
  postoperative period
  review
  vitamin supplementation
CAS REGISTRY NUMBERS
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
  fish oil (8016-13-5)
  flecainide (54143-55-4)
  propafenone (34183-22-7, 54063-53-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00597220, NCT00970489)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013200927
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 301
TITLE
  Exploring barriers to optimal anticoagulation for atrial fibrillation: 
Interviews with clinicians
AUTHOR NAMES
  Decker C.
  Garavalia L.
  Garavalia B.
  Simon T.
  Loeb M.
  Spertus J.A.
  Daniel W.C.
AUTHOR ADDRESSES
  (Decker C., c1decker@saint-lukes.org; Garavalia B.) Mid America Heart 
Institute at Saint Luke's Hospital in Kansas City Missouri, University of 
Missouri-Kansas City, School of Nursing, Kansas City, MO, United States.
(Garavalia L.) University of Missouri-Kansas City, School of Pharmacy, 
Kansas City, MO, United States.
(Simon T.) Bristol-Myers Squibb, Princeton, NJ, United States.
(Loeb M.) Plaza Primary Care and Geriatrics, Kansas City, MO, United States.
(Daniel W.C.) Saint Luke's Cardiovascular Consultants, Kansas City, MO, 
United States.
(Spertus J.A.) Mid America Heart Institute at Saint Luke's Hospital in 
Kansas City Missouri, University of Missouri-Kansas City, School of 
Medicine, Kansas City, MO, United States.
CORRESPONDENCE ADDRESS
  C. Decker, Mid America Heart Institute, Saint Luke's Hospital, 4401 Wornall 
Road, Kansas City, MO 64111, United States. Email: c1decker@saint-lukes.org
SOURCE
  Journal of Multidisciplinary Healthcare (2012) 5 (129-135). Date of 
Publication: 2012
ISSN
  1178-2390 (electronic)
BOOK PUBLISHER
  Dove Medical Press Ltd, Beechfield House, Winterton Way, Macclesfield, 
United Kingdom.
ABSTRACT
  Background: Warfarin, the most commonly used antithrombotic agent for stroke 
prophylaxis in atrial fibrillation (AF), requires regular monitoring, 
frequent dosage adjustments, and dietary restrictions. Clinicians' 
perceptions of barriers to optimal AF management are an important factor in 
treatment. Anticoagulation management for AF is overseen by both cardiology 
and internal medicine (IM) practices. Thus, gaining the perspective of 
specialists and generalists is essential in understanding barriers to 
treatment. We used qualitative research methods to define key issues in the 
prescription of warfarin therapy for AF by cardiology specialists and IM 
physicians. Methods and results: Clinicians were interviewed to identify 
barriers to warfarin treatment in a large Midwestern city. Interviews were 
conducted until thematic saturation occurred. Content analysis yielded 
several themes. The most salient theme that emerged from clinician 
interviews was use of characteristics other than the patient's CHADS(2) 
score to enact a treatment plan, such as the patient's social situation and 
past medication-taking behavior. Other themes included patient knowledge, 
real-world problems, breakdown in communication, and clinician reluctance. 
Conclusion: Warfarin treatment is associated with many challenges. The 
barriers identified by clinicians highlight the unmet need associated with 
stroke prophylaxis in AF and the opportunity to improve anticoagulation 
treatment in AF. Social and lifestyle factors were important considerations 
in determining treatment. © 2012 Decker et al, publisher and licensee Dove 
Medical Press Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulation
  atrial fibrillation
EMTREE MEDICAL INDEX TERMS
  article
  attitude to health
  cardiologist
  cerebrovascular accident
  CHADS2 score
  clinical decision making
  content analysis
  controlled study
  descriptive research
  female
  human
  interdisciplinary communication
  internist
  lifestyle
  male
  patient attitude
  physician attitude
  prescription
  prophylaxis
  qualitative research
  semi structured interview
  social aspect
  social status
  treatment planning
CAS REGISTRY NUMBERS
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013151696
FULL TEXT LINK
  http://dx.doi.org/10.2147/JMDH.S33045
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 302
TITLE
  High E/e′ disrupts the rapid lowering of blood glucose in response to 
exercise training
AUTHOR NAMES
  Fukuda Y.
  Yoshimura K.
  Fukuda Y.
  Fukuda N.
AUTHOR ADDRESSES
  (Fukuda Y., svx@muse.dti.ne.jp; Fukuda N.) Department of Cardiology and 
Clinical Research, National Hospital Organization Zentsuji Hospital, 
Senyu-cho 2-1-1, Zentsuji, Kagawa, 765-0806, Japan.
(Yoshimura K.; Fukuda Y.) Department of Cardiology, Fukuda Cardiovascular 
Surgery and Digestive Internal Medicine Clinic, Higashijinzenji 67-1, Kochi, 
780-0023, Japan.
CORRESPONDENCE ADDRESS
  Y. Fukuda, Department of Cardiology and Clinical Research, National Hospital 
Organization Zentsuji Hospital, Senyu-cho 2-1-1, Zentsuji, Kagawa, 765-0806, 
Japan. Email: svx@muse.dti.ne.jp
SOURCE
  Journal of Echocardiography (2012) 10:4 (119-124). Date of Publication: 
December 2012
ISSN
  1349-0222
  1880-344X (electronic)
BOOK PUBLISHER
  Springer Japan, 1-11-11 Kudan-kita, Chiyoda-ku, No. 2 Funato Bldg., Tokyo, 
Japan.
ABSTRACT
  Background: No relationship between the ratio of peak early velocity of left 
ventricular inflow to peak systolic longitudinal velocity of the mitral 
annulus velocity (E/e′) and insulin resistance has yet been shown in 
patients with cardiac disease. We hypothesized that patients with high E/e′ 
values would tend not to show the rapid blood glucose-lowering in response 
to exercise training characteristic of impaired glucose tolerance (IGT) or 
diabetes mellitus (DM) patients. Methods: The subjects were continuous 
IGT/DM patients (n = 27) participating in cardiac rehabilitation. All 
patients' E/e′ values were measured by echocardiography. The patients' blood 
glucose levels (mg/dl) were measured just before (pre-BS) and after 
(post-BS) exercise training. Post-BS was subtracted from pre-BS to obtain 
ΔBS, and the relationship between E/e′ and ΔBS was investigated. Results: 
E/e′ correlated negatively with ΔBS. Moreover, E/e′ was a significant 
predictor of ΔBS and as such was independent of hemoglobin A1c (HbA1c), 
pre-BS, and presence of atrial fibrillation on multivariate analysis. 
Conclusions: Patients with high E/e′, indicating high left ventricular 
filling pressure, were unlikely to exhibit the rapid glucose-lowering 
response. © 2012 Japanese Society of Echocardiography.
EMTREE DRUG INDEX TERMS
  glucose (endogenous compound)
  hemoglobin A1c (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  blood glucose monitoring
  cardiovascular parameters
  diabetes mellitus
  exercise
  impaired glucose tolerance
  peak systolic longitudinal velocity of the mitral annulus velocity
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  clinical article
  controlled study
  coronary artery bypass graft
  correlation analysis
  echocardiography
  female
  glucose blood level
  heart failure (rehabilitation)
  heart hemodynamics
  heart left ventricle filling pressure
  heart rehabilitation
  human
  ischemic heart disease
  male
  multivariate analysis
  outcome assessment
CAS REGISTRY NUMBERS
  glucose (50-99-7, 84778-64-3)
  hemoglobin A1c (62572-11-6)
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012721277
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12574-012-0134-0
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 303
TITLE
  Exercise tolerance in asymptomatic patients with moderate-severe valvular 
heart disease and preserved ejection fraction
AUTHOR NAMES
  Olaf S.
  Debora B.
  Ricarda B.
  Gunnar B.
  Jochen K.
  Schimke I.
  Halle M.
  Jaffe A.
AUTHOR ADDRESSES
  (Olaf S., oschulz@cath-lab-spandau.de; Debora B.; Ricarda B.; Gunnar B.; 
Jochen K.) Interventionelle Kardiologie Spandau, Neuendorfer Str. 70, 13585 
Berlin, Germany.
(Schimke I.) Department of Cardiology, Charité Universitätsmedizin, Berlin, 
Germany.
(Halle M.) Department of Prevention and Sports Medicine, Technische 
Universität Munich, Germany.
(Jaffe A.) Mayo Clinic and Medical School, Rochester, MN, United States.
CORRESPONDENCE ADDRESS
  S. Olaf, Interventionelle Kardiologie Spandau, Neuendorfer Str. 70, 13585 
Berlin, Germany. Email: oschulz@cath-lab-spandau.de
SOURCE
  Archives of Medical Science (2012) 8:6 (1018-1026). Date of Publication: 
December 2012
ISSN
  1734-1922
BOOK PUBLISHER
  Termedia Publishing House Ltd., Kleeberqa St.2, Poznan, Poland.
ABSTRACT
  Introduction: For asymptomatic patients with moderate-severe valvular heart 
disease, in whom symptoms may be obscured, objective exercise tolerance 
measures are warranted for decisions concerning physical activities and 
surgical treatment. Material and methods: We compared 61 patients (39 with 
aortic stenosis, 22 with aortic or mitral regurgitation) to 23 controls 
without valvular heart disease but with indications for stress testing. All 
participants underwent cardiopulmonary function testing and dobutamine 
stress echocardiography. Blood was drawn before as well as after bicycle 
stress to assess high-sensitivity cardiac troponin T (hscTnT). Patients who 
underwent surgery were re-evaluated 1.5 ±0.9 years after the operation. 
Results: Conventional bicycle test following guideline criteria revealed a 
pathologic result in 26% of the patients, whereas spiroergometry showed an 
objectively reduced exercise tolerance in 59%, reaching a prognostically 
relevant feature in 39%. Stress echocardiography detected a reduced systolic 
reserve in 33% and elevated filling pressures in 62%. These abnormalities 
were significantly less present in the control group (4, 17, 9, 9, 4% 
respectively, p <0.05 each). Baseline hscTnT detected patients with the 
prognostically important feature of reduced exercise tolerance (area under 
the curve 0.689 (95% CI:0.546-0.831), p = 0.015). Objective preoperative 
exercise tolerance predicted sustained cardiocirculatory and myocardial 
dysfunction postoperatively. Conclusions: Cardiopulmonary function testing 
and dobutamine stress echocardiography identify exercise intolerance in 
patients with asymptomatic valvular heart disease beyond stress-test 
criteria recommended in recent guidelines. High-sensitivity cardiac troponin 
I may be of additional value. Results of these tests presage post-operative 
function. Copyright © 2012 Termedia & Banach.
EMTREE DRUG INDEX TERMS
  dobutamine
  troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aorta valve regurgitation (surgery)
  exercise tolerance
  heart left ventricle ejection fraction
  mitral valve regurgitation (surgery)
EMTREE MEDICAL INDEX TERMS
  adult
  aorta stenosis
  article
  atrial fibrillation (complication)
  bicycle ergometry
  blood sampling
  cardiopulmonary hemodynamics
  cerebrovascular accident (complication)
  circulation
  disease severity
  exercise test
  female
  heart function test
  heart left ventricle enddiastolic volume
  heart left ventricle filling pressure
  heart left ventricle mass
  heart rate
  human
  ischemia (complication)
  lung function test
  major clinical study
  male
  myocardial disease
  postoperative period
  prognosis
  respiratory quotient
  ST segment depression
  stress echocardiography
CAS REGISTRY NUMBERS
  dobutamine (34368-04-2, 49745-95-1, 52663-81-7, 61661-06-1)
  troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013078217
FULL TEXT LINK
  http://dx.doi.org/10.5114/aoms.2012.32409
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 304
TITLE
  Thigh haematoma following acupuncture treatment in a patient on warfarin
AUTHOR NAMES
  Kenz S.
  Webb H.
  Laggan S.
AUTHOR ADDRESSES
  (Kenz S., samikenz71@yahoo.co.uk; Webb H.; Laggan S.) Department of Diabetes 
and Endocrinology, Trafford General Hospital, Manchester, United Kingdom.
CORRESPONDENCE ADDRESS
  S. Kenz, Department of Diabetes and Endocrinology, Trafford General 
Hospital, Manchester, United Kingdom. Email: samikenz71@yahoo.co.uk
SOURCE
  BMJ Case Reports (2012). Date of Publication: 2012
ISSN
  1757-790X (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, Tavistock Square, London, United Kingdom.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin (drug therapy)
EMTREE DRUG INDEX TERMS
  hemoglobin (endogenous compound)
  vitamin K group (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  hematoma (drug therapy, complication, drug therapy)
  thigh hematoma (drug therapy, complication, drug therapy)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation (drug therapy)
  bursitis (therapy)
  case report
  drug withdrawal
  echography
  female
  hemoglobin blood level
  human
  international normalized ratio
  priority journal
  trochanteric bursitis (therapy)
CAS REGISTRY NUMBERS
  hemoglobin (9008-02-0)
  vitamin K group (12001-79-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Orthopedic Surgery (33)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2013025820
MEDLINE PMID
  23087270 (http://www.ncbi.nlm.nih.gov/pubmed/23087270)
FULL TEXT LINK
  http://dx.doi.org/10.1136/bcr-2012-006676
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 305
TITLE
  All that glitters is not gold: Apical hypertrophic cardiomyopathy mimicking 
acute coronary syndrome
AUTHOR NAMES
  Lakshmanadoss U.
  Kulkarni A.
  Balakrishnan S.
  Shree N.
  Harjai K.
  Jagasia D.
AUTHOR ADDRESSES
  (Lakshmanadoss U.; Kulkarni A., abhi30882@gmail.com; Harjai K.; Jagasia D.) 
Division of Cardiology, Department of Medicine, Guthrie Health System, 
Sayre, PA, 18840, United States.
(Balakrishnan S.; Shree N.) Division of Hospital Medicine, Johns Hopkins 
Bayview Medical Center, Baltimore, MD, United States.
CORRESPONDENCE ADDRESS
  A. Kulkarni, Division of Cardiology, Department of Medicine, Guthrie Health 
System, Sayre, PA, 18840, United States. Email: abhi30882@gmail.com
SOURCE
  Cardiology Research (2012) 3:3 (137-139). Date of Publication: 2012
ISSN
  1923-2829
  1923-2837 (electronic)
BOOK PUBLISHER
  Elmer Press, 8230 Boul Taschereau, CP 50577,Brossard, Quebec, Canada.
ABSTRACT
  Hypertrophic cardiomyopathy is characterized by the idiopathic hypertrophy 
of the left ventricle (and occasionally right ventricle). HCM is an 
autosomal dominant disease, with variable penetration. In Asian population, 
apical hypertrophic cardiomyopathy is relatively common (25%). However, this 
is relatively rare in Caucasian population (0.2%). Patients with HCM, often 
presents with typical exertional chest pain and shortness of breath. Apical 
HCM patients tend to have milder symptoms. However, the clinical 
presentation and electrocardiographic features of Apical HCM often mimic 
acute coronary syndrome and high index of suspicion is warranted in 
differentiating this condition. Patients with apical HCM have relatively 
better prognosis when compare to the other varieties. Here, we are 
presenting a patient who presented with typical exertional chest pain whose 
electrocardiographic changes are concerning for acute ischemic changes. © 
The authors | Journal compilation © Cardiol Res and Elmer Press™.
EMTREE DRUG INDEX TERMS
  diltiazem
  lisinopril
  metoprolol
  pantoprazole
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acute coronary syndrome
  hypertrophic cardiomyopathy
EMTREE MEDICAL INDEX TERMS
  aged
  arteriovenous malformation
  article
  ascending colon
  auscultation
  blood cell count
  case report
  CHADS2 score
  duodenal ulcer bleeding (surgery)
  electrocardiography
  emergency ward
  essential hypertension
  exercise
  heart catheterization
  heart left ventricle hypertrophy
  heart palpitation
  heart ventricle tachycardia
  human
  laser coagulation
  male
  medical history
  paroxysmal atrial fibrillation
  prostate hypertrophy
  supraventricular tachycardia
  T wave inversion
  thorax pain
  transient ischemic attack
CAS REGISTRY NUMBERS
  diltiazem (33286-22-5, 42399-41-7)
  lisinopril (76547-98-3, 83915-83-7)
  metoprolol (37350-58-6)
  pantoprazole (102625-70-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2013604514
FULL TEXT LINK
  http://dx.doi.org/10.4021/cr180w
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 306
TITLE
  Perioperative optimization of patients undergoing bariatric surgery
AUTHOR NAMES
  Owers C.E.
  Abbas Y.
  Ackroyd R.
  Barron N.
  Khan M.
AUTHOR ADDRESSES
  (Owers C.E., corinneowers@doctors.org.uk; Abbas Y., yabbas@doctors.org.uk; 
Ackroyd R., roger.ackroyd@sth.nhs.uk; Khan M., manskhan@doctors.org.uk) 
Department of Upper GI Surgery, Sheffield Teaching Hospitals, South 
Yorkshire, Sheffield S5 7AU, United Kingdom.
(Barron N., nicholas.barron@sth.nhs.uk) Department of Anaesthesia, Sheffield 
Teaching Hospitals, South Yorkshire, Sheffield S10 2JF, United Kingdom.
CORRESPONDENCE ADDRESS
  C.E. Owers, Department of Upper GI Surgery, Sheffield Teaching Hospitals, 
South Yorkshire, Sheffield S5 7AU, United Kingdom. Email: 
corinneowers@doctors.org.uk
SOURCE
  Journal of Obesity (2012) 2012 Article Number: 781546. Date of Publication: 
2012
ISSN
  2090-0708
  2090-0716 (electronic)
BOOK PUBLISHER
  Hindawi Publishing Corporation, 410 Park Avenue, 15th Floor, 287 pmb, New 
York, United States.
ABSTRACT
  Bariatric surgery is fast becoming an efficient and safe method of weight 
reduction, especially for patients in whom conservative measures have 
failed. As the obese population of the world increases, so will the number 
of patients requesting or requiring surgical weight loss methods. Bariatric 
patients however have numerous co-morbidities that make their operative 
course more difficult, and therefore is important to have a good 
understanding of the important issues surrounding their pre, peri and post 
operative management. This article aims to educate the reader about optimal 
management of the bariatric surgical patient. © 2012 C. E. Owers et al.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  bariatric surgery
  perioperative period
  surgical patient
EMTREE MEDICAL INDEX TERMS
  alpha tocopherol deficiency (complication)
  anastomosis leakage (complication)
  anemia (complication)
  article
  asthma
  atrial fibrillation
  body mass
  cerebrovascular accident
  culture optimization
  deep vein thrombosis
  dyspnea
  emphysema
  fatty liver
  gastric sleeve
  health behavior
  health practitioner
  heart atrium flutter
  heart failure
  hemoptysis
  hepatomegaly
  human
  hyperlipidemia
  hypertension
  hypoglycemia
  insulin resistance
  intestine injury (complication)
  laparoscopic surgery
  limb swelling
  low calory diet
  lung embolism (etiology)
  meta analysis (topic)
  mortality
  non insulin dependent diabetes mellitus
  nutritional deficiency (etiology)
  obesity
  oxygenation
  pain assessment
  patient positioning
  peroperative complication (complication)
  pneumothorax (complication)
  polysomnography
  positive end expiratory pressure
  postoperative complication (complication)
  psychological aspect
  retinol deficiency (complication)
  sleep disordered breathing (etiology)
  smoking cessation
  stomach bypass
  thiamine deficiency (complication)
  vein thrombosis
  venous thromboembolism
  vitamin D deficiency (complication)
  vitamin K deficiency (complication)
  weight reduction
EMBASE CLASSIFICATIONS
  Surgery (9)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012646536
FULL TEXT LINK
  http://dx.doi.org/10.1155/2012/781546
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 307
TITLE
  Recommendations regarding dietary intake and caffeine and alcohol 
consumption in patients with cardiac arrhythmias: What do you tell your 
patients to do or not to do?
AUTHOR NAMES
  Glatter K.A.
  Myers R.
  Chiamvimonvat N.
AUTHOR ADDRESSES
  (Glatter K.A., kaglatter@gmail.com) Woodland Clinic Medical Group, 632 West 
Gibson Road, Woodland, CA 95695, United States.
(Myers R.; Chiamvimonvat N.) Division of Cardiovascular Medicine, University 
of California, Davis, One Shields Avenue, GBSF 6315, Davis, CA 95616, United 
States.
(Chiamvimonvat N.) Department of Veteran's Affairs, Northern California 
Health Care System, Mather, CA, United States.
CORRESPONDENCE ADDRESS
  K.A. Glatter, Woodland Clinic Medical Group, 632 West Gibson Road, Woodland, 
CA 95695, United States. Email: kaglatter@gmail.com
SOURCE
  Current Treatment Options in Cardiovascular Medicine (2012) 14:5 (529-535). 
Date of Publication: October 2012
ISSN
  1092-8464
  1534-3189 (electronic)
BOOK PUBLISHER
  Current Science Inc., 34-42 Cleveland Street, London, United Kingdom.
ABSTRACT
  The etiology of arrhythmias including atrial fibrillation is multifactorial. 
Most arrhythmias are associated with comorbid illnesses like hypertension, 
diabetes, thyroid disease, or advanced age. Although it is tempting to blame 
a stimulant like caffeine as a trigger for arrhythmias, the literature does 
not support this idea. There is no real benefit to having patients with 
arrhythmias limit their caffeine intake. Caffeine is a vasoactive substance 
that also may promote the release of norepinephrine and epinephrine. 
However, acute ingestion of caffeine (as coffee or tea) does not cause 
atrial fibrillation. Even patients suffering a myocardial infarction do not 
have an increased incidence of ventricular or other arrhythmias after 
ingesting several cups of coffee. Large epidemiologic studies have also 
failed to find a connection between the amount of coffee/caffeine used and 
the development of arrhythmias. As such, it does not make sense to suggest 
that patients with palpitations, paroxysmal atrial fibrillation, or 
supraventricular tachycardia, abstain from caffeine use. Energy drinks are a 
new phenom.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  caffeine
EMTREE DRUG INDEX TERMS
  adrenalin
  noradrenalin
  sugar
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alcohol consumption
  dietary intake
  heart arrhythmia (etiology)
EMTREE MEDICAL INDEX TERMS
  adrenalin release
  aging
  article
  atrial fibrillation (diagnosis, etiology)
  beverage
  coffee
  comorbidity
  diabetes mellitus
  energy drink
  exercise
  heart infarction
  heart palpitation
  heart ventricle arrhythmia
  human
  hypertension
  noradrenalin release
  sudden death
  supraventricular tachycardia
  tea
  thyroid disease
CAS REGISTRY NUMBERS
  adrenalin (51-43-4, 55-31-2, 6912-68-1)
  caffeine (58-08-2)
  noradrenalin (1407-84-7, 51-41-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012701778
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11936-012-0193-6
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 308
TITLE
  Association of angiotensin-converting enzyme gene I/D and CYP11B2 gene 
-344T/C polymorphisms with lone atrial fibrillation and its recurrence after 
catheter ablation
AUTHOR NAMES
  Zhang X.-L.
  Wu L.-Q.
  Liu X.
  Yang Y.-Q.
  Tan H.-W.
  Wang X.-H.
  Zhou L.
  Jiang W.-F.
  Li Z.
AUTHOR ADDRESSES
  (Zhang X.-L.; Liu X., xkliuxu@126.com; Tan H.-W.; Wang X.-H.; Zhou L.; Jiang 
W.-F.; Li Z.) Department of Cardiology, Shanghai Chest Hospital, Shanghai 
Jiaotong University School of Medicine, Shanghai, China.
(Zhang X.-L.) Department of Cardiology, Shanghai Tenth People's Hospital, 
Tongji University, Shanghai, China.
(Wu L.-Q.) Department of Cardiology, Shanghai Ruijin Hospital, Shanghai 
Jiaotong University School of Medicine, Shanghai, China.
(Yang Y.-Q.) Department of Cardiovascular Research, Shanghai Chest Hospital, 
Shanghai Jiaotong University School of Medicine, Shanghai, China.
CORRESPONDENCE ADDRESS
  X. Liu, Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong 
University School of Medicine, 241 West Huaihai Road, Shanghai 200030, 
China. Email: xkliuxu@126.com
SOURCE
  Experimental and Therapeutic Medicine (2012) 4:4 (741-747). Date of 
Publication: 2012
ISSN
  1792-0981
  1792-1015 (electronic)
BOOK PUBLISHER
  Spandidos Publications Ltd., 10 Vriaxidos Street, Athens, Greece.
ABSTRACT
  The renin-angiotensin-aldosterone system (RAAS) plays a key role in atrial 
structural and electrical remodeling. The aim of this study was to 
investigate the potential associations of angiotensin--converting enzyme 
(ACE) gene insertion/deletion (I/D) and aldosterone synthase (CYP11B2) gene 
-344T/C polymorphisms with the risk and recurrence of lone atrial 
fibrillation (AF). One hundred and ninety-three patients who underwent 
successful catheter ablation for lone AF were recruited. Two hundred and 
ninety-seven sinus rhythm subjects without a history of arrhythmia served as 
controls. The subjects were genotyped for ACE gene I/D and CYP11B2 gene 
-344T/C polymorphisms. Results showed that the ACE gene DD genotype and D 
allele were associated with a greater prevalence of lone AF (both P<0.01). 
In addition, the ACE gene DD genotype had a significantly larger left atrial 
dimension (LAD; 41.6±5.7 mm vs. 39.6±5.2 mm; P=0.043) and higher risk of AF 
recurrence [44.7% vs. 23.2%; odds ratio (OR), 2.68; 95% confidence interval 
(CI), 1.28-5.61; P=0.008] compared with the II+ID genotype in lone AF 
patients. After adjustment for a variety of risk factors, the ACE gene DD 
genotype had a 1.97--fold increased risk for lone AF (OR, 1.97; 95% CI, 
1.15-3.37; P=0.013) and 2.35-fold increased risk for AF recurrence (RR, 
2.35; 95% CI, 1.10-5.04; P=0.028) compared with the ACE gene II+ID genotype. 
However, no correlation between the CYP11B2 gene -344T/C polymorphism and 
lone AF or its recurrence was observed in this cohort. In conclusion, the 
ACE gene DD genotype was associated with an increased incidence of lone AF 
and its recurrence following ablation, which was partly mediated by LAD.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  aldosterone synthase (endogenous compound)
  dipeptidyl carboxypeptidase (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (therapy)
  DNA polymorphism
  gene deletion
  gene insertion
EMTREE MEDICAL INDEX TERMS
  adult
  article
  catheter ablation
  Chinese
  controlled study
  female
  genotype
  human
  major clinical study
  male
  recurrent disease
  risk factor
  sinus rhythm
CAS REGISTRY NUMBERS
  aldosterone synthase (122933-89-5)
  dipeptidyl carboxypeptidase (9015-82-1)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Human Genetics (22)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012500031
FULL TEXT LINK
  http://dx.doi.org/10.3892/etm.2012.650
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 309
TITLE
  Abstracts of the 15th Congress of Chest Pain Centers
AUTHOR ADDRESSES
  SOURCE
  Critical Pathways in Cardiology (2012) 11:3. Date of Publication: September 
2012
CONFERENCE NAME
  15th Congress of Chest Pain Centers
CONFERENCE LOCATION
  Orlando, FL, United States
CONFERENCE DATE
  2012-05-02 to 2012-05-03
ISSN
  1535-282X
BOOK PUBLISHER
  Lippincott Williams and Wilkins
ABSTRACT
  The proceedings contain 18 papers. The topics discussed include: does 
limiting prehospital 12 lead ECGs to patients who complain of chest pain 
delay diagnosing AMI?; STEMI door-to-balloon times: EMS transmitted 12 lead 
EKGs to Geisinger Wyoming Valley versus other arrival modalities; 
exercise-induced nonsustained ventricular tachycardia; impact of 
point-of-care testing and a physician in triage on the timely assessment of 
patients with chest pain; validation of high-sensitivity troponin I method 
in ACS patients; clopidogrel provision for indigent patients with 
ST-elevation; cost analysis in acute coronary syndrome patients using a 
high-sensitivity troponin I method; allowing EMS to activate the Cath lab 
from the field will decrease D2B times; there is no level of cTnI that is 
safe to discharge from the ED; a protocol for definitive therapy with 
flecainide in patients with rapid atrial fibrillation: pill in the pocket; 
and qualitative analysis of chest pain center education.
EMTREE DRUG INDEX TERMS
  clopidogrel
  flecainide
  troponin I
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  pain clinic
  thorax pain
EMTREE MEDICAL INDEX TERMS
  acute coronary syndrome
  atrial fibrillation
  cost benefit analysis
  education
  emergency health service
  exercise
  heart ventricle tachycardia
  human
  indigent
  patient
  physician
  pill
  point of care testing
  qualitative analysis
  ST segment elevation
  ST segment elevation myocardial infarction
  therapy
  United States
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 310
TITLE
  Stroke: Causes and clinical features
AUTHOR NAMES
  Markus H.
AUTHOR ADDRESSES
  (Markus H.) Department of Neurology, St George's University of London, 
United Kingdom.
CORRESPONDENCE ADDRESS
  H. Markus, Department of Neurology, St George's University of London, United 
Kingdom.
SOURCE
  Medicine (United Kingdom) (2012) 40:9 (484-489). Date of Publication: 
September 2012
ISSN
  1357-3039
  1365-4357 (electronic)
BOOK PUBLISHER
  Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
  Stroke represents a clinical syndrome rather than a specific disease. It can 
be caused by a number of different pathologies which all result in a usually 
sudden-onset focal cerebral damage. This article reviews risk factors for 
stroke, and the different pathologies that can cause stroke. Approximately 
20% of strokes are due to cerebral haemorrhage, most of which is 
intracerebral, with a significant minority due to subarachnoid haemorrhage. 
The remaining 80% are due to ischaemic stroke which itself has a number of 
different subtypes, including large artery disease, cardio-embolism, and 
small vessel disease. Differentiation of cerebral ischaemia from haemorrhage 
is impossible without brain imaging. Assessment of a patient with ischaemic 
stroke requires knowledge of the cerebral arterial supply and cerebral 
anatomy, which allows one to determine which particular vascular territory 
(anterior versus posterior) is involved. © 2012 Published by Elsevier Ltd.
EMTREE DRUG INDEX TERMS
  cholesterol (endogenous compound)
  homocysteine (endogenous compound)
  oral contraceptive agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  age
  alcohol consumption
  blood pressure
  body mass
  cerebrovascular accident (etiology)
  diabetes mellitus
  ethnicity
  exercise
  gender
  smoking
EMTREE MEDICAL INDEX TERMS
  arterial circulation
  atrial fibrillation
  brain hemorrhage
  brain ischemia
  cerebrovascular disease
  clinical feature
  heart failure
  human
  migraine
  neuroimaging
  priority journal
  review
  subarachnoid hemorrhage
  transient ischemic attack
  vascular disease
CAS REGISTRY NUMBERS
  cholesterol (57-88-5)
  homocysteine (454-28-4, 6027-13-0)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012496945
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.mpmed.2012.06.005
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 311
TITLE
  Stroke and mortality in patients with incident heart failure: The Diet, 
Cancer and Health (DCH) cohort study
AUTHOR NAMES
  Lip G.Y.H.
  Rasmussen L.H.
  Skjøth F.
  Overvad K.
  Larsen T.B.
AUTHOR ADDRESSES
  (Lip G.Y.H., g.y.h.lip@bham.ac.uk) Centre for Cardiovascular Sciences, 
University of Birmingham, City Hospital, Birmingham, United Kingdom.
(Lip G.Y.H., g.y.h.lip@bham.ac.uk; Rasmussen L.H.; Skjøth F.; Larsen T.B.) 
Thrombosis Research Centre, Clinical Institute, Aalborg University, Denmark, 
Denmark.
(Rasmussen L.H.; Skjøth F.; Overvad K.; Larsen T.B.) Department of 
Cardiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.
(Overvad K.) School of Public Health, Aarhus University, Aarhus, Denmark.
CORRESPONDENCE ADDRESS
  G.Y.H. Lip, Centre for Cardiovascular Sciences, University of Birmingham, 
City Hospital, Birmingham, United Kingdom. Email: g.y.h.lip@bham.ac.uk
SOURCE
  BMJ Open (2012) 2:4 Article Number: e000975. Date of Publication: 2012
ISSN
  2044-6055 (electronic)
BOOK PUBLISHER
  BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
  Objective: The objective was to test the hypothesis that the risk of stroke, 
death and the composite of 'stroke and death' would be increased among 
patients with incident heart failure (HF). While HF increases the risk of 
mortality, stroke and thromboembolism in general, the 'extreme high-risk' 
nature of incident HF is perhaps under-recognised in everyday clinical 
practice. Design: Prospective cohort study. Setting: Large Danish 
prospective epidemiological cohort. Participants: Subjects in the Diet, 
Cancer and Health study. Outcome measures: Stroke, death and the composite 
of 'stroke and death' among patients with incident cases of HF, without 
concomitant atrial fibrillation. Results: From the original cohort, 1239 
patients with incident HF were identified. Incidence rates show a higher 
incidence in the initial period following the diagnosis of HF, with a 
markedly higher rate of death and stroke (ischaemic or haemorrhagic) in the 
initial 30 days following the diagnosis of incident HF. While lower than the 
risk at 0-30 days, the higher risk did not return to normal at 6+ months 
after the diagnosis of incident HF. This risk increase was apparent for the 
end points of stroke (ischaemic or haemorrhagic or both) whether or not a 
vitamin K antagonist (VKA) was used. With VKA use, there was a lower 
adjusted HR for death and the composite of 'death or stroke' compared to 
non-VKA use at the three time intervals following diagnosis of HF, whether 
0-30 days, 30 days to 6 months and 6+ months. On multivariate analysis, 
previous stroke/ transient ischaemic attack/thromboembolism was a predictor 
of higher risk of stroke, death and the composite of 'stroke and death', 
while VKA treatment was a highly significant predictor of a lower risk for 
death (adjusted HR 0.46, 95% CI 0.28 to 0.74, p<0.001) and the combined end 
point of death or stroke (adjusted HR 0.64, 95% CI 0.43 to 0.96, p=0.003). 
Conclusions: Based on relative hazards, incident HF is clearly a major risk 
factor for stroke, death and the composite of 'stroke and death', especially 
in the initial 30 days following initial diagnosis. The use of VKA therapy 
was associated with a lower risk of these end points. These findings would 
have major implications for the approach to management of patients 
presenting with incident HF, given the high risk of this population for 
death and stroke, which may be ameliorated by VKA therapy.
EMTREE DRUG INDEX TERMS
  antivitamin K (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (etiology)
  heart failure
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  brain hemorrhage (drug therapy)
  brain ischemia (drug therapy)
  cardiac patient
  clinical practice
  cohort analysis
  controlled study
  death
  Denmark
  female
  hazard ratio
  high risk population
  human
  incidence
  major clinical study
  male
  mortality
  multivariate analysis
  patient identification
  prospective study
  risk
  thromboembolism (etiology)
  transient ischemic attack
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012433787
FULL TEXT LINK
  http://dx.doi.org/10.1136/bmjopen-2012-000975
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 312
TITLE
  Effect of omega-3 polyunsaturated fatty acid supplementation in patients 
with atrial fibrillation
AUTHOR NAMES
  Kumar S.
  Qu S.
  Kassotis J.T.
AUTHOR ADDRESSES
  (Kumar S.; Qu S.; Kassotis J.T., John.Kassotis@downstate.edu) Department of 
Cardiovascular Diseases, Electrophysiology Section, SUNY Downstate Medical 
Center, 450 Clarkson Avenue-Box 1199, Brooklyn, NY 11203, United States.
CORRESPONDENCE ADDRESS
  J.T. Kassotis, Department of Cardiovascular Diseases, Electrophysiology 
Section, SUNY Downstate Medical Center, 450 Clarkson Avenue-Box 1199, 
Brooklyn, NY 11203, United States. Email: John.Kassotis@downstate.edu
SOURCE
  Journal of Atrial Fibrillation (2012) 5:2. Date of Publication: August 2012
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
  Atrial fibrillation (AF) is the most common sustained atrial arrhythmia 
conferring a higher morbidity and mortality. Despite the increasing 
incidence of AF; available therapies are far from perfect. Dietary fish 
oils, containing omega 3 fatty acids, also called polyunsaturated fatty acid 
[PUFA] have demonstrated beneficial electrophysiological, autonomic and 
anti-inflammatory effects on both atrial and ventricular tissue. Multiple 
clinical trials, focusing on various subsets of patients with AF, have 
studied the role of PUFA and their potential role in reducing the incidence 
of this common arrhythmia. While PUFA appears to have a beneficial effect in 
the primary prevention of AF in the elderly with structural heart disease, 
this benefit has not been universally observed. In the secondary prevention 
of AF, PUFA seems to have a greater impact in the reducing AF in patients 
with paroxysmal or persistent AF, stages of AF associated with less atrial 
fibrosis and negative structural remodeling. However, AF suppression has not 
been consistently demonstrated in clinical trials. In patients undergoing 
heart surgery, increasing PUFA intake has yielded mixed results in terms of 
AF prevention post-operatively; however, increased PUFA has been associated 
with a reduction in hospital stay. Therefore recommending the use of PUFA 
for the purpose of AF reduction remains controversial. This is in part 
attributable to the complexity of AF. Other conflicting variables include: 
heterogeneous patient populations studied; variable dosing; duration of 
follow-up; comorbidities; and, concomitant pharmacotherapy. This review 
article reviews in detail available basic and clinical research studies of 
fish oil in the treatment of AF, and its role in the treatment of this 
common disorder.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  antiarrhythmic agent (clinical trial, drug therapy)
  omega 3 fatty acid (clinical trial, drug therapy)
EMTREE DRUG INDEX TERMS
  connexin 40
  fish oil
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, complication, drug therapy, etiology, 
prevention)
EMTREE MEDICAL INDEX TERMS
  antiarrhythmic activity
  autonomic nerve
  calcium transport
  coronary artery bypass surgery
  disease classification
  fat intake
  fibrosing alveolitis
  genetic association
  heart atrium pressure
  heart depolarization
  heart muscle fibrosis
  heart muscle potential
  heart muscle refractory period
  human
  inflammation
  intention to treat analysis
  multicenter study (topic)
  nonhuman
  paroxysmal atrial fibrillation
  pathogenesis
  postoperative complication (complication)
  primary prevention
  randomized controlled trial (topic)
  review
  secondary prevention
  sleep
  supplementation
  sympathetic tone
  vagus tone
CAS REGISTRY NUMBERS
  fish oil (8016-13-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00552084, NCT00597220, NCT00791089, NCT00841451, NCT01235130)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012524422
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 313
TITLE
  Acupuncture for paroxysmal and persistent atrial fibrillation: An effective 
non-pharmacological tool?
AUTHOR NAMES
  Lombardi F.
  Belletti S.
  Battezzati P.M.
  Lomuscio A.
AUTHOR ADDRESSES
  (Lombardi F., federico.lombardi@unimi.it; Belletti S.; Battezzati P.M.; 
Lomuscio A.) Department of Medicine, Surgery and Dentistry, University of 
Milan, 20147 Milan, Italy.
(Lombardi F., federico.lombardi@unimi.it; Belletti S.; Lomuscio A.) 
Cardiology, San Paolo Hospital, 20147 Milan, Italy.
(Battezzati P.M.) Internal Medicine Section VI, San Paolo Hospital, 20147 
Milan, Italy.
CORRESPONDENCE ADDRESS
  F. Lombardi, Department of Medicine, Surgery and Dentistry, University of 
Milan, Via A. di Rudinì 8, 20147 Milan, Italy. Email: 
federico.lombardi@unimi.it
SOURCE
  World Journal of Cardiology (2012) 4:3 (60-65). Date of Publication: 2012
ISSN
  1949-8462 (electronic)
BOOK PUBLISHER
  Baishideng Publishing Group Co, Room 1701, 17/F, Henan Bulding,, No.90 Jaffe 
Road, Wanchai,Hong Kong, China, China.
ABSTRACT
  In Traditional Chinese Medicine, stimulation of the Neiguan spot has been 
utilized to treat palpitations and symptoms related to different 
cardiovascular diseases. We evaluated whether acupuncture might exert an 
antiarrhythmic effect on patients with paroxysmal or persistent atrial 
fibrillation (AF). Two sets of data are reviewed. The first included 
patients with persistent AF who underwent electrical cardioversion to 
restore sinus rhythm. The second included patients with symptomatic 
paroxysmal AF. All subjects had normal ventricular function. Acupuncture 
treatment consisted of 10 acupuncture sessions on a once a week basis with 
puncturing of the Neiguan, Shenmen and Xinshu spots. In patients with 
persistent AF, the recurrence rate after acupuncture treatment was similar 
to that observed in patients on amiodarone, but significantly smaller than 
that measured after sham acupuncture treatment or in the absence of any 
antiarrhythmic drugs. In a small group of patients with paroxysmal AF, 
acupuncture resulted in a significant reduction in the number and duration 
of symptomatic AF episodes. In conclusion, we observed that acupuncture of 
the Neiguan spot was associated with an antiarrhythmic effect, which was 
evident in patients with both persistent and paroxysmal AF. These 
preliminary data, observed in 2 small groups of AF patients, need to be 
validated in a larger population but strongly suggest that acupuncture may 
be an effective non-invasive and safe antiarrhythmic tool in the management 
of these patients. © 2012 Baishideng.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy, therapy)
  paroxysmal atrial fibrillation (therapy)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  adult
  aged
  cardioversion
  controlled study
  female
  heart ventricle function
  human
  major clinical study
  male
  randomized controlled trial
  recurrence risk
  review
  sham procedure
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012382569
FULL TEXT LINK
  http://dx.doi.org/10.4330/wjc.v4.i3.60
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 314
TITLE
  25th World Congress of the International Union of Angiology, IUA 2012
AUTHOR NAMES
  Baumgartner I.
AUTHOR ADDRESSES
  (Baumgartner I.) , Switzerland.
SOURCE
  Phlebolymphology (2013) 20:1 (6). Date of Publication: 2013
CONFERENCE NAME
  25th World Congress of the International Union of Angiology, IUA 2012
CONFERENCE LOCATION
  Prague, Czech Republic
CONFERENCE DATE
  2012-07-01 to 2012-07-05
ISSN
  1286-0107
BOOK PUBLISHER
  Les Laboratoires Servier
ABSTRACT
  The proceedings contain 69 papers. The special focus in this conference is 
on Angiology. The topics include: The Amsterdam ruptured aneurysm trial; 
screening for abdominal aortic aneurysm; pharmacological therapy for 
abdominal aortic aneurysm; role of conventional and endovascular treatment 
of abdominal aortic aneurysms; medical management of carotid stenosis; 
determination of the stability of atherosclerotic plaques in vivo and its 
clinical relevance; emergency carotid interventions; restenosis after open 
carotid endarterectomy and after carotid stenting; exercise prescription for 
peripheral arterial disease; inflammation markers and assessment of vascular 
risk; management of hypertension in patients with peripheral arterial 
disease; critical limb ischemia; percutaneous transluminal angioplasty 
versus primary stenting in below the knee arteries in critical limb 
ischemia; long-term results of intra-arterial infusion of autologous bone 
marrow mononuclear cells in patients with critical limb ischemia; clinical 
efficacy and safety issues with newer anticoagulants in atrial fibrillation; 
impact of newer anticoagulants on the management of atrial fibrillation; 
high risk patients for stroke can now be identified using TCD, silent brain 
infarcts on CT or carotid plaque image analysis; management of patients with 
polyvascular atherosclerotic disease; upper extremity arterial disease; 
Loeys-Dietz syndrome; controlled compression ultrasound for peripheral and 
central venous pressure measurement; endovascular abdominal aortic surgery, 
our experience; robot-assisted vascular surgery, state of the art; venous 
thrombosis in hospitalized patients; thrombotic risk in cancer patients; 
predicting the risk of recurrent venous thrombosis; treatment of venous 
thrombosis; oral anti-IIa and anti-Xa drugs. pharmacological and clinical 
differentiation and their impact on therapeutic outcome; inhibition of FVIII 
with TB-402 for the prevention of venous thromboembolism after total knee 
and hip replacement; venous thromboembolism prophylaxis in spinal surgery; 
prophylaxis in high-risk abdominal surgery; home treatment of pulmonary 
embolism; interplay of inflammation and venous thrombosis; facts and 
controversies on the new anticoagulants; an update on the clinical 
development of defibrotide; generic and biosimilar low-molecular-weight 
heparins; heparin-induced thrombocytopenia and its management; 
interrelationship between arterial atherosclerotic and venous thromboembolic 
disease; a European perspective on generic anticoagulants drugs; 
contemporary outcome following catheter thrombolysis for iliofemoral deep 
vein thrombosis; diagnostic algorithm for superficial thrombophlebitis; a 
new consensus on management of superficial thrombophlebitis; venous 
hypertension in chronic venous insufficiency; hemodynamic performance using 
four compression stockings in postthrombotic syndrome correlates with the 
degree of reflux; inelastic compression in mixed ulcers increases arterial 
inflow and venous output; severely dilated truncal varicose veins treated 
with endovenous laser therapy; radiofrequency ablation of the great 
saphenous vein as a part of the therapy of chronic venous insufficiency; 
evaluation of the efficacy of adjunctive treatment with endovenous thermal 
ablation; infrequent indications of endovenous laser therapy; low thrombotic 
risk following endovenous laser ablation for chronic venous disease and 
management of chronic venous disease.
EMTREE DRUG INDEX TERMS
  anticoagulant agent
  defibrotide
  low molecular weight heparin
  marker
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  angiology
EMTREE MEDICAL INDEX TERMS
  abdominal aorta aneurysm
  abdominal surgery
  algorithm
  aneurysm rupture
  arm
  artery
  artery disease
  atherosclerotic plaque
  atrial fibrillation
  blood clot lysis
  bone marrow
  brain infarction
  cancer patient
  carotid artery
  carotid artery obstruction
  carotid artery stenting
  carotid artery surgery
  carotid endarterectomy
  catheter
  central venous pressure
  cerebrovascular accident
  chronic vein insufficiency
  compression
  compression stocking
  consensus
  critical limb ischemia
  deep vein thrombosis
  descending aorta surgery
  diagnosis
  disease management
  drug therapy
  emergency
  exercise
  heparin induced thrombocytopenia
  high risk patient
  hip arthroplasty
  home care
  hospital patient
  human
  hypertension
  image analysis
  inflammation
  intraarterial drug administration
  knee
  laser surgery
  Loeys Dietz syndrome
  low level laser therapy
  lung embolism
  mononuclear cell
  patient
  percutaneous transluminal angioplasty
  peripheral occlusive artery disease
  postthrombosis syndrome
  prescription
  pressure measurement
  prevention
  prophylaxis
  radiofrequency ablation
  restenosis
  risk
  robotics
  safety
  saphenous vein
  screening
  spine surgery
  stent
  superficial thrombophlebitis
  therapy
  thromboembolism
  ulcer
  ultrasound
  varicosis
  vascular surgery
  vein disease
  vein thrombosis
  venous thromboembolism
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 315
TITLE
  Association Between Adiponectin and Heart Failure Risk in the Physicians' 
Health Study
AUTHOR NAMES
  Djoussé L.
  Wilk J.B.
  Hanson N.Q.
  Glynn R.J.
  Tsai M.Y.
  Gaziano J.M.
AUTHOR ADDRESSES
  (Djoussé L.; Gaziano J.M.) 1] Department of Medicine, Brigham and Women's 
Hospital and Harvard Medical School, Boston, Massachusetts, USA
(Djoussé L.; Gaziano J.M.) Department of Medicine, Division of Aging, The 
Massachusetts Veterans Epidemiology and Research Information Center 
(MAVERIC) and Geriatric Research, Education, and Clinical Center (GRECC), 
Boston Veterans Affairs Healthcare System, Boston, Massachusetts, USA
(Wilk J.B.; Glynn R.J.) Department of Medicine, Brigham and Women's Hospital 
and Harvard Medical School, Boston, Massachusetts, USA
(Hanson N.Q.; Tsai M.Y.) Department of Laboratory Medicine and Pathology, 
University of Minnesota, Minneapolis, Minnesota, USA
CORRESPONDENCE ADDRESS
  1] Department of Medicine, Brigham and Women's Hospital and Harvard Medical 
School, Boston, Massachusetts, USA
SOURCE
  Obesity (2012). Date of Publication: 15 Jun 2012
ISSN
  1930-7381
  1930-739X (electronic)
BOOK PUBLISHER
  The Obesity Society
ABSTRACT
  Limited data are available on the association between adiponectin and 
incident heart failure (HF). In the current ancillary study to the 
Physicians' Health Study (PHS), we used a prospective nested case-control 
design to examine whether plasma adiponectin concentration was related to 
the risk of HF. We selected 787 incident HF cases and 787 matched controls 
for the current analysis. Each control was selected using a risk set 
sampling technique at the time of the occurrence of the index case and 
matched on year of birth, age at blood collection, and race. Adiponectin was 
measured using enzyme-linked immunosorbent assay. HF occurrence was 
self-reported in annual follow-up questionnaire. Validation of self-reported 
HF in this cohort has been published. The mean age was 58.7 years. In a 
conditional logistic regression adjusting for age, race, time of blood 
collection, year of birth, hypertension, atrial fibrillation, smoking, 
alcohol intake, and exercise, estimates of the relative risk (95% confidence 
interval) were 1.0 (reference), 0.74 (0.53-1.04), 0.67 (0.48-0.94), 0.70 
(0.50-0.99), and 0.92 (0.65-1.30) from the lowest to the highest quintile of 
adiponectin, respectively, P for quadratic trend 0.004. Additional 
adjustment for potential mediating factors including diabetes, C-reactive 
protein, and BMI led to the attenuation of the estimate of effect (1.0 
(reference), 0.81 (0.57-1.15), 0.75 (0.53-1.06), 0.83 (0.58-1.18), and 1.26 
(0.87-1.81) across consecutive quintiles of adiponectin). Our data are 
consistent with a J-shaped association between total adiponectin and the 
risk of HF among US male physicians.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  adiponectin
EMTREE DRUG INDEX TERMS
  C reactive protein
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  health
  heart failure
  human
  physician
  risk
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  atrial fibrillation
  attenuation
  blood sampling
  confidence interval
  diabetes mellitus
  enzyme linked immunosorbent assay
  exercise
  follow up
  hypertension
  logistic regression analysis
  male
  plasma
  questionnaire
  risk factor
  sampling
  smoking
LANGUAGE OF ARTICLE
  English
FULL TEXT LINK
  http://dx.doi.org/10.1038/oby.2012.153
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 316
TITLE
  Prevention and treatment of osteoporosis in women: An update
AUTHOR NAMES
  Daroszewska A.
AUTHOR ADDRESSES
  (Daroszewska A.) The Molecular Medicine Centre, MRC Institute of Genetics 
and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
CORRESPONDENCE ADDRESS
  A. Daroszewska, The Molecular Medicine Centre, MRC Institute of Genetics and 
Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
SOURCE
  Obstetrics, Gynaecology and Reproductive Medicine (2012) 22:6 (162-169). 
Date of Publication: June 2012
ISSN
  1751-7214
  1879-3622 (electronic)
BOOK PUBLISHER
  Churchill Livingstone, 1-3 Baxter's Place, Leith Walk, Edinburgh, United 
Kingdom.
ABSTRACT
  Osteoporosis is a growing health problem in the ageing population. A 
postmenopausal woman has an approximately 50% lifetime risk of suffering an 
osteoporotic fracture with hip fractures carrying the highest morbidity and 
mortality. Non-pharmacological prevention strategies focus on attainment and 
maintenance of a high peak bone mass and include a healthy lifestyle, 
nutritious and balanced diet, maintenance of optimal vitamin D level and 
physical exercise with skeletal mechanical loading. Pharmacological 
interventions include hormone replacement therapy in women with early 
menopause and postmenopausal women until the age of 60 in the absence of 
contraindications. Bisphosphonates (e.g. alendronate, risedronate and 
zoledronate) remain the mainstay of antiresorptive treatment and the novel 
biologic antiresorptive agent, denosumab is a safe option in patients 
intolerant or with contraindications to bisphosphonates. Anabolic therapy 
with PTH peptides is currently reserved for severe osteoporosis. A number of 
novel treatments e.g. cathepsin K inhibitors, calcilytic drugs 
anti-sclerostin antibodies are being assessed in clinical trials. © 2012 
Elsevier Ltd.
EMTREE DRUG INDEX TERMS
  25 hydroxyvitamin D (endogenous compound)
  alendronic acid (adverse drug reaction, clinical trial, drug comparison, 
drug therapy, oral drug administration)
  bazedoxifene (drug therapy)
  calcium (clinical trial, drug therapy)
  cathepsin K inhibitor (clinical trial, drug therapy)
  clodronic acid (drug therapy)
  colecalciferol (clinical trial, drug therapy)
  denosumab (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, pharmacokinetics)
  estrogen (drug combination, drug therapy)
  etidronic acid (drug therapy)
  ibandronic acid (adverse drug reaction, drug therapy, intravenous drug 
administration)
  lasofoxifene (drug therapy)
  medroxyprogesterone acetate (drug combination, drug therapy)
  mk 5442 (clinical trial, drug therapy)
  odanacatib (clinical trial, drug therapy)
  ono 5334 (clinical trial, drug therapy)
  parathyroid hormone (drug therapy)
  parathyroid hormone[1-34] (clinical trial, drug comparison, drug therapy, 
subcutaneous drug administration)
  placebo
  raloxifene (drug therapy)
  risedronic acid (adverse drug reaction, drug therapy, oral drug 
administration)
  romosozumab (clinical trial, drug comparison, drug therapy, subcutaneous 
drug administration)
  salcatonin (adverse drug reaction, drug therapy, intranasal drug 
administration)
  strontium ranelate (adverse drug reaction, clinical trial, drug therapy, 
oral drug administration)
  tiludronic acid (drug therapy)
  unclassified drug
  zoledronic acid (adverse drug reaction, clinical trial, drug therapy, 
intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  postmenopause osteoporosis (drug therapy, disease management, drug therapy, 
prevention)
EMTREE MEDICAL INDEX TERMS
  abdominal pain (side effect)
  aging
  alcohol abstinence
  alcohol consumption
  article
  atrial fibrillation (side effect)
  body mass
  bone density
  bone mass
  bone mineralization
  bone remodeling
  breast cancer (drug therapy, prevention)
  calcium intake
  cellulitis (side effect)
  corticosteroid induced osteoporosis (drug therapy)
  creatine kinase blood level
  creatinine clearance
  diarrhea (side effect)
  diet
  drug approval
  drug cost
  drug efficacy
  drug half life
  drug tolerability
  drug withdrawal
  eophageal irritation (side effect)
  eophageal irritation (side effect)
  esophagus disease (side effect)
  exercise
  fall risk
  fever (side effect)
  flushing
  fragility fracture
  hip fracture (drug therapy, prevention)
  hormone substitution
  human
  hypocalcemia
  instillation site irritation (side effect)
  jaw osteonecrosis
  lifestyle
  lymphocytopenia (side effect)
  menopause
  meta analysis (topic)
  morbidity
  mortality
  myalgia (side effect)
  nausea (side effect)
  obesity
  osteolysis
  osteomalacia
  osteopenia
  phase 1 clinical trial (topic)
  phase 2 clinical trial (topic)
  phase 3 clinical trial (topic)
  postmenopause
  randomized controlled trial (topic)
  side effect (side effect)
  smoking cessation
  spine fracture (drug therapy, prevention)
  vitamin blood level
  vitamin D deficiency
  X ray absorption spectroscopy
CAS REGISTRY NUMBERS
  25 hydroxyvitamin D (64719-49-9)
  alendronic acid (66376-36-1)
  bazedoxifene (198481-32-2, 198481-33-3)
  calcium (14092-94-5, 7440-70-2)
  clodronic acid (10596-23-3, 22560-50-5)
  colecalciferol (1406-16-2, 67-97-0)
  denosumab (615258-40-7)
  etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
  ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
  lasofoxifene (180915-85-9, 180916-16-9, 190791-29-8)
  medroxyprogesterone acetate (71-58-9)
  odanacatib (603139-19-1)
  parathyroid hormone (12584-96-2, 68893-82-3, 9002-64-6)
  parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
  raloxifene (82640-04-8, 84449-90-1)
  risedronic acid (105462-24-6, 122458-82-6)
  romosozumab (909395-70-6)
  salcatonin (47931-85-1)
  strontium ranelate (135459-87-9)
  tiludronic acid (96538-83-9)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  Obstetrics and Gynecology (10)
  Orthopedic Surgery (33)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012267380
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ogrm.2012.02.007
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 317
TITLE
  Left main coronary artery origin from the right coronary sinus: Rare, 
dangerous, and easy to miss on routine transoesophageal echocardiography
AUTHOR NAMES
  Robaei D.
  Nayyar D.
  Buchholz S.
AUTHOR ADDRESSES
  (Robaei D.; Nayyar D.) Department of Cardiology, St Vincent's Hospital, 
Sydney, NSW, Australia.
(Buchholz S., stefanbuchholz@hotmail.com) Cardiac Services, Mackay Base 
Hospital, 475 Bridge Road, Mackay, QLD 4740, Australia.
CORRESPONDENCE ADDRESS
  S. Buchholz, Cardiac Services, Mackay Base Hospital, 475 Bridge Road, 
Mackay, QLD 4740, Australia. Email: stefanbuchholz@hotmail.com
SOURCE
  Journal of Echocardiography (2012) 10:2 (72-73). Date of Publication: June 
2012
ISSN
  1349-0222
  1880-344X (electronic)
BOOK PUBLISHER
  Springer Japan, 1-11-11 Kudan-Kita,, Chiyoda-ku,Tokyo, Japan.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anomalous left coronary artery arising from the right coronary sinus 
(diagnosis)
  cardiac imaging
  coronary artery anomaly (diagnosis)
  coronary sinus
  left coronary artery
  transesophageal echocardiography
EMTREE MEDICAL INDEX TERMS
  angiocardiography
  article
  atrial fibrillation
  computer assisted tomography
  exercise
  faintness
  heart dilatation
  heart ventricle arrhythmia
  human
  image analysis
  image processing
  single coronary artery (congenital disorder, diagnosis)
  sudden death
  thorax pain
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2012325149
FULL TEXT LINK
  http://dx.doi.org/10.1007/s12574-012-0113-5
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 318
TITLE
  Hemodynamic findings in severe tricuspid regurgitation
AUTHOR NAMES
  Rao S.
  Tate D.A.
  Stouffer G.A.
AUTHOR ADDRESSES
  (Rao S.; Tate D.A.; Stouffer G.A., rstouff@med.unc.edu) Division of 
Cardiology, University of North Carolina, Chapel Hill, NC
CORRESPONDENCE ADDRESS
  G.A. Stouffer, Division of Cardiology, University of North Carolina, Chapel 
Hill, NC 27599-7075, . Email: rstouff@med.unc.edu
SOURCE
  Catheterization and Cardiovascular Interventions (2012) 45:4. Date of 
Publication: 2012
ISSN
  1522-1946
  1522-726X (electronic)
BOOK PUBLISHER
  Blackwell Publishing Ltd
ABSTRACT
  Tricuspid regurgitation (TR) most commonly occurs in response to right 
ventricular (RV) dilation with structural abnormalities in the tricuspid 
valve being rarer. In addition to RV size and valvular integrity, the amount 
of TR is influenced by RV preload and afterload, the respiratory cycle, left 
heart function and atrial fibrillation. Hemodynamic changes in right atrial 
(RA) pressures in severe TR include elevated mean pressures, a large 
systolic wave called an "s" wave, a prominent 'Y' descent and a blunted 'X' 
descent. In addition, RV end diastolic pressure is elevated and cardiac 
output is reduced, especially with exercise. "Ventricularization" of the RA 
pressure tracing, in which the contour of the RA pressure is similar to, but 
of lower amplitude than, the contour of the RV pressure is the most specific 
finding but is found in a minority of patients with severe TR. In summary, 
alterations in the RA pressure tracing are common in patients with severe TR 
but specific hemodynamic findings lack sensitivity, which may in part be due 
to the large effects of RV preload, RV afterload and RA compliance on the 
amount of TR. © 2012 Wiley Periodicals, Inc.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diagnosis
  heart catheterization
  heart right ventricle
  hemodynamics
  tricuspid valve regurgitation
  valvular heart disease
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  breathing pattern
  exercise
  heart afterload
  heart function
  heart output
  heart preload
  heart right atrium pressure
  heart ventricle enddiastolic pressure
  human
  patient
  tricuspid valve
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
FULL TEXT LINK
  http://dx.doi.org/10.1002/ccd.24309
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 319
TITLE
  Tai chi exercise for patients with heart disease: a systematic review of 
controlled clinical trials.
AUTHOR NAMES
  Ng S.M.
  Wang C.W.
  Tin-Hung Ho R.
  Tat-Chi Ziea E.
  He J.
  Chi-Woon Taam Wong V.
  Lai-Wan Chan C.
AUTHOR ADDRESSES
  (Ng S.M.) Centre on Behavioral Health and Department of Social Work and 
Social Administration, University of Hong Kong.
(Wang C.W.; Tin-Hung Ho R.; Tat-Chi Ziea E.; He J.; Chi-Woon Taam Wong V.; 
Lai-Wan Chan C.)
CORRESPONDENCE ADDRESS
  S.M. Ng, Centre on Behavioral Health and Department of Social Work and 
Social Administration, University of Hong Kong.
SOURCE
  Alternative therapies in health and medicine (2012) 18:3 (16-22). Date of 
Publication: 2012 May-Jun
ISSN
  1078-6791
ABSTRACT
  To summarize and evaluate the available evidence from controlled clinical 
trials of tai chi (TC) exercise for patients with heart disease. Fourteen 
databases were searched up to November 2010 with the terms tai chi, taichi, 
tai ji, taiji, taijichuan, cardiac, heart, coronary, myocardial, and atrial 
fibrillation in the title, abstract, or key words. No language restrictions 
were imposed. The quality and validity of randomized clinical trials (RCTs) 
were evaluated using the Jadad Scale. The strength of the evidence for all 
included studies was evaluated using the Oxford Centre for Evidence-based 
Medicine Levels of Evidence. Nine studies including 5 RCTs and 4 
nonrandomized controlled clinical trials met the inclusion criteria. Three 
studies examined the effectiveness of TC exercise for patients with chronic 
heart failure (CHF), and 6 studies examined the effectiveness of TC exercise 
among patients with coronary heart disease (CHD). Overall, these studies 
demonstrated favorable effects of TC exercise for the patients with heart 
disease. The existing evidence suggests that TC exercise is a good option 
for heart patients with very limited exercise tolerance and can be an 
adjunct to rehabilitation programs for patients with CHD or CHF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  coronary artery disease (rehabilitation)
  evidence based medicine
  quality of life
  Tai Chi
EMTREE MEDICAL INDEX TERMS
  controlled clinical trial (topic)
  daily life activity
  health behavior
  heart infarction (rehabilitation)
  human
  methodology
  outcome assessment
  randomized controlled trial (topic)
  review
LANGUAGE OF ARTICLE
  English
MEDLINE PMID
  22875558 (http://www.ncbi.nlm.nih.gov/pubmed/22875558)
COPYRIGHT
  MEDLINE® is the source for the citation and abstract of this record.

RECORD 320
TITLE
  Chronic pain management in the elderly: An update on safe, effective options
AUTHOR NAMES
  King S.A.
AUTHOR ADDRESSES
  (King S.A.) New York University, School of Medicine, New York, NY, United 
States.
CORRESPONDENCE ADDRESS
  S.A. King, New York University, School of Medicine, New York, NY, United 
States.
SOURCE
  Consultant (2012) 52:5 (326-331). Date of Publication: May 2012
ISSN
  0010-7069
BOOK PUBLISHER
  Cliggott Publishing Co., 330 Boston Post Road, Box 4027, Darien, United 
States.
ABSTRACT
  Chronic pain is a significant problem for many elderly patients. 
Unfortunately, it is often accepted as a normal part of aging, and these 
patients may be undertreated for it. There are many challenges that can make 
it difficult to treat pain in this age group, most notably the presence of 
other significant health problems and the difficulty of assessing pain in 
the cognitively impaired. Medication management remains a mainstay of the 
treatment of chronic pain. Recent literature has called into question the 
use of NSAIDs as one of the first-line drugs and indicates that it may be 
safer to try an opioid before an NSAID. The decision about which medication 
to use should be based on the type of pain, the side-effect profile of the 
drugs, and the overall health status of the individual patient.
EMTREE DRUG INDEX TERMS
  amitriptyline (adverse drug reaction, drug therapy)
  anticonvulsive agent (adverse drug reaction, drug therapy)
  antidepressant agent (adverse drug reaction, drug therapy)
  benzodiazepine derivative (adverse drug reaction, drug therapy)
  celecoxib (adverse drug reaction, drug therapy)
  choline magnesium trisalicylate (drug therapy)
  cyclooxygenase 2 inhibitor (adverse drug reaction, drug therapy)
  desipramine (adverse drug reaction, drug therapy)
  diclofenac (adverse drug reaction, drug therapy)
  duloxetine (drug therapy)
  etodolac (adverse drug reaction, drug therapy)
  gabapentin (adverse drug reaction, drug therapy)
  ibuprofen (adverse drug reaction, drug therapy)
  lidocaine (adverse drug reaction, drug therapy, topical drug administration)
  milnacipran (drug therapy)
  naproxen (adverse drug reaction, drug therapy)
  nonsteroid antiinflammatory agent (adverse drug reaction, drug 
administration, drug therapy, oral drug administration, topical drug 
administration)
  nortriptyline (adverse drug reaction, drug therapy)
  opiate (adverse drug reaction, drug therapy)
  oxycodone (adverse drug reaction, drug therapy)
  paracetamol (adverse drug reaction, drug therapy)
  pethidine (adverse drug reaction, drug therapy)
  pregabalin (adverse drug reaction, drug therapy)
  rofecoxib (adverse drug reaction, drug therapy)
  salsalate (drug therapy)
  serotonin noradrenalin reuptake inhibitor (drug therapy)
  tricyclic antidepressant agent (adverse drug reaction, drug therapy)
  unindexed drug
  venlafaxine (drug therapy)
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aging
  chronic pain (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  anticholinergic syndrome (side effect)
  arthritis (drug therapy)
  atrial fibrillation (side effect)
  backache (drug therapy)
  bone pain (drug therapy)
  cardiotoxicity (side effect)
  cerebrovascular accident (side effect)
  cognitive defect (side effect)
  constipation (side effect)
  delirium (side effect)
  diabetic neuropathy (drug therapy)
  drug efficacy
  drug indication
  drug safety
  drug withdrawal
  fibromyalgia (drug therapy)
  fracture (side effect)
  gastrointestinal hemorrhage (side effect)
  gastrointestinal toxicity (side effect)
  geriatric patient
  health status
  heart atrium flutter (side effect)
  heart infarction (side effect)
  heart muscle conduction disturbance (side effect)
  human
  low back pain (drug therapy)
  medical decision making
  micturition disorder (side effect)
  musculoskeletal pain (drug therapy)
  nephrotoxicity (side effect)
  occupational therapy
  opiate addiction (side effect)
  osteoarthritis (drug therapy)
  pain assessment
  physiotherapy
  postherpetic neuralgia (drug therapy)
  priority journal
  psychotherapy
  respiration depression (side effect)
  review
  risk benefit analysis
  risk reduction
  sedation
  side effect (side effect)
  transcutaneous nerve stimulation
  unspecified side effect (side effect)
CAS REGISTRY NUMBERS
  amitriptyline (50-48-6, 549-18-8)
  celecoxib (169590-42-5)
  choline magnesium trisalicylate (64425-90-7)
  desipramine (50-47-5, 58-28-6)
  diclofenac (15307-79-6, 15307-86-5)
  duloxetine (116539-59-4, 136434-34-9)
  etodolac (41340-25-4)
  gabapentin (60142-96-3)
  ibuprofen (15687-27-1, 31121-93-4, 527688-20-6, 79261-49-7)
  lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
  milnacipran (101152-94-7, 175131-60-9, 86181-08-0, 92623-85-3, 96847-55-1)
  naproxen (22204-53-1, 26159-34-2)
  nortriptyline (72-69-5, 894-71-3)
  opiate (53663-61-9, 8002-76-4, 8008-60-4)
  oxycodone (124-90-3, 76-42-6)
  paracetamol (103-90-2)
  pethidine (28097-96-3, 50-13-5, 57-42-1)
  pregabalin (148553-50-8)
  rofecoxib (162011-90-7, 186912-82-3)
  salsalate (552-94-3)
  venlafaxine (93413-69-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Gerontology and Geriatrics (20)
  Arthritis and Rheumatism (31)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012283547
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 321
TITLE
  Variants of the lamin AC (LMNA) gene in non-valvular atrial fibrillation 
patients: A possible pathogenic role of the Thr528Met mutation
AUTHOR NAMES
  Saj M.
  Dabrowski R.
  Labib S.
  Jankowska A.
  Szperl M.
  Broda G.
  Szwed H.
  Tesson F.
  Bilinska Z.T.
  Ploski R.
AUTHOR ADDRESSES
  (Saj M.; Szperl M.) Laboratory of Molecular Biology, Institute of 
Cardiology, Warsaw, Poland.
(Dabrowski R.; Jankowska A.; Szwed H.) 2nd Ischemic Heart Disease and 
Clinical Department, Institute of Cardiology, Warsaw, Poland.
(Labib S.; Tesson F.) Faculty of Health Sciences, University of Ottawa, 
Ottawa, ON, Canada.
(Broda G.) Department of Cardiovascular Epidemiology and Prevention, And 
Health Promotion, Institute of Cardiology, Warsaw, Poland.
(Bilinska Z.T.) Department of Coronary Artery and Structural Heart Diseases, 
Institute of Cardiology, Warsaw, Poland.
(Bilinska Z.T.) Unit for Screening Studies in Inherited Cardiovascular 
Diseases, Institute of Cardiology, Warsaw, Poland.
(Ploski R., rploski@wp.pl) Department of Medical Genetics, Centre of 
Biostructure, Medical University of Warsaw, Pawinskiego 3C, 02-106 Warsaw, 
Poland.
CORRESPONDENCE ADDRESS
  R. Ploski, Department of Medical Genetics, Centre of Biostructure, Medical 
University of Warsaw, Pawinskiego 3C, 02-106 Warsaw, Poland. Email: 
rploski@wp.pl
SOURCE
  Molecular Diagnosis and Therapy (2012) 16:2 (99-107). Date of Publication: 
2012
ISSN
  1177-1062
  1179-2000 (electronic)
BOOK PUBLISHER
  Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, 
Auckland 10, New Zealand.
ABSTRACT
  Background and Objective: Lamin A/C (LMNA) gene mutations cause dilated 
cardiomyopathy, often accompanied by conduction disturbances. Our aim was to 
search for LMNA mutations in individuals with atrial fibrillation. Methods: 
A cohort of Polish subjects (N = 103) with non-valvular atrial fibrillation 
with a high (48.5%) prevalence of conduction system disturbances was 
screened for LMNA variants by direct DNA sequencing. Results: We found a 
single non-synonymous variant (Thr528Met) in a 72-year-old patient with 
normal left ventricular function and episodes of advanced atrioventricular 
block. One of his two mutation-carrying daughters had episodes of type I 
second-degree atrioventricular block on a 24-hour Holter ECG and peak 
exercise arrhythmia. Interpretation of cardiac anomalies observed in the 
other daughter was complicated by thyroid insufficiency. A Thr528Met weak 
pathogenic effect was supported by transient transfections of C2C12 mouse 
myoblasts and computationally. Another interesting variant was Ile26Ile 
(c.78C>T), found in a New York Heart Association class III patient with a 
depressed left ventricular ejection fraction (30%), left bundle branch 
block, and a family history of heart disease. Ile26Ile was absent in 246 
healthy individuals and was computationally predicted to interfere with 
splicing. Conclusion: LMNA mutations are not a frequent cause of atrial 
fibrillation even when conduction disease is present. Unlike the majority of 
LMNA mutations clearly associated with a severe clinical phenotype and a 
poor prognosis, Thr528Met results in a more subtle pathogenic effect, while 
Ile26Ile should be considered as a variant of unknown significance. © 2012 
Springer International Publishing AG. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  lamin A (endogenous compound)
  lamin C (endogenous compound)
EMTREE DRUG INDEX TERMS
  isoleucine (endogenous compound)
  methionine (endogenous compound)
  threonine (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (diagnosis, epidemiology, etiology)
  genetic variability
  nonvalvular atrial fibrillation (diagnosis, epidemiology, etiology)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  amino acid substitution
  article
  atrioventricular block (diagnosis, epidemiology, etiology)
  case report
  cohort analysis
  conduction system disturbance
  controlled study
  DNA isolation
  DNA sequence
  exercise
  family history
  female
  gene mutation
  genetic screening
  genetic transfection
  heart arrhythmia
  heart left bundle branch block
  heart left ventricle ejection fraction
  heart left ventricle function
  heart ventricle function
  heterozygote
  Holter monitoring
  human
  hypothyroidism
  major clinical study
  male
  myoblast
  pathogenesis
  prevalence
  priority journal
  RNA splicing
CAS REGISTRY NUMBERS
  isoleucine (7004-09-3, 73-32-5)
  methionine (59-51-8, 63-68-3, 7005-18-7)
  threonine (36676-50-3, 72-19-5)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Human Genetics (22)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012217749
FULL TEXT LINK
  http://dx.doi.org/10.2165/11594880-000000000-00000
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 322
TITLE
  Integrating pain management in clinical practice
AUTHOR NAMES
  Jamison R.N.
  Edwards R.R.
AUTHOR ADDRESSES
  (Jamison R.N., RJamison@partners.org; Edwards R.R.) Departments of 
Anesthesiology, Perioperative, and Pain Medicine and Psychiatry, Brigham and 
Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
(Jamison R.N., RJamison@partners.org) Pain Management Center, Brigham and 
Women's Hospital, 850 Boylston Street, Chestnut Hill, MA 02467, United 
States.
CORRESPONDENCE ADDRESS
  R.N. Jamison, Pain Management Center, Brigham and Women's Hospital, 850 
Boylston Street, Chestnut Hill, MA 02467, United States. Email: 
RJamison@partners.org
SOURCE
  Journal of Clinical Psychology in Medical Settings (2012) 19:1 (49-64). Date 
of Publication: March 2012
  Preparing Psychologists for a Rapidly Changing Healthcare Environment, Book 
Series Title:
ISSN
  1068-9583
  1573-3572 (electronic)
BOOK PUBLISHER
  Springer New York, 233 Spring Street, New York, United States.
ABSTRACT
  There is much evidence to suggest that psychological and social issues are 
predictive of pain severity, emotional distress, work disability, and 
response to medical treatments among persons with chronic pain. 
Psychologists can play an important role in the identification of 
psychological and social dysfunction and in matching personal 
characteristics to effective interventions as part of a multidisciplinary 
approach to pain management, leading to a greater likelihood of treatment 
success. The assessment of different domains using semi-structured clinical 
interviews and standardized self-report measures permits identification of 
somatosensory, emotional, cognitive, behavioral and social issues in order 
to facilitate treatment planning. In this paper, we briefly describe 
measures to assess constructs related to pain and intervention strategies 
for the behavioral treatment of chronic pain and discuss related psychiatric 
and substance abuse issues. Finally, we offer a future look at the role of 
integrating pain management in clinical practice in the psychological 
assessment and treatment for persons with chronic pain. © 2012 Springer 
Science+Business Media, LLC.
EMTREE DRUG INDEX TERMS
  morphine (drug therapy, intravenous drug administration)
  opiate (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  analgesia
  chronic pain (drug therapy, disease management, drug therapy, therapy)
  clinical practice
EMTREE MEDICAL INDEX TERMS
  advanced cancer
  anger
  anxiety
  anxiety disorder
  atrial fibrillation
  Beck Depression Inventory
  behavioral science
  catastrophizing
  Center for Epidemiological Studies Depression Scale
  chronic obstructive lung disease
  clinical assessment tool
  clinical trial (topic)
  cognition
  comorbidity
  constipation (side effect)
  coping behavior
  cultural factor
  depression
  dizziness (side effect)
  electronic medical record
  emotional stress
  ethnicity
  facial expression
  fatigue (side effect)
  fibromyalgia
  General Health Questionnaire
  health care personnel
  health program
  helplessness
  Hospital Anxiety and Depression Scale
  human
  hypnosis
  limb injury
  low back pain
  mental disease
  microcomputer
  Minnesota Multiphasic Personality Inventory
  mobile phone
  mood
  mood disorder
  muscle strain
  nausea (side effect)
  neuroimaging
  nociception
  patient monitoring
  personality
  personality test
  priority journal
  prognosis
  pruritus (side effect)
  psychiatry
  psychologic assessment
  psychological aspect
  psychologist
  psychopathy
  quality of life
  relaxation training
  review
  rheumatoid arthritis
  risk assessment
  self concept
  self esteem
  self monitoring
  self report
  semi structured interview
  sexual abuse
  sexual dysfunction
  Short Form 36
  Sickness Impact Profile
  smoking
  social psychology
  stretching
  substance abuse
  Symptom Checklist 90
  tension headache
  treatment planning
  urine retention (side effect)
  visual analog scale
CAS REGISTRY NUMBERS
  morphine (52-26-6, 57-27-2)
  opiate (53663-61-9, 8002-76-4, 8008-60-4)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Psychiatry (32)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012210182
MEDLINE PMID
  22383018 (http://www.ncbi.nlm.nih.gov/pubmed/22383018)
FULL TEXT LINK
  http://dx.doi.org/10.1007/s10880-012-9295-2
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 323
TITLE
  Czech Society of Cardiology guidelines for the diagnosis and treatment of 
chronic heart failure 2011
AUTHOR NAMES
  Špmar J.
  Vítovec J.
  Hradec J.
  Málek I.
  Meluzín J.
  Špmarová L.
  Hošková L.
  Hegarová M.
  Ludka O.
  Táhorský M.
AUTHOR ADDRESSES
  (Špmar J.; Ludka O.) Department of Internal Medicine - Cardiology, Masaryk 
University, University Hospital Brno, Jihlavska 20, Brno, Czech Republic.
(Vítovec J., jiri.vitovec@fnusa.cz; Meluzín J.; Špmarová L.) 1st Department 
of Internal Medicine - Cardioangiology, Masaryk University, St. Anne's 
University Hospital Brno, Pekařska 53, Brno, Czech Republic.
(Hradec J.) 3rd Department of Internal Medicine, Charles University, General 
University Hospital in Prague, U Nemocnice 2, Prague 2, Czech Republic.
(Málek I.; Hošková L.; Hegarová M.) Department of Cardiology, Institute of 
Clinical and Experimental Medicine, Vídeňská 1958/9, Prague 4, Czech 
Republic.
(Táhorský M.) 1st. Department of Internal Medicine - Cardiology, Faculty of 
Medicine, Palacký University and University Hospital, I. P. Pavlova 6, 
Olomouc, Czech Republic.
CORRESPONDENCE ADDRESS
  J. Vítovec, 1st Department of Internal Medicine - Cardioangiology, Masaryk 
University, St. Anne's University Hospital Brno, Pekařska 53, Brno, Czech 
Republic. Email: jiri.vitovec@fnusa.cz
SOURCE
  Cor et Vasa (2012) 54:2 (E113-E134). Date of Publication: March-April 2012
ISSN
  0010-8650
  1803-7712 (electronic)
BOOK PUBLISHER
  Elsevier Science B.V., P.O. Box 1527, Amsterdam, Netherlands.
ABSTRACT
  Guidelines of Czech Society of Cardiology are released in accordance with 
ESC guidelines for the diagnosis and treatment of acute and chronic heart 
failure. Guidelines summarise and evaluate all currently available knowledge 
about a particular issue, and whenever it is possible they are based on 
EBM-Evidence Based Medicine. Two classifications of level of evidence and 
the strength of recommendation are used as seen below. © 2012 The Czech 
Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All 
rights reserved.
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (drug therapy)
  amino terminal pro brain natriuretic peptide
  amiodarone (drug therapy)
  antithrombocytic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  brain natriuretic peptide (endogenous compound)
  candesartan (drug therapy)
  captopril (drug therapy)
  corticosteroid (drug therapy)
  creatinine (endogenous compound)
  diclofenac (drug therapy)
  digoxin (drug therapy)
  dihydropyridine (drug therapy)
  diltiazem (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  enalapril (drug therapy)
  ibuprofen (drug therapy)
  influenza vaccine (drug therapy)
  inotropic agent (drug therapy)
  lisinopril (drug therapy)
  losartan (drug therapy)
  perindopril tert butylamine (drug therapy)
  ramipril (drug therapy)
  spironolactone (drug therapy)
  trandolapril (drug therapy)
  tricyclic antidepressant agent (drug therapy)
  unindexed drug (drug therapy)
  valsartan (drug therapy)
  vasodilator agent (drug therapy)
  verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (drug therapy, diagnosis, drug therapy, epidemiology, 
etiology, surgery, therapy)
  medical society
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  angina pectoris
  aorta valve replacement
  article
  ascites
  asthma
  atrial fibrillation
  auscultation
  blood cell count
  body mass
  cachexia
  cardiac resynchronization therapy
  catabolism
  central venous pressure
  clinical trial (topic)
  computed tomographic angiography
  constipation
  coronary artery bypass graft
  coughing
  creatinine blood level
  cyanosis
  defibrillator
  diabetes mellitus
  diet
  disease classification
  disease course
  disease severity
  dyspnea
  electrocardiogram
  electrolyte blood level
  epidemiology
  evidence based medicine
  exercise
  fatigue
  health program
  heart catheterization
  heart dilatation
  heart left ventricle ejection fraction
  heart left ventricle hypertrophy
  heart left ventricle overload
  heart muscle revascularization
  heart palpitation
  heart preload
  heart transplantation
  hematocrit
  hemodialysis
  hepatomegaly
  human
  influenza vaccination
  insomnia
  kidney dysfunction
  left ventricular assist device
  liver function test
  lung congestion
  morbidity
  mortality
  nausea
  nocturia
  nuclear magnetic resonance imaging
  oliguria
  oxygen saturation
  pathophysiology
  percutaneous coronary intervention
  peripheral edema
  phase 3 clinical trial (topic)
  pleura effusion
  prognosis
  pulmonary hypertension
  quality of life
  sexual behavior
  smoking
  systolic dysfunction
  tachycardia
  thorax pain
  thorax radiography
  three dimensional echocardiography
  tissue Doppler imaging
  transthoracic echocardiography
  travel
  treatment contraindication
  treatment indication
  urinalysis
  vomiting
  weight gain
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  brain natriuretic peptide (114471-18-0)
  candesartan (139481-59-7)
  captopril (62571-86-2)
  creatinine (19230-81-0, 60-27-5)
  diclofenac (15307-79-6, 15307-86-5)
  digoxin (20830-75-5, 57285-89-9)
  dihydropyridine (27790-75-6)
  diltiazem (33286-22-5, 42399-41-7)
  enalapril (75847-73-3)
  ibuprofen (15687-27-1, 31121-93-4, 527688-20-6, 79261-49-7)
  lisinopril (76547-98-3, 83915-83-7)
  losartan (114798-26-4)
  perindopril tert butylamine (107133-36-8)
  ramipril (87333-19-5)
  spironolactone (52-01-7)
  trandolapril (87679-37-6)
  valsartan (137862-53-4)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012336285
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.crvasa.2012.03.002
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 324
TITLE
  The use of mobile cardiac telemetry to improve diagnostic accuracy and 
enable more efficient patient care
AUTHOR NAMES
  Zweibel S.
  Trelfa M.
AUTHOR ADDRESSES
  (Zweibel S., szweibel@harthosp.org) Hartford Hospital, University of 
Connecticut School of Medicine, United States.
(Trelfa M.) eCardio, United States.
CORRESPONDENCE ADDRESS
  S. Zweibel, Hartford Hospital, University of Connecticut School of Medicine, 
80 Seymour Street, Hartford, CT 06102, United States. Email: 
szweibel@harthosp.org
SOURCE
  US Cardiology (2012) 9:1 (43-46). Date of Publication: February 2012
ISSN
  1758-3896
  1758-390X (electronic)
BOOK PUBLISHER
  Touch Briefings, Saffron House, 6-10 Kirby St,, London, United Kingdom.
ABSTRACT
  Mobile cardiac telemetry (MCT) is a relatively new technology, first 
approved in 2002 by the US Food and Drug Administration (FDA), which 
provides continuous realtime outpatient electrocardiographic monitoring for 
extended periods of time. MCT allows detection of both symptomatic and 
asymptomatic arrhythmias and has been proven to provide superior diagnostic 
capability for patients with palpitations, syncope, and pre-syncope. It also 
allows accurate monitoring of a patient's rhythm during outpatient drug 
titration, as well as detection of both symptomatic and asymptomatic atrial 
fibrillation after cardiac ablation. Since recording of the rhythm is 
continuous, monitoring of a patient's heart rate (as well as specific 
documentation of the initiation and termination of arrhythmias) is possible. 
This article will focus on how the use of MCT can improve diagnostic 
accuracy and, when combined with the use of a monitoring service that 
integrates the patient's tracings within an electronic medical record, can 
also improve the efficiency of care given to patients. © Touch Briefings 
2012.
EMTREE DRUG INDEX TERMS
  flecainide (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  mobile cardiac telemetry
  telemetry
EMTREE MEDICAL INDEX TERMS
  adult
  aerobic exercise
  article
  atrial fibrillation (diagnosis, drug therapy)
  case report
  clinical effectiveness
  diagnostic accuracy
  diagnostic test accuracy study
  diagnostic value
  electronic medical record
  heart palpitation
  histogram
  human
  male
  outpatient care
  patient monitoring
  sinus tachycardia (diagnosis)
  supraventricular tachycardia (diagnosis, drug therapy)
CAS REGISTRY NUMBERS
  flecainide (54143-55-4)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012572491
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 325
TITLE
  Dexmedetomidine: Current Role in Anesthesia and Intensive Care
ORIGINAL (NON-ENGLISH) TITLE
  Dexmedetomidina: Papel Atual em Anestesia e Cuidados Intensivos
AUTHOR NAMES
  Afonso J.
  Reis F.
AUTHOR ADDRESSES
  (Afonso J., joanaafonsoo@gmail.com) Anesthesiology Consultant, Coimbra 
University, Portugal.
(Reis F.) Laboratory of Pharmacology and Experimental Therapeutics, IBILI, 
Medicine Faculty, Coimbra University, Portugal.
CORRESPONDENCE ADDRESS
  J. Afonso, Hospital Pedro Hispano, Rua Dr. Eduardo Torres 4464-513, 
Matosinhos, Portugal. Email: joanaafonsoo@gmail.com
SOURCE
  Revista Brasileira de Anestesiologia (2012) 62:1 (118-133). Date of 
Publication: January 2012
ISSN
  0034-7094
  1806-907X (electronic)
BOOK PUBLISHER
  Elsevier Editora Ltda, Rua Sete de Setembro, 111 15, 16 and 17th floor, Rio 
de Janeiro, Brazil.
ABSTRACT
  Background and objectives: To update and review the application of 
dexmedetomidine in anesthesia and intensive care. This study is a 
comprehensive review of clinical uses, pharmacology, pharmacokinetics, 
mechanism of action and adverse effects of dexmedetomidine. Content: The 
effective use of sedative-hypnotic agents and analgesics is an integral part 
of comfort and safety of patients. Dexmedetomidine is a potent and highly 
selective α-2 adrenoceptor agonist with sympatholytic, sedative, amnestic, 
and analgesic properties, which has been described as a useful and safe 
adjunct in many clinical applications. It provides a unique " conscious 
sedation" , analgesia, without respiratory depression. The current reviewed 
uses include sedation at Intensive Care Unit - ICU (both adult and 
pediatric), emergency department, regional and general anesthesia, 
neurosurgery, sedation for pediatric procedures, awake fiber-optic 
intubation, cardiac surgery and bariatric surgery. Conclusions: 
Dexmedetomidine offers a unique ability of providing both sedation and 
analgesia without respiratory depression. It is a new agent with a wide 
safety margin, excellent sedative capacity and moderate analgesic 
properties. Although its wide use is currently in patients of surgical and 
non-surgical intensive care units, dexmedetomidine seems to have promising 
future applications in neuroprotection, cardioprotection and renoprotection. 
More detailed studies are required to define its role as sedative in 
critical, neurosurgical and pediatric patients, as anesthesia adjunct and 
sedative during procedures. © 2012 Elsevier Editora Ltda.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dexmedetomidine (adverse drug reaction, drug comparison, drug therapy, 
intramuscular drug administration, intravenous drug administration, oral 
drug administration, pharmacokinetics, pharmacology, transdermal drug 
administration)
EMTREE DRUG INDEX TERMS
  alpha 2 adrenergic receptor (endogenous compound)
  atropine (drug therapy)
  calcium activated potassium channel (endogenous compound)
  clonidine (drug comparison)
  ephedrine (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anesthesia
  intensive care
EMTREE MEDICAL INDEX TERMS
  adrenergic activity
  analgesic activity
  atrial fibrillation (side effect)
  bariatric surgery
  bradycardia (drug therapy, side effect)
  brain ischemia (drug therapy, prevention)
  cardiovascular response
  conscious sedation
  drug absorption
  drug bioavailability
  drug clearance
  drug distribution
  drug efficacy
  drug elimination
  drug half life
  drug metabolism
  drug safety
  drug structure
  emergency ward
  fiber optics
  first degree atrioventricular block (side effect)
  general anesthesia
  heart arrest (side effect)
  heart arrest (side effect)
  heart muscle ischemia (drug therapy, prevention)
  heart protection
  heart surgery
  human
  hyperpolarization
  hypertension (side effect)
  hypnosis
  hypotension (side effect)
  hypoxia (side effect)
  hypoxic ischemic encephalopathy (drug therapy, prevention)
  liver metabolism
  nausea (side effect)
  negative feedback
  neuroprotection
  neurosurgery
  neurotransmitter release
  nonhuman
  noradrenalin release
  patient safety
  pediatric surgery
  regional anesthesia
  renal protection
  respiration depression
  review
  second degree atrioventricular block (side effect)
  single drug dose
  steady state
  thermoregulation
  tranquilizing activity
  withdrawal syndrome (drug therapy)
DRUG TRADE NAMES
  precedex  , United StatesAbbott

DRUG MANUFACTURERS
   (United States)Abbott
CAS REGISTRY NUMBERS
  atropine (51-55-8, 55-48-1)
  clonidine (4205-90-7, 4205-91-8, 57066-25-8)
  dexmedetomidine (113775-47-6)
  ephedrine (299-42-3, 50-98-6)
EMBASE CLASSIFICATIONS
  Anesthesiology (24)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English, Portuguese
LANGUAGE OF SUMMARY
  English, Portuguese
EMBASE ACCESSION NUMBER
  2012037260
MEDLINE PMID
  22248773 (http://www.ncbi.nlm.nih.gov/pubmed/22248773)
FULL TEXT LINK
  http://dx.doi.org/10.1016/S0034-7094(12)70110-1
COPYRIGHT
  Copyright 2013 Elsevier B.V., All rights reserved.

RECORD 326
TITLE
  Neural mechanisms of atrial arrhythmias
AUTHOR NAMES
  Shen M.J.
  Choi E.-K.
  Tan A.Y.
  Lin S.-F.
  Fishbein M.C.
  Chen L.S.
  Chen P.-S.
AUTHOR ADDRESSES
  (Shen M.J.) Department of Internal Medicine, University of Illinois at 
Chicago, Advocate Christ Medical Center, 4440 West 95th Street, 131 NO, Oak 
Lawn, IL 60453, United States.
(Choi E.-K.) Department of Internal Medicine, Seoul National University 
Hospital, 28 Yongon-dong, Chongno-gu Seoul 110-744, South Korea.
(Tan A.Y.) Beth Israel Deaconess Medical Center, Harvard Medical School, 330 
Brookline Avenue, Boston, MA 02215, United States.
(Lin S.-F.; Chen P.-S., chenpp@iupui.edu) Department of Medicine, Indiana 
University, School of Medicine, 1801 North Capitol Avenue, E475, 
Indianapolis, IN 46202, United States.
(Fishbein M.C.) Department of Pathology and Laboratory Medicine, David 
Geffen School of Medicine, University of California Los Angeles, 10833 Le 
Conte Avenue, Los Angeles, CA 90095, United States.
(Chen L.S.) Department of Neurology, Indiana University, School of Medicine, 
545 Barnhill Drive, EH 125, Indianapolis, IN 46202, United States.
CORRESPONDENCE ADDRESS
  P.-S. Chen, Department of Medicine, Indiana University, School of Medicine, 
1801 North Capitol Avenue, E475, Indianapolis, IN 46202, United States. 
Email: chenpp@iupui.edu
SOURCE
  Nature Reviews Cardiology (2012) 9:1 (30-39). Date of Publication: January 
2012
ISSN
  1759-5002
  1759-5010 (electronic)
BOOK PUBLISHER
  Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
  The past 5 years have seen great advances in the knowledge of neural 
mechanisms of atrial arrhythmogenesis. Direct autonomic nerve recordings 
demonstrate that simultaneous sympathovagal discharges and intrinsic cardiac 
nerve activities are common triggers of paroxysmal atrial tachycardia and 
atrial fibrillation. While activity of the autonomous nervous system (ANS) 
is crucial in triggering paroxysmal atrial fibrillation, a high incidence of 
sympathovagal co-activation at baseline is associated with a high 
vulnerability to pacing-induced sustained atrial fibrillation, suggesting 
that ANS has a role in the development of persistent atrial fibrillation. 
Modulation of ANS activity may constitute an important therapeutic strategy 
for the management of atrial tachyarrhythmias. Specifically, continuous, 
low-level stimulation of the left cervical vagus nerve effectively 
suppresses atrial tachyarrhythmias by reducing the nerve activity of the 
stellate ganglion. Clinically, compared with pulmonary vein isolation alone, 
the addition of ablation of intrinsic cardiac ganglia may confer better 
outcomes for patients with paroxysmal atrial fibrillation. These findings 
suggest that further investigation of the neural mechanisms of atrial 
arrhythmias might lead to better management of patients with atrial 
arrhythmias. In this article, we review the role of the ANS in the induction 
and maintenance of atrial arrhythmias and the role of neural modulation as a 
treatment strategy for atrial arrhythmias. © 2011 Macmillan Publishers 
Limited. All rights reserved.
EMTREE DRUG INDEX TERMS
  acetylcholine
  dopachrome
  melanin
  stem cell factor receptor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart atrium arrhythmia
EMTREE MEDICAL INDEX TERMS
  acupuncture
  atrial fibrillation
  atrioventricular canal
  autonomic nervous system
  catheter ablation
  electrostimulation
  follow up
  heart atrioventricular node
  heart failure
  heart nerve
  heart rate
  inferior cava vein
  long QT syndrome
  nerve cell network
  nerve conduction
  nonhuman
  parasympathetic innervation
  priority journal
  refractory period
  review
  sarcoplasmic reticulum
  sinus node disease
  spinal cord
  superior cervical ganglion
  supraventricular tachycardia
  sympathetic tone
  tachycardia
  vagus nerve
CAS REGISTRY NUMBERS
  acetylcholine (51-84-3, 60-31-1, 66-23-9)
  dopachrome (3571-34-4)
  melanin (8049-97-6)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011693515
MEDLINE PMID
  21946776 (http://www.ncbi.nlm.nih.gov/pubmed/21946776)
FULL TEXT LINK
  http://dx.doi.org/10.1038/nrcardio.2011.139
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 327
TITLE
  Heart failure with a normal ejection fraction: Treatments for a complex 
syndrome?
AUTHOR NAMES
  Bernard S.
  Maurer M.S.
AUTHOR ADDRESSES
  (Bernard S., msm10@columbia.edu; Maurer M.S.) Clinical Cardiovascular 
Research Laboratory for the Elderly, Columbia University, Allen Hospital of 
New York, 5141 Broadway, New York, NY 10034, United States.
CORRESPONDENCE ADDRESS
  S. Bernard, Clinical Cardiovascular Research Laboratory for the Elderly, 
Columbia University, Allen Hospital of New York, 5141 Broadway, New York, NY 
10034, United States. Email: msm10@columbia.edu
SOURCE
  Current Treatment Options in Cardiovascular Medicine (2012) 14:4 (305-318). 
Date of Publication: August 2012
ISSN
  1534-3189 (electronic)
  1092-8464
BOOK PUBLISHER
  Springer Healthcare
ABSTRACT
  Heart failure with a normal ejection fraction (HFNEF) now comprises more 
than 50 % of all patients with heart failure. As the population ages, HFNEF 
will continue to be a growing public health problem. Recent studies 
highlight the heterogeneity of this syndrome with regards to underlying 
pathophysiologic mechanisms. It has been recognized that multiple 
physiologic domains of cardiovascular function are abnormal in afflicted 
patients resulting in a reduced reserve capacity, which contributes in an 
integrated fashion to produce the observed phenotype. Additionally, the 
realization that differing aspects of this syndrome (eg, exercise 
limitations, pulmonary edema, and labile blood pressure) likely each have 
distinct physiologic causes further adds to the complexity. As a result of 
the heterogeneous nature of the pathophysiologic processes and comorbid 
illnesses in this population, there is a wide range of clinical outcomes. 
Accordingly, appreciation of the global nature of HFNEF ideally will better 
inform optimal design for future diagnostic and therapeutic strategies. 
Completed clinical trials have not resulted in any evidence-based treatments 
available for improving survival. Given the disappointing results of these 
investigations, there has been renewed interest in developing interventions 
that target underlying comorbidities and peripheral mechanisms. 
Additionally, nonpharmacologic interventions such as diet and exercise have 
shown promise in early, small clinical investigations. Finally, methods to 
more rationally subgroup patients to identify cohorts that could respond to 
targeted intervention are essential. Recognizing the success achieved in the 
treatment of systolic heart failure, or heart failure with a reduced 
ejection fraction (HFREF) by addressing neurohormonal and renal mechanisms, 
new therapies for HFNEF may be achieved by a similar shift in attention away 
from the heart. © Springer Science+Business Media, LLC 2012.
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (clinical trial, drug therapy)
  amlodipine (clinical trial, drug comparison, drug therapy)
  angiotensin receptor antagonist (drug therapy)
  beta adrenergic receptor blocking agent (drug comparison, drug therapy)
  calcium channel blocking agent (drug comparison, drug therapy)
  candesartan (clinical trial, drug therapy)
  digoxin (drug comparison, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  diuretic agent (clinical trial, drug comparison, drug therapy, intravenous 
drug administration)
  doxazosin (clinical trial, drug comparison, drug therapy)
  irbesartan (clinical trial, drug therapy)
  lisinopril (clinical trial, drug comparison, drug therapy)
  loop diuretic agent (drug therapy, intravenous drug administration)
  losartan (drug therapy)
  nebivolol (clinical trial, drug therapy)
  perindopril (clinical trial, drug therapy)
  placebo
  thiazide diuretic agent (clinical trial, drug therapy)
  verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (drug therapy, complication, drug therapy, etiology, surgery, 
therapy)
  heart failure with normal ejection fraction (drug therapy, complication, 
drug therapy, etiology, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  alcohol abstinence
  aorta valve stenosis (surgery)
  atrial fibrillation (drug therapy)
  blood pressure regulation
  cardiac resynchronization therapy
  clinical feature
  comorbidity
  coronary artery bypass surgery
  diabetes mellitus (drug therapy)
  diastolic dysfunction (drug therapy)
  evidence based medicine
  glycemic control
  heart failure with reduced ejection fraction (drug therapy, surgery, 
therapy)
  heart failure with reduced ejection fraction (drug therapy)
  heart left ventricle ejection fraction
  human
  hypertension (drug therapy, therapy)
  hypertrophic cardiomyopathy (drug therapy)
  hypervolemia (drug therapy)
  kidney failure (drug therapy)
  kinesiotherapy
  lung edema (drug therapy)
  nonhuman
  pathophysiology
  percutaneous coronary intervention
  quality of life
  review
  sodium restriction
  speech therapy
  systolic heart failure (therapy)
  systolic hypertension (therapy)
  transcatheter aortic valve implantation
  treatment outcome
  weight reduction
CAS REGISTRY NUMBERS
  amlodipine (88150-42-9, 103129-82-4, 736178-83-9)
  candesartan (139481-59-7)
  digoxin (20830-75-5, 57285-89-9)
  doxazosin (74191-85-8)
  irbesartan (138402-11-6)
  lisinopril (76547-98-3, 83915-83-7)
  losartan (114798-26-4)
  nebivolol (99200-09-6, 118457-15-1, 118457-16-2)
  perindopril (82834-16-0, 99149-83-4)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012516213
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11936-012-0187-4
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 328
TITLE
  The functional role of fish protein hydrolysate derived bioactive compounds 
in cardioprotection and antioxdative functions
AUTHOR NAMES
  Vignesh R.
  Srinivasan M.
  Jayaprabha N.
  Badhul Haq M.A.
AUTHOR ADDRESSES
  (Vignesh R.; Srinivasan M.; Jayaprabha N.; Badhul Haq M.A.) Centre of 
Advanced Study in Marine Biology, Faculty of Marine Sciences Annamalai 
University, Parangipettai, Tamilnadu, India.
CORRESPONDENCE ADDRESS
  R Vignesh, Centre of Advanced Study in Marine Biology, Faculty of Marine 
Sciences Annamalai University, Parangipettai, Tamilnadu, India.
SOURCE
  International Journal of Pharma and Bio Sciences (2012) 3:1 (B560-B566). 
Date of Publication: 2012
ISSN
  0975-6299 (electronic)
BOOK PUBLISHER
  International Journal of Pharma and Bio Sciences, prasmol@rediffmail.com
ABSTRACT
  Bioactive peptides isolated from various fish protein hydrolysates have 
shown a numerous bioactivities such as antihypertensive, antithrombotic, 
immunomodulatory and antioxidative activities. Fish protein hydrolysate 
extracts performs the regulation of the immune system, gastrointestinal 
functions, blood pressure, glucose inhibitory activity, antihypertensive 
effect, antioxidant properties and angiotensin converting enzyme inhibitory 
activity. Fish waste is rich in potentially valuable oils, minerals, 
enzymes, pigments and flavors etc. These may also have many alternative uses 
in food, pharmaceutical, agricultural, aquaculture and industrial 
applications. Fish proteins can have not only nutritional but also 
functional and biological applications. Intake of fish oil, which is an 
excellent source of omega- 3 fatty acids, has been linked to promotion of 
human health to fight against numerous diseases. Peptides derived from fish 
proteins have shown the ability of exerting potent antioxidative activities 
in different oxidative systems. This review paper focuses on the important 
role of fish protein extracts in various pharmacological aspects.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  fish protein (pharmacology)
EMTREE DRUG INDEX TERMS
  docosahexaenoic acid
  doxorubicin (adverse drug reaction, drug therapy)
  fish oil (pharmacology)
  icosapentaenoic acid
  linoleic acid
  muscle protein
  omega 3 fatty acid (drug therapy)
  omega 6 fatty acid
  protein hydrolysate
  reactive oxygen metabolite (endogenous compound)
  taurine (clinical trial, drug therapy)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  antioxidant activity
  heart protection
EMTREE MEDICAL INDEX TERMS
  acute heart failure (side effect)
  antiarrhythmic activity
  atrial fibrillation (drug therapy)
  calcium absorption
  congestive heart failure (drug therapy, side effect)
  coronary artery atherosclerosis
  coronary artery disease
  diet supplementation
  grass carp
  heart arrhythmia (side effect)
  heart muscle ischemia
  heart ventricle arrhythmia (drug therapy)
  heart ventricle extrasystole (drug therapy)
  human
  hydrolysis
  hypertension (drug therapy)
  ischemic heart disease (drug therapy, prevention)
  leukemia (drug therapy)
  lipid peroxidation
  lymphoma (drug therapy)
  nonhuman
  reperfusion injury
  review
  sea food
  solid tumor (drug therapy)
  sudden death
  Tilapia
  tuna
CAS REGISTRY NUMBERS
  docosahexaenoic acid (25167-62-8, 32839-18-2)
  doxorubicin (23214-92-8, 25316-40-9)
  fish oil (8016-13-5)
  icosapentaenoic acid (25378-27-2, 32839-30-8)
  linoleic acid (1509-85-9, 2197-37-7, 60-33-3, 822-17-3)
  protein hydrolysate (76773-71-2, 9015-54-7)
  taurine (107-35-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2014901991
COPYRIGHT
  Copyright 2015 Elsevier B.V., All rights reserved.

RECORD 329
TITLE
  A randomized, double-blind, placebo-controlled, crossover, dose-ranging 
multicenter study to determine the effect of sublingual nitroglycerin spray 
on exercise capacity in patients with chronic stable angina
AUTHOR NAMES
  Thadani U.
  Wittig T.
AUTHOR ADDRESSES
  (Thadani U., udho-thadani@ouhsc.edu) Department of Medicine, Cardiovascular 
Section, University of Oklahoma Health Sciences Center and VA Medical 
Center, Oklahoma City, OK, Germany.
(Wittig T.) G. Pohl-Boskamp GmbH and Co. KG, Germany.
CORRESPONDENCE ADDRESS
  U. Thadani, Department of Medicine, Cardiovascular Section, University of 
Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, OK, 
Germany. Email: udho-thadani@ouhsc.edu
SOURCE
  Clinical Medicine Insights: Cardiology (2012) 6 (87-95). Date of 
Publication: 2012
ISSN
  1179-5468 (electronic)
  1179-5468
BOOK PUBLISHER
  Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay, 
Auckland, New Zealand.
ABSTRACT
  Background: Sublingual nitroglycerin increases exercise duration in patients 
with stable angina. Brief results from this study were published previously 
in German. Here, we more fully describe the study methodology, patient 
characteristics, and detailed results. Methods: This double-blind, crossover 
study enrolled 51 patients with stable angina. Patients were randomized to 1 
of 5 treatment sequences and were administered placebo or nitroglycerin 
spray (0.2 mg, 0.4 mg, 0.8 mg, or 1.6 mg). Patients carried out 1 control 
exercise tolerance test (ETT) and 1 investigational ETT at each visit. 
Results: Dose-dependent increases in time to onset of angina, time to onset 
of moderate angina, and the occurrence of a minimum 1.0-mm ST-segment 
depression were seen following administration of nitroglycerin spray. 
Conclusions: These results support the use of sublingual nitroglycerin spray 
in patients with stable angina who are being managed with medical therapy 
and in patients who have persistent angina post-revascularization. © the 
author(s). publisher and licensee Libertas Academica Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  glyceryl trinitrate (adverse drug reaction, clinical trial, drug dose, drug 
therapy, sublingual drug administration)
EMTREE DRUG INDEX TERMS
  placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise tolerance
  stable angina pectoris (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aerosol
  aged
  article
  atrial fibrillation (complication, therapy)
  cardioversion
  controlled study
  crossover procedure
  dizziness (side effect)
  dose response
  double blind procedure
  drug efficacy
  drug induced headache (side effect)
  drug safety
  exercise
  exercise duration
  female
  heart ventricle tachycardia (complication, therapy)
  human
  hypotension (side effect)
  major clinical study
  male
  multicenter study
  open study
  outcome assessment
  pharmacologic stress testing
  quality of life
  randomized controlled trial
  side effect (side effect)
  ST segment depression
  systolic blood pressure
  time
  time to onset angina
  time to onset moderate angina
DRUG TRADE NAMES
  nitrolingual  , GermanyPohl Boskamp

DRUG MANUFACTURERS
   (Germany)Pohl Boskamp
CAS REGISTRY NUMBERS
  glyceryl trinitrate (55-63-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012387954
FULL TEXT LINK
  http://dx.doi.org/10.4137/CMC.S9132
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 330
TITLE
  Complementary and alternative medicine treatments among stroke patients in 
India
AUTHOR NAMES
  Pandian J.
  Toor G.
  Arora R.
  Kaur P.
  Dheeraj K.V.
  Bhullar R.
  Sylaja P.
AUTHOR ADDRESSES
  (Pandian J.; Toor G.; Kaur P.; Bhullar R.) Stroke Unit, Department of 
Neurology, Christian Medical College, Ludhiana, Punjab, India.
(Arora R.; Dheeraj K.V.) College of Physiotherapy, Christian Medical 
College, Ludhiana, Punjab, India.
(Sylaja P.) Stroke Unit, Department of Neurology, Sree Chitra Tirunal 
Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, 
India.
CORRESPONDENCE ADDRESS
  J. Pandian, Stroke Unit, Department of Neurology, Christian Medical College, 
Ludhiana, Punjab, India.
SOURCE
  Topics in Stroke Rehabilitation (2012) 19:5 (384-394). Date of Publication: 
1 Jan 2012
ISSN
  1074-9357
  1945-5119 (electronic)
BOOK PUBLISHER
  Thomas Land Publishers Inc., 255 Jefferson Road, St. Louis, United States.
ABSTRACT
  Background: Complementary and alternative medicine (CAM) is commonly used by 
persons with stroke throughout the world, particularly in Asia. Objective: 
The objectives of this study were to determine the frequency of CAM use and 
the factors that predict the use of CAM in stroke patients. Methods: This 
study was carried out in the stroke units of Christian Medical College, 
Ludhiana, and Sree Chitra Tirunal Institute for Medical Sciences and 
Technology, Thiruvananthapuram, India, from June 2010 to December 2010. 
Participants were interviewed using a structured questionnaire (≥6 months 
post stroke). Outcomes were assessed using a modifi ed Rankin Scale (mRS). 
Results: Three hundred fourteen stroke patients were interviewed; mean age 
was 57.4 ± 12.9 years, and 230 (73.2%) patients were men. Of 314 patients, 
114 (36.3%) had used the following CAM treatments: ayurvedic massage, 67 
(59.3%); intravenous fl uids, 22 (19.5%); herbal medicines, 17 (15%); 
homeopathy, 15 (13.3%); witchcraft, 3 (2.7%); acupuncture, 3 (2.7%); opium 
intake, 10 (8.8%); and other nonconventional treatments, 10 (8.8%). Patients 
with severe stroke (P < .0001), limb weakness (P < .0001), dysphagia (P = 
.02), dyslipidemia (P = .007), hypertension (P = .03), or hemorrhagic stroke 
(P<.0001) and patients with poor outcome (mRS >2;P < .0001) often used CAM 
treatments. Conclusion: More than one-third of the patients in this study 
opted for CAM. Presence of limb weakness, dysphagia, dyslipidemia, 
hypertension, hemorrhagic stroke, severe stroke, and poor outcome predicted 
the use of CAM. © 2012 Thomas Land Publishers, Inc.
EMTREE DRUG INDEX TERMS
  opiate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alternative medicine
  cerebrovascular accident (disease management, rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  adult
  aged
  alcohol consumption
  aphasia
  article
  atrial fibrillation
  Ayurveda
  brain hemorrhage
  carotid artery obstruction
  clinical effectiveness
  consciousness disorder
  coronary artery disease
  cost effectiveness analysis
  diabetes mellitus
  diplopia
  dizziness
  dyslipidemia
  dysphagia
  dysphasia
  educational status
  emergency treatment
  employment status
  female
  fluid therapy
  headache
  health care system
  herbal medicine
  homeopathy
  human
  hyperlipidemia
  hypertension
  India
  limb weakness
  major clinical study
  male
  massage
  outcome assessment
  prospective study
  Rankin scale
  Reiki
  religion
  seizure
  slurred speech
  smoking
  stroke patient
  stroke unit
  structured questionnaire
  transient ischemic attack
  treatment duration
  unsteadiness
  visual field defect
  witchcraft
CAS REGISTRY NUMBERS
  opiate (53663-61-9, 8002-76-4, 8008-60-4)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Rehabilitation and Physical Medicine (19)
  Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012561157
MEDLINE PMID
  22982825 (http://www.ncbi.nlm.nih.gov/pubmed/22982825)
FULL TEXT LINK
  http://dx.doi.org/10.1310/tsr1905-384
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 331
TITLE
  Does collateral circulation protect against acute myocardial infarction? Two 
hemodynamically important collateral circulation examples: Case report
AUTHOR NAMES
  Bostan M.
  Şatiroǧlu Ö.
  Mungan U.
  Çanga A.
  Bozkurt E.
AUTHOR ADDRESSES
  (Bostan M., drmehmetbostan@hotmail.com; Şatiroǧlu Ö.; Bozkurt E.) Rize 
University, Faculty of Medicine, Department of Cardiology, Rize, Turkey.
(Mungan U.) Clinic of Cardiovascular Surgery, Rize Training and Research 
Hospital, Rize, Turkey.
(Çanga A.) Clinic of Cardiology, Rize Training and Research Hospital, Rize, 
Turkey.
CORRESPONDENCE ADDRESS
  M. Bostan, Rize University, Faculty of Medicine, Department of Cardiology, 
Rize, Turkey. Email: drmehmetbostan@hotmail.com
SOURCE
  Turkiye Klinikleri Cardiovascular Sciences (2011) 23:3 (256-259). Date of 
Publication: 2011
ISSN
  1306-7656
BOOK PUBLISHER
  Turkiye Klinikleri, Turkocagi Caddesi No. 30, Balgat, Turkey.
ABSTRACT
  Coronary collateral vessels interconnect the major coronary arteries. They 
are small in (<200 μm) caliber. Collateral channels can not be seen in 
patients with normal or mildly diseased coronary arteries. The coronary 
collateral circulation is a complementary source of blood supply to 
myocardium jeopardized by stenosis of a coronary vessel. If they are 
adequate size, collaterals may protect against myocardial infarction in 
cases of total occlusion. The myocardial infarct size is smaller in patients 
with abundant collateral vessels than in patients without collaterals. 
Therefore total occlusion of a major epicardial artery may not lead to left 
ventricule dysfunction. Presented cases are important examples that the 
myocardium was protected against left ventricule dysfunction owing to total 
occlusion of one or more major coronary arteries. Copyright © 2011 by 
Türkiye Klinikleri.
EMTREE DRUG INDEX TERMS
  C reactive protein (endogenous compound)
  fibrinogen (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
  troponin T (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acute heart infarction
  collateral circulation
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  anastomosis
  angiocardiography
  aorta valve regurgitation
  article
  atrial fibrillation
  case report
  daily life activity
  diabetes mellitus
  echocardiography
  electrocardiography
  exercise
  female
  heart atrium enlargement
  heart hemodynamics
  heart infarction size
  heart left ventricle failure
  heart muscle revascularization
  human
  left anterior descending coronary artery
  male
  mitral valve regurgitation
  right coronary artery
  smoking
  ST segment elevation
  stable angina pectoris
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  fibrinogen (9001-32-5)
  troponin T (60304-72-5)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, Turkish
EMBASE ACCESSION NUMBER
  2011676413
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 332
TITLE
  Epidemiology and risk factors
AUTHOR NAMES
  Elkind M.S.V.
AUTHOR ADDRESSES
  (Elkind M.S.V., mse13@mail.cumc.columbia.edu) Neurological Institute, 710 
West 168th Street, New York, NY 10032, United States.
CORRESPONDENCE ADDRESS
  M.S.V. Elkind, Neurological Institute, 710 West 168th Street, New York, NY 
10032, United States. Email: mse13@mail.cumc.columbia.edu
SOURCE
  CONTINUUM Lifelong Learning in Neurology (2011) 17:6 (1213-1232). Date of 
Publication: December 2011
ISSN
  1080-2371
  1538-6899 (electronic)
BOOK PUBLISHER
  Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327, 
Philadelphia, United States.
ABSTRACT
  Purpose of Review: This article presents current knowledge on stroke 
epidemiology. It covers recent data on the global burden of stroke, 
disparities, silent stroke, traditional and novel risk factors, and stroke 
triggers as well as the clinical implications of these findings. Recent 
Findings: Stroke is the third leading cause of death and the leading cause 
of chronic disability in the United States, and the burden of stroke 
worldwide is even greater. Large international and US case-control and 
prospective cohort studies have demonstrated disparities in stroke mortality 
and incidence. They have also shed light on the relative importance of 
several well-established, modifiable risk factors for ischemic stroke, such 
as hypertension, atrial fibrillation, other cardiac diseases, 
hyperlipidemia, diabetes, cigarette smoking, physical inactivity, alcohol 
consumption, abdominal obesity, diet, and TIA. Research on other putative 
stroke risk factors (including inflammation, infection, renal disease, 
depression, stress, and others) is ongoing. Identifying stroke triggers may 
be another way to minimize stroke incidence if high-risk time windows can be 
determined. Summary: Stroke is a major global health burden. While many of 
the risk factors for stroke are well known and have been studied for 
decades, recent studies continue to shed light on the distribution and 
severity of these problems. © 2011, American Academy of Neurology. All 
rights reserved.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug combination)
  alpha smooth muscle actin (endogenous compound)
  antithrombocytic agent
  arachidonate 5 lipoxygenase (endogenous compound)
  arachidonate 5 lipoxygenase activating protein (endogenous compound)
  C reactive protein (endogenous compound)
  clopidogrel
  collagen type 4 (endogenous compound)
  copeptin (endogenous compound)
  cyclin dependent kinase inhibitor 2A (endogenous compound)
  cyclin dependent kinase inhibitor 2B (endogenous compound)
  cystatin C (endogenous compound)
  dipyridamole (drug combination)
  hydrochlorothiazide
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  low density lipoprotein cholesterol (endogenous compound)
  oral contraceptive agent (adverse drug reaction)
  phosphodiesterase (endogenous compound)
  phosphodiesterase 4D (endogenous compound)
  pravastatin
  serotonin uptake inhibitor (adverse drug reaction)
  tissue plasminogen activator (intravenous drug administration)
  tricyclic antidepressant agent (adverse drug reaction)
  unclassified drug
  very low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia (diagnosis, epidemiology, etiology, prevention)
EMTREE MEDICAL INDEX TERMS
  African American
  alcohol consumption
  Alzheimer disease
  aortic arch atheroma
  atheroma
  atrial fibrillation
  autosomal recessive disorder
  basal ganglion
  blood pressure
  brain atherosclerosis
  brain hemorrhage
  brain infarction
  CADASIL
  carotid artery obstruction
  Cerebral autosomal recessive arteriopathy with subcortical infarct and 
leukoencephalopathy
  cerebrovascular accident
  cerebrovascular accident (side effect)
  childhood disease (etiology)
  Chlamydia pneumoniae
  chromosome 9p
  chronic kidney disease
  Cytomegalovirus
  dementia
  diabetes mellitus
  diffusion weighted imaging
  disease classification
  disease duration
  drug dose increase
  Fabry disease
  fatality
  genetic association
  genetic disorder
  genetic variability
  glomerulus filtration rate
  heart infarction
  heart left ventricle aneurysm
  Helicobacter pylori
  Herpes simplex virus 1
  Herpes simplex virus 2
  Hispanic
  human
  Human immunodeficiency virus
  hyperlipidemia
  immobilization
  inflammation
  influenza (prevention)
  influenza vaccination
  insulin resistance
  leukoencephalopathy
  malnutrition
  Marfan syndrome
  metabolic syndrome X
  microalbuminuria
  migraine with aura
  mitral valve disease
  mitral valve strand
  mortality
  obesity
  onset age
  patent foramen ovale
  periodontal disease
  prediction
  prevalence
  prognosis
  protein blood level
  race difference
  review
  risk assessment
  salt intake
  sanitation
  scoring system
  secondary prevention
  sedentary lifestyle
  sex difference
  sickle cell anemia
  silent stroke
  smoking
  speech disorder
  stroke patient
  subarachnoid hemorrhage
  systolic hypertension
  transient ischemic attack (diagnosis)
  upper respiratory tract infection
  urinary tract infection
  valvular heart disease
  weakness
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  arachidonate 5 lipoxygenase (80619-02-9)
  arachidonate 5 lipoxygenase activating protein (137546-36-2)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  dipyridamole (58-32-2)
  hydrochlorothiazide (58-93-5)
  pravastatin (81093-37-0, 81131-70-6)
  tissue plasminogen activator (105913-11-9)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012046802
FULL TEXT LINK
  http://dx.doi.org/10.1212/01.CON.0000410031.34477.8d
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 333
TITLE
  Tongue hematoma induced by warfarin overdose
AUTHOR NAMES
  Bilen M.N.
  Kara H.
AUTHOR ADDRESSES
  (Bilen M.N.) Department of Cardiology, Bingol State Hospital, Bingol, 
Turkey.
(Kara H.) Department of Emergency Medicine, Konya Numune Education and 
Research Hospital, Konya, Turkey.
CORRESPONDENCE ADDRESS
  M. N. Bilen, Department of Cardiology, Bingol State Hospital, Bingol, 
Turkey.
SOURCE
  Cardiology (Pakistan) (2011) 6:3 (18-19). Date of Publication: 2011
ISSN
  1811-8194
  1993-6117 (electronic)
BOOK PUBLISHER
  Medwell Journals, ANSInet Building, 308-Lasani Town Sargodha Road, 
Faisalabad, Pakistan.
ABSTRACT
  Warfarin is one of the common oral anticoagulants. Anticoagulant response is 
affected by the amount of dietary Vitamin K, various drugs, foods and herbal 
treatments. Although, hemorrhage is one of the side effects of warfarin, 
tongue hematoma is a rare complication. In this research, 50 years old male 
patient developed tongue hematoma during the prophylactic warfarin treatment 
due to the atrial fibrillation is presented. © Medwell Journals, 2011.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin (adverse drug reaction, drug therapy)
EMTREE DRUG INDEX TERMS
  fresh frozen plasma (drug therapy)
  low molecular weight heparin (drug therapy)
  propylthiouracil
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, diagnosis, drug therapy)
  drug induced disease
  hematoma (drug therapy, side effect, diagnosis, drug therapy, side effect, 
therapy)
  tongue disease (side effect, diagnosis, side effect, therapy)
  tongue hematoma (drug therapy, diagnosis, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  abnormal laboratory result
  adult
  article
  blood substitution
  case report
  clinical feature
  coronary artery bypass graft
  drug overdose
  drug substitution
  drug withdrawal
  electrocardiogram
  human
  hyperthyroidism
  international normalized ratio
  male
  physical examination
  tongue swelling
  treatment outcome
DRUG TRADE NAMES
  coumadin
CAS REGISTRY NUMBERS
  propylthiouracil (51-52-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Otorhinolaryngology (11)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012392496
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 334
TITLE
  Prevention of stroke in patients with atrial fibrillation
AUTHOR NAMES
  Moukabary T.
  Naccarelli G.V.
AUTHOR ADDRESSES
  (Moukabary T.; Naccarelli G.V., gnaccarelli@hmc.psu.edu) Electrophysiology 
Program, Heart and Vascular Institute, Penn. State University College of 
Medicine, Hershey, PA, United States.
CORRESPONDENCE ADDRESS
  G.V. Naccarelli, Heart and Vascular Institute, Penn. State University 
College of Medicine, MC H047, 500 University Drive, Hershey, PA 17033, 
United States. Email: gnaccarelli@hmc.psu.edu
SOURCE
  Journal of Atrial Fibrillation (2011) 2:8. Date of Publication: December 
2011
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
ABSTRACT
  The presence of atrial fibrillation (AF) increases the risk of stroke, 
especially in patients with risk factors as outlined by the CHADS(2) and 
CHA2DS(2)-VASc scoring systems. Although warfarin can reduce stroke rates by 
over 65%, only 55% of patients, in the USA, who should be on warfarin for AF 
and stroke prevention are taking the drug due to the need of INR monitoring, 
difficulties in maintaining a therapeutic INR in the therapeutic range and 
dietary and drug interactions. Dabigatran, an oral direct thrombin inhibitor 
and rivaroxaban and apixaban, factor Xa inhibitors, have demonstrated 
efficacy in reducing stroke in large clinical trials. These novel 
anticoagulants will change the therapeutic landscape since patients will be 
able to prevent stroke with a lower risk of intracranial hemorrhage and 
without the need for INR monitoring and less drug-dietary interactions.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (clinical trial, drug combination, drug comparison, 
drug therapy)
  apixaban (clinical trial, drug comparison, drug therapy, pharmacokinetics)
  betrixaban
  clopidogrel (clinical trial, drug combination, drug therapy)
  dabigatran (clinical trial, drug comparison, drug therapy, oral drug 
administration, pharmacokinetics)
  dabigatran etexilate
  edoxaban (clinical trial, drug comparison, drug therapy, pharmacokinetics)
  multidrug resistance protein (endogenous compound)
  placebo
  rivaroxaban (clinical trial, drug therapy, pharmacokinetics)
  warfarin (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy)
  cerebrovascular accident (drug therapy, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
  comparative study
  drug excretion
  drug half life
  embolism (drug therapy)
  embolism prevention
  human
  international normalized ratio
  randomized controlled trial (topic)
  review
  thromboembolism (drug therapy)
  United States
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  apixaban (503612-47-3)
  betrixaban (330942-05-7)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  edoxaban (480449-70-5, 480449-71-6, 912273-65-5)
  rivaroxaban (366789-02-8)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011709011
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 335
TITLE
  Maintenance of sinus rhythm and treatment of atrial fibrillation in mitral 
stenosis
AUTHOR NAMES
  Sahin M.
  Simsek H.
  Ekici B.
  Akdag S.
  Tuncer M.
AUTHOR ADDRESSES
  (Sahin M.; Ekici B.) Department of Cardiology, Bitlis State Hospital, 
Bitlis, Turkey.
(Simsek H., dr.hsimsek@hotmail.com) Department of Cardiology, Osmaniye State 
Hospital, Osmaniye, Turkey.
(Akdag S.; Tuncer M.) Department of Cardiology, Yuzunci Yil University, 
Faculty of Medicine, Van, Turkey.
CORRESPONDENCE ADDRESS
  H. Simsek, Department of Cardiology, Bitlis State Hospital, Bitlis, Turkey. 
Email: dr.hsimsek@hotmail.com
SOURCE
  Eastern Journal of Medicine (2011) 16:4 (235-239). Date of Publication: 2011
ISSN
  1301-0883
BOOK PUBLISHER
  Yuzuncu Yil University, Eastern Journal of Medicine, Van, Turkey.
ABSTRACT
  Rheumatic fever is the most common cause of mitral stenosis. The most common 
complication of mitral stenosis is atrial fibrillation (AF). AF precipitates 
symptoms, greatly increases the risk of systemic embolisation, and reduces 
cardiac output and exercise capacity. Systemic embolization most often 
occurs in patients with both AF and mitral stenosis. Maintenance of the 
sinus rhythm in patients with mitral stenosis is very important because of 
reduce the risk of cerebral embolism, conservation of cardiac output and 
exercise capacity, and reduction of symptoms.
EMTREE DRUG INDEX TERMS
  amiodarone (intravenous drug administration, oral drug administration)
  anticoagulant agent (drug therapy)
  atenolol
  digoxin (drug therapy, intravenous drug administration)
  heparin (drug therapy, intravenous drug administration)
  metoprolol
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, complication, drug therapy, prevention, 
surgery, therapy)
  mitral valve stenosis (drug therapy, drug therapy)
  sinus rhythm
EMTREE MEDICAL INDEX TERMS
  age distribution
  angina pectoris
  article
  brain embolism (prevention)
  cardiovascular risk
  cardioversion
  disease association
  disease severity
  dyspnea
  embolism (drug therapy)
  exercise
  heart atrium thrombosis (drug therapy)
  heart infarction
  heart output
  heart ventricle pressure
  human
  hypertension (complication)
  kidney artery embolism
  lung edema
  mitral valve repair
  mitral valve replacement
  rheumatic fever
  rheumatic heart disease
  risk reduction
  sex difference
  treatment duration
  valvuloplasty
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  atenolol (29122-68-7, 93379-54-5)
  digoxin (20830-75-5, 57285-89-9)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  metoprolol (37350-58-6)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012525086
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 336
TITLE
  DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in 
adults full-text version
AUTHOR ADDRESSES
  SOURCE
  Osteologie (2011) 20:1 (55-74). Date of Publication: 2011
ISSN
  1019-1291
BOOK PUBLISHER
  Schattauer GmbH, Hoelderlinstr 3 Stuttgart, , Germany.
ABSTRACT
  The letters (A -D) show the relevant grade of recommendation with reference 
to fracture prediction or fracture reduction according to the SIGN criteria 
(therapy) and Oxford criteria (diagnosis). Recommendations which were 
included after 2006 are marked by "(E)". One is referred to the basic 
full-text version of the pre-version from 2006 with regard to the other 
recommendations. © Schattauer 2011.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  alendronic acid (adverse drug reaction, drug combination, drug therapy, oral 
drug administration)
  calcium (adverse drug reaction, drug combination, drug therapy)
  colecalciferol (adverse drug reaction, drug combination, drug therapy, oral 
drug administration)
  raloxifene (adverse drug reaction, drug therapy, oral drug administration)
  recombinant parathyroid hormone (adverse drug reaction, subcutaneous drug 
administration)
  risedronic acid (adverse drug reaction, drug combination, drug therapy, oral 
drug administration)
EMTREE DRUG INDEX TERMS
  alfacalcidol (drug therapy)
  alkaline phosphatase (endogenous compound)
  anticonvulsive agent (adverse drug reaction)
  antidepressant agent (adverse drug reaction)
  aromatase inhibitor
  C reactive protein (endogenous compound)
  calcitonin (drug therapy)
  calcitriol
  cyanocobalamin (endogenous compound)
  etidronic acid (drug therapy)
  fluoride (drug therapy)
  folic acid (endogenous compound)
  glitazone derivative
  homocysteine (endogenous compound)
  ibandronic acid (adverse drug reaction, intravenous drug administration, 
oral drug administration)
  levothyroxine (drug therapy)
  nandrolone decanoate (drug therapy)
  neuroleptic agent (adverse drug reaction)
  parathyroid hormone[1-34]
  phosphate (endogenous compound)
  prednisolone (adverse drug reaction, drug therapy, oral drug administration)
  proton pump inhibitor (adverse drug reaction)
  sedative agent (adverse drug reaction)
  strontium ranelate
  thyrotropin (endogenous compound)
  unindexed drug
  zoledronic acid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  osteoporosis (drug therapy, side effect, diagnosis, drug therapy, 
epidemiology, etiology, prevention, rehabilitation, side effect)
  practice guideline
EMTREE MEDICAL INDEX TERMS
  abdominal pain (side effect)
  Addison disease (drug therapy)
  alkaline phosphatase blood level
  arthralgia (side effect)
  atrial fibrillation (side effect)
  biochemistry
  blood cell count
  body mass
  bone density
  bone necrosis (side effect)
  bone pain (side effect)
  cardiovascular risk
  cerebrovascular accident (side effect)
  clinical examination
  clinical feature
  constipation (side effect)
  creatinine clearance
  Cushing syndrome
  diarrhea (side effect)
  dizziness (side effect)
  drug megadose
  drug withdrawal
  dual energy X ray absorptiometry
  esophagitis (side effect)
  exercise
  fall risk
  flu like syndrome (side effect)
  follow up
  fracture reduction
  fragility fracture (drug therapy, etiology, rehabilitation, side effect)
  gastrectomy
  gastroesophageal reflux
  gender
  growth hormone deficiency
  headache (side effect)
  hip fracture (etiology, rehabilitation)
  human
  hypercalcemia (side effect)
  hypercalciuria (side effect)
  hypercortisolism
  hyperthyroidism (drug therapy)
  hypocalcemia (side effect)
  hypogonadotropic hypogonadism
  hypophosphatemia (side effect)
  hypophysis disease
  immobilization
  incidence
  insulin dependent diabetes mellitus
  jaw osteonecrosis (side effect)
  kyphoplasty
  limb pain (side effect)
  medical history
  mortality
  motor coordination
  muscle cramp (side effect)
  muscle strength
  muscle training
  nausea (side effect)
  orthosis
  osteomalacia
  pain
  patient care
  percutaneous vertebroplasty
  peripheral edema (side effect)
  phosphate blood level
  physiotherapy
  postmenopause
  postmenopause osteoporosis (drug therapy)
  prevalence
  primary hyperparathyroidism
  quality of life
  randomized controlled trial (topic)
  review
  rheumatoid arthritis
  risk assessment
  secondary osteoporosis
  side effect (side effect)
  smoking
  spine fracture (etiology, rehabilitation, side effect, surgery)
  sun exposure
  thromboembolism (side effect)
  thyrotropin blood level
  underweight
  vasodilatation
  vitamin D deficiency (drug therapy, therapy)
  vomiting (side effect)
DRUG TRADE NAMES
  aclasta
  actonel
  bonviva
  evista
  forsteo
  fosamax
  optruma
  preotact
  protelos
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  alendronic acid (66376-36-1)
  alfacalcidol (41294-56-8)
  alkaline phosphatase (9001-78-9)
  calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
  calcitriol (32222-06-3, 32511-63-0, 66772-14-3)
  calcium (14092-94-5, 7440-70-2)
  colecalciferol (1406-16-2, 67-97-0)
  cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
  etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
  fluoride (16984-48-8)
  folic acid (59-30-3, 6484-89-5)
  homocysteine (454-28-4, 6027-13-0)
  ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
  levothyroxine (51-48-9)
  nandrolone decanoate (360-70-3)
  parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
  phosphate (14066-19-4, 14265-44-2)
  prednisolone (50-24-8)
  raloxifene (82640-04-8, 84449-90-1)
  risedronic acid (105462-24-6, 122458-82-6)
  strontium ranelate (135459-87-9)
  thyrotropin (9002-71-5)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Gerontology and Geriatrics (20)
  Orthopedic Surgery (33)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012046271
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 337
TITLE
  Physiotherapy of patients with motoric or neurological dysfunctions, 
simultaneously treated for arrhythmia - Physiotherapist's viewpoint
ORIGINAL (NON-ENGLISH) TITLE
  Fizjoterapia osób z dysfunkcjami narza̧du ruchu lub różnymi schorzeniami 
neurologicznymi, leczonych równolegle z powodu zaburzeń rytmu serca - Punkt 
widzenia fizjoterapeuty
AUTHOR NAMES
  Domosławska D.
AUTHOR ADDRESSES
  (Domosławska D., agaavi@poczta.fm) Wydział Wychowania Fizycznego, Szkoła 
Wyzsza Im. Pawła Włodkowica, Płocku, Poland.
CORRESPONDENCE ADDRESS
  D. Domosławska, Szkoła Wyzsza Im. Pawła Włodkowica, Sekretariat Wydziału 
Wychowania Fizycznego, al. Kilińskiego 12, 09-402 Płock, Poland. Email: 
agaavi@poczta.fm
SOURCE
  Fizjoterapia (2011) 19:3 (50-62). Date of Publication: 2011
ISSN
  1230-8323
BOOK PUBLISHER
  Academy of Physical Education, Rzezbiarska 4, Wroclaw, Poland.
ABSTRACT
  A high percentage of patients undergoing physiotherapeutic treatment due to 
motor organ dysfunctions or neurological problems are the ones who 
additionally suffer from heart rhythm disorder (arrhythmia). This paper 
presents the most common types of heart rhythm disorders, the health risk 
factors they involve as well as the treatment methods. Some important 
aspects of kinesiotherapy and physiotherapy of patients treated 
pharmacologically or with implanted pacemaker or cardioverter-defibrillator 
have been considered. The general rules for contraindications against 
physiotherapy have also been raised. The significance of patient education, 
the psychical effects and safety during physiotherapy have been emphasized.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
  digitalis (drug therapy)
  sotalol (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart arrhythmia (drug therapy, drug therapy, therapy)
  motor dysfunction (therapy)
  neurologic disease (therapy)
  physiotherapy
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (drug therapy, therapy)
  cardioversion
  defibrillator
  exercise
  faintness
  heart ventricle arrhythmia (therapy)
  human
  pacemaker
  patient education
  patient safety
  review
  risk factor
  sudden death
  supraventricular tachycardia (therapy)
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digitalis (8031-42-3, 8053-83-6)
  sotalol (3930-20-9, 80456-07-1, 959-24-0)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  Polish, English
LANGUAGE OF SUMMARY
  English, Polish
EMBASE ACCESSION NUMBER
  2012347342
FULL TEXT LINK
  http://dx.doi.org/10.2478/v10109-011-0019-1
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 338
TITLE
  Heart failure in the elderly
AUTHOR NAMES
  Baker S.
  Ramani G.V.
AUTHOR ADDRESSES
  (Baker S.) Saint Joseph's Cardiovascular Associates, Towson, MD, United 
States.
(Ramani G.V.) Department of Medicine, University of Maryland, School of 
Medicine, Baltimore, United States.
CORRESPONDENCE ADDRESS
  S. Baker, Saint Joseph's Cardiovascular Associates, Towson, MD, United 
States.
SOURCE
  Clinical Geriatrics (2011) 19:12 (21-28). Date of Publication: December 2011
ISSN
  1095-1598
BOOK PUBLISHER
  HMP Communications LLP, 4365 U.S. Highway 1 Suite 250, Princeton, United 
States.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction, drug comparison, drug therapy)
  beta adrenergic receptor blocking agent (adverse drug reaction)
  captopril (clinical trial, drug comparison, drug therapy)
  dabigatran (oral drug administration)
  digoxin (adverse drug reaction, drug concentration, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, drug 
combination, drug therapy)
  diuretic agent (adverse drug reaction, drug combination)
  eplerenone
  hydralazine (adverse drug reaction, drug combination)
  loop diuretic agent
  losartan (clinical trial, drug comparison, drug therapy)
  metoprolol succinate (clinical trial, drug therapy)
  nebivolol (clinical trial, drug therapy)
  nitrate (adverse drug reaction, drug combination, oral drug administration)
  non prescription drug
  nonsteroid antiinflammatory agent (adverse drug reaction)
  prescription drug
  spironolactone (adverse drug reaction, clinical trial, drug therapy)
  warfarin (adverse drug reaction, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  geriatric disorder (disease management, surgery)
  heart failure (drug therapy, side effect, disease management, drug therapy, 
side effect, surgery)
EMTREE MEDICAL INDEX TERMS
  age
  aging
  angioneurotic edema (side effect)
  anticoagulant therapy
  article
  atrial fibrillation
  brain hemorrhage (side effect)
  cardiac resynchronization therapy
  cerebrovascular accident (complication, drug therapy, prevention)
  clinical assessment tool
  congestive heart failure (drug therapy)
  coronary artery disease
  coughing (side effect)
  defibrillator
  depression
  disease association
  diuretic therapy
  dizziness (side effect)
  drug efficacy
  drug tolerability
  drug withdrawal
  dyspnea
  exercise
  gynecomastia (side effect)
  health education
  heart arrest
  heart failure with preserved ejection fraction
  heart infarction
  heart left ventricle ejection fraction
  heart transplantation
  heart ventricle arrhythmia (therapy)
  heart ventricle pacing
  hospital readmission
  hospitalization
  human
  hyperkalemia (side effect)
  hypertension
  kidney dysfunction (side effect)
  left ventricular assist device
  leg edema
  low drug dose
  meta analysis (topic)
  mortality
  multidimensional prognostic index
  orthostatic hypotension
  overall survival
  palliative therapy
  patient compliance
  personalized medicine
  physician attitude
  QRS complex
  quality of life
  randomized controlled trial (topic)
  risk assessment
  risk factor
  sedentary lifestyle
  sleep disordered breathing
  sodium restriction
  systolic heart failure (drug therapy)
  unspecified side effect (side effect)
  very elderly
  veteran
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  captopril (62571-86-2)
  digoxin (20830-75-5, 57285-89-9)
  eplerenone (107724-20-9)
  hydralazine (304-20-1, 86-54-4)
  losartan (114798-26-4)
  metoprolol succinate (98418-47-4)
  nebivolol (118457-15-1, 118457-16-2, 99200-09-6)
  nitrate (14797-55-8)
  spironolactone (52-01-7)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2012011276
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 339
TITLE
  Chronic non-communicable diseases in Cameroon - burden, determinants and 
current policies
AUTHOR NAMES
  Echouffo-Tcheugui J.B.
  Kengne A.P.
AUTHOR ADDRESSES
  (Echouffo-Tcheugui J.B., jechouf@emory.edu) Hubert Department of Global 
Health, Rollins School of Public Health, Emory University, Atlanta, GA, 
United States.
(Kengne A.P., apkengne@yahoo.com) Medical Research Council of South Africa, 
University of Cape Town, South Africa.
CORRESPONDENCE ADDRESS
  J.B. Echouffo-Tcheugui, Hubert Department of Global Health, Rollins School 
of Public Health, Emory University, Atlanta, GA, United States. Email: 
jechouf@emory.edu
SOURCE
  Globalization and Health (2011) 7 Article Number: 44. Date of Publication: 
23 Nov 2011
ISSN
  1744-8603 (electronic)
BOOK PUBLISHER
  BioMed Central Ltd., Floor 6, 236 Gray's Inn Road, London, United Kingdom.
ABSTRACT
  Cameroon is experiencing an increase in the burden of chronic 
non-communicable diseases (NCDs), which accounted for 43% of all deaths in 
2002. This article reviews the published literature to critically evaluate 
the evidence on the frequency, determinants and consequences of NCDs in 
Cameroon, and to identify research, intervention and policy gaps. The rising 
trends in NCDs have been documented for hypertension and diabetes, with a 
2-5 and a 10-fold increase in their respective prevalence between 1994 and 
2003. Magnitudes are much higher in urban settings, where increasing 
prevalence of overweight/obesity (by 54-82%) was observed over the same 
period. These changes largely result from the adoption of unfavorable eating 
habits, physical inactivity, and a probable increasing tobacco use. These 
behavioral changes are driven by the economic development and social 
mobility, which are part of the epidemiologic transition. There is still a 
dearth of information on chronic respiratory diseases and cancers, as well 
as on all NDCs and related risk factors in children and adolescents. More 
nationally representative data is needed to tract risk factors and 
consequences of NCDs. These conditions are increasingly been recognized as a 
priority, mainly through locally generated evidence. Thus, national-level 
prevention and control programs for chronic diseases (mainly diabetes and 
hypertension) have been established. However, the monitoring and evaluation 
of these programs is necessary. Budgetary allocations data by the ministry 
of health would be helpful, to evaluate the investment in NCDs prevention 
and control. Establishing more effective national-level tobacco control 
measures and food policies, as well as campaigns to promote healthy diets, 
physical activity and tobacco cessation would probably contribute to 
reducing the burden of NCDs. © 2011 Echouffo-Tcheugui and Kengne; licensee 
BioMed Central Ltd.
EMTREE DRUG INDEX TERMS
  steroid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  chronic disease (epidemiology, prevention)
  chronic respiratory tract disease (epidemiology)
  diabetes mellitus (epidemiology, prevention)
  hypertension (epidemiology, prevention)
  neoplasm (epidemiology)
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  anemia
  asthma (epidemiology)
  atrial fibrillation
  body mass
  breast cancer (epidemiology)
  Cameroon
  cancer screening
  cerebrovascular accident
  child
  chronic obstructive lung disease (epidemiology)
  comorbidity
  cross-sectional study
  diabetic foot (complication)
  diabetic macular edema (complication)
  diabetic neuropathy (complication)
  diabetic retinopathy (complication)
  diastolic blood pressure
  diastolic heart failure (complication)
  dietary intake
  disease control
  dyslipidemia (epidemiology)
  eating habit
  economic development
  glycemic control
  gout
  health care cost
  health care policy
  health care system
  heart failure (complication)
  heart left ventricle failure (complication)
  human
  hypercholesterolemia (epidemiology)
  immobilization
  ischemic heart disease
  kidney dysfunction
  microalbuminuria (complication)
  obesity
  organization and management
  physical activity
  prevalence
  priority journal
  prostate cancer (epidemiology)
  review
  risk factor
  social class
  spirometry
  systematic review
  systolic blood pressure
  systolic dysfunction (complication)
  urban area
  urban rural difference
  urbanization
  uterine cervix cancer (epidemiology)
  waist hip ratio
  wheezing
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012012736
FULL TEXT LINK
  http://dx.doi.org/10.1186/1744-8603-7-44
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 340
TITLE
  Anaesthesia for cardioversion: A prospective randomised comparison of 
propofol and etomidate combined with fentanyl
AUTHOR NAMES
  Kalogridaki M.
  Souvatzis X.
  Mavrakis H.E.
  Kanoupakis E.M.
  Panteli A.
  Kasotaki S.
  Vardas P.
  Askitopoulou H.
AUTHOR ADDRESSES
  (Kalogridaki M.; Souvatzis X., x.souvatzis@gmx.de; Panteli A.; Askitopoulou 
H.) Department of Anaesthesiology, University Hospital of Heraklion, 
Heraklion, Greece.
(Mavrakis H.E.; Kanoupakis E.M.; Vardas P.) Department of Cardiology, 
University Hospital of Heraklion, Heraklion, Greece.
(Kasotaki S.) Department of Computer Science, University of Crete, 
Heraklion, Greece.
CORRESPONDENCE ADDRESS
  X. Souvatzis, Department of Anaesthesiology, University Hospital of 
Heraklion, PO Box 1352, 71110 Heraklion, Greece. Email: x.souvatzis@gmx.de
SOURCE
  Hellenic Journal of Cardiology (2011) 52:6 (483-488). Date of Publication: 
November / December 2011
ISSN
  1011-7970
BOOK PUBLISHER
  Hellenic Cardiological Society, Potamianou 8, Athens, Greece.
ABSTRACT
  Introduction: External electrical cardioversion is mostly performed solely 
under sedatives or hypnotics, although the procedure is painful. The aim of 
this prospective randomised study was to compare two anaesthetic protocols 
that included analgesia. Methods: Patients with persistent atrial 
fibrillation were randomised to receive intravenously either fentanyl 50 μg 
and propofol 0.5 mg/kg (group P) or fentanyl 50 μg and etomidate 0.1 mg/kg 
(group E), while breathing spontaneously 100% oxygen. In the case of 
inadequate anaesthesia, repeated doses of 20 mg propofol (group P) or 4 mg 
etomidate (group E) were given as often as necessary until loss of eyelid 
reflex. Cardioversion was achieved with an extracardiac biphasic electrical 
shock ranging from 200 to 300 J, performed three times at most. Results: 
Forty-six patients (25 in group P, 21 in group E), aged 64 ± 9 years, were 
enrolled in the study. There were no differences between the study groups 
concerning left ventricular ejection fraction, the dimension of the left 
atrium, the number of shocks needed or the number of unsuccessful 
cardioversions. Patients in group E had a shorter time from injection of the 
induction agents until loss of consciousness (49 vs. 118 s, p=0.003) and 
until the first shock was given (61 vs. 135 s, p=0.004). Systolic blood 
pressure decreased significantly (repeated measurements ANOVA with 
Bonferroni adjustment) in group P when the baseline value was compared to 
that after anaesthesia induction (mean decrease 15.2 mmHg, 95% CI 5.6-24.8 
mmHg, p=0.001) and to the value after recovery (mean decrease 15.2 mmHg, 95% 
CI 4.8-25.7 mmHg, p=0.002). Manual ventilation was required in 7 and 9 
patients in groups P and E, respectively (p=0.360). Conclusion: Both 
anaesthetic regimens provided excellent conditions for external electric 
cardioversion. In addition, etomidate in combination with fentanyl had a 
shorter induction time and ensured haemodynamic stability.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  etomidate (clinical trial, drug combination, drug comparison, intravenous 
drug administration)
  fentanyl (clinical trial, drug combination, intravenous drug administration)
  propofol (clinical trial, drug combination, drug comparison, intravenous 
drug administration)
EMTREE MEDICAL INDEX TERMS
  adult
  analgesia
  anesthesia induction
  article
  atrial fibrillation
  cardioversion
  clinical article
  consciousness
  controlled study
  female
  heart left ventricle ejection fraction
  human
  male
  manual ventilation
  oxygen breathing
  randomized controlled trial
  reflex
  systolic blood pressure
CAS REGISTRY NUMBERS
  etomidate (15301-65-2, 33125-97-2, 51919-80-3)
  fentanyl (437-38-7)
  propofol (2078-54-8)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Anesthesiology (24)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011674263
MEDLINE PMID
  22143010 (http://www.ncbi.nlm.nih.gov/pubmed/22143010)
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 341
TITLE
  High Blood Pressure Research 2011 Scientific Sessions Abstracts, HBPR 2011
AUTHOR ADDRESSES
  SOURCE
  Hypertension (2011) 58:5. Date of Publication: November 2011
CONFERENCE NAME
  High Blood Pressure Research 2011 Scientific Sessions, HBPR 2011
CONFERENCE LOCATION
  Orlando, FL, United States
CONFERENCE DATE
  2011-09-20 to 2011-09-24
ISSN
  0194-911X
BOOK PUBLISHER
  Lippincott Williams and Wilkins
ABSTRACT
  The proceedings contain 625 papers. The topics discussed include: 
postprandial hypertension, an overlooked risk factor for arterial stiffness; 
different mechanisms in weight loss and weight loss-induced blood pressure 
reduction between a calorie restricted diet and exercise; clinical 
differences between resistant hypertensive patients and patients treated and 
controlled with 3 or less drugs; impact of blood pressure and pulse rate on 
the risk of incident atrial fibrillation in the Suita study: an urban cohort 
study; the inhibition of phosphodiesterase 5 improves the diastolic 
dysfunction in resistant hypertensive patients an independent mechanism of 
blood pressure and endothelial function; bone marrow deficiency of ACE2 
promotes macrophage infiltration into adipose tissue and disrupts glucose 
homeostasis in high fat-fed mice; and comparison between central and 
peripheral pulse pressure as determinants of intermediate cardiovascular 
phenotypes.
EMTREE DRUG INDEX TERMS
  phosphodiesterase V
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  hypertension
EMTREE MEDICAL INDEX TERMS
  adipose tissue
  arterial stiffness
  atrial fibrillation
  blood pressure
  bone marrow depression
  calorie
  cohort analysis
  diastolic dysfunction
  diet restriction
  exercise
  glucose homeostasis
  human
  macrophage
  mouse
  patient
  phenotype
  pulse pressure
  pulse rate
  risk
  risk factor
  weight reduction
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 342
TITLE
  The use of acupuncture in the emergency room
AUTHOR NAMES
  Cecconi A.
AUTHOR ADDRESSES
  (Cecconi A., cecconi@scuolatao.com) Montegiorgio and Sant'Elpidio A Mare 
Hospital, Italy.
(Cecconi A., cecconi@scuolatao.com) Scuolatao, Bologna, Italy.
(Cecconi A., cecconi@scuolatao.com) La Sapienza University, Rome, Italy.
CORRESPONDENCE ADDRESS
  A. Cecconi, Scuolatao, Bologna, Italy. Email: cecconi@scuolatao.com
SOURCE
  Journal of Chinese Medicine (2011) :97 (60-64). Date of Publication: October 
2011
ISSN
  0143-8042
BOOK PUBLISHER
  Journal of Chinese Medicine, 22 Cromwell Road, Hove, Sussex, United Kingdom.
ABSTRACT
  Emergency Room (ER) doctors have to deal with severe health conditions that 
require swift intervention, usually with rapidly-acting drugs. There may 
appear to be no space for traditional Chinese medicine (TCM) - and 
acupuncture in particular - in this context, thanks to the widespread belief 
that this kind of traditional medicine requires more time to act. This 
article describes the use of TCM in an ER in Italy. Through the description 
of several cases the author shows that acupuncture can be effective either 
alone, or in combination with Western medicine, for both diagnosis and 
treatment of conditions not normally seen in private TCM clinics.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  emergency ward
EMTREE MEDICAL INDEX TERMS
  article
  asthma
  atrial fibrillation
  Chinese medicine
  epistaxis
  fever
  human
  hypertensive crisis
  Italy
  nephrolithiasis
  panic
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011611168
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 343
TITLE
  Treadmill exercise stress echocardiography in patients with no history of 
coronary artery disease: A single-center experience in Korean population
AUTHOR NAMES
  Jang J.Y.
  Sohn I.S.
  Kim J.N.
  Park J.H.
  Park C.B.
  Jin E.S.
  Cho J.M.
  Kim C.J.
  Bae J.H.
AUTHOR ADDRESSES
  (Jang J.Y.; Sohn I.S., issohn@khu.ac.kr; Kim J.N.; Park J.H.; Park C.B.; Jin 
E.S.; Cho J.M.; Kim C.J.; Bae J.H.) Department of Cardiology, Kyung Hee 
University Hospital at Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 
134-727, South Korea.
CORRESPONDENCE ADDRESS
  I.S. Sohn, Department of Cardiology, Kyung Hee University Hospital at 
Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, South Korea. Email: 
issohn@khu.ac.kr
SOURCE
  Korean Circulation Journal (2011) 41:9 (528-534). Date of Publication: 
September 2011
ISSN
  1738-5520
  1738-5555 (electronic)
BOOK PUBLISHER
  Korean Society of Circulation, 553 Dowha-dong, Mapo-gu, Seoul, South Korea.
ABSTRACT
  Background and Objectives: Treadmill exercise stress echocardiography (TSE) 
has superior diagnostic accuracy than exercise electrocardiography (ECG). 
The objectives of the study are 1) to define the diagnostic accuracy and 
safety of TSE in patients without a history of coronary artery disease 
(CAD), 2) to identify the clinical characteristics that predict positive TSE 
results and 3) to assess the differential predictive value between TSE and 
concomitant exercise ECG in a Korean population. Subjects and Methods: A 
total of 1,287 patients among 1,500 consecutive patients with no prior 
history of CAD and who were referred for TSE during a 4-year 3-month period 
were enrolled. Results: Of the 1,287 patients, 95 (7.4%) showed positive TSE 
results (newly developed regional wall motion abnormality). Among the 154 
patients with coronary angiography, 94 patients (61%) showed significant CAD 
(30 of 77 patients with negative TSE results and 64 of 77 patients with 
positive TSE results). The TSE positive population had more cardiovascular 
risk factors and showed a higher Duke treadmill score and wall motion score 
index than the TSE negative group. TSE showed relatively good sensitivity 
(68%), specificity (78%) and positive and negative predictive values (83% 
and 61%, respectively), and TSE also had higher diagnostic accuracy than 
concomitant exercise ECG (72% vs. 64%, respectively). Conclusion: TSE is 
safe and offers greater diagnostic power for CAD than exercise ECG in Korean 
population without a history of CAD. Its prognostic value in this population 
needs to be confirmed in a larger prospective study. Copyright © 2011 The 
Korean Society of Cardiology.
EMTREE DRUG INDEX TERMS
  high density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  coronary artery disease (diagnosis)
  diagnostic accuracy
  patient safety
  stress echocardiography
  treadmill exercise
  treadmill exercise stress echocardiography
EMTREE MEDICAL INDEX TERMS
  adult
  angiography
  article
  atrial fibrillation (complication)
  cardiovascular risk
  cholesterol blood level
  clinical effectiveness
  clinical feature
  comparative study
  controlled study
  coronary artery recanalization
  diagnostic test accuracy study
  electrocardiography monitoring
  faintness (complication)
  female
  heart ejection fraction
  heart ventricle wall motion
  human
  hypotension
  Korea
  major clinical study
  male
  paroxysmal supraventricular tachycardia (complication)
  predictive value
  sensitivity and specificity
  thorax pain (complication)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011579682
FULL TEXT LINK
  http://dx.doi.org/10.4070/kcj.2011.41.9.528
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 344
TITLE
  Nitric oxide-mediated coronary flow regulation in patients with coronary 
artery disease: Recent advances
AUTHOR NAMES
  Toda N.
  Tanabe S.
  Nakanishi S.
AUTHOR ADDRESSES
  (Toda N., n.toda.toyama-bldg@orion.ocn.ne.jp) Toyama Institute for 
Cardiovascular Pharmacology Research, 7-13, 1-Chome, Azuchi-machi, Chuo-ku, 
Osaka 541-0052, Japan.
(Tanabe S.) Cardiology Section, Department of Internal Medicine, Social 
Insurance Kyoto Hospital, Japan.
(Nakanishi S.) Department of Internal Medicine, Kyoto Prefectural University 
of Medicine, Japan, Kyoto, Japan.
CORRESPONDENCE ADDRESS
  N. Toda, Toyama Institute for Cardiovascular Pharmacology Research, 7-13, 
1-Chome, Azuchi-machi, Chuo-ku, Osaka 541-0052, Japan. Email: 
n.toda.toyama-bldg@orion.ocn.ne.jp
SOURCE
  International Journal of Angiology (2011) 20:3 (121-134). Date of 
Publication: September 2011
ISSN
  1061-1711
  1615-5939 (electronic)
BOOK PUBLISHER
  Thieme Medical Publishers, Inc., 333 7th Avenue, New York, United States.
ABSTRACT
  Nitric oxide (NO) formed via endothelial NO synthase (eNOS) plays crucial 
roles in the regulation of coronary blood flow through vasodilatation and 
decreased vascular resistance, and in inhibition of platelet aggregation and 
adhesion, leading to the prevention of coronary circulatory failure, 
thrombosis, and atherosclerosis. Endothelial function is impaired by several 
pathogenic factors including smoking, chronic alcohol intake, 
hypercholesterolemia, obesity, hyperglycemia, and hypertension. The 
mechanisms underlying endothelial dysfunction include reduced NO synthase 
(NOS) expression and activity, decreased NO bioavailability, and increased 
production of oxygen radicals and endogenous NOS inhibitors. Atrial 
fibrillation appears to be a risk factor for endothelial dysfunction. 
Endothelial dysfunction is an important predictor of coronary artery disease 
(CAD) in humans. Penile erectile dysfunction, associated with impaired 
bioavailability of NO produced by eNOS and neuronal NOS, is also considered 
to be highly predictive of ischemic heart disease. There is evidence 
suggesting an important role of nitrergic innervation in coronary blood flow 
regulation. Prophylactic and therapeutic measures to eliminate pathogenic 
factors inducing endothelial and nitrergic nerve dysfunction would be quite 
important in preventing the genesis and development of CAD. Copyright © 2011 
by Thieme.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  endothelial nitric oxide synthase (endogenous compound)
EMTREE DRUG INDEX TERMS
  alloprinol (drug dose, drug therapy)
  angiotensin 2 receptor antagonist (drug therapy)
  antioxidant (drug therapy)
  arginine (drug combination, drug therapy, intravenous drug administration)
  atorvastatin (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  C reactive protein (endogenous compound)
  caveolin (endogenous compound)
  celiprolol (drug therapy)
  citrulline
  colony stimulating factor 1 (endogenous compound)
  folic acid (drug therapy)
  garlic extract (drug therapy)
  Ginkgo biloba extract (drug therapy)
  glyceryl trinitrate
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  losartan (drug combination, drug therapy, oral drug administration)
  placebo
  Rho kinase (endogenous compound)
  superoxide dismutase (endogenous compound)
  temocapril (drug therapy)
  tetrahydrobiopterin (drug therapy)
  unclassified drug
  urapidil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  coronary artery blood flow
  coronary artery disease (drug therapy, drug therapy, etiology, surgery)
EMTREE MEDICAL INDEX TERMS
  angina pectoris (drug therapy)
  angiocardiography
  atrial fibrillation
  bioavailability
  blood clot lysis
  coronary artery bypass graft
  coronary flow reserve
  cytokine production
  drug megadose
  endothelial dysfunction
  endothelium
  enzyme activity
  erectile dysfunction
  exercise
  human
  hypertension (drug therapy)
  macrophage
  mucocutaneous lymph node syndrome
  obesity
  oxygen consumption
  pathogenesis
  percutaneous coronary intervention
  priority journal
  protein binding
  protein degradation
  protein expression
  protein function
  protein synthesis
  review
  risk factor
  shear stress
  ST segment depression
  stable angina pectoris (drug therapy)
  thrombocyte adhesion
  thrombocyte aggregation
  variable number of tandem repeat
  vascular resistance
  vasodilatation
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  arginine (1119-34-2, 15595-35-4, 7004-12-8, 74-79-3)
  atorvastatin (134523-00-5, 134523-03-8)
  celiprolol (56980-93-9, 57470-78-7)
  citrulline (372-75-8)
  colony stimulating factor 1 (81627-83-0)
  endothelial nitric oxide synthase (503473-02-7)
  folic acid (59-30-3, 6484-89-5)
  glyceryl trinitrate (55-63-0)
  losartan (114798-26-4)
  superoxide dismutase (37294-21-6, 9016-01-7, 9054-89-1)
  temocapril (110221-44-8)
  tetrahydrobiopterin (17528-72-2)
  urapidil (34661-75-1)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011526713
FULL TEXT LINK
  http://dx.doi.org/10.1055/s-0031-1283220
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 345
TITLE
  Vascular contributions to cognitive impairment and dementia: A statement for 
healthcare professionals from the American Heart Association/American Stroke 
Association
AUTHOR NAMES
  Gorelick P.B.
  Scuteri A.
  Black S.E.
  Decarli C.
  Greenberg S.M.
  Iadecola C.
  Launer L.J.
  Laurent S.
  Lopez O.L.
  Nyenhuis D.
  Petersen R.C.
  Schneider J.A.
  Tzourio C.
  Arnett D.K.
  Bennett D.A.
  Chui H.C.
  Higashida R.T.
  Lindquist R.
  Nilsson P.M.
  Roman G.C.
  Sellke F.W.
  Seshadri S.
AUTHOR ADDRESSES
  (Gorelick P.B.; Scuteri A.; Black S.E.; Decarli C.; Greenberg S.M.; Iadecola 
C.; Launer L.J.; Laurent S.; Lopez O.L.; Nyenhuis D.; Petersen R.C.; 
Schneider J.A.; Tzourio C.; Arnett D.K.; Bennett D.A.; Chui H.C.; Higashida 
R.T.; Lindquist R.; Nilsson P.M.; Roman G.C.; Sellke F.W.; Seshadri S.)
CORRESPONDENCE ADDRESS
  P.B. Gorelick,
SOURCE
  Stroke (2011) 42:9 (2672-2713). Date of Publication: September 2011
ISSN
  0039-2499
  1524-4628 (electronic)
BOOK PUBLISHER
  Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327, 
Philadelphia, United States.
ABSTRACT
  Background and Purpose-This scientific statement provides an overview of the 
evidence on vascular contributions to cognitive impairment and dementia. 
Vascular contributions to cognitive impairment and dementia of later life 
are common. Definitions of vascular cognitive impairment (VCI), 
neuropathology, basic science and pathophysiological aspects, role of 
neuroimaging and vascular and other associated risk factors, and potential 
opportunities for prevention and treatment are reviewed. This statement 
serves as an overall guide for practitioners to gain a better understanding 
of VCI and dementia, prevention, and treatment. Methods-Writing group 
members were nominated by the writing group co-chairs on the basis of their 
previous work in relevant topic areas and were approved by the American 
Heart Association Stroke Council Scientific Statement Oversight Committee, 
the Council on Epidemiology and Prevention, and the Manuscript Oversight 
Committee. The writing group used systematic literature reviews (primarily 
covering publications from 1990 to May 1, 2010), previously published 
guidelines, personal files, and expert opinion to summarize existing 
evidence, indicate gaps in current knowledge, and, when appropriate, 
formulate recommendations using standard American Heart Association 
criteria. All members of the writing group had the opportunity to comment on 
the recommendations and approved the final version of this document. After 
peer review by the American Heart Association, as well as review by the 
Stroke Council leadership, Council on Epidemiology and Prevention Council, 
and Scientific Statements Oversight Committee, the statement was approved by 
the American Heart Association Science Advisory and Coordinating Committee. 
Results-The construct of VCI has been introduced to capture the entire 
spectrum of cognitive disorders associated with all forms of cerebral 
vascular brain injury-not solely stroke-ranging from mild cognitive 
impairment through fully developed dementia. Dysfunction of the 
neurovascular unit and mechanisms regulating cerebral blood flow are likely 
to be important components of the pathophysiological processes underlying 
VCI. Cerebral amyloid angiopathy is emerging as an important marker of risk 
for Alzheimer disease, microinfarction, microhemorrhage and macrohemorrhage 
of the brain, and VCI. The neuropathology of cognitive impairment in later 
life is often a mixture of Alzheimer disease and microvascular brain damage, 
which may overlap and synergize to heighten the risk of cognitive 
impairment. In this regard, magnetic resonance imaging and other 
neuroimaging techniques play an important role in the definition and 
detection of VCI and provide evidence that subcortical forms of VCI with 
white matter hyperintensities and small deep infarcts are common. In many 
cases, risk markers for VCI are the same as traditional risk factors for 
stroke. These risks may include but are not limited to atrial fibrillation, 
hypertension, diabetes mellitus, and hypercholesterolemia. Furthermore, 
these same vascular risk factors may be risk markers for Alzheimer disease. 
Carotid intimal-medial thickness and arterial stiffness are emerging as 
markers of arterial aging and may serve as risk markers for VCI. Currently, 
no specific treatments for VCI have been approved by the US Food and Drug 
Administration. However, detection and control of the traditional risk 
factors for stroke and cardiovascular disease may be effective in the 
prevention of VCI, even in older people. Conclusions-Vascular contributions 
to cognitive impairment and dementia are important. Understanding of VCI has 
evolved substantially in recent years, based on preclinical, 
neuropathologic, neuroimaging, physiological, and epidemiological studies. 
Transdisciplinary, translational, and transactional approaches are 
recommended to further our understanding of this entity and to better 
characterize its neuropsychological profile. There is a need for 
prospective, quantitative, clinical-pathological-neuroimaging studies to 
improve knowledge of the pathological basis of neuroimaging change and the 
complex interplay between vascular and Alzheimer disease pathologies in the 
evolution of clinical VCI and Alzheimer disease. Long-term vascular risk 
marker interventional studies beginning as early as midlife may be required 
to prevent or postpone the onset of VCI and Alzheimer disease. Studies of 
intensive reduction of vascular risk factors in high-risk groups are another 
important avenue of research. © 2011 American Heart Association. All rights 
reserved.
EMTREE DRUG INDEX TERMS
  angiotensin receptor antagonist (clinical trial, drug combination, drug 
comparison, drug therapy)
  atenolol (clinical trial, drug therapy)
  beta adrenergic receptor blocking agent (clinical trial, drug therapy)
  candesartan hexetil (clinical trial, drug therapy)
  chlortalidone (clinical trial, drug therapy)
  choline derivative (clinical trial, drug therapy)
  cholinesterase inhibitor (clinical trial, drug therapy)
  cytidinediphosphocholine (clinical trial, drug therapy)
  dihydropyridine (clinical trial, drug combination, drug therapy)
  diuretic agent (clinical trial, drug combination, drug therapy)
  donepezil (clinical trial, drug therapy)
  enalapril maleate (clinical trial, drug combination, drug therapy)
  galantamine (clinical trial, drug therapy)
  huperzine A (clinical trial, drug therapy)
  hydrochlorothiazide (clinical trial, drug combination, drug therapy)
  indapamide (clinical trial, drug combination, drug therapy)
  indapamide plus perindopril (clinical trial, drug therapy)
  lisinopril (clinical trial, drug comparison, drug therapy)
  memantine (drug therapy)
  nimodipine (clinical trial, drug therapy)
  nitrendipine (drug therapy)
  perindopril (clinical trial, drug combination, drug therapy)
  piracetam (clinical trial, drug therapy)
  placebo
  reserpine (clinical trial, drug therapy)
  rivastigmine (clinical trial, drug therapy)
  sertraline (drug therapy)
  telmisartan (clinical trial, drug therapy)
  unclassified drug
  unindexed drug
  vinpocetine (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cognitive defect (drug therapy, diagnosis, drug therapy, prevention, 
rehabilitation, therapy)
  dementia (drug therapy, diagnosis, drug therapy, prevention)
  vascular cognitive impairment (drug therapy, diagnosis, drug therapy, 
prevention, rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  alcohol consumption
  Alzheimer disease (drug therapy, prevention)
  arterial stiffness
  arterial wall thickness
  atrial fibrillation
  blood pressure
  brain blood flow
  brain hemorrhage
  brain infarction
  cardiovascular risk
  cerebrovascular accident
  cerebrovascular disease
  chronic kidney disease
  cognitive rehabilitation
  coronary artery disease
  depression
  diabetes mellitus
  diet
  disease association
  disease course
  education
  forward heart failure
  health care personnel
  heredity
  homeostasis
  human
  hypercholesterolemia
  hyperglycemia
  hypertension (drug therapy)
  inflammation
  insulin resistance
  lifestyle
  medical society
  metabolic syndrome X
  microangiopathy
  mild cognitive impairment (diagnosis)
  multiinfarct dementia (drug therapy, therapy)
  neuroimaging
  neuropsychological test
  nonhuman
  nuclear magnetic resonance imaging
  obesity
  oxidative stress
  pathophysiology
  peripheral occlusive artery disease
  physical activity
  priority journal
  randomized controlled trial (topic)
  review
  small vessel vasculitis (drug therapy)
  smoking
  social network
  social support
  vascular amyloidosis
DRUG TRADE NAMES
  preterax
CAS REGISTRY NUMBERS
  atenolol (29122-68-7, 93379-54-5)
  candesartan hexetil (145040-37-5)
  chlortalidone (77-36-1)
  dihydropyridine (27790-75-6)
  donepezil (120011-70-3, 120014-06-4, 142057-77-0)
  enalapril maleate (76095-16-4)
  galantamine (1953-04-4, 357-70-0)
  huperzine A (102518-79-6, 92138-20-0)
  hydrochlorothiazide (58-93-5)
  indapamide (26807-65-8)
  lisinopril (76547-98-3, 83915-83-7)
  memantine (19982-08-2, 41100-52-1)
  nimodipine (66085-59-4)
  nitrendipine (39562-70-4)
  perindopril (82834-16-0, 99149-83-4)
  piracetam (7491-74-9)
  reserpine (50-55-5, 8001-95-4)
  rivastigmine (129101-54-8)
  sertraline (79617-96-2)
  telmisartan (144701-48-4)
  vinpocetine (42971-09-5)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011492251
MEDLINE PMID
  21778438 (http://www.ncbi.nlm.nih.gov/pubmed/21778438)
FULL TEXT LINK
  http://dx.doi.org/10.1161/STR.0b013e3182299496
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 346
TITLE
  Gastroparesis: Pathogenesis, diagnosis and management
AUTHOR NAMES
  Hasler W.L.
AUTHOR ADDRESSES
  (Hasler W.L., whasler@umich.edu) Division of Gastroenterology, University of 
Michigan Hospital, 3912 Taubman Center, Ann Arbor, MI 5362, United States.
CORRESPONDENCE ADDRESS
  W.L. Hasler, Division of Gastroenterology, University of Michigan Hospital, 
3912 Taubman Center, Ann Arbor, MI 5362, United States. Email: 
whasler@umich.edu
SOURCE
  Nature Reviews Gastroenterology and Hepatology (2011) 8:8 (438-453). Date of 
Publication: August 2011
ISSN
  1759-5045
  1759-5053 (electronic)
BOOK PUBLISHER
  Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
  Gastroparesis is a prevalent condition that produces symptoms of delayed 
gastric emptying in the absence of physical blockage. The most common 
etiologies of gastroparesis are idiopathic, diabetic, and postsurgical 
disease, although some cases stem from autoimmune, paraneoplastic, 
neurologic or other conditions. Histologic examination of gastric tissues 
from patients with severe gastroparesis reveals heterogeneous and 
inconsistent defects in the morphology of enteric neurons, smooth muscle and 
interstitial cells of Cajal, and increased levels of inflammatory cells. 
Diagnosis is most commonly made by gastric emptying scintigraphy; however, 
wireless motility capsules and nonradioactive isotope breath tests have also 
been validated. A range of treatments have been used for gastroparesis 
including dietary modifications and nutritional supplements, gastric motor 
stimulatory or antiemetic medications, endoscopic or surgical procedures, 
and psychological interventions. Most treatments have not been subjected to 
controlled testing in patients with gastroparesis. The natural history of 
this condition is poorly understood. Active ongoing research is providing 
important insights into the pathogenesis, diagnosis, treatment and outcomes 
of this disease. © 2011 Macmillan Publishers Limited. All rights reserved.
EMTREE DRUG INDEX TERMS
  azithromycin (drug comparison, drug therapy, intravenous drug 
administration, oral drug administration)
  bethanechol (adverse drug reaction, drug therapy)
  botulinum toxin (clinical trial, drug therapy)
  clarithromycin (drug comparison, drug therapy)
  domperidone (adverse drug reaction, drug comparison, drug therapy, 
intravenous drug administration, oral drug administration)
  erythromycin (adverse drug reaction, drug comparison, drug therapy, 
intravenous drug administration, oral drug administration)
  metoclopramide (adverse drug reaction, drug comparison, drug therapy, 
intravenous drug administration, subcutaneous drug administration)
  mirtazapine (drug therapy)
  placebo
  pyridostigmine (drug therapy)
  ulimorelin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  stomach paresis (drug therapy, complication, diagnosis, drug therapy, 
etiology, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal cramp (side effect)
  abdominal pain (side effect)
  acupuncture
  agitation
  amenorrhea (side effect)
  anastomosis leakage (complication)
  anastomosis stenosis (complication)
  article
  atrial fibrillation (side effect)
  breath analysis
  clinical feature
  diabetes mellitus
  diet supplementation
  disease course
  drug dose comparison
  dystonia (side effect)
  electrostimulation therapy
  endoscopic surgery
  fatigue (side effect)
  galactorrhea (side effect)
  heart arrhythmia (side effect)
  histopathology
  human
  hyperprolactinemia (side effect)
  hypotension (side effect)
  idiopathic disease (etiology, therapy)
  intestine obstruction (complication)
  nausea (side effect)
  nonhuman
  pathogenesis
  postoperative complication (complication)
  priority journal
  psychologic assessment
  QT prolongation (side effect)
  side effect (side effect)
  sleep disorder (side effect)
  stomach emptying
  stomach motility
  stomach scintiscanning
  sudden death
  tardive dyskinesia (side effect)
  treatment outcome
  urinary urgency (side effect)
  vomiting (side effect)
  wheezing (side effect)
DRUG TRADE NAMES
  tzp 101
CAS REGISTRY NUMBERS
  azithromycin (83905-01-5)
  bethanechol (590-63-6, 674-38-4, 91609-06-2)
  clarithromycin (81103-11-9)
  domperidone (57808-66-9)
  erythromycin (114-07-8, 70536-18-4)
  metoclopramide (12707-59-4, 2576-84-3, 364-62-5, 7232-21-5)
  mirtazapine (61337-67-5)
  pyridostigmine (101-26-8, 155-97-5)
  ulimorelin (842131-33-3, 951326-02-6)
EMBASE CLASSIFICATIONS
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011439418
MEDLINE PMID
  21769117 (http://www.ncbi.nlm.nih.gov/pubmed/21769117)
FULL TEXT LINK
  http://dx.doi.org/10.1038/nrgastro.2011.116
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 347
TITLE
  Stroke: Classification and diagnosis
AUTHOR NAMES
  Parmar P.
  Sumaria S.
  Hashi S.
AUTHOR ADDRESSES
  (Parmar P., pareshparmar@nhs.net) Northwick Park Hospital, North West London 
Hospitals NHS Trust, United Kingdom.
(Sumaria S.; Hashi S.) University College London Hospitals NHS Foundation 
Trust, United Kingdom.
CORRESPONDENCE ADDRESS
  P. Parmar, Northwick Park Hospital, North West London Hospitals NHS Trust, 
United Kingdom. Email: pareshparmar@nhs.net
SOURCE
  Clinical Pharmacist (2011) 3:7 (200-202). Date of Publication: July-August 
2011
ISSN
  1758-9061
BOOK PUBLISHER
  Pharmaceutical Press, 1 Lambeth High Street, London, United Kingdom.
ABSTRACT
  Stroke is a major cause of morbidity and mortality in the UK, yet about 80% 
of strokes are preventable. Factors that are known to increase the risk of 
stroke include age, gender, hypertension, atrial fibrillation, diabetes and 
cigarette smoking. Broadly, a stroke can be classified as either ischaemic 
(caused by a thrombus) or haemorrhagic (caused by the rupture of blood 
vessels). Stroke is a medical emergency and the sooner that it is diagnosed 
and treated the better the outcome.
EMTREE DRUG INDEX TERMS
  cholesterol (endogenous compound)
  electrolyte (endogenous compound)
  glucose (endogenous compound)
  urea (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (diagnosis)
EMTREE MEDICAL INDEX TERMS
  age
  arm weakness
  artery dissection
  atrial fibrillation
  blood cell count
  brain hemorrhage
  brain ischemia
  cardiovascular risk
  carotid artery disease
  carotid duplex ultrasonograpy
  cholesterol blood level
  computer assisted tomography
  delirium
  dementia
  diabetes mellitus
  diet
  disease classification
  disorders of mitochondrial functions
  drug overdose
  electrocardiography
  electrolyte blood level
  erythrocyte sedimentation rate
  ethnicity
  Fabry disease
  family history
  fibromuscular dysplasia
  gender
  glucose blood level
  health care personnel
  hematologic disease
  heredity
  homocystinuria
  hormonal contraception
  human
  hyperlipidemia
  hypertension
  hypoxia
  infection
  injury
  intravascular ultrasound
  ischemic heart disease
  migraine
  moyamoya disease
  nuclear magnetic resonance imaging
  obesity
  paradoxical embolism
  peripheral occlusive artery disease
  pregnancy
  seizure
  sepsis
  short survey
  sleep disordered breathing
  slurred speech
  smoking
  Sneddon syndrome
  spinal cord lesion
  stroke patient
  thyroid function test
  urea blood level
  urinalysis
  vasculitis
  vestibular disorder
CAS REGISTRY NUMBERS
  cholesterol (57-88-5)
  glucose (50-99-7, 84778-64-3)
  urea (57-13-6)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011649384
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 348
TITLE
  Yoga may help reduce episodes of atrial fibrillation. The calming and 
balancing effects of yoga may cut down on common triggers for AF episodes 
and may have other health benefits, too.
AUTHOR ADDRESSES
  SOURCE
  Heart advisor / the Cleveland Clinic (2011) 14:6 (7). Date of Publication: 
Jun 2011
ISSN
  1523-9004
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (etiology, prevention)
  yoga
EMTREE MEDICAL INDEX TERMS
  article
  human
  psychological aspect
LANGUAGE OF ARTICLE
  English
MEDLINE PMID
  23189370 (http://www.ncbi.nlm.nih.gov/pubmed/23189370)
COPYRIGHT
  MEDLINE® is the source for the citation and abstract of this record.

RECORD 349
TITLE
  Belgian Society of Cardiology, 30th Annual Scientific Meeting
AUTHOR ADDRESSES
  SOURCE
  Acta Cardiologica (2011) 66:1. Date of Publication: 2011
CONFERENCE NAME
  30th Annual Scientific Meeting of the Belgian Society of Cardiology
CONFERENCE LOCATION
  Brussels, Belgium
CONFERENCE DATE
  2011-02-10 to 2011-02-11
ISSN
  0001-5385
BOOK PUBLISHER
  Acta Cardiologica
ABSTRACT
  The proceedings contain 61 papers. The topics discussed include: underuse of 
anticoagulation in older patients with atrial fibrillation; appropriateness 
of anticoagulation in older patients with atrial fibrillation; usefulness of 
the magnetic navigation system in ablation of ventricular tachycardia: acute 
and mid-term follow-up results compared to manual ablation; predicting the 
occurrence of atrial aarhythmia after closure of an atrial septal defect 
type secundum; cryotherapy is a very effective and safe method for ablation 
of parahissian accessory pathways; suppressed increase in blood endothelial 
progenitor cell content as result of single exhaustive exercise bout in male 
revascularized coronary artery disease patients; effects of diesel exhaust 
microparticles on vascular endothelial function; and in vivo assessment of 
hemodynamic effects of nanobodies therapy for neutralizing scorpion toxin 
effects in a small animal model.
EMTREE DRUG INDEX TERMS
  scorpion venom
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiology
  society
EMTREE MEDICAL INDEX TERMS
  animal model
  anticoagulation
  atrial fibrillation
  blood
  book
  coronary artery disease
  cryotherapy
  endothelial progenitor cell
  exercise
  exhaust gas
  follow up
  heart atrium septum defect
  heart ventricle tachycardia
  hemodynamics
  human
  male
  patient
  therapy
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 350
TITLE
  Arrhythmogenic Cardiomyopathy: Natural History and Risk Stratification
AUTHOR NAMES
  Migliore F.
  Baritussio A.
  Rigato I.
  Perazzolo Marra M.
  Bauce B.
  Basso C.
  Iliceto S.
  Corrado D.
AUTHOR ADDRESSES
  (Migliore F.; Baritussio A.; Rigato I.; Perazzolo Marra M.; Bauce B.; 
Iliceto S.; Corrado D., domenico.corrado@unipd.it) Division of Cardiology, 
Department of Cardiac, Thoracic and Vascular Sciences, University of Padua 
Medical School, Via Giustiniani, 2-35121 Padua, Italy.
(Basso C.) Cardiovascular Pathology, Department of Medical-Diagnostic 
Sciences and Special Therapies, University of Padua Medical School, Via A. 
Gabelli, 35121 Padua, Italy.
CORRESPONDENCE ADDRESS
  D. Corrado, Division of Cardiology, Department of Cardiac, Thoracic and 
Vascular Sciences, University of Padua Medical School, Via Giustiniani, 
2-35121 Padua, Italy. Email: domenico.corrado@unipd.it
SOURCE
  Cardiac Electrophysiology Clinics (2011) 3:2 (281-291). Date of Publication: 
June 2011
ISSN
  1877-9182
BOOK PUBLISHER
  W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
  Arrhythmogenic cardiomyopathy (AC) is an inherited heart muscle disease 
whose clinical manifestations are related to ventricular electrical 
instability, which may lead to sudden cardiac death, mostly in young people. 
Later in the disease history, the right ventricle becomes more diffusely 
affected and the involvement of the left ventricle may result in 
biventricular heart failure. This article addresses the disease natural 
history and analyzes the clinical predictors of sudden arrhythmic death and 
clinical outcome of patients with AC. © 2011.
EMTREE DRUG INDEX TERMS
  anticoagulant agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart right ventricle dysplasia (congenital disorder, diagnosis, therapy)
EMTREE MEDICAL INDEX TERMS
  anticoagulant therapy
  atrial fibrillation (complication, drug therapy, therapy)
  cardiac patient
  defibrillator
  diagnostic test accuracy study
  disease course
  echocardiography
  electrocardiogram
  electrophysiology
  exercise
  faintness
  genotype
  heart arrest
  heart arrhythmia (drug therapy)
  heart failure (therapy)
  heart left bundle branch block
  heart right bundle branch block
  heart right ventricle
  heart right ventricle ejection fraction
  heart right ventricle outflow tract obstruction
  heart ventricle tachycardia
  history
  Holter monitoring
  human
  incidence
  phenotype
  priority journal
  QRS complex
  review
  sensitivity and specificity
  stratified sample
  sudden death
  thromboembolism (complication, drug therapy, therapy)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011215887
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ccep.2011.02.012
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 351
TITLE
  Precipitating factors leading to decompensation of chronic heart failure in 
the elderly patient in South-American community hospital
AUTHOR NAMES
  Diaz A.
  Ciocchini C.
  Esperatti M.
  Becerra A.
  Mainardi S.
  Farah A.
AUTHOR ADDRESSES
  (Diaz A., alejandrounicen@gmail.com; Becerra A.; Mainardi S.; Farah A.) 
Department of Cardiology, Hospital Privado de Comunidad, Cordoba 4545, Mar 
del Plata 7600, Argentina.
(Ciocchini C.; Esperatti M.) Department of Internal Medicine, Hospital 
Privado de Comunidad, Cordoba 4545, Mar del Plata 7600, Argentina.
CORRESPONDENCE ADDRESS
  A. Diaz, Department of Medical Physiology, School of Health Sciences, 
Universidad Nacional del Centro de la Provincia de Buenos Aires, 4 de abril 
618, Tandil (7000), Argentina. Email: alejandrounicen@gmail.com
SOURCE
  Journal of Geriatric Cardiology (2011) 8:1 (12-14). Date of Publication: 
2011
ISSN
  1671-5411
BOOK PUBLISHER
  Institute of Geriatric Cardiology, 28 Fuxing Road, Beijing, China.
ABSTRACT
  Background: Exacerbations of heart failure appear frequently associated with 
precipitating factors not directly related to the evolution of cardiac 
disease. There still a paucity of data on the proportional distribution of 
precipitating factors specifically in elderly patients. The aim of this 
study was to examine prospectively the precipitating factors leading to 
hospitalization in elderly patients with heart failure in our community 
hospital. Methods: We evaluate elderly patients who need admissions for 
decompensate heart failure. All patients were reviewed daily by the study 
investigators at the first 24 h and closely followed-up. Decompensation was 
defined as the worsening in clinical NYHA class associated with the need for 
an increase in medical treatment (at minimum intravenously diuretics). 
Results: We included 102 patients (mean age 79 ± 12 years). Precipitating 
factors were identified in 88.5%. The decompensation was sudden in 35% of 
the cases. Noncompliance with diet was identified in 52% of the patients, 
lack of adherence to the prescribed medications amounted to 30%. Others 
precipitating factors were infections (29%), arrhythmias (25%), acute 
coronary ischemia (22%), and uncontrolled hypertension (15%), miscellaneous 
causes were detected in 18% of the cases (progression of renal disease 60%, 
anemia 30% and iatrogenic factors 10%). Concomitant cause was not 
recognizable in 11.5%. Conclusions: Large proportion heart failure 
hospitalizations are associated with preventable precipitating factors. 
Knowledge of potential precipitating factors may help to optimize treatment 
and provide guidance for patients with heart failure. The presence of 
potential precipitating factors should be routinely evaluated in patients 
presenting chronic heart failure. ©2011 IGC All rights reserved.
EMTREE DRUG INDEX TERMS
  diuretic agent (drug therapy, intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  coronary risk
  geriatric patient
  heart failure (drug therapy, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
  acute coronary syndrome
  aged
  anemia
  article
  atrial fibrillation
  bacterial endocarditis
  blood pressure regulation
  diet therapy
  disease course
  disease exacerbation
  disease predisposition
  follow up
  heart arrhythmia
  heart atrium flutter
  heart ejection fraction
  heart muscle ischemia
  heart ventricle tachycardia
  hospital admission
  hospitalization
  human
  hypertension
  iatrogenic disease
  kidney disease
  kidney dysfunction
  major clinical study
  patient compliance
  South America
  supraventricular tachycardia
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011196344
FULL TEXT LINK
  http://dx.doi.org/10.3724/SP.J.1263.2011.00012
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 352
TITLE
  Efficacy of acupuncture in preventing atrial fibrillation recurrences after 
electrical cardioversion
AUTHOR NAMES
  Lomuscio A.
  Belletti S.
  Battezzati P.M.
  Lombardi F.
AUTHOR ADDRESSES
  (Lomuscio A.; Belletti S.; Lombardi F., Federico.Lombardi@unimi.it) 
Cardiologia Osp. San Paolo, DMCO, University of Milan, Via A. di Rudunì 8, 
20147 Milan, Italy.
(Battezzati P.M.) Medicina Interna VI, Osp. San Paolo, Dipartimento di 
Medicina, Chirurgia e Odontoiatria, Università Degli Studi di Milano, Milan, 
Italy.
CORRESPONDENCE ADDRESS
  F. Lombardi, Cardiologia Osp. San Paolo, DMCO, University of Milan, Via A. 
di Rudunì 8, 20147 Milan, Italy. Email: Federico.Lombardi@unimi.it
SOURCE
  Journal of Cardiovascular Electrophysiology (2011) 22:3 (241-247). Date of 
Publication: March 2011
ISSN
  1045-3873
  1540-8167 (electronic)
BOOK PUBLISHER
  Blackwell Publishing Inc., 350 Main Street, Malden, United States.
ABSTRACT
  Antiarrhythmic Effect of Acupuncture. Introduction: In traditional Chinese 
medicine, stimulation of the Neiguan spot has been utilized to treat 
palpitations. We evaluated whether acupuncture might prevent or reduce the 
rate of arrhythmia recurrences in patients with persistent atrial 
fibrillation (AF). Methods and Results: We studied 80 patients with 
persistent AF after restoring sinus rhythm with electrical cardioversion. 
Twenty-six subjects who were already on amiodarone treatment constituted the 
AMIO reference group. The remaining patients were randomly allocated to 
receive acupuncture (ACU group, n = 17), sham acupuncture (ACU-sham group, n 
= 13), or neither acupuncture nor antiarrhythmic therapy (CONTROL group, n = 
24). Patients in the ACU and ACU-sham groups attended 10 acupuncture 
sessions on a once-a-week basis. Only in the former group the Neiguan, 
Shenmen, and Xinshu spots were punctured. During a 12-month follow-up, AF 
recurred in 35 patients. Cumulative AF recurrence rates in the AMIO, ACU, 
ACU-sham, and CONTROL patients were 27%, 35%, 69%, and 54%, respectively (P 
= 0.0075, log-rank test). Ejection fraction (P = 0.0005), hypertension 
(0.0293), and left atrial diameter (P = 0.0361) were also significantly 
associated with AF recurrence. Compared with AMIO group, recurrence rate was 
similar in ACU patients (hazard ratio: 1.15, 95% CI: 0.38-3.49; P = 0.801) 
but significantly higher in ACU-sham and CONTROL patients (3.77, 1.39-10; P 
= 0.009 and 3.15, 1.23-8.06; P = 0.017, respectively) after adjustment for 
ejection fraction, hypertension, and left atrial diameter using Cox 
modeling. Conclusion: Our data indicate that acupuncture treatment prevents 
arrhythmic recurrences after cardioversion in patients with persistent AF. 
This minimally invasive procedure was safe and well tolerated. © 2010 Wiley 
Periodicals, Inc.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  diuretic agent (drug therapy)
  oral antidiabetic agent (drug therapy)
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  atrial fibrillation (drug therapy, drug therapy, prevention, therapy)
  recurrent disease (prevention, therapy)
EMTREE MEDICAL INDEX TERMS
  anticoagulant therapy
  antihypertensive therapy
  article
  cardioversion
  clinical article
  diabetes mellitus (drug therapy)
  female
  follow up
  heart ejection fraction
  heart left atrium
  human
  hypertension (drug therapy)
  male
  priority journal
  randomized controlled trial
  sinus rhythm
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011141897
MEDLINE PMID
  20807278 (http://www.ncbi.nlm.nih.gov/pubmed/20807278)
FULL TEXT LINK
  http://dx.doi.org/10.1111/j.1540-8167.2010.01878.x
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 353
TITLE
  Warfarin and supplement interactions: Survey of published literature
AUTHOR NAMES
  Marino J.
  Motz D.
  Shields K.
AUTHOR ADDRESSES
  (Marino J.) Walgreens, Alexandria, VA, United States.
(Motz D.) Case Medical Center Rainbow Babies and Children, Cleveland, OH, 
United States.
(Shields K., k-shields@onu.edu) Department of Pharmacy Practice, Ohio 
Northern University, Raabe College of Pharmacy, Ada, OH, United States.
CORRESPONDENCE ADDRESS
  K. Shields, Department of Pharmacy Practice, Ohio Northern University, Raabe 
College of Pharmacy, Ada, OH, United States. Email: k-shields@onu.edu
SOURCE
  Journal of Pharmacy Technology (2011) 27:2 (63-70). Date of Publication: 
March-April 2011
ISSN
  8755-1225
BOOK PUBLISHER
  Harvey Whitney Books Company, 8044 Montgomery Road, Suite 415, Cincinnati, 
United States.
ABSTRACT
  Objective: To review published literature related to potential interactions 
between warfarin and common dietary supplement products. Data Sources: 
Tertiary databases including Micromedex, LexiComp, and Natural Medicines 
Comprehensive Database were used to assess drug interactions with warfarin. 
Searches of literature from database inception through July 2010 were 
conducted in MEDLINE, International Pharmaceutical Abstracts, and Iowa Drug 
Information Service and were restricted to the English language. The 
following search terms were used: warfarin, ginkgo biloba, St. John's wort, 
garlic, coenzyme Q10, ginger, ginseng, red clover, fish oil, dong quai, 
cranberry, green tea, saw palmetto, bilberry, soy, chamomile, glucosamine, 
chondroitin, echinacea, interactions, anticoagulation/antiplatelet, 
bleeding, herbals, and pharmacokinetics/ pharmacodynamics. Study Selection 
and Data Extraction: Thirty-two English language publications were 
identified and analyzed. Reference lists of each of the included articles 
were reviewed to obtain related articles for further analysis. Data 
Synthesis: Quality of existing data for interactions between warfarin and 
commonly available dietary supplements varies greatly. The majority of 
information available is derived from case reports, although for some 
products pharmacokinetic studies have been performed to assess the effect of 
supplement use in patients concurrently using warfarin. Some of the data 
that suggest interactions with warfarin were gleaned from case reports or 
from an understanding of supplement mechanisms of action that would indicate 
such an interaction. The strength of evidence for the majority of the herbal 
products studied seems to be lacking and therefore it is difficult to draw 
firm conclusions. Conclusions: Based on the narrow therapeutic window of 
warfarin therapy, practitioners should be encouraged to document any 
potential drug interaction. However, it seems inappropriate to suggest 
absolute avoidance of all dietary supplements in all patients using warfarin 
therapy. Instead, diligent monitoring and reporting should be implemented to 
detect such events.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin (clinical trial, drug combination, drug dose, drug interaction, 
drug therapy, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (clinical trial, drug combination)
  Angelica sinensis extract (drug interaction, drug therapy, pharmacokinetics)
  chamomile (drug interaction, pharmacokinetics)
  chondroitin (drug interaction, drug therapy, pharmacokinetics)
  cranberry extract (clinical trial, drug interaction)
  Echinacea purpurea extract (clinical trial, drug interaction, 
pharmacokinetics, pharmacology)
  garlic extract (clinical trial, drug interaction, drug therapy, 
pharmacokinetics, pharmacology)
  ginger extract (clinical trial, drug interaction, drug therapy, 
pharmacokinetics, pharmacology)
  Ginkgo biloba extract (clinical trial)
  ginseng extract (clinical trial, drug combination, drug interaction, oral 
drug administration, pharmacokinetics, pharmacology)
  glucosamine (drug interaction, drug therapy, pharmacokinetics)
  green tea extract (drug interaction)
  Hypericum perforatum extract (clinical trial, drug combination, drug 
interaction, drug therapy, pharmacokinetics, pharmacology)
  omega 3 fatty acid (clinical trial, drug combination, drug interaction)
  placebo
  red clover extract (drug interaction, drug therapy)
  Sabal extract (drug combination, drug interaction, drug therapy)
  ubidecarenone (clinical trial, drug interaction, drug therapy)
  Vaccinium myrtillus extract (drug interaction, drug therapy, oral drug 
administration, pharmacokinetics, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diet supplementation
  herb drug interaction
EMTREE MEDICAL INDEX TERMS
  Angelica sinensis
  anxiety disorder (drug therapy)
  atrial fibrillation (drug therapy)
  bilberry
  cardiovascular disease (drug therapy)
  cataract (drug therapy)
  cerebrovascular accident (drug therapy)
  clinical trial
  cranberry
  depression (drug therapy)
  diabetes mellitus (drug therapy)
  drug effect
  drug mechanism
  dyspepsia (drug therapy)
  Echinacea
  flatulence (drug therapy)
  gastrointestinal symptom (drug therapy)
  ginger
  Ginkgo biloba
  ginseng
  health survey
  herbal medicine
  human
  Hypericum perforatum
  hyperlipidemia (drug therapy)
  hypertension (drug therapy)
  ischemic heart disease (drug therapy)
  mastalgia (drug therapy)
  menopausal syndrome (drug therapy)
  menstrual irregularity (drug therapy)
  mood disorder (drug therapy)
  morning sickness (drug therapy)
  motion sickness (drug therapy)
  nausea and vomiting (drug therapy)
  nonhuman
  obsessive compulsive disorder (drug therapy)
  osteoarthritis (drug therapy)
  premenstrual syndrome (drug therapy)
  prostate hypertrophy (drug therapy)
  red clover
  review
  rheumatic heart disease (drug therapy)
  Sabal
  seasonal affective disorder (drug therapy)
  single drug dose
  soybean
  tea
  visual disorder (drug therapy)
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  chondroitin (9007-27-6)
  glucosamine (3416-24-8, 4607-22-1)
  ubidecarenone (303-98-0)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011274185
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 354
TITLE
  Year in review: Medication mishaps in the elderly
AUTHOR NAMES
  Peron E.P.
  Marcum Z.A.
  Boyce R.
  Hanlon J.T.
  Handler S.M.
AUTHOR ADDRESSES
  (Peron E.P.; Marcum Z.A.; Hanlon J.T., jth14@pitt.edu; Handler S.M.) 
Department of Medicine, School of Medicine, University of Pittsburgh, 
Pittsburgh, PA, United States.
(Boyce R.; Hanlon J.T., jth14@pitt.edu; Handler S.M.) Department of 
Biomedical Informatics, School of Medicine, University of Pittsburgh, 
Pittsburgh, PA, United States.
(Hanlon J.T., jth14@pitt.edu; Handler S.M.) Geriatric Research Education and 
Clinical Center, Center for Health Equity Research and Promotion, Veterans 
Affairs Pittsburgh Health System, Pittsburgh, PA, United States.
(Hanlon J.T., jth14@pitt.edu) Department of Pharmacy and Therapeutics, 
School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
(Hanlon J.T., jth14@pitt.edu) Department of Epidemiology, Graduate School of 
Public Health, University of Pittsburgh, Pittsburgh, PA, United States.
CORRESPONDENCE ADDRESS
  J. T. Hanlon, Department of Medicine (Geriatrics), University of Pittsburgh, 
Kaufmann Medical Building, 3471 5th Avenue, Pittsburgh, PA 15213, United 
States. Email: jth14@pitt.edu
SOURCE
  American Journal Geriatric Pharmacotherapy (2011) 9:1 (1-10). Date of 
Publication: February 2011
ISSN
  1543-5946
BOOK PUBLISHER
  Excerpta Medica Inc., 105 Raider Blvd, Suite 101, Hillsborough, United 
States.
ABSTRACT
  Objective: This paper reviews articles from 2010 that examined medication 
mishaps (ie, medication errors and adverse drug events [ADEs]) in the 
elderly. Methods: The MEDLINE and EMBASE databases were searched for 
English-language articles published in 2010 using a combination of search 
terms including medication errors, medication adherence, medication 
compliance, suboptimal prescribing, monitoring, adverse drug events, adverse 
drug withdrawal events, therapeutic failures, and aged. A manual search of 
the reference lists of the identified articles and the authors' article 
files, book chapters, and recent reviews was conducted to identify 
additional publications. Five studies of note were selected for annotation 
and critique. From the literature search, this paper also generated a 
selected bibliography of manuscripts published in 2010 (excluding those 
previously published in the American Journal of Geriatric Pharmacotherapy or 
by one of the authors) that address various types of medication errors and 
ADEs in the elderly. Results: Three studies focused on types of medication 
errors. One study examined underuse (due to prescribing) as a type of 
medication error. This before-and-after study from the Netherlands reported 
that those who received comprehensive geriatric assessments had a reduction 
in the rate of undertreatment of chronic conditions by over one third (from 
32.9% to 22.3%, P < 0.05). A second study focused on reducing medication 
errors due to the prescribing of potentially inappropriate medications. This 
quasi-experimental study found that a computerized provider order entry 
clinical decision support system decreased the number of potentially 
inappropriate medications ordered for patients < 65 years of age who were 
hospitalized (11.56 before to 9.94 orders per day after, P < 0.001). The 
third medication error study was a cross-sectional phone survey of 
managed-care elders, which found that more blacks than whites had low 
antihypertensive medication adherence as per a self-reported measure (18.4% 
vs 12.3%, respectively; P < 0.001). Moreover, blacks used more complementary 
and alternative medicine (CAM) than whites for the treatment of hypertension 
(30.5% vs 24.7%, respectively; P = 0.005). In multivariable analyses 
stratified by race, blacks who used CAM were more likely than those who did 
not to have low antihypertensive medication adherence (prevalence rate ratio 
= 1.56; 95% CI, 1.14-2.15; P = 0.006). The remaining two studies addressed 
some form of medication-related adverse patient events. A case-control study 
of Medicare Advantage patients revealed for the first time that the use of 
skeletal muscle relaxants was associated significantly with an increased 
fracture risk (adjusted odds ratio = 1.40; 95% CI, 1.15-1.72; P < 0.001). 
This increased risk was even more pronounced with the concomitant use of 
benzodiazepines. Finally, a randomized controlled trial across 16 centers in 
France used a 1-week educational intervention about high-risk medications 
and ADEs directed at rehabilitation health care teams. Results indicated 
that the rate of ADEs in the intervention group was lower than that in the 
usual care group (22% vs 36%, respectively, P = 0.004). Conclusion: 
Information from these studies may advance health professionals' 
understanding of medication errors and ADEs and may help guide research and 
clinical practices in years to come. © 2011 Elsevier HS Journals, Inc.
EMTREE DRUG INDEX TERMS
  anticoagulant agent (oral drug administration)
  antihypertensive agent (drug therapy)
  arginine
  benzodiazepine (adverse drug reaction)
  beta adrenergic receptor blocking agent
  bisphosphonic acid derivative
  carisoprodol (adverse drug reaction)
  chlorzoxazone (adverse drug reaction)
  cholinergic receptor blocking agent (adverse drug reaction)
  corticosteroid
  cyclobenzaprine (adverse drug reaction)
  dipeptidyl carboxypeptidase inhibitor
  fish oil
  laxative
  metaxalone (adverse drug reaction)
  methocarbamol (adverse drug reaction)
  morphine
  nonsteroid antiinflammatory agent (adverse drug reaction)
  opiate
  proton pump inhibitor
  steroid (oral drug administration)
  ubidecarenone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  adverse drug reaction
  geriatric patient
  medication error
EMTREE MEDICAL INDEX TERMS
  African American
  aged
  alternative medicine
  angina pectoris
  antihypertensive therapy
  atrial fibrillation
  case control study
  cerebrovascular accident
  Chinese herb
  chronic disease
  chronic drug administration
  clinical assessment
  clinical decision making
  computerized provider order entry
  corticosteroid therapy
  cross-sectional study
  diabetes mellitus
  diet supplementation
  drug dose titration
  Embase
  ethnicity
  European American
  falling
  fiber
  fracture (side effect)
  France
  geriatric care
  health care personnel
  health survey
  heart failure
  heart infarction
  hospital patient
  human
  hypertension (drug therapy)
  leisure
  meditation
  Medline
  osteoporosis
  patient compliance
  patient education
  patient monitoring
  peripheral occlusive artery disease
  prescription
  priority journal
  quasi experimental study
  race
  randomized controlled trial (topic)
  rehabilitation care
  review
  risk reduction
  self report
  transient ischemic attack
  treatment failure
  treatment withdrawal
  unspecified side effect (side effect)
  yoga
CAS REGISTRY NUMBERS
  arginine (1119-34-2, 15595-35-4, 7004-12-8, 74-79-3)
  benzodiazepine (12794-10-4)
  carisoprodol (78-44-4)
  chlorzoxazone (95-25-0)
  cyclobenzaprine (303-53-7, 6202-23-9)
  fish oil (8016-13-5)
  metaxalone (1665-48-1)
  methocarbamol (532-03-6)
  morphine (52-26-6, 57-27-2)
  opiate (53663-61-9, 8002-76-4, 8008-60-4)
  ubidecarenone (303-98-0)
EMBASE CLASSIFICATIONS
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011187510
MEDLINE PMID
  21459304 (http://www.ncbi.nlm.nih.gov/pubmed/21459304)
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.amjopharm.2011.01.003
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 355
TITLE
  Dabigatran: A new orally available anticoagulant for prevention of strokes 
and thrombosis in patients with atrial fibrillation
AUTHOR NAMES
  Talati R.
  White M.C.
AUTHOR ADDRESSES
  (Talati R.) Hartford Hospital, Hartford, CT, United States.
(Talati R.; White M.C.) Department of Pharmacy, University of Connecticut, 
Storrs, United States.
(White M.C.) UCONN/Hartford Hospital, Evidence-based Practice Center, 
Hartford, CT, United States.
CORRESPONDENCE ADDRESS
  R. Talati, Hartford Hospital, Hartford, CT, United States.
SOURCE
  Formulary (2011) 46:2 (44-53). Date of Publication: February 2011
ISSN
  1082-801X
BOOK PUBLISHER
  Advanstar Communications, One Park Avenue, New York, United States.
ABSTRACT
  Atrial fibrillation (AF) is the most common clinically significant cardiac 
arrhythmia in the United States and increases the risk of stroke 4.5-fold. 
Stroke can result in substantial morbidity, mortality, decreased quality of 
life, and related healthcare costs. Vitamin K antagonists such as warfarin 
are effective for stroke prevention in AF, but have several drawbacks. There 
is a need for new anticoagulant agents that are effective, safe, and 
convenient to use. Dabigatran etexilate (Pradaxa) is an orally administered 
reversible direct thrombin inhibitor approved by FDA on October 19, 2010, 
for the prevention of stroke and thrombosis in patients with AF. In clinical 
studies, it was given orally by fixed once-or twice-daily dosing, does not 
require dietary adjustments or routine laboratory monitoring, and is not 
expected to have cytochrome P450-dependent drug interactions, although it 
does have P-glycoprotein interactions. In the RE-LY trial, in patients with 
AF and at least 1 other risk factor for stroke (average CHADS2 score 2.1), 
dabigatran etexilate 150 mg twice daily was superior to warfarin at 
preventing the combination of stroke and systemic embolic events with a 
similar rate of major bleeding.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dabigatran (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug concentration, drug dose, drug interaction, drug therapy, 
oral drug administration, pharmacoeconomics, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (clinical trial, drug combination, drug comparison, 
drug therapy)
  amiodarone (drug interaction, pharmacokinetics)
  atorvastatin (drug interaction, pharmacokinetics)
  clarithromycin (drug interaction, pharmacokinetics)
  clopidogrel (drug interaction, pharmacokinetics)
  cytochrome P450 (endogenous compound)
  dabigatran etexilate
  diclofenac (drug interaction, pharmacokinetics)
  digoxin (drug interaction, pharmacokinetics)
  multidrug resistance protein (endogenous compound)
  pantoprazole (drug interaction, pharmacokinetics)
  ranitidine (drug interaction, pharmacokinetics)
  rifampicin (drug interaction)
  thrombin (endogenous compound)
  warfarin (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  cerebrovascular accident (drug therapy, complication, drug therapy, 
prevention)
  thrombosis (drug therapy, complication, drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
  alanine aminotransferase blood level
  area under the curve
  article
  aspartate aminotransferase blood level
  bleeding (side effect)
  brain hemorrhage (side effect)
  drug absorption
  drug approval
  drug bioavailability
  drug contraindication
  drug cost
  drug efficacy
  drug half life
  drug hydrolysis
  drug protein binding
  drug safety
  dyspepsia (side effect)
  food and drug administration
  human
  maximum plasma concentration
  morbidity
  mortality
  quality of life
  randomized controlled trial (topic)
  recommended drug dose
  side effect (side effect)
  thromboembolism (drug therapy)
  time to maximum plasma concentration
DRUG TRADE NAMES
  pradaxa  Boehringer Ingelheim

DRUG MANUFACTURERS
  Boehringer Ingelheim
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  atorvastatin (134523-00-5, 134523-03-8)
  clarithromycin (81103-11-9)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  cytochrome P450 (9035-51-2)
  diclofenac (15307-79-6, 15307-86-5)
  digoxin (20830-75-5, 57285-89-9)
  pantoprazole (102625-70-7)
  ranitidine (66357-35-5, 66357-59-3)
  rifampicin (13292-46-1)
  thrombin (869858-13-9, 9002-04-4)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011134125
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 356
TITLE
  Diffuse idiopathic skeletal hyperostosis (DISH)-A rare etiology of dysphagia
AUTHOR NAMES
  Krishnarasa B.
  Vivekanandarajah A.
  Ripoll L.
  Chang E.
  Wetz R.
AUTHOR ADDRESSES
  (Krishnarasa B., doc_bala@yahoo.com; Vivekanandarajah A.; Ripoll L.; Chang 
E.; Wetz R.) Staten Island University Hospital, Staten Island, NY, United 
States.
CORRESPONDENCE ADDRESS
  B. Krishnarasa, Staten Island University Hospital, Staten Island, NY, United 
States. Email: doc_bala@yahoo.com
SOURCE
  Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders (2011) 4 
(71-75). Date of Publication: 2011
ISSN
  1179-5441 (electronic)
  1179-5441
BOOK PUBLISHER
  Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay, 
Auckland, New Zealand.
ABSTRACT
  A 72-year-old gentleman presented to the hospital with progressively 
worsening dysphagia to soft foods and liquids. He was diagnosed with severe 
pharyngeal dysphagia by modified barium swallow. A CT scan of the neck with 
IV contrast showed anterior flowing of bridging osteophytes from C3-C6, 
indicative of DISH, resulting in esophageal impingement. He underwent 
resection of the DISH segments. Following the surgery, a PEG tube for 
nutrition supplementation was placed. However, the PEG tube was removed 
after five months when the speech and swallow evaluation showed no residual 
dysphagia. DISH is a rare non-inflammatory condition that results in 
pathological ossification and calcification of the anterolateral spinal 
ligaments. © the author(s), publisher and licensee Libertas Academica Ltd.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diffuse idiopathic skeletal hyperostosis (diagnosis, surgery)
  dysphagia (complication, diagnosis)
  hyperostosis (diagnosis, surgery)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  bone demineralization
  case report
  cervical spine radiography
  computer assisted tomography
  coronary artery disease
  diet supplementation
  disease association
  disease exacerbation
  disease severity
  dysarthria
  dyspnea
  fatigue
  gout
  hoarseness
  human
  hypertension
  limb weakness
  male
  neck dissection
  neck pain
  ossification
  osteophyte
  paresthesia
  pathogenesis
  ptosis
  rare disease (diagnosis)
  sleep disordered breathing
  stomach tube
EMBASE CLASSIFICATIONS
  Otorhinolaryngology (11)
  Orthopedic Surgery (33)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011609845
FULL TEXT LINK
  http://dx.doi.org/10.4137/CMAMD.S6949
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 357
TITLE
  Safety and efficacy of dronedarone in the treatment of atrial 
fibrillation/flutter
AUTHOR NAMES
  Naccarelli G.V.
  Wolbrette D.L.
  Levin V.
  Samii S.
  Banchs J.E.
  Penny-Peterson E.
  Gonzalez M.D.
AUTHOR ADDRESSES
  (Naccarelli G.V., gnaccarelli@hmc.psu.edu; Wolbrette D.L.; Samii S.; Banchs 
J.E.; Penny-Peterson E.; Gonzalez M.D.) State Hershey Heart and vascular 
Institute, Hershey, PA, United States.
(Levin V.) Lehigh valley Hospital Electrophysiology Laboratory, Allentown, 
PA, United States.
CORRESPONDENCE ADDRESS
  G. V. Naccarelli, State Hershey Heart and vascular Institute, Hershey, PA, 
United States. Email: gnaccarelli@hmc.psu.edu
SOURCE
  Clinical Medicine Insights: Cardiology (2011) 5 (103-119) Article Number: 3. 
Date of Publication: 2011
ISSN
  1179-5468 (electronic)
  1179-5468
BOOK PUBLISHER
  Libertas Academica Ltd., PO Box 300-874, Albany 0751, Mairangi Bay, 
Auckland, New Zealand.
ABSTRACT
  Dronedarone is an amiodarone analog but differs structurally from amiodarone 
in that the iodine moiety was removed and a methane-sulfonyl group was 
added. These modifcations reduced thyroid and other end-organ adverse 
effects and makes dronedarone less lipophilic, shortening its half-life. 
Dronedarone has been shown to prevent atrial fbrillation/futter (AF/AFl) 
recurrences in several multi-center trials. In addition to its rhythm 
control properties, dronedarone has rate control properties and slows the 
ventricular response during AF. Dronedarone is approved in Europe for rhythm 
and rate control indications. In patients with decompensated heart failure, 
dronedarone treatment increased mortality and cardiovascular 
hospitalizations. However, when dronedarone was used in elderly high risk 
AF/AFl patients excluding such high risk heart failure, cardiovascular 
hospitalizations were signifcantly reduced and the drug was approved in the 
USA for this indication in 2009 by the Food and Drug Administration. Updated 
guidelines suggest dronedarone as a front-line antiarrhythmic in many 
patients with AF/Fl but caution that the drug should not be used in patients 
with advanced heart failure. In addition, the recent results of the PALLAS 
trial suggest that dronedarone should not be used in the long-term treatment 
of patients with permanent AF. © the author(s), publisher and licensee 
Libertas Academica Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dronedarone (adverse drug reaction, drug combination, drug comparison, drug 
concentration, drug dose, drug interaction, drug therapy, intravenous drug 
administration, oral drug administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  amiodarone (adverse drug reaction, drug combination, drug comparison, drug 
interaction, drug therapy, intravenous drug administration, oral drug 
administration, pharmacokinetics, pharmacology)
  angiotensin receptor antagonist (drug therapy)
  anticoagulant agent (drug combination, oral drug administration)
  atorvastatin (drug interaction)
  calcium channel blocking agent (drug therapy)
  calcium channel L type (endogenous compound)
  cytochrome P450 2C9 (endogenous compound)
  cytochrome P450 2D6 (endogenous compound)
  cytochrome P450 3A4 (endogenous compound)
  cytochrome P450 inhibitor (drug combination, drug interaction)
  dabigatran (drug combination, drug concentration, drug dose, drug 
interaction)
  digoxin (drug combination, drug concentration, drug dose, drug interaction, 
drug therapy)
  diltiazem (drug combination, drug dose, drug interaction)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  drug metabolite
  lidocaine (drug comparison, drug therapy)
  metoprolol (drug interaction, pharmacokinetics)
  placebo
  pravastatin (drug interaction)
  ranolazine (drug combination, drug comparison, drug therapy)
  rosuvastatin (drug interaction)
  simvastatin (drug combination, drug concentration, drug dose, drug 
interaction)
  sodium channel (endogenous compound)
  sotalol (drug comparison, drug therapy)
  verapamil (drug combination, drug dose, drug interaction)
  warfarin (adverse drug reaction, drug combination, drug dose, drug 
interaction, pharmacokinetics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy, therapy)
  heart atrium flutter (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  acute coronary syndrome
  acute heart failure (drug therapy)
  antiarrhythmic activity
  beta adrenergic receptor blocking
  bleeding (side effect)
  bradycardia (side effect)
  brain hemorrhage (side effect)
  brain ischemia
  cardioversion
  cerebrovascular accident (prevention)
  congestive heart failure (drug therapy, side effect)
  creatinine blood level
  defibrillator
  diarrhea (side effect)
  drug absorption
  drug bioavailability
  drug blood level
  drug contraindication
  drug dose comparison
  drug dose increase
  drug dose reduction
  drug efficacy
  drug excretion
  drug fatality (side effect)
  drug half life
  drug indication
  drug metabolism
  drug monitoring
  drug potency
  drug protein binding
  drug safety
  drug structure
  drug tolerability
  drug withdrawal
  eye toxicity (side effect)
  faintness
  first pass effect
  food
  food drug interaction
  gastrointestinal symptom (side effect)
  heart arrest
  heart arrhythmia (drug therapy)
  heart atrioventricular node
  heart electrophysiology
  heart repolarization
  heart ventricle arrhythmia (drug therapy)
  heart ventricle fibrillation (drug therapy, prevention)
  hemoglobin blood level
  high risk patient
  hospitalization
  human
  hyperthyroidism (side effect)
  international normalized ratio
  interstitial lung disease (side effect)
  lipid diet
  liver dysfunction (side effect)
  liver function test
  liver toxicity (side effect)
  low drug dose
  lung toxicity (side effect)
  mortality
  nausea (side effect)
  neurotoxicity (side effect)
  nonhuman
  pneumonia (side effect)
  potassium current
  QT interval
  QT prolongation (side effect)
  recommended drug dose
  recurrence risk
  review
  risk reduction
  side effect (side effect)
  skin toxicity (side effect)
  sodium current
  systolic blood pressure
  tachycardia (drug therapy)
  teratogenicity
  thyroid disease (side effect)
  torsade des pointes (side effect)
  transient ischemic attack
  vasodilatation
  volume of distribution
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  atorvastatin (134523-00-5, 134523-03-8)
  cytochrome P450 3A4 (329736-03-0)
  digoxin (20830-75-5, 57285-89-9)
  diltiazem (33286-22-5, 42399-41-7)
  dronedarone (141626-36-0)
  lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
  metoprolol (37350-58-6)
  pravastatin (81093-37-0, 81131-70-6)
  ranolazine (95635-55-5)
  rosuvastatin (147098-18-8, 147098-20-2)
  simvastatin (79902-63-9)
  sotalol (3930-20-9, 80456-07-1, 959-24-0)
  verapamil (152-11-4, 52-53-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2012010528
FULL TEXT LINK
  http://dx.doi.org/10.4137/CMC.S6677
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 358
TITLE
  Evaluation of anticoagulation management and chronic disease state control 
in a pharmacist-run pharmacotherapy/anticoagulation clinic
AUTHOR NAMES
  Sease J.M.
  Blake E.W.
  Gowan M.
  Shealy K.M.
AUTHOR ADDRESSES
  (Sease J.M., jmsease@presby.edu; Gowan M.) Department of Pharmacy Practice, 
School of Pharmacy, Presbyterian College, Clinton, SC, United States.
(Blake E.W.) Department of Clinical Pharmacy and Outcomes Sciences, South 
Carolina College of Pharmacy, Columbia, SC, United States.
(Gowan M.) Critical Care, Barnes-Jewish Hospital, St. Louis, MO, United 
States.
(Shealy K.M.) Department of Pharmacy Practice, School of Pharmacy, 
Presbyterian College, United States.
CORRESPONDENCE ADDRESS
  J. M. Sease, Department of Pharmacy Practice, School of Pharmacy, 
Presbyterian College, Clinton, SC, United States. Email: jmsease@presby.edu
SOURCE
  Journal of Pharmacy Technology (2011) 27:1 (3-8). Date of Publication: 
January-February 2011
ISSN
  8755-1225
BOOK PUBLISHER
  Harvey Whitney Books Company, 8044 Montgomery Road, Suite 415, Cincinnati, 
United States.
ABSTRACT
  Background: The benefit of pharmacist-run clinics for anticoagulation, 
dyslipidemia, diabetes, and hypertension has been described in the 
literature as individual services. We describe a clinic model in which 
anticoagulation and other chronic disease states are managed concomitantly. 
Objective: To evaluate the control of anticoagulation, hypertension, 
dyslipidemia, and diabetes in anticoagulation patients enrolled in a 
pharmacotherapy/anticoagulation clinic. Methods: Patients seen in the 
pharmacotherapy/anticoagulation clinic for management of anticoagulation 
were included in a retrospective review. Demographic information, blood 
pressure measurements, and laboratory values were recorded. Initial and 
final results were compared and statistically analyzed. Benchmark goals were 
set for each parameter analyzed. Results: Between August 2007 and July 2008, 
282 patients were enrolled in the clinic. While slightly increasing the 
average time in therapeutic range from 69.9% to 70.7%, the clinical 
pharmacists also managed hypertension, dyslipidemia, and diabetes, if 
present. Systolic (p = 0.0075; 95% CI 0.98 to 6.31) and diastolic (p = 
0.004; 95% CI 1.26 to 4.33) blood pressures decreased during the study 
period such that the number of patients with controlled blood pressure 
increased to 81%. Low-density lipoprotein cholesterol measurements decreased 
by an average of 5.9 mg/dL (p < 0.0001; 95% CI 3.121 to 8.789), with an 
increase in number of patients at goal to 86%. Although not significant, 
mean hemoglobin A (1c) (A1C) values decreased an average of 0.12% (p = 
0.1138; 95% CI 0.029 to 0.271), with an increase to 59% of those achieving a 
goal A1C. Conclusions: A pharmacotherapy/anticoagulation clinic can be 
considered a practice model for effective management of anticoagulation 
patients who require management of other chronic disease states.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (drug therapy)
EMTREE DRUG INDEX TERMS
  hemoglobin A1c (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS
  aged
  anticoagulant therapy
  article
  atrial fibrillation (drug therapy)
  blood pressure measurement
  cerebrovascular accident (drug therapy)
  chronic disease
  deep vein thrombosis (drug therapy)
  demography
  diabetes mellitus
  dyslipidemia
  female
  human
  hypertension
  lung embolism (drug therapy)
  major clinical study
  male
  peripheral vascular disease (drug therapy)
  pharmaceutical care
  pharmacist
  transient ischemic attack (drug therapy)
CAS REGISTRY NUMBERS
  hemoglobin A1c (62572-11-6)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011157653
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 359
TITLE
  Musculoskeletal rehabilitation after hip fracture: A review
AUTHOR NAMES
  Pfeifer M.
  Minne H.W.
AUTHOR ADDRESSES
  (Pfeifer M., iko_pyrmont@t-online.de; Minne H.W.) Institute of Clinical 
Osteology Gustav Pommer, Clinic der FURSTENHOF, Am Hylligen Born 7, Bad 
Pyrmont 31812, Germany.
CORRESPONDENCE ADDRESS
  M. Pfeifer, Institute of Clinical Osteology Gustav Pommer, Clinic der 
FURSTENHOF, Am Hylligen Born 7, Bad Pyrmont 31812, Germany. Email: 
iko_pyrmont@t-online.de
SOURCE
  Archives of Osteoporosis (2010) 5:1-2 (49-59). Date of Publication: December 
2010
ISSN
  1862-3522
  1862-3514 (electronic)
BOOK PUBLISHER
  Springer London, The Guildway, Old Portsmouth Road, Artington, Guildford, 
United Kingdom.
ABSTRACT
  This review article on musculoskeletal rehabilitation after hip fractures 
summarizes current scientific evidence concerning prevention, treatment and 
post-fracture surveillance of patients who sustained a low-trauma hip 
fracture due to osteoporosis. Introduction: With increasing longevity, hip 
fractures become more and more a serious burden not only for societies in 
developed civilization, but also for emerging countries. According to 
world-wide projections 1.5 million people are affected each year. Although a 
lot of research has been performed over the last decade, there is still a 
lack of standardized and evidence-based approaches for prevention, treatment 
and rehabilitation of this worst complication of osteoporosis. Therefore, 
the evidence base for this article was synthesized in accordance with SIGN 
methodology. Databases searched include Medline, Embase, CINAHL and the 
Cochrane Library between January 1996 and March 2010. The following terms 
are used: osteoporosis, hip fracture, rehabilitation, falls, muscle 
strength, nutrition, exercise, balance, sway, and hip protectors. Moreover, 
reference lists from included studies were checked and author's names were 
searched for additional studies. Possibly, the best approach to 
rehabilitation after hip fracture is a multi-disciplinary team co-ordinating 
medical, social, educational and vocational measure for training or 
retraining the individual to the highest possible level of function. In 
order to prevent thromboembolism fondaparinux should be used for 28 days 
starting 6 h after surgery. This should be accompanied by a daily 
nutritional intake of at least 20-g protein, 1,200 mg of elemental calcium 
and 800 IU of vitamin D; whereas in severe vitamin D insufficiencies, 
recommendations may be certainly higher. After surgical repair of the hip 
fracture, an anti-resorptive medication should be started. While balance 
training and performing of Tai Chi has been shown to reduce fall risk and 
thereby also decrease hip fracture risk, the use of hip protectors is still 
under evaluation and cannot be generally advocated. © 2010 International 
Osteoporosis Foundation and National Osteoporosis Foundation and National 
Osteoporosis Foundation.
EMTREE DRUG INDEX TERMS
  alendronic acid (drug therapy)
  calcium
  fondaparinux (drug therapy)
  placebo
  risedronic acid (drug therapy)
  strontium ranelate (drug therapy)
  vitamin D
  zoledronic acid (adverse drug reaction, clinical trial, drug therapy, 
intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  hip fracture (drug therapy, drug therapy, prevention, rehabilitation, 
surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (side effect)
  body equilibrium
  bone pain (side effect)
  cardiovascular disease (side effect)
  cerebrovascular accident (side effect)
  clinical practice
  decubitus (complication)
  deep vein thrombosis (complication)
  diet supplementation
  drug fever (side effect)
  evidence based practice
  exercise
  fall risk
  functional assessment
  heterotopic ossification (complication)
  hip pain (complication)
  human
  jaw osteonecrosis (side effect)
  kidney disease (side effect)
  kyphosis
  longevity
  mobilization
  muscle strength
  musculoskeletal pain (side effect)
  myalgia (side effect)
  neurological complication (complication)
  nutrition
  osteoporosis
  oxygen saturation
  priority journal
  protective equipment
  quality of life
  rehabilitation medicine
  resistance training
  review
  risk assessment
  risk reduction
  Tai Chi
  thromboembolism (complication, drug therapy, prevention)
  vitamin D deficiency
CAS REGISTRY NUMBERS
  alendronic acid (66376-36-1)
  calcium (14092-94-5, 7440-70-2)
  fondaparinux (104993-28-4, 114870-03-0)
  risedronic acid (105462-24-6, 122458-82-6)
  strontium ranelate (135459-87-9)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Rehabilitation and Physical Medicine (19)
  Orthopedic Surgery (33)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011064229
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11657-010-0050-8
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 360
TITLE
  2nd International Symposium on Hypertension
AUTHOR ADDRESSES
  SOURCE
  Kidney and Blood Pressure Research (2010) 33:6. Date of Publication: 
December 2010
CONFERENCE NAME
  2nd International Symposium on Hypertension
CONFERENCE LOCATION
  Osijek, Croatia
CONFERENCE DATE
  2010-11-18 to 2010-11-21
CONFERENCE EDITORS
  Drenjancevic I.
ISSN
  1420-4096
BOOK PUBLISHER
  S. Karger AG
ABSTRACT
  The proceedings contain 50 papers. The topics discussed include: prevalence 
of arterial hypertension and obesity in seven year old children; 
hypertension as the most prevalent etiological condition in chronic and 
transitory atrial fibrillation in patients at canton hospital zenica; 
arterial hypertension in peritoneal dialysis patients; investigation of 
parameters of blood vessels with the finometer device in diabetic and 
non-diabetic hypertensive patients; artery plaque score and arterial 
hypertension; influence of high salt diet on microvascular reactivity in 
young healthy female human subjects; vasomotor effects of hemolyzed blood in 
isolated rat cerebral arteries; prevalence, treatment, control and 
distribution of hypertension in endemic nephropathy; hypertension protective 
allele of toll-like receptor 2 polymorphic gene; and cumulative incidence of 
arterial hypertension in normotensive subjects cohorta.
EMTREE DRUG INDEX TERMS
  toll like receptor 2
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  hypertension
EMTREE MEDICAL INDEX TERMS
  allele
  artery
  atrial fibrillation
  blood
  blood vessel
  brain artery
  child
  devices
  diabetes mellitus
  diet
  female
  gene
  hemodialysis patient
  hospital
  human
  kidney disease
  obesity
  patient
  peritoneal dialysis
  prevalence
  rat
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 361
TITLE
  Factors influencing concomitant use of complementary and alternative 
medicines with warfarin
AUTHOR NAMES
  Hasan S.S.
  Feng S.R.
  Ahmadi K.
  Ahmad K.M.
  Chong D.W.K.
  Anwar M.
  Badarudin N.Z.
AUTHOR ADDRESSES
  (Hasan S.S., shahzad_hasan@imu.edu.my; Feng S.R.; Ahmadi K.; Anwar M.) 
Department of Pharmacy Practice, School of Pharmacy and Health Sciences, 
International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia.
(Ahmad K.M.; Chong D.W.K.) Clinical Coordinator, Hospital Serdang, Selangor, 
Malaysia.
(Badarudin N.Z.) Pharmacistin-Charge, Anticoagulation Clinic, Hospital 
Serdang, Selangor, Malaysia.
CORRESPONDENCE ADDRESS
  S. S. Hasan, Department of Pharmacy Practice, School of Pharmacy and Health 
Sciences, International Medical University, Bukit Jalil 57000, Kuala Lumpur, 
Malaysia. Email: shahzad_hasan@imu.edu.my
SOURCE
  Journal of Pharmacy Practice and Research (2010) 40:4 (294-299). Date of 
Publication: December 2010
ISSN
  1445-937X
BOOK PUBLISHER
  Society of Hospital Pharmacists of Australia, P.O.Box 1774, Collingwood, 
Australia.
ABSTRACT
  Aim: To investigate factors influencing complementary and alternative 
medicines (CAM) use among patients on warfarin. Method: Cross-sectional 
study of randomly selected patients at a hospital-based anticoagulation 
clinic in Malaysia. A 38- item validated data collection form was used to 
interview patients and investigate the reasons, perceived efficacy and 
adverse drug events experienced. Data were also collected on potential drug 
interactions and the international normalised ratio (INR). Results: Of the 
138 randomly selected patients, 76 (55%) reported using CAM - 46 (61%) used 
biologically based practices such as herbal products, vitamins and 
supplements. Monthly household income (p = 0.05, r = 0.13) and family 
history of CAM use (p = 0.001, r = 0.32) were significantly associated and 
positively correlated with CAM use. 19 patients reported adverse events with 
warfarin use while none reported adverse events with CAM use. 19 and 58 
patients, respectively, were identified as being at risk of potential 
interactions between warfarin-CAM and warfarin-conventional medicines. No 
significant difference in the mean INR was found between CAM and non-CAM 
users. Conclusion: A large number of patients attending the anticoagulation 
clinic reported using CAM. Socioeconomic factors such as monthly household 
income, education level and family history of CAM use were significantly 
related with CAM use. Routine medication interviews should include questions 
about concomitant CAM use.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  warfarin (adverse drug reaction, drug interaction)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug interaction)
  allopurinol (drug interaction)
  alpha tocopherol (drug interaction)
  fish oil (drug interaction)
  glucosamine (drug interaction)
  mineral
  Panax notoginseng extract (drug therapy)
  vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alternative medicine
EMTREE MEDICAL INDEX TERMS
  acupuncture
  adult
  adverse outcome
  anorexia (side effect)
  anticoagulant therapy
  article
  atrial fibrillation
  Chinese medicine
  cross-sectional study
  cryotherapy
  dizziness (side effect)
  drug efficacy
  drug induced headache (side effect)
  female
  flatulence (side effect)
  gingiva bleeding (drug therapy, side effect, therapy)
  heart valve replacement
  herbal medicine
  human
  international normalized ratio
  kinesiotherapy
  major clinical study
  Malaysia
  male
  massage
  myalgia (side effect, therapy)
  skin bruising (drug therapy, side effect, therapy)
  stomach pain (side effect)
  traditional medicine
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  allopurinol (315-30-0)
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  fish oil (8016-13-5)
  glucosamine (3416-24-8, 4607-22-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Pharmacy (39)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011039705
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 362
TITLE
  Atrial fibrillation ablation: Safety and efficacy
AUTHOR NAMES
  Lyne J.
AUTHOR ADDRESSES
  (Lyne J., j.lyne@rbht.nhs.uk) Royal Brompton and Harefield NHS Trust, Sydney 
Street, London, SW3 6NP, United Kingdom.
CORRESPONDENCE ADDRESS
  J. Lyne, Royal Brompton and Harefield NHS Trust, Sydney Street, London, SW3 
6NP, United Kingdom. Email: j.lyne@rbht.nhs.uk
SOURCE
  British Journal of Cardiology (2010) 17:6 (255-256). Date of Publication: 
November-December 2010
ISSN
  0969-6113
BOOK PUBLISHER
  MediNews (Cardiology) Ltd, 3 Duchess Place, Edgbaston, Birmingham, United 
Kingdom.
ABSTRACT
  This study is a single centre historical cohort of 100 consecutive patients 
treated in a UK centre with catheter ablation for symptomatic drug 
refractory AF. The results document outcomes in keeping with published case 
series with acceptable complication rates. Although medical therapy is the 
cornerstone of treatment for AF, ablation is assuming an ever greater role. 
As these procedures become more common and both centres and operators alike 
become more experienced and comfortable in addressing more advanced disease, 
the indications for this procedure are likely to expand and encompass more 
patients. Copyright Medinews (Cardiology) Limited Reproduction Prohibited.
EMTREE DRUG INDEX TERMS
  antiarrhythmic agent (drug therapy)
  dabigatran (drug therapy)
  dronedarone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  allergy (complication)
  catheter ablation
  cerebrovascular accident (drug therapy)
  electrocardiogram
  exercise
  heart failure
  heart left ventricle function
  heart tamponade (complication)
  hospitalization
  human
  mortality
  pain (complication)
  patient selection
  pericarditis (complication)
  prognosis
  pulmonary vein isolation
  quality of life
  review
  supraventricular tachycardia (complication)
  thromboembolism
CAS REGISTRY NUMBERS
  dronedarone (141626-36-0)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011539962
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 363
TITLE
  Endurance sport practice and atrial fibrillation
AUTHOR NAMES
  Calvo N.
  Mont L.
AUTHOR ADDRESSES
  (Calvo N.; Mont L., lmont@clinic.ub.es) Thorax Institute (ICT), Hospital 
Clinic, University of Barcelona, Villarroel 170, Barcelona 08036, Catalonia, 
Spain.
CORRESPONDENCE ADDRESS
  L. Mont, Thorax Institute (ICT), Hospital Clinic, University of Barcelona, 
Villarroel 170, Barcelona 08036, Catalonia, Spain. Email: lmont@clinic.ub.es
SOURCE
  Journal of Atrial Fibrillation (2010) 2:2 (762-769). Date of Publication: 
October 2010
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  endurance sport
EMTREE MEDICAL INDEX TERMS
  athlete
  autonomic nervous system
  cardiovascular risk
  dilatation
  exercise
  fibrosis
  heart arrhythmia
  human
  inflammation
  pathophysiology
  review
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2010607326
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 364
TITLE
  Epidemiology and risk factors of cerebral ischemia and ischemic heart 
diseases: Similarities and differences
AUTHOR NAMES
  Soler E.P.
  Ruiz V.C.
AUTHOR ADDRESSES
  (Soler E.P., epalomeras@csdm.cat; Ruiz V.C.) Unitat de Neurologia, Hospital 
de Mataró, Carretera de Cirera, s/n, 08304 Mataró, Spain.
CORRESPONDENCE ADDRESS
  E. P. Soler, Unitat de Neurologia, Hospital de Mataró, Carretera de Cirera, 
s/n, 08304 Mataró, Spain. Email: epalomeras@csdm.cat
SOURCE
  Current Cardiology Reviews (2010) 6:3 (138-149). Date of Publication: 2010
ISSN
  1573-403X
BOOK PUBLISHER
  Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
  Cerebral ischemia and ischemic heart diseases, common entities nowadays, are 
the main manifestation of circulatory diseases. Cardiovascular diseases, 
followed by stroke, represent the leading cause of mortality worldwide. Both 
entities share risk factors, pathophisiology and etiologic aspects by means 
of a main common mechanism, atherosclerosis. However, each entity has its 
own particularities. Ischemic stroke shows a variety of pathogenic 
mechanisms not present in ischemic heart disease. An ischemic stroke 
increases the risk of suffering a coronary heart disease, and viceversa. The 
aim of this chapter is to review data on epidemiology, pathophisiology and 
risk factors for both entities, considering the differences and similarities 
that could be found in between them. We discuss traditional risk factors, 
obtained from epidemiological data, and also some novel ones, such as 
hyperhomocisteinemia or sleep apnea. We separate risk factors, as 
clasically, in two groups: nonmodifiables, which includes age, sex, or 
ethnicity, and modifiables, including hypertension, dyslipidemia or 
diabetis, in order to discuss the role of each factor in both ischemic 
events, ischemic stroke and coronary heart disease. © 2010 Bentham Science 
Publishers Ltd.
EMTREE DRUG INDEX TERMS
  alcohol
  biological marker (endogenous compound)
  C reactive protein (endogenous compound)
  lipoprotein (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia (epidemiology)
  cerebrovascular accident (epidemiology)
  ischemic heart disease (epidemiology, prevention)
EMTREE MEDICAL INDEX TERMS
  age distribution
  alcohol consumption
  artery embolism (epidemiology, etiology)
  article
  atherosclerosis (epidemiology, etiology)
  atrial fibrillation (epidemiology, etiology)
  blood clotting disorder (epidemiology, etiology)
  cardiovascular disease (diagnosis, epidemiology, prevention)
  cerebrovascular disease (epidemiology)
  clinical trial
  cohort analysis
  comorbidity
  coronary artery embolism (epidemiology, etiology)
  diabetes mellitus (epidemiology, etiology)
  diet
  dyslipidemia (epidemiology, etiology)
  epidemiological data
  ethnicity
  heart infarction (epidemiology, prevention)
  heredity
  human
  hypercholesterolemia (epidemiology, etiology)
  hypercoagulopathy (epidemiology, etiology)
  hyperhomocysteinemia (epidemiology, etiology)
  hypertension (epidemiology, etiology)
  immobilization
  incidence
  inflammation
  lipoprotein blood level
  Mediterranean diet
  mortality
  obesity (etiology)
  pathophysiology
  physical activity
  prevalence
  priority journal
  prospective study
  risk factor
  sex difference
  sleep disordered breathing (epidemiology, etiology)
  smoking
  thrombophilia (epidemiology, etiology)
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  alcohol (64-17-5)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010496000
FULL TEXT LINK
  http://dx.doi.org/10.2174/157340310791658785
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 365
TITLE
  Is lenient rate control effective for atrial fibrillation?
AUTHOR NAMES
  Moon K.T.
AUTHOR ADDRESSES
  (Moon K.T.)
CORRESPONDENCE ADDRESS
  K. T. Moon,
SOURCE
  American Family Physician (2010) 82:6 (684-686). Date of Publication: 
September 15, 2010
ISSN
  0002-838X
  0002-838X (electronic)
BOOK PUBLISHER
  American Academy of Family Physicians, 11400 Tomahawk Creek Parkway, Suite 
440, Leawood, United States.
ABSTRACT
  Background: Rate control is the cornerstone of atrial fibrillation 
management, but the optimal target heart rate is unknown. Guidelines 
recommend strict rate control, but whether this approach actually improves 
patient outcomes has not been proven. Van Gelder and colleagues studied 
lenient rate control to determine if it is as effective as strict rate 
control in preventing cardiovascular morbidity and mortality in persons with 
atrial fibrillation. The Study: The authors evaluated data from the Rate 
Control Efficacy in Permanent Atrial Fibrillation: A Comparison between 
Lenient versus Strict Rate Control II study, a prospective randomized trial 
examining whether lenient rate control (less than 110 beats per minute [bpm] 
at rest) was noninferior to strict rate control (less than 80 bpm at rest 
and less than 110 bpm with moderate exercise) in preventing cardiovascular 
events over two to three years. Eligible patients were younger than 80 
years, had permanent atrial fibrillation for up to 12 months, were receiving 
anticoagulant therapy, and had a mean resting heart rate greater than 80 
bpm. A total of 614 patients were given one or more rate-controlling drugs 
(i.e., beta blockers, nondihydropyridine calcium channel blockers, and 
digoxin) to achieve their target heart rate. The primary outcome was a 
composite of cardiovascular-associated outcomes, including death, embolism, 
sustained ventricular tachycardia, syncope, hospitalization for heart 
failure, and implantation of a cardioverter-defibrillator. Results: 
Significantly more patients were able to achieve their target heart rates in 
the lenient rate-control group compared with the strict rate-control group 
(97.7 versus 75.2 percent, respectively), and significantly fewer followup 
visits were needed in the lenient rate-control group to achieve the target 
heart rate. No difference was noted between the groups regarding the primary 
outcome. There was also no difference between the groups with regard to 
all-cause mortality, heart failure stage, hospitalization rate, or adverse 
events, although the lenient ratecontrol group had a lower risk of stroke 
(hazard ratio = 0.35). There was no difference between the groups in the 
prevalence of atrial fibrillation symptoms, including palpitations, dyspnea, 
or fatigue. Conclusion: The authors conclude that lenient rate control is 
easier to achieve than strict rate control in patients with permanent atrial 
fibrillation, with a similar rate of major clinical events. © 2010 by the 
American Academy of Family Physicians.
EMTREE DRUG INDEX TERMS
  anticoagulant agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
  digoxin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy)
  heart rate
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  cardiovascular disease (prevention)
  cerebrovascular accident
  controlled study
  dyspnea
  exercise
  fatigue
  heart failure
  heart palpitation
  hospitalization
  human
  major clinical study
  mortality
  outcome assessment
  prevalence
  randomized controlled trial (topic)
  symptomatology
CAS REGISTRY NUMBERS
  digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2011283797
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 366
TITLE
  The role of medical practitioners in clinical pathways for stroke
AUTHOR NAMES
  Kondo T.
AUTHOR ADDRESSES
  (Kondo T., taro-mail-1122@dance.ocn.ne.jp) Kondo Clinic, Tokyo, Japan.
CORRESPONDENCE ADDRESS
  T. Kondo, Kondo Clinic, Tokyo, Japan. Email: taro-mail-1122@dance.ocn.ne.jp
SOURCE
  Japan Medical Association Journal (2010) 53:5 (290-293). Date of 
Publication: September/October 2010
ISSN
  1346-8650
BOOK PUBLISHER
  Japan Medical Association, 2-28-16 Hongkomagome, Bunkyo-Ku, tokyo, Japan.
ABSTRACT
  Stroke is the number one causative disease for conditions requiring care. 
Considering the sequelae of stroke as well as vascular dementia, vascular 
parkinsonism, fall-related fractures, and disuse syndrome, involvement in 
clinical pathways for stroke is perhaps the most important issue for 
healthcare practitioners. In order to initiate medical treatment immediately 
after the onset of stroke, first it is vital to suspect that a patient is 
having a stoke. If one or more symptoms of "facial distortion," "arm 
paralysis," and "dysarthria" are present, there is a high possibility of 
stroke. Spreading the use and knowledge of the Cincinnati Prehospital Stroke 
Scale (CPSS) broadly would help people not to hesitate to call an ambulance. 
In order to prevent the onset and recurrence of stroke, I wish to address 
risk factors that can be corrected or modified, such as hypertension, 
diabetes, hyperlipidemia, atrial fibrillation, obesity, smoking, alcohol 
consumption, and lack of physical exercise. Increased efforts to carefully 
respond to transient cerebral ischemic attacks can further reduce the 
overall need for long-term care from stroke.
EMTREE DRUG INDEX TERMS
  tissue plasminogen activator (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (prevention)
  medical care
  medical practice
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  article
  atrial fibrillation
  brain infarction (drug therapy)
  brain ischemia
  cincinnati prehospital stroke scale
  diabetes mellitus
  disuse syndrome
  dysarthria
  exercise
  face disorder
  fracture
  health promotion
  home care
  hospital care
  human
  hyperlipidemia
  hypertension
  long term care
  multiinfarct dementia
  obesity
  paralysis
  parkinsonism
  patient care
  preventive health service
  primary medical care
  rating scale
  recurrent disease (prevention)
  risk factor
  risk management
  smoking
  symptom
  syndrome
  transient ischemic attack
CAS REGISTRY NUMBERS
  tissue plasminogen activator (105913-11-9)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010634751
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 367
TITLE
  Acupuncture-induced intramuscular hematoma in patients taking 
anticoagulation drugs: An emerging clinical entity
AUTHOR NAMES
  Han Z.-Q.
  Zhou X.
  Jiang T.-M.
  Li Y.-M.
AUTHOR ADDRESSES
  (Han Z.-Q.; Zhou X.; Jiang T.-M.; Li Y.-M., cardiolab@gmail.com) Institute 
of Cardiovascular Disease, Pingjin Hospital, Medical College of Chinese 
People's Armed Police Forces, 220, Cheng-Lin Road, Tianjin 300162, China.
CORRESPONDENCE ADDRESS
  Y.-M. Li, Institute of Cardiovascular Disease, Pingjin Hospital, Medical 
College of Chinese People's Armed Police Forces, 220, Cheng-Lin Road, 
Tianjin 300162, China. Email: cardiolab@gmail.com
SOURCE
  Medical Acupuncture (2010) 22:3 (207-211). Date of Publication: 1 Sep 2010
ISSN
  1933-6586
BOOK PUBLISHER
  Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, United States.
ABSTRACT
  Background: Oral anticoagulation is used extensively for prevention of 
thromboembolic events. Whether acupuncture is safe for patients taking 
anticoagulants is not clear. Objective: To describe a patient with a history 
of ischemic stroke and paroxysmal nonvalvular atrial fibrillation who was in 
stroke rehabilitation including acupuncture. Design, Setting, and Patient 
The patient developed sudden calf hematoma when optimal therapeutic 
intensity of international normalized ratio (INR) was achieved. Results: 
This patient was treated conservatively, without symptoms of compartment 
syndrome, and calf hematomas were resolved in 3 months. Conclusions: With 
increased acceptance of acupuncture worldwide and enforcement of clinical 
guidelines for prevention of thromboembolism, acupuncture-induced hematoma 
will be an emerging clinical entity. To minimize hemorrhagic complications, 
caution should be exercised when patients receiving oral anticoagulation 
request acupuncture treatment. © 2010, Mary Ann Liebert, Inc.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (drug therapy, oral drug administration)
  warfarin (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  muscle hematoma (complication, etiology)
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation (rehabilitation, therapy)
  brain ischemia (drug therapy, prevention, rehabilitation, therapy)
  case report
  conservative treatment
  drug use
  female
  human
  international normalized ratio
  practice guideline
  priority journal
  thromboembolism (prevention)
  venous thromboembolism (drug therapy)
CAS REGISTRY NUMBERS
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
  Rehabilitation and Physical Medicine (19)
  Hematology (25)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010498695
FULL TEXT LINK
  http://dx.doi.org/10.1089/acu.2009.0736
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 368
TITLE
  Primary and secondary prevention of cerebral ischemia
AUTHOR NAMES
  Diener H.-C.
  Aichner F.
  Bode C.
  Böhm M.
  Eckstein H.-H.
  Einhäupl K.
  Endres M.
  Forsting F.
  Gesenhues S.
  Grond M.
  Haberl R.L.
  Hacke W.
  Hennerici M.
  Lyrer P.
  Link A.
  Ringelstein B.
  Ringleb P.A.
  Schrader J.
  Weimar C.
AUTHOR ADDRESSES
  (Diener H.-C., h.diener@uni-essen.de; Weimar C.) Department of Neurology, 
University Hospital Essen, Hufelandstr. 55, 45147 Essen, Belgium.
(Aichner F.) Neurological Department, Wagner-Jauregg-Krankenhaus, Linz, 
Austria.
(Bode C.) Department of Cardiology, University Hospital, Freiburg, Germany.
(Böhm M.) Department of Internal Medicine III, University of the Saarland, 
Homburg/Saar, Germany.
(Eckstein H.-H.) Department of Vascular Surgery, TU, Munich, Germany.
(Einhäupl K.) Department of Neurology, University Hospital, Charité, Berlin, 
Germany.
(Endres M.) Department of Neurology und Clinical Neurophysiology, Charité, 
Campus Benjamin Franklin, Berlin, Germany.
(Forsting F.) Department of Diagnostic und Interventional Radiology and 
Neuroradiology, University Hospital, Essen, Belgium.
(Gesenhues S.) Institute of General Medicine, University Hospital, Essen, 
Belgium.
(Grond M.) Department of Neurology, Kreisklinikum Siegen (DSG), Germany.
(Haberl R.L.) Department of Neurology, Klinikum Harlaching, Städt. Klinikum 
München GmbH, Germany.
(Hacke W.; Ringleb P.A.) Department of Neurology, University Hospital 
Heidelberg (DSG), Germany.
(Hennerici M.) University Department of Neurology, University of Mannheim, 
Germany.
(Lyrer P.) Neurological Department, University Hospital, Basel, Switzerland.
(Link A.) Neurologist in Private Practice, Celle, Germany.
(Ringelstein B.) Department of Neurology, University Hospital Münster, 
Germany.
(Schrader J.) Department of Internal Medicine, St. Joseph-Hospital, 
Cloppenburg, Germany.
CORRESPONDENCE ADDRESS
  H.-C. Diener, Department of Neurology, University Hospital Essen, 
Hufelandstr. 55, 45147 Essen, Belgium. Email: h.diener@uni-essen.de
SOURCE
  Aktuelle Neurologie (2010) 37:4 (e2-e22). Date of Publication: 2010
ISSN
  0302-4350
  1438-9428 (electronic)
BOOK PUBLISHER
  Georg Thieme Verlag, Rudigerstrasse 14, Stuttgart, Germany.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (drug combination, drug therapy, oral drug 
administration)
  antithrombocytic agent (drug combination, drug therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug dose, drug therapy)
  acetylsalicylic acid plus dipyridamole (adverse drug reaction, drug 
comparison, drug dose, drug therapy)
  amfebutamone (drug comparison, drug therapy)
  antihypertensive agent (drug therapy)
  atenolol (drug combination, drug comparison, drug therapy)
  atorvastatin (clinical trial, drug comparison, drug dose, drug therapy)
  calcium antagonist (drug combination, drug comparison)
  clopidogrel (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug dose, drug therapy)
  cyanocobalamin (clinical trial, drug combination, drug therapy, 
pharmacology)
  dipeptidyl carboxypeptidase inhibitor (drug combination, drug comparison, 
drug therapy)
  dipyridamole (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug therapy)
  folic acid (clinical trial, drug combination, drug therapy, pharmacology)
  hydrochlorothiazide (drug combination, drug comparison, drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy, 
pharmacology)
  indapamide (clinical trial, drug combination, drug comparison, drug therapy)
  low density lipoprotein cholesterol (endogenous compound)
  perindopril (clinical trial, drug combination, drug comparison, drug 
therapy)
  placebo
  pravastatin (drug comparison, drug therapy)
  proton pump inhibitor (drug combination, drug therapy)
  pyridoxine (clinical trial, drug combination, drug therapy, pharmacology)
  rimonabant (drug therapy)
  sex hormone
  simvastatin (clinical trial, drug therapy)
  telmisartan (drug therapy)
  unindexed drug
  varenicline (adverse drug reaction, clinical trial, drug comparison, drug 
therapy)
  warfarin (adverse drug reaction, drug comparison, drug therapy, oral drug 
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia (drug therapy, complication, drug therapy, etiology, 
prevention)
  cerebrovascular accident (drug therapy, complication, drug therapy, 
etiology, prevention)
  primary prevention
  secondary prevention
EMTREE MEDICAL INDEX TERMS
  acute coronary syndrome
  amino acid blood level
  anticoagulant therapy
  antihypertensive therapy
  artery disease (drug therapy)
  atrial fibrillation (drug therapy)
  bleeding (side effect)
  brain hemorrhage (side effect)
  carotid angioplasty
  carotid artery stenting
  carotid endarterectomy
  clinical trial
  combination chemotherapy
  diabetes mellitus
  diet
  drug contraindication
  drug dose comparison
  drug dose reduction
  drug induced headache (side effect)
  drug withdrawal
  duodenum ulcer (drug therapy)
  dyspepsia (side effect)
  embolism (drug therapy)
  gastrointestinal hemorrhage (side effect)
  gastrointestinal symptom (side effect)
  heart infarction (drug therapy)
  homocysteine blood level
  hormone substitution
  human
  hypercholesterolemia (drug therapy)
  hyperhomocysteinemia (drug therapy)
  hypertension (drug therapy)
  insomnia (side effect)
  internal carotid artery occlusion (surgery)
  international normalized ratio
  lifestyle
  migraine
  mitral valve replacement
  monotherapy
  mortality
  nausea (side effect)
  obesity (drug therapy)
  patent foramen ovale
  physical activity
  postmenopause
  prophylaxis
  recommended drug dose
  review
  risk factor
  risk reduction
  smoking cessation
  stomach ulcer (drug therapy)
  transient ischemic attack (complication, drug therapy, prevention)
  withdrawal syndrome (drug therapy)
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amfebutamone (31677-93-7, 34911-55-2)
  atenolol (29122-68-7)
  atorvastatin (134523-00-5, 134523-03-8)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
  dipyridamole (58-32-2)
  folic acid (59-30-3, 6484-89-5)
  hydrochlorothiazide (58-93-5)
  indapamide (26807-65-8)
  perindopril (82834-16-0, 99149-83-4)
  pravastatin (81131-74-0)
  pyridoxine (12001-77-3, 58-56-0, 65-23-6, 8059-24-3)
  rimonabant (158681-13-1, 168273-06-1)
  simvastatin (79902-63-9)
  telmisartan (144701-48-4)
  varenicline (249296-44-4, 375815-87-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2010322386
FULL TEXT LINK
  http://dx.doi.org/10.1055/s-0029-1223537
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 369
TITLE
  Blinding assessment in clinical trials: A review of statistical methods and 
a proposal of blinding assessment protocol
AUTHOR NAMES
  Bang H.
  Flaherty S.P.
  Kolahi J.
  Park J.
AUTHOR ADDRESSES
  (Bang H., heb2013@med.cornell.edu) Division of Biostatics and Epidemiology, 
Department of Public Health, Weill Medical College of Cornell University, 
New York, NY, United States.
(Flaherty S.P.; Park J.) Asian Medicine and Acupuncture Research, Department 
of Physical Medicine and Rehabilitation, University of North Carolina at 
Chapel Hill, Chapel Hill, NC, United States.
(Kolahi J.) Torabinejad Research Center, Isfahan University of Medical 
Sciences, Isfahan, Iran.
CORRESPONDENCE ADDRESS
  H. Bang, 402 East 67th Street, New York, NY 10065, United States. Email: 
heb2013@med.cornell.edu
SOURCE
  Clinical Research and Regulatory Affairs (2010) 27:2 (42-51). Date of 
Publication: June 2010
ISSN
  1060-1333
  1532-2521 (electronic)
BOOK PUBLISHER
  Informa Healthcare, 69-77 Paul Street, London, United Kingdom.
ABSTRACT
  There is strong consensus in the clinical trial community that blinding is 
an important issue in randomized controlled trials. At present grossly 
incomplete reporting of procedures and the use of any assessment for 
blinding still prevails. The term 'double-blind' has almost become a 
convention without any checks or balances. Also there is a lack of consensus 
on quantitative procedures for evaluating the success of blinding in the 
literature. This article reviews statistical methods of blinding assessment 
along with software options, and discusses some of the most pressing issues 
surrounding the acquisition, interpretation, and reporting of blinding data. 
Finally, it proposes a sample blinding assessment protocol to address some 
of these issues. © 2010 Informa UK Ltd.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (clinical trial, drug comparison)
  warfarin (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  clinical research
  statistical analysis
EMTREE MEDICAL INDEX TERMS
  acupuncture
  atrial fibrillation
  cerebrovascular accident (drug therapy, prevention, rehabilitation)
  chi square test
  clinical trial
  human
  kappa statistics
  McNemar test
  methodology
  quantitative analysis
  questionnaire
  randomization
  review
  sham procedure
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010289387
FULL TEXT LINK
  http://dx.doi.org/10.3109/10601331003777444
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 370
TITLE
  Approved treatments for osteoporosis and what's in the pipeline
AUTHOR NAMES
  Davis S.
  Sachdeva A.
  Goeckeritz B.
  Oliver A.
AUTHOR ADDRESSES
  (Davis S.; Sachdeva A.; Goeckeritz B.; Oliver A.) Section of Rheumatology, 
Department of Medicine, Medical College of Georgia, Augusta, GA, United 
States.
CORRESPONDENCE ADDRESS
  S. Davis, Section of Rheumatology, Department of Medicine, Medical College 
of Georgia, Augusta, GA, United States.
SOURCE
  Drug Benefit Trends (2010) 22:4 (121-124). Date of Publication: May 2010
ISSN
  1080-5826
BOOK PUBLISHER
  CMP Healthcare Media LLC, 330 Boston Post Road, Darien, United States.
ABSTRACT
  Along with the release of revised guidelines, several pharmacological 
therapies have become available or are under investigation to help improve 
outcomes in patients with osteoporosis. Lifestyle modifications have been 
shown to be useful in osteoporosis management, and the use of medications 
associated with the risk of osteoporosis should be minimized. Adherence to 
therapy remains a challenge. Continued research and the development of 
additional diagnostic and therapeutic modalities are needed.
EMTREE DRUG INDEX TERMS
  alendronic acid (clinical trial, drug therapy, oral drug administration)
  anabolic agent (drug therapy)
  arzoxifene (drug development, drug therapy)
  bazedoxifene (drug development, drug therapy)
  bisphosphonic acid derivative (adverse drug reaction, drug therapy, oral 
drug administration)
  calcitonin (drug therapy, intranasal drug administration)
  calcium (drug therapy)
  collagen (endogenous compound)
  creatinine (endogenous compound)
  denosumab (drug development, drug therapy, subcutaneous drug administration)
  estrogen (drug therapy, oral drug administration, transdermal drug 
administration)
  ibandronic acid (drug therapy, intravenous drug administration, oral drug 
administration)
  lasofoxifene (drug development, drug therapy)
  odanacatib (drug development, drug therapy)
  osteocalcin (clinical trial)
  parathyroid hormone derivative (drug development, inhalational drug 
administration)
  parathyroid hormone[1-34] (adverse drug reaction, drug therapy, subcutaneous 
drug administration)
  raloxifene (drug therapy, oral drug administration)
  risedronic acid (drug therapy, oral drug administration)
  strontium (drug development, drug therapy)
  tibolone (drug therapy)
  unclassified drug
  vitamin D (drug therapy)
  zoledronic acid (adverse drug reaction, clinical trial, drug therapy, 
intravenous drug administration)
  zt 031 (drug development, drug therapy, inhalational drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  corticosteroid induced osteoporosis (drug therapy, drug therapy)
  osteoporosis (drug therapy, drug therapy)
  postmenopause osteoporosis (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  arthralgia (side effect)
  article
  atrial fibrillation (side effect)
  bone density
  clinical trial
  creatinine clearance
  diet
  dual energy X ray absorptiometry
  estrogen therapy
  exercise
  fragility fracture
  human
  hypercalcemia (side effect)
  hypercalciuria (side effect)
  hypogonadal osteoporosis (drug therapy)
  hypogonadal osteoporosis (drug therapy)
  jaw osteonecrosis (side effect)
  lifestyle modification
  morbidity
  mortality
  myalgia (side effect)
  osteosarcoma (side effect)
  patient compliance
  recommended drug dose
  risk
  smoking cessation
  spine radiography
DRUG TRADE NAMES
  zt 031
CAS REGISTRY NUMBERS
  alendronic acid (66376-36-1)
  arzoxifene (182133-25-1, 182133-27-3)
  bazedoxifene (198481-32-2, 198481-33-3)
  calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
  calcium (14092-94-5, 7440-70-2)
  collagen (9007-34-5)
  creatinine (19230-81-0, 60-27-5)
  denosumab (615258-40-7)
  ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
  lasofoxifene (180915-85-9, 180916-16-9, 190791-29-8)
  odanacatib (603139-19-1)
  osteocalcin (136461-80-8)
  parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
  raloxifene (82640-04-8, 84449-90-1)
  risedronic acid (105462-24-6, 122458-82-6)
  strontium (7440-24-6)
  tibolone (5630-53-5)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Obstetrics and Gynecology (10)
  Orthopedic Surgery (33)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010337571
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 371
TITLE
  2010 CAEP/ACMU Scientific Abstracts
AUTHOR ADDRESSES
  SOURCE
  Canadian Journal of Emergency Medicine (2010) 12:3. Date of Publication: May 
2010
CONFERENCE NAME
  2010 CAEP/ACMU
CONFERENCE LOCATION
  Montreal, QC, Canada
CONFERENCE DATE
  2010-05-29 to 2010-06-02
ISSN
  1481-8035
BOOK PUBLISHER
  BC Decker Inc.
ABSTRACT
  The proceedings contain 166 papers. The topics discussed include: the impact 
of a triage nurse ordering on ED overcrowding: a systematic review; 
prospective evaluation of the ABCD and ABCD2 scores in a Canadian ED 
setting; additive value of codeine for pain management of children 
presenting to the emergency department with a musculoskeletal trauma; the 
impact of ED admission delays on inpatient outcomes; emergency physician 
survey of American and Canadian emergency department management of 
recent-onset atrial fibrillation; visibility of the urethral opening does 
not correlate with risk of urinary tract infection in uncircumcised boys; 
the development and validation of a simulation-based OSCE with basic 
resuscitation scenarios in emergency medicine; road testing a new ED before 
going live: how to use exercises to design and test a new patient flow 
model; and short-term functional impacts of minor injuries in community 
elders seen in an emergency department.
EMTREE DRUG INDEX TERMS
  codeine
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  boy
  child
  community
  crowding (area)
  emergency health service
  emergency medicine
  emergency physician
  emergency ward
  exercise
  hospital patient
  human
  injury
  male
  model
  musculoskeletal injury
  nurse
  pain
  patient
  resuscitation
  risk
  simulation
  systematic review
  systematic review (topic)
  urinary tract infection
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 372
TITLE
  Toxicology of Dysosma versipallis rhizome: A review
AUTHOR NAMES
  Liang M.
  Liu Y.
  Ananda S.
  Zhuo L.
  Liu L.
AUTHOR ADDRESSES
  (Liang M.; Liu Y.; Ananda S.; Zhuo L.) Department of Forensic Medicine, 
Tongji Medical College, Huazhong University of Science and Technology, 
430030, Wuhan, China.
(Liu L., casper603@gmail.com) Key Laboratory of Evidence Science (China 
University of Political Science and Law), Ministry of Education, 100040, 
Beijing, China.
CORRESPONDENCE ADDRESS
  L. Liu, Key Laboratory of Evidence Science (China University of Political 
Science and Law), Ministry of Education, 100040, Beijing, China. Email: 
casper603@gmail.com
SOURCE
  Journal of Medicinal Plants Research (2010) 4:9 (717-721). Date of 
Publication: May 2010
ISSN
  1996-0875
  1996-0875 (electronic)
BOOK PUBLISHER
  Academic Journals, PO Box 5170-00200 Nairobi, Victoria Island, Lagos, 
Nigeria.
ABSTRACT
  According to the World Health Organization and the National Institutes of 
Health, Traditional Chinese medicine originated more than 3000 years ago. 
While there are quite obvious medical values suggesting that Dysosma 
versipallis rhizome is both desirable and achievable, there are still 
obstacles. Since the therapeutic dose and toxic dose are very close, D. 
versipallis rhizome poisoning cases were frequently reported. In this paper, 
the plant source, chemical constituent, toxicity reason, toxic dose, 
mechanism of toxicity, poisoning symptoms, pathological changes of body 
tissues after ingestion of D. versipallis rhizome poisoning and medical 
management are reviewed. © 2010 Academic Journals.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  Dysosma versipallis extract (drug analysis, drug dose, drug toxicity, 
intraperitoneal drug administration, oral drug administration)
  plant extract (drug analysis, drug dose, drug toxicity, intraperitoneal drug 
administration, oral drug administration)
EMTREE DRUG INDEX TERMS
  activated carbon (drug therapy)
  adenosine triphosphate (drug therapy)
  ascorbic acid (drug therapy)
  coenzyme A (drug therapy)
  immunoglobulin (drug therapy, intravenous drug administration)
  podophyllotoxin (drug analysis, drug therapy, drug toxicity, intragastric 
drug administration, intraperitoneal drug administration, subcutaneous drug 
administration)
  unclassified drug
EMTREE MEDICAL INDEX TERMS
  acupuncture
  atrial fibrillation (drug therapy, therapy)
  blood clotting disorder (drug therapy, therapy)
  cardiotoxicity
  central nervous system disease
  chemical composition
  Chinese medicine
  clinical feature
  condyloma acuminatum (drug therapy)
  dermatitis
  drug efficacy
  drug overdose
  drug structure
  Dysosma versipallis
  fluid resuscitation
  gastrointestinal toxicity
  hemodialysis
  herbal medicine
  high performance liquid chromatography
  histopathology
  human
  intoxication (drug therapy, therapy)
  LD50
  medicinal plant
  myocarditis
  nonhuman
  review
  rhizome
  stomach lavage
  thin layer chromatography
  thrombocyte transfusion
  toxicity testing
CAS REGISTRY NUMBERS
  activated carbon (64365-11-3, 82228-96-4)
  adenosine triphosphate (15237-44-2, 56-65-5, 987-65-5)
  ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
  coenzyme A (85-61-0)
  immunoglobulin (9007-83-4)
  podophyllotoxin (518-28-5)
EMBASE CLASSIFICATIONS
  Drug Literature Index (37)
  Toxicology (52)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010330621
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 373
TITLE
  Impact of aerobic physical activity on cardiovascular and noncardiovascular 
outcomes: Is anyone too old to exercise?
AUTHOR NAMES
  Sawyer K.
  Castaneda-Sceppa C.
AUTHOR ADDRESSES
  (Sawyer K., sawyer.k@husky.neu.edu; Castaneda-Sceppa C., c.sceppa@neu.edu) 
Bouve College of Health Sciences, Northeastern University, 360 Huntington 
Avenue, Boston, MA 02115, United States.
CORRESPONDENCE ADDRESS
  C. Castaneda-Sceppa, Bouve College of Health Sciences, Northeastern 
University, 360 Huntington Avenue, Boston, MA 02115, United States. Email: 
c.sceppa@neu.edu
SOURCE
  Aging Health (2010) 6:2 (251-260). Date of Publication: April 2010
ISSN
  1745-509X
  1745-5103 (electronic)
BOOK PUBLISHER
  Future Medicine Ltd., 2nd Albert Place, Finchley Central, London, United 
Kingdom.
ABSTRACT
  The aim of this review is to discuss the impact of physical activity on 
cardiovascular and noncardiovascular outcomes in the older adult population. 
While age, gender and family history are nonmodifiable risk factors of 
cardiovascular disease, physical inactivity is a modifiable risk factor at 
all ages. Regular physical activity throughout life is a key component in 
reducing chronic diseases such as cardiovascular disease. This review 
specifically emphasizes walking as the preferred modality of physical 
activity, since it is known to have an effect on the traditional and 
nontraditional risk factors of cardiovascular disease. © 2010 Future 
Medicine Ltd.
EMTREE DRUG INDEX TERMS
  C reactive protein (endogenous compound)
  high density lipoprotein cholesterol (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aerobic exercise
  cardiovascular disease
  physical activity
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  body composition
  cardiovascular risk
  cerebrovascular accident
  chronic inflammation
  dyslipidemia
  energy expenditure
  exercise intensity
  functional status
  glycemic control
  health promotion
  human
  hypertension
  impaired glucose tolerance
  insulin resistance
  ischemic heart disease
  lifestyle modification
  mortality
  obesity
  prognosis
  review
  risk reduction
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010193606
FULL TEXT LINK
  http://dx.doi.org/10.2217/ahe.10.10
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 374
TITLE
  Heart and athlete
AUTHOR NAMES
  Alasti M.
  Omidvar B.
  Jadbabaei M.H.
AUTHOR ADDRESSES
  (Alasti M., alastip@gmail.com) Department of Cardiology, Jondishpour 
University of Medical Sciences, Imam Khomeini Hospital, Azadegan Avenue, 
Ahwaz, Iran.
(Omidvar B.; Jadbabaei M.H.) Golestan Hospital, Jondishapour University of 
Medical Sciences, Ahwaz, Iran.
CORRESPONDENCE ADDRESS
  M. Alasti, Department of Cardiology, Jondishpour University of Medical 
Sciences, Imam Khomeini Hospital, Azadegan Avenue, Ahwaz, Iran. Email: 
alastip@gmail.com
SOURCE
  Journal of Tehran University Heart Center (2010) 5:1 (1-8). Date of 
Publication: 2010
ISSN
  1735-8620
BOOK PUBLISHER
  Tehran University of Medical Sciences, North Kargar Street, Tehran, Iran.
ABSTRACT
  Regular participation in intensive physical exercise is associated with 
electro-morphological changes in the heart. This benign process is called 
athlete's heart. Athlete's heart resembles few pathologic conditions in some 
aspects. So differentiation of these conditions is very important which 
otherwise may lead to a catastrophic event such as sudden death. The most 
common causes of sudden death in young athletes are cardiomyopathies, 
congenital coronary anomalies, and ion channelopathies. The appropriate 
screening strategy to prevent sudden cardiac death in athletes remains a 
challenging issue. The purpose of this review is to describe the 
characteristics of athlete's heart and demonstrate how to differentiate it 
from pathologic conditions that can cause sudden death.
EMTREE DRUG INDEX TERMS
  amino terminal pro brain natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athletic heart syndrome
  heart disease
EMTREE MEDICAL INDEX TERMS
  anamnesis
  angiocardiography
  athlete
  atrial fibrillation
  cardiac patient
  cardiovascular disease (epidemiology)
  cardiovascular risk
  cause of death
  commotio cordis
  computed tomographic angiography
  congestive cardiomyopathy (diagnosis)
  coronary artery anomaly (diagnosis)
  diagnostic value
  differential diagnosis
  Doppler echocardiography
  ECG abnormality
  electrocardiogram
  exercise
  faintness
  first degree atrioventricular block
  functional assessment
  heart arrhythmia
  heart death (epidemiology)
  heart function
  heart left ventricle hypertrophy (diagnosis)
  heart muscle oxygen consumption
  heart right bundle branch block
  heart right ventricle dysplasia (diagnosis)
  heart size
  heart stress
  heart ventricle tachycardia
  high risk population
  human
  hypertrophic cardiomyopathy (diagnosis)
  incidence
  nuclear magnetic resonance imaging
  patient participation
  physical examination
  presyncope
  prevalence
  Q wave
  QRS complex
  review
  screening test
  second degree atrioventricular block
  sinus bradycardia (diagnosis)
  sport
  ST segment elevation
  sudden death
  T wave inversion
  training
  Wolff Parkinson White syndrome
EMBASE CLASSIFICATIONS
  Radiology (14)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010096249
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 375
TITLE
  Atrial fibrillation in athletes - The story behind the running hearts
AUTHOR NAMES
  Li S.
  Zhang Z.
  Scherlag B.J.
  Po S.S.
AUTHOR ADDRESSES
  (Li S.) Department of Cardiology, Yun-Nan St. John Cardiology Hospital, 
Yun-Nan, China.
(Zhang Z.) Department of Cardiology, Third Xiangya Hospital, Central South 
University, HuNan, China.
(Scherlag B.J.; Po S.S., sunny-po@ouhsc.edu) Heart Rhythm Research 
Institute, Department of Medicine, University of Oklahoma Health Sciences 
Center, Oklahoma City, OK, United States.
CORRESPONDENCE ADDRESS
  S. S. Po, Heart Rhythm Research Institute, Department of Medicine, 
University of Oklahoma Health Sciences Center, Oklahoma City, OK, United 
States. Email: sunny-po@ouhsc.edu
SOURCE
  Journal of Atrial Fibrillation (2010) 1:11 (626-631). Date of Publication: 
March 2010
ISSN
  1941-6911 (electronic)
BOOK PUBLISHER
  CardioFront LLC, 135th St, Ste 264, Overland Park, United States.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  atrial fibrillation (drug therapy, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
  autonomic nervous system
  clinical feature
  endurance
  exercise
  heart atrium enlargement
  heart left ventricle ejection fraction
  heart muscle refractory period
  human
  incidence
  inflammation
  nonhuman
  review
  sinus rhythm
  training
  vagus tone
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2010278189
FULL TEXT LINK
  http://dx.doi.org/10.4022/jafib.v1i11.563
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 376
TITLE
  Obesity and preclinical changes of cardiac geometry and function
AUTHOR NAMES
  Sung J.K.
  Kim J.-Y.
AUTHOR ADDRESSES
  (Sung J.K.; Kim J.-Y., kimjy@yonsei.ac.kr) Department of Internal Medicine, 
Wonju Christian Hospital, Yonsei University, 162 Ilsan-dong, Wonju 220-701, 
South Korea.
(Kim J.-Y., kimjy@yonsei.ac.kr) Institute of Genomic Cohort, Yonsei 
University, Wonju College of Medicine, Wonju, South Korea.
CORRESPONDENCE ADDRESS
  J.-Y. Kim, Department of Internal Medicine, Wonju Christian Hospital, Yonsei 
University, 162 Ilsan-dong, Wonju 220-701, South Korea. Email: 
kimjy@yonsei.ac.kr
SOURCE
  Korean Circulation Journal (2010) 40:2 (55-61). Date of Publication: 
February 2010
ISSN
  1738-5520
  1738-5555 (electronic)
BOOK PUBLISHER
  Korean Society of Circulation, 553 Dowha-dong, Mapo-gu, Seoul, South Korea.
ABSTRACT
  Overweight and obesity are rapidly increasing in prevalence due to adoption 
of the westernized life style in Korea. Obesity is strongly associated with 
the development of cardiovascular risk factors such as diabetes, 
hypertension, and dyslipidemia. In addition, accumulating evidence suggests 
that obesity per se has a direct effect on cardiac functional and structural 
changes that may not be the result of atherosclerosis. In this review, we 
focus on the view that obesity can influence on the structural and 
functional changes of the heart, drawing evidence from human and animal 
studies. We also review influencing factors such as physical, neurohormonal, 
and metabolic alterations that are associated with changes of the heart in 
obesity. Copyright © 2010 The Korean Society of Cardiology.
EMTREE DRUG INDEX TERMS
  adenosine triphosphate (endogenous compound)
  adipocytokine (endogenous compound)
  adiponectin (endogenous compound)
  angiotensinogen (endogenous compound)
  C reactive protein (endogenous compound)
  catecholamine (endogenous compound)
  CD36 antigen (endogenous compound)
  fatty acid (endogenous compound)
  fatty acid transporter (endogenous compound)
  fatty acid transporter protein 1 (endogenous compound)
  gelatinase A (endogenous compound)
  interleukin 1beta (endogenous compound)
  interleukin 6 (endogenous compound)
  leptin (endogenous compound)
  monocyte chemotactic protein 1 (endogenous compound)
  neurohormone (endogenous compound)
  peroxisome proliferator activated receptor gamma (endogenous compound)
  reactive oxygen metabolite (endogenous compound)
  rimonabant
  sibutramine
  somatomedin C (endogenous compound)
  somatomedin C receptor (endogenous compound)
  tetrahydrolipstatin
  tissue inhibitor of metalloproteinase (endogenous compound)
  tumor necrosis factor alpha (endogenous compound)
  unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart function
  heart size
  obesity
EMTREE MEDICAL INDEX TERMS
  adipocyte
  adipose tissue
  apoptosis
  atrial fibrillation
  blood volume
  body mass
  collagen synthesis
  diet
  disorders of mitochondrial functions
  echocardiography
  epicardial adipose tissue
  extracellular matrix
  fatty acid oxidation
  fibrosis
  glucose metabolism
  heart atrium enlargement
  heart left atrium
  heart left ventricle contraction
  heart left ventricle filling
  heart left ventricle hypertrophy
  heart left ventricle mass
  heart muscle cell
  heart muscle metabolism
  heart muscle oxygen consumption
  heart output
  heart ventricle overload
  heart ventricle remodeling
  hemodynamics
  human
  hyperinsulinemia
  hyperlipidemia
  hypertension
  hypoxemia
  insulin resistance
  oxidative stress
  oxygen consumption
  protein blood level
  protein expression
  renin angiotensin aldosterone system
  review
  sleep disordered breathing
  thorax pressure
  weight reduction
CAS REGISTRY NUMBERS
  C reactive protein (9007-41-4)
  adenosine triphosphate (15237-44-2, 56-65-5, 987-65-5)
  adiponectin (283182-39-8)
  angiotensinogen (11002-13-4, 64315-16-8)
  gelatinase A (146480-35-5)
  rimonabant (158681-13-1, 168273-06-1)
  sibutramine (106650-56-0)
  somatomedin C (67763-96-6)
  tetrahydrolipstatin (96829-58-2)
  tissue inhibitor of metalloproteinase (97837-28-0)
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Immunology, Serology and Transplantation (26)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010169944
FULL TEXT LINK
  http://dx.doi.org/10.4070/kcj.2010.40.2.55
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 377
TITLE
  Abstracts - Belgian Society of Cardiology 29th Annual Scientific Meeting
AUTHOR ADDRESSES
  SOURCE
  Acta Cardiologica (2010) 65:1. Date of Publication: February 2010
CONFERENCE NAME
  29th Annual Scientific Meeting of the Belgian Society of Cardiology
CONFERENCE LOCATION
  Brussels, Belgium
CONFERENCE DATE
  2010-01-28 to 2010-01-30
ISSN
  0001-5385
BOOK PUBLISHER
  Acta Cardiologica
ABSTRACT
  The proceedings contain 66 papers. The topics discussed include: clinical 
characteristics and 1-year outcome of patients aged 75 years or older 
hospitalised for heart failure; pulmonary vein isolation with the high 
density mesh ablation catheter: acute results and long-term clinical 
outcome; triggering pulmonary veins: a paradoxical predictor for atrial 
fibrillation recurrence after PV isolation; BNP as a predictive factor of 
recurrence of atrial fibrillation after external electrical cardioversion; 
microvolt T-wave alternans in risk stratification of patients with ischemic 
and nonischemic dilated cardiomyopathy: can it help to better select 
candidates for lCD implantation? first experience of a single Belgian 
centre; prospective randomized comparison between conventional 
electroanatomical system and 3D rotational angiography during catheter 
ablation for atrial fibrillation; Effects of pharmacologic 2-adrenergic 
blockade and 2-adrenergic stimulation on exercise capacity in normal 
subjects.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiology
  society
EMTREE MEDICAL INDEX TERMS
  adrenergic receptor blocking
  adrenergic stimulation
  angiography
  atrial fibrillation
  cardioversion
  catheter
  catheter ablation
  congestive cardiomyopathy
  density
  exercise
  heart failure
  implantation
  patient
  pulmonary vein
  risk
  stratification
  T wave
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 378
TITLE
  Heart Failure in NCVC Jakarta and 5 hospitals in Indonesia
AUTHOR NAMES
  Siswanto B.B.
  Radi B.
  Kalim H.
  Santoso A.
  Suryawan R.
  Erwinanto
  Antono E.
  Santoso T.
AUTHOR ADDRESSES
  (Siswanto B.B., bambbs@cbn.net.id; Radi B.; Kalim H.) Department of 
Cardiology and Vascular Medicine, University of Indonesia, Indonesia.
(Santoso A.) Indonesia and Department of Cardiology and Vascular Medicine, 
University Udayana, Sanglah Hospital Denpasar Bali, Indonesia.
(Suryawan R.) Department of Cardiology and Vascular Medicine, University 
Airlangga Dr Sutomo Hospital, Surabaya, Indonesia.
(Erwinanto; Antono E.) Department of Cardiology, Vascular Medicine 
University Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia.
(Santoso T.) Medistra Hospital Jakarta, Indonesia.
CORRESPONDENCE ADDRESS
  B. B. Siswanto, Department of Cardiology and Vascular Medicine, University 
of Indonesia, Indonesia. Email: bambbs@cbn.net.id
SOURCE
  CVD Prevention and Control (2010) 5:1 (35-38). Date of Publication: January 
2010
ISSN
  1875-4570
BOOK PUBLISHER
  Elsevier, P.O. Box 211, Amsterdam, Netherlands.
ABSTRACT
  Indonesia is an archipelago consisting of 17,000 islands (6000 inhabited) to 
spanning by the equator in South East Asia. The total area is 741,096 sq mil 
(1,919,440 km sq). The population in 2005 was 241,973,879, with a population 
growth rate of 1.5%, a birth rate of 20.7/1000 population and a life 
expectancy of 69.6 years. There are 1246 hospitals in Indonesia, of which 
49.8% are in private hospitals and 50.5% are located in Java. There is a 
total of 132,231 beds or one hospital bed per 1628 population. In 2005 we 
did a pilot cohort study of 100 consecutive new cases of Acute Decompensated 
Heart Failure (ADHF) at NCVC Jakarta to search for predictors of mortality 
and re-hospitalization. We found the independent predictors for mortality 
and re-hospitalization are high NT proBNP at entry, NT proBNP at discharge, 
not decreased >35% during hospitalization, NYHA functional class 4, edema 
with a BMI >30 kg/m (2), ejection fraction <20%, acute pulmonary edema, not 
on a beta-blocker, hemoglobin <12 g/dl and Hyponatremia <130 mmol/L. More 
than 78% using ACEI/ARB, diuretic and aldosterone antagonist, but only 32% 
using beta-blocker. In 2006, we conducted an Acute Decompensated Heart 
Failure Registry (ADHERE) with the participation of five hospitals including 
National Cardiovascular Center (NCVC) Jakarta, the top cardiovascular 
referral hospital. In total, there were 1687 patients admitted with ADHF. 
The mean age was 60 years and male patients were 64.5%. Compared to other 
countries, our heart failure patients were younger, had more severe symptoms 
and there were more new patients (de novo acute ADHF). Hypertension (54.8%), 
coronary artery disease (49.9%), diabetes (31.2%), myocardial infarction 
(23.3%) and atrial fibrillation (14.6%) are the leading etiologies of our 
ADHF patients. There were 62.7% patients with ejection fraction (EF) <40% 
and the mean EF was 33%. The median hospital length of stay was 7.1 days and 
the hospital mortality was 6.7% [15]. In NCVC Jakarta, compliance with 
medical evaluation and drugs and diets are the predictors of 
hospitalizations. There were 47%, non compliant patients and the survival 
probability at 5 years was only 54%. The 5 year predictors of mortality are 
poor EF, Diabetes and male gender. The 5 year survival of males with poor EF 
and Diabetes was only 36%. Among socio-economic factors, only 33.5% had 
health insurance and 54.5% lived >20 km from hospital [16]. There are 
increasing numbers of hospitalized heart failure patients in NCVC Jakarta. 
In 2007 there were 1409 patients and an increase in 2008 to 1476 hospital 
admissions. Also there has been an increase in in-hospital morality to 
around 12 %. Conclusion: Heart failure is a leading cause of hospitalization 
and readmission in NCVC. Indonesian heart failure patients were younger, 
sicker, with a poor EF and Diabetes compared to others. The in-hospital 
mortality ranges from 6% to 12% and the re-hospitalization rate is 29%. Poor 
compliance, poor EF and Diabetes are the predictor for readmission. Health 
insurance improves survival probability. There is a need for better heart 
failure services. © 2010 World Heart Federation. Published by Elsevier Ltd. 
All rights reserved.
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  diuretic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (drug therapy, disease management, drug therapy, epidemiology, 
etiology)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  Asia
  atrial fibrillation
  birth rate
  cohort analysis
  controlled study
  coronary artery disease
  diabetes mellitus
  disease registry
  female
  health insurance
  heart ejection fraction
  heart infarction
  hospital admission
  hospital bed
  hospital charge
  hospital readmission
  hospitalization
  human
  hypertension
  hyponatremia
  Indonesia
  length of stay
  life expectancy
  lung edema
  major clinical study
  male
  medical assessment
  morality
  mortality
  patient compliance
  patient referral
  population growth
  priority journal
  private hospital
  probability
  survival rate
  symptom
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Internal Medicine (6)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010503382
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.cvdpc.2010.03.005
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 379
TITLE
  Thrombi of different pathologies: Implications for diagnosis and treatment
AUTHOR NAMES
  Santos-Gallego C.G.
  Bayón J.
  Badimón J.J.
AUTHOR ADDRESSES
  (Santos-Gallego C.G.; Badimón J.J., juan.badimon@mssm.edu) Atherothrombosis 
Research Unit, Zena and Michael A. Wiener Cardiovascular Institute, Mount 
Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029, United 
States.
(Bayón J.) Cardiology Department, Hospital Central de Asturias, Oviedo, 
Spain.
CORRESPONDENCE ADDRESS
  J. J. Badimón, Atherothrombosis Research Unit, Zena and Michael A. Wiener 
Cardiovascular Institute, Mount Sinai School of Medicine, 1 Gustave Levy 
Place, New York, NY 10029, United States. Email: juan.badimon@mssm.edu
SOURCE
  Current Treatment Options in Cardiovascular Medicine (2010) 12:3 (274-291). 
Date of Publication: June 2010
ISSN
  1092-8464
BOOK PUBLISHER
  Springer Healthcare
ABSTRACT
  Stroke is the second leading cause of cardiovascular mortality in the modern 
world, accounting for 80% of strokes of ischemic origin. There are two main 
etiologies of ischemic stroke: 70% to 80% are caused by carotid 
atherosclerotic plaque rupture and superimposed thrombus formation, whereas 
30% are caused by systemic embolism of a cardiac thrombus (mainly in atrial 
fibrillation [AF] patients). Therefore, antithrombotic therapy is the 
cornerstone of stroke treatment. In AF patients, thrombotic risk should be 
assessed by means of the CHADS2 score. Patients with a score of 0 should be 
treated with aspirin; for those with a score of 1, oral anticoagulation 
(target international normalized ratio, 2-3) or aspirin is recommended. For 
patients with a CHADS2 score ≥2, oral anticoagulation with warfarin should 
be initiated (unless contraindicated). If warfarin is contraindicated, 
antithrombotic treatment should be prescribed (the combination of aspirin 
and clopidogrel seems to be superior to aspirin alone). For primary 
prevention in atherosclerotic patients, low-dose aspirin is useful only in 
women older than 45 years who are not at risk for intracranial hemorrhage 
and do not have gastrointestinal intolerance (a very small but significant 
effect). For secondary prevention in atherosclerotic patients, 
antithrombotic therapy should be administered. It is recommended that 
patients who do not require anticoagulation receive clopidogrel or a 
combination of aspirin and dipyridamole. Alternatively, aspirin alone or 
triflusal may be used. Within 4.5 h of onset of acute stroke, thrombolytic 
therapy (recombinant tissue plasminogen activator) must be injected urgently 
(unless contraindicated). Dabigatran is a new oral anticoagulant 
(competitive thrombin inhibitor) with a promising role in stroke prevention; 
at low doses, it is noninferior to warfarin for stroke prevention and is 
safer, whereas at high doses, it is superior to warfarin in stroke 
prevention with the same incidence of bleeding. Percutaneous left atrial 
appendage occluders recently were approved for systemic embolism prevention. 
The use of warfarin after implantation is still under discussion. 
Dronedarone, a new antiarrhythmic agent, has been shown to decrease 
cardiovascular mortality and stroke in patients with AF. Carotid 
endarterectomy surgery is indicated in symptomatic patients with stenosis 
greater than 70% and in selected patients with 50% to 70% stenosis. 
Currently, carotid endarterectomy surgery is superior to carotid angioplasty 
and stenting. © Springer Science+Business Media, LLC 2010.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (clinical trial, drug therapy, pharmacoeconomics, 
pharmacology)
  antithrombocytic agent (clinical trial, drug therapy, pharmacoeconomics, 
pharmacology)
  fibrinolytic agent (clinical trial, drug therapy, pharmacoeconomics, 
pharmacology)
EMTREE DRUG INDEX TERMS
  acetazolamide (drug interaction)
  acetylsalicylic acid (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug interaction, drug therapy, 
pharmacoeconomics, pharmacology)
  alteplase (adverse drug reaction, clinical trial, drug therapy, intravenous 
drug administration, pharmacology)
  antidiabetic agent (drug interaction)
  apixaban (drug comparison, drug therapy)
  beta adrenergic receptor blocking agent (drug interaction)
  cilostazol (drug comparison, drug therapy)
  clopidogrel (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug interaction, drug therapy, pharmacoeconomics, pharmacology)
  dabigatran (clinical trial, drug comparison, drug therapy, pharmacology)
  dabigatran etexilate (adverse drug reaction, drug comparison, drug dose, 
drug therapy, oral drug administration)
  dipyridamole (adverse drug reaction, clinical trial, drug combination, drug 
interaction, drug therapy, pharmacoeconomics, pharmacology)
  dronedarone (adverse drug reaction, clinical trial, drug therapy, 
pharmacology)
  fluoxetine (drug interaction)
  irbesartan (drug combination, drug therapy)
  ketoconazole (drug interaction)
  methotrexate (drug interaction)
  nonsteroid antiinflammatory agent (drug interaction)
  omeprazole (drug interaction)
  placebo
  prasugrel (clinical trial, drug comparison, drug therapy)
  psychostimulant agent (drug interaction)
  rivaroxaban (drug comparison, drug therapy)
  terutroban (drug comparison, drug therapy)
  tissue plasminogen activator (adverse drug reaction, drug therapy)
  unindexed drug
  valproic acid (drug interaction)
  warfarin (adverse drug reaction, clinical trial, drug comparison, drug 
interaction, drug therapy, oral drug administration, pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain ischemia (drug therapy, side effect, disease management, drug therapy, 
etiology, prevention, side effect, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  angioneurotic edema (side effect)
  anticoagulant therapy
  asthma
  atherosclerosis (drug therapy)
  atrial fibrillation (drug therapy)
  bleeding (side effect)
  bleeding disorder
  blood clotting
  body mass
  brain atherosclerosis
  brain edema (side effect)
  brain hemorrhage (side effect)
  brain hernia (side effect)
  bronchospasm (side effect)
  cardiovascular disease
  cardiovascular risk
  carotid angioplasty
  carotid artery stenting
  carotid artery surgery
  carotid atherosclerosis
  carotid endarterectomy
  catheter ablation
  catheter occlusion
  cerebrovascular accident (drug therapy)
  clinical evaluation
  clinical trial
  clip
  cost effectiveness analysis
  creatinine blood level
  diet
  drug activity
  drug contraindication
  drug cost
  drug efficacy
  drug hypersensitivity
  drug induced headache (side effect)
  drug safety
  dyspepsia (side effect)
  embolism (drug therapy)
  epistaxis (side effect)
  exercise
  food intake
  fruit
  gastrointestinal hemorrhage (side effect)
  gastrointestinal symptom (side effect)
  gout
  headache (side effect)
  heart atrium appendage
  heart atrium flutter (drug therapy)
  heart infarction (drug therapy, side effect)
  human
  hypertension
  hypotension
  intermethod comparison
  international normalized ratio
  kidney disease
  kidney dysfunction
  lifestyle modification
  liver disease
  liver dysfunction
  nausea and vomiting (side effect)
  neutropenia (side effect)
  peptic ulcer
  pregnancy
  pruritus (side effect)
  purpura (side effect)
  rash (side effect)
  recanalization
  review
  risk factor
  seizure (side effect)
  side effect (side effect)
  skin necrosis (side effect)
  smoking
  smoking cessation
  thromboembolism (drug therapy)
  thrombosis (drug therapy)
  thrombotic thrombocytopenic purpura (side effect)
  transient ischemic attack (drug therapy)
  treatment contraindication
  treatment outcome
  treatment planning
  unstable angina pectoris
  urticaria (side effect)
  vasculitis (side effect)
  vegetable
  virus infection
  vitamin supplementation
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetazolamide (1424-27-7, 59-66-5)
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alteplase (105857-23-6)
  apixaban (503612-47-3)
  cilostazol (73963-72-1)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  dipyridamole (58-32-2)
  dronedarone (141626-36-0)
  fluoxetine (54910-89-3, 56296-78-7, 59333-67-4)
  irbesartan (138402-11-6)
  ketoconazole (65277-42-1)
  methotrexate (15475-56-6, 59-05-2, 7413-34-5)
  omeprazole (73590-58-6, 95510-70-6)
  prasugrel (389574-19-0, 150322-43-3)
  rivaroxaban (366789-02-8)
  terutroban (165537-73-5, 165538-40-9, 609340-89-8)
  tissue plasminogen activator (105913-11-9)
  valproic acid (1069-66-5, 99-66-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010330925
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11936-010-0075-8
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 380
TITLE
  Omega-3 fatty acids for cardiovascular disease prevention
AUTHOR NAMES
  DeFilippis A.P.
  Blaha M.J.
  Jacobson T.A.
AUTHOR ADDRESSES
  (DeFilippis A.P., APDeF@yahoo.com; Blaha M.J.; Jacobson T.A.) Johns Hopkins 
Ciccarone Center, Prevention of Heart Disease, 600 North Wolfe Street, 
Carnegie 568, Baltimore, MD 21224, United States.
CORRESPONDENCE ADDRESS
  A. P. DeFilippis, Johns Hopkins Ciccarone Center, Prevention of Heart 
Disease, 600 North Wolfe Street, Carnegie 568, Baltimore, MD 21224, United 
States. Email: APDeF@yahoo.com
SOURCE
  Current Treatment Options in Cardiovascular Medicine (2010) 12:4 (365-380). 
Date of Publication: August 2010
ISSN
  1092-8464
BOOK PUBLISHER
  Springer Healthcare
ABSTRACT
  Major dietary sources of omega-3 fatty acids are fish containing 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as well as nuts, 
seeds, and vegetable oils containing α-linolenic acid (ALA). Omega-3 fatty 
acids, especially those derived from marine sources, may be a useful tool 
for the primary and secondary prevention of cardiovascular disease. Omega-3s 
exert their cardioprotective effects through multiple mechanisms, including 
reducing arrhythmias and altering production of prostaglandins, which 
reduces inflammation and improves platelet and endothelial function. To 
date, no serious adverse effects of omega-3s have been identified, despite 
extensive study. In adults, any potential harm from mercury exposure from 
consuming fish rich in omega-3s is outweighed by the proven cardiovascular 
benefits of eating fish. Concerns over increased bleeding complications have 
not materialized despite the increased concomitant use of aspirin and 
clopidogrel. We recommend one serving (200-400 g) of fatty fish two times 
per week and a diet that includes foods rich in ALA for the primary 
prevention of cardiovascular disease. We recommend one serving (200-400 g) 
of fatty fish or a fish oil supplement containing 900 mg of EPA + DHA every 
day and a diet rich in ALA for patients with known cardiovascular disease or 
congestive heart failure. © Springer Science+Business Media, LLC 2010.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  omega 3 fatty acid (adverse drug reaction, clinical trial, drug combination, 
drug therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug combination)
  alpha tocopherol (drug combination, drug therapy)
  atorvastatin (drug combination, drug therapy)
  C reactive protein (endogenous compound)
  clopidogrel (drug combination)
  dioxin
  docosahexaenoic acid (drug combination)
  fish oil (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (clinical trial, drug 
combination, drug therapy)
  icosapentaenoic acid (clinical trial, drug combination, drug therapy)
  interleukin 6 (endogenous compound)
  linolenic acid
  methylmercury
  placebo
  polychlorinated biphenyl
  simvastatin (drug combination, drug therapy)
  stromelysin (endogenous compound)
  thromboxane A2 (endogenous compound)
  tumor necrosis factor alpha (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (drug therapy, drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
  adjuvant therapy
  antiinflammatory activity
  article
  atrial fibrillation (drug therapy, prevention)
  bleeding (side effect)
  clinical trial
  congestive heart failure
  contaminated fish
  defibrillator
  diet supplementation
  dietary reference intake
  fatty acid metabolism
  gastrointestinal symptom (side effect)
  heart arrhythmia
  heart failure (drug therapy)
  heart protection
  human
  hypercholesterolemia (drug therapy)
  hypertriglyceridemia (drug therapy)
  ischemic heart disease (prevention)
  Mediterranean diet
  primary prevention
  secondary prevention
  telomere
  thrombocyte aggregation inhibition
  water pollutant
DRUG TRADE NAMES
  lovaza  , United StatesGlaxo SmithKline

DRUG MANUFACTURERS
   (United States)Glaxo SmithKline
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  atorvastatin (134523-00-5, 134523-03-8)
  C reactive protein (9007-41-4)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  docosahexaenoic acid (25167-62-8, 32839-18-2)
  fish oil (8016-13-5)
  icosapentaenoic acid (25378-27-2, 32839-30-8)
  linolenic acid (1955-33-5, 463-40-1)
  methylmercury (16056-34-1, 593-74-8)
  simvastatin (79902-63-9)
  stromelysin (79955-99-0)
  thromboxane A2 (57576-52-0)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00127452)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010688790
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11936-010-0079-4
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 381
TITLE
  Highlights of the 2009 Scientific Sessions of the Heart Failure Society of 
America, Boston, MA, September 13-16, 2009
AUTHOR NAMES
  O'Connor C.M.
  Koch W.J.
  Mann D.L.
AUTHOR ADDRESSES
  (O'Connor C.M., oconn@mc.duke.edu) Duke University Medical Center, Durham, 
NC, United States.
(Koch W.J.) Thomas Jefferson University, Jefferson Medical College, 
Philadelphia, PA, United States.
(Mann D.L.) Washington University School of Medicine, St. Louis, MO, United 
States.
CORRESPONDENCE ADDRESS
  C.M. O'Connor, Duke University Medical Center, Durham, NC, United States. 
Email: oconn@mc.duke.edu
SOURCE
  Journal of Cardiac Failure (2010) 16:1 (2-8). Date of Publication: January 
2010
ISSN
  1071-9164
  1532-8414 (electronic)
BOOK PUBLISHER
  Churchill Livingstone Inc., 650 Avenue of the Americas, New York, United 
States.
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (clinical trial, drug therapy)
  amiodarone (clinical trial, drug therapy)
  anthracycline derivative (adverse drug reaction, clinical trial, drug 
therapy)
  anticoagulant agent (clinical trial, drug therapy)
  beta adrenergic receptor blocking agent (clinical trial, drug combination, 
drug therapy)
  biological marker (endogenous compound)
  digoxin (clinical trial, drug combination, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
  diuretic agent (clinical trial, drug therapy, intravenous drug 
administration)
  dopamine (clinical trial, drug combination, drug therapy)
  furosemide (clinical trial, drug combination, drug therapy)
  G protein coupled receptor kinase (endogenous compound)
  galectin 3 (endogenous compound)
  hydralazine (clinical trial, drug therapy)
  irbesartan (clinical trial, drug therapy)
  isosorbide dinitrate (clinical trial, drug therapy)
  metoprolol (clinical trial, drug therapy)
  placebo
  rolofylline (adverse drug reaction, clinical trial, drug therapy)
  vardenafil (drug therapy, pharmacology)
  warfarin (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (drug therapy, diagnosis, drug therapy, etiology, prevention, 
surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  acute heart failure (drug therapy)
  acute heart failure (drug therapy)
  acute heart failure (drug therapy)
  anticoagulation
  atrial fibrillation (drug therapy)
  cancer radiotherapy
  cancer therapy
  cardiac resynchronization therapy
  cardiomyopathy (drug therapy)
  cardiotoxicity (side effect)
  cardiovascular effect
  cardiovascular risk
  cell therapy
  cerebrovascular accident (side effect)
  childhood cancer (drug therapy, radiotherapy)
  clinical research
  clinical trial
  comparative study
  congestive cardiomyopathy (drug therapy)
  congestive heart failure (etiology, therapy)
  death
  defibrillator
  Dressler syndrome (drug therapy, therapy)
  drug effect
  drug megadose
  drug safety
  evidence based practice
  exercise
  fibrosis
  health education
  heart arrhythmia (drug therapy)
  heart atrium arrhythmia (therapy)
  heart catheterization
  heart left ventricle ejection fraction
  heart muscle perfusion
  heart ventricle arrhythmia (therapy)
  hospital patient
  hospitalization
  human
  hydrothorax
  hypertension
  implantation
  kidney disease (drug therapy)
  low drug dose
  medical personnel
  medical research
  medical society
  medicine
  mortality
  myoblast
  North America
  outpatient care
  patient education
  patient monitoring
  priority journal
  prognosis
  protein expression
  renal protection
  review
  scientific literature
  seizure (side effect)
  thromboembolism (drug therapy, prevention)
  United States
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digoxin (20830-75-5, 57285-89-9)
  dopamine (51-61-6, 62-31-7)
  furosemide (54-31-9)
  galectin 3 (208128-56-7)
  hydralazine (304-20-1, 86-54-4)
  irbesartan (138402-11-6)
  isosorbide dinitrate (87-33-2)
  metoprolol (37350-58-6)
  rolofylline (136199-02-5)
  vardenafil (224785-90-4, 224785-91-5, 224789-15-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2009661975
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.cardfail.2009.11.001
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 382
TITLE
  Disease management programs for heart failure
AUTHOR NAMES
  McDonald K.
AUTHOR ADDRESSES
  (McDonald K., Kenneth.mcdonald@ucd.ie) Heart Failure Unit, St. Vincent's 
University Hospital, Dublin, Ireland.
CORRESPONDENCE ADDRESS
  K. McDonald, Heart Failure Unit, St. Vincent's University Hospital, Dublin, 
Ireland. Email: Kenneth.mcdonald@ucd.ie
SOURCE
  Current Treatment Options in Cardiovascular Medicine (2010) 12:6 (578-586). 
Date of Publication: December 2010
ISSN
  1092-8464
BOOK PUBLISHER
  Springer Healthcare
ABSTRACT
  Opinion statement: The impact of the very significant advances in the 
management of heart failure over the past several decades had been limited 
by a lack of appropriate infrastructure for heart failure care delivery in 
the community. The development of disease management programs has brought 
about significant advances in ensuring improved care of the wider heart 
failure population, allowing for effective prescription of proven 
strategies, structured follow-up, and education of patients and families to 
encourage involvement in self-care. The impact of these programs on 
reduction in hard cardiovascular endpoints, including death and heart 
failure rehospitalization, has been substantial. Continued research aims to 
optimize this strategy in terms of what additional aspects are necessary to 
enhance this approach. From recent work, it is clear that heart failure 
patients may derive incremental benefit from exercise programs as an 
adjunctive therapy; additional work is required to address how we should use 
the rapidly developing home telemonitoring technologies. © 2010 Springer 
Science+Business Media, LLC.
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (drug therapy)
  antithrombocytic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  candesartan (drug therapy)
  hydralazine plus isosorbide dinitrate (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  Pneumococcus vaccine
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  adjuvant therapy
  atrial fibrillation (drug therapy)
  clinical effectiveness
  exercise
  exercise intensity
  family counseling
  health care cost
  home care
  hospitalization
  human
  medicare
  mortality
  non invasive measurement
  patient attitude
  patient compliance
  patient education
  quality of life
  review
  self care
  survival time
  teleconsultation
  telemonitoring
  treadmill exercise
  treatment outcome
  walking
CAS REGISTRY NUMBERS
  candesartan (139481-59-7)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010673755
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11936-010-0094-5
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 383
TITLE
  Ventricular rhythm in atrial fibrillation under anaesthetic infusion with 
propofol
AUTHOR NAMES
  Cervigón R.
  Moreno J.
  Reilly R.B.
  Pérez-Villacastín J.
  Castells F.
AUTHOR ADDRESSES
  (Cervigón R., raquel.cervigon@uclm.es) Escuela Universitaria Politécnica, 
Campus Universitario, Group of Bioengineering Innovation (GIBI), Camino del 
Pozuelo sn. 16071, Spain.
(Moreno J.; Pérez-Villacastín J.) Unidad de Arritmias, Hospital Clínico San 
Carlos, Plaza de Cristo Rey sn, Madrid, 28040, Spain.
(Reilly R.B.) Trinity Centre for Bioengineering, Trinity College Dublin, 
Dublin 2, Ireland.
(Castells F.) Universidad Politécnica de Valencia, Bioengineering Electronic 
Telemedicine (BET), DIE, Camino de la Vera sn., Valencia, 46022, Spain.
CORRESPONDENCE ADDRESS
  R. Cervigón, Escuela Universitaria Politécnica, Campus Universitario, Group 
of Bioengineering Innovation (GIBI), Camino del Pozuelo sn. 16071, Spain. 
Email: raquel.cervigon@uclm.es
SOURCE
  Physiological Measurement (2009) 30:8 (833-845). Date of Publication: 2009
ISSN
  0967-3334
  1361-6579 (electronic)
BOOK PUBLISHER
  Institute of Physics Publishing, Temple Circus, Temple Way, Bristol, United 
Kingdom.
ABSTRACT
  Changes in patients' autonomic tone and specific pharmacologic interventions 
may modify the ventricular response (actual heart rate) during atrial 
fibrillation (AF). Hypnotic agents such as propofol may modify autonomic 
balance as they promote a sedative state. It has been shown that propofol 
slightly slows atrial fibrillatory activity, but the net global effect on 
the ventricular response remains unknown. We aimed to evaluate in patients 
in AF the effect of a propofol bolus on the ventricular rate and regularity 
at ECG. We analysed the possible relation with local atrial fibrillatory 
activities, as ratios between atrial and ventricular rates (AVRs), analysing 
atrial activity from intracardiac electrograms at the free wall of the right 
and left atria and at the interatrial septum. We compared data at the 
baseline and after complete hypnosis. Propofol was associated with a more 
homogeneous ventricular response and lower AVR values at the interatrial 
septum. © 2009 Institute of Physics and Engineering in Medicine.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  propofol (drug therapy, intravenous drug administration, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anesthesia induction
  atrial fibrillation (drug therapy, drug therapy)
  heart rate
  heart rhythm
EMTREE MEDICAL INDEX TERMS
  adult
  article
  controlled study
  drug effect
  electrocardiography
  female
  heart atrium septum
  heart ventricle function
  human
  male
  priority journal
CAS REGISTRY NUMBERS
  propofol (2078-54-8)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Anesthesiology (24)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009580487
MEDLINE PMID
  19590112 (http://www.ncbi.nlm.nih.gov/pubmed/19590112)
FULL TEXT LINK
  http://dx.doi.org/10.1088/0967-3334/30/8/008
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 384
TITLE
  Coenzyme Q10 effects in neurodegenerative disease
AUTHOR NAMES
  Spindler M.
  Flint Beal M.
  Henchcliffe C.
AUTHOR ADDRESSES
  (Spindler M., mes9051@nyp.org; Flint Beal M.; Henchcliffe C.) Department of 
Neurology, Weill Medical College, Cornell University, 525 East 68th Street, 
New York, NY, United States.
(Flint Beal M.; Henchcliffe C.) Department of Neuroscience, Weill Medical 
College, Cornell University, New York, NY, United States.
CORRESPONDENCE ADDRESS
  M. Spindler, Department of Neurology, Weill Medical College, Cornell 
University, 525 East 68th Street, New York, NY, United States. Email: 
mes9051@nyp.org
SOURCE
  Neuropsychiatric Disease and Treatment (2009) 5:1 (597-610). Date of 
Publication: 2009
ISSN
  1176-6328
  1178-2021 (electronic)
BOOK PUBLISHER
  DOVE Medical Press Ltd., PO Box 300-008, Albany, Auckland, New Zealand.
ABSTRACT
  Coenzyme Q10 (CoQ10) is an essential cofactor in the mitochondrial 
respiratory chain, and as a dietary supplement it has recently gained 
attention for its potential role in the treatment of neurodegenerative 
disease. Evidence for mitochondrial dysfunction in neurodegenerative 
disorders derives from animal models, studies of mitochondria from patients, 
identification of genetic defects in patients with neurodegenerative 
disease, and measurements of markers of oxidative stress. Studies of in 
vitro models of neuronal toxicity and animal models of neurodegenerative 
disorders have demonstrated potential neuroprotective effects of CoQ10. With 
this data in mind, several clinical trials of CoQ10 have been performed in 
Parkinson's disease and atypical Parkinson's syndromes, Huntington's 
disease, Alzheimer disease, Friedreich's ataxia, and amyotrophic lateral 
sclerosis, with equivocal findings. CoQ10 is widely available in multiple 
formulations and is very well tolerated with minimal adverse effects, making 
it an attractive potential therapy. Phase III trials of high-dose CoQ10 in 
large sample sizes are needed to further ascertain the effects of CoQ10 in 
neurodegenerative diseases. © 2009 Spindler et al, publisher and licensee 
Dove Medical Press Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  ubidecarenone (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug concentration, drug dose, drug interaction, drug therapy, 
oral drug administration, pharmaceutics, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  creatine (drug combination, drug interaction, drug therapy)
  idebenone (clinical trial, drug therapy, pharmacology)
  minocycline (drug combination)
  placebo
  remacemide (drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Alzheimer disease (drug therapy, drug therapy)
  amyotrophic lateral sclerosis (drug therapy, drug therapy)
  Friedreich ataxia (drug therapy, drug therapy)
  Huntington chorea (drug therapy, drug therapy)
  Parkinson disease (drug therapy, drug therapy)
  progressive supranuclear palsy (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal pain (side effect)
  anxiety
  arthralgia (side effect)
  atrial fibrillation (side effect)
  blood cell count
  blood chemistry
  clinical trial
  coenzyme Q10 deficiency (drug therapy)
  coenzyme Q10 deficiency (drug therapy)
  constipation (side effect)
  coughing (side effect)
  degenerative disease (drug therapy)
  diarrhea (side effect)
  disorders of mitochondrial functions
  diverticulosis (side effect)
  drug absorption
  drug bioavailability
  drug blood level
  drug delivery system
  drug dose escalation
  drug efficacy
  drug eruption (side effect)
  drug formulation
  drug induced headache (side effect)
  drug megadose
  drug response
  drug safety
  drug structure
  drug tolerability
  enzyme deficiency (drug therapy)
  faintness (side effect)
  falling
  gallbladder disease (side effect)
  gastroesophageal reflux (side effect)
  gastrointestinal symptom (side effect)
  heartburn (side effect)
  human
  in vitro study
  infection (side effect)
  low drug dose
  nausea (side effect)
  nephrolithiasis (side effect)
  neuroprotection
  nonhuman
  peripheral edema (side effect)
  review
  side effect (side effect)
  structure analysis
  suicide attempt (side effect)
  upper respiratory tract infection (side effect)
  urinalysis
  urinary tract infection (side effect)
CAS REGISTRY NUMBERS
  creatine (57-00-1)
  idebenone (58186-27-9)
  minocycline (10118-90-8, 11006-27-2, 13614-98-7)
  remacemide (111686-79-4)
  ubidecarenone (303-98-0)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
CLINICAL TRIAL NUMBERS
  ClinicalTrials.gov (NCT00382824, NCT00608881, NCT00740714)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009601145
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 385
TITLE
  Abdominal angina due to recurrence of cancer of the papilla of Vater: A case 
report
AUTHOR NAMES
  Biolato M.
  Gabrieli M.L.
  Parente A.
  Racco S.
  Costantini M.
  Bonomo L.
  Rapaccini G.L.
  Gasbarrini G.
  Grieco A.
AUTHOR ADDRESSES
  (Biolato M., marcobiolato@alice.it; Gabrieli M.L., letigabri@libero.it; 
Parente A., aparente73@libero.it; Racco S., simonaracco@libero.it; Rapaccini 
G.L., rapaccini@rm.unicatt.it; Gasbarrini G., ggasbarrini@rm.unicatt.it; 
Grieco A., agrieco@rm.unicatt.it) Department of Internal Medicine, Catholic 
University of Rome, 8 Largo A Gemelli, Rome 00168, Italy.
(Costantini M., mcostantini@rm.unicatt.it; Bonomo L., lbonomo@rm.unicatt.it) 
Department of Radiology, Institute of Internal Medicine, Catholic University 
of Rome, 8 Largo A Gemelli, Rome 00168, Italy.
CORRESPONDENCE ADDRESS
  A. Grieco, Department of Internal Medicine, Catholic University of Rome, 8 
Largo A Gemelli, Rome 00168, Italy. Email: agrieco@rm.unicatt.it
SOURCE
  Journal of Medical Case Reports (2009) 3 Article Number: 9314. Date of 
Publication: 2009
ISSN
  1752-1947
  1752-1947 (electronic)
BOOK PUBLISHER
  BioMed Central Ltd., 34 - 42 Cleveland Street, London, United Kingdom.
ABSTRACT
  Introduction. Abdominal angina is usually caused by atherosclerotic disease, 
and other causes are considered uncommon. This is the first report of a case 
of abdominal angina secondary to neoplastic vascular stenosis caused by 
local recurrence of an adenocarcinoma of the papilla of Vater. Case 
presentation. An 80-year-old woman of Caucasian origin presented with 
abdominal pain and diarrhea. She had undergone a pancreaticoduodenectomy for 
adenocarcinoma of the papilla of Vater four years earlier. Computed 
tomography revealed a mass surrounding her celiac trunk and superior 
mesenteric artery. Her abdominal pain responded poorly to analgesic drugs, 
but disappeared when oral feedings were withheld. A duplex ultrasonography 
of the patient's splanchnic vessels was consistent with vascular stenosis. 
Parenteral nutrition was started and the patient remained pain free until 
her death. Conclusion. Pain relief is an important therapeutic target in 
patients with cancer. In this case, abdominal pain was successfully managed 
only after the ischemic cause had been identified. The conventional 
analgesic therapy algorithm based on nonsteroidal anti-inflammatory drugs 
and opioids had been costly and pointless, whereas the simple withdrawal of 
oral feeding spared the patient of the discomfort of additional invasive 
procedures and allowed her to spend her remaining days in a completely 
pain-free state. © 2009 Biolato et al; licensee BioMed Central Ltd.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
  celecoxib
  cocodamol
  enoxaparin (drug combination, drug therapy, subcutaneous drug 
administration)
  esomeprazole
  fentanyl (drug therapy, transdermal drug administration)
  glyceryl trinitrate (drug combination, drug therapy, transdermal drug 
administration)
  manidipine
  paracetamol (drug therapy, oral drug administration)
  scopolamine (drug therapy, intravenous drug administration)
  tramadol (drug therapy, oral drug administration)
  zofenopril
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  abdominal angina (drug therapy, complication, diagnosis, drug therapy)
  cancer recurrence
  Vater papilla carcinoma (surgery)
EMTREE MEDICAL INDEX TERMS
  abdominal pain (drug therapy)
  aged
  article
  atrial fibrillation (drug therapy)
  cancer surgery
  case report
  Caucasian
  computer assisted tomography
  diarrhea
  Doppler echography
  female
  human
  pancreaticoduodenectomy
  parenteral nutrition
  priority journal
  superior mesenteric artery
  Vater papilla
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  celecoxib (169590-42-5)
  enoxaparin (9041-08-1)
  esomeprazole (119141-88-7, 202742-32-3, 217087-09-7, 217087-10-0)
  fentanyl (437-38-7)
  glyceryl trinitrate (55-63-0)
  manidipine (89226-50-6)
  paracetamol (103-90-2)
  scopolamine (138-12-5, 51-34-3, 55-16-3)
  tramadol (27203-92-5, 36282-47-0)
  zofenopril (81872-10-8)
EMBASE CLASSIFICATIONS
  Cancer (16)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2010038582
FULL TEXT LINK
  http://dx.doi.org/10.1186/1752-1947-3-9314
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 386
TITLE
  The use of intravenous aminobisphosphonates for the treatment of Paget's 
disease of bone
AUTHOR NAMES
  Gennari L.
  Merlotti D.
  Mossetti G.
  Rendina D.
  De Paola V.
  Martini G.
  Nuti R.
AUTHOR ADDRESSES
  (Gennari L., gennari@unisi.it) Department of Internal Medicine, 
Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Viale 
Bracci 1, 53100 Siena, Italy.
(Merlotti D.; Mossetti G.; Rendina D.; De Paola V.; Martini G.; Nuti R.)
CORRESPONDENCE ADDRESS
  L. Gennari, Department of Internal Medicine, Endocrine-Metabolic Sciences 
and Biochemistry, University of Siena, Viale Bracci 1, 53100 Siena, Italy. 
Email: gennari@unisi.it
SOURCE
  Mini-Reviews in Medicinal Chemistry (2009) 9:9 (1052-1063). Date of 
Publication: 2009
ISSN
  1389-5575
BOOK PUBLISHER
  Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
  Paget's disease of bone is a focal skeletal disorder characterized by the 
formation of structurally abnormal bone, deformity and other complications 
leading to significant disability and bone pain. Recently, the availability 
of newer, more potent nitrogen-containing bisphosphonates has improved 
treatment outcomes, allowing a more effective and convenient management of 
this disorder. © 2009 Bentham Science Publishers Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  aminobisphosphonic acid derivative (adverse drug reaction, drug analysis, 
drug therapy, intravenous drug administration, oral drug administration, 
pharmacology)
  bisphosphonic acid derivative (adverse drug reaction, drug analysis, drug 
comparison, drug therapy, intravenous drug administration, oral drug 
administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  alendronic acid (adverse drug reaction, drug analysis, drug therapy, oral 
drug administration, pharmacokinetics, pharmacology)
  antibiotic agent (drug therapy)
  calcitonin (drug comparison, drug therapy, pharmacology, subcutaneous drug 
administration)
  calcium (drug therapy)
  clodronic acid (drug therapy, intravenous drug administration)
  etidronic acid (adverse drug reaction, drug comparison, drug therapy, oral 
drug administration, pharmacology)
  ibandronic acid (drug analysis, drug therapy)
  narcotic analgesic agent (drug therapy)
  neridronic acid (adverse drug reaction, clinical trial, drug analysis, drug 
comparison, drug therapy, intramuscular drug administration, intravenous 
drug administration, oral drug administration, pharmacoeconomics, 
pharmacology)
  pamidronic acid (adverse drug reaction, clinical trial, drug analysis, drug 
comparison, drug dose, drug therapy, intravenous drug administration, 
pharmacology)
  paracetamol (drug therapy)
  placebo
  risedronic acid (adverse drug reaction, clinical trial, drug analysis, drug 
comparison, drug therapy, oral drug administration, pharmacokinetics, 
pharmacology)
  tiludronic acid (drug comparison, drug therapy)
  unclassified drug
  vitamin D (drug therapy)
  zoledronic acid (adverse drug reaction, clinical trial, drug analysis, drug 
comparison, drug dose, drug therapy, intravenous drug administration, 
pharmacoeconomics, pharmacology, subcutaneous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Paget bone disease (drug therapy, diagnosis, drug resistance, drug therapy, 
epidemiology, etiology, therapy)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  Albers Schoenberg disease (side effect)
  arthritis (drug therapy)
  atrial fibrillation (side effect)
  bone disease (drug therapy)
  bone malformation
  bone pain
  bone structure
  bone turnover
  clinical effectiveness
  clinical trial
  cost effectiveness analysis
  creatinine blood level
  dosage schedule comparison
  drug absorption
  drug bioavailability
  drug choice
  drug dose comparison
  drug efficacy
  drug mechanism
  drug megadose
  drug potency
  drug safety
  drug structure
  electrostimulation
  esophagus disease (side effect)
  fever (side effect)
  flu like syndrome (drug therapy, side effect)
  gastrointestinal symptom (side effect)
  heart arrhythmia (side effect)
  hematologic disease (side effect)
  human
  hyperparathyroidism (drug therapy)
  hypocalcemia (drug therapy, side effect)
  jaw osteonecrosis (drug therapy, side effect)
  kidney dysfunction (side effect)
  multiple myeloma (drug therapy)
  musculoskeletal pain (side effect)
  nephrotoxicity (side effect)
  nerve stimulation
  nonhuman
  osteogenesis imperfecta (drug therapy)
  osteomalacia (side effect)
  osteoporosis (drug therapy)
  patient compliance
  physical disability
  postmenopause osteoporosis (drug therapy)
  prevalence
  review
  side effect (side effect)
  single drug dose
  structure activity relation
  tachyphylaxis
  treatment indication
  treatment response
  walking aid
CAS REGISTRY NUMBERS
  alendronic acid (66376-36-1)
  calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
  calcium (14092-94-5, 7440-70-2)
  clodronic acid (10596-23-3, 22560-50-5)
  etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
  ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
  neridronic acid (79778-41-9)
  pamidronic acid (40391-99-9, 57248-88-1)
  paracetamol (103-90-2)
  risedronic acid (105462-24-6, 122458-82-6)
  tiludronic acid (96538-83-9)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Clinical and Experimental Pharmacology (30)
  Orthopedic Surgery (33)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009606270
MEDLINE PMID
  19689402 (http://www.ncbi.nlm.nih.gov/pubmed/19689402)
FULL TEXT LINK
  http://dx.doi.org/10.2174/138955709788922683
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 387
TITLE
  Treatment of hypertension in the elderly
AUTHOR NAMES
  Eaton-Maxwell A.
  Ebeid A.
  Azuike C.
  Crain D.
AUTHOR ADDRESSES
  (Eaton-Maxwell A.; Ebeid A.; Azuike C.; Crain D.) Texas Southern University, 
College of Pharmacy and Health Sciences, Houston, TX, United States.
CORRESPONDENCE ADDRESS
  A. Eaton-Maxwell, Texas Southern University, College of Pharmacy and Health 
Sciences, Houston, TX, United States.
SOURCE
  U.S. Pharmacist (2009) 34:6 (HS12-HS18). Date of Publication: 2009
ISSN
  0148-4818
BOOK PUBLISHER
  Jobson Publishing Corporation, 100 Avenue of the Americas, New York, United 
States.
EMTREE DRUG INDEX TERMS
  alpha adrenergic receptor blocking agent (adverse drug reaction, clinical 
trial, drug therapy, pharmacology)
  amlodipine (clinical trial, drug comparison, drug therapy)
  angiotensin receptor antagonist (adverse drug reaction, clinical trial, drug 
therapy, pharmacology)
  antihypertensive agent (adverse drug reaction, clinical trial, drug therapy)
  atenolol (adverse drug reaction, clinical trial, drug comparison, drug 
therapy)
  beta adrenergic receptor (endogenous compound)
  beta adrenergic receptor blocking agent (adverse drug reaction, clinical 
trial, drug comparison, drug therapy, pharmacology)
  calcium channel blocking agent (adverse drug reaction, clinical trial, drug 
comparison, drug therapy, pharmacology)
  candesartan (adverse drug reaction, clinical trial, drug therapy)
  chlortalidone (clinical trial, drug comparison, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical 
trial, drug comparison, drug therapy, pharmacology)
  diuretic agent (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, pharmacology)
  doxazosin (clinical trial, drug comparison, drug therapy)
  enalapril (clinical trial, drug therapy)
  hydrochlorothiazide (clinical trial, drug therapy)
  lisinopril (clinical trial, drug therapy)
  loop diuretic agent (drug therapy)
  losartan (adverse drug reaction, clinical trial, drug comparison, drug 
therapy)
  potassium sparing diuretic agent (drug therapy)
  thiazide diuretic agent (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  hypertension (drug therapy, diagnosis, drug therapy, epidemiology, etiology, 
therapy)
EMTREE MEDICAL INDEX TERMS
  aged
  angioneurotic edema (side effect)
  anorexia (side effect)
  antihypertensive activity
  atrial fibrillation (side effect)
  atrioventricular block (side effect)
  bradycardia (side effect)
  bronchospasm (side effect)
  cause of death
  clinical practice
  clinical protocol
  clinical trial
  congestive heart failure
  constipation (side effect)
  coughing (side effect)
  depression (side effect)
  diarrhea (side effect)
  diet therapy
  dizziness (side effect)
  drug efficacy
  drug eruption (side effect)
  drug receptor binding
  drug tolerability
  dysgeusia (side effect)
  exercise
  faintness (side effect)
  fatigue (side effect)
  floppy iris syndrome (side effect)
  floppy iris syndrome (side effect)
  flushing
  heart disease
  heart ventricle fibrillation (side effect)
  human
  hyperglycemia (side effect)
  hyperkalemia (side effect)
  hyperuricemia (side effect)
  hypochloremia (side effect)
  hypoglycemia (side effect)
  hypokalemia (side effect)
  hypomagnesemia (side effect)
  hypotension (side effect)
  impotence (side effect)
  insomnia (side effect)
  iris disease (side effect)
  lifestyle modification
  myalgia (side effect)
  nausea and vomiting (side effect)
  nose obstruction (side effect)
  orthostatic hypotension (side effect)
  ototoxicity (side effect)
  pathophysiology
  peripheral edema (side effect)
  prevalence
  priapism (side effect)
  review
  side effect (side effect)
  sinus tachycardia (side effect)
  tachycardia (side effect)
  unspecified side effect (side effect)
  vertigo (side effect)
CAS REGISTRY NUMBERS
  amlodipine (88150-42-9)
  atenolol (29122-68-7)
  candesartan (139481-59-7)
  chlortalidone (77-36-1)
  doxazosin (74191-85-8)
  enalapril (75847-73-3)
  hydrochlorothiazide (58-93-5)
  lisinopril (76547-98-3, 83915-83-7)
  losartan (114798-26-4)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2010010403
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 388
TITLE
  Identification and Evaluation of the Patient with Lung Disease
AUTHOR NAMES
  Sweitzer B.J.
  Smetana G.W.
AUTHOR ADDRESSES
  (Sweitzer B.J., bsweitzer@dacc.uchicago.edu) Department of Anesthesia and 
Critical Care, University of Chicago, 5841 S, Maryland Avenue, Chicago, IL 
60637, United States.
(Sweitzer B.J., bsweitzer@dacc.uchicago.edu) Department of Medicine, 
University of Chicago, 5841 S, Maryland Avenue, Chicago, IL 60637, United 
States.
(Sweitzer B.J., bsweitzer@dacc.uchicago.edu) Anesthesia Perioperative 
Medicine Clinic, University of Chicago Medical Center, 5841 S, Maryland 
Avenue, Chicago, IL 60637, United States.
(Smetana G.W.) Division of General Medicine and Primary Care, Beth Israel 
Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, 
Boston, MA, United States.
CORRESPONDENCE ADDRESS
  B.J. Sweitzer, Department of Anesthesia and Critical Care, University of 
Chicago, 5841 S, Maryland Avenue, Chicago, IL 60637, United States. Email: 
bsweitzer@dacc.uchicago.edu
SOURCE
  Anesthesiology Clinics (2009) 27:4 (673-686). Date of Publication: December 
2009
ISSN
  1932-2275
BOOK PUBLISHER
  W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
  Preoperative pulmonary evaluation and optimization improves postoperative 
patient outcomes. Clinicians frequently evaluate patients with pulmonary 
disease before surgery who are at increased risk for pulmonary and 
nonpulmonary perioperative complications. Postoperative pulmonary 
complications are as common and costly as cardiac complications. In this 
article, the evaluation of patients with the most common conditions 
encountered in the preoperative setting, including unexplained dyspnea, 
asthma, chronic obstructive pulmonary disease, obstructive sleep apnea, and 
cigarette use, are discussed. Risk stratification for postoperative 
pulmonary complications and strategies to reduce them for high-risk patients 
are also discussed. From the available literature, high-risk patients and 
those patients for whom a multidisciplinary collaboration will be most 
helpful can be accurately identified. © 2009 Elsevier Inc. All rights 
reserved.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent (drug therapy, inhalational drug 
administration)
  beta adrenergic receptor stimulating agent (drug comparison, drug therapy)
  bronchodilating agent (drug comparison, drug therapy)
  cholinergic receptor blocking agent (drug therapy, inhalational drug 
administration)
  corticosteroid (drug combination, drug therapy, inhalational drug 
administration)
  prednisone (drug therapy, oral drug administration)
  salbutamol (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  lung disease (rehabilitation, therapy)
  patient assessment
  preoperative evaluation
EMTREE MEDICAL INDEX TERMS
  airflow
  airway obstruction
  anesthesist
  asthma (drug therapy)
  atrial fibrillation
  bradycardia
  breathing exercise
  bronchospasm (drug therapy)
  cerebrovascular accident
  chronic obstructive lung disease (drug therapy, rehabilitation, therapy)
  clinical practice
  comorbidity
  congestive heart failure
  diastolic dysfunction
  dyspnea
  echocardiography
  elective surgery
  endotracheal intubation
  epidural anesthesia
  general anesthesia
  heart left ventricle ejection fraction
  high risk patient
  human
  lung infection
  muscle training
  nerve block
  patient compliance
  physiotherapy
  pneumonia (complication)
  polysomnography
  positive end expiratory pressure
  postoperative complication (complication)
  practice guideline
  pulmonary hypertension
  pulmonary rehabilitation
  review
  risk factor
  risk reduction
  sleep disordered breathing (therapy)
  smoking
  smoking cessation
  spinal anesthesia
  spirometry
  surgeon
  surgical risk
  thorax radiography
  weight reduction
  wheezing
CAS REGISTRY NUMBERS
  prednisone (53-03-2)
  salbutamol (18559-94-9)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Rehabilitation and Physical Medicine (19)
  Anesthesiology (24)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009603749
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.anclin.2009.09.004
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 389
TITLE
  Managing risk factors to prevent stroke
AUTHOR NAMES
  Dunbabin D.W.
AUTHOR ADDRESSES
  (Dunbabin D.W.) Royal Hobart Hospital, .
(Dunbabin D.W.) University of Tasmania, TAS.
CORRESPONDENCE ADDRESS
  D. W. Dunbabin, Royal Hobart Hospital, .
SOURCE
  Medicine Today (2009) 10:9 (58-68). Date of Publication: 2009
ISSN
  1443-430X
BOOK PUBLISHER
  Medicine Today Pty Ltd, P.O. Box 1473, Neutral Bay, Australia.
ABSTRACT
  Preventing stroke by modifying risk factors in the individual and the 
population as a whole still represents the most potent and cost-effective 
way of reducing the burden of stroke in our community. Important risk 
factors for stroke include elevated blood pressure, smoking, 
hypercholesterolaemia, diabetes mellitus, atrial fibrillation and lifestyle 
factors. Patients who have had a previous stroke or TIA are at especially 
high risk of further stroke and require early assessment and therapy.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug therapy, pharmacoeconomics)
  angiotensin receptor antagonist (drug therapy)
  anticoagulant agent
  antihypertensive agent
  antioxidant
  antithrombocytic agent
  atorvastatin (drug therapy)
  calcium channel blocking agent (drug therapy)
  cholesterol (endogenous compound)
  clopidogrel (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug therapy)
  cyanocobalamin
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  dipyridamole (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug therapy, pharmacoeconomics)
  folic acid
  homocysteine (endogenous compound)
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  pravastatin (drug therapy)
  pyridoxine
  ramipril (adverse drug reaction, drug combination, drug comparison, drug 
therapy)
  simvastatin (drug therapy)
  telmisartan (adverse drug reaction, drug combination, drug comparison, drug 
therapy)
  thiazide diuretic agent (drug therapy)
  ticlopidine (drug therapy)
  warfarin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (drug therapy, disease management, drug therapy, 
prevention)
  risk factor
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  angioplasty
  antihypertensive therapy
  atrial fibrillation (drug therapy)
  attributable risk
  Australia
  bleeding (side effect)
  blood pressure
  cardiovascular risk
  carotid artery obstruction (surgery)
  carotid endarterectomy
  cerebrovascular accident (drug therapy)
  cholesterol blood level
  clinical trial
  coronary artery disease (drug therapy)
  cost effectiveness analysis
  diabetes mellitus
  diarrhea (side effect)
  diet
  drug cost
  drug efficacy
  faintness (side effect)
  general practitioner
  headache (side effect)
  high risk patient
  human
  hypercholesterolemia
  hypertension (drug therapy)
  hypotension (side effect)
  kidney dysfunction (side effect)
  lifestyle
  lifestyle modification
  morbidity
  mortality
  nausea (side effect)
  patient compliance
  rash (side effect)
  review
  risk reduction
  smoking
  transient ischemic attack (drug therapy)
  vitamin supplementation
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  atorvastatin (134523-00-5, 134523-03-8)
  cholesterol (57-88-5)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
  dipyridamole (58-32-2)
  folic acid (59-30-3, 6484-89-5)
  homocysteine (454-28-4, 6027-13-0)
  pravastatin (81131-74-0)
  pyridoxine (12001-77-3, 58-56-0, 65-23-6, 8059-24-3)
  ramipril (87333-19-5)
  simvastatin (79902-63-9)
  telmisartan (144701-48-4)
  ticlopidine (53885-35-1, 55142-85-3)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009543814
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 390
TITLE
  Current pharmacological approaches to prevent and treat post-menopausal 
osteoporosis
AUTHOR NAMES
  Yang R.S.
  Liu S.H.
AUTHOR ADDRESSES
  (Yang R.S., rsyang@ntuh.gov.tw) Department of Orthopaedics, College of 
Medicine, National Taiwan University, Jen-Ai Road, Taipei 10051, Taiwan.
(Liu S.H., shinghwaliu@ntu.edu.tw) Institute of Toxicology, College of 
Medicine, National Taiwan University, Jen-Ai Road, Taipei 10051, Taiwan.
(Liu S.H., shinghwaliu@ntu.edu.tw) Department of Surgery, National Taiwan 
University Hospital, Taipei, Taiwan.
CORRESPONDENCE ADDRESS
  R.S. Yang, Department of Orthopaedics, College of Medicine, National Taiwan 
University, Taipei 10051, Taiwan. Email: rsyang@ntuh.gov.tw
SOURCE
  Recent Patents on Endocrine, Metabolic and Immune Drug Discovery (2009) 3:1 
(42-53). Date of Publication: 2009
ISSN
  1872-2148
BOOK PUBLISHER
  Bentham Science Publishers B.V., P.O. Box 294, Bussum, Netherlands.
ABSTRACT
  Osteoporosis characterized by low bone mass and structural deterioration of 
bone tissue; has a huge impact on public health through high morbidity, 
mortality and economic costs associated with resultant fractures. The 
prevention and treatment of fragility fractures in the osteoporosis patients 
worldwide becomes an important issue in the current clinical practice. Women 
often have an accelerated bone loss after menopause and result in a lower 
bone mass than men. Since the bone loss is irreversible, early prevention 
and treatment of osteoporosis is important in the early postmenopausal 
period. The goal of prevention needs to be not only effective, but also 
safe, to diminish the risk of vertebral, hip and other nonvertebral 
fractures. Non-pharmacological treatments, such as calcium, vitamin D, 
exercise and reduction of risk factors may diminish the impact of menopause 
and age-mediated bone loss. Current pharmacological options available 
include bisphosphonates, calcitonin, hormone replacement therapy, selective 
estrogen receptor modulators, teriparatide, and strontium ranelate, etc. 
Lots of natural products including dietary components and herbal products 
have also been demonstrated to be capable of modifying bone metabolism, 
particularly of inhibiting bone resorption. These natural products may 
provide as an alternative treatment for osteoporosis. More than 150 patents 
have recently been issued for the prevention and treatment of postmenopausal 
osteoporosis. The development of other new medications also sheds light on 
either prevention or treatment of osteoporosis, such as human monoclonal 
anti-RANKL antibody, cathepsin K inhibitors, and cannabinoid-based drugs. © 
2009 Bentham Science Publishers Ltd.
EMTREE DRUG INDEX TERMS
  25 acetylcimigenol xylopyranoside (pharmacology)
  adlay (drug therapy)
  alendronic acid (drug therapy)
  bisphosphonic acid derivative (adverse drug reaction, drug therapy, 
pharmacokinetics, pharmacology)
  calcitonin (adverse drug reaction, drug therapy, intranasal drug 
administration, oral drug administration, subcutaneous drug administration)
  calcium (drug therapy)
  calcium carbonate
  Chinese drug (drug therapy)
  colecalciferol
  conjugated estrogen
  estradiol (adverse drug reaction, drug therapy)
  estradiol plus norethisterone acetate
  glycoside (pharmacology)
  herbaceous agent (drug therapy)
  ibandronic acid (drug therapy, intravenous drug administration, oral drug 
administration)
  isoflavone (drug therapy)
  parathyroid hormone[1-34] (adverse drug reaction, drug therapy, subcutaneous 
drug administration)
  piperazine estrone sulfate
  raloxifene (adverse drug reaction, drug therapy)
  risedronic acid (drug therapy)
  salcatonin
  soybean protein (drug therapy)
  unclassified drug
  vitamin D
  zoledronic acid (drug therapy, intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  postmenopause osteoporosis (drug therapy, drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation (side effect)
  bone mass
  bone necrosis (side effect)
  bone pain (side effect)
  breast cancer (side effect)
  calcium blood level
  cerebrovascular accident (side effect)
  continuous infusion
  cost effectiveness analysis
  deep vein thrombosis (side effect)
  dementia (side effect)
  dizziness (side effect)
  drug approval
  drug bioavailability
  drug contraindication
  drug induced headache (side effect)
  drug safety
  drug tolerability
  dysphagia (side effect)
  environmental factor
  epistaxis (side effect)
  esophagitis (side effect)
  esophagus ulcer (side effect)
  exercise
  falling
  flu like syndrome (side effect)
  gastrointestinal symptom (side effect)
  hormonal therapy
  hot flush (side effect)
  human
  ischemic heart disease (side effect)
  leg cramp (side effect)
  limb pain (side effect)
  musculoskeletal pain (side effect)
  myalgia (side effect)
  nausea (side effect)
  nonhuman
  orthostatic hypotension (side effect)
  phlebitis (side effect)
  priority journal
  rhinitis (side effect)
  risk factor
  side effect (side effect)
  stomach ulcer (side effect)
  vein thrombosis (side effect)
  venous thromboembolism (side effect)
  visual disorder (side effect)
  weight bearing
DRUG TRADE NAMES
  activella
  actonel
  boniva
  calcimar
  climara
  estrace
  estraderm
  estratab
  evista
  forteo
  fortical
  fosamax
  miacalcin
  ogen
  ortho est
  premarin
  reclast
  vivelle
CAS REGISTRY NUMBERS
  alendronic acid (66376-36-1)
  calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
  calcium (7440-70-2)
  calcium carbonate (13397-26-7, 13701-58-1, 14791-73-2, 471-34-1)
  colecalciferol (1406-16-2, 67-97-0)
  estradiol (50-28-2)
  ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
  isoflavone (574-12-9)
  parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
  piperazine estrone sulfate (7280-37-7)
  raloxifene (82640-04-8, 84449-90-1)
  risedronic acid (105462-24-6, 122458-82-6)
  salcatonin (47931-85-1)
  soybean protein (9010-10-0)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Obstetrics and Gynecology (10)
  Clinical and Experimental Pharmacology (30)
  Orthopedic Surgery (33)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009495112
FULL TEXT LINK
  http://dx.doi.org/10.2174/187221409787002958
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 391
TITLE
  Comparing ablation and antiarrhythmic drug therapy for atrial fibrillation
AUTHOR NAMES
  Callans D.J.
AUTHOR ADDRESSES
  (Callans D.J., david.callans@uphs.upenn.edu) University of Pennsylvania 
School of Medicine, Department of Medicine, Philadelphia, PA, United States.
(Callans D.J., david.callans@uphs.upenn.edu) University of Pennsylvania 
Health System, Department of Electrophysiology, Philadelphia, PA, United 
States.
(Callans D.J., david.callans@uphs.upenn.edu) 3400 Spruce Street, 
Philadelphia, PA 19104, United States.
CORRESPONDENCE ADDRESS
  D.J. Callans, 3400 Spruce Street, Philadelphia, PA 19104, United States. 
Email: david.callans@uphs.upenn.edu
SOURCE
  Current Cardiology Reports (2009) 11:5 (321-322). Date of Publication: 2009
ISSN
  1523-3782
BOOK PUBLISHER
  Current Medicine Group, 5 Marine View Plaza, Suite 218, Hoboken, United 
States.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  antiarrhythmic agent (clinical trial, drug combination, drug therapy)
EMTREE DRUG INDEX TERMS
  amiodarone (clinical trial, drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, drug therapy, prevention, therapy)
  catheter ablation
EMTREE MEDICAL INDEX TERMS
  abdominal disease (complication)
  clinical trial
  comparative study
  drug efficacy
  drug safety
  exercise
  hematoma (complication)
  human
  percutaneous drainage
  pericardial effusion (complication, surgery)
  pulmonary vein obstruction (therapy)
  quality of life
  short survey
  stent
  therapy effect
  treatment failure
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2009497698
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11886-009-0055-3
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 392
TITLE
  Management of Osteoporosis in elderly women
AUTHOR NAMES
  Aguirre L.E.
  Lewiecki E.M.
AUTHOR ADDRESSES
  (Aguirre L.E.) University of New Mexico, Health Sciences Center, 
Albuquerque, United States.
(Lewiecki E.M.) New Mexico Clinical Research, Osteoporosis Center, 
Albuquerque, United States.
CORRESPONDENCE ADDRESS
  L. E. Aguirre, University of New Mexico, Health Sciences Center, 
Albuquerque, United States.
SOURCE
  Annals of Long-Term Care (2009) 17:10 (35-39). Date of Publication: October 
2009
ISSN
  1524-7929
BOOK PUBLISHER
  HMP Communications LLP, 4365 U.S. Highway 1 Suite 250, Princeton, United 
States.
ABSTRACT
  Osteoporosis is characterized by low bone mineral density (BMD) and poor 
bone quality, resulting in reduced bone strength and increased risk of 
fracture. Osteoporotic fractures are associated with increased morbidity and 
mortality, particularly in the elderly, as well as high healthcare costs. 
The risk of fragility fractures increases with aging, independently of BMD. 
Many therapeutic agents are available for the treatment of osteoporosis, yet 
there are limited data on their efficacy and safety in the elderly. Post-hoc 
analyses of data from prospective, randomized, placebo-controlled clinical 
trials evaluating drugs for the treatment of postmenopausal osteoporosis 
have shown a similar response in elderly postmenopausal women as compared 
with younger postmenopausal women. This article reviews the evidence 
regarding the treatment of osteoporosis in elderly women and provides 
suggestions for long-term management in clinical practice.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  bisphosphonic acid derivative (adverse drug reaction, clinical trial, drug 
therapy)
  parathyroid hormone[1-34] (clinical trial, drug comparison, drug therapy)
EMTREE DRUG INDEX TERMS
  alendronic acid (clinical trial, drug comparison, drug therapy, oral drug 
administration)
  calcium (drug therapy)
  colecalciferol (clinical trial, drug therapy)
  ibandronic acid (clinical trial, drug therapy)
  placebo
  risedronic acid (clinical trial, drug therapy)
  vitamin D (clinical trial, drug therapy)
  zoledronic acid (clinical trial, drug therapy, intravenous drug 
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  postmenopause osteoporosis (drug therapy, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  atrial fibrillation (side effect)
  body mass
  calcium intake
  clinical practice
  clinical trial
  conservative treatment
  corticosteroid induced osteoporosis (drug therapy)
  drug safety
  exercise
  falling
  female
  femur fracture (complication, prevention, side effect)
  fragility fracture (complication, prevention)
  gastrointestinal symptom (side effect)
  geriatric patient
  hip fracture (complication, prevention)
  human
  hypocalcemia (side effect)
  jaw osteonecrosis (side effect)
  kidney dysfunction (side effect)
  lifestyle modification
  long term care
  musculoskeletal pain (side effect)
  osteopenia
  patient compliance
  review
  risk reduction
  smoking
  spine fracture (complication, prevention)
  vitamin D deficiency (drug therapy)
  vitamin supplementation
  weight bearing
CAS REGISTRY NUMBERS
  alendronic acid (66376-36-1)
  calcium (7440-70-2)
  colecalciferol (1406-16-2, 67-97-0)
  ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
  parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
  risedronic acid (105462-24-6, 122458-82-6)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Obstetrics and Gynecology (10)
  Gerontology and Geriatrics (20)
  Orthopedic Surgery (33)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009588572
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 393
TITLE
  Electrocardiogram and arrhythmias
AUTHOR NAMES
  Singh R.
  Murphy J.J.
AUTHOR ADDRESSES
  (Singh R.; Murphy J.J.) County Durham and Darlington Foundation Trust, 
Centre of Integrated Health Care Research, Durham University, United 
Kingdom.
(Singh R.; Murphy J.J.) County Durham and Darlington Foundation Trust, 
Durham University, United Kingdom.
CORRESPONDENCE ADDRESS
  R. Singh, County Durham and Darlington Foundation Trust, Centre of 
Integrated Health Care Research, Durham University, United Kingdom.
SOURCE
  Anaesthesia and Intensive Care Medicine (2009) 10:8 (381-384). Date of 
Publication: August 2009
ISSN
  1472-0299
BOOK PUBLISHER
  Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
  Introduced by Einthoven, electrocardiography remains the most common 
diagnostic procedure readily available to the physician in primary and 
secondary care. It is a graphical display of the electrical potential 
difference as it spreads through the heart and is recorded at the body 
surface. The electrocardiogram (ECG) is an indispensable tool to screen and 
monitor cardiac patients. Exercise ECG is used to diagnose coronary artery 
disease and ambulatory ECG to assess arrhythmias. © 2009 Elsevier Ltd. All 
rights reserved.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent (drug therapy)
  digitalis (adverse drug reaction)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  electrocardiogram
  heart arrhythmia (diagnosis)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (diagnosis)
  atrioventricular block (diagnosis, drug therapy, side effect)
  bradycardia
  cardiac patient
  complete heart block
  coronary artery disease (diagnosis)
  diagnostic procedure
  electric potential
  electrocardiography monitoring
  exercise
  heart atrium flutter (diagnosis)
  heart left bundle branch block (diagnosis)
  heart right bundle branch block (diagnosis)
  heart ventricle tachycardia (diagnosis)
  human
  P wave
  patient monitoring
  primary medical care
  priority journal
  QRS complex
  review
  second degree atrioventricular block
  T wave
  tachycardia
CAS REGISTRY NUMBERS
  digitalis (8031-42-3, 8053-83-6)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009386916
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.mpaic.2009.04.017
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 394
TITLE
  QT interval disturbances in hospitalized elderly patients
AUTHOR NAMES
  Lubat E.
  Segal R.
  Yearovoi A.
  Fridenson A.
  Baumoehl Y.
  Leobovitz A.
AUTHOR ADDRESSES
  (Lubat E.; Segal R., rsegal@post.tau.ac.il; Yearovoi A.; Fridenson A.; 
Baumoehl Y.; Leobovitz A.) Shmuel Harofe Hospital, Geriatric Medical Center, 
P.O. Box 2, Beer Yaakov 60350, Israel.
(Segal R., rsegal@post.tau.ac.il) Sackler Faculty of Medicine, Tel Aviv 
University, Ramat Aviv, Israel.
CORRESPONDENCE ADDRESS
  R. Segal, Shmuel Harofe Hospital, Geriatric Medical Center, P.O. Box 2, Beer 
Yaakov 60350, Israel. Email: rsegal@post.tau.ac.il
SOURCE
  Israel Medical Association Journal (2009) 11:3 (147-150). Date of 
Publication: 2009
ISSN
  1565-1088
BOOK PUBLISHER
  Israel Medical Association, 2 Twin Towers,11th Floor,35 Jabotinsky Street,PO 
Box 3566, Ramat Gan, Israel.
ABSTRACT
  Background: The QT interval reflects the total duration of ventricular 
myocardial repolarization. Its prolongation is associated with increased 
risk of polymorphic ventricular tachycardia, or torsade de pointes, which 
can be fatal. Objectives: To assess the prevalence of both prolonged and 
short QT interval in patients admitted to an acute geriatric ward. Methods: 
This retrospective study included the records over 6 months of all patients 
hospitalized in an acute geriatric ward. Excluded were patients with 
pacemaker, bundle branch block and slow or rapid atrial fibrillation. The 
standard 12 lead electrocardiogram of each patient was used for the QT 
interval evaluation. Results: We screened the files of 422 patients. QTc 
prolongation based on the mean of 12 ECG leads was detected in 115 patients 
(27%). Based on lead L2 only, QTc was prolonged in 136 (32%). Associated 
factors with QT prolongation were congestive heart failure and use of 
hypnotics. Short QT was found in 30 patients (7.1%) in lead L2 and in 19 
(4.5%) by the mean 12 leads. Short QT was related to a higher heart rate, 
chronic atrial fibrillation and schizophrenia. Conclusions: Our study 
detected QT segment disturbances in a considerable number of elderly 
patients admitted acutely to hospital. Further studies should confirm these 
results and clinicians should consider a close QT interval follow-up in 
predisposed patients.
EMTREE DRUG INDEX TERMS
  antiarrhythmic agent
  antidepressant agent
  benzodiazepine derivative
  cholinergic receptor blocking agent
  digoxin
  hypnotic agent
  neuroleptic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  elderly care
  QT prolongation (diagnosis)
  short QT interval (diagnosis)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation
  congestive heart failure
  drug use
  electrocardiogram
  female
  follow up
  geriatric patient
  heart rate
  high risk population
  hospital patient
  human
  major clinical study
  male
  prevalence
  retrospective study
  schizophrenia
CAS REGISTRY NUMBERS
  digoxin (20830-75-5, 57285-89-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009301710
MEDLINE PMID
  19544703 (http://www.ncbi.nlm.nih.gov/pubmed/19544703)
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 395
TITLE
  Follow your heart: Optimal care after a heart attack - A guide for you and 
your patients
AUTHOR NAMES
  Sivers F.
  Begg A.
  Milne D.
  Morrell J.
  Neely D.
  Norton M.
  Nuttall M.
  Walker M.
  Ellis B.
  Ratcliffe C.
  Thomas A.
  Bosworth R.
  Ong S.
AUTHOR ADDRESSES
  (Sivers F., fransivers@pccs.org.uk; Begg A.; Milne D.; Morrell J.; Norton 
M.; Nuttall M.) Primary Care Cardiovascular Society, 36 Berrymede Road, 
London, W4 5JD.
(Neely D.; Ellis B.; Ratcliffe C.) HEART UK, 7 North Road, Maidenhead, SL6 
1PE.
(Walker M.) University College Hospital, London, NW1 2BU.
(Thomas A.; Bosworth R.; Ong S.) Pfizer Ltd., Walton Oaks, Dorking Road, 
Tadworth, Surrey, KT20 7NS.
CORRESPONDENCE ADDRESS
  F. Sivers, Primary Care Cardiovascular Society, 36 Berrymede Road, London, 
W4 5JD. Email: fransivers@pccs.org.uk
SOURCE
  British Journal of Cardiology (2009) 16:4 (187-191). Date of Publication: 
July/August 2009
ISSN
  0969-6113
BOOK PUBLISHER
  MediNews (Cardiology) Ltd, 3 Duchess Place, Edgbaston, Birmingham, United 
Kingdom.
ABSTRACT
  Considerable variation exists in adherence to and implementation of 
post-myocardial infarction (post-MI) clinical guidelines in the UK. The 
Follow Your Heart Steering Group has consolidated existing clinical evidence 
and published guidance into a consensus of succinct recommendations for 
optimal post-MI management, which includes separate healthcare professional 
and patient-focused components. This guidance should help encourage two-way 
dialogues between patients and healthcare professionals, reduce practice 
variation, raise standards of care, maximise healthcare resource utilisation 
and improve outcomes in post-MI patients. It is our intention to develop and 
widely disseminate a simple algorithm for healthcare professionals and for 
patients that summarises the guidance.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  aldosterone antagonist (drug therapy)
  angiotensin receptor antagonist (drug therapy)
  antithrombocytic agent (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  antilipemic agent (drug therapy)
  atorvastatin (drug dose, drug therapy)
  beta adrenergic receptor blocking agent (drug dose, drug therapy)
  bisoprolol (drug dose, drug therapy)
  cholesterol
  clopidogrel (drug therapy)
  eplerenone (drug therapy)
  ezetimibe (drug dose, drug therapy)
  hemoglobin A1c (endogenous compound)
  high density lipoprotein cholesterol
  losartan (drug therapy)
  low density lipoprotein cholesterol
  perindopril (drug therapy)
  ramipril (drug therapy)
  rosuvastatin (drug dose, drug therapy)
  simvastatin (drug dose, drug therapy)
  spironolactone (drug dose, drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart infarction (drug therapy, disease management, drug therapy, 
rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
  add on therapy
  algorithm
  anticoagulant therapy
  atrial fibrillation
  blood pressure regulation
  clinical practice
  coronary stent
  drug dose titration
  drug substitution
  drug withdrawal
  evidence based practice
  exercise
  glucose blood level
  heart failure (complication, drug therapy)
  heart rehabilitation
  hospital discharge
  human
  hyperlipidemia (drug therapy)
  hypertension (drug therapy)
  kidney function test
  laboratory test
  lifestyle modification
  lipid blood level
  liver function test
  low drug dose
  low fat diet
  Mediterranean diet
  national health service
  patient care
  patient monitoring
  percutaneous coronary intervention
  practice guideline
  primary medical care
  recommended drug dose
  review
  risk benefit analysis
  smoking cessation
  sodium restriction
  thromboembolism (complication, drug therapy, prevention)
  treatment indication
  United Kingdom
  weight reduction
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  atorvastatin (134523-00-5, 134523-03-8)
  bisoprolol (66722-44-9)
  cholesterol (57-88-5)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  eplerenone (107724-20-9)
  ezetimibe (163222-33-1)
  hemoglobin A1c (62572-11-6)
  losartan (114798-26-4)
  perindopril (82834-16-0)
  ramipril (87333-19-5)
  rosuvastatin (147098-18-8, 147098-20-2)
  simvastatin (79902-63-9)
  spironolactone (52-01-7)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009425790
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 396
TITLE
  Howtoavoidaheartattack: Putting it all together
AUTHOR NAMES
  Haffey T.A.
AUTHOR ADDRESSES
  (Haffey T.A., thaffey@yahoo.com) Department of Medicine, Western University, 
Health Sciences College of Osteopathic Medicine of the Pacific, Pomona, CA, 
United States.
(Haffey T.A., thaffey@yahoo.com) Department of Medicine, Kirksville College 
of Osteopathic Medicine, A.T. Still University, Kirksville, MO, United 
States.
(Haffey T.A., thaffey@yahoo.com) American College of Cardiology Colorado, .
(Haffey T.A., thaffey@yahoo.com) 9141 Grant St, Thornton, CO 80229-4367, 
United States.
CORRESPONDENCE ADDRESS
  T. A. Haffey, 9141 Grant St, Thornton, CO 80229-4367, United States. Email: 
thaffey@yahoo.com
SOURCE
  Journal of the American Osteopathic Association (2009) 109:5 SUPPL. 1 
(S14-S20). Date of Publication: May 2009
ISSN
  0098-6151
  0098-6151 (electronic)
BOOK PUBLISHER
  American Osteopathic Association, 142 East Ontario Street, Chicago, United 
States.
ABSTRACT
  Cardiovascular disease (eg, myocardial infarction, ischemic stroke) is the 
leading cause of death in patients who have metabolic syndrome and diabetes 
mellitus. By effectively treating the whole patient, however, the risk of 
death from cardiovascular disease can be reduced or prevented. The author 
describes clinical approaches for achieving this goal. He reviews 
information that is useful to know about patients regarding modifiable and 
potentially modifiable risk factors for cardiovascular disease, including 
hypertension, hyperlipidemia, smoking, activity levels, dietary habits, 
obesity, carotid artery stenosis, and atrial fibrillation. He also notes the 
importance of evaluating patients for relevant psychosocial factors such as 
depression. Finally, the author analyzes treatment options for patients, 
including effective medications, dietary modification, and exercise - 
emphasizing the use of pedometers - as well as participation by patients in 
weight-control support groups.
EMTREE DRUG INDEX TERMS
  apolipoprotein A (endogenous compound)
  apolipoprotein B (endogenous compound)
  high density lipoprotein cholesterol (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  abdominal obesity
  diabetes mellitus
  heart infarction
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  diet
  exercise
  fruit
  human
  pedometer
  review
  risk
  risk factor
  smoking
  smoking
  social psychology
  vegetable
  weight control
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009281280
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 397
TITLE
  Recent landmark studies in cardiology presented at American College of 
Cardiology '09
AUTHOR NAMES
  Jain P.
  Chopra H.K.
AUTHOR ADDRESSES
  (Jain P., peeyush.jain@fortishealthcare.com) Deapartment of Preventive 
Cardiolofy, Escorts Heart Institute and Research Centre, Okhla Road, New 
Delhi 110 025, India.
(Chopra H.K.) Moolchand Medicity, New Delhi 11 0024, India.
CORRESPONDENCE ADDRESS
  P. Jain, Deapartment of Preventive Cardiolofy, Escorts Heart Institute and 
Research Centre, Okhla Road, New Delhi 110 025, India. Email: 
peeyush.jain@fortishealthcare.com
SOURCE
  Indian Heart Journal (2009) 61:3 (292-295). Date of Publication: May-June 
2009
ISSN
  0019-4832
  0019-4832 (electronic)
BOOK PUBLISHER
  Cardiology Society of India, Okhla Road, New Delhi, India.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug combination, drug therapy)
  alteplase (intravenous drug administration)
  atorvastatin (drug therapy)
  brain natriuretic peptide (endogenous compound)
  clopidogrel (drug combination, drug therapy)
  creatine kinase (endogenous compound)
  diuretic agent (drug therapy)
  eptifibatide (drug therapy)
  fluindostatin (drug therapy)
  heparin (drug therapy)
  high density lipoprotein cholesterol (endogenous compound)
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  low density lipoprotein cholesterol (endogenous compound)
  pitavastatin (drug therapy)
  placebo
  pravastatin (drug therapy)
  rosuvastatin
  troponin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease
EMTREE MEDICAL INDEX TERMS
  acute coronary syndrome (drug therapy)
  atrial fibrillation (drug therapy)
  bleeding
  catheter ablation
  cause of death
  cerebrovascular disease
  coronary artery atherosclerosis (drug therapy)
  coronary artery bypass graft
  drug megadose
  exercise
  heart catheterization
  heart failure (epidemiology)
  heart infarction (drug therapy)
  heart muscle ischemia
  hemodiafiltration
  human
  hypertension (drug therapy)
  kidney failure (therapy)
  morbidity
  mortality
  non st segment elevation acute coronary syndrome (drug therapy)
  non st segment elevation acute coronary syndrome (drug therapy)
  percutaneous coronary intervention
  review
  stable angina pectoris (drug therapy)
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alteplase (105857-23-6)
  atorvastatin (134523-00-5, 134523-03-8)
  brain natriuretic peptide (114471-18-0)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  creatine kinase (9001-15-4)
  eptifibatide (148031-34-9)
  fluindostatin (93957-54-1)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  pitavastatin (147526-32-7)
  pravastatin (81131-74-0)
  rosuvastatin (147098-18-8, 147098-20-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2010013492
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 398
TITLE
  Improving outcomes in cardiovascular disease: An Invest to Save guide for 
practice based commissioners
AUTHOR NAMES
  Kearney M.
  Chellaswamy H.
AUTHOR ADDRESSES
  (Kearney M.) NHS Knowsley, Westmorland Road, Huyton, L36 6GA, United 
Kingdom.
(Chellaswamy H.) Deputy Director of Public Health, NHS Sefton, Burlington 
House, Crosby Rd North, Liverpool, L22 0QB, United Kingdom.
CORRESPONDENCE ADDRESS
  M. Kearney, NHS Knowsley, Westmorland Road, Huyton, L36 6GA, United Kingdom.
SOURCE
  Primary Care Cardiovascular Journal (2009) 2:2 (83-86). Date of Publication: 
April/May/June 2009
ISSN
  1756-5138
  1756-5146 (electronic)
BOOK PUBLISHER
  Sherborne Gibbs Limited, 3 Duchess Place, Edgbaston Birmingham, United 
Kingdom.
ABSTRACT
  Context: Cardiovascular disease has an enormous impact on people's lives. It 
is a major cause of disability and reduced life expectancy, and accounts for 
one third of all deaths. It consumes vast resources in primary and secondary 
care. It is also very preventable. Comparison of our mortality rates with 
those in countries such as Japan, France and Spain suggests that eight out 
of 10 CVD deaths in England could be avoided through improved treatment and 
active prevention. Yet, although many patients receive excellent care, there 
is significant variation between practices in the diagnosis and treatment of 
this group of conditions. In common with other long-term conditions, there 
is also substantial under-diagnosis. Such variation in management and delay 
in detection worsens patient outcomes and heightens health inequalities. It 
is also very expensive as it increases rates of complication and hospital 
admission. Design: The Invest to Save guide reviews the extensive evidence 
base for promoting prevention and optimising treatment in CVD. It examines 
current gaps in prevention and treatment in primary care and provides a 
framework for practice based commissioning (PBC) groups to use savings to 
fund a more systematic approach to the management of CVD in primary care. 
The framework focuses on increasing case-finding in CVD risk, hypertension, 
atrial fibrillation and diabetes, targeting preventive interventions on 
those at high CVD risk and improving the management of those with 
established disease.
EMTREE DRUG INDEX TERMS
  cholesterol (endogenous compound)
  hydroxymethylglutaryl coenzyme A reductase inhibitor
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (disease management, prevention)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  cardiovascular risk
  cholesterol blood level
  clinical practice
  diabetes mellitus
  diet
  disability
  funding
  health care quality
  health promotion
  heart death
  hospital admission
  human
  hypertension
  life expectancy
  mortality
  obesity
  outcome assessment
  patient care
  physical activity
  primary medical care
  review
  smoking
CAS REGISTRY NUMBERS
  cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009282404
FULL TEXT LINK
  http://dx.doi.org/10.3132/pccj.2009.021
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 399
TITLE
  Alternative and Complementary Medicine for Preventing and Treating 
Cardiovascular Disease
AUTHOR NAMES
  Frishman W.H.
  Beravol P.
  Carosella C.
AUTHOR ADDRESSES
  (Frishman W.H.; Beravol P.; Carosella C.)
SOURCE
  Disease-a-Month (2009) 55:3 (121-192). Date of Publication: March 2009
ISSN
  0011-5029
BOOK PUBLISHER
  Mosby Inc., 11830 Westline Industrial Drive, St. Louis, United States.
EMTREE DRUG INDEX TERMS
  alpha tocopherol (clinical trial, drug therapy, pharmacology)
  ascorbic acid (adverse drug reaction, drug therapy, pharmacology)
  beta carotene (drug therapy, pharmacology)
  carotenoid (drug therapy)
  chondroitin (drug combination, drug therapy)
  cyanocobalamin
  Echinacea extract (drug therapy)
  flavonoid
  folic acid
  garlic extract (drug therapy)
  Ginkgo biloba extract (drug therapy)
  ginseng extract (drug therapy)
  glucosamine (drug combination, drug therapy)
  herbaceous agent (drug therapy)
  lycopene (drug therapy)
  magnesium (drug therapy, intravenous drug administration)
  nicotinamide (drug therapy, pharmacology)
  nicotinic acid (adverse drug reaction, drug therapy, pharmaceutics, 
pharmacokinetics, pharmacology)
  placebo
  polyphenol derivative
  proanthocyanidin derivative
  pyridoxine
  quercetin
  reserpine (drug therapy)
  resveratrol (pharmacology)
  thiamine
  unindexed drug
  vitamin B group (clinical trial, drug therapy)
  vitamin D (drug therapy)
  vitamin K group
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
  acanthosis nigricans (side effect)
  alternative medicine
  angina pectoris (complication, drug therapy)
  antioxidant activity
  aromatherapy
  asthma (side effect)
  atherosclerosis (drug therapy)
  atrial fibrillation (drug therapy, prevention)
  behavior therapy
  breathing exercise
  cacao
  cardiovascular risk
  cerebrovascular accident (drug therapy, prevention)
  chelation therapy
  Chinese medicine
  clinical trial
  coronary artery disease (drug therapy, prevention)
  coronary artery spasm
  diet supplementation
  drug formulation
  drug megadose
  drug metabolism
  drug safety
  feedback system
  flushing
  gastrointestinal symptom (side effect)
  grape juice
  guided imagery
  heart infarction (drug therapy, prevention)
  heart protection
  heart ventricle arrhythmia (drug therapy, prevention)
  herbal medicine
  homeopathy
  human
  humor
  hypercholesterolemia (drug therapy)
  hyperhomocysteinemia (drug therapy)
  hyperlipidemia (drug therapy)
  hypertension (drug therapy)
  iron overload (side effect)
  liver toxicity (side effect)
  magnesium deficiency
  magnetotherapy
  medical practice
  meditation
  muscle cramp (drug therapy)
  music therapy
  nonhuman
  nonverbal communication
  osteopathic medicine
  patient satisfaction
  pet therapy
  Polygalaceae
  prophylaxis
  pruritus (side effect)
  red wine
  reflexology
  review
  sauna
  side effect (side effect)
  spinal cord stimulation
  Stephania
  sustained drug release
  Tai Chi
  tea
  transcutaneous nerve stimulation
  vasodilatation
  vitamin supplementation
  yoga
DRUG TRADE NAMES
  niaspan
CAS REGISTRY NUMBERS
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
  beta carotene (7235-40-7)
  chondroitin (9007-27-6)
  cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
  folic acid (59-30-3, 6484-89-5)
  glucosamine (3416-24-8, 4607-22-1)
  lycopene (502-65-8)
  magnesium (7439-95-4)
  nicotinamide (11032-50-1, 98-92-0)
  nicotinic acid (54-86-4, 59-67-6)
  pyridoxine (12001-77-3, 58-56-0, 65-23-6, 8059-24-3)
  quercetin (117-39-5)
  reserpine (50-55-5, 8001-95-4)
  resveratrol (501-36-0)
  thiamine (59-43-8, 67-03-8)
  vitamin B group (12001-76-2)
  vitamin K group (12001-79-5)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Pharmacy (39)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2009064269
MEDLINE PMID
  19215737 (http://www.ncbi.nlm.nih.gov/pubmed/19215737)
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.disamonth.2008.12.002
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 400
TITLE
  Detection and treatment of sublesional osteoporosis among patients with 
chronic spinal cord injury: Proposed paradigms
AUTHOR NAMES
  Craven B.C.
  Robertson L.A.
  McGillivray C.F.
  Adachi J.D.
AUTHOR ADDRESSES
  (Craven B.C.; Robertson L.A.) Toronto Rehabilitation Institute, Lyndhurst 
Centre, Toronto, ON, Canada.
(Craven B.C.; McGillivray C.F.) Department of Medicine, University of 
Toronto, Toronto, ON, Canada.
(McGillivray C.F.) Toronto Rehabilitation Institute, Lyndhurst Centre, 
Spinal Cord Rehab. Program, Toronto, ON, Canada.
(Adachi J.D.) Department of Medicine, McMaster University, St. Joseph's 
Hospital, Hamilton, ON, Canada.
CORRESPONDENCE ADDRESS
  B. C. Craven, Toronto Rehabilitation Institute, Lyndhurst Centre, Toronto, 
ON, Canada.
SOURCE
  Topics in Spinal Cord Injury Rehabilitation (2009) 14:4 (1-22). Date of 
Publication: 1 Mar 2009
ISSN
  1082-0744
BOOK PUBLISHER
  Thomas Land Publishers Inc., 255 Jefferson Road, St. Louis, United States.
ABSTRACT
  Low hip and knee region bone mineral density (BMD) after spinal cord injury 
(SCI) results in an increased risk of lower extremity fragility fractures or 
sublesional osteoporosis (SLOP). There are currently no guidelines for the 
identification and treatment of SLOP among patients with chronic SCI. A 
paradigm for identification (medical screening, fracture risk, and bone 
mineral density assessment) of persons with SLOP who warrant treatment and 
selection of appropriate SLOP treatment(s) (lifestyle/nutrition 
modifications, bisphosphonate/rehabilitation therapies) is proposed. Content 
is based on the authors' opinions/expertise and available published and 
unpublished literature and is intended for use by rehabilitation 
professionals. © 2009 Thomas Land Publishers, Inc.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction)
  alendronic acid (adverse drug reaction, clinical trial, drug comparison, 
drug therapy, oral drug administration)
  bisphosphonic acid derivative (drug therapy, oral drug administration)
  caffeine
  calcium (clinical trial, drug comparison)
  carbamazepine (drug therapy)
  colecalciferol (drug therapy)
  corticosteroid (adverse drug reaction)
  nonsteroid antiinflammatory agent (adverse drug reaction)
  pregabalin (drug therapy)
  valproic acid (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  fragility fracture (complication, diagnosis, prevention, rehabilitation, 
therapy)
  osteoporosis (drug therapy, complication, diagnosis, drug therapy, 
prevention, rehabilitation, therapy)
  spinal cord injury (rehabilitation, therapy)
  sublesional osteoporosis (complication, diagnosis, prevention, 
rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal pain (side effect)
  aging
  alcohol consumption
  atrial fibrillation (side effect)
  bone densitometry
  bone density
  chronic disease
  clinical assessment
  clinical trial
  coffee
  diagnostic test
  diarrhea (side effect)
  drug substitution
  drug withdrawal
  dyspepsia (side effect)
  flatulence (side effect)
  gastrointestinal reflux (side effect)
  gastrointestinal symptom (side effect)
  health
  health program
  health status
  hip
  human
  hypocalcemia (side effect)
  hypogonadism (drug therapy)
  jaw osteonecrosis (side effect)
  knee
  lifestyle modification
  liver toxicity (side effect)
  neuropathic pain (drug therapy)
  nutritional assessment
  patient identification
  practice guideline
  quadriplegia
  review
  risk factor
  screening
  smoking
  smoking cessation
  sport
  stomach ulcer (side effect)
  vitamin supplementation
  world health organization
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alendronic acid (66376-36-1)
  caffeine (58-08-2)
  calcium (7440-70-2)
  carbamazepine (298-46-4, 8047-84-5)
  colecalciferol (1406-16-2, 67-97-0)
  pregabalin (148553-50-8)
  valproic acid (1069-66-5, 99-66-1)
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  Neurology and Neurosurgery (8)
  Rehabilitation and Physical Medicine (19)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009376334
FULL TEXT LINK
  http://dx.doi.org/10.1310/sci1404-1
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 401
TITLE
  Ventricular hypertrophy and heart failure in elderly and very old population 
with high blood pressure
AUTHOR NAMES
  Cârstea D.
  Streba L.M.
  Cârstea A.P.
AUTHOR ADDRESSES
  (Cârstea D., dag_carstea@yahoo.com; Streba L.M.; Cârstea A.P.) Department of 
Cardiology, Clinical Municipals Hospital Filantropia, University of Medicine 
and Pharmacy of Craiova, No. 3 Street Constantin Brâncusi, 200314 Craiova, 
Romania.
CORRESPONDENCE ADDRESS
  D. Cârstea, Department of Cardiology, Clinical Municipals Hospital 
Filantropia, University of Medicine and Pharmacy of Craiov, No. 3 Street 
Constantin Brâncusi, 200314 Craiova, Romania. Email: dag_carstea@yahoo.com
SOURCE
  Archives of the Balkan Medical Union (2009) 44:1 (56-60). Date of 
Publication: March 2009
ISSN
  1584-9244
BOOK PUBLISHER
  Celsius Publishing House, G. Clemenceau Street 1, Bucharest, Romania.
ABSTRACT
  Framingham Study reveals in 2003 that from the patients with heart failure, 
about 75% of them had a history of arterial hypertension and only 25% 
suffered a myocardial infarction. During the evolution of high blood 
pressure (HBP), in years, the increase of left ventricular mass, appears to 
be initially a useful compensatory process, but with ages might reflect the 
influence that other risk factors exert with time. From hypertrophy to 
dilatation of the left ventricular and to the heart failure are only two 
steps! Hypertesion in elderly (those over the age of 65), and very old 
people (over 80 years old), is an extremely increasing public health 
concern. Prospective studies have examined the potential benefits of 
regression of the left ventricular hypertrophy, and have demonstrated that 
changes in left ventricular mass, during treatment may imply an important 
benefit. Hypertension usually is followed by left ventricular hypertrophy, 
but can also lead directly to the developement of heart failure by several 
mechanisms, alone or in combination. Hospitalizations for congestive heart 
failure (CHF) are increasing dramatically all over the world reason for 
which the prevention of CHF should be a major treatment goal. Copyright © 
2009 Celsius.
EMTREE DRUG INDEX TERMS
  antihypertensive agent (drug therapy)
  brain natriuretic peptide (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  congestive heart failure (diagnosis, prevention)
  elderly care
  heart ventricle hypertrophy (diagnosis)
  hypertension (drug therapy, drug therapy)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  blood pressure monitoring
  blood pressure regulation
  capillary pressure
  comorbidity
  coronary artery blood flow
  diabetes mellitus
  Doppler echocardiography
  echocardiography
  electrocardiography
  exercise
  heart dilatation
  heart ejection fraction
  heart hemodynamics
  heart left ventricle mass
  heart muscle contractility
  heart repolarization
  hospitalization
  human
  morbidity
  mortality
  prevalence
  protein blood level
  regression analysis
  review
CAS REGISTRY NUMBERS
  brain natriuretic peptide (114471-18-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, French
EMBASE ACCESSION NUMBER
  2009257815
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 402
TITLE
  Atrial fibrillation: Pathogenesis, medical-surgical management and dental 
implications
AUTHOR NAMES
  Friedlander A.H.
  Yoshikawa T.T.
  Chang D.S.
  Feliciano Z.
  Scully C.
AUTHOR ADDRESSES
  (Friedlander A.H., arthur.friedlander@med.va.gov) VA Greater Los Angeles 
Healthcare System, 11301 Wilshire Blvd., Los Angeles, CA 90073, United 
States.
(Yoshikawa T.T.) Geriatric Research Education and Clinical Center, VA 
Greater Los Angeles Healthcare System, David Geffen School of Medicine at 
UCLA, Los Angeles, United States.
(Chang D.S.) UCLA-VA, VA Greater Los Angeles/San Fernando Valley Program, 
David Geffen School of Medicine at UCLA, Los Angeles, United States.
(Feliciano Z.) VA Greater Los Angeles Healthcare System, David Geffen School 
of Medicine at UCLA, Los Angeles, United States.
(Scully C.) University College London Eastman Dental Institute, .
CORRESPONDENCE ADDRESS
  A.H. Friedlander, VA Greater Los Angeles Healthcare System, 11301 Wilshire 
Blvd., Los Angeles, CA 90073, United States. Email: 
arthur.friedlander@med.va.gov
SOURCE
  Journal of the American Dental Association (2009) 140:2 (167-177). Date of 
Publication: February 2009
ISSN
  0002-8177
BOOK PUBLISHER
  American Dental Association, 211 E. Chicago Avenue, Chicago, United States.
ABSTRACT
  Background. Atrial fibrillation (AF) is a cardiac rhythm disturbance arising 
from disorganized electrical activity in the atria, and it is accompanied by 
an irregular and often rapid ventricular response. It is the most common 
clinically significant dysrhythmia in the general and older population. 
Types of Studies Reviewed. The authors conducted a MEDLINE search using the 
key terms "atrial fibrillation," "epidemiology," "pathophysiology," 
"treatment" and "dentistry." They selected contemporaneous articles 
published in peer-reviewed journals and gave preference to articles 
reporting randomized controlled trials. Clinical Implications. The 
anticoagulant warfarin frequently is prescribed to prevent stroke caused by 
cardiogenic thromboemboli arising from stagnant blood in poorly contracting 
atria. Most dental procedures and a limited number of surgical procedures 
can be performed without altering warfarin dosage if the international 
normalized ratio value is within the therapeutic range of 2.0 to 3.0. 
Certain analgesic agents, antibiotic agents, antifungal agents and sedative 
hypnotics, however, should not be prescribed without consultation with the 
patient's physician because these medications may alter the patient's risk 
of hemorrhage and stroke. Conclusions. AF affects nearly 2.5 million 
Americans, most of who are older than 60 years. Consultation with the 
patient's physician to discuss the planned dental treatment often is 
appropriate, especially for people who frequently have comorbid diseases 
such as coronary artery disease, congestive heart failure, diabetes and 
thyrotoxicosis, which are treated with multiple drug regimens.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (therapy)
  dental procedure
EMTREE MEDICAL INDEX TERMS
  bleeding (prevention)
  cerebrovascular accident (prevention)
  drug contraindication
  human
  oral surgery
  pathophysiology
  review
CAS REGISTRY NUMBERS
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
MEDLINE PMID
  19188413 (http://www.ncbi.nlm.nih.gov/pubmed/19188413)
COPYRIGHT
  MEDLINE® is the source for the citation and abstract of this record.

RECORD 403
TITLE
  American Society for Clinical Pharmacology and Therapeutics - Abstracts of 
Papers, 2009 Annual Meeting
AUTHOR ADDRESSES
  SOURCE
  Clinical Pharmacology and Therapeutics (2009) 85 SUPPL. 1. Date of 
Publication: February 2009
CONFERENCE NAME
  110th Annual Meeting of the American Society for Clinical Pharmacology and 
Therapeutics, ASCPT 2009
CONFERENCE LOCATION
  National Harbor, MD, United States
CONFERENCE DATE
  2009-03-18 to 2009-03-21
ISSN
  0009-9236
BOOK PUBLISHER
  Nature Publishing Group
ABSTRACT
  The proceedings contain 303 papers. The topics discussed include: prediction 
of infant drug exposure through breastfeeding: population PK modeling and 
simulation of fluoxetine; atrial fibrillation and inflammation: modulation 
by ACE inhibitors and statins; effect of genetic variation in ABCC2 on the 
renal clearance of cisplatin; validation of physiologically-based 
simulations for cidofovir pharmacokinetics in critically ill paediatric 
patients; norepinephrine transporter polymorphisms affect blood pressure 
response to exercise; the application of pharmacometabolomics to predict the 
pharmacokinetics of tacrolimus in healthy Korean subjects; design, 
synthesis, and in vivo pharmacologic actions of a novel peptide integrating 
human C-type natriuretic peptide, urodilatin, and B-type natriuretic 
peptide; and matrix metalloproteinase-9 functional polymorphism affects the 
enzyme plasma levels in HIV patients in antiretroviral therapy.
EMTREE DRUG INDEX TERMS
  brain natriuretic peptide
  cidofovir
  cisplatin
  dipeptidyl carboxypeptidase inhibitor
  enzyme
  fluoxetine
  gelatinase B
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  natriuretic peptide type C
  noradrenalin transporter
  peptide
  tacrolimus
  urodilatin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  clinical pharmacology
  society
  therapy
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  blood level
  blood pressure
  critically ill patient
  drug exposure
  drug mechanism
  exercise
  genetic variability
  human
  Human immunodeficiency virus
  infant
  inflammation
  model
  modulation
  patient
  pharmacokinetics
  population
  prediction
  renal clearance
  simulation
  synthesis
LANGUAGE OF ARTICLE
  English
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 404
TITLE
  Interventions to improve treatment of osteoporosis following fracture
AUTHOR NAMES
  Schafer A.L.
  Sellmeyer D.E.
AUTHOR ADDRESSES
  (Schafer A.L., anne.schafer@ucsf.edu) Division of Endocrinology, Metabolism, 
and Osteoporosis, University of California, San Francisco, San Francisco, 
CA.
(Sellmeyer D.E.) Division of Endocrinology and Metabolism, Johns Hopkins 
Bayview Medical Center, Baltimore, MD.
(Schafer A.L., anne.schafer@ucsf.edu) 2200 Post St., San Francisco, CA 
94115.
CORRESPONDENCE ADDRESS
  A. L. Schafer, 2200 Post St., San Francisco, CA 94115. Email: 
anne.schafer@ucsf.edu
SOURCE
  Journal of Clinical Outcomes Management (2008) 15:12 (587-594). Date of 
Publication: December 2008
ISSN
  1079-6533
BOOK PUBLISHER
  Turner White Communications Inc., 125 Strafford Avenue, Suite 220, Wayne, 
United States.
ABSTRACT
  Objective: To review the approach to osteoporosis treatment following 
fracture. Methods: Review of the literature. Results: Despite the tremendous 
medical and economic impact of osteoporotic fractures, the majority of older 
patients with fragility fractures do not subsequently receive appropriate 
evaluation and therapy for osteoporosis. Relatively simple interventions can 
increase the likelihood that a patient who sustains a fracture will receive 
subsequent evaluation and therapy; however, the implementation of 
interdisciplinary approaches and coordination of fracture treatment among 
primary care providers, orthopedists, metabolic bone experts, dietitians, 
physical therapists, and other pertinent health care professionals has been 
a challenge for health care delivery systems. The comprehensive management 
of osteoporosis includes evaluation of bone mineral density, assessment for 
secondary causes of low bone density, initiation of nonpharmacologic 
therapies such as improved nutrition and physical activity, and selection of 
appropriate pharmacologic therapy. Effective pharmacologic options now 
include oral or intravenous bisphosphonates, anabolic therapy with 
parathyroid hormone, selective estrogen receptor modulator therapy with 
raloxifene, intranasal calcitonin, and estrogen therapy. Conclusion: 
Individual clinicians and health systems alike must minimize missed 
opportunities for meaningful secondary prevention of fractures, especially 
as the options expand for safe and efficacious treatment of osteoporosis.
EMTREE DRUG INDEX TERMS
  alendronic acid (adverse drug reaction, clinical trial, drug combination, 
drug therapy, oral drug administration)
  anticonvulsive agent
  calcitonin (adverse drug reaction, clinical trial, drug therapy, intranasal 
drug administration)
  calcium (clinical trial, drug therapy)
  estrogen (clinical trial, drug combination, drug therapy)
  gestagen (clinical trial, drug combination, drug therapy)
  glucocorticoid
  heparin
  ibandronic acid (adverse drug reaction, clinical trial, drug combination, 
drug therapy, intravenous drug administration, oral drug administration)
  parathyroid hormone (clinical trial, drug combination, drug therapy)
  parathyroid hormone[1-34] (adverse drug reaction, drug therapy)
  placebo
  raloxifene (clinical trial, drug combination, drug therapy, pharmacology)
  risedronic acid (adverse drug reaction, clinical trial, drug combination, 
drug therapy, oral drug administration)
  vitamin D (clinical trial, drug dose, drug therapy)
  zoledronic acid (adverse drug reaction, clinical trial, drug combination, 
drug therapy, intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  fragility fracture (complication, drug therapy, prevention, therapy)
  osteoporosis (diagnosis, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (side effect)
  bone density
  bone pain (side effect)
  caregiver
  clinical trial
  continuous infusion
  diet supplementation
  dietitian
  disease exacerbation
  drug substitution
  drug withdrawal
  fever (side effect)
  flu like syndrome (side effect)
  groups by age
  health care delivery
  human
  jaw osteonecrosis (side effect)
  myalgia (side effect)
  nose irritation (side effect)
  osteosarcoma (side effect)
  physical activity
  physiotherapist
  recommended drug dose
  review
  vitamin supplementation
CAS REGISTRY NUMBERS
  alendronic acid (66376-36-1)
  calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
  calcium (7440-70-2)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  ibandronic acid (114084-78-5, 138844-81-2, 138926-19-9)
  parathyroid hormone (12584-96-2, 68893-82-3, 9002-64-6)
  parathyroid hormone[1-34] (12583-68-5, 52232-67-4)
  raloxifene (82640-04-8, 84449-90-1)
  risedronic acid (105462-24-6, 122458-82-6)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Orthopedic Surgery (33)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009079882
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 405
TITLE
  Early complications of ischemic stroke
AUTHOR NAMES
  Bart van der Worp H.
  Dianne Raaijmakers T.W.M.
  Jaap Kappelle L.
AUTHOR ADDRESSES
  (Bart van der Worp H., h.b.vanderworp@umcutrecht.nl; Dianne Raaijmakers 
T.W.M.; Jaap Kappelle L.) Department of Neurology, Rudolf Magnus Institute 
of Neuroscience, University Medical Center Utrecht, Heidelberglaan 100, 3584 
CX Utrecht, Netherlands.
CORRESPONDENCE ADDRESS
  H. Bart van der Worp, Department of Neurology, Rudolf Magnus Institute of 
Neuroscience, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX 
Utrecht, Netherlands. Email: h.b.vanderworp@umcutrecht.nl
SOURCE
  Current Treatment Options in Neurology (2008) 10:6 (440-449). Date of 
Publication: 2008
ISSN
  1092-8480
BOOK PUBLISHER
  Current Science Ltd, 34-42 Cleveland Street, London, United Kingdom.
ABSTRACT
  Patients with acute ischemic stroke are at high risk of neurologic and 
medical complications, such as space-occupying edema formation, hemorrhagic 
transformation of the infarct, epileptic seizures, depression, and venous 
thromboembolism. They should therefore be monitored closely for early 
detection of these complications. Care is best when the patient is admitted 
to a specialized stroke unit. The multidisciplinary approach provided by 
stroke units, including specialized medical, nursing, and remedial 
therapies, reduces the duration of hospitalization and improves functional 
outcome. For many complications, however, optimal treatment and its effect 
on functional outcome after stroke has not been established. Therefore, in 
addition to the ongoing acute intervention trials, well-designed, large 
randomized trials are needed to address the prevention and treatment of 
complications and their effect on functional outcome. © Springer 
Science+Business Media, LLC 2008.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  alteplase (drug therapy)
  antibiotic agent (drug therapy)
  anticoagulant agent (adverse drug reaction, drug therapy)
  antihypertensive agent (drug therapy)
  chlorpromazine (adverse drug reaction, drug therapy)
  glucose (clinical trial, drug combination, drug therapy)
  haloperidol (drug dose, drug therapy)
  heparin (drug dose, drug therapy, subcutaneous drug administration)
  insulin (clinical trial, drug combination, drug therapy)
  labetalol (drug therapy, intravenous drug administration)
  low molecular weight heparin (drug therapy, subcutaneous drug 
administration)
  meclofenoxate (drug therapy)
  nitroprusside sodium (drug therapy)
  paracetamol (drug dose, drug therapy)
  potassium (clinical trial, drug combination, drug therapy)
  serotonin uptake inhibitor (drug therapy)
  tricyclic antidepressant agent (adverse drug reaction, drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (drug therapy)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (complication, drug therapy)
  brain edema (complication, surgery, therapy)
  brain hemorrhage (complication, drug therapy, side effect)
  clinical trial
  compression therapy
  coronary artery disease (complication, diagnosis)
  decompression surgery
  decubitus (complication, prevention, therapy)
  deep vein thrombosis (complication, diagnosis, drug therapy, therapy)
  delirium (complication, drug therapy)
  depression (complication, drug therapy)
  diet supplementation
  drug megadose
  drug treatment failure
  dysphagia (complication, therapy)
  ECG abnormality (complication)
  exercise
  feeding apparatus
  fever (complication, drug therapy)
  functional status
  hiccup (complication, drug therapy)
  human
  hyperglycemia (complication, drug therapy)
  hypertension (complication, drug therapy)
  hypotension (complication)
  intracranial pressure
  leg phlebography
  low drug dose
  lung embolism (complication)
  malnutrition (complication, therapy)
  mortality
  physiotherapy
  pneumonia (complication, drug therapy, prevention)
  prognosis
  recurrent disease
  respiratory tract infection (complication, drug therapy, prevention)
  review
  sedation
  seizure (complication, drug therapy, prevention)
  shoulder pain (complication, prevention, therapy)
  side effect (side effect)
  therapeutic hyperventilation
  unspecified side effect (side effect)
  urine incontinence (complication, drug therapy)
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alteplase (105857-23-6)
  chlorpromazine (50-53-3, 69-09-0)
  glucose (50-99-7, 84778-64-3)
  haloperidol (52-86-8)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  insulin (9004-10-8)
  labetalol (32780-64-6, 36894-69-6)
  meclofenoxate (3685-84-5, 51-68-3)
  nitroprusside sodium (14402-89-2, 15078-28-1)
  paracetamol (103-90-2)
  potassium (7440-09-7)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009044554
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11940-008-0046-5
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 406
TITLE
  Ivabradine - A novel treatment for chronic stable angina
AUTHOR NAMES
  Jackson J.M.
  Kassianos G.
AUTHOR ADDRESSES
  (Jackson J.M.; Kassianos G., editor@csfmedical.com) CSF Medical 
Communications Ltd, Montpellier Drive, Cheltenham GL50 1TA, United Kingdom.
CORRESPONDENCE ADDRESS
  G. Kassianos, CSF Medical Communications Ltd, Montpellier Drive, Cheltenham 
GL50 1TA, United Kingdom. Email: editor@csfmedical.com
SOURCE
  Drugs in Context (2008) 4:2 (135-152). Date of Publication: 2008
ISSN
  1745-1981
  1740-4398 (electronic)
BOOK PUBLISHER
  CSF Medical Communications Ltd, Suite 119, Eagle TowerMontpellier Drive, 
Cheltenham, United Kingdom.
ABSTRACT
  Heart rate is an important determinant of myocardial oxygen consumption and 
elevated heart rate is a known risk factor in coronary artery disease. Heart 
rate reduction has been the cornerstone of antianginal and antiischemic 
therapy for many years and is most often achieved by β-blockers. The 
discovery of the f-channel and its role in regulating pacemaker activity in 
the sinoatrial node led to the development of new pharmacological agents 
such as ivabradine, which target these f-channels causing a reduction in 
heart rate by inhibiting the I(f) current. Due to its specific and selective 
action, ivabradine does not display any of the negative inotropic peripheral 
vascular or central nervous system side-effects that have limited the use of 
β-blockers in some patients. Ivabradine efficacy has been investigated in a 
large clinical development programme involving 5000 participants including 
over 3500 patients with chronic stable angina, and was shown to reduce 
resting and exercise induced heart rate without modifying any 
electrophysiological parameters. It has been shown to reduce heart rate at 
rest and during exercise and improve measurable parameters of angina in a 
dose-dependent manner. Its antiianginal and antiischemic effects have also 
has been shown to be non-inferior to commonly use doses of atenolol and 
amlodipine. Ivabradine is currently licensed for oral use at 5 and 7.5mg 
twice daily for symptomatic treatment of chronic stable angina in patients 
with normal sinus rhythm who are either intolerant of β-blockers or for whom 
they are contraindicated. © 2008 CSF Medical Communications Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  ivabradine (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug concentration, drug dose, drug interaction, drug therapy, 
oral drug administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  amlodipine (adverse drug reaction, clinical trial, drug comparison, drug 
therapy)
  anticoagulant agent (drug combination, drug therapy)
  antilipemic agent (drug combination, drug therapy)
  atenolol (adverse drug reaction, clinical trial, drug comparison, drug 
therapy)
  cytochrome P450 3A4 (endogenous compound)
  dihydropyridine derivative (drug combination, drug therapy)
  diltiazem
  erythromycin
  ketoconazole
  lansoprazole (drug combination, drug interaction, oral drug administration)
  nitrate (drug combination, drug therapy)
  omeprazole (drug combination, drug interaction, oral drug administration)
  oxygen (endogenous compound)
  placebo
  propranolol (clinical trial, drug comparison, drug therapy)
  verapamil
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  stable angina pectoris (drug therapy)
EMTREE MEDICAL INDEX TERMS
  angina pectoris (side effect)
  article
  atrial fibrillation (side effect)
  atrioventricular block (side effect)
  channel gating
  clinical trial
  coronary artery disease
  drug absorption
  drug bioavailability
  drug blood level
  drug clearance
  drug contraindication
  drug dose comparison
  drug dose increase
  drug efficacy
  drug half life
  drug mechanism
  drug metabolism
  drug protein binding
  drug safety
  drug selectivity
  drug targeting
  drug tolerability
  evening dosage
  exercise
  heart electrophysiology
  heart infarction (side effect)
  heart left ventricle function
  heart muscle
  heart muscle ischemia (side effect)
  heart palpitation (side effect)
  heart rate
  heart ventricle extrasystole (side effect)
  heart ventricle tachycardia (side effect)
  human
  inotropism
  maximum plasma concentration
  morning dosage
  nonhuman
  oxygen consumption
  pacemaker
  prognosis
  rest
  risk factor
  single drug dose
  sinus bradycardia (side effect)
  sinus node
  sinus rhythm
  supraventricular premature beat (side effect)
  supraventricular tachycardia (side effect)
  time to maximum plasma concentration
  treatment outcome
  unstable angina pectoris (side effect)
  visual disorder (side effect)
DRUG TRADE NAMES
  procoralan
  s 16257
CAS REGISTRY NUMBERS
  amlodipine (88150-42-9)
  atenolol (29122-68-7)
  cytochrome P450 3A4 (329736-03-0)
  diltiazem (33286-22-5, 42399-41-7)
  erythromycin (114-07-8, 70536-18-4)
  ivabradine (148849-67-6, 148870-80-8, 155974-00-8)
  ketoconazole (65277-42-1)
  lansoprazole (103577-45-3)
  nitrate (14797-55-8)
  omeprazole (73590-58-6, 95510-70-6)
  oxygen (7782-44-7)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008508969
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 407
TITLE
  Predictors of Intention to Reduce Stroke Risk Among People at Risk of 
Stroke: An Application of an Extended Health Belief Model
AUTHOR NAMES
  Sullivan K.A.
  White K.M.
  Young R.M.
  Chang A.
  Roos C.
  Scott C.
AUTHOR ADDRESSES
  (Sullivan K.A., ka.sullivan@qut.edu.au; White K.M.; Young R.M.; Chang A.; 
Roos C.; Scott C.) Institute of Health and Biomedical Innovation, .
(Sullivan K.A., ka.sullivan@qut.edu.au; White K.M.; Roos C.; Scott C.) 
School of Psychology and Counselling, Queensland University of Technology, 
QLD, Australia.
(Chang A.) School of Nursing, Queensland University of Technology, QLD, 
Australia.
CORRESPONDENCE ADDRESS
  K.A. Sullivan, Institute of Health and Biomedical Innovation, . Email: 
ka.sullivan@qut.edu.au
SOURCE
  Rehabilitation Psychology (2008) 53:4 (505-512). Date of Publication: 
November 2008
ISSN
  0090-5550
BOOK PUBLISHER
  American Psychological Association Inc., 750 First Street NE, Washington, 
United States.
ABSTRACT
  Purpose: To examine predictors of intention to reduce stroke risk in a 
sample of at risk individuals through the application of an expanded Health 
Belief Model. Research Method: Predictors included stroke knowledge, 
demographic variables, beliefs about stroke, and measures of subjective norm 
and self-efficacy. The dependent variable was intention to reduce stroke 
risk. Of the 276 surveys distributed to bowling clubs, senior citizens clubs 
or retirement villages, 101 surveys were returned. Data from 76 of these 
respondents were used for analysis. Results: With regard to exercise 
intention, a pattern of significant correlations between HBM variables, 
subjective norm, and self-efficacy was observed. Results of multiple 
hierarchical regression analyses showed that perceived benefits of 
undertaking exercise and self-efficacy in relation exercise were the two 
most important determinants of exercise intentions. Conclusions: Findings 
suggest that health beliefs may play an important role in stroke prevention. 
Practice Implications: Stroke education and prevention programs that 
selectively target beliefs about the perceived benefits of, and 
self-efficacy related to, exercise to reduce stroke risk may prove most 
efficacious. © 2008 American Psychological Association.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (etiology)
  health behavior
  Health Belief Model
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  alcohol consumption
  article
  atrial fibrillation
  bowling
  cardiovascular disease
  diabetes mellitus
  exercise
  female
  health survey
  high risk patient
  human
  hypercholesterolemia
  hypertension
  immobilization
  major clinical study
  male
  obesity
  retirement
  risk factor
  risk reduction
  self concept
  smoking
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
  Public Health, Social Medicine and Epidemiology (17)
  Psychiatry (32)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008603874
FULL TEXT LINK
  http://dx.doi.org/10.1037/a0013359
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 408
TITLE
  Paget disease of bone: Therapeutic options
AUTHOR NAMES
  Silverman S.L.
AUTHOR ADDRESSES
  (Silverman S.L., stuarts@slsdss.net) OMC Clinical Research Center, Beverly 
Hills, CA.
(Silverman S.L., stuarts@slsdss.net) Department of Medicine and 
Rheumatology, Cedars-Sinai/UCLA, 8641 Wilshire Blvd, Beverly Hills, CA.
CORRESPONDENCE ADDRESS
  S. L. Silverman, Department of Medicine and Rheumatology, Cedars-Sinai/UCLA, 
8641 Wilshire Blvd, Beverly Hills, CA. Email: stuarts@slsdss.net
SOURCE
  Journal of Clinical Rheumatology (2008) 14:5 (299-305). Date of Publication: 
October 2008
ISSN
  1076-1608
BOOK PUBLISHER
  Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327, 
Philadelphia, United States.
ABSTRACT
  Paget disease of bone is a disorder of unknown etiology involving 
disturbances in bone remodeling, typically leading to bone pain and other 
complications such as skeletal deformities, fractures, hearing loss, and 
neurologic complications. Bisphosphonates (BPs), both oral and intravenous, 
have improved Paget treatment by reducing and normalizing bone turnover, as 
measured by biochemical markers and by alleviating symptoms. Six BPs are 
currently approved by the US Food and Drug Administration (FDA) for the 
treatment of Paget disease, and each has unique characteristics, such as 
response rates and requirements for dosage and administration, relevant to 
clinical outcome. This review provides an overview of these agents-including 
oral drugs such as alendronate and risedronate, and the intravenous agent 
zoledronic acid-and briefly discusses other options for managing Paget 
disease and monitoring treatment efficacy. © 2008 Lippincott Williams & 
Wilkins.
EMTREE DRUG INDEX TERMS
  alendronic acid (adverse drug reaction, clinical trial, drug comparison, 
drug therapy, oral drug administration)
  analgesic agent (drug combination, drug therapy)
  bisphosphonic acid derivative (drug comparison, drug therapy, intravenous 
drug administration, oral drug administration, pharmacoeconomics, 
pharmacology)
  calcitonin (drug therapy)
  calcium (drug therapy)
  clodronic acid (drug therapy, intravenous drug administration)
  cyclooxygenase 2 inhibitor (drug therapy)
  dactinomycin (drug therapy)
  etidronic acid (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, oral drug administration, pharmacology)
  gallium nitrate (drug therapy)
  glucagon derivative (drug therapy)
  mithramycin (drug therapy)
  nonsteroid antiinflammatory agent (drug therapy)
  olpadronic acid (drug therapy, pharmacology)
  opiate (drug therapy)
  pamidronic acid (adverse drug reaction, drug therapy, intravenous drug 
administration, oral drug administration, pharmacology)
  placebo
  risedronic acid (adverse drug reaction, clinical trial, drug comparison, 
drug therapy, oral drug administration)
  tiludronic acid (adverse drug reaction, drug comparison, drug therapy, 
pharmacology)
  tricyclic antidepressant agent (drug combination, drug therapy)
  vitamin D (drug therapy)
  zoledronic acid (adverse drug reaction, clinical trial, drug comparison, 
drug therapy, intravenous drug administration, pharmacoeconomics, 
pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Paget bone disease (drug therapy, diagnosis, disease management, drug 
therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal pain (side effect)
  acupuncture
  atrial fibrillation (side effect)
  backache (side effect)
  bone biopsy
  bone pain (drug therapy, therapy)
  bone scintiscanning
  clinical assessment
  clinical feature
  clinical trial
  diet supplementation
  disease severity
  drug approval
  drug cost
  drug efficacy
  drug fever (side effect)
  drug mechanism
  drug safety
  drug tolerability
  drug withdrawal
  dyspepsia (side effect)
  esophagus stenosis (side effect)
  esophagus ulcer (side effect)
  flu like syndrome (side effect)
  fracture (complication)
  gastrointestinal symptom (side effect)
  heartburn (side effect)
  human
  hydrotherapy
  hypocalcemia (drug therapy, side effect)
  iritis (side effect)
  joint prosthesis
  laboratory test
  low back pain (complication)
  low drug dose
  morning dosage
  nausea (side effect)
  nerve root compression (complication, drug therapy, therapy)
  nerve stimulation
  neurologic disease (complication)
  osteoarthritis (complication)
  priority journal
  radiculopathy (complication)
  recommended drug dose
  review
  single drug dose
  treatment response
  walking aid
  X ray
DRUG TRADE NAMES
  actonel
  aredia
  didronel
  fosamax
  reclast
  skelid
CAS REGISTRY NUMBERS
  alendronic acid (66376-36-1)
  calcitonin (12321-44-7, 21215-62-3, 9007-12-9)
  calcium (14092-94-5, 7440-70-2)
  clodronic acid (10596-23-3, 22560-50-5)
  dactinomycin (1402-38-6, 1402-58-0, 50-76-0)
  etidronic acid (2809-21-4, 3794-83-0, 58449-82-4, 7414-83-7)
  gallium nitrate (13494-90-1)
  mithramycin (18378-89-7)
  olpadronic acid (63132-39-8)
  opiate (53663-61-9, 8002-76-4, 8008-60-4)
  pamidronic acid (40391-99-9, 57248-88-1)
  risedronic acid (105462-24-6, 122458-82-6)
  tiludronic acid (96538-83-9)
  zoledronic acid (118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7)
EMBASE CLASSIFICATIONS
  Arthritis and Rheumatism (31)
  Orthopedic Surgery (33)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2009259168
MEDLINE PMID
  18838910 (http://www.ncbi.nlm.nih.gov/pubmed/18838910)
FULL TEXT LINK
  http://dx.doi.org/10.1097/RHU.0b013e318188b1f3
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 409
TITLE
  The prone position: A short clinical piece
AUTHOR NAMES
  Traffas M.
  Lewis C.B.
AUTHOR ADDRESSES
  (Traffas M., marktraffas@yahoo.com) Vista Manor Nursing and Rehabilitation, 
San Jose, CA.
(Lewis C.B.) George Washington College of Medicine, Bethesda, MD.
(Traffas M., marktraffas@yahoo.com) Vista Manor Nursing and Rehabilitation, 
San Jose, CA 95116.
CORRESPONDENCE ADDRESS
  M. Traffas, Vista Manor Nursing and Rehabilitation, San Jose, CA 95116. 
Email: marktraffas@yahoo.com
SOURCE
  Topics in Geriatric Rehabilitation (2008) 24:4 (354-356). Date of 
Publication: October-December 2008
ISSN
  0882-7524
BOOK PUBLISHER
  Lippincott Williams and Wilkins, 530 Walnut Street, Philadelphia, United 
States.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  body posture
  geriatric patient
  patient positioning
EMTREE MEDICAL INDEX TERMS
  acute kidney failure
  adult
  aged
  aspiration pneumonia
  atrial fibrillation
  bronchitis
  cardiopulmonary hemodynamics
  cardiovascular function
  cerebrovascular accident
  clinical assessment
  exercise
  gout
  heart infarction
  hip fracture
  human
  knee amputation
  oxygen saturation
  Parkinson disease
  pneumonia
  respiratory failure
  risk benefit analysis
  safety
  short survey
  sitting
  subarachnoid hemorrhage
  total knee replacement
  treatment planning
EMBASE CLASSIFICATIONS
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2009346915
FULL TEXT LINK
  http://dx.doi.org/10.1097/TGR.0b013e31818cd117
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 410
TITLE
  Challenges to consider in practicing specialized medicine
AUTHOR NAMES
  Kannel W.B.
AUTHOR ADDRESSES
  (Kannel W.B., billkannel@yahoo.com) Boston University, Framingham Study, 
Framingham, MA, United States.
(Kannel W.B., billkannel@yahoo.com) Boston University, Framingham Study, 73 
Mount Wayte Avenue, Framingham, MA 01702, United States.
CORRESPONDENCE ADDRESS
  W. B. Kannel, Boston University, Framingham Study, 73 Mount Wayte Avenue, 
Framingham, MA 01702, United States. Email: billkannel@yahoo.com
SOURCE
  Ochsner Journal (2008) 8:3 (105-107). Date of Publication: Fall 2008
ISSN
  1524-5012
BOOK PUBLISHER
  Ochsner Clinic, 1514 Jefferson Highway, New Orleans, United States.
EMTREE DRUG INDEX TERMS
  uric acid
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  clinical research
  medical education
EMTREE MEDICAL INDEX TERMS
  abdominal aorta aneurysm
  acute myeloblastic leukemia
  Alzheimer disease
  asthma
  atherosclerosis
  atrial fibrillation
  breast cancer
  bronchitis
  cardiovascular disease
  cataract
  cerebrovascular accident
  cholecystitis
  colon cancer
  coronary artery disease
  dementia
  diabetes mellitus
  dyslipidemia
  eating disorder
  emphysema
  endometrium cancer
  environmental exposure
  esophagus cancer
  exercise
  gallstone
  genetic predisposition
  gout
  health care
  health care organization
  health care personnel
  health status
  heart failure
  heart ventricle hypertrophy
  human
  hypertension
  infertility
  insulin resistance
  kidney cancer
  lung cancer
  medical practice
  medicine
  menstrual irregularity
  mortality
  mouth cancer
  nephrolithiasis
  obesity
  osteoarthritis
  osteoporosis
  pancreas cancer
  periodontitis
  pharynx cancer
  pneumonia
  preeclampsia
  pregnancy diabetes mellitus
  prematurity
  prostate cancer
  proteinuria
  review
  risk assessment
  risk factor
  sleep disorder
  sleep disordered breathing
  smoking
  smoking cessation
  stomach cancer
  stress incontinence
  uterine cervix cancer
  weight gain
CAS REGISTRY NUMBERS
  uric acid (69-93-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2008494709
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 411
TITLE
  Management of gastroparesis
AUTHOR NAMES
  Hasler W.L.
AUTHOR ADDRESSES
  (Hasler W.L., whasler@umich.edu) Division of Gastroenterology, University of 
Michigan Health System, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109, 
United States.
CORRESPONDENCE ADDRESS
  W.L. Hasler, Division of Gastroenterology, University of Michigan Health 
System, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109, United States. 
Email: whasler@umich.edu
SOURCE
  Expert Review of Gastroenterology and Hepatology (2008) 2:3 (411-423). Date 
of Publication: June 2008
ISSN
  1747-4124
BOOK PUBLISHER
  Expert Reviews Ltd., 2 Albert Place, London, United Kingdom.
ABSTRACT
  Gastroparesis presents with nausea, vomiting, early satiety and abdominal 
discomfort, as well as a range of nongastrointestinal manifestations in 
association with delays in gastric emptying. The disorder may be a 
consequence of systemic illnesses, such as diabetes mellitus, occur as a 
complication of gastroesophageal surgery or develop in an idiopathic fashion 
and may mimic other disorders with normal gastric emptying. Some cases of 
idiopathic gastroparesis present after a viral infection. Management relies 
primarily on therapies that accelerate gastric emptying or reduce vomiting, 
although endoscopic or surgical options are available for refractory cases. 
Current research is focusing on the cellular and molecular mechanisms 
underlying development of delayed gastric emptying, as well as factors 
unrelated to motor dysfunction that may elicit some symptoms. Future 
pharmaceuticals will target the contractile and nonmotor defects via novel 
pathways. Novel electrical stimulation techniques will be employed either 
alone or in combination with medications. © 2008 Expert Reviews Ltd.
EMTREE DRUG INDEX TERMS
  antidepressant agent (drug interaction)
  antiemetic agent (drug combination, drug interaction, drug therapy)
  azithromycin (drug therapy)
  benzodiazepine derivative (drug therapy)
  bethanechol (adverse drug reaction, drug therapy, pharmacology)
  botulinum toxin (clinical trial, drug dose, drug therapy)
  cannabinoid (drug therapy)
  cisapride (adverse drug reaction, drug therapy)
  clarithromycin (drug therapy)
  corticosteroid (drug therapy)
  domperidone (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, intravenous drug administration, oral drug administration, 
pharmacokinetics, pharmacology)
  dopamine receptor blocking agent (drug therapy)
  erythromycin (adverse drug reaction, clinical trial, drug comparison, drug 
dose, drug interaction, drug therapy, intravenous drug administration, oral 
drug administration, pharmacology)
  ghrelin (drug therapy, parenteral drug administration)
  histamine H1 receptor antagonist (drug therapy)
  macrolide (drug therapy)
  metoclopramide (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, intravenous drug administration, pharmacology, subcutaneous drug 
administration)
  mirtazapine (drug therapy)
  mitemcinal (drug therapy, oral drug administration)
  mosapride (drug therapy)
  muscarinic receptor blocking agent (drug therapy)
  neurokinin 1 receptor antagonist (drug therapy)
  phenothiazine derivative (drug therapy)
  prokinetic agent (drug combination, drug therapy)
  pyridostigmine (drug therapy, pharmacology)
  serotonin 3 antagonist (drug therapy)
  tegaserod (adverse drug reaction, clinical trial, drug therapy)
  thiethylperazine (drug therapy)
  tricyclic antidepressant agent (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  stomach paresis (complication, diagnosis, drug therapy, etiology, surgery, 
therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal discomfort
  abdominal pain (side effect)
  acupressure
  agitation
  amenorrhea (side effect)
  atrial fibrillation (side effect)
  bronchospasm (side effect)
  cardiovascular disease (side effect)
  central nervous system disease (side effect)
  clinical feature
  clinical trial
  combination chemotherapy
  diabetes mellitus
  diaphoresis
  diet therapy
  differential diagnosis
  drug dose comparison
  drug fatality (side effect)
  drug mechanism
  drug megadose
  drug penetration
  drug potentiation
  dystonia (side effect)
  electrostimulation therapy
  enteric feeding
  esophagus candidiasis (diagnosis)
  fatigue (side effect)
  galactorrhea (side effect)
  gastrointestinal surgery
  gastrointestinal symptom (side effect)
  heart arrhythmia (side effect)
  human
  hyperprolactinemia (side effect)
  hypotension (side effect)
  monotherapy
  myoelectricity
  nausea (side effect)
  pathogenesis
  pathophysiology
  physical examination
  psychotherapy
  QT interval
  review
  satiety
  sedation
  side effect (side effect)
  sleep disorder (side effect)
  stomach emptying
  stomach function disorder
  stomach scintiscanning
  sudden death
  tardive dyskinesia (side effect)
  urinary urgency (side effect)
  virus infection
  vomiting (side effect)
CAS REGISTRY NUMBERS
  azithromycin (83905-01-5)
  bethanechol (590-63-6, 674-38-4, 91609-06-2)
  cisapride (81098-60-4)
  clarithromycin (81103-11-9)
  domperidone (57808-66-9)
  erythromycin (114-07-8, 70536-18-4)
  ghrelin (258279-04-8, 304853-26-7)
  metoclopramide (12707-59-4, 2576-84-3, 364-62-5, 7232-21-5)
  mirtazapine (61337-67-5)
  mitemcinal (154738-42-8, 154802-96-7)
  mosapride citrate (112885-42-4)
  pyridostigmine (101-26-8, 155-97-5)
  tegaserod (145158-71-0, 189188-57-6)
  thiethylperazine (1420-55-9)
EMBASE CLASSIFICATIONS
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008517750
MEDLINE PMID
  19072389 (http://www.ncbi.nlm.nih.gov/pubmed/19072389)
FULL TEXT LINK
  http://dx.doi.org/10.1586/17474124.2.3.411
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 412
TITLE
  History-taking in cardiology
AUTHOR NAMES
  Cripps T.
AUTHOR ADDRESSES
  (Cripps T.) Bristol Royal Infirmary, United Kingdom.
CORRESPONDENCE ADDRESS
  T. Cripps, Bristol Royal Infirmary, United Kingdom.
SOURCE
  Foundation Years (2008) 4:3 (92-98). Date of Publication: June 2008
ISSN
  1744-1889
BOOK PUBLISHER
  Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
  History taking is central to making a diagnosis in patients with heart 
disease. Chest pain should be evaluated with particular attention to its 
reproducible precipitation by exertion and prompt relief by rest. Only four 
common arrhythmias cause palpitation. Ectopic beats present as a sensation 
of missed beats and thumps; paroxysmal supraventricular tachycardia with 
very clearly defined attacks usually lasting minutes only; paroxysmal atrial 
fibrillation with longer but still clearly defined attacks. In sinus 
tachycardia there is an almost constant feeling of palpitation, often with 
other symptoms of anxiety. Cardiac breathlessness may be associated with 
orthopnoea, paroxysmal nocturnal dyspnoea and peripheral oedema, though can 
be very difficult to distinguish from other causes. Syncope is most commonly 
vasovagal with recognisable precipitants; when due to arrhythmia is very 
sudden in onset and recovery. Epilepsy is distinguished by an aura and 
abnormal movements at the onset; maintained (rather than floppy) body tone 
during the attack and a post-ictal phase. Time spent taking a careful 
history will yield more towards a diagnosis than any number of sophisticated 
and expensive tests. © 2008 Elsevier Ltd. All rights reserved.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anamnesis
  cardiology
  heart disease (diagnosis)
EMTREE MEDICAL INDEX TERMS
  anxiety
  atrial fibrillation
  dyspnea
  epilepsy (diagnosis)
  exercise
  extrasystole
  faintness (diagnosis, etiology)
  heart arrhythmia
  heart palpitation
  human
  paroxysmal supraventricular tachycardia
  peripheral edema
  priority journal
  rest
  review
  sinus tachycardia
  thorax pain
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008329363
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.mpfou.2008.04.008
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 413
TITLE
  Propofol infusion syndrome: An overview of a perplexing disease
AUTHOR NAMES
  Fodale V.
  La Monaca E.
AUTHOR ADDRESSES
  (Fodale V., vfodale@unime.it; La Monaca E.) Department of Neurosciences, 
Psychiatric and Anaesthesiological Sciences, University of Messina, Messina, 
Italy.
(Fodale V., vfodale@unime.it) Department of Neurosciences, Psychiatric and 
Anaesthesiological Sciences, University of Messina, Policlinico 
Universitario, via C. Valeria, Messina, 98125, Italy.
CORRESPONDENCE ADDRESS
  V. Fodale, Department of Neurosciences, Psychiatric and Anaesthesiological 
Sciences, University of Messina, Policlinico Universitario, via C. Valeria, 
Messina, 98125, Italy. Email: vfodale@unime.it
SOURCE
  Drug Safety (2008) 31:4 (293-303). Date of Publication: 2008
ISSN
  0114-5916
BOOK PUBLISHER
  Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, 
Auckland 10, New Zealand.
ABSTRACT
  Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent 
that is widely used in adults and children for sedation and the induction 
and maintenance of anaesthesia. Propofol has gained popularity for its rapid 
onset and rapid recovery even after prolonged use, and for the 
neuroprotection conferred. However, a review of the literature reveals 
multiple instances in which prolonged propofol administration (>48 hours) at 
high doses (>4 mg/kg/h) may cause a rare, but frequently fatal complication 
known as propofol infusion syndrome (PRIS). PRIS is characterized by 
metabolic acidosis, rhabdomyolysis of both skeletal and cardiac muscle, 
arrhythmias (bradycardia, atrial fibrillation, ventricular and 
supraventricular tachycardia, bundle branch block and asystole), myocardial 
failure, renal failure, hepatomegaly and death. PRIS has been described as 
an 'all or none' syndrome with sudden onset and probable death. The 
literature does not provide evidence of degrees of symptoms, nor of mildness 
or severity of signs in the clinical course of the syndrome. Recently, a 
fatal case of PRIS at a low infusion rate (1.9-2.6 mg/kg/h) has been 
reported. Common laboratory and instrumental findings in PRIS are 
myoglobinuria, downsloping ST-segment elevation, an increase in plasma 
creatine kinase, troponin I, potassium, creatinine, azotaemia, 
malonylcarnitine and C5-acylcarnitine, whereas in the mitochondrial 
respiratory electron transport chain, the activity of complex IV and 
cytochrome oxidase ratio is reduced. Propofol should be used with caution 
for sedation in critically ill children and adults, as well as for long-term 
anesthesia in otherwise healthy patients, and doses exceeding 4-5 mg/kg/h 
for long periods (>48 h) should be avoided. If PRIS is suspected, propofol 
must be stopped immediately and cardiocirculatory stabilization and 
correction of metabolic acidosis initiated. So, PRIS must be kept in mind as 
a rare, but highly lethal, complication of propofol use, not necessarily 
confined to its prolonged use. Furthermore, the safe dosage of propofol may 
need re-evaluation, and new studies are needed. © 2008 Adis Data Information 
BV. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  propofol (adverse drug reaction, intravenous drug administration)
EMTREE DRUG INDEX TERMS
  barbituric acid derivative
  benzodiazepine derivative
  catecholamine
  corticosteroid
  dexmedetomidine
  dopamine (endogenous compound)
  midazolam
  noradrenalin (endogenous compound)
  pentobarbital
  serotonin (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anesthesia induction
  sedation
EMTREE MEDICAL INDEX TERMS
  anesthetic recovery
  atrial fibrillation (side effect)
  blood clotting disorder (side effect)
  bradycardia (side effect)
  brain disease (side effect)
  coma (side effect)
  creatine kinase blood level
  creatinine blood level
  critically ill patient
  death
  differential diagnosis
  drug withdrawal
  fatality
  fever (side effect)
  heart arrest (side effect)
  heart arrhythmia (side effect)
  heart bundle branch block (side effect)
  heart failure (side effect)
  heart right bundle branch block (side effect)
  heart ventricle fibrillation (side effect)
  heart ventricle tachycardia (side effect)
  hepatomegaly (side effect)
  human
  hyperkalemia (side effect)
  hyperlipidemia (side effect)
  hyperphosphatemia (side effect)
  hypotension (side effect)
  hypoxia (side effect)
  kidney failure (side effect)
  metabolic acidosis (side effect)
  muscle necrosis (side effect)
  muscle weakness (side effect)
  myoglobinuria (side effect)
  neuroprotection
  oliguria (side effect)
  pathophysiology
  potassium blood level
  priority journal
  propofol infusion syndrome (side effect)
  propofol infusion syndrome (side effect)
  rare disease
  respiratory acidosis (side effect)
  respiratory chain
  review
  rhabdomyolysis (side effect)
  risk factor
  shock (side effect)
  side effect (side effect)
  ST segment elevation
  supraventricular tachycardia (side effect)
  syndrome
  tachycardia (side effect)
  uremia (side effect)
  urine color
CAS REGISTRY NUMBERS
  dexmedetomidine (113775-47-6)
  dopamine (51-61-6, 62-31-7)
  midazolam (59467-70-8)
  noradrenalin (1407-84-7, 51-41-2)
  pentobarbital (57-33-0, 76-74-4)
  propofol (2078-54-8)
  serotonin (50-67-9)
EMBASE CLASSIFICATIONS
  Anesthesiology (24)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008150653
MEDLINE PMID
  18366240 (http://www.ncbi.nlm.nih.gov/pubmed/18366240)
FULL TEXT LINK
  http://dx.doi.org/10.2165/00002018-200831040-00003
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 414
TITLE
  Challenges of implementing a feasibility study of acupuncture in acute and 
critical care settings.
AUTHOR NAMES
  Lindquist R.
  Sendelbach S.
  Windenburg D.C.
  Vanwormer A.
  Treat-Jacobson D.
  Chose D.
AUTHOR ADDRESSES
  (Lindquist R.; Sendelbach S.; Windenburg D.C.; Vanwormer A.; Treat-Jacobson 
D.; Chose D.) University of Minnesota School of Nursing, Minneapolis, MN 
55455, USA.
CORRESPONDENCE ADDRESS
  R. Lindquist, University of Minnesota School of Nursing, Minneapolis, MN 
55455, USA. Email: lindq002@umn.edu
SOURCE
  AACN advanced critical care (2008) 19:2 (202-210). Date of Publication: 2008 
Apr-Jun
ISSN
  1559-7768
ABSTRACT
  A majority of people in the United States use complementary and alternative 
therapies, and this use is increasing. With the increasing interest, 
providers must evaluate potential risks and benefits of these therapies. 
This article describes challenges of a feasibility study of acupuncture as a 
potential therapeutic adjunct to prevent atrial fibrillation following 
coronary artery bypass graft surgery. Institutional review board approval, 
consent logistics, implementation issues, and rapid changes in clinical 
practice were the primary challenges faced. Unique technological features of 
the institution helped address these challenges. The study protocol was 
acceptable to staff, patients, and family and was considered safe for these 
patients. However, the protocol was not feasible as designed; therefore, the 
efficacy of acupuncture could not be determined. Continued research is 
needed to evaluate the effectiveness of acupuncture to prevent atrial 
fibrillation following coronary artery bypass graft surgery. Recommendations 
for future studies of complementary and alternative therapies in acute and 
critical care settings are offered.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  intensive care
EMTREE MEDICAL INDEX TERMS
  acute disease
  article
  feasibility study
  pilot study
LANGUAGE OF ARTICLE
  English
MEDLINE PMID
  18560289 (http://www.ncbi.nlm.nih.gov/pubmed/18560289)
COPYRIGHT
  MEDLINE® is the source for the citation and abstract of this record.

RECORD 415
TITLE
  Gastroparesis - Current concepts and considerations
AUTHOR NAMES
  Hasler W.L.
AUTHOR ADDRESSES
  (Hasler W.L., whasler@umich.edu) Department of Internal Medicine, Division 
of Gastroenterology, University of Michigan Health System, Ann Arbor, MI, 
United States.
CORRESPONDENCE ADDRESS
  W.L. Hasler, Department of Internal Medicine, Division of Gastroenterology, 
University of Michigan Health System, Ann Arbor, MI, United States. Email: 
whasler@umich.edu
SOURCE
  MedGenMed Medscape General Medicine (2008) 10:1 Article Number: 16. Date of 
Publication: 2008
ISSN
  1531-0132
BOOK PUBLISHER
  Medscape Health Network, 224 W. 30th Street, New York, United States.
EMTREE DRUG INDEX TERMS
  antiarrhythmic agent (adverse drug reaction, drug combination, drug 
interaction)
  antidepressant agent (adverse drug reaction, drug combination, drug 
interaction)
  antiemetic agent (adverse drug reaction, drug combination, drug interaction, 
drug therapy)
  antifungal agent (adverse drug reaction, drug combination, drug interaction)
  antineoplastic agent (adverse drug reaction)
  azithromycin (drug comparison, drug therapy)
  bethanechol (adverse drug reaction, drug therapy)
  buspirone (drug therapy)
  calcium antagonist (adverse drug reaction, drug combination, drug 
interaction)
  cholinesterase inhibitor (drug therapy)
  cisapride (adverse drug reaction, drug therapy)
  clarithromycin (drug comparison, drug therapy)
  corticosteroid (drug therapy)
  domperidone (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, intravenous drug administration, oral drug administration)
  erythromycin (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug dose, drug interaction, drug therapy, intravenous drug 
administration, oral drug administration)
  ghrelin (drug therapy, parenteral drug administration)
  ginger extract (drug therapy)
  metoclopramide (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, intravenous drug administration, oral drug administration, 
subcutaneous drug administration)
  mirtazapine (drug therapy)
  mitemcinal (drug therapy, oral drug administration)
  neuroleptic agent (adverse drug reaction, drug combination, drug 
interaction)
  pertechnetic acid tc 99m (intravenous drug administration)
  prochlorperazine (drug therapy)
  prokinetic agent (clinical trial, drug combination, drug therapy)
  pyridostigmine (drug therapy)
  sumatriptan (drug therapy)
  tegaserod (adverse drug reaction, clinical trial, drug therapy)
  thiethylperazine (drug therapy)
  tricyclic antidepressant agent (drug therapy)
  unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  stomach paresis (complication, diagnosis, drug therapy, epidemiology, 
etiology, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal cramp (side effect)
  abdominal pain (side effect)
  acupressure
  agitation
  amenorrhea (side effect)
  article
  atrial fibrillation (side effect)
  bronchospasm (side effect)
  cardiovascular disease (side effect)
  chemotherapy induced emesis (drug therapy, prevention, side effect)
  clinical feature
  clinical trial
  diabetic stomach paresis (diagnosis, drug therapy, epidemiology, etiology, 
surgery, therapy)
  diaphoresis
  diet therapy
  differential diagnosis
  digestive system function disorder
  disease association
  disease severity
  drug dose regimen
  drug fatality (side effect)
  drug megadose
  drug potentiation
  drug withdrawal
  dystonia (side effect)
  electrogastrography
  electrostimulation
  enteric feeding
  fatigue (side effect)
  feedback system
  galactorrhea (side effect)
  heart arrhythmia (side effect)
  human
  hyperprolactinemia (side effect)
  hypnosis
  hypotension (side effect)
  idiopathic gastroparesis (diagnosis, drug therapy, epidemiology, etiology, 
surgery, therapy)
  monotherapy
  nausea (side effect)
  nausea and vomiting (drug therapy)
  parenteral nutrition
  pathogenesis
  postoperative nausea (complication, prevention, therapy)
  QT prolongation (side effect)
  side effect (side effect)
  single photon emission computer tomography
  sleep disorder (side effect)
  stomach disease (diagnosis, drug therapy, epidemiology, etiology, surgery, 
therapy)
  stomach emptying
  stomach motility
  sudden death
  tardive dyskinesia (side effect)
  urinary urgency (side effect)
  vomiting (side effect)
CAS REGISTRY NUMBERS
  azithromycin (83905-01-5)
  bethanechol (590-63-6, 674-38-4, 91609-06-2)
  buspirone (33386-08-2, 36505-84-7)
  cisapride (81098-60-4)
  clarithromycin (81103-11-9)
  domperidone (57808-66-9)
  erythromycin (114-07-8, 70536-18-4)
  ghrelin (258279-04-8, 304853-26-7)
  metoclopramide (12707-59-4, 2576-84-3, 364-62-5, 7232-21-5)
  mirtazapine (61337-67-5)
  mitemcinal (154738-42-8, 154802-96-7)
  pertechnetic acid tc 99m (23288-60-0)
  prochlorperazine (58-38-8)
  pyridostigmine (101-26-8, 155-97-5)
  sumatriptan (103628-46-2)
  tegaserod (145158-71-0, 189188-57-6)
  thiethylperazine (1420-55-9)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Radiology (14)
  Public Health, Social Medicine and Epidemiology (17)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2008077376
MEDLINE PMID
  18324326 (http://www.ncbi.nlm.nih.gov/pubmed/18324326)
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 416
TITLE
  Clinical hypnosis for reduction of atrial fibrillation after coronary artery 
bypass graft surgery.
AUTHOR NAMES
  Novoa R.
  Hammonds T.
AUTHOR ADDRESSES
  (Novoa R.; Hammonds T.) Aultman Heart Center, Aultman Health Foundation, 
Canton, OH 44714, USA.
CORRESPONDENCE ADDRESS
  R. Novoa, Aultman Heart Center, Aultman Health Foundation, Canton, OH 44714, 
USA. Email: rnovoa@neo.rr.com
SOURCE
  Cleveland Clinic journal of medicine (2008) 75 Suppl 2 (S44-47). Date of 
Publication: Mar 2008
ISSN
  0891-1150
ABSTRACT
  The belief that postoperative atrial fibrillation (PAF) results from 
transient autonomic dysfunction suggests that interventions such as clinical 
hypnosis may reduce the incidence of PAF. To explore this hypothesis, we 
retrospectively compared outcomes between two groups of patients undergoing 
coronary artery bypass graft surgery: 50 consecutive patients who received 
preoperative hypnoidal explanation of the surgical procedure and 50 
case-matched historical controls who received no clinical hypnosis. The 
patients who received hypnosis were significantly less likely to experience 
an episode of PAF (P = .003) and showed nonsignificant trends toward 
superior outcomes in terms of length of stay, narcotic use, and total 
hospital charges. Our findings indicate that prospective randomized trials 
are warranted to further delineate the potential benefit of clinical 
hypnosis for prevention of PAF.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (etiology, prevention, therapy)
  coronary artery bypass graft (adverse drug reaction)
  hypnosis
EMTREE MEDICAL INDEX TERMS
  aged
  article
  autonomic nervous system
  case control study
  female
  human
  incidence
  male
  pathophysiology
  retrospective study
  risk factor
LANGUAGE OF ARTICLE
  English
MEDLINE PMID
  18540146 (http://www.ncbi.nlm.nih.gov/pubmed/18540146)
COPYRIGHT
  MEDLINE® is the source for the citation and abstract of this record.

RECORD 417
TITLE
  Possible effects of acupuncture on atrial fibrillation and post-herpetic 
neuralgia - A case report
AUTHOR NAMES
  Valaskatgis P.
  Macklin E.A.
  Schachter S.C.
  Wayne P.M.
AUTHOR ADDRESSES
  (Valaskatgis P., peterval@comcast.net) New England School of Acupuncture, 
Newton, MA, United States.
(Macklin E.A.) Massachusetts General Hospital, Boston, MA, United States.
(Macklin E.A.) Department of Medicine, Harvard Medical School, Boston, MA, 
United States.
(Schachter S.C.) Osher Research Center, Harvard Medical School, Boston, MA, 
United States.
(Wayne P.M.) Tai Chi Research Programs, Osher Research Center, Harvard 
Medical School, Boston, MA, United States.
CORRESPONDENCE ADDRESS
  P. Valaskatgis, New England School of Acupuncture, Newton, MA, United 
States. Email: peterval@comcast.net
SOURCE
  Acupuncture in Medicine (2008) 26:1 (51-56). Date of Publication: March 2008
ISSN
  0964-5284
BOOK PUBLISHER
  BMJ Publishing Group, Tavistock Square, London, United Kingdom.
ABSTRACT
  A 72 year old female with a main complaint of severe post-herpetic neuralgia 
and a secondary complaint of atrial fibrillation (AF) received two series of 
acupuncture treatments totalling 20 treatments over a four month period. Her 
standard medical treatment remained unchanged. The primary focus of the 
acupuncture was pain relief; however, two acupuncture points (PC6, SP4) were 
included in both treatment series because of possible effects on both costal 
or chest pain and cardiac arrhythmias, according to Traditional Chinese 
Medicine (TCM) teaching and limited research. As recorded by her pacemaker, 
estimated weekly episodes of AF in the patient decreased significantly, and 
percentage time in AF decreased with borderline statistical significance, 
from the pretreatment estimates during the second series of treatments 
(weekly AF episode estimates: pretreatment =71.4; second series =16.5, 
difference estimates =-54.9, 95% CI -6.5 to -103.3, P=0.02; percentage time 
in AF estimates: pretreatment =30.6; 2 second series =18.0, difference 
estimates =-12.6, 95% CI 0.9 to -26.0, P=0.08). The pain levels were also 
significantly reduced following the acupuncture treatment series by more 
than 67%. Further studies are warranted to further explore these 
observations of a possible effect of acupuncture on both atrial fibrillation 
and post-herpetic neuralgia.
EMTREE DRUG INDEX TERMS
  amitriptyline
  analgesic agent (drug therapy)
  atorvastatin
  calcium carbonate
  digoxin
  gabapentin (drug therapy)
  glibenclamide
  levothyroxine
  meprednisone (drug therapy)
  paracetamol
  verapamil
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  atrial fibrillation (therapy)
  postherpetic neuralgia (drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  aged
  analgesia
  article
  case report
  confidence interval
  diabetes mellitus
  female
  heart arrhythmia
  human
  hyperlipidemia
  hypothyroidism
  pacemaker
  pain assessment
  skin sensitivity
  statistical significance
  thorax pain
CAS REGISTRY NUMBERS
  amitriptyline (50-48-6, 549-18-8)
  atorvastatin (134523-00-5, 134523-03-8)
  calcium carbonate (13397-26-7, 13701-58-1, 14791-73-2, 471-34-1)
  digoxin (20830-75-5, 57285-89-9)
  gabapentin (60142-96-3)
  glibenclamide (10238-21-8)
  levothyroxine (51-48-9)
  meprednisone (1247-42-3)
  paracetamol (103-90-2)
  verapamil (152-11-4, 52-53-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008164524
MEDLINE PMID
  18356799 (http://www.ncbi.nlm.nih.gov/pubmed/18356799)
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 418
TITLE
  Use of dietary supplements by patients taking digoxin
AUTHOR NAMES
  Ting L.S.L.
  Shalansky S.J.
  Neall E.
  Ensom M.H.H.
AUTHOR ADDRESSES
  (Ting L.S.L., lting@shaw.ca; Neall E.) Faculty of Pharmaceutical Sciences, 
University of British Columbia, 2146 East Mall, Vancouver, BC V6T 1Z3, 
Canada.
(Shalansky S.J.) Department of Pharmacy, St Paul's Hospital, Providence 
Health Care, Vancouver, BC, Canada.
(Ensom M.H.H.) Children's and Women's Health Care of British Columbia, 
Faculty of Pharmaceutical Sciences, University of British Columbia, 
Vancouver, BC, Canada.
CORRESPONDENCE ADDRESS
  L.S.L. Ting, Faculty of Pharmaceutical Sciences, University of British 
Columbia, 2146 East Mall, Vancouver, BC V6T 1Z3, Canada. Email: 
lting@shaw.ca
SOURCE
  Canadian Journal of Hospital Pharmacy (2008) 61:1 (30-40). Date of 
Publication: January/February 2008
ISSN
  0008-4123
BOOK PUBLISHER
  Canadian Society of Hospital Pharmacists, 30 Concourse Gate, Unit 3, Ottawa, 
Canada.
ABSTRACT
  Background: The use of dietary supplements is common, and interactions with 
digoxin have been proposed. However, little is known about usage patterns of 
these supplements among patients taking digoxin. Objectives: To determine 
the prevalence of use of dietary supplements and over-the-counter (OTC) 
medications among patients taking digoxin, and to correlate the occurrence 
of symptoms related to digoxin toxicity with supplement use. Methods: One 
hundred and seventy-two adult patients who had been receiving digoxin 
therapy for at least 3 months were recruited. An open-label, 
cross-sectional, interviewer-administered survey was conducted to assess 
demographic characteristics, health status, details of digoxin therapy, and 
use of prescription and nonprescription medications. The use of supplements 
and interacting prescription medications was compared between participants 
reporting symptoms of digoxin toxicity and those who did not report such 
symptoms. Results: Most of the patients (122 or 70.9%) were men; the mean 
age ± standard deviation was 65.2 ± 12.0 years, and patients had been taking 
digoxin for a mean of 5.9 years at 174.8 ± 77.9 μg/day. Thirty-seven (21.5%) 
of the patients were using herbal supplements, and 153 (89.0%) were taking 
OTC medications or nonherbal supplements. Four (2.3%) patients were taking 
herbal supplements that might interact with digoxin, and 50 (29.1%) took OTC 
drugs or nonherbal supplements with potential interactions. Between patients 
who reported symptoms of digoxin toxicity and those who did not reports such 
symptoms, there was no difference in the use of OTC medications or nonherbal 
supplements, herbal supplements, or prescription medications (except for 
diltiazem). Conclusions: In this study, few of the patients were taking 
herbal supplements that could interact with digoxin, and no clinically 
significant herb-digoxin interactions were observed.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  digoxin (adverse drug reaction, drug combination, drug concentration, drug 
therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug combination)
  amiodarone (drug combination)
  antacid agent (drug combination)
  carvedilol (drug combination)
  cascara sagrada (drug combination)
  Cassia augustifolia extract (drug combination)
  Cassia extract (drug combination)
  cranberry extract (drug combination)
  diltiazem (drug combination)
  Echinacea extract (drug combination)
  furosemide (drug combination)
  garlic extract (drug combination)
  Ginkgo biloba extract (drug combination)
  ginseng extract (drug combination)
  Glycyrrhiza extract (drug combination)
  herbaceous agent (drug combination)
  hydrochlorothiazide (drug combination)
  kaolin pectin (drug combination)
  mineral (drug combination)
  non prescription drug (drug combination)
  omeprazole (drug combination)
  paracetamol (drug combination)
  potassium (drug combination)
  primrose oil (drug combination)
  quinine (drug combination)
  Sabal extract (drug combination)
  spironolactone (drug combination)
  unclassified drug
  unindexed drug
  vitamin (drug combination)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diet supplementation
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  anorexia (side effect)
  article
  atrial fibrillation (drug therapy)
  controlled study
  cross-sectional study
  diarrhea (side effect)
  digoxin blood level
  female
  health status
  heart failure (drug therapy)
  herb drug interaction
  human
  major clinical study
  male
  nausea (side effect)
  open study
  prescription
  prevalence
  visual disorder (side effect)
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  carvedilol (72956-09-3)
  digoxin (20830-75-5, 57285-89-9)
  diltiazem (33286-22-5, 42399-41-7)
  furosemide (54-31-9)
  hydrochlorothiazide (58-93-5)
  kaolin pectin (8047-39-0)
  omeprazole (73590-58-6, 95510-70-6)
  paracetamol (103-90-2)
  potassium (7440-09-7)
  primrose oil (65546-85-2)
  quinine (130-89-2, 130-95-0, 14358-44-2, 549-48-4, 549-49-5, 60-93-5, 
7549-43-1)
  spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, French
EMBASE ACCESSION NUMBER
  2008113869
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 419
TITLE
  Thoracic epidural analgesia in cardiac surgery: impact on postoperative 
morbidity
AUTHOR NAMES
  Bracco D.
  Hemmerling T.M.
AUTHOR ADDRESSES
  (Bracco D., David.Bracco@mcgill.ca; Hemmerling T.M.) Department of 
Anesthesia, Perioperative Cardiac Research Group, McGill University, 
Montreal, Canada.
CORRESPONDENCE ADDRESS
  D. Bracco, Department of Anesthesia, Perioperative Cardiac Research Group, 
McGill University, Montreal, Canada. Email: David.Bracco@mcgill.ca
SOURCE
  Techniques in Regional Anesthesia and Pain Management (2008) 12:1 (32-40). 
Date of Publication: January 2008
  Regional anesthesia for Cardiac Surgery, Book Series Title:
ISSN
  1084-208X
BOOK PUBLISHER
  W.B. Saunders, Independence Square West, Philadelphia, United States.
ABSTRACT
  Application of thoracic epidural analgesia in cardiac surgery offers several 
advantages but requires an adaptation of the postoperative clinical 
pathways. These adaptations are mandatory to minimize the risks related to 
the use of epidural catheters in cardiac anesthesia and to gain the maximum 
benefits from the technique. It involves lower doses of opioids, aggressive 
temperature and fluid management, strict anticoagulation guidelines, and 
clear staff information. Thoracic epidural analgesia has the potential to 
improve outcome after cardiac surgery: better analgesia, better 
postoperative respiratory physiotherapy, better pulmonary outcome, better 
myocardial protection, attenuation of stress response, and possibly shorter 
hospital stay. This potential needs to be supported by a change in all 
aspects of postoperative patient management and the creation of new clinical 
pathways. © 2008 Elsevier Inc. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  narcotic analgesic agent
EMTREE DRUG INDEX TERMS
  catecholamine (endogenous compound)
  small heat shock protein
  troponin I (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  epidural anesthesia
  heart surgery
  morbidity
EMTREE MEDICAL INDEX TERMS
  acute kidney failure
  anticoagulant therapy
  article
  artificial ventilation
  atrial fibrillation
  breathing exercise
  coronary artery bypass graft
  delirium
  extubation
  fluid resuscitation
  health care utilization
  heart protection
  human
  intensive care unit
  length of stay
  mortality
  pneumonia
  postoperative analgesia
  sedation
  surgical stress
  warming
CAS REGISTRY NUMBERS
  troponin I (77108-40-8)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Anesthesiology (24)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007619457
FULL TEXT LINK
  http://dx.doi.org/10.1053/j.trap.2007.10.005
COPYRIGHT
  Copyright 2008 Elsevier B.V., All rights reserved.

RECORD 420
TITLE
  Functional capacity after traditional Chinese medicine (qi gong) training in 
patients with chronic atrial fibrillation: a randomized controlled trial.
AUTHOR NAMES
  Pippa L.
  Manzoli L.
  Corti I.
  Congedo G.
  Romanazzi L.
  Parruti G.
AUTHOR ADDRESSES
  (Pippa L.; Manzoli L.; Corti I.; Congedo G.; Romanazzi L.; Parruti G.) 
Camillo de Lellis per la Ricera Clinica Applicata, Pescara, Italy.
CORRESPONDENCE ADDRESS
  L. Pippa, Camillo de Lellis per la Ricera Clinica Applicata, Pescara, Italy.
SOURCE
  Preventive cardiology (2007) 10:1 (22-25). Date of Publication: 2007 Winter
ISSN
  1520-037X
ABSTRACT
  Evidence indicates that low energy expenditure protocols derived from 
traditional Chinese medicine may benefit patients with cardiac impairment; 
therefore, the authors carried out a randomized controlled trial to test a 
16-week medically assisted qi gong training program for the physical 
rehabilitation of patients with stable chronic atrial fibrillation and 
preserved left ventricular function. Functional capacity variation was 
evaluated using the 6-minute walk test, which was performed at baseline, at 
the end of the intervention, and after 16 weeks. Thirty men and 13 women 
(mean age, 68+/-8 years) were randomized to the intervention protocol or to 
a wait-list control group. Qi gong training was well tolerated and, compared 
with baseline, trained patients walked an average 114 meters more (27%) at 
the end of treatment (P<.001) and 57 meters more (13.7%) 16 weeks later 
(P=.008). Control subjects showed no variation in functional capacity. These 
results seem promising and deserve confirmation with further research.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (therapy)
  breathing exercise
  Chinese medicine
EMTREE MEDICAL INDEX TERMS
  aged
  article
  chronic disease
  clinical trial
  controlled clinical trial
  controlled study
  exercise tolerance
  female
  human
  male
  middle aged
  pathophysiology
  randomized controlled trial
LANGUAGE OF ARTICLE
  English
MEDLINE PMID
  17215629 (http://www.ncbi.nlm.nih.gov/pubmed/17215629)
FULL TEXT LINK
  http://dx.doi.org/10.1111/j.1520-037X.2007.05721.x
COPYRIGHT
  MEDLINE® is the source for the citation and abstract of this record.

RECORD 421
TITLE
  Toxicity of Panax genseng - An herbal medicine and dietary supplement
AUTHOR NAMES
  Chan P.-C.
  Fu P.P.
AUTHOR ADDRESSES
  (Chan P.-C., chanp@niehs.nih.gov) National Institute of Environmental Health 
Sciences, Research Triangle Park, NC 27709, United States.
(Fu P.P., peter.fu@fda.hhs.gov) National Center for Toxicological Research, 
Jefferson, AR 72079, United States.
CORRESPONDENCE ADDRESS
  P.-C. Chan, National Institute of Environmental Health Sciences, Research 
Triangle Park, NC 27709, United States. Email: chanp@niehs.nih.gov
SOURCE
  Journal of Food and Drug Analysis (2007) 15:4 (416-427). Date of 
Publication: December 2007
  Quality Assurance and Safety of Herbal Dietary Supplements, Book Series 
Title:
ISSN
  1021-9498
BOOK PUBLISHER
  National Laboratories of Foods and Drugs, 161-2 Kuen Yang Street, Nankang, 
Taipei, Taiwan.
ABSTRACT
  Ginseng is one of the most popular herbal dietary supplements in the U.S. 
market, with five to six million persons using it even before the recent 
boom in the herbal supplement industry. Ginsana (G115 ginseng), a 
standardized extract of Panax ginseng (Asian ginseng, also called Chinese or 
Korean ginseng) controls half of this market. Numerous reports of adverse 
effects from products containing ginseng have been filed with the U.S. Food 
and Drug Administration (FDA). The literature also documents "ginseng abuse 
syndrome" among regular users. The chronic effects of ginseng are not well 
characterized. Because of its significant human exposure and little 
information on toxicity is available, Panax ginseng has been nominated by 
the U.S. National Institutes of Health (NTH) to the U.S. National Toxicology 
Program (NTP) for assessing its carcinogenic potential. In this review, we 
discuss the environmental occurrence, purported therapeutic effects, 
biological effects, and toxicity of ginseng, with focus on Panax ginseng. To 
demonstrate how NTP chronic tumorigenicity bioassays are conducted, the 
turnorigenicity bioassay of Panax ginseng is detailed described.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  ginseng extract (adverse drug reaction, drug analysis, drug dose, drug 
interaction, drug therapy, drug toxicity, oral drug administration, 
pharmacology)
EMTREE DRUG INDEX TERMS
  2,3,7,8 tetrachlorodibenzo para dioxin (drug therapy)
  cyclophosphamide (adverse drug reaction, drug toxicity)
  cytochrome P450 (drug interaction)
  ginseng saponin (drug toxicity, pharmacology)
  ginsenoside (drug analysis, pharmacology)
  ginsenoside Rb 1 (drug analysis, drug therapy, oral drug administration, 
pharmacokinetics)
  ginsenoside Rb 2 (drug analysis, drug therapy, oral drug administration, 
pharmacokinetics)
  ginsenoside Rc (drug analysis, oral drug administration)
  ginsenoside Rd (drug analysis)
  ginsenoside Re (drug analysis)
  ginsenoside Rf (drug analysis)
  ginsenoside Rg 1 (drug analysis, drug therapy, pharmacokinetics)
  ginsenoside Rg 2 (drug analysis)
  ginsenoside Rg 3 (oral drug administration, pharmacokinetics, pharmacology)
  ginsenoside rh 1 (drug analysis)
  ginsenoside Rh 2 (drug toxicity, pharmacology)
  protopanaxadiol (pharmacokinetics)
  unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diet supplementation
  herbal medicine
EMTREE MEDICAL INDEX TERMS
  agitation
  atrial fibrillation (side effect)
  blurred vision (side effect)
  bone marrow necrosis (side effect)
  cerebrovascular accident (side effect)
  chemical composition
  coma (side effect)
  concentration loss (side effect)
  dermatomyositis (side effect)
  diabetes mellitus (drug therapy)
  diarrhea (side effect)
  dizziness (side effect)
  drug absorption
  drug eruption (side effect)
  drug fatality (side effect)
  drug half life
  drug induced headache (side effect)
  drug megadose
  drug metabolism
  edema (side effect)
  environmental exposure
  esophagus injury (side effect)
  euphoria
  genotoxicity (side effect)
  heart palpitation (side effect)
  human
  hypertension (side effect)
  insomnia (side effect)
  jaundice (side effect)
  liver injury (drug therapy)
  mastalgia (side effect)
  mental health
  nausea (side effect)
  nausea and vomiting (side effect)
  neurologic disease (drug therapy)
  neuroprotection
  nonhuman
  pain (side effect)
  Parkinson disease (drug therapy)
  pruritus (side effect)
  rash (side effect)
  reproductive toxicity (side effect)
  restlessness (side effect)
  review
  side effect (side effect)
  spinal cord injury (drug therapy)
  standardization
  Stevens Johnson syndrome (side effect)
  stomach pain (side effect)
  sweating
  thorax pain (side effect)
  thrombocytopenia (side effect)
  tonic clonic seizure (side effect)
  uterus bleeding (side effect)
  vagina bleeding (side effect)
  vomiting (side effect)
CAS REGISTRY NUMBERS
  2,3,7,8 tetrachlorodibenzo para dioxin (1746-01-6)
  cyclophosphamide (50-18-0)
  cytochrome P450 (9035-51-2)
  ginsenoside (74749-74-9)
  ginsenoside Rb 1 (41753-43-9)
  ginsenoside Rb 2 (11021-13-9)
  ginsenoside Rc (11021-14-0)
  ginsenoside Rd (52705-93-8)
  ginsenoside Re (52286-59-6)
  ginsenoside Rg 1 (22427-39-0)
  ginsenoside Rg 2 (52286-74-5)
  ginsenoside rf (52286-58-5)
  ginsenoside rh 1 (63223-86-9)
  protopanaxadiol (7755-01-3)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Clinical and Experimental Biochemistry (29)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Toxicology (52)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008130783
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 422
TITLE
  Congestive heart failure in the elderly
AUTHOR NAMES
  Chiu C.-Z.
  Cheng J.-J.
AUTHOR ADDRESSES
  (Chiu C.-Z.; Cheng J.-J., juice243@hotmail.com) School of Medicine, Fu Jen 
Catholic University, Taipei Medical University, Taipei, Taiwan.
(Chiu C.-Z.; Cheng J.-J., juice243@hotmail.com) Division of Cardiology, 
Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, 95 
Wen-Chan Road, Shih-Lin, Taipei, Taiwan.
(Cheng J.-J., juice243@hotmail.com) School of Medicine, Taipei Medical 
University, Taipei, Taiwan.
CORRESPONDENCE ADDRESS
  J.-J. Cheng, Division of Cardiology, Department of Internal Medicine, 
Shin-Kong Wu Ho-Su Memorial Hospital, 95 Wen-Chan Road, Shih-Lin, Taipei, 
Taiwan. Email: juice243@hotmail.com
SOURCE
  International Journal of Gerontology (2007) 1:4 (143-152). Date of 
Publication: December 2007
ISSN
  1873-9598
BOOK PUBLISHER
  Elsevier (Singapore) Pte Ltd, 3 Killiney Road, 08-01, Winsland House I, 
Singapore, Singapore.
ABSTRACT
  Over the past 30 years, the prevalence and incidence of heart failure (HF) 
have increased markedly with age, with increases of approximately fivefold 
from the age of 40 to 70 years. HF is predominantly a disorder of the 
elderly, and over 70% of HF patients are over 65 years old. The most 
important factor in the increasing prevalence and incidence of HF is the 
growing proportion of elderly with new-onset diastolic HF resulting from 
chronic hypertension and coronary heart disease. Other predictors of HF 
include diabetes, prior stroke, atrial fibrillation, renal dysfunction, 
reduced ankle-brachial index, increased C-reactive protein, left ventricular 
hypertrophy, reduced forced expiratory volume, and obesity. At least half of 
all elderly HF patients have preserved left ventricular systolic function, 
and they are classified as diastolic HF. There was a strong female 
predominance (67%) in diastolic HF when compared with male HF patients. The 
morbidity and mortality of older HF patients are the highest of any chronic 
cardiovascular disorder. Mortality increases markedly with age. Mortality 
from diastolic HF is about half of that reported for systolic HF. There are 
some comorbidities in older HF patients, including renal dysfunction, 
chronic lung disease, cognitive dysfunction, depression, postural 
hypotension, urine incontinence, sensory deprivation, nutritional disorders, 
polypharmacy and frailty, which may precipitate and exacerbate the 
underlying HF symptoms. Clinical diagnosis of HF may be more difficult in 
the elderly because of frequently inadequate history taking, less evident HF 
symptoms for reduced daily activity, and similar symptoms to other frequent 
disorders. The treatment goals in older HF patients resemble those for any 
chronic disorder and include relief of symptoms, improvement in functional 
status, exercise tolerance, quality of life, prevention of acute 
exacerbation, and finally, prolongation of long-term survival. © 2007 
Elsevier.
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (clinical trial, drug combination, drug therapy)
  angiotensin receptor antagonist (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug therapy)
  beta adrenergic receptor blocking agent (adverse drug reaction, clinical 
trial, drug combination, drug dose, drug therapy)
  calcium antagonist (adverse drug reaction, clinical trial, drug comparison, 
drug therapy)
  calcium channel blocking agent (clinical trial, drug therapy)
  candesartan (clinical trial, drug combination, drug therapy)
  captopril (clinical trial, drug comparison, drug therapy)
  carvedilol (clinical trial, drug combination, drug dose, drug therapy)
  catecholamine derivative (drug therapy)
  digoxin (clinical trial, drug combination, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical 
trial, drug combination, drug comparison, drug therapy)
  diuretic agent (clinical trial, drug combination, drug comparison, drug 
dose, drug therapy, intravenous drug administration)
  dobutamine (drug therapy)
  dopamine (drug combination, drug dose, drug therapy)
  enalapril (clinical trial, drug therapy)
  loop diuretic agent (drug therapy)
  losartan (clinical trial, drug comparison, drug therapy)
  metolazone (drug combination, drug therapy)
  perindopril (clinical trial, drug therapy)
  placebo
  thiazide diuretic agent (drug combination, drug therapy)
  valsartan (clinical trial, drug therapy)
  verapamil (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  congestive heart failure (diagnosis, drug therapy, epidemiology, etiology, 
therapy)
  elderly care
EMTREE MEDICAL INDEX TERMS
  acute heart infarction (drug therapy)
  aerobic exercise
  aneurysm surgery
  ankle brachial index
  aorta stenosis (surgery)
  aorta valve replacement
  artery compliance
  atrial fibrillation (drug therapy)
  cardiac resynchronization therapy
  chronic disease (complication)
  clinical trial
  comorbidity
  coronary artery recanalization
  coughing (side effect)
  defibrillation
  diastolic heart failure (drug therapy)
  disease exacerbation
  dose response
  drug choice
  drug contraindication
  drug dose titration
  drug efficacy
  drug hypersensitivity (side effect)
  echocardiography
  exercise tolerance
  heart left ventricle aneurysm (surgery)
  heart left ventricle ejection fraction
  heart left ventricle relaxation
  human
  hypertension (complication)
  hypertrophic cardiomyopathy (drug therapy)
  incidence
  ischemic heart disease (complication)
  kidney disease (side effect)
  low drug dose
  outcome assessment
  pathophysiology
  prediction
  prevalence
  priority journal
  review
  sex difference
  side effect (side effect)
  sodium restriction
  systolic heart failure (drug therapy)
  unspecified side effect (side effect)
CAS REGISTRY NUMBERS
  candesartan (139481-59-7)
  captopril (62571-86-2)
  carvedilol (72956-09-3)
  digoxin (20830-75-5, 57285-89-9)
  dobutamine (34368-04-2, 52663-81-7)
  dopamine (51-61-6, 62-31-7)
  enalapril (75847-73-3)
  losartan (114798-26-4)
  metolazone (17560-51-9)
  perindopril (82834-16-0, 99149-83-4)
  valsartan (137862-53-4)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008092191
FULL TEXT LINK
  http://dx.doi.org/10.1016/S1873-9598(08)70038-3
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 423
TITLE
  Atrial fibrillation-related cardiomyopathy: A case report
AUTHOR NAMES
  Peake S.T.C.
  Mehta P.A.
  Dubrey S.W.
AUTHOR ADDRESSES
  (Peake S.T.C., s_peake@doctors.org.uk; Mehta P.A., p.mehta@imperial.ac.uk; 
Dubrey S.W., simon.dubrey@thh.nhs.uk) Department of Cardiology, The 
Hillingdon Hospital, Middlesex, United Kingdom.
CORRESPONDENCE ADDRESS
  S.T.C. Peake, Department of Cardiology, The Hillingdon Hospital, Middlesex, 
United Kingdom. Email: s_peake@doctors.org.uk
SOURCE
  Journal of Medical Case Reports (2007) 1 Article Number: 111. Date of 
Publication: 22 Oct 2007
ISSN
  1752-1947
  1752-1947 (electronic)
BOOK PUBLISHER
  BioMed Central Ltd., 34 - 42 Cleveland Street, London, United Kingdom.
ABSTRACT
  Sustained chronic tachyarrhythmias often cause a deterioration of cardiac 
function known as tachycardia-induced cardiomyopathy or tachycardiomyopathy. 
The incidence of tachycardia-induced cardiomyopathy is unknown, but in 
selected studies of patients with atrial fibrillation, approximately 25% to 
50% of those with left ventricular dysfunction had some degree of 
tachycardia-induced cardiomyopathy. It is an important clinical entity due 
to the high incidence and potential reversibility of the disease process. 
This case describes a cardiomyopathy induced by excess caffeine consumption. 
Six months following withdrawal of caffeine from the subject's diet, full 
resolution of symptoms occurred. © 2007 Peake et al; licensee BioMed Central 
Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  caffeine
EMTREE DRUG INDEX TERMS
  digoxin (drug therapy)
  ramipril (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (diagnosis, drug therapy)
  congestive cardiomyopathy (complication, diagnosis, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
  adult
  angiocardiography
  article
  case report
  clinical feature
  dietary intake
  disease association
  dyspnea
  electrocardiogram
  follow up
  heart ejection fraction
  heart left ventricle hypertrophy (diagnosis)
  heart palpitation
  human
  male
  priority journal
  tachycardia induced cardiomyopathy (complication, etiology)
  transthoracic echocardiography
  treatment response
CAS REGISTRY NUMBERS
  caffeine (30388-07-9, 58-08-2)
  digoxin (20830-75-5, 57285-89-9)
  ramipril (87333-19-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008286713
FULL TEXT LINK
  http://dx.doi.org/10.1186/1752-1947-1-111
COPYRIGHT
  Copyright 2008 Elsevier B.V., All rights reserved.

RECORD 424
TITLE
  The current role of photodynamic therapy in oesophageal dysplasia and cancer
AUTHOR NAMES
  Gray J.
  Fullarton G.
AUTHOR ADDRESSES
  (Gray J., jojo.gray@gmail.com; Fullarton G., grant.fullarton@btinternet.com) 
Department of Gastrointestinal Surgery, Gartnavel General Hospital, 1053 
Great Western Road, Glasgow, G12 0YN, United Kingdom.
CORRESPONDENCE ADDRESS
  G. Fullarton, Department of Gastrointestinal Surgery, Gartnavel General 
Hospital, 1053 Great Western Road, Glasgow, G12 0YN, United Kingdom. Email: 
grant.fullarton@btinternet.com
SOURCE
  Photodiagnosis and Photodynamic Therapy (2007) 4:3 (151-159). Date of 
Publication: September 2007
ISSN
  1572-1000
BOOK PUBLISHER
  Elsevier, P.O. Box 211, Amsterdam, Netherlands.
ABSTRACT
  Over the last 15 years photodynamic therapy (PDT) has become a viable 
treatment for pre-malignant and malignant disease of the oesophagus. Its 
initial use was in the palliation of oesophageal malignant obstruction 
bringing improved swallowing hence increasing nutritional intake and 
improving general quality of life. As the therapeutic boundaries of PDT have 
stretched, current studies look at the role of PDT in the treatment of 
pre-malignant dysplastic Barrett's epithelium and early malignancy as a 
curative mucosal ablative technique. As a curative treatment in early 
oesophageal cancer, PDT provides an alternative treatment to oesophagectomy 
for those more elderly or less medically fit patients. This paper reviews 
the uses of photodynamic therapy in oesophageal cancer with reference to the 
available publications on its use in the palliation of oesophageal cancer 
and treatment of early cancer and high grade dysplasia in Barrett's mucosa. 
© 2007 Elsevier B.V. All rights reserved.
EMTREE DRUG INDEX TERMS
  aminolevulinic acid (adverse drug reaction, clinical trial, drug 
concentration, drug therapy, oral drug administration)
  omeprazole (drug therapy)
  photofrin (adverse drug reaction, clinical trial, drug concentration, drug 
therapy, intravenous drug administration)
  temoporfin (adverse drug reaction, drug concentration, drug therapy, 
intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  esophagus cancer (drug therapy, radiotherapy, surgery)
  esophagus malformation
  photodynamic therapy
EMTREE MEDICAL INDEX TERMS
  argon plasma coagulation
  atrial fibrillation (side effect)
  Barrett esophagus (drug therapy, surgery)
  bleeding (complication)
  brachytherapy
  cancer palliative therapy
  cancer patient
  cancer survival
  clinical trial
  congestive heart failure (side effect)
  dosimetry
  dysphagia (side effect)
  endoscopic echography
  endoscopic mucosal resection
  esophagitis (side effect)
  esophagus resection
  esophagus stenosis (complication)
  external beam radiotherapy
  fever (side effect)
  fistula (side effect)
  human
  leukocytosis (side effect)
  neodymium laser
  perforation (side effect)
  photosensitivity (side effect)
  phototoxicity (complication)
  pleura effusion (side effect)
  pneumonia (side effect)
  priority journal
  review
  stenosis (side effect)
  supraventricular tachycardia (complication)
DRUG TRADE NAMES
  foscan  , Irelandbiolitec

  photofrin  , United KingdomAxcan

DRUG MANUFACTURERS
   (United Kingdom)Axcan
   (Ireland)biolitec
   (Germany)Medac
CAS REGISTRY NUMBERS
  aminolevulinic acid (106-60-5)
  omeprazole (73590-58-6, 95510-70-6)
  photofrin (85189-42-0)
  temoporfin (122341-38-2)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Cancer (16)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007395104
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.pdpdt.2007.04.003
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 425
TITLE
  Type 1 diabetes and gastroparesis: Diagnosis and treatment
AUTHOR NAMES
  Hasler W.L.
AUTHOR ADDRESSES
  (Hasler W.L., whasler@umich.edu) Division of Gastroenterology, University of 
Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109, United 
States.
CORRESPONDENCE ADDRESS
  W.L. Hasler, Division of Gastroenterology, University of Michigan Health 
System, 3912 Taubman Center, Ann Arbor, MI 48109, United States. Email: 
whasler@umich.edu
SOURCE
  Current Gastroenterology Reports (2007) 9:4 (261-269). Date of Publication: 
August 2007
ISSN
  1522-8037
BOOK PUBLISHER
  Current Medicine Group LLC, 400 Market St,, Ste 700 Philadelphia, United 
States.
ABSTRACT
  Patients with gastroparesis present with gastrointestinal symptoms and 
non-gastrointestinal manifestations in association with objective delays in 
gastric emptying. The condition complicates the course of many patients with 
type 1 diabetes mellitus, usually in those with longstanding poor glycemic 
control with other associated diabetic complications. The diagnosis is made 
by directed evaluation to exclude organic diseases that can mimic the 
clinical presentation of gastroparesis, coupled with verification of gastric 
retention. Current therapy relies on dietary modifications, medications to 
stimulate gastric evacuation, and agents to reduce vomiting. Endoscopic and 
surgical options are increasingly used in patients who are refractory to 
drug treatment. Copyright © 2007 by Current Medicine Group LLC.
EMTREE DRUG INDEX TERMS
  azithromycin (drug comparison, drug therapy, pharmacology)
  bethanechol (adverse drug reaction, drug therapy, pharmacology)
  botulinum toxin (drug dose, drug therapy, pharmacology)
  buspirone (pharmacology)
  cisapride (adverse drug reaction, drug therapy, pharmacology)
  clarithromycin (drug comparison, drug therapy, pharmacology)
  clonidine (drug therapy, pharmacology)
  domperidone (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, intravenous drug administration, oral drug administration, 
pharmacology)
  erythromycin (adverse drug reaction, clinical trial, drug comparison, drug 
dose, drug therapy, intravenous drug administration, pharmacology)
  ghrelin (pharmacology)
  ginger extract (drug therapy, pharmacology)
  glucose (endogenous compound)
  macrolide (drug therapy, pharmacology)
  metoclopramide (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, intravenous drug administration, pharmacology, subcutaneous drug 
administration)
  mirtazapine (drug therapy)
  mitemcinal (drug therapy)
  mosapride (drug therapy)
  nitrate (pharmacology)
  phenothiazine (drug therapy, pharmacology)
  prochlorperazine (drug therapy, pharmacology)
  prokinetic agent (drug therapy, pharmacology)
  pyridostigmine (drug therapy, pharmacology)
  renzapride (drug therapy)
  serotonin agonist (drug therapy)
  serotonin uptake inhibitor (pharmacology)
  sumatriptan (pharmacology)
  tegaserod (adverse drug reaction, drug therapy, pharmacology)
  thiethylperazine (drug therapy, pharmacology)
  tricyclic antidepressant agent (drug therapy)
  unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  insulin dependent diabetes mellitus (drug therapy, prevention, therapy)
  stomach paresis (complication, diagnosis, drug therapy, etiology, surgery, 
therapy)
EMTREE MEDICAL INDEX TERMS
  abdominal cramp (side effect)
  abdominal pain (side effect)
  acupuncture
  agitation
  amenorrhea (side effect)
  antiemetic activity
  anxiety disorder (complication)
  atrial fibrillation (side effect)
  bronchospasm (side effect)
  cardiovascular disease (side effect)
  clinical feature
  clinical trial
  depression (complication)
  device removal
  diabetic neuropathy (complication, prevention)
  diabetic retinopathy (complication, prevention)
  diaphoresis
  diet therapy
  drug efficacy
  drug megadose
  drug potency
  drug tolerance
  drug withdrawal
  dystonia (side effect)
  electrogastrography
  electrostimulation therapy
  endoscopic surgery
  enteric feeding
  fatality
  fatigue (side effect)
  galactorrhea (side effect)
  gastroenterostomy
  gastrointestinal endoscopy
  glucose blood level
  glycemic control
  heart arrhythmia (side effect)
  heart death (side effect)
  human
  hyperprolactinemia (side effect)
  hypotension (side effect)
  impotence (side effect)
  infection (complication)
  jejunostomy
  long term care
  mental disease (complication)
  muscle spasm (side effect)
  nausea and vomiting (side effect)
  pancreas transplantation
  parenteral nutrition
  pathophysiology
  pyloroplasty
  review
  side effect (side effect)
  single photon emission computer tomography
  sleep disorder (side effect)
  somatization (complication)
  stomach emptying
  stomach obstruction (complication, diagnosis)
  stomach scintiscanning
  tardive dyskinesia (side effect)
  total stomach resection
  treatment indication
  urinary urgency (side effect)
CAS REGISTRY NUMBERS
  azithromycin (83905-01-5)
  bethanechol (590-63-6, 674-38-4, 91609-06-2)
  buspirone (33386-08-2, 36505-84-7)
  cisapride (81098-60-4)
  clarithromycin (81103-11-9)
  clonidine (4205-90-7, 4205-91-8, 57066-25-8)
  domperidone (57808-66-9)
  erythromycin (114-07-8, 70536-18-4)
  ghrelin (258279-04-8, 304853-26-7)
  glucose (50-99-7, 84778-64-3)
  metoclopramide (12707-59-4, 2576-84-3, 364-62-5, 7232-21-5)
  mirtazapine (61337-67-5)
  mitemcinal (154738-42-8, 154802-96-7)
  mosapride citrate (112885-42-4)
  nitrate (14797-55-8)
  phenothiazine (92-84-2)
  prochlorperazine (58-38-8)
  pyridostigmine (101-26-8, 155-97-5)
  renzapride (109872-41-5)
  sumatriptan (103628-46-2)
  tegaserod (145158-71-0, 189188-57-6)
  thiethylperazine (1420-55-9)
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  General Pathology and Pathological Anatomy (5)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007475140
MEDLINE PMID
  17883972 (http://www.ncbi.nlm.nih.gov/pubmed/17883972)
FULL TEXT LINK
  http://dx.doi.org/10.1007/s11894-007-0029-9
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 426
TITLE
  Ultrasoundcardiography in mitral stenosis, with particular reference to the 
relationship to hemodynamic and surgical findings
AUTHOR NAMES
  Gustafson A.
AUTHOR ADDRESSES
  (Gustafson A.) Cardiol. Clin., Dept. of Int. Med., Univ. Hosp., Lund.
CORRESPONDENCE ADDRESS
  Cardiol. Clin., Dept. of Int. Med., Univ. Hosp., Lund.
SOURCE
  Acta medica Scandinavica (1973) 1966:SUPPL. 461
ISSN
  0001-6101
ABSTRACT
  The purpose of the present investigation was to study the place of the 
ultrasoundcardiogram (UCG) in the preoperative evaluation of patients with 
mitral valvular disease. In addition a methodological study of UCG was 
performed. It was shown that measurements of the diastolic descent-rate of 
the UCG during 10 heart cycles and of the maximal amplitude during 5 heart 
cycles provide a determination of the two variables in each UCG-tracing that 
is sufficiently accurate for clinical use. The method showed a good 
reproducibility in duplicate recordings and in recordings performed on 
different days. The most important cause for the variation of the 
UCG-findings was the site on the chest wall from which the recording was 
performed. The diastolic descent-rate showed no significant difference 
between recordings performed during atrial fibrillation and during sinus 
rhythm in the same patients. The influence of the respiratory movements upon 
the UCG-tracing was also studied. In a series of 71 patients with 
predominant mitral stenosis the UCG-findings were related to clinical, 
hemodynamic and surgical findings. Patients with descent-rates of ≤ 15 mm/s. 
and > 15 mm/s. were compared. In those with sinus rhythm the mean values of 
pulmonary arterial and pulmonary arterial wedge pressures at rest and during 
exercise were significantly higher in the group with the lower descent-rate. 
The mitral valve area calculated on the basis of hemodynamic data showed a 
statistically significant correlation to the descent-rate of UCG in the 
patients with sinus rhythm but not in those with atrial fibrillation. The 
mitral valve area was determined in square centimeters by a method which 
showed a relatively good reproducibility. The descent-rate of UCG showed a 
highly significant correlation to the mitral valve area in the whole 
material. This correlation was poor in patients with an UCG-tracing of low 
maximal amplitude (≤ 15 mm). The best correlation between descent-rate and 
valve area was found in patients with sinus rhythm. The maximal amplitude of 
UCG was related to the mobility of the anterior mitral leaflet and to the 
degree of calcification of the mitral valve: patients with an UCG-tracing of 
low amplitude often had a mitral valve with restricted mobility of the 
anterior leaflet and advanced calcifications. By analysis of variance these 
relationships were shown to be statistically highly significant. The origin 
and significance of the UCG-tracing in relation to the movements of the 
anterior mitral leaflet studied by angiocardiography in different anatomical 
types of mitral stenosis is discussed. The slow descent-rate is postulated 
to be mainly caused by the narrowing of the mitral orifice in patients with 
a thin and pliable anterior leaflet in contrast to those with an immobile 
and calcified valve where it may be mainly caused by the rigidity of the 
leaflet. The accuracy of the UCG and of the mitral valve area calculated by 
the Gorlin formula, in predicting the valve area found at operation was 
compared. It was concluded that the former method is probably slightly 
better for predicting the degree of mitral stenosis. Finally, the 
descent-rate of UCG, the calculated mitral valve area and the valve area 
estimated by the surgeon were correlated to hemodynamic data obtained by 
right heart catheterization. The coefficients of correlation for the three 
estimates of the degree of mitral stenosis were on the whole of the same 
order.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  mitral valve stenosis
EMTREE MEDICAL INDEX TERMS
  analysis of variance
  angiocardiography
  atrial fibrillation
  breathing mechanics
  calcification
  echocardiography
  exercise
  heart catheterization
  heart cycle
  mitral valve
  mitral valve disease
  patient
  preoperative evaluation
  recording
  reproducibility
  restenosis
  rigidity
  sinus rhythm
  surgeon
  thorax wall
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007875080
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 427
TITLE
  Adverse events among high-risk participants in a home-based walking study: A 
descriptive study
AUTHOR NAMES
  Goodrich D.E.
  Larkin A.R.
  Lowery J.C.
  Holleman R.G.
  Richardson C.R.
AUTHOR ADDRESSES
  (Goodrich D.E., david.goodrich2@va.gov; Larkin A.R., angela.larkin@va.gov; 
Lowery J.C., julie.lowery@va.gov; Holleman R.G., rholle@umich.edu; 
Richardson C.R., caroli@umich.edu) HSRandD Center for Excellence, VA Health 
Care Medical Center, P.O. Box 130170, Ann Arbor, MI 48113-0170, United 
States.
(Goodrich D.E., david.goodrich2@va.gov; Holleman R.G., rholle@umich.edu; 
Richardson C.R., caroli@umich.edu) Department of Family Medicine, University 
of Michigan, 1018 Fuller St., Ann Arbor, MI 48109-5708, United States.
CORRESPONDENCE ADDRESS
  C.R. Richardson, HSRandD Center for Excellence, VA Health Care Medical 
Center, P.O. Box 130170, Ann Arbor, MI 48113-0170, United States. Email: 
caroli@umich.edu
SOURCE
  International Journal of Behavioral Nutrition and Physical Activity (2007) 4 
Article Number: 20. Date of Publication: 23 May 2007
ISSN
  1479-5868 (electronic)
BOOK PUBLISHER
  BioMed Central Ltd., 34 - 42 Cleveland Street, London, United Kingdom.
ABSTRACT
  Background: For high-risk individuals and their healthcare providers, 
finding the right balance between promoting physical activity and minimizing 
the risk of adverse events can be difficult. More information on the 
prevalence and influence of adverse events is needed to improve providers' 
ability to prescribe effective and safe exercise programs for their 
patients. Methods: This study describes the type and severity of adverse 
events reported by participants with cardiovascular disease or at-risk for 
cardiovascular disease that occurred during an unsupervised, home-based 
walking study. This multi-site, randomized controlled trial tested the 
feasibility of a diet and lifestyle activity intervention over 1.5 years. At 
month 13, 274 eligible participants (male veterans) were recruited who were 
ambulatory, BMI > 28, and reporting one or more cardiovascular disease risk 
factors. All participants attended five, face-to-face dietitian-delivered 
counseling sessions during the six-month intervention. Participants were 
randomized to three study arms: 1) time-based walking goals, 2) simple 
pedometer-based walking goals, and 3) enhanced pedometer-based walking goals 
with Internet-mediated feedback. Two physicians verified adverse event 
symptom coding. Results: Enrolled participants had an average of five 
medical comorbidities. During 1110 person months of observation, 87 of 274 
participants reported 121 adverse events. One serious study-related adverse 
event (atrial fibrillation) was reported; the individual resumed study 
participation within three days. Non-serious, study related adverse events 
made up 12% of all symptoms - predominantly minor musculoskeletal events. 
Serious, non-study related adverse events represented 32% of all symptoms 
while non-serious, non-study related adverse events made up 56% of symptoms. 
Cardiovascular disease events represented over half of the non-study related 
adverse event symptoms followed by musculoskeletal complaints. Adverse 
events caused 50 temporary suspensions averaging 26 days in duration before 
physician medical clearance was obtained to resume walking. Conclusion: Men 
at high risk for adverse cardiovascular events can safely be advised to 
start a progressive walking program. Results suggest that minor to serious 
medical problems unrelated to exercise are a major barrier to walking 
adherence. Helping individuals with chronic illness return to physical 
activity quickly but safely after an adverse event is an important component 
of any physical activity intervention targeting this population. © 2007 
Goodrich et al; licensee BioMed Central Ltd.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (complication)
  exercise
  home rehabilitation
  walking
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  cardiovascular risk
  clinical trial
  controlled clinical trial
  controlled study
  coronary artery disease
  diabetes mellitus
  exercise recovery
  health care personnel
  health care policy
  health program
  health promotion
  high risk population
  home care
  human
  hypercholesterolemia
  hypertension
  lifestyle modification
  male
  multicenter study
  nutrition education
  obesity
  patient safety
  physical activity
  randomized controlled trial
  rehabilitation
  weight reduction
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007296223
FULL TEXT LINK
  http://dx.doi.org/10.1186/1479-5868-4-20
COPYRIGHT
  Copyright 2010 Elsevier B.V., All rights reserved.

RECORD 428
TITLE
  Combination sedoanalgesia with remifentanil and propofol versus remifentanil 
and midazolam for elective cardioversion after coronary artery bypass 
grafting
AUTHOR NAMES
  Yildirim V.
  Doganci S.
  Bolcal C.
  Oz B.S.
  Kucukarslan N.
  Cosar A.
  Guzeldemir M.E.
AUTHOR ADDRESSES
  (Yildirim V.; Cosar A.; Guzeldemir M.E.) Department of Anesthesiology and 
Reanimation, Gulhane Military Academy of Medicine, Ankara, Turkey.
(Doganci S., suat_doganci@yahoo.com; Bolcal C.; Oz B.S.; Kucukarslan N.) 
Department of Cardiovascular Surgery, Gulhane Military Academy of Medicine, 
Ankara, Turkey.
(Doganci S., suat_doganci@yahoo.com) Department of Cardiovascular Surgery, 
Gulhane Military Academy of Medicine, 06018 Etlik-Ankara, Turkey.
CORRESPONDENCE ADDRESS
  S. Doganci, Department of Cardiovascular Surgery, Gulhane Military Academy 
of Medicine, 06018 Etlik-Ankara, Turkey. Email: suat_doganci@yahoo.com
SOURCE
  Advances in Therapy (2007) 24:3 (662-670). Date of Publication: May/June 
2007
ISSN
  0741-238X
BOOK PUBLISHER
  Springer Healthcare Communications, Lower Makefield Corporate Center South, 
770 Township Line RD, Suite 300, Yardley, United States.
ABSTRACT
  Postoperative atrial fibrillation (AF) occurs in up to 50% of cardiac 
surgery patients and represents the most common postoperative arrhythmic 
complication. Elective cardioversion, a short but painful procedure, remains 
an option for patients who do not convert to sinus rhythm with medical 
therapy. Combinations of remifentanil (a potent analgesic with a short 
elimination time) with propofol (a hypnotic agent) or midazolam (a sedative 
agent) produce a synergistic interaction. This study was undertaken to 
compare these combinations in terms of effectiveness and pain relief when 
given as sedoanalgesia for elective cardioversion. In this prospective, 
randomized trial, 60 adult patients with postoperative AF after coronary 
artery bypass grafting were given a single dose of propofol 1 mg/kg combined 
with remifentanil 0.1 μg/kg (group 1), or midazolam 0.05 mg/kg combined with 
remifentanil 0.1 μg/kg (group 2). Cardiorespiratory parameters were 
monitored and recorded. Demographic data were similar (P>.05) and sufficient 
sedoanalgesia and successful cardioversion were achieved in both groups. 
Hemodynamic parameters revealed no significant differences between groups 
(P>.05); however, induction time, time to eye opening, recuperation time, 
and time to full recovery of psychomotor function were faster in group 1 
than in group 2 (P<.05). The remifentanil/propofol combination provided 
sufficient analgesia, satisfactory hemodynamic stability, and mild 
respiratory depression, along with faster recovery and discharge times from 
the intensive care unit. ©2007 Health Communications Inc.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  midazolam (adverse drug reaction, drug combination, drug therapy, 
intravenous drug administration, pharmacokinetics, pharmacology)
  propofol (adverse drug reaction, drug combination, drug therapy, intravenous 
drug administration, pharmacokinetics, pharmacology)
  remifentanil (drug combination, drug dose, drug therapy, intravenous drug 
administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  midazolam maleate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (complication, drug therapy)
  cardioversion
  coronary artery bypass graft
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  analgesia
  anesthesia mechanism
  anesthesiological procedure
  anesthetic recovery
  apnea (side effect)
  article
  combination chemotherapy
  coughing (side effect)
  drug mechanism
  elective surgery
  female
  heart surgery
  human
  major clinical study
  male
  oxygen saturation
  postoperative period
  respiration depression (side effect)
  sedation
  side effect (side effect)
DRUG TRADE NAMES
  diprivan  , SwedenAstra Zeneca

  dormicum  , SwitzerlandHoffmann La Roche

  ultiva  , BelgiumGlaxo SmithKline

DRUG MANUFACTURERS
   (Sweden)Astra Zeneca
   (Belgium)Glaxo SmithKline
   (Switzerland)Hoffmann La Roche
CAS REGISTRY NUMBERS
  midazolam (59467-70-8)
  midazolam maleate (59467-94-6, 65506-68-5)
  propofol (2078-54-8)
  remifentanil (132539-07-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Anesthesiology (24)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007412506
MEDLINE PMID
  17660177 (http://www.ncbi.nlm.nih.gov/pubmed/17660177)
FULL TEXT LINK
  http://dx.doi.org/10.1007/BF02848791
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 429
TITLE
  Influence of CYP2C9 genotype on warfarin dose among African-Americans and 
European-Americans
AUTHOR NAMES
  Limdi N.A.
  Goldstein J.A.
  Blaisdell J.A.
  Beasley T.M.
  Rivers C.A.
  Acton R.T.
AUTHOR ADDRESSES
  (Limdi N.A., nlimdi@uab.edu) University of Alabama at Birmingham, Department 
of Neurology, 1719 6th Avenue South, Birmingham, AL 35294-0021, United 
States.
(Goldstein J.A.; Blaisdell J.A.) University of Alabama at Birmingham, 
National Institute of Environmental Health Sciences, Birmingham, AL, United 
States.
(Beasley T.M.) University of Alabama at Birmingham, Section on Statistical 
Genetics, Department of Biostatistics, Birmingham, AL, United States.
(Rivers C.A.) University of Alabama at Birmingham, Department of 
Microbiology, Birmingham, AL, United States.
(Acton R.T.) University of Alabama at Birmingham, Department of Medicine 
Genetics and Epidemiology, Department of International Health, Birmingham, 
AL, United States.
CORRESPONDENCE ADDRESS
  N.A. Limdi, University of Alabama at Birmingham, Department of Neurology, 
1719 6th Avenue South, Birmingham, AL 35294-0021, United States. Email: 
nlimdi@uab.edu
SOURCE
  Personalized Medicine (2007) 4:2 (157-169). Date of Publication: May 2007
ISSN
  1741-0541
  1744-828X (electronic)
BOOK PUBLISHER
  Future Medicine Ltd., 2nd Albert Place, Finchley Central, London, United 
Kingdom.
ABSTRACT
  Background: Cytochrome P450 (CYP)2C9 plays a vital role in drug metabolism. 
There has been an increased effort to identify polymorphisms within the gene 
and to determine their clinical consequences. However, most of these efforts 
have focused on populations of European descent. Herein we report the 
influence of CYP2C9 genotype on warfarin dose among European-American and 
African-American patients. We also identify two new mutations, one in the 
coding region and one in the noncoding region of the CYP2C9 gene. Methods: 
Patients (aged >20 years) were enrolled after obtaining medical, lifestyle 
and concomitant medication history. Changes in international normalized 
ratio, warfarin dose, co-medications, diet, physical activity and the 
occurrence of complications were documented. CYP2C9 genotype was determined 
using PCR with restriction fragment length polymorphisms, and 
pyrosequencing. Differences in genotype frequencies and Hardy-Weinberg 
equilibrium assumptions were assessed using X(2) statistics and exact tests. 
The genotype-dose association was evaluated using multivariable linear 
regression. Results: This report includes 490 patients (mean age: 60.6 ± 
15.6 years; 51.3% men). African-American patients comprised 48.9% of the 
cohort, with a mean follow-up of 13.5 (±10.6) months. Both the CYP2C9*2 and 
*3 allele were more frequent in European-Americans (11.24 and 5.1 %, 
respectively) compared with African-Americans (1.1 and 1.8%). CYP2C9*5 
(0.9%), *6 (0.4%) and *11 (1.1%) variants were only observed in 
African-Americans. The variant genotype is more frequent among 
European-Americans compared with African-Americans (29.8 vs 9.73%; p < 
0.0001). Warfarin dose was significantly related to CYP2C9 genotype (p < 
0.0001), both in univariate and multivariate analyses. Multivariable 
race-specific analyses highlight the contribution of CYP2C9 genotype among 
European-American but not among African-American patients. Conclusion: The 
variant CYP2C9 genotype is more frequent among European-Americans compared 
with African-Americans. Among African-Americans the variant genotype. 
frequency is higher than previously reported. CYP2C9 genotype predicts 
warfarin dose in European-Americans, but not in African-Americans. © 2007 
Future Medicine Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  cytochrome P450 2C9 (endogenous compound)
  warfarin (drug dose, drug therapy)
EMTREE DRUG INDEX TERMS
  vitamin K group
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  pharmacogenetics
EMTREE MEDICAL INDEX TERMS
  adult
  African American
  aged
  allele
  anamnesis
  article
  atrial fibrillation (drug therapy)
  cerebrovascular accident (drug therapy)
  cohort analysis
  comorbidity
  controlled study
  dietary intake
  dose response
  European American
  female
  gene frequency
  gene mutation
  genetic variability
  genotype
  human
  international normalized ratio
  linear regression analysis
  major clinical study
  male
  multivariate analysis
  physical activity
  polymerase chain reaction
  prediction
  priority journal
  race difference
  restriction fragment length polymorphism
  thromboembolism (drug therapy)
  treatment indication
  univariate analysis
CAS REGISTRY NUMBERS
  vitamin K group (12001-79-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Human Genetics (22)
  Hematology (25)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007266718
FULL TEXT LINK
  http://dx.doi.org/10.2217/17410541.4.2.157
COPYRIGHT
  Copyright 2008 Elsevier B.V., All rights reserved.

RECORD 430
TITLE
  Incident atrial fibrillation: Impact of obstructive sleep apnea and obesity
AUTHOR NAMES
  Somers V.K.
  Gami A.S.
  Block P.C.
AUTHOR ADDRESSES
  (Somers V.K.; Gami A.S.; Block P.C.)
SOURCE
  ACC Cardiosource Review Journal (2007) 16:5 (6-8). Date of Publication: May 
2007
ISSN
  1556-8571
BOOK PUBLISHER
  Elsevier USA, 6277 Sea Harbor Drive, Orlando, United States.
ABSTRACT
  In the United States, the major clinical risk factors for atrial 
fibrillation (AF) include age, diabetes, hypertension, heart failure, and 
coronary artery disease. Recently, long-term follow-up data of more than 
5,000 subjects in the Framingham Heart Study and nearly 48,000 subjects in 
the Danish Diet, Cancer, and Health Study showed that AF also is predicted 
by obesity, and this association is independent of other clinical 
characteristics. However, the mechanisms by which obesity leads to AF are 
unknown. This is an important question given the magnitude of both the 
obesity and AF epidemics. Obstructive sleep apnea (OSA) is highly prevalent 
in obese individuals, and it is estimated that more than 25 million US 
adults have OSA. We have previously shown in a cross-sectional analysis that 
OSA is strongly associated with AF, independent of age, gender, 
hypertension, heart failure, and obesity (Slide 1). It is estimated that 
about one-half of patients with medically complicated AF and about one-third 
of patients with lone AF have OSA. However, no study yet has identified the 
risk of incident AF attributable to OSA during long-term follow-up. We 
report in the Journal of the American College of Cardiology a historical 
cohort study that included 3,542 consecutive adult residents of our county 
who underwent their first diagnostic polysomnography between 1987 and 2003. 
Individuals with AF or a previous history of AF were excluded. Those 
enrolled in our study were followed up until death or last follow-up for the 
occurrence of incident AF or flutter, which was confirmed by an 
electrocardiogram. After an average of 5 years of follow-up (maximum 15 
years), the cumulative frequency of AF was 14% and this was predicted by 
several well-established risk factors, such as male sex, age, hypertension, 
coronary artery disease, and heart failure. We also found that body mass 
index, OSA, the apnea-hypopnea index, and several oxygen saturation 
parameters strongly predicted AF (Slide 2). In multivariate regression 
models, age, male sex, coronary artery disease, body mass index (per 1 
kg/m(2); hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.05-1.10; p 
< 0.001), and a decrease in nocturnal oxygen saturation (per 0.5 unit change 
in the log; HR, 3.29; 95% CI, 1.35-8.04; p = 0.009) were independent 
predictors of incident AE For subjects ≥65 years old, only heart failure 
independently predicted incident AF (HR, 7.68; 95% CI, 4.32-13.66; p < 
0.001).
EMTREE DRUG INDEX TERMS
  oxygen (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (diagnosis)
  obesity
  sleep disordered breathing (diagnosis)
EMTREE MEDICAL INDEX TERMS
  adult
  age
  article
  body mass
  comorbidity
  coronary artery disease
  cross-sectional study
  death
  diabetes mellitus
  disease association
  electrocardiography
  female
  follow up
  heart failure
  human
  hypertension
  male
  multivariate analysis
  oxygen saturation
  pathophysiology
  polysomnography
  prediction
  prevalence
  risk factor
  sex difference
  United States
CAS REGISTRY NUMBERS
  oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Neurology and Neurosurgery (8)
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007428098
COPYRIGHT
  Copyright 2008 Elsevier B.V., All rights reserved.

RECORD 431
TITLE
  Oral anticoagulation in atrial fibrillation: A pan-European patient survey
AUTHOR NAMES
  Lip G.Y.H.
  Agnelli G.
  Thach A.A.
  Knight E.
  Rost D.
  Tangelder M.J.D.
AUTHOR ADDRESSES
  (Lip G.Y.H., g.y.h.lip@bham.ac.uk) Haemostasis, Thrombosis and Vascular 
Biology Unit, University Department of Medicine, Birmingham, B18 7QH, United 
Kingdom.
(Agnelli G.) Division of Internal and Cardiovascular Medicine, Department of 
Internal Medicine, University of Perugia, Perugia, Italy.
(Thach A.A.) IPSOS Health, Harrow, United Kingdom.
(Knight E.) Anticoagulation Europe, Bromley, United Kingdom.
(Rost D.) Christiansfeld, Denmark.
(Tangelder M.J.D.) AstraZeneca R and D, Clinical Science, Mölndal, Sweden.
CORRESPONDENCE ADDRESS
  G.Y.H. Lip, Haemostasis, Thrombosis and Vascular Biology Unit, University 
Department of Medicine, Birmingham, B18 7QH, United Kingdom. Email: 
g.y.h.lip@bham.ac.uk
SOURCE
  European Journal of Internal Medicine (2007) 18:3 (202-208). Date of 
Publication: May 2007
ISSN
  0953-6205
BOOK PUBLISHER
  Elsevier, P.O. Box 211, Amsterdam, Netherlands.
ABSTRACT
  Background: Anticoagulation with vitamin K antagonists (VKAs) provides 
effective stroke prophylaxis in patients with atrial fibrillation (AF). 
Optimisation of such therapy requires frequent monitoring, dose adjustments 
and stringent lifestyle restrictions. We conducted a large multinational 
survey in patients with chronic AF to gain insights into their perceptions 
and understanding of VKA use. Methods: Eligible patients were adults with AF 
who had been prescribed VKAs for at least 1 year. A total of 711 patient 
interviews were conducted in seven European countries during June and July 
2004. Results: The majority of patients (58% male; mean age 68 years) 
claimed to understand their treatment programme; despite this, only 7% knew 
that VKA use is aimed at preventing strokes and 24% stated that they would 
have liked more information. Patients attended an average of 14 monitoring 
sessions in the previous year; however, 21% missed appointments, especially 
younger patients (< 65 years). The International Normalized Ratio (INR) was 
within the target range in most or all of the last five to ten visits in 64% 
of patients; nonetheless, 38% were not aware that an INR outside the target 
range is associated with health risks. On average, patients required dose 
adjustments every four sessions. VKA treatment impacted 67% of patients in 
terms of diet, socialising, career and independence, especially younger 
patients (74%). Conclusions: Monitoring, dose adjustments and lifestyle 
restrictions to optimise the intensity of anticoagulation with VKAs are 
problematic for patients with AF, and their knowledge of the consequences of 
such therapy is often poor. © 2007 European Federation of Internal Medicine.
EMTREE DRUG INDEX TERMS
  antivitamin K (drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  career
  cerebrovascular accident (drug therapy, prevention)
  female
  health hazard
  health survey
  human
  independence
  interview
  lifestyle
  major clinical study
  male
  patient monitoring
  social life
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007197113
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ejim.2006.11.005
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 432
TITLE
  Postoperative care of adult cardiac surgery patients
AUTHOR NAMES
  Walcot N.
  Marchbank A.
AUTHOR ADDRESSES
  (Walcot N.; Marchbank A.) Derriford Hospital, Plymouth, United Kingdom.
(Walcot N.; Marchbank A.) Derriford Hospital, Plymouth, United Kingdom.
CORRESPONDENCE ADDRESS
  N. Walcot, Derriford Hospital, Plymouth, United Kingdom.
SOURCE
  Surgery (2007) 25:5 (211-214). Date of Publication: May 2007
  Heart, Book Series Title:
ISSN
  0263-9319
BOOK PUBLISHER
  Elsevier Ltd, Langford Lane, Kidlington, Oxford, United Kingdom.
ABSTRACT
  Cardiac surgical patients require intensive management postoperatively. 
Bleeding, infection, cardiovascular disturbances, respiratory problems and 
other end-organ dysfunction may be encountered. © 2007.
EMTREE DRUG INDEX TERMS
  adrenalin (drug therapy)
  amiodarone (drug therapy)
  aprotinin (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  digoxin (drug therapy)
  dobutamine (drug therapy)
  dopamine (drug therapy)
  fresh frozen plasma (drug therapy)
  milrinone (drug therapy)
  noradrenalin (drug therapy)
  oxygen (drug therapy)
  protamine (drug therapy)
  prothrombin (endogenous compound)
  thromboplastin (endogenous compound)
  tranexamic acid (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular surgery
  postoperative care
EMTREE MEDICAL INDEX TERMS
  acute kidney failure (complication, therapy)
  aorta balloon
  artificial heart pacemaker
  artificial ventilation
  atrial fibrillation (complication, drug therapy, surgery, therapy)
  blood clotting
  breathing exercise
  cardiovascular disease (complication, drug therapy, prevention, surgery, 
therapy)
  cardioversion
  cerebrovascular accident (complication)
  cerebrovascular disease (complication)
  coma (complication)
  confusion (complication)
  cryoprecipitate
  debridement
  delirium (complication)
  extubation
  forward heart failure (complication, drug therapy)
  gastrointestinal hemorrhage (complication)
  hemodialysis
  human
  intensive care
  intestine ischemia (complication, prevention)
  nose feeding
  partial thromboplastin time
  peritoneal dialysis
  physiotherapy
  positive end expiratory pressure
  postoperative hemorrhage (complication, drug therapy, prevention, surgery, 
therapy)
  postoperative infection (complication, surgery)
  postoperative period
  priority journal
  prothrombin time
  reoperation
  respiratory tract disease (complication, drug therapy, therapy)
  review
  surgical patient
  surgical technique
  thorax radiography
  thrombocyte count
  thrombocyte transfusion
  thromboelastography
  vasodilatation
  wound dressing
CAS REGISTRY NUMBERS
  adrenalin (51-43-4, 55-31-2, 6912-68-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  aprotinin (11004-21-0, 12407-79-3, 50936-63-5, 52229-70-6, 58591-29-0, 
9050-74-2, 9075-10-9, 9087-70-1)
  digoxin (20830-75-5, 57285-89-9)
  dobutamine (34368-04-2, 52663-81-7)
  dopamine (51-61-6, 62-31-7)
  milrinone (78415-72-2)
  noradrenalin (1407-84-7, 51-41-2)
  oxygen (7782-44-7)
  protamine (11061-43-1, 9007-31-2, 9012-00-4)
  prothrombin (9001-26-7)
  thromboplastin (9035-58-9)
  tranexamic acid (1197-18-8, 701-54-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Urology and Nephrology (28)
  Drug Literature Index (37)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007269388
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.mpsur.2007.04.017
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 433
TITLE
  Cardiac resynchronization therapy in patients with congestive heart failure 
and atrial fibrillation
AUTHOR NAMES
  Adornato E.M.F.
  Adornato E.
AUTHOR ADDRESSES
  (Adornato E.M.F.) Dipartimento di Cardiologia, Azienda Ospedaliera Bianchi 
Melacrino Morelli, Reggio Calabria, Italy.
(Adornato E.) Casa di Cura S. Feliciano, Roma, Italy.
(Adornato E.) Via Vicenza 8, 89100 Reggio Calabria, Italy.
CORRESPONDENCE ADDRESS
  E. Adornato, Via Vicenza 8, 89100 Reggio Calabria, Italy.
SOURCE
  Mediterranean Journal of Pacing and Electrophysiology (2007) 9:2 (102-105). 
Date of Publication: April/June 2007
ISSN
  1128-4293
BOOK PUBLISHER
  Edizioni Luigi Pozzi S.r.l., Via Panama 68, Roma, Italy.
ABSTRACT
  AF is a very frequent cardiac arrhythmia in patients with congestive HF and 
this association represents a major public health problem because of the 
negative impact on quality of life and survival of patients. The prevalence 
of AF in HF patients progressively increases with age and with the degree of 
left ventricular dysfunction, tipically judged by NYHA functional class. 
Clinical studies have documented that in patients with congestive HF the 
presence of AF confers a greater risk for death, largely because of an 
increase of risk for pump failure, in comparison with patients with sinus 
rhythm. In the last decade biventricular pacing at optimum AV delay has been 
proposed as supplemental treatment for moderate to severe congestive HF and 
a meta-analysis of 4 randomized trials has documented a significant 
improvement in cardiac performance, exercise capacity and quality of life. 
These results of biventricular pacing have been obtained from patients who 
had sinus rhythm, but recently the results of some prospective trials have 
confirmed the usefulness of biventricular pacing systems also in patients 
with congestive HF and chronic AF independently of any optimisation of AV 
interval and of contribution of atrial systole to the diastolic ventricular 
filling.
EMTREE DRUG INDEX TERMS
  dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (therapy)
  cardiac resynchronization therapy
  congestive heart failure (drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  catheter ablation
  clinical trial
  exercise
  functional status
  heart left bundle branch block
  heart left ventricle ejection fraction
  heart left ventricle failure
  heart performance
  heart ventricle filling
  human
  mortality
  prevalence
  prognosis
  public health problem
  quality of life
  review
  sinus rhythm
  survival rate
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008368554
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 434
TITLE
  NYHA functional class IV patients: Cardiac Resynchronization therapy with 
defibrillator back up
AUTHOR NAMES
  Fusco A.
AUTHOR ADDRESSES
  (Fusco A.) Department of Cardioloy, Pederzoli Clinic, 37019 Peschiera del 
Garda, VR, Italy.
CORRESPONDENCE ADDRESS
  A. Fusco, Department of Cardioloy, Pederzoli Clinic, 37019 Peschiera del 
Garda, VR, Italy.
SOURCE
  Mediterranean Journal of Pacing and Electrophysiology (2007) 9:2 (106-108). 
Date of Publication: April/June 2007
ISSN
  1128-4293
BOOK PUBLISHER
  Edizioni Luigi Pozzi S.r.l., Via Panama 68, Roma, Italy.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiac resynchronization therapy
  defibrillator
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  cardiomyopathy
  clinical trial
  exercise
  functional status
  heart arrhythmia (prevention, therapy)
  heart failure
  hospitalization
  human
  mortality
  quality of life
  sudden death
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2008368555
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 435
TITLE
  Rate control in atrial fibrillation
AUTHOR NAMES
  Zagaria M.A.E.
AUTHOR ADDRESSES
  (Zagaria M.A.E.) MZ Associates Inc., Staten Island, NY, United States.
CORRESPONDENCE ADDRESS
  M.A.E. Zagaria, MZ Associates Inc., Staten Island, NY, United States.
SOURCE
  U.S. Pharmacist (2007) 32:2. Date of Publication: 20 Mar 2007
ISSN
  0148-4818
BOOK PUBLISHER
  Jobson Publishing Corporation, 100 Avenue of the Americas, New York, United 
States.
ABSTRACT
  Atrial fibrillation is one of the most common types of arrhrythmias. Its 
prevalence increases with age and tends to occur in individuals with a 
cardiac disorder. The risk of cardiovascular morbidity and mortality is 
considerably increased in seniors with atrial fibrillation, even if they do 
not have organic heart disease. The longer the duration of atrial 
fibrillation, the less likely spontaneous conversion will occur and the more 
difficult cardioversion is to attain. Chronic tachycardias can potentially 
result in a progressive decline in left ventricular function. Effective 
ventricular rate control benefits patients by reducing the risk of 
tachycardia-induced atrial remodeling in patients who have poor rate 
control. The treatment of atrial fibrillation focuses on ventricular rate 
control with medications, prevention of thromboembolism with anticoagulant 
therapy, and if necessary, conversion to normal sinus rhythm using 
medications or procedural cardioversion. Medications and ablation are 
effective for both rate and rhythm control.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction, drug comparison, drug therapy)
  adenosine (drug therapy, intravenous drug administration, pharmacology)
  amiodarone (adverse drug reaction, drug therapy)
  angiotensin receptor antagonist (drug therapy, pharmacology)
  antiarrhythmic agent (adverse drug reaction, drug therapy)
  beta adrenergic receptor blocking agent (drug combination, drug therapy, 
intravenous drug administration, oral drug administration, pharmacology)
  calcium channel blocking agent (drug combination, drug therapy, intravenous 
drug administration, oral drug administration, pharmacology)
  digitalis (drug therapy, intravenous drug administration, pharmacology)
  digoxin (adverse drug reaction, drug combination, drug therapy, intravenous 
drug administration, oral drug administration, pharmacology)
  dipeptidyl carboxypeptidase inhibitor (drug therapy, pharmacology)
  esmolol (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy, 
pharmacology)
  lidocaine (drug therapy, intravenous drug administration, pharmacology)
  metoprolol (drug therapy)
  warfarin (adverse drug reaction, drug comparison, drug dose, drug therapy)
  ximelagatran (drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (diagnosis, drug therapy, epidemiology, etiology, 
prevention, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  age distribution
  antiarrhythmic activity
  article
  artificial heart pacemaker
  bleeding (side effect)
  cardioversion
  cerebrovascular disease (complication, drug therapy, prevention)
  clinical feature
  dizziness
  drug contraindication
  drug dose titration
  drug mechanism
  drug substitution
  drug withdrawal
  dyspnea
  electrocardiography
  exercise
  fatigue
  heart failure (drug therapy)
  heart left ventricle function
  heart palpitation
  heart rhythm
  human
  morbidity
  mortality
  prevalence
  QT prolongation (side effect)
  radiofrequency ablation
  recurrent disease (complication, drug therapy, prevention)
  renal clearance
  risk reduction
  side effect (side effect)
  sinus rhythm
  tachycardia (complication)
  thorax pain
  thromboembolism (complication, drug therapy, prevention)
  torsade des pointes (side effect)
  unspecified side effect (side effect)
  weakness
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  adenosine (58-61-7)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digitalis (8031-42-3, 8053-83-6)
  digoxin (20830-75-5, 57285-89-9)
  esmolol (81147-92-4, 81161-17-3)
  lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
  metoprolol (37350-58-6)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
  ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008360952
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 436
TITLE
  Evidence-based guidelines for cardiovascular disease prevention in women: 
2007 Update
AUTHOR NAMES
  Mosca L.
  Banka C.L.
  Benjamin E.J.
  Berra K.
  Bushnell C.
  Dolor R.J.
  Ganiats T.G.
  Gomes A.S.
  Gornik H.L.
  Gracia C.
  Gulati M.
  Haan C.K.
  Judelson D.R.
  Keenan N.
  Kelepouris E.
  Michos E.D.
  Newby L.K.
  Oparil S.
  Ouyang P.
  Oz M.C.
  Petitti D.
  Pinn V.W.
  Redberg R.F.
  Scott R.
  Sherif K.
  Smith S.C.
  Sopko G.
  Steinhorn R.H.
  Stone N.J.
  Taubert K.A.
  Todd B.A.
  Urbina E.
  Wenger N.K.
AUTHOR ADDRESSES
  (Mosca L.; Banka C.L.; Benjamin E.J.; Berra K.; Bushnell C.; Dolor R.J.; 
Gomes A.S.; Gornik H.L.; Kelepouris E.; Michos E.D.; Newby L.K.; Oparil S.; 
Ouyang P.; Oz M.C.; Redberg R.F.; Steinhorn R.H.; Stone N.J.; Taubert K.A.; 
Urbina E.; Wenger N.K.) American Heart Association, United States.
(Ganiats T.G.) American Academy of Family Physicians, United States.
(Gracia C.) American College of Obstetricians and Gynecologists, United 
States.
(Gulati M.) American College of Cardiology Foundation, United States.
(Haan C.K.) Society of Thoracic Surgeons, United States.
(Judelson D.R.) American Medical Women's Association, United States.
(Keenan N.) Centers for Disease Control and Prevention, United States.
(Pinn V.W.) Office of Research on Women's Health, United States.
(Scott R.) Association of Black Cardiologists, .
(Sherif K.) American College of Physicians, United States.
(Smith S.C.) World Heart Federation, .
(Sopko G.) National Heart, Lung, and Blood Institute, United States.
(Todd B.A.) American College of Nurse Practitioners, United States.
(Petitti D.)
CORRESPONDENCE ADDRESS
  L. Mosca, American Heart Association, United States.
SOURCE
  Circulation (2007) 115:11 (1481-1501). Date of Publication: March 2007
ISSN
  0009-7322
BOOK PUBLISHER
  Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327, 
Philadelphia, United States.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  alcohol
  aldosterone antagonist (drug therapy)
  alpha tocopherol
  angiotensin receptor antagonist (drug therapy)
  antiarrhythmic agent (drug therapy)
  antilipemic agent (drug therapy)
  antioxidant
  antithrombocytic agent (drug therapy)
  ascorbic acid
  beta adrenergic receptor blocking agent (drug therapy)
  beta carotene
  clopidogrel (drug therapy)
  cyanocobalamin
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  docosapentaenoic acid (drug therapy)
  fibric acid derivative (drug therapy)
  folic acid
  hormone
  icosapentaenoic acid (drug therapy)
  lipid (endogenous compound)
  lipoprotein (endogenous compound)
  nicotine
  nicotinic acid (drug therapy)
  omega 3 fatty acid (drug therapy)
  pyridoxine
  selective estrogen receptor modulator
  thiazide diuretic agent (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (drug therapy, prevention, rehabilitation, therapy)
EMTREE MEDICAL INDEX TERMS
  adjuvant therapy
  alcohol consumption
  algorithm
  atrial fibrillation (drug therapy)
  body weight
  cardiovascular risk
  cerebrovascular accident (rehabilitation)
  cholesterol intake
  congestive heart failure (rehabilitation)
  depression
  diabetes mellitus
  diet
  diet supplementation
  diet therapy
  drug substitution
  evidence based medicine
  fat intake
  female
  heart rehabilitation
  high risk patient
  hormone substitution
  human
  hyperlipidemia (drug therapy)
  hypertension (drug therapy)
  kinesiotherapy
  lifestyle modification
  medical research
  nicotine replacement therapy
  peripheral vascular disease (rehabilitation)
  physical activity
  practice guideline
  primary prevention
  priority journal
  prophylaxis
  review
  risk factor
  smoking
  smoking cessation
  social psychology
  sodium restriction
  stress management
  systematic review
  vitamin supplementation
  weight control
  weight reduction
  yoga
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alcohol (64-17-5)
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
  beta carotene (7235-40-7)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
  docosapentaenoic acid (25448-00-4, 32839-34-2)
  folic acid (59-30-3, 6484-89-5)
  icosapentaenoic acid (25378-27-2, 32839-30-8)
  lipid (66455-18-3)
  nicotine (54-11-5)
  nicotinic acid (54-86-4, 59-67-6)
  pyridoxine (12001-77-3, 58-56-0, 65-23-6, 8059-24-3)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2007203716
MEDLINE PMID
  17309915 (http://www.ncbi.nlm.nih.gov/pubmed/17309915)
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCULATIONAHA.107.181546
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 437
TITLE
  Pulmonary hypertension in connective tissue disease
AUTHOR NAMES
  Upadhyaya S.K.
  Kumar A.
AUTHOR ADDRESSES
  (Upadhyaya S.K., sundeepupadhyaya@hotmail.com) Rheumatology Service, 
Indraprastha Apollo Hospital, India.
(Kumar A.) Department of Medicine, All India Institute of Medical Sciences, 
New Delhi, India.
CORRESPONDENCE ADDRESS
  S.K. Upadhyaya, Rheumatology Service, Indraprastha Apollo Hospital, India. 
Email: sundeepupadhyaya@hotmail.com
SOURCE
  Indian Journal of Rheumatology (2007) 2:3 (114-119). Date of Publication: 
September 2007
ISSN
  0973-3698
BOOK PUBLISHER
  Elsevier (India) Pte Ltd
ABSTRACT
  Pulmonary hypertension (PH) is common to a large number of cardiac, 
pulmonary, and connective tissue diseases (CTDs). Chronic thromboembolism is 
a well-recognized cause. A substantial proportion of cases are idiopathic. 
Miscellaneous categories include familial pulmonary hypertension, HIV 
disease related PH and portal hypertension related PH. CTD-related PH may be 
secondary to interstitial lung disease or isolated, i.e. "classical" (in 
absence of pulmonary fibrosis). The latter is more commonly associated with 
the CREST Syndrome and MCTD. CTD-related isolated PH and idiopathic PH (IPH) 
are similar in their clinical presentation, histopathology and response to 
treatment. Early in CTD, the signs and symptoms of PH are subtle and 
non-specific and easily overlooked. There are now many guidelines for proper 
evaluation and treatment of idiopathic PH, which apply equally well to 
CTD-related PH. Doppler echocardiogram is an excellent screening tool to 
evaluate early PH. Rheumatologists and cardiologists should insist on the 
right-sided cardiac catheterization in these patients to help stage the 
disease and guide therapy. Until recently, clinicians were able to offer 
patients only symptomatic therapy but now there are several specific and 
effective therapies like prostacyclins, endothelin-receptor antagonists and 
phosphodiesterase inhibitors.
EMTREE DRUG INDEX TERMS
  adenosine (intravenous drug administration)
  bosentan (adverse drug reaction, drug dose, drug therapy)
  calcium channel blocking agent (drug therapy)
  digoxin (drug therapy)
  diuretic agent (drug therapy)
  endothelin receptor antagonist (drug therapy)
  iloprost (drug comparison, drug therapy, inhalational drug administration, 
pharmacokinetics)
  nitric oxide (inhalational drug administration)
  oxygen
  phosphodiesterase inhibitor (drug therapy)
  phosphodiesterase V inhibitor (pharmacology)
  placebo
  prostacyclin (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, intravenous drug administration, pharmacology, subcutaneous drug 
administration)
  sildenafil (drug therapy, oral drug administration, pharmacology)
  sitaxsentan (drug therapy)
  treprostinil (adverse drug reaction, drug comparison, drug dose, drug 
therapy, pharmacokinetics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  connective tissue disease
  pulmonary hypertension (diagnosis, drug therapy, etiology, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (drug therapy)
  bone pain (side effect)
  clinical feature
  clinical trial
  computer assisted tomography
  diarrhea (side effect)
  Doppler echocardiography
  drug fatality (side effect)
  drug half life
  drug induced headache (side effect)
  drug mechanism
  drug safety
  drug tolerance
  drug withdrawal
  dyspnea (drug therapy)
  electrocardiogram
  exercise
  flushing
  heart catheterization
  heart disease
  hemodynamics
  histopathology
  human
  Human immunodeficiency virus infection
  idiopathic disease
  injection site pain (side effect)
  interstitial lung disease
  leg pain (side effect)
  lung artery pressure
  lung disease
  lung function test
  lung transplantation
  lung ventilation perfusion ratio
  mixed connective tissue disease
  pathogenesis
  pathophysiology
  portal hypertension
  priority journal
  prognosis
  quality of life
  review
  risk factor
  side effect (side effect)
  survival rate
  syndrome CREST
  thorax radiography
  thromboembolism
  treatment response
  vomiting (side effect)
CAS REGISTRY NUMBERS
  adenosine (58-61-7)
  bosentan (147536-97-8, 157212-55-0)
  digoxin (20830-75-5, 57285-89-9)
  iloprost (78919-13-8, 82889-99-4)
  nitric oxide (10102-43-9)
  oxygen (7782-44-7)
  prostacyclin (35121-78-9, 61849-14-7)
  sildenafil (139755-83-2)
  sitaxsentan (184036-34-8, 210421-74-2)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Clinical and Experimental Pharmacology (30)
  Arthritis and Rheumatism (31)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008088443
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 438
TITLE
  Reducing risk in type 2 diabetes: A practical approach
AUTHOR NAMES
  Rivera-Woll L.
  Newnham H.H.
AUTHOR ADDRESSES
  (Rivera-Woll L.; Newnham H.H.) Box Hill Hospital, Box Hill, VIC, Australia.
CORRESPONDENCE ADDRESS
  L. Rivera-Woll, Box Hill Hospital, Box Hill, VIC, Australia.
SOURCE
  Medicine Today (2007) 8:1 (14-19). Date of Publication: January 2007
ISSN
  1443-430X
BOOK PUBLISHER
  Medicine Today Pty Ltd, P.O. Box 1473, Neutral Bay, Australia.
ABSTRACT
  • Even before patients are diagnosed with diabetes they are at increased 
risk of macrovascular disease. • The complications of diabetes do not 
develop in isolation so the effects of one complication may profoundly 
impact on others. • Attention to detail is essential to detect and manage 
effectively the risk factors and complications of diabetes. • The ability to 
view the patient 'globally', directing attention to where treatment is most 
likely to be of benefit and least likely to cause harm, is the key to 
diabetes management. • Multifactorial approaches to diabetes care appear to 
be the most effective.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  amlodipine plus atorvastatin (drug therapy)
  angiotensin II antagonist (drug combination, drug therapy, 
pharmacoeconomics)
  antidiabetic agent (drug therapy, pharmacoeconomics)
  aylide
  beta adrenergic receptor blocking agent (drug therapy)
  diapride
  dimirel
  dipeptidyl carboxypeptidase inhibitor (drug combination, drug therapy, 
pharmacoeconomics)
  ezetimibe plus simvastatin (drug therapy)
  fibric acid derivative (adverse drug reaction, drug combination, drug 
therapy)
  glibenclamide plus metformin (drug therapy)
  gliclazide (drug therapy)
  glimepiride (drug therapy)
  glitazone derivative (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (adverse drug reaction, 
drug combination, drug therapy, pharmacoeconomics)
  insulin (drug comparison, drug therapy)
  metformin (drug comparison, drug therapy)
  metformin plus rosiglitazone (drug therapy)
  pioglitazone (drug therapy)
  sulfonylurea (drug comparison, drug therapy)
  thiazide diuretic agent (drug combination, drug therapy)
  unclassified drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  non insulin dependent diabetes mellitus (disease management, drug therapy, 
prevention)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  blood glucose monitoring
  cerebrovascular accident (complication, drug therapy, prevention)
  cost benefit analysis
  cost effectiveness analysis
  diabetic angiopathy (complication, disease management, drug therapy, 
prevention)
  diabetic microangiopathy (complication, drug therapy, prevention)
  diabetic nephropathy (complication, drug therapy, prevention)
  diabetic neuropathy (complication, prevention)
  diabetic retinopathy (complication, drug therapy, prevention)
  disease severity
  drug cost
  drug efficacy
  electrocardiogram
  exercise
  high risk patient
  human
  hyperglycemia
  hypertension
  ischemic heart disease (complication, disease management, drug therapy, 
prevention)
  lifestyle modification
  low drug dose
  myositis (side effect)
  peripheral vascular disease (complication, drug therapy, prevention)
  primary prevention
  review
  risk factor
  risk reduction
DRUG TRADE NAMES
  amaryl
  aspirin
  avandamet
  aylide
  caduet
  diabex
  diamicron
  diapride
  dimirel
  glucovance
  vytorin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  gliclazide (21187-98-4)
  glimepiride (93479-97-1)
  insulin (9004-10-8)
  metformin (1115-70-4, 657-24-9)
  pioglitazone (105355-27-9, 111025-46-8)
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007101900
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 439
TITLE
  Remifentanil: A review of its analgesic and sedative use in the Intensive 
Care Unit
AUTHOR NAMES
  Battershill A.J.
  Keating G.M.
AUTHOR ADDRESSES
  (Battershill A.J.; Keating G.M., demail@adis.co.nz) Adis International 
Limited, Auckland, New Zealand.
(Keating G.M., demail@adis.co.nz) Adis International Limited, 41 Centorian 
Drive, Mairangi Bay, Auckland 1311, New Zealand.
CORRESPONDENCE ADDRESS
  G.M. Keating, Adis International Limited, 41 Centorian Drive, Mairangi Bay, 
Auckland 1311, New Zealand. Email: demail@adis.co.nz
SOURCE
  Drugs (2006) 66:3 (365-385). Date of Publication: 2006
ISSN
  0012-6667
  0012-6667 (electronic)
BOOK PUBLISHER
  Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, 
Auckland 10, New Zealand.
ABSTRACT
  Remifentanil (Ultiva™), a 4-anilidopiperidine derivative of fentanyl, is an 
ultra-short-acting μ-opioid receptor agonist indicated to provide analgesia 
and sedation in mechanically ventilated intensive care unit (ICU) patients. 
Analgesia-based sedation with remifentanil is a useful option for 
mechanically ventilated patients in the ICU setting. Its unique properties 
(e.g. organ-independent metabolism, lack of accumulation, rapid offset of 
action) set it apart from other opioid agents. Remifentanil is at least as 
effective as comparator opioids such as fentanyl, morphine and sufentanil in 
providing pain relief and sedation in mechanically ventilated ICU patients. 
Moreover, it allows fast and predictable extubation, as well as being 
associated with a shorter duration of mechanical ventilation and quicker ICU 
discharge than comparators in some studies. In addition, remifentanil is 
generally well tolerated in this patient population. Thus, remifentanil is a 
welcome addition to the currently available pharmacological agents employed 
in the management of mechanically ventilated ICU patients. Pharmacological 
Properties: Remifentanil is a 4-anilidopiperidine derivative of fentanyl 
containing an ester linkage to propanoic acid. It is ultra-short acting and 
displays analgesic effects, consistent with its agonist activity at the 
μ-receptor. The primary metabolite, remifentanil acid, has negligible 
activity compared with remifentanil. Remifentanil has a rapid onset of 
action (≈1 minute) and a rapid offset of action following discontinuation 
(≈3-10 minutes). The time to offset of action was not prolonged to a 
clinically significant extent by renal impairment or prolonged infusion in 
post-surgical or medical ICU patients who received remifentanil for up to 72 
hours. In mechanically ventilated ICU patients, the median time to offset of 
action was significantly shorter with remifentanil than with morphine or 
fentanyl after 10 days' treatment. The effect of remifentanil on 
haemodynamics is typical of opioids (e.g. decreased blood pressure and heart 
rate). In ICU patients, remifentanil was generally associated with an 
acceptable degree of haemodynamic stability. There were no significant 
differences between remifentanil, fentanyl and morphine recipients in mean 
intracranial pressure (ICP) or cerebral perfusion pressure in mechanically 
ventilated ICU patients with acute brain injury or who had undergone 
neurosurgery. However, compared with baseline, ICP was significantly 
increased and cerebral perfusion pressure was significantly reduced with 
remifentanil in mechanically ventilated patients with severe traumatic brain 
injury in another study. Remifentanil is rapidly distributed throughout the 
body and demonstrates linear, dose-dependent, multicompartmental 
pharmacokinetics. The drug undergoes widespread extravascular metabolism and 
is rapidly metabolised via extrahepatic, nonspecific blood and tissue 
esterases to remifentanil acid. The pharmacokinetics of remifentanil were 
not altered to a clinically significant extent in ICU patients with moderate 
to severe renal impairment who received the drug for up to 72 hours, 
compared with ICU patients with normal renal function or mild renal 
impairment. The pharmacokinetics of remifentanil were also not altered to a 
clinically significant extent in patients with severe chronic liver disease. 
Remifentanil has a context-sensitive half-time of ≈3-4 minutes, irrespective 
of the duration of infusion. Age-related changes in clearance and volume of 
distribution occurred in paediatric patients receiving remifentanil. 
Therapeutic Efficacy: A number of well designed trials have compared the use 
of analgesia-based sedation with remifentanil with that of morphine, 
fentanyl or sufentanil in post-surgical, trauma and/or medical patients (n ≥ 
20) who were being mechanically ventilated in an ICU setting. Remifentanil 
provided effective analgesia-based sedation in mechanically ventilated 
patients in the ICU setting. Optimal sedation was achieved for ≥78% of the 
time with remifentanil. Moreover, with remifentanil, the duration of optimal 
sedation and the percentage of hours during which patients had no or mild 
pain was generally similar to that with fentanyl or morphine. In addition, 
compared with remifentanil, the need for additional sedation generally 
appeared greater with fentanyl and morphine regimens, but not with 
sufentanil regimens. Remifentanil was at least as effective as fentanyl, 
morphine and sufentanil in terms of recovery parameters. In some studies, 
including a study examining longer-term mechanical ventilation, remifentanil 
was associated with a significantly shorter duration of mechanical 
ventilation than fentanyl or morphine. In addition, remifentanil was 
associated with a significantly shorter extubation time than fentanyl, 
morphine or sufentanil and a shorter time to ICU discharge than fentanyl or 
morphine in some studies. Two studies noted an absence of tolerance to 
remifentanil, although tolerance was seen in 29% of remifentanil recipients 
in another study. A remifentanil-based regimen may also be associated with 
savings in staff costs, according to the results of a prospective 
cost-consequence analysis. Remifentanil was associated with rapid and 
predictable emergence from sedation in mechanically ventilated ICU patients 
with acute brain injury or who had undergone neurosurgery in a randomised, 
nonblind study. Significantly less between-patient variability in the time 
to neurological assessment occurred in patients receiving analgesia-based 
sedation with remifentanil than in those receiving hypnotic-based sedation 
incorporating fentanyl or morphine. Remifentanil patients requiring 
mechanical ventilation were extubated significantly earlier than patients 
receiving the morphine-based regimen. The extubation time and time until ICU 
discharge were also significantly shorter with remifentanil plus propofol 
than with fentanyl plus midazolam in mechanically ventilated ICU patients 
who had undergone supratentorial brain surgery in a retrospective study. 
Remifentanil provided similar analgesia-based sedation to fentanyl in 
paediatric patients aged 3-16 years who were being mechanically ventilated 
following orthopaedic spinal surgery. Remifentanil also demonstrated 
efficacy in mechanically ventilated newborns. Remifentanil provided adequate 
analgesia in ICU patients with severe burns during dressing changes, and an 
intravenous infusion of remifentanil effectively reduced stress during 
endotracheal suctioning in mechanically ventilated post-surgical ICU 
patients sedated with sufentanil. Tolerability: Remifentanil was generally 
well tolerated in ICU patients requiring mechanical ventilation. The most 
commonly occurring adverse events in remifentanil recipients relate to its 
μ-opioid agonist properties (e.g. bradycardia, hypotension). The 
tolerability of remifentanil was generally similar to that of fentanyl or 
morphine in ICU patients requiring short-term mechanical ventilation for up 
to ≈3 days. In terms of the proportion of patients experiencing drug-related 
adverse effects, there was no significant difference between remifentanil 
and morphine recipients (22% vs 16%), or between remifentanil and fentanyl 
recipients (23% vs 17%). Moreover, there was no significant difference 
between remifentanil and fentanyl recipients in the incidence of 
hypotension, nausea, fever or vomiting. In critically ill patients 
mechanically ventilated for up to 10 days, drug-related adverse events 
occurred in 11% of recipients and in 8% of patients receiving a comparator 
regimen (midazolam with fentanyl or morphine). The most commonly occurring 
adverse events in remifentanil recipients (occurring in ≥5% of patients, not 
necessarily drug related) included hypotension, atrial fibrillation and 
vomiting. Muscle rigidity did not occur in either treatment group. 
Remifentanil was also generally well tolerated in mechanically ventilated 
paediatric patients in the ICU setting. © 2006 Adis Data Information BV. All 
rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  remifentanil (adverse drug reaction, clinical trial, drug analysis, drug 
combination, drug comparison, drug dose, drug therapy, intravenous drug 
administration, pharmacoeconomics, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  alfentanil (drug comparison)
  fentanyl (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug dose, intravenous drug administration)
  isoflurane (drug combination)
  midazolam (clinical trial, drug combination, drug comparison, drug dose, 
intravenous drug administration)
  morphine (clinical trial, drug combination, drug comparison, intravenous 
drug administration)
  placebo
  propofol (clinical trial, drug combination, drug comparison, drug dose, 
intravenous drug administration)
  sufentanil (clinical trial, drug combination, drug comparison, drug dose, 
intravenous drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  analgesia
  intensive care unit
  pain (drug therapy)
  sedation
EMTREE MEDICAL INDEX TERMS
  analgesic activity
  anesthesia induction
  artificial ventilation
  atrial fibrillation (side effect)
  blood pressure
  bradycardia (side effect)
  brain injury
  brain perfusion
  clinical trial
  drug accumulation
  drug activity
  drug distribution
  drug dose titration
  drug effect
  drug infusion
  drug mechanism
  drug metabolism
  drug tolerability
  drug use
  extubation
  fever (side effect)
  heart rate
  hemodynamics
  hospital discharge
  hospitalization
  human
  hypotension (side effect)
  intensive care
  intracranial pressure
  metabolite
  nausea (side effect)
  review
  septic shock (side effect)
  tracheobronchial toilet
  traumatic brain injury
  treatment duration
  vomiting (side effect)
DRUG TRADE NAMES
  ultiva
CAS REGISTRY NUMBERS
  alfentanil (69049-06-5, 71195-58-9)
  fentanyl (437-38-7)
  isoflurane (26675-46-7)
  midazolam (59467-70-8)
  morphine (52-26-6, 57-27-2)
  propofol (2078-54-8)
  remifentanil (132539-07-2)
  sufentanil (56030-54-7)
EMBASE CLASSIFICATIONS
  Anesthesiology (24)
  Clinical and Experimental Pharmacology (30)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007103492
MEDLINE PMID
  16526829 (http://www.ncbi.nlm.nih.gov/pubmed/16526829)
FULL TEXT LINK
  http://dx.doi.org/10.2165/00003495-200666030-00013
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 440
TITLE
  Atrial fibrillation as a prognostic factor in patients with systolic heart 
failure
AUTHOR NAMES
  Grzybczak R.
  Nessler J.
  Piwowarska W.
AUTHOR ADDRESSES
  (Grzybczak R., rafal_grzybczak@interia.pl; Nessler J.; Piwowarska W.) 
Department of Coronary Heart Disease, Jagiellonian University, John Paul II 
Hospital, Cracow, Poland.
(Grzybczak R., rafal_grzybczak@interia.pl) Os. Dywizjonu 303 41/47, 31-875 
Cracow, Poland.
CORRESPONDENCE ADDRESS
  R. Grzybczak, Os. Dywizjonu 303 41/47, 31-875 Cracow, Poland. Email: 
rafal_grzybczak@interia.pl
SOURCE
  Folia Cardiologica (2006) 13:6 (503-510). Date of Publication: 2006
ISSN
  1507-4145
ABSTRACT
  Background: Atrial fibrillation (AF) decreases left ventricular stroke 
volume, impaires the mechanical function of heart valves, and disturbes 
neurohumoral activity of the miocardium. This study evaluated the influence 
of AF on clinical presentation and long-term follow-up of the patients with 
systolic heart failure. Methods: A retrospective analysis of the data on 
clinical presentation of 152 patients (38 women and 114 men) with systolic 
heart failure (EF < 40%) was performed. The following parameters were 
compared between patients with and without AF: heart rate and presence of 
LBBB, several echocardiographic parameters (EF, LVEDV, size of LA, LVEDd, 
LVESd), oxygen consumption per minute, and frequency of end-point's (death, 
stroke, rehospitalization, CABG) during mean 936-day follow-up. Results: The 
53 (35%) AF patients in comparison with 99 non-AF were characterized by: 
lower exercise performance (VO(2) max = 10.9 vs. 17.2 ml/kg/min), greater 
diameter of the left atrium (49.9 vs. 45.9 mm) and decreased end-diastolic 
volume (LVEDV = 159.5 vs. 183.7 ml), ess frequent occurrence of LBBB (7.5% 
vs. 13.0%), higher overall mortality (28.3% vs. 17.1%), and more frequent 
rehospitalizations (15% vs. 8%). In patients with persistent AF (40%) with 
HR < 75/min the mortality was 29% and was statistically significantly lower 
than in patients with HR > 75/ min in whom it was 54%. Conclusions: Atrial 
fibrillation in patients with systolic heart failure is a disadvantageous, 
but not independent risk factor. In patients with persistent atrial 
fibrillation the control of heart rate < 75/min was associated with 
significant decrease in mortality. Copyright © 2006 Via Medica.
EMTREE DRUG INDEX TERMS
  oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (surgery)
  heart failure
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  artificial heart pacemaker
  cerebrovascular accident
  controlled study
  coronary artery bypass graft
  echocardiography
  exercise
  female
  follow up
  heart left bundle branch block
  heart left ventricle ejection fraction
  heart left ventricle enddiastolic volume
  heart muscle oxygen consumption
  heart rate
  hospital readmission
  human
  major clinical study
  male
  mortality
  prognosis
  retrospective study
  statistical significance
  systole
CAS REGISTRY NUMBERS
  oxygen (7782-44-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006518470
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 441
TITLE
  Efficacy of CRT on exercise tolerance and disease progression: The 
importance of AV junction ablation in patients with atrial fibrillation
AUTHOR NAMES
  Gasparini M.
  Block P.C.
AUTHOR ADDRESSES
  (Gasparini M.; Block P.C.)
SOURCE
  ACC Cardiosource Review Journal (2006) 15:11 (39-42). Date of Publication: 
November 2006
ISSN
  1556-8571
BOOK PUBLISHER
  Elsevier USA, 6277 Sea Harbor Drive, Orlando, United States.
ABSTRACT
  In summary, this study found that heart failure patients with ventricular 
conduction disturbance and permanent AF treated with CRT showed large and 
sustained long-term (up to 4 years) improvement of LV function and 
functional capacity, similar to patients in SR, but only if AVJ ablation was 
performed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (surgery, therapy)
  atrioventricular junction ablation
  cardiac resynchronization therapy
  heart surgery
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  clinical effectiveness
  clinical trial
  controlled clinical trial
  controlled study
  disease course
  drug use
  exercise tolerance
  female
  functional status
  heart failure (therapy)
  heart left ventricle enddiastolic volume
  heart ventricle function
  human
  implantation
  major clinical study
  male
  outcome assessment
  sinus rhythm
  statistical significance
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007203165
COPYRIGHT
  Copyright 2008 Elsevier B.V., All rights reserved.

RECORD 442
TITLE
  Antithrombotic therapy in secondary stroke prevention
AUTHOR NAMES
  Akhtar N.
  Deleu D.
  Shuaib A.
AUTHOR ADDRESSES
  (Akhtar N.; Deleu D., ddeleu@hmc.org.qa) Department of Neurology (Medicine), 
Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
(Shuaib A.) Department of Neurology, University of Edmonton, Edmonton, AB, 
Canada.
CORRESPONDENCE ADDRESS
  D. Deleu, Department of Neurology (Medicine), Hamad Medical Corporation, 
P.O. Box 3050, Doha, Qatar. Email: ddeleu@hmc.org.qa
SOURCE
  Aging Health (2006) 2:5 (787-797). Date of Publication: Oct 2006
ISSN
  1745-509X
  1745-5103 (electronic)
ABSTRACT
  Ischemic stroke is a major cause of morbidity and mortality. The choice of 
antithrombotic therapy is largely dependent on the type of stroke. In this 
article, the authors focus on the secondary prevention of stroke, providing 
evidence from the literature. The mechanism of action of each of the 
antithrombotic drugs is discussed. Anticoagulation with warfarin for 
cardioembolic stroke, particularly atrial fibrillation, is strongly 
recommended, while no clear advantage for warfarin over aspirin exists for 
ischemic stroke secondary to atherothrombotic or patent foramen ovale. 
Combination therapies of aspirin plus warfarin do not offer any additional 
therapeutic benefit and carry an increased risk of hemorrhage. Aspirin and 
clopidogrel present similar risks for stroke recurrence. The combination of 
aspirin with extended-release dipyridamole has a lower risk of stroke than 
aspirin alone and does not enhance the risk of hemorrhage. Finally, some 
recommendations and future perspectives are included. © 2006 Future Medicine 
Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug therapy, oral drug administration, 
pharmacology)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug therapy, pharmacology)
  adenosine diphosphate (endogenous compound)
  antihypertensive agent (drug therapy)
  antithrombocytic agent (drug therapy)
  cell adhesion molecule (endogenous compound)
  clopidogrel (clinical trial, drug combination, drug comparison, drug 
therapy, pharmacology)
  cyclic AMP (endogenous compound)
  cyclooxygenase 1 (endogenous compound)
  dipyridamole (adverse drug reaction, clinical trial, drug combination, drug 
therapy, pharmacology)
  fibrinogen (endogenous compound)
  fibrinogen receptor antagonist (drug therapy, pharmacology)
  irbesartan (clinical trial, drug combination, drug therapy)
  nonsteroid antiinflammatory agent (adverse drug reaction)
  phosphodiesterase (endogenous compound)
  placebo
  prostacyclin (endogenous compound)
  telmisartan (clinical trial, drug combination, drug comparison, drug 
therapy)
  thrombin inhibitor (adverse drug reaction, clinical trial, drug therapy, 
oral drug administration)
  thromboxane A2 (endogenous compound)
  ticlopidine (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, pharmacology)
  vitamin K group (endogenous compound)
  warfarin (adverse drug reaction, clinical trial, drug combination, drug 
comparison, drug therapy, pharmacology)
  ximelagatran (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (complication, drug therapy, prevention, surgery, 
therapy)
EMTREE MEDICAL INDEX TERMS
  acute heart infarction (drug therapy)
  anticoagulation
  artery calcification (drug therapy)
  atherosclerosis (drug therapy)
  atrial fibrillation (drug therapy)
  behavior modification
  bleeding (side effect)
  brain hemorrhage (side effect)
  carotid artery surgery
  clinical trial
  deep vein thrombosis (complication, drug therapy, prevention)
  diarrhea (side effect)
  dietary intake
  drug choice
  drug mechanism
  drug safety
  drug withdrawal
  enzyme inhibition
  evidence based medicine
  exercise
  gastrointestinal hemorrhage (side effect)
  headache (side effect)
  heart atrium septum defect
  human
  international normalized ratio
  lifestyle
  liver dysfunction (side effect)
  medical literature
  morbidity
  mortality
  neutropenia (side effect)
  paradoxical embolism (complication, drug therapy, prevention)
  patient monitoring
  prostaglandin synthesis inhibition
  rash (side effect)
  recurrence risk
  review
  risk assessment
  risk factor
  secondary prevention
  smoking cessation
  sustained release formulation
  thrombotic thrombocytopenic purpura (side effect)
  transient ischemic attack (drug therapy, prevention)
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  adenosine diphosphate (20398-34-9, 58-64-0)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  cyclic AMP (60-92-4)
  dipyridamole (58-32-2)
  fibrinogen (9001-32-5)
  irbesartan (138402-11-6)
  prostacyclin (35121-78-9, 61849-14-7)
  telmisartan (144701-48-4)
  thromboxane A2 (57576-52-0)
  ticlopidine (53885-35-1, 55142-85-3)
  vitamin K group (12001-79-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
  ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Internal Medicine (6)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006558234
FULL TEXT LINK
  http://dx.doi.org/10.2217/1745509X.2.5.787
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 443
TITLE
  Mechanical events and the pressure-volume relationships
AUTHOR NAMES
  Kirkman E.
AUTHOR ADDRESSES
  (Kirkman E.) University of Durham, United Kingdom.
CORRESPONDENCE ADDRESS
  E. Kirkman, University of Durham, United Kingdom.
SOURCE
  Anaesthesia and Intensive Care Medicine (2006) 7:9 (313-316). Date of 
Publication: 1 Sep 2006
  Cardiac, Physiology and Statistics, Book Series Title:
ISSN
  1472-0299
ABSTRACT
  Depolarization of cardiac muscle fibres spreads from fibre to fibre 
throughout the myocardium. In a single fibre, contraction starts just after 
depolarization and lasts until just after repolarization is complete. The 
atria contract, completing the filling of the ventricles and thus enhancing 
their action. In the absence of effective atrial contraction (e.g. atrial 
fibrillation) cardiac output is decreased on average by 15%. During 
diastole, when cardiac muscle is relaxed, blood returns to the heart and 
passes through the atrioventricular (AV) valves into the ventricles. The 
semilunar valves, between the ventricles and the arteries, are closed as 
arterial pressure exceeds ventricular pressure. Under normal circumstances, 
70% of ventricular filling occurs by late diastole. © 2006.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart contraction
  heart ventricle pressure
  heart volume
EMTREE MEDICAL INDEX TERMS
  arterial pressure
  atrial fibrillation
  bleeding
  coronary artery blood flow
  diastole
  exercise
  heart atrioventricular valve
  heart atrium
  heart depolarization
  heart function
  heart muscle
  heart muscle cell
  heart output
  heart ventricle
  human
  muscle relaxation
  priority journal
  review
EMBASE CLASSIFICATIONS
  Physiology (2)
  Anesthesiology (24)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006601622
FULL TEXT LINK
  http://dx.doi.org/10.1053/j.mpaic.2006.06.004
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 444
TITLE
  Cardiac resynchronization therapy: Redefining the role of device therapy in 
heart failure
AUTHOR NAMES
  Viswanathan K.
  Ghosh J.
  Kaye G.C.
  Cleland J.G.F.
AUTHOR ADDRESSES
  (Viswanathan K., drkarthikv@hotmail.com; Ghosh J., justinmg@doctors.org.uk; 
Cleland J.G.F., j.g.cleland@hull.ac.uk) Castle Hill Hospital, Department of 
Cardiology, Kingston-upon-Hull HU16 5JQ, United Kingdom.
(Kaye G.C., Gerald_Kaye@health.qld.gov.au) Department of Cardiology, 
Princess Alexandra Hospital, Brisbane, QLD 4102, Australia.
CORRESPONDENCE ADDRESS
  J.G.F. Cleland, Department of Cardiology, Castle Hill Hospital, 
Kingston-upon-Hull HU16 5JQ, United Kingdom. Email: j.g.cleland@hull.ac.uk
SOURCE
  Expert Review of Pharmacoeconomics and Outcomes Research (2006) 6:4 
(455-469). Date of Publication: Aug 2006
ISSN
  1473-7167
  1744-8379 (electronic)
ABSTRACT
  That cardiac dyssynchrony can contribute to a decline in cardiac efficiency 
has been recognized in one form or another for at least 50 years. Although 
revascularization and β-blockers can improve cardiac synchrony, there was 
little interest in or awareness of this clinical entity until the advent of 
specific, highly effective therapy using atriobiventricular pacing, often 
described as cardiac resynchronization therapy. Over the last few years, 
significant advances in cardiac resynchronization therapy technology and the 
publication of large-scale clinical trials using cardiac resynchronization 
therapy devices in patients with heart failure have led to the widespread 
use of these devices. This review will briefly describe the complex nature 
of cardiac dyssynchrony, what is known about its epidemiology, the effects 
of cardiac resynchronization therapy, appropriate patient selection, 
practical aspects, such as implantation and monitoring, and some still 
unanswered questions. © 2006 Future Drugs Ltd.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent (drug therapy)
  cardiovascular agent (clinical trial, drug therapy, pharmacoeconomics)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiac resynchronization therapy
  heart dyssynchrony (diagnosis, disease management, epidemiology, therapy)
  heart failure (disease management, drug therapy, surgery, therapy)
  heart muscle conduction disturbance (diagnosis, disease management, 
epidemiology, therapy)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (disease management, therapy)
  atrioventricular block (disease management, prevention, therapy)
  clinical trial
  complete heart block (complication)
  cost effectiveness analysis
  defibrillator
  echocardiography
  epidemiological data
  exercise
  fatality
  heart assist device
  heart hemodynamics
  heart left bundle branch block
  heart muscle revascularization
  heart pacing
  heart tamponade (complication)
  hospitalization
  human
  long term care
  mortality
  patient monitoring
  patient selection
  publication
  QRS complex
  quality of life
  review
  survival
  symptom
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006418343
FULL TEXT LINK
  http://dx.doi.org/10.1586/14737167.6.4.455
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 445
TITLE
  ACC/AHA 2006 guidelines for the management of patients with valvular heart 
disease: Executive summary. A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines 
(Writing Committee to Revise the 1998 Guidelines for the Management of 
Patients with Valvular Heart Disease)
AUTHOR NAMES
  Bonow R.O.
  Carabello B.A.
  Chatterjee K.
  De Leon Jr. A.C.
  Faxon D.P.
  Freed M.D.
  Gaasch W.H.
  Lytle B.W.
  Nishimura R.A.
  O'Gara P.T.
  O'Rourke R.A.
  Otto C.M.
  Shah P.M.
  Shanewise J.S.
AUTHOR ADDRESSES
  (Bonow R.O.; Carabello B.A.; Chatterjee K.; De Leon Jr. A.C.; Faxon D.P.; 
Freed M.D.; Gaasch W.H.; Lytle B.W.; Nishimura R.A.; O'Gara P.T.; O'Rourke 
R.A.; Otto C.M.; Shah P.M.; Shanewise J.S.)
SOURCE
  Circulation (2006) 114:5 (450-527). Date of Publication: August 2006
ISSN
  0009-7322
BOOK PUBLISHER
  Lippincott Williams and Wilkins, 530 Walnut Street,P O Box 327, 
Philadelphia, United States.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug dose, drug therapy)
  amiodarone (drug administration, drug therapy, intravenous drug 
administration, oral drug administration)
  anorexigenic agent (adverse drug reaction)
  antibiotic agent (drug therapy)
  antihypertensive agent (drug therapy)
  antiinfective agent (drug therapy)
  antilipemic agent (drug therapy)
  antithrombocytic agent (drug therapy)
  atorvastatin (drug therapy)
  calcium channel blocking agent (drug therapy)
  carvedilol (drug therapy)
  dexfenfluramine (adverse drug reaction)
  digoxin (clinical trial, drug comparison, drug therapy, intravenous drug 
administration)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  dipyridamole (adverse drug reaction)
  dobutamine (drug combination, drug therapy)
  dopamine (drug therapy)
  enalapril (drug comparison, drug therapy)
  ergotamine (adverse drug reaction)
  fenfluramine (adverse drug reaction)
  heparin (adverse drug reaction, drug administration, drug comparison, drug 
therapy, intravenous drug administration, subcutaneous drug administration)
  inotropic agent (drug combination, drug therapy)
  low molecular weight heparin (adverse drug reaction, drug comparison, drug 
therapy, subcutaneous drug administration)
  methysergide (adverse drug reaction)
  nifedipine (clinical trial, drug comparison, drug therapy)
  nitroprusside sodium (drug combination, drug therapy)
  pergolide (adverse drug reaction)
  unindexed drug
  vasodilator agent (drug therapy)
  warfarin (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  practice guideline
  valvular heart disease (congenital disorder, diagnosis, drug therapy, side 
effect, surgery, therapy)
EMTREE MEDICAL INDEX TERMS
  aorta disease (drug therapy)
  aorta root
  aorta stenosis (diagnosis, drug therapy)
  aorta valve
  aorta valve disease (drug therapy, surgery)
  aorta valve regurgitation (diagnosis, drug therapy, surgery, therapy)
  aorta valve replacement
  aorta valve stenosis (drug therapy, surgery)
  ascending aorta
  atherosclerosis (drug therapy)
  atrial fibrillation (drug therapy, surgery, therapy)
  autotransplantation
  bacterial endocarditis (complication, drug therapy, etiology, prevention)
  bleeding (side effect)
  cerebrovascular accident (drug therapy)
  clinical trial
  coronary artery bypass graft
  coronary artery disease (diagnosis, drug therapy)
  disease severity
  echocardiography
  electrocardiography
  embryopathy (side effect)
  endocarditis (complication, drug therapy, etiology, prevention)
  exercise
  exercise test
  fetal hemorrhage (side effect)
  fetus risk
  heart auscultation
  heart catheterization
  heart disease (diagnosis, drug therapy, surgery, therapy)
  heart left ventricle function
  heart murmur (diagnosis)
  heart surgery
  heart valve
  heart valve surgery
  human
  hypertension (drug therapy)
  infection (side effect)
  lung blood flow
  Marfan syndrome
  mitral valve
  mitral valve commissurotomy
  mitral valve prolapse (drug therapy)
  mitral valve regurgitation (diagnosis, drug therapy)
  mitral valve stenosis (diagnosis, drug therapy)
  nuclear magnetic resonance imaging
  osteoporosis (side effect)
  physical activity
  physical examination
  pregnancy
  prematurity (side effect)
  priority journal
  review
  rheumatic fever (drug therapy, etiology, prevention)
  short stature
  side effect (side effect)
  stillbirth
  thorax radiography
  thrombocytopenia (side effect)
  thromboembolism (side effect)
  transthoracic echocardiography
  tricuspid valve disease (diagnosis, drug therapy, surgery)
  valvuloplasty
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  atorvastatin (134523-00-5, 134523-03-8)
  carvedilol (72956-09-3)
  dexfenfluramine (3239-44-9, 3239-45-0)
  digoxin (20830-75-5, 57285-89-9)
  dipyridamole (58-32-2)
  dobutamine (34368-04-2, 52663-81-7)
  dopamine (51-61-6, 62-31-7)
  enalapril (75847-73-3)
  ergotamine (113-15-5, 52949-35-6)
  fenfluramine (404-82-0, 458-24-2)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  methysergide (16509-15-2, 361-37-5, 62288-72-6)
  nifedipine (21829-25-4)
  nitroprusside sodium (14402-89-2, 15078-28-1)
  pergolide (66104-22-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  General Pathology and Pathological Anatomy (5)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2006405009
FULL TEXT LINK
  http://dx.doi.org/10.1161/CIRCULATIONAHA.106.177303
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 446
TITLE
  Dexmedetomidine: as safe as safe can be
AUTHOR NAMES
  Wagner D.S.
  Brummett C.M.
AUTHOR ADDRESSES
  (Wagner D.S., debbiew@umich.edu; Brummett C.M.) Department of 
Anesthesiology, University of Michigan Health Systems, Ann Arbor, MI, United 
States.
CORRESPONDENCE ADDRESS
  D.S. Wagner, Department of Anesthesiology, University of Michigan Health 
Systems, Ann Arbor, MI, United States. Email: debbiew@umich.edu
SOURCE
  Seminars in Anesthesia, Perioperative Medicine and Pain (2006) 25:2 (77-83). 
Date of Publication: Jun 2006
ISSN
  0277-0326
ABSTRACT
  Dexmedetomidine (DMET) is an alpha-2 adrenoceptor agonist approved for 
short-term use as a sedative for mechanically ventilated patients. Alpha-2 
adrenoceptor agonists exhibit sedative-hypnotic, analgesic, anxiolytic, and 
sympatholytic effects. The ability of DMET to produce a readily arousable 
state of moderate-deep sedation and analgesia with a lack of respiratory 
depression has led to an increased interest in its use. Very little 
published data exists on the side effects/adverse event profile of the drug, 
especially with high-dose prolonged infusions. In addition, the ceiling dose 
is not really known. This article reviews the current literature with 
regards to multiple organ systems and the effects of DMET. © 2006 Elsevier 
Inc. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dexmedetomidine (adverse drug reaction, drug combination, drug 
concentration, drug dose, drug therapy, drug toxicity, pharmacology)
EMTREE DRUG INDEX TERMS
  alpha 2 adrenergic receptor stimulating agent (adverse drug reaction, drug 
combination, drug concentration, drug dose, drug therapy, drug toxicity, 
pharmacology)
  atipamezole (pharmacology)
  clonidine (pharmacology)
  midazolam (clinical trial, drug dose, pharmacology)
  nitric oxide synthase inhibitor (pharmacology)
  noradrenalin (endogenous compound)
  phenylephrine (adverse drug reaction, drug combination)
  placebo
EMTREE MEDICAL INDEX TERMS
  adrenergic activity
  analgesia
  analgesic activity
  article
  atrial fibrillation (side effect)
  blood pressure regulation
  bradycardia (side effect)
  cancer pain (drug therapy)
  cardiovascular system
  clinical trial
  drug dose regimen
  drug effect
  drug megadose
  drug overdose
  drug potentiation
  drug safety
  electrocardiography
  endocrine system
  epidural anesthesia
  epileptic discharge (side effect)
  heart rate
  human
  hypnosis
  hypotension (side effect)
  medical literature
  neuromuscular blocking
  nonhuman
  noradrenalin release
  priority journal
  respiration depression (side effect)
  respiratory system
  sedation
  seizure (side effect)
  tranquilizing activity
  unspecified side effect (side effect)
  ventilated patient
CAS REGISTRY NUMBERS
  atipamezole (104054-27-5)
  clonidine (4205-90-7, 4205-91-8, 57066-25-8)
  dexmedetomidine (113775-47-6)
  midazolam (59467-70-8)
  noradrenalin (1407-84-7, 51-41-2)
  phenylephrine (532-38-7, 59-42-7, 61-76-7)
EMBASE CLASSIFICATIONS
  Anesthesiology (24)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006260167
FULL TEXT LINK
  http://dx.doi.org/10.1053/j.sane.2006.02.003
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 447
TITLE
  3, 5-diiodothyronine: Biological actions and therapeutic perspectives
AUTHOR NAMES
  Lombardi A.
  Lanni A.
  Silvestri E.
  de Lange P.
  Goglia F.
  Moreno M.
AUTHOR ADDRESSES
  (Lombardi A.) Dipartimento delle Scienze Biologiche, Sezione Fisiologia ed 
Igiene, Università degli Studi di Napoli Federico II, Via Mezzocannone 8, 
80134 Napoli, Italy.
(Lanni A.; de Lange P.) Dipartimento di Scienze della Vita, Seconda 
Università degli Studi di Napoli, Via Vivaldi 43, 81100 Caserta, Italy.
(Silvestri E.; Goglia F., goglia@unisannio.it; Moreno M., 
moreno@unisannio.it) Dipartimento di Scienze Biologiche ed Ambientali, 
Università degli Studi del Sannio, Via Port' Arsa 11, 82100 Benevento, 
Italy.
CORRESPONDENCE ADDRESS
  F. Goglia, Dipartimento di Scienze Biologiche ed Ambientali, Via Port' Arsa 
11, 82100 Benevento, Italy. Email: goglia@unisannio.it
SOURCE
  Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry (2006) 6:3 
(255-265). Date of Publication: Jun 2006
ISSN
  1871-5214
ABSTRACT
  The purpose of this review is to summarize the current state of knowledge 
concerning the biological activities of 3, 5-diiodothyronine (T(2)) and its 
potential use as a pharmacological agent Until recent years, T(2) was 
considered an inactive metabolite of thyroid hormones thyroxine (T(4)) and 
triiodo-L-thyronine (T(3)). Several observations, however, led to a 
reconsideration of this idea. Early studies dealing with the biological 
activities of this iodothyronine revealed its ability to stimulate cellular 
/mitochondrial respiration, essentially by a nuclear-independent pathway. 
Mitochondria and the energy-transduction apparatus seem to be major targets 
of T(2), although outside the mitochondria T(2) also has effects on 
carriers, ion-exchangers and enzymes. Recent studies suggest that T(2) may 
also affect the transcription of some genes, but again the underlying 
mechanisms seem to differ from those actuated by T(3). The accumulated 
evidence permits the conclusion that the actions of T(2) do not simply mimic 
those of T(3) but instead are specific actions exerted through mechanisms 
that are independent of those actuated by T(3) and do not involve thyroid 
hormone receptors. In addition, very recent evidence leads us to suggest 
that T(2) may be a potentially useful agent for the treatment of 
diet-dependent overweight (and the consequent hypertriglyceridemia and high 
cholesterol level) without inducing thyrotoxicosis. © 2006 Bentham Science 
Publishers Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  diiodothyronine (adverse drug reaction, drug therapy, drug toxicity, 
pharmacology)
EMTREE DRUG INDEX TERMS
  acetyl coenzyme A carboxylase (endogenous compound)
  cholesterol (endogenous compound)
  liothyronine (adverse drug reaction, pharmacology)
  malonyl coenzyme A (endogenous compound)
  sodium ion (endogenous compound)
  sodium proton exchange protein (endogenous compound)
  thyroid hormone receptor (endogenous compound)
  thyroxine (adverse drug reaction, pharmacology)
  triacylglycerol (endogenous compound)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (side effect)
  cell nucleus
  cell respiration
  dietary intake
  drug mechanism
  drug targeting
  energy expenditure
  energy metabolism
  energy transfer
  evidence based medicine
  fatty acid oxidation
  fatty liver (drug therapy)
  genetic transcription
  human
  hypercholesterolemia (drug therapy)
  hypertriglyceridemia (drug therapy)
  ion exchange
  mammal
  metabolic rate
  mitochondrial respiration
  mitochondrion
  nonhuman
  obesity (drug therapy)
  rat
  review
  sodium current
  tachycardia (side effect)
  thyrotoxicosis (side effect)
  weight reduction
CAS REGISTRY NUMBERS
  acetyl coenzyme A carboxylase (9023-93-2)
  cholesterol (57-88-5)
  diiodothyronine (1041-01-6)
  liothyronine (6138-47-2, 6893-02-3)
  malonyl coenzyme A (524-14-1)
  sodium ion (17341-25-2)
  sodium proton exchange protein (204597-32-0)
  thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
  Clinical and Experimental Biochemistry (29)
  Endocrinology (3)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Toxicology (52)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006353305
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 448
TITLE
  The investigation and treatment of chronic heart failure
AUTHOR NAMES
  Gardner R.S.
  McDonagh T.A.
AUTHOR ADDRESSES
  (Gardner R.S.) Roy S Gardner MRCP is a Specialist Registrar in Cardiology in 
Glasgow with a specialist interest in, .
(McDonagh T.A.) Royal Brompton Hospital, London, United Kingdom.
CORRESPONDENCE ADDRESS
  R.S. Gardner, Roy S Gardner MRCP is a Specialist Registrar in Cardiology in 
Glasgow with a specialist interest in, .
SOURCE
  Medicine (2006) 34:6 (215-219). Date of Publication: 1 Jun 2006
  Cardiovascular Disorders III, Book Series Title:
ISSN
  1357-3039
ABSTRACT
  Chronic heart failure (CHF) is a clinical syndrome defined by the presence 
of symptoms (primarily breathlessness, fatigue and fluid retention), 
objective evidence of cardiac dysfunction, and in cases where the diagnosis 
is in doubt, a response to treatment directed towards it. It is not only 
important to investigate to ascertain the diagnosis, but also to identify 
the aetiology (as this might be reversible) and to give some indication of 
the prognosis of the condition. The treatment of CHF has been 
revolutionalized by large randomized controlled clinical trials studying the 
effects of antagonism of the renin-angiotensin-aldosterone and sympathetic 
nervous systems, as well as more recently, device therapy. These therapies 
now form the cornerstones in the management of the condition, and prognosis 
for this syndrome has improved as a result. However, cardiac transplantation 
remains an option for patients who remain severely symptomatic, and at high 
risk, despite optimal medical and appropriate device therapy. © 2006 
Elsevier Ltd. All rights reserved.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  aldosterone antagonist (drug combination, drug therapy)
  allopurinol (clinical trial, drug therapy)
  angiotensin 2 receptor antagonist (clinical trial, drug combination, drug 
therapy)
  beta adrenergic receptor blocking agent (clinical trial, drug combination, 
drug therapy)
  brain natriuretic peptide (endogenous compound)
  candesartan (clinical trial, drug combination, drug therapy)
  captopril (clinical trial, drug therapy, pharmacology)
  carvedilol (clinical trial, drug comparison, drug therapy)
  digoxin (clinical trial, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical 
trial, drug combination, drug therapy)
  diuretic agent (drug combination, drug therapy)
  electrolyte (endogenous compound)
  enalapril (clinical trial, drug therapy, pharmacology)
  eplerenone (drug therapy)
  erythropoietin (drug therapy)
  ferritin (endogenous compound)
  hydralazine (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (clinical trial, drug 
therapy)
  immunosuppressive agent (adverse drug reaction)
  iron (drug therapy, intravenous drug administration)
  metoprolol succinate (clinical trial, drug comparison, drug therapy)
  metoprolol tartrate (clinical trial, drug therapy)
  nitrate (drug therapy)
  placebo
  spironolactone (clinical trial, drug combination, drug therapy)
  unindexed drug
  urate (endogenous compound)
  urea (endogenous compound)
  warfarin (clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (complication, diagnosis, drug therapy, etiology, surgery, 
therapy)
EMTREE MEDICAL INDEX TERMS
  aerobic exercise
  anemia (drug therapy)
  angiocardiography
  angioneurotic edema
  article
  atrial fibrillation (diagnosis, drug therapy)
  blood cell count
  bradycardia (diagnosis)
  cardiac resynchronization therapy
  cardiomegaly (diagnosis)
  clinical trial
  coughing (side effect)
  defibrillator
  disease exacerbation
  drug contraindication
  drug dose titration
  drug mechanism
  drug megadose
  echocardiography
  electrocardiography
  exercise test
  fluid retention
  heart left ventricle hypertrophy (complication, diagnosis)
  heart muscle conduction disturbance (diagnosis, therapy)
  heart muscle revascularization
  heart transplantation
  hemochromatosis
  human
  hypertension
  hyperuricemia
  hyponatremia
  hypothyroidism
  ischemic heart disease (drug therapy, prevention)
  kidney disease
  liver function test
  low drug dose
  mortality
  nuclear magnetic resonance imaging
  priority journal
  prognosis
  radioisotope ventriculography
  smoking cessation
  thorax radiography
  thyroid function test
  thyrotoxicosis
  unspecified side effect (side effect)
  weight reduction
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  allopurinol (315-30-0)
  brain natriuretic peptide (114471-18-0)
  candesartan (139481-59-7)
  captopril (62571-86-2)
  carvedilol (72956-09-3)
  digoxin (20830-75-5, 57285-89-9)
  enalapril (75847-73-3)
  eplerenone (107724-20-9)
  erythropoietin (11096-26-7)
  ferritin (9007-73-2)
  hydralazine (304-20-1, 86-54-4)
  iron (14093-02-8, 53858-86-9, 7439-89-6)
  metoprolol succinate (98418-47-4)
  metoprolol tartrate (56392-17-7)
  nitrate (14797-55-8)
  spironolactone (52-01-7)
  urate (1198-77-2, 3106-08-9, 59216-10-3)
  urea (57-13-6)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006601493
FULL TEXT LINK
  http://dx.doi.org/10.1383/medc.2006.34.6.215
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 449
TITLE
  Re - Appraisal of risk factors for stroke in Nigerian Africans - A 
prospective case - Control study
AUTHOR NAMES
  Amu E.
  Ogunrin O.
  Danesi M.
AUTHOR ADDRESSES
  (Amu E., bfunmi@uniben.edu; Ogunrin O.) Department of Medicine, University 
Teaching Hospital, Benin City, Nigeria.
(Danesi M.) Dept. of Medicine, LUTH, Lagos.
CORRESPONDENCE ADDRESS
  E. Amu, Department of Medicine, University Teaching Hospital, Benin City, 
Nigeria. Email: bfunmi@uniben.edu
SOURCE
  African Journal of Neurological Sciences (2005) 24:2 (20-27). Date of 
Publication: 2005
ISSN
  1015-8618
  1015-8618 (electronic)
ABSTRACT
  Stroke is one of the major challenges facing medicine with a frightening 
statistics of being the second leading cause of death and the leading cause 
of physical disability worldwide. Identification and management of risk 
factors remains the key to reducing morbidity and mortality from stroke. 
Eighty patients with clinical presentation of stroke were recruited 
consecutively from the Emergency Departments of the University Teaching 
Hospital and Specialist Hospital - both situated in Benin City, Nigeria. The 
patients were followed up for a two year period (June 2000 - June 2002) and 
risk factors analysis was done on all patients. The patients were compared 
with eighty age and sex matched subjects without stroke (controls). 
Hypertension remained the dominant risk factor with an odds ratio of 2.68 
(95% CI 1.29 - 5.59). Diabetes mellitus independently conferred a risk of 
3.23 (95% CI 1.09 - 5.71) and in combination with hypertension enhanced 
stroke risk (odds ratio 7.21; 95% CI 5.79 - 13.27; p<0.05). Cigarette 
smoking, obesity, atrial fibrillation and physical inactivity significantly 
increased stroke risk (p<0.05). On the other hand, dietary habits, alcohol 
consumption and serum cholesterol were not important risk factors in 
Nigerians. This study emphasized the significance of optimal blood pressure 
and glycemic control in stroke prevention. The message for all is to 
exercise, maintain a healthy weight, avoid smoking and monitor blood 
pressure and glucose levels regularly.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  alcohol consumption
  article
  atrial fibrillation
  blood pressure measurement
  body weight
  case control study
  cause of death
  cholesterol blood level
  clinical feature
  comparative study
  confidence interval
  controlled study
  diabetes mellitus
  diet
  disability
  emergency ward
  exercise
  female
  follow up
  glucose blood level
  glycemic control
  human
  hypertension
  immobilization
  major clinical study
  male
  morbidity
  mortality
  Nigeria
  obesity
  prospective study
  risk assessment
  risk factor
  smoking
  statistics
  time series analysis
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, French
EMBASE ACCESSION NUMBER
  2006166775
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 450
TITLE
  Symptomatic despite multiple drug therapy: Where do you turn next?
AUTHOR NAMES
  Maggioni A.P.
AUTHOR ADDRESSES
  (Maggioni A.P., maggioni@anmco.it) ANMCO Research Centre, Florence, Italy.
CORRESPONDENCE ADDRESS
  A.P. Maggioni, ANMCO Research Centre, Florence, Italy. Email: 
maggioni@anmco.it
SOURCE
  JRAAS - Journal of the Renin-Angiotensin-Aldosterone System (2005) 6:SUPPL. 
2 (S13-S14). Date of Publication: Dec 2005
ISSN
  1470-3203
ABSTRACT
  Clinicians may be reluctant to implement evidence-based guideline 
recommendations because they believe that patients with chronic heart 
failure (CHF) who are enrolled into clinical trials are not truly 
representative of those seen in routine practice. Moreover, there may also 
be perceived safety issues associated with polypharmacy in patients with 
CHF. Clinicians should strive to implement guideline recommendations for the 
management of CHF to ensure optimal patient outcome in routine clinical 
practice. This case report demonstrates that symptom control may require a 
large number of pharmacological treatments, to be administered in accordance 
with guidelines.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug combination, drug therapy)
  amiodarone (drug therapy)
  bisoprolol (drug combination, drug dose, drug therapy)
  brain natriuretic peptide (endogenous compound)
  candesartan (drug combination, drug dose, drug therapy)
  creatinine (endogenous compound)
  furosemide (drug combination, drug therapy, intravenous drug administration)
  low density lipoprotein cholesterol (endogenous compound)
  ramipril (drug combination, drug dose, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (diagnosis, drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation (drug therapy, therapy)
  blood pressure measurement
  cardioversion
  case report
  chronic obstructive lung disease
  coronary artery disease
  diet
  disease association
  disease course
  drug efficacy
  dyspnea (drug therapy, therapy)
  echocardiography
  follow up
  heart arrhythmia (drug therapy, prevention)
  heart infarction (complication)
  heart left bundle branch block (diagnosis)
  heart left ventricle failure (diagnosis, drug therapy)
  hospital readmission
  human
  impaired glucose tolerance
  lifestyle
  male
  maximum permissible dose
  maximum tolerated dose
  QRS complex
  sinus rhythm
  smoking cessation
  symptomatology
  thorax radiography
  treatment contraindication
  treatment outcome
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  bisoprolol (66722-44-9)
  brain natriuretic peptide (114471-18-0)
  candesartan (139481-59-7)
  creatinine (19230-81-0, 60-27-5)
  furosemide (54-31-9)
  ramipril (87333-19-5)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006088684
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 451
TITLE
  Industry pulse (Editorial development by Adis International Limited, Italy)
AUTHOR ADDRESSES
  SOURCE
  High Blood Pressure and Cardiovascular Prevention (2005) 12:4 (239-243). 
Date of Publication: 2005
ISSN
  1120-9879
  1120-9879 (electronic)
ABSTRACT
  To help the reader keep up-to-date with the very latest developments in 
experimental and clinical research, this section of the journal aims to 
provide the reader with information selected by the journal sponsors 
regarding emerging clinical evidence on their compounds, new areas of 
research interest, and any other topic which might be potentially relevant 
to the reader. © 2005 Adis Data Information BV. All rights reserved.
EMTREE DRUG INDEX TERMS
  2,4 thiazolidinedione derivative (drug therapy)
  acarbose (clinical trial, drug therapy)
  atenolol (drug comparison, drug therapy, pharmacology)
  beta adrenergic receptor blocking agent (drug comparison, drug therapy, 
pharmacology)
  dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
  enalapril (clinical trial, drug therapy)
  losartan (clinical trial, drug comparison, drug therapy, pharmacology)
  metformin (drug therapy, pharmacoeconomics)
  pioglitazone (clinical trial, drug therapy)
  rosiglitazone (clinical trial, drug therapy)
  trandolapril (clinical trial, drug therapy)
  troglitazone (adverse drug reaction, clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, epidemiology)
  diabetes mellitus (disease management, drug therapy, epidemiology, 
prevention)
  essential hypertension (drug therapy)
EMTREE MEDICAL INDEX TERMS
  body mass
  cardiovascular risk
  clinical research
  clinical trial
  cost benefit analysis
  diet
  exercise
  high risk population
  human
  impaired glucose tolerance
  lifestyle
  liver toxicity (side effect)
  medical information
  metabolic syndrome X (diagnosis)
  non insulin dependent diabetes mellitus (drug therapy)
  nutrition
  obesity (epidemiology)
  priority journal
  review
  risk assessment
  screening
CAS REGISTRY NUMBERS
  acarbose (56180-94-0)
  atenolol (29122-68-7)
  enalapril (75847-73-3)
  losartan (114798-26-4)
  metformin (1115-70-4, 657-24-9)
  pioglitazone (105355-27-9, 111025-46-8)
  rosiglitazone (122320-73-4, 155141-29-0)
  trandolapril (87679-37-6)
  troglitazone (97322-87-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006108092
FULL TEXT LINK
  http://dx.doi.org/10.2165/00151642-200512040-00006
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 452
TITLE
  Overcoming gaps in the management of asthma in older patients: New insights
AUTHOR NAMES
  Barua P.
  O'Mahony M.S.
AUTHOR ADDRESSES
  (Barua P.; O'Mahony M.S., omahonyms@cf.ac.uk) University Department of 
Geriatric Medicine, Academic Centre, Llandough Hospital, Cardiff, United 
Kingdom.
(O'Mahony M.S., omahonyms@cf.ac.uk) Academic Centre, Llandough Hospital, 
Penlan Road, Penarth, CF64 2XX, United Kingdom.
CORRESPONDENCE ADDRESS
  M.S. O'Mahony, Academic Centre, Llandough Hospital, Penlan Road, Penarth, 
CF64 2XX, United Kingdom. Email: omahonyms@cf.ac.uk
SOURCE
  Drugs and Aging (2005) 22:12 (1029-1059). Date of Publication: 2005
ISSN
  1170-229X
  1170-229X (electronic)
BOOK PUBLISHER
  Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, 
Auckland 10, New Zealand.
ABSTRACT
  Asthma is under-recognised and undertreated in older populations. This is 
not surprising, given that one-third of older people experience significant 
breathlessness. The differential diagnosis commonly includes asthma, chronic 
obstructive pulmonary disease (COPD), heart failure, malignancy, aspiration 
and infections. Because symptoms and signs of several cardiorespiratory 
diseases are nonspecific in older people and diseases commonly co-exist, 
investigations are important. A simple strategy for the investigation of 
breathlessness in older people should include a full blood count, chest 
radiograph, ECG, peak flow diary and/or spirometry with reversibility as a 
minimum. If there are major abnormalities on the ECG, an echocardiogram 
should also be performed. Diurnal variability in peak flow readings ≥20% or 
≥15% reversibility in forced expiratory volume in 1 second, spontaneously or 
with treatment, support a diagnosis of asthma. Distinguishing asthma from 
COPD is important to allow appropriate management of disease based on 
aetiology, accurate prediction of treatment response, correct prognosis and 
appropriate management of the chest condition and co-morbidities. The two 
conditions are usually readily differentiated by clinical features, 
particularly age at onset, variability of symptoms and nocturnal symptoms in 
asthma, supported by the results of reversibility testing. Full lung 
function tests may not necessarily help in differentiating the two entities, 
although gas transfer factor is characteristically reduced in COPD and 
usually normal or high in asthma. Methacholine challenge tests previously 
mainly used in research are now also used widely and safely to confirm 
asthma in clinical settings. Interest in exhaled nitric oxide as a biomarker 
of airways inflammation is increasing as a noninvasive tool in the diagnosis 
and monitoring of asthma. Regular inhaled corticosteroids (ICS) are the 
mainstay of treatment of asthma. Even in mild disease in older adults, 
regular preventive treatment should be considered, given the poor perception 
of bronchoconstriction by older asthmatic patients. If symptoms persist 
despite ICS, addition of long-acting β2-adrenoceptor agonists (LABA) should 
be considered. Addition of LABA to ICS improves asthma control and allows 
reduction in ICS dose. However, older people have been grossly 
under-represented in trials of LABA, many trials having excluded those ≥65 
years of age. On meta-analysis, β2-adrenoceptor agonists (both short acting 
and long acting) are associated with increased cardiovascular mortality and 
morbidity in asthma and COPD. While the evidence for excess cardiovascular 
mortality is stronger for short-acting β2-adrenoceptor agonists, it would be 
prudent to exercise particular care in using β2-adrenoceptor agonists (long 
acting and short acting) in those at risk of adverse cardiovascular 
outcomes, including older people. Regular review of cardiovascular status 
(and monitoring of serum potassium concentration) in patients taking 
β2-adrenoceptor agonists is crucial. The response to LABA should be 
carefully monitored and alternative 'add-on' therapy such as leukotriene 
receptor antagonists (LRA) should be considered. LRA have fewer adverse 
effects and in individual cases may be more effective and appropriate than 
LABA. Long-term trials evaluating β2-adrenoceptor agonists and other 
bronchodilator strategies are needed particularly in the elderly and in 
patients with cardiovascular co-morbidities. There is no evidence that 
addition of anticholinergics improves control of asthma further, although 
the role of long-acting anticholinergics in the prevention of disease 
progression is currently being researched. Older patients need to be taught 
good inhaler technique to improve delivery of medications to lungs, minimise 
adverse effects and reduce the need for oral corticosteroids. Nurse-led 
education programmes that include a written asthma self-management plan have 
the potential to improve outcomes. © 2005 Adis Data Information BV. All 
rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  antiasthmatic agent (adverse drug reaction, clinical trial, drug comparison, 
drug concentration, drug dose, drug interaction, drug therapy, inhalational 
drug administration, oral drug administration, pharmaceutics, 
pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction)
  antifungal agent (drug therapy, oral drug administration)
  beclometasone (adverse drug reaction, drug comparison, drug dose, drug 
therapy)
  beta 2 adrenergic receptor stimulating agent (adverse drug reaction, 
clinical trial, drug combination, drug therapy, pharmacology)
  bisphosphonic acid derivative (drug therapy, oral drug administration)
  budesonide (drug therapy)
  calcium (drug therapy)
  cholinergic receptor blocking agent (adverse drug reaction, drug dose, drug 
therapy, inhalational drug administration, pharmacology)
  cholinergic receptor stimulating agent (adverse drug reaction, drug therapy)
  cimetidine (drug interaction)
  corticosteroid (adverse drug reaction, drug dose, drug therapy, oral drug 
administration, pharmacokinetics, pharmacology)
  dipeptidyl carboxypeptidase inhibitor (adverse drug reaction)
  fluticasone propionate (drug comparison, drug therapy)
  formoterol (clinical trial, drug therapy)
  histamine (adverse drug reaction, drug comparison)
  ipratropium bromide (adverse drug reaction, drug therapy, pharmacology)
  methacholine (adverse drug reaction, drug comparison)
  methylxanthine (adverse drug reaction, drug concentration, drug dose, drug 
interaction, drug therapy, oral drug administration, pharmaceutics, 
pharmacokinetics, pharmacology)
  mometasone furoate (drug comparison, drug therapy)
  nonsteroid antiinflammatory agent (adverse drug reaction, drug therapy)
  orciprenaline (drug therapy, pharmacology)
  prednisolone (drug therapy, oral drug administration)
  salbutamol (drug therapy, inhalational drug administration, pharmacology)
  salmeterol (clinical trial, drug therapy)
  theophylline (adverse drug reaction, drug concentration, drug dose, drug 
interaction, drug therapy, oral drug administration, pharmaceutics, 
pharmacokinetics, pharmacology)
  tiopropium bromide (drug therapy, pharmacology)
  unclassified drug
  unindexed drug
  vitamin D (drug therapy)
  zileuton (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  asthma (diagnosis, drug therapy, side effect)
EMTREE MEDICAL INDEX TERMS
  adrenal suppression
  airway obstruction
  allergy test
  arterial gas
  aspiration
  atrial fibrillation (side effect)
  attention disturbance (side effect)
  blood analysis
  blood cell count
  bronchospasm (side effect)
  bronchus secretion
  cataract (side effect)
  chronic obstructive lung disease
  clinical trial
  convulsion (side effect)
  coughing (side effect)
  depression (drug therapy)
  diabetes mellitus (side effect)
  diagnostic test
  differential diagnosis
  dizziness (side effect)
  drug half life
  drug induced headache (side effect)
  drug tolerability
  dysphonia (side effect)
  electrocardiogram
  essential tremor (drug therapy)
  exercise
  flushing
  forced expiratory flow
  fracture (drug therapy, side effect)
  gastroesophageal reflux (side effect)
  gastrointestinal disease (side effect)
  glaucoma (drug therapy, side effect)
  heart disease (drug therapy)
  heart left ventricle failure
  heart palpitation (side effect)
  heart ventricle arrhythmia (side effect)
  human
  hypertension (drug therapy, side effect)
  hypokalemia (side effect)
  hypothalamus hypophysis adrenal system
  immune paralysis (side effect)
  immunotherapy
  intraocular pressure abnormality (side effect)
  lung embolism
  lung function test
  malignant neoplastic disease
  memory disorder (side effect)
  meta analysis
  mood disorder (side effect)
  morbidity
  mortality
  myopathy (side effect)
  nervousness
  osteoporosis (drug therapy, side effect)
  priority journal
  QT prolongation (side effect)
  respiratory tract infection
  review
  side effect (side effect)
  spirometry
  supraventricular tachycardia (side effect)
  symptomatology
  systematic review
  tachycardia (side effect)
  thorax radiography
  throat irritation (side effect)
  thrush (drug therapy, side effect)
  tremor (side effect)
  urine retention (drug therapy, side effect)
  yoga
DRUG TRADE NAMES
  aspirin
DEVICE TRADE NAMES
  Autohaler
  Diskhaler
  Nebuhaler
  Rotahaler
  Spinhaler
  Turbohaler
  volumatic
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  beclometasone (4419-39-0)
  budesonide (51333-22-3)
  calcium (7440-70-2)
  cimetidine (51481-61-9, 70059-30-2)
  fluticasone propionate (80474-14-2)
  formoterol (73573-87-2)
  histamine (51-45-6, 56-92-8, 93443-21-1)
  ipratropium bromide (22254-24-6)
  methacholine (55-92-5)
  methylxanthine (28109-92-4)
  mometasone furoate (83919-23-7)
  orciprenaline (586-06-1, 5874-97-5)
  prednisolone (50-24-8)
  salbutamol (18559-94-9)
  salmeterol (89365-50-4)
  theophylline (58-55-9, 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9)
  zileuton (111406-87-2, 132880-11-6)
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Pharmacy (39)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005580856
MEDLINE PMID
  16363886 (http://www.ncbi.nlm.nih.gov/pubmed/16363886)
FULL TEXT LINK
  http://dx.doi.org/10.2165/00002512-200522120-00004
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 453
TITLE
  Ximelagatran: An oral direct thrombin inhibitor for anticoagulant therapy
AUTHOR NAMES
  Rossi M.L.
  Zavalloni D.
  Belli G.
  Presbitero P.
AUTHOR ADDRESSES
  (Rossi M.L., marcolrossi@hotmail.com; Zavalloni D.; Belli G.; Presbitero P.) 
Unità Operativa di Emodinamica e Cardiologia Interventistica, Istituto 
Clinico Humanitas, Rozzano, Milan, Italy.
(Rossi M.L., marcolrossi@hotmail.com) Unità Operativa di Emodinamica e 
Cardiologia Interventistica, Istituto Clinico Humanitas, Via Manzoni, 56, 
20089 Rozzano, Milan, Italy.
CORRESPONDENCE ADDRESS
  M.L. Rossi, Unità Operativa di Emodinamica e Cardiologia Interventistica, 
Istituto Clinico Humanitas, Via Manzoni, 56, 20089 Rozzano, Milan, Italy. 
Email: marcolrossi@hotmail.com
SOURCE
  Letters in Drug Design and Discovery (2005) 2:7 (503-506). Date of 
Publication: Nov 2005
ISSN
  1570-1808
ABSTRACT
  Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, 
competitive and reversible inhibitor of the active site of human α-thrombin. 
Its effect is independent from diet, plasma antithrombin levels, obesity or 
ethnicity. It has little effect on bleeding time at doses up to twice those 
required, and interference with other drugs is avoided by the absence of 
interaction with cytochrome P450. Ximelagatran has been documented in a 
large clinical programme with proven efficacy in prevention and treatment of 
venous thromboembolism, prevention of stroke in patients with atrial 
fibrillation and prevention of major cardiovascular events following a 
recent myocardial infarction. Bleeding has not been a problem, but increase 
in liver enzymes is a cause of concern for long term use until more 
information is available. © 2005 Bentham Science Publishers Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  melagatran (drug administration, drug therapy, oral drug administration, 
pharmacokinetics, pharmacology, subcutaneous drug administration)
  thrombin inhibitor (drug therapy, oral drug administration, pharmacology)
  ximelagatran (drug combination, drug therapy, oral drug administration, 
pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug combination, drug therapy)
  cytochrome P450 (endogenous compound)
  enoxaparin (drug comparison, drug therapy, subcutaneous drug administration)
  liver enzyme (endogenous compound)
  low molecular weight heparin (drug therapy)
  prodrug
  warfarin (drug therapy, oral drug administration, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  venous thromboembolism (drug therapy)
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation (drug therapy)
  blood clotting
  cardiovascular disease
  cerebrovascular accident
  diet
  drug effect
  drug efficacy
  ethnology
  human
  nonhuman
  obesity
  priority journal
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  cytochrome P450 (9035-51-2)
  enoxaparin (9041-08-1)
  melagatran (159776-70-2)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
  ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005550309
FULL TEXT LINK
  http://dx.doi.org/10.2174/157018005774479168
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 454
TITLE
  Dexmedetomidine as a sole sedating agent with local anesthesia in a 
high-risk patient for axillofemoral bypass graft: A case report
AUTHOR NAMES
  Rich J.M.
AUTHOR ADDRESSES
  (Rich J.M., jrofdallas@gmail.com)
(Rich J.M., jrofdallas@gmail.com) Baylor University Medical Center, Dallas, 
TX, United States.
CORRESPONDENCE ADDRESS
  J.M. Rich, Baylor University Medical Center, Dallas, TX, United States. 
Email: jrofdallas@gmail.com
SOURCE
  AANA Journal (2005) 73:5 (357-360). Date of Publication: October 2005
ISSN
  0094-6354
BOOK PUBLISHER
  AANA Publishing Inc., 222 South Prospect Road, Park Ridge, United States.
ABSTRACT
  The α(2)-agonist dexmedetomidine is indicated for sedation of patients 
receiving mechanical ventilation in the intensive care unit. It has 
additional off-label uses for coadministration with local, regional, and 
general anesthesia. This report describes the use of dexmedetomidine as a 
sole sedating agent in conjunction with local anesthesia for major vascular 
surgery. A PubMed literature search produced no previous report of the use 
of dexmedetomidine as a sole sedating agent used in conjunction with local 
anesthesia. The anxiolytic, hypnotic-sedative, anesthetic-sparing, and 
analgesic actions of the drug along with the lack of significant respiratory 
depressant effects are described. The patient required no airway management 
with the exception of supplemental mask oxygen. He tolerated the procedure 
well and was discharged without sequelae on the third postoperative day. 
Dexmedetomidine should be used judiciously, and understanding the potential 
adverse effects and how to treat them is of paramount importance. However, 
with vigilant intraoperative monitoring of blood pressure, heart rate, and 
level of consciousness, it can be administered safely, thus lessening the 
anesthetic requirements and possibly improving the surgical outcome of the 
high-risk patient. This report describes the indications, dosing, off-label 
uses, pharmacodynamics, pharmacokinetics, and common adverse effects of 
dexmedetomidine.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  dexmedetomidine (adverse drug reaction, drug comparison, drug dose, drug 
interaction, pharmacoeconomics, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  alpha 2 adrenergic receptor stimulating agent (adverse drug reaction, drug 
comparison, drug dose, drug interaction, pharmacoeconomics, 
pharmacokinetics, pharmacology)
  amlodipine (drug therapy)
  calcium acetate
  famotidine
  fluticasone (drug therapy)
  furosemide (drug therapy)
  lidocaine
  local anesthetic agent
  losartan (drug therapy)
  midazolam (drug comparison, pharmacokinetics)
  opiate (drug interaction)
  prednisone
  propofol (drug comparison, pharmacoeconomics, pharmacokinetics)
  salmeterol (drug therapy)
  sedative agent (adverse drug reaction, drug comparison, drug dose, drug 
interaction, pharmacoeconomics, pharmacokinetics, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  axillofemoral artery anastomosis
  local anesthesia
  sedation
EMTREE MEDICAL INDEX TERMS
  aged
  anemia (side effect)
  article
  atrial fibrillation
  bradycardia (side effect)
  case report
  chronic obstructive lung disease (drug therapy)
  congestive heart failure (drug therapy)
  drug indication
  drug monitoring
  drug use
  fever (side effect)
  geriatric patient
  high risk patient
  human
  hypertension (drug therapy, side effect)
  hypotension (side effect)
  hypoxia (side effect)
  male
  nausea (side effect)
  off label drug use
  rating scale
  surgical patient
  tachycardia (side effect)
  thromboembolism (complication, drug therapy, prevention)
  vascular surgery
  vomiting (side effect)
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amlodipine (88150-42-9)
  calcium acetate (62-54-4)
  dexmedetomidine (113775-47-6)
  famotidine (76824-35-6)
  fluticasone (90566-53-3)
  furosemide (54-31-9)
  lidocaine (137-58-6, 24847-67-4, 56934-02-2, 73-78-9)
  losartan (114798-26-4)
  midazolam (59467-70-8)
  opiate (53663-61-9, 8002-76-4, 8008-60-4)
  prednisone (53-03-2)
  propofol (2078-54-8)
  salmeterol (89365-50-4)
EMBASE CLASSIFICATIONS
  Anesthesiology (24)
  Clinical and Experimental Pharmacology (30)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005460125
MEDLINE PMID
  16261851 (http://www.ncbi.nlm.nih.gov/pubmed/16261851)
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 455
TITLE
  Clinical experience in acupuncture treatment of apoplexy
AUTHOR NAMES
  Liu R.
AUTHOR ADDRESSES
  (Liu R.) Pukou Hospital, Nanjing, Jiangsu 210031, China.
CORRESPONDENCE ADDRESS
  R. Liu, Pukou Hospital, Nanjing, Jiangsu 210031, China.
SOURCE
  Journal of Traditional Chinese Medicine (2005) 25:3 (190-192). Date of 
Publication: September 2005
ISSN
  0255-2922
BOOK PUBLISHER
  Journal of Traditional Chinese Medicine, 18 Beixincang, Dongzhimen Nei, 
Beijing, China.
EMTREE DRUG INDEX TERMS
  antihypertensive agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  cerebrovascular accident (therapy)
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation (therapy)
  brain circulation
  brain hemorrhage (drug therapy)
  hemiplegia
  human
  hypertension (drug therapy)
  ischemic heart disease (therapy)
  mental disease (therapy)
  muscle rigidity (therapy)
  paralysis (therapy)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2005530005
MEDLINE PMID
  16334721 (http://www.ncbi.nlm.nih.gov/pubmed/16334721)
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 456
TITLE
  A 68-year-old woman with multiple NSAID-induced adverse effects
AUTHOR NAMES
  Collins R.J.
  Brokaw D.K.
AUTHOR ADDRESSES
  (Collins R.J., rjcollins@vcu.edu; Brokaw D.K.) Virginia Commonwealth 
University, School of Pharmacy, Richmond, VA, United States.
(Collins R.J., rjcollins@vcu.edu) Virginia Commonwealth University, School 
of Pharmacy, P.O. Box 980533, Richmond, VA 23298-0533, United States.
CORRESPONDENCE ADDRESS
  R.J. Collins, Virginia Commonwealth University, School of Pharmacy, P.O. Box 
980533, Richmond, VA 23298-0533, United States. Email: rjcollins@vcu.edu
SOURCE
  Consultant Pharmacist (2005) 20:8 (685-688). Date of Publication: Aug 2005
ISSN
  0888-5109
ABSTRACT
  Common comorbid conditions such as atrial fibrillation, hypertension, 
congestive heart failure, and osteoarthritis put geriatric patients at risk 
for toxicity while using nonsteroidal anti-inflammatory drugs (NSAIDs). 
Concomitant medications also can contribute to complications associated with 
NSAID therapy. However, NSAID therapy is widely used for pain management in 
this patient population. This case describes a 68-year-old patient, with a 
history of hypertension and osteoarthritis, who presented with multiple 
NSAID-induced adverse effects. Upon admission to the hospital, this patient 
was found to have renal and hepatic failure, fluid overload, and 
electrocardiogram changes, most likely as a result of excessive naproxen 
ingestion. This patient also was taking hydrochlorothiazide and had not had 
any laboratory values drawn to monitor her medication regimen. Subsequently, 
she required hemodialysis and a long hospital course. Her hepatic failure, 
fluid overload, and electrocardiogram changes resolved with treatment. 
Multiple health care providers could have detected probl ems with this 
patient's pain management. Adverse events associated with NSAIDs can be 
prevented with patient monitoring and education. Health care providers also 
need education to learn how to optimize the pain management of their 
geriatric patients. Recommendations for preventing NSAID-induced adverse 
effects and for optimizing pain management are presented. Copyright© 2005, 
American Society of Consultant Pharmacists, Inc. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  nonsteroid antiinflammatory agent (adverse drug reaction, drug combination)
EMTREE DRUG INDEX TERMS
  capsaicin (drug combination, drug therapy, topical drug administration)
  cyclooxygenase 2 inhibitor (drug combination)
  dimethyl sulfone
  diuretic agent (drug combination)
  herbaceous agent
  hydrochlorothiazide (drug combination, drug interaction, drug therapy, oral 
drug administration)
  levofloxacin (drug therapy)
  naproxen (adverse drug reaction, drug combination, drug interaction, drug 
therapy)
  paracetamol (drug therapy)
  prednisone (drug therapy, oral drug administration)
  promethazine (drug therapy, rectal drug administration)
  salicylic acid methyl ester (drug combination, drug therapy, topical drug 
administration)
  tramadol (drug combination)
EMTREE MEDICAL INDEX TERMS
  acute kidney tubule necrosis (side effect)
  aged
  article
  atrial fibrillation
  blood pressure
  case report
  comorbidity
  congestive heart failure
  digestive system ulcer (side effect)
  drug withdrawal
  edema (side effect)
  electrocardiogram
  electrolyte disturbance (side effect)
  exercise
  female
  fluid retention
  gastrointestinal disease (side effect)
  gastrointestinal hemorrhage (side effect)
  geriatric patient
  heart failure (side effect)
  hemodialysis
  hospitalization
  human
  hypertension (side effect)
  kidney failure (side effect, therapy)
  kidney injury (side effect)
  knee osteoarthritis (drug therapy)
  liver dysfunction (side effect)
  liver failure (side effect)
  nausea (drug therapy)
  nephrotoxicity (side effect)
  oliguria (side effect)
  osteoarthritis
  pain (drug therapy, therapy)
  patient education
  patient monitoring
  pharmacist
  potassium blood level
  risk factor
  side effect (side effect)
  sodium absorption
  stomach disease (side effect)
  urinary tract infection (drug therapy)
  vomiting (drug therapy)
  weight reduction
CAS REGISTRY NUMBERS
  capsaicin (404-86-4)
  dimethyl sulfone (67-71-0)
  hydrochlorothiazide (58-93-5)
  levofloxacin (100986-85-4, 138199-71-0)
  naproxen (22204-53-1, 26159-34-2)
  paracetamol (103-90-2)
  prednisone (53-03-2)
  promethazine (58-33-3, 60-87-7)
  salicylic acid methyl ester (119-36-8)
  tramadol (27203-92-5, 36282-47-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Urology and Nephrology (28)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Gastroenterology (48)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2006597199
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 457
TITLE
  Preventing dementia
AUTHOR NAMES
  Purandare N.
  Ballard C.
  Burns A.
AUTHOR ADDRESSES
  (Purandare N., nitin.purandare@man.ac.uk) University of Manchester, School 
of Psychiatry and Behavioural Sciences, Wythenshawe Hospital, Manchester M23 
9LT, United Kingdom.
(Ballard C.) Department of Old Age Psychiatry, King's College, London, 
United Kingdom.
(Burns A.) Department of Old Age Psychiatry, School of Psychiatry and 
Behavioural Sciences, University of Manchester, Manchester M23 9LT, United 
Kingdom.
CORRESPONDENCE ADDRESS
  N. Purandare, University of Manchester, School of Psychiatry and Behavioural 
Sciences, Wythenshawe Hospital, Manchester M23 9LT, United Kingdom. Email: 
nitin.purandare@man.ac.uk
SOURCE
  Advances in Psychiatric Treatment (2005) 11:3 (176-183). Date of 
Publication: May 2005
ISSN
  1355-5146
ABSTRACT
  Epidemiological evidence has identified key strategies that may be used in 
the prevention of both Alzheimer's disease and vascular dementia. These 
strategies may be loosely divided into three areas: treatment of vascular 
risk factors, neuroprotection and increasing neuronal reserves. Evidence 
from randomised controlled trials already exists for treatment of 
hypertension but results for statins have been disappointing. Most of the 
intervention trials currently in progress focus on one or two risk factors 
and include cognition or dementia only as a secondary outcome. The potential 
of intervention strategies awaits confirmation by randomised controlled 
trials that target multiple risk factors in at-risk people with mild 
cognitive impairment, with incident dementia as the primary outcome.
EMTREE DRUG INDEX TERMS
  alpha tocopherol (clinical trial, drug combination, drug comparison, drug 
therapy)
  antidiabetic agent (clinical trial, drug therapy)
  antihypertensive agent (clinical trial, drug therapy)
  apolipoprotein E (endogenous compound)
  ascorbic acid (drug therapy)
  calcium channel blocking agent (drug therapy)
  compactin (adverse drug reaction, clinical trial, drug therapy)
  cyanocobalamin (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (clinical trial, drug therapy)
  folic acid (drug therapy)
  green tea extract (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (adverse drug reaction, 
clinical trial, drug therapy)
  mevinolin (adverse drug reaction, clinical trial, drug therapy)
  nonsteroid antiinflammatory agent (clinical trial, drug therapy)
  placebo
  pravastatin (adverse drug reaction, clinical trial, drug therapy)
  selegiline (clinical trial, drug combination, drug comparison, drug therapy)
  simvastatin (adverse drug reaction, clinical trial, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Alzheimer disease (drug therapy, prevention)
  multiinfarct dementia (drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  article
  atherosclerosis
  atrial fibrillation
  cardiovascular risk
  carotid artery obstruction
  clinical trial
  cognition
  cognitive defect (side effect)
  diabetes mellitus (drug therapy)
  epidemiological data
  evidence based medicine
  exercise
  heart infarction
  human
  hypercholesterolemia (drug therapy)
  hypertension (drug therapy)
  leisure
  meta analysis
  neuroprotection
  physical activity
  risk factor
  risk management
  risk reduction
  smoking
  social behavior
  systematic review
  treatment outcome
CAS REGISTRY NUMBERS
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
  compactin (73573-88-3)
  cyanocobalamin (53570-76-6, 68-19-9, 8064-09-3)
  folic acid (59-30-3, 6484-89-5)
  mevinolin (75330-75-5)
  pravastatin (81131-74-0)
  selegiline (14611-51-9, 14611-52-0, 2079-54-1, 2323-36-6)
  simvastatin (79902-63-9)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Psychiatry (32)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005223499
FULL TEXT LINK
  http://dx.doi.org/10.1192/apt.11.3.176
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 458
TITLE
  High-dose torasemide is equivalent to high-dose furosemide with hypertonic 
saline in the treatment of refractory congestive heart failure
AUTHOR NAMES
  Paterna S.
  Fasullo S.
  Di Pasquale P.
AUTHOR ADDRESSES
  (Paterna S.) Department of Internal Medicine, University of Palermo, 
Palermo, Italy.
(Fasullo S.; Di Pasquale P.) Div. of Cardiology Paolo Borsellino, G.F. 
Ingrassia Hospital, Palermo, Italy.
(Di Pasquale P.) Div. of Cardiology Paolo Borsellino, Via Val Platani 3, 
Palermo, 90144, Italy.
CORRESPONDENCE ADDRESS
  P. Di Pasquale, Div. of Cardiology Paolo Borsellino, Via Val Platani 3, 
Palermo, 90144, Italy.
SOURCE
  Clinical Drug Investigation (2005) 25:3 (165-173). Date of Publication: 2005
ISSN
  1173-2563
ABSTRACT
  Objective: A randomised, double-blind study was performed to evaluate the 
effects of the combination of high-dose torasemide and hypertonic saline 
solution (HSS) infusion versus high-dose furosemide (frusemide) and HSS in 
the treatment of refractory New York Heart Association class IV congestive 
heart failure (CHF). Materials and methods: Eighty-four patients (55 males, 
29 females) with refractory CHF, aged 55-84 years, with an ejection fraction 
<35%, serum creatinine <2 mg/dL, blood urea nitrogen ≤60 mg/dL, a reduced 
urinary volume and a low natriuresis, were randomised to two groups. Group 1 
(27 males, 15 females) received an intravenous infusion of furosemide 500mg 
plus HSS (150mL of 1.4-4.6% sodium chloride) twice daily in 30 minutes. 
Group 2 (28 males, 14 females) received torasemide 200mg twice daily plus 
HSS during a period lasting 4-8 days. Physical examination, measurement of 
bodyweight, blood pressure, heart rate, evaluation of signs of CHF, and 
serum and urinary parameters were controlled daily during hospitalisation. 
Chest x-ray, ECG and echocardiogram were obtained at entry, during 
hospitalisation and at discharge. During the treatment and after discharge 
the daily dietary sodium intake was 120 mmol, with a fluid intake of 
1.0-1.5L in both groups. Bodyweight and 24-hour urinary volume, serum and 
urinary laboratory parameters, until reaching a compensated state, were 
controlled daily, when intravenous furosemide and torasemide were replaced 
with oral furosemide administration only (250-500mg twice daily). After 
discharge the double-blind design was discontinued and the subsequent period 
was an open-label study with furosemide only; the patients were followed up 
as outpatients weekly for the first 3 months and subsequently once a month. 
Results: Baseline clinical characteristics of patients were similar in both 
groups. A significant increase in daily diuresis and natriuresis was 
observed in both groups. No difference was observed in serum sodium or 
potassium. Bodyweight was reduced in both groups. Blood pressure values 
decreased, and heart rate was corrected to normal values in both groups. In 
the follow-up period (12 ± 3.9 months), 17 patients were re-admitted to the 
hospital for heart failure. Thirteen patients died during follow-up. 
Conclusion: We conclude that high-dose torasemide is equivalent to high-dose 
furosemide in the treatment of refractory CHF. © 2005 Adis Data Information 
BV. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  furosemide (clinical trial, drug combination, drug comparison, drug dose, 
drug therapy, intravenous drug administration, oral drug administration)
  torasemide (clinical trial, drug comparison, drug dose, drug therapy, 
intravenous drug administration)
EMTREE DRUG INDEX TERMS
  aldosterone antagonist (drug combination, drug therapy)
  beta adrenergic receptor blocking agent (drug combination, drug therapy)
  captopril (drug combination, drug therapy)
  creatinine (endogenous compound)
  digoxin (drug combination, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug combination, drug therapy)
  nitrate (drug combination, drug therapy)
  nitrogen (endogenous compound)
  potassium (endogenous compound)
  sodium (endogenous compound)
  sodium chloride
  urea (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  congestive heart failure (drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation (drug therapy)
  bioequivalence
  blood pressure
  body weight
  clinical trial
  congestive cardiomyopathy (drug therapy)
  controlled study
  coronary artery disease (drug therapy)
  creatinine blood level
  death
  double blind procedure
  drug megadose
  echocardiography
  electrocardiography
  female
  fluid intake
  follow up
  heart ejection fraction
  heart rate
  human
  hypertension (drug therapy)
  major clinical study
  male
  natriuresis
  open study
  physical examination
  potassium blood level
  priority journal
  randomized controlled trial
  sodium blood level
  sodium intake
  statistical analysis
  thorax radiography
  urea nitrogen blood level
  urine volume
CAS REGISTRY NUMBERS
  captopril (62571-86-2)
  creatinine (19230-81-0, 60-27-5)
  digoxin (20830-75-5, 57285-89-9)
  furosemide (54-31-9)
  nitrate (14797-55-8)
  nitrogen (7727-37-9)
  potassium (7440-09-7)
  sodium chloride (7647-14-5)
  sodium (7440-23-5)
  torasemide (56211-40-6)
  urea (57-13-6)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005150059
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 459
TITLE
  Fast-track cardiac anesthesia: Choice of anesthetic agents and techniques
AUTHOR NAMES
  Myles P.S.
  McIlroy D.
AUTHOR ADDRESSES
  (Myles P.S., p.myles@alfred.org.au; McIlroy D.) Dept. of Anaesthesia and 
Pain Mgmt., Alfred Hospital, Australia.
(Myles P.S., p.myles@alfred.org.au) Depts. Anaesthesia, Epidemiol. P., 
Monash University, Australia.
(Myles P.S., p.myles@alfred.org.au) Ctr. for Clin. Research Excellence, 
Canberra, ACT, Australia.
(Myles P.S., p.myles@alfred.org.au) Dept. of Anaesthesia and Pain Mgmt., 
Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia.
CORRESPONDENCE ADDRESS
  P.S. Myles, Dept. of Anaesthesia and Pain Mgmt., Alfred Hospital, Commercial 
Road, Melbourne, Vic. 3004, Australia. Email: p.myles@alfred.org.au
SOURCE
  Seminars in Cardiothoracic and Vascular Anesthesia (2005) 9:1 (5-16). Date 
of Publication: March 2005
ISSN
  1089-2532
BOOK PUBLISHER
  SAGE Publications Inc., 2455 Teller Road, Thousand Oaks, United States.
ABSTRACT
  Fast-track cardiac anesthesia (FTCA) incorporates early tracheal extubation, 
decreased length of intensive care unit (ICU) and hospital stay, and 
(ideally) should avoid or reduce complications to safely achieve 
cost-savings. A growing body of evidence from randomized trials has 
identified many anesthetic interventions that can improve outcome after 
cardiac surgery. These include new short-acting hypnotic, opioid, and 
neuromuscular blocking drugs. An effective FTCA program requires the 
appropriate selection of suitable patients, a low-dose opioid anesthetic 
technique, early tracheal extubation, a short stay in the ICU, and 
coordinated perioperative care. It is also dependent on the avoidance of 
postoperative complications such as excessive bleeding, myocardial ischemia, 
low cardiac output state, arrhythmias, sepsis, and renal failure. These 
complications will have a much greater adverse effect on hospital length of 
stay and healthcare costs. A number of clinical trials have identified 
interventions that can reduce some of these complications. The adoption of 
effective treatments into clinical practice should improve the effectiveness 
of FTCA. ©2005 Westminster Publications, Inc.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  adrenergic receptor stimulating agent (drug therapy)
  amiodarone (drug comparison, drug therapy)
  anesthetic agent (drug therapy, epidural drug administration)
  aprotinin (drug therapy)
  bupivacaine (drug combination, drug comparison, drug therapy, epidural drug 
administration)
  calcium channel stimulating agent (drug therapy)
  catecholamine (endogenous compound)
  clonidine (drug combination, drug concentration, drug therapy, epidural drug 
administration)
  creatinine (endogenous compound)
  desmopressin (drug therapy)
  dexmedetomidine (drug therapy)
  diclofenac (drug therapy)
  dopamine
  dopexamine
  enflurane (drug comparison, drug therapy)
  fentanyl (drug combination, drug comparison, drug dose, drug therapy)
  hydrocortisone (endogenous compound)
  isoflurane (drug combination, drug therapy)
  methylprednisolone
  morphine (drug combination, drug therapy, intrathecal drug administration)
  nonsteroid antiinflammatory agent (drug combination, drug therapy)
  opiate (drug therapy, intrathecal drug administration)
  pancuronium (drug comparison)
  propofol (drug combination, drug comparison, drug therapy)
  remifentanil (drug comparison, drug therapy, pharmacoeconomics)
  rocuronium (drug comparison)
  sotalol (drug comparison, drug therapy)
  tranexamic acid (drug therapy)
  unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Fast Track cardiac anesthesia
  heart surgery
  postoperative analgesia
EMTREE MEDICAL INDEX TERMS
  anesthesia
  atrial fibrillation (complication, drug therapy, prevention)
  coronary artery bypass graft
  cost control
  extubation
  general anesthesia
  health care cost
  heart arrhythmia (complication, drug therapy, prevention)
  heart muscle ischemia (complication, drug therapy, prevention)
  hospitalization
  human
  intensive care unit
  kidney failure (complication, drug therapy, prevention)
  neuromuscular blocking
  perioperative period
  postoperative care
  postoperative complication (complication, prevention, therapy)
  postoperative hemorrhage (complication, drug therapy, prevention)
  postoperative pain (disease management, drug therapy, prevention)
  review
  sepsis (complication, prevention)
  thorax epidural anesthesia
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  aprotinin (11004-21-0, 12407-79-3, 50936-63-5, 52229-70-6, 58591-29-0, 
9050-74-2, 9075-10-9, 9087-70-1)
  bupivacaine (18010-40-7, 2180-92-9, 55750-21-5)
  clonidine (4205-90-7, 4205-91-8, 57066-25-8)
  creatinine (19230-81-0, 60-27-5)
  desmopressin (16679-58-6)
  dexmedetomidine (113775-47-6)
  diclofenac (15307-79-6, 15307-86-5)
  dopamine (51-61-6, 62-31-7)
  dopexamine (86197-47-9, 86484-91-5)
  enflurane (13838-16-9)
  fentanyl (437-38-7)
  hydrocortisone (50-23-7)
  isoflurane (26675-46-7)
  methylprednisolone (6923-42-8, 83-43-2)
  morphine (52-26-6, 57-27-2)
  opiate (53663-61-9, 8002-76-4, 8008-60-4)
  propofol (2078-54-8)
  remifentanil (132539-07-2)
  rocuronium (119302-91-9)
  sotalol (3930-20-9, 80456-07-1, 959-24-0)
  tranexamic acid (1197-18-8, 701-54-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Anesthesiology (24)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005110938
MEDLINE PMID
  15735840 (http://www.ncbi.nlm.nih.gov/pubmed/15735840)
FULL TEXT LINK
  http://dx.doi.org/10.1177/108925320500900102
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 460
TITLE
  Concomitant drug, dietary, and lifestyle issues in patients with atrial 
fibrillation receiving anticoagulation therapy for stroke prophylaxis
AUTHOR NAMES
  Nutescu E.A.
  Helgason C.M.
AUTHOR ADDRESSES
  (Nutescu E.A., enutescu@uic.edu) Antithrombosis Service, College of Pharmacy 
- Pharmacy Practice, University of Illinois at Chicago, 833 South Wood 
Street, Chicago, IL 60612, United States.
(Helgason C.M.)
CORRESPONDENCE ADDRESS
  E.A. Nutescu, Antithrombosis Service, College of Pharmacy - Pharmacy 
Practice, University of Illinois at Chicago, 833 South Wood Street, Chicago, 
IL 60612, United States. Email: enutescu@uic.edu
SOURCE
  Current Treatment Options in Cardiovascular Medicine (2005) 7:3 (241-250). 
Date of Publication: July 2005
ISSN
  1092-8464
BOOK PUBLISHER
  Springer Healthcare
ABSTRACT
  Atrial fibrillation is a common cardiac arrhythmia and the leading risk 
factor for stroke. In those at moderate to high risk of stroke, oral 
anticoagulation therapy with warfarin (a vitamin K antagonist) significantly 
reduces not only the frequency of such events but also their severity and 
the associated risk of death. However, achieving optimal anticoagulation 
with this agent is clinically challenging in view of its complex 
pharmacokinetic and pharmacodynamic profile. In this regard, concomitant 
drug therapy (both prescription and over-the-counter medications, including 
herbal products, vitamins, and various nutritional supplements), along with 
alcohol intake, dietary factors, and changes in lifestyle, can significantly 
affect anticoagulation control and thereby expose patients to the risk of 
bleeding or thromboembolic complications (due to over- and 
underanticoagulation, respectively). Therefore, it is recommended that 
intensified monitoring of anticoagulation be performed at initiation and 
discontinuation of concomitant drug therapy, and in the case of significant 
dietary and lifestyle changes. Moreover, many patients receive inadequate 
education and are unaware of such risks and their implications, highlighting 
the need for better awareness and education on this important aspect of 
anticoagulation therapy. Copyright © 2005 by Current Science Inc.
EMTREE DRUG INDEX TERMS
  amiodarone (adverse drug reaction, drug interaction)
  analgesic agent (drug interaction)
  antiarrhythmic agent (drug interaction)
  antiinflammatory agent (drug interaction)
  carbamazepine (drug interaction)
  chlordiazepoxide (drug interaction)
  cimetidine (drug interaction)
  clofibrate (drug interaction)
  colestyramine (drug interaction)
  cotrimoxazole (drug interaction)
  erythromycin (drug interaction)
  fluconazole (drug interaction)
  griseofulvin (drug interaction)
  herbaceous agent (drug therapy)
  isoniazid (drug interaction)
  metronidazole (drug interaction)
  miconazole (drug interaction)
  nafcillin (drug interaction)
  non prescription drug (drug therapy)
  omeprazole (drug interaction)
  phenylbutazone (drug interaction)
  piroxicam (drug interaction)
  propafenone (drug interaction)
  propranolol (drug interaction)
  rifampicin (drug interaction)
  sucralfate (drug interaction)
  sulfinpyrazone (drug interaction)
  unindexed drug
  vitamin (drug therapy)
  warfarin (adverse drug reaction, drug dose, drug interaction, drug therapy, 
oral drug administration, pharmacokinetics, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
  atrial fibrillation (drug therapy, therapy)
  cerebrovascular accident (complication, drug therapy, etiology, prevention, 
therapy)
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  anticoagulation
  awareness
  bleeding (complication)
  diet
  diet therapy
  disease severity
  drug mechanism
  drug metabolism
  drug sensitivity
  drug use
  food intake
  frequency analysis
  human
  hypothyroidism (side effect)
  lifestyle
  mortality
  patient compliance
  patient education
  patient monitoring
  pharmacodynamics
  prescription
  prophylaxis
  review
  risk assessment
  risk factor
  risk reduction
  thyrotoxicosis (side effect)
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  carbamazepine (298-46-4, 8047-84-5)
  chlordiazepoxide (438-41-5, 58-25-3)
  cimetidine (51481-61-9, 70059-30-2)
  clofibrate (637-07-0)
  colestyramine (11041-12-6, 58391-37-0)
  cotrimoxazole (8064-90-2)
  erythromycin (114-07-8, 70536-18-4)
  fluconazole (86386-73-4)
  griseofulvin (126-07-8)
  isoniazid (54-85-3, 62229-51-0, 65979-32-0)
  metronidazole (39322-38-8, 443-48-1)
  miconazole (22916-47-8)
  nafcillin (147-52-4, 985-16-0)
  omeprazole (73590-58-6, 95510-70-6)
  phenylbutazone (129-18-0, 50-33-9, 8054-70-4)
  piroxicam (36322-90-4)
  propafenone (34183-22-7, 54063-53-5)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
  rifampicin (13292-46-1)
  sucralfate (54182-58-0)
  sulfinpyrazone (57-96-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Hematology (25)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005517671
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 461
TITLE
  Treatment of heart failure with a normal ejection fraction
AUTHOR NAMES
  Bhakta S.
  Dunlap M.E.
AUTHOR ADDRESSES
  (Bhakta S.; Dunlap M.E., mark.dunlap@med.va.gov) Heart Failure Program, 
Louis B. Stokes Veterans Affairs Medical Center, 10701 East Boulevard, 
Cleveland, OH 44106, United States.
CORRESPONDENCE ADDRESS
  S. Bhakta, Heart Failure Program, Louis B. Strokes Veterans Affairs Medical 
Center, 10701 East Boulevard, Cleveland, OH 44106, United States.
SOURCE
  Current Treatment Options in Cardiovascular Medicine (2005) 7:4 (317-325). 
Date of Publication: August 2005
ISSN
  1092-8464
BOOK PUBLISHER
  Springer Healthcare
ABSTRACT
  Treatment of diastolic heart failure is divided into acute and chronic 
management. During acute management, the focus should be treatment of the 
presenting syndrome, including correction of volume overload, treating 
hypertension, alleviating ischemia, and controlling tachyarrhythmias. 
Therefore, acute treatment should include several components: treating 
volume overload with sodium restriction and diuretics; treating ischemic 
heart disease with antiplatelet therapy, anticoagulants, and β blockers; 
treating hypertension aggressively, using multiple agents if necessary; and 
treating atrial tachyarrhythmias such as atrial fibrillation with 
rate-controlling agents, such as β blockers and possibly nondihydropyridine 
calcium channel blockers such as diltiazem and verapamil. Antiarrhythmic 
agents with or without electrical cardioversion may be necessary. Thoroughly 
evaluate and manage extracardiac precipitants such as anemia and renal 
failure. Chronic management should also focus on precipitating factors, for 
which adequate control of hypertension is paramount. Patient education 
regarding dietary and medication compliance and lifestyle changes is also 
important. If ischemic heart disease is present, aggressive anti-ischemic 
therapy is necessary, including revascularization when indicated. Copyright 
© 2005 by Current Science Inc.
EMTREE DRUG INDEX TERMS
  angiotensin receptor antagonist (adverse drug reaction, clinical trial, drug 
combination, drug dose, drug interaction, drug therapy, pharmacoeconomics)
  antiarrhythmic agent (drug therapy)
  anticoagulant agent (drug therapy)
  antithrombocytic agent (drug therapy)
  beta adrenergic receptor blocking agent (adverse drug reaction, clinical 
trial, drug combination, drug comparison, drug dose, drug interaction, drug 
therapy, pharmacoeconomics)
  calcium channel blocking agent (drug combination, drug interaction, drug 
therapy)
  candesartan (adverse drug reaction, drug combination, drug comparison, drug 
dose, drug interaction, drug therapy, pharmacoeconomics)
  carvedilol (adverse drug reaction, drug combination, drug comparison, drug 
dose, drug interaction, drug therapy, pharmacoeconomics)
  diltiazem (drug combination, drug interaction, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical 
trial, drug combination, drug dose, drug interaction, drug therapy, 
pharmacoeconomics)
  diuretic agent (drug therapy)
  esmolol (drug therapy)
  glyceryl trinitrate (drug therapy)
  loop diuretic agent (drug therapy)
  mineralocorticoid receptor (endogenous compound)
  nesiritide (drug therapy)
  placebo
  verapamil (drug combination, drug interaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (diagnosis, disease management, drug therapy, etiology, 
therapy)
EMTREE MEDICAL INDEX TERMS
  anemia
  atrial fibrillation (drug therapy)
  bradycardia (side effect)
  cardioversion
  clinical protocol
  clinical trial
  cost effectiveness analysis
  coughing (side effect)
  diet therapy
  disease control
  drowsiness (side effect)
  drug contraindication
  drug cost
  drug dose regimen
  drug eruption (side effect)
  drug potentiation
  drug tolerability
  fatigue (side effect)
  follow up
  heart ejection fraction
  heart muscle ischemia (drug therapy)
  heart ventricle overload (drug therapy)
  human
  hyperkalemia (side effect)
  hypertension (drug therapy)
  hypotension (side effect)
  kidney failure (side effect)
  lifestyle
  patient education
  prognosis
  review
  risk factor
  tachycardia
CAS REGISTRY NUMBERS
  candesartan (139481-59-7)
  carvedilol (72956-09-3)
  diltiazem (33286-22-5, 42399-41-7)
  esmolol (81147-92-4, 81161-17-3)
  glyceryl trinitrate (55-63-0)
  nesiritide (124584-08-3, 189032-40-4)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005487432
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 462
TITLE
  Managing stroke survivors in the community
AUTHOR NAMES
  Faux S.
AUTHOR ADDRESSES
  (Faux S.) Rehabilitation Medicine, St. Vincent's Hospital, Sydney, NSW, 
Australia.
CORRESPONDENCE ADDRESS
  S. Faux, Rehabilitation Medicine, St. Vincent's Hospital, Sydney, NSW, 
Australia.
SOURCE
  Medicine Today (2005) 6:1 (12-19). Date of Publication: Jan 2005
ISSN
  1443-430X
ABSTRACT
  • To optimise a stroke survivor's quality of life it is important to become 
re-acquainted with the patient and to be aware of all aspects of his or her 
new care infrastructure. • As stroke survivors have a 6 to 10% yearly risk 
of recurrence, secondary prevention is essential. Tight control of blood 
pressure and diabetes, the use of antiplatelet agents (or warfarin in those 
with atrial fibrillation), cholesterol level reduction, smoking cessation, a 
healthy diet and avoiding excessive alcohol intake are all important. • 
Daily exercise is central to maintaining mobility and quality of life in 
stroke survivors. • General deterioration in a stroke survivor is not always 
'the final curtain' once acute causes have been excluded; quite often some 
simple rehabilitation is all that is required. • Stroke rehabilitation helps 
patients maximise their potential for recovery and provides practical ways 
of dealing with ongoing disability. It involves an intense multidisciplinary 
program that can be undertaken in the community or as an inpatient.
EMTREE DRUG INDEX TERMS
  alcohol
  anticonvulsive agent (adverse drug reaction)
  antithrombocytic agent (drug therapy)
  carbamazepine (adverse drug reaction)
  carbamazepine bc
  carbamazepine sandoz
  celepram
  cholesterol (endogenous compound)
  citalopram (drug therapy)
  citalopram
  genrx citalopram
  phenytoin (adverse drug reaction)
  phenytoin injection
  serotonin uptake inhibitor (adverse drug reaction, drug therapy)
  sertraline (drug therapy)
  talohexal
  tricyclic antidepressant agent (adverse drug reaction, drug therapy)
  valproic acid (adverse drug reaction)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (diagnosis, prevention, rehabilitation, therapy)
  community care
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  anamnesis
  article
  atrial fibrillation (drug therapy)
  awareness
  blood pressure regulation
  cholesterol blood level
  cognitive defect (side effect)
  daily life activity
  depression (drug therapy)
  diabetes control
  dietary intake
  dysphagia (side effect)
  exercise
  follow up
  general condition deterioration
  health care facility
  health program
  hospital discharge
  hospital patient
  human
  interpersonal communication
  liver dysfunction (side effect)
  medical examination
  mobilization
  patient care
  physical disability (prevention, rehabilitation, therapy)
  quality of life
  recurrent disease (prevention, rehabilitation, therapy)
  risk assessment
  rural health care
  skill
  smoking cessation
  survival
  treatment planning
  urinary tract disease (side effect)
DRUG TRADE NAMES
  carbamazepine bc
  carbamazepine sandoz
  celepram
  cipramil
  coumadin
  dilantin
  epilim
  genrx citalopram
  marevan
  phenytoin injection
  talam
  talohexal
  tegretol
  teril
  valpro
  zoloft
CAS REGISTRY NUMBERS
  alcohol (64-17-5)
  carbamazepine (298-46-4, 8047-84-5)
  cholesterol (57-88-5)
  citalopram (59729-33-8)
  phenytoin (57-41-0, 630-93-3)
  sertraline (79617-96-2)
  valproic acid (1069-66-5, 99-66-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Rehabilitation and Physical Medicine (19)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005076164
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 463
TITLE
  Biofeedback training in clinical settings
AUTHOR NAMES
  Saito I.
  Saito Y.
AUTHOR ADDRESSES
  (Saito I., yaiku@u01.gate01.com) Medical Service Center, Muroran Institute 
of Technology, 27-1 Mizumoto-cho, Muroran, Hokkaido 050-8585, Japan.
(Saito Y.) Sapporo Hukujuji Clinic, Sapporo 060-0808, Japan.
CORRESPONDENCE ADDRESS
  I. Saito, Medical Service Center, Muroran Institute of Technology, 27-1 
Mizumoto-cho, Muroran, Hokkaido 050-8585, Japan. Email: yaiku@u01.gate01.com
SOURCE
  Biogenic Amines (2004) 18:3-6 (463-476). Date of Publication: 2004
ISSN
  0168-8561
ABSTRACT
  Self-control of body functions by biofeedback training (BFT) has been 
developed and BFT is now employed in treatment over all medical sections as 
a complementary and alternative medicine (CAM). BFT is also useful in 
education and sports training. BFT uses electrical equipment to monitor very 
small signals from the body which are unrecognizable in usual life. Subjects 
are requested to learn physiology and the mechanism of BFT and then they 
make a voluntary effort to accomplish the stepwise task goal of BFT. This 
mini-review includes history and current application of BFT and also 
discusses future usefulness of BFT. © VSP 2004.
EMTREE DRUG INDEX TERMS
  alpha adrenergic receptor blocking agent (endogenous compound)
  anxiolytic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium antagonist (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  diuretic agent (drug therapy)
  neuroleptic agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  psychophysiology
EMTREE MEDICAL INDEX TERMS
  alternative medicine
  anxiety disorder (drug therapy, therapy)
  article
  asthma (therapy)
  atrial fibrillation (therapy)
  attention deficit disorder (therapy)
  autogenic training
  blepharospasm (therapy)
  blood pressure measurement
  body movement
  bruxism (therapy)
  cardiovascular disease (therapy)
  cerebral palsy (therapy)
  cerebrovascular accident (therapy)
  cervical dystonia (therapy)
  chronic pain (therapy)
  depression (therapy)
  dysmenorrhea (therapy)
  education
  electrical equipment
  electromyography
  emphysema (therapy)
  erectile dysfunction (therapy)
  essential hypertension (drug therapy, therapy)
  feces incontinence (therapy)
  foot disease (therapy)
  hand disease (therapy)
  headache (therapy)
  heart ejection fraction
  heart rate
  heart ventricle extrasystole (therapy)
  human
  hyperventilation (therapy)
  hypnosis
  insomnia (therapy)
  intermethod comparison
  irritable colon (therapy)
  learning disorder (therapy)
  low back pain (therapy)
  mental stress
  myalgia (therapy)
  myopia (therapy)
  nystagmus (therapy)
  Parkinson disease (therapy)
  Raynaud phenomenon (therapy)
  relaxation training
  schizophrenia (therapy)
  scoliosis (therapy)
  self control
  sexual dysfunction (therapy)
  signal transduction
  sleep disorder (therapy)
  strabismus (therapy)
  stuttering (therapy)
  temporomandibular joint disorder (therapy)
  tension headache (therapy)
  tinnitus (therapy)
  training
  transcendental meditation
  urine incontinence (therapy)
  vascular resistance
  yoga
EMBASE CLASSIFICATIONS
  Otorhinolaryngology (11)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Urology and Nephrology (28)
  Psychiatry (32)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004372200
FULL TEXT LINK
  http://dx.doi.org/10.1163/1569391041501870
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 464
TITLE
  Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial 
fibrillation: A study based on interviews with 100 patients seeking hospital 
assistance
AUTHOR NAMES
  Hansson A.
  Madsen-Härdig B.
  Olsson S.B.
AUTHOR ADDRESSES
  (Hansson A., Anders.Hansson@kard.lu.se; Madsen-Härdig B., 
Bjarne.Madsen-Hardig@kard.lu.se; Olsson S.B., Bertil.Olsson@kard.lu.se) 
Department of Cardiology, University Hospital, Lund, Sweden.
CORRESPONDENCE ADDRESS
  A. Hansson, Department of Cardiology, University Hospital, Lund, Sweden. 
Email: Anders.Hansson@kard.lu.se
SOURCE
  BMC Cardiovascular Disorders (2004) 4. Date of Publication: 3 Aug 2004
ISSN
  1471-2261
ABSTRACT
  Background: Surprisingly little information on symptoms of paroxysmal atrial 
fibrillation is available in scientific literature. Using questionnaires, we 
have analyzed the symptoms associated with arrhythmia attacks. Methods: One 
hundred randomly-selected patients with idiopathic paroxysmal atrial 
fibrillation filled in a structured questionnaire. Results: Psychic stress 
was the most common factor triggering arrhythmia (54%), followed by physical 
exertion (42%), tiredness (41%) coffee (25%) and infections (22%). 
Thirty-four patients cited alcohol, 26 in the form of red wine, 16 as white 
wine and 26 as spirits. Among these 34, red wine and spirits produced 
significantly more episodes of arrhythmia than white wine (p = 0.01 and 
0.005 respectively). Symptoms during arrhythmia were palpitations while 
exerting (88%), reduced physical ability (87%), palpitations at rest (86%), 
shortage of breath during exertion (70%) and anxiety (59%). Significant 
differences between sexes were noted regarding swollen legs (women 21%, men 
6%, p = 0.027), nausea (women 36%, men 13%, p = 0.012) and anxiety (females 
79%, males 51%, p = 0.014). Conclusion: Psychic stress was the commonest 
triggering factor in hospitalized patients with paroxysmal atrial 
fibrillation. Red wine and spirits were more proarrhythmic than white wine. 
Symptoms in women in connection with attacks of arrhythmia vary somewhat 
from those in men. © 2004 Hansson et al; licensee BioMed Central Ltd.
EMTREE DRUG INDEX TERMS
  amiodarone (endogenous compound)
  atenolol (drug therapy)
  bisoprolol (drug therapy)
  digoxin (drug therapy)
  disopyramide (drug therapy)
  flecainide (drug therapy)
  metoprolol (drug therapy)
  propranolol (drug therapy)
  sotalol (drug therapy)
  verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (diagnosis, drug therapy, etiology)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  alcoholic beverage
  anxiety
  article
  coffee
  controlled study
  dyspnea
  exercise
  fatigue
  female
  heart palpitation
  hospital care
  hospital patient
  human
  infection
  interview
  leg edema
  major clinical study
  male
  mental stress
  nausea
  patient selection
  physical capacity
  priority journal
  questionnaire
  randomization
  red wine
  risk factor
  sex difference
  statistical analysis
  symptom
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  atenolol (29122-68-7)
  bisoprolol (66722-44-9)
  digoxin (20830-75-5, 57285-89-9)
  disopyramide (3737-09-5)
  flecainide (54143-55-4)
  metoprolol (37350-58-6)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
  sotalol (3930-20-9, 80456-07-1, 959-24-0)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005059545
FULL TEXT LINK
  http://dx.doi.org/10.1186/1471-2261-4-13
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 465
TITLE
  Cardiac rehabilitation of older patients
AUTHOR NAMES
  West R.
AUTHOR ADDRESSES
  (West R.) Univ. of Wales College of Medicine, Cardiff, Wales, United 
Kingdom.
(West R.) Wales Heart Research Institute, Univ. of Wales College of 
Medicine, Heath Park, Cardiff CF14 4XN, United Kingdom.
CORRESPONDENCE ADDRESS
  R. West, Wales Heart Research Institute, Univ. of Wales College of Medicine, 
Heath Park, Cardiff CF14 4XN, United Kingdom.
SOURCE
  Reviews in Clinical Gerontology (2003) 13:3 (241-255). Date of Publication: 
Aug 2004
ISSN
  0959-2598
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular disease (rehabilitation, therapy)
  heart rehabilitation
EMTREE MEDICAL INDEX TERMS
  acute heart infarction
  adult
  age
  aged
  anxiety
  atrial fibrillation
  clinical trial
  coronary artery bypass surgery
  depression
  dietary intake
  exercise
  geriatric care
  health education
  health promotion
  heart failure
  human
  leisure
  mobilization
  outcomes research
  patient counseling
  patient education
  patient referral
  physiotherapy
  psychological aspect
  quality of life
  review
  risk factor
  secondary prevention
  social support
  transluminal coronary angioplasty
  treatment planning
  unstable angina pectoris
  vocational rehabilitation
  work capacity
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2004316190
FULL TEXT LINK
  http://dx.doi.org/10.1017/S0959259804001066
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 466
TITLE
  Older man with exertional dyspnea and leg swelling
AUTHOR NAMES
  Quick G.
  Walker J.S.
  Kerns C.
AUTHOR ADDRESSES
  (Quick G.) Emergency Medicine, .
(Walker J.S.; Kerns C.) Oklahoma Heart Hospital, .
(Quick G.; Walker J.S.; Kerns C.) Oklahoma Heart Hospital, Oklahoma City, 
OK, United States.
CORRESPONDENCE ADDRESS
  G. Quick, Oklahoma Heart Hospital, Oklahoma City, OK, United States.
SOURCE
  Consultant (2004) 44:9 (1283-1285). Date of Publication: Aug 2004
ISSN
  0010-7069
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  dyspnea (diagnosis)
  leg swelling (diagnosis)
EMTREE MEDICAL INDEX TERMS
  aged
  anamnesis
  article
  atrial fibrillation
  case report
  clinical feature
  computer assisted tomography
  coughing
  deep vein thrombosis
  dizziness
  echocardiography
  faintness
  fever
  hemoptysis
  human
  lung embolism (diagnosis)
  male
  primary medical care
  priority journal
  thorax pain
EMBASE CLASSIFICATIONS
  Chest Diseases, Thoracic Surgery and Tuberculosis (15)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2005087739
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 467
TITLE
  The secondary prevention of ischemic stroke
AUTHOR NAMES
  Tabereaux P.B.
  Brass L.M.
  Bravata D.M.
AUTHOR ADDRESSES
  (Tabereaux P.B.; Bravata D.M.) Department of Internal Medicine, Yale 
University School of Medicine, 333 Cedar St., New Haven, CT 06520-8088, 
United States.
(Brass L.M.) Department of Neurology, Yale University School of Medicine, 
333 Cedar St., New Haven, CT 06520-8088, United States.
CORRESPONDENCE ADDRESS
  D.M. Bravata, Yale University School of Medicine, 333 Cedar St., New Haven, 
CT 06520-8088, United States.
SOURCE
  Journal of Clinical Outcomes Management (2004) 11:6 (371-382). Date of 
Publication: Jun 2004
ISSN
  1079-6533
ABSTRACT
  • Objective: To provide an overview of the evidence and clinical approach to 
secondary stroke prevention for patients following an ischemic stroke or 
transient ischemic attack (TIA). • Methods: Overview of the literature. • 
Results: Patients with acute ischemic strokes and TIAs are at increased risk 
for secondary vascular events, including recurrent stroke. Nonmodifiable 
risk factors should be evaluated to identify patients who are at high risk 
of recurrent stroke. Risk factor modification includes diagnosing and 
treating hypertension, hyperlipidemia, and diabetes. Patients with 
high-grade symptomatic carotid artery stenosis should be evaluated for 
carotid endarterectomy Stroke patients with atrial fibrillation should 
receive warfarin unless a contraindication is present. All other stroke 
patients should receive an antiplatelet agent unless contraindicated. 
Recommendations for lifestyle changes, including stopping smoking, avoiding 
heavy alcohol use, reducing overweight, and increasing exercise, should be 
made during the acute stroke period. • Conclusion: Post-stroke care should 
involve an assessment of both nonmodifiable and modifiable risk factors in 
all patients. Risk factor modifications should be initiated early after the 
first event.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug therapy)
  alpha tocopherol (drug therapy)
  angiotensin receptor antagonist (clinical trial, drug combination, drug 
comparison, drug therapy)
  anticoagulant agent (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug therapy, oral drug administration)
  antidiabetic agent (drug therapy)
  antihypertensive agent (clinical trial, drug combination, drug comparison, 
drug therapy)
  antithrombocytic agent (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug therapy, oral drug administration)
  ascorbic acid (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy, intravenous drug 
administration)
  beta carotene (drug therapy)
  clopidogrel (clinical trial, drug combination, drug comparison, drug 
therapy)
  dipeptidyl carboxypeptidase inhibitor (clinical trial, drug combination, 
drug comparison, drug therapy)
  dipyridamole (drug combination, drug comparison, drug therapy)
  diuretic agent (drug combination, drug therapy)
  estrogen (clinical trial, drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (clinical trial, drug 
therapy)
  perindopril (clinical trial, drug combination, drug therapy)
  thrombin inhibitor (clinical trial, drug comparison, drug therapy, oral drug 
administration)
  ticlopidine (adverse drug reaction, clinical trial, drug comparison, drug 
therapy)
  warfarin (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, oral drug administration)
  ximelagatran (clinical trial, drug comparison, drug therapy, oral drug 
administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
  alcohol abstinence
  atrial fibrillation (drug therapy)
  behavior modification
  bleeding (side effect)
  carotid artery obstruction (surgery)
  carotid endarterectomy
  clinical trial
  diabetes mellitus (diagnosis, drug therapy)
  diarrhea (side effect)
  diet therapy
  drug eruption (side effect)
  exercise
  high risk patient
  human
  hyperlipidemia (diagnosis, drug therapy)
  hypertension (diagnosis, drug therapy)
  laboratory diagnosis
  lifestyle
  medical literature
  neutropenia (side effect)
  recurrent disease (prevention)
  review
  risk assessment
  risk factor
  secondary prevention
  smoking cessation
  transient ischemic attack (prevention)
  weight reduction
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
  beta carotene (7235-40-7)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  dipyridamole (58-32-2)
  perindopril (82834-16-0)
  ticlopidine (53885-35-1, 55142-85-3)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
  ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004409261
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 468
TITLE
  Prevention and treatment of erectile dysfunction using lifestyle changes and 
dietary supplements: What works and what is worthless, part I
AUTHOR NAMES
  Moyad M.A.
  Barada J.H.
  Lue T.F.
  Mulhall J.P.
  Goldstein I.
  Fawzy A.
AUTHOR ADDRESSES
  (Moyad M.A., moyad@umich.edu) Department of Urology, Univ. of Michigan 
Medical Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330, 
United States.
(Barada J.H.) Center for Male Sexual Health, Albany Medical College, 43 New 
Scotland Avenue, Albany, NY 12208, United States.
(Lue T.F.) Univ. of California, San Francisco, 505 Parnassus Avenue, San 
Francisco, CA 94122, United States.
(Mulhall J.P.) Sexual Medicine Program, Weill Medical College, Cornell 
University, 445 East 69th Street, New York, NY 10021, United States.
(Goldstein I.) Institute for Sexual Medicine, Center for Sexual Medicine, 
Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, 
United States.
(Fawzy A.) Department of Urology, Louisiana State University, School of 
Medicine, 1532 Tulane Avenue, New Orleans, LA 70112, United States.
CORRESPONDENCE ADDRESS
  M.A. Moyad, Department of Urology, Univ. of Michigan Medical Center, 1500 
East Medical Center Drive, Ann Arbor, MI 48109-0330, United States. Email: 
moyad@umich.edu
SOURCE
  Urologic Clinics of North America (2004) 31:2 (249-257). Date of 
Publication: May 2004
ISSN
  0094-0143
BOOK PUBLISHER
  W.B. Saunders, Independence Square West, Philadelphia, United States.
EMTREE DRUG INDEX TERMS
  16 dehydroepiandrosterone
  ascorbic acid (drug therapy, pharmacology)
  Echinacea extract (drug interaction)
  Ephedra extract (drug interaction)
  epiandrosterone
  garlic extract (drug interaction)
  Ginkgo biloba extract (drug interaction)
  ginseng extract (drug interaction)
  hydroxymethylglutaryl coenzyme A reductase inhibitor
  Hypericum perforatum extract (drug interaction)
  kava extract (drug interaction)
  placebo
  sildenafil (clinical trial, drug dose, drug therapy, oral drug 
administration, pharmacology)
  tadalafil (drug therapy, oral drug administration, pharmacology)
  unclassified drug
  valerian (drug interaction)
  vardenafil (drug therapy, oral drug administration, pharmacology)
  yohimbine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diet supplementation
  erectile dysfunction (disease management, prevention, therapy)
  lifestyle
EMTREE MEDICAL INDEX TERMS
  acupuncture
  alternative medicine
  atrial fibrillation (drug therapy, prevention)
  cardiovascular system
  clinical trial
  dose response
  electroacupuncture
  electrostimulation
  health
  health care cost
  heat
  human
  laser
  practice guideline
  prescription
  priority journal
  quality control
  quality of life
  review
  sexual function
  urology
  vitamin supplementation
DRUG TRADE NAMES
  viagra
CAS REGISTRY NUMBERS
  ascorbic acid (134-03-2, 15421-15-5, 50-81-7)
  epiandrosterone (481-29-8)
  sildenafil (139755-83-2)
  tadalafil (171596-29-5)
  valerian (8057-49-6)
  vardenafil (224785-90-4, 224785-91-5, 224789-15-5)
  yohimbine (146-48-5, 65-19-0)
EMBASE CLASSIFICATIONS
  Urology and Nephrology (28)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2004198191
MEDLINE PMID
  15123405 (http://www.ncbi.nlm.nih.gov/pubmed/15123405)
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ucl.2004.01.006
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 469
TITLE
  Anticoagulation in the Elderly
AUTHOR NAMES
  Dowd M.B.
AUTHOR ADDRESSES
  (Dowd M.B., mdowd@wpahs.org) A-K. Med. Ctr.-West P.A. Hlth. Syst., Pharmacy 
Department, 1301 Carlisle Street, Natrona Heights, PA 15065, United States.
CORRESPONDENCE ADDRESS
  M.B. Dowd, A-K. Med. Ctr.-West P.A. Hlth. Syst., Pharmacy Department, 1301 
Carlisle Street, Natrona Heights, PA 15065, United States. Email: 
mdowd@wpahs.org
SOURCE
  Journal of Pharmacy Practice (2004) 17:2 (94-102). Date of Publication: Apr 
2004
ISSN
  0897-1900
ABSTRACT
  Oral anticoagulation has been shown to provide great benefit in preventing 
and treating thromboembolic disorders. The challenges of oral 
anticoagulation management in the elderly involve balancing the risks of 
bleeding versus the benefits of a life-saving treatment. Due to the complex 
nature of warfarin, therapy must be individualized with frequent monitoring, 
reeducation, and adjustments based on concurrent illness and drug therapy. 
This review focuses on the use of warfarin, including indications, dosing 
recommendations, drug and dietary interactions, and reversal of 
anticoagulation. Methods to determine bleeding risks in this population and 
barriers that interfere with the prescribing of warfarin are discussed. 
Strategies to improve patient outcome and reduce adverse events are provided 
to assist clinicians in their decision-making skills. The potential 
advantages of anticoagulation clinics are summarized with regards to 
coordinating the care and minimizing the risks of anticoagulant therapy. The 
role of new-generation anticoagulants is also discussed as to their place in 
therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (adverse drug reaction, drug dose, drug interaction, 
drug therapy, oral drug administration)
  warfarin (adverse drug reaction, drug dose, drug interaction, drug therapy, 
oral drug administration)
EMTREE DRUG INDEX TERMS
  azithromycin (drug interaction)
  barbituric acid derivative (drug interaction)
  capecitabine (drug interaction)
  carbamazepine (drug interaction)
  clofibrate (drug interaction)
  corticosteroid (drug interaction)
  dicloxacillin (drug interaction)
  fenofibrate (drug interaction)
  fluorouracil (drug interaction)
  gefitinib (drug interaction)
  gemfibrozil (drug interaction)
  isoniazid (drug interaction)
  mevinolin (drug interaction)
  nafcillin (drug interaction)
  nonsteroid antiinflammatory agent (drug interaction)
  paracetamol (drug interaction)
  phenytoin (drug interaction)
  propylthiouracil (drug interaction)
  rifampicin (drug interaction)
  salicylic acid derivative (drug interaction)
  sucralfate (drug interaction)
  tamsulosin (drug interaction)
  tetracycline derivative (drug interaction)
  thyroid hormone (drug interaction)
  tramadol (drug interaction)
  ximelagatran (drug interaction, drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aging
  anticoagulation
EMTREE MEDICAL INDEX TERMS
  aged
  atrial fibrillation (drug therapy)
  bleeding (side effect)
  dose response
  drug indication
  drug monitoring
  human
  outcomes research
  prescription
  review
  risk benefit analysis
  risk factor
  venous thromboembolism (drug therapy, prevention)
CAS REGISTRY NUMBERS
  azithromycin (83905-01-5)
  capecitabine (154361-50-9)
  carbamazepine (298-46-4, 8047-84-5)
  clofibrate (637-07-0)
  dicloxacillin (13412-64-1, 3116-76-5, 343-55-5)
  fenofibrate (49562-28-9)
  fluorouracil (51-21-8)
  gefitinib (184475-35-2, 184475-55-6, 184475-56-7)
  gemfibrozil (25812-30-0)
  isoniazid (54-85-3, 62229-51-0, 65979-32-0)
  mevinolin (75330-75-5)
  nafcillin (147-52-4, 985-16-0)
  paracetamol (103-90-2)
  phenytoin (57-41-0, 630-93-3)
  propylthiouracil (51-52-5)
  rifampicin (13292-46-1)
  sucralfate (54182-58-0)
  tamsulosin (106133-20-4, 106138-88-9, 106463-17-6, 80223-99-0, 94666-07-6)
  tramadol (27203-92-5, 36282-47-0)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
  ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004129696
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 470
TITLE
  Improving secondary prevention of coronary heart disease: Using the new GP 
contract to drive change
AUTHOR ADDRESSES
  SOURCE
  British Journal of Cardiology (2004) 11:2 (106-111). Date of Publication: 
Mar 2004
ISSN
  0969-6113
ABSTRACT
  The evidence for implementing the NSF is overwhelming. Ranging from the 
simple to the innovative, there are some excellent ways of achieving this, 
bolstering practice income and enhancing the care and experience of 
patients. • For more information about the work of the CHDC, visit 
www.modern.nhs.uk/chd where you can find contact details for your local CHDC 
programme.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  general practice
  ischemic heart disease (drug therapy, prevention)
  secondary prevention
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation (drug therapy)
  cerebrovascular accident (prevention)
  diet restriction
  doctor patient relation
  exercise
  heart death (prevention)
  heart infarction (drug therapy, prevention)
  heart left ventricle failure (drug therapy)
  human
  lifestyle
  medical fee
  national health service
  patient care
  patient counseling
  primary medical care
  risk reduction
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004179153
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 471
TITLE
  Complementary and alternative medicine in cardiovascular disease: A review 
of biologically based approaches
AUTHOR NAMES
  Miller K.L.
  Liebowitz R.S.
  Newby L.K.
AUTHOR ADDRESSES
  (Miller K.L.; Liebowitz R.S.) Div. of General Internal Medicine, Department 
of Medicine, Duke University Medical Center, Durham, NC, United States.
(Newby L.K., newby001@mc.duke.edu) Division of Cardiology, Department of 
Medicine, Duke University Medical Center, Durham, NC, United States.
(Newby L.K., newby001@mc.duke.edu) Duke Clinical Research Institute, PO Box 
17969, Durham, NC 27715-7969, United States.
CORRESPONDENCE ADDRESS
  L.K. Newby, Duke Clinical Research Institute, PO Box 17969, Durham, NC 
27715-7969, United States. Email: newby001@mc.duke.edu
SOURCE
  American Heart Journal (2004) 147:3 (401-411). Date of Publication: March 
2004
ISSN
  0002-8703
BOOK PUBLISHER
  Mosby Inc., 11830 Westline Industrial Drive, St. Louis, United States.
ABSTRACT
  Background The use of complementary and alternative medical (CAM) practices 
in the United States is growing rapidly. In this manuscript, we review some 
of the most commonly used biologically based approaches, including herbs, 
supplements, and other pharmacological therapies, that are encountered in 
caring for patients with cardiovascular disease, focusing on potential 
effects, adverse effects, and treatment interactions. Methods Between 
November 2002 and April 2003, we searched Medline and the National Center 
for Complementary and Alternative Medicine (NCCAM) web site and its various 
references and several complementary medicine text books. The key words used 
were: "cardiovascular diseases," "coronary disease," "heart failure, 
congestive," "complementary and alternative medicine," "complementary 
therapies," "drug interactions," and "plants, medicinal." A keyword search 
of each individual supplement identified was also performed. Additionally, 
we relied on expert opinion in the field. Results Potentially serious 
adverse effects and interactions with conventional cardiovascular therapies 
exist for many herbs and supplements. There are currently scarce mechanistic 
data and very limited data on the effect of CAM therapies on clinical 
outcomes. Conclusions Randomized clinical trials with adequate power to 
detect effects of CAM therapies on clinical outcomes and safety are needed. 
Until these data are available, clinicians must be aware of the increasing 
use of CAM approaches by their patients and the potential for interactions 
with conventional therapies and should focus on treatment with proven, 
evidence-based strategies.
EMTREE DRUG INDEX TERMS
  alpha tocopherol (drug interaction, drug therapy, pharmacology)
  amiodarone (adverse drug reaction, drug interaction, drug therapy)
  antiemetic agent (drug interaction, drug therapy, pharmacology)
  antiinfective agent (drug interaction, drug therapy, pharmacology)
  antithrombocytic agent (drug interaction, drug therapy)
  cardiovascular agent (drug interaction, drug therapy)
  carnitine (drug interaction, drug therapy, pharmacology)
  Crataegus extract (clinical trial, drug interaction, drug therapy, 
pharmacology)
  cyclosporin (clinical trial, drug interaction, drug therapy, pharmacology)
  digoxin (clinical trial, drug interaction, pharmacology)
  diltiazem (drug interaction, pharmacology)
  garlic extract (drug interaction, drug therapy, pharmacology)
  ginger extract (drug interaction, drug therapy, pharmacology)
  ginseng extract (drug interaction, drug therapy, pharmacology)
  guggulsterone (drug interaction, drug therapy, pharmacology)
  herbaceous agent (drug interaction, drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (adverse drug reaction, 
drug interaction, drug therapy, pharmacology)
  kava extract (adverse drug reaction, drug therapy, pharmacology)
  ketoconazole (drug interaction)
  macrolide (drug interaction)
  policosanol (drug interaction, drug therapy, pharmacology)
  propranolol derivative (drug interaction)
  proteinase inhibitor (drug interaction)
  spasmolytic agent (drug interaction, drug therapy, pharmacology)
  Tanacetum parthenium extract (drug interaction, drug therapy, pharmacology)
  ubidecarenone (adverse drug reaction, clinical trial, drug dose, drug 
interaction, drug therapy, oral drug administration, pharmacology)
  unindexed drug
  vasoactive agent (drug interaction, drug therapy, pharmacology)
  verapamil (drug interaction)
  warfarin (drug dose, drug interaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alternative medicine
  cardiovascular disease (drug therapy)
  congestive heart failure (drug therapy)
  coronary artery disease (drug therapy)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  Alzheimer disease (drug therapy)
  angina pectoris (drug therapy)
  anxiety disorder (drug therapy)
  atherosclerosis (drug therapy)
  atrial fibrillation (drug therapy)
  bleeding
  blood clotting
  cardiomyopathy (side effect)
  Chinese medicine
  clinical trial
  coronary artery dilatation
  depression
  diet supplementation
  exercise
  gastrointestinal symptom (side effect)
  heart muscle
  herbal medicine
  homeopathy
  human
  hypertension (drug therapy)
  hypocholesterolemia (drug therapy)
  immunosuppressive treatment
  insomnia (drug therapy)
  leukocytosis (drug therapy)
  liver disease (side effect)
  liver toxicity (side effect)
  lung fibrosis (side effect)
  medicinal plant
  myopathy
  photosensitivity (side effect)
  priority journal
  review
  thrombocyte function
  thyroid disease (side effect)
  vitamin supplementation
DRUG TRADE NAMES
  ws 1442
CAS REGISTRY NUMBERS
  Crataegus extract (82374-45-6)
  alpha tocopherol (1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  carnitine (461-06-3, 541-15-1, 56-99-5)
  cyclosporin (79217-60-0)
  digoxin (20830-75-5, 57285-89-9)
  diltiazem (33286-22-5, 42399-41-7)
  guggulsterone (39025-23-5, 39025-24-6, 95975-55-6)
  ketoconazole (65277-42-1)
  policosanol (142583-61-7)
  proteinase inhibitor (37205-61-1)
  ubidecarenone (303-98-0)
  verapamil (152-11-4, 52-53-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004290656
MEDLINE PMID
  14999187 (http://www.ncbi.nlm.nih.gov/pubmed/14999187)
FULL TEXT LINK
  http://dx.doi.org/10.1016/j.ahj.2003.10.021
COPYRIGHT
  Copyright 2012 Elsevier B.V., All rights reserved.

RECORD 472
TITLE
  Current status of cardiac resynchronization therapy
AUTHOR NAMES
  Breithardt O.A.
  Stellbrink C.
AUTHOR ADDRESSES
  (Breithardt O.A., olebreithardt@gmx.de; Stellbrink C.) Department of 
Cardiology, University Hospital Aachen, D-52057 Aachen, Germany.
(Breithardt O.A., olebreithardt@gmx.de) Medizinische Klinik I, University 
Klinikum Aachen, Pauwelsstrasse 30, D-52057 Aachen, Germany.
CORRESPONDENCE ADDRESS
  O.A. Breithardt, Medizinische Klinik I, University Klinikum Aachen, 
Pauwelsstrasse 30, D-52057 Aachen, Germany. Email: olebreithardt@gmx.de
SOURCE
  Current Opinion in Anaesthesiology (2004) 17:1 (75-83). Date of Publication: 
Feb 2004
ISSN
  0952-7907
ABSTRACT
  Purpose of review: Cardiac resynchronization therapy with biventricular 
pacing has rapidly emerged as an indispensable treatment option in patients 
with moderate-to-advanced heart failure and left bundle branch block. New 
findings on the pathophysiology of cardiac resynchronization therapy and its 
clinical effects are reviewed. Recent findings: Several randomized trials 
have evaluated the effects of cardiac resynchronization therapy on cardiac 
haemodynamics and clinical parameters in selected heart failure patients 
with left bundle branch block. The effects of cardiac resynchronization 
therapy on mechanical synchrony have been evaluated by different imaging 
modalities, such as echocardiography and radionuclide angiography. Cardiac 
resynchronization therapy leads to improved haemodynamics at a diminished 
energy cost, and improves functional mitral regurgitation. This haemodynamic 
improvement is associated with a significantly better quality of life, 
improved exercise capacity, and less frequent hospitalization. Recent 
preliminary data suggest a positive effect on cardiac mortality. However, 
approximately a third of implanted patients do not benefit from cardiac 
resynchronization therapy, and therefore additional criteria for the 
identification of mechanical dyssynchrony are needed to identify those 
patients who will respond before implantation. Summary Many randomized 
trials have confirmed the benefits of cardiac resynchronization therapy in 
selected heart failure patients. The successful resynchronization of the 
ventricular activation-contraction sequence is the major determinant of 
acute haemodynamic and long-term clinical improvement. The diagnostic 
sensitivity and specificity of the non-invasive identification of mechanical 
dyssynchrony may be improved by echocardiography, but further research is 
needed to identify the optimal strategy for patient identification.
EMTREE DRUG INDEX TERMS
  angiotensin receptor antagonist (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  digoxin (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  diuretic agent (drug therapy)
  spironolactone (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiac resynchronization therapy
  electrostimulation therapy
  heart failure (drug therapy, therapy)
  heart ventricle pacing
EMTREE MEDICAL INDEX TERMS
  artery dissection (complication)
  artery perforation (complication)
  artificial heart pacemaker
  atrial fibrillation (complication)
  cardiomyopathy (therapy)
  clinical trial
  defibrillator
  devices
  echocardiography
  electrocardiogram
  exercise
  heart hemodynamics
  heart infarction (therapy)
  heart left bundle branch block
  heart left ventricle contraction
  heart ventricle contraction
  hemodynamic monitoring
  hospitalization
  human
  implantation
  meta analysis
  mitral valve regurgitation
  mortality
  pathophysiology
  peroperative complication (complication)
  phrenic nerve
  priority journal
  quality of life
  review
  scintiangiography
  surgical risk
  survival rate
CAS REGISTRY NUMBERS
  digoxin (20830-75-5, 57285-89-9)
  spironolactone (52-01-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Anesthesiology (24)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Drug Literature Index (37)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004093623
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 473
TITLE
  Cardiac pacing for bradycardia support: Evidence-based approach to pacemaker 
selection and programming
AUTHOR NAMES
  Galtes I.
  Lamas G.A.
AUTHOR ADDRESSES
  (Lamas G.A., most95@aol.com) Mount Sinai Medical Center, Butler Building, 
4300 Alton Road, Miami Beach, FL 33140, United States.
(Galtes I.)
CORRESPONDENCE ADDRESS
  G.A. Lamas, Mount Sinai Medical Center, Butler Building, 4300 Alton Road, 
Miami Beach, FL 33140, United States. Email: most95@aol.com
SOURCE
  Current Treatment Options in Cardiovascular Medicine (2004) 6:5 (385-395). 
Date of Publication: October 2004
ISSN
  1092-8464
BOOK PUBLISHER
  Springer Healthcare
ABSTRACT
  The vast majority of pacemakers implanted in the United States for the 
treatment of symptomatic bradycardia are dual-chamber systems with a complex 
array of functions, such as rate responsiveness, dynamic atrioventricular 
delay, and automatic mode switching. Basic hemodynamic studies have 
convincingly demonstrated the superiority of maintaining atrioventricular 
synchrony. However, clinical trials have failed to demonstrate the 
impressive results expected based on physiologic data. The most recent 
randomized clinical trials have demonstrated that dual-chamber devices, when 
compared with single-chamber ventricutar pacing, do not prevent mortality or 
stroke, and lead to an unexpectedly small reduction in heart failure 
hospitalizations. Although improvements in quality of life have not been 
consistently found when comparing ventricular-based versus atrial-based 
pacing, a reduction in the incidence of newly diagnosed atrial fibrillation 
in dual chamber-paced patients has been reported by most trials. 
Dual-chamber pacing has been reported to reduce pacemaker syndrome in US 
trials. The addition of rate modulation, in spite of attempting to replicate 
the normal response to exercise, has not shown a consistently positive 
impact on quality of life or treadmill time. The use of pacemakers for the 
treatment of vasovagal syncope is controversial. Adding dual-chamber sensing 
ability to current implanted defibrillators considerably reduces the number 
of inappropriate shocks but may increase mortality if not programmed to 
minimize ventricular stimulation. Copyright © 2004 by Current Science Inc.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  artificial heart pacemaker
  bradycardia (surgery)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (surgery)
  atrioventricular conduction
  automation
  cerebrovascular accident (complication, prevention)
  clinical trial
  defibrillation
  equipment design
  evidence based medicine
  exercise
  faintness (prevention, surgery)
  heart failure (surgery)
  heart hemodynamics
  heart rate
  heart ventricle function
  hospitalization
  human
  intermethod comparison
  medical decision making
  meta analysis
  mortality
  practice guideline
  quality of life
  review
  shock (complication, prevention)
  surgical technique
  systematic review
  time
  treadmill
  treatment outcome
  United States
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004438483
COPYRIGHT
  Copyright 2014 Elsevier B.V., All rights reserved.

RECORD 474
TITLE
  Coeliac disease presenting with tetany in an 87 year old patient
AUTHOR NAMES
  Jani B.
  Sivakumar R.
  Ghosh P.
  Khan S.A.
AUTHOR ADDRESSES
  (Jani B.; Sivakumar R.; Ghosh P.; Khan S.A., shahidak@aol.com) Department of 
Elderly Care, Lister Hospital, Corey's Mill Lane, Stevenage, Herts SG1 4AB, 
United Kingdom.
CORRESPONDENCE ADDRESS
  S.A. Khan, Department of Elderly Care, Lister Hospital, Corey's Mill Lane, 
Stevenage, Herts SG1 4AB, United Kingdom. Email: shahidak@aol.com
SOURCE
  CME Journal Geriatric Medicine (2003) 5:3 (127-128). Date of Publication: 
2003
ISSN
  1475-1453
ABSTRACT
  Coeliac disease is a common condition which may affect 1 in 200 individuals. 
The majority of patients are diagnosed in adulthood, many presenting with 
atypical symptoms. Metabolic bone disease can be a feature of coeliac 
disease but is generally under recognised. Clinical manifestations can be at 
any age though first presentation at extreme old age is rare. We describe an 
elderly patient who presented with severe hypocalcaemia secondary to coeliac 
disease.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug combination, drug therapy)
  calcium (drug combination, drug therapy, intravenous drug administration)
  digoxin (drug combination, drug therapy)
  folic acid (drug combination, drug therapy)
  furosemide (drug combination, drug therapy)
  magnesium (drug combination, drug therapy, intravenous drug administration)
  multivitamin (drug combination, drug therapy)
  vitamin D (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  celiac disease (drug therapy)
  tetany (drug therapy)
EMTREE MEDICAL INDEX TERMS
  aged
  anamnesis
  article
  atrial fibrillation (drug therapy)
  calcium blood level
  case report
  cataract (drug therapy)
  coping behavior
  disease severity
  falling
  female
  geriatric patient
  gluten free diet
  human
  hypocalcemia (drug therapy)
  laboratory test
  malaise
  muscle cramp (drug therapy)
  patient referral
  psoriasis (drug therapy)
  skin bruising
  treatment outcome
  vitamin supplementation
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  calcium (7440-70-2)
  digoxin (20830-75-5, 57285-89-9)
  folic acid (59-30-3, 6484-89-5)
  furosemide (54-31-9)
  magnesium (7439-95-4)
EMBASE CLASSIFICATIONS
  Gerontology and Geriatrics (20)
  Clinical and Experimental Biochemistry (29)
  Endocrinology (3)
  Drug Literature Index (37)
  Gastroenterology (48)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004050271
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 475
TITLE
  Cardiac Arrhythmia in a Professional Football Player: Was Ephedrine to 
Blame?
AUTHOR NAMES
  Krome C.N.
  Tucker A.M.
AUTHOR ADDRESSES
  (Krome C.N., ckrome@adelphia.net) Precision Orthopedic Specialties, .
(Tucker A.M.) Primary Care Sports Medicine, University of Maryland, 
Timonium, MD, United States.
(Tucker A.M.) Department of Family Medicine, University of Maryland, 
Baltimore, MD, United States.
(Krome C.N., ckrome@adelphia.net) 228 Manchester Dr, Aurora, OH 44202, 
United States.
CORRESPONDENCE ADDRESS
  C.N. Krome, 228 Manchester Dr, Aurora, OH 44202, United States. Email: 
ckrome@adelphia.net
SOURCE
  Physician and Sportsmedicine (2003) 31:12 (21-25+29). Date of Publication: 
Dec 2003
ISSN
  0091-3847
ABSTRACT
  Sympathomimetic symptoms in an otherwise healthy patient, such as in this 
case of a 27-year-old professional football player, may suggest an adverse 
reaction to a dietary supplement containing ephedra. Awareness of supplement 
use patterns and possible side effects in active patients may help 
physicians intervene before catastrophic events occur.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  ephedrine
EMTREE DRUG INDEX TERMS
  alkaloid
  Ephedra extract
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  football
  heart arrhythmia (diagnosis)
EMTREE MEDICAL INDEX TERMS
  adult
  article
  artificial heart pacemaker
  athlete
  atrial fibrillation
  cardiomyopathy
  cardioversion
  case report
  consultation
  diet supplementation
  electrocardiography monitoring
  fatality
  heart hypertrophy
  heart muscle necrosis
  human
  male
  nephrolithiasis
  seizure
  sudden death
  weight reduction
CAS REGISTRY NUMBERS
  ephedrine (299-42-3, 50-98-6)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2003506176
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 476
TITLE
  Preventing and treating stroke
AUTHOR NAMES
  Zahn D.
AUTHOR ADDRESSES
  (Zahn D.) B.C. Drug and Poison Info. Centre, .
CORRESPONDENCE ADDRESS
  B.C. Drug and Poison Info. Centre, .
SOURCE
  Canadian Pharmaceutical Journal (2003/2004) 136:10 (32). Date of 
Publication: Dec 2003
ISSN
  0828-6914
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction)
  alteplase (drug therapy)
  antithrombocytic agent
  asasantine
  clopidogrel
  dipyridamole (adverse drug reaction)
  heparin (adverse drug reaction)
  herbaceous agent
  plasminogen activator (drug therapy)
  ticlopidine
  warfarin (adverse drug reaction)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (drug therapy, prevention, therapy)
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  atrial fibrillation
  bleeding (side effect)
  blood clot lysis
  diabetes mellitus
  diet therapy
  disease severity
  drug choice
  drug dose regimen
  drug utilization
  emergency treatment
  exercise
  gastrointestinal symptom (side effect)
  human
  hypercholesterolemia
  hypertension
  patient care
  pharmacist
  practice guideline
  prescription
  risk factor
  short survey
  smoking cessation
  thrombocyte aggregation inhibition
  weight reduction
DRUG TRADE NAMES
  activase
  asasantine
  aspirin
  coumadin
  plavix
  ticlid
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alteplase (105857-23-6)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  dipyridamole (58-32-2)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  plasminogen activator (9039-53-6)
  ticlopidine (53885-35-1, 55142-85-3)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Hematology (25)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2004102332
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 477
TITLE
  Biventricular pacing in heart failure: Current status and future horizons
AUTHOR NAMES
  Kaprielian R.
  Lefroy D.C.
AUTHOR ADDRESSES
  (Kaprielian R.) Department of Cardiology, West Middlesex Hospital, DuCane 
Road, London W12 0HS, United Kingdom.
(Lefroy D.C.) Department of Cardiology, Hammersmith Hospital, DuCane Road, 
London W12 0HS, United Kingdom.
CORRESPONDENCE ADDRESS
  R. Kaprielian, Department of Cardiology, Hammersmith Hospitals NHS Trust, 
DuCane Road, London W12 0HS, United Kingdom.
SOURCE
  Continuing Medical Education - Cardiology (2003) 2:3 (177-184). Date of 
Publication: 2003
ISSN
  1463-0486
ABSTRACT
  Biventricular pacing is a rapidly developing technique that offers hope for 
a significant sub-group of patients with severe heart failure refractory to 
medical treatment and intra-ventricular conduction delay (LBBB). This 
technique is thought to improve cardiac function by reducing 
intra-ventricular dysynchrony caused by intra-ventricular conduction block. 
Technology is now available for low-risk implantation of atrio-biventricular 
pacing systems with a high level of success in appropriately experienced 
hands. The short-term haemodynamic effects of such pacing are favourable and 
published randomised clinical trials have shown benefit with improvement in 
symptoms and objective measures of exercise capacity. Many questions still 
remain to be answered. Appropriate selection of patients who will respond to 
this treatment, the localisation of ideal left ventricular pacing sites, and 
the development of techniques for optimisation of atrioventricular and 
interventricular pacing delays are current areas under investigation. Most 
importantly, the effect of biventricular pacing on overall mortality is 
unknown. Longer-term mortality studies are underway to investigate whether 
multi-site pacing alters the natural history of heart failure. Furthermore, 
combination devices that provide atrio-BV pacing and an ICD facility are 
available. These devices promise to prevent heart failure progression as 
well as sudden cardiac death through ventricular arrhythmia. The results of 
these studies may have profound implications on the management of heart 
failure in the future.
EMTREE DRUG INDEX TERMS
  inotropic agent (clinical trial, drug therapy, pharmacology)
  noradrenalin (clinical trial, drug therapy, pharmacology)
  placebo
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (disease management, drug therapy, surgery, therapy)
  heart ventricle pacing
EMTREE MEDICAL INDEX TERMS
  artificial heart pacemaker
  atrial fibrillation (surgery, therapy)
  clinical practice
  clinical trial
  congestive cardiomyopathy (disease management, surgery, therapy)
  coronary artery bypass surgery
  coronary vein
  defibrillation
  disease course
  disease severity
  drug effect
  equipment design
  exercise
  heart assist device
  heart atrium pacing
  heart death (complication, prevention, therapy)
  heart function
  heart hemodynamics
  heart left bundle branch block (therapy)
  heart ventricle arrhythmia (complication, prevention, therapy)
  heart ventricle conduction
  human
  medical technology
  mortality
  pacemaker failure (complication)
  patient selection
  quality of life
  review
  surgical approach
  symptom
  theoretical study
  treatment failure
  treatment indication
  vein injury (complication)
  vein perforation (complication)
  vein thrombosis (complication)
CAS REGISTRY NUMBERS
  noradrenalin (1407-84-7, 51-41-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004058334
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 478
TITLE
  Atrial flutter in a college football player: Return to play or not?
AUTHOR NAMES
  Wen D.Y.
  Flaker G.
  Sharp R.L.
  Smith P.A.
AUTHOR ADDRESSES
  (Smith P.A.) Columbia Orthopedic Group, Columbia, MO, United States.
(Wen D.Y., wend@health.missouri.edu) Dept. of Fam. and Community Medicine, 
University of Missouri-Columbia, M245 Medical Sciences Bldg., Columbia, MO 
65212, United States.
(Flaker G.; Sharp R.L.)
CORRESPONDENCE ADDRESS
  D.Y. Wen, Dept. of Fam. and Community Medicine, University of 
Missouri-Columbia, M245 Medical Sciences Bldg., Columbia, MO 65212, United 
States. Email: wend@health.missouri.edu
SOURCE
  Physician and Sportsmedicine (2003) 31:10 (21-24+35). Date of Publication: 1 
Oct 2003
ISSN
  0091-3847
ABSTRACT
  Exercise isn't thought to precipitate atrial fibrillation, yet 
return-to-activity decisions can be complex. The case of a 19-year-old 
college football player who had the condition demonstrates how new 
treatments have made certain Bethesda conference recommendations outdated.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
  esmolol (drug combination, drug therapy, intravenous drug administration)
  ibutilide fumarate (drug therapy)
  warfarin (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  football
  heart atrium flutter (drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  article
  atrial fibrillation
  cardioversion
  case report
  catheter ablation
  clinical feature
  college student
  decision making
  disease course
  exercise
  human
  male
  practice guideline
  sports medicine
  treatment outcome
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  esmolol (81147-92-4, 81161-17-3)
  ibutilide fumarate (130350-52-6)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2003406014
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 479
TITLE
  Ximelagatran: A new era in oral anticoagulation
AUTHOR NAMES
  McCall K.L.
  MacLaughlin E.J.
AUTHOR ADDRESSES
  (McCall K.L., kenneth@ama.ttuhsc.edu; MacLaughlin E.J.) School of Pharmacy, 
Texas Tech. Univ. Hlth. Sci. Center, Amarillo, TX, United States.
(McCall K.L., kenneth@ama.ttuhsc.edu) School of Pharmacy, Texas Tech. Univ. 
Hlth. Sci. Center, 1300 Coulter Dr., Amarillo, TX 79106-1712, United States.
CORRESPONDENCE ADDRESS
  K.L. McCall, School of Pharmacy, Texas Tech. Univ. Hlth. Sci. Center, 1300 
Coulter Dr., Amarillo, TX 79106-1712, United States. Email: 
kenneth@ama.ttuhsc.edu
SOURCE
  Journal of Pharmacy Technology (2003) 19:4 (222-228). Date of Publication: 
Jul 2003
ISSN
  8755-1225
ABSTRACT
  Objective: To review the pharmacology, pharmacokinetics, and clinical trials 
of the oral direct thrombin inhibitor ximelagatran. Data Sources: All 
primary articles involving ximelagatran or its active form, melagatran, and 
indexed on MEDLINE or International Pharmaceutical Abstracts databases 
(1966-December 2002) were evaluated. Recent ximelagatran and melagatran 
abstracts were also obtained online from the American Society of Hematology 
at www.hematology.org/meeting/abstracts.cfm (2001 and 2002). Data Synthesis: 
Ximelagatran is an orally bioavailable prodrug of melagatran that directly 
blocks unbound thrombin and fibrin-bound thrombin. Ximelagatran displays 
predictable pharmacodynamic and pharmacokinetic properties with a linear 
dose-response relationship and low interpatient variability. These 
parameters allow fixed dosing of ximelagatran without routine coagulation 
monitoring. Ximelagatran has yet to be approved by the FDA; however, several 
major clinical trials have been completed. These clinical trials have 
revealed that an easier-to-manage ximelagatran regimen is at least as 
effective and has a similar safety profile as conventional therapy for 
prevention of venous thromboembolism (VTE). The results of studies with 
ximelagatran for treatment of VTE and prevention of thrombosis associated 
with atrial fibrillation are promising, but need further investigation. 
Conclusions: Ximelagatran possesses several advantages over warfarin 
including fixed dosing and the lack of coagulation monitoring, the absence 
of known diet or drug interactions, and a faster onset of action. 
Ximelagatran appears to be at least as effective as warfarin for prevention 
of VTE. Further research is needed with ximelagatran in the treatment of VTE 
and atrial fibrillation.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (adverse drug reaction, clinical trial, drug comparison, 
drug dose, drug therapy, oral drug administration, pharmacokinetics, 
pharmacology)
  thrombin inhibitor (adverse drug reaction, clinical trial, drug comparison, 
drug dose, drug therapy, oral drug administration, pharmacokinetics, 
pharmacology)
  ximelagatran (adverse drug reaction, clinical trial, drug comparison, drug 
dose, drug therapy, oral drug administration, pharmacokinetics, 
pharmacology)
EMTREE DRUG INDEX TERMS
  dalteparin (drug comparison, drug therapy, subcutaneous drug administration)
  enoxaparin (adverse drug reaction, drug comparison, drug therapy, 
subcutaneous drug administration)
  melagatran (pharmacokinetics)
  warfarin (drug comparison, drug therapy, oral drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulation
EMTREE MEDICAL INDEX TERMS
  bleeding (side effect)
  cerebrovascular accident (prevention)
  clinical trial
  dose response
  drug efficacy
  food and drug administration
  human
  multicenter study
  pharmacodynamics
  review
  thromboembolism (drug therapy, prevention)
  thrombosis (drug therapy, prevention)
  thrombosis prevention
CAS REGISTRY NUMBERS
  enoxaparin (9041-08-1)
  melagatran (159776-70-2)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
  ximelagatran (192939-46-1, 260790-58-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2003295432
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 480
TITLE
  7-oxo-DHEA and Raynaud's phenomenon
AUTHOR NAMES
  Ihler G.
  Chami-Stemmann H.
AUTHOR ADDRESSES
  (Ihler G., gmihler@tamu.edu; Chami-Stemmann H.) Dept. of Med. Biochem./Med. 
Genetics, Texas A and M College of Medicine, College Station, TX, United 
States.
(Ihler G., gmihler@tamu.edu) Dept. of Med. Biochem./Med. Genetics, Texas A 
and M College of Medicine, College Station, TX 77843-1114, United States.
(Chami-Stemmann H.) Department of Rheumatology, C.H.U Nice, Rte St. Antoine 
La Ginestiere, Nice, France.
CORRESPONDENCE ADDRESS
  G. Ihler, Dept. of Med. Biochem./Med. Genetics, Texas A and M College of 
Medicine, College Station, TX 77843-1114, United States. Email: 
gmihler@tamu.edu
SOURCE
  Medical Hypotheses (2003) 60:3 (391-397). Date of Publication: 1 Mar 2003
ISSN
  0306-9877
BOOK PUBLISHER
  Churchill Livingstone, 1-3 Baxter's Place, Leith Walk, Edinburgh, United 
Kingdom.
ABSTRACT
  Patients with Raynaud's phenomenon have abnormal digital vasoconstriction in 
response to cold. The pathogenesis remains unknown but may involve a local 
neurovascular defect leading to vasoconstriction. Diagnosis of primary 
Raynaud's phenomenon is based on typical symptomatology coupled with normal 
physical examination, normal laboratory studies and lack of observable 
pathology by nail fold capillaroscopy. Secondary Raynaud's phenomenon is 
known to occur associated with several connective tissue diseases, vascular 
injury due to repeated vibrational trauma, and other causes which produce 
demonstrable vascular and microcirculatory damage. Treatment of Raynaud's 
symptoms is conservative and aimed at prevention of attacks. Patients are 
advised to remain warm and, if possible, to live in warm climates. We 
suggest that an ergogenic (thermogenic) steroid, 7-oxo-DHEA 
(3-acetoxyandrost-5-ene-7,17-dione), which is available without prescription 
as the trademarked 7-keto DHEA, may be very helpful in prevention of primary 
Raynaud's attacks by increasing the basal metabolic rate and inhibiting 
vasospasm. © 2002 Elsevier Science Ltd. All rights reserved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  3beta acetoxyandrost 5 ene 7,17 dione (adverse drug reaction, clinical 
trial, drug dose, drug therapy, oral drug administration, pharmacokinetics, 
pharmacology)
  alpha adrenergic receptor blocking agent (adverse drug reaction, drug 
therapy)
  calcium channel blocking agent (adverse drug reaction, drug therapy)
  nifedipine (adverse drug reaction, drug therapy)
  steroid (adverse drug reaction, clinical trial, drug dose, drug therapy, 
oral drug administration, pharmacokinetics, pharmacology)
EMTREE DRUG INDEX TERMS
  adenosine triphosphate
  antidiabetic agent (pharmacology)
  beta adrenergic receptor stimulating agent (drug therapy)
  dihydropyridine derivative (adverse drug reaction, drug therapy)
  glucose
  levothyroxine (drug therapy)
  liothyronine (clinical trial, drug dose, drug therapy)
  metformin (pharmacology)
  nitrate (drug therapy)
  placebo
  prostaglandin (drug therapy)
  proton transporting adenosine triphosphate synthase
  reduced nicotinamide adenine dinucleotide
  serotonin antagonist (drug therapy)
  thromboxane synthase
  thyroid hormone (clinical trial, drug dose, drug therapy)
  unclassified drug
  uncoupling protein 1
  uncoupling protein 2
  uncoupling protein 3
  vasodilator agent (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Raynaud phenomenon (diagnosis, drug therapy, etiology, prevention, surgery, 
therapy)
EMTREE MEDICAL INDEX TERMS
  acupuncture
  animal model
  article
  atrial fibrillation (complication)
  clinical article
  clinical trial
  controlled clinical trial
  controlled study
  drug mechanism
  drug safety
  edema (side effect)
  faintness (side effect)
  feedback system
  flushing
  gluconeogenesis
  headache (side effect)
  heart palpitation (side effect)
  Horner syndrome (complication)
  human
  hypothyroidism (drug therapy)
  microcirculation
  muscle weakness (side effect)
  nonhuman
  patient education
  peripheral vascular disease (diagnosis, drug therapy, etiology, prevention, 
surgery, therapy)
  pleura effusion (complication)
  pneumothorax (complication)
  priority journal
  rat
  relaxation training
  side effect (side effect)
  steroid therapy
  stress
  sympathectomy
  symptomatology
  tachycardia (side effect)
  thermogenesis
  vasoconstriction
  vasospasm (etiology)
CAS REGISTRY NUMBERS
  adenosine triphosphate (15237-44-2, 56-65-5, 987-65-5)
  glucose (50-99-7, 84778-64-3)
  levothyroxine (51-48-9)
  liothyronine (6138-47-2, 6893-02-3)
  metformin (1115-70-4, 657-24-9)
  nifedipine (21829-25-4)
  nitrate (14797-55-8)
  proton transporting adenosine triphosphate synthase (37205-63-3)
  reduced nicotinamide adenine dinucleotide (58-68-4)
  thromboxane synthase (60832-04-4, 61276-89-9)
EMBASE CLASSIFICATIONS
  Internal Medicine (6)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2003087207
MEDLINE PMID
  12581618 (http://www.ncbi.nlm.nih.gov/pubmed/12581618)
FULL TEXT LINK
  http://dx.doi.org/10.1016/S0306-9877(02)00409-7
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 481
TITLE
  Sports and lone atrial fibrillation
AUTHOR NAMES
  Mont L.
  Sambola A.
  Brugada J.
  Vacca M.
  Marrugat J.
  Elosua R.
  Paré C.
  Azqueta M.
  Sanz G.
AUTHOR ADDRESSES
  (Mont L.; Sambola A.; Brugada J.; Vacca M.; Marrugat J.; Elosua R.; Paré C.; 
Azqueta M.; Sanz G.) Hospital Clínic, University of Barcelona, Cardiovasc. 
Epidemiology Res. Unit, Barcelona, Spain.
CORRESPONDENCE ADDRESS
  L. Mont, Hospital Clínic, University of Barcelona, Cardiovasc. Epidemiology 
Res. Unit, Barcelona, Spain.
SOURCE
  Cardiology Review (2003) 20:1 (15-18). Date of Publication: Jan 2003
ISSN
  1092-6607
ABSTRACT
  We noticed that several patients with lone atrial fibrillation practiced 
sports on a regular basis and sought to determine whether long-term sports 
practice predisposed these patients to this arrhythmia. After evaluating the 
records of 51 male patients with lone atrial fibrillation, we found 32 men 
(63%) had been practicing sports on a regular basis. The percentage of 
athletic men in the same age group in the general population is only 15%. 
These data suggest that long-term sports practice may play a role in the 
development of lone atrial fibrillation.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  acenocoumarol
  anticoagulant agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (diagnosis, therapy)
  sport
EMTREE MEDICAL INDEX TERMS
  adult
  anticoagulant therapy
  article
  athlete
  bradycardia (diagnosis)
  brain embolism (complication)
  cardioversion
  controlled study
  disease predisposition
  echocardiography
  electrophysiology
  exercise
  heart atrium flutter (diagnosis, therapy)
  heart ventricle hypertrophy (complication, diagnosis)
  human
  major clinical study
  male
  sex ratio
  Spain
  vagus tone
CAS REGISTRY NUMBERS
  acenocoumarol (152-72-7)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2003053934
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 482
TITLE
  Older woman with worsening weakness, dyspnea on exertion, and syncope
AUTHOR NAMES
  Rubin R.N.
AUTHOR ADDRESSES
  (Rubin R.N.) Temple University School of Medicine, Department of Medicine, 
Temple University Hospital, Philadelphia, PA, United States.
CORRESPONDENCE ADDRESS
  R.N. Rubin, Temple University School of Medicine, Department of Medicine, 
Temple University Hospital, Philadelphia, PA, United States.
SOURCE
  Consultant (2003) 43:1 (105-106). Date of Publication: Jan 2003
ISSN
  0010-7069
EMTREE DRUG INDEX TERMS
  amiodarone (drug interaction, drug therapy)
  cotrimoxazole (drug interaction, drug therapy)
  metoprolol (drug therapy)
  nifedipine (drug therapy)
  warfarin (drug interaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  dyspnea
  faintness
  muscle weakness
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation (drug therapy)
  bradycardia
  case report
  drug effect
  electrocardiogram
  fatigue
  female
  human
  hypertension (drug therapy)
  patient monitoring
  priority journal
  telemetry
  urinary tract infection (drug therapy)
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  cotrimoxazole (8064-90-2)
  metoprolol (37350-58-6)
  nifedipine (21829-25-4)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2003068191
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 483
TITLE
  Follow-up of patients with suspected transient ischaemic attack who 
underwent fast-track carotid doppler scanning but did not proceed to carotid 
endarterectomy
AUTHOR NAMES
  Demetriades A.K.
  Cameron A.
  Osman I.
  Phillips P.
AUTHOR ADDRESSES
  (Demetriades A.K.; Cameron A.; Osman I.; Phillips P., 
peter.phillips@ntlworld.com) Ipswich Hospital NHS Trust, Heath Road, 
Ipswich, Suffolk IP4 2XA, United Kingdom.
CORRESPONDENCE ADDRESS
  P. Phillips, Ipswich Hospital NHS Trust, Heath Road, Ipswich, Suffolk IP4 
2XA, United Kingdom. Email: peter.phillips@ntlworld.com
SOURCE
  Journal of Clinical Excellence (2002) 4:2 (245-250). Date of Publication: 
2002
ISSN
  1465-9883
ABSTRACT
  Objectives: To determine the clinical outcomes and effectiveness of medical 
interventions following suspected transient ischaemic attack (TIA) or minor 
stroke. Design: Questionnaires were sent to the general practitioners (GPs) 
of the 217 patients who suffered from TIA or minor stroke in 1997 and who 
were found not to have surgically treatable carotid stenosis after carotid 
duplex scan. Setting: GPs' referrals to the fast-track carotid doppler 
service at the Ipswich Hospital. Main outcome measures: Accuracy of original 
diagnosis, effectiveness of secondary prevention, incidence of further 
vascular events and mortality over a four-year follow-up period. Results: Of 
the total 217 questionnaires sent out, 149 (69%) were returned fully 
completed. Mortality data were obtained on a total of 178 (82%) patients. Of 
the 149 patients studied, 13 were found to have non-cerebrovascular causes 
for their presenting symptoms. Fifty-two were prescribed antiplatelet 
medication, 38 were given advice on exercise, 13 out of 26 smokers quit, 49 
out of 73 patients with systolic pressure over 150 mm Hg were controlled 
within that target, 25 out of 41 patients with a total fasting cholesterol 
over 5 mmol/L were controlled within that limit. Twelve out of 14 patients 
in atrial fibrillation were anticoagulated. Fifty-two patients suffered 
further cerebrovascular, coronary or peripheral vascular events during the 
four-year follow-up. Thirty-four (19%) of 178 patients for whom mortality 
data were available died during the four-year follow-up. This compares with 
a mortality rate of 1.35% in the population of East Suffolk matched for age 
and followed up for the same four-year period. Eighteen deaths (53%) were 
due to vascular causes. Conclusions: Patients presenting with suspected TIA 
or minor stroke have greatly increased morbidity and mortality rates 
particularly due to vascular causes. Various service models in primary and 
secondary care need to be evaluated in order to determine the most effective 
system for minimising the burden of disease in this group of patients.
EMTREE DRUG INDEX TERMS
  anticoagulant agent (drug therapy)
  antithrombocytic agent (drug therapy)
  cholesterol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  carotid endarterectomy
  Doppler echography
  transient ischemic attack (diagnosis, drug therapy, epidemiology, surgery, 
therapy)
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation (drug therapy)
  cerebrovascular accident (diagnosis, drug therapy, epidemiology, surgery, 
therapy)
  cerebrovascular disease (drug therapy)
  clinical trial
  coronary artery disease (drug therapy)
  diagnostic accuracy
  diet restriction
  exercise
  follow up
  general practitioner
  hospital service
  human
  incidence
  major clinical study
  morbidity
  mortality
  patient referral
  peripheral vascular disease (drug therapy)
  prescription
  primary medical care
  questionnaire
  secondary prevention
  smoking cessation
  statistical model
  stenosis
  systolic blood pressure
  United Kingdom
CAS REGISTRY NUMBERS
  cholesterol (57-88-5)
EMBASE CLASSIFICATIONS
  Radiology (14)
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2003406464
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 484
TITLE
  Chronic heart failure: 10 Questions physicians often ask
AUTHOR NAMES
  Tang W.H.W.
  Francis G.S.
AUTHOR ADDRESSES
  (Tang W.H.W.; Francis G.S.) Cleveland Clinic Foundation, Cleveland, OH, 
United States.
CORRESPONDENCE ADDRESS
  W.H.W. Tang, Cleveland Clinic Foundation, Cleveland, OH, United States.
SOURCE
  Consultant (2002) 42:6 (678-686). Date of Publication: 2002
ISSN
  0010-7069
ABSTRACT
  The key test in the initial evaluation is the standard echocardiogram. 
Elevated plasma levels of B-type natriuretic peptide strongly suggest 
underlying cardiac dysfunction in patients with symptoms of heart failure 
(HF). Consider angiotensinconverting enzyme (ACE) inhibitors and B-blockers 
for all patients with HF, unless contraindicated. High doses of ACE 
inhibitors have not been shown to be more effective than lower ones; the 
goal is to reach target dosages comparable to those used in clinical trials. 
Angiotensin II receptor blockers do not reduce mortality more effectively 
than standard doses of ACE inhibitors, which remain first-line agents. Oral 
coagulation is not routinely recommended for patients with HF, although 
high-risk patients (such as those with atrial fibrillation) may benefit. 
Patient education, self-monitoring, and compliance with medication and 
dietary regimens are vital components of treatment.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  aldosterone antagonist (adverse drug reaction, clinical trial, drug dose, 
drug therapy)
  angiotensin receptor antagonist (clinical trial, drug dose, drug therapy)
  beta adrenergic receptor blocking agent (clinical trial, drug comparison, 
drug dose, drug therapy)
  brain natriuretic peptide (endogenous compound)
  dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical 
trial, drug comparison, drug dose, drug therapy)
  spironolactone (adverse drug reaction, clinical trial, drug dose, drug 
therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (clinical trial, drug comparison, drug therapy)
  amlodipine (clinical trial, drug dose, drug therapy)
  anticoagulant agent (clinical trial, drug comparison, drug therapy)
  antithrombocytic agent (clinical trial, drug comparison, drug therapy)
  bisoprolol (clinical trial, drug dose, drug therapy)
  candesartan (clinical trial, drug dose, drug therapy)
  captopril (adverse drug reaction, clinical trial, drug dose, drug therapy)
  carvedilol (clinical trial, drug comparison, drug dose, drug therapy)
  clopidogrel (clinical trial, drug comparison, drug therapy)
  digoxin (clinical trial, drug dose, drug therapy)
  enalapril (adverse drug reaction, clinical trial, drug dose, drug therapy)
  glyceryl trinitrate (drug comparison, drug therapy, pharmacoeconomics)
  lisinopril (adverse drug reaction, clinical trial, drug dose, drug therapy)
  losartan (clinical trial, drug comparison, drug dose, drug therapy)
  metoprolol (clinical trial, drug comparison, drug dose, drug therapy)
  milrinone (drug comparison, drug therapy, pharmacoeconomics)
  nesiritide (clinical trial, drug administration, drug comparison, drug 
therapy, pharmacoeconomics)
  nitroprusside sodium (drug comparison, drug therapy, pharmacoeconomics)
  nonsteroid antiinflammatory agent (adverse drug reaction)
  placebo
  ramipril (adverse drug reaction, clinical trial, drug dose, drug therapy)
  unindexed drug
  valsartan (clinical trial, drug comparison, drug dose, drug therapy)
  warfarin (clinical trial, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart arrhythmia (diagnosis, disease management, drug therapy, therapy)
  heart failure (diagnosis, disease management, drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  angioneurotic edema (side effect)
  cardiovascular disease (diagnosis, disease management, drug therapy, 
epidemiology, prevention, rehabilitation, therapy)
  cardioversion
  chronic disease
  clinical trial
  controlled study
  coughing (side effect)
  defibrillation
  diagnostic test
  diet restriction
  disease severity
  drug cost
  drug induced disease (side effect)
  drug megadose
  electrocardiogram
  exercise
  heart pacing
  heart rehabilitation
  heart ventricle fibrillation (diagnosis, disease management, drug therapy, 
therapy)
  human
  major clinical study
  multicenter study
  nephrotoxicity (side effect)
  patient education
  practice guideline
  priority journal
  randomized controlled trial
  review
  treatment indication
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amlodipine (88150-42-9)
  bisoprolol (66722-44-9)
  brain natriuretic peptide (114471-18-0)
  candesartan (139481-59-7)
  captopril (62571-86-2)
  carvedilol (72956-09-3)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  digoxin (20830-75-5, 57285-89-9)
  enalapril (75847-73-3)
  glyceryl trinitrate (55-63-0)
  lisinopril (76547-98-3, 83915-83-7)
  losartan (114798-26-4)
  metoprolol (37350-58-6)
  milrinone (78415-72-2)
  nesiritide (124584-08-3, 189032-40-4)
  nitroprusside sodium (14402-89-2, 15078-28-1)
  ramipril (87333-19-5)
  spironolactone (52-01-7)
  valsartan (137862-53-4)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2002191296
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 485
TITLE
  Management of stroke in the new millennium
AUTHOR NAMES
  Ho R.T.K.
AUTHOR ADDRESSES
  (Ho R.T.K.) The Brain Centre, Canossa Hospital, No. 1 Old Peak Road, Hong 
Kong, Hong Kong.
CORRESPONDENCE ADDRESS
  R.T.K. Ho, The Brain Centre, Canossa Hospital, No. 1 Old Peak Road, Hong 
Kong, Hong Kong.
SOURCE
  Hong Kong Practitioner (2002) 24:2 (83-91). Date of Publication: 2002
ISSN
  1027-3948
ABSTRACT
  Stroke (brain attack) is the number 3 killer worldwide. It is the leading 
cause of disability in adults. It is estimated that up to one half of all 
strokes can be prevented through stroke risk detection and risk management. 
Therefore in spite of new and exciting treatments for acute stroke, 
prevention remains the key objective.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  antidiabetic agent (drug therapy)
  antihypertensive agent (drug therapy)
  antilipemic agent (drug therapy)
  clopidogrel (drug therapy)
  dipyridamole (drug therapy)
  hydroxymethylglutaryl coenzyme A reductase inhibitor (drug therapy)
  lipid (endogenous compound)
  ticlopidine (drug therapy)
  tissue plasminogen activator (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (diagnosis, drug therapy, prevention, surgery, 
therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  age
  alcohol consumption
  article
  atrial fibrillation (drug therapy)
  brain hemorrhage (surgery)
  brain surgery
  carotid artery obstruction (drug therapy, surgery, therapy)
  carotid endarterectomy
  cause of death
  cerebrovascular accident (drug therapy, prevention, therapy)
  computer assisted tomography
  diabetes mellitus (drug therapy)
  diet therapy
  exercise
  family history
  female
  gender
  human
  hyperlipidemia (drug therapy)
  hypertension (drug therapy)
  male
  nuclear magnetic resonance imaging
  obesity
  patient education
  physical activity
  physical disability
  race
  risk assessment
  risk factor
  risk management
  smoking cessation
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  dipyridamole (58-32-2)
  lipid (66455-18-3)
  ticlopidine (53885-35-1, 55142-85-3)
  tissue plasminogen activator (105913-11-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2002176943
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 486
TITLE
  The National Service Framework for Coronary Heart Disease
AUTHOR NAMES
  Hobbs F.D.R.
AUTHOR ADDRESSES
  (Hobbs F.D.R.) Medical School, University of Birmingham, Edgbaston, 
Birmingham B15 2TT, United Kingdom.
CORRESPONDENCE ADDRESS
  F.D.R. Hobbs, Medical School, University of Birmingham, Edgbaston, 
Birmingham B15 2TT, United Kingdom. Email: F.D.R.Hobbs@bham.ac.uk
SOURCE
  British Journal of Cardiology (2002) 9:SUPPL. 3 (S29-S32). Date of 
Publication: 2002
ISSN
  0969-6113
ABSTRACT
  Cardiovascular disease is the most important cause of illness in Britain. 
The focus of the National Service Framework for Coronary Heart Disease (NSF 
for CHD) is appropriate since the burden of CHD is high in the UK. 
Interventions for primary and secondary prevention include advice on 
reducing modifiable risk factors, smoking, maintaining blood pressure < 
140/85 mmHg and using statins and dietary advice to lower serum cholesterol. 
Identification of those at greatest risk will require practice-based 
registers. Audits will be needed to ensure that the stipulated interventions 
are offered to those on the disease registers. The biggest implication for 
primary prevention will be selection of patients at increased risk of CHD. 
Implementation of the NSF will increase GPs' workload.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug dose, drug therapy)
  antilipemic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  cholesterol (endogenous compound)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  glucose (endogenous compound)
  low density lipoprotein (endogenous compound)
  nicotine (drug therapy)
  nitrate (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  ischemic heart disease (disease management, drug therapy, prevention)
  national health service
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (drug therapy)
  blood pressure monitoring
  cardiovascular disease (disease management, drug therapy, prevention)
  cardiovascular risk
  cholesterol blood level
  cost effectiveness analysis
  diabetes mellitus (drug therapy)
  diet therapy
  dose response
  general practitioner
  heart infarction (drug therapy)
  heart left ventricle failure (drug therapy)
  high risk population
  human
  nicotine replacement therapy
  patient selection
  primary health care
  register
  review
  risk factor
  secondary prevention
  smoking
  United Kingdom
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  cholesterol (57-88-5)
  glucose (50-99-7, 84778-64-3)
  nicotine (54-11-5)
  nitrate (14797-55-8)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2002150788
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 487
TITLE
  Non-toxic multinondular goitres
AUTHOR NAMES
  Kalk W.J.
  Vangu M.D.T.H.
AUTHOR ADDRESSES
  (Kalk W.J.; Vangu M.D.T.H.) Division of Endocrinol./Metabolism, University 
of Witwatersrand, Johannesburg, South Africa.
CORRESPONDENCE ADDRESS
  W.J. Kalk, Division of Endocrinol./Metabolism, University of Witwatersrand, 
Johannesburg, South Africa.
SOURCE
  South African Journal of Obstetrics and Gynaecology (2002) 8:1 (10-13). Date 
of Publication: Apr 2002
ISSN
  0038-2469
ABSTRACT
  Thyroid nodules, are common, especially in women, and most are benign (∼7% 
are malignant). Recent research into the pathogenesis of simple, nodular 
goitres has shown a strong genetic predisposition which interacts with 
environmental factors such as dietary goitrogens, smoking, and iodine 
deficiency. Most benign nodules in multinodular goitres seem to result from 
genetic mutations which result in monoclonal overgrowth of thyrocytes with a 
growth advantage but a range of function, resulting in cold, warm or hot 
nodules seen on isotopic thyroid scans. In most mutations thyrocyte growth 
appears to be autonomous and independent of thyrotrophin stimulation. 
Management options for multinodular goitres include regular clinical and 
functional assessment only (for small euthyroid goitres), surgery and 
radio-iodine. Suppression of thyrotrophin with thyroxine therapy is often 
ineffective, must be lifelong, and is associated with serious potential 
hazards (osteoporosis and an increased risk of atrial fibrillation). Total 
thyroidectomy eliminates the high risk of recurrent goitre (up to 60% at 10 
years), but requires a practiced surgeon. Radio-iodine therapy (2.2 GBq, 60 
mCi, single or fractionated dose) is effective in safely reducing goitre 
size (by ∼50%) and relieving obstructive symptoms. Fine-needle aspiration 
cytological evaluation is essential for all apparently single nodules and 
for dominant nodules.
EMTREE DRUG INDEX TERMS
  iodine (endogenous compound)
  iodine 131 (adverse drug reaction, drug comparison, drug dose, drug therapy)
  radioactive iodine (adverse drug reaction, drug comparison, drug dose, drug 
therapy)
  recombinant thyrotropin (drug combination, drug dose, drug therapy, 
pharmacology)
  thyrotropin (endogenous compound)
  thyroxine (adverse drug reaction, drug comparison, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  nodular goiter (diagnosis, drug therapy, etiology, radiotherapy, surgery)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (side effect)
  benign tumor
  clinical examination
  dietary intake
  dose response
  drug efficacy
  drug safety
  environmental factor
  fine needle aspiration biopsy
  gene mutation
  genetic predisposition
  heart left ventricle function
  heart left ventricle hypertrophy (side effect)
  human
  hypothyroidism (side effect)
  iodine deficiency
  osteoporosis (side effect)
  pathogenesis
  radioiodination
  recurrence risk
  review
  smoking
  symptomatology
  thyroid function test
  thyroid scintiscanning
  thyroidectomy
  tumor volume
CAS REGISTRY NUMBERS
  iodine 131 (10043-66-0, 15124-39-7)
  iodine (7553-56-2)
  recombinant thyrotropin (194100-83-9)
  thyrotropin (9002-71-5)
  thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
  General Pathology and Pathological Anatomy (5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2002304812
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 488
TITLE
  Non-toxic multinodular goitres
AUTHOR NAMES
  Kalk W.J.
  Vangu M.D.T.H.
AUTHOR ADDRESSES
  (Kalk W.J.) Div. of Endocrinology and Metabolism, University of the 
Witwatersrand, Johannesburg, South Africa.
(Vangu M.D.T.H.) Department of Nuclear Medicine, University of the 
Witwatersrand, Johannesburg, South Africa.
CORRESPONDENCE ADDRESS
  W.J. Kalk, Div. of Endocrinology and Metabolism, University of the 
Witwatersrand, Johannesburg, South Africa.
SOURCE
  Journal of Endocrinology, Metabolism and Diabetes of South Africa (2002) 7:1 
(10-13). Date of Publication: Apr 2002
ISSN
  1608-9677
ABSTRACT
  Thyroid nodules are common, especially in women, and most are benign (∼7% 
are malignant). Recent research into the pathogenesis of simple, nodular 
goitres has shown a strong generic predisposition which interacts with 
environmental factors such as dietary goitrogerts, smoking, and iodine 
deficiency. Most benign nodules in multinodular goitres seem to result from 
generic mutations which result in monoclonal overgrowth of thyrocytes with a 
growth advantage but a range of function, resulting in cold, warm or hot 
nodules seen on isotopic thyroid scans. In most mutations thyrocyte growth 
appears to be autonomous and independent of thyrotrophin stimulation. 
Management options for multinodular goitres include regular clinical and 
functional assessment only (for small euthyroid goitres), surgery and 
radio-iodine. Suppression of thyrotrophin with thyroxine therapy is often 
ineffective, must be lifelong, and is associated with serious potential 
hazards (osteoporosis and an increased risk of atrial fibrillation). Total 
thyroidectomy eliminates the high risk of recurrent goitre (up to 60% at 10 
years), but requires a practiced surgeon. Radio-iodine therapy (2.2 GBq, 60 
mCi, single or fractionated dose) is effective in safely reducing goitre 
size (by ∼50%) and relieving obstructive symptoms. Fine-needle aspiration 
cytological evaluation is essential for all apparently single nodules and 
for dominant nodules.
EMTREE DRUG INDEX TERMS
  radioactive iodine
  recombinant thyrotropin (drug dose, drug therapy, pharmacology)
  thyroxine (adverse drug reaction, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  nodular goiter (disease management, drug therapy, radiotherapy, surgery)
  toxic goiter (disease management, drug therapy, radiotherapy, surgery)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (side effect)
  biosafety
  correlation analysis
  cytology
  drug effect
  follow up
  gene mutation
  genetic polymorphism
  human
  hypothyroidism (complication)
  low drug dose
  needle biopsy
  osteoporosis (side effect)
  pathogenesis
  pathophysiology
  radiation dose fractionation
  review
  risk factor
  side effect (side effect)
  thyroidectomy
CAS REGISTRY NUMBERS
  recombinant thyrotropin (194100-83-9)
  thyroxine (7488-70-2)
EMBASE CLASSIFICATIONS
  Endocrinology (3)
  Clinical and Experimental Pharmacology (30)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2005004529
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 489
TITLE
  Alternative medicine - Boom or bust?
AUTHOR NAMES
  Olshansky B.
AUTHOR ADDRESSES
  (Olshansky B., brian-olshansky@uiowa.edu) Section of Electrophysiology, 
Division of Cardiology, University of Iowa Hospitals, Iowa City, IA, United 
States.
CORRESPONDENCE ADDRESS
  B. Olshansky, The Section of Electophysiology, Division of Cardiology, The 
University of Iowa Hospitals, 200 Hawkins Drive, Iowa City, IA 52242, United 
States. Email: brian-olshansky@uiowa.edu
SOURCE
  Cardiac Electrophysiology Review (2002) 6:1-2 (170-173). Date of 
Publication: 2002
ISSN
  1385-2264
BOOK PUBLISHER
  Kluwer Academic Publishers, Van Godewijckstraat 30, Dordrecht, Netherlands.
EMTREE DRUG INDEX TERMS
  1,4 butanediol
  amino acid
  antidepressant agent (drug interaction)
  antioxidant
  beta adrenergic receptor blocking agent (drug interaction)
  carnitine (drug therapy)
  cyclosporin (drug interaction)
  digoxin (drug interaction)
  Ephedra extract (adverse drug reaction, drug interaction)
  fish oil (drug therapy)
  Ginkgo biloba extract (drug interaction, pharmacology)
  Glycyrrhiza extract (adverse drug reaction, drug therapy, pharmacology)
  herbaceous agent (adverse drug reaction, drug interaction, drug therapy, 
pharmacology)
  Hypericum perforatum extract (adverse drug reaction, drug interaction, drug 
therapy, pharmacology)
  isoflavone derivative
  mineral
  nandrolone (oral drug administration)
  nonsteroid antiinflammatory agent (drug interaction)
  omega 3 fatty acid (drug therapy)
  phytoestrogen
  proteinase inhibitor (drug interaction)
  pseudoephedrine (drug interaction)
  serotonin uptake inhibitor (drug interaction)
  testosterone derivative (oral drug administration)
  tyramine (drug interaction)
  ubidecarenone (adverse drug reaction, drug therapy)
  vitamin
  yohimbine (adverse drug reaction)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alternative medicine
EMTREE MEDICAL INDEX TERMS
  acupuncture
  article
  atrial fibrillation (drug therapy)
  Chinese medicine
  diagnostic error
  diet supplementation
  diet therapy
  doctor patient relation
  drug antagonism
  drug marketing
  drug mechanism
  drug potentiation
  extrasystole
  faintness (drug therapy)
  heart arrhythmia (drug therapy)
  homeopathy
  hospitalization
  human
  hypertension (side effect)
  meditation
  patient attitude
  primary medical care
  torsade des pointes (side effect)
CAS REGISTRY NUMBERS
  1,4 butanediol (110-63-4)
  amino acid (65072-01-7)
  carnitine (461-06-3, 541-15-1, 56-99-5)
  cyclosporin (79217-60-0)
  digoxin (20830-75-5, 57285-89-9)
  fish oil (8016-13-5)
  nandrolone (434-22-0)
  proteinase inhibitor (37205-61-1)
  pseudoephedrine (345-78-8, 7460-12-0, 90-82-4)
  tyramine (51-67-2, 60-19-5)
  ubidecarenone (303-98-0)
  yohimbine (146-48-5, 65-19-0)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  2002096794
MEDLINE PMID
  11984042 (http://www.ncbi.nlm.nih.gov/pubmed/11984042)
FULL TEXT LINK
  http://dx.doi.org/10.1023/A:1017984532559
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 490
TITLE
  Prevention of vascular disease following acute ischaemic stroke
AUTHOR NAMES
  Rodgers H.
AUTHOR ADDRESSES
  (Rodgers H.) Centre for Health Services Research, University, 21 Claremont 
Place, Newcastle-Upon-Tyne NE2 4AA, United Kingdom.
CORRESPONDENCE ADDRESS
  H. Rodgers, Centre for Health Services Research, University, 21 Claremont 
Place, Newcastle-Upon-Tyne NE2 4AA, United Kingdom. Email: 
helen.rodgers@newcastle.ac.uk
SOURCE
  British Journal of Cardiology (2001) 8:12 (704-705+708-711). Date of 
Publication: 2001
ISSN
  0969-6113
ABSTRACT
  Considerable progress has been made in identifying stroke risk factors and 
factors associated with recurrence. Because aspirin is only moderately 
effective in secondary prevention, other agents such as dipyridamole and 
clopidogrel have been evaluated. Warfarin is of benefit in patients who have 
valvular and non-valvular atrial fibrillation. Carotid endarterectomy is 
beneficial to the small number of patients with transient ischaemic attack 
(TIA) or non-disabling stroke who have a significant carotid stenosis. 
Recent evidence suggests that all patients with TIA or ischaemic stroke may 
benefit from blood pressure and cholesterol lowering (including those who 
are normotensive or who have a 'normal cholesterol'). All patients should be 
given appropriate advice on lifestyle factors such as diet, regular exercise 
and stopping smoking.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (clinical trial, drug combination, drug comparison, drug 
therapy, oral drug administration, pharmacology)
  antithrombocytic agent (adverse drug reaction, clinical trial, drug 
comparison, drug dose, drug therapy, pharmaceutics, pharmacology)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (adverse drug reaction, clinical trial, drug 
combination, drug comparison, drug dose, drug therapy, pharmacology)
  cholesterol (endogenous compound)
  clopidogrel (clinical trial, drug comparison, drug dose, drug therapy, 
pharmacology)
  dipyridamole (clinical trial, drug combination, drug comparison, drug dose, 
drug therapy, pharmaceutics, pharmacology)
  homocysteine (endogenous compound)
  hypocholesterolemic agent (drug therapy)
  indapamide (clinical trial, drug combination, drug comparison, drug dose, 
drug therapy, pharmacology)
  lipid (endogenous compound)
  nicotine derivative (drug therapy)
  perindopril (clinical trial, drug combination, drug comparison, drug dose, 
drug therapy, pharmacology)
  placebo
  simvastatin (clinical trial, drug dose, drug therapy, pharmacology)
  warfarin (clinical trial, drug combination, drug comparison, drug therapy, 
oral drug administration, pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (drug therapy, prevention, surgery)
  vascular disease (complication, drug therapy, prevention, surgery)
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation (drug therapy)
  blood regurgitation
  carotid artery obstruction (surgery)
  carotid artery surgery
  carotid endarterectomy
  cerebrovascular accident (complication, drug therapy, prevention)
  clinical protocol
  clinical trial
  diabetes mellitus
  diet
  disability
  drug choice
  drug contraindication
  drug effect
  drug efficacy
  drug indication
  drug release
  evaluation study
  evidence based medicine
  exercise
  human
  hypertension (drug therapy)
  lifestyle
  meta analysis
  patient counseling
  practice guideline
  recurrent disease (drug therapy, prevention)
  review
  risk factor
  secondary prevention
  side effect (side effect)
  smoking cessation
  tobacco dependence (drug therapy)
  transient ischemic attack (complication, drug therapy, surgery)
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  cholesterol (57-88-5)
  clopidogrel (113665-84-2, 120202-66-6, 90055-48-4, 94188-84-8)
  dipyridamole (58-32-2)
  homocysteine (454-28-4, 6027-13-0)
  indapamide (26807-65-8)
  lipid (66455-18-3)
  perindopril (82834-16-0)
  simvastatin (79902-63-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Internal Medicine (6)
  Pharmacy (39)
  Adverse Reactions Titles (38)
  Drug Literature Index (37)
  Clinical and Experimental Pharmacology (30)
  Clinical and Experimental Biochemistry (29)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Public Health, Social Medicine and Epidemiology (17)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2002024290
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 491
TITLE
  Interaction between warfarin and a vitamin K-containing nutritional 
supplement: A case report
AUTHOR NAMES
  Bransgrove L.L.
AUTHOR ADDRESSES
  (Bransgrove L.L.) Department of Pharmacy, Veterans Affairs Medical Center, 
6010 Amarillo Boulevard West, Amarillo, TX 79106, United States.
CORRESPONDENCE ADDRESS
  L.L. Bransgrove, Department of Pharmacy, Veterans Affairs Medical Center, 
6010 Amarillo Boulevard West, Amarillo, TX 79106, United States.
SOURCE
  Journal of Herbal Pharmacotherapy (2001) 1:1 (85-89). Date of Publication: 
2001
ISSN
  1522-8940
ABSTRACT
  A 72-year-old man receiving warfarin to prevent thromboembolism related to 
atrial fibrillation/flutter experienced a significant increase in the 
international normalized ratio (INR) after discontinuing an over the counter 
nutritional supplement containing vitamin K. Laboratory testing revealed 
critical elevations of INR and prothrombin time. After resumption of the 
nutritional supplement, the patient's laboratory values returned to within 
the desired range. With the explosion in popularity of herbal products, 
practitioners need to be aware of all nutritional supplements being consumed 
by patients as well as over the counter drugs.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  vitamin K group (drug interaction, pharmaceutics, pharmacology)
  warfarin (drug dose, drug interaction, drug therapy, pharmacology)
EMTREE DRUG INDEX TERMS
  amcinonide (drug therapy, topical drug administration)
  amitriptyline (drug therapy)
  benazepril (drug therapy)
  clobetasol (drug therapy, topical drug administration)
  coal tar (drug therapy, topical drug administration)
  diltiazem (drug therapy)
  fluocinolone (drug therapy)
  hydrochlorothiazide (drug therapy)
  insulin (drug therapy)
  isophane insulin (drug therapy)
  isosorbide (drug therapy)
  ketoconazole (drug therapy, topical drug administration)
  metformin (drug therapy)
  natures life green
  non prescription drug (drug interaction)
  paracetamol (drug therapy)
  simvastatin (drug therapy)
  unclassified drug
  urea (drug therapy, topical drug administration)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diet supplementation
  herb (drug interaction, pharmaceutics, pharmacology)
  nutritional support
EMTREE MEDICAL INDEX TERMS
  aged
  alfalfa
  Arthrospira platensis
  article
  atrial fibrillation (drug therapy)
  barley
  Brassica
  case report
  Chlorella
  dyslipidemia (drug therapy)
  Fucus
  garlic
  heart atrium flutter (drug therapy)
  human
  hypertension (drug therapy)
  international standard unit
  laboratory test
  Laminaria
  male
  non insulin dependent diabetes mellitus (drug therapy)
  onion
  pea
  pepper
  priority journal
  prothrombin time
  psoriasis (drug therapy)
  spinach
  tea
  thromboembolism (drug therapy, prevention)
  vegetable
DRUG TRADE NAMES
  coumadin  DuPont

  natures life green  , United StatesNatures Life

DRUG MANUFACTURERS
  DuPont
   (United States)Natures Life
CAS REGISTRY NUMBERS
  amcinonide (51022-69-6)
  amitriptyline (50-48-6, 549-18-8)
  benazepril (86541-75-5)
  clobetasol (25122-41-2)
  coal tar (8007-45-2)
  diltiazem (33286-22-5, 42399-41-7)
  fluocinolone (807-38-5)
  hydrochlorothiazide (58-93-5)
  insulin (9004-10-8)
  isophane insulin (9004-17-5)
  isosorbide (652-67-5)
  ketoconazole (65277-42-1)
  metformin (1115-70-4, 657-24-9)
  paracetamol (103-90-2)
  simvastatin (79902-63-9)
  urea (57-13-6)
  vitamin K group (12001-79-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Biochemistry (29)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Pharmacy (39)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2001083884
FULL TEXT LINK
  http://dx.doi.org/10.1300/J157v01n01_07
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 492
TITLE
  Management of hyperlipidaemia in primary care: The implications of the 
National Service Framework for Coronary Heart Disease
AUTHOR NAMES
  Hobbs R.
AUTHOR ADDRESSES
  (Hobbs R.) Dept. Prim. Care and Gen. Practice, Medical School, University of 
Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
CORRESPONDENCE ADDRESS
  R. Hobbs, Dept. Prim. Care and Gen. Practice, Medical School, University of 
Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
SOURCE
  British Journal of Cardiology (2000) 7:SUPPL. 4 (S6-S10). Date of 
Publication: 2000
ISSN
  0969-6113
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  acetylsalicylic acid (drug dose, drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  statin (protein) (drug therapy)
  warfarin (drug therapy)
EMTREE DRUG INDEX TERMS
  glucose (endogenous compound)
  low density lipoprotein cholesterol (endogenous compound)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  hyperlipidemia (drug therapy, therapy)
  ischemic heart disease (drug therapy, prevention, therapy)
  risk management
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  atrial fibrillation (drug therapy)
  blood pressure monitoring
  body weight
  cholesterol diet
  diabetes mellitus
  diet
  heart infarction (drug therapy)
  heart left ventricle failure (drug therapy)
  human
  medical audit
  physical activity
  primary health care
  primary prevention
  review
  risk factor
  secondary prevention
  smoking cessation
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  glucose (50-99-7, 84778-64-3)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2000427298
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 493
TITLE
  VVI versus physiologic pacing. New data on an old topic
AUTHOR NAMES
  Wiegand U.K.H.
AUTHOR ADDRESSES
  (Wiegand U.K.H.) Medizinische Universität zu Lübeck, Medizinische Klinik II, 
Ratzeburger Allee 160, 23538 Lübeck, Germany.
CORRESPONDENCE ADDRESS
  U.K.H. Wiegand, Medizinische Universitat zu Lubeck, Medizinische Klinik II, 
Ratzeburger Allee 160, 23538 Lubeck, Germany.
SOURCE
  Herzschrittmachertherapie und Elektrophysiologie (2000) 11:SUPPL. 2 
(II43-II48). Date of Publication: 2000
ISSN
  0938-7412
ABSTRACT
  Aim: Review of current literature on physiologic versus VVI pacing. Methods: 
Data of five prospective randomized trials including recently reported 
PAC-A-TACH and CTOPP results were summarized and interpreted. Results: 
According to CTOPP results, mortality was not substantially improved by 
physiologic pacing (PP) as compared to VVI pacing in a general population of 
pacemaker recipients. In patients with sinus node disease, the influence of 
pacing mode on survival was inconsistent among randomised trials, and there 
is little prospective data on patients with AV-block. Sub-groups like 
patients < 75 years and pacemaker dependent patients however benefited from 
PP. Incidence of atrial fibrillation was reduced by PP, particularly in 
patients with sinus node disease. Heart failure, exercise capacity and 
quality of life were not substantially improved by PP except in the subgroup 
of pacemaker dependent patients. Conclusions: Benefit of PPis less extensive 
as suggested by retrospective trials. However, there is evidence that 
relevant sub-groups such as patients with sinus node disease or with 
persistent bradycardia benefit from PP.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  supraventricular tachycardia
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  atrioventricular block
  bradycardia
  clinical trial
  controlled study
  exercise
  health care cost
  heart failure
  human
  meta analysis
  mortality
  pacemaker
  quality of life
  sinus node disease
  survival
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Health Policy, Economics and Management (36)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2000423935
FULL TEXT LINK
  http://dx.doi.org/10.1007/s003990070007
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 494
TITLE
  Pivotal research in cardiovascular syndromes in the elderly
AUTHOR NAMES
  McKay C.R.
  Rich M.W.
  Vlietstra R.E.
  Kitzman D.W.
  Fleg J.L.
  Krumholz H.M.
  Lakatta E.G.
  Cooke J.P.
  Cannon C.P.
  Ezekowitz M.D.
  Frolich E.D.
  Jalife J.
  Kass D.A.
  Kottke B.A.
  Muller J.E.
  Saltin B.
  Shen W.K.
  Somers V.K.
AUTHOR ADDRESSES
  (McKay C.R.; Rich M.W.; Vlietstra R.E.; Kitzman D.W.; Fleg J.L.; Krumholz 
H.M.; Lakatta E.G.; Cooke J.P.; Cannon C.P.; Ezekowitz M.D.; Frolich E.D.; 
Jalife J.; Kass D.A.; Kottke B.A.; Muller J.E.; Saltin B.; Shen W.K.; Somers 
V.K.) Harbor UCLA Medical Center-REI, 1124 West Carson Street, Torrance, CA 
90502, United States.
CORRESPONDENCE ADDRESS
  C.R. McKay, Harbor UCLA Medical Center-REI, 1124 West Carson Street, 
Torrance, CA 90502, United States.
SOURCE
  American Journal of Geriatric Cardiology (2000) 9:5 (243-250). Date of 
Publication: 2000
ISSN
  1076-7460
ABSTRACT
  The PRICE-1 conference was designed to identify near term priorities for 
funding cardiovascular research in the elderly. Twenty topics were 
identified with either break throughs in fundamental mechanisms of aging 
with cardiovascular systems or with, critical importance to cardiovascular 
carve of the elderly. © 2000 by Cardiovascular Reviews & Reports, Inc.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiovascular system
  elderly care
EMTREE MEDICAL INDEX TERMS
  acute heart failure
  aged
  atrial fibrillation
  exercise
  faintness
  financial management
  heart muscle ischemia
  human
  medical research
  organization
  review
  systolic hypertension
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2001055683
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 495
TITLE
  An elderly man with progressive dyspnea on exertion and atrial fibrillation 
as manifestations of senile cardiac amyloidosis
AUTHOR NAMES
  Yunis N.A.
  Petrasko M.S.
  Cannistra L.B.
AUTHOR ADDRESSES
  (Yunis N.A.; Petrasko M.S.; Cannistra L.B.) Department of Medicine, Brown 
University School of Medicine, Memorial Hospital of Rhode Island, 111 
Brewster Street, Pawtucket, RI 02860, United States.
CORRESPONDENCE ADDRESS
  L.B. Cannistra, Department of Medicine, Brown University School of Medicine, 
Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860, 
United States.
SOURCE
  American Journal of Geriatric Cardiology (2000) 9:2 (69-72). Date of 
Publication: 2000
ISSN
  1076-7460
ABSTRACT
  Senile cardiac amyloidosis is a form of amyloidosis seen more commonly in 
the elderly population. It was previously believed to have no functional 
significance, but more recent studies suggest that it is an important cause 
for cardiovascular morbidity and mortality in the elderly. The diagnosis may 
be challenging and it is important to have a high suspicion for this disease 
in the proper clinical setting. A patient with cardiac amyloidosis is 
presented in this paper to illustrate the clinical context in which one 
should consider this diagnosis. Information regarding diagnostic evaluation 
and a brief review of senile cardiac amyloidosis is presented. (C) 2000 by 
Cardiovascular Reviews and Reports, Inc.
EMTREE DRUG INDEX TERMS
  digoxin
  furosemide
  hydrochlorothiazide
  prealbumin (endogenous compound)
  warfarin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aging
  atrial fibrillation
  dyspnea
  heart amyloidosis (diagnosis, etiology)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  case report
  clinical feature
  electrocardiogram
  exercise test
  heart muscle biopsy
  human
  human tissue
  immunoelectrophoresis
  isoelectric focusing
  male
CAS REGISTRY NUMBERS
  digoxin (20830-75-5, 57285-89-9)
  furosemide (54-31-9)
  hydrochlorothiazide (58-93-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Gerontology and Geriatrics (20)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2000303872
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 496
TITLE
  The development of polypharmacy. A longitudinal study
AUTHOR NAMES
  Veehof L.J.G.
  Stewart R.E.
  Haaijer-Ruskamp F.M.
  Meyboom-de Jong B.
AUTHOR ADDRESSES
  (Veehof L.J.G.) Ant. Deusinglaan 4, 9713 AW Groningen, Netherlands.
(Stewart R.E.; Haaijer-Ruskamp F.M.; Meyboom-de Jong B.)
CORRESPONDENCE ADDRESS
  L.J.G. Veehof, Ant. Deusinglaan 4, 9713 AW Groningen, Netherlands.
SOURCE
  Family Practice (2000) 17:3 (261-267). Date of Publication: June 2000
ISSN
  0263-2136
BOOK PUBLISHER
  Oxford University Press, Great Clarendon Street, Oxford, United Kingdom.
ABSTRACT
  Background. To date, only a few studies have been carried out on the 
development and progress of polypharmacy in relation to morbidity in general 
practices in The Netherlands. Objective. The aim of this study was to 
investigate the relationship between an increase in long-term drug use and 
the incidence and severity of some chronic diseases, particularly in the 
elderly. Methods. Data on medication and morbidity of 1544 elderly people 
were collected for the period 1994-1997 from three family practices in the 
medication and morbidity Registration Network of Groningen (RNG) in the 
northern part of The Netherlands. Polypharmacy is defined as the long-term 
simultaneous use of two or more drugs; long-term is defined as > 240 days in 
a year. We looked for differences in incidences of some chronic diseases in 
those subgroups of the elderly in whom multiple long-term drug use 
respectively increased, stayed constant or did not exist. Polypharmacy at 
the end of the period was predicted using regression analysis. Results. 
Polypharmacy occurred in 42% of the elderly at the end of 1997, with major 
polypharmacy (> 5 drugs) in only 4%. The average number of drugs used 
long-term increased from 1.3 to 1.8 in 4 years. Predictors for the increase 
of polypharmacy were the number of drugs at the start, age, diabetes, 
coronary ischaemic diseases and use of medication without a clear indication 
(P < 0.005). The average number of diseases also increased, especially in 
the elderly who showed the greatest increase in long-term drug use; however, 
there was no significant difference from the groups with a slow or no 
increase in drug use. Discussion. Polypharmacy showed a slow increase over 4 
years: almost 20% of the elderly developed polypharmacy, i.e. going from no 
drugs or one drug to two or more drugs. Polypharmacy develops mainly in 
elderly patients who already use several drugs, who are known to suffer from 
cardiovascular diseases, diabetes or stomach symptoms, those who often take 
drugs (especially sedatives/hypnotics) without clear indication and those 
who develop hypertension or atrial fibrillation over time.
EMTREE DRUG INDEX TERMS
  analgesic agent
  antidepressant agent
  antidiabetic agent (drug therapy)
  antihypertensive agent (drug therapy)
  cardiovascular agent (drug therapy)
  gastrointestinal agent (drug therapy)
  hypnotic agent
  laxative
  sedative agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  polypharmacy
EMTREE MEDICAL INDEX TERMS
  aged
  article
  atrial fibrillation (drug therapy)
  cardiovascular disease (drug therapy)
  chronic disease
  diabetes mellitus (drug therapy)
  disease severity
  drug use
  female
  general practice
  heart muscle ischemia (drug therapy)
  human
  hypertension (drug therapy)
  incidence
  longitudinal study
  major clinical study
  male
  morbidity
  Netherlands
  registration
  regression analysis
  stomach disease (drug therapy)
  treatment indication
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Gerontology and Geriatrics (20)
  Health Policy, Economics and Management (36)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2000209329
MEDLINE PMID
  10846147 (http://www.ncbi.nlm.nih.gov/pubmed/10846147)
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 497
TITLE
  Secondary prevention of myocardial infarction
AUTHOR ADDRESSES
  SOURCE
  MeReC Bulletin (1999) 10:2 (5-8). Date of Publication: 1999
ISSN
  1465-5659
ABSTRACT
  Many patients do not receive optimal secondary prevention after myocardial 
infarction (MI), despite good evidence that certain interventions reduce 
mortality. After an MI, patients should be advised to stop smoking and, 
provided there are no contraindications, take aspirin and a beta- blocker. 
ACE inhibitors are likely to benefit patients with signs of heart failure or 
evidence of left ventricular dysfunction. The use of statins post- MI, along 
with dietary advice, should be considered when total cholesterol is ≥ 
5mmol/l and/or LDL-cholesterol is ≥ 3mmol/l. Before prescribing statins, GPs 
should ensure that all suitable patients are receiving aspirin and a 
beta-blocker as a first priority. Lifestyle measures, such as eating a 
Mediterranean diet and oily fish, may also reduce mortality post-MI as can 
cardiac rehabilitation programmes. Maintaining blood pressure below 140/85mm 
Hg reduces the risk of further cardiovascular events. Anticoagulants are 
usually reserved for those post-MI patients with, for example, a large 
anterior infarction or atrial fibrillation, as they are no more beneficial 
than aspirin alone. Calcium-channel blockers should not be used routinely 
post-MI. However, diltiazem or verapamil may benefit patients without heart 
failure who have continuing angina, if beta-blockers are inappropriate. 
Amiodarone may be of benefit to patients with severe, symptomatic arrythmias 
post-MI. However, class I antiarrythmics, such as flecainide, should be 
avoided as they increase mortality post-MI.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  anticoagulant agent (drug therapy)
  antithrombocytic agent (drug therapy)
  beta adrenergic receptor blocking agent (drug therapy)
  calcium channel blocking agent (drug therapy)
EMTREE DRUG INDEX TERMS
  acebutolol (drug therapy)
  acetylsalicylic acid (drug therapy)
  amiodarone (drug therapy)
  antilipemic agent (drug therapy)
  atenolol (drug therapy)
  diltiazem (drug therapy)
  dipeptidyl carboxypeptidase inhibitor (drug therapy)
  insulin
  metoprolol (drug therapy)
  pravastatin (drug therapy)
  propranolol (drug therapy)
  simvastatin (drug therapy)
  timolol (drug therapy)
  verapamil (drug therapy)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart infarction (drug therapy, prevention)
  heart reinfarction (drug therapy, prevention)
  secondary prevention
EMTREE MEDICAL INDEX TERMS
  clinical trial
  diet
  exercise
  heart arrhythmia (drug therapy)
  human
  hyperlipidemia (drug therapy)
  ischemic heart disease (prevention)
  lifestyle
  meta analysis
  mortality
  review
  risk factor
  smoking cessation
CAS REGISTRY NUMBERS
  acebutolol (34381-68-5, 37517-30-9)
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  atenolol (29122-68-7)
  diltiazem (33286-22-5, 42399-41-7)
  insulin (9004-10-8)
  metoprolol (37350-58-6)
  pravastatin (81131-74-0)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
  simvastatin (79902-63-9)
  timolol (26839-75-8)
  verapamil (152-11-4, 52-53-9)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1999249198
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 498
TITLE
  Preventing a first stroke: The NSA's recommendations
AUTHOR ADDRESSES
  SOURCE
  Journal of Critical Illness (1999) 14:7 (407-410). Date of Publication: 1999
ISSN
  1040-0257
ABSTRACT
  Consider these measures to reduce risk from conditions that contribute to 
the 731,000 strokes in the United States each year.
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  cholesterol (endogenous compound)
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (drug therapy, prevention)
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  anticoagulation
  atrial fibrillation
  diabetes mellitus
  exercise
  heart infarction
  human
  hypercholesterolemia
  hypertension
  lifestyle
  patient education
  primary prevention
  review
  risk factor
  risk management
  secondary prevention
  smoking
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  cholesterol (57-88-5)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1999248813
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 499
TITLE
  Case reports in heart failure
AUTHOR NAMES
  Vokonas P.S.
AUTHOR ADDRESSES
  (Vokonas P.S.) Boston University School of Medicine, Vet. Affairs Norm. 
Aging Study Dept., Boston, MA, United States.
CORRESPONDENCE ADDRESS
  P.S. Vokonas, Boston University School of Medicine, Vet. Affairs Norm. Aging 
Study Dept., Boston, MA, United States.
SOURCE
  Cardiology Review (1998) 15:9 (26-27). Date of Publication: 1998
ISSN
  1092-6607
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (complication)
  valvular heart disease (diagnosis)
EMTREE MEDICAL INDEX TERMS
  abdominal discomfort
  adult
  article
  atrial fibrillation (diagnosis)
  case report
  clinical feature
  disease association
  dyspnea
  electrocardiogram
  exercise
  exercise test
  fatigue
  female
  heart murmur (diagnosis)
  human
  male
  mitral valve regurgitation (complication)
  vein occlusion plethysmography
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1998380937
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 500
TITLE
  Achieving optimum outcomes in the treatment of stroke
AUTHOR NAMES
  Barnett H.J.M.
  Meldrum H.E.
AUTHOR ADDRESSES
  (Barnett H.J.M.; Meldrum H.E.) John P. Robarts Research Institute, London, 
Ont., Canada.
(Barnett H.J.M.) John P. Robarts Research Institute, 100 Perth Drive, 
London, Ont. N6A 5K8, Canada.
CORRESPONDENCE ADDRESS
  H.J.M. Barnett, John P. Robarts Research Institute, 100 Perth Drive, London, 
Ont. N6A 5K8, Canada.
SOURCE
  CNS Drugs (1998) 9:SUPPL. 1 (11-18). Date of Publication: 1998
ISSN
  1172-7047
ABSTRACT
  Treatment for patients with ischaemic stroke is one of the rapidly advancing 
frontiers in the struggle against disability from brain disease. Transient 
ischaemic attack and minor stroke have been identified, and the fact that 
they are a warning of more serious stroke or potentially fatal stroke has 
been recognised. Patients with these symptoms should receive urgent 
treatment, including management of risk factors and administration of 
properly selected antithrombotic agents. Investigations must be performed to 
determine whether or not the patient is an appropriate candidate for carotid 
endarterectomy. Serious ischaemic lesions no longer represent universally 
and discouragingly untreatable situations. Every patient with a developing 
or recently developed ischaemic stroke must be urgently transferred to a 
specialised unit providing expert surveillance and investigation. Experience 
has shown that the care of these patients in a specialised stroke unit is 
the ideal, and the development of such units should be encouraged. General 
measures play a major role in reducing the extent of the disability 
resulting from stroke and in expediting the rehabilitation of patients. The 
following are each of vital importance: care of the airway; careful 
monitoring of patients so that pneumonia and pulmonary emboli are avoided; 
maintenance of adequate fluid intake and nutrition; maintenance of normal 
systemic circulation (maintaining cardiac output and treating rhythm 
disorders); and avoidance of pressure sores. Some patients with certain 
types of ischaemic strokes, especially those caused by cardiac embolisation 
(with and without atrial fibrillation), will benefit from anticoagulation. 
Recent studies suggest that aspirin has prophylactic benefit for the 
majority of non- embolic strokes. Traditional therapy with corticosteroids, 
as anti-oedema agents, does not help patients with ischaemic infarction and 
is not advised. Other agents that reduce brain oedema or alter blood volume 
are of unproven value and are not advised as routine measures for ischaemic 
stroke victims. Intravenous hyperglycaemic therapy should be avoided. The 
most exciting finding in recent years is the proven benefit of intravenous 
administration of alteplase (recombinant tissue plasminogen activator; 
rt-PA) in patients with ischaemic stroke. The lesion must be of no more than 
3 hours' duration, and there should be no evidence of infarction on 
computerised tomography scan. This potentially dangerous therapy requires 
expert management, since there is a high risk of severe and fatal 
haemorrhage if the strict principles for its use are not scrupulously 
adhered to. Neuroresuscitation is an exciting prospect and recent trials 
suggest that useful agents will be available in the near future. These 
putative therapies will be used to reduce the amount of brain damage and 
thus diminish the degree of functional impairment. Rehabilitation should 
begin as soon as the neurological disability is stabilised and, ideally, 
should involve a multidisciplinary team approach.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  acetylsalicylic acid (drug therapy)
  alteplase (drug therapy)
  anticoagulant agent (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (diagnosis, drug therapy, prevention, surgery)
  treatment outcome
EMTREE MEDICAL INDEX TERMS
  anticoagulation
  bleeding (complication)
  brain edema (complication)
  brain injury (complication)
  carotid endarterectomy
  cerebrovascular accident (drug therapy)
  computer assisted tomography
  fluid intake
  human
  lung embolism (complication)
  nutritional support
  patient monitoring
  pneumonia (complication)
  practice guideline
  priority journal
  review
  risk factor
  scoring system
  transient ischemic attack (drug therapy)
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alteplase (105857-23-6)
EMBASE CLASSIFICATIONS
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Neurology and Neurosurgery (8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1998204305
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 501
TITLE
  A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM 
sleep behavior disorder in 33 polysomnographically confirmed cases
AUTHOR NAMES
  Schenck C.H.
  Boyd J.L.
  Mahowald T.W.
AUTHOR ADDRESSES
  (Schenck C.H.; Boyd J.L.) Department of Psychiatry, Hennepin County Medical 
Center, .
(Mahowald T.W.) Department of Neurology, Hennepin County Medical Center, .
(Schenck C.H.) Hennepin County Medical Center, Department of Psychiatry 
(844), 701 Park Avenue South, Minneapolis, MN 55415, United States.
CORRESPONDENCE ADDRESS
  C.H. Schenck, Hennepin County Medical Center, Department of Psychiatry, 701 
Park Avenue South, Minneapolis, MN 55415, United States.
SOURCE
  Sleep (1997) 20:11 (972-981). Date of Publication: 1997
ISSN
  0161-8105
BOOK PUBLISHER
  American Academy of Sleep Medicine, 1 Westbrook Corporate Center, Suite 920, 
Westchester, United States.
ABSTRACT
  A series of 33 patients with combined (injurious) sleepwalking, sleep 
terrors, and rapid eye movement (REM) sleep behavior disorder (viz. 
'parasomnia overlap disorder') was gathered over an 8-year period. Patients 
underwent clinical and polysomnographic evaluations. Mean age was 34 ± 14 
(SD) years; mean age of parasomnia onset was 15 ± 16 years (range 1-66); 70% 
(n = 23) were males. An idiopathic subgroup (n = 22) had a significantly 
earlier mean age of parasomnia onset (9 ± 7 years) than a symptomatic 
subgroup (n = 11) (27 ± 23 years, p = 0.002), whose parasomnia began with 
either of the following: neurologic disorders, n = 6 [congenital Mobius 
syndrome, narcolepsy, multiple sclerosis, brain tumor (and treatment), brain 
trauma, indeterminate disorder (exaggerated startle response/atypical 
cataplexy)]; nocturnal paroxysmal atrial fibrillation, n = 1; posttraumatic 
stress disorder/major depression, n = 1; chronic ethanol/amphetamine abuse 
and withdrawal, n = 1; or mixed disorders (schizophrenia, brain trauma, 
substance abuse), n = 2. The rate of DSM-III-R (Diagnostic and Statistical 
Manual, 3rd edition, revised) Axis I psychiatric disorders was not elevated; 
group scores on various psychometric tests were not elevated. Forty-five 
percent (n = 15) had previously received psychologic or psychiatric therapy 
for their parasomnia, without benefit. Treatment outcome was available for n 
= 20 patients; 90% (n = 18) had substantial parasomnia control with bedtime 
clonazepam (n = 13), alprazolam and/or carbamazepine (n = 4), or self- 
hypnosis (n = 1). Thus, 'parasomnia overlap disorder' is a treatable 
condition that emerges in various clinical settings and can be understood 
within the context of current knowledge on parasomnias and motor 
control/dyscontrol during sleep.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  REM sleep
  sleep disorder (diagnosis)
  sleep walking (diagnosis)
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  clinical article
  human
  Moebius syndrome
  neurologic disease
  polysomnography
  priority journal
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Psychiatry (32)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1998029002
MEDLINE PMID
  9456462 (http://www.ncbi.nlm.nih.gov/pubmed/9456462)
COPYRIGHT
  Copyright 2009 Elsevier B.V., All rights reserved.

RECORD 502
TITLE
  Managing symptomatic heart failure in 1997: Strategies for the end- stage 
patient
AUTHOR NAMES
  McNamara D.
  Alvarez R.J.
  Rosenblum W.
  Murali S.
  Feldman A.
AUTHOR ADDRESSES
  (McNamara D.; Alvarez R.J.; Rosenblum W.; Murali S.; Feldman A.) Heart 
Institute, Univ. of Pittsburgh Medical Center, Pittsburgh, PA, United 
States.
CORRESPONDENCE ADDRESS
  D. McNamara, Heart Institute, Univ. of Pittsburgh Medical Center, 
Pittsburgh, PA, United States.
SOURCE
  IM - Internal Medicine (1997) 18:6 (18-24). Date of Publication: 1997
ISSN
  1056-9286
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  captopril (adverse drug reaction, clinical trial, drug dose, drug therapy)
  digoxin (clinical trial, drug dose, drug therapy)
  dipeptidyl carboxypeptidase inhibitor (adverse drug reaction, clinical 
trial, drug dose, drug therapy)
  diuretic agent (adverse drug reaction, drug dose, drug therapy)
  furosemide (adverse drug reaction, drug dose, drug therapy)
  inotropic agent (clinical trial, drug dose, drug therapy)
EMTREE DRUG INDEX TERMS
  amiodarone (clinical trial, drug dose, drug therapy)
  amlodipine (clinical trial, drug therapy)
  angiotensin receptor antagonist (clinical trial, drug dose, drug therapy)
  beta adrenergic receptor blocking agent (clinical trial, drug therapy)
  bucindolol (clinical trial, drug therapy)
  bumetanide (adverse drug reaction, drug dose, drug therapy)
  calcium channel blocking agent (clinical trial, drug therapy)
  cardiac glycoside (clinical trial, drug therapy)
  carvedilol (clinical trial, drug therapy)
  enalapril (adverse drug reaction, clinical trial, drug dose, drug therapy)
  etacrynic acid (adverse drug reaction, drug dose, drug therapy)
  hydralazine (clinical trial, drug combination, drug dose, drug therapy)
  hydrochlorothiazide (adverse drug reaction, drug dose, drug therapy)
  isosorbide dinitrate (clinical trial, drug combination, drug dose, drug 
therapy)
  lisinopril (adverse drug reaction, clinical trial, drug dose, drug therapy)
  losartan (clinical trial, drug dose, drug therapy)
  metolazone (adverse drug reaction, drug dose, drug therapy)
  phosphodiesterase inhibitor (adverse drug reaction, clinical trial, drug 
therapy)
  piperanometozine (clinical trial, drug dose, drug therapy, pharmacology)
  potassium sparing diuretic agent (drug dose, drug therapy)
  spironolactone (drug dose, drug therapy)
  triamterene (drug dose, drug therapy)
  unindexed drug
  warfarin (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart failure (drug therapy, surgery)
EMTREE MEDICAL INDEX TERMS
  anticoagulant therapy
  assisted circulation
  atrial fibrillation (drug therapy)
  cardiovascular disease (drug therapy, surgery)
  clinical trial
  controlled study
  coughing (side effect)
  dietary intake
  exercise
  female
  heart transplantation
  heart ventricle arrhythmia (drug therapy, side effect)
  human
  hypokalemia (side effect)
  hypomagnesemia (side effect)
  intravenous drug administration
  major clinical study
  male
  multicenter study
  oral drug administration
  patient education
  review
  sudden death
  survival rate
  thromboembolism (complication, drug therapy, prevention)
  treatment planning
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  amlodipine (88150-42-9)
  bucindolol (71119-11-4)
  bumetanide (28395-03-1)
  captopril (62571-86-2)
  carvedilol (72956-09-3)
  digoxin (20830-75-5, 57285-89-9)
  enalapril (75847-73-3)
  etacrynic acid (58-54-8)
  furosemide (54-31-9)
  hydralazine (304-20-1, 86-54-4)
  hydrochlorothiazide (58-93-5)
  isosorbide dinitrate (87-33-2)
  lisinopril (76547-98-3, 83915-83-7)
  losartan (114798-26-4)
  metolazone (17560-51-9)
  piperanometozine (81840-15-5)
  spironolactone (52-01-7)
  triamterene (396-01-0)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cancer (16)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1997243470
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 503
TITLE
  Stroke is an emergency
AUTHOR ADDRESSES
  SOURCE
  Disease-a-Month (1996) 42:4 (202-264). Date of Publication: 1996
ISSN
  0011-5029
BOOK PUBLISHER
  Mosby Inc., 11830 Westline Industrial Drive, St. Louis, United States.
ABSTRACT
  Stroke is an emergency. Ischemic stroke is similar to myocardial infarction 
in that the pathogenesis is loss of blood supply to the tissue, which can 
result in irreversible damage if blood flow is not restored quickly. Public 
education is needed to emphasize the warning signs of stroke. Patients 
should seek medical help immediately, using emergency transport systems. 
Therapy geared toward minimizing the damage from an acute stroke should be 
started without delay in the emergency room. This includes measures to 
protect brain tissue, support perfusion pressure, and minimize cerebral 
edema. Strategies for improving recovery should also begin immediately. All 
major medical centers need stroke teams and stroke units. Stroke prevention 
should be given high priority as a public health strategy. Risk factor 
management should be part of general health care and should begin in 
childhood, with emphasis on nutrition, exercise, weight control, and 
avoidance of tobacco. Health screening and early treatment of hypertension 
and hypercholesterolemia has decreased the incidence of stroke and heart 
disease, but these efforts need to be expanded to reach all segments of the 
population. Basic research has opened the door to new therapies aimed at 
re-establishing blood flow and limiting tissue damage. Clinical trials have 
already led to changes in stroke prevention, including studies of carotid 
endarterectomy and ticlopidine and warfarin therapy (for patients with 
atrial fibrillation). Trials in progress are testing the usefulness of 
ancrod, neuroprotective agents, antioxidant agents, anti- inflammatory 
agents, low-molecular-weight heparin, thrombolytic drugs, and angioplasty. 
Any delay starting therapy after an acute stroke will result in progressive, 
irreversible loss of brain tissue. Clinicians should remember that for a 
stroke patient, time is brain tissue.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  acetylsalicylic acid (drug comparison, drug dose, drug therapy, 
pharmacology)
  ancrod (clinical trial, drug therapy, pharmacology)
  glutamate receptor antagonist (adverse drug reaction, clinical trial, 
pharmacology)
  heparin (drug administration, drug comparison, drug therapy)
  intercellular adhesion molecule 1 antibody (clinical trial, pharmacology)
  low molecular weight heparin (clinical trial, drug combination, drug 
comparison, drug therapy)
  ticlopidine (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, pharmacology)
  warfarin (adverse drug reaction, clinical trial, drug administration, drug 
therapy, pharmacology)
EMTREE DRUG INDEX TERMS
  antibiotic agent
  anticoagulant agent (drug combination, drug therapy)
  antiinflammatory agent (clinical trial)
  antioxidant (clinical trial)
  antithrombocytic agent (drug combination, drug therapy)
  blood clotting factor (endogenous compound)
  clonidine
  codeine (drug therapy)
  estrogen (clinical trial, endogenous compound)
  fibrin (endogenous compound)
  fibrinolytic agent (clinical trial, drug combination, drug therapy)
  free radical
  glucose (endogenous compound)
  glutamic acid (drug toxicity)
  glyceryl trinitrate (drug administration, drug therapy)
  hydrogen peroxide
  insulin (drug therapy)
  phospholipid antibody (endogenous compound)
  prazosin
  steroid (drug therapy)
  unindexed drug
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cerebrovascular accident (diagnosis, drug therapy, epidemiology, etiology, 
prevention, rehabilitation, surgery)
EMTREE MEDICAL INDEX TERMS
  angioplasty
  bleeding (side effect)
  bypass surgery
  carotid endarterectomy
  clinical trial
  computer assisted tomography
  echography
  education
  embolism (drug therapy, prevention)
  emergency ward
  heart infarction (drug therapy)
  human
  hyperglycemia (drug therapy)
  hypertension (diagnosis, drug therapy)
  intravenous drug administration
  nonhuman
  nuclear magnetic resonance imaging
  oral drug administration
  prothrombin time
  review
  risk factor
  subcutaneous drug administration
  tobacco
  transient ischemic attack (drug therapy)
DRUG TRADE NAMES
  coumadin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  ancrod (9046-56-4)
  clonidine (4205-90-7, 4205-91-8, 57066-25-8)
  codeine (76-57-3)
  fibrin (9001-31-4)
  glucose (50-99-7, 84778-64-3)
  glutamic acid (11070-68-1, 138-15-8, 56-86-0, 6899-05-4)
  glyceryl trinitrate (55-63-0)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  hydrogen peroxide (7722-84-1)
  insulin (9004-10-8)
  prazosin (19216-56-9, 19237-84-4)
  ticlopidine (53885-35-1, 55142-85-3)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Neurology and Neurosurgery (8)
  Radiology (14)
  Rehabilitation and Physical Medicine (19)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1996133105
COPYRIGHT
  Copyright 2011 Elsevier B.V., All rights reserved.

RECORD 504
TITLE
  Cardioversion of atrial fibrillation
AUTHOR NAMES
  Lip G.Y.H.
  Watson R.D.S.
  Singh S.P.
AUTHOR ADDRESSES
  (Lip G.Y.H.; Watson R.D.S.; Singh S.P.) University Department of Medicine, 
City Hospital, Birmingham, United Kingdom.
CORRESPONDENCE ADDRESS
  G.Y.H. Lip, University Department of Medicine, City Hospital, Birmingham, 
United Kingdom.
SOURCE
  British Medical Journal (1996) 312:7023 (112-115). Date of Publication: 1996
ISSN
  0959-8146
ABSTRACT
  Cardioversion to sinus rhythm should be considered for all suitable patients 
in atrial fibrillation. In the short term both pharmacological and 
electrical cardioversion restore sinus rhythm. Prophylactic treatment with 
antiarrhythmic drugs is advisable after cardioversion in high risk patients 
in view of the high relapse rate. Anticoagulants should be started before 
non-emergency cardioversion - ideally two to three weeks before - and 
continued for at least four weeks after cardioversion in patients with 
atrial fibrillation of > 48 hours' duration.
EMTREE DRUG INDEX TERMS
  amiodarone (drug therapy)
  antiarrhythmic agent (adverse drug reaction, drug therapy)
  anticoagulant agent (drug therapy)
  digoxin (adverse drug reaction, drug therapy)
  flecainide (adverse drug reaction, drug therapy)
  heparin (drug therapy)
  propafenone (drug therapy)
  quinidine (adverse drug reaction, drug therapy)
  verapamil (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, therapy)
  cardioversion
  sinus rhythm
EMTREE MEDICAL INDEX TERMS
  article
  electrocardiography
  exercise
  heart repolarization
  high risk patient
  human
  intravenous drug administration
  oral drug administration
  priority journal
  prognosis
  recurrence risk
  side effect
  thromboembolism (complication, drug therapy, prevention)
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
  digoxin (20830-75-5, 57285-89-9)
  flecainide (54143-55-4)
  heparin (37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5)
  propafenone (34183-22-7, 54063-53-5)
  quinidine (56-54-2)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1996021205
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 505
TITLE
  Control of rapid ventricular response by laser catheter modification of the 
atrioventricular node in a patient with medically refractory atrial 
fibrillation
AUTHOR NAMES
  Weber H.P.
  Heinze A.
AUTHOR ADDRESSES
  (Weber H.P.; Heinze A.) Laser Electrophysiology Laboratory, Medical 
Department, Harlaching Hosp., University of Munich, Munich, Germany.
CORRESPONDENCE ADDRESS
  H.P. Weber, Laser Electrophysiology Laboratory, Medical Department, 
Harlaching Hosp., University of Munich, Munich, Germany.
SOURCE
  European Journal of Cardiac Pacing and Electrophysiology (1995) 5:4 
(215-217). Date of Publication: 1995
ISSN
  0939-6780
ABSTRACT
  An 84-year-old female with chronic atrial fibrillation and drug resistant 
rapid ventricular response underwent laser catheter modification of the 
atrioventricular node. The procedure reduced mean heart rate during exercise 
from 148 ± 50 to 89 ± 25 beats min(-1) and was without complication.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (therapy)
  catheter ablation
  heart atrioventricular node
  laser coagulation
EMTREE MEDICAL INDEX TERMS
  aged
  article
  case report
  exercise
  female
  heart muscle
  heart rate
  human
  priority journal
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1995353916
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 506
TITLE
  Safety and antithrombotic effects of fixed low-dose warfarin-aspirin 
combination in rheumatic mitral stenosis associated with atrial fibrillation
AUTHOR NAMES
  Handjani A.M.
  Khosropanah S.
  Habibzadeh F.
AUTHOR ADDRESSES
  (Handjani A.M.; Khosropanah S.; Habibzadeh F.) Division of Cardiology, 
Department of Internal Medicine, Shiraz Univ. of Medical Sciences, Shiraz, 
Iran.
CORRESPONDENCE ADDRESS
  A.M. Handjani, Division of Cardiology, Department of Internal Medicine, 
Shiraz Univ. of Medical Sciences, Shiraz, Iran.
SOURCE
  Iranian Journal of Medical Sciences (1995) 20:3-4 (93-95). Date of 
Publication: 1995
ISSN
  0253-0716
ABSTRACT
  The incidence of thromboembolic complications in cases of mitral stenosis 
(MS) associated with atrial fibrillation (AF) is around 20%. To prevent this 
complication, warfarin and aspirin is administered to keep the INR between 2 
and 3. However, this treatment is associated with increased risk of 
hemorrhagic episodes. Fifty-five patients with both rheumatic MS and AF, 
were randomly divided into two groups; Twenty-five patients received 2,5-mg 
of warfarin and 100-mg of aspirin daily, and thirty patients served as 
control. The mean ± SD INR in the treatment group (1.58 ± 0.45) was 
significantly higher than that of the control group (1.175 ± 0.21) (p < 
0.001). Twenty per cent of the control group developed thromboembolic 
complications. However, none of the patients in the treatment group had any 
thromboembolic or hemorrhagic events. No inter- or intra-patient INR 
variability was seen. Therefore, the use of low-dose warfarin-aspirin 
combination for the prevention of thromboembolic complications in patients 
with MS associated with AF is effective and safe, and thus, is strongly 
suggested.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  acetylsalicylic acid (drug combination, drug therapy)
  warfarin (drug combination, drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy)
  mitral valve stenosis (drug therapy)
  thromboembolism (complication, drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  clinical trial
  controlled study
  drug efficacy
  drug safety
  human
  major clinical study
  randomized controlled trial
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Hematology (25)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1996181202
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 507
TITLE
  Clinical interest of once-daily felodipine extended-release in patients with 
mixed and exertional angina: Results of a double-blind crossover study 
versus amlodipine
AUTHOR NAMES
  Corradi L.
  Colombo G.
  Ravera E.
  Lotto A.
AUTHOR ADDRESSES
  (Corradi L.; Colombo G.; Ravera E.; Lotto A.) Schering-Plough SpA, Via 
Ripamonti 89, 20141 Milan, Italy.
CORRESPONDENCE ADDRESS
  E. Ravera, Schering-Plough SpA, Via Ripamonti 89, 20141 Milan, Italy.
SOURCE
  Clinical Drug Investigation (1995) 9:6 (324-333). Date of Publication: 1995
ISSN
  0114-2402
ABSTRACT
  24 patients with mixed or exertional angina pectoris were enrolled in a 
double-blind crossover clinical study to compare the efficacy and safety of 
felodipine extended-release (ER) 10 mg once daily versus amlodipine 10 mg 
once daily. Admission criteria did not restrict patient selection according 
to exercise endurance. The crossover treatment with two 4-week phases 
started after washout of all antianginal drugs except sublingual nitrates. 
Maximal multistage exercise tests were performed before initial 
administration at baseline and 23 hours after the last dose of each of the 2 
study drugs. Two patients dropped out, so that efficacy could be evaluated 
on an intention-to-treat basis in 22 patients (15 with mixed and 7 with 
exertional angina). At baseline the ischaemic threshold (time to onset of ST 
depression 21 mm) was high, with a mean of 485.3 ± 174.8 seconds (n = 22, 
range 180 to 840 seconds). After 4 weeks of treatment, time to test 
termination showed an increase with both drugs, which attained statistical 
significance only with felodipine ER (n = 22, +9.03%; p < 0.05). The 
duration of ischaemia showed a decrease that was more evident with 
felodipine ER (n = 17, -31.19%) than with amlodipine (n = 18, -16.70%), 
without straining statistical significance in either case. The significant 
decrease in maximal ST depression was more evident with felodipine ER (n = 
17, -27.72%; p < 0.001) than with amlodipine (n = 18, -19.12%; p < 0.01). 
Furthermore, the increase in the time to onset of angina attained 
statistical significance with felodipine ER (n = 7, +34.25%; p < 0.05) and 
not with amlodipine (n = 10, +20.72%). The decrease in the duration of 
angina also attained statistical significance with felodipine ER (n = 7, 
-24.34%; p < 0.05) and not with amlodipine (n = 10, -24.58%. Adverse 
reactions occurred with felodipine ER in 2 of 24 (8.3%) cases and with 
amlodipine in 6 of 24 (25%) cases. The most frequent adverse reaction was 
mild to moderate peripheral oedema that occurred only during treatment with 
amlodipine (16.7% cases). The possible pharmacological rationale for the 
better therapeutic results obtained with felodipine ER is discussed by 
considering both its efficacy and safety.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  amlodipine (adverse drug reaction, clinical trial, drug comparison, drug 
therapy)
  felodipine (adverse drug reaction, clinical trial, drug comparison, drug 
therapy, pharmaceutics)
EMTREE DRUG INDEX TERMS
  antacid agent
  antilipemic agent
  antithrombocytic agent
  anxiolytic agent
  glyceryl trinitrate (drug therapy)
  nonsteroid antiinflammatory agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  angina pectoris (drug therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  atrial fibrillation (side effect)
  clinical article
  clinical trial
  controlled study
  crossover procedure
  disease duration
  double blind procedure
  drug efficacy
  drug formulation
  drug safety
  edema (side effect)
  exercise test
  female
  headache (side effect)
  heart muscle ischemia (drug therapy)
  heart palpitation (side effect)
  human
  male
  oral drug administration
  patient selection
  priority journal
  randomized controlled trial
  ST segment depression
  statistical analysis
  sublingual drug administration
  time
CAS REGISTRY NUMBERS
  amlodipine (88150-42-9)
  felodipine (72509-76-3)
  glyceryl trinitrate (55-63-0)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1995180228
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 508
TITLE
  Atrial tissue conductivity and refractoriness in patients with lone 
paroxysmal atrial fibrillation
AUTHOR NAMES
  Papadopoulos C.L.
  Sakadamis G.C.
  Kononidis I.E.
  Kotridis P.S.
  Kyriakou P.A.
  Koukoulekidis G.N.
  Poulantzas N.
  Gitsios C.T.
AUTHOR ADDRESSES
  (Papadopoulos C.L.; Sakadamis G.C.; Kononidis I.E.; Kotridis P.S.; Kyriakou 
P.A.; Koukoulekidis G.N.; Poulantzas N.; Gitsios C.T.) Second Department of 
Cardiology, Aristotle University, Thessaloniki, Greece.
CORRESPONDENCE ADDRESS
  C.L. Papadopoulos, Second Department of Cardiology, Aristotle University, 
Thessaloniki, Greece.
SOURCE
  European Journal of Cardiac Pacing and Electrophysiology (1995) 5:2 (90-96). 
Date of Publication: 1995
ISSN
  0939-6780
ABSTRACT
  Eighty three patients were submitted to electrophysiological study during 
which induction of atrial fibrillation was attempted and atrial 
electrophysiological parameters (effective refractory period and intraatrial 
conduction time) were evaluated. According to the results of the 
electrophysiological study and medical history patients were divided into 
four groups: a) Group SI comprised 19 patients with spontaneous and induced 
episodes of atrial fibrillation. b) Group S comprised 23 patients with 
spontaneous but not induced episodes of atrial fibrillation. c) Group I 
comprised 13 patients with only induced episodes of atrial fibrillation. d) 
Group C comprised 28 patients without spontaneous or induced episodes of 
atrial. fibrillation who served as controls. Group SI had a normal effective 
refractory period but a long intra-atrial conduction time. Group I had an 
effective refractory period shorter than normal under basal conditions which 
was even shorter during rapid pacing. Intra-atrial conduction time in this 
group was normal under basal conditions but was highly increased during 
rapid pacing. Group S had a normal effective refractory period and a 
slightly but not significantly shorter intra-atrial conduction time compared 
with normal values. In conclusion a long intra-atrial conduction time is a 
determinant factor in the pathogenesis of atrial fibrillation while 
effective refractory period plays a facilitating role. Other extrinsic 
factors (e.g. parasympathetic activity) not operating during the 
electrophysiological study might also play a critical role in the induction 
of atrial fibrillation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (etiology)
  heart atrium conduction
  heart electrophysiology
EMTREE MEDICAL INDEX TERMS
  adolescent
  adult
  aged
  article
  controlled study
  female
  heart pacing
  human
  major clinical study
  male
  priority journal
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1995175478
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 509
TITLE
  Short term amiodarone treatment facilitates electrical cardioversion in 
patients with chronic atrial flutter/fibrillation
AUTHOR NAMES
  Jong G.-P.
  Hou Z.-Y.
  Juang G.-H.
  Chen C.-Y.
AUTHOR ADDRESSES
  (Jong G.-P.; Hou Z.-Y.; Juang G.-H.; Chen C.-Y.) Division of Cardiology, 
Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung 813, Taiwan.
CORRESPONDENCE ADDRESS
  C.-Y. Chen, Division of Cardiology, Veterans General Hospital, 386 Ta-Chung 
1st Road, Kaohsiung 813, Taiwan.
SOURCE
  Acta Cardiologica Sinica (1995) 11:1 (39-46). Date of Publication: 1995
ISSN
  1011-6842
ABSTRACT
  Background. Conversion of atrial flutter/fibrillation, either by electrical 
cardioversion or by drugs, often ameliorates patients' symptoms, reduces the 
risk of ischemic stroke and improves cardiovascular hemodynamics. To 
evaluate whether four week therapy of amiodarone (200 mg Tid, PO) can 
facilitate the success of electrical cardioversion (EC), a prospective trial 
was performed for two groups of patients. Methods. Eighty-seven cases were 
collected from December 1991 to October 1993, all with chronic atrial 
flutter (AF)/fibrillation(Af) for more than six months and adequate 
anticoagulation. For AF, EC started with energy 10, then 20, 50, 100, 200, 
300 and up to 360 Joules; for Af, EC started with 100, and then 200, 300, 
and up to 360 Joules. Success of cardioversion indicated the restoration of 
normal sinus rhythm (NSR), and lasted for at least 24 hours. Group 1, 43 
patients (36 males, 7 females, and aged 62 ± 11 years) served as controls, 
receiving no amiodarone. Group 2, 44 patients (38 males, 6 females, aged 63 
± 12 years) received amiodarone therapy before EC was carried out. Results. 
Seven patients (16%) in Group 2, converted on amiodarone alone. Success rate 
of EC was 58% and 87%, respectively, for Groups 1 and 2. The target and 
accumulated energy required for successful EC were significantly higher in 
Group 1 (293 ± 63 and 596 ±240 J) than in Group 2 (176 ± 93 and 318 ± 220 J) 
(p < 0.05). There was no difference between surgery and balloon 
valvuloplasty patients in the success rate or energy required for EC. No 
Group 2 patient suffered any side effect from amiodarone throughout the 
course of the study. Conclusion. Short-term amiodarone does facilitate the 
success of EC and maintenance of NSR during short-term follow-up, without 
significant side effect.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  amiodarone (drug comparison, drug therapy)
EMTREE DRUG INDEX TERMS
  placebo (drug comparison)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation (drug therapy, therapy)
  heart atrium flutter (drug therapy, therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  cardioversion
  chronic disease
  clinical trial
  controlled study
  drug effect
  facilitation
  female
  human
  major clinical study
  male
CAS REGISTRY NUMBERS
  amiodarone (1951-25-3, 19774-82-4, 62067-87-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, Chinese
EMBASE ACCESSION NUMBER
  1995122138
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 510
TITLE
  A comparison between single atrial and dual chamber rate adaptive (AAIR and 
DDDR) and non adaptive AAI and DDD cardiac pacing using cardiopulmonary 
exercise testing in patients with atrial chronotropic incompetence
AUTHOR NAMES
  Lamaison D.
  Page E.
  Aupetit J.F.
  Defaye P.
  Rozand J.Y.
  Mouton E.
  Salvi R.
AUTHOR ADDRESSES
  (Lamaison D.; Page E.; Aupetit J.F.; Defaye P.; Rozand J.Y.; Mouton E.; 
Salvi R.) Service de Cardiologie, Hopital G Montpied Place, H Dunant, 63000 
Clermont-Ferrand, France.
CORRESPONDENCE ADDRESS
  D. Lamaison, Service de Cardiologie, Hopital G Montpied Place, H Dunant, 
63000 Clermont-Ferrand, France.
SOURCE
  European Journal of Cardiac Pacing and Electrophysiology (1993) 3:3 
(197-204). Date of Publication: 1993
ISSN
  0939-6780
ABSTRACT
  In 19 patients in whom atrial chronotropic incompetence had been 
demonstrated before pacemaker implantation, (defined as heart rate during 
maximal treadmill exercise < 100 beats/mn) a minute ventilation sensor, dual 
chamber rate-adaptive pacemaker was implanted (META DDDR 1250, Telectronics, 
Englewood, Colorado). Eleven had associated sino-atrial block, 7 had 
brady-tachy syndrome, 2 had second or third degree atrioventricular block. 
An incremental, symptom-limited, single blind randomly assigned 
cardiopulmonary exercise test using a bicycle ergometer was performed in 
respectively DDD and DDDR or AAI and AAIR modes on the same day, 137 days 
(32-418) after pacemaker implantation in 14 patients. Exercise tests could 
not be achieved in five patients, due to permanent atrial fibrillation in 4 
and pacemaker failure in one. Despite partial regression or complete 
disappearance of the atrial chronotropic incompetence in some patients, the 
rate adaptive, as compared with the non adaptive mode, significantly 
improved exercise duration (512 ± 41 s vs 471 ± 38 s p = 0.028), maximal 
work rate (96.7 ± 41.4 W vs 88.5-38.7 W, p = 0.001), the time of occurrence 
of anaerobic threshold (398 ± 148 s vs 327 ± 133 s p = 0.0015), the oxygen 
uptake at anaerobic threshold (14.97 ± 5.11 ml/kg/mn vs 12.96 ± 4.55 
ml/kg/mn, p = 0.0015), and the work rate at anaerobic threshold (75 ± 42 W 
vs 57.14 ± 37 W, p = 0.0032). Thus AAIR or DDDR mode is strongly recommended 
in patients with atrial chronotropic incompetence.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart atrium
  heart failure (therapy)
  heart pacing
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  article
  artificial heart pacemaker
  atrial fibrillation (complication)
  atrioventricular block (complication, therapy)
  bicycle ergometry
  clinical article
  clinical trial
  controlled study
  exercise test
  female
  heart rate
  heart sinoatrial block (complication, therapy)
  human
  intermethod comparison
  lung minute volume
  male
  oxygen consumption
  pacemaker failure (complication)
  randomized controlled trial
  sinus node disease (therapy)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English, French, German
EMBASE ACCESSION NUMBER
  1993351284
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 511
TITLE
  Weekly clinicopathological exercises
AUTHOR NAMES
  Nash I.S.
  Dinsmore R.E.
  Fallon J.T.
  Hansell D.M.
  Gilbert J.
AUTHOR ADDRESSES
  (Nash I.S.; Dinsmore R.E.; Fallon J.T.; Hansell D.M.; Gilbert J.) 
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United 
States.
CORRESPONDENCE ADDRESS
  I.S. Nash, Massachusetts General Hospital, Harvard Medical School, Boston, 
MA, United States.
SOURCE
  New England Journal of Medicine (1993) 330:2 (126-134). Date of Publication: 
1993
ISSN
  0028-4793
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  constrictive pericarditis (diagnosis, etiology, therapy)
  mitral valve regurgitation (diagnosis, etiology, therapy)
EMTREE MEDICAL INDEX TERMS
  adult
  amyloidosis
  angiocardiography
  article
  asbestosis
  atrial fibrillation
  calcification
  case report
  clinical feature
  differential diagnosis
  heart muscle biopsy
  hemochromatosis
  human
  male
  pericardiectomy
  priority journal
  recurrent disease
  sarcoidosis
  tuberculosis
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1994027950
FULL TEXT LINK
  http://dx.doi.org/10.1056/NEJM199401133300209
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 512
TITLE
  The safety and utility of exercise testing in octogenarians
AUTHOR NAMES
  Martin D.
  Graboys T.B.
AUTHOR ADDRESSES
  (Martin D.; Graboys T.B.) Lown Cardiovascular Laboratory, 21 Longwood 
Avenue, Boston, MA 02115, United States.
CORRESPONDENCE ADDRESS
  T.B. Graboys, Lown Cardiovascular Laboratory, 21 Longwood Avenue, Boston, MA 
02115, United States.
SOURCE
  American Journal of Noninvasive Cardiology (1992) 6:6 (345-348). Date of 
Publication: 1992
ISSN
  0258-4425
ABSTRACT
  We reviewed 112 treadmill exercise tests performed by 62 octogenarian 
patients between 1980 and 1988. Forty were male, and mean age was 82 with 
range 80-88. The indications for testing were comparable to those in a 
younger population. The average exercise duration was 252 s, and there was a 
wide range of hemodynamic responses to exercise with a peak heart rate range 
of 50-210 bpm, and peak blood pressure range of 90-250/40-120 mm Hg. 
Exercise provoked repetitive ventricular ectopy in 23 (21%) tests, and 
atrial fibrillation was present during 13 (12%). No life-threatening 
complications were provoked by exercise, and no tests led to 
hospitalization. No patient required cardioversion. We conclude that 
symptom-limited treadmill testing in octogenarians can be safely and 
usefully performed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aged
  exercise test
  safety
EMTREE MEDICAL INDEX TERMS
  article
  atrial fibrillation
  blood pressure
  female
  heart rate
  heart ventricle extrasystole
  hemodynamics
  human
  human experiment
  male
  treadmill exercise
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Physiology (2)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1993040357
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 513
TITLE
  Lone atrial fibrillation. It needn't slow down an active patient
AUTHOR NAMES
  Cantwell J.D.
  Lammert S.
  Kessler C.
AUTHOR ADDRESSES
  (Cantwell J.D.; Lammert S.; Kessler C.) Preventive Medicine Center, Georgia 
Baptist Hospital, 300 Boulevard NE, Atlanta, GA 30312
CORRESPONDENCE ADDRESS
  Preventive Medicine Center, Georgia Baptist Hospital, 300 Boulevard NE, 
Atlanta, GA 30312
SOURCE
  Physician and Sportsmedicine (1991) 19:8 (71-72+75-76+78-82). Date of 
Publication: 1991
ISSN
  0091-3847
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  alcohol
  atenolol (drug therapy)
  caffeine
  digoxin (drug therapy)
  quinidine gluconate (drug therapy)
  warfarin (drug therapy)
EMTREE DRUG INDEX TERMS
  acetylsalicylic acid (drug therapy)
  antiarrhythmic agent (drug therapy)
  propranolol (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  atrial fibrillation (complication, drug therapy, etiology, rehabilitation, 
therapy)
  cold
  drinking
  exercise
  jogging
  sports medicine
  Wolff Parkinson White syndrome (complication)
EMTREE MEDICAL INDEX TERMS
  adult
  article
  cerebrovascular accident (etiology)
  clinical article
  heart arrhythmia (complication, drug therapy, etiology, rehabilitation, 
therapy)
  human
  male
  paroxysmal supraventricular tachycardia (drug therapy, etiology, 
rehabilitation)
  thyrotoxicosis (complication)
DRUG TRADE NAMES
  aspirin
CAS REGISTRY NUMBERS
  acetylsalicylic acid (493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1)
  alcohol (64-17-5)
  atenolol (29122-68-7)
  caffeine (30388-07-9, 58-08-2)
  digoxin (20830-75-5, 57285-89-9)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
  quinidine gluconate (7054-25-3)
  warfarin (129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Occupational Health and Industrial Medicine (35)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1991349342
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 514
TITLE
  Superior vena cava and ventricular inflow in constrictive pericarditis and 
restrictive cardiomyopathy as measured by pulsed doppler echocardiography
AUTHOR NAMES
  Izumi S.
  Miyatake K.
  Beppu S.
  Morioka S.
  Nagata S.
  Sakakibara H.
  Moriyama K.
  Nimura Y.
AUTHOR ADDRESSES
  (Izumi S.; Miyatake K.; Beppu S.; Morioka S.; Nagata S.; Sakakibara H.; 
Moriyama K.; Nimura Y.) National Cardiovascular Center, Research Institute 
and Hospital, Osaka
CORRESPONDENCE ADDRESS
  National Cardiovascular Center, Research Institute and Hospital, Osaka
SOURCE
  Journal of Cardiovascular Technology (1990) 9:1 (19-24). Date of 
Publication: 1990
ISSN
  0730-8396
ABSTRACT
  In patients with either constrictive pericarditis (13 cases) or restrictive 
cardiomyopathy (6 cases), right atrial filling and both right and left 
ventricular filling were analyzed by pulsed Doppler echocardiography. 
Sixteen healthy volunteers, and 14 cases with lone atrial fibrillation, 
served as controls. In patients with constrictive pericarditis, a reduction 
in the right atrial filling velocity during ventricular systole, and a 
shortening in the right atrial filling time during systole and diastole, 
were noted. In patients with restrictive myocardial disease, similar 
findings were noted during ventricular systole, but no difference from 
healthy subjects was noted during diastole. Regarding ventricular filling, 
in constrictive pericarditis a shortening of the rapid filling time in the 
right ventricle was noted, while the restrictive myocardial disease patients 
showed an abnormality only in the early phase of the left ventricular rapid 
filling and no abnormality in right ventricular rapid filling. We conclude 
that right atrial and ventricular fillings in constrictive pericarditis and 
restrictive myocardial disease are different from normal and from each 
other.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardiomyopathy
  pericarditis
EMTREE MEDICAL INDEX TERMS
  adult
  article
  clinical article
  Doppler echocardiography
  female
  human
  male
  methodology
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Physiology (2)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1990331971
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 515
TITLE
  Adaptive rate pacing at submaximal exercise: The importance of the 
programmed upper rate
AUTHOR NAMES
  Lau C.-P.
  Leung W.-H.
  Wong C.-K.
  Cheng C.-H.
  Tai Y.-T.
AUTHOR ADDRESSES
  (Lau C.-P.; Leung W.-H.; Wong C.-K.; Cheng C.-H.; Tai Y.-T.) Department of 
Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
CORRESPONDENCE ADDRESS
  Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong 
Kong
SOURCE
  Journal of Electrophysiology (1989) 3:4 (283-288). Date of Publication: 1989
ISSN
  0892-1059
ABSTRACT
  The contributions of rate response and different programmed upper rates to 
submaximal exercise were studied in 12 patients with implanted adaptive rate 
pacemakers (9 Meta, 3 Activitrax). Their median age was 69 years (range 
33-80). All were paced from the right ventricle except for one patient with 
sinoatrial disease who received an atrial Meta pacemaker. In the constant 
rate pacing (SSI) mode, the reproducibility of a submaximal stress test 
(maximum distance covered within a 12-minute walking test) was investigated 
by repeating the test three times. An initial training effect was observed 
between the first and the second test, but no further increase in walking 
distance occurred between the second and third test and the distances 
covered were highly reproducible (r = 0.99). The rate adaptive function was 
activated with the upper rate randomly programmed to 100, 125, 150, and 165 
beats/min. Compared with exercise in the SSI mode, rate adaptive pacing with 
the upper rate programmed to 125 and 150 beats/min resulted in enhancement 
of exercise distance (4.7% ± 1.2% and 4.4% ± 1.2%, respectively, P < 0.005). 
Upper rates of 100 and 165 beats/min did not improve submaximal exercise 
performance, and at an upper rate of 165 beats/min, three patients developed 
complications (angina, dyspnea, and atrial fibrillation). It is concluded 
that the 12-minute walking test is a reproducible method to assess exercise 
capacity in pacemaker patients. Adaptive rate pacing improved exercise 
performance during daily activities, although the extent of the benefit 
appeared to be small and dependent on the programmed upper rate. An exercise 
test such as a 12-minute walking test should be performed before a high 
upper rate is programmed.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise
  heart rate
  pacemaker
  tachycardia
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  clinical article
  clinical trial
  controlled study
  human
  randomized controlled trial
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1989261149
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 516
TITLE
  Comparison of VVIR, DDD, and DDDR pacing
AUTHOR NAMES
  Jutzy R.V.
  Isaeff D.M.
  Bansal R.C.
  Florio J.
  Marsa R.J.
  Jutzy K.R.
AUTHOR ADDRESSES
  (Jutzy R.V.; Isaeff D.M.; Bansal R.C.; Florio J.; Marsa R.J.; Jutzy K.R.) 
Section of Cardiology, Department of Medicine, Loma Linda University Medical 
Center, Loma Linda, CA 92354
CORRESPONDENCE ADDRESS
  Section of Cardiology, Department of Medicine, Loma Linda University Medical 
Center, Loma Linda, CA 92354
SOURCE
  Journal of Electrophysiology (1989) 3:3 (194-201). Date of Publication: 1989
ISSN
  0892-1059
ABSTRACT
  In the past several years there has been continued improvement in pacemaker 
technology, resulting in the availability of a large variety of pacemaker 
generators and pacing modes. The introduction of single-chamber rate 
modulated pacemakers provided a further improvement in pacing therapy. With 
the recent introduction of dual-chamber rate responsive pacemakers, it is 
now possible to more closely restore physiological function with pacing in a 
large number of patients. In deciding which pacing mode is most beneficial 
to a given patient, it is essential to understand the various 
characteristics of the different pacing modes that are available. It is 
essential to have knowledge of the underlying electrophysiological 
characteristics of the patient and how they would be affected by the 
different modes available. The VVIR mode will control bradycardia and 
provide rate adaptation but at the expense of AV synchrony. The DDD mode 
will control bradycardia and provide AV synchrony, but will not provide rate 
adaptation in patients with chronotropic incompetence. The DDDR mode will 
control bradycardia, maintain AV synchrony, and provide for rate adaptation 
in the presence of chronotropic incompetence. The chronotropic response to 
physiological stress and/or pacemaker syndrome are major determining factors 
in the choice of the best pacing mode. The primary goal of pacing therapy is 
to restore the heart function as close as possible to normal. When at all 
possible, this should include provision of both AV synchrony and rate 
modulation. The DDDR mode is preferable in most patients since it is capable 
of providing both AV synchrony and rate response (except those with chronic 
supraventricular arrhythmias). The VVIR mode is as effective in patients who 
have chronic atrial fibrillation or frequent episodes of supraventricular 
arrhythmias.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  artificial heart pacemaker
  heart rate
EMTREE MEDICAL INDEX TERMS
  exercise
  human
  short survey
  therapy
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1989191770
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 517
TITLE
  Rehabilitation in patients after commissurotomy and artificial valve 
replacement
AUTHOR NAMES
  Rudnicki S.
  Slipko Z.
  Wojtkowska E.
  Latuchowska B.
  Bilinska M.
AUTHOR ADDRESSES
  (Rudnicki S.; Slipko Z.; Wojtkowska E.; Latuchowska B.; Bilinska M.) 
Institute of Cardiology, 04-628 Warsaw
CORRESPONDENCE ADDRESS
  Institute of Cardiology, 04-628 Warsaw
SOURCE
  Rehabilitacia Supplementum (1988) 21:36-37 (20-26). Date of Publication: 
1988
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  breathing exercise
  ergometry
  heart valve replacement
  heart valve surgery
  kinesiotherapy
  valvuloplasty
EMTREE MEDICAL INDEX TERMS
  adult
  complication
  education
  female
  human
  major clinical study
  male
  rehabilitation
  sex difference
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1989018396
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 518
TITLE
  Maximal steptreadmill exercise and treadmill exercise by patients with 
coronary heart disease: A comparison
AUTHOR NAMES
  Holland G.J.
  Weber F.
  Heng M.K.
  Reese S.S.
  Marin J.J.
  Vincent W.J.
  Mayers M.M.
  Hoffmann J.J.
  Caston A.L.
AUTHOR ADDRESSES
  (Holland G.J.; Weber F.; Heng M.K.; Reese S.S.; Marin J.J.; Vincent W.J.; 
Mayers M.M.; Hoffmann J.J.; Caston A.L.) Exercise Physiology Laboratory, 
California State University, Northridge, CA 91330
CORRESPONDENCE ADDRESS
  Exercise Physiology Laboratory, California State University, Northridge, CA 
91330
SOURCE
  Journal of Cardiopulmonary Rehabilitation (1988) 8:2 (58+63-68). Date of 
Publication: 1988
ISSN
  0883-9212
ABSTRACT
  Thirteen male patients from a phase III community cardiac rehabilitation 
program were maximally exercise tested by use of a modified Bruce treadmill 
protocol and a newly developed revolving-stair ergometer. The study design 
provided for approximately equivalent metabolic work in each of four stages 
on the two test modes. Results showed that there were no significant 
differences in peak response to the two test modes as measured by maximal 
oxygen consumption, maximal heart rate, maximal systolic blood pressure, 
maximal ventilation, respiratory exchange ratio, and peak work time. 
Significant differences in physiologic response were manifest only between 
stages in the same exercise mode. The patients with cardiac disease did not 
achieve predicted MET response on either of the two ergometry modes at 
higher stages of work. No significant differences in clinical manifestations 
were observed between conventional treadmill exercise and revolving-stair 
ergometer exercise. Steptreadmill ergometry may be a valid alternative 
ergometry mode for testing and training clinically stable and moderately fit 
populations of patients with cardiac disease.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  coronary artery bypass graft
  exercise test
  heart infarction (rehabilitation)
  ischemic heart disease
  treadmill
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  clinical article
  education
  human
  male
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  1988068595
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 519
TITLE
  Transient thickening of left ventricular wall of the heart accompanied with 
arrhythmias, atrio-ventricular conduction disturbances and decrease of 
physical exercise capacity during the endurance training of 13 years old boy
AUTHOR NAMES
  Karvonen J.
  Uusitalo A.
AUTHOR ADDRESSES
  (Karvonen J.; Uusitalo A.) Department of Clinical Physiology, University 
Hospital, Tampere
CORRESPONDENCE ADDRESS
  Department of Clinical Physiology, University Hospital, Tampere
SOURCE
  International Journal of Sports Cardiology (1985) 2:1 (61-66). Date of 
Publication: 1985
ISSN
  0393-6066
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrioventricular block
  endurance
  heart arrhythmia
  heart left ventricle hypertrophy
EMTREE MEDICAL INDEX TERMS
  adolescent
  age
  case report
  controlled study
  diagnosis
  etiology
  heart
  human
  training
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Occupational Health and Industrial Medicine (35)
  Pediatrics and Pediatric Surgery (7)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1986036957
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 520
TITLE
  Induction of supraventricular tachyarrhythmia at rest and during exercise 
with transesophageal atrial pacing in the electrophysiological evaluation of 
asymptomatic athletes with cardiac preexcitation: Report on 56 consecutive 
athletes
AUTHOR NAMES
  Vergara G.
  Disertori M.
  Bettini R.
AUTHOR ADDRESSES
  (Vergara G.; Disertori M.; Bettini R.) Divisione di Cardiologia e Centro 
Aritmologico, Ospedale S. Chiara, Trento
CORRESPONDENCE ADDRESS
  Divisione di Cardiologia e Centro Aritmologico, Ospedale S. Chiara, Trento
SOURCE
  New Trends in Arrhythmias (1985) 1:3 (315-319). Date of Publication: 1985
ISSN
  0393-5302
ABSTRACT
  56 symptom-free athletes with cardiac preexcitation (W.P.W.) and without 
heart disease underwent a study protocol whose end-point was the induction 
of supraventricular tachyarrhythmia (S.T.A.), i.e. atrial fibrillation or, 
if not possible, atrial flutter or atrial tachycardia, in basal state and 
under ergometric stress test, with the evaluation of the shortest R-R 
interval between preexcited beats. This study was carried out in order to 
evaluate the electrophysiological patterns of the athletes and their fitness 
for sports activity. In 52 subjects an atrial fibrillation and in 2 a S.T.A. 
at synchronized electrical activity were induced; in 2 subjects it was not 
possible to induce any S.T.A. According to our criterion, i.e. shortest R-R 
interval ≤ 240 ms in basal state, and/or ≤ 210 ms under ergometric stress 
test, 22/54 athletes (40.7%) were judged as being at risk. The discrepancy 
with respect to the usual non-invasive evaluation (i.e. Holter monitoring, 
ergometric stress test, ajmaline test) was of 37%. On the basis of the basal 
state evaluation, we were able to identify only 15 athletes as being at 
risk, while on the basis of the complete study protocol 22 athletes were 
judged as such. Therefore, the induction of S.T.A. under ergometric stress 
test increased the diagnosis power by 31.8%. On the basis of our results we 
conclude: the non-invasive evaluation of the electrophysiological patterns 
of the W.P.W. athletes is inadequate. The induction of hyperkinetic 
supraventricular arrhythmia under ergometric stress test gives a remarkable 
increase of the diagnostic power with respect to the evaluation only in 
basal state. Since it is simple to execute and economical, and because of 
its high diagnostic yield, we regard this protocol as fundamental for the 
electrophysiological evaluation of W.P.W. athletes. The method is also able 
to the systematic study of W.P.W. in non-athletes.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  esophagus
  heart pacing
  supraventricular tachycardia
  Wolff Parkinson White syndrome
EMTREE MEDICAL INDEX TERMS
  diagnosis
  heart
  heart ventricle fibrillation
  human
  major clinical study
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1987037694
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 521
TITLE
  Physical capacity of older patients with atrial flutter and fibrillation
AUTHOR NAMES
  Schwela H.
  Oltmanns G.
  Gerlach B.
AUTHOR ADDRESSES
  (Schwela H.; Oltmanns G.; Gerlach B.)
SOURCE
  Rehabilitacia Supplementum (1985) 18:30-31 (114-124). Date of Publication: 
1985
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  bicycle ergometry
  exercise
  heart arrhythmia
  heart rate
  oxygen consumption
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  cardiovascular system
  diagnosis
  heart
  human
  human experiment
  normal human
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Gerontology and Geriatrics (20)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1986021253
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 522
TITLE
  Progress in the study of Wolff-Parkinson-White syndrome of the athletes. The 
transesophageal atrial pacing during bicycle exercise
AUTHOR NAMES
  Furlanello F.
  Vergara G.
  Bettini R.
AUTHOR ADDRESSES
  (Furlanello F.; Vergara G.; Bettini R.) Divisione di Cardiologia, Ospedale 
S. Chiara, 38100 Trento
CORRESPONDENCE ADDRESS
  Divisione di Cardiologia, Ospedale S. Chiara, 38100 Trento
SOURCE
  International Journal of Sports Cardiology (1984) 1:2 (102-110). Date of 
Publication: 1984
ISSN
  0393-6066
ABSTRACT
  When the talk about 'siletn arrhythmogenic cardiopathy of the athlete', we 
mean the existence of risk of sudden dropout of the cardiac electric 
stability which may result in sudden death during or immediately after the 
athletic effort. This implies the presence of a cardiopathy, even totally 
asymptomatic, or of a primary electrical cardiac alteration such as the 
Wolff-Parkinson-White (W.P.W.) syndrome. The prognostic arrhythmologic 
evaluation of the athletes must include the study of the arrhythmias in a 
situation as similar as possible to that of the athletic effort of the 
subject. We have developed a method which can be adapted for the athletes, 
for the electrophysiological study of the W.P.W. This method involves 
inducing atrial fibrillation by means of transesophageal pacing during 
bicycle ergometer tests. With this method it is possible to see immediately 
the electrophysiological and clinical consequences of the atrial 
fibrillation in each athlete with W.P.W. during physical effort, even though 
asymptomatic. The advantage of this simple and rapid method, which does not 
require X-ray control for positioning of the catheter, is that it does not 
require 'hospitalisation', thus permitting frequent check-ups of 
electrophysiological characteristics of arrhythmias both for subjects at 
risk and for ones who appear to be fit.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  athlete
  heart arrhythmia
  heart disease
  sudden death
  Wolff Parkinson White syndrome
EMTREE MEDICAL INDEX TERMS
  adult
  case report
  clinical article
  diagnosis
  electrocardiography
  esophagus
  etiology
  exercise test
  fatality
  heart
  heart atrium pacing
  human
  methodology
EMBASE CLASSIFICATIONS
  Public Health, Social Medicine and Epidemiology (17)
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1985090612
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 523
TITLE
  Exercise test in patients with atrial flutter and fibrillation
AUTHOR NAMES
  Schwela H.
  Oltmanns G.
  Gerlach B.
AUTHOR ADDRESSES
  (Schwela H.; Oltmanns G.; Gerlach B.) Dep. Cardiol., Med. Acad., Erfurt
CORRESPONDENCE ADDRESS
  Dep. Cardiol., Med. Acad., Erfurt
SOURCE
  Rehabilitacia Supplementum (1982) 15:25 (36-43). Date of Publication: 1982
ABSTRACT
  Our experience permits to raise the questions for the characteristics of the 
exercise response of patients with atrial fibrillation or flutter. The 
following statements should be made: Patients with atrial fibrillation and 
flutter can be stressed on a bicycle ergometer by giving consideration to 
the usual indications and contra-indications. A higher risk in the 
examination that can be deduced from the relative frequency of additional 
dysrhythmias could not be observed in our patients. Exact monitoring of the 
cardiac rhythm, however, is essential. The exercise capacity as compared to 
untrained healthy subjects is considerably reduced however, in single 
patients it must be considered normal or even outstanding. General physical 
exhaustion, dyspnea and muscular fatigue dominate as symptoms limiting the 
exercise. A tendency towards tachycardic exercise response is markedly 
dominating, especially in cases with valvular heart disease. No conclusion 
as to the maximum stress tolerance of the single patient can be drawn from 
the heart rate response: Maximal or almost maximal mean heart rates can be 
tolerated for a longer time under exercise, in some cases even an increase 
in the work loads is tolerated. Relative bradycardia and the inability to 
change the heart rate were to be considered as rare findings. The 
recommendation of an exercise stop at fixed boundary heart rates must be 
considered inadequate in evaluating patients with artial fibrillation and 
flutter. Blood pressure regulation in most cases was normotensive or 
hypertensive, respectively. An excessive stress hypertension was observed 
regardless of the heart rate response. The double product shows a broad 
range of scatter and correlates to the exercise tolerance and oxygen uptake 
only in rough. Repoloarisation abnormalities in the ECG appear in 85 p.c. of 
the patients, considerably more frequently when being treated with 
glycoside. For the differentiation of a myocardial ischemic exercise 
response the repolarisation patterns in patients with atrial fibrillation 
and flutter apparently is not mainly determined by the hemodynamic effects 
of the dysrhythmias, but by the degree of severity of the basic heart 
disease with its hemodynamic and myocardial factors instead.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  bicycle ergometry
  exercise electrocardiography
  heart rate
  oxygen consumption
EMTREE MEDICAL INDEX TERMS
  cardiovascular system
  heart
  human
  major clinical study
  therapy
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1983084426
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 524
TITLE
  Safety of exercise testing volunteer subjects: the Lipid Research Clinics' 
Prevalence Study experience
AUTHOR NAMES
  Sheffield L.T.
  Haskel W.
  Heiss G.
AUTHOR ADDRESSES
  (Sheffield L.T.; Haskel W.; Heiss G.) Cent. Electrocardiogr. Lab., Univ. 
Alabama Sch. Med., Univ. Alabama, Birmingham, AL 35294
CORRESPONDENCE ADDRESS
  Cent. Electrocardiogr. Lab., Univ. Alabama Sch. Med., Univ. Alabama, 
Birmingham, AL 35294
SOURCE
  Journal of Cardiac Rehabilitation (1982) 2:5 (395-400). Date of Publication: 
1982
ISSN
  0275-1429
ABSTRACT
  Previous reports of the complication rates of near-maximal and maximal 
exercise tests have involved the limited experience of one or a few 
coordinated laboratories or have represented surveys of facilities employing 
diverse protocols and instrumentation. We report the experience of 12 widely 
separated laboratories employing identical protocols and equipment. 
Near-maximal graded treadmill exercise tests were performed by 9,464 men and 
women participants in the Lipid Research Clinics' Prevalence Survey. 
Subjects were randomly selected (N = 5,317) or were hyperlipidemic (N = 
4,147). Participants exercised to 85% to 90% of age-adjusted predicted 
maximal heart rate unless medical contraindication to continued exercise or 
limiting symptoms occurred first. Electrocardiographic data, blood pressure, 
appearance, and symptoms were monitored at rest and during exercise and 
recovery. No deaths, myocardial infarctions, or cardiac arrests occurred 
during or within 24 hours following testing. Runs of two or more ventricular 
premature complexes occurred in 127 tests, but all spontaneously reverted to 
normal sinus rhythm. Ten subjects experienced chest discomfort that lasted 
10 minutes or longer without further complications. Atrial fibrillation, 
vasovagal collapse, and nausea with chest pain lasting 24 hours without 
sequelae occurred once each. These data indicate that near-maximal and 
maximal testing can be performed safely with proper screening and 
monitoring.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise electrocardiography
  hyperlipidemia
  treadmill ergometry
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  cardiovascular system
  diagnosis
  heart
  human
  human experiment
  normal human
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Physiology (2)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1983225367
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 525
TITLE
  Arrhythmias caused by exercise
AUTHOR NAMES
  Goldschlager N.
AUTHOR ADDRESSES
  (Goldschlager N.) Dep. Med., Univ. California, San Francisco, CA
CORRESPONDENCE ADDRESS
  Dep. Med., Univ. California, San Francisco, CA
SOURCE
  Primary Cardiology (1982) 8:7 (97-108). Date of Publication: 1982
ISSN
  0363-5104
ABSTRACT
  In patients with coronary artery disease, exercise-induced ventricular 
arrhythmias serve as a marker for severe vascular involvement and left 
ventricular dysfunction. Such arrhythmias include ventricular and 
supraventricular tachyarrhythmias, bradyarrhythmias, and atrioventricular 
block. Ventricular arrhythmias may be of greater concern, but the discovery 
and management of supraventricular arrhythmias and AV conduction 
disturbances are also highly significant in individual patient management. 
Supraventricular arrhythmias do not necessarily connote heart disease - 
specifically coronary artery disease - but ventricular arrhythmias are often 
associated with serious heart disease. Management of exercise-induced 
arrhythmias is usually accomplished with the use of a beta-blocking agent or 
a Type 1 antiarrhythmic agent, although total suppression of the arrhythmia 
is not always achieved.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise
  heart arrhythmia
EMTREE MEDICAL INDEX TERMS
  etiology
  heart
  therapy
EMBASE CLASSIFICATIONS
  Rehabilitation and Physical Medicine (19)
  Occupational Health and Industrial Medicine (35)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1982226706
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 526
TITLE
  Arrhythmias caused by exercise. Part II
AUTHOR NAMES
  Goldschlager N.
AUTHOR ADDRESSES
  (Goldschlager N.) Univ. California, San Francisco, CA
CORRESPONDENCE ADDRESS
  Univ. California, San Francisco, CA
SOURCE
  Primary Cardiology (1982) 8:8 (15-25). Date of Publication: 1982
ISSN
  0363-5104
ABSTRACT
  In patients with coronary artery disease, exercise induced ventricular 
arrhythmias serve as a marker for severe vascular involvement and left 
ventricular dysfunction. Such arrhythmias include ventricular and 
supraventricular tachyarrhythmias, bradyarrhythmias, and atrioventricular 
block. Ventricular arrhythmias may be of greater concern, but the discovery 
and management of supraventricular arrhythmias and AV conduction 
disturbances are also highly significant in individual patient management. 
Supraventricular arrhythmias do not necessarily connote heart disease - 
specifically coronary artery disease - but ventricular arrhythmias are often 
associated with serious heart disease. Management of exercise-induced 
arrhythmias is usually accomplished with the use of a beta-blocking agent or 
a Type 1 antiarrhythmic agent, although total suppression of the arrhythmia 
is not always achieved.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  antiarrhythmic agent
  beta adrenergic receptor blocking agent
  calcium antagonist
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise
  heart arrhythmia
  ischemic heart disease
EMTREE MEDICAL INDEX TERMS
  clinical study
  heart
  short survey
  survey
  therapy
EMBASE CLASSIFICATIONS
  Occupational Health and Industrial Medicine (35)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1982208881
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 527
TITLE
  Effect of propranolol on exercise capacity in chronic atrial fibrillation
AUTHOR NAMES
  Brink L.S.
  Moss K.A.
  Ustby P.A.
AUTHOR ADDRESSES
  (Brink L.S.; Moss K.A.; Ustby P.A.) La Crosse Exercise Program, Res. Unit, 
Univ. Wisconsin, La Crosse, Wis.
CORRESPONDENCE ADDRESS
  La Crosse Exercise Program, Res. Unit, Univ. Wisconsin, La Crosse, Wis.
SOURCE
  Medicine and Science in Sports and Exercise (1979) 11:1 (110). Date of 
Publication: 1979
ISSN
  0195-9131
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  digoxin
  propranolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  work capacity
EMTREE MEDICAL INDEX TERMS
  abstract report
  case report
  exercise
  heart
CAS REGISTRY NUMBERS
  digoxin (20830-75-5, 57285-89-9)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
EMBASE CLASSIFICATIONS
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1979253188
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 528
TITLE
  Role of exercise stress testing in assessing digoxin dosage in chronic 
atrial fibrillation
AUTHOR NAMES
  Davidson D.M.
  Hagan A.D.
AUTHOR ADDRESSES
  (Davidson D.M.; Hagan A.D.) Div. Cardiol., Nav. Reg. Med. Cent., San Diego, 
Calif.
CORRESPONDENCE ADDRESS
  Div. Cardiol., Nav. Reg. Med. Cent., San Diego, Calif.
SOURCE
  Cardiovascular Medicine (1979) 4:6 (671-678). Date of Publication: 1979
ISSN
  0199-6614
ABSTRACT
  Relying on the resting ventricular rate as an index to digoxin efficacy in 
patients with chronic atrial fibrillation may result in suboptimal dosage. 
Conversely, signs of digitalis toxicity are often overlooked in these 
patients. To determine optimal daily dosage, 11 patients were studied by 
serial multistage maximal exercise treadmill tests. All patients were taking 
at least 0.25 mg digoxin daily when the study was begun, but in each case 
the dosage appeared suboptimal. When their doses were increased, all 
patients showed both subjective and objective improvement in exercise 
tolerance; the mean heart rate and systolic blood pressure, and the 
rate-pressure product, were lowered in the resting, exercise, and recovery 
states, and maximal tolerable exercise levels were increased. Thus exercise 
testing provides a useful means of assessing digitalis dosage so as to 
ensure optimal cardiac performance and exercise capacity in the patient with 
chronic atrial fibrillation.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  digoxin
  furosemide
  propranolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  exercise
  exercise electrocardiography
  exercise test
  heart ventricle rate
EMTREE MEDICAL INDEX TERMS
  drug dose
  drug therapy
  heart
  therapy
DRUG TRADE NAMES
  inderal
  lanoxin
  lasix
CAS REGISTRY NUMBERS
  digoxin (20830-75-5, 57285-89-9)
  furosemide (54-31-9)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Rehabilitation and Physical Medicine (19)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1979234752
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 529
TITLE
  Wolff Parkinson White syndrome. (Study of 20 symptomatic cases)
AUTHOR NAMES
  Das J.P.
AUTHOR ADDRESSES
  (Das J.P.) Dept. Cardiol., SCB Med. Coll., Cuttack
CORRESPONDENCE ADDRESS
  Dept. Cardiol., SCB Med. Coll., Cuttack
SOURCE
  Indian Heart Journal (1973) 25:sup (237-242). Date of Publication: 1973
ISSN
  0019-4832
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  procainamide
  propranolol
  quinidine
EMTREE DRUG INDEX TERMS
  verapamil
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  clinical study
  diagnosis
  drug therapy
  electrocardiography
  exercise
  heart failure
  internal medicine
  paroxysmal tachycardia
  Wolff Parkinson White syndrome
EMTREE MEDICAL INDEX TERMS
  drug administration
  major clinical study
  methodology
  therapy
DRUG TRADE NAMES
  isoptin
CAS REGISTRY NUMBERS
  procainamide (51-06-9, 614-39-1)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
  quinidine (56-54-2)
  verapamil (152-11-4, 52-53-9)
EMBASE CLASSIFICATIONS
  Cardiovascular Diseases and Cardiovascular Surgery (18)
  Drug Literature Index (37)
  Internal Medicine (6)
LANGUAGE OF ARTICLE
  English
EMBASE ACCESSION NUMBER
  1975079792
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 530
TITLE
  Acupuncture for cardioversion.
AUTHOR NAMES
  Berman R.H.
AUTHOR ADDRESSES
  (Berman R.H.)
CORRESPONDENCE ADDRESS
  R.H. Berman,
SOURCE
  Annals of internal medicine (1973) 79:2 (285). Date of Publication: Aug 1973
ISSN
  0003-4819
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  acupuncture
  atrial fibrillation (therapy)
  tachycardia (therapy)
EMTREE MEDICAL INDEX TERMS
  aged
  article
  female
  human
  male
  middle aged
LANGUAGE OF ARTICLE
  English
MEDLINE PMID
  4726548 (http://www.ncbi.nlm.nih.gov/pubmed/4726548)
COPYRIGHT
  MEDLINE® is the source for the citation and abstract of this record.

RECORD 531
TITLE
  The prognostic significance of certain clinical and roentgenological data 
for assessment of danger from mitral commissurotomy
AUTHOR NAMES
  Putov N.V.
  Gorentsvit I.E.
  Koblents Mishke A.I.
AUTHOR ADDRESSES
  (Putov N.V.; Gorentsvit I.E.; Koblents Mishke A.I.) Kaf. Obshch. Khir., 
Voenno Med. Akad., Leningrad, Russian Federation.
CORRESPONDENCE ADDRESS
  N.V. Putov, Kaf. Obshch. Khir., Voenno Med. Akad., Leningrad, Russian 
Federation.
SOURCE
  Kardiologiya (1972) 12:10 (53-57). Date of Publication: 1972
ISSN
  0022-9040
ABSTRACT
  A study was made of 57 cases of severely ill patients (27 with lethal 
outcome, 30 survivals) who had had at least one of the three following signs 
of severity of circulatory failure: (1) auricular fibrillation (40 
patients); (2) cardiomegaly with a cardiothoracic index not less than Wt (20 
cases); and (3) terminal (dystrophic) stage of circulatory failure (21 
patients). An electronic computer was used to study all the paired 
combinations from 18 clinical and X ray signs. A number of unusual 
relationships were recorded. For instance, any considerable degree of 
dyspnea was an unfavorable prognostic sign only when the volume of the heart 
exceeded 1400 cm' and when corresponding disorders had already affected the 
state of general nutrition of the patient. A substantial increase of the 
size of the liver unprovoked by a secondary pulmonary hypertension proved to 
be more dangerous than a similar increase of the liver size in patients with 
considerable widening of the pulmonary artery. A bad prognosis was noted in 
cases of marked dilatation of the left atrium, which is always accompanied 
by auricular fibrillation. When no such dilatation existed an operation was 
roughly equally dangerous with sinus rhythm as with auricular fibrillation.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  mitral valve commissurotomy
EMTREE MEDICAL INDEX TERMS
  angiocardiography
  atrial fibrillation
  cardiomegaly
  computer
  dyspnea
  heart
  heart left atrium
  ischemia
  liver
  liver size
  nutrition
  patient
  prognosis
  pulmonary artery
  pulmonary hypertension
  sinus rhythm
  survival
  thorax radiography
  X ray
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008449458
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 532
TITLE
  The effect of digitalis on the heart rate during exercise in patients with 
atrial fiberillation
AUTHOR NAMES
  Aberg H.
  Strom G.
  Werner I.
AUTHOR ADDRESSES
  (Aberg H.; Strom G.; Werner I.) Dept Int. Med, Univ. Hasp, Uppsala, Sweden.
CORRESPONDENCE ADDRESS
  H. Aberg, Dept Int. Med, Univ. Hasp, Uppsala, Sweden.
SOURCE
  Acta Mbd. Acand. (1972) 191:5 (109-113). Date of Publication: 1972
ABSTRACT
  Twenty eight clinically compensated cardiac patients with atrial 
fibrillation were investigated with the graded exercise teat Twenty four 
patients had one test with a lowci doae of digitalis and one with a higher 
dose, both doae rates being within the therapeutic range. Four panents 
performed one exercise teat with and one without digital!s. The heart 
(ventricular) rate attained at a given exercise load was significantly lower 
(with a difference of 5-25 beats/min at the different loads) with the higher 
dose. This was interpreted as a beneficial effect on working capacity. The 
individual beat to beat variability of heart rate was not influenced. The 
beneficial effect of an increase in digitalis dose thus seems to depend on a 
decrease in average ventricular rate during exercise and not on a decreased 
degree of arrhythmia.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise
  heart rate
  patient
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  cardiac patient
  exercise test
  heart arrhythmia
  nipple
  work capacity
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008772619
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 533
TITLE
  Effects of practolol administration on cardiac and renal function in 
patients with chronic atrial fibrillation
AUTHOR NAMES
  Gibson D.G.
AUTHOR ADDRESSES
  (Gibson D.G.) Dept. Cardiol., St Bartholomew's Hospn, London.
CORRESPONDENCE ADDRESS
  D.G. Gibson, Dept. Cardiol., St Bartholomew's Hospn, London.
SOURCE
  Acta Cardiol (1972) 15 (139-148). Date of Publication: 1972
ABSTRACT
  Studies in patients with chronic atrial fibrillation suggest that practolol 
is tees likely than propranolol to cause a reduction in cardiac output, an 
increase in left ventricular filling pressure or renal sodium retention. 
These results suggest that practolol has a place in the treatment of 
patients with chronic atrial fibrillation, particularly in those in whom 
inappropriate tachycardia on exercise is a significant cause of symptoms.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  practolol
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent
  propranolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  kidney function
  patient
EMTREE MEDICAL INDEX TERMS
  aged
  aging
  angina pectoris
  athlete
  exercise
  exercise tolerance
  heart arrhythmia
  heart disease
  heart left ventricle filling pressure
  heart output
  kidney
  sodium retention
  tachycardia
CAS REGISTRY NUMBERS
  practolol (6673-35-4)
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008772623
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 534
TITLE
  Evaluation of the pulse contour method of determining stroke volume in man
AUTHOR NAMES
  Alderman E.L.
  Branzi A.
  Sanders W.
AUTHOR ADDRESSES
  (Alderman E.L.; Branzi A.; Sanders W.) Cardiol. Biostatist. Div., Stanford 
Univ., Sch. Med., Stanford, CA, United States.
CORRESPONDENCE ADDRESS
  E.L. Alderman, Cardiol. Biostatist. Div., Stanford Univ., Sch. Med., 
Stanford, CA, United States.
SOURCE
  Circulation (1972) 46:3 (1243-1245). Date of Publication: 1972
ISSN
  0009-7322
ABSTRACT
  The pulse contour method for determining stroke volume has been employed as 
a continuous rapid method of monitoring the cardiovascular status of 
patients. Twenty one patients with ischemic heart disease and 21 patients 
with mitral valve disease were subjected to a variety of hemodynamic 
interventions. These included exercise, isoproterenol infusion, and 
practolol, morphine or pentazocine administration. The pulse contour 
estimations, using 3 different formulae derived by Warner, Kouchoukos, and 
Herd, were compared with indicator dilution outputs. The pressure pulse 
contour computations were performed by a small on line cardiac 
catheterization laboratory computer. A comparison of the results of the 2 
methods for determining stroke volume yielded correlation coefficients 
ranging from 0.59 to 0.84. The better performing Warner formula yielded a 
coefficient of variation of about 20% The type of hemodynamic interventions 
employed did not significantly affect the results using the pulse contour 
method. This method yielded nearly as reliable results with the catheter 
positioned in the axillary artery as in the central aorta. Good results were 
obtained using the pulse contour method in patients with atrial fibrillation 
as compared to those with sinus rhythm. Although the correlation of the 
pulse contour and indicator dilution stroke volumes is high, the coefficient 
of variation is such that small changes in stroke volume cannot be 
accurately assessed by the pulse contour method. However, the simplicity and 
rapidity of this method compared to determination of cardiac output by Fick 
or indicator dilution methods makes it a potentially useful adjunct for 
monitoring critically ill patients.
EMTREE DRUG INDEX TERMS
  isoprenaline
  morphine
  pentazocine
  practolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart stroke volume
  human
  pulse rate
EMTREE MEDICAL INDEX TERMS
  aorta
  atrial fibrillation
  axillary artery
  blood
  blood pressure
  catheter
  computer
  correlation coefficient
  critically ill patient
  dilution
  exercise
  heart
  heart catheterization
  heart disease
  heart output
  herd
  indicator dilution curve
  infusion
  ischemic heart disease
  laboratory
  mitral valve disease
  monitoring
  patient
  sinus rhythm
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008637576
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 535
TITLE
  Hemodynamic effects of cardioversion in chroaic atrical fibrillation. 
special reference to ceronary artery disease
AUTHOR NAMES
  Khaja F.
AUTHOR ADDRESSES
  (Khaja F.) Parker Univ., Kingston.
CORRESPONDENCE ADDRESS
  F. Khaja, Parker Univ., Kingston.
SOURCE
  Arch. Intern.Med. (1972) 129:3 (419-422). Date of Publication: 1972
ABSTRACT
  The heroodynamic effects of conversion in chronic «trial fibrillation (AF) 
were studied in eight patients with coronary artery disease (CAD) (group 1) 
and five patients with AF of varied etiology (group 2). The resting stroke 
index (SI) in group 1 increased from 28 2 ml/sq m to 34.6 ml/sq m (p>) 30 
minutes after conversion but the other parameters did not change. In 
patients who maintained normal sinus rhythm (NSR) three weeks following 
cardioversion the response to exercise was improved, with lower heart rate 
and higher cardiac index (CIX SI and stroke work (SWX In relating filling 
pressures to SW, ventricular function was improved with NSR Right atrial a 
waves returned simultaneously with NSR in 75% of patients whereas left 
atrial a waves appeared in 55%. Patients who failed to develop left atrial a 
waves immediately after cardioversion reverted to AF within three weeks.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  artery disease
  cardioversion
  hemodynamics
EMTREE MEDICAL INDEX TERMS
  A wave
  atrial fibrillation
  cerebrovascular accident
  coronary artery disease
  etiology
  exercise
  exercise test
  heart arrhythmia
  heart disease
  heart index
  heart rate
  heart ventricle function
  ischemic heart disease
  patient
  sinus rhythm
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008772664
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 536
TITLE
  Influence of nitrazepam on oral anticoagulation with phenprocoumon
AUTHOR NAMES
  Bieger R.
  De Jonge H.
  Loeliger E.A.
AUTHOR ADDRESSES
  (Bieger R.; De Jonge H.; Loeliger E.A.) Haematology Division, Department of 
Internal Medicine, Department of Medical Statistics, Leiden University 
Hospital, Leiden, Netherlands.
SOURCE
  Clinical Pharmacology and Therapeutics (1972) 13:3 (361-365). Date of 
Publication: 1 May 1972
ISSN
  1532-6535 (electronic)
  0009-9236
BOOK PUBLISHER
  Nature Publishing Group, Houndmills, Basingstoke, Hampshire, United Kingdom.
ABSTRACT
  A double-blind trial was carried out on 22 volunteer patients to observe the 
influence of nitrazepam on the course of long-term anticoagulant therapy 
with phenprocoumon. Dosage of phenprocoumon remained unchanged for all 
patients during the 8 week trial. Nitrazepam or placebo, assigned at random, 
was taken every night for a 2 week period; a subsequent 2 week period 
without test drugs was followed by a second series with the other tablet. 
The last 2 weeks of the trial were without test drugs. There was no 
difference between the effects of the placebo and the nitrazepam on the 
hypocoagulability due to the oral anticoagulant therapy. It is concluded 
that nitrazepam can safely be prescribed as a hypnotic for patients on 
long-term anticoagulant therapy.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  nitrazepam (clinical trial, drug comparison - placebo, drug interaction)
  phenprocoumon (clinical trial, drug interaction, drug therapy, oral drug 
administration)
EMTREE DRUG INDEX TERMS
  placebo
  prothrombin complex (endogenous compound)
  secbutabarbital
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  anticoagulant therapy
EMTREE MEDICAL INDEX TERMS
  adult
  aged
  anesthesia level
  angina pectoris (drug therapy)
  article
  atrial fibrillation (drug therapy)
  blood clotting test
  blood clotting time
  clinical article
  controlled study
  double blind procedure
  evening dosage
  heart infarction (drug therapy)
  human
  middle aged
  outcome assessment
  peripheral occlusive artery disease (drug therapy)
  pilot study
  priority journal
  randomized controlled trial
DRUG TRADE NAMES
  liquamar
  marcumar
  mogadon
CAS REGISTRY NUMBERS
  nitrazepam (146-22-5)
  phenprocoumon (435-97-2)
  prothrombin complex (37224-63-8)
  secbutabarbital (125-40-6, 143-81-7)
EMBASE CLASSIFICATIONS
  Anesthesiology (24)
  Hematology (25)
  Drug Literature Index (37)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  20160024650
MEDLINE PMID
  4554660 (http://www.ncbi.nlm.nih.gov/pubmed/4554660)
FULL TEXT LINK
  http://dx.doi.org/10.1002/cpt1972133361
COPYRIGHT
  Copyright 2016 Elsevier B.V., All rights reserved.

RECORD 537
TITLE
  Efectroversion of lone atrial fibrillation and flutter including 
haemodynaniic studies at rest and on exercise -
AUTHOR NAMES
  Resnekov L.
  McDonald L.
AUTHOR ADDRESSES
  (Resnekov L.; McDonald L.) Inst. Cardiol., Nat Heart Hosp., London.
CORRESPONDENCE ADDRESS
  L. Resnekov, Inst. Cardiol., Nat Heart Hosp., London.
SOURCE
  Britheart J. (1971) 33:3 (339-350). Date of Publication: 1971
ABSTRACT
  Thirty patients with atrial fibrillation and seven with atrial flutter, all 
of whom were carefully examined to exclude any associated underlying heart 
disease, were treated by direct current shock. Sinus rhythm was achieved in 
24 of the 30 patients with atrial fibrillation; all patients with atrial 
flutter were brought into sinus rhythm. The incidence of complications was 
particularly high in those with lone atrial fibrillation and could be 
related to the higher energy level setting required. No complications 
occurred in the group treated for lone atrial flutter in whom low energy 
level settings were uniformly successful. Only 4 patients treated for atrial 
fibrillation remained in sinus rhythm at the end of a 36 mth followup. 
Reversion to the dysrhythmia occurred within minutes or days of 
electroversion and the majority who reverted did so within the first month. 
Quinidine was of little use in maintaining sinus rhythm. In contrast, 
patients with lone atrial flutter maintained sinus rhythm for a 
significantly longer period of time. Four of the patients with atrial 
fibrillation and 2 with atrial flutter were studied at rest and on graded 
exercise before and after conversion to sinus rhythm. Clear hemodynamic 
evidence of the benefit of sinus rhythm was obtained, particularly at the 
higher levels of exercise which could be related not only to the longer 
diastolic filling time in sinus rhythm, but also to the booster action of 
atrial systole. Despite the evidence of hemodynamic benefit in sinus rhythm, 
it is concluded that there is no indication for attempting to convert 
asymptomatic lone atrial fibrillation to sinus rhythm by direct current 
shock. This dysrhythmia is relatively resistant to treatment, complications 
are frequent, and sinus rhythm is maintained for a disappointingly short 
time. Patients with lone atrial flutter, however, are converted to sinus 
rhythm with relatively low electrical energies; complications are therefore 
fewer and sinus rhythm is maintained more frequently. Thus with lone atrial 
flutter, electroversion is usually indicated.
EMTREE DRUG INDEX TERMS
  quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  exercise
EMTREE MEDICAL INDEX TERMS
  direct current
  follow up
  heart atrium contraction
  heart atrium flutter
  heart disease
  patient
  sinus rhythm
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008469645
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 538
TITLE
  R/R interval analysis at rest and during exercise in patients with atrial 
fibrillation and in healthy subjects
AUTHOR NAMES
  Bootsma B.K.
AUTHOR ADDRESSES
  (Bootsma B.K.)
SOURCE
  Van Gorcum. Assen (1971). Date of Publication: 1971
ABSTRACT
  In this monograph the electrophysiological properties of atrial activation 
in atrial fibrillation are discussed. Studying healthy subjects and patients 
with atrial fibrillation both with and without the use of digitalis, the 
author concludes that the absolute irregular ventricular rhythm in atrial 
fibrillation is not determined exclusively by properties of the 
atrioventricular node. The statement is made that the irregular ventricular 
rhythm is mainly determined by the occurrence of random spaced series of 
atrial activation of random strength. The given facts are statistically 
analyzed.
EMTREE DRUG INDEX TERMS
  cardiac glycoside
  digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  exercise
  normal human
  patient
EMTREE MEDICAL INDEX TERMS
  atrioventricular conduction
  book
  heart atrioventricular node
  heart atrium arrhythmia
  heart atrium conduction
  heart muscle refractory period
  hypertension
  rhythm
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008528498
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 539
TITLE
  Phannacokinetics of gentamicin. distribution and plasma and renal clearance
AUTHOR NAMES
  Gyselynck A.M.
  Forrey A.
  Cutler R.
AUTHOR ADDRESSES
  (Gyselynck A.M.; Forrey A.; Cutler R.) Dept. Med., Harborview Med. Cent, 
Seattle, WA, United States.
CORRESPONDENCE ADDRESS
  A.M. Gyselynck, Dept. Med., Harborview Med. Cent, Seattle, WA, United 
States.
SOURCE
  J.Infect.Dis. (1971) 124 (s70-s76). Date of Publication: 1971
ABSTRACT
  The renal clearance and volume of distribution of gentamicin was measured by 
the continuous infusion technique in 18 patients with different degrees of 
renal function. Renal clearance of gentamicin did not differ from that of 
inulin. Because 20%-30% of gentamicin in serum is bound to protein, it is 
likely that some of the antibiotic is secreted by the renal tubules. The 
mean apparent volume of distribution of gentamicin was 24% of the body 
weight and was comparable to that of inulin. Twenty additional patients were 
studied; gentamicin, inulin, and radioactive iothalamate were injected by a 
single injection technique. The clearance of these compounds from plasma was 
slightly greater than their renal clearance, which suggests extrarenal 
elimination. Confirmatory evidence was seen in the lack of total urinary 
excretion. The half life in plasma of all compounds correlated well except 
in cases of severe renal failure, where half life of gentamicin was 
unusually prolonged due to a larger distribution volume. A formula for the 
calculation of half life of gentamicin in plasma is given.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  gentamicin
EMTREE DRUG INDEX TERMS
  antibiotic agent
  digoxin
  inulin
  iotalamic acid
  protein
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  plasma
  renal clearance
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  body weight
  continuous infusion
  ergometry
  exercise
  half life time
  injection
  kidney failure
  kidney function
  kidney tubule
  patient
  serum
  urinary excretion
  volume of distribution
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008445576
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 540
TITLE
  Sinus brsdycardia
AUTHOR NAMES
  Eraut D.
  Shaw D.B.
AUTHOR ADDRESSES
  (Eraut D.; Shaw D.B.) Cardiac Dept., Roy ai Devon and Exeter Hosp., Exeter.
CORRESPONDENCE ADDRESS
  D. Eraut, Cardiac Dept., Roy ai Devon and Exeter Hosp., Exeter.
SOURCE
  British Heart Journal (1971) 33:5 (742-749). Date of Publication: 1971
ISSN
  0007-0769
ABSTRACT
  This paper presents the features of 46 patients with unexplained 
bradycardia. Patients were admitted to the study if their resting atrial 
rate was below 56 a min on two consecutive occasions. Previous 
electrocardiograms and the response to exercise, atropine, and isoprenaline 
were studied. The ages of the patients varied from 13 to 88 years. Only 8 
had a past history of cardiovascular disease other than bradycardia, but 36 
had syncopal or dizzy attacks. Of the 46 patients, 35 had another arrhythmia 
in addition to bradycardia; at some stage, 16 had sinus arrest, 15 had 
junctional rhythm, 12 had fast atrial arrhythmia, 16 had frequent 
extrasystoles, and 6 had atrioventricular block. None had the classical 
features of sinoatrial block. Arrhythmias were often produced by exercise, 
atropine, or isoprenaline. Drug treatment was rarely satisfactory, but only 
1 patient needed a permanent pacemaker. It is suggested that the majority of 
the patients were suffering from a pathological form of sinus bradycardia. 
The aetiology remains unproven, but the most likely explanation is a loss of 
the inherent rhythmicity of the sinoatrial node due to a primary 
degenerative disease. The descriptive title of the lazy sinus syndrome1 is 
suggested.
EMTREE DRUG INDEX TERMS
  atropine
  isoprenaline
EMTREE MEDICAL INDEX TERMS
  Arthus phenomenon
  artificial heart pacemaker
  aspergillosis
  atrioventricular block
  atrioventricular junction arrhythmia
  bradycardia
  cardiovascular disease
  degenerative disease
  drug therapy
  electrocardiogram
  etiology
  exercise
  extrasystole
  heart arrhythmia
  heart atrium arrhythmia
  heart sinoatrial block
  lung disease
  patient
  sinus arrest
  sinus bradycardia
  sinus node
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008444402
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 541
TITLE
  Effect of propranolol on exercise tolerance of patients with alrial 
fibrillation
AUTHOR NAMES
  Brown R.W.
  Goble A.J.
AUTHOR ADDRESSES
  (Brown R.W.; Goble A.J.) Roy. Melbourne Hosp., Melbourne.
CORRESPONDENCE ADDRESS
  R.W. Brown, Roy. Melbourne Hosp., Melbourne.
SOURCE
  Britmed.J. (1969) 2:5652 (496-499). Date of Publication: 1969
ABSTRACT
  Six patients with atrial fibrillation who were taking digitalis were 
exercised before and after 30 mg of propranolol twice daily. Though there 
was a lower pulse rate at rest and on exercise in all patients, three 
suffered deterioration of exercise tolerance. It is concluded that 
propranolol does not improve the exercise tolerance of patients with atrial 
fibrillation whose resting ventricular rate is controlled with digitalis.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  propranolol
EMTREE DRUG INDEX TERMS
  digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise tolerance
  patient
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  deterioration
  exercise
  exercise test
  pulse rate
CAS REGISTRY NUMBERS
  propranolol (13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008755819
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 542
TITLE
  Effects of ouabain on the memodynamic kesponse to exercise in patients with 
mitral stenosis in normal sinus rhythm
AUTHOR NAMES
  Beiser G.D.
  Epstein S.E.
  Stampfer M.
  Robinson B.
  Braunwald E.
AUTHOR ADDRESSES
  (Beiser G.D.; Epstein S.E.; Stampfer M.; Robinson B.; Braunwald E.) C 
Ardiol. Branch, Nat. Heart Inst., Bethesda, MD, United States.
CORRESPONDENCE ADDRESS
  G.D. Beiser, C Ardiol. Branch, Nat. Heart Inst., Bethesda, MD, United 
States.
SOURCE
  New England journal of medicine (Print) (1968) 278:3 (131-137). Date of 
Publication: 1968
ISSN
  0028-4793
ABSTRACT
  The efficacy of cardiac glycosides was evaluated in 8 symptomatic patients 
with pure mitral stenosis in normal sinus rhythm and in 3 patients in atrial 
fibrillation. The patients were studied at rest and during moderate and 
intense levels of treadmill exercise before and after the acute i.v. 
administration of ouabain. During maximal exercise ouabain slowed the 
ventricular rate considerably in 2 of the 3 patients in atrial fibrillation, 
and this reduction was associated with significant hemodynamic improvement. 
However, in the patients in sinus rhythm ouabain produced no significant 
change in heart rate and had no beneficial effect on cardiac output, oxygen 
consumption or severity of pulmonary hypertension either at rest or during 
exercise. Since patients with pure mitral stenosis in normal sinus rhythm 
are not benefited by the acute administration of ouabain, there is a 
reasonable doubt whether the routine use of digitalis in the medical 
management of such patients is advisable.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  ouabain
EMTREE DRUG INDEX TERMS
  cardiac glycoside
  digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise
  mitral valve stenosis
  patient
  sinus rhythm
EMTREE MEDICAL INDEX TERMS
  acute drug administration
  atrial fibrillation
  disease management
  heart output
  heart performance
  heart rate
  oxygen consumption
  pulmonary hypertension
  treadmill exercise
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007811844
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 543
TITLE
  Diazepam. A useful hypnotic drug for direct-current cardioversion.
AUTHOR NAMES
  Winters Jr. W.L.
  McDonough M.T.
  Hafer J.
  Dietz R.
AUTHOR ADDRESSES
  (Winters Jr. W.L.; McDonough M.T.; Hafer J.; Dietz R.)
CORRESPONDENCE ADDRESS
  W.L. Winters,
SOURCE
  JAMA : the journal of the American Medical Association (1968) 204:10 
(926-928). Date of Publication: 3 Jun 1968
ISSN
  0098-7484
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  diazepam (drug therapy)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  cardioversion
  heart arrhythmia (therapy)
EMTREE MEDICAL INDEX TERMS
  adolescent
  adult
  aged
  article
  atrial fibrillation (therapy)
  blood pressure
  breathing
  drug effect
  female
  heart atrium flutter (therapy)
  heart rate
  heart ventricle fibrillation (therapy)
  human
  male
  middle aged
  tachycardia (therapy)
CAS REGISTRY NUMBERS
  diazepam (439-14-5)
LANGUAGE OF ARTICLE
  English
MEDLINE PMID
  5694607 (http://www.ncbi.nlm.nih.gov/pubmed/5694607)
COPYRIGHT
  MEDLINE® is the source for the citation and abstract of this record.

RECORD 544
TITLE
  Electrolyte and water distribution in familial hypokalaemic periodic 
paralysis
AUTHOR NAMES
  Coppen A.J.
AUTHOR ADDRESSES
  (Coppen A.J.) Med. Res. Counc, Neuropsychiat. Res. CJnIt4 West Park Hoep, 
Epsom.
CORRESPONDENCE ADDRESS
  A.J. Coppen, Med. Res. Counc, Neuropsychiat. Res. CJnIt4 West Park Hoep, 
Epsom.
SOURCE
  Journal of Neurology, Neurosurgery and Psychiatry (1966) 29:2 (107-112). 
Date of Publication: 1966
ISSN
  0022-3050
ABSTRACT
  Distribution of water, sodium, and potassium was studied by a multiple 
isotope technique in apatients with familial hypokalemic periodic paralysis. 
One patient aged 60, had developed a proximal myopathy confirmed by biopsy, 
he had moreover a mild hypertension, cardiac enlargement, auricular 
fibrillation and inversion of ã-waves on his ECG. It remains unsettled 
whether these cardiac abnormalities are part of the periodic paralysis. Ail 
patients had a low total body potassium (K) and low intracellular K 
concentration between attacks. Residual sodium (Na) concentration was 
normal. Total body water, and its partition between intracellular and 
extracellular spaces were normal. Treatment with a low-Na diet and K 
supplements in one patient resulted in the return of intracellular K to 
normal, considerable elevation of residual Na and decrease in the volume of 
intracellular water. Marked clinical improvement was seen.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  electrolyte
EMTREE DRUG INDEX TERMS
  isotope
  potassium
  sodium
  water
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  periodic paralysis
  water supply
EMTREE MEDICAL INDEX TERMS
  A wave
  aged
  atrial fibrillation
  biopsy
  borderline hypertension
  cardiomegaly
  case study
  diet
  electrocardiogram
  electrocorticography
  extracellular space
  hypokalemic periodic paralysis
  myopathy
  patient
  total body potassium
  total body water
CAS REGISTRY NUMBERS
  water (7732-18-5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007907346
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 545
TITLE
  Treatment of cardiac arrhythmias in unanesthetized patients. Role of 
adrenergic beta receptor blockade
AUTHOR NAMES
  Bath J.C.J.L.
AUTHOR ADDRESSES
  (Bath J.C.J.L.) Cardiac Dept., West. Gen. Hosp., Edinburgh.
CORRESPONDENCE ADDRESS
  Cardiac Dept., West. Gen. Hosp., Edinburgh.
SOURCE
  American journal of cardiology (1966) 18:3 (416-425). Date of Publication: 
1966
ISSN
  0002-9149
ABSTRACT
  Fifty-two patients with cardiac arrhythmia were treated by the β adrenergic 
blocking agents, propranolol and pronethalol. The overall conversion rate to 
sinus rhythm was 44%. Conversion was more frequent in atrial tachycardia 
with atrioventricular block and paroxysmal supraventricular tachycardia 
(71%) than in ventricular tachycardia (55%) and in atrial fibrillation or 
flutter (13%). Severe side effects developed in 4 cases: hypotension twice 
and pulmonary edema twice. There were 4 deaths within approximately 24 hr of 
starting treatment, but beta blockade therapy was considered a possible 
contributory factor in only one. Moderate side effects occurred in a further 
9 patients and included nausea, dizziness, headache, weakness and epigastric 
discomfort. It is concluded that propranolol is the treatment of choice for 
atrial tachycardia with atrioventricular block. It is also of use in the 
management of recurrent paroxysmal supraventricular tachycardia not 
controlled by digitalis. It is effective for the control of fast ventricular 
rates in atrial fibrillation and atrial flutter, but clinical improvement 
does not necessarily follow and conversion to sinus rhythm is unusual. 
Ventricular extrasystoles are reduced in number in some patients, and the 
response may depend on their mode of production. Adrenergic beta blockade 
can be effective in terminating ventricular tachycardia but severe 
hypotension may occur, and other methods of treatment are preferable. It may 
prevent recurrent bouts of ventricular tachycardia, especially those due to 
drugs or exercise.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  beta adrenergic receptor
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent
  digitalis
  pronetalol
  propranolol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  beta adrenergic receptor blocking
  heart arrhythmia
  patient
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  atrioventricular block
  death
  dizziness
  epigastric discomfort
  exercise
  headache
  heart atrium flutter
  heart ventricle extrasystole
  heart ventricle tachycardia
  hypotension
  lung edema
  nausea
  paroxysmal supraventricular tachycardia
  pressoreceptor
  side effect
  sinus rhythm
  supraventricular tachycardia
  therapy
  weakness
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007873596
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 546
TITLE
  Alcoholic cardiomyopathy
AUTHOR NAMES
  Dines D.E.
AUTHOR ADDRESSES
  (Dines D.E.)
CORRESPONDENCE ADDRESS
  D.E. Dines, Rochester, MN, United States.
SOURCE
  Rocky Mtn Med. J. (1965) 62:1 (617-621). Date of Publication: 1965
ABSTRACT
  A case of alcoholic cardiomyopathy is reported. Electrocardiograms of this 
patient were typical of the entity, consisting of sinus tachycardia, supra 
ventricular tachycardia, atrial fibrillation, and abnormal P-wave and T-wave 
changes. These electrocardiographic changes occurred in an alcoholic male 
each time following heavy alcohol intake. The electrocardiographic 
abnormalities were associated clinically with a rapid pulse rate and an 
increase in the mean blood pressure. The electrocardiogram reversed to 
normal prior to discharge from the hospital. The patient herein described 
has had a balanced diet and been physically active. It is thought that in 
this case alcohol has a direct toxic effect on the myocardium and that 
neither nutrition nor vitamin deficiency has played a role. Alcoholic 
cardiomyopathy has been reviewed.
EMTREE DRUG INDEX TERMS
  alcohol
  corticotropin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alcoholic cardiomyopathy
EMTREE MEDICAL INDEX TERMS
  alcohol consumption
  alcoholism
  atrial fibrillation
  cardiomyopathy
  diet
  ECG abnormality
  electrocardiogram
  heart disease
  heart muscle
  heart ventricle tachycardia
  hospital
  male
  mean arterial pressure
  nutrition
  P wave
  patient
  pulse rate
  sinus tachycardia
  T wave
  toxicity
  vitamin deficiency
CAS REGISTRY NUMBERS
  alcohol (64-17-5)
  corticotropin (11136-52-0, 9002-60-2, 9061-27-2)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007871445
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 547
TITLE
  Some data on atherosclerotic cardiosclerosis in very old people (Russian)
AUTHOR NAMES
  Chebotarev D.F.
  Korkuehko O.V.
  Sachuk N.N.
  Voloshchenko I.I.
AUTHOR ADDRESSES
  (Chebotarev D.F.; Korkuehko O.V.; Sachuk N.N.; Voloshchenko I.I.) Inet. 
Ofgerontol, USSR Acad. of Med. Scis, Kiev, Ukraine.
CORRESPONDENCE ADDRESS
  D.F. Chebotarev, Inet. Ofgerontol, USSR Acad. of Med. Scis, Kiev, Ukraine.
SOURCE
  Krovoobrashchenie Starost (1965) (159-166). Date of Publication: 1965
ABSTRACT
  Data were obtained on cardiovascular function and its anomalies in subjects 
aged 80- 89 and 90 yr. and over on a mass survey basis in Ukraine embracing 
12.600 subjects of these ages with special detailed investigation of 181 of 
them. More than 1/2 the subjects had clinical evidence of cardiosclerosis 
and 10% had hypertension; these were more pronounced infernales than in 
males, and were more frequent in town dwellers than in rural inhabitants. 
Cardiosclerosis was more frequent in those who had formerly been occupied in 
mental work, and it was less frequent among those who had habitually 
subsisted on a milk and vegetable dietary regime. More detailed 
(instrumental) investigation showed atherosclerotic cardiosclerosis to be 
present in all of the 181 cases so investigated, itsgrade being mild to 
moderate in 83% and severe in 17%. Clinical manifestations and pain were 
infrequent. Electrocardiography was performed: the pulse rate was below 
70/min. in 43%. 70- 90/min. in 50% and over 90/min. in 7%. Arrhythmia was 
noted in 36% of cases of mild cardiosclerosis and in 50% of those with 
severe cardiosclerosis. most often in the form of auricular extrasystole, 
less often ventricular extrasystole and and least often auricular 
fibrillation. Duration of electric systole of the heart was prolonged in 
65.2% of cases, and there was left deviation of the electric axis in 84%, 
The systemic blood pressure was not greatly influenced by the 
atherosclerosis of vessels. In the event of acute myocardial infarction 
acute cardiovascular failure frequently ensued rapidly. Kozhura - Kiev.
EMTREE DRUG INDEX TERMS
  adenosine triphosphate
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart muscle fibrosis
  very elderly
EMTREE MEDICAL INDEX TERMS
  acute heart infarction
  aged
  atherosclerosis
  atrial fibrillation
  blood pressure
  cardiovascular function
  city
  coronary artery atherosclerosis
  electrocardiography
  extrasystole
  heart
  heart arrhythmia
  heart ventricle extrasystole
  hypertension
  male
  milk
  pain
  pulse rate
  systole
  Ukraine
  vegetable
CAS REGISTRY NUMBERS
  adenosine triphosphate (15237-44-2, 56-65-5, 987-65-5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008131551
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 548
TITLE
  Acquired heart disease and cerebral embolism
AUTHOR NAMES
  Nakayama K.
AUTHOR ADDRESSES
  (Nakayama K.) Tokyo Wom. Med. Coll., Tokyo, Japan.
CORRESPONDENCE ADDRESS
  K. Nakayama, Tokyo Wom. Med. Coll., Tokyo, Japan.
SOURCE
  Resp. Circulat. (1965) 13:5 (343-349). Date of Publication: 1965
ABSTRACT
  Among 878 patients hospitalized for heart disease, 67 (7.6%) developed 91 
attacks of cerebral embolism. The incidence was highest (8%) in cases of 
mitral stenosis. Atrial fibrillation was an important predisposing factor. 
In more than half of the cases, cerebral embolism occurred within 1 yr. 
after the onset of atrial fibrillation. Cerebral embolism occurring within 1 
yr. after the start of digitalis treatment was found in 87%. Its incidence 
was especially high in patients who had been fully digitalized rapidly. The 
degree of cardiac enlargement and the cerebral embolism were not correlated, 
but cerebral embolism was frequent in cases of heart disease with cardiac 
enlargement other than mitral stenosis. There was little correlation between 
the severity of heart disease and the incidence of cerebral embolism. There 
was no relationship between physical exertion and cerebral embolism. The 
initial attack of cerebral embolism was seen most frequently in patients 
aged 14-35 yr., especially 31-35 yr. The male/female ratio for hemiplegia 
was 39/28. Paralysis was seen on the left side in 42 and on the right side 
in 46. Repeated episodes of cerebral embolism occurred in 17 cases. The 
interval between episodes wap usually less than 6 months. In 54.3%, 
paralysis disappeared completely or almost completely within 1 yr. Cerebral 
embolism was detected in 26 (19.3%) of 135 autopsy cases. The middle 
cerebral artery was the most frequent site of embolism.
EMTREE DRUG INDEX TERMS
  digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  brain embolism
  heart disease
EMTREE MEDICAL INDEX TERMS
  aged
  atrial fibrillation
  autopsy
  cardiomegaly
  cerebrovascular accident
  disease predisposition
  embolism
  exercise
  hemiplegia
  middle cerebral artery
  mitral valve stenosis
  paralysis
  patient
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007790891
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 549
TITLE
  Alcoholic heart disease
AUTHOR NAMES
  Brigden W.
  Robinson J.
AUTHOR ADDRESSES
  (Brigden W.; Robinson J.) Nat. Heart Hosp., London.
CORRESPONDENCE ADDRESS
  W. Brigden, Nat. Heart Hosp., London.
SOURCE
  British medical Journal (1857) (1964) 5420 (1283-1289). Date of Publication: 
1964
ISSN
  0007-1447
ABSTRACT
  Fifty patients with evidence of myocardial disease and a long-standing high 
consumption of alcohol were seen over a 10-year period. The usual causes of 
myocardial disease were excluded as far as possible. All but one were male, 
and their ages ranged from the 4th to 8th decades. Three clinical syndromes 
which depend on the dominant derangement of circulatory function at any one 
time were recognized. Cardiac beriberi (aneurin-responsive disease) was the 
least frequent and least serious disorder. It occurred in 5 heavy 
beer-drinkers and 2 of these had had a previous gastrectomy, which was 
thought to provide an additional adverse nutritional factor. Therapeutic 
response to aneurin and withdrawal of alcohol was good in these patients, 
but relapse has occurred following resumption of previous habits in at least 
one, and another has cardiographic evidence of persistent myocardial 
abnormality. A second, larger, group of patients presented with arrhythmia - 
especially atrial fibrillation - with or without varying degrees of heart 
failure. The ventricular rate tended to be fast and multifocal ventricular 
ectopics were common. Spontaneous return to sinus rhythm occurred in some, 
but usually relapse followed after a variable period. Fast heart rates, 
frequent extrasystoles, cardiomegaly, and abnormal QRST complexes on the 
cardiogram distinguished the condition from so-called idiopathic atrial 
fibrillation. Treatment with digitalis, diuretics, and conversion of rhythm 
met with variable success in this group. Reasonable health has been 
maintained in some when total abstinence has been observed and when the 
disease process was not far advanced on first presentation. The development 
of an arrhythmia with accompanying palpitation may draw attention to 
alcoholic heart disease before irreversible damage has been done. A third 
group of patients presented with hypokinetic heart failure, cardiomegaly, 
and electrocardiographic evidence of severe myocardial disease. Response to 
treatment was moderate at first but an episodic downhill course was usual. 
The electrocardiogram showed a wide range of abnormality as in other forms 
of cardiomyopathy. There was a fairly close correlation between the degree 
of cardiographic abnormality and the severity of the myocardial disease as 
judged by heart size and response to treatment. Mild polycythemia was 
observed in many patients, and was thought to be a response to low-grade 
chronic cardiac insufficiency. Serum cholesterol levels tended to be lower 
than average and were believed to be the result of dietary replacement by 
ethanol. The pathological findings on 9 necropsy cases are described and 
possible mechanisms of pathogenesis discussed. It is concluded that the 
association of high alcohol consumption for a long time and myocardial 
disease, manifest by arrhythmia and heart failure, is not fortuitous but 
causal. However, there is no evidence on the pathogenesis of the process or 
on the nature of individual susceptibility.
EMTREE DRUG INDEX TERMS
  alcohol
  digitalis
  diuretic agent
  thiamine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  alcoholic cardiomyopathy
EMTREE MEDICAL INDEX TERMS
  abstinence
  alcohol consumption
  atrial fibrillation
  autopsy
  beer
  beriberi
  cardiomegaly
  cardiomyopathy
  cholesterol blood level
  electrocardiogram
  extrasystole
  gastrectomy
  habit
  health
  heart arrhythmia
  heart failure
  heart palpitation
  heart rate
  heart size
  male
  myocardial disease
  pathogenesis
  patient
  polycythemia
  relapse
  rhythm
  sinus rhythm
  treatment response
CAS REGISTRY NUMBERS
  alcohol (64-17-5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007767026
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 550
TITLE
  Response of the heart to exercise
AUTHOR NAMES
  Sowton E.
AUTHOR ADDRESSES
  (Sowton E.) Inst. of Cardiol., London.
CORRESPONDENCE ADDRESS
  Inst. of Cardiol., London.
SOURCE
  Res. Rev. Clin. Trials (1964/1965) (41-47). Date of Publication: 1964
ABSTRACT
  There is some evidence to show that the maximum heart rate reached by 
patients who have undergone cardiac surgery is lower than normal. At the 
same time there is a subnormal increment in stroke volume, substantiated by 
investigators who found no increase in stroke volume on exercise, but that 
there was a subnormal rise in cardiac output mediated entirely by heart 
rate. The subnormal increment in stroke volume found on exercise when heart 
disease is present is a constant finding and this effect has been used to 
distinguish normal individuals from those with mild cardiac lesions. The 
response of the heart during exercise, expressed in terms of the 
relationships between stroke volume and cardiac rate and their effects upon 
cardiac output and work load, is discussed for atrial fibrillation, mitral 
stenosis, atrio-ventricular block and ischemic heart disease. Discussion is 
also included of the response of the normal heart to exercise in terms of 
heart rate, stroke volume, ventricular filling and the effect of training 
upon cardiac output, oxygen uptake and external power produced.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  exercise
  heart
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  atrioventricular block
  heart disease
  heart injury
  heart output
  heart rate
  heart stroke volume
  heart surgery
  ischemic heart disease
  mitral valve stenosis
  oxygen consumption
  patient
  workload
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007912035
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 551
TITLE
  Mitral valvular disease. Hemodynamic studies of the consequences for the 
circulation
AUTHOR NAMES
  Werkö L.
AUTHOR ADDRESSES
  (Werkö L.)
CORRESPONDENCE ADDRESS
  L. Werkö, Göteborg, Sweden.
SOURCE
  Almquist Wiksell (1964). Date of Publication: 1964
ABSTRACT
  Personal studies are presented of the hemodynamics of naturally occurring 
mitral valve disease. Pulmonary artery and wedge pressures, and 
arteriovenous oxygen differences correlated directly with the degree of 
disablement; cardiac output did so reciprocally. The wedge pressure was, 
however, of little value in differentiating stenosis from incompetence. 
Stressful procedures such as exercise, tilting, or the injection of plasma 
expanders also had effects which correlated closely with disability. But 
these effects were not specific for mitral valve as compared with other 
cardiac disease. The degree of elevation of pulmonary artery pressure at 
rest and its further rise on exercise were good guides to the severity of 
the mitral valve disease, whilst the low state of the cardiac output at rest 
and its failure to rise on stress reflected poor condition of the 
myocardium. Digitalis given to cases of acute failure increased cardiac 
output and lowered pulmonary artery pressure, both when the heart was in 
sinus rhythm and when the atria were fibrillating, though more so in the 
latter circumstances. Its effect was mostly on the myocardium. When the 
atria were fibrillating but the patient was not in failure, digitalis 
lowered pulmonary artery pressure but did not increase output. Its effect 
then was mostly on the conduction of impulses. The lower cardiac output of 
cases of atrial fibrillation as compared with sinus rhythm even when 
digitalization was optimal was also clearly demonstrated. Renal blood flow 
was reduced proportionately to the severity of the disease and glomerular 
filtration rate also but less quickly. Exercise exaggerated these effects 
and sodium excretion was diminished. With successful valvotomy these changes 
were reversed. Digitalis glycosides intravenously also improved renal 
circulation and did so before they improved the systemic one, thus, 
indicating a direct effect of the drug upon the kidneys. In pregnancy both 
cardiac output and renal blood flow were substantially increased despite 
valve obstruction, and it is this increased output which tends to lead to 
pulmonary edema.
EMTREE DRUG INDEX TERMS
  digitalis
  digitalis glycoside
  oxygen
  plasma substitute
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  mitral valve disease
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  digitalization
  disability
  exercise
  glomerulus filtration rate
  heart
  heart atrium
  heart disease
  heart muscle
  heart output
  hemodynamics
  injection
  kidney
  kidney blood flow
  kidney circulation
  lung artery pressure
  lung edema
  mitral valve
  obstruction
  patient
  pregnancy
  pulmonary artery
  sinus rhythm
  sodium excretion
  stenosis
  tilting
  valvuloplasty
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007766266
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 552
TITLE
  Hypertensive heart disease
AUTHOR NAMES
  Fleming P.R.
AUTHOR ADDRESSES
  (Fleming P.R.) Dept. of Med., Westminster Hosp., Med. Sch, London.
CORRESPONDENCE ADDRESS
  P.R. Fleming, Dept. of Med., Westminster Hosp., Med. Sch, London.
SOURCE
  Practitioner (1964) 193:1153 (441-451). Date of Publication: 1964
ISSN
  0032-6518
ABSTRACT
  Persistent hypertension leads to hypertrophy and usually some dilatation of 
the left ventricle in response to the increased load. Diffusion of oxygen 
into the bulky myocardiai fibres is impeded, resulting, especially if 
coronary arteriosclerosis co-exists, in patchy ischaemic fibrosis of the 
myocardium. Symptoms: Dyspnoea on exertion arises from secondary 
hypertension in the left atrium. Left ventricular failure or congestive 
heart failure is often superadded. Signs: Auricular fibrillation in about 
10% of cases. Pulsus alternate in incipient left ventricular failure. Left 
displacement and increased force of apex beat. A third heart sound is often 
heard ('gallop rhythm'). X-rays show the enlarged heart, with signs of 
pulmonary venous hypertension if failure is present. In the 
electrocardiogram the characteristic findings are left axis deviation and 
heightened R-waves. Prognosis is closely correlated with retinopathy and 
evidence of renal failure. It is improved by hypotensive treatment, which 
should always be given. Ottley - Hove.
EMTREE DRUG INDEX TERMS
  antihypertensive agent
  oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart disease
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  congestive heart failure
  coronary artery atherosclerosis
  diffusion
  dyspnea
  electrocardiogram
  exercise
  fiber
  fibrosis
  heart
  heart left atrium
  heart left ventricle
  heart left ventricle failure
  heart muscle
  heart sound
  hypertension
  hypertrophy
  kidney failure
  prognosis
  R wave
  retinopathy
  rhythm
  X ray
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007749578
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 553
TITLE
  Mitral valvular disease. hemodynainic studies of tue conséquences for the 
circulation
AUTHOR NAMES
  Werko L.
AUTHOR ADDRESSES
  (Werko L.)
SOURCE
  Almquist Wiksell (1964) (83-97). Date of Publication: 1964
ABSTRACT
  Personal studies are presented of the haemodynamics of naturally occurring 
mitral valve disease. Pulmonary artery and wedge pressures, and 
arteriovenous oxygen differences correlated directly with the degree of 
disablement; cardiac output did so reciprocally. The wedge pressure was, 
however, of little value in differentiating stenosis from incompetence. 
Stressful procedures such as exercise, tilting, or the injection of plasma 
expanders also had effects which correlated closely with disability. But 
these effects were not spécifie for mitral valve as compared with other 
cardiac diseases. The degree of elevation of pulmonary artery pressure at 
rest and its further rise on exercise were good guides to the severity of 
the mitral valve disease, whilst the low state of the cardiac output at rest 
and its failure to rise on stress reflected poor condition of the 
myocardium. Digitalis given to cases of acute failure increased cardiac 
output and lowered pulmonary artery pressure, both when the heart was in 
sinus rhythm and when the atria were fibrillating, though more so in the 
latter circumstances. Its effect was mostly on the myocardium. When the 
atria were fibrillating but the patient was not in failure, digitalis 
lowered pulmonary artery pressure but did not increase output. Its effect 
then was mostly on the conduction of impulses. The lower cardiac output of 
cases of atrial fibrillation as compared with sinus rhythm even when 
digitalisation was optimal was also clearly demonstrated. Renal blood flow 
was reduced proportionately to the severity of the disease and glomerular 
filtration rate also, but less quickly. Exercise exaggerated these effects 
and sodium secretion was diminished. With successful valvotomy these changes 
were reversed. Digitalis glycosides i.v. also improved renal circulation and 
did so before they improved the systemic one, thus indicating a direct 
effect of the drug upon the kidneys. In pregnancy both cardiac output and 
renal blood flow were substantially increased despite valve obstruction, and 
it is this increased output which tends to lead to pulmonary oedema. Dewar - 
Newcastle-upon-Tyne (XVIII, 6, 9).
EMTREE DRUG INDEX TERMS
  digitalis
  digitalis glycoside
  oxygen
  plasma substitute
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  mitral valve disease
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  digitalization
  disability
  exercise
  glomerulus filtration rate
  heart
  heart atrium
  heart disease
  heart muscle
  heart output
  hemodynamics
  injection
  kidney
  kidney blood flow
  kidney circulation
  lung artery pressure
  lung edema
  mitral valve
  obstruction
  patient
  pregnancy
  pulmonary artery
  sinus rhythm
  sodium excretion
  stenosis
  tilting
  valvuloplasty
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007870443
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 554
TITLE
  A diffuse endocardial fibro-elastosis with marked dilatation of the atrium 
observed in an adult
AUTHOR NAMES
  Yoshida T.
  Nimura Y.
  Sakakibara H.
  Matsutani K.
  Nishizaki K.
  Nakata T.
AUTHOR ADDRESSES
  (Yoshida T.; Nimura Y.; Sakakibara H.; Matsutani K.; Nishizaki K.; Nakata 
T.) First Dept. of Int. Med., Osaka Univ. Med. Sch, Osaka, Japan.
CORRESPONDENCE ADDRESS
  T. Yoshida, First Dept. of Int. Med., Osaka Univ. Med. Sch, Osaka, Japan.
SOURCE
  Japanese Heart Journal (1964) 5:1 (85-92). Date of Publication: 1964
ISSN
  0021-4868
ABSTRACT
  A 39-year-old woman complained of severe abdominal distension and dyspnea on 
exertion. Physical examination revealed slight cyanosis, slight peripheral 
edema and marked distension of the cervical veins. The third heart sound was 
audible at the apex but there was no murmur. The abdomen was markedly 
distended with shifting dulness and a fluid wave. The liver was palpable 7 
cm. below the right costal margin. X-ray of the chest revealed marked 
globular enlargement of the heart and pulmonary congestion, and the ECG 
showed atrial fibrillation. Marked enlargement of the right atrium was noted 
by angiocardiography. The right atrial pressure determined by cardiac 
catheterization was 3018 mm. Hg. Treatment with dig it ox in, mercurial 
diuretics, chlorothiazides and salt restriction had only little effect, and 
the patient died about 10 mth. after admission. Post-mortem examination 
revealed a markedly dilated right atrium, a dilated left atrium and small 
ventricles. Diffuse endocardial fibro-elastosis and peripheral fibrosis of 
the liver were seen histologic-ally.
EMTREE DRUG INDEX TERMS
  chlorothiazide
  diuretic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  adult
  elastosis
  endocardium
  heart atrium
EMTREE MEDICAL INDEX TERMS
  abdomen
  abdominal distension
  angiocardiography
  atrial fibrillation
  autopsy
  cyanosis
  dyspnea
  electrocardiogram
  endocardial fibroelastosis
  exercise
  female
  fibrosis
  heart
  heart catheterization
  heart left atrium
  heart right atrium
  heart right atrium pressure
  heart sound
  liquid
  liver
  lung congestion
  patient
  peripheral edema
  physical examination
  sodium restriction
  thorax
  vein
  X ray
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007742648
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 555
TITLE
  Diagnosis and treatment of tricospid stenosis
AUTHOR NAMES
  Kitchin A.
  Turner R.
AUTHOR ADDRESSES
  (Kitchin A.; Turner R.) Cardiac Dept, Western Gen. Hosp., Edinburgh.
CORRESPONDENCE ADDRESS
  A. Kitchin, Cardiac Dept, Western Gen. Hosp., Edinburgh.
SOURCE
  British Heart Journal (1964) 26:3 (354-379). Date of Publication: 1964
ISSN
  0007-0769
ABSTRACT
  The diagnosis, circulatory effects, and surgical treatment of rheumatic 
tricuspid stenosis associated with mitral stenosis is discussed in relation 
to 17 patients subjected to combined valvotomy. The diagnosis of tricuspid 
stenosis may be difficult and is frequently overlooked. Although a large 
flicking 'a* wave in the venous pulses a tricuspid diastolic murmurs right 
atrial enlargement in the radiograph, right atrial hypertrophy hi the ECG, 
and a pressure gradient across the tricuspid valve in diastote, offer 
presumptive evidence for tricuspid stenosis, each of these features may 
occur in other conditions. Large *a* waves occur in pulmonary stenosis, in 
pulmonary hypertension, including that of mitral stenosis, and in organic 
tricuspid incompetence. There is, however, a particular pattern of a 
flicking V wave unaccompanied by a systolic wave which is characteristic of 
severe tricuspid stenosis. Tricuspid diastolic murmurs may occur in dominant 
tricuspid incompetence. They indicate organic tricuspid disease but are no 
guide to the severity of the stenosis. Tall P waves in the ECG and right 
atrial enlargement in the radiograph though present in tricuspid stenosis 
are common findings in tricuspid incompetence and in right ventricular 
hypertrophy with a normal tricuspid valve. Enlargement of the pulmonary 
artery, congestion of the lung fields, and right ventricular hypertrophy do 
not exclude severe tricuspid stenosis. A pressure gradient in diastole 
across the tricuspid valve occurs both in dominant stenosis and in dominant 
organic incompetence and is unreliable as a guide to tricuspid stenosis of a 
severity requiring operation. Valve area calculations are similarly 
unreliable if incompetence is present. Atrial fibrillation increases the 
difficulty of diagnosis. When tricuspid disease is present with 
fibrillation, a prominent systolic wave in the venous pulse may be 
associated with severe stenosis and only minor régurgitation. The presence 
of any one of these features should raise the suspicion of severe tricuspid 
stenosis, and a combination is strongly suggestive. The most consistent 
confirmatory evidence of severe stenosis in the presence of a tricuspid 
pressure gradient proved to be the dissociation of right atrial and right 
ventricular diastolic pressures during respiration. The relation of 
tricuspid murmurs to respiration is discussed, and it is pointed out that in 
severe tricuspid stenosis a systolic murmur from associated tricuspid 
incompetence tends to decrease on inspiration. The explanation for this is 
discussed in detail. Tricuspid stenosis causes a disability similar to that 
in mitral stenosis but which may be unrelieved by mitral valvotomy. The 
cardiac output is severely restricted both at rest and on exercise. When 
atrial fibrillation occurs the venous pressure remains permanently raised. 
Symptoms were relieved in 12 patients after operation. Cardiac 
catheterization was repeated after operation in 5, and showed a reduction 
but not complete abolition of the valve gradient. Right atrial size did not 
decrease. Regression of the P pulmonate pattern in the electrocardiogram was 
usual but not always complete. Three patients died during the operation, but 
no death was considered to be due to the tricuspid valvotomy itself. 
Traumatic, i.e. operative valvular incompetence of significant degree, only 
resulted in one case. Two patients subsequently died, after éand 2 years 
respectively, and this was considered to be due to the overall effects of 
severe rheumatic heart disease, pleven of the 12 remaining survivors have 
remained weO 2 to 6 years later: one had only a fair result. (XVIII, 6).
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diagnosis
  stenosis
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  death
  diastole
  disability
  dissociation
  electrocardiogram
  exercise
  heart atrium enlargement
  heart catheterization
  heart output
  heart right ventricle hypertrophy
  heart ventricle enddiastolic pressure
  lung
  mitral valve commissurotomy
  mitral valve stenosis
  P wave
  patient
  pressure gradient
  pulmonary artery
  pulmonary hypertension
  pulmonary valve stenosis
  pulse rate
  rheumatic heart disease
  surgery
  survivor
  systolic heart murmur
  tricuspid valve
  tricuspid valve disease
  tricuspid valve stenosis
  valvuloplasty
  venous pressure
  X ray film
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007747607
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 556
TITLE
  Statistical and clinical analysis of 405 cases of myocardial infarction 
treated in the period 1948-1960 in the ist and 2nd medical clinics in lublin 
ocena statystyczno-kliniczna 405 przypadkow zawalu serca (leczonych w latach 
1948-1960 w i i ii klinice choroob wewnětrznych a.m. w lublinie)
AUTHOR NAMES
  Kedra K.
  Kolber-Postepska B.
  Wielfus R.
AUTHOR ADDRESSES
  (Kedra K.; Kolber-Postepska B.; Wielfus R.) Klin. Chor. Wewn. AM, .
CORRESPONDENCE ADDRESS
  K. Kedra, Klin. Chor. Wewn. AM, .
SOURCE
  Lublin Pol. Tyg. Uk. (1963) 18:9 (1117-1137). Date of Publication: 1963
ABSTRACT
  In the period 1948-1960, 30,912 patients were treated in the ist and 2nd 
Medical Clinics in Lublin. Recent myocardial infarction occurred in 405 
(1.31%). The ratio of the patients with myocardial infarction to the other 
patients had increased 3 times in 1951 and twice in 1956 compared with 1950. 
No further increase of this ratio is reported since 1956. There are probably 
multiple causes of this increase in 1951 and 1956 (improved diagnosis, 
changes in habit, nutrition, etc.). The male: female ratio among patients 
with recent myocardial infarction was 3.5 : i. The men were mostly in the 
50-60 age group, the women in the 60-70 53.2% were workers and farmers, and 
46.8% were employees and pensioners. No seasonal effect was noticed. 
Adiposity occurred in 33% of the cases (45.5% in women and 20.3% in men). 
Diabetes was noted in 3.2% of the patients, hypertension in 17 Smoking 
occurred in 67.5% of the patients. The following clinical forms of acute 
myocardial infarction were noted: anginal attack (69.3%), status asthmaticus 
(7.8%), gastralgia (8.3%). Collapse was observed in 11.9% and asymptomatic 
form of myocardial infarction in 1.7%. Cardiac rhythm disorders occurred in 
11.6%. Atrial fibrillation was the most common form of arrhythmia but it has 
had no prognostic significance. The greatest mortality rate occurred among 
patients with complete atrio-ventricular block and branch block (66.7% and 
50%, respectively). Thrombi and emboli were noted in 8.9% of the cases, 
pneumonia in 7.6%, chronic circulatory failure in 4.9%. 108 patients died in 
hospital, 44.4% of the deaths occurring during the first 2 days. Death was 
due to shock with acute left-sided failure (75%), ventricular fibrillation 
(13.1%), embolism, heart rupture and Stokes-Adams syndrome (12.9%). The 
mortality among 278 patients who were given anticoagulants was 2.5 times 
higher than among the 127 persons who did not receive them. No effect of the 
anticoagulants on the appearance of emboli and thrombi was noted. In 4 
patients who had received anticoagulants severe renal haemorrhage appeared, 
and several blood transfusions were necessary. The followup of 71.7% of 
discharged patients is reported. The mortality after éand 5 yr. was 37.6 and 
49.3%, respectively. Autopsy was performed in 51 cases (47.1%). Complete 
confirmation of the clinical diagnosis was noted in 82.3% of the cases. The 
partial discrepancy observed in 11.7% of the cases concerned localization of 
the infarct. In 6 cases, in spite of undoubted clinical signs of infarct, 
autopsy did not reveal characteristic changes as death had occurred within 
an hour of onset. (XVII, 19).
EMTREE DRUG INDEX TERMS
  anticoagulant agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart infarction
  hospital
EMTREE MEDICAL INDEX TERMS
  acute heart infarction
  Adams Stokes attack
  agricultural worker
  angina pectoris
  asthmatic state
  atrial fibrillation
  atrioventricular block
  autopsy
  blood transfusion
  death
  diabetes mellitus
  diagnosis
  embolism
  employee
  female
  follow up
  groups by age
  habit
  heart arrhythmia
  heart rhythm
  heart rupture
  heart ventricle fibrillation
  hypertension
  infarction
  ischemia
  kidney hemorrhage
  male
  mortality
  nutrition
  obesity
  patient
  pensioner
  pneumonia
  smoking
  statistics
  stomach pain
  thrombus
  worker
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007745608
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 557
TITLE
  Beta-adrenergic receptor blockade in cardiac arrhythmias
AUTHOR NAMES
  Stock J.P.P.
  Dale N.
AUTHOR ADDRESSES
  (Stock J.P.P.; Dale N.)
SOURCE
  British medical Journal (1857) (1963) 5367 (1230-1233). Date of Publication: 
1963
ISSN
  0007-1447
ABSTRACT
  The effect of a beta-receptor adrenergic blocking agent, pronethalol, has 
been studied in patients with atrial fibrillation and other cardiac 
arrhythmias. In atrial fibrillation pronethalol effectively controls the 
ventricular rate, and when combined with digitalis the action of the two 
drugs summmate. When the two drugs are given together they prevent the 
excessive rise in ventricular rate on exercise which often occurs with 
digitalis alone. This action appears to be of therapeutic value in some 
patients with mitral or tricuspid stenosis. The drug seems to have little 
effect in atrial flutter or paroxysmal tachycardia, but will abolish some 
forms of atrial and ventricular extrasystoles. In seven patients with 
digitalis-induced arrhythmias the toxic rhythm was immediately suppressed by 
the drug. Pronethalol should be given with great care to patients with 
incipient or established heart failure.
EMTREE DRUG INDEX TERMS
  beta adrenergic receptor blocking agent
  digitalis
  pronetalol
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  beta adrenergic receptor blocking
  heart arrhythmia
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  exercise
  heart atrium flutter
  heart failure
  heart ventricle extrasystole
  paroxysmal tachycardia
  patient
  rhythm
  tricuspid valve stenosis
CAS REGISTRY NUMBERS
  pronetalol (51-02-5, 54-80-8)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007741823
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 558
TITLE
  Digitalis in surgery: extension of classical indications
AUTHOR NAMES
  Wheat Jr. M.W.
  Burford T.K.
AUTHOR ADDRESSES
  (Wheat Jr. M.W.; Burford T.K.)
SOURCE
  J.Thorac.Cardiov.Surg. (1961) 41:2 (67-74). Date of Publication: 1961
ABSTRACT
  It is a well-known clinical experience that in patients over the age of 60 
intrathoracic resections are often followed by cardiac complications. These 
arrhythmias are predominantly atrial fibrillation or flutter that uniformly 
respond to digitalis. In the study of patients with or without digitalis 
preparation before thoracic surgery a reduction of cardiac arrhythmias from 
20 to 10% in patients over the age of 55 after digitalis preparation was 
demonstrated. All patients over 60 years of age in whom a major 
intrathoracic resection is contemplated should be digitalised routinely pre 
operative Iy. KIe in t - Prague.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  surgery
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  diet
  digestive system
  feeding
  heart arrhythmia
  nutrition
  patient
  thorax surgery
CAS REGISTRY NUMBERS
  digitalis (8031-42-3, 8053-83-6)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008477264
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 559
TITLE
  Cardiac amyloidosis
AUTHOR NAMES
  Eliot R.S.
  McGee H.J.
  Blount Jr. S.G.
AUTHOR ADDRESSES
  (Eliot R.S.; McGee H.J.; Blount Jr. S.G.)
SOURCE
  Circulation (1961) 23:4 (613-622). Date of Publication: 1961
ISSN
  0009-7322
ABSTRACT
  A case of cardiac amyloidosis with a i ,ogo-g. heart is presented in detail. 
This is believed to be the largest amyloid heart reported, especially since 
the heart represented 2.7% of the patient's total body weight, or 5 times 
the normal. Eighty-two cases from the literature and 20 personal cases are 
analysed, and the literature on cardiac amyloidosis reviewed. Most patients 
are men over 70 yr. of age, in poor nutritional state, who have 
predominantly intractable left ventricular failure, a systolic cardiac 
murmur, minimal coronary atherosclerosis, cardiomegaly (av. 452 gr.), 
variably positive Congo-red tests, and cardinal involvement of the heart 
over other organs. ECGs in 31 cases of cardiac amyloidpsis are analysed, and 
some useful correlations of special interest are made. Left axis deviation, 
parietal block, and a heart weight 01450 g. or more appear in a significant 
number of cases in which cardiac amyloidosis is the primary cause of death. 
Atrial fibrillation is frequently found in patients with cardiac amyloid 
with or without significant coronary atherosclerosis.
EMTREE DRUG INDEX TERMS
  amyloid
  congo red
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart amyloidosis
EMTREE MEDICAL INDEX TERMS
  amyloidosis
  atrial fibrillation
  body weight
  cardiomegaly
  cause of death
  coronary artery atherosclerosis
  heart
  heart left ventricle failure
  heart weight
  nutritional status
  patient
  systolic heart murmur
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007501404
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 560
TITLE
  Cardiac amyloidorsis
AUTHOR NAMES
  Eliot R.S.
AUTHOR ADDRESSES
  (Eliot R.S.)
SOURCE
  Circulation (1961) 23:4 (613-622). Date of Publication: 1961
ISSN
  0009-7322
ABSTRACT
  A case of cardiac amyloidosis with a i,ogo-g. heart is presented in detail. 
This is believed to be the largest amyloid heart reported especially since 
the heart represented 2.7% of the patient's total body weight, or 5 times 
the normal. Eightytwo cases from the literature and 20 personal cases are 
analysed, and the literature on cardiac amyloidosis reviewed. Most patients 
are men over 70 yr. of age, in poor nutritional state, who have 
predominantly intractable left ventricular failure, a systolic cardiac 
murmur, minimal coronary atherosclerosis, cardiomegaly (av. 452 g.), 
variably positive Congo-red tests, and cardinal involvement of the heart 
over other organs. EGGs in 31 cases of cardiac amyloidosis are analysed, and 
some useful correlations of special interest are made. Left axis deviation, 
parietal block, and a heart weight 0/450 g. or more appear in a significant 
number of cases in which cardiac amyloidosis is the primary cause of death. 
Atrial fibrillation is frequently found in patients with cardiac amyloid 
with or without significant coronary atherosclerosis. (XVIII, 5, 6, 20).
EMTREE DRUG INDEX TERMS
  amyloid
  congo red
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  body weight
  cardiomegaly
  cause of death
  coronary artery atherosclerosis
  egg
  heart
  heart amyloidosis
  heart left ventricle failure
  heart weight
  nutritional status
  patient
  systolic heart murmur
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007404152
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 561
TITLE
  A correlation of clinical and hemodynamic studies in pahents with 
hyperthyroidism with and without congestive heart failure
AUTHOR NAMES
  Graettinger J.S.
  Muenster J.J.
  Selverstone L.A.
  Campbell J.A.
AUTHOR ADDRESSES
  (Graettinger J.S.; Muenster J.J.; Selverstone L.A.; Campbell J.A.) 
Cardio-Resp. Div., Dept. of Med., Presbytcnan Hosp., Boston, MA, United 
States.
CORRESPONDENCE ADDRESS
  J.S. Graettinger, Cardio-Resp. Div., Dept. of Med., Presbytcnan Hosp., 
Boston, MA, United States.
SOURCE
  J. Din. Invesl. (1959) 38:8 (190-200). Date of Publication: 1959
ABSTRACT
  Twenty thyrotoxic patients were studied before and after they were rendered 
euthyroid, in order to attempt to determine the mechanism of heart failure 
in thyrotoxicosis. Fourteen of the patients did not have congestive heart 
failure, and, although 6 of them had antecedent heart disease, all 
demonstrated normai haemodynamic responses to exercise. All of the patients 
who had been in congestive failure showed inadequate response of the cardiac 
output to exercise, but only 3 of them had an elevated cardiac output at 
rest. Atrial fibrillation was not found in the thyrotoxic patients without 
heart disease. The authors feel that the excessive load on the peripheral 
circulation that occurs in thyrotoxicosis is of similar iaagrntude to that 
which occurs in systemic arterio-venous fistulae. They conclude that the 
increased circulatory load of thvrotoxicosis may lead to congestive heart 
failure in the following circumstances. (1) When myocarchal reserve has been 
impaired by heart disease of other aetiology. (2) When the thyrotoxicosis 
itself becomes so severe that it causes a temporary myocardial failure. (3) 
When the peripheral circulatory load is increased so much by thyrotoxicosis 
that it overcomes the reserve of the previously normal heart.
EMTREE DRUG INDEX TERMS
  phosphorus
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  congestive heart failure
  hyperthyroidism
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  blood pressure
  etiology
  exercise
  fistula
  heart
  heart disease
  heart failure
  heart output
  patient
  peripheral circulation
  thyrotoxicosis
CAS REGISTRY NUMBERS
  phosphorus (7723-14-0)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007679459
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 562
TITLE
  The use of ganglionblocking substance (promethazine and diethazine) in 
operations on the thyroid gland in patients with thyrotoxicosis under local 
anaesthesia with 0.5% novocaine solution
AUTHOR NAMES
  Agafonov F.A.
AUTHOR ADDRESSES
  (Agafonov F.A.)
SOURCE
  Problemy Endokrinologii (1958) 4:4 (104-106). Date of Publication: 1958
ISSN
  0375-9660
ABSTRACT
  Promethazine and diethazine, phenothiazine derivatives, were administered 
before the operation to 62 patients with thyrotoxicosis aged from 11 to 60 
yr. These included 27 cases with a grave form of thyrotoxicosis, 31 with 
thyrotoxicosis of average severity and 4 with a mild form of this disease. 
After the usual breakfast the patients were given 0.025 g. of promethazine 
and 0.15% of diethazine in tablets (children under 15 yr. received a lower 
dose). In about an hour after administration of the drugs the patients 
exhibited drowsiness with decreased reaction to external stimulations. This 
condition lasted 4 to 6 hr. after the operation. Patients with 
thyrotoxicosis and auricular fibrillation have a poor tolerance to 
ganglion-blocking preparations.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  diethazine
  procaine
  promethazine
EMTREE DRUG INDEX TERMS
  ganglion blocking agent
  phenothiazine derivative
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  local anesthesia
  patient
  thyroid gland
  thyrotoxicosis
EMTREE MEDICAL INDEX TERMS
  aged
  anesthesia
  atrial fibrillation
  child
  drowsiness
  gallbladder
  ganglion block
  meal
  stimulation
  surgery
  tablet
  thyroid surgery
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007927778
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 563
TITLE
  Experience with intramuscular digoxin
AUTHOR NAMES
  Fletcher E.
  Brennan C.F.
AUTHOR ADDRESSES
  (Fletcher E.; Brennan C.F.) Belfast City Hosp., Belfast, United Kingdom.
CORRESPONDENCE ADDRESS
  E. Fletcher, Belfast City Hosp., Belfast, United Kingdom.
SOURCE
  Irish Journal of Medical Science (1958) 6:290 (273-280). Date of 
Publication: 1958
ISSN
  0021-1265
ABSTRACT
  Intramuscular digoxin in doses of 1-2 mg. reduced the ventricular frequency 
to less than 90/min. within 5 to 19 hr. in 15 of 18 cardiac patients with 
atrial fibrillation. 0.5 mg. every 8 to 24 hr. was sufficient as a 
maintenance dose in 9 out of 10 cases. Comparative examinations of the heart 
frequency in 17 patients showed no significant difference between the 
effects of 1 mg. digoxin administered i.v. and i.m. in the same patients 
during an observation period of 10 hr. Combination with a mercurial diuretic 
(mersalyl) increased the effect of i.m. administered digoxin. In this series 
of experiments, 2 types of systolic retardation occurred : one, with rapid 
onset, lasting from 2 to 3 hr., which was attributed to a vagus function and 
was eliminated by physical exercise or atropine injections; and a 2nd type, 
provoked by digoxin, and seen most markedly 6 hr. after injection of the 
drug. Toxic arrhythmias were caused in 3 cases within 6-14 hr., by doses of 
1 to 1.5 mg. In 2 cases nausea was observed following doses of over 4 mg. 
The otherwise effective i.m. digoxin therapy imposes certain restrictions, 
because of consistent painfulness of the injection, starting one-half to 3 
hr. after administration and sometimes lasting 2 weeks or more. Frequent 
injections increased the painlulness. finally necessitating discontinuation 
of the therapy. The pain is a direct result of the effect of digoxin on the 
skeletal muscles; the solvent has no painful effect.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  digoxin
EMTREE DRUG INDEX TERMS
  atropine
  diuretic agent
  mersalyl
  solvent
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  cardiac patient
  examination
  exercise
  heart arrhythmia
  heart rate
  injection
  intramuscular drug administration
  maintenance drug dose
  nausea
  pain
  patient
  skeletal muscle
  therapy
  vagus nerve
CAS REGISTRY NUMBERS
  digoxin (20830-75-5, 57285-89-9)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008306752
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 564
TITLE
  The effect of 2-diethylaminoethyl-isonicolimamide on cardiac arrhythmia in 
man
AUTHOR NAMES
  Werner I.
AUTHOR ADDRESSES
  (Werner I.) Med. Clin., Univ. of Uppsala, .
CORRESPONDENCE ADDRESS
  Med. Clin., Univ. of Uppsala, .
SOURCE
  Acta medica Scandinavica (1957) 158:3-4 (225-233). Date of Publication: 1957
ISSN
  0001-6101
ABSTRACT
  The drug was administered orally in gelatmated capsules containing 0.250 g. 
and i.v. in an aqueous solution containing 0.100 g./ml. The oral 
administration, in which the dose varied from 2 to 5 g. daily, was totally 
ineffective. Slow i.v. administration of a total dose of 1 to 2 g., at a 
speed not exceeding 0.100 g. per min. was effective only in 1 out of 8 cases 
of paroxysmal tachycardia. As these results were not in accordance with 
those obtained experimentally, the speed of the injection was increased to 
0.1 g. in 1 to 2 sec. A very good effect was then observed in atrial 
paroxysmal tachycardia, the change in rhythm being instantaneous in all 
cases. Four patients with other types of atrial tachycardia and not 
presenting a history of paroxysmal onset did not benefit from the treatment. 
One case of atrial flutter was treated 7 times with rapid i.v. injections, 
with good results each time. Of fourteen cases with atrial fibrillation and 
a high ventricular rate normal rhythm was restored in 5, in 3 a definite 
slowing of the ventricular rate was observed. In 6 cases no effect was 
observed. In ventricular arrhythmia no beneficial effects were obtained. 
One-third of the cases presented a transitory fall in the systolic pressure, 
between 5 and 15 mm. Hg, which lasted only a few minutes. In 2 cases of 
atrial fibrillation there were ventricular extrasystoles before normal sinus 
rhythm was established. Subjectively, the majority of the patients 
experienced a feeling of heat in the face and the upper part of the trunk, 
which lasted 5 to 15 min. only. Nausea and vomiting occurred. The mode of 
action of the drug is not clear. It has been suggested that the principal 
effect is to prolong the refractory period without significantly influencing 
the conductivity. Probably there is also a direct depressing effect on 
ectopic atrial foci.
EMTREE DRUG INDEX TERMS
  cortisone
  isonicotinamide
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart arrhythmia
  human
EMTREE MEDICAL INDEX TERMS
  aortography
  aqueous solution
  atrial fibrillation
  conductance
  heart atrium flutter
  heart ventricle arrhythmia
  heart ventricle extrasystole
  heat
  injection
  nausea and vomiting
  oral drug administration
  paroxysmal supraventricular tachycardia
  paroxysmal tachycardia
  patient
  refractory period
  rhythm
  sinus rhythm
  supraventricular tachycardia
  systolic blood pressure
  velocity
CAS REGISTRY NUMBERS
  cortisone (53-06-5)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007428608
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 565
TITLE
  Falls in the elderly
AUTHOR NAMES
  Firth S.J.
AUTHOR ADDRESSES
  (Firth S.J.)
SOURCE
  Medical Press (1957) 238:15 (343-346). Date of Publication: 1957
ISSN
  0368-9492
ABSTRACT
  A fall or a tendency to fall may be the first symptoms of pathological 
processes in the elderly. They can be localized in: (1) The cardiovascular 
system. Degenerative changes in the arteries may lead to transient cerebral 
anaemia. Iron deficiency anaemia, often present in the elderly, may 
contribute to attacks of giddiness and a tendency to fall. Many cases of 
syncope are of cardiac origin and an ECG may reveal evidence of a recent 
myocardial infarction. (2) Skeletal system. Corns, burtons, hallux rigidus 
and pes planus contribute to unsteadiness. Rheumatoid and osteo-arthritic 
changes in joints may lead to disuse atrophy in groups of muscles and so 
predispose to a fall. Paget's disease and generalized osteoporosis 
predispose to spontaneous fracture of the femoral neck with a resultant 
fall. Generalized muscle weakness caused by inoperable growths or advanced 
pulmonary or cardiac conditions may lead to a shuffling gait and tripping. 
Obesity is often associated with weakening of muscle groups. (3) CNS. 
Defects of vision become a serious handicap. Cerebrovascular accidents 
produce more dramatic falls. These may be due to cerebral haemorrhage, 
cerebral embolus, usually as a consequence of auricular fibrillation and 
cerebral thrombosis, by far the most frequent cause of cerebral catastrophe 
and often leading to dizziness and falling as early symptoms. Parkinson's 
disease, epilepsy, cerebral tumour and alcoholism are also causes of falls. 
Prevention: better housing and accommodation, non-slip floors and short 
handrails in bathroom and lavatory. A sensible amount of physical exercise 
is necessary to maintain physical fitness and is very important for the 
prevention of accidents. Regular contact with other people, good nutritional 
standards and good standards of personal hygiene may also contribute to the 
prevention of falls.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aged
EMTREE MEDICAL INDEX TERMS
  accident
  accommodation
  alcoholism
  anemia
  artery
  atrial fibrillation
  atrophy
  bath
  brain hemorrhage
  callosity
  cardiovascular system
  catheter
  central nervous system
  cerebrovascular accident
  disability
  disaster
  dizziness
  electrocardiogram
  embolism
  epilepsy
  exercise
  faintness
  femur neck
  fitness
  flatfoot
  gait
  hallux rigidus
  heart infarction
  housing
  iron deficiency anemia
  muscle
  muscle weakness
  neoplasm
  obesity
  occlusive cerebrovascular disease
  osteoporosis
  Parkinson disease
  pathologic fracture
  personal hygiene
  prevention
  skeleton
  unsteadiness
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007929116
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 566
TITLE
  Disease of the sinoatrial node associated with bradycardia, asystole, 
syncope, and paroxysmal atrial fibrillation
AUTHOR NAMES
  Birchfield R.I.
  Menefee E.E.
  Bryant G.D.
AUTHOR ADDRESSES
  (Birchfield R.I.; Menefee E.E.; Bryant G.D.) N. Dept. of Med., Duke Univ., 
Durham, NC, United States.
CORRESPONDENCE ADDRESS
  R.I. Birchfield, N. Dept. of Med., Duke Univ., Durham, NC, United States.
SOURCE
  Circulation (1957) 16:1 (20-26). Date of Publication: 1957
ISSN
  0009-7322
ABSTRACT
  The clinical picture produced by disease of the sinoatrial (S-A) node is 
described and illustrated by a case report. Disease of the S-A node has been 
implicated as the cause of the persistent bradycardia. Autonomic influences 
over the A-V node have been implicated in the production of asystole. In 
this patient any manoeuvre decreasing vagal tone was of benefit because 
these circumstances allowed the rhythm of the heart to be controlled by the 
A-V node. Sitting up, exercise, and atropine were all effective means of 
initiating nodal rhythm.
EMTREE DRUG INDEX TERMS
  atropine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  bradycardia
  faintness
  heart arrest
  sinus node
EMTREE MEDICAL INDEX TERMS
  atrioventricular junction arrhythmia
  case report
  exercise
  heart
  patient
  rhythm
  sitting
  vagus tone
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007427011
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 567
TITLE
  The pathogenesis of systemic arterial embolism in rheumatic heart disease
AUTHOR NAMES
  Askey J.M.
AUTHOR ADDRESSES
  (Askey J.M.) Univ. of Southern California, Sch. of Med., Los Angeles, CA, 
United States.
CORRESPONDENCE ADDRESS
  J.M. Askey, Univ. of Southern California, Sch. of Med., Los Angeles, CA, 
United States.
SOURCE
  Modern Concepts of Cardiovascular Disease (1957) 26:7 (399-402). Date of 
Publication: 1957
ISSN
  0026-7600
ABSTRACT
  The origin of clots in the cardiac chambers is discussed. In about half the 
cases quoted from Söderström definite lesions of the heart chamber were 
found in atrial clots. The right-atrial clots were mainly non-rheumatic in 
type and the majority of the left were of rheumatic origin. Myocardial 
infarction following coronary disease produces a large percentage of thrombi 
being limited to the left ventricle and right atrium. The majority of left 
atrial thrombi due to rheumatic disease (84%) are in association with mitral 
stenosis and atrial fibrillation. There is no greater incidence of rheumatic 
disease of the chamber in fibrillation and consequently the factors of 
relative stasis or disturbed atrioventricular flow must also be included. 
Atrial dilatation also occurs with its consequent greater contained volume. 
Apparently only half of the left-atrial thrombi are detached into the 
general circulation. The reason for this proportion is conjectural. The 
initiation of an attack of fibrillation causes as many emboli as does the 
conversion of fibrillation into normal rhythm. This refutes the notion 
formerly held that most emboli occur in conversion of fibrillation to normal 
rhythm. No correlation has been found in the dislodgment of thrombi due to 
rapid heart beat or exercise and it is concluded that the mobilization of an 
embolus is in the main a fortuitous event.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  artery embolism
  pathogenesis
  rheumatic heart disease
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  coronary artery disease
  embolism
  exercise
  heart
  heart atrium enlargement
  heart atrium thrombosis
  heart beat
  heart disease
  heart infarction
  heart left ventricle
  heart right atrium
  mitral valve stenosis
  mobilization
  rheumatic disease
  rhythm
  thrombus
  weight reduction
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007925405
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 568
TITLE
  Cardiorespiratory function two years after mitral valvotomy
AUTHOR NAMES
  Donald K.W.
  Bishop J.M.
  Wade O.L.
  Wormald P.N.
AUTHOR ADDRESSES
  (Donald K.W.; Bishop J.M.; Wade O.L.; Wormald P.N.) Dept. of Med., Univ. of 
Birmingham, Queen Elizabeth Hosp., Birmingham, United Kingdom.
CORRESPONDENCE ADDRESS
  K.W. Donald, Dept. of Med., Univ. of Birmingham, Queen Elizabeth Hosp., 
Birmingham, United Kingdom.
SOURCE
  Clinical Science (1957) 16:2 (325-350). Date of Publication: 1957
ISSN
  0143-5221
ABSTRACT
  Measurements of the cardiac output, the pulmonary vascular pressures, 
ventilation and oxygen uptake at rest and on exercise have been made in 28 
patients with mitral stenosis before and 17-51 months after the operation of 
mitral valvotomy in which the surgeon considered that the patency and 
function of the mitral valve had been satisfactorily improved. Twenty-four 
of the 28 patients were greatly improved, as judged clinically, by the 
operation. Calcification of the mitral valve, auricular fibrillation, a 
raised sedimentation rate or a history of cardiac failure did not preclude a 
good result. The most striking finding was that ventilation at rest and on 
exercise was greatly reduced after operation in the large majority of 
patients. Despite the marked clinical improvement the resting cardiac output 
fell after operation in 24 of the 28 patients and in 20 it was below 2.5 
l./min./sq.m.. The response of the cardiac output to exercise was greater 
than before operation in only 6 patients. Before operation the resting 
oxygen uptake was considerably above the normal values in a number of these 
patients. This was attributed to the increased work of breathing. After 
operation the resting oxygen uptake fell in 24 of the 28 patients and was 
now normal in all but one instance. The wedge pressure was lower after 
operation in all but 2 of the series but remained abnormally high in almost 
all patients. On exercise the wedge pressure was extremely elevated even in 
those patients who now had no disability. The mean pulmonary arterial 
pressure at rest lea after the operation in all except 2 patients but 
remained abnormally high in all but 3 instances. The fall in pulmonary 
arterial pressure was greater than the fall in wedge pressure. The 
exercising pulmonary arterial pressure was lower after the operation in most 
patients but remained highly abnormal even in those who now had little or no 
disability. There was a marked reduction of the work of the right ventricle 
at rest after operation and it was now within normal limits in 24 of the 28 
patients. Reduction of the work of the right ventricle on exercise was not 
so marked. Intermediate post-operative studies were carried out in 9 
patients. There was objective evidence of some deterioration between the 
first and second postoperative studies in 6 patients of whom only 2 showed 
parallel clinical deterioration.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  mitral valve commissurotomy
EMTREE MEDICAL INDEX TERMS
  air conditioning
  atrial fibrillation
  blood pressure
  calcification
  cardiomegaly
  deterioration
  disability
  exercise
  heart failure
  heart output
  heart right ventricle
  lung artery pressure
  lung function test
  mitral valve
  mitral valve stenosis
  normal value
  oxygen consumption
  patient
  sedimentation rate
  surgeon
  vagus nerve
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007426563
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 569
TITLE
  A clinical study of one hundred cases of severe aortic insufficiency
AUTHOR NAMES
  Segal J.
  Harvey W.P.
  Hufnagel C.
AUTHOR ADDRESSES
  (Segal J.; Harvey W.P.; Hufnagel C.) Depts of Mod. (Sect, of Cardiol.) and 
Surg., Georgetown Univ. Med. Center, Washington, DC, United States.
CORRESPONDENCE ADDRESS
  J. Segal, Depts of Mod. (Sect, of Cardiol.) and Surg., Georgetown Univ. Med. 
Center, Washington, DC, United States.
SOURCE
  American Journal of Medicine (1956) 21:2 (200-210). Date of Publication: 
1956
ISSN
  0002-9343
ABSTRACT
  The clinical features in 100 cases of severe aortic insufficiency are 
reviewed. Eightythree cases were rheumatic, 12 syphilitic, 4 congenital and 
one traumatic. The average age of the patients was 34 yr. The natural 
clinical course of rheumatic aortic insufficiency and syphilitic aortic 
insufficiency are compared. The progression of symptoms in syphilitic aortic 
insufficiency was twice as rapid as in the rheumatic group. In the rheumatic 
group, the average patient had rheumatic fever at age 13, developed 
haemodynamically significant aortic insufficiency at age 20, and noted 
symptoms at age 30. The symptomatic period ranged from 2 months to 30 yr., 
averaging 6.4 yr. Cardiac palpitation and dyspnoea on exertion were the 
earliest and most frequent symptoms in aortic insufficiency of any 
aetiology. Angina pectoris occurred in almost 50% of the rheumatic group. 
This was not related to coronary artery disease or to coronary ostial 
involvement. The average blood pressure was 155/37 mm. Hg, An aortic 
systolic and diastolic murmur, apical systolic murmur, ventricular diastolic 
gallop and Austin Flint murmur were present in every case. Hepatomegaly 
occurred in over 50% of the cases. Radiologie findings included left 
ventricular enlargement, aortic "jump" and "rocking" motion of the heart. 
Posterior displacement of the oesophagus occurred in approximately 50% of 
the patients and 60% of these had systolic expansion of the left auricle. 
ECG's usually demonstrated normal sinus rhythm, left ventricular hypertrophy 
and, frequently, first degree AV block. Auricular fibrillation or a vertical 
electrical axis with large P waves often indicated mitral stenosis. 
Bacterial endocarditis had occurred in 22% of the rheumatic group and was 
frequently followed by progressive cardiac, decompensation. The following 
factors indicated a poor prognosis: (1) recent occurrence of bacterial 
endocarditis with subsequently increasing signs of aortic insufficiency; (2) 
coexistence of angina pectoris and congestive heart failure; (3) syphilitic 
aetiology; (4) marked cardiomegaly; (5) increasing age (over 40) and/ or 
increasing duration of symptoms. The authors' experience, like that of 
others, indicates that patients with "free" aortic insufficiency often 
remain asymptomatic for many years. Congestive failure and/or angina 
pectoris frequently were present for many years, often with remissions and 
exacerbations which were related to rheumatic activity. Some patients were 
maintained for years on conservative medical management but usually 
progressive failure occurred.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aorta valve regurgitation
  clinical study
EMTREE MEDICAL INDEX TERMS
  angina pectoris
  atrial fibrillation
  atrioventricular block
  bacterial endocarditis
  blood pressure
  cardiomegaly
  clinical feature
  congestive heart failure
  coronary artery disease
  disease course
  disease management
  dyspnea
  electrocardiogram
  esophagus
  etiology
  exercise
  heart
  heart failure
  heart left ventricle hypertrophy
  heart palpitation
  hepatomegaly
  mitral valve stenosis
  P wave
  patient
  prognosis
  remission
  rheumatic fever
  sinus rhythm
  systolic heart murmur
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007393132
FULL TEXT LINK
  http://dx.doi.org/10.1016/0002-9343(56)90053-5
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 570
TITLE
  Auricular fibrillation with special reference to rheumatic heart disease
AUTHOR NAMES
  Eraser H.R.L.
  Turner R.W.D.
AUTHOR ADDRESSES
  (Eraser H.R.L.; Turner R.W.D.)
SOURCE
  British medical Journal (1857) (1955) 4953 (1414-1418). Date of Publication: 
1955
ISSN
  0007-1447
ABSTRACT
  Over a period of 5 years a study has been made of auricular fibrillation (A. 
F. ) in relation to 500 patients with rheumatic mitral disease. Of these 250 
were treated surgically. Factors which may precipitate A. F. include 
exercise, emotion, infection and active carditis, but usually no cause is 
apparent. The onset of A. F. may pass unnoticed or be responsible for 
dyspnoea., pulmonary oedema, pulmonary infarction, systemic embolism, 
cardiac failure, loss of consciousness, or anxiety. Relative advantages of 
established A. F. include freedom from paroxysmal attacks, ease of control 
of heart rate with digitalis, and comparative freedom from bacterial 
endocarditis. Persons with A. F. tend to have larger hearts than those in 
sinus rhythm, but reasons are given for concluding that enlargement is not 
directly related to the arrhythmia. Possible factors in the pathogenesis of 
A. F. are reviewed, and it is concluded that there is presumptive evidence 
that myocardial damage may be the most important. A. F. is not a 
contraindication to valvotomy, but a disadvantage from the presumed presence 
of myocardial damage and the increased probability of clot being present, 
with the consequent risk of embolism. A. F. had occurred pre-operatively in 
42% of the surgical series. In these 106 patients clot was found in the left 
auricle or atrium in 40%, but in only 3 of 144 patients in sinus rhythm. The 
presence of a régurgitant jet seems to militate against thrombus formation. 
Good operative results may be obtained in cases of A. F. and life thereby 
prolonged, but the operative risk is greater and the ultimate prognosis 
poorer than in cases with sinus rhythm. Post-operative A. F. occurred in 23% 
of those previously in sinus rhythm. In the first 10 postoperative days it 
is rarely possible to restore sinus rhythm with quinidine, but thereafter 
success is almost always obtained. Pre-operative prophylactic quinidine is 
ineffective.
EMTREE DRUG INDEX TERMS
  digitalis
  quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  rheumatic heart disease
EMTREE MEDICAL INDEX TERMS
  anxiety
  bacterial endocarditis
  blood clotting
  carditis
  consciousness
  dyspnea
  embolism
  emotion
  exercise
  heart
  heart arrhythmia
  heart atrium
  heart failure
  heart muscle injury
  heart rate
  infection
  lung edema
  lung infarction
  mitral valve disease
  pathogenesis
  patient
  prognosis
  risk
  sinus rhythm
  surgical risk
  valvuloplasty
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007385004
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 571
TITLE
  Cardiac arrhythmias in the aged
AUTHOR NAMES
  Scherf D.
AUTHOR ADDRESSES
  (Scherf D.) Dept. of Med., New York Med. Coll., Metropolitan Hosp. Div., New 
York, NY, United States.
CORRESPONDENCE ADDRESS
  D. Scherf, Dept. of Med., New York Med. Coll., Metropolitan Hosp. Div., New 
York, NY, United States.
SOURCE
  Geriatrics (1954) 9:2 (47-56). Date of Publication: 1954
ISSN
  0016-867X
ABSTRACT
  There are no arrhythmias nor ECG changes characteristic of old age. Sinus 
bradycardia may be present in 13% of subjects over the age of 70. As 
atropine causes no increase of heart-rate it is possible that the 
bradycardia is due to changes in the blood supply or metabolism of the sinus 
node. Sinus tachycardia is present in 8% of subjects over 70. Sinus 
arrhythmia which is unrelated to respiration may be found in the elderly and 
it is believed to be associated with changes in the vessels supplying blood 
to the sinus node tissue. Similar changes are believed to be the cause of 
shifting of the pace-maker from sinus node to upper atrioventricular node 
with the presence in the ECG of varying P waves. The carotid sinus syndrome 
is probably no commoner in the elderly than in younger subjects, but its 
symptoms are more severe. In the normal heart the ventricular centres which 
are not under vagal control take over when auricular inhibition occurs. In 
the elderly these centres do not perform so efficiently and prolonged 
cardiac standstill occurs and is not without dangers. Extrasystoles are 
commoner in the elderly than in the young; auricular extrasystoles sometimes 
precede the appearance of auricular fibrillation. The appearance of 
ventricular extrasystoles after exercise suggests the presence of 
coronary-arterial disease as do the presence of multiple forms of 
ventricular extrasystoles. 'Anarchie ventriculaire', the presence of 
frequent and variable ventricular extrasystoles forebodes sudden death. It 
is sometimes, but not invariably, caused by the administration of digitalis. 
If not caused by digitalis, administration of this drug may be beneficial. 
Quinidine seems to precipitate ventricular fibrillation and should be 
avoided in this condition. Paroxysmal tachycardia is commoner in the elderly 
than in the young and is often associated with the presence of 
atrioventricular heart block which may be due to the administration of 
digitalis. Conduction defects often cause slow ventricular rates in the 
presence of auricular fibrillation in the elderly. Paroxysms of auricular 
fibrillation or flutter are often missed clinically unless the patient is 
questioned about transient palpitations, dizziness and chest pain. 
Atrioventricular heart block is related to the presence of atherosclerosis. 
Stokes-Adams attacks are more frequently found in the elderly because 
idioventricular rhythm is not established as promptly as in the young. In 
this condition quinidine, ephedrine and adrenaline sometimes precipitate 
ventricular fibrillation.
EMTREE DRUG INDEX TERMS
  adrenalin
  atropine
  digitalis
  ephedrine
  quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aged
  heart arrhythmia
EMTREE MEDICAL INDEX TERMS
  Adams Stokes attack
  artery disease
  atherosclerosis
  atrial fibrillation
  atrioventricular block
  blood
  bradycardia
  carotid sinus syndrome
  dizziness
  electrocardiogram
  exercise
  extrasystole
  heart
  heart atrioventricular node
  heart muscle conduction disturbance
  heart palpitation
  heart rate
  heart ventricle extrasystole
  heart ventricle fibrillation
  metabolism
  P wave
  paroxysmal tachycardia
  patient
  rhythm
  senescence
  sinus arrhythmia
  sinus bradycardia
  sinus node
  sinus tachycardia
  sudden death
  thorax pain
  tissues
  vascularization
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008546707
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 572
TITLE
  Lone auricular fibrillation
AUTHOR NAMES
  Evans W.
  Swann P.
AUTHOR ADDRESSES
  (Evans W.; Swann P.) Cardiac Dept., London Hosp., London, United Kingdom.
CORRESPONDENCE ADDRESS
  W. Evans, Cardiac Dept., London Hosp., London, United Kingdom.
SOURCE
  British Heart Journal (1954) 16:2 (189-194). Date of Publication: 1954
ISSN
  0007-0769
ABSTRACT
  The term 'lone auricular fibrillation' is suggested to describe auricular 
fibrillation which occurs in the absence of heart disease or thyroid 
toxaemia. This condition is not the same as paroxysmal fibrillation which 
probably originates from a separate mechanism and requires different 
management. 'Lone' fibrillation was not seen in women, all the 20 patients 
observed being men. The basic heart rate is slow and the condition is often 
symptom less until discovered by a routine examination: if symptoms do occur 
palpitation is the predominant symptom, dependent on exertion and consequent 
tachycardia for its production. Radiological examination reveals no general 
cardiac enlargement or enlargement of the left auricle and no pulmonary 
congestion. The condition does not jeopardise life or even prove a handicap 
as a rule, but if the patient follows a heavy occupation where exertion 
increases the heart rate sufficiently to cause palpitation, daily medication 
with digitalis fol. is the treatment of choice. Attempts to restore normal 
rhythm in elderly patients should not be made.
EMTREE DRUG INDEX TERMS
  digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
EMTREE MEDICAL INDEX TERMS
  aged
  cardiomegaly
  disability
  drug therapy
  exercise
  female
  heart disease
  heart palpitation
  heart rate
  lung congestion
  medical examination
  occupation
  patient
  radiodiagnosis
  rhythm
  tachycardia
  thyroid gland
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007303551
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 573
TITLE
  Ventricular rate response following exercise during auricular fibrillation 
and after conversion to normal sinus rhythm
AUTHOR NAMES
  Wetherbee D.G.
  Brown M.G.
  Holzman D.
AUTHOR ADDRESSES
  (Wetherbee D.G.; Brown M.G.; Holzman D.) Med. Serv., Cushing Vet. Adm. 
Hosp., Framingham, MA, United States.
CORRESPONDENCE ADDRESS
  D.G. Wetherbee, Med. Serv., Cushing Vet. Adm. Hosp., Framingham, MA, United 
States.
SOURCE
  Amer. J. Med. Sci. (1952) 223:6 (667-670). Date of Publication: 1952
ABSTRACT
  The ventricular rate response following exercise on die Master seeps was 
studied during auricular fibrillation in 10 patients. Four had 
arterio-sclerotic heart disease and 4 had rheumatic heart disease. Seven had 
been in congestive heart failure but cardiac compensation was restored. The 
exercise test was repeated after normal sinus rhythm was restored - by 
quinidine in 9, spontaneously in one. All 10 patients had an exaggerated 
ventricular peak rate response during fibrillation, whether or not they had 
received digitalis, and all showed significantly reduced peak rate response 
after restoration to normal sinus rhythm.
EMTREE DRUG INDEX TERMS
  digitalis
  quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  exercise
  sinus rhythm
EMTREE MEDICAL INDEX TERMS
  compensation
  congestive heart failure
  exercise test
  heart disease
  malaria
  multiple myeloma
  patient
  rheumatic heart disease
  therapy
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2008917847
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 574
TITLE
  Treatment of mitral stenosis by finger fracture valvulotomy
AUTHOR NAMES
  Gerbode F.
  Holman E.
  Hultgren H.
AUTHOR ADDRESSES
  (Gerbode F.; Holman E.; Hultgren H.) Dept. of Surg., Cardiovascular Lab., 
Stanford Univ. Sch. of Med., San Francisco.
CORRESPONDENCE ADDRESS
  Dept. of Surg., Cardiovascular Lab., Stanford Univ. Sch. of Med., San 
Francisco.
SOURCE
  Trans. W. Surg. Ass. (1952) 59 (343-357). Date of Publication: 1952
ABSTRACT
  Patients with mitral stenosis with little or no regurgitation who are 
experiencing increasing disability from their disease should be considered 
for operation. The mere diagnosis of mitral stenosis is insufficient reason 
for operation, since many of these patients do extremely well on a proper 
medical regimen. Contraindications to operation are: uncontrollable failure, 
moderate to severe mitral regurgitation, other valvular involvement, 
enlargement of the left ventricle, active rheumatic disease, and 
endocarditis. Auricular fibrillation and slight mitral regurgitation are not 
contraindications. Patients whose intake of salt and fluid has been markedly 
restricted and who have received mercurial diuretics should probably be 
allowed a liberalized salt intake for several days before operation. An 
anterolateral approach through the fourth interspace with division of the 
third and fourth costal cartilages is recommended. The finger fracture type 
of valvulotomy is recommended because of its relative simplicity and the 
excellent results which have followed its use in most instances. Forty-four 
patients have had valvulotomy performed by this method, with 5 deaths. 
Fourteen of these cases have been followed up for more than four months 
after operation. Nine of these have had marked improvement in their physical 
status, two have had only moderate improvement, and three have shown slight 
or no improvement. Twelve patients have had extensive physiological studies 
with the aid of cardiac catheterization before and at various intervals 
after operation. From these data the following objective conclusions can be 
drawn: 2 patients showed no improvement, 10 patients showed moderate to 
striking degrees of improvement in cardiac function, as indicated by 
increases in cardiac output at rest and with exercise and by decreases in 
pulmonary artery and right ventricular diastolic pressures. Three patients 
with severe pulmonary hypertension and some right ventricular failure showed 
striking improvement. The physiological improvement is sustained and is 
often progressive.
EMTREE DRUG INDEX TERMS
  diuretic agent
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  finger fracture
  mitral valve stenosis
  valvuloplasty
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  death
  diagnosis
  disability
  endocarditis
  exercise
  heart catheterization
  heart function
  heart left ventricle
  heart output
  heart right ventricle failure
  heart ventricle enddiastolic pressure
  liquid
  mitral valve regurgitation
  patient
  physiology
  pulmonary artery
  pulmonary hypertension
  rheumatic disease
  rib cartilage
  salt intake
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007627251
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 575
TITLE
  Clinical diagnosis of abnormal cardiac rhythms or cardiac arrhythmias
AUTHOR NAMES
  Vakil R.J.
  Golwalla A.
AUTHOR ADDRESSES
  (Vakil R.J.; Golwalla A.) Cardiol. Unit., K. E. M. Hosp., Bombay, India.
CORRESPONDENCE ADDRESS
  R.J. Vakil, Cardiol. Unit., K. E. M. Hosp., Bombay, India.
SOURCE
  Indian Heart Journal (1952) 4:2 (72-88). Date of Publication: 1952
ISSN
  0019-4832
ABSTRACT
  Most arrhythmias encountered in practice can be accurately diagnosed without 
the aid of an electrocardiogram if due attention is paid to the history, 
physical signs and, less often, roentgenographic findings. Certain 
disturbances of cardiac rhythm are prone to occur in definite age groups. 
Others, auricular fibrillation for example, tend to be more common in 
females when hyperthyroidism or mitral stenosis coexists. The mode of onset 
(abrupt or slow) or the associated circumstances (premature ventricular 
contractions shortly after coronary thrombosis) may prove informative. The 
symptomatic manifestations (palpitation, vertigo, anginal pain and the like) 
often provide clues to the diagnosis. The same situation prevails in respect 
of the duration of the attack, drugs or poisons ingested, probable causes, 
and methods of terminating the episode. Determination of the presence or 
absence of an arrhythmia, the apical rate, type of jugular pulsations, the 
effect of exercise or other cardiac accelerating measures, the effect of 
carotid sinus stimulation and the character of the heart sounds constitute 
essential items in the physical examination. The presence of associated 
heart disease, pulse deficit, and character of the apex beat should also be 
noted. A clinical classification of abnormal cardiac rhythms is also given. 
There are regular, irregular and clinically silent rhythms. The regular 
rhythms may be slow, fast, normal, or inconstant and so forth. The clinician 
is urged to develop all sources of clinical information before resorting to 
instrumental aids.
EMTREE DRUG INDEX TERMS
  poison
  sulfanilamide
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  diagnosis
  heart arrhythmia
  heart rhythm
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  carotid sinus massage
  clinical classification
  coronary artery thrombosis
  electrocardiogram
  electroencephalogram
  exercise
  female
  groups by age
  heart disease
  heart palpitation
  heart sound
  heart ventricle extrasystole
  hyperthyroidism
  mitral valve stenosis
  pain
  physical examination
  pulse rate
  rhythm
  vertigo
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007293254
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 576
TITLE
  Isolated mitral stenosis. A short summary of clinical, roentgenological, 
phonocardiographic, electrocardiographic, and pathophysiologic examinations 
of 200 cases
AUTHOR NAMES
  Nylin G.
AUTHOR ADDRESSES
  (Nylin G.)
SOURCE
  Acta medica Scandinavica (1952) 142:SUPPL. 266 (797-815). Date of 
Publication: 1952
ISSN
  0001-6101
ABSTRACT
  A study on 200 cases of mitral stenosis without associated disease of other 
valves. They were divided into two main groups, those compensated and chose 
decompensated at rest; the presence or absence of decompensation being 
mainly determined by venous pressure measurements. The age at which they 
came under observation was variable. The average known duration of mitral 
stenosis was 5-20 years, but in some who had been followed up for many years 
it was found that mitral stenosis had been present for from 40 to 60 years. 
Acute rheumatic fever or chorea had occurred in 110 cases, endocarditis in 5 
and syphilis in 5. Hypertension was found in at least 15 cases. Embolism, 
cerebral, intestinal or peripheral, occurred in 19 cases. There were 21 
autopsies, at which the size of the mitral valve opening was found to vary 
from that of a little finger to a narrow chink. Left auricular enlargement 
and right ventricular hypertrophy were present in all. The chief indications 
for operation are (1) repeated attacks for several years of haemoptysis and 
congestion of the lungs without marked cardiac enlargement, (2) very marked 
dyspnoea of exertion over a long period. The diagnostic importance of the 
presystolic murmur and rumbling diastolic murmur is emphasized. The use of 
photocardiography to verify the sounds and to refer them to the right point 
in the cardiac cycle is stressed. Photocardiography is also of use in 
establishing the presence or absence of an 'opening snap'. The heart volumes 
were estimated radiologically in every case, the maximum normal volume being 
500 cm(3) per M(2) body surface. Most of the compensated cases had a volume 
between 350 and 700 cm(3) per M(2) body surface. The majority of the 
decompensated cases, however, had a volume between 550 and 1,200 cm(3). It 
was concluded that cardiac enlargement preceded the signs of congestive 
cardiac failure and was therefore an early and important sign of 
decompensation. Auricular fibrillation was found to occur more frequently in 
conjunction with large cardiac volumes. The roenterological appearances are 
analysed. Backward bulging of the left auricle in the lateral view was noted 
in 188 cases. The right border of the left auricle was clearly seen in the 
frontal projection in 155 cases. The left auricular appendage formed a local 
bulge in the upper left cardiac border in 81 cases. The frequent finding of 
right axis deviation and broadening of the P waves in the ECG was considered 
significant. Nylin's heart function test was used in an attempt to judge the 
efficiency of the heart. In this test the oxygen uptake of the of the 
subject before and after graded exercise is measured and hence the relative 
oxygen debt estimated. It was thought that this test might be of importance 
in decisions as to the management and treatment of cases of mitral stenosis.
EMTREE DRUG INDEX TERMS
  buphenine
  oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  examination
  mitral valve stenosis
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  autopsy
  body surface
  cardiomegaly
  chorea
  congestive heart failure
  diagnosis
  dyspnea
  electrocardiogram
  embolism
  endocarditis
  exercise
  heart
  heart cycle
  heart function test
  heart right ventricle hypertrophy
  heart volume
  hemoptysis
  hypertension
  lung
  mitral valve
  oxygen consumption
  P wave
  pressure measurement
  rheumatic fever
  stenosis
  stomach ulcer
  syphilis
  venous pressure
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007347477
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 577
TITLE
  Observations on the daily changes in venous pressure and weight in a case of 
chronic congestive heart failure
AUTHOR NAMES
  Newman W.
  Fishel L.
AUTHOR ADDRESSES
  (Newman W.; Fishel L.) Cardiac Service, Vet. Adm. Hosp., Bronx, NY, United 
States.
CORRESPONDENCE ADDRESS
  W. Newman, Cardiac Service, Vet. Adm. Hosp., Bronx, NY, United States.
SOURCE
  Circulation (1950) 1:4 (706-711). Date of Publication: 1950
ISSN
  0009-7322
ABSTRACT
  A patient with hypertensive and arteriosclerotic heart disease and auricular 
fibrillation, who required digitalis, mercurials, and a low-sodium diet to 
remain in cardiac compensation, was put into decompensation first by the 
administration of salt and then by the withholding of digitalis. With salt 
administration the patient's body weight and venous pressure (brachial) rose 
simultaneously and was not accompanied by discomfort or dyspnoea. Salt 
restriction brought about a simultaneous fall in both. However, with 
discontinuation of digitalis the venous pressure rose but the body weight 
remained unchanged and the patient became dyspnoeic. Mercurials were not of 
much value, and digitalis had to be given to restore compensation. It is 
suggested that two types of cardiac failure exist; one on the basis of salt 
and water retention (forward failure) and the other due to a brief 
discrepancy in the output of the two ventricles.
EMTREE DRUG INDEX TERMS
  digitalis
  mercury
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  congestive heart failure
  venous pressure
  weight
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  body weight
  compensation
  coronary artery atherosclerosis
  dyspnea
  forward heart failure
  heart failure
  patient
  sodium restriction
  water retention
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007165648
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 578
TITLE
  Studies on diethylaminoethanol. I. Physiological disposition and action on 
cardiac arrhythmias
AUTHOR NAMES
  Rosenberg B.
  Kayden H.J.
  Lief P.A.
  Mark L.C.
  Steele J.M.
  Brodie B.B.
AUTHOR ADDRESSES
  (Rosenberg B.; Kayden H.J.; Lief P.A.; Mark L.C.; Steele J.M.; Brodie B.B.)
SOURCE
  Journal of Pharmacology and Experimental Therapeutics (1949) 95:1 (18-27). 
Date of Publication: 1949
ISSN
  0022-3565
ABSTRACT
  When procaine, which has been used intravenously to control cardiac 
arrhythmias during cyclopropane anesthesia, is hydrolysed in the body, 
p-aminobenzoic acid and dimethylaminoethanol are produced. The latter was 
procured as a pure substance (from Winthrop-Stearns) and tested to determine 
whether the procaine results were due to this hydrolytic product. In dogs 
ventricular premature beats and ventricular tachycardia were prevented by 
its use, and in human subjects ventricular premature beats were suppressed 
temporarily. Six cases of ventricular tachycardia were successfully treated. 
There was no control of auricular fibrillation or supra-ventricular 
tachycardia. This drug is less active than procaine but the effective dose 
is safer. 25% is excreted in the urine, the fate of the remainder is still 
unknown. A single dose is either metabolized or excreted within eight hours. 
Considerable amounts are found in the organs. The control of the ventricular 
activity occurs only when the plasma content is high, and lasts for about 20 
minutes, hence the intravenous route is demanded. Some side reactions, e.g. 
peculiar taste, warmth, dizziness, optical disturbance, nausea and fall in 
blood pressure, were noted. None lasted over 20 minutes.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  2 diethylaminoethanol
EMTREE DRUG INDEX TERMS
  4 aminobenzoic acid
  cyclopropane
  deanol
  procaine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart arrhythmia
EMTREE MEDICAL INDEX TERMS
  anesthesia
  atrial fibrillation
  blood pressure
  dizziness
  dog
  dose response
  heart fibrillation
  heart ventricle contraction
  heart ventricle extrasystole
  heart ventricle tachycardia
  human
  nausea
  optics
  plasma
  side effect
  single drug dose
  taste
  urine
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007221765
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 579
TITLE
  The heart rate with exercise in patients with auricular fibrillation
AUTHOR NAMES
  Knox J.A.C.
AUTHOR ADDRESSES
  (Knox J.A.C.) Dept. of Physiology, King's Coll., London.
CORRESPONDENCE ADDRESS
  J.A.C. Knox, Dept. of Physiology, King's Coll., London.
SOURCE
  British Heart Journal (1949) 11:2 (119-125). Date of Publication: 1949
ISSN
  0007-0769
ABSTRACT
  The effect of exercise on 13 ambulant patients with auricular fibrillation 
was com-pared with the results in 100 normal subjects. In auricular 
fibrillation there was occasionally an initial slowing of the heart but 
there was always a later acceleration at about 12 seconds, the maximum heart 
rate reaching a higher level and the subsequent secondary slowing taking 
longer than in normal subjects. The response of a given patient remained 
remarkably constant. Digitalis considerably decreased the excessive 
acceleration in rate but did not abolish it.
EMTREE DRUG INDEX TERMS
  digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  atrial fibrillation
  exercise
  heart rate
  patient
EMTREE MEDICAL INDEX TERMS
  acceleration
  heart
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007422991
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 580
TITLE
  Heart disease in pregnancy
AUTHOR NAMES
  Hudson K.
AUTHOR ADDRESSES
  (Hudson K.)
SOURCE
  Ulster Medical Journal (1949) 18:1 (93-100). Date of Publication: 1949
ISSN
  0041-6193
ABSTRACT
  The cases in this series, 31 primiparae and 39 multiparae, representing 
together an incidence of 2.72% of admissions, were classified according to 
the New York Heart Association classification. There were 22 cases (31.43%) 
in Class 1, 42 (60%) in Class 2, 4 (5.72%) in Class 3 and 2 (2.85%) in Class 
4. A history of rheumatic infection in one or another of its forms was noted 
in 67.14% of the cases. A summary of the distribution of the vascular 
lesions showed mitral stenosis present in 55 cases (79.57%), mitral 
insufficiency in 3 (2.30%), mitral stenosis and aortic regurgitation in 11 
(16.21%) and mitral stenosis and insufficiency in 1 (1.92%). A recent 
reactivation of the lesion prior to or during pregnancy has an adverse 
prognostic significance. The response of the heart to effort, and therefore 
to pregnancy and parturition as shown by the response of the pulse rate and 
blood pressure to exercise, constitutes a sign of greater importance 
prognostically than the character of the lesion, heart sounds or area of 
cardiac dullness. The only indication for interruption of pregnancy is heart 
failure which doet nos respond to treatment and, if prior to the fourth 
month of pregnancy, auricular fibrillation and recurrent heart failure. In 
the absence of cardiac distress labour was allowed to proceed in the 
ordinary manner. A pulse rate of 110 per minute and a respiratory rate of 
over 24 per minute are considered omens of intra- or postpartum heart 
failure and and for rapid digitalization. Further treatment consists of 
oxygen therapy, the upright position and operative delivery as soon as 
cervical dilatation permits. Forceps delivery was used in almost 30% of the 
series, twice the rate of their clinic as a whole. Caesarean section was 
done four times and then for obstetrical and not cardiac reasons. Three 
deaths (4.28%) occurred in the series; two infants were lost. Although 
pregnancy throws a heavy additional strain on the already reduced cardiac 
reserve, it is a temporary strain, and rest and proper treatment may prevent 
further inroads on the cardiac reserve. Repeated pregnancies, however, may 
disastrously reduce the cardiac reserve. No statistical evidence is 
available which satisfactorily proves that patients with one or two 
pregnancies die at any earlier age than do nulliparous patients with 
equivalent heart lesions. To reduce maternal mortality, all patients should 
be under early supervision by both obstetrician and cardiologist. Previous 
performance of the patient is all-important in the detection of progressive 
deterioration of the cardiac reserve. Sound treatment rests on the early 
supervision of such cases by trained personnel, the proper study and 
evaluation of the cardiac condition, facilities for rest and treatment in 
hospital prior to delivery and special care during labour.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart disease
  pregnancy
EMTREE MEDICAL INDEX TERMS
  aorta valve regurgitation
  atrial fibrillation
  birth
  blood pressure
  breathing rate
  cardiologist
  cesarean section
  classification
  death
  deterioration
  digitalization
  exercise
  forceps delivery
  heart
  heart failure
  heart injury
  heart sound
  hospital
  infant
  infection
  instrumental delivery
  maternal mortality
  mitral valve regurgitation
  mitral valve stenosis
  multipara
  outpatient department
  oxygen therapy
  patient
  personnel
  primipara
  pulse rate
  standing
  United States
  uterine cervix dilatation
  vascular lesion
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007065367
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 581
TITLE
  Mitral stenosis in late life
AUTHOR NAMES
  Cookson H.
AUTHOR ADDRESSES
  (Cookson H.)
SOURCE
  British Heart Journal (1949) 11:2 (155-164). Date of Publication: 1949
ISSN
  0007-0769
ABSTRACT
  This report concerns 37 patients with mitral stenosis and one with mitral 
incompetence aged from 51 to 77 years. The females outnumbered the males by 
3 to i, a ratio higher than that of mitral stenosis in general. Rheumatism 
was believed to be the cause of the valvular lesion in all; 60% gave a clear 
history of rheumatic fever or of a cardiac lesion having been discovered in 
early life. The first recognized attack of rheumatic fever occurred over the 
age of 30 in a few of the cases. All the cases had shown at least an average 
capacity for work although some admitted to shortness of breath curtailing 
strenuous exercise; 18 of the women had borne children (in one case, five). 
Half the cases had arterial hypertension, taking a minimum diastolic 
pressure of 100 mm., thus showing a relatively high incidence of this 
disorder. Despite this feature anginal pain was present in only one case. 
Auricular fibrillation or, in a few, auricular tachycardia, was seen in all 
but two cases. The onset of arrhythmia seemed to mark the onset of serious 
symptoms in most of the cases. The main point in the clinical diagnosis was 
the presence of a low-pitched, usually but not invariably rough murmur, 
heard in the neighbourhood of the mitral area. In the ten cases with aortic 
incompetence as well, the diagnosis of mitral stenosis was not made unless 
confirmatory radiological changes were present. The principal radiological 
differences from those seen in the younger group of mitral stenosis cases 
were due to the concomitant degenerative vascular changes and consisted of 
broadening of the vascular pedicle, prominence of the aortic knob and left 
ventricular enlargement. Sixteen cases died after an average duration of 
symptoms of 4$ years, the average age at death being 62 years. Twelve died 
with systemic congestion complicated in two by cerebral vascular lesions, 
acute rheumatism in one and pulmonary infarction in one. Two died from acute 
pulmonary congestion and two from a left auricular thrombus obstructing the 
pulmonary orifice. It is suggested that mitral stenosis is not rare in 
patients over 50 years of age and that careful auscultation of elderly 
subjects with auricular fibrillation will reveal this lesion where formerly 
it was not suspected.
EMTREE DRUG INDEX TERMS
  sulfanilamide
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  mitral valve stenosis
EMTREE MEDICAL INDEX TERMS
  aged
  aorta valve regurgitation
  atrial fibrillation
  auscultation
  cerebrovascular disease
  child
  death
  diagnosis
  diastolic blood pressure
  dyspnea
  exercise
  female
  heart arrhythmia
  heart injury
  heart left ventricle hypertrophy
  hypertension
  lung congestion
  lung infarction
  male
  mitral valve disease
  mitral valve regurgitation
  pain
  patient
  rheumatic disease
  rheumatic fever
  tachycardia
  thrombus
  vascular pedicle
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007422999
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 582
TITLE
  Effect of lanatoside C on the circulation of patients with congestive 
failure. A study using catheterization of the right side of the heart
AUTHOR NAMES
  Stead E.A.
  Warren J.V.
  Brannon S.
AUTHOR ADDRESSES
  (Stead E.A.; Warren J.V.; Brannon S.)
SOURCE
  archives of internal medicine (1948) 81:3 (282-291). Date of Publication: 
1948
ISSN
  0730-188X
ABSTRACT
  Presentation of the results in 22 patients with congestive heart failure 
studied by right heart catheterization. The changes in the circulation 
induced by the intravenous administration of 1.6 mg. of lanatoside G were 
investigated on admission to the hospital. All patients had dyspnoea on 
slight exertion prior to sedation. Right atrial pressure was elevated in 21. 
Auricular fibrillation was present in three, auricular tachycardia in two; 
the remainder had normal rhythm. The group included 13 patients with 
hypertensive or coronary disease, four with rheumatic mitral stenosis, three 
with luetic heart disease, and two unclassified. The first observed effect 
was a fall in venous pressure (in 5-10 minutes). The fall in venous pressure 
could not be related to a reduced blood volume or diuresis. The haematocrit 
fell. The stroke volume increased in 20; the response of the cardiac rate 
was variable. There were no consistent changes in oxygen consumption. The 
mean arterial pressure increased in 16 patients (by 1-50 mm. Hg.). All 
patients showed an increase in systolic blood pressure; the alterations in 
diastolic pressure were inconstant. The peripheral mean pressure in mm. 
resistance R = mean presure in mm Hg. 1332/ cardic putput in ml. fell in 18 
patients. The arteno- cardiac output in ml. per second venous difference 
decreased in all but one instance; in 16 the fall was at least 0.9 volume 
per cent. The cardiac index rose in 20 instances. In eight of the 22 
subjects the cardiac output increased significantly, the average increase 
being 1.6 1. per minute. Patients with severe anaemia are discussed who had 
a high cardiac output despite the presence of congestive heart failure; the 
cardiac output increased further with digitalis. Attention is again called 
to the disproportion between tissue need and cardiac output in the 
initiation of congestive heart failure. The data indicate that lanatoside G 
increases the output of the heart in the presence of a normal rhythm, and 
that the prime effect of digitalis is on the ventricular muscle. The authors 
classify cardiac output in congestive heart failure with regard to the 
response to hospital therapy. Fishman - Chicago.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  lanatoside C
EMTREE DRUG INDEX TERMS
  digitalis
  lanatoside
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  catheterization
  heart
  patient
EMTREE MEDICAL INDEX TERMS
  anemia
  atrial fibrillation
  blood volume
  congestive heart failure
  coronary artery disease
  diastolic blood pressure
  diuresis
  dyspnea
  exercise
  giardiasis
  heart catheterization
  heart disease
  heart failure
  heart index
  heart output
  heart rate
  heart right atrium pressure
  heart stroke volume
  hematocrit
  hospital
  intravenous drug administration
  mean arterial pressure
  mitral valve stenosis
  muscle
  oxygen consumption
  rhythm
  sedation
  systolic blood pressure
  tachycardia
  therapy
  tissues
  United States
  venous pressure
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007419297
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 583
TITLE
  Aortic stenosis: A study of the clinical and pathologic aspects of 107 
proved cases
AUTHOR NAMES
  Kumpe C.W.
  Bean W.B.
AUTHOR ADDRESSES
  (Kumpe C.W.; Bean W.B.) Dept. of Internal Medicine, Univ. of Cincinnati, 
Cincinnati Gen. Hosp., .
CORRESPONDENCE ADDRESS
  C.W. Kumpe, Dept. of Internal Medicine, Univ. of Cincinnati, Cincinnati Gen. 
Hosp., .
SOURCE
  Medicine (1948) 27:2 (139-185). Date of Publication: 1948
ISSN
  1357-3039
ABSTRACT
  The conclusions of this monographic paper are: (i) A series of 107 proved 
cases of aortic stenosis, uncomplicated by deforming lesions of other 
valves, has been studied from the clinical and morphological aspects. (2) 
Aortic stenosis found at autopsy is preponderantly a disease of the !ate 
yeai* of life, although suine cases occur in the early decades. Roughly 
three-fourths of the cases were males. Colour, anthropologie type and 
occupation played no significant rôle in the disease. (3) A history of acute 
rheumatic fever was obtained in two-thirds of the cases, with relevant data. 
(4) Cases were divided into 'cardiac* (Group I) and 'non-cardiac* (Group II) 
on the basis of history and status on hospital admission. Of the 78 
cardiacs, 34 had chronic congestive failure, 10 had intermittent bouts of 
failure, and 19 had an abrupt onset of failure shortly before they were 
admitted. Severe epistaxes precipitated failure in three cases. Five 
patients with congestive failure had chiefly complaints of mental disorders, 
four had severe dizziness, four had repeated syncope, and cardiac pain was 
responsible for the admission of three. In many cardiacs congestive failure 
commenced or became more severe following strenuous exercise. (5) Three 
grades of severity of the anatomical lesions were established. There was a 
higher average admission rate for those with mild lesions ( é.37) than for 
those with moderate (1.36) or severe lesions (1.34), many of the latter 
being admitted only once and remaining until the fatal issue. (6) Group I 
patients had an increased frequency of admission in the fall months of 
September, October and November, but no such trend occurred in Group II. (7) 
Group II patients were admitted for infection (endocarditis) and various 
diseases of old age. Injury following syncope was a minor though significant 
cause of admission. (8) Pulse rate was accelerated, but not to extreme 
degrees, averaging 96 for cardiacs, 86 for the others. Respirations were 
increased. Blood pressure was not characteristic; some had systolic 
hypertension, and others had low diastolic pressures, but relatively few had 
the low systolic, low pulse pressure described as typical of aortic 
stenosis. (9) Enlargement of the heart was detected clinically in 78 % of 
the cardiac patients and 52 % of the others. Muffling of the apical sounds 
was common. At the base the second sound over the aortic valve was usually 
absent or much reduced in intensity. Occasionally it was loud and must have 
been transmitted from the pulmonary valve. Comparison of second sounds in 
the right and left second interspaces was not always helpful, since loss 
OfA1 or increase of P1 were not regular in occurrence. (10) A systolic 
murmur was heard at the base in only 83 % of the cases, with transmission 
into the neck vessels in slightly less than half. Basal diastolic murmurs 
were heard in a third of the cases. Apical systolic murmurs were heard in 82 
% of the cases, and an apical diastolic murmur was noted in slightly less 
than a third. Thrills were felt in 33 cases. The systolic murmurs and 
thrills were related in intensity to the degree of stenosis, but they were 
absent in several cases with severe valvular obstruction, (u) Manifestations 
of congestive heart failure were commonplace but were not of a peculiar 
variety except for an unusual frequency of sweating. (12) Fluoroscopic 
demonstration of calcified aortic valves verified the diagnosis five times. 
With routine study a much larger number would have been found. (13) 
Laboratory studies of blood and urine were not helpful in making a 
diagnosis. (14) Nothing pathognomonic was found in the electrocardiograms. 
Auricular fibrillation occurred in 19 % of the cases, a higher incidence 
than reported elsewhere. Left axis deviation, conduction defects and signs 
of myocardial disease were frequent. (15) The hospital course was 
characterized by signs of congestive failure unusually refractory to 
treatment with digitalis, oxygen or diuretics. Episodes of sweating, 
cyanosis, restlessness and confusion occurred in 28 patients. They came and 
went uninfluenced by special therapy. Signs and symptoms referable to the 
brain were conspicuous in 13 patients. (16) Treatment was unsatisfactory. 
Digitalis and oxygen gave poorer response than is usually seen in other 
forms of congestive failure. Diuretics were only slightly more helpful. (17) 
Cardiac pain occurred in 37 % of the patients before hospitalization and in 
8 % while under observation. It differed from typical angina pectoris in its 
lack ' of radiation or its radiation to the right, its advent after rather 
than during exercise, and its refractoriness to nitroglycerine. It was much 
more closely associated with severe aortic stenosis than with coronary 
arteriosclerosis. (18) The type of sudden death which ended the life of 21 % 
of the pauenls was uuTcicauaicu fïùiu iiislaui. syncopal death and 
unexpected death where the terminal stage lasts for hours. In our material 
sudden death occurred in a matter of minutes, usually between 5 and 30. In 
contradistinction to those with instant death following myocardial 
infarction, a history of syncopal attacks was not common in those bedfast 
patients who died suddenly. Indeed, it was less than half as common in those 
who died suddenly as in the whole group. (19) The lesions of aortic stenosis 
were graded into three classes on the basis of severity. In every valve 
calcium was found grossly or histologically, and it varied in quantity with 
the severity of the lesion. In severe lesions the coronary ostia were 
distorted. Fusion of cusps and nodule formation were common. The hearts were 
enlarged in the majority of cases and the heart weight was related to the 
extent of valvular obstruction. There was also a relation of heart weight to 
congestive failure, the cardiacs with each grade of stenosis having heavier 
hearts than the noncardiacs. (20) Coronary arteriosclerosis was common, and 
had given rise to thrombosis and myocardial infarction in an appreciable 
number, (21) Sclerosis was extensive in the abdominal and descending portion 
of the thoracic aorta, but not in the ascending portion. (22) The remainder 
of the lesions found at autopsy were related to advanced arterial disease, 
congestive failure, bacterial endocarditis and the numerous intercurrent 
diseases which proved lethal to those in Group II. (23) Clinical diagnosis 
was made in only 24 % of all cases, reflecting both unfamiliarity with the 
diagnostic criteria and too great acceptance of the classic triad of basal 
systolic murmur, thrill, and small slowly rising pulse.
EMTREE DRUG INDEX TERMS
  calcium
  digitalis
  diuretic agent
  glyceryl trinitrate
  oxygen
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  aorta stenosis
EMTREE MEDICAL INDEX TERMS
  angina pectoris
  aorta valve
  artery disease
  atrial fibrillation
  autopsy
  bacterial endocarditis
  blood
  blood pressure
  brain
  cardiac patient
  color
  congestive heart failure
  coronary artery atherosclerosis
  cyanosis
  death
  diagnosis
  diastolic blood pressure
  dizziness
  electrocardiogram
  endocarditis
  exercise
  faintness
  heart
  heart infarction
  heart muscle conduction disturbance
  heart weight
  hospital
  hospital admission
  hospitalization
  infection
  injury
  laboratory
  male
  mental disease
  myocardial disease
  neck
  obstruction
  occupation
  pain
  patient
  physical disease by body function
  pulmonary valve
  pulse pressure
  pulse rate
  radiation
  restlessness
  rheumatic fever
  sclerosis
  senescence
  stenosis
  sudden death
  sweating
  systolic heart murmur
  systolic hypertension
  therapy
  thoracic aorta
  thrombosis
  urine
  valve
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007418650
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 584
TITLE
  Endothelial dystrophy
AUTHOR NAMES
  Colvin C.S.
AUTHOR ADDRESSES
  (Colvin C.S.)
SOURCE
  Transactions of the Ophthalmological Society of Australia, Sydney (1947) 7 
(106). Date of Publication: 1947
ABSTRACT
  A case of endothelial dystrophy is described. The patient was an elderly 
woman, thin and a sufferer from chronic indigestion and auricular 
fibrillation. Her vision had improved from 6/9 to 6/6 in the right eye, and 
from 6/60 to 6/12 in the left eye. The treatment consisted of improved diet, 
mixed glandular therapy and vitamin capsules. She had seen rainbows for 
years, and a diagnosis of glaucoma had been made elsewhere. The tension and 
the fields and the fundi were normal. The slit-lamp appearance was typical. 
In discussion, six other patients with a similar condition were described by 
members.
EMTREE DRUG INDEX TERMS
  vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  dystrophy
EMTREE MEDICAL INDEX TERMS
  aged
  atrial fibrillation
  cornea
  cornea dystrophy
  diagnosis
  diet
  endothelium
  eye
  female
  glaucoma
  indigestion
  patient
  slit lamp
  therapy
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007280731
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 585
TITLE
  The management of hyperihyroidism
AUTHOR NAMES
  Davis H.H.
AUTHOR ADDRESSES
  (Davis H.H.)
SOURCE
  Rocky Mountain medical journal (1947) 44:3 (840-843). Date of Publication: 
1947
ISSN
  0035-760X
ABSTRACT
  After introductory remarks on the relation of iodine to the pathogenesis of 
goitre, the author presents a study of goitre cases at the Nebraska Hospital 
over a ten-year period. 82 % were operated upon, with satisfactory results 
in 91 %. The wellestablished pre-operative procedure of using Lugol's iodine 
with a high caloric, high protein and high vitamin diet is discussed. 10 % 
of auricular fibrillations are due to hyperthyroidism; such patients are 
usually 35 years or older. This complication should not be treated with 
quinidine, but with digitalis. When the patient recovers from the operation 
the basal metabolic rate should be determined at monthly intervals, and 
desiccated thyroid should be given when indicated. Postoperative 
complications are haemorrhage, cyanosis, dyspnoea (due to haematoma or 
injury of the laryngeal nerve), thyroid crisis and tetany. The author 
discusses the use of thiouracil as a means of pre-operative care; it has a 
depressant effect on the bone marrow. Additional therapeutic measures are 
irradiation therapy, radioactive iodine may be given orally. It has the 
taste of stale water and is absorbed and concentrated in the thyroid gland. 
This radio-active substance may have a greater effect than roentgen rays 
delivered through the skin and overlying tissues. Tolstoi - New York.
EMTREE DRUG INDEX TERMS
  digitalis
  iodine
  lugol
  protein
  quinidine
  radioactive iodine
  thiouracil
  vitamin
  water
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  basal metabolic rate
  bleeding
  bone marrow
  cyanosis
  diet
  dyspnea
  goiter
  hematoma
  hospital
  hyperthyroidism
  injury
  laryngeal nerve
  pathogenesis
  patient
  postoperative complication
  radiotherapy
  skin
  taste
  tetany
  thyroid crisis
  thyroid gland
  tissues
  United States
  X ray
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007417807
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 586
TITLE
  The heart in thyroid disease
AUTHOR NAMES
  Starr P.
AUTHOR ADDRESSES
  (Starr P.) University of Southern California School of Medicine, Los 
Angeles, CA, United States.
CORRESPONDENCE ADDRESS
  P. Starr, University of Southern California School of Medicine, Los Angeles, 
CA, United States.
SOURCE
  Clinical Medicine (1947) 54:6 (179-181). Date of Publication: 1947
ISSN
  0412-7994
ABSTRACT
  Deficiency of the thyroid hormone produces its cardiovascular effects at two 
levels. The slighter deficiency is associated with loss of the pharmacologic 
function of the thyroid hormone in relation to the sympathetic cardiac 
nervous mechanisms. The greater deficiency (myxoedema) produces degenerative 
changes in the heart and blood vessels. The changes in myxoedema consist of 
dilatation and pseudohypertrophy of the heart. There are interstitial oedema 
and fibrosis, the fibres being widely separated and the myocardium friable. 
The heart is enlarged in all diameters and roentgenoscopically it beats with 
extreme feebleness. Cardiac output and circulation time are decreased in the 
presence of myxoedema, the pulse pressure is low and rises with thyroid 
treatment; arteriovenous oxygen difference is greatly increased in 
myxoedema. The electrocardiographic manifestations of myxoedema are 
decreased amplitude of P and QRS waves and absence or inversion of the T 
wave in all leads. Clinically, the patients experience dyspnoea on effort, 
and some have angina pectoris. Congestive failure does not result from 
myxoedema in itself and when it does occur, it is because some other 
pathologic cause exists. In the treatment of myxoedema, the daily dose of 
thyroid is usually from a fraction of maintenance dose (0.25 grain U.S.P. 
desiccated thyroid for two weeks; 0.5 grain for two weeks; 0.75 grain for 
two weeks) up to a maintenance dose of 1 grain daily. By this means, the 
full driving force of the maintenance dose is not reached until the 
histopathologic changes have been corrected. If evidence of coronary 
insufficiency develops under treatment, thyroid medication is discontinued 
and is reinitiated at the previous lower level. Excess thyroid hormone also 
produces its effects by two mechanisms, the pharmacologic and the 
pathologic. The pathogenic action of hyperthyroidism on the heart is 
summarized as follows: (1) Continuous day and night excessive work due to 
elevated metabolism (no sleep relief); (2) pharmacologic effects due to 
adrenergic synergism and peripheral capillary dilatation, and simulated 
arteriovenous shunt in the goitre; (5) disturbance of cardiac rhythm; 
auricular fibrillation in 20 per cent of all cases (two-third permanent; 
one-third paroxysmal) and in 50 per cent of those with congestive failure; 
(4) disorders of protein and carbohydrate storage in hyperthyroidism as 
evidenced by creatinuria and insulin intensity. There are no established 
histological changes in the heart due to hyperthyroidism, and in the absence 
of auricular fibrillation or hypertension, the heart is not enlarged. 
Congestive heart failure is frequently, though not always, associated with 
some underlying cardiac disease. The diagnosis is based on the classic signs 
and symptoms of hyperthyroidism, on the failure of a fibrillating heart to 
slow on adequate administration of digitalis and on a history of 
thyrotoxicity prior to the onset of congestive failure, especially in the 
presence of auricular fibrillation. There are no characteristic 
electrocardiographic signs of hyperthyroidism. The pre-operative management 
of hyperthyroidism includes sedation (small doses of morphine) and the 
restoration of compensation (salt-free diet, diuretic agents and digitalis). 
During this time thiouracil could be used, to be combined with the 
employment of iodine for ten days before operation.
EMTREE DRUG INDEX TERMS
  carbohydrate
  digitalis
  diuretic agent
  insulin
  iodine
  morphine
  oxygen
  protein
  thiouracil
  thyroid hormone
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart
  thyroid disease
EMTREE MEDICAL INDEX TERMS
  angina pectoris
  arteriovenous shunt
  atrial fibrillation
  blood vessel
  capillary
  cardiovascular effect
  circulation time
  compensation
  congestive heart failure
  diagnosis
  diet
  drug therapy
  dyspnea
  edema
  employment
  fiber
  fibrosis
  goiter
  grain
  heart disease
  heart muscle
  heart output
  heart rhythm
  hypertension
  hyperthyroidism
  ischemic heart disease
  maintenance drug dose
  metabolism
  myxedema
  night
  patient
  physical disease by body function
  pulse pressure
  sedation
  sleep
  storage
  T wave
  thyroid gland
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007024833
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 587
TITLE
  Editorial. Rheumatic fever. Abridged interim report from the Royal College 
of Physicians
AUTHOR ADDRESSES
  SOURCE
  Medical Press (1947) 109:5636 (418-421). Date of Publication: 1947
ISSN
  0368-9492
ABSTRACT
  Available evidence suggests that in Great Britain there are 300,000 persons 
whose lives are or will be affected by rheumatic fever. It is the dominating 
cause of heart disease under the age of 40, and usually begins between the 
ages of five and fifteen years. Environment, and perhaps an inherited 
susceptibility, may favour its occurrence. Infection of the supper 
respiratory tract with haemolytic streptococci of the Lancefield A group 
sometimes precedes the initial attack. The latent period between an 
antecedent streptococcal infection and the rheumatic fever illness is 
commonly two to three weeks. Modes of onset: (a) Failing health. Insidious 
onset, sore throat, early fatigue, pallor, and loss of weight. (b) Multiple 
arthritis. All grades, high fever. Subcutaneous rheumatic nodules, swelling 
of joints. (c) Carditis, tachycardia and cardiac murmurs and later failing 
health, pyrexia, nodules and arthritis. (d) Chorea. This seldom occurs at 
the same time as joint manifestations, but may alternate with frank attacks 
of rheumatic fever. The heart is less frequently involved. Clinical features 
and general signs include carditis (essential lesion) pyrexia, pain and 
tenderness in large joints; rapid pulse (regular), systolic murmurs and 
sometimes a pericardial rub. Apart from the symptoms already mentioned blood 
examination shows moderate reduction in red cells, to about 4 million per 
cmm and haemoglobin may fall to 60 per cent or less. Leucocyte count varies 
between 10,000 and 15,000 or more. Increased erythrocyte sedimentation rate 
(E.S.R.) is found during the active stage of the disease. Inflammation of 
the heart (carditis) is evidenced by tachycardia, murmurs, pericarditis, 
cardiac enlargement, and electrocardiographic signs such as prolongation of 
P.R. interval and changes in the form or duration of the QRS or in the T 
waves. Auricular fibrillation is uncommon in children but in severe cases 
signs of heart failure may appear, such as extreme tachycardia, dyspnoea, 
venous distension, enlargement of liver and oedema of dependent parts; 
vomiting and abdominal pain are grave developments. Differential diagnosis: 
Congenital heart disease. History may be misleading but rheumatic fever 
below the age of three is rare. The murmur is more often basal than apical. 
Osteomyelitis: persistence of swelling at one joint should arouse suspicion. 
Tuberculosis also affects a single joint. Rheumatoid arthritis occasionally 
begins acutely and closely simulates rheumatic fever. Acute poliomyelitis in 
its early stages may produce considerable pain in the limbs but seldom 
selects joints. Course and prognosis: Pains and swellings in joints will 
usually disappear with treatment, but carditis often continues for weeks or 
months. Relapses are frequent. The younger the patient, the more certainly 
will the heart be involved and severe signs of persistent carditis are 
unfavourable. Treatment: Rest in bed is essential and in carditis the child 
may be more comfortable in the semi-recumbent position with all voluntary 
effort excluded. Diet: milk, custards, bread and butter and as soon as 
possible a good mixed diet to combat anaemia. As a general rule 1.5 grains 
of sodium salicylate should be given for every year of the child's age, 
administered in three or four doses in 24 hours. An opiate should be given 
if pain is severe and prevents sleep. Duration of rest in bed: Every patient 
with carditis should remain in bed for four weeks after the disappearance of 
the last sign of activity. The persistence of a systolic murmur is of little 
significance. Resumption of activity must be watched with care. Return to 
activity should be gradual but not too slow but a watch should be kept for 
any indication of reactivation of the rheumatic disease. The importance of 
open-air activity during suitable weather to raise resistance to further 
attacks is stressed. Adequate rest each night, medical observation of 
febrile attacks (especially of sore throats), of any septic condition, or 
persistent anaemia is advisable. More strenuous competitive games, such as 
running, cycling, swimming and hill climbing are inadvisable for the 
majority of sufferers from heart disease, but football and other games need 
not be ruled out automatically. Public health aspects: Co-ordinated action 
between medical practitioners and local health and educational authorities 
is advised, as also is the co-operation of the Institution of Rheumatic 
Supervision Centres, Hospitals Schools and Special Schools including 
residence for the child suffering from residual cardiac damage. Employment: 
The school medical officer should explain to parents the advantage to be 
gained by registration under the Disabled Persons (Employment) Act 1944 to 
ensure receiving any necessary vocational training.
EMTREE DRUG INDEX TERMS
  hemoglobin
  opiate
  salicylate sodium
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  college
  physician
  rheumatic fever
EMTREE MEDICAL INDEX TERMS
  abdominal pain
  anemia
  arthritis
  atrial fibrillation
  blood examination
  bread
  butter
  cardiomegaly
  carditis
  child
  chorea
  climbing
  clinical feature
  congenital heart disease
  diet
  differential diagnosis
  disabled person
  dyspnea
  edema
  employment
  environment
  erythrocyte
  erythrocyte sedimentation rate
  fatigue
  fever
  football
  general aspects of disease
  grain
  health
  heart
  heart disease
  heart failure
  heart injury
  heart murmur
  hemolytic Streptococcus
  hospital
  infection
  inflammation
  latent period
  leukocyte count
  limb
  liver
  medical personnel
  milk
  night
  osteomyelitis
  pain
  pallor
  parent
  patient
  pericarditis
  poliomyelitis
  prognosis
  public health
  pulse rate
  registration
  relapse
  respiratory system
  rheumatic disease
  rheumatoid arthritis
  rheumatoid nodule
  school
  sleep
  sore throat
  Streptococcus infection
  swelling
  swimming
  systolic heart murmur
  T wave
  tachycardia
  tuberculosis
  United Kingdom
  vocational education
  vomiting
  weather
  weight
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007189863
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 588
TITLE
  Preoperative management of hyperthyroidism. Use of thiouracil and 
thiobarbital
AUTHOR NAMES
  Guthrie R.F.
AUTHOR ADDRESSES
  (Guthrie R.F.)
SOURCE
  Journal of the Medical Association of the State of Alabama (1947) 16:9 
(281-285). Date of Publication: 1947
ABSTRACT
  Twenty-five patients were treated with 0.2 Gm of thiouracil three times a 
day and three patients with thiobarbital in daily doses of 50 to 100 mgm. 
Lugol's solution, 10 minims three times a day, was given three weeks prior 
to surgery, thiouracil being omitted one week before surgery. Improvement, 
except for exophthalmos, was seen in all patients treated. High caloric diet 
of 3,500 to 5,000 calories, supplemented by vitamins, was recommended. In 
cardiac decompensation, thiouracil and iodine alone should be tried. If 
these are unsuccessful ammonium chloride, aminophyllin or mercurial 
diuretics can be used. In cases of chronic auricular fibrillation, digitalis 
is the remedy of choice; in paroxysmal fibrillation or flutter, quinidine is 
advised. Suitability for operation may be judged chiefly by gain in weight. 
In patients treated with iodine alone, a pulse rate of under 110 is required 
- in those on thiouracil, below 100 - plus improvement in symptoms. 
Thiouracil provides greater safety when used in pre-operative preparation 
than can be obtained by other means.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  thiobarbital
  thiouracil
EMTREE DRUG INDEX TERMS
  aminophylline
  ammonium chloride
  digitalis
  diuretic agent
  iodine
  lugol
  quinidine
  vitamin
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  hyperthyroidism
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  calorie
  diet
  exophthalmos
  heart failure
  human
  patient
  preoperative treatment
  pulse rate
  safety
  surgery
  thyroidectomy
  thyrotoxicosis
  weight
CAS REGISTRY NUMBERS
  thiobarbital (77-32-7)
  thiouracil (141-90-2)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007010776
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 589
TITLE
  The efficacy of maintenance doses of digitalis in preventing the recurrence 
of congestive heart failure
AUTHOR NAMES
  Ladue J.S.
  Carter S.B.
AUTHOR ADDRESSES
  (Ladue J.S.; Carter S.B.)
SOURCE
  Annals of Internal Medicine (1947) 27:6 (923-928). Date of Publication: 1947
ISSN
  0003-4819
ABSTRACT
  It is well known that congestive failure ensues in patients with heart 
disease and auricular fibrillation if digitalis is withheld. Katz, Sokolow, 
Weinberg and Plant were the first to investigate this effect of maintenance 
doses of digitalis in such patients with normal rhythm. A similar study was 
started by the present authors prior to the publication of this work. One 
hundred and four patients with heart disease were studied following 
discharge from the hospital, most of them had been receiving daily doses of 
0.1 to 0.3 Gm digitalis. Measurements of venous pressure, circulation time, 
vital capacity, and weight were made prior to and after omission of 
digitalis. Signs and symptoms of congestive failure were noted, the patients 
were cautioned against sudden exertion, and fluid and salt intake were 
limited. Of the 104 patients studied 65 developed congestive heart failure 
after omission of digitalis, but the levels of the selected objective 
criteria of decompensation rarely indicated its approach. Confirming 
previous observers it was found that cardiac patients not in failure have, 
on the average, lower vital capacity and longer circulation times than 
normals. Change in weight was as sensitive an indicator of failure as 
changes in venous pressure, circulation time, or vital capacity. The latter 
was of more value, however, in left ventricular failure. The symptoms and 
clinical signs were more reliable in discovering congestive failure than 
were repeated measurements of circulation time, venous pressure, or heart 
size. The transverse diameter of the heart is not appreciably affected by 
taking folia digitalis over a period of two to twenty-four months in the 
fully compensated patient with heart disease and regular sinus rhythm. 
Maintenance daily doses of 0.1 to 0.3 Gm digitalis leaf should be given to 
those with sinus rhythm. None of the criteria selected for the study gives 
any accurate appraisal of the proper maintenance dose for patients with 
sinus rhythm.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  digitalis
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  congestive heart failure
  maintenance drug dose
EMTREE MEDICAL INDEX TERMS
  atrial fibrillation
  cardiac patient
  circulation time
  exercise
  forced expiratory volume
  heart
  heart disease
  heart left ventricle failure
  heart size
  hospital
  liquid
  patient
  physical disease by body function
  plant
  plant leaf
  rhythm
  salt intake
  sinus rhythm
  therapy
  venous pressure
  vital capacity
  weight
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007192442
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 590
TITLE
  Recent myocardial infarction
AUTHOR NAMES
  Mintz S.S.
  Katz L.N.
AUTHOR ADDRESSES
  (Mintz S.S.; Katz L.N.) Cardiovascular Department, Michael Reese Hospital, .
CORRESPONDENCE ADDRESS
  Cardiovascular Department, Michael Reese Hospital, .
SOURCE
  archives of internal medicine (1947) 80:2 (205-236). Date of Publication: 
1947
ISSN
  0730-188X
ABSTRACT
  A study of 572 cases, extending over a five-year period from 1940-1945, of 
unequivocal myocardial infarction. The ratio of men to women was 2.2:1 and 
the average age was 62.4 years for the women and 58.4 for the men. The 
immediate mortality (within the first two weeks) was 18.6 per cent for men 
and 28.9 per cent for women. Seasonal incidence was an unimportant factor. 
Although a possible precipitating factor (exertion, infection, emotion) was 
present in 50 cases, the vast majority apparently occurred without 
precipitating events. Hypertension was pre-existent in 49.4 per cent of the 
women and 29.7 per cent of the men. There was a low incidence of 
hypertension in the younger group (32-36 years). Hypertension incidence 
increased with age, especially in the women. The hypertension had no 
influence on the immediate mortality rate. Diabetes was present in 16.2 per 
cent and these had a higher immediate mortality for both sexes, due entirely 
to those who showed ketosis. Controlled diabetes had the same mortality rate 
as the entire general series and a high blood sugar level per se appeared 
advantageous. Syphilis was a possible factor rarely (0.8 per cent of the 
cases). Angina pectoris prior to the infarction existed in 72.9 per cent but 
had little, if any, prognostic significance. The presence of angina pectoris 
following the infarction gave a grave prognosis. The absence of pain 
('silent myocardial infarction') and the character, location, radiation, and 
duration of the pain had no prognostic significance. The hypertensive 
patients had a greater drop in blood pressure than the normotensive. The 
pulse pressure fell in all groups and when it fell below 25 mm Hg, the 
prognosis was grave. The degree of drop in systolic pressure was of no 
significance provided the pressure was not below 100 mm Hg. If levels below 
90 mm Hg persisted for several days the prognosis was poor. The presence of 
shock, thought by the authors to be cardiogenic, in which forward failure 
developed because of reduced cardiac output, was grave (77.8 per cent of 
those in shock died). Although the mortality was about the same in anterior 
(17.6 per cent) and posterior (23.1 per cent) infarction it was greatest in 
septal and in the atypical and combined varieties. Most arrhythmias 
increased the mortality rate. Patients with complete heart block or with 
runs of ventricular premature systoles had 100 per cent mortality, with 
auricular flutter 75 per cent, supraventricular tachycardia 66.6 per cent, 
ventricular tachycardia 60 per cent, auricular fibrillation 29.4 per cent, 
and auriculoventricular block 23.1 per cent. The mortality was apparently 
increased in the arrhythmias treated with digitalis (50 per cent of the 30 
treated) or quinidine (41.2 per cent of the 17 treated) and 58.2 per cent in 
the 12 persons treated with both drugs. It is pointed cut that these drugs 
were used in those patients who suffered cardiac failure besides the 
arrhythmia. Occasional premature systoles (ventricular, auricular, or nodal) 
had no significance in the immediate mortality. Intraventricular block 
increased the mortality percentage. Congestive failure was an extremely 
grave sign, more so in men (46.2 per cent) than in women (37.5 per cent). 
Sinus tachycardia (a ventricular rate of over 100 in the first 
electrocardiogram) was a grave prognostic sign. Of the 79 men and the 37 
women in the entire series of 572 cases who developed this tachycardia the 
mortality was 50.6 and 67.6 per cent respectively. Of the 116 cases of 
tachycardia 56 had congestive heart failure and the mortality for this 
combination was 71.4 per cent. Of the 213 patients with heart failure 101 
received digitalis and 47 (46.5 per cent) died; of the 20 heart failures not 
given digitalis only four died. This poor record for digitalis may be due to 
the fact that only the graver cases received it, and the authors believe in 
the careful use of the drug when there are clear indications of heart 
failure (persistent dyspnoea, cyanosis, and râles in the bases of the lungs 
when not due to pneumonia). Although digitalis may shorten coagulation time 
of the blood its real danger is the initiation of ventricular fibrillation. 
Forward failure and shock are centra-indications to use of digitalis. In the 
572 cases there were 26 instances of pulmonary emboli, 11 of cerebral 
emboli, and two patients with a combination of both with a mortality of 
53.8, 81.8, and 100 per cent respectively. One patient had a mesenteric 
thrombosis (fatal). The remainder of the 9.9 per cent of the series that 
exhibited thrombo-embolism were distributed to the lower extremities, 
kidneys, and spleen. Of 20 of the patients with thrombo-embolism who 
received digitalis, 80 per cent died and 40.6 per cent of the 32 who did not 
get digitalis died. The authors advise ligation of vessels and/or the use of 
anticoagulants in indicated cases, but are not yet ready to advise 
anticoagulants to every patient prophylactically. Proved pericarditis 
developed in 26 cases in the series and had a death rate of 19.2 per cent, 
which compared favourably with the rate for the entire series. Thus it was 
not considered prognostically poor. Pneumonia developed in 52 (9.9 per cent) 
of the cases and exhibited a mortality of 57.7 per cent. It is to be 
considered a grave accompaniment, and penicillin therapy is indicated. 
Proved glycosuria (non-diabetic) occurred in only 10 cases. It could 
possibly be due to the release of epinephrine as a sequel to pain and fear 
or to a decrease in the circulation of blood to the liver. Of the 125 
patients who died, 46 were studied at autopsy. Eight cases showed cardiac 
aneurysm and five heart ruptures with haemo-pericardium. The infarction was 
posterior on the left ventricle in most cases which had exhibited partial 
and complete A-V block although two such cases were infarcted anteriorly. 
Most of the patients with intraventricular block showed the septum involved 
by fibrosis or acute infarction. Most infarctions were located as indicated 
by the electrocardiogram.
EMTREE DRUG INDEX TERMS
  adrenalin
  anticoagulant agent
  digitalis
  penicillin G
  quinidine
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  heart infarction
EMTREE MEDICAL INDEX TERMS
  angina pectoris
  atrial fibrillation
  atrioventricular block
  autopsy
  blood
  blood clotting time
  blood pressure
  complete heart block
  congestive heart failure
  cyanosis
  diabetes mellitus
  dyspnea
  electrocardiogram
  embolism
  emotion
  epidemiology
  exercise
  fear
  female
  fibrosis
  forward heart failure
  glucose blood level
  glucosuria
  heart aneurysm
  heart arrhythmia
  heart atrium flutter
  heart failure
  heart left ventricle
  heart output
  heart rupture
  heart ventricle fibrillation
  heart ventricle tachycardia
  hypertension
  infarction
  infection
  ketoacidosis
  kidney
  leg
  ligation
  liver
  lung
  lung embolism
  mortality
  pain
  patient
  pericarditis
  pericardium
  pneumonia
  prognosis
  pulse pressure
  radiation
  seasonal variation
  silent myocardial infarction
  sinus tachycardia
  spleen
  supraventricular tachycardia
  syphilis
  systole
  systolic blood pressure
  tachycardia
  therapy
  thromboembolism
  thrombosis
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007210772
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.

RECORD 591
TITLE
  Early diagnosis of rheumatic valvular disease in recruits
AUTHOR NAMES
  Parkinson J.
  Hartley R.
AUTHOR ADDRESSES
  (Parkinson J.; Hartley R.) Cardiac Department, London Hospital, .
CORRESPONDENCE ADDRESS
  Cardiac Department, London Hospital, .
SOURCE
  British Heart Journal (1946) 8:4 (212-232). Date of Publication: 1946
ISSN
  0007-0769
ABSTRACT
  This paper is based on 2,500 recruits referred for cardiological opinion to 
Medical Boards. The commonest cause of reference was a systolic murmur 
which, in 259 (10 per cent), was considered to be incidental or functional, 
the criteria of benignity being softness and shortness, variability with 
posture, respiration and heart rate. Normal radiological appearances were a 
great help in regarding such murmurs as trivial. It is emphasized that a 
split first sound, a loud or reduplicated second pulmonary sound, as well as 
the normal third heart sound may all erroneously be regarded as evidence of 
disease. An individual with an innocent systolic murmur runs a risk of a 
'doctor made' cardiac neurosis, as many medical men fail to give the patient 
firm reassurance. Minor degrees of scoliosis were frequently found to 
displace the apex beat. In 72 cases a simple nervous tachycardia of 90 to 
130 was noted falling on rest and as excitement abated. A persistent rate of 
over 100 should lead to a careful search for a cause such as thyrotoxicosis, 
pyrexia or pulmonary disease. Smoking or drinking to excess may be a cause. 
Bradycardia was rarely worthy of note; when the patient is under 50 years of 
age an attempt should be made to raise the rate by exercise and when under 
40 years an electrocardiogram is indicated. Irregularity of the pulse was 
the cause of reference in 31 out of 1,000 consecutive cases. The two 
principal causes were extrasystoles (ten) and sinus arrhythmia (ten). In 
discussing the thorny problem of what should be regarded as the upper limit 
of normal blood-pressure the authors suggest that the limit of the systolic 
pressure (after the exclusion of renal disease and coarctation of the aorta) 
might with safety be placed higher than 160 mm provided that the diastolic 
pressure is 90 or below and that the X-ray picture of the left ventricle is 
normal. In the whole group a history of rheumatic fever, chorea or dyspnoea 
was found unreliable, as the desires of the patient tended to cause error in 
both directions. Of the purely clinical methods of examination auscultation 
is the most important. Emphasis is placed on the value of listening in the 
left lateral position immediately after exercise as a method of eliciting 
the mitral presystolic murmur. Auscutation over the left border of the 
sternum with the patient in the left lateral position during the falling 
heart rate subsequent to exercise facilitated hearing the soft early murmur 
of aortic incompetence. This murmur is also accentuated when the patient 
leans forwards, expires and holds the breath. Formal exercise tolerance 
tests were not employed. Electro-cardiography was in general not found 
helpful and was abandoned as a routine procedure after the first 500 cases. 
Radioscopy proved invaluable in early diagnosis in that 80-90 per cent of 
cases furnished convincing X-ray evidence. Left auricular enlargement in 
mitral stenosis proved equal in importance to the presystolic murmur in the 
diagnosis of mitral stenosis. This enlargement is best seen in the right 
oblique view with the oesophagus delineated by barium; this view also 
demonstrates the prominent anterior cardiac border and the broadening of the 
normal slim neck of the heart shadow. The A.P. view in early mitral stenosis 
shows a characteristic 'filling in' of the left border with a small aortic 
knuckle. Mention is made of the unreliability of 'buttressing' of the right 
border and extent of hilar markings as evidence of early mitral disease. 
Extension outwards and increased convexity of the left lower border are 
regarded as the earliest signs - of the left ventricular enlargement - of 
aortic incompetence; these features are best seen in the left oblique 
position. Mention is made of the fact that a trivial scoliosis, a high 
diaphragm or a simple bradycardia may result in the radiological simulation 
of early mitral stenosis or aortic incompetence; conversely either lesion 
may be concealed by a low diaphragm. Mitral valvular disease was diagnosed 
in 264 of all rheumatic cases (609). It is considered that the weight of 
pathological evidence supports the view that mitral incompetence without 
stenosis is rare except perhaps in early life. This group was subdivided 
into mitral stenosis with a presystolic murmur, numbering 104. All had a 
loud first sound. Left auricular enlargement was the characteristic X-ray 
sign. The authors include in this group five cases in which a loud first 
sound and characteristic X-ray changes were present without a presystolic 
murmur, and 13 cases in which a mitral diastolic murmur alone was heard. 
Mitral stenosis with a systolic murmur. These amounted to 60 cases, of whom 
more than half gave a strong rheumatic history; all had a loud systolic 
murmur and 54 showed radiological evidence. Mitral valvular disease 
(probable). In this group of 68 cases the history, symptoms and signs, 
although not conclusive, were sufficiently suggestive to warrant rejection 
for service. Mitral stenosis without murmur. In two cases, one with 
auricular fibrillation, no abnormal auscultatory signs were noted, but the 
left auricular enlargement was considered diagnostic. Aortic valvular 
disease without mitral stenosis was found in 229 cases. Of these 202 had 
pure aortic incompetence, all with an aortic diastolic murmur, half with an 
additional apical systolic murmur of no great length or intensity. Left 
ventricular enlargement was demonstrated in 169. Emphasis is placed on the 
fact that aortic incompetence, either alone, or with mitral stenosis is far 
more common than is thought. Pure aortic stenosis was found in 14 cases, 13 
of whom had an aortic systolic thrill, and yet the arotic second sound was 
present. Aortic stenosis and incompetence was combined in 13 cases. Combined 
aortic and mitral valvular lesions were found in 76 cases, a figure which 
the authors regard as disproportionately small, as the grosser cases are 
easily recognized and were graded by the Medical Boards without reference to 
a cardiologist. It is noteworthy that of the total of 2,500 cases seen, 71 
had congenital cardiac lesions and only four syphilitic aortic incompetence.
EMTREE DRUG INDEX TERMS
  barium
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  early diagnosis
  rheumatic heart disease
EMTREE MEDICAL INDEX TERMS
  aorta
  aorta stenosis
  aorta valve disease
  aorta valve regurgitation
  atrial fibrillation
  auscultation
  blood pressure
  body posture
  bradycardia
  breathing
  cardiac anxiety
  cardiologist
  chorea
  diagnosis
  diaphragm
  diastolic blood pressure
  drinking
  dyspnea
  electrocardiogram
  electrocardiography
  esophagus
  examination
  excitement
  exercise
  exercise tolerance
  extrasystole
  fever
  hardness
  hearing
  heart
  heart injury
  heart left ventricle
  heart left ventricle hypertrophy
  heart rate
  heart sound
  kidney disease
  lung disease
  mitral valve disease
  mitral valve regurgitation
  mitral valve stenosis
  neck
  patient
  physician
  pulse rate
  reassurance
  rheumatic disease
  rheumatic fever
  risk
  safety
  scoliosis
  simulation
  sinus arrhythmia
  smoking
  stenosis
  sternum
  systolic blood pressure
  systolic heart murmur
  tachycardia
  thyrotoxicosis
  weight
  X ray
  X ray picture
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2007001890
COPYRIGHT
  Copyright 2007 Elsevier B.V., All rights reserved.